Sequential	10	O
involvement	11	O
of	2	O
NFAT	4	B-Gene
and	3	O
Egr	3	B-Gene
transcription	13	I-Gene
factors	7	I-Gene
in	2	O
FasL	4	B-Gene
regulation	10	O
.	1	O

The	3	O
critical	8	O
function	8	O
of	2	O
NFAT	4	B-Gene
proteins	8	I-Gene
in	2	O
maintaining	11	O
lymphoid	8	O
homeostasis	11	O
was	3	O
revealed	8	O
in	2	O
mice	4	O
lacking	7	O
both	4	O
NFATp	5	B-Gene
and	3	O
NFAT4	5	B-Gene
(	1	O
DKO	3	O
)	1	O
.	1	O

DKO	3	O
mice	4	O
exhibit	7	O
increased	9	O
lymphoproliferation	19	O
,	1	O
decreased	9	O
activation	10	O
-induced	8	O
cell	4	O
death	5	O
,	1	O
and	3	O
impaired	8	O
induction	9	O
of	2	O
FasL	4	B-Gene
.	1	O

The	3	O
transcription	13	B-Gene
factors	7	I-Gene
Egr2	4	I-Gene
and	3	O
Egr3	4	B-Gene
are	3	O
potent	6	O
activators	10	O
of	2	O
FasL	4	B-Gene
expression	10	O
.	1	O

Here	4	O
we	2	O
find	4	O
that	4	O
Egr2	4	B-Gene
and	3	O
Egr3	4	B-Gene
are	3	O
NFAT	4	B-Gene
target	6	O
genes	5	O
.	1	O

Activation	10	O
of	2	O
FasL	4	B-Gene
occurs	6	O
via	3	O
the	3	O
NFAT	4	B-Gene
-dependent	10	O
induction	9	O
of	2	O
Egr3	4	B-Gene
,	1	O
as	2	O
demonstrated	12	O
by	2	O
the	3	O
ability	7	O
of	2	O
exogenously	11	O
provided	8	O
NFATp	5	B-Gene
to	2	O
restore	7	O
Egr	3	B-Gene
-dependent	10	O
FasL	4	B-Gene
promoter	8	I-Gene
activity	8	O
in	2	O
DKO	3	O
lymph	5	O
node	4	O
cells	5	O
.	1	O

Further	7	O
,	1	O
Egr3	4	B-Gene
expression	10	O
is	2	O
enriched	8	O
in	2	O
Th1	3	O
cells	5	O
,	1	O
suggesting	10	O
a	1	O
molecular	9	O
basis	5	O
for	3	O
the	3	O
known	5	O
preferential	12	O
expression	10	O
of	2	O
FasL	4	B-Gene
in	2	O
the	3	O
Th1	3	O
versus	6	O
Th2	3	O
subset	6	O
.	1	O

LIGHT	5	B-Gene
,	1	O
a	1	O
TNF	3	B-Gene
-like	5	O
molecule	8	O
,	1	O
costimulates	12	O
T	1	O
cell	4	O
proliferation	13	O
and	3	O
is	2	O
required	8	O
for	3	O
dendritic	9	O
cell	4	O
-mediated	9	O
allogeneic	10	O
T	1	O
cell	4	O
response	8	O
.	1	O

LIGHT	5	B-Gene
is	2	O
a	1	O
recently	8	O
identified	10	O
member	6	O
of	2	O
the	3	O
TNF	3	B-Gene
superfamily	11	O
and	3	O
its	3	O
receptors	9	O
,	1	O
herpesvirus	11	O
entry	5	O
mediator	8	O
and	3	O
lymphotoxin	11	B-Gene
beta	4	I-Gene
receptor	8	I-Gene
,	1	O
are	3	O
found	5	O
in	2	O
T	1	O
cells	5	O
and	3	O
stromal	7	O
cells	5	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
we	2	O
demonstrate	11	O
that	4	O
LIGHT	5	B-Gene
is	2	O
selectively	11	O
expressed	9	O
on	2	O
immature	8	O
dendritic	9	O
cells	5	O
(	1	O
DCs	3	O
)	1	O
generated	9	O
from	4	O
human	5	O
PBMCs	5	O
.	1	O

In	2	O
contrast	8	O
,	1	O
LIGHT	5	B-Gene
is	2	O
not	3	O
detectable	10	O
in	2	O
DCs	3	O
either	6	O
freshly	7	O
isolated	8	O
from	4	O
PBMCs	5	O
or	2	O
rendered	8	O
mature	6	O
in	2	O
vitro	5	O
by	2	O
LPS	3	B-Chemical
treatment	9	O
.	1	O

Blockade	8	O
of	2	O
LIGHT	5	B-Gene
by	2	O
its	3	O
soluble	7	O
receptors	9	O
,	1	O
lymphotoxin	11	B-Gene
beta	4	I-Gene
receptor-Ig	11	I-Gene
or	2	O
HVEM-Ig	7	B-Gene
,	1	O
inhibits	8	O
the	3	O
induction	9	O
of	2	O
DC	2	O
-mediated	9	O
primary	7	O
allogeneic	10	O
T	1	O
cell	4	O
response	8	O
.	1	O

Furthermore	11	O
,	1	O
engagement	10	O
of	2	O
LIGHT	5	B-Gene
costimulates	12	O
human	5	O
T	1	O
cell	4	O
proliferation	13	O
,	1	O
amplifies	9	O
the	3	O
NF-kappaB	9	B-Gene
signaling	9	O
pathway	7	O
,	1	O
and	3	O
preferentially	14	O
induces	7	O
the	3	O
production	10	O
of	2	O
IFN-gamma	9	B-Gene
,	1	O
but	3	O
not	3	O
IL-4	4	B-Gene
,	1	O
in	2	O
the	3	O
presence	8	O
of	2	O
an	2	O
antigenic	9	O
signal	6	O
.	1	O

Our	3	O
results	7	O
suggest	7	O
that	4	O
LIGHT	5	B-Gene
is	2	O
a	1	O
costimulatory	13	O
molecule	8	O
involved	8	O
in	2	O
DC	2	O
-mediated	9	O
cellular	8	O
immune	6	O
responses	9	O
.	1	O

Tumor	5	B-Gene
necrosis	8	I-Gene
factor-alpha	12	I-Gene
-induced	8	O
proliferation	13	O
requires	8	O
synthesis	9	O
of	2	O
granulocyte-macrophage	22	B-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
.	1	O

OBJECTIVE	9	O
:	1	O
Tumor	5	B-Gene
necrosis	8	I-Gene
factor-	7	I-Gene
alpha	5	I-Gene
(	1	O
TNF-alpha	9	B-Gene
)	1	O
induces	7	O
a	1	O
variety	7	O
of	2	O
cellular	8	O
responses	9	O
,	1	O
some	4	O
of	2	O
them	4	O
being	5	O
at	2	O
least	5	O
seemingly	9	O
contradictory	13	O
.	1	O

Thus	4	O
,	1	O
we	2	O
set	3	O
out	3	O
to	2	O
find	4	O
differences	11	O
in	2	O
the	3	O
modes	5	O
of	2	O
proliferative	13	O
and	3	O
apoptotic	9	O
responses	9	O
to	2	O
TNF-	4	B-Gene
alpha	5	I-Gene
.	1	O

MATERIALS	9	O
AND	3	O
METHODS	7	O
:	1	O
We	2	O
screened	8	O
a	1	O
panel	5	O
of	2	O
acute	5	B-Disease
myeloid	7	I-Disease
leukemia	8	I-Disease
-derived	8	O
cell	4	O
lines	5	O
for	3	O
TNF-	4	B-Gene
alpha	5	I-Gene
-responsiveness	15	O
.	1	O

In	2	O
two	3	O
lines	5	O
(	1	O
OCI-AML-1	9	O
,	1	O
OCI-AML-11	10	O
)	1	O
,	1	O
TNF-	4	B-Gene
alpha	5	I-Gene
acted	5	O
as	2	O
an	2	O
apoptotic	9	O
agent	5	O
;	1	O
in	2	O
others	6	O
(	1	O
HU-3	4	O
,	1	O
M-07e	5	O
,	1	O
TF-1	4	O
)	1	O
,	1	O
it	2	O
had	3	O
the	3	O
opposite	8	O
effect	6	O
,	1	O
preventing	10	O
apoptosis	9	O
and	3	O
inducing	8	O
proliferation	13	O
.	1	O

Direct	6	O
and	3	O
indirect	8	O
signaling	9	O
mechanisms	10	O
,	1	O
including	9	O
NF-kappaB	9	B-Gene
activation	10	O
and	3	O
cytokine	8	O
synthesis	9	O
,	1	O
were	4	O
analyzed	8	O
.	1	O

RESULTS	7	O
:	1	O
All	3	O
cell	4	O
lines	5	O
tested	6	O
expressed	9	O
TNF-	4	B-Gene
alpha	5	I-Gene
receptors	9	I-Gene
I	1	I-Gene
and	3	O
II	2	B-Partial_Gene
and	3	O
responded	9	O
to	2	O
TNF-	4	B-Gene
alpha	5	I-Gene
by	2	O
upregulation	12	O
of	2	O
intercellular	13	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
.	1	O

In	2	O
contrast	8	O
to	2	O
granulocyte-macrophage	22	B-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
(	1	O
GM-CSF	6	B-Gene
)	1	O
,	1	O
TNF-	4	B-Gene
alpha	5	I-Gene
did	3	O
not	3	O
activate	8	O
the	3	O
MAP	3	B-Gene
kinase	6	I-Gene
and	3	O
p70S6	5	B-Gene
kinase	6	I-Gene
pathways	8	O
.	1	O

Nevertheless	12	O
,	1	O
inhibitors	10	O
of	2	O
these	5	O
pathways	8	O
clearly	7	O
reduced	7	O
the	3	O
TNF-alpha	9	B-Gene
-induced	8	O
cell	4	O
growth	6	O
,	1	O
indicating	10	O
that	4	O
TNF-	4	B-Gene
alpha	5	I-Gene
-proliferative	14	O
cells	5	O
produced	8	O
a	1	O
growth	6	O
factor	6	O
that	4	O
induced	7	O
proliferation	13	O
upon	4	O
stimulation	11	O
of	2	O
the	3	O
above	5	O
pathways	8	O
.	1	O

Anti-GM-CSF	11	B-Gene
antibodies	10	I-Gene
inhibited	9	O
the	3	O
TNF-alpha	9	B-Gene
-induced	8	O
growth	6	O
,	1	O
suggesting	10	O
the	3	O
presence	8	O
of	2	O
an	2	O
autocrine	9	O
loop	4	O
for	3	O
cell	4	O
proliferation	13	O
mediated	8	O
by	2	O
GM-CSF	6	B-Gene
.	1	O

Supporting	10	O
this	4	O
notion	6	O
,	1	O
TNF-alpha	9	B-Gene
-induced	8	O
upregulation	12	O
of	2	O
GM-CSF	6	B-Gene
mRNA	4	I-Gene
levels	6	O
and	3	O
protein	7	O
secretion	9	O
in	2	O
the	3	O
TNF-alpha	9	B-Gene
-proliferative	14	O
,	1	O
but	3	O
not	3	O
in	2	O
the	3	O
TNF-alpha-apoptotic	19	B-Gene
cell	4	O
lines	5	O
.	1	O

CONCLUSION	10	O
:	1	O
These	5	O
data	4	O
identify	8	O
GM-CSF	6	B-Gene
synthesis	9	O
as	2	O
an	2	O
early	5	O
and	3	O
essential	9	O
step	4	O
in	2	O
TNF-	4	B-Gene
alpha	5	I-Gene
-induced	8	O
proliferation	13	O
.	1	O

We	2	O
show	4	O
for	3	O
the	3	O
first	5	O
time	4	O
that	4	O
TNF-alpha	9	B-Gene
-treated	8	O
cell	4	O
lines	5	O
producing	9	O
no	2	O
or	2	O
only	4	O
minimal	7	O
amounts	7	O
of	2	O
GM-CSF	6	B-Gene
demonstrate	11	O
an	2	O
apoptotic	9	O
phenotype	9	O
,	1	O
while	5	O
cell	4	O
lines	5	O
with	4	O
high	4	O
GM-CSF	6	B-Gene
expression	10	O
rates	5	O
can	3	O
escape	6	O
from	4	O
growth	6	O
arrest	6	O
or	2	O
even	4	O
apoptosis	9	O
.	1	O

In	2	O
this	4	O
context	7	O
,	1	O
we	2	O
discuss	7	O
arguments	9	O
pointing	8	O
at	2	O
NF-kappaB	9	B-Gene
as	2	O
regulator	9	O
of	2	O
GM-CSF	6	B-Gene
synthesis	9	O
and	3	O
thus	4	O
indirectly	10	O
as	2	O
regulator	9	O
for	3	O
the	3	O
escape	6	O
of	2	O
TNF-alpha	9	B-Gene
-induced	8	O
apoptosis	9	O

Transcriptional	15	O
activation	10	O
of	2	O
heme	4	B-Gene
oxygenase-1	11	I-Gene
and	3	O
its	3	O
functional	10	O
significance	12	O
in	2	O
acetaminophen	13	B-Chemical
-induced	8	O
hepatitis	9	B-Disease
and	3	O
hepatocellular	14	O
injury	6	O
in	2	O
the	3	O
rat	3	O
.	1	O

BACKGROUND	10	O
/	1	O
AIM	3	O
:	1	O
Glutathione	11	B-Chemical
depletion	9	O
contributes	11	O
to	2	O
acetaminophen	13	B-Chemical
hepatotoxicity	14	O
and	3	O
is	2	O
known	5	O
to	2	O
induce	6	O
the	3	O
oxidative	9	O
stress	6	O
reactant	8	O
heme	4	B-Gene
oxygenase-1	11	I-Gene
.	1	O

The	3	O
metabolites	11	O
of	2	O
the	3	O
heme	4	B-Gene
oxygenase	9	I-Gene
pathway	7	O
,	1	O
biliverdin	10	B-Chemical
,	1	O
carbon	6	B-Chemical
monoxide	8	I-Chemical
,	1	O
and	3	O
iron	4	B-Chemical
may	3	O
modulate	8	O
acetaminophen	13	B-Chemical
toxicity	8	O
.	1	O

The	3	O
aim	3	O
of	2	O
this	4	O
study	5	O
was	3	O
to	2	O
assess	6	O
cell-type	9	O
specific	8	O
expression	10	O
of	2	O
heme	4	B-Gene
oxygenase-1	11	I-Gene
and	3	O
its	3	O
impact	6	O
on	2	O
liver	5	B-Disease
injury	6	I-Disease
and	3	O
microcirculatory	16	O
disturbances	12	O
in	2	O
a	1	O
model	5	O
of	2	O
acetaminophen	13	B-Chemical
-induced	8	O
hepatitis	9	B-Disease
.	1	O

METHODS	7	O
:	1	O
Gene	4	O
expression	10	O
of	2	O
heme	4	B-Gene
oxygenase-1	11	I-Gene
was	3	O
studied	7	O
by	2	O
Northern-	9	O
and	3	O
Western	7	O
analysis	8	O
as	2	O
well	4	O
as	2	O
immunohistochemistry	20	O
.	1	O

The	3	O
time	4	O
course	6	O
of	2	O
heme	4	B-Gene
oxygenase-1	11	I-Gene
and	3	O
-2	2	B-Partial_Gene
,	1	O
cytokine	8	B-Gene
-induced	8	I-Gene
neutrophil	10	I-Gene
chemoattractant-1	17	I-Gene
,	1	O
and	3	O
intercellular	13	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
was	3	O
studied	7	O
by	2	O
Northern	8	O
analysis	8	O
.	1	O

DNA	3	O
-binding	8	O
activity	8	O
of	2	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
was	3	O
determined	10	O
by	2	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assay	5	O
.	1	O

Sinusoidal	10	O
perfusion	9	O
and	3	O
leukocyte-endothelial	21	O
interactions	12	O
were	4	O
assessed	8	O
by	2	O
intravital	10	O
microscopy	10	O
.	1	O

RESULTS	7	O
:	1	O
Acetaminophen	13	B-Chemical
caused	6	O
a	1	O
moderate	8	O
sinusoidal	10	O
perfusion	9	O
failure	7	O
(	1	O
-15	3	O
%	1	O
)	1	O
and	3	O
infiltration	12	O
of	2	O
neutrophils	11	O
along	5	O
with	4	O
activation	10	O
of	2	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
and	3	O
intercellular	13	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
and	3	O
cytokine	8	B-Gene
-induced	8	I-Gene
neutrophil	10	I-Gene
chemoattractant-1	17	I-Gene
mRNAs	5	I-Gene
.	1	O

Induction	9	O
of	2	O
heme	4	B-Gene
oxygenase-1	11	I-Gene
mRNA	4	I-Gene
and	3	O
protein	7	O
(	1	O
approximately	13	O
30-fold	7	O
)	1	O
in	2	O
hepatocytes	11	O
and	3	O
non-parenchymal	15	O
cells	5	O
paralleled	10	O
the	3	O
inflammatory	12	O
response	8	O
.	1	O

Blockade	8	O
of	2	O
heme	4	B-Gene
oxygenase	9	I-Gene
activity	8	O
with	4	O
tin-protoporphyrin-IX	21	B-Chemical
abrogated	9	O
acetaminophen	13	B-Chemical
-induced	8	O
hepatic	7	O
neutrophil	10	O
accumulation	12	O
and	3	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
activation	10	O
,	1	O
but	3	O
failed	6	O
to	2	O
affect	6	O
sinusoidal	10	O
perfusion	9	O
and	3	O
liver	5	B-Disease
injury	6	I-Disease
.	1	O

CONCLUSIONS	11	O
:	1	O
The	3	O
inflammatory	12	O
response	8	O
associated	10	O
with	4	O
acetaminophen	13	B-Chemical
hepatotoxicity	14	O
is	2	O
modulated	9	O
by	2	O
the	3	O
parallel	8	O
induction	9	O
of	2	O
the	3	O
heme	4	B-Gene
oxygenase-1	11	I-Gene
gene	4	I-Gene
.	1	O

However	7	O
,	1	O
heme	4	B-Gene
oxygenase-1	11	I-Gene
has	3	O
no	2	O
permissive	10	O
effect	6	O
on	2	O
sinusoidal	10	O
perfusion	9	O
and	3	O
does	4	O
not	3	O
affect	6	O
liver	5	B-Disease
injury	6	I-Disease
in	2	O
this	4	O
model	5	O
.	1	O

These	5	O
data	4	O
argue	5	O
against	7	O
a	1	O
central	7	O
role	4	O
of	2	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
activation	10	O
and	3	O
neutrophil	10	O
infiltration	12	O
as	2	O
perpetuating	12	O
factors	7	O
of	2	O
liver	5	B-Disease
injury	6	I-Disease
in	2	O
acetaminophen	13	B-Chemical
toxicity	8	O
.	1	O

Functional	10	O
characterization	16	O
of	2	O
the	3	O
two	3	O
alternative	11	O
promoters	9	O
of	2	O
human	5	B-Gene
p45	3	I-Gene
NF-E2	5	I-Gene
gene	4	I-Gene
.	1	O

OBJECTIVE	9	O
:	1	O
The	3	O
transcription	13	B-Gene
factor	6	I-Gene
NF-E2	5	I-Gene
,	1	O
a	1	O
heterodimeric	13	O
protein	7	O
complex	7	O
composed	8	O
of	2	O
p45	3	B-Gene
and	3	O
small	5	B-Gene
Maf	3	I-Gene
family	6	I-Gene
proteins	8	I-Gene
,	1	O
is	2	O
considered	10	O
crucial	7	O
for	3	O
the	3	O
proper	6	O
differentiation	15	O
of	2	O
erythrocytes	12	O
and	3	O
megakaryocytes	14	O
in	2	O
vivo	4	O
.	1	O

We	2	O
report	6	O
the	3	O
results	7	O
of	2	O
studies	7	O
aimed	5	O
at	2	O
understanding	13	O
the	3	O
regulatory	10	O
mechanisms	10	O
controlling	11	O
p45	3	B-Gene
gene	4	I-Gene
expression	10	O
in	2	O
erythroid	9	O
cells	5	O
.	1	O

MATERIALS	9	O
AND	3	O
METHODS	7	O
:	1	O
Human	5	B-Gene
p45	3	I-Gene
mRNAs	5	I-Gene
have	4	O
two	3	O
alternative	11	O
isoforms	8	O
,	1	O
aNF-E2	6	B-Gene
and	3	O
fNF-E2	6	B-Gene
,	1	O
and	3	O
these	5	O
isoforms	8	O
are	3	O
transcribed	11	O
from	4	O
the	3	O
alternative	11	O
promoters	9	O
.	1	O

We	2	O
investigated	12	O
lineage-specific	16	O
expression	10	O
of	2	O
both	4	O
isomers	7	O
in	2	O
human	5	O
erythroid	9	O
and	3	O
megakaryocytic	14	O
cells	5	O
by	2	O
reverse	7	O
transcriptase	13	O
polymerase	10	O
chain	5	O
reaction	8	O
or	2	O
Northern	8	O
blot	4	O
analysis	8	O
.	1	O

For	3	O
functional	10	O
characterization	16	O
of	2	O
both	4	O
promoters	9	O
,	1	O
plasmids	8	O
in	2	O
which	5	O
reporter	8	O
genes	5	O
were	4	O
placed	6	O
under	5	O
the	3	O
control	7	O
of	2	O
a	1	O
series	6	O
of	2	O
truncated	9	O
or	2	O
mutated	7	O
promoter	8	O
fragments	9	O
were	4	O
transfected	11	O
to	2	O
human	5	O
hematopoietic	13	O
cell	4	O
lines	5	O
.	1	O

RESULTS	7	O
:	1	O
When	4	O
CD34	4	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
cells	5	O
isolated	8	O
from	4	O
human	5	O
cord	4	O
blood	5	O
were	4	O
induced	7	O
to	2	O
unilineage	10	O
erythroid	9	O
or	2	O
megakaryocytic	14	O
differentiation	15	O
in	2	O
liquid	6	O
suspension	10	O
culture	7	O
,	1	O
both	4	O
transcripts	11	O
,	1	O
although	8	O
barely	6	O
detected	8	O
at	2	O
day	3	O
0	1	O
,	1	O
were	4	O
induced	7	O
in	2	O
both	4	O
erythroid	9	O
and	3	O
megakaryocytic	14	O
cultures	8	O
.	1	O

fNF-E2	6	B-Gene
mRNA	4	I-Gene
was	3	O
found	5	O
to	2	O
be	2	O
more	4	O
abundant	8	O
in	2	O
erythroid	9	O
cells	5	O
than	4	O
megakaryocytic	14	O
cells	5	O
at	2	O
day	3	O
7	1	O
of	2	O
culture	7	O
.	1	O

Although	8	O
both	4	O
isomers	7	O
were	4	O
expressed	9	O
in	2	O
human	5	O
erythroid-megakaryocytic	24	O
cell	4	O
lines	5	O
,	1	O
megakaryocytic	14	O
maturation	10	O
with	4	O
loss	4	O
of	2	O
erythroid	9	O
phenotype	9	O
induced	7	O
by	2	O
phorbol	7	B-Chemical
12-myristate	12	I-Chemical
13-acetate	10	I-Chemical
(	1	O
PMA	3	B-Chemical
)	1	O
resulted	8	O
in	2	O
exclusive	9	O
downregulation	14	O
of	2	O
fNF-E2	6	B-Gene
,	1	O
suggesting	10	O
that	4	O
fNF-E2	6	B-Gene
promoter	8	I-Gene
is	2	O
more	4	O
erythroid	9	O
specific	8	O
.	1	O

Functional	10	O
analysis	8	O
of	2	O
fNF-E2	6	B-Gene
promoter	8	I-Gene
showed	6	O
that	4	O
the	3	O
promoter	8	O
is	2	O
active	6	O
only	4	O
in	2	O
erythroid-megakaryocytic	24	O
cells	5	O
and	3	O
that	4	O
the	3	O
double	6	O
GATA	4	B-Gene
sit	3	O
e	1	O
in	2	O
the	3	O
proximal	8	O
region	6	O
is	2	O
necessary	9	O
for	3	O
its	3	O
efficient	9	O
activity	8	O
.	1	O

CONCLUSION	10	O
:	1	O
These	5	O
results	7	O
suggest	7	O
that	4	O
GATA	4	B-Gene
proteins	8	I-Gene
,	1	O
which	5	O
govern	6	O
the	3	O
differentiation	15	O
of	2	O
erythroid	9	O
lineage	7	O
cells	5	O
,	1	O
are	3	O
required	8	O
for	3	O
full	4	O
promoter	8	O
activity	8	O
of	2	O
the	3	O
p45	3	B-Gene
gene	4	I-Gene
.	1	O

Activation	10	O
of	2	O
the	3	O
Lck	3	B-Gene
tyrosine	8	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
by	2	O
the	3	O
Herpesvirus	11	B-Gene
saimiri	7	I-Gene
tip	3	I-Gene
protein	7	I-Gene
involves	8	O
two	3	O
binding	7	O
interactions	12	O
.	1	O

The	3	O
Tip	3	B-Gene
protein	7	I-Gene
of	2	O
Herpesvirus	11	O
saimiri	7	O
strain	6	O
484C	4	O
binds	5	O
to	2	O
and	3	O
activates	9	O
the	3	O
Lck	3	B-Gene
tyrosine	8	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
.	1	O

Two	3	O
sequences	9	O
in	2	O
the	3	O
Tip	3	B-Gene
protein	7	I-Gene
were	4	O
previously	10	O
shown	5	O
to	2	O
be	2	O
involved	8	O
in	2	O
binding	7	O
to	2	O
Lck	3	B-Gene
.	1	O

A	1	O
proline-rich	12	B-Chemical
region	6	O
,	1	O
residues	8	O
132-141	7	O
,	1	O
binds	5	O
to	2	O
the	3	O
SH3	3	O
domain	6	O
of	2	O
the	3	O
Lck	3	B-Gene
protein	7	I-Gene
.	1	O

We	2	O
show	4	O
here	4	O
that	4	O
the	3	O
other	5	O
Lck	3	B-Gene
-binding	8	O
domain	6	O
,	1	O
residues	8	O
104-113	7	O
,	1	O
binds	5	O
to	2	O
the	3	O
carboxyl-terminal	17	B-Chemical
half	4	O
of	2	O
Lck	3	B-Gene
and	3	O
that	4	O
this	4	O
binding	7	O
does	4	O
not	3	O
require	7	O
the	3	O
Lck	3	B-Gene
SH3	3	O
domain	6	O
.	1	O

Mutated	7	B-Gene
Tip	3	I-Gene
containing	10	O
only	4	O
one	3	O
functional	10	O
Lck	3	B-Gene
-binding	8	O
domain	6	O
can	3	O
bind	4	O
stably	6	O
to	2	O
Lck	3	B-Gene
,	1	O
although	8	O
not	3	O
as	2	O
strongly	8	O
as	2	O
wild-type	9	O
Tip	3	B-Gene
.	1	O

Interaction	11	O
of	2	O
Tip	3	B-Gene
with	4	O
Lck	3	B-Gene
through	7	O
either	6	O
Lck	3	B-Gene
-binding	8	O
domain	6	O
increases	9	O
the	3	O
activity	8	O
of	2	O
Lck	3	B-Gene
in	2	O
vivo	4	O
.	1	O

Simultaneous	12	O
binding	7	O
of	2	O
both	4	O
domains	7	O
is	2	O
required	8	O
for	3	O
maximal	7	O
activation	10	O
of	2	O
Lck	3	B-Gene
.	1	O

The	3	O
transient	9	O
expression	10	O
of	2	O
Tip	3	B-Gene
in	2	O
T	1	O
cells	5	O
was	3	O
found	5	O
to	2	O
stimulate	9	O
both	4	O
Stat3	5	B-Gene
-dependent	10	O
and	3	O
NF-AT	5	B-Gene
-dependent	10	O
transcription	13	O
.	1	O

Mutant	6	O
forms	5	O
of	2	O
Tip	3	B-Gene
lacking	7	O
one	3	O
or	2	O
the	3	O
other	5	O
of	2	O
the	3	O
two	3	O
Lck	3	B-Gene
-binding	8	O
domains	7	O
retained	8	O
the	3	O
ability	7	O
to	2	O
stimulate	9	O
Stat3	5	B-Gene
-dependent	10	O
transcription	13	O
.	1	O

Tip	3	B-Gene
lacking	7	O
the	3	O
proline-rich	12	B-Chemical
Lck	3	B-Gene
-binding	8	O
domain	6	O
exhibited	9	O
almost	6	O
wild-type	9	O
activity	8	O
in	2	O
this	4	O
assay	5	O
.	1	O

In	2	O
contrast	8	O
,	1	O
ablation	8	O
of	2	O
either	6	O
Lck	3	B-Gene
-binding	8	O
domain	6	O
abolished	9	O
the	3	O
ability	7	O
of	2	O
Tip	3	B-Gene
to	2	O
stimulate	9	O
NF-AT	5	B-Gene
-dependent	10	O
transcription	13	O
.	1	O

Full	4	O
biological	10	O
activity	8	O
of	2	O
Tip	3	B-Gene
,	1	O
therefore	9	O
,	1	O
appears	7	O
to	2	O
require	7	O
both	4	O
Lck	3	B-Gene
-binding	8	O
domains	7	O
.	1	O

The	3	O
Epstein-Barr	12	O
virus	5	O
promoter	8	O
initiating	10	O
B-cell	6	O
transformation	14	O
is	2	O
activated	9	O
by	2	O
RFX	3	B-Gene
proteins	8	I-Gene
and	3	O
the	3	O
B-cell-specific	15	B-Gene
activator	9	I-Gene
protein	7	I-Gene
BSAP	4	I-Gene
/	1	I-Gene
Pax5	4	I-Gene
.	1	O

Epstein-Barr	12	O
virus	5	O
(	1	O
EBV	3	O
)	1	O
-induced	8	O
B-cell	6	O
growth	6	O
transformation	14	O
,	1	O
a	1	O
central	7	O
feature	7	O
of	2	O
the	3	O
virus	5	O
'strategy	9	O
for	3	O
colonizing	10	O
the	3	O
human	5	O
B-cell	6	O
system	6	O
,	1	O
requires	8	O
full	4	O
virus	5	O
latent	6	O
gene	4	O
expression	10	O
and	3	O
is	2	O
initiated	9	O
by	2	O
transcription	13	O
from	4	O
the	3	O
viral	5	O
promoter	8	O
Wp	2	B-Gene
.	1	O

Interestingly	13	O
,	1	O
when	4	O
EBV	3	O
accesses	8	O
other	5	O
cell	4	O
types	5	O
,	1	O
this	4	O
growth	6	O
-transforming	13	O
program	7	O
is	2	O
not	3	O
activated	9	O
.	1	O

The	3	O
present	7	O
work	4	O
focuses	7	O
on	2	O
a	1	O
region	6	O
of	2	O
Wp	2	B-Gene
which	5	O
in	2	O
reporter	8	O
assays	6	O
confers	7	O
B-cell	6	O
-specific	9	O
activity	8	O
.	1	O

Bandshift	9	O
studies	7	O
indicate	8	O
that	4	O
this	4	O
region	6	O
contains	8	O
three	5	O
factor	6	O
binding	7	O
sites	5	O
,	1	O
termed	6	O
sites	5	O
B	1	O
,	1	O
C	1	O
,	1	O
and	3	O
D	1	O
,	1	O
in	2	O
addition	8	O
to	2	O
a	1	O
previously	10	O
characterized	13	O
CREB	4	B-Gene
site	4	O
.	1	O

Here	4	O
we	2	O
show	4	O
that	4	O
site	4	O
C	1	O
binds	5	O
members	7	O
of	2	O
the	3	O
ubiquitously	12	O
expressed	9	O
RFX	3	B-Gene
family	6	I-Gene
of	2	O
proteins	8	O
,	1	O
notably	7	O
RFX1	4	B-Gene
,	1	O
RFX3	4	B-Gene
,	1	O
and	3	O
the	3	O
associated	10	O
factor	6	O
MIBP1	5	B-Gene
,	1	O
whereas	7	O
sites	5	O
B	1	O
and	3	O
D	1	O
both	4	O
bind	4	O
the	3	O
B-cell-specific	15	B-Gene
activator	9	I-Gene
protein	7	I-Gene
BSAP	4	I-Gene
/	1	I-Gene
Pax5	4	I-Gene
.	1	O

In	2	O
reporter	8	O
assays	6	O
with	4	O
mutant	6	O
Wp	2	B-Gene
constructs	10	O
,	1	O
the	3	O
loss	4	O
of	2	O
factor	6	O
binding	7	O
to	2	O
any	3	O
one	3	O
of	2	O
these	5	O
sites	5	O
severely	8	O
impaired	8	O
promoter	8	O
activity	8	O
in	2	O
B	1	O
cells	5	O
,	1	O
while	5	O
the	3	O
wild-type	9	O
promoter	8	O
could	5	O
be	2	O
activated	9	O
in	2	O
non-B	5	O
cells	5	O
by	2	O
ectopic	7	O
BSAP	4	B-Gene
expression	10	O
.	1	O

We	2	O
suggest	7	O
that	4	O
Wp	2	B-Gene
regulation	10	O
by	2	O
BSAP	4	B-Gene
helps	5	O
to	2	O
ensure	6	O
the	3	O
B-cell	6	O
specificity	11	O
of	2	O
EBV	3	O
's	2	O
growth	6	O
-transforming	13	O
function	8	O
.	1	O

Functional	10	O
uncoupling	10	O
of	2	O
the	3	O
Janus	5	B-Gene
kinase	6	I-Gene
3-Stat5	7	I-Gene
pathway	7	O
in	2	O
malignant	9	O
growth	6	O
of	2	O
human	5	O
T	1	B-Disease
cell	4	I-Disease
leukemia	8	I-Disease
virus	5	O
type	4	O
1	1	O
-transformed	12	O
human	5	O
T	1	O
cells	5	O
.	1	O

Human	5	O
T	1	B-Disease
cell	4	I-Disease
leukemia	8	I-Disease
virus	5	O
type	4	O
1	1	O
(	1	O
HTLV-1	6	O
)	1	O
transforms	10	O
cytokine	8	O
-dependent	10	O
T	1	O
lymphocytes	11	O
and	3	O
causes	6	O
adult	5	B-Disease
T	1	I-Disease
cell	4	I-Disease
leukemia	8	I-Disease
.	1	O

Janus	5	B-Gene
tyrosine	8	I-Gene
kinase	6	I-Gene
(	1	I-Gene
Jak	3	I-Gene
)	1	I-Gene
3	1	I-Gene
and	3	O
transcription	13	B-Gene
factors	7	I-Gene
Stat5a	6	I-Gene
and	3	O
Stat5b	6	B-Gene
are	3	O
essential	9	O
for	3	O
the	3	O
proliferation	13	O
of	2	O
normal	6	O
T	1	O
cells	5	O
and	3	O
are	3	O
constitutively	14	O
hyperactivated	14	O
in	2	O
both	4	O
HTLV-1	6	O
-transformed	12	O
human	5	O
T	1	O
cell	4	O
lines	5	O
and	3	O
lymphocytes	11	O
isolated	8	O
from	4	O
HTLV-1	6	O
-infected	9	O
patients	8	O
;	1	O
therefore	9	O
,	1	O
a	1	O
critical	8	O
role	4	O
for	3	O
the	3	O
Jak3-Stat5	10	B-Gene
pathway	7	O
in	2	O
the	3	O
progression	11	O
of	2	O
this	4	O
disease	7	O
has	3	O
been	4	O
postulated	10	O
.	1	O

We	2	O
recently	8	O
reported	8	O
that	4	O
tyrphostin	10	B-Chemical
AG-490	6	I-Chemical
selectively	11	O
blocked	7	O
IL-2	4	B-Gene
activation	10	O
of	2	O
Jak3	4	B-Gene
/	1	I-Gene
Stat5	5	I-Gene
and	3	O
growth	6	O
of	2	O
murine	6	O
T	1	O
cell	4	O
lines	5	O
.	1	O

Here	4	O
we	2	O
demonstrate	11	O
that	4	O
disruption	10	O
of	2	O
Jak3	4	B-Gene
/	1	I-Gene
Stat5a	6	I-Gene
/	1	I-Gene
b	1	I-Gene
signaling	9	O
with	4	O
AG-490	6	B-Chemical
(	1	O
50	2	O
&	1	O
mgr	3	O
;	1	O
M	1	O
)	1	O
blocked	7	O
the	3	O
proliferation	13	O
of	2	O
primary	7	O
human	5	O
T	1	O
lymphocytes	11	O
,	1	O
but	3	O
paradoxically	13	O
failed	6	O
to	2	O
inhibit	7	O
the	3	O
proliferation	13	O
of	2	O
HTLV-1	6	O
-transformed	12	O
human	5	O
T	1	O
cell	4	O
lines	5	O
,	1	O
HuT-102	7	O
and	3	O
MT-2	4	O
.	1	O

Structural	10	O
homologues	10	O
of	2	O
AG-490	6	B-Chemical
also	4	O
inhibited	9	O
the	3	O
proliferation	13	O
of	2	O
primary	7	O
human	5	O
T	1	O
cells	5	O
,	1	O
but	3	O
not	3	O
HTLV-1	6	O
-infected	9	O
cells	5	O
.	1	O

Disruption	10	O
of	2	O
constitutive	12	O
Jak3	4	B-Gene
/	1	I-Gene
Stat5	5	I-Gene
activation	10	O
by	2	O
AG-490	6	B-Chemical
was	3	O
demonstrated	12	O
by	2	O
inhibition	10	O
of	2	O
1	1	O
)	1	O
tyrosine	8	B-Chemical
phosphorylation	15	O
of	2	O
Jak3	4	B-Gene
,	1	O
Stat5a	6	B-Gene
(	1	O
Tyr	3	B-Chemical
(	1	O
694	3	O
)	1	O
)	1	O
,	1	O
and	3	O
Stat5b	6	B-Gene
(	1	O
Tyr	3	B-Chemical
(	1	O
699	3	O
)	1	O
)	1	O
;	1	O
2	1	O
)	1	O
serine	6	B-Chemical
phosphorylation	15	O
of	2	O
Stat5a	6	B-Gene
(	1	O
Ser	3	B-Chemical
(	1	O
726	3	O
)	1	O
)	1	O
as	2	O
determined	10	O
by	2	O
a	1	O
novel	5	O
phosphospecific	15	O
Ab	2	O
;	1	O
and	3	O
3	1	O
)	1	O
Stat5a	6	B-Gene
/	1	I-Gene
b	1	I-Gene
DNA	3	I-Gene
binding	7	O
to	2	O
the	3	O
Stat5	5	B-Gene
-responsive	11	O
beta-casein	11	B-Gene
promoter	8	I-Gene
.	1	O

In	2	O
contrast	8	O
,	1	O
AG-490	6	B-Chemical
had	3	O
no	2	O
effect	6	O
on	2	O
DNA	3	O
binding	7	O
by	2	O
p50	3	B-Gene
/	1	I-Gene
p65	3	I-Gene
components	10	I-Gene
of	2	O
NF-kappaB	9	B-Gene
,	1	O
a	1	O
transcription	13	O
factor	6	O
activated	9	O
by	2	O
the	3	O
HTLV-1	6	O
-encoded	8	O
phosphoprotein	14	O
,	1	O
Tax	3	B-Gene
.	1	O

Collectively	12	O
,	1	O
these	5	O
data	4	O
suggest	7	O
that	4	O
the	3	O
Jak3-Stat5	10	B-Gene
pathway	7	O
in	2	O
HTLV-1	6	O
-transformed	12	O
T	1	O
cells	5	O
has	3	O
become	6	O
functionally	12	O
redundant	9	O
for	3	O
proliferation	13	O
.	1	O

Reversal	8	O
of	2	O
this	4	O
functional	10	O
uncoupling	10	O
may	3	O
be	2	O
required	8	O
before	6	O
Jak3	4	B-Gene
/	1	I-Gene
Stat5	5	I-Gene
inhibitors	10	O
will	4	O
be	2	O
useful	6	O
in	2	O
the	3	O
treatment	9	O
of	2	O
this	4	O
malignancy	10	B-Disease
.	1	O

Characterization	16	O
of	2	O
IL-4	4	B-Gene
and	3	O
IL-13	5	B-Gene
signals	7	O
dependent	9	O
on	2	O
the	3	O
human	5	B-Gene
IL-13	5	I-Gene
receptor	8	I-Gene
alpha	5	I-Gene
chain	5	I-Gene
1	1	I-Gene
:	1	O
redundancy	10	O
of	2	O
requirement	11	O
of	2	O
tyrosine	8	B-Chemical
residue	7	I-Chemical
for	3	O
STAT3	5	B-Gene
activation	10	O
.	1	O

IL-4	4	B-Gene
and	3	O
IL-13	5	B-Gene
are	3	O
pleiotropic	11	O
cytokines	9	O
whose	5	O
biological	10	O
activities	10	O
overlap	7	O
with	4	O
each	4	O
other	5	O
.	1	O

IL-13	5	B-Gene
receptor	8	I-Gene
alpha	5	I-Gene
chain	5	I-Gene
1	1	I-Gene
(	1	O
IL-13R	6	B-Gene
alpha	5	I-Gene
1	1	I-Gene
)	1	O
is	2	O
necessary	9	O
for	3	O
binding	7	O
to	2	O
IL-13	5	B-Gene
,	1	O
and	3	O
the	3	O
heterodimer	11	O
composed	8	O
of	2	O
IL-13R	6	B-Gene
alpha	5	I-Gene
1	1	I-Gene
and	3	O
IL-4R	5	B-Gene
alpha	5	I-Gene
chain	5	I-Gene
transduces	10	O
IL-13	5	B-Gene
and	3	O
IL-4	4	B-Gene
signals	7	O
;	1	O
however	7	O
,	1	O
the	3	O
functional	10	O
mapping	7	O
of	2	O
the	3	O
intracellular	13	O
domain	6	O
of	2	O
IL-13R	6	B-Gene
alpha	5	I-Gene
1	1	I-Gene
is	2	O
not	3	O
fully	5	O
understood	10	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
we	2	O
constructed	11	O
wild	4	O
and	3	O
mutated	7	O
types	5	O
of	2	O
human	5	B-Gene
IL-13R	6	I-Gene
alpha	5	I-Gene
1	1	I-Gene
,	1	O
and	3	O
analyzed	8	O
IL-4	4	B-Gene
and	3	O
IL-13	5	B-Gene
signals	7	O
using	5	O
an	2	O
IL-13R	6	B-Gene
alpha	5	I-Gene
1	1	I-Gene
-transfected	12	O
human	5	O
B	1	O
cell	4	O
line	4	O
.	1	O

Expression	10	O
of	2	O
IL-13R	6	B-Gene
alpha	5	I-Gene
1	1	I-Gene
evoked	6	O
STAT3	5	B-Gene
activation	10	O
by	2	O
IL-4	4	B-Gene
and	3	O
IL-13	5	B-Gene
,	1	O
and	3	O
in	2	O
stimulated	10	O
human	5	O
B	1	O
cells	5	O
,	1	O
on	2	O
which	5	O
IL-13R	6	B-Gene
alpha	5	I-Gene
1	1	I-Gene
was	3	O
highly	6	O
expressed	9	O
,	1	O
IL-4	4	B-Gene
and	3	O
IL-13	5	B-Gene
induced	7	O
STAT3	5	B-Gene
activation	10	O
.	1	O

Replacement	11	O
of	2	O
the	3	O
two	3	O
tyrosine	8	B-Chemical
residues	8	I-Chemical
completely	10	O
abolished	9	O
STAT3	5	B-Gene
activation	10	O
,	1	O
although	8	O
replacing	9	O
either	6	O
tyrosine	8	B-Chemical
residue	7	I-Chemical
alone	5	O
retained	8	O
it	2	O
.	1	O

Furthermore	11	O
,	1	O
we	2	O
found	5	O
that	4	O
the	3	O
Box1	4	O
region	6	O
and	3	O
the	3	O
C-terminal	10	O
tail	4	O
of	2	O
IL-13R	6	B-Gene
alpha	5	I-Gene
1	1	I-Gene
were	4	O
critical	8	O
for	3	O
binding	7	O
to	2	O
Tyk2	4	B-Gene
,	1	O
and	3	O
activation	10	O
of	2	O
Jak1	4	B-Gene
,	1	O
Tyk2	4	B-Gene
,	1	O
the	3	O
insulin	7	B-Gene
receptor	8	I-Gene
substrate-1	11	I-Gene
and	3	O
STAT6	5	B-Gene
respectively	12	O
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
STAT3	5	B-Gene
activation	10	O
is	2	O
involved	8	O
with	4	O
IL-4	4	B-Gene
and	3	O
IL-13	5	B-Gene
signals	7	O
in	2	O
human	5	O
B	1	O
cells	5	O
along	5	O
with	4	O
the	3	O
activation	10	O
of	2	O
STAT6	5	B-Gene
,	1	O
and	3	O
that	4	O
there	5	O
is	2	O
a	1	O
unique	6	O
sequence	8	O
in	2	O
IL-13R	6	B-Gene
alpha	5	I-Gene
1	1	I-Gene
to	2	O
activate	8	O
STAT3	5	B-Gene
.	1	O

Effects	7	O
of	2	O
deregulated	11	O
Raf	3	B-Gene
activation	10	O
on	2	O
integrin	8	B-Gene
,	1	O
cytokine-receptor	17	B-Gene
expression	10	O
and	3	O
the	3	O
induction	9	O
of	2	O
apoptosis	9	O
in	2	O
hematopoietic	13	O
cells	5	O
.	1	O

The	3	O
effects	7	O
of	2	O
deregulated	11	O
Raf	3	B-Gene
activation	10	O
on	2	O
the	3	O
growth	6	O
and	3	O
differentiation	15	O
of	2	O
hematopoietic	13	O
cells	5	O
were	4	O
investigated	12	O
.	1	O

The	3	O
cytokine	8	O
-dependent	10	O
murine	6	O
myeloid	7	O
FDC-P1	6	O
and	3	O
human	5	O
erythroleukemic	15	O
TF-1	4	O
cell	4	O
lines	5	O
were	4	O
transformed	11	O
to	2	O
grow	4	O
in	2	O
response	8	O
to	2	O
deregulated	11	O
Raf	3	B-Gene
expression	10	O
in	2	O
the	3	O
absence	7	O
of	2	O
exogenous	9	O
cytokines	9	O
.	1	O

The	3	O
conditionally	13	O
active	6	O
Raf	3	B-Gene
proteins	8	I-Gene
were	4	O
regulated	9	O
by	2	O
beta-estradiol	14	B-Chemical
as	2	O
cDNAs	5	O
containing	10	O
the	3	O
Raf	3	B-Gene
catalytic	9	O
,	1	O
but	3	O
lacking	7	O
negative-regulatory	19	O
domains	7	O
,	1	O
were	4	O
ligated	7	O
to	2	O
the	3	O
hormone	7	O
binding	7	O
domain	6	O
of	2	O
the	3	O
estrogen	8	B-Gene
receptor	8	I-Gene
(	1	O
deltaRaf	8	B-Gene
:	1	O
ER	2	B-Gene
)	1	O
.	1	O

Continuous	10	O
deltaRaf	8	B-Gene
expression	10	O
prevented	9	O
apoptosis	9	O
in	2	O
the	3	O
absence	7	O
of	2	O
exogenous	9	O
cytokines	9	O
and	3	O
altered	7	O
the	3	O
morphology	10	O
of	2	O
the	3	O
FD	2	O
/	1	O
deltaRaf	8	B-Gene
:	1	O
ER	2	B-Gene
cells	5	O
as	2	O
they	4	O
grew	4	O
in	2	O
large	5	O
aggregated	10	O
masses	6	O
(	1	O
>	1	O
100	3	O
cells	5	O
)	1	O
whereas	7	O
the	3	O
parental	8	O
cytokine	8	O
-dependent	10	O
FDC-P1	6	O
cells	5	O
grew	4	O
in	2	O
smaller	7	O
grape	5	O
-like	5	O
clusters	8	O
(	1	O
<	1	O
10	2	O
cells	5	O
)	1	O
.	1	O

FD	2	O
/	1	O
deltaRaf-1	10	B-Gene
:	1	O
ER	2	B-Gene
cells	5	O
growing	7	O
in	2	O
response	8	O
to	2	O
Raf	3	B-Gene
activation	10	O
displayed	9	O
decreased	9	O
levels	6	O
of	2	O
the	3	O
Mac-2	5	B-Gene
and	3	O
Mac-3	5	B-Gene
molecules	9	O
on	2	O
their	5	O
cell	4	O
surface	7	O
.	1	O

In	2	O
contrast	8	O
,	1	O
when	4	O
these	5	O
cells	5	O
were	4	O
cultured	8	O
in	2	O
IL-3	4	B-Gene
,	1	O
higher	6	O
levels	6	O
of	2	O
these	5	O
adhesion	8	O
molecules	9	O
were	4	O
detected	8	O
.	1	O

Expression	10	O
of	2	O
activated	9	B-Gene
Raf	3	I-Gene
oncoproteins	12	I-Gene
also	4	O
abrogated	9	O
cytokine	8	O
dependency	10	O
and	3	O
prevented	9	O
apoptosis	9	O
of	2	O
TF-1	4	O
cells	5	O
.	1	O

Moreover	8	O
,	1	O
the	3	O
differentiation	15	O
status	6	O
of	2	O
these	5	O
Raf	3	B-Gene
-responsive	11	O
cells	5	O
was	3	O
more	4	O
immature	8	O
upon	4	O
Raf	3	B-Gene
activation	10	O
as	2	O
culture	7	O
with	4	O
the	3	O
differentiation	15	O
-inducing	9	O
agent	5	O
phorbol	7	B-Chemical
12	2	I-Chemical
myristate	9	I-Chemical
13-acetate	10	I-Chemical
(	1	O
PMA	3	B-Chemical
)	1	O
and	3	O
beta-estradiol	14	B-Chemical
resulted	8	O
in	2	O
decreased	9	O
levels	6	O
of	2	O
the	3	O
CD11b	5	B-Gene
and	3	O
CD18	4	B-Gene
integrin	8	I-Gene
molecules	9	O
on	2	O
the	3	O
cell	4	O
surface	7	O
.	1	O

In	2	O
contrast	8	O
when	4	O
the	3	O
Raf	3	B-Gene
-responsive	11	O
cells	5	O
were	4	O
induced	7	O
to	2	O
differentiate	13	O
with	4	O
PMA	3	B-Chemical
and	3	O
GM-CSF	6	B-Gene
,	1	O
in	2	O
the	3	O
absence	7	O
of	2	O
deltaRaf	8	B-Gene
:	1	O
ER	2	B-Gene
activation	10	O
,	1	O
increased	9	O
levels	6	O
of	2	O
the	3	O
CD11b	5	B-Gene
and	3	O
CD18	4	B-Gene
molecules	9	O
were	4	O
detected	8	O
.	1	O

Retinoic	8	B-Chemical
acid	4	I-Chemical
(	1	O
RA	2	B-Chemical
)	1	O
inhibited	9	O
3H-thymidine	12	B-Chemical
incorporation	13	O
in	2	O
response	8	O
to	2	O
GM-CSF	6	B-Gene
.	1	O

Interestingly	13	O
,	1	O
Raf	3	B-Gene
activation	10	O
counterbalanced	15	O
the	3	O
inhibition	10	O
of	2	O
DNA	3	O
synthesis	9	O
caused	6	O
by	2	O
RA	2	B-Chemical
but	3	O
not	3	O
PMA	3	B-Chemical
.	1	O

Thus	4	O
deregulated	11	O
Raf	3	B-Gene
expression	10	O
can	3	O
alter	5	O
cytokine	8	O
dependency	10	O
,	1	O
integrin	8	B-Gene
expression	10	O
and	3	O
the	3	O
stage	5	O
of	2	O
differentiation	15	O
.	1	O

These	5	O
Raf	3	B-Gene
-responsive	11	O
cell	4	O
lines	5	O
will	4	O
be	2	O
useful	6	O
in	2	O
elucidating	11	O
the	3	O
roles	5	O
of	2	O
the	3	O
MAP	3	B-Gene
kinase	6	I-Gene
cascade	7	O
on	2	O
hematopoietic	13	O
cell	4	O
differentiation	15	O
and	3	O
malignant	9	O
transformation	14	O

Cyclic	6	B-Chemical
AMP	3	I-Chemical
activates	9	O
p38	3	B-Gene
mitogen	7	I-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
in	2	O
Th2	3	O
cells	5	O
:	1	O
phosphorylation	15	O
of	2	O
GATA-3	6	B-Gene
and	3	O
stimulation	11	O
of	2	O
Th2	3	O
cytokine	8	O
gene	4	O
expression	10	O
.	1	O

cAMP	4	B-Chemical
is	2	O
an	2	O
important	9	O
second	6	O
messenger	9	O
with	4	O
immunomodulatory	16	O
properties	10	O
.	1	O

Elevation	9	O
of	2	O
intracellular	13	O
cAMP	4	B-Chemical
in	2	O
T	1	O
cells	5	O
,	1	O
induced	7	O
by	2	O
agents	6	O
such	4	O
as	2	O
IL-1alpha	9	B-Gene
or	2	O
PGs	3	B-Chemical
,	1	O
inhibits	8	O
T	1	O
cell	4	O
activation	10	O
.	1	O

In	2	O
effector	8	O
T	1	O
cells	5	O
,	1	O
an	2	O
increase	8	O
in	2	O
the	3	O
level	5	O
of	2	O
intracellular	13	O
cAMP	4	B-Chemical
inhibits	8	O
cytokine	8	O
production	10	O
in	2	O
Th1	3	O
cells	5	O
but	3	O
stimulates	10	O
cytokine	8	O
production	10	O
in	2	O
Th2	3	O
cells	5	O
.	1	O

Here	4	O
we	2	O
report	6	O
that	4	O
cAMP	4	B-Chemical
-induced	8	O
effects	7	O
in	2	O
Th2	3	O
cells	5	O
occur	5	O
independently	13	O
of	2	O
the	3	O
protein	7	B-Gene
kinase	6	I-Gene
A	1	I-Gene
pathway	7	O
,	1	O
which	5	O
is	2	O
the	3	O
major	5	O
mediator	8	O
of	2	O
cAMP	4	B-Chemical
-induced	8	O
signaling	9	O
events	6	O
in	2	O
most	4	O
cell	4	O
types	5	O
.	1	O

Instead	7	O
,	1	O
cAMP	4	B-Chemical
stimulates	10	O
activation	10	O
of	2	O
p38	3	B-Gene
mitogen	7	I-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
in	2	O
Th2	3	O
cells	5	O
.	1	O

This	4	O
appears	7	O
to	2	O
be	2	O
a	1	O
Th2	3	O
-selective	10	O
event	5	O
because	7	O
cAMP	4	B-Chemical
barely	6	O
increased	9	O
p38	3	B-Gene
phosphorylation	15	O
in	2	O
Th1	3	O
cells	5	O
.	1	O

We	2	O
show	4	O
that	4	O
in	2	O
Th2	3	O
cells	5	O
,	1	O
cAMP	4	B-Chemical
promotes	8	O
the	3	O
production	10	O
of	2	O
both	4	O
IL-5	4	B-Gene
and	3	O
IL-13	5	B-Gene
,	1	O
which	5	O
play	4	O
distinct	8	O
but	3	O
critical	8	O
roles	5	O
in	2	O
asthma	6	B-Disease
pathogenesis	12	O
.	1	O

Our	3	O
data	4	O
also	4	O
show	4	O
that	4	O
cAMP	4	B-Chemical
causes	6	O
increased	9	O
phosphorylation	15	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
GATA-3	6	I-Gene
,	1	O
which	5	O
we	2	O
have	4	O
shown	5	O
is	2	O
a	1	O
critical	8	O
regulator	9	O
of	2	O
Th2	3	O
cytokine	8	O
gene	4	O
expression	10	O
and	3	O
,	1	O
in	2	O
turn	4	O
,	1	O
of	2	O
airway	6	B-Disease
inflammation	12	I-Disease
in	2	O
mice	4	O
.	1	O

Thus	4	O
,	1	O
Th2	3	O
-specific	9	O
GATA-3	6	B-Gene
expression	10	O
and	3	O
p38	3	B-Gene
mitogen	7	I-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
activation	10	O
together	8	O
provide	7	O
a	1	O
molecular	9	O
basis	5	O
for	3	O
the	3	O
differential	12	O
effects	7	O
of	2	O
cAMP	4	B-Chemical
in	2	O
the	3	O
two	3	O
T	1	O
helper	6	O
cell	4	O
subsets	7	O
.	1	O

2	1	B-Chemical
,	1	I-Chemical
2',	3	I-Chemical
4	1	I-Chemical
,	1	I-Chemical
6	1	I-Chemical
,	1	I-Chemical
6'-pentachlorobiphenyl	22	I-Chemical
induces	7	O
apoptosis	9	O
in	2	O
human	5	O
monocytic	9	O
cells	5	O
.	1	O

Polychlorinatedbiphenyls	24	B-Chemical
(	1	O
PCBs	4	B-Chemical
)	1	O
are	3	O
a	1	O
group	5	O
of	2	O
persistent	10	O
and	3	O
widely	6	O
dispersed	9	O
environmental	13	O
pollutants	10	O
,	1	O
some	4	O
of	2	O
which	5	O
may	3	O
be	2	O
immunotoxic	11	O
.	1	O

In	2	O
the	3	O
present	7	O
study	5	O
,	1	O
we	2	O
investigated	12	O
the	3	O
effect	6	O
of	2	O
PCBs	4	B-Chemical
on	2	O
immune	6	O
system	6	O
by	2	O
assessing	9	O
apoptotic	9	O
cell	4	O
death	5	O
in	2	O
human	5	O
monocytic	9	O
U937	4	O
cells	5	O
.	1	O

Among	5	O
the	3	O
various	7	O
congeners	9	O
tested	6	O
,	1	O
2	1	B-Chemical
,	1	I-Chemical
2',	3	I-Chemical
4	1	I-Chemical
,	1	I-Chemical
6	1	I-Chemical
,	1	I-Chemical
6'-pentachlorobiphenyl	22	I-Chemical
(	1	O
PeCB	4	B-Chemical
)	1	O
,	1	O
a	1	O
highly	6	O
ortho	5	O
-substituted	12	O
congener	8	O
,	1	O
specifically	12	O
induced	7	O
DNA	3	O
fragmentation	13	O
,	1	O
a	1	O
hallmark	8	O
of	2	O
apoptosis	9	O
,	1	O
while	5	O
the	3	O
other	5	O
examined	8	O
di-	3	O
,	1	O
tri-	4	O
,	1	O
tetra-	6	O
,	1	O
and	3	O
pentachlorobiphenyls	20	B-Chemical
did	3	O
not	3	O
.	1	O

To	2	O
further	7	O
study	5	O
the	3	O
2	1	B-Chemical
,	1	I-Chemical
2',	3	I-Chemical
4	1	I-Chemical
,	1	I-Chemical
6	1	I-Chemical
,	1	I-Chemical
6'-PeCB	7	I-Chemical
-induced	8	O
cell	4	O
death	5	O
,	1	O
various	7	O
features	8	O
of	2	O
apoptosis	9	O
were	4	O
examined	8	O
.	1	O

2	1	B-Chemical
,	1	I-Chemical
2',	3	I-Chemical
4	1	I-Chemical
,	1	I-Chemical
6	1	I-Chemical
,	1	I-Chemical
6'-PeCB	7	I-Chemical
caused	6	O
a	1	O
decrease	8	O
in	2	O
cell	4	O
viability	9	O
and	3	O
induced	7	O
cellular	8	O
morphologic	11	O
features	8	O
characteristic	14	O
of	2	O
apoptosis	9	O
such	4	O
as	2	O
chromatin	9	O
aggregation	11	O
and	3	O
apoptotic	9	O
bodies	6	O
.	1	O

In	2	O
addition	8	O
,	1	O
caspase-3	9	B-Gene
,	1	O
an	2	O
executioner	11	O
of	2	O
apoptosis	9	O
,	1	O
was	3	O
activated	9	O
and	3	O
its	3	O
substrate	9	O
,	1	O
poly	4	B-Gene
(	1	I-Gene
ADP-ribose	10	I-Gene
)	1	I-Gene
polymerase	10	I-Gene
(	1	O
PARP	4	B-Gene
)	1	O
,	1	O
was	3	O
cleaved	7	O
during	6	O
2	1	B-Chemical
,	1	I-Chemical
2',	3	I-Chemical
4	1	I-Chemical
,	1	I-Chemical
6	1	I-Chemical
,	1	I-Chemical
6'-PeCB	7	I-Chemical
-induced	8	O
apoptosis	9	O
.	1	O

In	2	O
contrast	8	O
,	1	O
3	1	B-Chemical
,	1	I-Chemical
3',	3	I-Chemical
4	1	I-Chemical
,	1	I-Chemical
4',	3	I-Chemical
5-PeCB	6	I-Chemical
,	1	O
a	1	O
congener	8	O
of	2	O
coplanar	8	O
structure	9	O
,	1	O
as	2	O
well	4	O
as	2	O
2	1	B-Chemical
,	1	I-Chemical
3	1	I-Chemical
,	1	I-Chemical
7	1	I-Chemical
,	1	I-Chemical
8-TCDD	6	I-Chemical
did	3	O
not	3	O
induce	6	O
apoptosis	9	O
in	2	O
these	5	O
human	5	O
monocytic	9	O
cells	5	O
,	1	O
although	8	O
they	4	O
potently	8	O
induced	7	O
CYP	3	B-Gene
1A1	3	I-Gene
in	2	O
human	5	O
hepatoma	8	B-Disease
Hep	3	O
G2	2	O
cells	5	O
.	1	O

Taken	5	O
together	8	O
,	1	O
the	3	O
data	4	O
indicate	8	O
that	4	O
2	1	B-Chemical
,	1	I-Chemical
2',	3	I-Chemical
4	1	I-Chemical
,	1	I-Chemical
6	1	I-Chemical
,	1	I-Chemical
6'-PeCB	7	I-Chemical
induces	7	O
apoptosis	9	O
in	2	O
human	5	O
monocytic	9	O
cells	5	O
through	7	O
a	1	O
mechanism	9	O
that	4	O
is	2	O
independent	11	O
of	2	O
the	3	O
arylhydrocarbon	15	B-Gene
receptor	8	I-Gene
.	1	O

This	4	O
suggests	8	O
a	1	O
possibly	8	O
separate	8	O
mechanism	9	O
by	2	O
which	5	O
PCBs	4	B-Chemical
cause	5	O
immunosuppression	17	O
.	1	O

Activation	10	O
of	2	O
oncogenic	9	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
AP-1	4	I-Gene
in	2	O
T	1	O
cells	5	O
infected	8	O
with	4	O
human	5	O
T	1	B-Disease
cell	4	I-Disease
leukemia	8	I-Disease
virus	5	O
type	4	O
1	1	O
.	1	O

Human	5	B-Gene
T	1	I-Gene
cell	4	I-Gene
leukemia	8	I-Gene
virus	5	I-Gene
type	4	I-Gene
1	1	I-Gene
(	1	I-Gene
HTLV-1	6	I-Gene
)	1	I-Gene
Tax	3	I-Gene
protein	7	I-Gene
transforms	10	O
primary	7	O
human	5	O
T	1	O
cells	5	O
in	2	O
vitro	5	O
.	1	O

We	2	O
previously	10	O
showed	6	O
that	4	O
Tax	3	B-Gene
induces	7	O
the	3	O
expression	10	O
of	2	O
various	7	O
family	6	O
members	7	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
AP-1	4	I-Gene
such	4	O
as	2	O
c-Jun	5	B-Gene
,	1	O
JunD	4	B-Gene
,	1	O
c-Fos	5	B-Gene
,	1	O
and	3	O
Fra-1	5	B-Gene
at	2	O
the	3	O
mRNA	4	O
level	5	O
in	2	O
T	1	O
cells	5	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
we	2	O
have	4	O
examined	8	O
the	3	O
ability	7	O
of	2	O
Tax	3	B-Gene
to	2	O
activate	8	O
transcription	13	O
through	7	O
the	3	O
AP-1	4	B-Gene
-binding	8	O
site	4	O
(	1	O
AP-1	4	B-Gene
site	4	O
)	1	O
.	1	O

A	1	O
transient	9	O
transfection	12	O
study	5	O
showed	6	O
that	4	O
Tax	3	B-Gene
can	3	O
activate	8	O
transcription	13	O
through	7	O
the	3	O
AP-1	4	B-Gene
-binding	8	O
site	4	O
in	2	O
a	1	O
human	5	O
T	1	O
cell	4	O
line	4	O
,	1	O
whereas	7	O
any	3	O
combination	11	O
of	2	O
AP-1	4	B-Gene
proteins	8	I-Gene
did	3	O
so	2	O
much	4	O
less	4	O
than	4	O
Tax	3	B-Gene
,	1	O
indicating	10	O
that	4	O
the	3	O
activation	10	O
of	2	O
the	3	O
AP-1	4	B-Gene
site	4	O
by	2	O
Tax	3	B-Gene
may	3	O
require	7	O
a	1	O
mechanism	9	O
other	5	O
than	4	O
the	3	O
induction	9	O
of	2	O
AP-1	4	B-Gene
mRNA	4	I-Gene
.	1	O

Fresh	5	O
peripheral	10	O
blood	5	O
leukemia	8	B-Disease
cells	5	O
of	2	O
all	3	O
surveyed	8	O
ATL	3	B-Disease
patients	8	O
displayed	9	O
constitutive	12	O
AP-1	4	B-Gene
DNA	3	I-Gene
-binding	8	O
activity	8	O
,	1	O
whereas	7	O
no	2	O
normal	6	O
individuals	11	O
did	3	O
.	1	O

However	7	O
,	1	O
the	3	O
HTLV-1	6	O
genes	5	O
,	1	O
including	9	O
tax	3	B-Gene
,	1	O
are	3	O
not	3	O
significantly	13	O
expressed	9	O
in	2	O
fresh	5	O
leukemia	8	B-Disease
cells	5	O
from	4	O
ATL	3	B-Disease
patients	8	O
.	1	O

Our	3	O
present	7	O
results	7	O
suggest	7	O
that	4	O
activation	10	O
of	2	O
AP-1	4	B-Gene
occurs	6	O
through	7	O
Tax	3	B-Gene
-dependent	10	O
and	3	O
-independent	12	O
mechanisms	10	O
in	2	O
HTLV-1	6	O
-infected	9	O
T	1	O
cells	5	O
,	1	O
which	5	O
may	3	O
play	4	O
some	4	O
roles	5	O
in	2	O
dysregulated	12	O
phenotypes	10	O
of	2	O
HTLV-1	6	O
-infected	9	O
cells	5	O
.	1	O

Cutting	7	O
edge	4	O
:	1	O
STAT6	5	B-Gene
-deficient	10	O
mice	4	O
have	4	O
enhanced	8	O
tumor	5	B-Disease
immunity	8	O
to	2	O
primary	7	O
and	3	O
metastatic	10	O
mammary	7	B-Disease
carcinoma	9	I-Disease
.	1	O

STAT4	5	B-Gene
and	3	O
STAT6	5	B-Gene
are	3	O
essential	9	O
for	3	O
the	3	O
development	11	O
of	2	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
Th1	3	O
and	3	O
Th2	3	O
development	11	O
,	1	O
respectively	12	O
.	1	O

Tumor	5	B-Disease
immunologists	13	O
have	4	O
hypothesized	12	O
that	4	O
Th1	3	O
cells	5	O
are	3	O
critical	8	O
in	2	O
tumor	5	B-Disease
immunity	8	O
because	7	O
they	4	O
facilitate	10	O
differentiation	15	O
of	2	O
CD8	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
T	1	O
cells	5	O
,	1	O
which	5	O
are	3	O
potent	6	O
anti-tumor	10	B-Disease
effectors	9	O
.	1	O

We	2	O
have	4	O
used	4	O
STAT4	5	B-Gene
(	1	I-Gene
-	1	I-Gene
/	1	I-Gene
-	1	I-Gene
)	1	I-Gene
and	3	O
STAT6	5	B-Gene
(	1	I-Gene
-	1	I-Gene
/	1	I-Gene
-	1	I-Gene
)	1	I-Gene
mice	4	O
to	2	O
test	4	O
this	4	O
hypothesis	10	O
.	1	O

BALB	4	O
/	1	O
c	1	O
and	3	O
knockout	8	O
mice	4	O
were	4	O
challenged	10	O
in	2	O
the	3	O
mammary	7	O
gland	5	O
with	4	O
the	3	O
highly	6	O
malignant	9	O
and	3	O
spontaneously	13	O
metastatic	10	O
BALB	4	O
/	1	O
c	1	O
-derived	8	O
4T1	3	O
mammary	7	B-Disease
carcinoma	9	I-Disease
.	1	O

Primary	7	O
tumor	5	B-Disease
growth	6	O
and	3	O
metastatic	10	O
disease	7	O
are	3	O
reduced	7	O
in	2	O
STAT6	5	B-Gene
(	1	I-Gene
-	1	I-Gene
/	1	I-Gene
-	1	I-Gene
)	1	I-Gene
mice	4	O
relative	8	O
to	2	O
BALB	4	O
/	1	O
c	1	O
and	3	O
STAT4	5	B-Gene
(	1	I-Gene
-	1	I-Gene
/	1	I-Gene
-	1	I-Gene
)	1	I-Gene
mice	4	O
.	1	O

Ab	2	O
depletions	10	O
demonstrate	11	O
that	4	O
the	3	O
effect	6	O
is	2	O
mediated	8	O
by	2	O
CD8	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
T	1	O
cells	5	O
,	1	O
and	3	O
immunized	9	O
STAT6	5	B-Gene
(	1	I-Gene
-	1	I-Gene
/	1	I-Gene
-	1	I-Gene
)	1	I-Gene
mice	4	O
have	4	O
higher	6	O
levels	6	O
of	2	O
4T1-specific	12	O
CTL	3	O
than	4	O
BALB	4	O
/	1	O
c	1	O
or	2	O
STAT4	5	B-Gene
(	1	I-Gene
-	1	I-Gene
/	1	I-Gene
-	1	I-Gene
)	1	I-Gene
mice	4	O
.	1	O

Surprisingly	12	O
,	1	O
Th1	3	O
or	2	O
Th2	3	O
cells	5	O
are	3	O
not	3	O
involved	8	O
,	1	O
because	7	O
CD4	3	B-Gene
depletion	9	O
does	4	O
not	3	O
diminish	8	O
the	3	O
anti-tumor	10	B-Disease
effect	6	O
.	1	O

Therefore	9	O
,	1	O
deletion	8	O
of	2	O
the	3	O
STAT6	5	B-Gene
gene	4	I-Gene
facilitates	11	O
development	11	O
of	2	O
potent	6	O
anti-tumor	10	B-Disease
immunity	8	O
via	3	O
a	1	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
-independent	12	O
pathway	7	O
.	1	O

hsp70	5	B-Gene
interacting	11	I-Gene
protein	7	I-Gene
Hip	3	I-Gene
does	4	O
not	3	O
affect	6	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
folding	7	O
by	2	O
the	3	O
hsp90	5	B-Gene
-based	6	I-Gene
chaperone	9	I-Gene
machinery	9	O
except	6	O
to	2	O
oppose	6	O
the	3	O
effect	6	O
of	2	O
BAG-1	5	B-Gene
.	1	O

Reticulocyte	12	O
lysate	6	O
contains	8	O
a	1	O
chaperone	9	O
system	6	O
that	4	O
assembles	9	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
(	1	I-Gene
GR	2	I-Gene
)	1	I-Gene
.hsp90	6	I-Gene
heterocomplexes	15	I-Gene
.	1	O

Using	5	O
purified	8	O
proteins	8	O
,	1	O
we	2	O
have	4	O
prepared	8	O
a	1	O
five-protein	12	O
heterocomplex	13	O
assembly	8	O
system	6	O
consisting	10	O
of	2	O
two	3	O
proteins	8	O
essential	9	O
for	3	O
heterocomplex	13	O
assembly-	9	O
hsp90	5	B-Gene
and	3	O
hsp70	5	B-Gene
-and	4	O
three	5	O
proteins	8	O
that	4	O
act	3	O
as	2	O
co-chaperones	13	O
to	2	O
enhance	7	O
assembly-	9	O
Hop	3	B-Gene
,	1	O
hsp40	5	B-Gene
,	1	O
p23	3	B-Gene
[	1	O
Morishima	9	O
,	1	O
Y.	2	O
,	1	O
Kanelakis	9	O
,	1	O
K.	2	O
C.	2	O
,	1	O
Silverstein	11	O
,	1	O
A.	2	O
M.	2	O
,	1	O
Dittmar	7	O
,	1	O
K.	2	O
D.	2	O
,	1	O
Estrada	7	O
,	1	O
L.	2	O
,	1	O
and	3	O
Pratt	5	O
,	1	O
W.	2	O
B.	2	O
(	1	O
2000	4	O
)	1	O
J.	2	O
Biol.	5	O
Chem.	5	O
275	3	O
,	1	O
6894-6900	9	O
]	1	O
.	1	O

The	3	O
hsp70	5	B-Gene
co-chaperone	12	I-Gene
Hip	3	I-Gene
has	3	O
been	4	O
recovered	9	O
in	2	O
receptor.hsp90	14	B-Gene
heterocomplexes	15	I-Gene
at	2	O
an	2	O
intermediate	12	O
stage	5	O
of	2	O
assembly	8	O
in	2	O
reticulocyte	12	O
lysate	6	O
,	1	O
and	3	O
Hip	3	B-Gene
is	2	O
also	4	O
thought	7	O
to	2	O
be	2	O
an	2	O
intrinsic	9	O
component	9	O
of	2	O
the	3	O
assembly	8	O
machinery	9	O
.	1	O

Here	4	O
we	2	O
show	4	O
that	4	O
immunodepletion	15	O
of	2	O
Hip	3	B-Gene
from	4	O
reticulocyte	12	O
lysate	6	O
or	2	O
addition	8	O
of	2	O
high	4	O
levels	6	O
of	2	O
Hip	3	B-Gene
to	2	O
the	3	O
purified	8	O
five-protein	12	O
system	6	O
does	4	O
not	3	O
affect	6	O
GR.hsp90	8	B-Gene
heterocomplex	13	I-Gene
assembly	8	O
or	2	O
the	3	O
activation	10	O
of	2	O
steroid	7	B-Chemical
binding	7	O
activity	8	O
that	4	O
occurs	6	O
with	4	O
assembly	8	O
.	1	O

Despite	7	O
the	3	O
fact	4	O
that	4	O
Hip	3	B-Gene
does	4	O
not	3	O
affect	6	O
assembly	8	O
,	1	O
it	2	O
is	2	O
recovered	9	O
in	2	O
GR.hsp90	8	B-Gene
heterocomplexes	15	I-Gene
assembled	9	O
by	2	O
both	4	O
systems	7	O
.	1	O

In	2	O
the	3	O
five-protein	12	O
system	6	O
,	1	O
Hip	3	B-Gene
prevents	8	O
inhibition	10	O
of	2	O
assembly	8	O
by	2	O
the	3	O
hsp70	5	B-Gene
co-chaperone	12	I-Gene
BAG-1	5	I-Gene
,	1	O
and	3	O
cotransfection	14	O
of	2	O
Hip	3	B-Gene
with	4	O
BAG-1	5	B-Gene
opposes	7	O
BAG-1	5	B-Gene
reduction	9	O
of	2	O
steroid	7	B-Chemical
binding	7	O
activity	8	O
in	2	O
COS	3	O
cells	5	O
.	1	O

We	2	O
conclude	8	O
that	4	O
Hip	3	B-Gene
is	2	O
not	3	O
a	1	O
component	9	O
of	2	O
the	3	O
assembly	8	O
machinery	9	O
but	3	O
that	4	O
it	2	O
could	5	O
play	4	O
a	1	O
regulatory	10	O
role	4	O
in	2	O
opposition	10	O
to	2	O
BAG-1	5	B-Gene
.	1	O

Identification	14	O
and	3	O
characterization	16	O
of	2	O
SKAT-2	6	B-Gene
,	1	O
a	1	O
novel	5	O
Th2-specific	12	O
zinc	4	O
finger	6	O
gene	4	O
.	1	O

We	2	O
have	4	O
identified	10	O
a	1	O
novel	5	O
Kruppel-type	12	O
zinc	4	O
finger	6	O
(	1	O
ZF	2	O
)	1	O
gene	4	O
,	1	O
SKAT-2	6	B-Gene
,	1	O
which	5	O
is	2	O
selectively	11	O
expressed	9	O
by	2	O
murine	6	O
Th2	3	O
cells	5	O
.	1	O

The	3	O
protein	7	O
encoded	7	O
by	2	O
this	4	O
gene	4	O
has	3	O
14	2	O
C2H2-type	9	O
ZF	2	O
tandemly	8	O
arrayed	7	O
at	2	O
its	3	O
C	1	O
terminus	8	O
and	3	O
N-terminal	10	O
SCAN	4	O
box	3	O
and	3	O
KRAB	4	O
domains	7	O
.	1	O

SKAT-2	6	B-Gene
is	2	O
tissue	6	O
restricted	10	O
in	2	O
expression	10	O
at	2	O
the	3	O
RNA	3	O
level	5	O
,	1	O
detectable	10	O
only	4	O
in	2	O
brain	5	O
and	3	O
at	2	O
low	3	O
levels	6	O
in	2	O
kidney	6	O
and	3	O
spleen	6	O
and	3	O
few	3	O
hematopoietic	13	O
cell	4	O
lines	5	O
.	1	O

By	2	O
in	2	O
situ	4	O
hybridization	13	O
,	1	O
SKAT-2	6	B-Gene
expression	10	O
was	3	O
found	5	O
to	2	O
peak	4	O
in	2	O
antigen	7	O
-stimulated	11	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
T	1	O
cells	5	O
after	5	O
2-3	3	O
days	4	O
of	2	O
culture	7	O
under	5	O
Th2	3	O
but	3	O
not	3	O
Th1	3	O
biasing	7	O
conditions	10	O
.	1	O

This	4	O
pattern	7	O
of	2	O
expression	10	O
closely	7	O
mirrored	8	O
that	4	O
of	2	O
GATA-3	6	B-Gene
in	2	O
the	3	O
same	4	O
cells	5	O
.	1	O

In	2	O
transient	9	O
transfection	12	O
experiments	11	O
in	2	O
phorbol	7	B-Chemical
12-myristate	12	I-Chemical
13-acetate	10	I-Chemical
/	1	O
ionomycin	9	B-Chemical
-stimulated	11	O
EL4	3	O
cells	5	O
,	1	O
SKAT-2	6	B-Gene
was	3	O
found	5	O
to	2	O
up-regulate	11	O
the	3	O
activity	8	O
of	2	O
the	3	O
IL-4	4	B-Gene
but	3	O
not	3	O
the	3	O
IL-5	4	B-Gene
promoter	8	I-Gene
,	1	O
contrasting	11	O
with	4	O
the	3	O
ability	7	O
of	2	O
GATA-3	6	B-Gene
to	2	O
activate	8	O
both	4	O
promoters	9	O
.	1	O

This	4	O
result	6	O
was	3	O
confirmed	9	O
using	5	O
clones	6	O
of	2	O
EL4	3	O
cells	5	O
stably	6	O
expressing	10	O
an	2	O
inducible	9	O
form	4	O
of	2	O
SKAT-2	6	B-Gene
,	1	O
thus	4	O
SKAT-2	6	B-Gene
is	2	O
a	1	O
novel	5	O
Th2-specific	12	O
gene	4	O
that	4	O
may	3	O
play	4	O
a	1	O
role	4	O
in	2	O
selective	9	O
regulation	10	O
of	2	O
cytokine	8	O
genes	5	O
in	2	O
T	1	O
cells	5	O
.	1	O

Adhesion	8	O
of	2	O
immature	8	O
and	3	O
mature	6	O
T	1	O
cells	5	O
induces	7	O
in	2	O
human	5	O
thymic	6	O
epithelial	10	O
cells	5	O
(	1	O
TEC	3	O
)	1	O
activation	10	O
of	2	O
IL-6	4	B-Gene
gene	4	I-Gene
trascription	12	I-Gene
factors	7	I-Gene
(	1	O
NF-kappaB	9	B-Gene
and	3	O
NF-IL6	6	B-Gene
)	1	O
and	3	O
IL-6	4	B-Gene
gene	4	I-Gene
expression	10	O
:	1	O
role	4	O
of	2	O
alpha3beta1	11	B-Partial_Gene
and	3	O
alpha6beta4	11	B-Gene
integrins	9	I-Gene
.	1	O

T	1	O
cell	4	O
precursors	10	O
homed	5	O
to	2	O
thymus	6	O
develop	7	O
in	2	O
close	5	O
contact	7	O
with	4	O
stromal	7	O
cells	5	O
.	1	O

Among	5	O
them	4	O
,	1	O
thymic	6	O
epithelial	10	O
cells	5	O
(	1	O
TEC	3	O
)	1	O
are	3	O
known	5	O
to	2	O
exert	5	O
dominant	8	O
roles	5	O
in	2	O
their	5	O
survival	8	O
and	3	O
functional	10	O
shaping	7	O
.	1	O

Key	3	O
molecules	9	O
mediating	9	O
TEC	3	O
/	1	O
thymocytes	10	O
interactions	12	O
include	7	O
cytokines	9	O
and	3	O
growth	6	O
factors	7	O
secreted	8	O
by	2	O
the	3	O
two	3	O
cell	4	O
types	5	O
and	3	O
adhesion	8	O
receptors	9	O
mediating	9	O
cell	4	O
contact	7	O
.	1	O

Signaling	9	O
events	6	O
triggered	9	O
in	2	O
thymocytes	10	O
by	2	O
adhesion	8	O
to	2	O
epithelial	10	O
cells	5	O
have	4	O
been	4	O
extensively	11	O
investigated	12	O
,	1	O
whereas	7	O
little	6	O
is	2	O
known	5	O
on	2	O
the	3	O
opposite	8	O
phenomenon	10	O
.	1	O

We	2	O
have	4	O
previously	10	O
investigated	12	O
this	4	O
issue	5	O
in	2	O
a	1	O
co-culture	10	O
system	6	O
composed	8	O
of	2	O
TEC	3	O
cultures	8	O
derived	7	O
from	4	O
human	5	O
normal	6	O
thymus	6	O
and	3	O
heterologous	12	O
thymocytes	10	O
.	1	O

We	2	O
demonstrated	12	O
that	4	O
thymocytes	10	O
adhere	6	O
to	2	O
TEC	3	O
involving	9	O
beta1	5	B-Partial_Gene
and	3	O
beta4	5	B-Gene
integrins	9	I-Gene
and	3	O
induce	6	O
the	3	O
clustering	10	O
of	2	O
alpha3beta1	11	B-Partial_Gene
and	3	O
alpha6beta4	11	B-Partial_Gene
heterodimers	12	O
at	2	O
the	3	O
TEC	3	O
surface	7	O
.	1	O

In	2	O
addition	8	O
thymocyte	9	O
adhesion	8	O
was	3	O
followed	8	O
by	2	O
activation	10	O
of	2	O
NF-kappaB	9	B-Gene
and	3	O
NF-IL6	6	B-Gene
gene	4	I-Gene
transcription	13	I-Gene
factors	7	I-Gene
and	3	O
enhanced	8	O
IL-6	4	B-Gene
production	10	O
.	1	O

The	3	O
two	3	O
latter	6	O
phenomena	9	O
were	4	O
reproduced	10	O
by	2	O
the	3	O
cross	5	O
-linking	8	O
of	2	O
the	3	O
alpha3	6	B-Partial_Gene
,	1	O
alpha6	6	B-Partial_Gene
,	1	O
beta1	5	B-Partial_Gene
and	3	O
beta4	5	B-Gene
integrins	9	I-Gene
,	1	O
thus	4	O
implying	8	O
that	4	O
the	3	O
alpha3beta1	11	B-Partial_Gene
and	3	O
alpha6beta4	11	B-Partial_Gene
heterodimers	12	O
can	3	O
signal	6	O
during	6	O
thymocyte	9	O
adhesion	8	O
.	1	O

We	2	O
have	4	O
extended	8	O
our	3	O
previous	8	O
work	4	O
investigating	13	O
in	2	O
the	3	O
same	4	O
experimental	12	O
setting	7	O
the	3	O
inducing	8	O
activity	8	O
of	2	O
non	3	O
stimulated	10	O
or	2	O
activated	9	O
policlonal	10	O
or	2	O
clonal	6	O
mature	6	O
T	1	O
cells	5	O
as	2	O
representative	14	O
of	2	O
the	3	O
more	4	O
mature	6	O
thymocyte	9	O
subset	6	O
.	1	O

We	2	O
found	5	O
that	4	O
adhesion	8	O
of	2	O
unstimulated	12	O
T	1	O
cell	4	O
i	1	O
)	1	O
involved	8	O
beta1	5	B-Partial_Gene
,	1	O
but	3	O
not	3	O
beta4	5	B-Gene
integrin	8	I-Gene
functions	9	O
at	2	O
the	3	O
surface	7	O
ii	2	O
)	1	O
induced	7	O
the	3	O
clustering	10	O
of	2	O
alpha3beta1	11	B-Partial_Gene
,	1	O
but	3	O
not	3	O
alpha2beta1	11	B-Partial_Gene
heterodimers	12	O
at	2	O
the	3	O
TEC	3	O
surface	7	O
and	3	O
iii	3	O
)	1	O
up	2	O
-regulated	10	O
the	3	O
nuclear	7	O
binding	7	O
activity	8	O
of	2	O
NF-kappaB	9	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
and	3	O
the	3	O
IL-6	4	B-Gene
secretion	9	O
.	1	O

We	2	O
propose	7	O
that	4	O
alpha3beta1	11	B-Partial_Gene
and	3	O
alpha6beta4	11	B-Partial_Gene
heterodimers	12	O
are	3	O
induced	7	O
to	2	O
cluster	7	O
at	2	O
the	3	O
TEC	3	O
surface	7	O
recognizing	11	O
yet	3	O
unknown	7	O
cellular	8	O
ligands	7	O
differentially	14	O
expressed	9	O
during	6	O
T	1	O
cell	4	O
development	11	O
.	1	O

Stromal	7	B-Gene
-derived	8	I-Gene
factor	6	I-Gene
1	1	I-Gene
and	3	O
thrombopoietin	14	B-Gene
regulate	8	O
distinct	8	O
aspects	7	O
of	2	O
human	5	O
megakaryopoiesis	16	O
.	1	O

The	3	O
role	4	O
of	2	O
the	3	O
chemokine	9	O
binding	7	O
stromal	7	B-Gene
-derived	8	I-Gene
factor	6	I-Gene
1	1	I-Gene
(	1	O
SDF-1	5	B-Gene
)	1	O
in	2	O
normal	6	O
human	5	O
megakaryopoiesis	16	O
at	2	O
the	3	O
cellular	8	O
and	3	O
molecular	9	O
levels	6	O
and	3	O
its	3	O
comparison	10	O
with	4	O
that	4	O
of	2	O
thrombopoietin	14	B-Gene
(	1	O
TPO	3	B-Gene
)	1	O
have	4	O
not	3	O
been	4	O
determined	10	O
.	1	O

In	2	O
this	4	O
study	5	O
it	2	O
was	3	O
found	5	O
that	4	O
SDF-1	5	B-Gene
,	1	O
unlike	6	O
TPO	3	B-Gene
,	1	O
does	4	O
not	3	O
stimulate	9	O
alpha	5	O
(	1	O
IIb	3	O
)	1	O
beta	4	O
(	1	O
3	1	O
)	1	O
(	1	O
+	1	O
)	1	O
cell	4	O
proliferation	13	O
or	2	O
differentiation	15	O
or	2	O
have	4	O
an	2	O
antiapoptotic	13	O
effect	6	O
.	1	O

However	7	O
,	1	O
it	2	O
does	4	O
induce	6	O
chemotaxis	10	O
,	1	O
trans-Matrigel	14	O
migration	9	O
,	1	O
and	3	O
secretion	9	O
of	2	O
matrix	6	B-Gene
metalloproteinase	17	I-Gene
9	1	I-Gene
(	1	O
MMP-9	5	B-Gene
)	1	O
and	3	O
vascular	8	B-Gene
endothelial	11	I-Gene
growth	6	I-Gene
factor	6	I-Gene
(	1	O
VEGF	4	B-Gene
)	1	O
by	2	O
these	5	O
cells	5	O
,	1	O
and	3	O
both	4	O
SDF-1	5	B-Gene
and	3	O
TPO	3	B-Gene
increase	8	O
the	3	O
adhesion	8	O
of	2	O
alpha	5	O
(	1	O
IIb	3	O
)	1	O
beta	4	O
(	1	O
3	1	O
)	1	O
(	1	O
+	1	O
)	1	O
cells	5	O
to	2	O
fibrinogen	10	B-Gene
and	3	O
vitronectin	11	B-Gene
.	1	O

Investigating	13	O
the	3	O
intracellular	13	O
signaling	9	O
pathways	8	O
induced	7	O
by	2	O
SDF-1	5	B-Gene
and	3	O
TPO	3	B-Gene
revealed	8	O
some	4	O
overlapping	11	O
patterns	8	O
of	2	O
protein	7	O
phosphorylation	15	O
/	1	O
activation	10	O
(	1	O
mitogen	7	B-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
[	1	O
MAPK	4	B-Gene
]	1	O
p42	3	B-Gene
/	1	I-Gene
44	2	I-Gene
,	1	O
MAPK	4	B-Gene
p38	3	I-Gene
,	1	O
and	3	O
AKT	3	B-Gene
[	1	O
protein	7	B-Gene
kinase	6	I-Gene
B	1	I-Gene
]	1	O
)	1	O
and	3	O
some	4	O
that	4	O
were	4	O
distinct	8	O
for	3	O
TPO	3	B-Gene
(	1	O
eg	2	O
,	1	O
JAK-STAT	8	B-Gene
)	1	O
and	3	O
for	3	O
SDF-1	5	B-Gene
(	1	O
eg	2	O
,	1	O
NF-kappa	8	B-Gene
B	1	I-Gene
)	1	O
.	1	O

It	2	O
was	3	O
also	4	O
found	5	O
that	4	O
though	6	O
inhibition	10	O
of	2	O
phosphatidyl-inositol	21	B-Gene
3-kinase	8	I-Gene
(	1	O
PI-3K	5	B-Gene
)	1	O
by	2	O
LY294002	8	B-Chemical
in	2	O
alpha	5	O
(	1	O
IIb	3	O
)	1	O
beta	4	O
(	1	O
3	1	O
)	1	O
(	1	O
+	1	O
)	1	O
cells	5	O
induced	7	O
apoptosis	9	O
and	3	O
inhibited	9	O
chemotaxis	10	O
adhesion	8	O
and	3	O
the	3	O
secretion	9	O
of	2	O
MMP-9	5	B-Gene
and	3	O
VEGF	4	B-Gene
,	1	O
the	3	O
inhibition	10	O
of	2	O
MAPK	4	B-Gene
p42	3	I-Gene
/	1	I-Gene
44	2	I-Gene
(	1	O
by	2	O
the	3	O
MEK	3	B-Gene
inhibitor	9	O
U0126	5	B-Chemical
)	1	O
had	3	O
no	2	O
effect	6	O
on	2	O
the	3	O
survival	8	O
,	1	O
proliferation	13	O
,	1	O
and	3	O
migration	9	O
of	2	O
these	5	O
cells	5	O
.	1	O

Hence	5	O
,	1	O
it	2	O
is	2	O
suggested	9	O
that	4	O
the	3	O
proliferative	13	O
effect	6	O
of	2	O
TPO	3	B-Gene
is	2	O
more	4	O
related	7	O
to	2	O
activation	10	O
of	2	O
the	3	O
JAK-STAT	8	B-Gene
pathway	7	O
(	1	O
unique	6	O
to	2	O
TPO	3	B-Gene
)	1	O
,	1	O
and	3	O
the	3	O
PI-3K-AKT	9	B-Gene
axis	4	O
is	2	O
differentially	14	O
involved	8	O
in	2	O
TPO-	4	B-Gene
and	3	O
SDF-1	5	B-Gene
-dependent	10	O
signaling	9	O
.	1	O

Accordingly	11	O
,	1	O
PI-3K	5	B-Gene
is	2	O
involved	8	O
in	2	O
TPO	3	B-Gene
-mediated	9	O
inhibition	10	O
of	2	O
apoptosis	9	O
,	1	O
TPO-	4	B-Gene
and	3	O
SDF-1	5	B-Gene
-regulated	10	O
adhesion	8	O
to	2	O
fibrinogen	10	B-Gene
and	3	O
vitronectin	11	B-Gene
,	1	O
and	3	O
SDF-1	5	B-Gene
-mediated	9	O
migration	9	O
.	1	O

This	4	O
study	5	O
expands	7	O
the	3	O
understanding	13	O
of	2	O
the	3	O
role	4	O
of	2	O
SDF-1	5	B-Gene
and	3	O
TPO	3	B-Gene
in	2	O
normal	6	O
human	5	O
megakaryopoiesis	16	O
and	3	O
indicates	9	O
the	3	O
molecular	9	O
basis	5	O
of	2	O
the	3	O
observed	8	O
differences	11	O
in	2	O
cellular	8	O
responses	9	O
.	1	O

(	1	O
Blood.	6	O
2000	4	O
;	1	O
96	2	O
:	1	O
4142-4151	9	B-Chemical
)	1	O

The	3	O
physical	8	O
association	11	O
of	2	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
theta	5	I-Gene
with	4	O
a	1	O
lipid	5	B-Chemical
raft	4	O
-associated	11	O
inhibitor	9	B-Gene
of	2	I-Gene
kappa	5	I-Gene
B	1	I-Gene
factor	6	I-Gene
kinase	6	I-Gene
(	1	I-Gene
IKK	3	I-Gene
)	1	I-Gene
complex	7	I-Gene
plays	5	O
a	1	O
role	4	O
in	2	O
the	3	O
activation	10	O
of	2	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
cascade	7	O
by	2	O
TCR	3	B-Gene
and	3	O
CD28	4	B-Gene
.	1	O

We	2	O
investigated	12	O
the	3	O
role	4	O
of	2	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
theta	5	I-Gene
(	1	O
PKCtheta	8	B-Gene
)	1	O
in	2	O
the	3	O
activation	10	O
of	2	O
the	3	O
NF-kappaB	9	B-Gene
cascade	7	O
in	2	O
primary	7	O
human	5	B-Gene
CD4	3	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
lymphocytes	11	O
.	1	O

Among	5	O
six	3	O
or	2	O
so	2	O
PKC	3	B-Gene
isoforms	8	I-Gene
expressed	9	O
in	2	O
T	1	O
cells	5	O
,	1	O
only	4	O
PKCtheta	8	B-Gene
participates	12	O
in	2	O
the	3	O
assembly	8	O
of	2	O
the	3	O
supramolecular	14	O
activation	10	O
clusters	8	O
at	2	O
the	3	O
contact	7	O
site	4	O
of	2	O
the	3	O
TCR	3	B-Gene
with	4	O
Ag	2	O
.	1	O

Signaling	9	O
via	3	O
both	4	O
the	3	O
TCR	3	B-Gene
and	3	O
CD28	4	B-Gene
is	2	O
required	8	O
for	3	O
optimal	7	O
activation	10	O
of	2	O
the	3	O
multisubunit	12	O
IkappaB	7	B-Gene
kinase	6	I-Gene
(	1	I-Gene
IKK	3	I-Gene
)	1	I-Gene
complex	7	I-Gene
in	2	O
primary	7	O
human	5	O
T	1	O
lymphocytes	11	O
;	1	O
this	4	O
activation	10	O
could	5	O
be	2	O
inhibited	9	O
by	2	O
a	1	O
Ca	2	O
(	1	O
2+	2	O
)	1	O
-independent	12	O
PKC	3	B-Gene
isoform	7	I-Gene
inhibitor	9	O
,	1	O
rottlerin	9	B-Chemical
.	1	O

Moreover	8	O
,	1	O
endogenous	10	B-Gene
PKCtheta	8	I-Gene
physically	10	O
associates	10	O
with	4	O
activated	9	B-Gene
IKK	3	I-Gene
complexes	9	I-Gene
in	2	O
CD3	3	B-Gene
/	1	I-Gene
CD28	4	I-Gene
-costimulated	13	O
primary	7	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
T	1	O
cells	5	O
.	1	O

The	3	O
same	4	O
set	3	O
of	2	O
stimuli	7	O
also	4	O
induced	7	O
relocation	10	O
of	2	O
endogenous	10	B-Gene
PKCtheta	8	I-Gene
and	3	O
IKKs	4	B-Gene
to	2	O
a	1	O
GM1	3	B-Chemical
ganglioside	11	I-Chemical
-enriched	9	O
,	1	O
detergent-insoluble	19	O
membrane	8	O
compartment	11	O
in	2	O
primary	7	O
T	1	O
cells	5	O
.	1	O

IKKs	4	B-Gene
recruited	9	O
to	2	O
these	5	O
lipid	5	B-Chemical
rafts	5	O
were	4	O
capable	7	O
of	2	O
phosphorylating	15	O
a	1	O
recombinant	11	B-Gene
IkappaBalpha	12	I-Gene
sustrate	8	O
.	1	O

Confocal	8	O
microscopy	10	O
further	7	O
demonstrated	12	O
that	4	O
exogenously	11	O
expressed	9	O
PKCtheta	8	B-Gene
and	3	O
IKKss	5	B-Gene
colocalize	10	O
in	2	O
the	3	O
membrane	8	O
of	2	O
CD3	3	B-Gene
/	1	I-Gene
CD28	4	I-Gene
-costimulated	13	O
Jurkat	6	O
T	1	O
cells	5	O
.	1	O

Constitutively	14	O
active	6	O
but	3	O
not	3	O
kinase	6	O
-inactive	9	O
PKCtheta	8	B-Gene
activated	9	O
IKKbeta	7	B-Gene
in	2	O
Jurkat	6	O
T	1	O
cells	5	O
.	1	O

Expression	10	O
of	2	O
dominant	8	O
-active	7	O
PKCtheta	8	B-Gene
also	4	O
had	3	O
stimulatory	11	O
effects	7	O
on	2	O
the	3	O
CD28	4	B-Gene
response	8	I-Gene
element	7	I-Gene
of	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
.	1	O

Taken	5	O
together	8	O
,	1	O
these	5	O
data	4	O
show	4	O
that	4	O
the	3	O
activation	10	O
of	2	O
PKCtheta	8	B-Gene
by	2	O
the	3	O
TCR	3	B-Gene
and	3	O
CD28	4	B-Gene
plays	5	O
an	2	O
important	9	O
role	4	O
in	2	O
the	3	O
assembly	8	O
and	3	O
activation	10	O
of	2	O
IKK	3	B-Gene
complexes	9	I-Gene
in	2	O
the	3	O
T	1	O
cell	4	O
membrane	8	O

Peroxisome	10	B-Gene
proliferator	12	I-Gene
activator	9	I-Gene
receptor-gamma	14	I-Gene
agonists	8	I-Gene
and	3	O
15-deoxy-Delta	14	B-Chemical
(	1	I-Chemical
12	2	I-Chemical
,	1	I-Chemical
14	2	I-Chemical
)	1	I-Chemical
(	1	I-Chemical
12	2	I-Chemical
,	1	I-Chemical
14	2	I-Chemical
)	1	I-Chemical
-PGJ	4	I-Chemical
(	1	I-Chemical
2	1	I-Chemical
)	1	I-Chemical
induce	6	O
apoptosis	9	O
in	2	O
normal	6	O
and	3	O
malignant	9	O
B-lineage	9	O
cells	5	O
.	1	O

The	3	O
research	8	O
described	9	O
herein	6	O
evaluates	9	O
the	3	O
expression	10	O
and	3	O
functional	10	O
significance	12	O
of	2	O
peroxisome	10	B-Gene
proliferator	12	I-Gene
activator	9	I-Gene
receptor-gamma	14	I-Gene
(	1	O
PPAR-gamma	10	B-Gene
)	1	O
on	2	O
B-lineage	9	O
cells	5	O
.	1	O

Normal	6	O
mouse	5	O
B	1	O
cells	5	O
and	3	O
a	1	O
variety	7	O
of	2	O
B	1	B-Disease
lymphoma	8	I-Disease
cells	5	O
reflective	10	O
of	2	O
stages	6	O
of	2	O
B	1	O
cell	4	O
differentiation	15	O
(	1	O
e.g.	4	O
,	1	O
70Z	3	O
/	1	O
3	1	O
,	1	O
CH31	4	O
,	1	O
WEHI-231	8	O
,	1	O
CH12	4	O
,	1	O
and	3	O
J558	4	O
)	1	O
express	7	O
PPAR-gamma	10	B-Gene
mRNA	4	I-Gene
and	3	O
,	1	O
by	2	O
Western	7	O
blot	4	O
analysis	8	O
,	1	O
the	3	O
67-kDa	6	B-Gene
PPAR-gamma	10	I-Gene
protein	7	I-Gene
.	1	O

15-Deoxy-Delta	14	B-Chemical
(	1	I-Chemical
12	2	I-Chemical
,	1	I-Chemical
14	2	I-Chemical
)	1	I-Chemical
-PGJ	4	I-Chemical
(	1	I-Chemical
2	1	I-Chemical
)	1	I-Chemical
(	1	O
15d-PGJ	7	B-Chemical
(	1	I-Chemical
2	1	I-Chemical
)	1	I-Chemical
)	1	O
,	1	O
a	1	O
PPAR-gamma	10	B-Gene
agonist	7	O
,	1	O
has	3	O
a	1	O
dose	4	O
-dependent	10	O
antiproliferative	17	O
and	3	O
cytotoxic	9	O
effect	6	O
on	2	O
normal	6	O
and	3	O
malignant	9	O
B	1	O
cells	5	O
as	2	O
shown	5	O
by	2	O
[	1	O
(	1	O
3	1	O
)	1	O
H	1	O
]	1	O
thymidine	9	O
and	3	O
3-	2	O
[	1	O
4	1	O
,	1	O
5-dimethylthiazol-2-yl	22	O
]	1	O
-2	2	O
,	1	O
5-diphenyltetrazolium	21	O
bromide	7	O
assays	6	O
.	1	O

Only	4	O
PPAR-gamma	10	B-Gene
agonists	8	O
(	1	O
thiazolidinediones	18	B-Chemical
)	1	O
,	1	O
and	3	O
not	3	O
PPAR-alpha	10	B-Gene
agonists	8	I-Gene
,	1	O
mimicked	8	O
the	3	O
effect	6	O
of	2	O
15d-PGJ	7	B-Chemical
(	1	I-Chemical
2	1	I-Chemical
)	1	I-Chemical
on	2	O
B-lineage	9	O
cells	5	O
,	1	O
indicating	10	O
that	4	O
the	3	O
mechanism	9	O
by	2	O
which	5	O
15d-PGJ	7	B-Chemical
(	1	I-Chemical
2	1	I-Chemical
)	1	I-Chemical
negatively	10	O
affects	7	O
B-lineage	9	O
cells	5	O
involves	8	O
in	2	O
part	4	O
PPAR-gamma	10	B-Gene
.	1	O

The	3	O
mechanism	9	O
by	2	O
which	5	O
PPAR-gamma	10	B-Gene
agonists	8	I-Gene
induce	6	O
cytotoxicity	12	O
is	2	O
via	3	O
apoptosis	9	O
,	1	O
as	2	O
shown	5	O
by	2	O
annexin	7	O
V	1	O
staining	8	O
and	3	O
as	2	O
confirmed	9	O
by	2	O
DNA	3	O
fragmentation	13	O
detected	8	O
using	5	O
the	3	O
TUNEL	5	O
assay	5	O
.	1	O

Interestingly	13	O
,	1	O
addition	8	O
of	2	O
PGF	3	B-Chemical
(	1	I-Chemical
2alpha	6	I-Chemical
)	1	I-Chemical
,	1	O
which	5	O
was	3	O
not	3	O
known	5	O
to	2	O
affect	6	O
lymphocytes	11	O
,	1	O
dramatically	12	O
attenuated	10	O
the	3	O
deleterious	11	O
effects	7	O
of	2	O
PPAR-gamma	10	B-Gene
agonists	8	I-Gene
on	2	O
B	1	B-Disease
lymphomas	9	I-Disease
.	1	O

Surprisingly	12	O
,	1	O
15d-PGJ	7	B-Chemical
(	1	I-Chemical
2	1	I-Chemical
)	1	I-Chemical
induced	7	O
a	1	O
massive	7	O
increase	8	O
in	2	O
nuclear	7	B-Gene
mitogen	7	I-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
activation	10	O
,	1	O
and	3	O
pretreatment	12	O
with	4	O
PGF	3	B-Chemical
(	1	I-Chemical
2alpha	6	I-Chemical
)	1	I-Chemical
blunted	7	O
the	3	O
mitogen	7	B-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
activation	10	O
.	1	O

This	4	O
is	2	O
the	3	O
first	5	O
study	5	O
evaluating	10	O
PPAR-gamma	10	B-Gene
expression	10	O
and	3	O
its	3	O
significance	12	O
on	2	O
B	1	O
lymphocytes	11	O
.	1	O

PPAR-gamma	10	B-Gene
agonists	8	I-Gene
may	3	O
serve	5	O
as	2	O
a	1	O
counterbalance	14	O
to	2	O
the	3	O
stimulating	11	O
effects	7	O
of	2	O
other	5	O
PGs	3	B-Chemical
,	1	O
namely	6	O
PGE	3	B-Chemical
(	1	I-Chemical
2	1	I-Chemical
)	1	I-Chemical
,	1	O
which	5	O
promotes	8	O
B	1	O
cell	4	O
differentiation	15	O
.	1	O

Finally	7	O
,	1	O
the	3	O
use	3	O
of	2	O
PGs	3	B-Chemical
,	1	O
such	4	O
as	2	O
15d-PGJ	7	B-Chemical
(	1	I-Chemical
2	1	I-Chemical
)	1	I-Chemical
,	1	O
and	3	O
synthetic	9	O
PPAR-gamma	10	B-Gene
agonists	8	I-Gene
to	2	O
induce	6	O
apoptosis	9	O
in	2	O
B-lineage	9	O
cells	5	O
may	3	O
lead	4	O
to	2	O
the	3	O
development	11	O
of	2	O
novel	5	O
therapies	9	O
for	3	O
fatal	5	O
B	1	B-Disease
lymphomas	9	I-Disease

The	3	O
murine	6	B-Gene
IL-2	4	I-Gene
promoter	8	I-Gene
contains	8	O
distal	6	O
regulatory	10	O
elements	8	O
responsive	10	O
to	2	O
the	3	O
Ah	2	B-Gene
receptor	8	I-Gene
,	1	O
a	1	O
member	6	O
of	2	O
the	3	O
evolutionarily	14	O
conserved	9	O
bHLH-PAS	8	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
family	6	I-Gene
.	1	O

Signaling	9	O
through	7	O
the	3	O
TCR	3	B-Gene
and	3	O
costimulatory	13	O
signals	7	O
primarily	9	O
control	7	O
transcription	13	O
of	2	O
the	3	O
IL-2	4	B-Gene
gene	4	I-Gene
in	2	O
naive	5	O
T	1	O
cells	5	O
.	1	O

The	3	O
minimal	7	O
promoter	8	O
necessary	9	O
for	3	O
this	4	O
expression	10	O
lies	4	O
proximal	8	O
,	1	O
between	7	O
-300	4	O
and	3	O
the	3	O
transcription	13	O
start	5	O
site	4	O
.	1	O

We	2	O
had	3	O
previously	10	O
shown	5	O
that	4	O
activation	10	O
of	2	O
the	3	O
arylhydrocarbon	15	B-Gene
receptor	8	I-Gene
(	1	O
AHR	3	B-Gene
)	1	O
,	1	O
a	1	O
member	6	O
of	2	O
the	3	O
bHLH-PAS	8	B-Gene
family	6	I-Gene
of	2	O
transcription	13	O
factors	7	O
,	1	O
leads	5	O
to	2	O
increased	9	O
mRNA	4	O
expression	10	O
of	2	O
IL-2	4	B-Gene
in	2	O
murine	6	O
fetal	5	O
thymocytes	10	O
.	1	O

The	3	O
AHR	3	B-Gene
is	2	O
abundant	8	O
in	2	O
the	3	O
thymus	6	O
and	3	O
may	3	O
play	4	O
a	1	O
role	4	O
for	3	O
the	3	O
development	11	O
of	2	O
the	3	O
immune	6	O
system	6	O
.	1	O

Moreover	8	O
,	1	O
its	3	O
overactivation	14	O
by	2	O
chemicals	9	O
such	4	O
as	2	O
dioxins	7	B-Chemical
leads	5	O
to	2	O
immunosuppression	17	O
and	3	O
thymic	6	O
involution	10	O
.	1	O

Binding	7	O
motifs	6	O
for	3	O
the	3	O
liganded	8	B-Gene
AHR	3	I-Gene
can	3	O
be	2	O
identified	10	O
in	2	O
the	3	O
distal	6	O
region	6	O
-1300	5	O
to	2	O
-800	4	O
of	2	O
the	3	O
mouse	5	B-Gene
IL-2	4	I-Gene
promoter	8	I-Gene
.	1	O

We	2	O
show	4	O
here	4	O
that	4	O
these	5	O
DNA	3	O
motifs	6	O
,	1	O
the	3	O
so	2	O
-called	7	O
dioxin	6	B-Chemical
response	8	O
elements	8	O
,	1	O
after	5	O
binding	7	O
to	2	O
the	3	O
liganded	8	B-Gene
AHR	3	I-Gene
are	3	O
sufficient	10	O
to	2	O
transactivate	13	O
luciferase	10	O
expression	10	O
in	2	O
a	1	O
reporter	8	O
gene	4	O
system	6	O
.	1	O

The	3	O
IL-2	4	B-Gene
gene	4	I-Gene
can	3	O
be	2	O
induced	7	O
by	2	O
the	3	O
AHR	3	B-Gene
also	4	O
in	2	O
thymocytes	10	O
in	2	O
vivo	4	O
after	5	O
injection	9	O
of	2	O
2	1	B-Chemical
,	1	I-Chemical
3	1	I-Chemical
,	1	I-Chemical
7	1	I-Chemical
,	1	I-Chemical
8-tetrachlorodibenzo-p-dioxin	29	I-Chemical
,	1	O
a	1	O
potent	6	O
ligand	6	O
of	2	O
the	3	O
AHR	3	B-Gene
.	1	O

The	3	O
AHR	3	B-Gene
mediates	8	O
the	3	O
IL-2	4	B-Gene
induction	9	O
as	2	O
shown	5	O
with	4	O
AHR	3	B-Gene
-deficient	10	O
mice	4	O
.	1	O

However	7	O
,	1	O
in	2	O
spleen	6	O
cells	5	O
in	2	O
vitro	5	O
costimulation	13	O
via	3	O
the	3	O
TCR	3	B-Gene
is	2	O
necessary	9	O
for	3	O
optimal	7	O
IL-2	4	B-Gene
gene	4	I-Gene
induction	9	O
.	1	O

Thus	4	O
,	1	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
region	6	O
contains	8	O
novel	5	O
distal	6	O
regulatory	10	O
elements	8	O
that	4	O
can	3	O
be	2	O
addressed	9	O
by	2	O
the	3	O
AHR	3	B-Gene
to	2	O
induce	6	O
IL-2	4	B-Gene
and	3	O
can	3	O
cooperate	9	O
with	4	O
the	3	O
proximal	8	O
promoter	8	O

Multiple	8	O
signals	7	O
required	8	O
for	3	O
cyclic	6	B-Gene
AMP	3	I-Gene
-responsive	11	I-Gene
element	7	I-Gene
binding	7	I-Gene
protein	7	I-Gene
(	1	I-Gene
CREB	4	I-Gene
)	1	I-Gene
binding	7	I-Gene
protein	7	I-Gene
interaction	11	O
induced	7	O
by	2	O
CD3	3	B-Gene
/	1	I-Gene
CD28	4	I-Gene
costimulation	13	O
.	1	O

The	3	O
optimal	7	O
activation	10	O
of	2	O
cAMP	4	B-Gene
-responsive	11	I-Gene
element	7	I-Gene
binding	7	I-Gene
protein	7	I-Gene
(	1	O
CREB	4	B-Gene
)	1	O
,	1	O
similar	7	O
to	2	O
the	3	O
full	4	O
activation	10	O
of	2	O
T	1	O
lymphocytes	11	O
,	1	O
requires	8	O
the	3	O
stimulation	11	O
of	2	O
both	4	O
CD3	3	B-Gene
and	3	O
CD28	4	B-Gene
.	1	O

Using	5	O
a	1	O
reporter	8	O
system	6	O
to	2	O
detect	6	O
interaction	11	O
of	2	O
CREB	4	B-Gene
and	3	O
CREB	4	B-Gene
-binding	8	I-Gene
protein	7	I-Gene
(	1	O
CBP	3	B-Gene
)	1	O
,	1	O
in	2	O
this	4	O
study	5	O
we	2	O
found	5	O
that	4	O
CREB	4	B-Gene
binds	5	O
to	2	O
CBP	3	B-Gene
only	4	O
by	2	O
engagement	10	O
of	2	O
both	4	O
CD3	3	B-Gene
and	3	O
CD28	4	B-Gene
.	1	O

CD3	3	B-Gene
/	1	I-Gene
CD28	4	I-Gene
-promoted	9	O
CREB	4	B-Gene
-	1	I-Gene
CBP	3	I-Gene
interaction	11	O
was	3	O
dependent	9	O
on	2	O
p38	3	B-Gene
mitogen	7	I-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
(	1	O
MAPK	4	B-Gene
)	1	O
and	3	O
calcium	7	B-Gene
/	1	I-Gene
calmodulin	10	I-Gene
-dependent	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
(	1	I-Gene
CaMK	4	I-Gene
)	1	I-Gene
IV	2	I-Gene
in	2	O
addition	8	O
to	2	O
the	3	O
previously	10	O
identified	10	O
extracellular	13	B-Gene
signal	6	I-Gene
-regulated	10	I-Gene
kinase	6	I-Gene
pathway	7	O
.	1	O

Extracellular	13	B-Gene
signal	6	I-Gene
-regulated	10	I-Gene
kinase	6	I-Gene
,	1	O
CaMKIV	6	B-Gene
,	1	O
and	3	O
p38	3	B-Gene
MAPK	4	I-Gene
were	4	O
also	4	O
the	3	O
kinases	7	O
involved	8	O
in	2	O
CREB	4	B-Gene
Ser	3	B-Chemical
(	1	O
133	3	O
)	1	O
phosphorylation	15	O
induced	7	O
by	2	O
CD3	3	B-Gene
/	1	I-Gene
CD28	4	I-Gene
.	1	O

A	1	O
reconstitution	14	O
experiment	10	O
illustrated	11	O
that	4	O
optimum	7	O
CREB	4	B-Gene
-	1	I-Gene
CBP	3	I-Gene
interaction	11	O
and	3	O
CREB	4	B-Gene
trans-activation	16	O
were	4	O
attained	8	O
when	4	O
these	5	O
three	5	O
kinase	6	O
pathways	8	O
were	4	O
simultaneously	14	O
activated	9	O
in	2	O
T	1	O
cells	5	O
.	1	O

Our	3	O
results	7	O
demonstrate	11	O
that	4	O
coordinated	11	O
activation	10	O
of	2	O
different	9	O
kinases	7	O
leads	5	O
to	2	O
full	4	O
activation	10	O
of	2	O
CREB	4	B-Gene
.	1	O

Notably	7	O
,	1	O
CD28	4	B-Gene
ligation	8	O
activated	9	O
p38	3	B-Gene
MAPK	4	I-Gene
and	3	O
CaMKIV	6	B-Gene
,	1	O
the	3	O
kinases	7	O
stimulated	10	O
by	2	O
CD3	3	B-Gene
engagement	10	O
,	1	O
suggesting	10	O
that	4	O
CD28	4	B-Gene
acts	4	O
by	2	O
increasing	10	O
the	3	O
activation	10	O
extent	6	O
of	2	O
p38	3	B-Gene
MAPK	4	I-Gene
and	3	O
CaMKIV	6	B-Gene
.	1	O

These	5	O
results	7	O
support	7	O
the	3	O
model	5	O
of	2	O
a	1	O
minimum	7	O
activation	10	O
threshold	9	O
for	3	O
CREB	4	B-Gene
-	1	I-Gene
CBP	3	I-Gene
interaction	11	O
that	4	O
can	3	O
be	2	O
reached	7	O
only	4	O
when	4	O
both	4	O
CD3	3	B-Gene
and	3	O
CD28	4	B-Gene
are	3	O
stimulated	10	O
.	1	O

Activation	10	O
of	2	O
signal	6	O
transduction	12	O
and	3	O
apoptosis	9	O
in	2	O
healthy	7	O
lymphomonocytes	15	O
exposed	7	O
to	2	O
bystander	9	O
HIV-1	5	O
-infected	9	O
cells	5	O
.	1	O

Persistent	10	O
activation	10	O
of	2	O
the	3	O
immune	6	O
system	6	O
is	2	O
one	3	O
of	2	O
the	3	O
hallmarks	9	O
of	2	O
HIV-1	5	O
infection	9	O
.	1	O

In	2	O
this	4	O
study	5	O
we	2	O
analysed	8	O
the	3	O
induction	9	O
of	2	O
factors	7	O
involved	8	O
in	2	O
cytokine	8	O
signal	6	O
transduction	12	O
,	1	O
such	4	O
as	2	O
STAT	4	B-Gene
1	1	I-Gene
proteins	8	I-Gene
and	3	O
IRF-1	5	B-Gene
mRNA	4	I-Gene
,	1	O
in	2	O
normal	6	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
(	1	O
PBMC	4	O
)	1	O
exposed	7	O
to	2	O
HIV	3	O
-infected	9	O
cells	5	O
,	1	O
and	3	O
the	3	O
induction	9	O
of	2	O
apoptosis	9	O
.	1	O

Western	7	O
blot	4	O
analyses	8	O
and	3	O
reverse	7	O
transcriptase-polymerase	24	O
chain	5	O
reaction	8	O
results	7	O
indicate	8	O
that	4	O
both	4	O
cells	5	O
infected	8	O
with	4	O
a	1	O
X4	2	O
strain	6	O
and	3	O
cells	5	O
infected	8	O
with	4	O
a	1	O
R5	2	O
strain	6	O
are	3	O
able	4	O
to	2	O
increase	8	O
intracellular	13	O
levels	6	O
of	2	O
STAT	4	B-Gene
1alpha	6	I-Gene
and	3	O
beta	4	B-Partial_Gene
proteins	8	I-Partial_Gene
as	2	O
well	4	O
as	2	O
IRF-1	5	B-Gene
mRNA	4	I-Gene
.	1	O

This	4	O
effect	6	O
was	3	O
prevented	9	O
by	2	O
neutralizing	12	O
antibodies	10	O
against	7	O
interferon-alpha	16	B-Gene
(	1	O
IFN-alpha	9	B-Gene
)	1	O
.	1	O

HIV-1	5	O
-infected	9	O
cells	5	O
dose	4	O
-dependently	12	O
induced	7	O
apoptotic	9	O
commitment	10	O
in	2	O
normal	6	O
PBMC	4	O
,	1	O
as	2	O
revealed	8	O
by	2	O
DNA	3	O
fragmentation	13	O
analysis	8	O
,	1	O
but	3	O
this	4	O
was	3	O
not	3	O
accompanied	11	O
by	2	O
an	2	O
increase	8	O
of	2	O
caspase-3	9	B-Gene
activity	8	O
,	1	O
even	4	O
if	2	O
a	1	O
slight	6	O
up-regulation	13	O
of	2	O
IL-1beta	8	B-Gene
-converting	11	I-Gene
enzyme	6	I-Gene
mRNA	4	I-Gene
was	3	O
detected	8	O
.	1	O

Apoptosis	9	O
induction	9	O
could	5	O
be	2	O
abrogated	9	O
mainly	6	O
by	2	O
antibodies	10	O
against	7	O
tumour	6	B-Gene
necrosis	8	I-Gene
factor-alpha	12	I-Gene
(	1	O
TNF-alpha	9	B-Gene
)	1	O
and	3	O
,	1	O
to	2	O
a	1	O
lesser	6	O
extent	6	O
,	1	O
by	2	O
antibodies	10	O
against	7	O
IFN-gamma	9	B-Gene
.	1	O

All	3	O
these	5	O
findings	8	O
suggest	7	O
that	4	O
uninfected	10	O
PBMC	4	O
can	3	O
undergo	7	O
activation	10	O
of	2	O
signal	6	O
transduction	12	O
and	3	O
apoptosis	9	O
after	5	O
exposure	8	O
to	2	O
bystander	9	O
HIV	3	O
-infected	9	O
cells	5	O
,	1	O
subsequent	10	O
to	2	O
the	3	O
induction	9	O
of	2	O
cytokines	9	O
such	4	O
as	2	O
IFNs	4	B-Gene
and	3	O
TNF-alpha	9	B-Gene
.	1	O

The	3	O
proteasome	10	O
regulates	9	O
receptor	8	O
-mediated	9	O
endocytosis	11	O
of	2	O
interleukin-2	13	B-Gene
.	1	O

Recent	6	O
studies	7	O
have	4	O
increasingly	12	O
implicated	10	O
the	3	O
proteasome	10	O
in	2	O
the	3	O
regulation	10	O
of	2	O
cell	4	O
surface	7	O
receptors	9	O
.	1	O

In	2	O
the	3	O
present	7	O
study	5	O
,	1	O
we	2	O
investigated	12	O
the	3	O
role	4	O
of	2	O
the	3	O
proteasome	10	O
for	3	O
ligand	6	O
-dependent	10	O
endocytosis	11	O
and	3	O
degradation	11	O
of	2	O
the	3	O
interleukin-2	13	B-Gene
(	1	I-Gene
IL-2	4	I-Gene
)	1	I-Gene
-interleukin-2	14	I-Gene
receptor	8	I-Gene
(	1	I-Gene
IL-2R	5	I-Gene
)	1	I-Gene
complex	7	I-Gene
.	1	O

Proteasome	10	O
inhibitors	10	O
impaired	8	O
internalization	15	O
of	2	O
IL-2.IL-2R	10	B-Gene
and	3	O
prevented	9	O
the	3	O
lysosomal	9	O
degradation	11	O
of	2	O
this	4	O
cytokine	8	O
.	1	O

Based	5	O
on	2	O
time-course	11	O
studies	7	O
,	1	O
proteasome	10	O
activity	8	O
is	2	O
primarily	9	O
required	8	O
after	5	O
initial	7	O
endocytosis	11	O
of	2	O
the	3	O
IL-2.IL-2R	10	B-Gene
.	1	O

Proteasome	10	O
function	8	O
was	3	O
also	4	O
necessary	9	O
for	3	O
the	3	O
lysosomal	9	O
degradation	11	O
of	2	O
IL-2	4	B-Gene
internalized	12	O
by	2	O
IL-2R	5	B-Gene
that	4	O
were	4	O
comprised	9	O
of	2	O
cytoplasmic	11	O
tailless	8	O
beta-	5	B-Partial_Gene
or	2	O
gamma	5	B-Gene
c-subunits	10	I-Gene
,	1	O
suggesting	10	O
that	4	O
the	3	O
target	6	O
protein	7	O
for	3	O
the	3	O
proteasome	10	O
is	2	O
independent	11	O
of	2	O
either	6	O
the	3	O
cytoplasmic	11	O
tail	4	O
of	2	O
the	3	O
IL-2R	5	B-Gene
beta-	5	I-Gene
or	2	O
gamma	5	B-Gene
c-subunits	10	I-Gene
and	3	O
their	5	O
associated	10	O
signaling	9	O
components	10	O
.	1	O

Therefore	9	O
,	1	O
a	1	O
functional	10	O
proteasome	10	O
is	2	O
required	8	O
for	3	O
optimal	7	O
endocytosis	11	O
of	2	O
the	3	O
IL-2R	5	B-Gene
/	1	I-Gene
ligand	6	I-Gene
complex	7	I-Gene
and	3	O
is	2	O
essential	9	O
for	3	O
the	3	O
subsequent	10	O
lysosomal	9	O
degradation	11	O
of	2	O
IL-2	4	B-Gene
,	1	O
possibly	8	O
by	2	O
regulating	10	O
trafficking	11	O
to	2	O
the	3	O
lysosome	8	O
.	1	O

Design	6	O
and	3	O
use	3	O
of	2	O
an	2	O
inducibly	9	O
activated	9	B-Gene
human	5	I-Gene
immunodeficiency	16	I-Gene
virus	5	I-Gene
type	4	I-Gene
1	1	I-Gene
Nef	3	I-Gene
to	2	O
study	5	O
immune	6	O
modulation	10	O
.	1	O

The	3	O
Nef	3	B-Gene
protein	7	I-Gene
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
(	1	O
HIV-1	5	O
)	1	O
has	3	O
been	4	O
shown	5	O
to	2	O
enhance	7	O
the	3	O
infectivity	11	O
of	2	O
virus	5	O
particles	9	O
,	1	O
downmodulate	12	O
cell	4	O
surface	7	O
proteins	8	O
,	1	O
and	3	O
associate	9	O
with	4	O
many	4	O
intracellular	13	O
proteins	8	O
that	4	O
are	3	O
thought	7	O
to	2	O
facilitate	10	O
HIV	3	O
infection	9	O
.	1	O

One	3	O
of	2	O
the	3	O
challenges	10	O
in	2	O
defining	8	O
the	3	O
molecular	9	O
events	6	O
regulated	9	O
by	2	O
Nef	3	B-Gene
has	3	O
been	4	O
obtaining	9	O
good	4	O
expression	10	O
of	2	O
Nef	3	B-Gene
protein	7	I-Gene
in	2	O
T	1	O
cells	5	O
.	1	O

This	4	O
has	3	O
been	4	O
attributed	10	O
to	2	O
effects	7	O
of	2	O
Nef	3	B-Gene
on	2	O
cell	4	O
proliferation	13	O
and	3	O
apoptosis	9	O
.	1	O

We	2	O
have	4	O
designed	8	O
a	1	O
Nef	3	B-Gene
protein	7	I-Gene
that	4	O
is	2	O
readily	7	O
expressed	9	O
in	2	O
T-cell	6	O
lines	5	O
and	3	O
whose	5	O
function	8	O
is	2	O
inducibly	9	O
activated	9	O
.	1	O

It	2	O
is	2	O
composed	8	O
of	2	O
a	1	O
fusion	6	O
between	7	O
full-length	11	O
Nef	3	B-Gene
and	3	O
the	3	O
estrogen	8	B-Gene
receptor	8	I-Gene
hormone	7	O
-binding	8	O
domain	6	O
(	1	O
Nef-ER	6	B-Gene
)	1	O
.	1	O

The	3	O
Nef-ER	6	B-Gene
is	2	O
kept	4	O
in	2	O
an	2	O
inactive	8	O
state	5	O
due	3	O
to	2	O
steric	6	O
hindrance	9	O
,	1	O
and	3	O
addition	8	O
of	2	O
the	3	O
membrane-permeable	18	O
drug	4	O
4-hydroxytamoxifen	18	B-Chemical
(	1	O
4-HT	4	B-Chemical
)	1	O
,	1	O
which	5	O
binds	5	O
to	2	O
the	3	O
ER	2	B-Gene
domain	6	O
,	1	O
leads	5	O
to	2	O
inducible	9	O
activation	10	O
of	2	O
Nef-ER	6	B-Gene
within	6	O
cells	5	O
.	1	O

We	2	O
demonstrate	11	O
that	4	O
Nef-ER	6	B-Gene
inducibly	9	O
associates	10	O
with	4	O
the	3	O
62-kDa	6	B-Gene
Ser	3	I-Gene
/	1	I-Gene
Thr	3	I-Gene
kinase	6	I-Gene
and	3	O
is	2	O
localized	9	O
to	2	O
specific	8	O
membrane	8	O
microdomains	12	O
(	1	O
lipid	5	B-Chemical
rafts	5	O
)	1	O
only	4	O
after	5	O
activation	10	O
.	1	O

Using	5	O
this	4	O
inducible	9	O
Nef	3	B-Gene
,	1	O
we	2	O
also	4	O
compared	8	O
the	3	O
specific	8	O
requirements	12	O
for	3	O
CD4	3	B-Gene
and	3	O
HLA-A2	6	B-Gene
downmodulation	14	O
in	2	O
a	1	O
SupT1	5	O
T-cell	6	O
line	4	O
.	1	O

Half-maximal	12	O
downmodulation	14	O
of	2	O
cell	4	B-Gene
surface	7	I-Gene
CD4	3	I-Gene
required	8	O
very	4	O
little	6	O
active	6	O
Nef-ER	6	B-Gene
and	3	O
occurred	8	O
as	2	O
early	5	O
as	2	O
4	1	O
h	1	O
after	5	O
addition	8	O
of	2	O
4-HT	4	B-Chemical
.	1	O

In	2	O
contrast	8	O
,	1	O
50	2	O
%	1	O
downmodulation	14	O
of	2	O
HLA-A2	6	B-Gene
by	2	O
Nef	3	B-Gene
required	8	O
16	2	O
to	2	O
24	2	O
h	1	O
and	3	O
about	5	O
50-	3	O
to	2	O
100-fold-greater	16	O
concentrations	14	O
of	2	O
4-HT	4	B-Chemical
.	1	O

These	5	O
data	4	O
suggest	7	O
that	4	O
HLA-A2	6	B-Gene
downmodulation	14	O
may	3	O
require	7	O
certain	7	O
threshold	9	O
levels	6	O
of	2	O
active	6	O
Nef	3	B-Gene
.	1	O

The	3	O
differential	12	O
timing	6	O
of	2	O
CD4	3	B-Gene
and	3	O
HLA-A2	6	B-Gene
downmodulation	14	O
may	3	O
have	4	O
implications	12	O
for	3	O
HIV	3	O
pathogenesis	12	O
and	3	O
immune	6	O
evasion	7	O
.	1	O

Strict	6	O
control	7	O
of	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
replication	11	O
by	2	O
a	1	O
genetic	7	O
switch	6	O
:	1	O
Tet	3	O
for	3	O
Tat	3	B-Gene
.	1	O

Live	4	O
-attenuated	11	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
(	1	O
HIV-1	5	O
)	1	O
variants	8	O
have	4	O
shown	5	O
great	5	O
promise	7	O
as	2	O
AIDS	4	B-Disease
vaccines	8	O
,	1	O
but	3	O
continued	9	O
replication	11	O
can	3	O
lead	4	O
to	2	O
the	3	O
selection	9	O
of	2	O
faster	6	O
-replicating	12	O
variants	8	O
that	4	O
are	3	O
pathogenic	10	O
.	1	O

We	2	O
therefore	9	O
designed	8	O
HIV-1	5	O
genomes	7	O
that	4	O
replicate	9	O
exclusively	11	O
upon	4	O
addition	8	O
of	2	O
the	3	O
nontoxic	8	O
effector	8	O
doxycycline	11	B-Chemical
(	1	O
dox	3	B-Chemical
)	1	O
.	1	O

This	4	O
was	3	O
achieved	8	O
by	2	O
replacement	11	O
of	2	O
the	3	O
viral	5	O
TAR-Tat	7	B-Gene
system	6	O
for	3	O
transcriptional	15	O
activation	10	O
by	2	O
the	3	O
Escherichia	11	O
coli	4	O
-derived	8	O
Tet	3	O
system	6	O
for	3	O
inducible	9	O
gene	4	O
expression	10	O
.	1	O

These	5	O
designer	8	O
``	2	O
HIV-rtTA	8	O
''viruses	9	O
replicate	9	O
in	2	O
a	1	O
strictly	8	O
dox	3	B-Chemical
-dependent	10	O
manner	6	O
both	4	O
in	2	O
a	1	O
T-cell	6	O
line	4	O
and	3	O
in	2	O
primary	7	O
blood	5	O
cells	5	O
,	1	O
and	3	O
the	3	O
rate	4	O
of	2	O
replication	11	O
can	3	O
be	2	O
fine	4	O
-tuned	6	O
by	2	O
simple	6	O
variation	9	O
of	2	O
the	3	O
dox	3	B-Chemical
concentration	13	O
.	1	O

These	5	O
HIV-rtTA	8	O
viruses	7	O
provide	7	O
a	1	O
tool	4	O
to	2	O
perform	7	O
genetics	8	O
,	1	O
e.g.	4	O
,	1	O
selection	9	O
and	3	O
optimization	12	O
experiments	11	O
,	1	O
with	4	O
the	3	O
E.	2	O
coli	4	O
-derived	8	O
Tet	3	O
reagents	8	O
in	2	O
a	1	O
eukaryotic	10	O
background	10	O
.	1	O

Furthermore	11	O
,	1	O
such	4	O
viruses	7	O
may	3	O
represent	9	O
improved	8	O
vaccine	7	O
candidates	10	O
because	7	O
their	5	O
replication	11	O
can	3	O
be	2	O
turned	6	O
on	2	O
and	3	O
off	3	O
at	2	O
will	4	O
.	1	O

Human	5	O
renal	5	O
mesangial	9	O
cells	5	O
are	3	O
a	1	O
target	6	O
for	3	O
the	3	O
anti-inflammatory	17	O
action	6	O
of	2	O
9-cis	5	B-Chemical
retinoic	8	I-Chemical
acid	4	I-Chemical
.	1	O

Mesangial	9	O
cells	5	O
play	4	O
an	2	O
active	6	O
role	4	O
in	2	O
the	3	O
inflammatory	12	O
response	8	O
to	2	O
glomerular	10	O
injury	6	O
.	1	O

We	2	O
have	4	O
studied	7	O
in	2	O
cultured	8	O
human	5	O
mesangial	9	O
cells	5	O
(	1	O
CHMC	4	O
)	1	O
several	7	O
effects	7	O
of	2	O
9-cis	5	B-Chemical
retinoic	8	I-Chemical
acid	4	I-Chemical
(	1	O
9-cRA	5	B-Chemical
)	1	O
,	1	O
an	2	O
activator	9	O
of	2	O
both	4	O
retinoic	8	B-Gene
acid	4	I-Gene
receptors	9	I-Gene
(	1	O
RARs	4	B-Gene
)	1	O
and	3	O
retinoid	8	B-Gene
X	1	I-Gene
receptors	9	I-Gene
(	1	O
RXRs	4	B-Gene
)	1	O
.	1	O

9-cRA	5	B-Chemical
inhibited	9	O
foetal	6	O
calf	4	O
serum	5	O
-induced	8	O
CHMC	4	O
proliferation	13	O
.	1	O

It	2	O
also	4	O
prevented	9	O
CHMC	4	O
death	5	O
induced	7	O
by	2	O
the	3	O
inflammatory	12	O
mediator	8	O
H	1	O
(	1	O
2	1	O
)	1	O
O	1	O
(	1	O
2	1	O
)	1	O
.	1	O

This	4	O
preventive	10	O
effect	6	O
was	3	O
not	3	O
due	3	O
to	2	O
any	3	O
increase	8	O
in	2	O
H	1	O
(	1	O
2	1	O
)	1	O
O	1	O
(	1	O
2	1	O
)	1	O
catabolism	10	O
and	3	O
it	2	O
persisted	9	O
even	4	O
when	4	O
both	4	O
catalase	8	B-Gene
and	3	O
glutathione	11	B-Chemical
synthesis	9	O
were	4	O
inhibited	9	O
.	1	O

Finally	7	O
,	1	O
9-cRA	5	B-Chemical
diminished	10	O
monocyte	8	O
adhesion	8	O
to	2	O
FCS	3	O
-stimulated	11	O
CHMC	4	O
.	1	O

Interestingly	13	O
,	1	O
the	3	O
retinoid	8	B-Chemical
also	4	O
inhibited	9	O
in	2	O
FCS	3	O
-stimulated	11	O
cells	5	O
the	3	O
protein	7	O
expression	10	O
of	2	O
two	3	O
mesangial	9	O
adhesion	8	O
molecules	9	O
,	1	O
fibronectin	11	B-Gene
and	3	O
osteopontin	11	B-Gene
,	1	O
but	3	O
it	2	O
did	3	O
not	3	O
modify	6	O
the	3	O
protein	7	O
expression	10	O
of	2	O
intercellular	13	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
and	3	O
vascular	8	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
.	1	O

All	3	O
major	5	O
RARs	4	B-Gene
and	3	O
RXRs	4	B-Gene
isotypes	8	O
were	4	O
expressed	9	O
in	2	O
CHMC	4	O
regardless	10	O
of	2	O
the	3	O
presence	8	O
or	2	O
absence	7	O
of	2	O
9-cRA	5	B-Chemical
.	1	O

Transcripts	11	O
to	2	O
RAR-alpha	9	B-Gene
,	1	O
RAR-beta	8	B-Gene
and	3	O
RXR-alpha	9	B-Gene
increased	9	O
after	5	O
incubation	10	O
with	4	O
9-cRA	5	B-Chemical
whereas	7	O
RXR-gamma	9	B-Gene
was	3	O
inhibited	9	O
,	1	O
suggesting	10	O
a	1	O
major	5	O
role	4	O
for	3	O
RARs	4	B-Gene
and	3	O
RXRs	4	B-Gene
in	2	O
9-cRA-anti-inflammatory	23	B-Chemical
effects	7	O
.	1	O

9-cRA	5	B-Chemical
was	3	O
toxic	5	O
only	4	O
at	2	O
50	2	O
microM	6	O
(	1	O
a	1	O
concentration	13	O
50	2	O
-	1	O
5000	4	O
times	5	O
higher	6	O
than	4	O
required	8	O
for	3	O
the	3	O
effects	7	O
above	5	O
)	1	O
.	1	O

Cell	4	O
death	5	O
occurred	8	O
by	2	O
apoptosis	9	O
,	1	O
whose	5	O
onset	5	O
was	3	O
associated	10	O
with	4	O
a	1	O
pronounced	10	O
increase	8	O
in	2	O
catalase	8	B-Gene
activity	8	O
and	3	O
reduced	7	O
glutathione	11	B-Chemical
content	7	O
,	1	O
being	5	O
more	4	O
effectively	11	O
induced	7	O
by	2	O
all-trans	9	B-Chemical
retinoic	8	I-Chemical
acid	4	I-Chemical
.	1	O

Modulation	10	O
of	2	O
the	3	O
oxidant	7	O
/	1	O
antioxidant	11	O
balance	7	O
failed	6	O
to	2	O
inhibit	7	O
apoptosis	9	O
.	1	O

We	2	O
conclude	8	O
that	4	O
mesangial	9	O
cells	5	O
might	5	O
be	2	O
a	1	O
target	6	O
for	3	O
the	3	O
treatment	9	O
of	2	O
inflammatory	12	O
glomerulopathies	16	B-Disease
with	4	O
9-cRA	5	B-Chemical
.	1	O

Combined	8	O
corticosteroid	14	B-Chemical
/	1	O
granulocyte	11	B-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
(	1	O
G-CSF	5	B-Gene
)	1	O
therapy	7	O
in	2	O
the	3	O
treatment	9	O
of	2	O
severe	6	B-Disease
congenital	10	I-Disease
neutropenia	11	I-Disease
unresponsive	12	O
to	2	O
G-CSF	5	B-Gene
:	1	O
Activated	9	B-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
synergize	9	O
with	4	O
G-CSF	5	B-Gene
signals	7	O
.	1	O

More	4	O
than	4	O
90	2	O
%	1	O
of	2	O
patients	8	O
with	4	O
severe	6	B-Disease
congenital	10	I-Disease
neutropenia	11	I-Disease
(	1	O
SCN	3	B-Disease
)	1	O
respond	7	O
to	2	O
granulocyte	11	B-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
(	1	O
G-CSF	5	B-Gene
)	1	O
therapy	7	O
.	1	O

The	3	O
basis	5	O
for	3	O
the	3	O
refractory	10	O
state	5	O
in	2	O
the	3	O
remaining	9	O
patients	8	O
is	2	O
unknown	7	O
.	1	O

To	2	O
address	7	O
this	4	O
issue	5	O
,	1	O
we	2	O
studied	7	O
a	1	O
child	5	O
with	4	O
SCN	3	B-Disease
who	3	O
was	3	O
totally	7	O
unresponsive	12	O
to	2	O
G-CSF	5	B-Gene
and	3	O
had	3	O
a	1	O
novel	5	O
point	5	O
mutation	8	O
in	2	O
the	3	O
extracellular	13	O
domain	6	O
of	2	O
the	3	O
G-CSF	5	B-Gene
receptor	8	I-Gene
(	1	O
GCSF-R	6	B-Gene
)	1	O
.	1	O

Marrow	6	O
stromal	7	O
support	7	O
of	2	O
granulopoiesis	14	O
was	3	O
evaluated	9	O
by	2	O
plating	7	O
CD34	4	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
cells	5	O
on	2	O
preformed	9	O
stromal	7	O
layers	6	O
.	1	O

Nonadherent	11	O
cells	5	O
were	4	O
harvested	9	O
and	3	O
assayed	7	O
in	2	O
clonogenic	10	O
assays	6	O
for	3	O
granulocytic	12	O
colony	6	O
production	10	O
.	1	O

The	3	O
in	2	O
vitro	5	O
effect	6	O
of	2	O
G-CSF	5	B-Gene
and	3	O
corticosteroids	15	B-Chemical
on	2	O
granulopoiesis	14	O
was	3	O
evaluated	9	O
in	2	O
clonogenic	10	O
assays	6	O
of	2	O
marrow	6	O
mononuclear	11	O
cells	5	O
,	1	O
by	2	O
proliferation	13	O
studies	7	O
of	2	O
the	3	O
murine	6	O
myeloid	7	O
cell	4	O
line	4	O
32D	3	O
expressing	10	O
the	3	O
patient	7	O
's	2	O
mutated	7	B-Gene
G-CSFR	6	I-Gene
,	1	O
and	3	O
by	2	O
measuring	9	O
STAT5	5	B-Gene
activation	10	O
in	2	O
nuclear	7	O
extracts	8	O
from	4	O
stimulated	10	O
cells	5	O
.	1	O

Patient	7	O
's	2	O
stroma	6	O
supported	9	O
granulopoiesis	14	O
derived	7	O
from	4	O
control	7	O
marrow	6	B-Gene
CD34	4	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
cells	5	O
in	2	O
a	1	O
normal	6	O
manner	6	O
.	1	O

Normal	6	O
stroma	6	O
,	1	O
however	7	O
,	1	O
failed	6	O
to	2	O
induce	6	O
granulopoiesis	14	O
from	4	O
patient	7	O
's	2	O
CD34	4	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
cells	5	O
.	1	O

Clonogenic	10	O
assays	6	O
of	2	O
the	3	O
patient	7	O
's	2	O
marrow	6	O
mononuclear	11	O
cells	5	O
incorporating	13	O
either	6	O
G-CSF	5	B-Gene
or	2	O
hydrocortisone	14	B-Chemical
produced	8	O
little	6	O
neutrophil	10	O
growth	6	O
.	1	O

In	2	O
contrast	8	O
,	1	O
inclusion	9	O
of	2	O
both	4	O
G-CSF	5	B-Gene
and	3	O
hydrocortisone	14	B-Chemical
in	2	O
the	3	O
cytokine	8	O
``	2	O
cocktail	8	O
''markedly	10	O
increased	9	O
the	3	O
neutrophil	10	O
numbers	7	O
.	1	O

Proliferation	13	O
of	2	O
32D	3	O
cells	5	O
expressing	10	O
the	3	O
mutated	7	O
receptor	8	O
and	3	O
STAT5	5	B-Gene
activation	10	O
were	4	O
improved	8	O
by	2	O
a	1	O
combination	11	O
of	2	O
G-CSF	5	B-Gene
and	3	O
dexamethasone	13	B-Chemical
.	1	O

When	4	O
small	5	O
daily	5	O
doses	5	O
of	2	O
oral	4	O
prednisone	10	B-Chemical
were	4	O
then	4	O
administered	12	O
to	2	O
the	3	O
patient	7	O
with	4	O
conventional	12	O
doses	5	O
of	2	O
subcutaneous	12	O
G-CSF	5	B-Gene
,	1	O
the	3	O
patient	7	O
responded	9	O
with	4	O
increased	9	O
neutrophil	10	O
numbers	7	O
and	3	O
with	4	O
a	1	O
complete	8	O
reversal	8	O
of	2	O
the	3	O
infectious	10	O
problems	8	O
.	1	O

These	5	O
data	4	O
provide	7	O
insight	7	O
into	4	O
SCN	3	B-Disease
unresponsive	12	O
to	2	O
standard	8	O
G-CSF	5	B-Gene
treatment	9	O
and	3	O
to	2	O
the	3	O
potential	9	O
corrective	10	O
action	6	O
of	2	O
combined	8	O
treatment	9	O
with	4	O
G-CSF	5	B-Gene
and	3	O
corticosteroids	15	B-Chemical
through	7	O
synergistic	11	O
activation	10	O
of	2	O
STAT5	5	B-Gene
.	1	O

Human	5	O
eosinophils	11	O
constitutively	14	O
express	7	O
nuclear	7	B-Gene
factor	6	I-Gene
of	2	I-Gene
activated	9	I-Gene
T	1	I-Gene
cells	5	I-Gene
p	1	I-Gene
and	3	O
c	1	B-Partial_Gene
.	1	O

BACKGROUND	10	O
:	1	O
Eosinophils	11	O
are	3	O
now	3	O
known	5	O
to	2	O
produce	7	O
a	1	O
variety	7	O
of	2	O
proinflammatory	15	O
cytokines	9	O
,	1	O
although	8	O
the	3	O
molecular	9	O
factors	7	O
that	4	O
regulate	8	O
their	5	O
production	10	O
are	3	O
poorly	6	O
understood	10	O
.	1	O

The	3	O
expression	10	O
of	2	O
almost	6	O
all	3	O
of	2	O
the	3	O
cytokines	9	O
produced	8	O
by	2	O
eosinophils	11	O
,	1	O
including	9	O
the	3	O
proallergic	11	B-Gene
cytokine	8	I-Gene
IL-4	4	I-Gene
,	1	O
is	2	O
now	3	O
known	5	O
to	2	O
be	2	O
regulated	9	O
at	2	O
the	3	O
level	5	O
of	2	O
transcription	13	O
by	2	O
members	7	O
of	2	O
the	3	O
nuclear	7	B-Gene
factor	6	I-Gene
of	2	I-Gene
activated	9	I-Gene
T	1	I-Gene
cells	5	I-Gene
(	1	I-Gene
NFAT	4	I-Gene
)	1	I-Gene
family	6	I-Gene
of	2	O
transcription	13	O
factors	7	O
.	1	O

OBJECTIVE	9	O
:	1	O
We	2	O
sought	6	O
to	2	O
characterize	12	O
the	3	O
expression	10	O
of	2	O
different	9	O
NFAT	4	B-Gene
proteins	8	I-Gene
in	2	O
resting	7	O
and	3	O
activated	9	O
eosinophils	11	O
.	1	O

METHODS	7	O
:	1	O
Nuclear	7	O
and	3	O
whole	5	O
cell	4	O
extracts	8	O
were	4	O
obtained	8	O
from	4	O
both	4	O
peripheral	10	O
blood	5	O
eosinophils	11	O
and	3	O
those	5	O
obtained	8	O
from	4	O
bronchoalveolar	15	O
lavage	6	O
fluid	5	O
of	2	O
asthmatic	9	O
subjects	8	O
after	5	O
endobronchial	13	O
allergen	8	O
challenge	9	O
.	1	O

NFAT	4	B-Gene
expression	10	O
was	3	O
determined	10	O
by	2	O
using	5	O
immunoprecipitation	19	O
and	3	O
Western	7	O
blot	4	O
analysis	8	O
,	1	O
DNA	3	O
-binding	8	O
assays	6	O
,	1	O
and	3	O
RT-PCR	6	O
analysis	8	O
of	2	O
eosinophil	10	O
mRNA	4	O
.	1	O

RESULTS	7	O
:	1	O
Both	4	O
peripheral	10	O
blood	5	O
and	3	O
bronchoalveolar	15	O
lavage	6	O
fluid	5	O
eosinophils	11	O
expressed	9	O
NFATp	5	B-Gene
and	3	O
NFATc	5	B-Gene
protein	7	I-Gene
.	1	O

Unlike	6	O
activated	9	O
T	1	O
cells	5	O
,	1	O
which	5	O
express	7	O
multiple	8	O
NFATc	5	B-Gene
isoforms	8	I-Gene
,	1	O
eosinophils	11	O
preferentially	14	O
express	7	O
the	3	O
approximately	13	O
85-kd	5	O
isoform	7	O
.	1	O

In	2	O
addition	8	O
,	1	O
eosinophils	11	O
were	4	O
found	5	O
to	2	O
constitutively	14	O
express	7	O
NFATc	5	B-Gene
mRNA	4	I-Gene
.	1	O

A	1	O
brief	5	O
incubation	10	O
with	4	O
the	3	O
T	1	O
(	1	O
H	1	O
)	1	O
2	1	O
cytokines	9	B-Gene
IL-4	4	I-Gene
and	3	O
IL-5	4	B-Gene
was	3	O
sufficient	10	O
to	2	O
induce	6	O
the	3	O
nuclear	7	O
translocation	13	O
of	2	O
NFATc	5	B-Gene
.	1	O

Eosinophil	10	O
nuclear	7	O
extracts	8	O
contain	7	O
multiple	8	O
factors	7	O
that	4	O
can	3	O
specifically	12	O
recognize	9	O
the	3	O
IL-4	4	B-Gene
promoter	8	I-Gene
P1	2	I-Gene
NFAT	4	I-Gene
site	4	O
in	2	O
DNA	3	O
-binding	8	O
assays	6	O
,	1	O
including	9	O
NFATp	5	B-Gene
.	1	O

CONCLUSION	10	O
:	1	O
NFATp	5	B-Gene
and	3	O
NFATc	5	B-Gene
can	3	O
regulate	8	O
the	3	O
expression	10	O
of	2	O
cytokines	9	O
and	3	O
other	5	O
genes	5	O
in	2	O
eosinophils	11	O
but	3	O
appear	6	O
to	2	O
be	2	O
regulated	9	O
by	2	O
a	1	O
novel	5	O
signal	6	O
transduction	12	O
mechanism	9	O
in	2	O
these	5	O
cells	5	O
.	1	O

Constitutive	12	O
expression	10	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
is	2	O
a	1	O
characteristic	14	O
feature	7	O
of	2	O
mycosis	7	B-Disease
fungoides	9	I-Disease
:	1	O
implications	12	O
for	3	O
apoptosis	9	O
resistance	10	O
and	3	O
pathogenesis	12	O
.	1	O

The	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
family	6	I-Gene
of	2	O
transcription	13	O
factors	7	O
is	2	O
an	2	O
important	9	O
regulator	9	O
of	2	O
genes	5	O
expressed	9	O
during	6	O
inflammatory	12	O
responses	9	O
,	1	O
immunoglobulin	14	B-Gene
(	1	O
Ig	2	B-Gene
)	1	O
class	5	O
switching	9	O
,	1	O
cellular	8	O
differentiation	15	O
,	1	O
and	3	O
apoptosis	9	O
.	1	O

Recently	8	O
,	1	O
members	7	O
of	2	O
the	3	O
NF-kappaB	9	B-Gene
family	6	I-Gene
,	1	O
including	9	O
p65	3	B-Gene
(	1	O
Rel	3	B-Gene
A	1	I-Gene
)	1	O
,	1	O
have	4	O
been	4	O
implicated	10	O
in	2	O
promoting	9	O
survival	8	O
of	2	O
various	7	O
hematopoeitic	13	B-Disease
neoplasms	9	I-Disease
,	1	O
including	9	O
T	1	O
cell	4	O
malignancies	12	O
such	4	O
as	2	O
adult	5	B-Disease
T	1	I-Disease
cell	4	I-Disease
leukemia-lymphoma	17	I-Disease
.	1	O

We	2	O
investigated	12	O
the	3	O
expression	10	O
of	2	O
active	6	O
NF-kappa	8	B-Gene
B	1	I-Gene
p65	3	I-Gene
(	1	O
Rel	3	B-Gene
A	1	I-Gene
)	1	O
in	2	O
cases	5	O
of	2	O
mycosis	7	B-Disease
fungoides	9	I-Disease
(	1	O
MF	2	B-Disease
)	1	O
and	3	O
the	3	O
effect	6	O
of	2	O
chemical	8	O
inhibitors	10	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
on	2	O
apoptosis	9	O
in	2	O
cutaneous	9	B-Disease
T	1	I-Disease
cell	4	I-Disease
lymphoma	8	I-Disease
(	1	O
CTCL	4	B-Disease
)	1	O
cell	4	O
lines	5	O
.	1	O

Paraffin	8	B-Chemical
-embedded	9	O
tissues	7	O
from	4	O
23	2	O
cutaneous	9	O
lesions	7	O
and	3	O
a	1	O
single	6	O
lymph	5	O
node	4	O
biopsy	6	O
from	4	O
patients	8	O
diagnosed	9	O
with	4	O
MF	2	B-Disease
were	4	O
evaluated	9	O
for	3	O
p65	3	B-Gene
(	1	O
Rel	3	B-Gene
A	1	I-Gene
)	1	O
expression	10	O
by	2	O
using	5	O
a	1	O
monoclonal	10	O
mouse	5	O
antibody	8	O
that	4	O
detects	7	O
the	3	O
activated	9	O
form	4	O
of	2	O
p65	3	B-Gene
(	1	O
Rel	3	B-Gene
A	1	I-Gene
)	1	O
.	1	O

Apoptosis	9	O
after	5	O
treatment	9	O
with	4	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
inhibitors	10	I-Gene
gliotoxin	9	B-Chemical
,	1	O
MG132	5	B-Chemical
,	1	O
BAY	3	B-Chemical
11-7082	7	I-Chemical
,	1	O
and	3	O
BAY	3	B-Chemical
11-7085	7	I-Chemical
was	3	O
quantitatively	14	O
measured	8	O
in	2	O
the	3	O
CTCL	4	B-Disease
cell	4	O
lines	5	O
HuT-78	6	O
and	3	O
HH	2	O
by	2	O
propidium	9	B-Chemical
iodide	6	I-Chemical
(	1	O
PI	2	B-Chemical
)	1	O
/	1	O
cell	4	O
cycle	5	O
analysis	8	O
for	3	O
detection	9	O
of	2	O
a	1	O
hypodiploid	11	O
(	1	O
sub-G	5	O
(	1	O
0	1	O
)	1	O
)	1	O
population	10	O
and	3	O
by	2	O
determination	13	O
of	2	O
increased	9	O
Annexin	7	B-Gene
V	1	I-Gene
/	1	O
7-amino-actinomycin	19	B-Chemical
D	1	I-Chemical
(	1	O
7-AAD	5	B-Chemical
)	1	O
expression	10	O
.	1	O

Nuclear	7	O
extracts	8	O
from	4	O
CTCL	4	B-Disease
cells	5	O
before	6	O
and	3	O
after	5	O
chemical	8	O
inhibition	10	O
were	4	O
analyzed	8	O
for	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
nuclear	7	I-Gene
DNA	3	I-Gene
-binding	8	O
activity	8	O
by	2	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assay	5	O
(	1	O
EMSA	4	O
)	1	O
with	4	O
quantitative	12	O
densitometry	12	O
.	1	O

Nuclear	7	O
expression	10	O
of	2	O
p65	3	B-Gene
(	1	O
Rel	3	B-Gene
A	1	I-Gene
)	1	O
before	6	O
and	3	O
after	5	O
treatment	9	O
with	4	O
the	3	O
various	7	O
inhibitory	10	O
compounds	9	O
was	3	O
measured	8	O
by	2	O
immunofluorescence	18	O
staining	8	O
in	2	O
each	4	O
CTCL	4	B-Disease
cell	4	O
line	4	O
.	1	O

Neoplastic	10	O
T	1	O
lymphocytes	11	O
from	4	O
22	2	O
of	2	O
24	2	O
cases	5	O
of	2	O
MF	2	B-Disease
showed	6	O
strong	6	O
nuclear	7	O
and	3	O
cytoplasmic	11	O
expression	10	O
of	2	O
active	6	O
p65	3	B-Gene
(	1	O
Rel	3	B-Gene
A	1	I-Gene
)	1	O
.	1	O

Compared	8	O
with	4	O
untreated	9	O
control	7	O
cells	5	O
,	1	O
a	1	O
marked	6	O
increase	8	O
in	2	O
apoptosis	9	O
,	1	O
a	1	O
significant	11	O
decrease	8	O
in	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
DNA	3	I-Gene
-binding	8	O
activity	8	O
,	1	O
and	3	O
a	1	O
marked	6	O
decrease	8	O
in	2	O
nuclear	7	B-Gene
p65	3	I-Gene
(	1	O
Rel	3	B-Gene
A	1	I-Gene
)	1	O
expression	10	O
were	4	O
seen	4	O
in	2	O
cells	5	O
from	4	O
both	4	O
CTCL	4	B-Disease
cell	4	O
lines	5	O
after	5	O
chemical	8	O
NF-kappa	8	B-Gene
B	1	I-Gene
inhibition	10	O
.	1	O

These	5	O
data	4	O
show	4	O
that	4	O
the	3	O
active	6	O
form	4	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
p65	3	I-Gene
(	1	O
Rel	3	B-Gene
A	1	I-Gene
)	1	O
is	2	O
commonly	8	O
expressed	9	O
in	2	O
neoplastic	10	O
T	1	O
lymphocytes	11	O
in	2	O
patients	8	O
with	4	O
MF	2	B-Disease
.	1	O

In	2	O
CTCL	4	B-Disease
cell	4	O
lines	5	O
,	1	O
the	3	O
significant	11	O
decrease	8	O
in	2	O
nuclear	7	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
expression	10	O
and	3	O
the	3	O
marked	6	O
increase	8	O
in	2	O
spontaneous	11	O
apoptosis	9	O
caused	6	O
by	2	O
chemical	8	O
NF-kappa	8	B-Gene
B	1	I-Gene
inhibition	10	O
suggest	7	O
a	1	O
critical	8	O
role	4	O
for	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
in	2	O
the	3	O
pathogenesis	12	O
and	3	O
tumor	5	B-Disease
cell	4	O
maintenance	11	O
of	2	O
CTCLs	5	B-Disease
.	1	O

HUM	3	O
PATHOL	6	O
31	2	O
:	1	O
1482-1490	9	O
.	1	O

Down-regulation	15	O
of	2	O
BOB.1	5	B-Gene
/	1	I-Gene
OBF.1	5	I-Gene
and	3	O
Oct2	4	B-Gene
in	2	O
classical	9	O
Hodgkin	7	B-Disease
disease	7	I-Disease
but	3	O
not	3	O
in	2	O
lymphocyte	10	O
predominant	11	O
Hodgkin	7	B-Disease
disease	7	I-Disease
correlates	10	O
with	4	O
immunoglobulin	14	B-Gene
transcription	13	O
.	1	O

In	2	O
contrast	8	O
to	2	O
the	3	O
tumor	5	B-Disease
cells	5	O
(	1	O
L	1	O
&	1	O
H	1	O
cells	5	O
)	1	O
of	2	O
lymphocyte	10	O
predominant	11	O
Hodgkin	7	B-Disease
disease	7	I-Disease
(	1	O
LPHD	4	B-Disease
)	1	O
,	1	O
Hodgkin	7	O
and	3	O
Reed-Sternberg	14	O
(	1	O
HRS	3	O
)	1	O
cells	5	O
of	2	O
classical	9	O
Hodgkin	7	B-Disease
disease	7	I-Disease
(	1	O
cHD	3	B-Disease
)	1	O
are	3	O
unable	6	O
to	2	O
transcribe	10	O
immunoglobulin	14	B-Gene
,	1	O
despite	7	O
the	3	O
presence	8	O
of	2	O
rearranged	10	O
immunoglobulin	14	B-Gene
genes	5	I-Gene
.	1	O

Although	8	O
initial	7	O
studies	7	O
have	4	O
suggested	9	O
crippling	9	O
immunoglobulin	14	B-Gene
gene	4	I-Gene
mutations	9	O
to	2	O
be	2	O
the	3	O
cause	5	O
of	2	O
absent	6	O
immunoglobulin	14	B-Gene
expression	10	O
in	2	O
cHD	3	B-Disease
,	1	O
recent	6	O
work	4	O
of	2	O
our	3	O
group	5	O
has	3	O
demonstrated	12	O
an	2	O
impaired	8	O
activation	10	O
of	2	O
the	3	O
immunoglobulin	14	B-Gene
promoter	8	I-Gene
as	2	O
a	1	O
superior	8	O
mechanism	9	O
.	1	O

As	2	O
immunoglobulin	14	B-Gene
transcription	13	O
is	2	O
mainly	6	O
regulated	9	O
by	2	O
the	3	O
B-cell	6	B-Gene
transcription	13	I-Gene
factors	7	I-Gene
Oct2	4	I-Gene
and	3	O
BOB.1	5	B-Gene
/	1	I-Gene
OBF.1	5	I-Gene
,	1	O
we	2	O
analyzed	8	O
35	2	O
cases	5	O
of	2	O
LPHD	4	B-Disease
,	1	O
32	2	O
cases	5	O
of	2	O
cHD	3	B-Disease
,	1	O
and	3	O
2	1	O
Hodgkin	7	B-Disease
disease	7	I-Disease
cell	4	O
lines	5	O
for	3	O
the	3	O
expression	10	O
of	2	O
these	5	O
transcription	13	O
factors	7	O
and	3	O
also	4	O
in	2	O
parallel	8	O
for	3	O
immunoglobulin	14	B-Gene
expression	10	O
.	1	O

Our	3	O
results	7	O
demonstrate	11	O
an	2	O
absence	7	O
of	2	O
Oct2	4	B-Gene
and	3	O
/	1	O
or	2	O
BOB.1	5	B-Gene
/	1	I-Gene
OBF.1	5	I-Gene
in	2	O
cHD	3	B-Disease
and	3	O
a	1	O
striking	8	O
overexpression	14	O
of	2	O
Oct2	4	B-Gene
in	2	O
LPHD	4	B-Disease
.	1	O

Immunoglobulin	14	B-Gene
expression	10	O
was	3	O
lacking	7	O
in	2	O
cHD	3	B-Disease
but	3	O
present	7	O
in	2	O
LPHD	4	B-Disease
.	1	O

Furthermore	11	O
,	1	O
the	3	O
reintroduction	14	O
of	2	O
BOB.1	5	B-Gene
/	1	I-Gene
OBF.1	5	I-Gene
and	3	O
Oct2	4	B-Gene
into	4	O
cultured	8	O
HRS	3	O
cells	5	O
restored	8	O
the	3	O
activity	8	O
of	2	O
cotransduced	12	O
immunoglobulin	14	B-Gene
promoter	8	I-Gene
constructs	10	O
.	1	O

Our	3	O
findings	8	O
dismiss	7	O
the	3	O
concept	7	O
that	4	O
the	3	O
different	9	O
immunoglobulin	14	B-Gene
expression	10	O
in	2	O
cHD	3	B-Disease
and	3	O
LPHD	4	B-Disease
is	2	O
due	3	O
to	2	O
disrupting	10	O
mutations	9	O
of	2	O
immunoglobulin	14	B-Gene
V	1	I-Gene
genes	5	I-Gene
in	2	O
cHD	3	B-Disease
but	3	O
is	2	O
most	4	O
likely	6	O
due	3	O
to	2	O
a	1	O
down-regulation	15	O
of	2	O
Oct2	4	B-Gene
and	3	O
/	1	O
or	2	O
BOB.1	5	B-Gene
/	1	I-Gene
OBF.1	5	I-Gene
.	1	O

This	4	O
study	5	O
further	7	O
revealed	8	O
Oct2	4	B-Gene
as	2	O
a	1	O
new	3	O
and	3	O
valuable	8	O
marker	6	O
for	3	O
the	3	O
identification	14	O
of	2	O
L	1	O
&	1	O
H	1	O
cells	5	O
and	3	O
their	5	O
distinction	11	O
from	4	O
HRS	3	O
cells	5	O
.	1	O

The	3	O
impairment	10	O
of	2	O
immunoglobulin	14	B-Gene
transcription	13	O
with	4	O
a	1	O
down	4	O
-regulated	10	O
synthesis	9	O
of	2	O
Oct2	4	B-Gene
and	3	O
BOB.1	5	B-Gene
/	1	I-Gene
OBF.1	5	I-Gene
is	2	O
the	3	O
first	5	O
established	11	O
general	7	O
recurrent	9	O
defect	6	O
found	5	O
in	2	O
HRS	3	O
cells	5	O
.	1	O

Suppression	11	O
of	2	O
HIV	3	O
type	4	O
1	1	O
replication	11	O
by	2	O
a	1	O
dominant	8	O
-negative	9	O
Ets-1	5	B-Gene
mutant	6	I-Gene
.	1	O

Activity	8	O
of	2	O
the	3	O
distal	6	O
region	6	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
(	1	O
HIV-1	5	O
)	1	O
long	4	O
terminal	8	O
repeat	6	O
(	1	O
LTR	3	O
)	1	O
,	1	O
which	5	O
contains	8	O
binding	7	O
sites	5	O
for	3	O
the	3	O
Ets-1	5	B-Gene
and	3	O
USF-1	5	B-Gene
proteins	8	I-Gene
,	1	O
is	2	O
integral	8	O
for	3	O
HIV-1	5	O
replication	11	O
.	1	O

The	3	O
Ets-1	5	B-Gene
and	3	O
USF-1	5	B-Gene
proteins	8	I-Gene
play	4	O
a	1	O
critical	8	O
role	4	O
in	2	O
the	3	O
activity	8	O
of	2	O
the	3	O
HIV-1	5	O
LTR	3	O
distal	6	O
enhancer	8	O
region	6	O
,	1	O
as	2	O
indicated	9	O
by	2	O
the	3	O
potent	6	O
dominant	8	O
negative	8	O
effect	6	O
of	2	O
a	1	O
mutant	6	B-Gene
Ets-1	5	I-Gene
lacking	7	O
trans-activation	16	O
domains	7	O
on	2	O
the	3	O
transcriptional	15	O
activity	8	O
of	2	O
the	3	O
LTR	3	O
.	1	O

To	2	O
determine	9	O
the	3	O
biological	10	O
relevance	9	O
of	2	O
the	3	O
Ets-1	5	B-Gene
and	3	O
USF-1	5	B-Gene
proteins	8	I-Gene
in	2	O
HIV-1	5	O
replication	11	O
,	1	O
we	2	O
examined	8	O
the	3	O
effect	6	O
of	2	O
expression	10	O
of	2	O
the	3	O
dominant	8	O
-negative	9	O
mutant	6	O
of	2	O
Ets-1	5	B-Gene
(	1	O
dnEts-1	7	B-Gene
)	1	O
on	2	O
HIV-1	5	O
infection	9	O
of	2	O
T	1	O
cells	5	O
.	1	O

We	2	O
demonstrated	12	O
that	4	O
expression	10	O
of	2	O
dnEts	5	B-Gene
markedly	8	O
suppressed	10	O
HIV-1	5	O
infection	9	O
of	2	O
a	1	O
T	1	O
cell	4	O
line	4	O
.	1	O

This	4	O
finding	7	O
indicates	9	O
that	4	O
formation	9	O
of	2	O
a	1	O
transcriptionaly	16	O
active	6	O
USF-1	5	B-Gene
/	1	I-Gene
Ets-1	5	I-Gene
complex	7	I-Gene
is	2	O
important	9	O
in	2	O
the	3	O
productive	10	O
infection	9	O
of	2	O
cells	5	O
by	2	O
HIV-1	5	O
,	1	O
and	3	O
suggests	8	O
that	4	O
inhibition	10	O
of	2	O
the	3	O
interaction	11	O
between	7	O
USF-1	5	B-Gene
and	3	O
Ets-1	5	B-Gene
with	4	O
the	3	O
HIV-1	5	O
LTR	3	O
may	3	O
provide	7	O
a	1	O
new	3	O
target	6	O
for	3	O
anti-HIV-1	10	O
gene	4	O
therapy	7	O
.	1	O

T-cell	6	O
-mediated	9	O
regulation	10	O
of	2	O
osteoclastogenesis	18	O
by	2	O
signalling	10	O
cross-talk	10	O
between	7	O
RANKL	5	B-Gene
and	3	O
IFN-gamma	9	B-Gene
.	1	O

Bone	4	O
resorption	10	O
is	2	O
regulated	9	O
by	2	O
the	3	O
immune	6	O
system	6	O
,	1	O
where	5	O
T-cell	6	O
expression	10	O
of	2	O
RANKL	5	B-Gene
(	1	O
receptor	8	B-Gene
activator	9	I-Gene
of	2	I-Gene
nuclear	7	I-Gene
factor	6	I-Gene
(	1	I-Gene
NF	2	I-Gene
)	1	I-Gene
-kappaB	7	I-Gene
ligand	6	I-Gene
)	1	O
,	1	O
a	1	O
member	6	O
of	2	O
the	3	O
tumour-necrosis	15	B-Gene
factor	6	I-Gene
family	6	I-Gene
that	4	O
is	2	O
essential	9	O
for	3	O
osteoclastogenesis	18	O
,	1	O
may	3	O
contribute	10	O
to	2	O
pathological	12	O
conditions	10	O
,	1	O
such	4	O
as	2	O
autoimmune	10	B-Disease
arthritis	9	I-Disease
.	1	O

However	7	O
,	1	O
whether	7	O
activated	9	O
T	1	O
cells	5	O
maintain	8	O
bone	4	O
homeostasis	11	O
by	2	O
counterbalancing	16	O
the	3	O
action	6	O
of	2	O
RANKL	5	B-Gene
remains	7	O
unknown	7	O
.	1	O

Here	4	O
we	2	O
show	4	O
that	4	O
T-cell	6	O
production	10	O
of	2	O
interferon	10	B-Gene
(	1	I-Gene
IFN	3	I-Gene
)	1	I-Gene
-gamma	6	I-Gene
strongly	8	O
suppresses	10	O
osteoclastogenesis	18	O
by	2	O
interfering	11	O
with	4	O
the	3	O
RANKL	5	B-Gene
-RANK	5	I-Gene
signalling	10	O
pathway	7	O
.	1	O

IFN-gamma	9	B-Gene
induces	7	O
rapid	5	O
degradation	11	O
of	2	O
the	3	O
RANK	4	B-Gene
adapter	7	I-Gene
protein	7	I-Gene
,	1	O
TRAF6	5	B-Gene
(	1	O
tumour	6	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
receptor	8	I-Gene
-associated	11	I-Gene
factor	6	I-Gene
6	1	I-Gene
)	1	O
,	1	O
which	5	O
results	7	O
in	2	O
strong	6	O
inhibition	10	O
of	2	O
the	3	O
RANKL	5	B-Gene
-induced	8	O
activation	10	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
NF-kappaB	9	I-Gene
and	3	O
JNK	3	B-Gene
.	1	O

This	4	O
inhibition	10	O
of	2	O
osteoclastogenesis	18	O
is	2	O
rescued	7	O
by	2	O
overexpressing	14	O
TRAF6	5	B-Gene
in	2	O
precursor	9	O
cells	5	O
,	1	O
which	5	O
indicates	9	O
that	4	O
TRAF6	5	B-Gene
is	2	O
the	3	O
target	6	O
critical	8	O
for	3	O
the	3	O
IFN-gamma	9	B-Gene
action	6	O
.	1	O

Furthermore	11	O
,	1	O
we	2	O
provide	7	O
evidence	8	O
that	4	O
the	3	O
accelerated	11	O
degradation	11	O
of	2	O
TRAF6	5	B-Gene
requires	8	O
both	4	O
its	3	O
ubiquitination	14	O
,	1	O
which	5	O
is	2	O
initiated	9	O
by	2	O
RANKL	5	B-Gene
,	1	O
and	3	O
IFN-gamma	9	B-Gene
-induced	8	O
activation	10	O
of	2	O
the	3	O
ubiquitin-proteasome	20	B-Gene
system	6	O
.	1	O

Our	3	O
study	5	O
shows	5	O
that	4	O
there	5	O
is	2	O
cross-talk	10	O
between	7	O
the	3	O
tumour	6	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
and	3	O
IFN	3	B-Gene
families	8	I-Gene
of	2	O
cytokines	9	O
,	1	O
through	7	O
which	5	O
IFN-gamma	9	B-Gene
provides	8	O
a	1	O
negative	8	O
link	4	O
between	7	O
T-cell	6	O
activation	10	O
and	3	O
bone	4	O
resorption	10	O
.	1	O

Our	3	O
results	7	O
may	3	O
offer	5	O
a	1	O
therapeutic	11	O
approach	8	O
to	2	O
treat	5	O
the	3	O
inflammation	12	O
-induced	8	O
tissue	6	O
breakdown	9	O
.	1	O

Synovial	8	O
fluid	5	O
induced	7	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
DNA	3	I-Gene
binding	7	O
in	2	O
a	1	O
monocytic	9	O
cell	4	O
line	4	O
.	1	O

OBJECTIVE	9	O
:	1	O
To	2	O
determine	9	O
the	3	O
effects	7	O
of	2	O
synovial	8	O
fluids	6	O
(	1	O
SF	2	O
)	1	O
on	2	O
DNA	3	O
binding	7	O
activity	8	O
of	2	O
transcription	13	B-Gene
factor	6	I-Gene
nuclear	7	I-Gene
factor-kappaB	13	I-Gene
(	1	O
NF-kappaB	9	B-Gene
)	1	O
in	2	O
the	3	O
Mono	4	O
Mac	3	O
6	1	O
monocytic	9	O
/	1	O
macrophage	10	O
cell	4	O
line	4	O
as	2	O
a	1	O
model	5	O
for	3	O
the	3	O
interaction	11	O
between	7	O
SF	2	O
and	3	O
synovial	8	O
tissue	6	O
macrophages	11	O
in	2	O
arthritis	9	B-Disease
.	1	O

METHODS	7	O
:	1	O
Mono	4	O
Mac	3	O
6	1	O
cells	5	O
were	4	O
incubated	9	O
with	4	O
SF	2	O
from	4	O
the	3	O
knee	4	O
joints	6	O
of	2	O
human	5	O
subjects	8	O
with	4	O
rheumatoid	10	B-Disease
arthritis	9	I-Disease
(	1	O
RA	2	B-Disease
)	1	O
,	1	O
undifferentiated	16	O
seronegative	12	O
oligoarthritis	14	B-Disease
,	1	O
and	3	O
osteoarthritis	14	B-Disease
(	1	O
OA	2	B-Disease
)	1	O
.	1	O

Nuclear	7	O
extracts	8	O
prepared	8	O
from	4	O
the	3	O
Mono	4	O
Mac	3	O
6	1	O
cells	5	O
and	3	O
RA	2	B-Disease
synovial	8	O
tissue	6	O
were	4	O
analyzed	8	O
by	2	O
electrophoretic	15	O
mobility	8	O
shift	5	O
analysis	8	O
(	1	O
EMSA	4	O
)	1	O
for	3	O
NF-kappaB	9	B-Gene
DNA	3	I-Gene
binding	7	I-Gene
proteins	8	I-Gene
.	1	O

RESULTS	7	O
:	1	O
Induction	9	O
of	2	O
NF-kappaB	9	B-Gene
DNA	3	I-Gene
binding	7	O
by	2	O
the	3	O
p65	3	B-Gene
(	1	I-Gene
RelA	4	I-Gene
)	1	I-Gene
/	1	I-Gene
p50	3	I-Gene
heterodimer	11	O
was	3	O
observed	8	O
in	2	O
response	8	O
to	2	O
incubation	10	O
of	2	O
Mono	4	O
Mac	3	O
6	1	O
cells	5	O
with	4	O
SF	2	O
(	1	O
20	2	O
%	1	O
in	2	O
culture	7	O
medium	6	O
)	1	O
from	4	O
5	1	O
of	2	O
8	1	O
subjects	8	O
with	4	O
RA	2	B-Disease
,	1	O
4	1	O
of	2	O
5	1	O
with	4	O
OA	2	B-Disease
,	1	O
and	3	O
none	4	O
of	2	O
3	1	O
with	4	O
undifferentiated	16	O
seronegative	12	O
oligoarthritis	14	B-Disease
.	1	O

Incubation	10	O
of	2	O
SF	2	O
with	4	O
neutralizing	12	O
antibodies	10	O
against	7	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor-alpha	12	I-Gene
(	1	O
TNF-alpha	9	B-Gene
)	1	O
,	1	O
but	3	O
not	3	O
antibodies	10	O
against	7	O
interleukin	11	B-Gene
6	1	I-Gene
(	1	O
IL-6	4	B-Gene
)	1	O
,	1	O
significantly	13	O
reduced	7	O
the	3	O
induction	9	O
of	2	O
p65	3	B-Gene
/	1	I-Gene
p50	3	I-Gene
binding	7	O
activity	8	O
in	2	O
SF	2	O
from	4	O
subjects	8	O
with	4	O
RA	2	B-Disease
and	3	O
OA	2	B-Disease
.	1	O

Unexpectedly	12	O
,	1	O
a	1	O
slowly	6	O
migrating	9	O
SF	2	O
inducible	9	O
NF-kappaB	9	B-Gene
-binding	8	O
complex	7	O
was	3	O
observed	8	O
in	2	O
EMSA	4	O
of	2	O
Mono	4	O
Mac	3	O
6	1	O
cells	5	O
after	5	O
incubation	10	O
with	4	O
SF	2	O
from	4	O
5	1	O
of	2	O
8	1	O
RA	2	B-Disease
and	3	O
2	1	O
of	2	O
5	1	O
OA	2	B-Disease
subjects	8	O
.	1	O

The	3	O
induction	9	O
of	2	O
this	4	O
complex	7	O
by	2	O
SF	2	O
was	3	O
not	3	O
affected	8	O
by	2	O
neutralization	14	O
of	2	O
TNF-alpha	9	B-Gene
or	2	O
IL-6	4	B-Gene
in	2	O
SF	2	O
,	1	O
and	3	O
the	3	O
complex	7	O
was	3	O
not	3	O
inducible	9	O
by	2	O
TNF-alpha	9	B-Gene
,	1	O
IL-1beta	8	B-Gene
,	1	O
TNF-alpha	9	B-Gene
/	1	I-Gene
IL-1beta	8	I-Gene
,	1	O
IL-6	4	B-Gene
,	1	O
platelet	8	B-Gene
derived	7	I-Gene
growth	6	I-Gene
factor	6	I-Gene
,	1	O
lipopolysaccharide	18	B-Chemical
,	1	O
or	2	O
tetradecanoyl	13	B-Chemical
phorbol	7	I-Chemical
acetate	7	I-Chemical
.	1	O

The	3	O
slowly	6	O
migrating	9	O
complex	7	O
could	5	O
not	3	O
be	2	O
supershifted	12	O
with	4	O
antibodies	10	O
against	7	O
NF-kappaB	9	B-Gene
,	1	O
Jun	3	B-Gene
,	1	O
or	2	O
the	3	O
transcriptional	15	B-Gene
coactivators	12	I-Gene
p300	4	I-Gene
or	2	O
CBP	3	B-Gene
.	1	O

A	1	O
NF-kappaB	9	B-Gene
-binding	8	O
complex	7	O
with	4	O
similar	7	O
slow	4	O
mobility	8	O
was	3	O
observed	8	O
in	2	O
nuclear	7	O
extracts	8	O
prepared	8	O
from	4	O
fresh	5	O
human	5	O
RA	2	B-Disease
synovial	8	O
tissue	6	O
.	1	O

CONCLUSION	10	O
:	1	O
Biological	10	O
activity	8	O
of	2	O
TNF-alpha	9	B-Gene
in	2	O
SF	2	O
from	4	O
RA	2	B-Disease
and	3	O
OA	2	B-Disease
subjects	8	O
is	2	O
capable	7	O
of	2	O
inducing	8	O
p65	3	B-Gene
/	1	I-Gene
p50	3	I-Gene
NF-kappaB	9	I-Gene
DNA	3	I-Gene
binding	7	O
activity	8	O
in	2	O
macrophages	11	O
.	1	O

A	1	O
property	8	O
of	2	O
SF	2	O
that	4	O
is	2	O
independent	11	O
of	2	O
TNF-alpha	9	B-Gene
and	3	O
other	5	O
cytokines	9	O
is	2	O
responsible	11	O
for	3	O
the	3	O
induction	9	O
of	2	O
a	1	O
novel	5	O
slowly	6	O
migrating	9	O
NF-kappaB	9	B-Gene
-binding	8	O
complex	7	O
.	1	O

Soluble	7	O
mediators	9	O
in	2	O
SF	2	O
of	2	O
subjects	8	O
with	4	O
RA	2	B-Disease
and	3	O
OA	2	B-Disease
can	3	O
therefore	9	O
modulate	8	O
binding	7	O
of	2	O
nuclear	7	O
proteins	8	O
to	2	O
the	3	O
NF-kappaB	9	B-Gene
binding	7	O
site	4	O
in	2	O
macrophages	11	O
and	3	O
may	3	O
play	4	O
a	1	O
role	4	O
in	2	O
inflammatory	12	O
gene	4	O
expression	10	O
in	2	O
arthritis	9	B-Disease
.	1	O

Expression	10	O
of	2	O
mammalian	9	B-Gene
defensin	8	I-Gene
genes	5	I-Gene
.	1	O

Antimicrobial	13	O
peptides	8	O
are	3	O
a	1	O
prevalent	9	O
mechanism	9	O
of	2	O
host	4	O
defense	7	O
found	5	O
throughout	10	O
nature	6	O
.	1	O

In	2	O
mammals	7	O
,	1	O
defensins	9	B-Gene
are	3	O
among	5	O
the	3	O
most	4	O
abundant	8	O
of	2	O
these	5	O
broad-spectrum	14	O
antibiotics	11	O
,	1	O
and	3	O
are	3	O
expressed	9	O
in	2	O
epithelial	10	O
and	3	O
hematopoietic	13	O
cells	5	O
.	1	O

The	3	O
defensin	8	B-Gene
peptides	8	O
are	3	O
especially	10	O
abundant	8	O
in	2	O
neutrophils	11	O
;	1	O
however	7	O
,	1	O
gene	4	O
expression	10	O
is	2	O
limited	7	O
to	2	O
the	3	O
promyelocyte	12	O
stage	5	O
.	1	O

In	2	O
epithelial	10	O
cells	5	O
,	1	O
defensin	8	B-Gene
genes	5	I-Gene
are	3	O
found	5	O
as	2	O
both	4	O
constitutively	14	O
expressed	9	O
and	3	O
inducible	9	O
.	1	O

Induction	9	O
has	3	O
been	4	O
observed	8	O
in	2	O
vitro	5	O
by	2	O
stimulation	11	O
with	4	O
bacterial	9	O
lipopolysaccharide	18	B-Chemical
as	2	O
well	4	O
as	2	O
inflammatory	12	O
mediators	9	O
.	1	O

In	2	O
vivo	4	O
,	1	O
up-regulation	13	O
of	2	O
several	7	O
defensin	8	B-Gene
genes	5	I-Gene
occurs	6	O
in	2	O
both	4	O
infectious	10	O
and	3	O
inflammatory	12	O
states	6	O
.	1	O

Gene	4	O
regulation	10	O
occurs	6	O
via	3	O
signal	6	O
transduction	12	O
pathways	8	O
common	6	O
to	2	O
other	5	O
innate	6	O
immune	6	O
responses	9	O
,	1	O
utilizing	9	O
transcription	13	O
factors	7	O
such	4	O
as	2	O
nuclear	7	B-Gene
factor	6	I-Gene
(	1	I-Gene
NF	2	I-Gene
)	1	I-Gene
-kappaB	7	I-Gene
and	3	O
NF	2	B-Gene
interleukin-6	13	I-Gene
.	1	O

Together	8	O
,	1	O
the	3	O
data	4	O
suggest	7	O
a	1	O
broad	5	O
-based	6	O
innate	6	O
host	4	O
defense	7	O
whereby	7	O
potent	6	O
antimicrobial	13	O
peptides	8	O
are	3	O
present	7	O
to	2	O
prevent	7	O
initial	7	O
colonization	12	O
by	2	O
pathogenic	10	O
microorganisms	14	O
.	1	O

In	2	O
addition	8	O
,	1	O
the	3	O
recognition	11	O
of	2	O
bacteria	8	O
coupled	7	O
with	4	O
a	1	O
nascent	7	O
inflammatory	12	O
response	8	O
can	3	O
bolster	7	O
this	4	O
defense	7	O
by	2	O
a	1	O
coordinated	11	O
up-regulation	13	O
of	2	O
the	3	O
peptides	8	O
.	1	O

Regulation	10	O
of	2	O
chemokine	9	O
mRNA	4	O
expression	10	O
in	2	O
a	1	O
rat	3	O
model	5	O
of	2	O
vanadium	8	B-Chemical
-induced	8	O
pulmonary	9	B-Disease
inflammation	12	I-Disease
.	1	O

Environmental	13	O
and	3	O
occupational	12	O
exposure	8	O
to	2	O
vanadium	8	B-Chemical
dusts	5	O
results	7	O
in	2	O
toxic	5	O
effects	7	O
mainly	6	O
confined	8	O
to	2	O
the	3	O
respiratory	11	O
system	6	O
.	1	O

Using	5	O
a	1	O
rat	3	O
model	5	O
of	2	O
acute	5	B-Disease
lung	4	I-Disease
inflammation	12	I-Disease
induced	7	O
by	2	O
intratracheal	13	O
instillation	12	O
of	2	O
sodium	6	B-Chemical
metavanadate	12	I-Chemical
(	1	O
NaVO3	5	O
)	1	O
at	2	O
the	3	O
dose	4	O
of	2	O
200	3	O
microg	6	O
V	1	O
/	1	O
kg	2	O
,	1	O
we	2	O
investigated	12	O
the	3	O
relationship	12	O
between	7	O
the	3	O
cytologic	9	O
characterization	16	O
of	2	O
pulmonary	9	B-Disease
inflammation	12	I-Disease
and	3	O
the	3	O
expression	10	O
of	2	O
chemokine	9	O
mRNA	4	O
.	1	O

Significant	11	O
polymorphonuclear	17	O
leukocyte	9	O
(	1	O
PMN	3	O
)	1	O
influx	6	O
(	1	O
P	1	O
<	1	O
0.01	4	O
)	1	O
into	4	O
the	3	O
lung	4	O
was	3	O
noted	5	O
4	1	O
h	1	O
after	5	O
NaVO3	5	O
instillation	12	O
,	1	O
whereas	7	O
alveolar	8	O
macrophages	11	O
(	1	O
AMs	3	O
)	1	O
in	2	O
bronchoalveolar	15	O
lavage	6	O
(	1	O
BAL	3	O
)	1	O
cells	5	O
appeared	8	O
to	2	O
decrease	8	O
significantly	13	O
.	1	O

In	2	O
contrast	8	O
,	1	O
neither	7	O
PMNs	4	O
nor	3	O
AMs	3	O
changed	7	O
substantially	13	O
1	1	O
h	1	O
after	5	O
NaVO3	5	O
instillation	12	O
.	1	O

By	2	O
Northern	8	O
analysis	8	O
,	1	O
macrophage	10	B-Gene
inflammatory	12	I-Gene
protein	7	I-Gene
(	1	I-Gene
MIP	3	I-Gene
)	1	I-Gene
-2	2	I-Gene
mRNA	4	I-Gene
in	2	O
BAL	3	O
cells	5	O
increased	9	O
markedly	8	O
1	1	O
h	1	O
after	5	O
NaVO3	5	O
instillation	12	O
and	3	O
reduced	7	O
a	1	O
little	6	O
bit	3	O
at	2	O
4	1	O
h	1	O
,	1	O
whereas	7	O
MIP-1alpha	10	B-Gene
mRNA	4	I-Gene
in	2	O
BAL	3	O
cells	5	O
was	3	O
expressed	9	O
relatively	10	O
high	4	O
1	1	O
h	1	O
after	5	O
NaVO3	5	O
instillation	12	O
,	1	O
although	8	O
a	1	O
basal	5	O
expression	10	O
was	3	O
detected	8	O
in	2	O
control	7	O
group	5	O
,	1	O
and	3	O
returned	8	O
rapidly	7	O
nearly	6	O
to	2	O
control	7	O
level	5	O
at	2	O
4	1	O
h	1	O
.	1	O

Since	5	O
MIP-2	5	B-Gene
is	2	O
a	1	O
potent	6	O
PMN	3	O
chemoattractant	15	O
and	3	O
MIP-1alpha	10	B-Gene
is	2	O
a	1	O
potent	6	O
macrophage	10	O
/	1	O
monocyte	8	O
chemoattractant	15	O
has	3	O
been	4	O
well	4	O
known	5	O
.	1	O

The	3	O
facts	5	O
that	4	O
PMN	3	O
influx	6	O
was	3	O
preceded	8	O
by	2	O
increased	9	O
MIP-2	5	B-Gene
mRNA	4	I-Gene
expression	10	O
,	1	O
suggesting	10	O
that	4	O
MIP-2	5	B-Gene
is	2	O
involved	8	O
in	2	O
the	3	O
development	11	O
of	2	O
NaVO3	5	O
-induced	8	O
pulmonary	9	B-Disease
inflammation	12	I-Disease
,	1	O
whereas	7	O
increased	9	O
MIP-1alpha	10	B-Gene
mRNA	4	I-Gene
expression	10	O
was	3	O
followed	8	O
by	2	O
decreased	9	O
AMs	3	O
in	2	O
BAL	3	O
cells	5	O
,	1	O
suggesting	10	O
AMs	3	O
might	5	O
be	2	O
activated	9	O
by	2	O
MIP-1alpha	10	B-Gene
,	1	O
adherent	8	O
to	2	O
the	3	O
lining	6	O
surface	7	O
of	2	O
the	3	O
airways	7	O
and	3	O
then	4	O
resistant	9	O
to	2	O
be	2	O
washed	6	O
out	3	O
.	1	O

To	2	O
delineate	9	O
the	3	O
mechanisms	10	O
of	2	O
transcriptional	15	O
activation	10	O
,	1	O
we	2	O
recently	8	O
cloned	6	O
the	3	O
5'-flanking	11	O
region	6	O
of	2	O
the	3	O
MIP-2	5	B-Gene
gene	4	I-Gene
.	1	O

The	3	O
promotor	8	O
region	6	O
contains	8	O
consensus	9	O
binding	7	O
sites	5	O
for	3	O
transcription	13	B-Gene
factor	6	I-Gene
nuclear	7	I-Gene
factor	6	I-Gene
kappaB	6	I-Gene
(	1	O
NF-kappaB	9	B-Gene
)	1	O
and	3	O
activator	9	B-Gene
protein-1	9	I-Gene
(	1	O
AP-1	4	B-Gene
)	1	O
.	1	O

Using	5	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assay	5	O
,	1	O
increased	9	O
nuclear	7	B-Gene
NF-kappaB	9	I-Gene
,	1	O
not	3	O
AP-1	4	B-Gene
,	1	O
binding	7	O
activity	8	O
was	3	O
detected	8	O
1	1	O
h	1	O
after	5	O
NaVO3	5	O
instillation	12	O
,	1	O
which	5	O
correlated	10	O
with	4	O
the	3	O
induction	9	O
of	2	O
MIP-2	5	B-Gene
mRNA	4	I-Gene
.	1	O

p65	3	B-Gene
(	1	O
Rel	3	B-Gene
A	1	I-Gene
)	1	O
and	3	O
p50	3	B-Gene
protein	7	I-Gene
appears	7	O
to	2	O
be	2	O
involved	8	O
in	2	O
MIP-2	5	B-Gene
NF-kappaB	9	I-Gene
binding	7	O
.	1	O

Taken	5	O
together	8	O
,	1	O
our	3	O
studies	7	O
suggest	7	O
that	4	O
MIP-2	5	B-Gene
is	2	O
an	2	O
important	9	O
mediator	8	O
of	2	O
NaVO3	5	O
-induced	8	O
pulmonary	9	B-Disease
inflammation	12	I-Disease
in	2	O
the	3	O
rat	3	O
model	5	O
.	1	O

In	2	O
addition	8	O
,	1	O
elevated	8	O
MIP-2	5	B-Gene
mRNA	4	I-Gene
levels	6	O
are	3	O
accompanied	11	O
by	2	O
increased	9	O
NF-kappaB	9	B-Gene
binding	7	O
activity	8	O
in	2	O
BAL	3	O
cells	5	O
,	1	O
suggesting	10	O
possible	8	O
MIP-2	5	B-Gene
transcriptional	15	O
regulation	10	O
through	7	O
NF-kappaB	9	B-Gene
.	1	O

High	4	O
glucose	7	B-Chemical
-induced	8	O
intercellular	13	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
(	1	O
ICAM-1	6	B-Gene
)	1	O
expression	10	O
through	7	O
an	2	O
osmotic	7	O
effect	6	O
in	2	O
rat	3	O
mesangial	9	O
cells	5	O
is	2	O
PKC-NF-kappa	12	B-Gene
B	1	I-Gene
-dependent	10	O
.	1	O

AIMS	4	O
/	1	O
HYPOTHESIS	10	O
:	1	O
Infiltration	12	O
of	2	O
mononuclear	11	O
cells	5	O
and	3	O
glomerular	10	O
enlargement	11	O
accompanied	11	O
by	2	O
glomerular	10	O
cell	4	O
proliferation	13	O
are	3	O
very	4	O
early	5	O
characteristics	15	O
of	2	O
the	3	O
pathophysiology	15	O
of	2	O
diabetes	8	B-Disease
.	1	O

To	2	O
clarify	7	O
the	3	O
mechanism	9	O
of	2	O
early	5	O
diabetic	8	B-Disease
nephropathy	11	I-Disease
,	1	O
we	2	O
measured	8	O
[	1	O
3H	2	O
]	1	O
-thymidine	10	B-Chemical
incorporation	13	O
and	3	O
cell	4	O
numbers	7	O
to	2	O
show	4	O
the	3	O
influence	9	O
of	2	O
a	1	O
high	4	O
ambient	7	O
glucose	7	B-Chemical
concentration	13	O
and	3	O
the	3	O
osmotic	7	O
effect	6	O
on	2	O
rat	3	O
mesangial	9	O
cell	4	O
proliferation	13	O
.	1	O

We	2	O
also	4	O
measured	8	O
the	3	O
effect	6	O
of	2	O
high	4	O
glucose	7	B-Chemical
on	2	O
the	3	O
expression	10	O
of	2	O
intercellular	13	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
and	3	O
vascular	8	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
by	2	O
flow	4	O
cytometry	9	O
and	3	O
semiquantitative	16	O
RT-PCR	6	O
in	2	O
mesangial	9	O
cells	5	O
and	3	O
the	3	O
adhesion	8	O
of	2	O
leukocytes	10	O
to	2	O
mesangial	9	O
cells	5	O
.	1	O

METHODS	7	O
/	1	O
RESULTS	7	O
:	1	O
Cells	5	O
exposed	7	O
to	2	O
high	4	O
D-glucose	9	B-Chemical
(	1	O
30	2	O
mmol	4	O
/	1	O
l	1	O
)	1	O
caused	6	O
an	2	O
increase	8	O
in	2	O
[	1	O
3H	2	O
]	1	O
-thymidine	10	B-Chemical
incorporation	13	O
and	3	O
cell	4	O
numbers	7	O
at	2	O
24	2	O
and	3	O
48	2	O
h	1	O
and	3	O
normalized	10	O
at	2	O
72	2	O
h	1	O
(	1	O
p	1	O
<	1	O
0.05	4	O
)	1	O
,	1	O
whereas	7	O
these	5	O
changes	7	O
were	4	O
not	3	O
found	5	O
in	2	O
high	4	O
mannitol	8	B-Chemical
(	1	O
30	2	O
mmol	4	O
/	1	O
l	1	O
)	1	O
,	1	O
IL-1	4	B-Gene
beta	4	I-Gene
,	1	O
or	2	O
TNF	3	B-Gene
alpha	5	I-Gene
-stimulated	11	O
mesangial	9	O
cells	5	O
.	1	O

Cells	5	O
exposed	7	O
to	2	O
high-glucose	12	B-Chemical
(	1	O
15	2	O
,	1	O
30	2	O
,	1	O
or	2	O
60	2	O
mmol	4	O
/	1	O
l	1	O
)	1	O
or	2	O
osmotic	7	O
agents	6	O
(	1	O
L-glucose	9	B-Chemical
,	1	O
raffinose	9	B-Chemical
and	3	O
mannitol	8	B-Chemical
)	1	O
showed	6	O
that	4	O
intercellular	13	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
expression	10	O
began	5	O
to	2	O
increase	8	O
after	5	O
24	2	O
h	1	O
,	1	O
reached	7	O
its	3	O
maximum	7	O
at	2	O
24	2	O
and	3	O
48	2	O
h	1	O
and	3	O
gradually	9	O
decreased	9	O
afterwards	10	O
.	1	O

The	3	O
stimulatory	11	O
effects	7	O
of	2	O
high	4	O
glucose	7	B-Chemical
and	3	O
high	4	O
mannitol	8	B-Chemical
on	2	O
mRNA	4	O
expression	10	O
were	4	O
observed	8	O
as	2	O
early	5	O
as	2	O
6	1	O
h	1	O
and	3	O
reached	7	O
its	3	O
maximum	7	O
at	2	O
12	2	O
h	1	O
.	1	O

Up-regulation	13	O
of	2	O
ICAM-1	6	B-Gene
protein	7	I-Gene
and	3	O
mRNA	4	O
was	3	O
also	4	O
found	5	O
in	2	O
IL-1-beta	9	B-Gene
and	3	O
TNF-alpha	9	B-Gene
-stimulated	11	O
mesangial	9	O
cells	5	O
.	1	O

Neither	7	O
vascular	8	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
protein	7	I-Gene
nor	3	O
mRNA	4	O
expression	10	O
was	3	O
,	1	O
however	7	O
,	1	O
affected	8	O
by	2	O
high	4	O
glucose	7	B-Chemical
and	3	O
high	4	O
mannitol	8	B-Chemical
.	1	O

Notably	7	O
,	1	O
the	3	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
inhibitors	10	O
calphostin	10	B-Chemical
C	1	I-Chemical
and	3	O
staurosporine	13	B-Chemical
reduced	7	O
high	4	O
glucose-	8	B-Chemical
or	2	O
high	4	O
mannitol	8	B-Chemical
-induced	8	O
intercellular	13	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
mRNA	4	I-Gene
expression	10	O
and	3	O
high	4	O
glucose	7	B-Chemical
-induced	8	O
proliferation	13	O
.	1	O

Furthermore	11	O
,	1	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
inhibitor	9	I-Gene
N-tosyl-L-phenylalanine	23	B-Chemical
chloromethyl	12	I-Chemical
ketone	6	I-Chemical
reduced	7	O
high	4	O
glucose-	8	B-Chemical
or	2	O
high	4	O
mannitol	8	B-Chemical
-induced	8	O
intercellular	13	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
mRNA	4	I-Gene
expression	10	O
and	3	O
high	4	O
glucose	7	B-Chemical
-induced	8	O
proliferation	13	O
.	1	O

Results	7	O
showed	6	O
that	4	O
high	4	O
glucose	7	B-Chemical
(	1	O
15	2	O
,	1	O
30	2	O
mmol	4	O
/	1	O
l	1	O
)	1	O
or	2	O
high	4	O
concentrations	14	O
of	2	O
osmotic	7	O
agents	6	O
remarkably	10	O
increased	9	O
the	3	O
number	6	O
of	2	O
adherent	8	O
leukocytes	10	O
to	2	O
mesangial	9	O
cells	5	O
(	1	O
p	1	O
<	1	O
0.01	4	O
)	1	O
compared	8	O
with	4	O
control	7	O
cells	5	O
(	1	O
5	1	O
mmol	4	O
/	1	O
l	1	O
D-glucose	9	B-Chemical
)	1	O
.	1	O

Functional	10	O
blocking	8	O
of	2	O
intercellular	13	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
on	2	O
mesangial	9	O
cells	5	O
with	4	O
rat	3	O
intercellular	13	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
monoclonal	10	I-Gene
antibody	8	I-Gene
,	1	O
calphostin	10	B-Chemical
C	1	I-Chemical
,	1	O
staurosporine	13	B-Chemical
,	1	O
or	2	O
N-tosyl-L-phenylalanine	23	B-Chemical
chloromethyl	12	I-Chemical
ketone	6	I-Chemical
significantly	13	O
inhibited	9	O
high	4	O
glucose-	8	B-Chemical
or	2	O
high	4	O
mannitol	8	B-Chemical
-induced	8	O
increase	8	O
in	2	O
leukocyte	9	O
adhesion	8	O
(	1	O
p	1	O
<	1	O
<	1	O
0.05	4	O
)	1	O
.	1	O

CONCLUSION	10	O
/	1	O
INTERPRETATION	14	O
:	1	O
These	5	O
results	7	O
suggest	7	O
that	4	O
high	4	O
glucose	7	B-Chemical
can	3	O
upregulate	10	O
intercellular	13	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
protein	7	I-Gene
and	3	O
mRNA	4	O
expression	10	O
but	3	O
not	3	O
vascular	8	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
expression	10	O
in	2	O
mesangial	9	O
cells	5	O
and	3	O
promote	7	O
leukocyte	9	O
adhesion	8	O
through	7	O
up-regulation	13	O
of	2	O
intercellular	13	B-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
through	7	O
osmotic	7	O
effect	6	O
,	1	O
possibly	8	O
depending	9	O
on	2	O
the	3	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
nuclear	7	I-Gene
factor-kappa	12	I-Gene
B	1	I-Gene
(	1	O
PKC	3	B-Gene
-	1	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
)	1	O
pathway	7	O
.	1	O

High	4	O
glucose	7	B-Chemical
itself	6	O
can	3	O
also	4	O
promote	7	O
mesangial	9	O
cell	4	O
proliferation	13	O
through	7	O
the	3	O
PKC-NF-kappa	12	B-Gene
B	1	I-Gene
pathways	8	O
.	1	O

We	2	O
conclude	8	O
that	4	O
hyperglycaemia	14	B-Disease
in	2	O
itself	6	O
seems	5	O
to	2	O
be	2	O
an	2	O
important	9	O
factor	6	O
in	2	O
the	3	O
development	11	O
of	2	O
early	5	O
diabetic	8	B-Disease
nephropathy	11	I-Disease
.	1	O

Mechanisms	10	O
and	3	O
clinical	8	O
relevance	9	O
of	2	O
nongenomic	10	O
glucocorticoid	14	B-Chemical
actions	7	O
.	1	O

Glucocorticoids	15	B-Chemical
have	4	O
profound	8	O
anti-inflammatory	17	O
and	3	O
immunosuppressive	17	O
actions	7	O
when	4	O
used	4	O
therapeutically	15	O
.	1	O

The	3	O
therapeutic	11	O
dose	4	O
is	2	O
quite	5	O
variable	8	O
and	3	O
depends	7	O
on	2	O
the	3	O
disease	7	O
,	1	O
but	3	O
ranges	6	O
from	4	O
very	4	O
low	3	O
to	2	O
extremely	9	O
high	4	O
.	1	O

The	3	O
rationale	9	O
for	3	O
the	3	O
use	3	O
of	2	O
various	7	O
dosage	6	O
regimens	8	O
for	3	O
specific	8	O
clinical	8	O
indications	11	O
is	2	O
the	3	O
existence	9	O
of	2	O
three	5	O
distinct	8	O
,	1	O
therapeutically	15	O
relevant	8	O
effects	7	O
:	1	O
genomic	7	O
,	1	O
specific	8	O
nongenomic	10	O
and	3	O
unspecific	10	O
nongenomic	10	O
.	1	O

Genomic	7	O
effects	7	O
are	3	O
mediated	8	O
by	2	O
cytosolic	9	O
receptors	9	O
that	4	O
alter	5	O
expression	10	O
of	2	O
specific	8	O
genes	5	O
.	1	O

Specific	8	O
nongenomic	10	O
effects	7	O
occur	5	O
within	6	O
a	1	O
few	3	O
minutes	7	O
and	3	O
are	3	O
mediated	8	O
by	2	O
steroid	7	B-Chemical
-selective	10	O
membrane	8	O
receptors	9	O
.	1	O

Unspecific	10	O
nongenomic	10	O
effects	7	O
occur	5	O
within	6	O
seconds	7	O
,	1	O
but	3	O
only	4	O
at	2	O
high	4	O
glucocorticoid	14	B-Chemical
dosages	7	O
,	1	O
and	3	O
seem	4	O
to	2	O
result	6	O
from	4	O
direct	6	O
interactions	12	O
with	4	O
biological	10	O
membranes	9	O
.	1	O

For	3	O
unspecific	10	O
nongenomic	10	O
effects	7	O
,	1	O
methylprednisolone	18	B-Chemical
and	3	O
other	5	O
glucocorticoids	15	B-Chemical
have	4	O
been	4	O
shown	5	O
to	2	O
inhibit	7	O
cation	6	O
cycling	7	O
across	6	O
the	3	O
plasma	6	O
membrane	8	O
,	1	O
but	3	O
to	2	O
have	4	O
little	6	O
effect	6	O
on	2	O
protein	7	O
synthesis	9	O
.	1	O

Thus	4	O
,	1	O
glucocorticoids	15	B-Chemical
could	5	O
diminish	8	O
or	2	O
prevent	7	O
the	3	O
acute	5	O
immune	6	O
response	8	O
by	2	O
interfering	11	O
with	4	O
processes	9	O
such	4	O
as	2	O
the	3	O
rise	4	O
in	2	O
intracellular	13	O
Ca2+	4	O
concentration	13	O
.	1	O

It	2	O
is	2	O
proposed	8	O
that	4	O
the	3	O
additional	10	O
therapeutic	11	O
benefit	7	O
of	2	O
higher	6	O
doses	5	O
is	2	O
obtained	8	O
via	3	O
these	5	O
nongenomic	10	O
effects	7	O
.	1	O

Inhibition	10	O
of	2	O
Th1	3	O
differentiation	15	O
by	2	O
IL-6	4	B-Gene
is	2	O
mediated	8	O
by	2	O
SOCS1	5	B-Gene
.	1	O

Interleukin	11	B-Gene
6	1	I-Gene
(	1	O
IL-6	4	B-Gene
)	1	O
is	2	O
a	1	O
cytokine	8	O
produced	8	O
by	2	O
immune	6	O
and	3	O
nonimmune	9	O
cells	5	O
and	3	O
exhibits	8	O
functional	10	O
pleiotropy	10	O
and	3	O
redundancy	10	O
.	1	O

IL-6	4	B-Gene
plays	5	O
an	2	O
important	9	O
role	4	O
in	2	O
the	3	O
differentiation	15	O
of	2	O
several	7	O
cell	4	O
types	5	O
.	1	O

Here	4	O
,	1	O
we	2	O
describe	8	O
a	1	O
novel	5	O
function	8	O
of	2	O
IL-6	4	B-Gene
:	1	O
the	3	O
negative	8	O
regulation	10	O
of	2	O
CD4	3	B-Gene
+	1	I-Gene
Th1	3	O
cell	4	O
differentiation	15	O
.	1	O

While	5	O
IL-6	4	B-Gene
-directed	9	O
CD4	3	B-Gene
+	1	I-Gene
Th2	3	O
differentiation	15	O
is	2	O
mediated	8	O
by	2	O
IL-4	4	B-Gene
,	1	O
inhibition	10	O
of	2	O
Th1	3	O
differentiation	15	O
by	2	O
IL-6	4	B-Gene
is	2	O
independent	11	O
of	2	O
IL-4	4	B-Gene
.	1	O

IL-6	4	B-Gene
upregulates	11	O
suppressor	10	B-Gene
of	2	I-Gene
cytokine	8	I-Gene
signaling	9	I-Gene
1	1	I-Gene
(	1	O
SOCS1	5	B-Gene
)	1	O
expression	10	O
in	2	O
activated	9	B-Gene
CD4+	4	I-Gene
T	1	O
cells	5	O
,	1	O
thereby	7	O
interfering	11	O
with	4	O
signal	6	B-Gene
transducer	10	I-Gene
and	3	I-Gene
activator	9	I-Gene
of	2	I-Gene
transcription	13	I-Gene
1	1	I-Gene
(	1	O
STAT1	5	B-Gene
)	1	O
phosphorylation	15	O
induced	7	O
by	2	O
interferon	10	B-Gene
gamma	5	I-Gene
(	1	O
IFNgamma	8	B-Gene
)	1	O
.	1	O

Inhibition	10	O
of	2	O
IFNgamma	8	B-Gene
receptor	8	I-Gene
-mediated	9	O
signals	7	O
by	2	O
IL-6	4	B-Gene
prevents	8	O
autoregulation	14	O
of	2	O
IFNgamma	8	B-Gene
gene	4	I-Gene
expression	10	O
by	2	O
IFNgamma	8	B-Gene
during	6	O
CD4+	4	B-Gene
T	1	O
cell	4	O
activation	10	O
,	1	O
thereby	7	O
preventing	10	O
Th1	3	O
differentiation	15	O
.	1	O

Thus	4	O
,	1	O
IL-6	4	B-Gene
promotes	8	O
CD4	3	B-Gene
+	1	I-Gene
Th2	3	O
differentiation	15	O
and	3	O
inhibits	8	O
Th1	3	O
differentiation	15	O
by	2	O
two	3	O
independent	11	O
molecular	9	O
mechanisms	10	O
.	1	O

BLyS	4	B-Gene
BINDS	5	O
TO	2	O
B	1	O
CELLS	5	O
WITH	4	O
HIGH	4	O
AFFINITY	8	O
AND	3	O
INDUCES	7	O
ACTIVATION	10	O
OF	2	O
THE	3	O
TRANSCRIPTION	13	B-Gene
FACTORS	7	I-Gene
NF-kappaB	9	I-Gene
AND	3	O
ELF-1	5	B-Gene
.	1	O

B	1	B-Gene
lymphocyte	10	I-Gene
stimulator	10	I-Gene
(	1	O
BLyS	4	B-Gene
)	1	O
is	2	O
a	1	O
novel	5	O
member	6	O
of	2	O
the	3	O
TNF	3	B-Gene
family	6	I-Gene
of	2	O
proteins	8	O
expressed	9	O
by	2	O
myeloid	7	O
cells	5	O
as	2	O
membrane-bound	14	O
and	3	O
soluble	7	O
forms	5	O
.	1	O

BLyS	4	B-Gene
was	3	O
shown	5	O
to	2	O
act	3	O
specifically	12	O
on	2	O
B	1	O
cells	5	O
,	1	O
inducing	8	O
proliferation	13	O
and	3	O
immunoglobulin	14	B-Gene
production	10	O
both	4	O
in	2	O
vitro	5	O
and	3	O
in	2	O
vivo	4	O
.	1	O

The	3	O
present	7	O
study	5	O
was	3	O
undertaken	10	O
to	2	O
characterize	12	O
binding	7	O
of	2	O
radiolabeled	12	O
BLyS	4	B-Gene
to	2	O
its	3	O
cognate	7	O
receptor	8	O
on	2	O
human	5	O
B	1	O
lymphocytes	11	O
and	3	O
examine	7	O
intracellular	13	O
events	6	O
initiated	9	O
by	2	O
BLyS	4	B-Gene
binding	7	O
.	1	O

Similar	7	O
to	2	O
other	5	O
TNF	3	B-Gene
family	6	I-Gene
members	7	O
,	1	O
BLyS	4	B-Gene
is	2	O
present	7	O
in	2	O
solution	8	O
as	2	O
a	1	O
homotrimer	10	O
as	2	O
determined	10	O
by	2	O
gel	3	O
filtration	10	O
chromatography	14	O
and	3	O
light	5	O
scattering	10	O
analysis	8	O
.	1	O

BLyS	4	B-Gene
binding	7	O
to	2	O
B	1	O
cells	5	O
is	2	O
specific	8	O
as	2	O
other	5	O
TNF	3	B-Gene
family	6	I-Gene
members	7	O
tested	6	O
did	3	O
not	3	O
compete	7	O
for	3	O
(	1	O
125	3	O
)	1	O
I-	2	O
BLyS	4	B-Gene
binding	7	O
.	1	O

Analysis	8	O
of	2	O
equilibrium	11	O
binding	7	O
of	2	O
(	1	O
125	3	O
)	1	O
I	1	O
-labeled	8	O
BLyS	4	B-Gene
to	2	O
purified	8	O
human	5	O
tonsillar	9	O
B	1	O
cells	5	O
demonstrated	12	O
saturable	9	O
binding	7	O
.	1	O

Scatchard	9	O
analysis	8	O
of	2	O
the	3	O
binding	7	O
data	4	O
revealed	8	O
a	1	O
single	6	O
class	5	O
of	2	O
high-affinity	13	O
binding	7	O
on	2	O
human	5	O
B	1	O
cells	5	O
with	4	O
approximately	13	O
2600	4	O
binding	7	O
sites	5	O
per	3	O
cell	4	O
and	3	O
an	2	O
apparent	8	O
dissociation	12	O
constant	8	O
(	1	O
K	1	O
(	1	O
D	1	O
)	1	O
)	1	O
of	2	O
about	5	O
0.1	3	O
nM	2	O
.	1	O

In	2	O
addition	8	O
we	2	O
report	6	O
that	4	O
BLyS	4	B-Gene
binding	7	O
to	2	O
B	1	O
cells	5	O
results	7	O
in	2	O
the	3	O
activation	10	O
of	2	O
NF-kappaB	9	B-Gene
and	3	O
the	3	O
Ets	3	B-Gene
family	6	I-Gene
transcription	13	I-Gene
factor	6	I-Gene
,	1	O
ELF-1	5	B-Gene
,	1	O
and	3	O
in	2	O
the	3	O
induction	9	O
of	2	O
mRNA	4	O
for	3	O
Polo	4	B-Gene
-like	5	I-Gene
kinase	6	I-Gene
(	1	O
PLK	3	B-Gene
)	1	O
.	1	O

Copyright	9	O
2001	4	O
Academic	8	O
Press	5	O
.	1	O

Human	5	B-Gene
T-cell	6	I-Gene
leukemia	8	I-Gene
virus	5	I-Gene
type	4	I-Gene
1	1	I-Gene
tax	3	I-Gene
protein	7	I-Gene
activates	9	O
transcription	13	O
through	7	O
AP-1	4	B-Gene
site	4	O
by	2	O
inducing	8	O
DNA	3	O
binding	7	O
activity	8	O
in	2	O
T	1	O
cells	5	O
.	1	O

Human	5	B-Gene
T-cell	6	I-Gene
leukemia	8	I-Gene
virus	5	I-Gene
type	4	I-Gene
1	1	I-Gene
(	1	I-Gene
HTLV-1	6	I-Gene
)	1	I-Gene
Tax	3	I-Gene
protein	7	I-Gene
induces	7	O
the	3	O
expression	10	O
of	2	O
various	7	O
family	6	O
members	7	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
AP-1	4	I-Gene
,	1	O
such	4	O
as	2	O
c-Jun	5	B-Gene
,	1	O
JunD	4	B-Gene
,	1	O
c-Fos	5	B-Gene
,	1	O
and	3	O
Fra-1	5	B-Gene
,	1	O
at	2	O
the	3	O
level	5	O
of	2	O
RNA	3	O
expression	10	O
in	2	O
T	1	O
cells	5	O
.	1	O

We	2	O
examined	8	O
the	3	O
activity	8	O
of	2	O
Tax	3	B-Gene
in	2	O
transcription	13	O
through	7	O
AP-1	4	B-Gene
-binding	8	O
sites	5	O
(	1	O
AP-1	4	B-Gene
site	4	O
)	1	O
in	2	O
T	1	O
cells	5	O
.	1	O

Transient	9	O
transfection	12	O
studies	7	O
showed	6	O
that	4	O
Tax	3	B-Gene
activated	9	O
the	3	O
expression	10	O
of	2	O
a	1	O
luciferase	10	O
gene	4	O
regulated	9	O
by	2	O
two	3	O
copies	6	O
of	2	O
an	2	O
AP-1	4	B-Gene
site	4	O
in	2	O
the	3	O
human	5	O
Jurkat	6	O
T-cell	6	O
line	4	O
.	1	O

Tax	3	B-Gene
activates	9	O
the	3	O
expression	10	O
of	2	O
viral	5	O
and	3	O
cellular	8	O
genes	5	O
through	7	O
two	3	O
different	9	O
enhancers	9	O
:	1	O
a	1	O
cAMP	4	B-Chemical
-responsive	11	O
(	1	O
CRE	3	O
)	1	O
-like	5	O
element	7	O
and	3	O
a	1	O
kappaB	6	O
element	7	O
.	1	O

Two	3	O
Tax	3	B-Gene
mutants	7	I-Gene
differentially	14	O
activated	9	O
expression	10	O
of	2	O
these	5	O
two	3	O
elements	8	O
.	1	O

Tax703	6	B-Gene
preferentially	14	O
activated	9	O
the	3	O
kappaB	6	O
element	7	O
but	3	O
not	3	O
the	3	O
CRE	3	O
-like	5	O
one	3	O
,	1	O
whereas	7	O
TaxM22	6	B-Gene
showed	6	O
the	3	O
reverse	7	O
.	1	O

In	2	O
addition	8	O
,	1	O
Tax703	6	B-Gene
and	3	O
Tax	3	B-Gene
,	1	O
but	3	O
not	3	O
TaxM22	6	B-Gene
,	1	O
converted	9	O
cell	4	O
growth	6	O
of	2	O
a	1	O
mouse	5	O
T-cell	6	O
line	4	O
from	4	O
being	5	O
interleukin	11	B-Gene
(	1	I-Gene
IL	2	I-Gene
)	1	I-Gene
-2	2	I-Gene
-dependent	10	O
to	2	O
being	5	O
IL-2	4	B-Gene
-independent	12	O
.	1	O

Unlike	6	O
the	3	O
wild-type	9	B-Gene
Tax	3	I-Gene
,	1	O
Tax703	6	B-Gene
and	3	O
TaxM22	6	B-Gene
only	4	O
weakly	6	O
activated	9	O
the	3	O
AP-1	4	B-Gene
site	4	O
in	2	O
the	3	O
T-cell	6	O
line	4	O
.	1	O

Thus	4	O
,	1	O
Tax	3	B-Gene
seems	5	O
to	2	O
activate	8	O
the	3	O
AP-1	4	B-Gene
site	4	O
via	3	O
mechanisms	10	O
distinct	8	O
from	4	O
those	5	O
of	2	O
kappaB	6	O
or	2	O
CRE	3	O
-like	5	O
elements	8	O
,	1	O
and	3	O
the	3	O
activation	10	O
of	2	O
the	3	O
AP-1	4	B-Gene
site	4	O
is	2	O
dispensable	11	O
for	3	O
IL-2	4	B-Gene
-independent	12	O
growth	6	O
of	2	O
CTLL-2	6	O
.	1	O

Electrophoretic	15	O
mobility	8	O
shift	5	O
assays	6	O
showed	6	O
that	4	O
Tax	3	B-Gene
induced	7	O
strong	6	O
binding	7	O
activity	8	O
to	2	O
an	2	O
AP-1	4	B-Gene
site	4	O
in	2	O
CTLL-2	6	O
,	1	O
whereas	7	O
Tax703	6	B-Gene
did	3	O
not	3	O
,	1	O
indicating	10	O
that	4	O
the	3	O
induction	9	O
of	2	O
binding	7	O
activity	8	O
to	2	O
the	3	O
AP-1	4	B-Gene
site	4	O
is	2	O
essential	9	O
for	3	O
the	3	O
transcriptional	15	O
activation	10	O
by	2	O
Tax	3	B-Gene
.	1	O

The	3	O
binding	7	O
complex	7	O
induced	7	O
by	2	O
Tax	3	B-Gene
in	2	O
CTLL-2	6	O
contained	9	O
JunD	4	B-Gene
and	3	O
Fra-2	5	B-Gene
.	1	O

Other	5	O
AP-1	4	B-Gene
proteins	8	I-Gene
were	4	O
undetectable	12	O
.	1	O

Activation	10	O
of	2	O
transcription	13	O
through	7	O
the	3	O
AP-1	4	B-Gene
site	4	O
in	2	O
Jurkat	6	O
cells	5	O
by	2	O
JunD	4	B-Gene
and	3	O
/	1	O
or	2	O
Fra-2	5	B-Gene
was	3	O
weak	4	O
.	1	O

c-Jun	5	B-Gene
,	1	O
JunB	4	B-Gene
,	1	O
and	3	O
c-Fos	5	B-Gene
activation	10	O
was	3	O
greater	7	O
,	1	O
although	8	O
the	3	O
level	5	O
was	3	O
still	5	O
less	4	O
than	4	O
that	4	O
with	4	O
Tax	3	B-Gene
.	1	O

Thus	4	O
,	1	O
the	3	O
induction	9	O
of	2	O
AP-1	4	B-Gene
mRNA	4	I-Gene
by	2	O
Tax	3	B-Gene
may	3	O
not	3	O
be	2	O
sufficient	10	O
for	3	O
a	1	O
complete	8	O
activation	10	O
of	2	O
AP-1	4	B-Gene
site	4	O
by	2	O
Tax	3	B-Gene
.	1	O

Our	3	O
results	7	O
suggest	7	O
that	4	O
Tax	3	B-Gene
activates	9	O
the	3	O
transcription	13	O
of	2	O
cellular	8	O
genes	5	O
with	4	O
AP-1	4	B-Gene
sites	5	O
by	2	O
inducing	8	O
the	3	O
DNA	3	O
-binding	8	O
activity	8	O
of	2	O
AP-1	4	B-Gene
proteins	8	I-Gene
in	2	O
T	1	O
cells	5	O
,	1	O
a	1	O
mechanism	9	O
distinct	8	O
from	4	O
those	5	O
of	2	O
CRE	3	O
-like	5	O
and	3	O
kappaB	6	O
elements	8	O
.	1	O

Copyright	9	O
2001	4	O
Academic	8	O
Press	5	O
.	1	O

Expression	10	O
and	3	O
function	8	O
of	2	O
a	1	O
stem	4	B-Gene
cell	4	I-Gene
promoter	8	I-Gene
for	3	O
the	3	O
murine	6	B-Gene
CBFalpha2	9	I-Gene
gene	4	I-Gene
:	1	O
distinct	8	O
roles	5	O
and	3	O
regulation	10	O
in	2	O
natural	7	O
killer	6	O
and	3	O
T	1	O
cell	4	O
development	11	O
.	1	O

The	3	O
Runt	4	B-Gene
family	6	I-Gene
transcription	13	I-Gene
factor	6	I-Gene
CBFalpha2	9	I-Gene
(	1	O
AML1	4	B-Gene
,	1	O
PEBP2alphaB	11	B-Gene
,	1	O
or	2	O
Runx1	5	B-Gene
)	1	O
is	2	O
required	8	O
by	2	O
hematopoietic	13	O
stem	4	O
cells	5	O
and	3	O
expressed	9	O
at	2	O
high	4	O
levels	6	O
in	2	O
T-lineage	9	O
cells	5	O
.	1	O

In	2	O
human	5	O
T	1	O
cells	5	O
CBFalpha2	9	B-Gene
is	2	O
usually	7	O
transcribed	11	O
from	4	O
a	1	O
different	9	O
promoter	8	O
(	1	O
distal	6	O
promoter	8	O
)	1	O
than	4	O
in	2	O
myeloid	7	O
cells	5	O
(	1	O
proximal	8	O
promoter	8	O
)	1	O
,	1	O
but	3	O
the	3	O
developmental	13	O
and	3	O
functional	10	O
significance	12	O
of	2	O
this	4	O
promoter	8	O
switch	6	O
has	3	O
not	3	O
been	4	O
known	5	O
.	1	O

Here	4	O
,	1	O
we	2	O
report	6	O
that	4	O
both	4	O
coding	6	O
and	3	O
noncoding	9	O
sequences	9	O
of	2	O
the	3	O
distal	6	O
5	1	O
'end	4	O
are	3	O
highly	6	O
conserved	9	O
between	7	O
the	3	O
human	5	O
and	3	O
the	3	O
murine	6	O
genes	5	O
,	1	O
and	3	O
the	3	O
distal	6	O
promoter	8	O
is	2	O
responsible	11	O
for	3	O
the	3	O
overwhelming	12	O
majority	8	O
of	2	O
CBFalpha2	9	B-Gene
expression	10	O
in	2	O
murine	6	O
hematopoietic	13	O
stem	4	O
cells	5	O
as	2	O
well	4	O
as	2	O
in	2	O
T	1	O
cells	5	O
.	1	O

Distal	6	O
promoter	8	O
activity	8	O
is	2	O
maintained	10	O
throughout	10	O
T	1	O
cell	4	O
development	11	O
and	3	O
at	2	O
lower	5	O
levels	6	O
in	2	O
B	1	O
cell	4	O
development	11	O
,	1	O
but	3	O
downregulated	13	O
in	2	O
natural	7	O
killer	6	O
cell	4	O
development	11	O
.	1	O

The	3	O
distal	6	O
N-terminal	10	O
isoform	7	O
binds	5	O
to	2	O
functionally	12	O
important	9	O
regulatory	10	O
sites	5	O
from	4	O
known	5	O
target	6	O
genes	5	O
with	4	O
two-	4	O
to	2	O
threefold	9	O
higher	6	O
affinity	8	O
than	4	O
the	3	O
proximal	8	O
N-terminal	10	O
isoform	7	O
.	1	O

Neither	7	O
full-length	11	O
isoform	7	O
alters	6	O
growth	6	O
of	2	O
a	1	O
myeloid	7	O
cell	4	O
line	4	O
under	5	O
nondifferentiating	18	O
conditions	10	O
,	1	O
but	3	O
the	3	O
proximal	8	O
isoform	7	O
selectively	11	O
delays	6	O
mitotic	7	O
arrest	6	O
of	2	O
the	3	O
cell	4	O
line	4	O
under	5	O
differentiating	15	O
conditions	10	O
,	1	O
resulting	9	O
in	2	O
the	3	O
generation	10	O
of	2	O
greater	7	O
numbers	7	O
of	2	O
neutrophils	11	O
.	1	O

Granulocytic	12	O
differentiation	15	O
of	2	O
human	5	O
NB4	3	O
promyelocytic	13	B-Disease
leukemia	8	I-Disease
cells	5	O
induced	7	O
by	2	O
all-trans	9	B-Chemical
retinoic	8	I-Chemical
acid	4	I-Chemical
metabolites	11	O
.	1	O

The	3	O
metabolism	10	O
of	2	O
all-trans	9	B-Chemical
retinoic	8	I-Chemical
acid	4	I-Chemical
(	1	O
ATRA	4	B-Chemical
)	1	O
has	3	O
been	4	O
reported	8	O
to	2	O
be	2	O
partly	6	O
responsible	11	O
for	3	O
the	3	O
in	2	O
vivo	4	O
resistance	10	O
to	2	O
ATRA	4	B-Chemical
seen	4	O
in	2	O
the	3	O
treatment	9	O
of	2	O
human	5	O
acute	5	B-Disease
promyelocytic	13	I-Disease
leukemia	8	I-Disease
(	1	O
APL	3	B-Disease
)	1	O
.	1	O

However	7	O
,	1	O
ATRA	4	B-Chemical
metabolism	10	O
appears	7	O
to	2	O
be	2	O
involved	8	O
in	2	O
the	3	O
growth	6	O
inhibition	10	O
of	2	O
several	7	O
cancer	6	B-Disease
cell	4	O
lines	5	O
in	2	O
vitro	5	O
.	1	O

The	3	O
purpose	7	O
of	2	O
this	4	O
study	5	O
was	3	O
to	2	O
evaluate	8	O
the	3	O
in	2	O
vitro	5	O
activity	8	O
of	2	O
the	3	O
principal	9	O
metabolites	11	O
of	2	O
ATRA	4	B-Chemical
[	1	O
4-hydroxy-retinoic	18	B-Chemical
acid	4	I-Chemical
(	1	O
4-OH-RA	7	B-Chemical
)	1	O
,	1	O
18-hydroxy-retinoic	19	B-Chemical
acid	4	I-Chemical
(	1	O
18-OH-RA	8	B-Chemical
)	1	O
,	1	O
4-oxo-retinoic	14	B-Chemical
acid	4	I-Chemical
(	1	O
4-oxo-RA	8	B-Chemical
)	1	O
,	1	O
and	3	O
5	1	B-Chemical
,	1	I-Chemical
6-epoxy-retinoic	16	I-Chemical
acid	4	I-Chemical
(	1	O
5	1	B-Chemical
,	1	I-Chemical
6-epoxy-RA	10	I-Chemical
)	1	O
]	1	O
in	2	O
NB4	3	O
,	1	O
a	1	O
human	5	O
promyelocytic	13	B-Disease
leukemia	8	I-Disease
cell	4	O
line	4	O
that	4	O
exhibits	8	O
the	3	O
APL	3	B-Disease
diagnostic	10	O
t	1	O
(	1	O
15	2	O
;	1	O
17	2	O
)	1	O
chromosomal	11	O
translocation	13	O
and	3	O
expresses	9	O
the	3	O
PML-RAR	7	B-Gene
alpha	5	I-Gene
fusion	6	I-Gene
protein	7	I-Gene
.	1	O

We	2	O
established	11	O
that	4	O
the	3	O
four	4	O
ATRA	4	B-Chemical
metabolites	11	O
were	4	O
indeed	6	O
formed	6	O
by	2	O
the	3	O
NB4	3	O
cells	5	O
in	2	O
vitro	5	O
.	1	O

NB4	3	O
cell	4	O
growth	6	O
was	3	O
inhibited	9	O
(	1	O
69-78	5	O
%	1	O
at	2	O
120	3	O
h	1	O
)	1	O
and	3	O
cell	4	O
cycle	5	O
progression	11	O
in	2	O
the	3	O
G1	2	O
phase	5	O
(	1	O
82-85	5	O
%	1	O
at	2	O
120	3	O
h	1	O
)	1	O
was	3	O
blocked	7	O
by	2	O
ATRA	4	B-Chemical
and	3	O
all	3	O
of	2	O
the	3	O
metabolites	11	O
at	2	O
1	1	O
microM	6	O
concentration	13	O
.	1	O

ATRA	4	B-Chemical
and	3	O
its	3	O
metabolites	11	O
could	5	O
induce	6	O
NB4	3	O
cells	5	O
differentiation	15	O
with	4	O
similar	7	O
activity	8	O
,	1	O
as	2	O
evaluated	9	O
by	2	O
cell	4	O
morphology	10	O
,	1	O
by	2	O
the	3	O
nitroblue	9	B-Chemical
tetrazolium	11	I-Chemical
reduction	9	O
test	4	O
(	1	O
82-88	5	O
%	1	O
at	2	O
120	3	O
h	1	O
)	1	O
or	2	O
by	2	O
the	3	O
expression	10	O
of	2	O
the	3	O
maturation	10	B-Gene
specific	8	I-Gene
cell	4	I-Gene
surface	7	I-Gene
marker	6	I-Gene
CD11c	5	I-Gene
.	1	O

In	2	O
addition	8	O
,	1	O
nuclear	7	O
body	4	O
reorganization	14	O
to	2	O
macropunctated	14	O
structures	10	O
,	1	O
as	2	O
well	4	O
as	2	O
the	3	O
degradation	11	O
of	2	O
PML-RAR	7	B-Gene
alpha	5	I-Gene
,	1	O
was	3	O
found	5	O
to	2	O
be	2	O
similar	7	O
for	3	O
ATRA	4	B-Chemical
and	3	O
all	3	O
of	2	O
its	3	O
metabolites	11	O
.	1	O

Comparison	10	O
of	2	O
the	3	O
relative	8	O
potency	7	O
of	2	O
the	3	O
retinoids	9	O
using	5	O
the	3	O
nitroblue	9	B-Chemical
tetrazolium	11	I-Chemical
reduction	9	O
test	4	O
showed	6	O
effective	9	O
concentrations	14	O
required	8	O
to	2	O
differentiate	13	O
50	2	O
%	1	O
of	2	O
cells	5	O
in	2	O
72	2	O
h	1	O
as	2	O
follows	7	O
:	1	O
ATRA	4	B-Chemical
,	1	O
15.8	4	O
+	1	O
/	1	O
-	1	O
1.7	3	O
nM	2	O
;	1	O
4-oxo-RA	8	B-Chemical
,	1	O
38.3	4	O
+	1	O
/	1	O
-	1	O
1.3	3	O
nM	2	O
;	1	O
18-OH-RA	8	B-Chemical
,	1	O
55.5	4	O
+	1	O
/	1	O
-	1	O
1.8	3	O
nM	2	O
;	1	O
4-OH-RA	7	B-Chemical
,	1	O
79.8	4	O
+	1	O
/	1	O
-	1	O
1.8	3	O
nM	2	O
;	1	O
and	3	O
5	1	B-Chemical
,	1	I-Chemical
6-epoxy-RA	10	I-Chemical
,	1	O
99.5	4	O
+	1	O
/	1	O
-	1	O
1.5	3	O
nM	2	O
.	1	O

The	3	O
ATRA	4	B-Chemical
metabolites	11	O
were	4	O
found	5	O
to	2	O
exert	5	O
their	5	O
differentiation	15	O
effects	7	O
via	3	O
the	3	O
RAR	3	B-Gene
alpha	5	I-Gene
nuclear	7	I-Gene
receptors	9	I-Gene
,	1	O
because	7	O
the	3	O
RAR	3	B-Gene
alpha-specific	14	I-Gene
antagonist	10	O
BMS614	6	O
blocked	7	O
metabolite	10	O
-induced	8	O
CD11c	5	B-Gene
expression	10	O
in	2	O
NB4	3	O
cells	5	O
.	1	O

These	5	O
data	4	O
demonstrate	11	O
that	4	O
the	3	O
principal	9	O
ATRA	4	B-Chemical
Phase	5	O
1	1	O
metabolites	11	O
can	3	O
elicit	6	O
leukemia	8	B-Disease
cell	4	O
growth	6	O
inhibition	10	O
and	3	O
differentiation	15	O
in	2	O
vitro	5	O
through	7	O
the	3	O
RAR	3	B-Gene
alpha	5	I-Gene
signaling	9	O
pathway	7	O
,	1	O
and	3	O
they	4	O
suggest	7	O
that	4	O
these	5	O
metabolites	11	O
may	3	O
play	4	O
a	1	O
role	4	O
in	2	O
ATRA	4	B-Chemical
antileukemic	12	O
activity	8	O
in	2	O
vivo	4	O
.	1	O

Homocysteine	12	B-Chemical
stimulates	10	O
the	3	O
expression	10	O
of	2	O
monocyte	8	B-Gene
chemoattractant	15	I-Gene
protein-1	9	I-Gene
in	2	O
endothelial	11	O
cells	5	O
leading	7	O
to	2	O
enhanced	8	O
monocyte	8	O
chemotaxis	10	O
.	1	O

Hyperhomocysteinemia	20	B-Disease
has	3	O
been	4	O
identified	10	O
as	2	O
an	2	O
independent	11	O
risk	4	O
factor	6	O
for	3	O
atherosclerosis	15	B-Disease
.	1	O

The	3	O
infiltration	12	O
of	2	O
monocytes	9	O
into	4	O
the	3	O
arterial	8	O
wall	4	O
is	2	O
one	3	O
of	2	O
the	3	O
key	3	O
events	6	O
during	6	O
atherogenesis	13	O
.	1	O

Monocyte	8	B-Gene
chemoattractant	15	I-Gene
protein-1	9	I-Gene
(	1	O
MCP-1	5	B-Gene
)	1	O
is	2	O
a	1	O
potent	6	O
chemokine	9	O
that	4	O
stimulates	10	O
the	3	O
migration	9	O
of	2	O
monocytes	9	O
into	4	O
the	3	O
intima	6	O
of	2	O
the	3	O
arterial	8	O
wall	4	O
.	1	O

The	3	O
mechanism	9	O
by	2	O
which	5	O
increased	9	O
monocyte	8	O
infiltration	12	O
occurs	6	O
in	2	O
atherosclerotic	15	B-Disease
lesions	7	I-Disease
in	2	O
patients	8	O
with	4	O
hyperhomocysteinemia	20	B-Disease
has	3	O
not	3	O
been	4	O
delineated	10	O
.	1	O

The	3	O
objective	9	O
of	2	O
the	3	O
present	7	O
study	5	O
was	3	O
to	2	O
investigate	11	O
the	3	O
effect	6	O
of	2	O
homocysteine	12	B-Chemical
on	2	O
MCP-1	5	B-Gene
production	10	O
in	2	O
endothelial	11	O
cells	5	O
.	1	O

Cells	5	O
were	4	O
incubated	9	O
with	4	O
homocysteine	12	B-Chemical
.	1	O

The	3	O
secretion	9	O
of	2	O
MCP-1	5	B-Gene
protein	7	I-Gene
was	3	O
significantly	13	O
increased	9	O
(	1	O
195	3	O
%	1	O
as	2	O
compared	8	O
to	2	O
the	3	O
control	7	O
)	1	O
in	2	O
cells	5	O
treated	7	O
with	4	O
pathological	12	O
concentrations	14	O
of	2	O
homocysteine	12	B-Chemical
.	1	O

Such	4	O
effect	6	O
was	3	O
accompanied	11	O
by	2	O
an	2	O
increased	9	O
expression	10	O
of	2	O
MCP-1	5	B-Gene
mRNA	4	I-Gene
(	1	O
176	3	O
%	1	O
as	2	O
compared	8	O
to	2	O
the	3	O
control	7	O
)	1	O
in	2	O
endothelial	11	O
cells	5	O
which	5	O
resulted	8	O
in	2	O
enhanced	8	O
monocyte	8	O
chemotaxis	10	O
.	1	O

The	3	O
p38	3	B-Gene
MAP	3	I-Gene
kinase	6	I-Gene
as	2	O
well	4	O
as	2	O
other	5	O
members	7	O
of	2	O
the	3	O
p38	3	B-Gene
MAP	3	I-Gene
kinase	6	I-Gene
pathway	7	O
,	1	O
including	9	O
MKK3	4	B-Gene
,	1	O
MKK6	4	B-Gene
,	1	O
ATF-2	5	B-Gene
and	3	O
Elk-1	5	B-Gene
,	1	O
were	4	O
activated	9	O
in	2	O
homocysteine	12	B-Chemical
-treated	8	O
cells	5	O
.	1	O

Homocysteine	12	B-Chemical
-induced	8	O
MCP-1	5	B-Gene
expression	10	O
and	3	O
subsequent	10	O
monocyte	8	O
chemotaxis	10	O
were	4	O
blocked	7	O
by	2	O
a	1	O
p38	3	B-Gene
MAP	3	I-Gene
kinase	6	I-Gene
inhibitor	9	O
(	1	O
SB203580	8	B-Chemical
)	1	O
suggesting	10	O
that	4	O
the	3	O
p38	3	B-Gene
MAP	3	I-Gene
kinase	6	I-Gene
pathway	7	O
might	5	O
be	2	O
involved	8	O
in	2	O
homocysteine	12	B-Chemical
-induced	8	O
MCP-1	5	B-Gene
expression	10	O
in	2	O
endothelial	11	O
cells	5	O
.	1	O

In	2	O
contrast	8	O
,	1	O
staurosporine	13	B-Chemical
,	1	O
a	1	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
inhibitor	9	I-Gene
,	1	O
had	3	O
no	2	O
effect	6	O
on	2	O
homocysteine	12	B-Chemical
-induced	8	O
MCP-1	5	B-Gene
expression	10	O
.	1	O

In	2	O
conclusion	10	O
,	1	O
our	3	O
results	7	O
indicate	8	O
that	4	O
homocysteine	12	B-Chemical
stimulates	10	O
MCP-1	5	B-Gene
expression	10	O
in	2	O
endothelial	11	O
cells	5	O
leading	7	O
to	2	O
enhanced	8	O
monocyte	8	O
chemotaxis	10	O
.	1	O

Transcription	13	B-Gene
factor	6	I-Gene
AP-4	4	I-Gene
is	2	O
a	1	O
ligand	6	O
for	3	O
immunoglobulin-kappa	20	B-Gene
promoter	8	I-Gene
E-box	5	O
elements	8	O
.	1	O

Immunoglobulin	14	B-Gene
(	1	I-Gene
Ig	2	I-Gene
)	1	I-Gene
-kappa	6	I-Gene
promoters	9	I-Gene
from	4	O
humans	6	O
and	3	O
mice	4	O
share	5	O
conserved	9	O
sequences	9	O
.	1	O

The	3	O
octamer	7	O
element	7	O
is	2	O
common	6	O
to	2	O
all	3	O
Ig	2	B-Gene
promoters	9	I-Gene
and	3	O
pivotal	7	O
for	3	O
their	5	O
function	8	O
.	1	O

However	7	O
,	1	O
other	5	O
conserved	9	O
sequence	8	O
motifs	6	O
,	1	O
that	4	O
differ	6	O
between	7	O
Ig	2	B-Gene
variable	8	I-Gene
gene	4	I-Gene
families	8	I-Gene
,	1	O
are	3	O
required	8	O
for	3	O
normal	6	O
promoter	8	O
function	8	O
.	1	O

These	5	O
conserved	9	O
motifs	6	O
do	2	O
not	3	O
stimulate	9	O
transcription	13	O
in	2	O
the	3	O
absence	7	O
of	2	O
an	2	O
octamer	7	O
.	1	O

One	3	O
example	7	O
is	2	O
an	2	O
E-box	5	O
of	2	O
the	3	O
E47	3	B-Gene
/	1	I-Gene
E12	3	I-Gene
type	4	O
(	1	O
5'-CAGCTG-3')	13	O
,	1	O
which	5	O
is	2	O
found	5	O
in	2	O
all	3	O
promoters	9	O
of	2	O
the	3	O
human	5	O
and	3	O
murine	6	B-Gene
Ig-kappa	8	I-Gene
gene	4	I-Gene
subgroups	9	O
/	1	O
families	8	O
,	1	O
with	4	O
the	3	O
exception	9	O
of	2	O
subgroups	9	O
II	2	O
and	3	O
VI	2	O
and	3	O
their	5	O
related	7	O
murine	6	O
families	8	O
.	1	O

In	2	O
the	3	O
present	7	O
study	5	O
we	2	O
show	4	O
that	4	O
the	3	O
ubiquitously	12	O
expressed	9	O
transcription	13	B-Gene
factor	6	I-Gene
AP-4	4	I-Gene
,	1	O
and	3	O
not	3	O
E47	3	B-Gene
,	1	O
interacts	9	O
specifically	12	O
with	4	O
the	3	O
kappa	5	O
promoter	8	O
E-boxes	7	O
when	4	O
tested	6	O
in	2	O
electrophoretic	15	O
mobility-shift	14	O
assays	6	O
using	5	O
nuclear	7	O
extracts	8	O
derived	7	O
from	4	O
human	5	O
and	3	O
murine	6	O
B-cell	6	O
lines	5	O
.	1	O

Furthermore	11	O
,	1	O
AP-4	4	B-Gene
,	1	O
unlike	6	O
E47	3	B-Gene
,	1	O
did	3	O
not	3	O
act	3	O
as	2	O
a	1	O
transactivator	14	O
,	1	O
which	5	O
is	2	O
in	2	O
agreement	9	O
with	4	O
previous	8	O
studies	7	O
on	2	O
intact	6	O
kappa	5	O
promoters	9	O
,	1	O
showing	7	O
that	4	O
transcription	13	O
is	2	O
absent	6	O
when	4	O
the	3	O
octamer	7	O
element	7	O
has	3	O
been	4	O
mutated	7	O
.	1	O

Based	5	O
on	2	O
these	5	O
data	4	O
,	1	O
and	3	O
the	3	O
conservation	12	O
of	2	O
the	3	O
5'-CAGCTG-3	11	O
'motif	6	O
among	5	O
human	5	O
and	3	O
murine	6	O
kappa	5	O
promoters	9	O
,	1	O
we	2	O
propose	7	O
that	4	O
AP-4	4	B-Gene
is	2	O
the	3	O
major	5	O
ligand	6	O
for	3	O
Ig-kappa	8	B-Gene
promoter	8	I-Gene
E-boxes	7	O
.	1	O

NF	2	B-Gene
kappa	5	I-Gene
b	1	I-Gene
signaling	9	O
in	2	O
posthypoxic	11	O
endothelial	11	O
cells	5	O
:	1	O
relevance	9	O
to	2	O
E-selectin	10	B-Gene
expression	10	O
and	3	O
neutrophil	10	O
adhesion	8	O
.	1	O

Our	3	O
previous	8	O
studies	7	O
have	4	O
implicated	10	O
the	3	O
nuclear	7	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
kappa	5	I-Gene
B	1	I-Gene
(	1	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
)	1	O
in	2	O
the	3	O
regulation	10	O
of	2	O
adhesion	8	O
molecule	8	O
expression	10	O
in	2	O
endothelial	11	O
cells	5	O
exposed	7	O
to	2	O
anoxia-reoxygenation	20	O
(	1	O
A	1	O
/	1	O
R	1	O
)	1	O
or	2	O
a	1	O
redox	5	O
imbalance	9	O
.	1	O

The	3	O
objectives	10	O
of	2	O
this	4	O
study	5	O
were	4	O
(	1	O
1	1	O
)	1	O
to	2	O
define	6	O
the	3	O
kinetics	8	O
of	2	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
activation	10	O
by	2	O
examining	9	O
I	1	B-Gene
kappa	5	I-Gene
B	1	I-Gene
alpha	5	I-Gene
degradation	11	O
and	3	O
the	3	O
nuclear	7	O
translocation	13	O
of	2	O
p65	3	B-Gene
in	2	O
response	8	O
to	2	O
A	1	O
/	1	O
R	1	O
or	2	O
redox	5	O
imbalance	9	O
(	1	O
induced	7	O
by	2	O
treatment	9	O
of	2	O
cells	5	O
with	4	O
diamide	7	B-Chemical
and	3	O
buthionine	10	B-Chemical
sulfoximine	11	I-Chemical
)	1	O
and	3	O
(	1	O
2	1	O
)	1	O
to	2	O
determine	9	O
whether	7	O
the	3	O
signal	6	O
for	3	O
I	1	B-Gene
kappa	5	I-Gene
B	1	I-Gene
alpha	5	I-Gene
degradation	11	O
,	1	O
nuclear	7	O
translocation	13	O
of	2	O
p65	3	B-Gene
,	1	O
and	3	O
E-selectin	10	B-Gene
-mediated	9	O
neutrophil	10	O
adhesion	8	O
is	2	O
related	7	O
to	2	O
the	3	O
activity	8	O
of	2	O
protein	7	B-Gene
tyrosine	8	I-Gene
kinase	6	I-Gene
(	1	O
PTK	3	B-Gene
)	1	O
,	1	O
protein	7	B-Gene
tyrosine	8	I-Gene
phosphatase	11	I-Gene
(	1	O
PTPase	6	B-Gene
)	1	O
and	3	O
/	1	O
or	2	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
(	1	O
PKC	3	B-Gene
)	1	O
.	1	O

The	3	O
results	7	O
demonstrate	11	O
that	4	O
both	4	O
A	1	O
/	1	O
R	1	O
and	3	O
redox	5	O
imbalance	9	O
led	3	O
to	2	O
I	1	B-Gene
kappa	5	I-Gene
B	1	I-Gene
alpha	5	I-Gene
degradation	11	O
within	6	O
30	2	O
min	3	O
and	3	O
the	3	O
concomitant	11	O
appearance	10	O
of	2	O
p65	3	B-Gene
in	2	O
the	3	O
nucleus	7	O
,	1	O
consistent	10	O
with	4	O
rapid	5	O
cytosolic	9	O
activation	10	O
of	2	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
and	3	O
subsequent	10	O
nuclear	7	O
translocation	13	O
of	2	O
the	3	O
activated	9	O
p65	3	B-Gene
subunit	7	I-Gene
.	1	O

Inhibition	10	O
of	2	O
PKC	3	B-Gene
blocked	7	O
I	1	B-Gene
kappa	5	I-Gene
B	1	I-Gene
alpha	5	I-Gene
degradation	11	O
and	3	O
p65	3	B-Gene
translocation	13	O
in	2	O
A	1	O
/	1	O
R	1	O
-challenged	11	O
,	1	O
but	3	O
not	3	O
redox	5	O
-altered	8	O
,	1	O
endothelial	11	O
cells	5	O
.	1	O

However	7	O
,	1	O
both	4	O
A	1	O
/	1	O
R-	2	O
and	3	O
redox	5	O
-induced	8	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
activation	10	O
was	3	O
blocked	7	O
by	2	O
inhibition	10	O
of	2	O
PTK	3	B-Gene
.	1	O

Similarly	9	O
,	1	O
A	1	O
/	1	O
R	1	O
-induced	8	O
E-selectin	10	B-Gene
expression	10	O
and	3	O
neutrophil-endothelial	22	O
cell	4	O
adhesion	8	O
were	4	O
blocked	7	O
by	2	O
inhibition	10	O
of	2	O
PKC	3	B-Gene
or	2	O
PTK	3	B-Gene
,	1	O
while	5	O
only	4	O
PTK	3	B-Gene
inhibited	9	O
the	3	O
redox	5	O
-induced	8	O
adhesion	8	O
response	8	O
.	1	O

Pretreatment	12	O
of	2	O
cells	5	O
with	4	O
N-acetyl	8	B-Chemical
cysteine	8	I-Chemical
effectively	11	O
blocked	7	O
A	1	O
/	1	O
R-	2	O
or	2	O
redox	5	O
-induced	8	O
I	1	B-Gene
kappa	5	I-Gene
B	1	I-Gene
degradation	11	O
and	3	O
significantly	13	O
attenuated	10	O
the	3	O
respective	10	O
neutrophil	10	O
adhesion	8	O
responses	9	O
.	1	O

Collectively	12	O
,	1	O
these	5	O
findings	8	O
indicate	8	O
that	4	O
A	1	O
/	1	O
R	1	O
-induced	8	O
E-selectin	10	B-Gene
expression	10	O
and	3	O
neutrophil-endothelial	22	O
cell	4	O
adhesion	8	O
are	3	O
mediated	8	O
by	2	O
both	4	O
PKC	3	B-Gene
and	3	O
PTK	3	B-Gene
,	1	O
which	5	O
signal	6	O
rapid	5	O
activation	10	O
of	2	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
.	1	O

This	4	O
A	1	O
/	1	O
R	1	O
-induced	8	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
signaling	9	O
response	8	O
appears	7	O
to	2	O
be	2	O
mediated	8	O
,	1	O
at	2	O
least	5	O
in	2	O
part	4	O
,	1	O
by	2	O
intracellular	13	O
redox	5	O
imbalance	9	O
.	1	O

Copyright	9	O
2001	4	O
S	1	O
.	1	O

Karger	6	O
AG	2	O
,	1	O
Basel	5	O

Renal	5	O
interstitial	12	O
fibrosis	8	O
is	2	O
reduced	7	O
in	2	O
angiotensin	11	B-Gene
II	2	I-Gene
type	4	I-Gene
1a	2	I-Gene
receptor	8	I-Gene
-deficient	10	O
mice	4	O
.	1	O

Unilateral	10	B-Disease
ureteral	8	I-Disease
obstruction	11	I-Disease
(	1	O
UUO	3	B-Disease
)	1	O
results	7	O
in	2	O
tubulointerstitial	18	O
fibrosis	8	O
of	2	O
the	3	O
affected	8	O
kidney	6	O
by	2	O
stimulating	11	O
the	3	O
renin-angiotensin	17	B-Gene
system	6	O
.	1	O

This	4	O
study	5	O
established	11	O
a	1	O
UUO	3	B-Disease
model	5	O
in	2	O
angiotensin	11	B-Gene
type	4	I-Gene
1a	2	I-Gene
receptor	8	I-Gene
(	1	O
AT1a	4	B-Gene
)	1	O
deficient	9	O
(	1	O
mutant	6	O
)	1	O
mice	4	O
to	2	O
elucidate	9	O
the	3	O
role	4	O
of	2	O
angiotensin	11	B-Gene
II	2	I-Gene
through	7	O
AT1a	4	B-Gene
on	2	O
the	3	O
fibrosis	8	O
of	2	O
the	3	O
obstructed	10	O
kidney	6	O
(	1	O
OBK	3	O
)	1	O
.	1	O

The	3	O
relative	8	O
volume	6	O
of	2	O
the	3	O
tubulointerstitium	18	O
was	3	O
measured	8	O
by	2	O
an	2	O
image	5	O
analyzer	8	O
;	1	O
deposition	10	O
of	2	O
collagen	8	B-Gene
types	5	I-Gene
III	3	I-Gene
and	3	O
IV	2	B-Gene
and	3	O
monocyte	8	O
/	1	O
macrophage	10	O
infiltration	12	O
were	4	O
histologically	14	O
examined	8	O
using	5	O
specific	8	O
antibodies	10	O
.	1	O

Also	4	O
determined	10	O
were	4	O
the	3	O
mRNA	4	O
levels	6	O
of	2	O
transforming	12	B-Gene
growth	6	I-Gene
factor-beta	11	I-Gene
by	2	O
Northern	8	O
blot	4	O
analysis	8	O
.	1	O

Nuclear	7	B-Gene
factor-kappaB	13	I-Gene
activity	8	O
was	3	O
assessed	8	O
by	2	O
gel	3	O
shift	5	O
assay	5	O
.	1	O

UUO	3	B-Disease
in	2	O
wild	4	O
mice	4	O
resulted	8	O
in	2	O
a	1	O
marked	6	O
expansion	9	O
of	2	O
relative	8	O
volume	6	O
of	2	O
the	3	O
tubulointerstitium	18	O
,	1	O
together	8	O
with	4	O
increased	9	O
deposition	10	O
of	2	O
collagen	8	B-Gene
types	5	I-Gene
III	3	I-Gene
and	3	O
IV	2	B-Gene
and	3	O
number	6	O
of	2	O
infiltrated	11	O
monocytes	9	O
/	1	O
macrophages	11	O
in	2	O
the	3	O
interstitium	12	O
,	1	O
relative	8	O
to	2	O
sham	4	O
-operated	9	O
mice	4	O
.	1	O

In	2	O
comparison	10	O
,	1	O
these	5	O
changes	7	O
were	4	O
significantly	13	O
lower	5	O
in	2	O
mutant	6	O
mice	4	O
with	4	O
UUO	3	B-Disease
.	1	O

The	3	O
mRNA	4	O
level	5	O
of	2	O
transforming	12	B-Gene
growth	6	I-Gene
factor-beta	11	I-Gene
was	3	O
significantly	13	O
higher	6	O
in	2	O
the	3	O
OBK	3	O
of	2	O
wild	4	O
mice	4	O
with	4	O
UUO	3	B-Disease
compared	8	O
with	4	O
sham	4	O
-operated	9	O
mice	4	O
.	1	O

In	2	O
contrast	8	O
,	1	O
the	3	O
increase	8	O
in	2	O
mRNA	4	O
level	5	O
in	2	O
the	3	O
OBK	3	O
of	2	O
mutant	6	O
mice	4	O
was	3	O
significantly	13	O
less	4	O
than	4	O
in	2	O
wild	4	O
mice	4	O
.	1	O

Finally	7	O
,	1	O
UUO	3	B-Disease
resulted	8	O
in	2	O
activation	10	O
of	2	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
in	2	O
wild	4	O
mice	4	O
but	3	O
was	3	O
inhibited	9	O
in	2	O
the	3	O
OBK	3	O
of	2	O
mutant	6	O
mice	4	O
.	1	O

The	3	O
results	7	O
provide	7	O
direct	6	O
evidence	8	O
that	4	O
angiotensin	11	B-Gene
II	2	I-Gene
acting	6	O
via	3	O
the	3	O
AT1a	4	B-Gene
plays	5	O
a	1	O
pivotal	7	O
role	4	O
in	2	O
the	3	O
development	11	O
of	2	O
tubulointerstitial	18	O
fibrosis	8	O
in	2	O
UUO	3	B-Disease
.	1	O

Decreased	9	O
immediate	9	O
inflammatory	12	O
gene	4	O
induction	9	O
in	2	O
activating	10	B-Gene
transcription	13	I-Gene
factor-2	8	I-Gene
mutant	6	O
mice	4	O
.	1	O

Transcription	13	B-Gene
factor	6	I-Gene
activating	10	I-Gene
transcription	13	I-Gene
factor	6	I-Gene
(	1	I-Gene
ATF	3	I-Gene
)	1	I-Gene
-2	2	I-Gene
is	2	O
activated	9	O
by	2	O
inflammatory	12	O
signals	7	O
transduced	10	O
by	2	O
the	3	O
JNK	3	B-Gene
and	3	O
p38	3	B-Gene
MAP	3	I-Gene
kinase	6	I-Gene
pathways	8	O
.	1	O

To	2	O
better	6	O
define	6	O
the	3	O
role	4	O
of	2	O
ATF-2	5	B-Gene
in	2	O
inflammation	12	O
,	1	O
adult	5	O
mice	4	O
expressing	10	O
small	5	O
amounts	7	O
of	2	O
a	1	O
mutant	6	B-Gene
ATF-2	5	I-Gene
protein	7	I-Gene
were	4	O
challenged	10	O
with	4	O
lipopolysaccharide	18	B-Chemical
(	1	O
LPS	3	B-Chemical
)	1	O
,	1	O
anti-CD3	8	B-Gene
antibody	8	I-Gene
or	2	O
virus	5	O
.	1	O

Within	6	O
3	1	O
h	1	O
of	2	O
challenge	9	O
by	2	O
LPS	3	B-Chemical
,	1	O
ATF-2	5	B-Gene
mutant	6	I-Gene
mice	4	O
had	3	O
decreased	9	O
induction	9	O
of	2	O
the	3	O
adhesion	8	O
molecules	9	O
E-selectin	10	B-Gene
,	1	O
P-selectin	10	B-Gene
and	3	O
VCAM-1	6	B-Gene
as	2	O
well	4	O
as	2	O
the	3	O
cytokines	9	B-Gene
tumor	5	I-Gene
necrosis	8	I-Gene
factor-alpha	12	I-Gene
,	1	O
IL-1beta	8	B-Gene
and	3	O
IL-6	4	B-Gene
compared	8	O
with	4	O
control	7	O
mice	4	O
.	1	O

Stimulation	11	O
of	2	O
T	1	O
lymphocytes	11	O
by	2	O
anti-CD3	8	B-Gene
antibody	8	I-Gene
also	4	O
showed	6	O
less	4	O
induction	9	O
of	2	O
IL-1	4	B-Gene
and	3	O
IL-6	4	B-Gene
in	2	O
ATF-2	5	B-Gene
mutant	6	I-Gene
tissues	7	O
.	1	O

ATF-2	5	B-Gene
mutant	6	I-Gene
thymocytes	10	O
treated	7	O
with	4	O
anti-CD3	8	B-Gene
antibody	8	I-Gene
in	2	O
vitro	5	O
demonstrated	12	O
reduced	7	O
induction	9	O
of	2	O
c-Jun	5	B-Gene
,	1	O
JunB	4	B-Gene
,	1	O
JunD	4	B-Gene
and	3	O
Fra-2	5	B-Gene
.	1	O

However	7	O
,	1	O
similar	7	O
to	2	O
what	4	O
was	3	O
observed	8	O
after	5	O
p38	3	B-Gene
kinase	6	I-Gene
inhibition	10	O
in	2	O
normal	6	O
mice	4	O
,	1	O
relative	8	O
ATF-2	5	B-Gene
deficiency	10	O
did	3	O
not	3	O
prevent	7	O
the	3	O
development	11	O
of	2	O
a	1	O
mononuclear	11	O
cell	4	O
infiltrate	10	O
in	2	O
the	3	O
week	4	O
following	9	O
an	2	O
inflammatory	12	O
stimulus	8	O
.	1	O

ATF-2	5	B-Gene
mutant	6	I-Gene
mice	4	O
proved	6	O
more	4	O
susceptible	11	O
to	2	O
death	5	O
than	4	O
control	7	O
mice	4	O
from	4	O
LPS	3	B-Chemical
plus	4	O
D-galactosamine	15	B-Chemical
injection	9	O
or	2	O
Coxsackievirus	14	O
B3	2	O
infection	9	O
and	3	O
had	3	O
a	1	O
higher	6	O
incidence	9	O
of	2	O
mononuclear	11	O
pulmonary	9	O
infiltrates	11	O
after	5	O
exposure	8	O
to	2	O
Herpes	6	O
simplex	7	O
virus-1	7	O
.	1	O

ATF-2	5	B-Gene
is	2	O
essential	9	O
for	3	O
maximal	7	O
immediate	9	O
induction	9	O
of	2	O
adhesion	8	O
molecules	9	O
and	3	O
cytokine	8	O
genes	5	O
,	1	O
but	3	O
at	2	O
later	5	O
time	4	O
points	6	O
may	3	O
even	4	O
protect	7	O
against	7	O
overactive	10	O
immune	6	O
responses	9	O
.	1	O

Lymphokine	10	O
dependence	10	O
of	2	O
STAT3	5	B-Gene
activation	10	O
produced	8	O
by	2	O
surface	7	B-Gene
immunoglobulin	14	I-Gene
cross	5	O
-linking	8	O
and	3	O
by	2	O
phorbol	7	B-Chemical
ester	5	I-Chemical
plus	4	O
calcium	7	B-Chemical
ionophore	9	O
treatment	9	O
in	2	O
B	1	O
cells	5	O
.	1	O

Stimulation	11	O
of	2	O
B	1	O
cells	5	O
by	2	O
surface	7	B-Gene
immunoglobulin	14	I-Gene
(	1	O
sIg	3	B-Gene
)	1	O
triggering	10	O
,	1	O
or	2	O
through	7	O
the	3	O
mitogenic	9	O
combination	11	O
of	2	O
phorbol	7	B-Chemical
ester	5	I-Chemical
and	3	O
calcium	7	B-Chemical
ionophore	9	O
,	1	O
is	2	O
accompanied	11	O
by	2	O
activation	10	O
of	2	O
STAT	4	B-Gene
transcription	13	I-Gene
factors	7	I-Gene
.	1	O

The	3	O
mechanism	9	O
responsible	11	O
for	3	O
the	3	O
delayed	7	O
nuclear	7	O
accumulation	12	O
of	2	O
phosphorylated	14	B-Gene
STAT3	5	I-Gene
was	3	O
examined	8	O
in	2	O
detail	6	O
,	1	O
focusing	8	O
on	2	O
the	3	O
role	4	O
of	2	O
B	1	O
cell	4	O
-derived	8	O
lymphokines	11	O
.	1	O

sIg	3	B-Gene
-induced	8	O
activation	10	O
of	2	O
STAT3	5	B-Gene
was	3	O
partially	9	O
inhibited	9	O
in	2	O
B	1	O
cells	5	O
obtained	8	O
from	4	O
IL-6-	5	B-Gene
or	2	O
IL-10	5	B-Gene
-deficient	10	O
mice	4	O
,	1	O
and	3	O
was	3	O
partially	9	O
blocked	7	O
by	2	O
neutralizing	12	O
antibodies	10	O
directed	8	O
against	7	O
either	6	O
of	2	O
these	5	O
lymphokines	11	O
.	1	O

sIg	3	B-Gene
-induced	8	O
STAT3	5	B-Gene
activation	10	O
was	3	O
completely	10	O
inhibited	9	O
by	2	O
combining	9	O
IL-6-	5	B-Gene
and	3	O
IL-10-specific	14	B-Gene
neutralizing	12	I-Gene
antibodies	10	I-Gene
,	1	O
or	2	O
by	2	O
adding	6	O
individual	10	O
neutralizing	12	O
antibodies	10	O
to	2	O
B	1	O
cells	5	O
obtained	8	O
from	4	O
lymphokine	10	O
-deficient	10	O
animals	7	O
.	1	O

In	2	O
contrast	8	O
,	1	O
IL-10	5	B-Gene
alone	5	O
appeared	8	O
to	2	O
account	7	O
for	3	O
STAT3	5	B-Gene
activation	10	O
resulting	9	O
from	4	O
B	1	O
cell	4	O
stimulation	11	O
with	4	O
phorbol	7	B-Chemical
ester	5	I-Chemical
and	3	O
calcium	7	B-Chemical
ionophore	9	O
.	1	O

In	2	O
keeping	7	O
with	4	O
these	5	O
results	7	O
,	1	O
soluble	7	O
IL-6	4	B-Gene
and	3	O
IL-10	5	B-Gene
were	4	O
found	5	O
in	2	O
supernatant	11	O
fluid	5	O
obtained	8	O
from	4	O
stimulated	10	O
B	1	O
cells	5	O
.	1	O

This	4	O
work	4	O
indicates	9	O
that	4	O
a	1	O
lymphokine	10	O
pathway	7	O
is	2	O
responsible	11	O
for	3	O
STAT3	5	B-Gene
activation	10	O
that	4	O
occurs	6	O
late	4	O
after	5	O
B	1	O
cell	4	O
stimulation	11	O
,	1	O
and	3	O
points	6	O
out	3	O
differences	11	O
in	2	O
B	1	O
cell	4	O
activation	10	O
that	4	O
result	6	O
from	4	O
stimulation	11	O
through	7	O
the	3	O
antigen	7	O
receptor	8	O
and	3	O
through	7	O
pharmacological	15	O
mimicry	7	O
of	2	O
signaling	9	O
mediators	9	O
.	1	O

Bone	4	O
marrow	6	O
cells	5	O
promote	7	O
TH2	3	O
polarization	12	O
and	3	O
inhibit	7	O
virus-specific	14	O
CTL	3	O
generation	10	O
.	1	O

This	4	O
laboratory	10	O
recently	8	O
reported	8	O
that	4	O
human	5	O
bone	4	O
marrow	6	O
cells	5	O
(	1	O
BMC	3	O
)	1	O
inhibit	7	O
the	3	O
generation	10	O
of	2	O
virus-specific	14	O
CTL	3	O
in	2	O
culture	7	O
.	1	O

The	3	O
culture	7	O
supernatants	12	O
contained	9	O
increased	9	O
levels	6	O
of	2	O
prostaglandin	13	B-Chemical
E	1	I-Chemical
(	1	O
2	1	O
)	1	O
(	1	O
PGE	3	B-Chemical
(	1	O
2	1	O
)	1	O
)	1	O
(	1	O
shown	5	O
to	2	O
favor	5	O
TH2	3	O
cell	4	O
development	11	O
)	1	O
and	3	O
also	4	O
inhibited	9	O
EBV-CTL	7	O
effector	8	O
cell	4	O
development	11	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
we	2	O
obtained	8	O
PBL	3	O
from	4	O
Epstein-Barr	12	B-Gene
virus	5	I-Gene
(	1	I-Gene
EBV	3	I-Gene
)	1	I-Gene
IgG	3	I-Gene
antibody	8	I-Gene
positive	8	O
kidney	6	O
transplant	10	O
recipients	10	O
(	1	O
R	1	O
)	1	O
and	3	O
their	5	O
living	6	O
-related	8	O
donors	6	O
(	1	O
LRD	3	O
)	1	O
one	3	O
year	4	O
after	5	O
renal	5	O
transplantation	15	O
.	1	O

EBV-specific	12	O
CTL	3	O
were	4	O
then	4	O
generated	9	O
in	2	O
vitro	5	O
by	2	O
stimulating	11	O
PBL	3	O
with	4	O
autologous	10	O
EBV	3	O
-transformed	12	O
B	1	O
cells	5	O
(	1	O
EBV-B	5	O
)	1	O
in	2	O
the	3	O
presence	8	O
or	2	O
absence	7	O
of	2	O
autologous	10	O
BMC	3	O
.	1	O

The	3	O
addition	8	O
of	2	O
BMC	3	O
to	2	O
the	3	O
EBV-CTL	7	O
generation	10	O
cultures	8	O
increased	9	O
the	3	O
intracellular	13	O
expression	10	O
in	2	O
CD3+	4	B-Gene
cells	5	O
of	2	O
IL-4	4	B-Gene
,	1	O
-5	2	B-Partial_Gene
,	1	O
-6	2	B-Partial_Gene
,	1	O
-10	3	B-Partial_Gene
,	1	O
and	3	O
-13	3	B-Partial_Gene
.	1	O

These	5	O
CD3+	4	B-Gene
cells	5	O
also	4	O
expressed	9	O
increased	9	O
levels	6	O
of	2	O
the	3	O
TH2	3	O
associated	10	O
receptor	8	B-Gene
CCR3	4	I-Gene
.	1	O

Inhibition	10	O
was	3	O
even	4	O
observed	8	O
by	2	O
preparing	9	O
EBV-CTL	7	O
generating	10	O
cultures	8	O
in	2	O
trans-wells	11	O
that	4	O
separated	9	O
the	3	O
autologous	10	O
BMC	3	O
from	4	O
the	3	O
PBL	3	O
+	1	O
EBV-B	5	O
.	1	O

It	2	O
was	3	O
then	4	O
observed	8	O
that	4	O
CD3+	4	B-Gene
cells	5	O
obtained	8	O
after	5	O
7	1	O
days	4	O
of	2	O
culture	7	O
in	2	O
the	3	O
presence	8	O
of	2	O
autologous	10	O
BMC	3	O
could	5	O
be	2	O
used	4	O
as	2	O
inhibitors	10	O
of	2	O
EBV-CTL	7	O
generation	10	O
.	1	O

Protein	7	B-Gene
Kinase	6	I-Gene
A	1	I-Gene
(	1	O
PKA	3	B-Gene
)	1	O
,	1	O
a	1	O
cAMP	4	B-Gene
kinase	6	I-Gene
that	4	O
is	2	O
involved	8	O
in	2	O
the	3	O
upregulation	12	O
of	2	O
TH2	3	O
cytokine	8	O
activity	8	O
,	1	O
was	3	O
increased	9	O
in	2	O
EBV-CTL	7	O
cultures	8	O
by	2	O
the	3	O
presence	8	O
of	2	O
BMC	3	O
.	1	O

Additionally	12	O
,	1	O
IL-4	4	B-Gene
-mediated	9	O
signal	6	B-Gene
transduction	12	I-Gene
and	3	I-Gene
activation	10	I-Gene
of	2	I-Gene
transcription	13	I-Gene
(	1	O
STAT-6	6	B-Gene
)	1	O
phosphorylation	15	O
was	3	O
slightly	8	O
increased	9	O
.	1	O

These	5	O
results	7	O
show	4	O
that	4	O
the	3	O
BMC	3	O
inhibition	10	O
is	2	O
mediated	8	O
by	2	O
soluble	7	O
factors	7	O
(	1	O
cytokines	9	O
)	1	O
and	3	O
that	4	O
cell-cell	9	O
contact	7	O
in	2	O
this	4	O
autologous	10	O
system	6	O
is	2	O
not	3	O
required	8	O
,	1	O
so	2	O
that	4	O
BMC	3	O
(	1	O
at	2	O
least	5	O
partially	9	O
,	1	O
via	3	O
cytokine	8	O
production	10	O
)	1	O
promote	7	O
TH2	3	O
polarization	12	O
in	2	O
culture	7	O
.	1	O

Moreover	8	O
,	1	O
TH2	3	O
cells	5	O
induced	7	O
by	2	O
culturing	9	O
with	4	O
autologous	10	O
BMC	3	O
directly	8	O
inhibit	7	O
EBV-CTL	7	O
generation	10	O
,	1	O
and	3	O
TH2	3	O
associated	10	O
PKA	3	B-Gene
,	1	O
CCR3	4	B-Gene
,	1	O
and	3	O
STAT-6	6	B-Gene
phosphorylation	15	O
are	3	O
enhanced	8	O
by	2	O
BMC	3	O
.	1	O

Induction	9	O
of	2	O
apoptosis	9	O
in	2	O
human	5	O
lymphocytes	11	O
by	2	O
the	3	O
herbicide	9	B-Chemical
2	1	I-Chemical
,	1	I-Chemical
4-dichlorophenoxyacetic	23	I-Chemical
acid	4	I-Chemical
.	1	O

Dimethylammonium	16	O
salt	4	O
of	2	O
2	1	B-Chemical
,	1	I-Chemical
4-dichlorophenoxyacetic	23	I-Chemical
acid	4	I-Chemical
(	1	O
DMA-2	5	B-Chemical
,	1	I-Chemical
4-D	3	I-Chemical
)	1	O
is	2	O
a	1	O
widely	6	O
used	4	O
herbicide	9	O
that	4	O
is	2	O
considered	10	O
moderately	10	O
toxic	5	O
.	1	O

In	2	O
the	3	O
present	7	O
study	5	O
we	2	O
found	5	O
that	4	O
DMA-2	5	B-Chemical
,	1	I-Chemical
4-D	3	I-Chemical
is	2	O
able	4	O
to	2	O
cause	5	O
apoptosis	9	O
in	2	O
peripheral	10	O
blood	5	O
lymphocytes	11	O
of	2	O
healthy	7	O
individuals	11	O
and	3	O
Jurkat	6	O
T	1	O
cells	5	O
.	1	O

Apoptosis	9	O
induced	7	O
by	2	O
DMA-2	5	B-Chemical
,	1	I-Chemical
4-D	3	I-Chemical
was	3	O
dose	4	O
and	3	O
time	4	O
dependent	9	O
,	1	O
independent	11	O
of	2	O
Fas	3	B-Gene
,	1	O
TNF	3	B-Gene
receptor	8	I-Gene
1	1	I-Gene
or	2	O
the	3	O
aromatic	8	B-Gene
hydrocarbon	11	I-Gene
receptor	8	I-Gene
,	1	O
and	3	O
involved	8	O
disruption	10	O
of	2	O
the	3	O
mitochondrial	13	O
transmembrane	13	O
potential	9	O
and	3	O
activation	10	O
of	2	O
caspase-9	9	B-Gene
.	1	O

ZVAD-FMK	8	B-Chemical
,	1	O
a	1	O
broad-spectrum	14	O
inhibitor	9	O
of	2	O
caspases	8	B-Gene
,	1	O
blocked	7	O
DMA-2	5	B-Chemical
,	1	I-Chemical
4-D	3	I-Chemical
-induced	8	O
apoptosis	9	O
completely	10	O
.	1	O

While	5	O
an	2	O
inhibitor	9	O
of	2	O
caspase-9	9	B-Gene
,	1	O
as	2	O
well	4	O
as	2	O
caspase-9	9	B-Gene
and	3	O
caspase-3	9	B-Gene
inhibitors	10	I-Gene
in	2	O
combination	11	O
,	1	O
strongly	8	O
blocked	7	O
DMA-2	5	B-Chemical
,	1	I-Chemical
4-D	3	I-Chemical
-induced	8	O
apoptosis	9	O
,	1	O
an	2	O
inhibitor	9	O
of	2	O
caspase-3	9	B-Gene
had	3	O
a	1	O
moderate	8	O
inhibitory	10	O
effect	6	O
.	1	O

Unlike	6	O
Fas	3	B-Gene
-mediated	9	O
apoptosis	9	O
,	1	O
the	3	O
initiator	9	B-Gene
caspase	7	I-Gene
,	1	O
caspase-8	9	B-Gene
,	1	O
was	3	O
not	3	O
involved	8	O
in	2	O
DMA-2	5	B-Chemical
,	1	I-Chemical
4-D	3	I-Chemical
-induced	8	O
apoptosis	9	O
.	1	O

Transfection	12	O
of	2	O
Jurkat	6	O
cells	5	O
with	4	O
Bcl-2	5	B-Gene
prevented	9	O
DMA-2	5	B-Chemical
,	1	I-Chemical
4-D	3	I-Chemical
-induced	8	O
disruption	10	O
of	2	O
the	3	O
mitochondrial	13	O
transmembrane	13	O
potential	9	O
and	3	O
led	3	O
to	2	O
a	1	O
complete	8	O
blockage	8	O
of	2	O
apoptosis	9	O
.	1	O

Our	3	O
data	4	O
indicate	8	O
that	4	O
DMA-2	5	B-Chemical
,	1	I-Chemical
4-D	3	I-Chemical
kills	5	O
human	5	O
lymphocytes	11	O
by	2	O
initiating	10	O
apoptosis	9	O
via	3	O
a	1	O
direct	6	O
effect	6	O
on	2	O
mitochondria	12	O
.	1	O

The	3	O
activation	10	O
of	2	O
caspases	8	B-Gene
occurs	6	O
downstream	10	O
of	2	O
mitochondrial	13	O
damage	6	O
,	1	O
and	3	O
the	3	O
dysfunction	11	O
of	2	O
mitochondria	12	O
appears	7	O
to	2	O
be	2	O
sufficient	10	O
for	3	O
triggering	10	O
all	3	O
downstream	10	O
events	6	O
leading	7	O
to	2	O
apoptosis	9	O
.	1	O

Inhibition	10	O
of	2	O
STAT3	5	B-Gene
signaling	9	O
leads	5	O
to	2	O
apoptosis	9	O
of	2	O
leukemic	8	O
large	5	O
granular	8	O
lymphocytes	11	O
and	3	O
decreased	9	O
Mcl-1	5	B-Gene
expression	10	O
.	1	O

Large	5	B-Disease
granular	8	I-Disease
lymphocyte	10	I-Disease
(	1	I-Disease
LGL	3	I-Disease
)	1	I-Disease
leukemia	8	I-Disease
is	2	O
characterized	13	O
by	2	O
the	3	O
expansion	9	O
of	2	O
antigen	7	O
-activated	10	O
cytotoxic	9	O
T	1	O
lymphocytes	11	O
.	1	O

These	5	O
leukemic	8	O
cells	5	O
are	3	O
resistant	9	O
to	2	O
Fas	3	B-Gene
-mediated	9	O
apoptosis	9	O
despite	7	O
expressing	10	O
high	4	O
levels	6	O
of	2	O
Fas	3	B-Gene
.	1	O

We	2	O
found	5	O
that	4	O
leukemic	8	O
LGL	3	O
from	4	O
19	2	O
patients	8	O
displayed	9	O
high	4	O
levels	6	O
of	2	O
activated	9	B-Gene
STAT3	5	I-Gene
.	1	O

Treatment	9	O
of	2	O
leukemic	8	O
LGL	3	O
with	4	O
the	3	O
JAK	3	B-Gene
-selective	10	I-Gene
tyrosine	8	I-Gene
kinase	6	I-Gene
inhibitor	9	O
AG-490	6	B-Chemical
induced	7	O
apoptosis	9	O
with	4	O
a	1	O
corresponding	13	O
decrease	8	O
in	2	O
STAT	4	B-Gene
-DNA	4	I-Gene
binding	7	O
activity	8	O
.	1	O

Moreover	8	O
,	1	O
using	5	O
an	2	O
antisense	9	O
oligonucleotide	15	O
approach	8	O
to	2	O
diminish	8	O
STAT3	5	B-Gene
expression	10	O
,	1	O
we	2	O
found	5	O
that	4	O
Fas	3	B-Gene
sensitivity	11	O
was	3	O
restored	8	O
in	2	O
leukemic	8	O
LGL	3	O
.	1	O

AG-490	6	B-Chemical
-induced	8	O
apoptosis	9	O
in	2	O
leukemic	8	O
LGL	3	O
was	3	O
independent	11	O
of	2	O
Bcl-xL	6	B-Gene
or	2	O
Bcl-2	5	B-Gene
expression	10	O
.	1	O

However	7	O
,	1	O
we	2	O
found	5	O
that	4	O
the	3	O
Bcl-2-family	12	B-Gene
protein	7	I-Gene
Mcl-1	5	I-Gene
was	3	O
significantly	13	O
reduced	7	O
by	2	O
AG-490	6	B-Chemical
treatment	9	O
.	1	O

Activated	9	B-Gene
STAT3	5	I-Gene
was	3	O
shown	5	O
to	2	O
bind	4	O
an	2	O
SIE	3	O
-related	8	O
element	7	O
in	2	O
the	3	O
murine	6	B-Gene
mcl-1	5	I-Gene
promoter	8	I-Gene
.	1	O

Using	5	O
a	1	O
luciferase	10	O
reporter	8	O
assay	5	O
,	1	O
we	2	O
demonstrated	12	O
that	4	O
v-src	5	B-Gene
overexpression	14	O
in	2	O
NIH3T3	6	O
induced	7	O
STAT3	5	B-Gene
-dependent	10	O
transcriptional	15	O
activity	8	O
from	4	O
the	3	O
mcl-1	5	B-Gene
promoter	8	I-Gene
and	3	O
increased	9	O
endogenous	10	B-Gene
Mcl-1	5	I-Gene
protein	7	I-Gene
levels	6	O
.	1	O

We	2	O
conclude	8	O
that	4	O
STAT3	5	B-Gene
activation	10	O
contributed	11	O
to	2	O
accumulation	12	O
of	2	O
the	3	O
leukemic	8	O
LGL	3	O
clones	6	O
.	1	O

These	5	O
findings	8	O
suggest	7	O
that	4	O
investigation	13	O
should	6	O
focus	5	O
on	2	O
novel	5	O
strategies	10	O
targeting	9	O
STAT3	5	B-Gene
in	2	O
the	3	O
treatment	9	O
of	2	O
LGL	3	B-Disease
leukemia	8	I-Disease
.	1	O

Visualization	13	O
of	2	O
Syk-antigen	11	B-Gene
receptor	8	I-Gene
interactions	12	O
using	5	O
green	5	O
fluorescent	11	O
protein	7	O
:	1	O
differential	12	O
roles	5	O
for	3	O
Syk	3	B-Gene
and	3	O
Lyn	3	B-Gene
in	2	O
the	3	O
regulation	10	O
of	2	O
receptor	8	O
capping	7	O
and	3	O
internalization	15	O
.	1	O

The	3	O
cross	5	O
-linking	8	O
of	2	O
the	3	O
B	1	B-Gene
cell	4	I-Gene
Ag	2	I-Gene
receptor	8	I-Gene
(	1	O
BCR	3	B-Gene
)	1	O
is	2	O
coupled	7	O
to	2	O
the	3	O
stimulation	11	O
of	2	O
multiple	8	O
intracellular	13	O
signal	6	O
transduction	12	O
cascades	8	O
via	3	O
receptor	8	O
-associated	11	O
,	1	O
protein	7	B-Gene
tyrosine	8	I-Gene
kinases	7	I-Gene
of	2	O
both	4	O
the	3	O
Src	3	B-Gene
and	3	O
Syk	3	B-Gene
families	8	I-Gene
.	1	O

To	2	O
monitor	7	O
changes	7	O
in	2	O
the	3	O
subcellular	11	O
distribution	12	O
of	2	O
Syk	3	B-Gene
in	2	O
B	1	O
cells	5	O
responding	10	O
to	2	O
BCR	3	B-Gene
cross	5	O
-linking	8	O
,	1	O
we	2	O
expressed	9	O
in	2	O
Syk	3	B-Gene
-deficient	10	O
DT40	4	O
B	1	O
cells	5	O
a	1	O
fusion	6	O
protein	7	O
consisting	10	O
of	2	O
Syk	3	B-Gene
coupled	7	O
to	2	O
green	5	O
fluorescent	11	O
protein	7	O
.	1	O

Treatment	9	O
of	2	O
these	5	O
cells	5	O
with	4	O
anti-IgM	8	B-Gene
Abs	3	I-Gene
leads	5	O
to	2	O
the	3	O
recruitment	11	O
of	2	O
the	3	O
kinase	6	O
from	4	O
cytoplasmic	11	O
and	3	O
nuclear	7	O
compartments	12	O
to	2	O
the	3	O
site	4	O
of	2	O
the	3	O
cross	5	O
-linked	7	O
receptor	8	O
at	2	O
the	3	O
plasma	6	O
membrane	8	O
.	1	O

The	3	O
Syk-receptor	12	B-Gene
complexes	9	I-Gene
aggregate	9	O
into	4	O
membrane	8	O
patches	7	O
that	4	O
redistribute	12	O
to	2	O
form	4	O
a	1	O
cap	3	O
at	2	O
one	3	O
pole	4	O
of	2	O
the	3	O
cell	4	O
.	1	O

Syk	3	B-Gene
is	2	O
not	3	O
demonstrably	12	O
associated	10	O
with	4	O
the	3	O
internalized	12	O
receptor	8	O
.	1	O

Catalytically	13	O
active	6	O
Syk	3	B-Gene
promotes	8	O
and	3	O
stabilizes	10	O
the	3	O
formation	9	O
of	2	O
tightly	7	O
capped	6	O
BCR	3	B-Gene
complexes	9	I-Gene
at	2	O
the	3	O
plasma	6	O
membrane	8	O
.	1	O

Lyn	3	B-Gene
is	2	O
not	3	O
required	8	O
for	3	O
the	3	O
recruitment	11	O
of	2	O
Syk	3	B-Gene
to	2	O
the	3	O
cross	5	O
-linked	7	O
receptor	8	O
,	1	O
but	3	O
is	2	O
required	8	O
for	3	O
the	3	O
internalization	15	O
of	2	O
the	3	O
clustered	9	O
BCR	3	B-Gene
complexes	9	I-Gene
.	1	O

In	2	O
the	3	O
absence	7	O
of	2	O
Lyn	3	B-Gene
,	1	O
receptor-Syk	12	B-Gene
complexes	9	I-Gene
at	2	O
the	3	O
plasma	6	O
membrane	8	O
are	3	O
long	4	O
lived	5	O
,	1	O
and	3	O
the	3	O
receptor	8	O
-mediated	9	O
activation	10	O
of	2	O
the	3	O
NF-AT	5	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
is	2	O
enhanced	8	O
.	1	O

Thus	4	O
,	1	O
Lyn	3	B-Gene
appears	7	O
to	2	O
function	8	O
to	2	O
negatively	10	O
regulate	8	O
aspects	7	O
of	2	O
BCR	3	B-Gene
-dependent	10	O
signaling	9	O
by	2	O
stimulating	11	O
receptor	8	O
internalization	15	O
and	3	O
down-regulation	15	O
.	1	O

NF-kappa	8	B-Gene
B	1	I-Gene
/	1	I-Gene
Rel	3	I-Gene
participation	13	O
in	2	O
the	3	O
lymphokine	10	O
-dependent	10	O
proliferation	13	O
of	2	O
T	1	O
lymphoid	8	O
cells	5	O
.	1	O

Proliferative	13	O
responses	9	O
of	2	O
lymphoid	8	O
cells	5	O
to	2	O
IL-2	4	B-Gene
and	3	O
IL-4	4	B-Gene
depend	6	O
on	2	O
activation	10	O
of	2	O
the	3	O
cells	5	O
,	1	O
but	3	O
the	3	O
mechanism	9	O
(	1	O
s	1	O
)	1	O
by	2	O
which	5	O
activation	10	O
enhances	8	O
cellular	8	O
competence	10	O
to	2	O
respond	7	O
to	2	O
cytokines	9	O
is	2	O
not	3	O
fully	5	O
understood	10	O
.	1	O

The	3	O
NF-kappaB	9	B-Gene
/	1	I-Gene
Rel	3	I-Gene
family	6	I-Gene
represents	10	O
one	3	O
signal	6	O
transduction	12	O
pathway	7	O
induced	7	O
during	6	O
such	4	O
activation	10	O
.	1	O

We	2	O
show	4	O
in	2	O
this	4	O
study	5	O
that	4	O
inhibition	10	O
of	2	O
NF-kappaB	9	B-Gene
through	7	O
the	3	O
expression	10	O
of	2	O
an	2	O
IkappaBalpha	12	B-Gene
(	1	O
inhibitory	10	O
protein	7	O
that	4	O
dissociates	11	O
from	4	O
NF-kappaB	9	B-Gene
)	1	O
mutant	6	O
refractory	10	O
to	2	O
signal	6	O
-induced	8	O
degradation	11	O
(	1	O
IkappaBalpha	12	B-Gene
(	1	O
DeltaN	6	O
)	1	O
)	1	O
interfered	10	O
with	4	O
the	3	O
acquisition	11	O
of	2	O
competence	10	O
to	2	O
proliferate	11	O
in	2	O
response	8	O
to	2	O
IL-4	4	B-Gene
as	2	O
well	4	O
as	2	O
IL-2	4	B-Gene
.	1	O

Thymocytes	10	O
and	3	O
T	1	O
cells	5	O
from	4	O
IkappaBalpha	12	B-Gene
(	1	O
DeltaN	6	O
)	1	O
transgenic	10	O
mice	4	O
expressed	9	O
normal	6	O
levels	6	O
of	2	O
IL-2R	5	B-Gene
subunits	8	O
.	1	O

However	7	O
,	1	O
transgenic	10	O
cells	5	O
exhibited	9	O
a	1	O
dramatic	8	O
defect	6	O
in	2	O
Stat5A	6	B-Gene
activation	10	O
treatment	9	O
with	4	O
IL-2	4	B-Gene
,	1	O
and	3	O
a	1	O
similar	7	O
defect	6	O
was	3	O
observed	8	O
for	3	O
IL-4	4	B-Gene
-induced	8	O
Stat5	5	B-Gene
.	1	O

In	2	O
contrast	8	O
,	1	O
T	1	O
lymphoid	8	O
cells	5	O
with	4	O
inhibition	10	O
of	2	O
NF-kappaB	9	B-Gene
showed	6	O
normal	6	O
insulin	7	B-Gene
receptor	8	I-Gene
substrate-2	11	I-Gene
phosphorylation	15	O
and	3	O
only	4	O
a	1	O
modest	6	O
decrease	8	O
in	2	O
Stat6	5	B-Gene
activation	10	O
and	3	O
insulin	7	B-Gene
receptor	8	I-Gene
substrate-1	11	I-Gene
phosphorylation	15	O
after	5	O
IL-4	4	B-Gene
stimulation	11	O
.	1	O

These	5	O
results	7	O
indicate	8	O
that	4	O
the	3	O
NF-kappaB	9	B-Gene
/	1	I-Gene
Rel	3	I-Gene
/	1	I-Gene
IkappaBalpha	12	I-Gene
system	6	O
can	3	O
regulate	8	O
cytokine	8	O
receptor	8	O
capacitation	12	O
through	7	O
effects	7	O
on	2	O
the	3	O
induction	9	O
of	2	O
downstream	10	O
signaling	9	O
by	2	O
the	3	O
Stat	4	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
family	6	I-Gene
.	1	O

Reduction	9	O
in	2	O
DNA	3	O
binding	7	O
activity	8	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
Pax-5a	6	I-Gene
in	2	O
B	1	O
lymphocytes	11	O
of	2	O
aged	4	O
mice	4	O
.	1	O

Aging	5	O
has	3	O
been	4	O
associated	10	O
with	4	O
intrinsic	9	O
changes	7	O
of	2	O
the	3	O
humoral	7	O
immune	6	O
response	8	O
,	1	O
which	5	O
may	3	O
lead	4	O
to	2	O
an	2	O
increased	9	O
occurrence	10	O
of	2	O
autoimmune	10	B-Disease
disorders	9	I-Disease
and	3	O
pathogenic	10	O
susceptibility	14	O
.	1	O

The	3	O
transcription	13	B-Gene
factor	6	I-Gene
Pax-5	5	I-Gene
is	2	O
a	1	O
key	3	O
regulator	9	O
of	2	O
B	1	O
cell	4	O
development	11	O
.	1	O

Pax-5a	6	B-Gene
/	1	I-Gene
B	1	I-Gene
cell-specific	13	I-Gene
activator	9	I-Gene
protein	7	I-Gene
and	3	O
an	2	O
alternatively	13	O
spliced	7	O
isoform	7	O
,	1	O
Pax-5d	6	B-Gene
,	1	O
may	3	O
have	4	O
opposing	8	O
functions	9	O
in	2	O
transcriptional	15	O
regulation	10	O
due	3	O
to	2	O
the	3	O
lack	4	O
of	2	O
a	1	O
transactivation	15	O
domain	6	O
in	2	O
Pax-5d	6	B-Gene
.	1	O

To	2	O
study	5	O
B	1	O
cell	4	O
-specific	9	O
changes	7	O
that	4	O
occur	5	O
during	6	O
the	3	O
aging	5	O
process	7	O
,	1	O
we	2	O
investigated	12	O
expression	10	O
patterns	8	O
of	2	O
Pax-5a	6	B-Gene
and	3	O
5d	2	B-Partial_Gene
in	2	O
mature	6	O
B	1	O
cells	5	O
of	2	O
young	5	O
and	3	O
aged	4	O
mice	4	O
.	1	O

RNase	5	O
protection	10	O
assays	6	O
showed	6	O
a	1	O
similar	7	O
transcriptional	15	O
pattern	7	O
for	3	O
both	4	O
age	3	O
groups	6	O
that	4	O
indicates	9	O
that	4	O
aging	5	O
has	3	O
no	2	O
affect	6	O
on	2	O
transcription	13	O
initiation	10	O
or	2	O
alternative	11	O
splicing	8	O
for	3	O
either	6	O
isoform	7	O
.	1	O

In	2	O
contrast	8	O
,	1	O
a	1	O
significant	11	O
reduction	9	O
in	2	O
the	3	O
DNA	3	O
binding	7	O
activity	8	O
of	2	O
Pax-5a	6	B-Gene
but	3	O
not	3	O
Pax-5d	6	B-Gene
protein	7	I-Gene
was	3	O
observed	8	O
in	2	O
aged	4	O
B	1	O
cells	5	O
in	2	O
vitro	5	O
,	1	O
while	5	O
Western	7	O
blot	4	O
analyses	8	O
showed	6	O
that	4	O
similar	7	O
levels	6	O
of	2	O
Pax-5a	6	B-Gene
and	3	O
5d	2	B-Gene
proteins	8	I-Gene
were	4	O
present	7	O
in	2	O
both	4	O
age	3	O
groups	6	O
.	1	O

The	3	O
observed	8	O
decrease	8	O
in	2	O
Pax-5a	6	B-Gene
binding	7	O
activity	8	O
correlated	10	O
with	4	O
changes	7	O
in	2	O
expression	10	O
of	2	O
two	3	O
Pax-5	5	B-Gene
target	6	I-Gene
genes	5	I-Gene
in	2	O
aged	4	O
B	1	O
cells	5	O
.	1	O

Expression	10	O
of	2	O
the	3	O
Ig	2	B-Gene
J	1	I-Gene
chain	5	I-Gene
and	3	O
the	3	O
secreted	8	O
form	4	O
of	2	O
Ig	2	B-Gene
mu	2	I-Gene
,	1	O
which	5	O
are	3	O
both	4	O
known	5	O
to	2	O
be	2	O
suppressed	10	O
by	2	O
Pax-5a	6	B-Gene
in	2	O
mature	6	O
B	1	O
cells	5	O
,	1	O
were	4	O
increased	9	O
in	2	O
B	1	O
cells	5	O
of	2	O
aged	4	O
mice	4	O
.	1	O

Together	8	O
,	1	O
our	3	O
studies	7	O
suggest	7	O
that	4	O
changes	7	O
associated	10	O
with	4	O
the	3	O
aging	5	O
phenotype	9	O
cause	5	O
posttranslational	17	O
modification	12	O
(	1	O
s	1	O
)	1	O
of	2	O
Pax-5a	6	B-Gene
but	3	O
not	3	O
Pax-5d	6	B-Gene
,	1	O
which	5	O
may	3	O
lead	4	O
to	2	O
an	2	O
abnormal	8	O
B	1	O
cell	4	O
phenotype	9	O
in	2	O
aged	4	O
mice	4	O
,	1	O
associated	10	O
with	4	O
elevated	8	O
levels	6	O
of	2	O
J	1	B-Partial_Gene
chain	5	I-Partial_Gene
,	1	O
and	3	O
secretion	9	O
of	2	O
IgM	3	B-Gene

Interaction	11	O
between	7	O
CCAAT	5	B-Gene
/	1	I-Gene
enhancer	8	I-Gene
binding	7	I-Gene
protein	7	I-Gene
and	3	O
cyclic	6	B-Gene
AMP	3	I-Gene
response	8	I-Gene
element	7	I-Gene
binding	7	I-Gene
protein	7	I-Gene
1	1	I-Gene
regulates	9	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
transcription	13	O
in	2	O
cells	5	O
of	2	O
the	3	O
monocyte	8	O
/	1	O
macrophage	10	O
lineage	7	O
.	1	O

Recent	6	O
observations	12	O
have	4	O
shown	5	O
two	3	O
CCAAT	5	B-Gene
/	1	I-Gene
enhancer	8	I-Gene
binding	7	I-Gene
protein	7	I-Gene
(	1	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
)	1	O
binding	7	O
sites	5	O
to	2	O
be	2	O
critically	10	O
important	9	O
for	3	O
efficient	9	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
(	1	O
HIV-1	5	O
)	1	O
replication	11	O
within	6	O
cells	5	O
of	2	O
the	3	O
monocyte	8	O
/	1	O
macrophage	10	O
lineage	7	O
,	1	O
a	1	O
cell	4	O
type	4	O
likely	6	O
involved	8	O
in	2	O
transport	9	O
of	2	O
the	3	O
virus	5	O
to	2	O
the	3	O
brain	5	O
.	1	O

Additionally	12	O
,	1	O
sequence	8	O
variation	9	O
at	2	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
site	4	O
I	1	O
,	1	O
which	5	O
lies	4	O
immediately	11	O
upstream	8	O
of	2	O
the	3	O
distal	6	O
nuclear	7	B-Gene
factor	6	I-Gene
kappa	5	I-Gene
B	1	I-Gene
site	4	O
and	3	O
immediately	11	O
downstream	10	O
of	2	O
a	1	O
binding	7	O
site	4	O
for	3	O
activating	10	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
(	1	O
ATF	3	B-Gene
)	1	O
/	1	O
cyclic	6	B-Gene
AMP	3	I-Gene
response	8	I-Gene
element	7	I-Gene
binding	7	I-Gene
protein	7	I-Gene
(	1	O
CREB	4	B-Gene
)	1	O
,	1	O
has	3	O
been	4	O
shown	5	O
to	2	O
affect	6	O
HIV-1	5	O
long	4	O
terminal	8	O
repeat	6	O
(	1	O
LTR	3	O
)	1	O
activity	8	O
.	1	O

Given	5	O
that	4	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
proteins	8	I-Gene
have	4	O
been	4	O
shown	5	O
to	2	O
interact	8	O
with	4	O
many	4	O
other	5	O
transcription	13	O
factors	7	O
including	9	O
members	7	O
of	2	O
the	3	O
ATF	3	B-Gene
/	1	I-Gene
CREB	4	I-Gene
family	6	I-Gene
,	1	O
we	2	O
proceeded	9	O
to	2	O
determine	9	O
whether	7	O
an	2	O
adjacent	8	O
ATF	3	B-Gene
/	1	I-Gene
CREB	4	I-Gene
binding	7	O
site	4	O
could	5	O
affect	6	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
protein	7	I-Gene
binding	7	O
to	2	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
site	4	O
I	1	O
.	1	O

Electrophoretic	15	O
mobility	8	O
shift	5	O
analyses	8	O
indicated	9	O
that	4	O
selected	8	O
ATF	3	B-Gene
/	1	I-Gene
CREB	4	I-Gene
site	4	O
variants	8	O
assisted	8	O
in	2	O
the	3	O
recruitment	11	O
of	2	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
proteins	8	I-Gene
to	2	O
an	2	O
adjacent	8	O
,	1	O
naturally	9	O
occurring	9	O
,	1	O
low-affinity	12	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
site	4	O
.	1	O

This	4	O
biophysical	11	O
interaction	11	O
appears	7	O
to	2	O
occur	5	O
via	3	O
at	2	O
least	5	O
two	3	O
mechanisms	10	O
.	1	O

First	5	O
,	1	O
low	3	O
amounts	7	O
of	2	O
CREB-1	6	B-Gene
and	3	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
appear	6	O
to	2	O
heterodimerize	14	O
and	3	O
bind	4	O
to	2	O
a	1	O
site	4	O
consisting	10	O
of	2	O
a	1	O
half	4	O
site	4	O
from	4	O
both	4	O
the	3	O
ATF	3	B-Gene
/	1	I-Gene
CREB	4	I-Gene
and	3	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
binding	7	O
sites	5	O
.	1	O

In	2	O
addition	8	O
,	1	O
CREB-1	6	B-Gene
homodimers	10	O
bind	4	O
to	2	O
the	3	O
ATF	3	B-Gene
/	1	I-Gene
CREB	4	I-Gene
site	4	O
and	3	O
recruit	7	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
dimers	6	O
to	2	O
their	5	O
cognate	7	O
weak	4	O
binding	7	O
sites	5	O
.	1	O

This	4	O
interaction	11	O
is	2	O
reciprocal	10	O
,	1	O
since	5	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
dimer	5	O
binding	7	O
to	2	O
a	1	O
strong	6	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
site	4	O
leads	5	O
to	2	O
enhanced	8	O
CREB-1	6	B-Gene
recruitment	11	O
to	2	O
ATF	3	B-Gene
/	1	I-Gene
CREB	4	I-Gene
sites	5	O
that	4	O
are	3	O
weakly	6	O
bound	5	O
by	2	O
CREB	4	B-Gene
.	1	O

Sequence	8	O
variation	9	O
at	2	O
both	4	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
and	3	O
ATF	3	B-Gene
/	1	I-Gene
CREB	4	I-Gene
sites	5	O
affects	7	O
the	3	O
molecular	9	O
interactions	12	O
involved	8	O
in	2	O
mediating	9	O
both	4	O
of	2	O
these	5	O
mechanisms	10	O
.	1	O

Most	4	O
importantly	11	O
,	1	O
sequence	8	O
variation	9	O
at	2	O
the	3	O
ATF	3	B-Gene
/	1	I-Gene
CREB	4	I-Gene
binding	7	O
site	4	O
affected	8	O
basal	5	O
LTR	3	O
activity	8	O
as	2	O
well	4	O
as	2	O
LTR	3	O
function	8	O
following	9	O
interleukin-6	13	B-Gene
stimulation	11	O
,	1	O
a	1	O
treatment	9	O
that	4	O
leads	5	O
to	2	O
increases	9	O
in	2	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
activation	10	O
.	1	O

Thus	4	O
,	1	O
HIV-1	5	O
LTR	3	O
ATF	3	B-Gene
/	1	I-Gene
CREB	4	I-Gene
binding	7	O
site	4	O
sequence	8	O
variation	9	O
may	3	O
modulate	8	O
cellular	8	O
signaling	9	O
at	2	O
the	3	O
viral	5	O
promoter	8	O
through	7	O
the	3	O
C	1	B-Gene
/	1	I-Gene
EBP	3	I-Gene
pathway	7	O

Epstein-barr	12	B-Gene
virus	5	I-Gene
immediate-early	15	I-Gene
protein	7	I-Gene
BZLF1	5	I-Gene
is	2	O
SUMO-1	6	B-Gene
modified	8	O
and	3	O
disrupts	8	O
promyelocytic	13	B-Gene
leukemia	8	I-Gene
bodies	6	O
.	1	O

Although	8	O
the	3	O
immediate-early	15	B-Gene
proteins	8	I-Gene
of	2	O
both	4	O
herpes	6	O
simplex	7	O
virus	5	O
(	1	O
HSV	3	O
)	1	O
and	3	O
cytomegalovirus	15	O
(	1	O
CMV	3	O
)	1	O
are	3	O
known	5	O
to	2	O
modify	6	O
promyelocytic	13	B-Gene
leukemia	8	I-Gene
(	1	O
PML	3	B-Gene
)	1	O
(	1	O
ND10	4	O
)	1	O
bodies	6	O
in	2	O
the	3	O
nucleus	7	O
of	2	O
the	3	O
host	4	O
cell	4	O
,	1	O
it	2	O
has	3	O
been	4	O
unclear	7	O
whether	7	O
lytic	5	O
infection	9	O
with	4	O
gamma	5	O
herpesviruses	13	O
induces	7	O
a	1	O
similar	7	O
effect	6	O
.	1	O

The	3	O
PML	3	B-Gene
protein	7	I-Gene
is	2	O
induced	7	O
by	2	O
interferon	10	O
,	1	O
involved	8	O
in	2	O
major	5	B-Gene
histocompatibility	18	I-Gene
complex	7	I-Gene
class	5	I-Gene
I	1	I-Gene
presentation	12	O
,	1	O
and	3	O
necessary	9	O
for	3	O
certain	7	O
types	5	O
of	2	O
apoptosis	9	O
.	1	O

Therefore	9	O
,	1	O
it	2	O
is	2	O
likely	6	O
that	4	O
PML	3	B-Gene
bodies	6	O
function	8	O
in	2	O
an	2	O
antiviral	9	O
capacity	8	O
.	1	O

SUMO-1	6	B-Gene
modification	12	O
of	2	O
PML	3	B-Gene
is	2	O
known	5	O
to	2	O
be	2	O
required	8	O
for	3	O
the	3	O
formation	9	O
of	2	O
PML	3	B-Gene
bodies	6	O
.	1	O

To	2	O
examine	7	O
whether	7	O
Epstein-Barr	12	O
virus	5	O
(	1	O
EBV	3	O
)	1	O
lytic	5	O
replication	11	O
interferes	10	O
with	4	O
PML	3	B-Gene
bodies	6	O
,	1	O
we	2	O
expressed	9	O
the	3	O
EBV	3	B-Gene
immediate-early	15	I-Gene
genes	5	I-Gene
BZLF1	5	I-Gene
(	1	O
Z	1	B-Gene
)	1	O
and	3	O
BRLF1	5	B-Gene
(	1	O
R	1	B-Gene
)	1	O
in	2	O
EBV	3	O
-positive	9	O
cell	4	O
lines	5	O
and	3	O
examined	8	O
PML	3	B-Gene
localization	12	O
.	1	O

Both	4	O
Z	1	B-Gene
and	3	O
R	1	B-Gene
expression	10	O
resulted	8	O
in	2	O
PML	3	B-Gene
dispersion	10	O
in	2	O
EBV	3	O
-positive	9	O
cells	5	O
.	1	O

Z	1	B-Gene
but	3	O
not	3	O
R	1	B-Gene
expression	10	O
is	2	O
sufficient	10	O
to	2	O
disrupt	7	O
PML	3	B-Gene
bodies	6	O
in	2	O
EBV	3	O
-negative	9	O
cell	4	O
lines	5	O
.	1	O

We	2	O
show	4	O
that	4	O
dispersion	10	O
of	2	O
PML	3	B-Gene
bodies	6	O
by	2	O
Z	1	B-Gene
requires	8	O
a	1	O
portion	7	O
of	2	O
the	3	O
transcriptional	15	O
activation	10	O
domain	6	O
of	2	O
Z	1	B-Gene
but	3	O
not	3	O
the	3	O
DNA	3	O
-binding	8	O
function	8	O
.	1	O

As	2	O
was	3	O
previously	10	O
reported	8	O
for	3	O
the	3	O
HSV-1	5	B-Gene
ICP0	4	I-Gene
and	3	O
CMV	3	B-Gene
IE1	3	I-Gene
proteins	8	I-Gene
,	1	O
Z	1	B-Gene
reduces	7	O
the	3	O
amount	6	O
of	2	O
SUMO-1	6	B-Gene
-modified	9	I-Gene
PML	3	I-Gene
.	1	O

We	2	O
also	4	O
found	5	O
that	4	O
Z	1	B-Gene
itself	6	O
is	2	O
SUMO-1	6	B-Gene
modified	8	O
(	1	O
through	7	O
amino	5	O
acid	4	O
12	2	O
)	1	O
and	3	O
that	4	O
Z	1	B-Gene
competes	8	O
with	4	O
PML	3	B-Gene
for	3	O
limiting	8	O
amounts	7	O
of	2	O
SUMO-1	6	B-Gene
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
disruption	10	O
of	2	O
PML	3	B-Gene
bodies	6	O
is	2	O
important	9	O
for	3	O
efficient	9	O
lytic	5	O
replication	11	O
of	2	O
EBV	3	O
.	1	O

Furthermore	11	O
,	1	O
Z	1	B-Gene
may	3	O
potentially	11	O
alter	5	O
the	3	O
function	8	O
of	2	O
a	1	O
variety	7	O
of	2	O
cellular	8	O
proteins	8	O
by	2	O
inhibiting	10	O
SUMO-1	6	B-Gene
modification	12	O

Expression	10	O
of	2	O
oestrogen	9	B-Chemical
and	3	O
progesterone	12	B-Gene
receptors	9	I-Gene
by	2	O
mast	4	O
cells	5	O
alone	5	O
,	1	O
but	3	O
not	3	O
lymphocytes	11	O
,	1	O
macrophages	11	O
or	2	O
other	5	O
immune	6	O
cells	5	O
in	2	O
human	5	O
upper	5	O
airways	7	O
.	1	O

BACKGROUND	10	O
:	1	O
Nasal	5	B-Disease
polyposis	9	I-Disease
often	5	O
coexists	8	O
with	4	O
asthma	6	B-Disease
in	2	O
airway	6	O
inflammatory	12	O
conditions	10	O
characterised	13	O
by	2	O
the	3	O
infiltration	12	O
of	2	O
a	1	O
range	5	O
of	2	O
immune	6	O
cells	5	O
.	1	O

A	1	O
potentially	11	O
important	9	O
role	4	O
for	3	O
ovarian	7	O
hormones	8	O
has	3	O
been	4	O
implicated	10	O
in	2	O
airway	6	B-Disease
inflammation	12	I-Disease
but	3	O
the	3	O
cellular	8	O
target	6	O
for	3	O
such	4	O
action	6	O
is	2	O
not	3	O
known	5	O
.	1	O

METHODS	7	O
:	1	O
Expression	10	O
of	2	O
oestrogen	9	B-Gene
receptors	9	I-Gene
(	1	O
ER	2	B-Gene
)	1	O
and	3	O
progesterone	12	B-Gene
receptors	9	I-Gene
(	1	O
PR	2	B-Gene
)	1	O
was	3	O
examined	8	O
using	5	O
immunohistochemistry	20	O
in	2	O
formalin	8	B-Chemical
fixed	5	O
nasal	5	B-Disease
polyp	5	I-Disease
tissues	7	O
from	4	O
47	2	O
subjects	8	O
.	1	O

The	3	O
cells	5	O
positive	8	O
for	3	O
ER	2	B-Gene
or	2	O
PR	2	B-Gene
were	4	O
confirmed	9	O
by	2	O
spatial	7	O
location	8	O
,	1	O
dual	4	O
immunolabelling	15	O
,	1	O
and	3	O
histochemical	13	O
staining	8	O
.	1	O

RESULTS	7	O
:	1	O
Consistent	10	O
with	4	O
the	3	O
known	5	O
features	8	O
of	2	O
nasal	5	B-Disease
polyps	6	I-Disease
,	1	O
CD4+	4	B-Gene
(	1	O
T	1	O
helper	6	O
/	1	O
inducer	7	O
)	1	O
,	1	O
CD8+	4	B-Gene
(	1	O
cytotoxic	9	O
/	1	O
suppressor	10	O
)	1	O
,	1	O
CD68+	5	B-Gene
(	1	O
macrophages	11	O
)	1	O
,	1	O
mast	4	O
cells	5	O
,	1	O
eosinophils	11	O
and	3	O
neutrophils	11	O
were	4	O
all	3	O
clearly	7	O
detected	8	O
by	2	O
their	5	O
relevant	8	O
monoclonal	10	O
antibodies	10	O
or	2	O
appropriate	11	O
histochemical	13	O
staining	8	O
,	1	O
but	3	O
only	4	O
mast	4	O
cells	5	O
tested	6	O
positive	8	O
for	3	O
ER	2	B-Gene
/	1	I-Gene
PR	2	I-Gene
labelling	9	O
with	4	O
their	5	O
polyclonal	10	O
and	3	O
monoclonal	10	O
antibodies	10	O
.	1	O

The	3	O
frequencies	11	O
for	3	O
expression	10	O
were	4	O
61.7	4	O
%	1	O
for	3	O
ER	2	B-Gene
positive	8	O
and	3	O
59.6	4	O
%	1	O
for	3	O
PR	2	B-Gene
positive	8	O
cells	5	O
.	1	O

The	3	O
expression	10	O
of	2	O
ER	2	B-Gene
/	1	I-Gene
PR	2	I-Gene
was	3	O
independent	11	O
of	2	O
patient	7	O
sex	3	O
and	3	O
age	3	O
but	3	O
was	3	O
highly	6	O
correlated	10	O
with	4	O
the	3	O
numbers	7	O
of	2	O
mast	4	O
cells	5	O
(	1	O
r	1	O
=	1	O
0.973	5	O
,	1	O
p	1	O
<	1	O
0.001	5	O
for	3	O
ER	2	B-Gene
;	1	O
r	1	O
=	1	O
0.955	5	O
,	1	O
p	1	O
<	1	O
0.001	5	O
for	3	O
PR	2	B-Gene
)	1	O
.	1	O

Fewer	5	O
than	4	O
5	1	O
%	1	O
of	2	O
mast	4	O
cells	5	O
were	4	O
found	5	O
to	2	O
be	2	O
negative	8	O
for	3	O
ER	2	B-Gene
/	1	I-Gene
PR	2	I-Gene
expression	10	O
.	1	O

CONCLUSIONS	11	O
:	1	O
Mast	4	O
cells	5	O
alone	5	O
,	1	O
but	3	O
not	3	O
lymphocytes	11	O
,	1	O
macrophages	11	O
,	1	O
or	2	O
other	5	O
immune	6	O
cells	5	O
,	1	O
express	7	O
ER	2	B-Gene
/	1	I-Gene
PR	2	I-Gene
in	2	O
human	5	O
upper	5	O
airways	7	O
.	1	O

Numerous	8	O
ER	2	B-Gene
/	1	I-Gene
PR	2	I-Gene
positive	8	O
mast	4	O
cells	5	O
exist	5	O
in	2	O
nasal	5	B-Disease
polyps	6	I-Disease
,	1	O
indicating	10	O
that	4	O
this	4	O
may	3	O
be	2	O
a	1	O
major	5	O
route	5	O
for	3	O
the	3	O
involvement	11	O
of	2	O
sex	3	O
hormones	8	O
in	2	O
airway	6	B-Disease
inflammation	12	I-Disease
when	4	O
exposed	7	O
to	2	O
the	3	O
higher	6	O
and	3	O
varying	7	O
concentration	13	O
of	2	O
oestrogen	9	B-Chemical
and	3	O
progesterone	12	B-Chemical
characteristic	14	O
of	2	O
females	7	O
.	1	O

A	1	O
16-mer	6	O
peptide	7	O
(	1	O
RQIKIWFQNRRMKWKK	16	O
)	1	O
from	4	O
antennapedia	12	B-Gene
preferentially	14	O
targets	7	O
the	3	O
Class	5	O
I	1	O
pathway	7	O
.	1	O

Translocation	13	O
of	2	O
antigenic	9	O
peptides	8	O
into	4	O
the	3	O
cytosol	7	O
of	2	O
antigen	7	O
presenting	10	O
cells	5	O
facilitates	11	O
proteosomal	11	O
processing	10	O
and	3	O
loading	7	O
into	4	O
Class	5	O
I	1	O
molecules	9	O
for	3	O
MHC	3	B-Gene
presentation	12	O
on	2	O
the	3	O
cell	4	O
surface	7	O
.	1	O

The	3	O
DNA	3	O
binding	7	O
domain	6	O
of	2	O
the	3	O
Drosophila	10	O
transcription	13	O
factor	6	O
(	1	O
Antennapedia	12	B-Gene
)	1	O
,	1	O
a	1	O
60	2	O
amino	5	O
acid	4	O
protein	7	O
,	1	O
is	2	O
rapidly	7	O
taken	5	O
up	2	O
by	2	O
cells	5	O
and	3	O
has	3	O
been	4	O
fused	5	O
to	2	O
selected	8	O
antigens	8	O
to	2	O
enhance	7	O
their	5	O
immunogenicity	14	O
.	1	O

We	2	O
now	3	O
demonstrate	11	O
that	4	O
a	1	O
16	2	O
amino	5	O
acid	4	O
peptide	7	O
from	4	O
antennapedia	12	B-Gene
can	3	O
facilitate	10	O
the	3	O
cytoplasmic	11	O
uptake	6	O
of	2	O
CTL	3	O
epitope	7	O
9-mer	5	O
peptides	8	O
.	1	O

Synthetic	9	O
peptides	8	O
were	4	O
made	4	O
containing	10	O
the	3	O
16-mer	6	O
antennapedia	12	B-Gene
peptide	7	O
linked	6	O
in	2	O
tandem	6	O
to	2	O
the	3	O
ovalbumin	9	B-Gene
SIINFEKL	8	O
CTL	3	O
peptide	7	O
.	1	O

The	3	O
peptide	7	O
complex	7	O
was	3	O
shown	5	O
to	2	O
rapidly	7	O
internalise	11	O
into	4	O
APCs	4	O
by	2	O
confocal	8	O
microscopy	10	O
.	1	O

This	4	O
peptide	7	O
induced	7	O
CTL	3	O
in	2	O
C57BL	5	O
/	1	O
6	1	O
mice	4	O
and	3	O
protected	9	O
them	4	O
against	7	O
growth	6	O
of	2	O
an	2	O
ovalbumin	9	B-Gene
expressing	10	O
tumour	6	B-Disease
cell	4	O
line	4	O
(	1	O
E.G7-OVA	8	O
)	1	O
.	1	O

The	3	O
ability	7	O
of	2	O
the	3	O
hybrid	6	O
peptide	7	O
to	2	O
be	2	O
processed	9	O
and	3	O
presented	9	O
by	2	O
APCs	4	O
was	3	O
similar	7	O
,	1	O
whether	7	O
the	3	O
SIINFEKL	8	O
sequence	8	O
was	3	O
appended	8	O
at	2	O
the	3	O
C-terminus	10	O
or	2	O
N-terminus	10	O
of	2	O
the	3	O
Antennapedia	12	B-Gene
peptide	7	O
.	1	O

The	3	O
production	10	O
of	2	O
synthetic	9	O
peptides	8	O
containing	10	O
other	5	O
CTL	3	O
peptide	7	O
epitopes	8	O
may	3	O
be	2	O
useful	6	O
for	3	O
priming	7	O
CTLs	4	O
in	2	O
vitro	5	O
and	3	O
in	2	O
vivo	4	O

NFATc1	6	B-Gene
and	3	O
NFATc2	6	B-Gene
together	8	O
control	7	O
both	4	O
T	1	O
and	3	O
B	1	O
cell	4	O
activation	10	O
and	3	O
differentiation	15	O
.	1	O

NFAT	4	B-Gene
transcription	13	I-Gene
factors	7	I-Gene
play	4	O
critical	8	O
roles	5	O
in	2	O
gene	4	O
transcription	13	O
during	6	O
immune	6	O
responses	9	O
.	1	O

To	2	O
investigate	11	O
further	7	O
the	3	O
two	3	O
most	4	O
prominent	9	O
NFAT	4	B-Gene
family	6	I-Gene
members	7	O
,	1	O
NFATc1	6	B-Gene
and	3	O
NFATc2	6	B-Gene
,	1	O
we	2	O
generated	9	O
mice	4	O
bearing	7	O
lymphoid	8	O
systems	7	O
devoid	6	O
of	2	O
both	4	O
.	1	O

Doubly	6	O
deficient	9	O
T	1	O
cells	5	O
displayed	9	O
cell	4	O
surface	7	O
markers	7	O
of	2	O
activation	10	O
yet	3	O
were	4	O
significantly	13	O
deficient	9	O
in	2	O
the	3	O
development	11	O
of	2	O
multiple	8	O
effector	8	O
functions	9	O
,	1	O
including	9	O
Th	2	O
cytokine	8	O
production	10	O
,	1	O
surface	7	O
effector	8	O
molecule	8	O
expression	10	O
,	1	O
and	3	O
cytolytic	9	O
activity	8	O
.	1	O

Nevertheless	12	O
,	1	O
doubly	6	O
deficient	9	O
B	1	O
cells	5	O
were	4	O
hyperactivated	14	O
,	1	O
as	2	O
evidenced	9	O
by	2	O
extremely	9	O
elevated	8	O
serum	5	B-Gene
IgG1	4	I-Gene
and	3	O
IgE	3	B-Gene
,	1	O
as	2	O
well	4	O
as	2	O
plasma	6	O
cell	4	O
expansion	9	O
and	3	O
infiltration	12	O
of	2	O
end	3	O
organs	6	O
.	1	O

Thus	4	O
,	1	O
in	2	O
T	1	O
cells	5	O
,	1	O
NFATc1	6	B-Gene
and	3	O
NFATc2	6	B-Gene
are	3	O
dispensable	11	O
for	3	O
inflammatory	12	O
reactivity	10	O
but	3	O
are	3	O
required	8	O
for	3	O
effector	8	O
differentiation	15	O
,	1	O
while	5	O
in	2	O
B	1	O
cells	5	O
,	1	O
NFATs	5	B-Gene
regulate	8	O
both	4	O
normal	6	O
homeostasis	11	O
and	3	O
differentiation	15	O
.	1	O

The	3	O
lack	4	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
transactivation	15	O
and	3	O
PKC	3	B-Gene
epsilon	7	I-Gene
expression	10	O
in	2	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
CD8	3	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
thymocytes	10	O
correlates	10	O
with	4	O
negative	8	O
selection	9	O
.	1	O

Deletion	8	O
of	2	O
autoreactive	12	O
thymocytes	10	O
at	2	O
the	3	O
DP	2	O
stage	5	O
is	2	O
the	3	O
basis	5	O
for	3	O
tolerance	9	O
to	2	O
thymus	6	O
-expressed	10	O
self	4	O
antigens	8	O
.	1	O

In	2	O
this	4	O
study	5	O
we	2	O
investigated	12	O
whether	7	O
distinct	8	O
signalling	10	O
pathways	8	O
are	3	O
induced	7	O
in	2	O
DP	2	O
thymocytes	10	O
as	2	O
compared	8	O
to	2	O
mature	6	O
T	1	O
cells	5	O
upon	4	O
stimulation	11	O
with	4	O
antigen	7	O
.	1	O

Using	5	O
triple	6	O
transgenic	10	O
mice	4	O
expressing	10	O
a	1	O
TCR	3	B-Gene
transgene	9	I-Gene
,	1	O
dominant	8	O
negative	8	O
ras	3	B-Gene
/	1	I-Gene
Mek	3	I-Gene
proteins	8	I-Gene
and	3	O
a	1	O
reporter	8	O
gene	4	O
construct	9	O
with	4	O
AP-1	4	B-Gene
or	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
binding	7	O
sites	5	O
,	1	O
we	2	O
showed	6	O
a	1	O
complete	8	O
lack	4	O
of	2	O
transcriptional	15	O
activity	8	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
but	3	O
not	3	O
AP-1	4	B-Gene
in	2	O
DP	2	O
thymocytes	10	O
,	1	O
whereas	7	O
both	4	O
were	4	O
transcriptionally	17	O
active	6	O
in	2	O
mature	6	O
T	1	O
cells	5	O
after	5	O
antigenic	9	O
stimulation	11	O
.	1	O

Lack	4	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
induction	9	O
correlated	10	O
with	4	O
increased	9	O
death	5	O
in	2	O
response	8	O
to	2	O
antigen	7	O
.	1	O

AP-1	4	B-Gene
induction	9	O
was	3	O
dependent	9	O
on	2	O
the	3	O
integrity	9	O
of	2	O
the	3	O
ras	3	B-Gene
/	1	I-Gene
Mek	3	I-Gene
pathway	7	O
indicating	10	O
that	4	O
this	4	O
pathway	7	O
was	3	O
activated	9	O
in	2	O
the	3	O
DP	2	O
thymocytes	10	O
.	1	O

In	2	O
contrast	8	O
,	1	O
we	2	O
found	5	O
a	1	O
complete	8	O
lack	4	O
of	2	O
constitutive	12	O
expression	10	O
of	2	O
the	3	O
epsilon	7	B-Partial_Gene
isoform	7	O
of	2	O
Protein	7	B-Gene
Kinase	6	I-Gene
C	1	I-Gene
(	1	O
PKC	3	B-Gene
)	1	O
in	2	O
DP	2	O
thymocytes	10	O
,	1	O
although	8	O
it	2	O
was	3	O
present	7	O
in	2	O
mature	6	O
thymocytes	10	O
and	3	O
peripheral	10	O
T	1	O
cells	5	O
.	1	O

Taken	5	O
together	8	O
the	3	O
results	7	O
suggest	7	O
that	4	O
the	3	O
lack	4	O
of	2	O
PKC	3	B-Gene
epsilon	7	I-Gene
in	2	O
DP	2	O
thymocytes	10	O
could	5	O
lead	4	O
to	2	O
the	3	O
absence	7	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
activity	8	O
after	5	O
antigenic	9	O
stimulation	11	O
contributing	12	O
to	2	O
negative	8	O
selection	9	O
.	1	O

Cell	4	O
Death	5	O
and	3	O
Differentiation	15	O
(	1	O
2000	4	O
)	1	O
7	1	O
,	1	O
1253	4	O
-	1	O
1262	4	O
.	1	O

BMS-189453	10	B-Chemical
,	1	O
a	1	O
novel	5	O
retinoid	8	B-Gene
receptor	8	I-Gene
antagonist	10	O
,	1	O
is	2	O
a	1	O
potent	6	O
testicular	10	O
toxin	5	O
.	1	O

BMS-189453	10	B-Chemical
is	2	O
a	1	O
synthetic	9	O
retinoid	8	B-Chemical
that	4	O
acts	4	O
as	2	O
an	2	O
antagonist	10	O
at	2	O
retinoic	8	B-Gene
acid	4	I-Gene
receptors	9	I-Gene
alpha	5	I-Gene
,	1	O
beta	4	B-Partial_Gene
,	1	O
and	3	O
gamma	5	B-Partial_Gene
.	1	O

In	2	O
Sprague	7	O
Dawley	6	O
rats	4	O
at	2	O
daily	5	O
oral	4	O
doses	5	O
of	2	O
15	2	O
,	1	O
60	2	O
,	1	O
or	2	O
240	3	O
mg	2	O
/	1	O
kg	2	O
for	3	O
1	1	O
month	5	O
,	1	O
BMS-189453	10	B-Chemical
produced	8	O
increases	9	O
in	2	O
leukocyte	9	O
counts	6	O
,	1	O
alkaline	8	B-Gene
phosphatase	11	I-Gene
and	3	O
alanine	7	B-Gene
aminotransferase	16	I-Gene
levels	6	O
,	1	O
and	3	O
marked	6	O
testicular	10	O
degeneration	12	O
and	3	O
atrophy	7	O
at	2	O
all	3	O
doses	5	O
.	1	O

Significant	11	O
overt	5	O
signs	5	O
of	2	O
toxicity	8	O
and	3	O
deaths	6	O
occurred	8	O
at	2	O
240	3	O
mg	2	O
/	1	O
kg	2	O
,	1	O
whereas	7	O
body-weight	11	O
and	3	O
food-consumption	16	O
decreases	9	O
occurred	8	O
at	2	O
60	2	O
and	3	O
240	3	O
mg	2	O
/	1	O
kg	2	O
.	1	O

When	4	O
BMS-189453	10	B-Chemical
was	3	O
administered	12	O
to	2	O
male	4	O
rats	4	O
at	2	O
daily	5	O
doses	5	O
ranging	7	O
from	4	O
12.5	4	O
to	2	O
100	3	O
mg	2	O
/	1	O
kg	2	O
for	3	O
1	1	O
week	4	O
,	1	O
only	4	O
minimal	7	O
testicular	10	O
changes	7	O
occurred	8	O
at	2	O
all	3	O
doses	5	O
,	1	O
shortly	7	O
after	5	O
the	3	O
dosing	6	O
period	6	O
.	1	O

However	7	O
,	1	O
after	5	O
a	1	O
1-month	7	O
drug-free	9	O
observation	11	O
period	6	O
,	1	O
marked	6	O
testicular	10	O
atrophy	7	O
was	3	O
evident	7	O
at	2	O
all	3	O
doses	5	O
.	1	O

BMS-189453	10	B-Chemical
was	3	O
then	4	O
administered	12	O
at	2	O
doses	5	O
of	2	O
2	1	O
,	1	O
10	2	O
,	1	O
or	2	O
50	2	O
mg	2	O
/	1	O
kg	2	O
to	2	O
male	4	O
rats	4	O
for	3	O
1	1	O
,	1	O
3	1	O
,	1	O
or	2	O
7	1	O
consecutive	11	O
days	4	O
.	1	O

Dose-	5	O
and	3	O
duration	8	O
-dependent	10	O
testicular	10	O
toxicity	8	O
that	4	O
occurred	8	O
after	5	O
a	1	O
1-month	7	O
observation	11	O
period	6	O
did	3	O
not	3	O
recover	7	O
,	1	O
and	3	O
,	1	O
in	2	O
some	4	O
cases	5	O
,	1	O
was	3	O
more	4	O
severe	6	O
4	1	O
months	6	O
after	5	O
the	3	O
last	4	O
dose	4	O
.	1	O

In	2	O
rabbits	7	O
administered	12	O
BMS-189453	10	B-Chemical
at	2	O
oral	4	O
doses	5	O
of	2	O
2	1	O
,	1	O
10	2	O
,	1	O
or	2	O
50	2	O
mg	2	O
/	1	O
kg	2	O
for	3	O
1	1	O
week	4	O
,	1	O
testicular	10	O
degeneration	12	O
and	3	O
atrophy	7	O
were	4	O
evident	7	O
in	2	O
the	3	O
high-dose	9	O
group	5	O
at	2	O
1	1	O
month	5	O
following	9	O
treatment	9	O
.	1	O

These	5	O
studies	7	O
indicate	8	O
that	4	O
retinoid	8	B-Chemical
antagonists	11	O
can	3	O
selectively	11	O
produce	7	O
progressive	11	O
and	3	O
prolonged	9	O
testicular	10	O
toxicity	8	O
after	5	O
single	6	O
or	2	O
repeated	8	O
oral	4	O
doses	5	O
that	4	O
are	3	O
otherwise	9	O
well	4	O
tolerated	9	O
.	1	O

Constitutive	12	O
PI3-K	5	B-Gene
activity	8	O
is	2	O
essential	9	O
for	3	O
proliferation	13	O
,	1	O
but	3	O
not	3	O
survival	8	O
,	1	O
of	2	O
Theileria	9	O
parva	5	O
-transformed	12	O
B	1	O
cells	5	O
.	1	O

Theileria	9	O
is	2	O
an	2	O
intracellular	13	O
parasite	8	O
that	4	O
causes	6	O
lymphoproliferative	19	B-Disease
disorders	9	I-Disease
in	2	O
cattle	6	O
,	1	O
and	3	O
infection	9	O
of	2	O
leucocytes	10	O
induces	7	O
a	1	O
transformed	11	O
phenotype	9	O
similar	7	O
to	2	O
tumour	6	B-Disease
cells	5	O
,	1	O
but	3	O
the	3	O
mechanisms	10	O
by	2	O
which	5	O
the	3	O
parasite	8	O
induces	7	O
this	4	O
phenotype	9	O
are	3	O
not	3	O
understood	10	O
.	1	O

Here	4	O
,	1	O
we	2	O
show	4	O
that	4	O
infected	8	O
B	1	O
lymphocytes	11	O
display	7	O
constitutive	12	O
phosphoinositide	16	B-Gene
3-kinase	8	I-Gene
(	1	O
PI3-K	5	B-Gene
)	1	O
activity	8	O
,	1	O
which	5	O
appears	7	O
to	2	O
be	2	O
necessary	9	O
for	3	O
proliferation	13	O
,	1	O
but	3	O
not	3	O
survival	8	O
.	1	O

Importantly	11	O
,	1	O
we	2	O
demonstrate	11	O
that	4	O
one	3	O
mechanism	9	O
by	2	O
which	5	O
PI3-K	5	B-Gene
mediates	8	O
the	3	O
proliferation	13	O
of	2	O
infected	8	O
B	1	O
lymphocytes	11	O
is	2	O
through	7	O
the	3	O
induction	9	O
of	2	O
a	1	O
granulocyte-monocyte	20	B-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
(	1	O
GM-CSF	6	B-Gene
)	1	O
-dependent	10	O
autocrine	9	O
loop	4	O
.	1	O

PI3-K	5	B-Gene
induction	9	O
of	2	O
GM-CSF	6	B-Gene
appears	7	O
to	2	O
be	2	O
at	2	O
the	3	O
transcriptional	15	O
level	5	O
and	3	O
,	1	O
consistently	12	O
,	1	O
we	2	O
demonstrate	11	O
that	4	O
PI3-K	5	B-Gene
is	2	O
also	4	O
involved	8	O
in	2	O
the	3	O
constitutive	12	O
induction	9	O
of	2	O
AP-1	4	B-Gene
and	3	O
NF-kappaB	9	B-Gene
,	1	O
which	5	O
characterizes	13	O
Theileria	9	O
-infected	9	O
leucocytes	10	O
.	1	O

Taken	5	O
together	8	O
,	1	O
our	3	O
results	7	O
highlight	9	O
a	1	O
novel	5	O
strategy	8	O
exploited	9	O
by	2	O
the	3	O
intracellular	13	O
parasite	8	O
Theileria	9	O
to	2	O
induce	6	O
continued	9	O
proliferation	13	O
of	2	O
its	3	O
host	4	O
leucocyte	9	O
.	1	O

Mechanism	9	O
of	2	O
the	3	O
inhibitory	10	O
effect	6	O
of	2	O
protease	8	O
inhibitor	9	O
on	2	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
alpha	5	I-Gene
production	10	O
of	2	O
monocytes	9	O
.	1	O

If	2	O
the	3	O
inflammatory	12	O
response	8	O
becomes	7	O
excessive	9	O
or	2	O
uncontrolled	12	O
by	2	O
some	4	O
stimuli	7	O
,	1	O
inappropriate	13	O
inflammatory	12	O
responses	9	O
occur	5	O
.	1	O

Monocytes	9	O
are	3	O
extremely	9	O
important	9	O
cells	5	O
for	3	O
regulating	10	O
the	3	O
cytokine	8	O
network	7	O
and	3	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
alpha	5	I-Gene
(	1	O
TNFalpha	8	B-Gene
)	1	O
and	3	O
interleukin-	12	B-Gene
(	1	I-Gene
IL	2	I-Gene
)	1	I-Gene
10	2	I-Gene
,	1	O
which	5	O
are	3	O
mainly	6	O
synthesized	11	O
by	2	O
monocytes	9	O
,	1	O
are	3	O
representative	14	O
cytokines	9	O
that	4	O
play	4	O
a	1	O
central	7	O
role	4	O
in	2	O
the	3	O
cytokine	8	O
network	7	O
.	1	O

Protease	8	O
inhibitors	10	O
such	4	O
as	2	O
gabexate	8	B-Chemical
mesilate	8	I-Chemical
(	1	O
GM	2	B-Chemical
)	1	O
and	3	O
ulinastatin	11	B-Chemical
(	1	O
UTI	3	B-Chemical
)	1	O
have	4	O
been	4	O
shown	5	O
to	2	O
have	4	O
various	7	O
beneficial	10	O
effects	7	O
by	2	O
inhibiting	10	O
the	3	O
activation	10	O
of	2	O
leukocytes	10	O
,	1	O
but	3	O
the	3	O
mechanism	9	O
for	3	O
this	4	O
has	3	O
yet	3	O
to	2	O
be	2	O
fully	5	O
elucidated	10	O
.	1	O

In	2	O
this	4	O
study	5	O
we	2	O
investigated	12	O
the	3	O
mechanism	9	O
of	2	O
the	3	O
inhibitory	10	O
effect	6	O
of	2	O
protease	8	O
inhibitors	10	O
on	2	O
the	3	O
proinflammatory	15	O
cytokine	8	O
production	10	O
of	2	O
lipopolysaccharide-	19	B-Chemical
(	1	O
LPS	3	B-Chemical
)	1	O
stimulated	10	O
monocytes	9	O
.	1	O

LPS	3	B-Chemical
-stimulated	11	O
monocytes	9	O
were	4	O
treated	7	O
with	4	O
GM	2	B-Chemical
or	2	O
UTI	3	B-Chemical
.	1	O

The	3	O
value	5	O
of	2	O
TNFalpha	8	B-Gene
and	3	O
IL-10	5	B-Gene
in	2	O
the	3	O
culture	7	O
medium	6	O
of	2	O
monocytes	9	O
was	3	O
measured	8	O
and	3	O
each	4	O
mRNA	4	O
expression	10	O
was	3	O
assayed	7	O
.	1	O

The	3	O
inhibitory	10	O
effect	6	O
of	2	O
protease	8	O
inhibitors	10	O
on	2	O
the	3	O
activity	8	O
of	2	O
intracellular	13	O
signal	6	O
transduction	12	O
pathways	8	O
such	4	O
as	2	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
(	1	O
PKC	3	B-Gene
)	1	O
and	3	O
nuclear	7	B-Gene
factor	6	I-Gene
kappa	5	I-Gene
B	1	I-Gene
(	1	O
NFkappaB	8	B-Gene
)	1	O
were	4	O
also	4	O
evaluated	9	O
.	1	O

GM	2	B-Chemical
decreased	9	O
the	3	O
TNFalpha	8	B-Gene
production	10	O
of	2	O
LPS	3	B-Chemical
-stimulated	11	O
monocytes	9	O
as	2	O
shown	5	O
by	2	O
the	3	O
inhibition	10	O
of	2	O
mRNA	4	O
expression	10	O
and	3	O
increased	9	O
the	3	O
IL-10	5	B-Gene
production	10	O
of	2	O
LPS	3	B-Chemical
-stimulated	11	O
monocytes	9	O
.	1	O

GM	2	B-Chemical
also	4	O
suppressed	10	O
the	3	O
NFkappaB	8	B-Gene
activity	8	O
of	2	O
LPS	3	B-Chemical
-stimulated	11	O
monocytes	9	O
.	1	O

UTI	3	B-Chemical
decreased	9	O
the	3	O
TNFalpha	8	B-Gene
production	10	O
of	2	O
LPS	3	B-Chemical
-stimulated	11	O
monocytes	9	O
,	1	O
but	3	O
did	3	O
not	3	O
inhibit	7	O
the	3	O
TNFalpha	8	B-Gene
mRNA	4	I-Gene
expression	10	O
.	1	O

The	3	O
present	7	O
study	5	O
shows	5	O
that	4	O
the	3	O
inhibitory	10	O
effect	6	O
of	2	O
GM	2	B-Chemical
on	2	O
the	3	O
TNFalpha	8	B-Gene
production	10	O
of	2	O
activated	9	O
human	5	O
monocytes	9	O
is	2	O
mediated	8	O
by	2	O
the	3	O
suppression	11	O
of	2	O
NFkappaB	8	B-Gene
activation	10	O
,	1	O
while	5	O
the	3	O
mechanism	9	O
of	2	O
UTI	3	B-Chemical
inhibiting	10	O
TNFalpha	8	B-Gene
production	10	O
of	2	O
human	5	O
monocytes	9	O
may	3	O
be	2	O
due	3	O
to	2	O
the	3	O
inhibition	10	O
of	2	O
either	6	O
the	3	O
translation	11	O
or	2	O
secretion	9	O
of	2	O
TNFalpha	8	B-Gene
.	1	O

Molecular	9	O
and	3	O
cellular	8	O
mediators	9	O
of	2	O
interleukin-1	13	B-Gene
-dependent	10	O
acute	5	O
inflammatory	12	O
arthritis	9	B-Disease
.	1	O

OBJECTIVE	9	O
:	1	O
To	2	O
examine	7	O
the	3	O
molecular	9	O
and	3	O
cellular	8	O
mechanisms	10	O
in	2	O
a	1	O
model	5	O
of	2	O
acute	5	O
inflammatory	12	O
monarticular	12	O
arthritis	9	B-Disease
induced	7	O
by	2	O
methylated	10	B-Gene
bovine	6	I-Gene
serum	5	I-Gene
albumin	7	I-Gene
(	1	O
mBSA	4	B-Gene
)	1	O
and	3	O
interleukin-1	13	B-Gene
(	1	O
IL-1	4	B-Gene
)	1	O
.	1	O

METHODS	7	O
:	1	O
Mice	4	O
were	4	O
injected	8	O
intraarticularly	16	O
with	4	O
mBSA	4	B-Gene
on	2	O
day	3	O
0	1	O
and	3	O
subcutaneously	14	O
with	4	O
recombinant	11	O
human	5	B-Gene
IL-1beta	8	I-Gene
on	2	O
days	4	O
0-2	3	O
.	1	O

At	2	O
day	3	O
7	1	O
,	1	O
knee	4	O
joints	6	O
were	4	O
removed	7	O
and	3	O
assessed	8	O
histologically	14	O
.	1	O

Flow	4	O
cytometry	9	O
and	3	O
RNase	5	O
protection	10	O
were	4	O
used	4	O
to	2	O
analyze	7	O
IL-1	4	B-Gene
-dependent	10	O
events	6	O
.	1	O

RESULTS	7	O
:	1	O
C57BL	5	O
/	1	O
6	1	O
(	1	O
B6	2	O
)	1	O
,	1	O
129	3	O
/	1	O
Sv	2	O
,	1	O
and	3	O
(	1	O
B6	2	O
x	1	O
129	3	O
/	1	O
Sv	2	O
)	1	O
F1	2	O
hybrid	6	O
mice	4	O
,	1	O
all	3	O
H-2b	4	O
strains	7	O
,	1	O
were	4	O
susceptible	11	O
to	2	O
mBSA	4	B-Gene
/	1	I-Gene
IL-1	4	I-Gene
-induced	8	O
arthritis	9	B-Disease
,	1	O
whereas	7	O
C3H	3	O
/	1	O
HeJ	3	O
(	1	O
H-2k	4	O
)	1	O
mice	4	O
were	4	O
not	3	O
.	1	O

B6	2	O
mice	4	O
lacking	7	O
T	1	O
and	3	O
B	1	O
cells	5	O
(	1	O
RAG1-	5	B-Gene
/	1	I-Gene
-	1	I-Gene
)	1	O
or	2	O
major	5	B-Gene
histocompatibility	18	I-Gene
complex	7	I-Gene
(	1	I-Gene
MHC	3	I-Gene
)	1	I-Gene
class	5	I-Gene
II	2	I-Gene
antigens	8	I-Gene
(	1	O
MHCII-	6	B-Gene
/	1	I-Gene
-	1	I-Gene
)	1	O
,	1	O
and	3	O
B6	2	O
mice	4	O
treated	7	O
with	4	O
a	1	O
CD4+	4	B-Gene
T	1	O
cell	4	O
-depleting	10	O
monoclonal	10	O
antibody	8	O
,	1	O
were	4	O
resistant	9	O
to	2	O
disease	7	O
.	1	O

In	2	O
contrast	8	O
,	1	O
B	1	O
cell	4	O
-deficient	10	O
(	1	O
muMT	4	O
/	1	O
muMT	4	O
)	1	O
mice	4	O
developed	9	O
arthritis	9	B-Disease
at	2	O
an	2	O
incidence	9	O
and	3	O
severity	8	O
similar	7	O
to	2	O
that	4	O
of	2	O
controls	8	O
.	1	O

RelB	4	B-Gene
-deficient	10	O
(	1	O
RelB-	5	B-Gene
/	1	I-Gene
-	1	I-Gene
)	1	O
bone	4	O
marrow	6	O
chimeric	8	O
mice	4	O
had	3	O
arthritis	9	B-Disease
that	4	O
was	3	O
significantly	13	O
reduced	7	O
in	2	O
incidence	9	O
and	3	O
severity	8	O
.	1	O

In	2	O
B6	2	O
mice	4	O
,	1	O
flow	4	O
cytometry	9	O
demonstrated	12	O
an	2	O
IL-1	4	B-Gene
-dependent	10	O
leukocyte	9	O
infiltration	12	O
into	4	O
the	3	O
synovial	8	O
compartment	11	O
and	3	O
RNase	5	O
protection	10	O
assays	6	O
revealed	8	O
induction	9	O
of	2	O
messenger	9	O
RNA	3	O
(	1	O
mRNA	4	O
)	1	O
for	3	O
the	3	O
chemokines	10	B-Gene
monocyte	8	I-Gene
chemoattractant	15	I-Gene
protein	7	I-Gene
1	1	I-Gene
,	1	O
macrophage	10	B-Gene
inhibitory	10	I-Gene
protein	7	I-Gene
2	1	I-Gene
(	1	O
MIP-2	5	B-Gene
)	1	O
,	1	O
RANTES	6	B-Gene
,	1	O
MIP-1alpha	10	B-Gene
,	1	O
and	3	O
MIP-1beta	9	B-Gene
,	1	O
in	2	O
vivo	4	O
and	3	O
in	2	O
vitro	5	O
.	1	O

CONCLUSION	10	O
:	1	O
Arthritis	9	B-Disease
induced	7	O
by	2	O
mBSA	4	B-Gene
/	1	I-Gene
IL-1	4	I-Gene
is	2	O
strain	6	O
specific	8	O
and	3	O
dependent	9	O
on	2	O
CD4+	4	B-Gene
T	1	O
lymphocytes	11	O
and	3	O
at	2	O
least	5	O
partially	9	O
on	2	O
RelB	4	B-Gene
,	1	O
but	3	O
not	3	O
on	2	O
B	1	O
lymphocytes	11	O
or	2	O
antibody	8	O
.	1	O

IL-1	4	B-Gene
contributes	11	O
to	2	O
leukocyte	9	O
recruitment	11	O
to	2	O
the	3	O
synovium	8	O
and	3	O
directly	8	O
induces	7	O
chemokine	9	O
mRNA	4	O
production	10	O
by	2	O
synovial	8	O
cells	5	O
.	1	O

This	4	O
model	5	O
of	2	O
acute	5	O
monarticular	12	O
arthritis	9	B-Disease
is	2	O
particularly	12	O
suitable	8	O
for	3	O
further	7	O
investigations	14	O
into	4	O
cell	4	O
-mediated	9	O
immunity	8	O
in	2	O
arthritis	9	B-Disease
and	3	O
the	3	O
role	4	O
of	2	O
IL-1	4	B-Gene
.	1	O

Positive	8	O
and	3	O
negative	8	O
regulation	10	O
of	2	O
granulopoiesis	14	O
by	2	O
endogenous	10	B-Gene
RARalpha	8	I-Gene
.	1	O

Acute	5	B-Disease
promyelocytic	13	I-Disease
leukemia	8	I-Disease
(	1	O
APL	3	B-Disease
)	1	O
is	2	O
always	6	O
associated	10	O
with	4	O
chromosomal	11	O
translocations	14	O
that	4	O
disrupt	7	O
the	3	O
retinoic	8	B-Gene
acid	4	I-Gene
receptor	8	I-Gene
alpha	5	I-Gene
(	1	I-Gene
RARalpha	8	I-Gene
)	1	I-Gene
gene	4	I-Gene
.	1	O

Whether	7	O
these	5	O
translocations	14	O
relate	6	O
to	2	O
a	1	O
role	4	O
for	3	O
endogenous	10	B-Gene
RARalpha	8	I-Gene
in	2	O
normal	6	O
granulopoiesis	14	O
remains	7	O
uncertain	9	O
because	7	O
most	4	O
studies	7	O
addressing	10	O
this	4	O
question	8	O
have	4	O
used	4	O
non-physiological	17	O
overexpression	14	O
systems	7	O
.	1	O

Granulocyte	11	O
differentiation	15	O
in	2	O
cells	5	O
derived	7	O
from	4	O
RARalpha	8	B-Gene
-deficient	10	O
(	1	O
RARalpha	8	B-Gene
(	1	I-Gene
-	1	I-Gene
/	1	I-Gene
-	1	I-Gene
)	1	I-Gene
)	1	O
mice	4	O
was	3	O
studied	7	O
and	3	O
evaluated	9	O
in	2	O
the	3	O
context	7	O
of	2	O
agonist-bound	13	O
and	3	O
ligand-free	11	O
RARalpha	8	B-Gene
.	1	O

Our	3	O
results	7	O
demonstrate	11	O
that	4	O
RARalpha	8	B-Gene
is	2	O
dispensable	11	O
for	3	O
granulopoiesis	14	O
,	1	O
as	2	O
RARalpha	8	B-Gene
(	1	I-Gene
-	1	I-Gene
/	1	I-Gene
-	1	I-Gene
)	1	I-Gene
mice	4	O
have	4	O
a	1	O
normal	6	O
granulocyte	11	O
population	10	O
despite	7	O
an	2	O
impaired	8	O
ability	7	O
to	2	O
respond	7	O
to	2	O
retinoids	9	B-Chemical
.	1	O

However	7	O
,	1	O
although	8	O
it	2	O
is	2	O
not	3	O
absolutely	10	O
required	8	O
,	1	O
RARalpha	8	B-Gene
can	3	O
bidirectionally	15	O
modulate	8	O
granulopoiesis	14	O
.	1	O

RARalpha	8	B-Gene
stimulates	10	O
differentiation	15	O
in	2	O
response	8	O
to	2	O
exogenous	9	O
retinoic	8	B-Chemical
acid	4	I-Chemical
.	1	O

Furthermore	11	O
,	1	O
endogenous	10	O
retinoids	9	B-Chemical
control	7	O
granulopoiesis	14	O
in	2	O
vivo	4	O
,	1	O
as	2	O
either	6	O
vitamin	7	B-Chemical
A	1	I-Chemical
-deficient	10	O
mice	4	O
or	2	O
animals	7	O
treated	7	O
with	4	O
an	2	O
RAR	3	B-Gene
antagonist	10	I-Gene
accumulate	10	O
more	4	O
immature	8	O
granulocytes	12	O
in	2	O
their	5	O
bone	4	O
marrow	6	O
.	1	O

Conversely	10	O
,	1	O
RARalpha	8	B-Gene
acts	4	O
to	2	O
limit	5	O
differentiation	15	O
in	2	O
the	3	O
absence	7	O
of	2	O
ligand	6	O
because	7	O
granulocyte	11	O
precursors	10	O
from	4	O
RARalpha	8	B-Gene
(	1	I-Gene
-	1	I-Gene
/	1	I-Gene
-	1	I-Gene
)	1	I-Gene
mice	4	O
differentiate	13	O
earlier	7	O
in	2	O
culture	7	O
.	1	O

Thus	4	O
,	1	O
the	3	O
block	5	O
in	2	O
granulopoiesis	14	O
exerted	7	O
by	2	O
RARalpha	8	B-Gene
fusion	6	I-Gene
proteins	8	I-Gene
expressed	9	O
in	2	O
APL	3	B-Disease
cells	5	O
may	3	O
correspond	10	O
to	2	O
an	2	O
amplification	13	O
of	2	O
a	1	O
normal	6	O
function	8	O
of	2	O
unliganded	10	O
RARalpha	8	B-Gene
.	1	O

In	2	O
vitro	5	O
-activated	10	O
human	5	O
lupus	5	B-Disease
T	1	O
cells	5	O
express	7	O
normal	6	O
estrogen	8	B-Gene
receptor	8	I-Gene
proteins	8	I-Gene
which	5	O
bind	4	O
to	2	O
the	3	O
estrogen	8	B-Chemical
response	8	O
element	7	O
.	1	O

We	2	O
have	4	O
shown	5	O
that	4	O
estrogen	8	B-Gene
receptor	8	I-Gene
(	1	O
ERalpha	7	B-Gene
,	1	O
ERbeta	6	B-Gene
)	1	O
transcripts	11	O
are	3	O
expressed	9	O
in	2	O
SLE	3	B-Disease
and	3	O
normal	6	O
T	1	O
cells	5	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
T	1	O
cell	4	O
nuclear	7	O
extracts	8	O
from	4	O
female	6	O
lupus	5	B-Disease
patients	8	O
and	3	O
normal	6	O
donors	6	O
were	4	O
tested	6	O
for	3	O
biologically	12	O
active	6	O
ER	2	B-Gene
proteins	8	I-Gene
capable	7	O
of	2	O
binding	7	O
to	2	O
the	3	O
human	5	O
estrogen	8	B-Chemical
response	8	O
element	7	O
(	1	O
hERE	4	O
)	1	O
by	2	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assays	6	O
.	1	O

When	4	O
peripheral	10	O
blood	5	O
T	1	O
cells	5	O
were	4	O
stimulated	10	O
with	4	O
17beta-estradiol	16	B-Chemical
(	1	O
E2	2	B-Chemical
)	1	O
,	1	O
PMA	3	B-Chemical
and	3	O
ionomycin	9	B-Chemical
,	1	O
two	3	O
major	5	O
retarded	8	O
bands	5	O
in	2	O
T	1	O
cell	4	O
nuclear	7	O
extracts	8	O
exhibited	9	O
a	1	O
migration	9	O
pattern	7	O
similar	7	O
to	2	O
slow	4	O
migrating	9	O
protein-ERE	11	B-Gene
complexes	9	I-Gene
in	2	O
human	5	O
breast	6	B-Disease
cancer	6	I-Disease
cell	4	O
extracts	8	O
.	1	O

T	1	O
cells	5	O
cultured	8	O
only	4	O
with	4	O
E2	2	B-Chemical
did	3	O
not	3	O
have	4	O
these	5	O
complexes	9	O
.	1	O

The	3	O
formation	9	O
of	2	O
the	3	O
complexes	9	O
was	3	O
inhibited	9	O
by	2	O
competition	11	O
with	4	O
the	3	O
hERE	4	O
cold	4	O
oligonucleotide	15	O
and	3	O
partially	9	O
with	4	O
anti-ERalpha	12	B-Gene
antibodies	10	I-Gene
.	1	O

There	5	O
was	3	O
no	2	O
notable	7	O
difference	10	O
in	2	O
the	3	O
migration	9	O
pattern	7	O
of	2	O
ERE	3	O
-binding	8	O
proteins	8	O
between	7	O
the	3	O
SLE	3	B-Disease
and	3	O
normal	6	O
T	1	O
cell	4	O
extracts	8	O
.	1	O

Together	8	O
,	1	O
these	5	O
results	7	O
suggest	7	O
that	4	O
activated	9	O
human	5	O
T	1	O
cells	5	O
,	1	O
whether	7	O
lupus	5	B-Disease
-derived	8	O
or	2	O
normal	6	O
-derived	8	O
,	1	O
contain	7	O
biologically	12	O
active	6	O
ERalpha	7	B-Gene
proteins	8	I-Gene
.	1	O

Other	5	O
factors	7	O
may	3	O
be	2	O
responsible	11	O
for	3	O
differential	12	O
sensitivity	11	O
of	2	O
lupus	5	B-Disease
T	1	O
cells	5	O
to	2	O
estrogen	8	B-Chemical
.	1	O

Existence	9	O
of	2	O
retinoic	8	B-Gene
acid-receptor	13	I-Gene
-independent	12	O
retinoid	8	B-Gene
X-receptor	10	I-Gene
-dependent	10	O
pathway	7	O
in	2	O
myeloid	7	O
cell	4	O
function	8	O
.	1	O

We	2	O
previously	10	O
reported	8	O
that	4	O
ER-27191	8	B-Chemical
(	1	O
4-	2	B-Chemical
[	1	I-Chemical
4	1	I-Chemical
,	1	I-Chemical
5	1	I-Chemical
,	1	I-Chemical
7	1	I-Chemical
,	1	I-Chemical
8	1	I-Chemical
,	1	I-Chemical
9	1	I-Chemical
,	1	I-Chemical
10-hexahydro-7	14	I-Chemical
,	1	I-Chemical
7	1	I-Chemical
,	1	I-Chemical
10	2	I-Chemical
,	1	I-Chemical
10-tetramethyl-1-	17	I-Chemical
(	1	I-Chemical
3-pyridylmethyl	15	I-Chemical
)	1	I-Chemical
anthra	6	I-Chemical
[	1	I-Chemical
1	1	I-Chemical
,	1	I-Chemical
2-b	3	I-Chemical
]	1	I-Chemical
pyrrol-3-yl	11	I-Chemical
]	1	I-Chemical
benzoic	7	I-Chemical
acid	4	I-Chemical
)	1	O
is	2	O
a	1	O
potent	6	O
antagonist	10	O
of	2	O
retinoic	8	B-Gene
acid	4	I-Gene
receptor	8	I-Gene
(	1	O
RAR	3	B-Gene
)	1	O
,	1	O
and	3	O
ER-35795	8	B-Chemical
(	1	O
(	1	B-Chemical
2E	2	I-Chemical
,	1	I-Chemical
4E	2	I-Chemical
,	1	I-Chemical
6E	2	I-Chemical
)	1	I-Chemical
-7-	3	I-Chemical
[	1	I-Chemical
1-	2	I-Chemical
(	1	I-Chemical
1-methylethyl	13	I-Chemical
)	1	I-Chemical
-8-chloro-1	11	I-Chemical
,	1	I-Chemical
2	1	I-Chemical
,	1	I-Chemical
3	1	I-Chemical
,	1	I-Chemical
4-tetrahydroquinolin-6-yl	25	I-Chemical
]	1	I-Chemical
-6-fluoro-3-methyl-2	20	I-Chemical
,	1	I-Chemical
4	1	I-Chemical
,	1	I-Chemical
6-nonatrienoic	14	I-Chemical
acid	4	I-Chemical
)	1	O
is	2	O
a	1	O
novel	5	O
retinoid	8	B-Gene
X	1	I-Gene
receptor	8	I-Gene
(	1	O
RXR	3	B-Gene
)	1	O
-specific	9	O
agonist	7	O
.	1	O

By	2	O
using	5	O
these	5	O
compounds	9	O
,	1	O
we	2	O
investigated	12	O
whether	7	O
distinct	8	O
RAR	3	B-Gene
-dependent	10	O
and	3	O
RXR	3	B-Gene
-dependent	10	O
pathways	8	O
operate	7	O
to	2	O
mediate	7	O
the	3	O
diverse	7	O
activities	10	O
of	2	O
retinoids	9	B-Chemical
,	1	O
particularly	12	O
,	1	O
the	3	O
effects	7	O
of	2	O
the	3	O
RXR	3	B-Gene
pathway	7	O
on	2	O
cellular	8	O
function	8	O
.	1	O

ER-27191	8	B-Chemical
completely	10	O
antagonized	11	O
HL60	4	O
cell	4	O
differentiation	15	O
induced	7	O
by	2	O
all-trans-retinoic	18	B-Chemical
acid	4	I-Chemical
(	1	O
atRA	4	B-Chemical
)	1	O
.	1	O

However	7	O
,	1	O
the	3	O
differentiation	15	O
induced	7	O
by	2	O
the	3	O
ER-35795	8	B-Chemical
was	3	O
not	3	O
antagonized	11	O
at	2	O
all	3	O
by	2	O
the	3	O
RAR	3	B-Gene
antagonist	10	I-Gene
,	1	O
but	3	O
was	3	O
inhibited	9	O
by	2	O
an	2	O
RXR	3	B-Gene
homodimer	9	O
antagonist	10	O
(	1	O
LGD100754	9	B-Chemical
,	1	O
(	1	B-Chemical
2E	2	I-Chemical
,	1	I-Chemical
4E	2	I-Chemical
,	1	I-Chemical
6Z	2	I-Chemical
)	1	I-Chemical
-7-	3	I-Chemical
(	1	I-Chemical
3-n-propoxy-5	13	I-Chemical
,	1	I-Chemical
6	1	I-Chemical
,	1	I-Chemical
7	1	I-Chemical
,	1	I-Chemical
8-tetrahydro-5	14	I-Chemical
,	1	I-Chemical
5	1	I-Chemical
,	1	I-Chemical
8	1	I-Chemical
,	1	I-Chemical
8-tetramethylnaphthalen-2-yl	28	I-Chemical
)	1	I-Chemical
-3-methylocta-2	15	I-Chemical
,	1	I-Chemical
4	1	I-Chemical
,	1	I-Chemical
6-trienoic	10	I-Chemical
acid	4	I-Chemical
)	1	O
.	1	O

Its	3	O
agonistic	9	O
action	6	O
on	2	O
RXR	3	B-Gene
/	1	I-Gene
RAR	3	I-Gene
heterodimer	11	O
,	1	O
on	2	O
the	3	O
other	5	O
hand	4	O
,	1	O
was	3	O
neutralized	11	O
by	2	O
the	3	O
RAR	3	B-Gene
antagonist	10	I-Gene
.	1	O

During	6	O
HL60	4	O
cell	4	O
differentiation	15	O
,	1	O
atRA	4	B-Chemical
induced	7	O
RARbeta	7	B-Gene
mRNA	4	I-Gene
,	1	O
while	5	O
the	3	O
RXR	3	B-Gene
had	3	O
no	2	O
effect	6	O
.	1	O

Interestingly	13	O
,	1	O
a	1	O
functional	10	O
RXR	3	B-Gene
-pathway	8	O
was	3	O
also	4	O
seen	4	O
in	2	O
lipopolysaccharide	18	B-Chemical
-induced	8	O
inhibition	10	O
of	2	O
mouse	5	O
splenocyte	10	O
proliferation	13	O
.	1	O

These	5	O
results	7	O
strongly	8	O
suggest	7	O
the	3	O
existence	9	O
of	2	O
a	1	O
pharmacological	15	O
RXR	3	B-Gene
-dependent	10	O
pathway	7	O
that	4	O
is	2	O
activated	9	O
by	2	O
a	1	O
ligand	6	O
that	4	O
can	3	O
bind	4	O
to	2	O
RXR	3	B-Gene
.	1	O

Selective	9	O
inhibition	10	O
of	2	O
interleukin-4	13	B-Gene
gene	4	I-Gene
expression	10	O
in	2	O
human	5	O
T	1	O
cells	5	O
by	2	O
aspirin	7	B-Chemical
.	1	O

Previous	8	O
studies	7	O
indicated	9	O
that	4	O
aspirin	7	B-Chemical
(	1	O
acetylsalicylic	15	B-Chemical
acid	4	I-Chemical
[	1	O
ASA	3	B-Chemical
]	1	O
)	1	O
can	3	O
have	4	O
profound	8	O
immunomodulatory	16	O
effects	7	O
by	2	O
regulating	10	O
cytokine	8	O
gene	4	O
expression	10	O
in	2	O
several	7	O
types	5	O
of	2	O
cells	5	O
.	1	O

This	4	O
study	5	O
is	2	O
the	3	O
first	5	O
in	2	O
which	5	O
concentrations	14	O
of	2	O
ASA	3	B-Chemical
in	2	O
the	3	O
therapeutic	11	O
range	5	O
were	4	O
found	5	O
to	2	O
significantly	13	O
reduce	6	O
interleukin	11	B-Gene
(	1	I-Gene
IL	2	I-Gene
)	1	I-Gene
-4	2	I-Gene
secretion	9	O
and	3	O
RNA	3	O
expression	10	O
in	2	O
freshly	7	O
isolated	8	O
and	3	O
mitogen	7	O
-primed	7	O
human	5	B-Gene
CD4+	4	I-Gene
T	1	O
cells	5	O
.	1	O

In	2	O
contrast	8	O
,	1	O
ASA	3	B-Chemical
did	3	O
not	3	O
affect	6	O
IL-13	5	B-Gene
,	1	O
interferon-gamma	16	B-Gene
,	1	O
and	3	O
IL-2	4	B-Gene
expression	10	O
.	1	O

ASA	3	B-Chemical
inhibited	9	O
IL-4	4	B-Gene
,	1	O
but	3	O
not	3	O
IL-2	4	B-Gene
,	1	O
promoter-driven	15	O
chloramphenicol	15	B-Gene
acetyltransferase	17	I-Gene
expression	10	O
in	2	O
transiently	11	O
transfected	11	O
Jurkat	6	O
T	1	O
cells	5	O
.	1	O

The	3	O
structurally	12	O
unrelated	9	O
nonsteroidal	12	O
anti-inflammatory	17	O
drugs	5	O
indomethacin	12	B-Chemical
and	3	O
flurbiprofen	12	B-Chemical
did	3	O
not	3	O
affect	6	O
cytokine	8	O
gene	4	O
expression	10	O
in	2	O
T	1	O
cells	5	O
,	1	O
whereas	7	O
the	3	O
weak	4	O
cyclo-oxygenase	15	B-Gene
inhibitor	9	I-Gene
salicylic	9	B-Chemical
acid	4	I-Chemical
was	3	O
at	2	O
least	5	O
as	2	O
effective	9	O
as	2	O
ASA	3	B-Chemical
in	2	O
inhibiting	10	O
IL-4	4	B-Gene
expression	10	O
and	3	O
promoter	8	O
activity	8	O
.	1	O

The	3	O
inhibitory	10	O
effect	6	O
of	2	O
ASA	3	B-Chemical
on	2	O
IL-4	4	B-Gene
transcription	13	O
was	3	O
not	3	O
mediated	8	O
by	2	O
decreased	9	O
nuclear	7	O
expression	10	O
of	2	O
the	3	O
known	5	O
salicylate	10	B-Chemical
target	6	O
nuclear	7	B-Gene
factor	6	I-Gene
(	1	I-Gene
NF	2	I-Gene
)	1	I-Gene
-kappaB	7	I-Gene
and	3	O
was	3	O
accompanied	11	O
by	2	O
reduced	7	O
binding	7	O
of	2	O
an	2	O
inducible	9	O
factor	6	O
to	2	O
an	2	O
IL-4	4	B-Gene
promoter	8	I-Gene
region	6	O
upstream	8	O
of	2	O
,	1	O
but	3	O
not	3	O
overlapping	11	O
,	1	O
the	3	O
NF	2	B-Gene
of	2	I-Gene
activated	9	I-Gene
T	1	I-Gene
cells-	6	I-Gene
and	3	O
NF-kappaB	9	B-Gene
-binding	8	I-Gene
P1	2	I-Gene
element	7	I-Gene
.	1	O

It	2	O
is	2	O
concluded	9	O
that	4	O
anti-inflammatory	17	O
salicylates	11	B-Chemical
,	1	O
by	2	O
means	5	O
of	2	O
a	1	O
previously	10	O
unrecognized	12	O
mechanism	9	O
of	2	O
action	6	O
,	1	O
can	3	O
influence	9	O
the	3	O
nature	6	O
of	2	O
adaptive	8	O
immune	6	O
responses	9	O
by	2	O
selectively	11	O
inhibiting	10	O
the	3	O
expression	10	O
of	2	O
IL-4	4	B-Gene
,	1	O
a	1	O
critical	8	O
effector	8	O
of	2	O
these	5	O
responses	9	O
,	1	O
in	2	O
CD4+	4	B-Gene
T	1	O
cells	5	O
.	1	O

Suppression	11	O
of	2	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
and	3	O
stimulation	11	O
of	2	O
inhibitor	9	B-Gene
kappaB	6	I-Gene
by	2	O
troglitazone	12	B-Chemical
:	1	O
evidence	8	O
for	3	O
an	2	O
anti-inflammatory	17	O
effect	6	O
and	3	O
a	1	O
potential	9	O
antiatherosclerotic	19	O
effect	6	O
in	2	O
the	3	O
obese	5	O
.	1	O

To	2	O
elucidate	9	O
whether	7	O
troglitazone	12	B-Chemical
exerts	6	O
an	2	O
antiinflammatory	16	O
effect	6	O
in	2	O
humans	6	O
,	1	O
in	2	O
vivo	4	O
,	1	O
we	2	O
investigated	12	O
the	3	O
suppression	11	O
of	2	O
nuclear	7	B-Gene
factor	6	I-Gene
kappaB	6	I-Gene
(	1	O
NFkappaB	8	B-Gene
)	1	O
in	2	O
mononuclear	11	O
cells	5	O
(	1	O
MNC	3	O
)	1	O
by	2	O
this	4	O
drug	4	O
.	1	O

We	2	O
measured	8	O
intranuclear	12	B-Gene
NFkappaB	8	I-Gene
,	1	O
total	5	O
cellular	8	B-Gene
NFkappaB	8	I-Gene
,	1	O
inhibitor	9	B-Gene
kappaB	6	I-Gene
(	1	I-Gene
IkappaB	7	I-Gene
)	1	I-Gene
alpha	5	I-Gene
,	1	O
reactive	8	B-Chemical
oxygen	6	I-Chemical
species	7	I-Chemical
(	1	O
ROS	3	B-Chemical
)	1	O
generation	10	O
,	1	O
and	3	O
p47	3	B-Gene
(	1	I-Gene
phox	4	I-Gene
)	1	I-Gene
subunit	7	O
(	1	O
a	1	O
key	3	O
component	9	O
protein	7	O
of	2	O
nicotinamide	12	B-Gene
adenine	7	I-Gene
dinucleotide	12	I-Gene
phosphate	9	I-Gene
oxidase	7	I-Gene
)	1	O
in	2	O
MNC	3	O
.	1	O

Plasma	6	B-Gene
tumor	5	I-Gene
necrosis	8	I-Gene
factor	6	I-Gene
(	1	I-Gene
TNF	3	I-Gene
)	1	I-Gene
-alpha	6	I-Gene
,	1	O
soluble	7	B-Gene
intercellular	13	I-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
(	1	O
sICAM-1	7	B-Gene
)	1	O
,	1	O
monocyte	8	B-Gene
chemoattractant	15	I-Gene
protein-1	9	I-Gene
(	1	O
MCP-1	5	B-Gene
)	1	O
,	1	O
plasminogen	11	B-Gene
activator	9	I-Gene
inhibitor	9	I-Gene
type	4	I-Gene
1	1	I-Gene
(	1	O
PAI-1	5	B-Gene
)	1	O
,	1	O
C	1	B-Gene
-reactive	9	I-Gene
protein	7	I-Gene
(	1	O
CRP	3	B-Gene
)	1	O
,	1	O
and	3	O
interleukin	11	B-Gene
(	1	I-Gene
IL	2	I-Gene
)	1	I-Gene
-10	3	I-Gene
(	1	O
antiinflammatory	16	O
cytokine	8	O
)	1	O
concentrations	14	O
were	4	O
also	4	O
measured	8	O
as	2	O
mediators	9	O
of	2	O
inflammatory	12	O
activity	8	O
that	4	O
are	3	O
regulated	9	O
by	2	O
the	3	O
proinflammatory	15	O
transcription	13	B-Gene
factor	6	I-Gene
NFkappaB	8	I-Gene
.	1	O

Seven	5	O
nondiabetic	11	O
obese	5	O
patients	8	O
were	4	O
given	5	O
400	3	O
mg	2	O
troglitazone	12	B-Chemical
daily	5	O
for	3	O
4	1	O
weeks	5	O
.	1	O

Blood	5	O
samples	7	O
were	4	O
collected	9	O
before	6	O
and	3	O
at	2	O
weekly	6	O
intervals	9	O
thereafter	10	O
.	1	O

MNC	3	O
were	4	O
separated	9	O
;	1	O
and	3	O
the	3	O
levels	6	O
of	2	O
intranuclear	12	B-Gene
NFkappaB	8	I-Gene
,	1	O
total	5	O
cellular	8	B-Gene
NFkappaB	8	I-Gene
,	1	O
IkappaBalpha	12	B-Gene
,	1	O
and	3	O
p47	3	B-Gene
(	1	I-Gene
phox	4	I-Gene
)	1	I-Gene
subunit	7	O
and	3	O
ROS	3	B-Chemical
generation	10	O
were	4	O
determined	10	O
.	1	O

Plasma	6	O
was	3	O
used	4	O
to	2	O
measure	7	O
insulin	7	B-Gene
glucose	7	B-Chemical
,	1	O
TNFalpha	8	B-Gene
,	1	O
sICAM	5	B-Gene
,	1	O
MCP-1	5	B-Gene
,	1	O
PAI-1	5	B-Gene
,	1	O
CRP	3	B-Gene
,	1	O
and	3	O
IL-10	5	B-Gene
.	1	O

Plasma	6	B-Gene
insulin	7	I-Gene
concentrations	14	O
fell	4	O
significantly	13	O
at	2	O
week	4	O
1	1	O
,	1	O
from	4	O
31.2	4	O
+	1	O
/	1	O
-	1	O
29.1	4	O
to	2	O
14.2	4	O
+	1	O
/	1	O
-	1	O
11.4	4	O
mU	2	O
/	1	O
L	1	O
(	1	O
P	1	O
<	1	O
0.01	4	O
)	1	O
and	3	O
remained	8	O
low	3	O
throughout	10	O
4	1	O
weeks	5	O
.	1	O

Plasma	6	O
glucose	7	B-Chemical
concentrations	14	O
did	3	O
not	3	O
alter	5	O
significantly	13	O
.	1	O

There	5	O
was	3	O
a	1	O
fall	4	O
in	2	O
intranuclear	12	B-Gene
NFkappaB	8	I-Gene
,	1	O
total	5	O
cellular	8	B-Gene
NFkappaB	8	I-Gene
,	1	O
and	3	O
p47	3	B-Gene
(	1	I-Gene
phox	4	I-Gene
)	1	I-Gene
subunit	7	O
,	1	O
with	4	O
an	2	O
increase	8	O
in	2	O
cellular	8	B-Gene
IkappaBalpha	12	I-Gene
at	2	O
week	4	O
2	1	O
,	1	O
which	5	O
persisted	9	O
until	5	O
week	4	O
4	1	O
.	1	O

There	5	O
was	3	O
a	1	O
parallel	8	O
fall	4	O
in	2	O
ROS	3	B-Chemical
generation	10	O
by	2	O
MNC	3	O
at	2	O
week	4	O
1	1	O
;	1	O
this	4	O
progressed	10	O
and	3	O
persisted	9	O
until	5	O
week	4	O
4	1	O
(	1	O
P	1	O
<	1	O
0.001	5	O
)	1	O
.	1	O

Plasma	6	B-Gene
TNF-alpha	9	I-Gene
,	1	O
sICAM-1	7	B-Gene
,	1	O
MCP-1	5	B-Gene
,	1	O
and	3	O
PAI-1	5	B-Gene
concentrations	14	O
fell	4	O
significantly	13	O
at	2	O
week	4	O
4	1	O
.	1	O

Plasma	6	B-Gene
IL-10	5	I-Gene
concentration	13	O
increased	9	O
significantly	13	O
,	1	O
whereas	7	O
plasma	6	B-Gene
CRP	3	I-Gene
concentrations	14	O
decreased	9	O
.	1	O

We	2	O
conclude	8	O
that	4	O
troglitazone	12	B-Chemical
has	3	O
an	2	O
antiinflammatory	16	O
action	6	O
that	4	O
may	3	O
contribute	10	O
to	2	O
its	3	O
putative	8	O
antiatherosclerotic	19	O
effects	7	O
.	1	O

An	2	O
instructive	11	O
component	9	O
in	2	O
T	1	O
helper	6	O
cell	4	O
type	4	O
2	1	O
(	1	O
Th2	3	O
)	1	O
development	11	O
mediated	8	O
by	2	O
GATA-3	6	B-Gene
.	1	O

Although	8	O
interleukin	11	B-Gene
(	1	I-Gene
IL	2	I-Gene
)	1	I-Gene
-12	3	I-Gene
and	3	O
IL-4	4	B-Gene
polarize	8	O
naive	5	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
T	1	O
cells	5	O
toward	6	O
T	1	O
helper	6	O
cell	4	O
type	4	O
1	1	O
(	1	O
Th1	3	O
)	1	O
or	2	O
Th2	3	O
phenotypes	10	O
,	1	O
it	2	O
is	2	O
not	3	O
known	5	O
whether	7	O
cytokines	9	O
instruct	8	O
the	3	O
developmental	13	O
fate	4	O
in	2	O
uncommitted	11	O
progenitors	11	O
or	2	O
select	6	O
for	3	O
outgrowth	9	O
of	2	O
cells	5	O
that	4	O
have	4	O
stochastically	14	O
committed	9	O
to	2	O
a	1	O
particular	10	O
fate	4	O
.	1	O

To	2	O
distinguish	11	O
these	5	O
instructive	11	O
and	3	O
selective	9	O
models	6	O
,	1	O
we	2	O
used	4	O
surface	7	O
affinity	8	O
matrix	6	O
technology	10	O
to	2	O
isolate	7	O
committed	9	O
progenitors	11	O
based	5	O
on	2	O
cytokine	8	O
secretion	9	O
phenotype	9	O
and	3	O
developed	9	O
retroviral	10	O
-based	6	O
tagging	7	O
approaches	10	O
to	2	O
directly	8	O
monitor	7	O
individual	10	O
progenitor	10	O
fate	4	O
decisions	9	O
at	2	O
the	3	O
clonal	6	O
and	3	O
population	10	O
levels	6	O
.	1	O

We	2	O
observe	7	O
IL-4	4	B-Gene
-dependent	10	O
redirection	11	O
of	2	O
phenotype	9	O
in	2	O
cells	5	O
that	4	O
have	4	O
already	7	O
committed	9	O
to	2	O
a	1	O
non-IL-4	8	B-Gene
-producing	10	O
fate	4	O
,	1	O
inconsistent	12	O
with	4	O
predictions	11	O
of	2	O
the	3	O
selective	9	O
model	5	O
.	1	O

Further	7	O
,	1	O
retroviral	10	O
tagging	7	O
of	2	O
naive	5	O
progenitors	11	O
with	4	O
the	3	O
Th2-specific	12	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
GATA-3	6	I-Gene
provided	8	O
direct	6	O
evidence	8	O
for	3	O
instructive	11	O
differentiation	15	O
,	1	O
and	3	O
no	2	O
evidence	8	O
for	3	O
the	3	O
selective	9	O
outgrowth	9	O
of	2	O
cells	5	O
committed	9	O
to	2	O
either	6	O
the	3	O
Th1	3	O
or	2	O
Th2	3	O
fate	4	O
.	1	O

These	5	O
data	4	O
would	5	O
seem	4	O
to	2	O
exclude	7	O
selection	9	O
as	2	O
an	2	O
exclusive	9	O
mechanism	9	O
in	2	O
Th1	3	O
/	1	O
Th2	3	O
differentiation	15	O
,	1	O
and	3	O
support	7	O
an	2	O
instructive	11	O
model	5	O
of	2	O
cytokine-driven	15	O
transcriptional	15	O
programming	11	O
of	2	O
cell	4	O
fate	4	O
decisions	9	O
.	1	O

Targeting	9	O
Src	3	B-Gene
homology	8	I-Gene
2	1	I-Gene
domain	6	I-Gene
-containing	11	I-Gene
tyrosine	8	I-Gene
phosphatase	11	I-Gene
(	1	O
SHP-1	5	B-Gene
)	1	O
into	4	O
lipid	5	B-Chemical
rafts	5	O
inhibits	8	O
CD3	3	B-Gene
-induced	8	O
T	1	O
cell	4	O
activation	10	O
.	1	O

To	2	O
study	5	O
the	3	O
mechanism	9	O
by	2	O
which	5	O
protein	7	B-Gene
tyrosine	8	I-Gene
phosphatases	12	I-Gene
(	1	O
PTPs	4	B-Gene
)	1	O
regulate	8	O
CD3	3	B-Gene
-induced	8	O
tyrosine	8	B-Chemical
phosphorylation	15	O
,	1	O
we	2	O
investigated	12	O
the	3	O
distribution	12	O
of	2	O
PTPs	4	B-Gene
in	2	O
subdomains	10	O
of	2	O
plasma	6	O
membrane	8	O
.	1	O

We	2	O
report	6	O
here	4	O
that	4	O
the	3	O
bulk	4	O
PTP	3	B-Gene
activity	8	O
associated	10	O
with	4	O
T	1	O
cell	4	O
membrane	8	O
is	2	O
present	7	O
outside	7	O
the	3	O
lipid	5	B-Chemical
rafts	5	O
,	1	O
as	2	O
determined	10	O
by	2	O
sucrose	7	O
density	7	O
gradient	8	O
sedimentation	13	O
.	1	O

In	2	O
Jurkat	6	O
T	1	O
cells	5	O
,	1	O
approximately	13	O
5	1	O
--	2	O
10	2	O
%	1	O
of	2	O
Src	3	B-Gene
homology	8	I-Gene
2	1	I-Gene
domain	6	I-Gene
-containing	11	I-Gene
tyrosine	8	I-Gene
phosphatase	11	I-Gene
(	1	O
SHP-1	5	B-Gene
)	1	O
is	2	O
constitutively	14	O
associated	10	O
with	4	O
plasma	6	O
membrane	8	O
,	1	O
and	3	O
nearly	6	O
50	2	O
%	1	O
of	2	O
SHP-2	5	B-Gene
is	2	O
translocated	12	O
to	2	O
plasma	6	O
membrane	8	O
after	5	O
vanadate	8	B-Chemical
treatment	9	O
.	1	O

Similar	7	O
to	2	O
transmembrane	13	O
PTP	3	B-Gene
,	1	O
CD45	4	B-Gene
,	1	O
the	3	O
membrane	8	O
-associated	11	O
populations	11	O
of	2	O
SHP-1	5	B-Gene
and	3	O
SHP-2	5	B-Gene
are	3	O
essentially	11	O
excluded	8	O
from	4	O
lipid	5	B-Chemical
rafts	5	O
,	1	O
where	5	O
other	5	O
signaling	9	O
molecules	9	O
such	4	O
as	2	O
Lck	3	B-Gene
,	1	O
linker	6	B-Gene
for	3	I-Gene
activation	10	I-Gene
of	2	I-Gene
T	1	I-Gene
cells	5	I-Gene
,	1	O
and	3	O
CD3	3	B-Gene
zeta	4	I-Gene
are	3	O
enriched	8	O
.	1	O

We	2	O
further	7	O
demonstrated	12	O
that	4	O
CD3	3	B-Gene
-induced	8	O
tyrosine	8	B-Chemical
phosphorylation	15	O
of	2	O
these	5	O
substrates	10	O
is	2	O
largely	7	O
restricted	10	O
to	2	O
lipid	5	B-Chemical
rafts	5	O
,	1	O
unless	6	O
PTPs	4	B-Gene
are	3	O
inhibited	9	O
.	1	O

It	2	O
suggests	8	O
that	4	O
a	1	O
restricted	10	O
partition	9	O
of	2	O
PTPs	4	B-Gene
among	5	O
membrane	8	O
subdomains	10	O
may	3	O
regulate	8	O
protein	7	O
tyrosine	8	B-Chemical
phosphorylation	15	O
in	2	O
T	1	O
cell	4	O
membrane	8	O
.	1	O

To	2	O
test	4	O
this	4	O
hypothesis	10	O
,	1	O
we	2	O
targeted	8	O
SHP-1	5	B-Gene
into	4	O
lipid	5	B-Chemical
rafts	5	O
by	2	O
using	5	O
the	3	O
N-terminal	10	O
region	6	O
of	2	O
Lck	3	B-Gene
(	1	O
residues	8	O
1	1	O
--	2	O
14	2	O
)	1	O
.	1	O

The	3	O
results	7	O
indicate	8	O
that	4	O
the	3	O
expression	10	O
of	2	O
Lck	3	B-Gene
/	1	I-Gene
SHP-1	5	I-Gene
chimera	7	I-Gene
inside	6	O
lipid	5	B-Chemical
rafts	5	O
profoundly	10	O
inhibits	8	O
CD3	3	B-Gene
-induced	8	O
tyrosine	8	B-Chemical
phosphorylation	15	O
of	2	O
CD3	3	B-Gene
zeta	4	I-Gene
/	1	I-Gene
epsilon	7	I-Gene
,	1	O
IL-2	4	B-Gene
generation	10	O
,	1	O
and	3	O
nuclear	7	O
mobilization	12	O
of	2	O
NF-AT	5	B-Gene
.	1	O

Collectively	12	O
,	1	O
these	5	O
results	7	O
suggest	7	O
that	4	O
the	3	O
exclusion	9	O
of	2	O
PTPs	4	B-Gene
from	4	O
lipid	5	B-Chemical
rafts	5	O
may	3	O
be	2	O
a	1	O
mechanism	9	O
that	4	O
potentiates	11	O
TCR	3	B-Gene
/	1	I-Gene
CD3	3	I-Gene
activation	10	O

Stromal	7	B-Gene
cell	4	I-Gene
-derived	8	I-Gene
factor	6	I-Gene
1	1	I-Gene
alpha	5	I-Gene
-induced	8	O
chemotaxis	10	O
in	2	O
T	1	O
cells	5	O
is	2	O
mediated	8	O
by	2	O
nitric	6	B-Chemical
oxide	5	I-Chemical
signaling	9	O
pathways	8	O
.	1	O

Stromal	7	B-Gene
cell	4	I-Gene
-derived	8	I-Gene
factor	6	I-Gene
1	1	I-Gene
alpha	5	I-Gene
(	1	O
SDF1	4	B-Gene
alpha	5	I-Gene
)	1	O
and	3	O
its	3	O
cognate	7	O
chemokine	9	B-Gene
receptor	8	I-Gene
CXCR4	5	I-Gene
act	3	O
as	2	O
potent	6	O
chemoattractants	16	O
and	3	O
regulate	8	O
trafficking	11	O
and	3	O
homing	6	O
of	2	O
hematopoietic	13	O
progenitor	10	O
cells	5	O
and	3	O
lymphocytes	11	O
.	1	O

However	7	O
,	1	O
the	3	O
molecular	9	O
mechanisms	10	O
regulating	10	O
SDF1	4	B-Gene
alpha	5	I-Gene
-driven	7	O
cell	4	O
migration	9	O
are	3	O
not	3	O
well	4	O
defined	7	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
we	2	O
have	4	O
explored	8	O
the	3	O
roles	5	O
of	2	O
the	3	O
second	6	O
messenger	9	O
NO	2	O
and	3	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
in	2	O
SDF1	4	B-Gene
alpha	5	I-Gene
-induced	8	O
T	1	O
cell	4	O
migration	9	O
.	1	O

SDF1	4	B-Gene
alpha	5	I-Gene
treatment	9	O
of	2	O
Jurkat	6	O
T	1	O
cells	5	O
increased	9	O
the	3	O
activity	8	O
of	2	O
NO	2	B-Gene
synthase	8	I-Gene
,	1	O
which	5	O
catalyzes	9	O
the	3	O
generation	10	O
of	2	O
NO	2	O
.	1	O

We	2	O
observed	8	O
that	4	O
pretreatment	12	O
of	2	O
Jurkat	6	O
cells	5	O
or	2	O
activated	9	O
PBLs	4	O
with	4	O
several	7	O
NO	2	O
donors	6	O
significantly	13	O
enhanced	8	O
the	3	O
SDF1	4	B-Gene
alpha	5	I-Gene
-induced	8	O
migration	9	O
,	1	O
whereas	7	O
various	7	O
inhibitors	10	O
of	2	O
NO	2	B-Gene
synthase	8	I-Gene
markedly	8	O
abrogated	9	O
the	3	O
chemotactic	11	O
response	8	O
in	2	O
a	1	O
concentration	13	O
-dependent	10	O
manner	6	O
.	1	O

Furthermore	11	O
,	1	O
we	2	O
observed	8	O
that	4	O
inhibitors	10	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
,	1	O
which	5	O
is	2	O
linked	6	O
to	2	O
NO	2	O
signaling	9	O
pathways	8	O
,	1	O
also	4	O
significantly	13	O
blocked	7	O
the	3	O
SDF1	4	B-Gene
alpha	5	I-Gene
-induced	8	O
chemotactic	11	O
response	8	O
.	1	O

However	7	O
,	1	O
these	5	O
compounds	9	O
did	3	O
not	3	O
have	4	O
a	1	O
significant	11	O
effect	6	O
on	2	O
SDF1	4	B-Gene
alpha	5	I-Gene
-induced	8	O
mitogen	7	B-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
activity	8	O
.	1	O

In	2	O
addition	8	O
,	1	O
the	3	O
MAP	3	B-Gene
/	1	I-Gene
Erk	3	I-Gene
kinase	6	I-Gene
kinase	6	I-Gene
inhibitor	9	O
PD98059	7	B-Chemical
did	3	O
not	3	O
abrogate	8	O
SDF1	4	B-Gene
alpha	5	I-Gene
-induced	8	O
chemotaxis	10	O
.	1	O

AKT	3	B-Gene
,	1	O
which	5	O
has	3	O
been	4	O
shown	5	O
to	2	O
mediate	7	O
NO	2	O
production	10	O
,	1	O
was	3	O
also	4	O
phosphorylated	14	O
upon	4	O
SDF1	4	B-Gene
alpha	5	I-Gene
stimulation	11	O
.	1	O

These	5	O
studies	7	O
suggest	7	O
that	4	O
NO	2	O
-related	8	O
signaling	9	O
pathways	8	O
may	3	O
mediate	7	O
SDF1	4	B-Gene
alpha	5	I-Gene
-induced	8	O
chemotaxis	10	O
,	1	O
but	3	O
not	3	O
mitogen	7	B-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
activation	10	O
.	1	O

Transcriptional	15	O
regulation	10	O
in	2	O
lymphocytes	11	O
.	1	O

Lymphocytes	11	O
have	4	O
been	4	O
used	4	O
to	2	O
investigate	11	O
many	4	O
cellular	8	O
processes	9	O
,	1	O
including	9	O
lineage	7	O
commitment	10	O
,	1	O
differentiation	15	O
,	1	O
proliferation	13	O
and	3	O
apoptosis	9	O
.	1	O

The	3	O
transcription	13	O
factors	7	O
that	4	O
mediate	7	O
these	5	O
processes	9	O
are	3	O
often	5	O
expressed	9	O
broadly	7	O
in	2	O
many	4	O
cell	4	O
types	5	O
.	1	O

The	3	O
emerging	8	O
theme	5	O
is	2	O
one	3	O
of	2	O
cell-type-specific	18	O
regulation	10	O
,	1	O
affecting	9	O
not	3	O
only	4	O
the	3	O
functional	10	O
activation	10	O
of	2	O
transcription	13	O
factors	7	O
but	3	O
also	4	O
their	5	O
access	6	O
to	2	O
appropriate	11	O
regions	7	O
of	2	O
DNA	3	O
.	1	O

Tyrosine	8	B-Chemical
phosphorylation	15	O
-dependent	10	O
activation	10	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
.	1	O

Requirement	11	O
for	3	O
p56	3	B-Gene
LCK	3	I-Gene
and	3	O
ZAP-70	6	B-Gene
protein	7	I-Gene
tyrosine	8	I-Gene
kinases	7	I-Gene
.	1	O

Phosphorylation	15	O
of	2	O
the	3	O
N-terminal	10	O
domain	6	O
of	2	O
I	1	B-Gene
kappa	5	I-Gene
B	1	I-Gene
inhibitory	10	O
subunits	8	O
induces	7	O
activation	10	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
.	1	O

Although	8	O
serine	6	B-Chemical
phosphorylation	15	O
has	3	O
been	4	O
shown	5	O
to	2	O
induce	6	O
ubiquitination	14	O
and	3	O
subsequent	10	O
proteasome	10	O
-mediated	9	O
degradation	11	O
of	2	O
I	1	B-Gene
kappa	5	I-Gene
B-alpha	7	I-Gene
,	1	O
little	6	O
is	2	O
known	5	O
about	5	O
the	3	O
mechanisms	10	O
that	4	O
lead	4	O
to	2	O
release	7	O
of	2	O
active	6	O
NF-kappa	8	B-Gene
B	1	I-Gene
in	2	O
T	1	O
cells	5	O
as	2	O
a	1	O
consequence	11	O
of	2	O
tyrosine	8	B-Chemical
phosphorylation	15	O
of	2	O
I	1	B-Gene
kappa	5	I-Gene
B-alpha	7	I-Gene
[	1	O
Imbert	6	O
,	1	O
V.	2	O
,	1	O
Rupec	5	O
,	1	O
R.A.	4	O
,	1	O
Livolsi	7	O
,	1	O
A.	2	O
,	1	O
Pahl	4	O
,	1	O
H.L.	4	O
,	1	O
Traenckner	10	O
,	1	O
B.M.	4	O
,	1	O
Mueller-Dieckmann	17	O
,	1	O
C.	2	O
,	1	O
Farahifar	9	O
,	1	O
D.	2	O
,	1	O
Rossi	5	O
,	1	O
B.	2	O
,	1	O
Auberger	8	O
,	1	O
P.	2	O
,	1	O
Baeuerle	8	O
,	1	O
P.	2	O
&	1	O
Peyron	6	O
,	1	O
J.F.	4	O
(	1	O
1996	4	O
)	1	O
Cell	4	O
86	2	O
,	1	O
787	3	O
--	2	O
798	3	O
]	1	O
.	1	O

The	3	O
involvement	11	O
of	2	O
the	3	O
tyrosine	8	B-Gene
kinases	7	I-Gene
p56	3	I-Gene
(	1	O
lck	3	B-Gene
)	1	O
and	3	O
ZAP-70	6	B-Gene
in	2	O
this	4	O
reaction	8	O
is	2	O
demonstrated	12	O
here	4	O
using	5	O
specific	8	O
pharmacological	15	O
inhibitors	10	O
and	3	O
Jurkat	6	O
mutants	7	O
unable	6	O
to	2	O
express	7	O
these	5	O
kinases	7	O
.	1	O

Although	8	O
the	3	O
inhibitors	10	O
prevented	9	O
both	4	O
pervanadate	11	B-Chemical
-induced	8	O
phosphorylation	15	O
of	2	O
I	1	B-Gene
kappa	5	I-Gene
B-alpha	7	I-Gene
on	2	O
Tyr42	5	B-Chemical
and	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
activation	10	O
,	1	O
we	2	O
observed	8	O
that	4	O
,	1	O
in	2	O
p56	3	B-Gene
(	1	O
lck	3	B-Gene
)	1	O
-deficient	10	O
Jurkat	6	O
mutants	7	O
,	1	O
NF-kappa	8	B-Gene
B	1	I-Gene
could	5	O
still	5	O
associate	9	O
with	4	O
I	1	B-Gene
kappa	5	I-Gene
B-alpha	7	I-Gene
despite	7	O
phosphorylation	15	O
on	2	O
Tyr42	5	B-Chemical
.	1	O

Furthermore	11	O
,	1	O
the	3	O
SH2	3	O
domain	6	O
of	2	O
p56	3	B-Gene
(	1	O
lck	3	B-Gene
)	1	O
appeared	8	O
to	2	O
be	2	O
required	8	O
for	3	O
pervanadate	11	B-Chemical
-induced	8	O
NF-kappa	8	B-Gene
B	1	I-Gene
activation	10	O
but	3	O
not	3	O
for	3	O
Tyr42	5	B-Chemical
phosphorylation	15	O
.	1	O

These	5	O
results	7	O
show	4	O
that	4	O
p56	3	B-Gene
(	1	O
lck	3	B-Gene
)	1	O
and	3	O
ZAP-70	6	B-Gene
are	3	O
key	3	O
components	10	O
of	2	O
the	3	O
signaling	9	O
pathway	7	O
that	4	O
leads	5	O
to	2	O
phosphotyrosine	15	B-Chemical
-dependent	10	O
NF-kappa	8	B-Gene
B	1	I-Gene
activation	10	O
in	2	O
T	1	O
cells	5	O
and	3	O
confirm	7	O
that	4	O
tyrosine	8	B-Gene
kinases	7	I-Gene
must	4	O
control	7	O
at	2	O
least	5	O
two	3	O
different	9	O
steps	5	O
to	2	O
induce	6	O
activation	10	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
.	1	O

Finally	7	O
,	1	O
we	2	O
show	4	O
that	4	O
H	1	O
(	1	O
2	1	O
)	1	O
O	1	O
(	1	O
2	1	O
)	1	O
,	1	O
which	5	O
stimulates	10	O
p56	3	B-Gene
(	1	O
lck	3	B-Gene
)	1	O
and	3	O
ZAP-70	6	B-Gene
in	2	O
T	1	O
cells	5	O
,	1	O
is	2	O
an	2	O
activator	9	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
through	7	O
tyrosine	8	B-Chemical
phosphorylation	15	O
of	2	O
I	1	B-Gene
kappa	5	I-Gene
B-alpha	7	I-Gene
.	1	O

CD28	4	B-Gene
and	3	O
T	1	O
cell	4	O
co-stimulation	14	O
.	1	O

Over	4	O
the	3	O
last	4	O
decade	6	O
the	3	O
concept	7	O
of	2	O
T	1	O
cell	4	O
co-stimulation	14	O
has	3	O
emerged	7	O
to	2	O
take	4	O
a	1	O
central	7	O
role	4	O
in	2	O
the	3	O
process	7	O
of	2	O
T	1	O
cell	4	O
activation	10	O
.	1	O

However	7	O
,	1	O
the	3	O
exact	5	O
definition	10	O
of	2	O
co-stimulation	14	O
is	2	O
still	5	O
unclear	7	O
.	1	O

In	2	O
this	4	O
review	6	O
,	1	O
we	2	O
re-examine	10	O
the	3	O
concept	7	O
of	2	O
co-stimulation	14	O
.	1	O

We	2	O
suggest	7	O
that	4	O
while	5	O
co-stimulation	14	O
is	2	O
important	9	O
,	1	O
there	5	O
is	2	O
little	6	O
evidence	8	O
to	2	O
link	4	O
co-stimulation	14	O
with	4	O
T	1	O
cell	4	O
anergy	6	O
.	1	O

We	2	O
then	4	O
suggest	7	O
a	1	O
framework	9	O
for	3	O
studying	8	O
co-stimulation	14	O
.	1	O

Focusing	8	O
on	2	O
recent	6	O
advances	8	O
in	2	O
our	3	O
understanding	13	O
of	2	O
CD28	4	B-Gene
,	1	O
we	2	O
discuss	7	O
four	4	O
areas	5	O
of	2	O
T	1	O
cell	4	O
activation	10	O
where	5	O
co-stimulation	14	O
may	3	O
play	4	O
a	1	O
role	4	O
.	1	O

Retinoic	8	B-Chemical
acid	4	I-Chemical
up-regulates	12	O
myeloid	7	B-Gene
ICAM-3	6	I-Gene
expression	10	O
and	3	O
function	8	O
in	2	O
a	1	O
cell-specific	13	O
fashion	7	O
--	2	O
evidence	8	O
for	3	O
retinoid	8	O
signaling	9	O
pathways	8	O
in	2	O
the	3	O
mast	4	O
cell	4	O
lineage	7	O
.	1	O

Investigation	13	O
of	2	O
mast	4	O
cell	4	O
responsiveness	14	O
toward	6	O
retinoic	8	B-Chemical
acid	4	I-Chemical
(	1	O
RA	2	B-Chemical
)	1	O
revealed	8	O
selective	9	O
promotion	9	O
of	2	O
ICAM-3	6	B-Gene
expression	10	O
in	2	O
the	3	O
human	5	O
mast	4	O
cell	4	O
line	4	O
HMC-1	5	O
.	1	O

This	4	O
process	7	O
was	3	O
dose-	5	O
and	3	O
time	4	O
-dependent	10	O
and	3	O
detectable	10	O
by	2	O
flow	4	O
cytometry	9	O
,	1	O
Western	7	O
blot	4	O
analysis	8	O
,	1	O
ELISA	5	O
,	1	O
and	3	O
Northern	8	O
blot	4	O
analysis	8	O
.	1	O

ICAM-3	6	B-Gene
modulation	10	O
was	3	O
found	5	O
to	2	O
be	2	O
cell-type	9	O
dependent	9	O
,	1	O
detectable	10	O
also	4	O
for	3	O
HL-60	5	O
cells	5	O
and	3	O
monocytes	9	O
but	3	O
not	3	O
U-937	5	O
and	3	O
only	4	O
weakly	6	O
for	3	O
KU812	5	O
cells	5	O
.	1	O

Terminally	10	O
differentiated	14	O
skin	4	O
mast	4	O
cells	5	O
also	4	O
failed	6	O
to	2	O
up-modulate	11	O
their	5	O
ICAM-3	6	B-Gene
,	1	O
suggesting	10	O
the	3	O
requirement	11	O
for	3	O
some	4	O
degree	6	O
of	2	O
immaturity	10	O
for	3	O
the	3	O
process	7	O
.	1	O

RA	2	B-Chemical
-mediated	9	O
effects	7	O
on	2	O
ICAM-1	6	B-Gene
expression	10	O
,	1	O
studied	7	O
in	2	O
parallel	8	O
,	1	O
were	4	O
clearly	7	O
distinct	8	O
from	4	O
those	5	O
on	2	O
ICAM-3	6	B-Gene
.	1	O

Investigation	13	O
of	2	O
retinoid	8	B-Gene
receptor	8	I-Gene
expression	10	O
,	1	O
known	5	O
to	2	O
mediate	7	O
intracellular	13	O
RA	2	B-Chemical
signaling	9	O
,	1	O
revealed	8	O
presence	8	O
of	2	O
RAR	3	B-Gene
alpha	5	I-Gene
,	1	O
RAR	3	B-Gene
gamma	5	I-Gene
,	1	O
RXR	3	B-Gene
beta	4	I-Gene
,	1	O
and	3	O
RXR	3	B-Gene
gamma	5	I-Gene
transcripts	11	O
in	2	O
all	3	O
cell	4	O
lines	5	O
studied	7	O
,	1	O
and	3	O
HMC-1	5	O
cells	5	O
were	4	O
the	3	O
only	4	O
line	4	O
lacking	7	O
RXR	3	B-Gene
alpha	5	I-Gene
.	1	O

RAR	3	B-Gene
beta	4	I-Gene
,	1	O
not	3	O
expressed	9	O
at	2	O
baseline	8	O
,	1	O
was	3	O
induced	7	O
by	2	O
RA	2	B-Chemical
in	2	O
a	1	O
fashion	7	O
obviously	9	O
correlating	11	O
with	4	O
ICAM-3	6	B-Gene
up-regulation	13	O
.	1	O

Increased	9	O
ICAM-3	6	B-Gene
expression	10	O
was	3	O
of	2	O
functional	10	O
significance	12	O
,	1	O
such	4	O
that	4	O
processes	9	O
stimulated	10	O
or	2	O
co	2	O
-stimulated	11	O
via	3	O
ICAM-3	6	B-Gene
(	1	O
homotypic	9	O
aggregation	11	O
,	1	O
IL-8	4	B-Gene
secretion	9	O
)	1	O
were	4	O
clearly	7	O
enhanced	8	O
upon	4	O
RA	2	B-Chemical
pretreatment	12	O
,	1	O
suggesting	10	O
that	4	O
RA	2	B-Chemical
may	3	O
contribute	10	O
via	3	O
hitherto	8	O
unrecognized	12	O
pathways	8	O
to	2	O
immune	6	O
function	8	O
and	3	O
host	4	O
defense	7	O
.	1	O

Specific	8	O
missense	8	O
mutations	9	O
in	2	O
NEMO	4	B-Gene
result	6	O
in	2	O
hyper-IgM	9	B-Disease
syndrome	8	I-Disease
with	4	O
hypohydrotic	12	B-Disease
ectodermal	10	I-Disease
dysplasia	9	I-Disease
.	1	O

The	3	O
gene	4	O
that	4	O
encodes	7	O
nuclear	7	B-Gene
factor	6	I-Gene
kappaB	6	I-Gene
(	1	I-Gene
NF-kappaB	9	I-Gene
)	1	I-Gene
essential	9	I-Gene
modulator	9	I-Gene
(	1	O
or	2	O
NEMO	4	B-Gene
,	1	O
also	4	O
known	5	O
as	2	O
IKKgamma	8	B-Gene
)	1	O
is	2	O
required	8	O
for	3	O
activation	10	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
NF-kappaB	9	I-Gene
.	1	O

We	2	O
describe	8	O
mutations	9	O
in	2	O
the	3	O
putative	8	O
zinc	4	O
-finger	7	O
domain	6	O
of	2	O
NEMO	4	B-Gene
that	4	O
result	6	O
in	2	O
an	2	O
X	1	B-Disease
-linked	7	I-Disease
primary	7	I-Disease
immunodeficiency	16	I-Disease
characterized	13	O
by	2	O
hyper-IgM	9	B-Disease
syndrome	8	I-Disease
and	3	O
hypohydrotic	12	B-Disease
ectodermal	10	I-Disease
dysplasia	9	I-Disease
(	1	O
XHM-ED	6	B-Disease
)	1	O
.	1	O

These	5	O
mutations	9	O
prevent	7	O
CD40	4	B-Gene
ligand	6	I-Gene
(	1	O
CD40L	5	B-Gene
)	1	O
-mediated	9	O
degradation	11	O
of	2	O
inhibitor	9	B-Gene
of	2	I-Gene
NF-kappaB	9	I-Gene
alpha	5	I-Gene
(	1	O
IkappaB-alpha	13	B-Gene
)	1	O
and	3	O
account	7	O
for	3	O
the	3	O
following	9	O
observations	12	O
:	1	O
B	1	O
cells	5	O
from	4	O
XHM-ED	6	B-Disease
patients	8	O
are	3	O
unable	6	O
to	2	O
undergo	7	O
immunoglobulin	14	B-Gene
class-switch	12	O
recombination	13	O
and	3	O
antigen	7	O
-presenting	11	O
cells	5	O
(	1	O
APCs	4	O
)	1	O
are	3	O
unable	6	O
to	2	O
synthesize	10	O
the	3	O
NF-kappaB	9	B-Gene
-regulated	10	O
cytokines	9	B-Gene
interleukin	11	I-Gene
12	2	I-Gene
(	1	O
IL-12	5	B-Gene
)	1	O
or	2	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
alpha	5	I-Gene
(	1	O
TNF-alpha	9	B-Gene
)	1	O
when	4	O
stimulated	10	O
with	4	O
CD40L	5	B-Gene
.	1	O

Nevertheless	12	O
,	1	O
innate	6	O
immunity	8	O
is	2	O
preserved	9	O
in	2	O
XHM-ED	6	B-Disease
patients	8	O
because	7	O
APCs	4	O
retain	6	O
the	3	O
capacity	8	O
to	2	O
respond	7	O
to	2	O
stimulation	11	O
by	2	O
lipopolysaccharide	18	B-Chemical
or	2	O
Staphylococcus	14	O
aureus	6	O
Cowan	5	O
's	2	O
antigen	7	O
(	1	O
SAC	3	O
)	1	O
.	1	O

Overall	7	O
,	1	O
the	3	O
phenotype	9	O
observed	8	O
in	2	O
XHM-ED	6	B-Disease
patients	8	O
shows	5	O
that	4	O
the	3	O
putative	8	O
zinc	4	O
-finger	7	O
domain	6	O
of	2	O
NEMO	4	B-Gene
has	3	O
a	1	O
regulatory	10	O
function	8	O
and	3	O
demonstrates	12	O
the	3	O
definite	8	O
requirement	11	O
of	2	O
CD40	4	B-Gene
-mediated	9	O
NF-kappaB	9	B-Gene
activation	10	O
for	3	O
B	1	B-Gene
cell	4	I-Gene
immunoglobulin	14	I-Gene
class	5	O
-switching	10	O
.	1	O

Regulation	10	O
of	2	O
the	3	O
helix-loop-helix	16	O
proteins	8	O
,	1	O
E2A	3	B-Gene
and	3	O
Id3	3	B-Gene
,	1	O
by	2	O
the	3	O
Ras	3	B-Gene
-	1	I-Gene
ERK	3	I-Gene
MAPK	4	I-Gene
cascade	7	O
.	1	O

Activation	10	O
of	2	O
mitogen	7	B-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
(	1	O
MAPK	4	B-Gene
)	1	O
pathways	8	O
leads	5	O
to	2	O
cellular	8	O
differentiation	15	O
and	3	O
/	1	O
or	2	O
proliferation	13	O
in	2	O
a	1	O
wide	4	O
variety	7	O
of	2	O
cell	4	O
types	5	O
,	1	O
including	9	O
developing	10	O
thymocytes	10	O
.	1	O

The	3	O
basic	5	B-Gene
helix-loop-helix	16	I-Gene
(	1	I-Gene
bHLH	4	I-Gene
)	1	I-Gene
proteins	8	I-Gene
E12	3	I-Gene
and	3	O
E47	3	B-Gene
and	3	O
an	2	O
inhibitor	9	O
HLH	3	O
protein	7	O
,	1	O
Id3	3	B-Gene
,	1	O
play	4	O
key	3	O
roles	5	O
in	2	O
thymocyte	9	O
differentiation	15	O
.	1	O

We	2	O
show	4	O
here	4	O
that	4	O
E2A	3	B-Gene
DNA	3	I-Gene
binding	7	O
is	2	O
lowered	7	O
in	2	O
primary	7	O
immature	8	O
thymocytes	10	O
consequent	10	O
to	2	O
T	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
(	1	O
TCR	3	B-Gene
)	1	O
-mediated	9	O
ligation	8	O
.	1	O

Whereas	7	O
expression	10	O
of	2	O
E2A	3	B-Gene
mRNA	4	I-Gene
and	3	O
protein	7	O
are	3	O
unaltered	9	O
,	1	O
Id3	3	B-Gene
transcripts	11	I-Gene
are	3	O
rapidly	7	O
induced	7	O
upon	4	O
signaling	9	O
from	4	O
the	3	O
TCR	3	B-Gene
.	1	O

Activation	10	O
of	2	O
Id3	3	B-Gene
transcription	13	O
is	2	O
regulated	9	O
in	2	O
a	1	O
dose	4	O
-dependent	10	O
manner	6	O
by	2	O
the	3	O
extracellular	13	B-Gene
signal	6	I-Gene
-regulated	10	I-Gene
kinase	6	I-Gene
(	1	I-Gene
ERK	3	I-Gene
)	1	I-Gene
MAPK	4	I-Gene
module	6	O
.	1	O

These	5	O
observations	12	O
directly	8	O
connect	7	O
the	3	O
ERK	3	B-Gene
MAPK	4	I-Gene
cascade	7	O
and	3	O
HLH	3	O
proteins	8	O
in	2	O
a	1	O
linear	6	O
pathway	7	O
.	1	O

Immunohistochemical	19	O
detection	9	O
of	2	O
interferon-gamma	16	B-Gene
-producing	10	O
cells	5	O
in	2	O
dermatophytosis	15	B-Disease
.	1	O

Skin	4	O
lesions	7	O
of	2	O
dermatophytosis	15	B-Disease
are	3	O
thought	7	O
to	2	O
be	2	O
a	1	O
result	6	O
of	2	O
a	1	O
T	1	O
cell	4	O
-dependent	10	O
inflammatory	12	O
response	8	O
that	4	O
is	2	O
mediated	8	O
by	2	O
various	7	O
cytokines	9	O
.	1	O

We	2	O
examined	8	O
whether	7	O
IFN-gamma	9	B-Gene
-positive	9	O
cells	5	O
(	1	O
as	2	O
expression	10	O
of	2	O
Th1	3	O
response	8	O
)	1	O
were	4	O
present	7	O
in	2	O
the	3	O
skin	4	O
lesions	7	O
of	2	O
dermatophytosis	15	B-Disease
in	2	O
situ	4	O
by	2	O
immunohistochemical	19	O
techniques	10	O
.	1	O

Mixtures	8	O
of	2	O
CD4	3	B-Gene
-positive	9	O
T	1	O
cells	5	O
and	3	O
CD8	3	B-Gene
-positive	9	O
T	1	O
cells	5	O
were	4	O
found	5	O
to	2	O
be	2	O
present	7	O
in	2	O
the	3	O
dermal	6	O
infiltrates	11	O
of	2	O
the	3	O
lesions	7	O
.	1	O

Considerable	12	O
numbers	7	O
of	2	O
CD1a	4	B-Gene
-positive	9	O
cells	5	O
were	4	O
detected	8	O
in	2	O
the	3	O
upper	5	O
dermis	6	O
and	3	O
epidermis	9	O
.	1	O

A	1	O
marked	6	O
accumulation	12	O
of	2	O
CD68	4	B-Gene
-positive	9	O
cells	5	O
was	3	O
found	5	O
in	2	O
the	3	O
upper	5	O
dermis	6	O
.	1	O

IFN-gamma	9	B-Gene
-positive	9	O
cells	5	O
were	4	O
present	7	O
in	2	O
the	3	O
upper	5	O
dermis	6	O
of	2	O
the	3	O
lesions	7	O
.	1	O

The	3	O
pattern	7	O
of	2	O
IFN-gamma	9	B-Gene
staining	8	O
appeared	8	O
to	2	O
be	2	O
intracellular	13	O
in	2	O
mononuclear	11	O
lymphoid	8	O
cells	5	O
.	1	O

The	3	O
staining	8	O
was	3	O
considered	10	O
to	2	O
be	2	O
highly	6	O
specific	8	O
because	7	O
it	2	O
could	5	O
be	2	O
completely	10	O
blocked	7	O
by	2	O
preabsorption	13	O
with	4	O
recombinant	11	B-Gene
IFN-gamma	9	I-Gene
.	1	O

Our	3	O
data	4	O
support	7	O
the	3	O
hypothesis	10	O
that	4	O
the	3	O
skin	4	O
lesions	7	O
of	2	O
dermatophytosis	15	B-Disease
may	3	O
be	2	O
associated	10	O
with	4	O
a	1	O
Th1	3	O
response	8	O
.	1	O

Th1	3	O
response	8	O
,	1	O
which	5	O
is	2	O
characterized	13	O
by	2	O
IFN-gamma	9	B-Gene
release	7	O
,	1	O
is	2	O
thought	7	O
to	2	O
be	2	O
involved	8	O
in	2	O
the	3	O
host	4	O
defense	7	O
against	7	O
dermatophytes	13	O
and	3	O
to	2	O
reflect	7	O
cutaneous	9	O
reaction	8	O
in	2	O
dermatophytosis	15	B-Disease
.	1	O

Decreased	9	O
expression	10	O
of	2	O
c-myc	5	B-Gene
family	6	I-Gene
genes	5	I-Gene
in	2	O
thymuses	8	O
from	4	O
myasthenia	10	B-Disease
gravis	6	I-Disease
patients	8	O
.	1	O

The	3	O
thymus	6	O
is	2	O
a	1	O
critical	8	O
organ	5	O
for	3	O
the	3	O
elimination	11	O
of	2	O
autoreactive	12	O
T	1	O
cells	5	O
by	2	O
apoptosis	9	O
.	1	O

We	2	O
studied	7	O
the	3	O
expression	10	O
of	2	O
apoptosis	9	O
-associated	11	O
genes	5	O
,	1	O
bcl-xL	6	B-Gene
,	1	O
bad	3	B-Gene
,	1	O
caspase-3	9	B-Gene
,	1	O
and	3	O
c-myc	5	B-Gene
family	6	I-Gene
genes	5	I-Gene
in	2	O
myasthenia	10	B-Disease
gravis	6	I-Disease
(	1	O
MG	2	B-Disease
)	1	O
thymuses	8	O
.	1	O

We	2	O
observed	8	O
that	4	O
the	3	O
mRNA	4	O
levels	6	O
of	2	O
myc	3	B-Gene
family	6	I-Gene
genes	5	I-Gene
,	1	O
c-myc	5	B-Gene
and	3	O
max	3	B-Gene
,	1	O
were	4	O
markedly	8	O
reduced	7	O
in	2	O
MG	2	B-Disease
thymuses	8	O
.	1	O

These	5	O
results	7	O
indicate	8	O
that	4	O
c-myc	5	B-Gene
-mediated	9	O
signaling	9	O
is	2	O
abnormal	8	O
in	2	O
MG	2	B-Disease
thymuses	8	O
.	1	O

The	3	O
levels	6	O
of	2	O
molecules	9	O
whose	5	O
expressions	11	O
are	3	O
associated	10	O
with	4	O
myc	3	B-Gene
,	1	O
such	4	O
as	2	O
STAM	4	B-Gene
,	1	O
prothymosin-alpha	17	B-Gene
,	1	O
and	3	O
NFkappaB	8	B-Gene

Expression	10	O
of	2	O
SART3	5	B-Gene
antigen	7	I-Gene
and	3	O
induction	9	O
of	2	O
CTLs	4	O
by	2	O
SART3	5	B-Gene
-derived	8	O
peptides	8	O
in	2	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
.	1	O

We	2	O
recently	8	O
reported	8	O
the	3	O
SART3	5	B-Gene
tumour-rejection	16	B-Disease
antigen	7	O
as	2	O
possessing	10	O
tumour	6	B-Disease
epitopes	8	O
capable	7	O
of	2	O
inducing	8	O
HLA-class	9	B-Gene
I	1	I-Gene
-restricted	11	O
cytotoxic	9	O
T	1	O
lymphocytes	11	O
(	1	O
CTLs	4	O
)	1	O
.	1	O

This	4	O
study	5	O
investigated	12	O
expression	10	O
of	2	O
the	3	O
SART3	5	B-Gene
antigen	7	I-Gene
in	2	O
breast	6	B-Disease
cancer	6	I-Disease
to	2	O
explore	7	O
an	2	O
appropriate	11	O
molecule	8	O
for	3	O
use	3	O
in	2	O
specific	8	O
immunotherapy	13	O
of	2	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
.	1	O

The	3	O
SART3	5	B-Gene
antigen	7	I-Gene
was	3	O
detected	8	O
in	2	O
all	3	O
of	2	O
the	3	O
breast	6	B-Disease
cancer	6	I-Disease
cell	4	O
lines	5	O
tested	6	O
,	1	O
30	2	O
of	2	O
40	2	O
(	1	O
75	2	O
%	1	O
)	1	O
breast	6	B-Disease
cancer	6	I-Disease
tissue	6	O
samples	7	O
,	1	O
and	3	O
0	1	O
of	2	O
3	1	O
non-tumourous	13	O
breast	6	O
tissue	6	O
samples	7	O
.	1	O

SART3	5	B-Gene
derived	7	O
peptides	8	O
at	2	O
positions	9	O
109-118	7	O
and	3	O
315-323	7	O
induced	7	O
HLA-A24	7	B-Gene
restricted	10	O
CTLs	4	O
that	4	O
reacted	7	O
to	2	O
breast	6	B-Disease
cancer	6	I-Disease
cells	5	O
from	4	O
the	3	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
(	1	O
PBMCs	5	O
)	1	O
of	2	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
.	1	O

Therefore	9	O
,	1	O
the	3	O
SART3	5	B-Gene
antigen	7	I-Gene
and	3	O
its	3	O
peptides	8	O
could	5	O
be	2	O
an	2	O
appropriate	11	O
molecule	8	O
for	3	O
use	3	O
in	2	O
specific	8	O
immunotherapy	13	O
of	2	O
the	3	O
majority	8	O
of	2	O
HLA-A24	7	B-Gene
-positive	9	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O

The	3	O
latency	7	O
pattern	7	O
of	2	O
Epstein-Barr	12	O
virus	5	O
infection	9	O
and	3	O
viral	5	B-Gene
IL-10	5	I-Gene
expression	10	O
in	2	O
cutaneous	9	O
natural	7	B-Disease
killer	6	I-Disease
/	1	I-Disease
T-cell	6	I-Disease
lymphomas	9	I-Disease
.	1	O

The	3	O
nasal	5	O
type	4	O
,	1	O
extranodal	10	O
natural	7	O
killer	6	O
or	2	O
T	1	B-Disease
(	1	I-Disease
NK	2	I-Disease
/	1	I-Disease
T	1	I-Disease
)	1	I-Disease
-cell	5	I-Disease
lymphoma	8	I-Disease
is	2	O
usually	7	O
associated	10	O
with	4	O
latent	6	O
Epstein-Barr	12	O
virus	5	O
(	1	O
EBV	3	O
)	1	O
infection	9	O
.	1	O

In	2	O
order	5	O
to	2	O
elucidate	9	O
the	3	O
EBV	3	O
gene	4	O
expression	10	O
patterns	8	O
in	2	O
vivo	4	O
,	1	O
we	2	O
examined	8	O
eight	5	O
patients	8	O
with	4	O
cutaneous	9	O
EBV	3	O
-related	8	O
NK	2	B-Disease
/	1	I-Disease
T-cell	6	I-Disease
lymphomas	9	I-Disease
,	1	O
including	9	O
six	3	O
patients	8	O
with	4	O
a	1	O
NK-cell	7	O
phenotype	9	O
and	3	O
two	3	O
patients	8	O
with	4	O
a	1	O
T-cell	6	O
phenotype	9	O
.	1	O

The	3	O
implication	11	O
of	2	O
EBV	3	O
in	2	O
the	3	O
skin	4	O
lesions	7	O
was	3	O
determined	10	O
by	2	O
the	3	O
presence	8	O
of	2	O
EBV-DNA	7	O
,	1	O
EBV	3	B-Gene
-encoded	8	I-Gene
nuclear	7	I-Gene
RNA	3	I-Gene
(	1	O
EBER	4	B-Gene
)	1	O
and	3	O
a	1	O
clonality	9	O
of	2	O
EBV-DNA	7	O
fragments	9	O
containing	10	O
the	3	O
terminal	8	O
repeats	7	O
.	1	O

Transcripts	11	O
of	2	O
EBV	3	O
-encoded	8	O
genes	5	O
were	4	O
screened	8	O
by	2	O
reverse	7	O
transcription-	14	O
polymerase	10	O
chain	5	O
reaction	8	O
(	1	O
RT-PCR	6	O
)	1	O
,	1	O
and	3	O
confirmed	9	O
by	2	O
Southern	8	O
blot	4	O
hybridization	13	O
.	1	O

The	3	O
expression	10	O
of	2	O
EBV	3	O
-related	8	O
antigens	8	O
was	3	O
examined	8	O
by	2	O
immunostaining	14	O
using	5	O
paraffin	8	B-Chemical
-embedded	9	O
tissue	6	O
sections	8	O
and	3	O
cell	4	O
pellets	7	O
of	2	O
EBV	3	O
-positive	9	O
cell	4	O
lines	5	O
.	1	O

Our	3	O
study	5	O
demonstrated	12	O
that	4	O
all	3	O
samples	7	O
from	4	O
the	3	O
patients	8	O
contained	9	O
EBV	3	B-Gene
nuclear	7	I-Gene
antigen	7	I-Gene
(	1	I-Gene
EBNA	4	I-Gene
)	1	I-Gene
-1	2	I-Gene
mRNA	4	I-Gene
which	5	O
was	3	O
transcribed	11	O
using	5	O
the	3	O
Q	1	O
promoter	8	O
,	1	O
whereas	7	O
both	4	O
the	3	O
Q	1	O
promoter	8	O
and	3	O
another	7	O
upstream	8	O
promoter	8	O
(	1	O
Cp	2	O
/	1	O
Wp	2	O
)	1	O
were	4	O
used	4	O
in	2	O
EBV	3	O
-positive	9	O
cell	4	O
lines	5	O
,	1	O
B95.8	5	O
,	1	O
Raji	4	O
and	3	O
Jiyoye	6	O
.	1	O

Latent	6	B-Gene
membrane	8	I-Gene
protein-1	9	I-Gene
(	1	I-Gene
LMP-1	5	I-Gene
)	1	I-Gene
mRNA	4	I-Gene
was	3	O
detected	8	O
in	2	O
seven	5	O
of	2	O
eight	5	O
patients	8	O
and	3	O
all	3	O
cell	4	O
lines	5	O
,	1	O
whereas	7	O
EBNA-2	6	B-Gene
transcripts	11	O
were	4	O
found	5	O
only	4	O
in	2	O
the	3	O
cell	4	O
lines	5	O
.	1	O

Immunostaining	14	O
showed	6	O
no	2	O
LMP-1	5	B-Gene
,	1	O
EBNA-2	6	B-Gene
or	2	O
ZEBRA	5	B-Gene
antigens	8	I-Gene
in	2	O
the	3	O
paraffin	8	B-Chemical
-embedded	9	O
tissue	6	O
sections	8	O
,	1	O
although	8	O
they	4	O
were	4	O
positive	8	O
in	2	O
the	3	O
cell	4	O
line	4	O
cells	5	O
.	1	O

Latent	6	O
BHRF1	5	B-Gene
transcripts	11	O
encoding	8	O
bcl-2	5	B-Gene
homologue	9	O
and	3	O
BCRF1	5	B-Gene
transcripts	11	O
encoding	8	O
viral	5	B-Gene
interleukin	11	I-Gene
(	1	I-Gene
vIL	3	I-Gene
)	1	I-Gene
-10	3	I-Gene
were	4	O
detected	8	O
in	2	O
one	3	O
and	3	O
two	3	O
of	2	O
eight	5	O
patients	8	O
,	1	O
respectively	12	O
.	1	O

A	1	O
patient	7	O
with	4	O
NK-cell	7	B-Disease
lymphoma	8	I-Disease
expressing	10	O
both	4	O
transcripts	11	O
died	4	O
of	2	O
rapid	5	O
progression	11	O
of	2	O
the	3	O
illness	7	O
.	1	O

Our	3	O
results	7	O
indicate	8	O
that	4	O
the	3	O
restricted	10	O
expression	10	O
of	2	O
the	3	O
latency	7	O
-associated	11	O
EBV	3	O
genes	5	O
and	3	O
the	3	O
production	10	O
of	2	O
vIL-10	6	B-Gene
and	3	O
bcl-2	5	B-Gene
homologue	9	O
may	3	O
favour	6	O
tumour	6	B-Disease
growth	6	O
,	1	O
evading	7	O
the	3	O
host	4	O
immune	6	O
surveillance	12	O
.	1	O

Copyright	9	O
2001	4	O
Cancer	6	B-Disease
Research	8	O
Campaign	8	O
.	1	O

Core	4	B-Gene
-binding	8	I-Gene
factor	6	I-Gene
beta	4	I-Gene
(	1	O
CBFbeta	7	B-Gene
)	1	O
,	1	O
but	3	O
not	3	O
CBFbeta-smooth	14	B-Gene
muscle	6	I-Gene
myosin	6	I-Gene
heavy	5	I-Gene
chain	5	I-Gene
,	1	O
rescues	7	O
definitive	10	O
hematopoiesis	13	O
in	2	O
CBFbeta	7	B-Gene
-deficient	10	O
embryonic	9	O
stem	4	O
cells	5	O
.	1	O

Core	4	B-Gene
-binding	8	I-Gene
factor	6	I-Gene
beta	4	I-Gene
(	1	O
CBFbeta	7	B-Gene
)	1	O
is	2	O
the	3	O
non-DNA	7	O
-binding	8	O
subunit	7	O
of	2	O
the	3	O
heterodimeric	13	O
CBFs	4	B-Gene
.	1	O

Genes	5	O
encoding	8	O
CBFbeta	7	B-Gene
(	1	O
CBFB	4	B-Gene
)	1	O
,	1	O
and	3	O
one	3	O
of	2	O
the	3	O
DNA	3	O
-binding	8	O
CBFalpha	8	B-Gene
subunits	8	I-Gene
,	1	O
Runx1	5	B-Gene
(	1	O
also	4	O
known	5	O
as	2	O
CBFalpha2	9	B-Gene
,	1	O
AML1	4	B-Gene
,	1	O
and	3	O
PEBP2alphaB	11	B-Gene
)	1	O
,	1	O
are	3	O
required	8	O
for	3	O
normal	6	O
hematopoiesis	13	O
and	3	O
are	3	O
also	4	O
frequent	8	O
targets	7	O
of	2	O
chromosomal	11	O
translocations	14	O
in	2	O
acute	5	B-Disease
leukemias	9	I-Disease
in	2	O
humans	6	O
.	1	O

Homozygous	10	O
disruption	10	O
of	2	O
either	6	O
the	3	O
Runx1	5	B-Gene
or	2	O
Cbfb	4	B-Gene
gene	4	I-Gene
in	2	O
mice	4	O
results	7	O
in	2	O
embryonic	9	O
lethality	9	O
at	2	O
midgestation	12	O
due	3	O
to	2	O
hemorrhaging	12	O
in	2	O
the	3	O
central	7	O
nervous	7	O
system	6	O
,	1	O
and	3	O
severely	8	O
impairs	7	O
fetal	5	O
liver	5	O
hematopoiesis	13	O
.	1	O

Results	7	O
of	2	O
this	4	O
study	5	O
show	4	O
that	4	O
Cbfb	4	B-Gene
-deficient	10	O
mouse	5	O
embryonic	9	O
stem	4	O
(	1	O
ES	2	O
)	1	O
cells	5	O
can	3	O
differentiate	13	O
into	4	O
primitive	9	O
erythroid	9	O
colonies	8	O
in	2	O
vitro	5	O
,	1	O
but	3	O
are	3	O
impaired	8	O
in	2	O
their	5	O
ability	7	O
to	2	O
produce	7	O
definitive	10	O
erythroid	9	O
and	3	O
myeloid	7	O
colonies	8	O
,	1	O
mimicking	9	O
the	3	O
in	2	O
vivo	4	O
defect	6	O
.	1	O

Definitive	10	O
hematopoiesis	13	O
is	2	O
restored	8	O
by	2	O
ectopic	7	O
expression	10	O
of	2	O
full-length	11	O
Cbfb	4	B-Gene
transgenes	10	I-Gene
,	1	O
as	2	O
well	4	O
as	2	O
by	2	O
a	1	O
transgene	9	O
encoding	8	O
only	4	O
the	3	O
heterodimerization	18	O
domain	6	O
of	2	O
CBFbeta	7	B-Gene
.	1	O

In	2	O
contrast	8	O
,	1	O
the	3	O
CBFbeta	7	B-Gene
-	1	I-Gene
smooth	6	I-Gene
muscle	6	I-Gene
myosin	6	I-Gene
heavy	5	I-Gene
chain	5	I-Gene
(	1	I-Gene
SMMHC	5	I-Gene
)	1	I-Gene
fusion	6	I-Gene
protein	7	I-Gene
generated	9	O
by	2	O
the	3	O
inv	3	O
(	1	O
16	2	O
)	1	O
associated	10	O
with	4	O
acute	5	B-Disease
myeloid	7	I-Disease
leukemias	9	I-Disease
(	1	O
M4Eo	4	O
)	1	O
can	3	O
not	3	O
rescue	6	O
definitive	10	O
hematopoiesis	13	O
by	2	O
Cbfb	4	B-Gene
-deficient	10	O
ES	2	O
cells	5	O
.	1	O

Sequences	9	O
responsible	11	O
for	3	O
the	3	O
inability	9	O
of	2	O
CBFbeta	7	B-Gene
-SMMHC	6	I-Gene
to	2	O
rescue	6	O
definitive	10	O
hematopoiesis	13	O
reside	6	O
in	2	O
the	3	O
SMMHC	5	B-Gene
portion	7	O
of	2	O
the	3	O
fusion	6	O
protein	7	O
.	1	O

Results	7	O
also	4	O
show	4	O
that	4	O
the	3	O
CBFbeta-SMMHC	13	B-Gene
fusion	6	I-Gene
protein	7	I-Gene
transdominantly	15	O
inhibits	8	O
definitive	10	O
hematopoiesis	13	O
,	1	O
but	3	O
not	3	O
to	2	O
the	3	O
same	4	O
extent	6	O
as	2	O
homozygous	10	O
loss	4	O
of	2	O
Runx1	5	B-Gene
or	2	O
Cbfb	4	B-Gene
.	1	O

CBFbeta-SMMHC	13	B-Gene
preferentially	14	O
inhibits	8	O
the	3	O
differentiation	15	O
of	2	O
myeloid	7	O
lineage	7	O
cells	5	O
,	1	O
while	5	O
increasing	10	O
the	3	O
number	6	O
of	2	O
blastlike	9	O
cells	5	O
in	2	O
culture	7	O
.	1	O

Analysis	8	O
of	2	O
BCL-6	5	B-Gene
mutations	9	O
in	2	O
classic	7	O
Hodgkin	7	B-Disease
disease	7	I-Disease
of	2	O
the	3	O
B-	2	O
and	3	O
T-cell	6	O
type	4	O
.	1	O

BCL-6	5	B-Gene
is	2	O
essential	9	O
for	3	O
germinal	8	O
center	6	O
formation	9	O
and	3	O
thus	4	O
for	3	O
affinity	8	O
maturation	10	O
of	2	O
immunoglobulin	14	B-Gene
(	1	I-Gene
Ig	2	I-Gene
)	1	I-Gene
genes	5	I-Gene
by	2	O
somatic	7	O
mutations	9	O
.	1	O

The	3	O
5'-noncoding	12	O
region	6	O
of	2	O
the	3	O
BCL-6	5	B-Gene
gene	4	I-Gene
is	2	O
even	4	O
a	1	O
target	6	O
for	3	O
the	3	O
mutation	8	O
machinery	9	O
.	1	O

Translocations	14	O
of	2	O
the	3	O
BCL-6	5	B-Gene
gene	4	I-Gene
to	2	O
heterologous	12	O
promoters	9	O
and	3	O
mutations	9	O
of	2	O
its	3	O
5'-noncoding	12	O
regulatory	10	O
region	6	O
were	4	O
reported	8	O
to	2	O
be	2	O
potential	9	O
mechanisms	10	O
for	3	O
deregulating	12	O
BCL-6	5	B-Gene
expression	10	O
and	3	O
for	3	O
playing	7	O
a	1	O
role	4	O
in	2	O
the	3	O
genesis	7	O
of	2	O
non-Hodgkin	11	B-Disease
lymphoma	8	I-Disease
.	1	O

In	2	O
line	4	O
with	4	O
this	4	O
hypothesis	10	O
is	2	O
the	3	O
observation	11	O
that	4	O
B-cell	6	B-Disease
lymphoma	8	I-Disease
with	4	O
somatic	7	O
mutations	9	O
,	1	O
such	4	O
as	2	O
diffuse	7	B-Disease
large	5	I-Disease
B-cell	6	I-Disease
lymphoma	8	I-Disease
and	3	O
follicular	10	B-Disease
lymphoma	8	I-Disease
,	1	O
also	4	O
carry	5	O
BCL-6	5	B-Gene
mutations	9	O
,	1	O
some	4	O
of	2	O
which	5	O
are	3	O
recurrently	11	O
detectable	10	O
.	1	O

Classic	7	O
Hodgkin	7	B-Disease
disease	7	I-Disease
(	1	O
cHD	3	B-Disease
)	1	O
is	2	O
also	4	O
derived	7	O
from	4	O
B	1	O
cells	5	O
with	4	O
high	4	O
loads	5	O
of	2	O
somatic	7	O
mutations	9	O
and	3	O
thus	4	O
a	1	O
further	7	O
candidate	9	O
for	3	O
BCL-6	5	B-Gene
mutations	9	O
.	1	O

To	2	O
determine	9	O
the	3	O
presence	8	O
and	3	O
potential	9	O
role	4	O
of	2	O
BCL-6	5	B-Gene
mutations	9	O
in	2	O
cHD	3	B-Disease
,	1	O
the	3	O
5'-noncoding	12	O
BCL-6	5	B-Gene
proportion	10	O
of	2	O
single	6	O
Hodgkin	7	O
and	3	O
Reed-Sternberg	14	O
(	1	O
HRS	3	O
)	1	O
cells	5	O
from	4	O
6	1	O
cases	5	O
of	2	O
cHD	3	B-Disease
and	3	O
6	1	O
cases	5	O
of	2	O
HD	2	B-Disease
-derived	8	O
cell	4	O
lines	5	O
was	3	O
analyzed	8	O
.	1	O

All	3	O
B-cell	6	O
-derived	8	O
HD	2	B-Disease
cases	5	O
and	3	O
cell	4	O
lines	5	O
harbored	8	O
BCL-6	5	B-Gene
mutations	9	O
.	1	O

In	2	O
contrast	8	O
,	1	O
both	4	O
T-cell	6	O
-derived	8	O
HD	2	B-Disease
cases	5	O
and	3	O
cell	4	O
lines	5	O
were	4	O
devoid	6	O
of	2	O
BCL-6	5	B-Gene
mutations	9	O
.	1	O

With	4	O
only	4	O
one	3	O
exception	9	O
,	1	O
there	5	O
were	4	O
no	2	O
lymphoma-specific	17	B-Disease
recurrent	9	O
BCL-6	5	B-Gene
mutations	9	O
detected	8	O
,	1	O
and	3	O
BCL-6	5	B-Gene
protein	7	I-Gene
was	3	O
absent	6	O
from	4	O
the	3	O
HRS	3	O
cells	5	O
of	2	O
most	4	O
cases	5	O
.	1	O

In	2	O
conclusion	10	O
,	1	O
(	1	O
1	1	O
)	1	O
somatic	7	O
BCL-6	5	B-Gene
mutations	9	O
are	3	O
restricted	10	O
to	2	O
cHD	3	B-Disease
cases	5	O
of	2	O
B-cell	6	O
origin	6	O
,	1	O
and	3	O
(	1	O
2	1	O
)	1	O
the	3	O
BCL-6	5	B-Gene
mutations	9	O
represent	9	O
mostly	6	O
irrelevant	10	O
somatic	7	O
base	4	O
substitutions	13	O
without	7	O
consequences	12	O
for	3	O
BCL-6	5	B-Gene
protein	7	I-Gene
expression	10	O
and	3	O
the	3	O
pathogenesis	12	O
of	2	O
cHD	3	B-Disease
.	1	O

Notch1	6	B-Gene
regulates	9	O
maturation	10	O
of	2	O
CD4+	4	B-Gene
and	3	O
CD8+	4	B-Gene
thymocytes	10	O
by	2	O
modulating	10	O
TCR	3	B-Gene
signal	6	O
strength	8	O
.	1	O

Notch	5	B-Gene
signaling	9	O
regulates	9	O
cell	4	O
fate	4	O
decisions	9	O
in	2	O
multiple	8	O
lineages	8	O
.	1	O

We	2	O
demonstrate	11	O
in	2	O
this	4	O
report	6	O
that	4	O
retroviral	10	O
expression	10	O
of	2	O
activated	9	O
Notch1	6	B-Gene
in	2	O
mouse	5	O
thymocytes	10	O
abrogates	9	O
differentiation	15	O
of	2	O
immature	8	O
CD4	3	B-Gene
+	1	I-Gene
CD8+	4	I-Gene
thymocytes	10	O
into	4	O
both	4	O
CD4	3	B-Gene
and	3	O
CD8	3	B-Gene
mature	6	O
single	6	O
-positive	9	O
T	1	O
cells	5	O
.	1	O

The	3	O
ability	7	O
of	2	O
Notch1	6	B-Gene
to	2	O
inhibit	7	O
T	1	O
cell	4	O
development	11	O
was	3	O
observed	8	O
in	2	O
vitro	5	O
and	3	O
in	2	O
vivo	4	O
with	4	O
both	4	O
normal	6	O
and	3	O
TCR	3	B-Gene
transgenic	10	O
thymocytes	10	O
.	1	O

Notch1	6	B-Gene
-mediated	9	O
developmental	13	O
arrest	6	O
was	3	O
dose	4	O
dependent	9	O
and	3	O
was	3	O
associated	10	O
with	4	O
impaired	8	O
thymocyte	9	O
responses	9	O
to	2	O
TCR	3	B-Gene
stimulation	11	O
.	1	O

Notch1	6	B-Gene
also	4	O
inhibited	9	O
TCR	3	B-Gene
-mediated	9	O
signaling	9	O
in	2	O
Jurkat	6	O
T	1	O
cells	5	O
.	1	O

These	5	O
data	4	O
indicate	8	O
that	4	O
constitutively	14	O
active	6	O
Notch1	6	B-Gene
abrogates	9	O
CD4+	4	B-Gene
and	3	O
CD8+	4	B-Gene
maturation	10	O
by	2	O
interfering	11	O
with	4	O
TCR	3	B-Gene
signal	6	O
strength	8	O
and	3	O
provide	7	O
an	2	O
explanation	11	O
for	3	O
the	3	O
physiological	13	O
regulation	10	O
of	2	O
Notch	5	B-Gene
expression	10	O
during	6	O
thymocyte	9	O
development	11	O
.	1	O

Suppression	11	O
of	2	O
lung	4	B-Disease
inflammation	12	I-Disease
in	2	O
rats	4	O
by	2	O
prevention	10	O
of	2	O
NF-kappaB	9	B-Gene
activation	10	O
in	2	O
the	3	O
liver	5	O
.	1	O

Activation	10	O
of	2	O
NF-kappaB	9	B-Gene
and	3	O
production	10	O
of	2	O
NF-kappaB	9	B-Gene
-dependent	10	I-Gene
chemokines	10	I-Gene
are	3	O
thought	7	O
to	2	O
be	2	O
involved	8	O
in	2	O
the	3	O
pathogenesis	12	O
of	2	O
neutrophilic	12	O
lung	4	B-Disease
inflammation	12	I-Disease
.	1	O

Calpain-1	9	B-Gene
inhibitor	9	I-Gene
(	1	O
CI-1	4	B-Gene
)	1	O
blocks	6	O
activation	10	O
of	2	O
NF-kappaB	9	B-Gene
by	2	O
preventing	10	O
proteolysis	11	O
of	2	O
the	3	O
inhibitory	10	B-Gene
protein	7	I-Gene
IkappaB-alpha	13	I-Gene
by	2	O
the	3	O
ubiquitin	9	B-Gene
/	1	O
proteasome	10	O
pathway	7	O
.	1	O

We	2	O
hypothesized	12	O
that	4	O
inhibition	10	O
of	2	O
proteasome	10	O
function	8	O
with	4	O
CI-1	4	B-Gene
would	5	O
block	5	O
NF-kappaB	9	B-Gene
activation	10	O
in	2	O
vivo	4	O
after	5	O
intraperitoneal	15	O
(	1	O
i.p.	4	O
)	1	O
treatment	9	O
with	4	O
bacterial	9	O
lipopolysaccharide	18	B-Chemical
(	1	O
LPS	3	B-Chemical
)	1	O
,	1	O
and	3	O
that	4	O
NF-kappaB	9	B-Gene
inhibition	10	O
would	5	O
be	2	O
associated	10	O
with	4	O
suppression	11	O
of	2	O
chemokine	9	O
gene	4	O
expression	10	O
and	3	O
attenuation	11	O
of	2	O
neutrophilic	12	O
alveolitis	10	B-Disease
.	1	O

We	2	O
treated	7	O
rats	4	O
with	4	O
a	1	O
single	6	O
i.p.	4	O
injection	9	O
of	2	O
CI-1	4	B-Gene
(	1	O
10	2	O
mg	2	O
/	1	O
kg	2	O
)	1	O
two	3	O
hours	5	O
prior	5	O
to	2	O
i.p	3	O
.	1	O

LPS	3	B-Chemical
(	1	O
7	1	O
mg	2	O
/	1	O
kg	2	O
)	1	O
.	1	O

Treatment	9	O
with	4	O
Cl-1	4	B-Gene
prevented	9	O
degradation	11	O
of	2	O
IkappaB-alpha	13	B-Gene
and	3	O
activation	10	O
of	2	O
NF-kappaB	9	B-Gene
in	2	O
the	3	O
liver	5	O
in	2	O
response	8	O
to	2	O
LPS	3	B-Chemical
;	1	O
however	7	O
,	1	O
Cl-1	4	B-Gene
treatment	9	O
had	3	O
no	2	O
detected	8	O
effect	6	O
on	2	O
NF-kappaB	9	B-Gene
activation	10	O
in	2	O
lung	4	O
tissue	6	O
.	1	O

CI-1	4	B-Gene
treatment	9	O
prior	5	O
to	2	O
LPS	3	B-Chemical
resulted	8	O
in	2	O
40	2	O
%	1	O
lower	5	O
MIP-2	5	B-Gene
concentration	13	O
in	2	O
lung	4	O
lavage	6	O
fluid	5	O
compared	8	O
to	2	O
rats	4	O
treated	7	O
with	4	O
vehicle	7	O
prior	5	O
to	2	O
LPS	3	B-Chemical
(	1	O
502	3	O
+	1	O
/	1	O
-	1	O
112	3	O
pg	2	O
/	1	O
ml	2	O
vs.	3	O
859	3	O
+	1	O
/	1	O
-144	4	O
pg	2	O
/	1	O
ml	2	O
,	1	O
P	1	O
<	1	O
0.05	4	O
)	1	O
.	1	O

In	2	O
addition	8	O
,	1	O
CI-1	4	B-Gene
treatment	9	O
substantially	13	O
inhibited	9	O
LPS	3	B-Chemical
-induced	8	O
neutrophilic	12	O
alveolitis	10	B-Disease
(	1	O
2.7+	4	O
/	1	O
-	1	O
1.2	3	O
x	1	O
10	2	O
(	1	O
5	1	O
)	1	O
vs.	3	O
43.7	4	O
+	1	O
/	1	O
-	1	O
12.2	4	O
x	1	O
10	2	O
(	1	O
5	1	O
)	1	O
lung	4	O
lavage	6	O
neutrophils	11	O
,	1	O
P	1	O
<	1	O
0.01	4	O
)	1	O
.	1	O

These	5	O
data	4	O
indicate	8	O
that	4	O
NF-kappaB	9	B-Gene
inhibition	10	O
in	2	O
the	3	O
liver	5	O
can	3	O
alter	5	O
lung	4	B-Disease
inflammation	12	I-Disease
induced	7	O
by	2	O
systemic	8	O
LPS	3	B-Chemical
treatment	9	O
and	3	O
suggest	7	O
that	4	O
a	1	O
liver-lung	10	O
interaction	11	O
contributes	11	O
to	2	O
the	3	O
inflammatory	12	O
response	8	O
of	2	O
the	3	O
lung	4	O
.	1	O

In	2	O
vivo	4	O
detection	9	O
of	2	O
intracellular	13	O
signaling	9	O
pathways	8	O
in	2	O
developing	10	O
thymocytes	10	O
.	1	O

Information	11	O
regarding	9	O
the	3	O
intracellular	13	O
signaling	9	O
processes	9	O
that	4	O
occur	5	O
during	6	O
the	3	O
development	11	O
of	2	O
T	1	O
cells	5	O
has	3	O
largely	7	O
been	4	O
obtained	8	O
with	4	O
the	3	O
use	3	O
of	2	O
transgenic	10	O
mouse	5	O
models	6	O
,	1	O
which	5	O
although	8	O
providing	9	O
invaluable	10	O
information	11	O
are	3	O
time	4	O
consuming	9	O
and	3	O
costly	6	O
.	1	O

To	2	O
this	4	O
end	3	O
,	1	O
we	2	O
have	4	O
developed	9	O
a	1	O
novel	5	O
system	6	O
that	4	O
facilitates	11	O
the	3	O
in	2	O
vivo	4	O
analysis	8	O
of	2	O
signal	6	O
transduction	12	O
pathways	8	O
during	6	O
T-lymphocyte	12	O
development	11	O
.	1	O

This	4	O
approach	8	O
uses	4	O
reporter-plasmids	17	O
for	3	O
the	3	O
detection	9	O
of	2	O
intracellular	13	O
signals	7	O
mediated	8	O
by	2	O
the	3	O
mitogen	7	B-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
or	2	O
cyclic	6	B-Gene
AMP	3	I-Gene
-dependent	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
.	1	O

Reporter-plasmids	17	O
are	3	O
transfected	11	O
into	4	O
thymocytes	10	O
in	2	O
fetal	5	O
thymic	6	O
organ	5	O
culture	7	O
by	2	O
accelerated	11	O
DNA	3	O
/	1	O
particle	8	O
bombardment	11	O
(	1	O
gene	4	O
gun	3	O
)	1	O
,	1	O
and	3	O
the	3	O
activation	10	O
of	2	O
a	1	O
signaling	9	O
pathway	7	O
is	2	O
determined	10	O
in	2	O
the	3	O
form	4	O
of	2	O
a	1	O
standard	8	O
luciferase	10	O
assay	5	O
.	1	O

Importantly	11	O
,	1	O
this	4	O
powerful	8	O
technique	9	O
preserves	9	O
the	3	O
structural	10	O
integrity	9	O
of	2	O
the	3	O
thymus	6	O
,	1	O
and	3	O
will	4	O
provide	7	O
an	2	O
invaluable	10	O
tool	4	O
to	2	O
study	5	O
how	3	O
thymocytes	10	O
respond	7	O
to	2	O
normal	6	O
environmental	13	O
stimuli	7	O
encountered	11	O
during	6	O
differentiation	15	O
within	6	O
the	3	O
thymic	6	O
milieu	6	O
.	1	O

Thus	4	O
,	1	O
this	4	O
method	6	O
allows	6	O
for	3	O
the	3	O
monitoring	10	O
of	2	O
signals	7	O
that	4	O
occur	5	O
in	2	O
a	1	O
biological	10	O
time	4	O
frame	5	O
,	1	O
such	4	O
as	2	O
during	6	O
differentiation	15	O
,	1	O
and	3	O
within	6	O
the	3	O
natural	7	O
environment	11	O
of	2	O
differentiating	15	O
cells	5	O
.	1	O

The	3	O
nuclear	7	B-Gene
receptor	8	I-Gene
PPAR	4	I-Gene
gamma	5	I-Gene
is	2	O
expressed	9	O
by	2	O
mouse	5	O
T	1	O
lymphocytes	11	O
and	3	O
PPAR	4	B-Gene
gamma	5	I-Gene
agonists	8	O
induce	6	O
apoptosis	9	O
.	1	O

Peroxisome	10	B-Gene
proliferator	12	I-Gene
-activated	10	I-Gene
receptor	8	I-Gene
(	1	I-Gene
PPAR	4	I-Gene
)	1	I-Gene
-gamma	6	I-Gene
is	2	O
a	1	O
nuclear	7	O
hormone	7	O
receptor	8	O
that	4	O
serves	6	O
as	2	O
a	1	O
trans	5	O
factor	6	O
to	2	O
regulate	8	O
lipid	5	B-Chemical
metabolism	10	O
.	1	O

Intense	7	O
interest	8	O
is	2	O
focused	7	O
on	2	O
PPAR-gamma	10	B-Gene
and	3	O
its	3	O
ligands	7	O
owing	5	O
to	2	O
its	3	O
putative	8	O
role	4	O
in	2	O
adipocyte	9	O
differentiation	15	O
.	1	O

Little	6	O
is	2	O
known	5	O
,	1	O
however	7	O
,	1	O
about	5	O
the	3	O
functions	9	O
of	2	O
PPAR-gamma	10	B-Gene
in	2	O
the	3	O
immune	6	O
system	6	O
,	1	O
especially	10	O
in	2	O
T	1	O
lymphocytes	11	O
.	1	O

We	2	O
demonstrate	11	O
that	4	O
both	4	O
naive	5	O
and	3	O
activated	9	O
ovalbumin-specific	18	B-Gene
T	1	O
cells	5	O
from	4	O
DO11.10-transgenic	18	O
mice	4	O
express	7	O
PPAR-gamma	10	B-Gene
mRNA	4	I-Gene
and	3	O
protein	7	O
.	1	O

In	2	O
order	5	O
to	2	O
determine	9	O
the	3	O
function	8	O
of	2	O
PPAR-gamma	10	B-Gene
,	1	O
T	1	O
cells	5	O
were	4	O
stimulated	10	O
with	4	O
phorbol	7	B-Chemical
12-myristate	12	I-Chemical
13-acetate	10	I-Chemical
and	3	O
ionomycin	9	B-Chemical
or	2	O
antigen	7	O
and	3	O
antigen	7	O
-presenting	11	O
cells	5	O
.	1	O

Simultaneous	12	O
exposure	8	O
to	2	O
PPAR-gamma	10	B-Gene
ligands	7	O
(	1	O
e.g.	4	O
15-deoxy-Delta	14	B-Chemical
(	1	I-Chemical
12	2	I-Chemical
,	1	I-Chemical
14	2	I-Chemical
)	1	I-Chemical
-prostaglandin	14	I-Chemical
J	1	I-Chemical
(	1	I-Chemical
2	1	I-Chemical
)	1	I-Chemical
,	1	O
troglitazone	12	B-Chemical
)	1	O
showed	6	O
drastic	7	O
inhibition	10	O
of	2	O
proliferation	13	O
and	3	O
significant	11	O
decreases	9	O
in	2	O
cell	4	O
viability	9	O
.	1	O

The	3	O
decrease	8	O
in	2	O
cell	4	O
viability	9	O
was	3	O
due	3	O
to	2	O
apoptosis	9	O
of	2	O
the	3	O
T	1	O
lymphocytes	11	O
,	1	O
and	3	O
occurred	8	O
only	4	O
when	4	O
cells	5	O
were	4	O
treated	7	O
with	4	O
PPAR-gamma	10	B-Gene
,	1	O
and	3	O
not	3	O
PPAR-alpha	10	B-Gene
agonists	8	I-Gene
,	1	O
revealing	9	O
specificity	11	O
of	2	O
this	4	O
response	8	O
for	3	O
PPAR-gamma	10	B-Gene
.	1	O

These	5	O
observations	12	O
suggest	7	O
that	4	O
PPAR-gamma	10	B-Gene
agonists	8	I-Gene
play	4	O
an	2	O
important	9	O
role	4	O
in	2	O
regulating	10	O
T	1	O
cell	4	O
-mediated	9	O
immune	6	O
responses	9	O
by	2	O
inducing	8	O
apoptosis	9	O
.	1	O

T	1	O
cell	4	O
death	5	O
via	3	O
PPAR-gamma	10	B-Gene
ligation	8	O
may	3	O
act	3	O
as	2	O
a	1	O
potent	6	O
anti-inflammatory	17	O
signal	6	O
in	2	O
the	3	O
immune	6	O
system	6	O
,	1	O
and	3	O
ligands	7	O
could	5	O
possibly	8	O
be	2	O
used	4	O
to	2	O
control	7	O
disorders	9	O
in	2	O
which	5	O
excessive	9	O
inflammation	12	O
occurs	6	O
.	1	O

T-cell	6	B-Gene
factor-1	8	I-Gene
expression	10	O
during	6	O
human	5	O
natural	7	O
killer	6	O
cell	4	O
development	11	O
and	3	O
in	2	O
circulating	11	O
CD56	4	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
bright	6	I-Gene
natural	7	O
killer	6	O
cells	5	O
.	1	O

Transcription	13	O
factors	7	O
are	3	O
essential	9	O
to	2	O
govern	6	O
differentiation	15	O
along	5	O
the	3	O
lymphoid	8	O
lineage	7	O
from	4	O
uncommitted	11	O
hematopoietic	13	O
stem	4	O
cells	5	O
.	1	O

Although	8	O
many	4	O
of	2	O
these	5	O
transcription	13	O
factors	7	O
have	4	O
putative	8	O
roles	5	O
based	5	O
on	2	O
murine	6	O
knockout	8	O
experiments	11	O
,	1	O
their	5	O
function	8	O
in	2	O
human	5	O
lymphoid	8	O
development	11	O
is	2	O
less	4	O
known	5	O
and	3	O
was	3	O
studied	7	O
further	7	O
.	1	O

Transcription	13	O
factor	6	O
expression	10	O
in	2	O
fresh	5	O
and	3	O
cultured	8	O
adult	5	O
human	5	O
bone	4	O
marrow	6	O
and	3	O
umbilical	9	O
cord	4	O
blood	5	O
progenitors	11	O
was	3	O
evaluated	9	O
.	1	O

We	2	O
found	5	O
that	4	O
fresh	5	O
CD34	4	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
Lin	3	O
(	1	O
-	1	O
)	1	O
cells	5	O
that	4	O
are	3	O
human	5	B-Gene
leukocyte	9	I-Gene
antigen	7	I-Gene
(	1	I-Gene
HLA	3	I-Gene
)	1	I-Gene
-DR	3	I-Gene
(	1	I-Gene
-	1	I-Gene
)	1	I-Gene
or	2	O
CD38	4	B-Gene
(	1	I-Gene
-	1	I-Gene
)	1	I-Gene
constitutively	14	O
express	7	O
GATA-3	6	B-Gene
but	3	O
not	3	O
T-cell	6	B-Gene
factor-1	8	I-Gene
(	1	O
TCF-1	5	B-Gene
)	1	O
or	2	O
Id-3	4	B-Gene
.	1	O

Culture	7	O
with	4	O
the	3	O
murine	6	O
fetal	5	O
liver	5	O
cell	4	O
line	4	O
AFT024	6	O
and	3	O
defined	7	O
cytokines	9	O
was	3	O
capable	7	O
of	2	O
inducing	8	O
TCF-1	5	B-Gene
mRNA	4	I-Gene
.	1	O

However	7	O
,	1	O
no	2	O
T-cell	6	B-Gene
receptor	8	I-Gene
gene	4	I-Gene
rearrangement	13	O
was	3	O
identified	10	O
in	2	O
cultured	8	O
progeny	7	O
.	1	O

Id-3	4	B-Gene
,	1	O
a	1	O
basic	5	O
helix	5	O
loop	4	O
helix	5	O
factor	6	O
with	4	O
dominant	8	O
negative	8	O
function	8	O
for	3	O
T-cell	6	O
differentiation	15	O
transcription	13	O
factors	7	O
,	1	O
also	4	O
was	3	O
upregulated	11	O
and	3	O
may	3	O
explain	7	O
unsuccessful	12	O
T-cell	6	O
maturation	10	O
.	1	O

To	2	O
better	6	O
understand	10	O
the	3	O
developmental	13	O
link	4	O
between	7	O
natural	7	O
killer	6	O
(	1	O
NK	2	O
)	1	O
cells	5	O
derived	7	O
from	4	O
progenitors	11	O
,	1	O
we	2	O
studied	7	O
NK	2	O
cell	4	O
subsets	7	O
circulating	11	O
in	2	O
blood	5	O
.	1	O

CD56	4	B-Gene
(	1	I-Gene
+bright	7	I-Gene
)	1	I-Gene
,	1	O
but	3	O
not	3	O
CD56	4	B-Gene
(	1	I-Gene
+dim	4	I-Gene
)	1	I-Gene
,	1	O
NK	2	O
cells	5	O
constitutively	14	O
express	7	O
TCF-1	5	B-Gene
by	2	O
reverse	7	O
transcriptase	13	O
polymerase	10	O
chain	5	O
reaction	8	O
and	3	O
Western	7	O
blot	4	O
analysis	8	O
.	1	O

The	3	O
TCF-1	5	B-Gene
isoform	7	I-Gene
found	5	O
in	2	O
CD56	4	B-Gene
(	1	I-Gene
+bright	7	I-Gene
)	1	I-Gene
cells	5	O
,	1	O
which	5	O
express	7	O
lectin	6	B-Gene
but	3	O
not	3	O
immunoglobulin	14	B-Gene
class	5	I-Gene
I	1	I-Gene
recognizing	11	O
inhibitory	10	O
receptors	9	O
,	1	O
was	3	O
identical	9	O
to	2	O
that	4	O
induced	7	O
in	2	O
NK	2	O
cell	4	O
differentiation	15	O
culture	7	O
and	3	O
was	3	O
distinctly	10	O
different	9	O
from	4	O
isoforms	8	O
in	2	O
T	1	O
cells	5	O
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
TCF-1	5	B-Gene
does	4	O
not	3	O
target	6	O
human	5	B-Gene
killer	6	I-Gene
immunoglobulin	14	I-Gene
receptor	8	I-Gene
genes	5	I-Gene
,	1	O
TCF-1	5	B-Gene
is	2	O
uniquely	8	O
expressed	9	O
in	2	O
circulating	11	O
CD56	4	B-Gene
(	1	I-Gene
+bright	7	I-Gene
)	1	I-Gene
NK	2	O
cells	5	O
,	1	O
and	3	O
specific	8	O
TCF-1	5	B-Gene
isoforms	8	I-Gene
may	3	O
play	4	O
an	2	O
important	9	O
role	4	O
in	2	O
regulating	10	O
NK	2	O
differentiation	15	O
from	4	O
a	1	O
common	6	O
NK	2	O
/	1	O
T-cell	6	O
progenitor	10	O
.	1	O

Benzene	7	B-Chemical
-extracted	10	O
components	10	O
are	3	O
important	9	O
for	3	O
the	3	O
major	5	O
activity	8	O
of	2	O
diesel	6	O
exhaust	7	O
particles	9	O
:	1	O
effect	6	O
on	2	O
interleukin-8	13	B-Gene
gene	4	I-Gene
expression	10	O
in	2	O
human	5	O
bronchial	9	O
epithelial	10	O
cells	5	O
.	1	O

Epidemiologic	13	O
and	3	O
experimental	12	O
studies	7	O
suggest	7	O
that	4	O
diesel	6	O
exhaust	7	O
particles	9	O
(	1	O
DEPs	4	O
)	1	O
may	3	O
be	2	O
related	7	O
to	2	O
increasing	10	O
respiratory	11	O
mortality	9	O
and	3	O
morbidity	9	O
.	1	O

We	2	O
have	4	O
shown	5	O
that	4	O
DEPs	4	O
augmented	9	O
the	3	O
production	10	O
of	2	O
inflammatory	12	O
cytokines	9	O
by	2	O
human	5	O
airway	6	O
epithelial	10	O
cells	5	O
in	2	O
vitro	5	O
.	1	O

To	2	O
better	6	O
understand	10	O
the	3	O
mechanisms	10	O
of	2	O
their	5	O
proinflammatory	15	O
activities	10	O
,	1	O
we	2	O
studied	7	O
the	3	O
effects	7	O
of	2	O
several	7	O
components	10	O
extracted	9	O
from	4	O
DEPs	4	O
on	2	O
interleukin	11	B-Gene
(	1	I-Gene
IL	2	I-Gene
)	1	I-Gene
-8	2	I-Gene
expression	10	O
in	2	O
human	5	O
bronchial	9	O
epithelial	10	O
cell	4	O
line	4	O
BEAS-2B	7	O
and	3	O
normal	6	O
human	5	O
airway	6	O
epithelial	10	O
cells	5	O
obtained	8	O
from	4	O
very	4	O
peripheral	10	O
airways	7	O
by	2	O
an	2	O
ultrathin	9	O
bronchoscope	12	O
.	1	O

We	2	O
used	4	O
several	7	O
agents	6	O
active	6	O
on	2	O
signal	6	O
transduction	12	O
pathways	8	O
in	2	O
cytokine	8	O
expression	10	O
,	1	O
such	4	O
as	2	O
the	3	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
inhibitor	9	O
staurosporin	12	B-Chemical
,	1	O
antioxidant	11	O
agents	6	O
including	9	O
N-acetyl	8	B-Chemical
cysteine	8	I-Chemical
(	1	O
NAC	3	B-Chemical
)	1	O
and	3	O
pyrrolidine	11	B-Chemical
dithiocarbamate	15	I-Chemical
(	1	O
PDTC	4	B-Chemical
)	1	O
,	1	O
and	3	O
p38	3	B-Gene
mitogen	7	I-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
(	1	O
MAPK	4	B-Gene
)	1	O
inhibitor	9	O
SB203580	8	B-Chemical
.	1	O

Benzene	7	B-Chemical
-extracted	10	O
components	10	O
showed	6	O
effects	7	O
mimicking	9	O
DEPs	4	O
on	2	O
IL-8	4	B-Gene
gene	4	I-Gene
expression	10	O
,	1	O
release	7	O
of	2	O
several	7	O
cytokines	9	O
(	1	O
IL-8	4	B-Gene
;	1	O
granulocyte	11	B-Gene
macrophage	10	I-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
;	1	O
and	3	O
regulated	9	B-Gene
on	2	I-Gene
activation	10	I-Gene
,	1	I-Gene
normal	6	I-Gene
T	1	I-Gene
cells	5	I-Gene
expressed	9	I-Gene
and	3	I-Gene
secreted	8	I-Gene
)	1	O
and	3	O
nuclear	7	B-Gene
factor	6	I-Gene
(	1	I-Gene
NF	2	I-Gene
)	1	I-Gene
-kappa	6	I-Gene
B	1	I-Gene
activation	10	O
.	1	O

We	2	O
also	4	O
found	5	O
that	4	O
NAC	3	B-Chemical
,	1	O
PDTC	4	B-Chemical
,	1	O
and	3	O
SB203580	8	B-Chemical
suppressed	10	O
the	3	O
activities	10	O
of	2	O
DEPs	4	O
and	3	O
their	5	O
benzene	7	B-Chemical
extracts	8	O
,	1	O
suggesting	10	O
the	3	O
roles	5	O
of	2	O
oxidants	8	O
-mediated	9	O
NF-kappa	8	B-Gene
B	1	I-Gene
activation	10	O
and	3	O
p38MAPK	7	B-Gene
pathways	8	O
.	1	O

Finally	7	O
,	1	O
benzo	5	B-Chemical
[	1	I-Chemical
a	1	I-Chemical
]	1	I-Chemical
pyrene	6	I-Chemical
,	1	O
one	3	O
of	2	O
the	3	O
important	9	O
compounds	9	O
included	8	O
in	2	O
the	3	O
benzene	7	B-Chemical
component	9	O
,	1	O
replicated	10	O
the	3	O
activities	10	O
shown	5	O
by	2	O
DEPs	4	O
.	1	O

Regulation	10	O
of	2	O
cytokine	8	O
production	10	O
in	2	O
T-cell	6	O
responses	9	O
to	2	O
inhalant	8	O
allergen	8	O
:	1	O
GATA-3	6	B-Gene
expression	10	O
distinguishes	13	O
between	7	O
Th1-	4	O
and	3	O
Th2	3	O
-polarized	10	O
immunity	8	O
.	1	O

BACKGROUND	10	O
:	1	O
The	3	O
precise	7	O
nature	6	O
of	2	O
allergen-specific	17	O
cytokine	8	O
responses	9	O
in	2	O
atopics	7	O
versus	6	O
non-atopics	11	O
,	1	O
in	2	O
particular	10	O
the	3	O
'Th1	4	O
polarity	8	O
'of	3	O
responses	9	O
in	2	O
non-atopics	11	O
,	1	O
remains	7	O
controversial	13	O
.	1	O

This	4	O
is	2	O
due	3	O
in	2	O
part	4	O
to	2	O
the	3	O
relative	8	O
insensitivity	13	O
of	2	O
cytokine	8	O
detection	9	O
systems	7	O
,	1	O
and	3	O
associated	10	O
variations	10	O
in	2	O
kinetics	8	O
of	2	O
cytokine	8	O
production	10	O
and	3	O
catabolism	10	O
in	2	O
in	2	O
vitro	5	O
culture	7	O
systems	7	O
.	1	O

As	2	O
an	2	O
alternative	11	O
to	2	O
cytokine	8	O
measurement	11	O
,	1	O
this	4	O
study	5	O
focuses	7	O
on	2	O
expression	10	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
GATA-3	6	I-Gene
for	3	O
analysis	8	O
of	2	O
allergen-specific	17	O
Th	2	O
cell	4	O
responses	9	O
.	1	O

METHODS	7	O
:	1	O
Cord	4	O
blood	5	O
mononuclear	11	O
cells	5	O
were	4	O
Th1-	4	O
or	2	O
Th2	3	O
-polarized	10	O
by	2	O
culture	7	O
in	2	O
IL-12-	6	B-Gene
or	2	O
IL-4	4	B-Gene
-employing	10	O
established	11	O
methods	7	O
;	1	O
PBMC	4	O
from	4	O
house	5	O
dust	4	O
mite	4	O
(	1	O
HDM	3	O
)	1	O
-sensitive	10	O
atopics	7	O
and	3	O
controls	8	O
were	4	O
stimulated	10	O
overnight	9	O
with	4	O
HDM	3	O
;	1	O
cytokine	8	O
production	10	O
was	3	O
measured	8	O
by	2	O
ELISA	5	O
and	3	O
GATA-3	6	B-Gene
mRNA	4	I-Gene
expression	10	O
by	2	O
PCR	3	O
.	1	O

RESULTS	7	O
:	1	O
Cytokine	8	O
-driven	7	O
Th2	3	O
polarization	12	O
of	2	O
naive	5	O
T	1	O
cells	5	O
is	2	O
associated	10	O
with	4	O
marked	6	O
upregulation	12	O
of	2	O
GATA-3	6	B-Gene
expression	10	O
,	1	O
whereas	7	O
a	1	O
reciprocal	10	O
expression	10	O
pattern	7	O
accompanies	11	O
differentiation	15	O
towards	7	O
the	3	O
Th1	3	O
cytokine	8	O
phenotype	9	O
.	1	O

In	2	O
T	1	O
cells	5	O
from	4	O
HDM	3	O
skin	4	O
prick	5	O
test	4	O
-positive	9	O
(	1	O
HDM-SPT+	8	O
/	1	O
HDM-IgE+	8	B-Gene
)	1	O
volunteers	10	O
,	1	O
overnight	9	O
stimulation	11	O
results	7	O
in	2	O
marked	6	O
upregulation	12	O
of	2	O
GATA-3	6	B-Gene
expression	10	O
,	1	O
compared	8	O
to	2	O
an	2	O
equally	7	O
marked	6	O
downregulation	14	O
of	2	O
expression	10	O
in	2	O
T	1	O
cells	5	O
from	4	O
SPT-	4	O
/	1	O
IgE-	4	B-Gene
subjects	8	O
.	1	O

In	2	O
subjects	8	O
who	3	O
are	3	O
HDM-SPT+	8	O
but	3	O
IgE-	4	B-Gene
,	1	O
GATA-3	6	B-Gene
expression	10	O
levels	6	O
remained	8	O
relatively	10	O
stable	6	O
during	6	O
culture	7	O
with	4	O
HDM	3	O
.	1	O

CONCLUSIONS	11	O
:	1	O
Upregulation	12	O
of	2	O
GATA-3	6	B-Gene
expression	10	O
in	2	O
PBMC	4	O
is	2	O
a	1	O
hallmark	8	O
of	2	O
the	3	O
early	5	O
phase	5	O
of	2	O
Th2	3	O
recall	6	O
responses	9	O
to	2	O
specific	8	O
allergen	8	O
in	2	O
atopics	7	O
.	1	O

The	3	O
reciprocal	10	O
expression	10	O
pattern	7	O
observed	8	O
in	2	O
HDM-specific	12	O
recall	6	O
responses	9	O
of	2	O
non-atopics	11	O
provides	8	O
independent	11	O
confirmation	12	O
of	2	O
the	3	O
presence	8	O
of	2	O
underlying	10	O
Th1	3	O
-like	5	O
immunity	8	O
in	2	O
these	5	O
subjects	8	O
.	1	O

The	3	O
parallel	8	O
findings	8	O
in	2	O
neonatal	8	O
T	1	O
cells	5	O
suggest	7	O
that	4	O
the	3	O
same	4	O
approach	8	O
may	3	O
be	2	O
utilized	8	O
for	3	O
monitoring	10	O
the	3	O
progress	8	O
of	2	O
allergen-specific	17	O
Th1	3	O
/	1	O
Th2	3	O
memory	6	O
development	11	O
during	6	O
early	5	O
childhood	9	O
,	1	O
and	3	O
hence	5	O
in	2	O
assessment	10	O
of	2	O
risk	4	O
for	3	O
future	6	O
allergic	8	O
disease	7	O
.	1	O

Copyright	9	O
2001	4	O
S	1	O
.	1	O

Karger	6	O
AG	2	O
,	1	O
Basel	5	O

Tumor	5	B-Disease
cells	5	O
regulate	8	O
the	3	O
lytic	5	O
activity	8	O
of	2	O
tumor-specific	14	B-Disease
cytotoxic	9	O
t	1	O
lymphocytes	11	O
by	2	O
modulating	10	O
the	3	O
inhibitory	10	O
natural	7	O
killer	6	O
receptor	8	O
function	8	O
.	1	O

Tumor	5	B-Disease
-infiltrating	13	O
p58+	4	B-Gene
T	1	O
cells	5	O
from	4	O
a	1	O
renal	5	B-Disease
tumor	5	I-Disease
were	4	O
specifically	12	O
expanded	8	O
in	2	O
response	8	O
to	2	O
tumor	5	B-Disease
cell	4	O
stimulation	11	O
and	3	O
cloned	6	O
.	1	O

These	5	O
p58+	4	B-Gene
T	1	O
cells	5	O
were	4	O
found	5	O
to	2	O
express	7	O
a	1	O
memory	6	O
phenotype	9	O
and	3	O
corresponded	12	O
to	2	O
clonal	6	O
TCRBV3	6	O
T-cell	6	O
expansion	9	O
.	1	O

Functionally	12	O
,	1	O
p58	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
CTLs	4	O
displayed	9	O
a	1	O
low	3	O
lytic	5	O
activity	8	O
for	3	O
HLA-A2	6	B-Gene
tumor	5	B-Disease
and	3	O
normal	6	O
cells	5	O
.	1	O

However	7	O
,	1	O
this	4	O
lytic	5	O
activity	8	O
was	3	O
significantly	13	O
increased	9	O
after	5	O
blockade	8	O
of	2	O
p58	3	B-Gene
with	4	O
specific	8	O
monoclonal	10	O
antibodies	10	O
.	1	O

Interestingly	13	O
,	1	O
we	2	O
demonstrated	12	O
that	4	O
stimulation	11	O
by	2	O
tumor	5	B-Disease
cells	5	O
was	3	O
required	8	O
to	2	O
trigger	7	O
the	3	O
inhibitory	10	O
effect	6	O
of	2	O
p58	3	B-Gene
on	2	O
the	3	O
lytic	5	O
activity	8	O
of	2	O
antigen-specific	16	O
CTLs	4	O
and	3	O
that	4	O
stimulation	11	O
of	2	O
the	3	O
inhibitory	10	O
function	8	O
of	2	O
p58	3	B-Gene
by	2	O
tumor	5	B-Disease
cells	5	O
correlated	10	O
with	4	O
an	2	O
inhibition	10	O
of	2	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
activation	10	O
in	2	O
p58+	4	B-Gene
tumor-specific	14	B-Disease
CTLS	4	O
.	1	O

The	3	O
heat	4	O
shock	5	O
response	8	O
reduces	7	O
myelin	6	B-Gene
oligodendrocyte	15	I-Gene
glycoprotein	12	I-Gene
-induced	8	O
experimental	12	B-Disease
autoimmune	10	I-Disease
encephalomyelitis	17	I-Disease
in	2	O
mice	4	O
.	1	O

The	3	O
stress	6	O
response	8	O
(	1	O
SR	2	O
)	1	O
can	3	O
block	5	O
inflammatory	12	O
gene	4	O
expression	10	O
by	2	O
preventing	10	O
activation	10	O
of	2	O
transcription	13	B-Gene
factor	6	I-Gene
nuclear	7	I-Gene
factor-kappa	12	I-Gene
B	1	I-Gene
(	1	O
NF-kappaB	9	B-Gene
)	1	O
.	1	O

As	2	O
inflammatory	12	O
gene	4	O
expression	10	O
contributes	11	O
to	2	O
the	3	O
pathogenesis	12	O
of	2	O
demyelinating	13	B-Disease
diseases	8	I-Disease
,	1	O
we	2	O
tested	6	O
the	3	O
effects	7	O
of	2	O
the	3	O
SR	2	O
on	2	O
the	3	O
progression	11	O
of	2	O
the	3	O
demyelinating	13	B-Disease
disease	7	I-Disease
experimental	12	B-Disease
autoimmune	10	I-Disease
encephalomyelitis	17	I-Disease
(	1	O
EAE	3	B-Disease
)	1	O
.	1	O

EAE	3	B-Disease
was	3	O
actively	8	O
induced	7	O
in	2	O
C57BL	5	O
/	1	O
6	1	O
mice	4	O
using	5	O
an	2	O
encephalitogenic	16	O
myelin	6	B-Gene
oligodendrocyte	15	I-Gene
glycoprotein	12	I-Gene
(	1	O
MOG	3	B-Gene
(	1	O
35-55	5	O
)	1	O
)	1	O
peptide	7	O
.	1	O

Whole	5	O
body	4	O
hyperthermia	12	O
was	3	O
used	4	O
to	2	O
induce	6	O
a	1	O
heat	4	O
shock	5	O
response	8	O
(	1	O
HSR	3	O
)	1	O
in	2	O
immunized	9	O
mice	4	O
2	1	O
days	4	O
after	5	O
the	3	O
booster	7	O
MOG	3	B-Gene
(	1	O
35-55	5	O
)	1	O
peptide	7	O
injection	9	O
.	1	O

The	3	O
HSR	3	O
reduced	7	O
the	3	O
incidence	9	O
of	2	O
EAE	3	B-Disease
by	2	O
70	2	O
%	1	O
,	1	O
delayed	7	O
disease	7	O
onset	5	O
by	2	O
6	1	O
days	4	O
,	1	O
and	3	O
attenuated	10	O
disease	7	O
severity	8	O
.	1	O

The	3	O
HSR	3	O
attenuated	10	O
leukocyte	9	O
infiltration	12	O
into	4	O
CNS	3	O
assessed	8	O
by	2	O
quantitation	12	O
of	2	O
perivascular	12	O
infiltrates	11	O
,	1	O
and	3	O
by	2	O
reduced	7	O
staining	8	O
for	3	O
CD4	3	B-Gene
and	3	O
CD25	4	B-Gene
immunopositive	14	O
T-cells	7	O
.	1	O

T-cell	6	O
activation	10	O
,	1	O
assessed	8	O
by	2	O
the	3	O
production	10	O
of	2	O
interferon	10	B-Gene
gamma	5	I-Gene
(	1	O
IFNgamma	8	B-Gene
)	1	O
in	2	O
response	8	O
to	2	O
MOG	3	B-Gene
(	1	O
35-55	5	O
)	1	O
,	1	O
was	3	O
also	4	O
decreased	9	O
by	2	O
the	3	O
HSR	3	O
.	1	O

The	3	O
HSR	3	O
reduced	7	O
inflammatory	12	O
gene	4	O
expression	10	O
in	2	O
the	3	O
brain	5	O
that	4	O
normally	8	O
occurs	6	O
during	6	O
EAE	3	B-Disease
,	1	O
including	9	O
the	3	O
early	5	O
increase	8	O
in	2	O
RANTES	6	O
(	1	O
regulated	9	O
on	2	O
activation	10	O
of	2	O
normal	6	O
T-cell	6	O
expressed	9	O
and	3	O
secreted	8	O
)	1	O
expression	10	O
,	1	O
and	3	O
the	3	O
later	5	O
expression	10	O
of	2	O
the	3	O
inducible	9	O
form	4	O
of	2	O
nitric	6	B-Gene
oxide	5	I-Gene
synthase	8	I-Gene
.	1	O

The	3	O
early	5	O
activation	10	O
of	2	O
transcription	13	B-Gene
factor	6	I-Gene
NF-kappaB	9	I-Gene
was	3	O
also	4	O
blocked	7	O
by	2	O
the	3	O
HSR	3	O
.	1	O

The	3	O
finding	7	O
that	4	O
the	3	O
SR	2	O
reduces	7	O
inflammation	12	O
in	2	O
the	3	O
brain	5	O
and	3	O
the	3	O
clinical	8	O
severity	8	O
of	2	O
EAE	3	B-Disease
opens	5	O
a	1	O
novel	5	O
therapeutic	11	O
approach	8	O
for	3	O
prevention	10	O
of	2	O
autoimmune	10	B-Disease
diseases	8	I-Disease
.	1	O

Differential	12	O
requirement	11	O
for	3	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
PU.1	4	I-Gene
in	2	O
the	3	O
generation	10	O
of	2	O
natural	7	O
killer	6	O
cells	5	O
versus	6	O
B	1	O
and	3	O
T	1	O
cells	5	O
.	1	O

PU.1	4	B-Gene
is	2	O
a	1	O
member	6	O
of	2	O
the	3	O
Ets	3	B-Gene
family	6	I-Gene
of	2	O
transcription	13	O
factors	7	O
required	8	O
for	3	O
the	3	O
development	11	O
of	2	O
various	7	O
lymphoid	8	O
and	3	O
myeloid	7	O
cell	4	O
lineages	8	O
,	1	O
but	3	O
its	3	O
role	4	O
in	2	O
natural	7	O
killer	6	O
(	1	O
NK	2	O
)	1	O
cell	4	O
development	11	O
is	2	O
not	3	O
known	5	O
.	1	O

The	3	O
study	5	O
shows	5	O
that	4	O
PU.1	4	B-Gene
is	2	O
expressed	9	O
in	2	O
NK	2	O
cells	5	O
and	3	O
that	4	O
,	1	O
on	2	O
cell	4	O
transfer	8	O
into	4	O
alymphoid	9	O
Rag2	4	B-Gene
/	1	O
gammac	6	O
(	1	O
-	1	O
/	1	O
-	1	O
)	1	O
mice	4	O
,	1	O
hematopoietic	13	O
progenitors	11	O
of	2	O
PU.1	4	B-Gene
(	1	I-Gene
-	1	I-Gene
/	1	I-Gene
-	1	I-Gene
)	1	I-Gene
fetal	5	O
liver	5	O
cells	5	O
could	5	O
generate	8	O
functional	10	O
NK	2	O
cells	5	O
but	3	O
not	3	O
B	1	O
or	2	O
T	1	O
cells	5	O
.	1	O

Nevertheless	12	O
,	1	O
the	3	O
numbers	7	O
of	2	O
bone	4	O
marrow	6	O
NK	2	O
cell	4	O
precursors	10	O
and	3	O
splenic	7	O
mature	6	O
NK	2	O
cells	5	O
were	4	O
reduced	7	O
compared	8	O
to	2	O
controls	8	O
.	1	O

Moreover	8	O
,	1	O
PU.1	4	B-Gene
(	1	I-Gene
-	1	I-Gene
/	1	I-Gene
-	1	I-Gene
)	1	I-Gene
NK	2	O
cells	5	O
displayed	9	O
reduced	7	O
expression	10	O
of	2	O
the	3	O
receptors	9	O
for	3	O
stem	4	B-Gene
cell	4	I-Gene
factor	6	I-Gene
and	3	O
interleukin	11	B-Gene
(	1	I-Gene
IL	2	I-Gene
)	1	I-Gene
-7	2	I-Gene
,	1	O
suggesting	10	O
a	1	O
nonredundant	12	O
role	4	O
for	3	O
PU.1	4	B-Gene
in	2	O
regulating	10	O
the	3	O
expression	10	O
of	2	O
these	5	O
cytokine	8	O
receptor	8	O
genes	5	O
during	6	O
NK	2	O
cell	4	O
development	11	O
.	1	O

PU.1	4	B-Gene
(	1	I-Gene
-	1	I-Gene
/	1	I-Gene
-	1	I-Gene
)	1	I-Gene
NK	2	O
cells	5	O
also	4	O
showed	6	O
defective	9	O
expression	10	O
of	2	O
inhibitory	10	O
and	3	O
activating	10	O
members	7	O
of	2	O
the	3	O
Ly49	4	B-Gene
family	6	I-Gene
and	3	O
failed	6	O
to	2	O
proliferate	11	O
in	2	O
response	8	O
to	2	O
IL-2	4	B-Gene
and	3	O
IL-12	5	B-Gene
.	1	O

Thus	4	O
,	1	O
despite	7	O
the	3	O
less	4	O
stringent	9	O
requirement	11	O
for	3	O
PU.1	4	B-Gene
in	2	O
NK	2	O
cell	4	O
development	11	O
compared	8	O
to	2	O
B	1	O
and	3	O
T	1	O
cells	5	O
,	1	O
PU.1	4	B-Gene
regulates	9	O
NK	2	O
cell	4	O
differentiation	15	O
and	3	O
homeostasis	11	O
.	1	O

The	3	O
involvement	11	O
of	2	O
TNF-alpha	9	B-Gene
-related	8	I-Gene
apoptosis	9	I-Gene
-inducing	9	I-Gene
ligand	6	I-Gene
in	2	O
the	3	O
enhanced	8	O
cytotoxicity	12	O
of	2	O
IFN-beta	8	B-Gene
-stimulated	11	O
human	5	O
dendritic	9	O
cells	5	O
to	2	O
tumor	5	B-Disease
cells	5	O
.	1	O

TNF-alpha	9	B-Gene
-related	8	I-Gene
apoptosis	9	I-Gene
-inducing	9	I-Gene
ligand	6	I-Gene
(	1	O
TRAIL	5	B-Gene
)	1	O
is	2	O
characterized	13	O
by	2	O
its	3	O
preferential	12	O
induction	9	O
of	2	O
apoptosis	9	O
of	2	O
tumor	5	B-Disease
cells	5	O
but	3	O
not	3	O
normal	6	O
cells	5	O
.	1	O

Dendritic	9	O
cells	5	O
(	1	O
DCs	3	O
)	1	O
,	1	O
besides	7	O
their	5	O
role	4	O
as	2	O
APCs	4	O
,	1	O
now	3	O
have	4	O
been	4	O
demonstrated	12	O
to	2	O
exert	5	O
cytotoxicity	12	O
or	2	O
cytostasis	10	O
on	2	O
some	4	O
tumor	5	B-Disease
cells	5	O
.	1	O

Here	4	O
,	1	O
we	2	O
report	6	O
that	4	O
both	4	O
human	5	B-Gene
CD34	4	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
stem	4	O
cell	4	O
-derived	8	O
DCs	3	O
(	1	O
CD34DCs	7	B-Gene
)	1	O
and	3	O
human	5	B-Gene
CD14	4	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
monocyte	8	O
-derived	8	O
DCs	3	O
(	1	O
MoDCs	5	O
)	1	O
express	7	O
TRAIL	5	B-Gene
and	3	O
exhibit	7	O
cytotoxicity	12	O
to	2	O
some	4	O
types	5	O
of	2	O
tumor	5	B-Disease
cells	5	O
partially	9	O
through	7	O
TRAIL	5	B-Gene
.	1	O

Moderate	8	O
expression	10	O
of	2	O
TRAIL	5	B-Gene
appeared	8	O
on	2	O
CD34DCs	7	B-Gene
from	4	O
the	3	O
8th	3	O
day	3	O
of	2	O
culture	7	O
and	3	O
was	3	O
also	4	O
seen	4	O
on	2	O
freshly	7	O
isolated	8	O
monocytes	9	O
.	1	O

The	3	O
level	5	O
of	2	O
TRAIL	5	B-Gene
expression	10	O
remained	8	O
constant	8	O
until	5	O
DC	2	O
maturation	10	O
.	1	O

TRAIL	5	B-Gene
expression	10	O
on	2	O
immature	8	O
CD34DCs	7	B-Gene
or	2	O
MoDCs	5	O
was	3	O
greatly	7	O
up	2	O
-regulated	10	O
after	5	O
IFN-beta	8	B-Gene
stimulation	11	O
.	1	O

Moreover	8	O
,	1	O
IFN-beta	8	B-Gene
could	5	O
strikingly	10	O
enhance	7	O
the	3	O
ability	7	O
of	2	O
CD34DCs	7	B-Gene
or	2	O
MoDCs	5	O
to	2	O
kill	4	O
TRAIL	5	B-Gene
-sensitive	10	O
tumor	5	B-Disease
cells	5	O
,	1	O
but	3	O
LPS	3	B-Chemical
did	3	O
not	3	O
have	4	O
such	4	O
an	2	O
effect	6	O
.	1	O

The	3	O
up-regulation	13	O
of	2	O
TRAIL	5	B-Gene
on	2	O
IFN-beta	8	B-Gene
-stimulated	11	O
DCs	3	O
partially	9	O
contributed	11	O
to	2	O
the	3	O
increased	9	O
cytotoxicity	12	O
of	2	O
DCS	3	O
:	1	O
Pretreatment	12	O
of	2	O
TRAIL	5	B-Gene
-sensitive	10	O
tumor	5	B-Disease
cells	5	O
with	4	O
caspase-3	9	B-Gene
inhibitor	9	I-Gene
could	5	O
significantly	13	O
increase	8	O
their	5	O
resistance	10	O
to	2	O
the	3	O
cytotoxicity	12	O
of	2	O
IFN-beta	8	B-Gene
-stimulated	11	O
DCS	3	O
:	1	O
In	2	O
contrast	8	O
,	1	O
NF-kappaB	9	B-Gene
inhibitor	9	I-Gene
could	5	O
significantly	13	O
increase	8	O
the	3	O
sensitivity	11	O
of	2	O
tumor	5	B-Disease
cells	5	O
to	2	O
the	3	O
killing	7	O
by	2	O
nonstimulated	13	O
or	2	O
LPS	3	B-Chemical
-stimulated	11	O
DCS	3	O
:	1	O
Our	3	O
studies	7	O
demonstrate	11	O
that	4	O
IFN-beta	8	B-Gene
-stimulated	11	O
DCs	3	O
are	3	O
functionally	12	O
cytotoxic	9	O
.	1	O

Thus	4	O
,	1	O
an	2	O
innate	6	O
mechanism	9	O
of	2	O
DC	2	O
-mediated	9	O
antitumor	9	O
immunity	8	O
might	5	O
exist	5	O
in	2	O
vivo	4	O
in	2	O
which	5	O
DCs	3	O
act	3	O
as	2	O
effectors	9	O
to	2	O
directly	8	O
kill	4	O
tumor	5	B-Disease
cells	5	O
partially	9	O
via	3	O
TRAIL	5	B-Gene
.	1	O

Subsequently	12	O
,	1	O
DCs	3	O
act	3	O
as	2	O
APCs	4	O
involved	8	O
in	2	O
the	3	O
uptake	6	O
,	1	O
processing	10	O
,	1	O
and	3	O
presentation	12	O
of	2	O
apoptotic	9	O
tumor	5	B-Disease
Ags	3	O
to	2	O
cross-prime	11	O
CD8	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
CTL	3	O
cells	5	O
.	1	O

Runx2	5	B-Gene
:	1	O
a	1	O
novel	5	O
oncogenic	9	O
effector	8	O
revealed	8	O
by	2	O
in	2	O
vivo	4	O
complementation	15	O
and	3	O
retroviral	10	O
tagging	7	O
.	1	O

The	3	O
Runx2	5	B-Gene
(	1	O
Cbfa1	5	B-Gene
,	1	O
Pebp2alphaA	11	B-Gene
,	1	O
Aml3	4	B-Gene
)	1	O
gene	4	O
was	3	O
previously	10	O
identified	10	O
as	2	O
a	1	O
frequent	8	O
target	6	O
for	3	O
transcriptional	15	O
activation	10	O
by	2	O
proviral	8	O
insertion	9	O
in	2	O
T-cell	6	B-Disease
lymphomas	9	I-Disease
of	2	O
CD2-MYC	7	B-Gene
transgenic	10	O
mice	4	O
.	1	O

We	2	O
have	4	O
recently	8	O
shown	5	O
that	4	O
over-expression	15	O
of	2	O
the	3	O
full-length	11	O
,	1	O
most	4	O
highly	6	O
expressed	9	O
Runx2	5	B-Gene
isoform	7	I-Gene
in	2	O
the	3	O
thymus	6	O
perturbs	8	O
T-cell	6	O
development	11	O
,	1	O
leads	5	O
to	2	O
development	11	O
of	2	O
spontaneous	11	O
lymphomas	9	B-Disease
at	2	O
low	3	O
frequency	9	O
and	3	O
is	2	O
strongly	8	O
synergistic	11	O
with	4	O
Myc	3	B-Gene
.	1	O

To	2	O
gain	4	O
further	7	O
insight	7	O
into	4	O
the	3	O
relationship	12	O
of	2	O
Runx2	5	B-Gene
to	2	O
other	5	O
lymphomagenic	13	O
pathways	8	O
,	1	O
we	2	O
tested	6	O
the	3	O
effect	6	O
of	2	O
combining	9	O
the	3	O
CD2-Runx2	9	B-Gene
transgene	9	I-Gene
either	6	O
with	4	O
a	1	O
Pim1	4	B-Gene
transgene	9	I-Gene
(	1	O
E	1	B-Gene
(	1	I-Gene
mu	2	I-Gene
)	1	I-Gene
-Pim1	5	I-Gene
)	1	O
or	2	O
with	4	O
the	3	O
p53	3	B-Gene
null	4	O
genotype	8	O
,	1	O
as	2	O
each	4	O
of	2	O
these	5	O
displays	8	O
independent	11	O
synergy	7	O
with	4	O
Myc	3	B-Gene
.	1	O

In	2	O
both	4	O
cases	5	O
we	2	O
observed	8	O
synergistic	11	O
tumour	6	B-Disease
development	11	O
.	1	O

However	7	O
,	1	O
Runx2	5	B-Gene
appeared	8	O
to	2	O
have	4	O
a	1	O
dominant	8	O
effect	6	O
on	2	O
the	3	O
tumour	6	B-Disease
phenotype	9	O
in	2	O
each	4	O
case	4	O
,	1	O
with	4	O
most	4	O
tumours	7	B-Disease
conforming	10	O
to	2	O
the	3	O
CD3	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
,	1	O
CD8	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
,	1	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
/	1	I-Gene
-	1	I-Gene
)	1	I-Gene
phenotype	9	O
seen	4	O
in	2	O
CD2-Runx2	9	B-Gene
mice	4	O
.	1	O

Neonatal	8	O
infection	9	O
of	2	O
CD2-Runx2	9	B-Gene
mice	4	O
with	4	O
Moloney	7	O
murine	6	O
leukaemia	9	B-Disease
virus	5	O
(	1	O
Moloney	7	O
MLV	3	O
)	1	O
also	4	O
led	3	O
to	2	O
a	1	O
dramatic	8	O
acceleration	12	O
of	2	O
tumour	6	B-Disease
onset	5	O
.	1	O

Analysis	8	O
of	2	O
known	5	O
Moloney	7	O
MLV	3	O
target	6	O
genes	5	O
in	2	O
these	5	O
lymphomas	9	B-Disease
showed	6	O
a	1	O
high	4	O
frequency	9	O
of	2	O
rearrangement	13	O
at	2	O
c-Myc	5	B-Gene
or	2	O
N-Myc	5	B-Gene
(	1	O
82	2	O
%	1	O
)	1	O
,	1	O
and	3	O
a	1	O
significant	11	O
number	6	O
at	2	O
Pim1	4	B-Gene
or	2	O
Pim2	4	B-Gene
(	1	O
23	2	O
%	1	O
)	1	O
,	1	O
and	3	O
at	2	O
Pal1	4	B-Gene
/	1	I-Gene
Gfi1	4	I-Gene
(	1	O
18	2	O
%	1	O
)	1	O
.	1	O

These	5	O
results	7	O
indicate	8	O
that	4	O
Runx2	5	B-Gene
makes	5	O
a	1	O
distinct	8	O
contribution	12	O
to	2	O
T-cell	6	B-Disease
lymphoma	8	I-Disease
development	11	O
which	5	O
does	4	O
not	3	O
coincide	8	O
with	4	O
any	3	O
of	2	O
the	3	O
oncogene	8	O
complementation	15	O
groups	6	O
previously	10	O
identified	10	O
by	2	O
retroviral	10	O
tagging	7	O
.	1	O

Expression	10	O
of	2	O
Mad1	4	B-Gene
in	2	O
T	1	O
cells	5	O
leads	5	O
to	2	O
reduced	7	O
thymic	6	O
cellularity	11	O
and	3	O
impaired	8	O
mitogen	7	O
-induced	8	O
proliferation	13	O
.	1	O

To	2	O
investigate	11	O
Mad1	4	B-Gene
function	8	O
in	2	O
vivo	4	O
,	1	O
transgenic	10	O
mice	4	O
were	4	O
generated	9	O
that	4	O
express	7	O
a	1	O
Mad1	4	B-Gene
transgene	9	I-Gene
in	2	O
T	1	O
lineage	7	O
cells	5	O
under	5	O
the	3	O
control	7	O
of	2	O
the	3	O
proximal	8	O
lck	3	B-Gene
promoter	8	I-Gene
.	1	O

Thymus	6	O
size	4	O
in	2	O
lck-Mad1	8	B-Gene
transgenic	10	O
mice	4	O
is	2	O
drastically	11	O
reduced	7	O
although	8	O
representation	14	O
of	2	O
the	3	O
various	7	O
thymocyte	9	O
sub	3	O
populations	11	O
appears	7	O
normal	6	O
.	1	O

To	2	O
investigate	11	O
more	4	O
closely	7	O
any	3	O
effects	7	O
of	2	O
Mad1	4	B-Gene
expression	10	O
on	2	O
thymocytes	10	O
,	1	O
we	2	O
examined	8	O
thymic	6	O
selection	9	O
using	5	O
MHC	3	B-Gene
class	5	I-Gene
I	1	I-Gene
-restricted	11	O
H-Y-TCR	7	B-Gene
transgenic	10	O
mice	4	O
.	1	O

Mad1	4	B-Gene
expression	10	O
in	2	O
vivo	4	O
reduces	7	O
the	3	O
efficiency	10	O
of	2	O
positive	8	O
selection	9	O
.	1	O

Furthermore	11	O
,	1	O
thymocytes	10	O
and	3	O
splenic	7	O
T	1	O
cells	5	O
from	4	O
lck-Mad1	8	B-Gene
transgenic	10	O
mice	4	O
display	7	O
a	1	O
profound	8	O
proliferative	13	O
defect	6	O
in	2	O
response	8	O
to	2	O
activation	10	O
with	4	O
either	6	O
PMA	3	B-Chemical
/	1	O
Ionomycin	9	B-Chemical
or	2	O
immobilized	11	O
anti-CD3	8	B-Gene
/	1	I-Gene
CD28	4	I-Gene
antibody	8	I-Gene
.	1	O

This	4	O
proliferative	13	O
defect	6	O
is	2	O
not	3	O
reversed	8	O
by	2	O
addition	8	O
of	2	O
exogenous	9	B-Gene
IL-2	4	I-Gene
and	3	O
is	2	O
p53	3	B-Gene
-independent	12	O
.	1	O

The	3	O
growth	6	O
inhibition	10	O
caused	6	O
by	2	O
Mad1	4	B-Gene
is	2	O
overcome	8	O
by	2	O
expression	10	O
of	2	O
active	6	O
c-Myc	5	B-Gene
.	1	O

Caspase	7	B-Gene
-dependent	10	O
cleavage	8	O
of	2	O
the	3	O
hematopoietic	13	B-Gene
specific	8	I-Gene
adaptor	7	I-Gene
protein	7	I-Gene
Gads	4	I-Gene
alters	6	O
signalling	10	O
from	4	O
the	3	O
T	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
.	1	O

Gads	4	B-Gene
is	2	O
a	1	O
SH2	3	O
and	3	O
SH3	3	O
domain	6	O
-containing	11	O
,	1	O
hematopoietic-specific	22	O
adaptor	7	O
protein	7	O
that	4	O
functions	9	O
in	2	O
signalling	10	O
from	4	O
the	3	O
T	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
.	1	O

Gads	4	B-Gene
acts	4	O
by	2	O
linking	7	O
SLP-76	6	B-Gene
,	1	O
bound	5	O
by	2	O
the	3	O
carboxy-terminal	16	O
Gads	4	B-Gene
SH3	3	O
domain	6	O
,	1	O
to	2	O
tyrosine	8	B-Chemical
phosphorylated	14	O
LAT	3	B-Gene
which	5	O
contains	8	O
binding	7	O
sites	5	O
for	3	O
the	3	O
Gads	4	B-Gene
SH2	3	O
domain	6	O
.	1	O

Gads	4	B-Gene
is	2	O
distinguished	13	O
from	4	O
Grb2	4	B-Gene
and	3	O
the	3	O
closely	7	O
related	7	O
Grap	4	B-Gene
protein	7	I-Gene
by	2	O
the	3	O
presence	8	O
of	2	O
a	1	O
120	3	O
amino	5	O
acid	4	O
unique	6	O
region	6	O
between	7	O
the	3	O
SH2	3	O
domain	6	O
and	3	O
the	3	O
carboxy	7	O
terminal	8	O
SH3	3	O
domain	6	O
.	1	O

Here	4	O
we	2	O
demonstrate	11	O
that	4	O
the	3	O
unique	6	O
region	6	O
of	2	O
Gads	4	B-Gene
contains	8	O
a	1	O
capase	6	B-Gene
cleavage	8	O
site	4	O
.	1	O

Induction	9	O
of	2	O
apoptosis	9	O
in	2	O
lymphocytes	11	O
results	7	O
in	2	O
detectable	10	O
Gads	4	B-Gene
cleavage	8	O
by	2	O
60	2	O
min	3	O
.	1	O

Gads	4	B-Gene
cleavage	8	O
is	2	O
blocked	7	O
in	2	O
vivo	4	O
by	2	O
treating	8	O
cells	5	O
with	4	O
a	1	O
caspase	7	B-Gene
3	1	I-Gene
inhibitor	9	I-Gene
.	1	O

A	1	O
putative	8	O
caspase	7	B-Gene
3	1	I-Gene
cleavage	8	O
site	4	O
was	3	O
identified	10	O
within	6	O
the	3	O
unique	6	O
region	6	O
and	3	O
mutation	8	O
of	2	O
this	4	O
site	4	O
prevented	9	O
Gads	4	B-Gene
cleavage	8	O
in	2	O
vitro	5	O
,	1	O
and	3	O
in	2	O
vivo	4	O
.	1	O

The	3	O
Gads	4	B-Gene
cleavage	8	O
products	8	O
retained	8	O
the	3	O
predicted	9	O
binding	7	O
specificity	11	O
for	3	O
SLP-76	6	B-Gene
and	3	O
LAT	3	B-Gene
.	1	O

Expression	10	O
of	2	O
the	3	O
Gads	4	B-Gene
cleavage	8	O
products	8	O
in	2	O
Jurkat	6	O
T	1	O
cells	5	O
inhibited	9	O
NFAT	4	B-Gene
activation	10	O
following	9	O
TCR	3	B-Gene
cross	5	O
linking	7	O
.	1	O

These	5	O
findings	8	O
indicate	8	O
that	4	O
cleavage	8	O
of	2	O
Gads	4	B-Gene
in	2	O
vivo	4	O
could	5	O
function	8	O
to	2	O
alter	5	O
signalling	10	O
downstream	10	O
of	2	O
the	3	O
T	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
by	2	O
disrupting	10	O
cross	5	O
talk	4	O
between	7	O
SLP-76	6	B-Gene
and	3	O
LAT	3	B-Gene
.	1	O

Comparison	10	O
of	2	O
hprt	4	B-Gene
and	3	O
lacI	4	B-Gene
mutant	6	I-Gene
frequency	9	O
with	4	O
DNA	3	O
adduct	6	O
formation	9	O
in	2	O
N-hydroxy-2-acetylaminofluorene	31	B-Chemical
-treated	8	O
Big	3	O
Blue	4	O
rats	4	O
.	1	O

N-Hydroxy-2-acetylaminofluorene	31	B-Chemical
(	1	O
N-OH-AAF	8	B-Chemical
)	1	O
is	2	O
the	3	O
proximate	9	O
carcinogenic	12	O
metabolite	10	O
of	2	O
the	3	O
powerful	8	O
rat	3	O
liver	5	O
carcinogen	10	O
2-acetylaminofluorene	21	B-Chemical
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
transgenic	10	O
Big	3	O
Blue	4	O
(	1	O
R	1	O
)	1	O
rats	4	O
were	4	O
used	4	O
to	2	O
examine	7	O
the	3	O
relationship	12	O
between	7	O
in	2	O
vivo	4	O
mutagenicity	12	O
and	3	O
DNA	3	O
adduct	6	O
formation	9	O
by	2	O
N-OH-AAF	8	B-Chemical
in	2	O
the	3	O
target	6	O
liver	5	O
compared	8	O
with	4	O
that	4	O
in	2	O
nontarget	9	O
tissues	7	O
.	1	O

Male	4	O
rats	4	O
were	4	O
given	5	O
one	3	O
,	1	O
two	3	O
,	1	O
or	2	O
four	4	O
doses	5	O
of	2	O
25	2	O
mg	2	O
N-OH-AAF	8	B-Chemical
/	1	O
kg	2	O
body	4	O
weight	6	O
by	2	O
i.p.	4	O
injection	9	O
at	2	O
4-day	5	O
intervals	9	O
,	1	O
and	3	O
groups	6	O
of	2	O
treated	7	O
and	3	O
control	7	O
rats	4	O
were	4	O
euthanized	10	O
up	2	O
to	2	O
10	2	O
weeks	5	O
after	5	O
beginning	9	O
the	3	O
dosing	6	O
.	1	O

Mutant	6	O
frequencies	11	O
were	4	O
measured	8	O
in	2	O
the	3	O
spleen	6	O
lymphocyte	10	O
hprt	4	B-Gene
gene	4	I-Gene
,	1	O
and	3	O
lacI	4	B-Gene
mutant	6	I-Gene
frequencies	11	O
were	4	O
determined	10	O
in	2	O
the	3	O
liver	5	O
and	3	O
spleen	6	O
lymphocytes	11	O
.	1	O

At	2	O
6	1	O
weeks	5	O
after	5	O
beginning	9	O
the	3	O
dosing	6	O
,	1	O
the	3	O
hprt	4	B-Gene
mutant	6	I-Gene
frequency	9	O
in	2	O
spleen	6	O
lymphocytes	11	O
from	4	O
the	3	O
four-dose	9	O
group	5	O
was	3	O
16.5	4	O
x	1	O
10	2	O
(	1	O
-6	2	O
)	1	O
compared	8	O
with	4	O
3.2	3	O
x	1	O
10	2	O
(	1	O
-6	2	O
)	1	O
in	2	O
control	7	O
animals	7	O
.	1	O

Also	4	O
at	2	O
6	1	O
weeks	5	O
,	1	O
rats	4	O
given	5	O
one	3	O
,	1	O
two	3	O
,	1	O
or	2	O
four	4	O
doses	5	O
of	2	O
N-OH-AAF	8	B-Chemical
had	3	O
lacI	4	B-Gene
mutant	6	I-Gene
frequencies	11	O
in	2	O
the	3	O
liver	5	O
of	2	O
97.6	4	O
,	1	O
155.6	5	O
,	1	O
and	3	O
406.8	5	O
x	1	O
10	2	O
(	1	O
-6	2	O
)	1	O
,	1	O
respectively	12	O
,	1	O
compared	8	O
with	4	O
a	1	O
control	7	O
frequency	9	O
of	2	O
25.7	4	O
x	1	O
10	2	O
(	1	O
-6	2	O
)	1	O
;	1	O
rats	4	O
given	5	O
four	4	O
doses	5	O
had	3	O
lacI	4	B-Gene
mutant	6	I-Gene
frequencies	11	O
in	2	O
spleen	6	O
lymphocytes	11	O
of	2	O
55.8	4	O
x	1	O
10	2	O
(	1	O
-6	2	O
)	1	O
compared	8	O
with	4	O
a	1	O
control	7	O
frequency	9	O
of	2	O
20.4	4	O
x	1	O
10	2	O
(	1	O
-6	2	O
)	1	O
.	1	O

Additional	10	O
rats	4	O
were	4	O
evaluated	9	O
for	3	O
DNA	3	O
adduct	6	O
formation	9	O
in	2	O
the	3	O
liver	5	O
,	1	O
spleen	6	O
lymphocytes	11	O
,	1	O
and	3	O
bone	4	O
marrow	6	O
by	2	O
(	1	O
32	2	O
)	1	O
P	1	O
-postlabeling	13	O
.	1	O

Adduct	6	O
analysis	8	O
was	3	O
conducted	9	O
1	1	O
day	3	O
after	5	O
one	3	O
,	1	O
two	3	O
,	1	O
and	3	O
four	4	O
treatments	10	O
with	4	O
N-OH-AAF	8	B-Chemical
,	1	O
5	1	O
days	4	O
after	5	O
one	3	O
treatment	9	O
,	1	O
and	3	O
9	1	O
days	4	O
after	5	O
two	3	O
treatments	10	O
.	1	O

N-	2	B-Chemical
(	1	I-Chemical
Deoxyguanosin-8-yl	18	I-Chemical
)	1	I-Chemical
-2-aminofluorene	16	I-Chemical
was	3	O
the	3	O
major	5	O
DNA	3	O
adduct	6	O
identified	10	O
in	2	O
all	3	O
the	3	O
tissues	7	O
examined	8	O
.	1	O

Adduct	6	O
concentrations	14	O
increased	9	O
with	4	O
total	5	O
dose	4	O
to	2	O
maximum	7	O
values	6	O
in	2	O
samples	7	O
taken	5	O
1	1	O
day	3	O
after	5	O
two	3	O
doses	5	O
,	1	O
and	3	O
remained	8	O
essentially	11	O
the	3	O
same	4	O
after	5	O
four	4	O
doses	5	O
.	1	O

In	2	O
samples	7	O
taken	5	O
after	5	O
four	4	O
doses	5	O
,	1	O
adduct	6	O
levels	6	O
were	4	O
103	3	O
,	1	O
28	2	O
,	1	O
and	3	O
7	1	O
fmol	4	O
/	1	O
microg	6	O
of	2	O
DNA	3	O
in	2	O
liver	5	O
,	1	O
spleen	6	O
lymphocytes	11	O
,	1	O
and	3	O
bone	4	O
marrow	6	O
,	1	O
respectively	12	O
.	1	O

The	3	O
results	7	O
indicate	8	O
that	4	O
the	3	O
extent	6	O
of	2	O
both	4	O
DNA	3	O
adduct	6	O
formation	9	O
and	3	O
mutant	6	O
induction	9	O
correlates	10	O
with	4	O
the	3	O
organ	5	O
specificity	11	O
for	3	O
N-OH-AAF	8	B-Chemical
carcinogenesis	14	O
in	2	O
the	3	O
rat	3	O
.	1	O

Environ	7	O
.	1	O

Mol	3	O
.	1	O

Mutagen	7	O
.	1	O

37	2	O
:	1	O
195-202	7	O
,	1	O
2001	4	O
.	1	O

Published	9	O
2001	4	O
Wiley-Liss	10	O
,	1	O
Inc	3	O
.	1	O

Gene-	5	O
and	3	O
tissue-specificity	18	O
of	2	O
mutation	8	O
in	2	O
Big	3	O
Blue	4	O
rats	4	O
treated	7	O
with	4	O
the	3	O
hepatocarcinogen	16	O
N-hydroxy-2-acetylaminofluorene	31	B-Chemical
.	1	O

In	2	O
a	1	O
previous	8	O
study	5	O
,	1	O
we	2	O
found	5	O
that	4	O
treating	8	O
transgenic	10	O
Big	3	O
Blue	4	O
rats	4	O
with	4	O
the	3	O
hepatocarcinogen	16	O
N-hydroxy-2-acetylaminofluorene	31	B-Chemical
(	1	O
N-OH-AAF	8	B-Chemical
)	1	O
produced	8	O
the	3	O
same	4	O
major	5	O
DNA	3	O
adduct	6	O
in	2	O
the	3	O
target	6	O
liver	5	O
and	3	O
the	3	O
nontarget	9	O
spleen	6	O
lymphocytes	11	O
and	3	O
bone	4	O
marrow	6	O
cells	5	O
,	1	O
induced	7	O
lacI	4	B-Gene
mutants	7	I-Gene
in	2	O
the	3	O
liver	5	O
,	1	O
and	3	O
induced	7	O
much	4	O
lower	5	O
frequencies	11	O
of	2	O
l	1	B-Gene
acI	3	I-Gene
and	3	O
hprt	4	B-Gene
mutants	7	I-Gene
in	2	O
spleen	6	O
lymphocytes	11	O
.	1	O

In	2	O
the	3	O
present	7	O
study	5	O
,	1	O
sequence	8	O
analysis	8	O
was	3	O
conducted	9	O
on	2	O
lacI	4	B-Gene
DNA	3	I-Gene
and	3	O
hprt	4	B-Gene
cDNA	4	I-Gene
from	4	O
the	3	O
mutants	7	O
,	1	O
to	2	O
determine	9	O
the	3	O
mutational	10	O
specificity	11	O
of	2	O
N-OH-AAF	8	B-Chemical
in	2	O
the	3	O
rat	3	O
.	1	O

All	3	O
the	3	O
mutation	8	O
spectra	7	O
from	4	O
N-OH-AAF	8	B-Chemical
-treated	8	O
rats	4	O
differed	8	O
significantly	13	O
from	4	O
corresponding	13	O
mutation	8	O
profiles	8	O
from	4	O
untreated	9	O
animals	7	O
(	1	O
P	1	O
=	1	O
0.02	4	O
to	2	O
P	1	O
<	1	O
0.0001	6	O
)	1	O
.	1	O

Although	8	O
there	5	O
were	4	O
similarities	12	O
among	5	O
the	3	O
mutational	10	O
patterns	8	O
derived	7	O
from	4	O
N-OH-AAF	8	B-Chemical
-treated	8	O
rats	4	O
(	1	O
e.g.	4	O
,	1	O
G	1	O
:	1	O
C	1	O
--	2	O
>	1	O
T	1	O
:	1	O
A	1	O
transversion	12	O
was	3	O
the	3	O
most	4	O
common	6	O
mutation	8	O
in	2	O
all	3	O
mutation	8	O
sets	4	O
)	1	O
,	1	O
there	5	O
were	4	O
significant	11	O
differences	11	O
in	2	O
the	3	O
patterns	8	O
of	2	O
basepair	8	O
substitution	12	O
and	3	O
frameshift	10	O
mutation	8	O
between	7	O
the	3	O
liver	5	O
and	3	O
spleen	6	O
lymphocyte	10	O
lacI	4	B-Gene
mutants	7	I-Gene
(	1	O
P	1	O
=	1	O
0.02	4	O
)	1	O
and	3	O
between	7	O
the	3	O
spleen	6	O
lymphocyte	10	O
lacI	4	B-Gene
and	3	O
hprt	4	B-Gene
mutants	7	I-Gene
(	1	O
P	1	O
=	1	O
0.04	4	O
)	1	O
.	1	O

Also	4	O
,	1	O
multiplex	9	O
PCR	3	O
analysis	8	O
of	2	O
genomic	7	O
DNA	3	O
from	4	O
the	3	O
hprt	4	B-Gene
mutants	7	I-Gene
indicated	9	O
that	4	O
12	2	O
%	1	O
of	2	O
mutants	7	O
from	4	O
treated	7	O
rats	4	O
had	3	O
major	5	O
deletions	9	O
in	2	O
the	3	O
hprt	4	B-Gene
gene	4	I-Gene
;	1	O
no	2	O
corresponding	13	O
incidence	9	O
of	2	O
large	5	O
deletions	9	O
was	3	O
evident	7	O
among	5	O
lacI	4	B-Gene
mutations	9	I-Gene
.	1	O

All	3	O
the	3	O
mutation	8	O
profiles	8	O
reflect	7	O
the	3	O
general	7	O
mutational	10	O
specificity	11	O
of	2	O
the	3	O
major	5	O
DNA	3	O
adduct	6	O
formed	6	O
by	2	O
N-OH-AAF	8	B-Chemical
.	1	O

The	3	O
differences	11	O
between	7	O
N-OH-AAF	8	B-Chemical
mutation	8	O
in	2	O
the	3	O
endogenous	10	O
gene	4	O
and	3	O
transgene	9	O
can	3	O
be	2	O
partially	9	O
explained	9	O
by	2	O
the	3	O
structures	10	O
of	2	O
the	3	O
two	3	O
genes	5	O
.	1	O

The	3	O
tissue-specificity	18	O
of	2	O
the	3	O
mutation	8	O
spectra	7	O
may	3	O
contribute	10	O
to	2	O
targeting	9	O
tumor	5	B-Disease
formation	9	O
to	2	O
the	3	O
liver	5	O
.	1	O

Environ	7	O
.	1	O

Mol	3	O
.	1	O

Mutagen	7	O
.	1	O

37	2	O
:	1	O
203-214	7	O
,	1	O
2001	4	O
.	1	O

Published	9	O
2001	4	O
Wiley-Liss	10	O
,	1	O
Inc	3	O
.	1	O

Gene	4	O
transfer	8	O
of	2	O
antisense	9	O
hypoxia	7	B-Gene
inducible	9	I-Gene
factor-1	8	I-Gene
alpha	5	I-Gene
enhances	8	O
the	3	O
therapeutic	11	O
efficacy	8	O
of	2	O
cancer	6	B-Disease
immunotherapy	13	O
.	1	O

Solid	5	O
tumors	6	B-Disease
meet	4	O
their	5	O
demands	7	O
for	3	O
nascent	7	O
blood	5	O
vessels	7	O
and	3	O
increased	9	O
glycolysis	10	O
,	1	O
to	2	O
combat	6	O
hypoxia	7	O
,	1	O
by	2	O
activating	10	O
multiple	8	O
genes	5	O
involved	8	O
in	2	O
angiogenesis	12	O
and	3	O
glucose	7	B-Chemical
metabolism	10	O
.	1	O

Hypoxia	7	B-Gene
inducible	9	I-Gene
factor-1	8	I-Gene
(	1	O
HIF-1	5	B-Gene
)	1	O
is	2	O
a	1	O
constitutively	14	O
expressed	9	O
basic	5	O
helix-loop-helix	16	O
transcription	13	O
factor	6	O
,	1	O
formed	6	O
by	2	O
the	3	O
assembly	8	O
of	2	O
HIF-1alpha	10	B-Gene
and	3	O
HIF-1beta	9	B-Gene
(	1	O
Arnt	4	B-Gene
)	1	O
,	1	O
that	4	O
is	2	O
stablized	9	O
in	2	O
response	8	O
to	2	O
hypoxia	7	O
,	1	O
and	3	O
rapidly	7	O
degraded	8	O
under	5	O
normoxic	8	O
conditions	10	O
.	1	O

It	2	O
activates	9	O
the	3	O
transcription	13	O
of	2	O
genes	5	O
important	9	O
for	3	O
maintaining	11	O
oxygen	6	B-Chemical
homeostasis	11	O
.	1	O

Here	4	O
,	1	O
we	2	O
demonstrate	11	O
that	4	O
engineered	10	O
down-regulation	15	O
of	2	O
HIF-1alpha	10	B-Gene
by	2	O
intratumoral	12	O
gene	4	O
transfer	8	O
of	2	O
an	2	O
antisense	9	O
HIF-1alpha	10	B-Gene
plasmid	7	O
leads	5	O
to	2	O
the	3	O
down-regulation	15	O
of	2	O
VEGF	4	B-Gene
,	1	O
and	3	O
decreased	9	O
tumor	5	B-Disease
microvessel	11	O
density	7	O
.	1	O

Antisense	9	O
HIF-1alpha	10	B-Gene
monotherapy	11	O
resulted	8	O
in	2	O
the	3	O
complete	8	O
and	3	O
permanent	9	O
rejection	9	O
of	2	O
small	5	O
(	1	O
0.1	3	O
cm	2	O
in	2	O
diameter	8	O
)	1	O
EL-4	4	O
tumors	6	B-Disease
,	1	O
which	5	O
is	2	O
unusual	7	O
for	3	O
an	2	O
anti-angiogenic	15	O
agent	5	O
where	5	O
transient	9	O
suppression	11	O
of	2	O
tumor	5	B-Disease
growth	6	O
is	2	O
the	3	O
norm	4	O
.	1	O

It	2	O
induced	7	O
NK	2	O
cell	4	O
-dependent	10	O
rejection	9	O
of	2	O
tumors	6	B-Disease
,	1	O
but	3	O
failed	6	O
to	2	O
stimulate	9	O
systemic	8	O
T	1	O
cell	4	O
-mediated	9	O
anti-tumor	10	B-Disease
immunity	8	O
,	1	O
and	3	O
synergized	10	O
with	4	O
B7-1	4	B-Gene
-mediated	9	O
immunotherapy	13	O
to	2	O
cause	5	O
the	3	O
NK	2	O
cell	4	O
and	3	O
CD8	3	B-Gene
T	1	O
cell	4	O
-dependent	10	O
rejection	9	O
of	2	O
larger	6	O
EL-4	4	O
tumors	6	B-Disease
(	1	O
0.4	3	O
cm	2	O
in	2	O
diameter	8	O
)	1	O
that	4	O
were	4	O
refractory	10	O
to	2	O
monotherapies	13	O
.	1	O

Mice	4	O
cured	5	O
of	2	O
their	5	O
tumors	6	B-Disease
by	2	O
combination	11	O
therapy	7	O
resisted	8	O
a	1	O
rechallenge	11	O
with	4	O
parental	8	O
tumor	5	B-Disease
cells	5	O
,	1	O
indicating	10	O
systemic	8	O
antitumor	9	O
immunity	8	O
had	3	O
been	4	O
achieved	8	O
.	1	O

In	2	O
summary	7	O
,	1	O
whilst	6	O
intensive	9	O
investigations	14	O
are	3	O
in	2	O
progress	8	O
to	2	O
target	6	O
the	3	O
many	4	O
HIF-1	5	B-Gene
effectors	9	I-Gene
,	1	O
the	3	O
results	7	O
herein	6	O
indicate	8	O
that	4	O
blocking	8	O
hypoxia-inducible	17	O
pathways	8	O
and	3	O
enhancing	9	O
NK	2	O
-mediated	9	O
antitumor	9	O
immunity	8	O
by	2	O
targeting	9	O
HIF-1	5	B-Gene
itself	6	O
may	3	O
be	2	O
advantageous	12	O
,	1	O
especially	10	O
when	4	O
combined	8	O
with	4	O
cancer	6	B-Disease
immunotherapy	13	O
.	1	O

Molecular	9	O
pathogenesis	12	O
of	2	O
influenza	9	B-Disease
A	1	O
virus	5	O
infection	9	O
and	3	O
virus	5	O
-induced	8	O
regulation	10	O
of	2	O
cytokine	8	O
gene	4	O
expression	10	O
.	1	O

Despite	7	O
vaccines	8	O
and	3	O
antiviral	9	O
substances	10	O
influenza	9	B-Disease
still	5	O
causes	6	O
significant	11	O
morbidity	9	O
and	3	O
mortality	9	O
world	5	O
wide	4	O
.	1	O

Better	6	O
understanding	13	O
of	2	O
the	3	O
molecular	9	O
mechanisms	10	O
of	2	O
influenza	9	B-Disease
virus	5	O
replication	11	O
,	1	O
pathogenesis	12	O
and	3	O
host	4	O
immune	6	O
responses	9	O
is	2	O
required	8	O
for	3	O
the	3	O
development	11	O
of	2	O
more	4	O
efficient	9	O
means	5	O
of	2	O
prevention	10	O
and	3	O
treatment	9	O
of	2	O
influenza	9	B-Disease
.	1	O

Influenza	9	B-Disease
A	1	O
virus	5	O
,	1	O
which	5	O
replicates	10	O
in	2	O
epithelial	10	O
cells	5	O
and	3	O
leukocytes	10	O
,	1	O
regulates	9	O
host	4	O
cell	4	O
transcriptional	15	O
and	3	O
translational	13	O
systems	7	O
and	3	O
activates	9	O
,	1	O
as	2	O
well	4	O
as	2	O
downregulates	13	O
apoptotic	9	O
pathways	8	O
.	1	O

Influenza	9	B-Disease
A	1	O
virus	5	O
infection	9	O
results	7	O
in	2	O
the	3	O
production	10	O
of	2	O
chemotactic	11	O
(	1	O
RANTES	6	B-Gene
,	1	O
MIP-1	5	B-Gene
alpha	5	I-Gene
,	1	O
MCP-1	5	B-Gene
,	1	O
MCP-3	5	B-Gene
,	1	O
and	3	O
IP-10	5	B-Gene
)	1	O
,	1	O
pro-inflammatory	16	O
(	1	O
IL-1	4	B-Gene
beta	4	I-Gene
,	1	O
IL-6	4	B-Gene
,	1	O
IL-18	5	B-Gene
,	1	O
and	3	O
TNF-alpha	9	B-Gene
)	1	O
,	1	O
and	3	O
antiviral	9	O
(	1	O
IFN-alpha	9	B-Gene
/	1	I-Gene
beta	4	I-Gene
)	1	O
cytokines	9	O
.	1	O

Cytokine	8	O
gene	4	O
expression	10	O
is	2	O
associated	10	O
with	4	O
the	3	O
activation	10	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
,	1	O
AP-1	4	B-Gene
,	1	O
STAT	4	B-Gene
and	3	O
IRF	3	B-Gene
signal	6	O
transducing	11	O
molecules	9	O
in	2	O
influenza	9	B-Disease
A	1	O
virus	5	O
-infected	9	O
cells	5	O
.	1	O

In	2	O
addition	8	O
of	2	O
upregulating	12	O
cytokine	8	O
gene	4	O
expression	10	O
,	1	O
influenza	9	B-Disease
A	1	O
virus	5	O
infection	9	O
activates	9	O
caspase-1	9	B-Gene
enzyme	6	I-Gene
,	1	O
which	5	O
is	2	O
involved	8	O
in	2	O
the	3	O
proteolytic	11	O
processing	10	O
of	2	O
proIL-1	7	B-Gene
beta	4	I-Gene
and	3	O
proIL-18	8	B-Gene
into	4	O
their	5	O
biologically	12	O
active	6	O
forms	5	O
.	1	O

Influenza	9	B-Disease
A	1	O
virus	5	O
-induced	8	O
IFN-alpha	9	B-Gene
/	1	I-Gene
beta	4	I-Gene
is	2	O
essential	9	O
in	2	O
host	4	O
's	2	O
antiviral	9	O
defence	7	O
by	2	O
activating	10	O
the	3	O
expression	10	O
of	2	O
antiviral	9	B-Gene
Mx	2	I-Gene
,	1	O
PKR	3	B-Gene
and	3	O
oligoadenylate	14	B-Gene
synthetase	10	I-Gene
genes	5	I-Gene
.	1	O

IFN-alpha	9	B-Gene
/	1	I-Gene
beta	4	I-Gene
also	4	O
prolongs	8	O
T	1	O
cell	4	O
survival	8	O
,	1	O
upregulates	11	O
IL-12	5	B-Gene
and	3	O
IL-18	5	B-Gene
receptor	8	I-Gene
gene	4	I-Gene
expression	10	O
and	3	O
together	8	O
with	4	O
IL-18	5	B-Gene
stimulates	10	O
NK	2	O
and	3	O
T	1	B-Gene
cell	4	I-Gene
IFN-gamma	9	I-Gene
production	10	O
and	3	O
the	3	O
development	11	O
of	2	O
Th1-type	8	O
immune	6	O
response	8	O
.	1	O

Epstein-Barr	12	O
Virus	5	O
and	3	O
its	3	O
glycoprotein-350	16	B-Gene
upregulate	10	O
IL-6	4	B-Gene
in	2	O
human	5	O
B-lymphocytes	13	O
via	3	O
CD21	4	B-Gene
,	1	O
involving	9	O
activation	10	O
of	2	O
NF-kappaB	9	B-Gene
and	3	O
different	9	O
signaling	9	O
pathways	8	O
.	1	O

Epstein-Barr	12	O
virus	5	O
(	1	O
EBV	3	O
)	1	O
is	2	O
a	1	O
ubiquitous	10	O
and	3	O
highly	6	O
immunotropic	12	O
gamma	5	O
herpesvirus	11	O
that	4	O
infects	7	O
more	4	O
than	4	O
90	2	O
%	1	O
of	2	O
humans	6	O
worldwide	9	O
.	1	O

Its	3	O
pathogenicity	13	O
leads	5	O
to	2	O
a	1	O
number	6	O
of	2	O
diseases	8	O
including	9	O
tumors	6	B-Disease
that	4	O
result	6	O
from	4	O
EBV	3	O
's	2	O
ability	7	O
to	2	O
readily	7	O
transform	9	O
B-lymphocytes	13	O
and	3	O
,	1	O
to	2	O
a	1	O
lesser	6	O
extent	6	O
,	1	O
epithelial	10	O
cells	5	O
.	1	O

EBV	3	O
utilizes	8	O
CD21	4	B-Gene
/	1	I-Gene
CR2	3	I-Gene
as	2	O
its	3	O
receptor	8	O
on	2	O
B	1	O
cells	5	O
to	2	O
initiate	8	O
the	3	O
infection	9	O
process	7	O
.	1	O

EBV	3	O
binds	5	O
to	2	O
CR2	3	B-Gene
through	7	O
its	3	O
major	5	B-Gene
envelope	8	I-Gene
glycoprotein-350	16	I-Gene
(	1	O
gp350	5	B-Gene
)	1	O
and	3	O
is	2	O
also	4	O
a	1	O
remarkable	10	O
immunomodulating	16	O
agent	5	O
.	1	O

We	2	O
had	3	O
previously	10	O
shown	5	O
that	4	O
EBV	3	O
is	2	O
capable	7	O
of	2	O
modulating	10	O
the	3	O
synthesis	9	O
of	2	O
a	1	O
number	6	O
of	2	O
cytokines	9	O
.	1	O

We	2	O
now	3	O
show	4	O
that	4	O
while	5	O
both	4	O
purified	8	O
recombinant	11	B-Gene
gp350	5	I-Gene
(	1	O
rgp350	6	B-Gene
)	1	O
and	3	O
EBV	3	O
upregulate	10	O
IL-6	4	B-Gene
mRNA	4	I-Gene
synthesis	9	O
in	2	O
B	1	O
cells	5	O
,	1	O
EBV	3	O
-induced	8	O
IL-6	4	B-Gene
gene	4	I-Gene
activation	10	O
occurs	6	O
for	3	O
a	1	O
significantly	13	O
longer	6	O
period	6	O
of	2	O
time	4	O
(	1	O
i.e.	4	O
12	2	O
hours	5	O
for	3	O
EBV	3	O
as	2	O
compared	8	O
to	2	O
6	1	O
hours	5	O
for	3	O
rgp350	6	B-Gene
)	1	O
.	1	O

Moreover	8	O
,	1	O
the	3	O
half-life	9	O
of	2	O
EBV	3	O
-induced	8	O
IL-6	4	B-Gene
mRNA	4	I-Gene
was	3	O
also	4	O
significantly	13	O
longer	6	O
(	1	O
10	2	O
hours	5	O
)	1	O
than	4	O
that	4	O
of	2	O
mRNA	4	O
induced	7	O
by	2	O
rgp350	6	B-Gene
(	1	O
about	5	O
6	1	O
hours	5	O
)	1	O
.	1	O

Both	4	O
EBV	3	O
and	3	O
gp350	5	B-Gene
enhance	7	O
the	3	O
binding	7	O
of	2	O
the	3	O
NF-kappaB	9	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
,	1	O
as	2	O
determined	10	O
by	2	O
band-shift	10	O
and	3	O
augment	7	O
NF-kappaB	9	B-Gene
-mediated	9	O
activation	10	O
of	2	O
a	1	O
CAT	3	O
reporter	8	O
plasmid	7	O
.	1	O

Furthermore	11	O
,	1	O
we	2	O
demonstrate	11	O
that	4	O
while	5	O
the	3	O
activation	10	O
of	2	O
IL-6	4	B-Gene
gene	4	I-Gene
expression	10	O
by	2	O
gp350	5	B-Gene
is	2	O
mediated	8	O
primarily	9	O
by	2	O
the	3	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
pathway	7	O
,	1	O
EBV	3	O
can	3	O
mediate	7	O
its	3	O
effects	7	O
through	7	O
multiple	8	O
signaling	9	O
pathways	8	O
.	1	O

To	2	O
our	3	O
knowledge	9	O
this	4	O
is	2	O
the	3	O
first	5	O
report	6	O
showing	7	O
that	4	O
the	3	O
binding	7	O
of	2	O
a	1	O
herpesvirus	11	O
envelope	8	O
glycoprotein	12	O
to	2	O
CR2	3	B-Gene
on	2	O
human	5	O
B	1	O
cells	5	O
results	7	O
in	2	O
the	3	O
activation	10	O
of	2	O
the	3	O
NF-kappaB	9	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
leading	7	O
to	2	O
the	3	O
upregulation	12	O
of	2	O
IL-6	4	B-Gene
gene	4	I-Gene
expression	10	O
in	2	O
these	5	O
lymphocytes	11	O
.	1	O

Copyright	9	O
2001	4	O
Academic	8	O
Press	5	O
.	1	O

Autostimulation	15	O
of	2	O
the	3	O
Epstein-Barr	12	B-Gene
virus	5	I-Gene
BRLF1	5	I-Gene
promoter	8	I-Gene
is	2	O
mediated	8	O
through	7	O
consensus	9	O
Sp1	3	B-Gene
and	3	O
Sp3	3	B-Gene
binding	7	O
sites	5	O
.	1	O

As	2	O
an	2	O
essential	9	O
step	4	O
in	2	O
the	3	O
lytic	5	O
cascade	7	O
,	1	O
the	3	O
Rta	3	B-Gene
homologues	10	I-Gene
of	2	O
gammaherpesviruses	18	O
all	3	O
activate	8	O
their	5	O
own	3	O
expression	10	O
.	1	O

Consistent	10	O
with	4	O
this	4	O
biologic	8	O
function	8	O
,	1	O
the	3	O
Epstein-Barr	12	B-Gene
virus	5	I-Gene
(	1	I-Gene
EBV	3	I-Gene
)	1	I-Gene
Rta	3	I-Gene
protein	7	I-Gene
powerfully	10	O
stimulates	10	O
the	3	O
promoter	8	O
of	2	O
its	3	O
own	3	O
gene	4	O
,	1	O
Rp	2	B-Gene
,	1	O
in	2	O
EBV	3	O
-positive	9	O
B	1	O
cells	5	O
in	2	O
transient-transfection	22	O
reporter	8	O
-based	6	O
assays	6	O
.	1	O

We	2	O
analyzed	8	O
the	3	O
activity	8	O
of	2	O
RpCAT	5	B-Gene
in	2	O
response	8	O
to	2	O
Rta	3	B-Gene
by	2	O
deletional	10	O
and	3	O
site	4	O
-directed	9	O
mutagenesis	11	O
.	1	O

Two	3	O
cognate	7	O
Sp1	3	B-Gene
binding	7	O
sites	5	O
located	7	O
at	2	O
-279	4	O
and	3	O
-45	3	O
relative	8	O
to	2	O
the	3	O
transcriptional	15	O
start	5	O
site	4	O
proved	6	O
crucial	7	O
for	3	O
Rta	3	B-Gene
-mediated	9	O
activation	10	O
.	1	O

Previously	10	O
described	9	O
binding	7	O
sites	5	O
for	3	O
the	3	O
cellular	8	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
Zif268	6	I-Gene
and	3	O
the	3	O
viral	5	B-Gene
transactivator	14	I-Gene
ZEBRA	5	I-Gene
were	4	O
found	5	O
to	2	O
be	2	O
dispensable	11	O
for	3	O
activation	10	O
of	2	O
RpCAT	5	B-Gene
by	2	O
Rta	3	B-Gene
.	1	O

Gel	3	O
shift	5	O
analysis	8	O
,	1	O
using	5	O
extracts	8	O
of	2	O
B	1	O
cells	5	O
in	2	O
latency	7	O
or	2	O
induced	7	O
into	4	O
the	3	O
lytic	5	O
cycle	5	O
,	1	O
identified	10	O
Sp1	3	B-Gene
and	3	O
Sp3	3	B-Gene
as	2	O
the	3	O
predominant	11	O
cellular	8	O
proteins	8	O
bound	5	O
to	2	O
Rp	2	B-Gene
near	4	O
-45	3	O
.	1	O

During	6	O
the	3	O
lytic	5	O
cycle	5	O
,	1	O
ZEBRA	5	B-Gene
bound	5	O
Rp	2	B-Gene
near	4	O
the	3	O
Sp1	3	B-Gene
/	1	I-Gene
Sp3	3	I-Gene
site	4	O
.	1	O

The	3	O
binding	7	O
of	2	O
Sp1	3	B-Gene
and	3	O
Sp3	3	B-Gene
to	2	O
Rp	2	B-Gene
correlated	10	O
with	4	O
the	3	O
reporter	8	O
activities	10	O
in	2	O
the	3	O
mutagenesis	11	O
study	5	O
,	1	O
establishing	12	O
a	1	O
direct	6	O
link	4	O
between	7	O
transcriptional	15	O
activation	10	O
of	2	O
Rp	2	B-Gene
by	2	O
Rta	3	B-Gene
and	3	O
DNA	3	O
binding	7	O
by	2	O
Sp1	3	B-Gene
and	3	O
/	1	O
or	2	O
Sp3	3	B-Gene
.	1	O

The	3	O
relative	8	O
abundance	9	O
or	2	O
functional	10	O
state	5	O
of	2	O
the	3	O
cellular	8	B-Gene
Sp1	3	I-Gene
and	3	O
Sp3	3	B-Gene
transcription	13	I-Gene
factors	7	I-Gene
may	3	O
be	2	O
altered	7	O
in	2	O
response	8	O
to	2	O
stimuli	7	O
that	4	O
induce	6	O
the	3	O
BRLF1	5	B-Gene
promoter	8	I-Gene
and	3	O
thereby	7	O
contribute	10	O
to	2	O
the	3	O
activation	10	O
of	2	O
the	3	O
viral	5	O
lytic	5	O
cycle	5	O
.	1	O

A	1	O
genetic	7	O
investigation	13	O
of	2	O
E2A	3	B-Gene
function	8	O
in	2	O
lymphocyte	10	O
development	11	O
.	1	O

Lymphocytes	11	O
are	3	O
derived	7	O
from	4	O
hematopoietic	13	O
stem	4	O
cells	5	O
(	1	O
HSC	3	O
)	1	O
following	9	O
a	1	O
series	6	O
of	2	O
regulated	9	O
differentiation	15	O
events	6	O
.	1	O

Multipotent	11	O
HSCs	4	O
become	6	O
committed	9	O
to	2	O
the	3	O
B	1	O
cell	4	O
lineage	7	O
in	2	O
bone	4	O
marrow	6	O
and	3	O
the	3	O
T	1	O
cell	4	O
lineage	7	O
in	2	O
the	3	O
thymus	6	O
after	5	O
receiving	9	O
appropriate	11	O
signals	7	O
from	4	O
the	3	O
corresponding	13	O
microenvironment	16	O
.	1	O

These	5	O
committed	9	O
lymphoid	8	O
cells	5	O
must	4	O
then	4	O
undergo	7	O
V	1	O
(	1	O
D	1	O
)	1	O
J	1	O
recombination	13	O
at	2	O
the	3	O
immunoglobulin	14	B-Gene
gene	4	I-Gene
or	2	O
T	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
gene	4	I-Gene
locus	5	I-Gene
resulting	9	O
in	2	O
clonal	6	O
production	10	O
of	2	O
functional	10	O
B	1	O
or	2	O
T	1	O
lymphocytes	11	O
,	1	O
respectively	12	O
.	1	O

Lymphocyte	10	O
commitment	10	O
and	3	O
differentiation	15	O
are	3	O
accompanied	11	O
by	2	O
programmed	10	O
gene	4	O
expression	10	O
or	2	O
repression	10	O
events	6	O
which	5	O
are	3	O
driven	6	O
by	2	O
lineage	7	O
and	3	O
stage	5	O
specific	8	O
transcription	13	O
factors	7	O
.	1	O

The	3	O
basic-helix-loop-helix	22	O
(	1	O
bHLH	4	O
)	1	O
transcription	13	O
factors	7	O
encoded	7	O
by	2	O
the	3	O
E2A	3	B-Gene
gene	4	I-Gene
are	3	O
involved	8	O
in	2	O
several	7	O
differentiation	15	O
events	6	O
during	6	O
B	1	O
and	3	O
T	1	O
cell	4	O
development	11	O
,	1	O
including	9	O
lineage	7	O
commitment	10	O
,	1	O
initiation	10	O
of	2	O
V	1	O
(	1	O
D	1	O
)	1	O
J	1	O
recombination	13	O
,	1	O
and	3	O
antigen	7	O
receptor	8	O
mediated	8	O
proliferation	13	O
and	3	O
differentiation	15	O
.	1	O

Several	7	O
recent	6	O
reviews	7	O
have	4	O
provided	8	O
a	1	O
comprehensive	13	O
discussion	10	O
of	2	O
biochemical	11	O
,	1	O
cellular	8	O
,	1	O
and	3	O
genetic	7	O
research	8	O
on	2	O
E2A	3	B-Gene
function	8	O
in	2	O
lymphocyte	10	O
development	11	O
(	1	O
1	1	O
,	1	O
2	1	O
)	1	O
.	1	O

Here	4	O
,	1	O
we	2	O
only	4	O
discuss	7	O
some	4	O
of	2	O
the	3	O
genetic	7	O
approaches	10	O
our	3	O
laboratory	10	O
(	1	O
except	6	O
where	5	O
it	2	O
is	2	O
noted	5	O
)	1	O
has	3	O
undertaken	10	O
to	2	O
investigate	11	O
the	3	O
molecular	9	O
pathways	8	O
mediated	8	O
by	2	O
E2A	3	B-Gene
transcription	13	I-Gene
factors	7	I-Gene
in	2	O
lymphocyte	10	O
development	11	O

Oxidized	8	O
alkyl	5	O
phospholipids	13	B-Chemical
are	3	O
specific	8	O
,	1	O
high	4	O
affinity	8	O
peroxisome	10	B-Gene
proliferator	12	I-Gene
-activated	10	I-Gene
receptor	8	I-Gene
gamma	5	I-Gene
ligands	7	I-Gene
and	3	O
agonists	8	O
.	1	O

Synthetic	9	O
high	4	O
affinity	8	O
peroxisome	10	B-Gene
proliferator	12	I-Gene
-activated	10	I-Gene
receptor	8	I-Gene
(	1	I-Gene
PPAR	4	I-Gene
)	1	I-Gene
agonists	8	I-Gene
are	3	O
known	5	O
,	1	O
but	3	O
biologic	8	O
ligands	7	O
are	3	O
of	2	O
low	3	O
affinity	8	O
.	1	O

Oxidized	8	O
low	3	O
density	7	O
lipoprotein	11	O
(	1	O
oxLDL	5	O
)	1	O
is	2	O
inflammatory	12	O
and	3	O
signals	7	O
through	7	O
PPARs	5	B-Gene
.	1	O

We	2	O
showed	6	O
,	1	O
by	2	O
phospholipase	13	B-Gene
A	1	I-Gene
(	1	O
1	1	O
)	1	O
digestion	9	O
,	1	O
that	4	O
PPARgamma	9	B-Gene
agonists	8	I-Gene
in	2	O
oxLDL	5	O
arise	5	O
from	4	O
the	3	O
small	5	O
pool	4	O
of	2	O
alkyl	5	B-Chemical
phosphatidylcholines	20	I-Chemical
in	2	O
LDL	3	O
.	1	O

We	2	O
identified	10	O
an	2	O
abundant	8	O
oxidatively	11	O
fragmented	10	O
alkyl	5	O
phospholipid	12	B-Chemical
in	2	O
oxLDL	5	O
,	1	O
hexadecyl	9	B-Chemical
azelaoyl	8	I-Chemical
phosphatidylcholine	19	I-Chemical
(	1	O
azPC	4	B-Chemical
)	1	O
,	1	O
as	2	O
a	1	O
high	4	O
affinity	8	O
ligand	6	O
and	3	O
agonist	7	O
for	3	O
PPARgamma	9	B-Gene
.	1	O

[	1	O
(	1	O
3	1	O
)	1	O
H	1	O
]	1	O
azPC	4	B-Chemical
bound	5	O
recombinant	11	O
PPARgamma	9	B-Gene
with	4	O
an	2	O
affinity	8	O
(	1	O
K	1	O
(	1	O
d	1	O
)	1	O
(	1	O
(	1	O
app	3	O
)	1	O
)	1	O
approximately	13	O
40	2	O
nm	2	O
)	1	O
that	4	O
was	3	O
equivalent	10	O
to	2	O
rosiglitazone	13	B-Chemical
(	1	O
BRL49653	8	B-Chemical
)	1	O
,	1	O
and	3	O
competition	11	O
with	4	O
rosiglitazone	13	B-Chemical
showed	6	O
that	4	O
binding	7	O
occurred	8	O
in	2	O
the	3	O
ligand	6	O
-binding	8	O
pocket	6	O
.	1	O

azPC	4	B-Chemical
induced	7	O
PPRE	4	B-Gene
reporter	8	O
gene	4	O
expression	10	O
,	1	O
as	2	O
did	3	O
rosiglitazone	13	B-Chemical
,	1	O
with	4	O
a	1	O
half-maximal	12	O
effect	6	O
at	2	O
100	3	O
nm	2	O
.	1	O

Overexpression	14	O
of	2	O
PPARalpha	9	B-Gene
or	2	O
PPARgamma	9	B-Gene
revealed	8	O
that	4	O
azPC	4	B-Chemical
was	3	O
a	1	O
specific	8	O
PPARgamma	9	B-Gene
agonist	7	I-Gene
.	1	O

The	3	O
scavenger	9	B-Gene
receptor	8	I-Gene
CD36	4	I-Gene
is	2	O
encoded	7	O
by	2	O
a	1	O
PPRE	4	B-Gene
-responsive	11	O
gene	4	O
,	1	O
and	3	O
azPC	4	B-Chemical
enhanced	8	O
expression	10	O
of	2	O
CD36	4	B-Gene
in	2	O
primary	7	O
human	5	O
monocytes	9	O
.	1	O

We	2	O
found	5	O
that	4	O
anti-CD36	9	B-Gene
inhibited	9	O
azPC	4	B-Chemical
uptake	6	O
,	1	O
and	3	O
it	2	O
inhibited	9	O
PPRE	4	B-Gene
reporter	8	O
induction	9	O
.	1	O

Results	7	O
with	4	O
a	1	O
small	5	O
molecule	8	O
phospholipid	12	B-Gene
flippase	8	I-Gene
mimetic	7	O
suggest	7	O
azPC	4	B-Chemical
acts	4	O
intracellularly	15	O
and	3	O
that	4	O
cellular	8	O
azPC	4	B-Chemical
accumulation	12	O
was	3	O
efficient	9	O
.	1	O

Thus	4	O
,	1	O
certain	7	O
alkyl	5	O
phospholipid	12	B-Chemical
oxidation	9	O
products	8	O
in	2	O
oxLDL	5	O
are	3	O
specific	8	O
,	1	O
high	4	O
affinity	8	O
extracellular	13	O
ligands	7	O
and	3	O
agonists	8	O
for	3	O
PPARgamma	9	B-Gene
that	4	O
induce	6	O
PPAR	4	B-Gene
-responsive	11	O
genes	5	O

Ligation	8	O
of	2	O
CD11b	5	B-Gene
and	3	O
CD11c	5	B-Gene
beta	4	I-Gene
(	1	I-Gene
2	1	I-Gene
)	1	I-Gene
integrins	9	I-Gene
by	2	O
antibodies	10	O
or	2	O
soluble	7	B-Gene
CD23	4	I-Gene
induces	7	O
macrophage	10	B-Gene
inflammatory	12	I-Gene
protein	7	I-Gene
1alpha	6	I-Gene
(	1	O
MIP-1alpha	10	B-Gene
)	1	O
and	3	O
MIP-1beta	9	B-Gene
production	10	O
in	2	O
primary	7	O
human	5	O
monocytes	9	O
through	7	O
a	1	O
pathway	7	O
dependent	9	O
on	2	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
.	1	O

Chemokines	10	O
and	3	O
adhesion	8	O
molecules	9	O
such	4	O
as	2	O
integrins	9	B-Gene
play	4	O
a	1	O
major	5	O
part	4	O
in	2	O
the	3	O
trafficking	11	O
,	1	O
extravasation	13	O
,	1	O
and	3	O
recruitment	11	O
of	2	O
leukocytes	10	O
to	2	O
inflammatory	12	O
sites	5	O
.	1	O

This	4	O
study	5	O
investigated	12	O
the	3	O
effects	7	O
of	2	O
beta	4	B-Gene
(	1	I-Gene
2	1	I-Gene
)	1	I-Gene
integrin	8	I-Gene
engagement	10	O
on	2	O
chemokine	9	O
production	10	O
by	2	O
freshly	7	O
isolated	8	O
human	5	O
monocytes	9	O
.	1	O

We	2	O
found	5	O
that	4	O
ligation	8	O
of	2	O
CD11b	5	B-Gene
or	2	O
CD11c	5	B-Gene
but	3	O
not	3	O
CD11a	5	B-Gene
alpha	5	I-Gene
chains	6	I-Gene
of	2	O
beta	4	B-Gene
(	1	I-Gene
2	1	I-Gene
)	1	I-Gene
integrins	9	I-Gene
by	2	O
antibodies	10	O
or	2	O
soluble	7	B-Gene
CD23	4	I-Gene
(	1	I-Gene
sCD23	5	I-Gene
)	1	I-Gene
fusion	6	I-Gene
proteins	8	I-Gene
rapidly	7	O
induced	7	O
transcription	13	O
and	3	O
secretion	9	O
of	2	O
interleukin	11	B-Gene
8	1	I-Gene
,	1	O
macrophage	10	B-Gene
inflammatory	12	I-Gene
protein	7	I-Gene
(	1	I-Gene
MIP	3	I-Gene
)	1	I-Gene
1alpha	6	I-Gene
,	1	O
and	3	O
MIP-1beta	9	B-Gene
.	1	O

Because	7	O
the	3	O
promoters	9	O
of	2	O
these	5	O
chemokine	9	O
genes	5	O
contain	7	O
kappaB	6	O
binding	7	O
sites	5	O
,	1	O
we	2	O
assessed	8	O
the	3	O
possible	8	O
role	4	O
of	2	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
(	1	O
NF-kappaB	9	B-Gene
)	1	O
in	2	O
controlling	11	O
induction	9	O
of	2	O
the	3	O
genes	5	O
through	7	O
beta	4	B-Gene
(	1	I-Gene
2	1	I-Gene
)	1	I-Gene
integrin	8	I-Gene
engagement	10	O
.	1	O

Electrophoretic	15	O
mobility	8	O
shift	5	O
assays	6	O
showed	6	O
that	4	O
sCD23	5	B-Gene
or	2	O
antibodies	10	O
to	2	O
CD11b	5	B-Gene
or	2	O
to	2	O
CD11c	5	B-Gene
up	2	O
-regulated	10	O
DNA	3	O
-binding	8	O
activity	8	O
of	2	O
NF-kappaB	9	B-Gene
.	1	O

Activation	10	O
of	2	O
NF-kappaB	9	B-Gene
was	3	O
accompanied	11	O
by	2	O
degradation	11	O
of	2	O
its	3	O
cytosolic	9	B-Gene
inhibitor	9	I-Gene
IkappaB-alpha	13	I-Gene
.	1	O

Blockade	8	O
of	2	O
depletion	9	O
of	2	O
IkappaB-alpha	13	B-Gene
by	2	O
proteasome	10	O
inhibitors	10	O
(	1	O
proteasome	10	B-Chemical
inhibitor	9	I-Chemical
I	1	I-Chemical
or	2	O
acetyl-leucinyl-leucinyl-norleucinal	36	B-Chemical
)	1	O
led	3	O
to	2	O
concomitant	11	O
inhibition	10	O
of	2	O
NF-kappaB	9	B-Gene
DNA	3	I-Gene
-binding	8	O
activity	8	O
and	3	O
expression	10	O
of	2	O
MIP-1alpha	10	B-Gene
and	3	O
MIP-1beta	9	B-Gene
messenger	9	I-Gene
RNA	3	I-Gene
induced	7	O
by	2	O
beta	4	B-Gene
(	1	I-Gene
2	1	I-Gene
)	1	I-Gene
integrin	8	I-Gene
ligation	8	O
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
triggering	10	O
of	2	O
CD11b	5	B-Gene
or	2	O
CD11c	5	B-Gene
beta	4	I-Gene
(	1	I-Gene
2	1	I-Gene
)	1	I-Gene
integrin	8	I-Gene
on	2	O
primary	7	O
human	5	O
monocytes	9	O
provides	8	O
activation	10	O
signals	7	O
leading	7	O
to	2	O
nuclear	7	O
translocation	13	O
of	2	O
NF-kappaB	9	B-Gene
and	3	O
subsequent	10	O
secretion	9	O
of	2	O
MIP-1alpha	10	B-Gene
and	3	O
MIP-1beta	9	B-Gene
that	4	O
may	3	O
have	4	O
an	2	O
important	9	O
role	4	O
in	2	O
recruitment	11	O
of	2	O
other	5	O
inflammatory	12	O
cells	5	O
during	6	O
initiation	10	O
of	2	O
an	2	O
inflammatory	12	O
response	8	O

Functional	10	O
correction	10	O
of	2	O
FA-C	4	B-Disease
cells	5	O
with	4	O
FANCC	5	B-Gene
suppresses	10	O
the	3	O
expression	10	O
of	2	O
interferon	10	B-Gene
gamma-inducible	15	I-Gene
genes	5	O
.	1	O

Because	7	O
hematopoietic	13	O
cells	5	O
derived	7	O
from	4	O
Fanconi	7	B-Disease
anemia	6	I-Disease
(	1	O
FA	2	B-Disease
)	1	O
patients	8	O
of	2	O
the	3	O
C	1	O
-complementation	16	O
group	5	O
(	1	O
FA-C	4	B-Disease
)	1	O
are	3	O
hypersensitive	14	O
to	2	O
the	3	O
inhibitory	10	O
effects	7	O
of	2	O
interferon	10	B-Gene
gamma	5	I-Gene
(	1	O
IFNgamma	8	B-Gene
)	1	O
,	1	O
the	3	O
products	8	O
of	2	O
certain	7	O
IFNgamma-inducible	18	B-Gene
genes	5	O
known	5	O
to	2	O
influence	9	O
hematopoietic	13	O
cell	4	O
survival	8	O
were	4	O
quantified	10	O
.	1	O

High	4	O
constitutive	12	O
expression	10	O
of	2	O
the	3	O
IFNgamma-inducible	18	B-Gene
genes	5	O
,	1	O
IFN	3	B-Gene
-stimulated	11	I-Gene
gene	4	I-Gene
factor	6	I-Gene
3	1	I-Gene
gamma	5	I-Gene
subunit	7	I-Gene
(	1	O
ISGF3gamma	10	B-Gene
)	1	O
,	1	O
IFN	3	B-Gene
regulatory	10	I-Gene
factor-1	8	I-Gene
(	1	O
IRF-1	5	B-Gene
)	1	O
,	1	O
and	3	O
the	3	O
cyclin	6	B-Gene
-dependent	10	I-Gene
kinase	6	I-Gene
inhibitor	9	I-Gene
p21	3	I-Gene
(	1	O
WAF1	4	B-Gene
)	1	O
was	3	O
found	5	O
in	2	O
FANCC	5	B-Gene
mutant	6	I-Gene
B	1	O
lymphoblasts	12	O
,	1	O
low-density	11	O
bone	4	O
marrow	6	O
cells	5	O
,	1	O
and	3	O
murine	6	O
embryonic	9	O
fibroblasts	11	O
.	1	O

Paradoxically	13	O
,	1	O
these	5	O
cells	5	O
do	2	O
not	3	O
activate	8	O
signal	6	B-Gene
transducer	10	I-Gene
and	3	I-Gene
activator	9	I-Gene
of	2	I-Gene
transcription	13	I-Gene
(	1	I-Gene
STAT	4	I-Gene
)	1	I-Gene
1	1	I-Gene
properly	8	O
.	1	O

In	2	O
an	2	O
attempt	7	O
to	2	O
clarify	7	O
mechanisms	10	O
by	2	O
which	5	O
FA-C	4	B-Disease
cells	5	O
overexpress	11	O
IFNgamma-inducible	18	B-Gene
genes	5	O
in	2	O
the	3	O
face	4	O
of	2	O
defective	9	O
STAT1	5	B-Gene
phosphorylation	15	O
,	1	O
it	2	O
was	3	O
reasoned	8	O
that	4	O
decreased	9	O
levels	6	O
of	2	O
activated	9	O
STAT1	5	B-Gene
might	5	O
result	6	O
in	2	O
reduced	7	O
expression	10	O
of	2	O
a	1	O
hematopoietic	13	B-Gene
IFNgamma	8	I-Gene
-responsive	11	I-Gene
protein	7	I-Gene
that	4	O
normally	8	O
modulates	9	O
expression	10	O
of	2	O
other	5	O
IFNgamma	8	B-Gene
-responsive	11	O
genes	5	O
.	1	O

Levels	6	O
of	2	O
the	3	O
IFNgamma	8	B-Gene
-inducible	10	O
factor	6	O
IFN	3	B-Gene
consensus	9	I-Gene
sequence	8	I-Gene
binding	7	I-Gene
protein	7	I-Gene
(	1	O
ICSBP	5	B-Gene
)	1	O
,	1	O
a	1	O
negative	8	O
trans	5	O
-acting	7	O
regulator	9	O
of	2	O
some	4	O
IFNgamma-inducible	18	B-Gene
genes	5	O
,	1	O
were	4	O
quantified	10	O
.	1	O

ICSBP	5	B-Gene
levels	6	O
were	4	O
reduced	7	O
in	2	O
FA-C	4	B-Disease
B	1	O
lymphoblasts	12	O
and	3	O
MEFs	4	O
.	1	O

However	7	O
,	1	O
enforced	8	O
expression	10	O
of	2	O
ICSBP	5	B-Gene
failed	6	O
to	2	O
down-regulate	13	O
IRF-1	5	B-Gene
,	1	O
ISGF3gamma	10	B-Gene
,	1	O
and	3	O
p21	3	B-Gene
(	1	O
WAF1	4	B-Gene
)	1	O
.	1	O

Thus	4	O
,	1	O
the	3	O
FANCC	5	B-Gene
protein	7	I-Gene
functions	9	O
to	2	O
modulate	8	O
expression	10	O
of	2	O
a	1	O
family	6	O
of	2	O
genes	5	O
that	4	O
in	2	O
normal	6	O
cells	5	O
are	3	O
inducible	9	O
only	4	O
by	2	O
specific	8	O
environmental	13	O
cues	4	O
for	3	O
apoptosis	9	O
or	2	O
mitogenic	9	O
inhibition	10	O
,	1	O
but	3	O
it	2	O
does	4	O
so	2	O
independently	13	O
of	2	O
the	3	O
classic	7	O
IFN-STAT1	9	B-Gene
pathway	7	O
and	3	O
is	2	O
not	3	O
the	3	O
direct	6	O
result	6	O
of	2	O
reduced	7	O
ICSBP	5	B-Gene
expression	10	O
.	1	O

Distinct	8	O
BMI-1	5	B-Gene
and	3	O
EZH2	4	B-Gene
expression	10	O
patterns	8	O
in	2	O
thymocytes	10	O
and	3	O
mature	6	O
T	1	O
cells	5	O
suggest	7	O
a	1	O
role	4	O
for	3	O
Polycomb	8	B-Gene
genes	5	I-Gene
in	2	O
human	5	O
T	1	O
cell	4	O
differentiation	15	O
.	1	O

BMI-1	5	B-Gene
and	3	O
EZH2	4	B-Gene
Polycomb-group	14	I-Gene
(	1	I-Gene
PcG	3	I-Gene
)	1	I-Gene
proteins	8	I-Gene
belong	6	O
to	2	O
two	3	O
distinct	8	O
protein	7	O
complexes	9	O
involved	8	O
in	2	O
the	3	O
regulation	10	O
of	2	O
hematopoiesis	13	O
.	1	O

Using	5	O
unique	6	O
PcG-specific	12	B-Gene
antisera	8	I-Gene
and	3	O
triple	6	O
immunofluorescence	18	O
,	1	O
we	2	O
found	5	O
that	4	O
mature	6	O
resting	7	O
peripheral	10	O
T	1	O
cells	5	O
expressed	9	O
BMI-1	5	B-Gene
,	1	O
whereas	7	O
dividing	8	O
blasts	6	O
were	4	O
EZH2	4	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
.	1	O

By	2	O
contrast	8	O
,	1	O
subcapsular	11	O
immature	8	O
double	6	O
-negative	9	O
(	1	O
DN	2	O
)	1	O
(	1	O
CD4	3	B-Gene
(	1	I-Gene
-	1	I-Gene
)	1	I-Gene
/	1	I-Gene
CD8	3	I-Gene
(	1	I-Gene
-	1	I-Gene
)	1	I-Gene
)	1	O
T	1	O
cells	5	O
in	2	O
the	3	O
thymus	6	O
coexpressed	11	O
BMI-1	5	B-Gene
and	3	O
EZH2	4	B-Gene
or	2	O
were	4	O
BMI-1	5	B-Gene
single	6	O
positive	8	O
.	1	O

Their	5	O
descendants	11	O
,	1	O
double	6	O
-positive	9	O
(	1	O
DP	2	O
;	1	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
/	1	I-Gene
CD8	3	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
)	1	O
cortical	8	O
thymocytes	10	O
,	1	O
expressed	9	O
EZH2	4	B-Gene
without	7	O
BMI-1	5	B-Gene
.	1	O

Most	4	O
EZH2	4	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
DN	2	O
and	3	O
DP	2	O
thymocytes	10	O
were	4	O
dividing	8	O
,	1	O
while	5	O
DN	2	O
BMI-1	5	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
/	1	I-Gene
EZH2	4	I-Gene
(	1	I-Gene
-	1	I-Gene
)	1	I-Gene
thymocytes	10	O
were	4	O
resting	7	O
and	3	O
proliferation	13	O
was	3	O
occasionally	12	O
noted	5	O
in	2	O
DN	2	O
BMI-1	5	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
/	1	I-Gene
EZH2	4	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
cells	5	O
.	1	O

Maturation	10	O
of	2	O
DP	2	O
cortical	8	O
thymocytes	10	O
to	2	O
single	6	O
-positive	9	O
(	1	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
/	1	I-Gene
CD8	3	I-Gene
(	1	I-Gene
-	1	I-Gene
)	1	I-Gene
or	2	O
CD8	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
/	1	I-Gene
CD4	3	I-Gene
(	1	I-Gene
-	1	I-Gene
)	1	I-Gene
)	1	O
medullar	8	O
thymocytes	10	O
correlated	10	O
with	4	O
decreased	9	O
detectability	13	O
of	2	O
EZH2	4	B-Gene
and	3	O
continued	9	O
relative	8	O
absence	7	O
of	2	O
BMI-1	5	B-Gene
.	1	O

Our	3	O
data	4	O
show	4	O
that	4	O
BMI-1	5	B-Gene
and	3	O
EZH2	4	B-Gene
expression	10	O
in	2	O
mature	6	O
peripheral	10	O
T	1	O
cells	5	O
is	2	O
mutually	8	O
exclusive	9	O
and	3	O
linked	6	O
to	2	O
proliferation	13	O
status	6	O
,	1	O
and	3	O
that	4	O
this	4	O
pattern	7	O
is	2	O
not	3	O
yet	3	O
established	11	O
in	2	O
thymocytes	10	O
of	2	O
the	3	O
cortex	6	O
and	3	O
medulla	7	O
.	1	O

T	1	O
cell	4	O
stage-specific	14	O
PcG	3	B-Gene
expression	10	O
profiles	8	O
suggest	7	O
that	4	O
PcG	3	B-Gene
genes	5	I-Gene
contribute	10	O
to	2	O
regulation	10	O
of	2	O
T	1	O
cell	4	O
differentiation	15	O
.	1	O

They	4	O
probably	8	O
reflect	7	O
stabilization	13	O
of	2	O
cell	4	O
type-specific	13	O
gene	4	O
expression	10	O
and	3	O
irreversibility	15	O
of	2	O
lineage	7	O
choice	6	O
.	1	O

The	3	O
difference	10	O
in	2	O
PcG	3	B-Gene
expression	10	O
between	7	O
medullar	8	O
thymocytes	10	O
and	3	O
mature	6	O
interfollicular	15	O
T	1	O
cells	5	O
indicates	9	O
that	4	O
additional	10	O
maturation	10	O
processes	9	O
occur	5	O
after	5	O
thymocyte	9	O
transportation	14	O
from	4	O
the	3	O
thymus	6	O
.	1	O

CD45	4	B-Gene
tyrosine	8	I-Gene
phosphatase	11	I-Gene
controls	8	O
common	6	B-Gene
gamma-chain	11	I-Gene
cytokine	8	I-Gene
-mediated	9	O
STAT	4	B-Gene
and	3	O
extracellular	13	O
signal	6	O
-related	8	O
kinase	6	O
phosphorylation	15	O
in	2	O
activated	9	O
human	5	O
lymphoblasts	12	O
:	1	O
inhibition	10	O
of	2	O
proliferation	13	O
without	7	O
induction	9	O
of	2	O
apoptosis	9	O
.	1	O

The	3	O
objective	9	O
of	2	O
this	4	O
study	5	O
was	3	O
to	2	O
test	4	O
whether	7	O
CD45	4	B-Gene
signals	7	O
can	3	O
influence	9	O
signaling	9	O
processes	9	O
in	2	O
activated	9	O
human	5	O
lymphoblasts	12	O
.	1	O

To	2	O
this	4	O
end	3	O
,	1	O
we	2	O
generated	9	O
lymphoblasts	12	O
which	5	O
proliferate	11	O
in	2	O
response	8	O
to	2	O
common	6	B-Gene
gamma-chain	11	I-Gene
cytokines	9	O
,	1	O
but	3	O
readily	7	O
undergo	7	O
apoptosis	9	O
after	5	O
cytokine	8	O
withdrawal	10	O
.	1	O

In	2	O
experiments	11	O
with	4	O
the	3	O
CD45R0	6	B-Gene
mAb	3	I-Gene
UCHL-1	6	I-Gene
,	1	O
but	3	O
not	3	O
control	7	O
CD45	4	B-Gene
mAbs	4	I-Gene
,	1	O
we	2	O
found	5	O
significant	11	O
inhibition	10	O
of	2	O
proliferation	13	O
.	1	O

Interestingly	13	O
,	1	O
the	3	O
pan-CD45	8	B-Gene
mAb	3	I-Gene
GAP8.3	6	O
,	1	O
which	5	O
is	2	O
most	4	O
effective	9	O
in	2	O
inhibition	10	O
of	2	O
OKT-3	5	B-Chemical
-mediated	9	O
proliferation	13	O
in	2	O
quiescent	9	O
lymphocytes	11	O
,	1	O
was	3	O
ineffective	11	O
in	2	O
lymphoblasts	12	O
.	1	O

Addition	8	O
of	2	O
CD3	3	B-Gene
mAb	3	I-Gene
OKT-3	5	B-Chemical
had	3	O
no	2	O
influence	9	O
on	2	O
IL-2	4	B-Gene
-mediated	9	O
proliferation	13	O
(	1	O
with	4	O
or	2	O
without	7	O
UCHL-1	6	B-Gene
)	1	O
.	1	O

In	2	O
contrast	8	O
,	1	O
after	5	O
addition	8	O
of	2	O
OKT-3	5	B-Chemical
to	2	O
IL-4	4	B-Gene
-	1	O
and	3	O
IL-7	4	B-Gene
-stimulated	11	O
proliferation	13	O
assays	6	O
,	1	O
UCHL-1	6	B-Gene
signals	7	O
could	5	O
not	3	O
significantly	13	O
alter	5	O
cellular	8	O
proliferation	13	O
.	1	O

We	2	O
did	3	O
not	3	O
find	4	O
induction	9	O
of	2	O
apoptosis	9	O
following	9	O
CD45R0	6	B-Gene
signaling	9	O
.	1	O

In	2	O
Western	7	O
blots	5	O
using	5	O
mAbs	4	O
detecting	9	O
phosphorylated	14	B-Gene
STAT-3	6	I-Gene
,	1	O
STAT-5	6	B-Gene
,	1	O
STAT-6	6	B-Gene
,	1	O
or	2	O
extracellular	13	B-Gene
signal	6	I-Gene
-related	8	I-Gene
kinase	6	I-Gene
1	1	I-Gene
/	1	I-Gene
2	1	I-Gene
,	1	O
we	2	O
found	5	O
that	4	O
CD45R0	6	B-Gene
signaling	9	O
could	5	O
effectively	11	O
diminish	8	O
phosphorylation	15	O
of	2	O
these	5	O
intracellular	13	O
signaling	9	O
components	10	O
.	1	O

Using	5	O
RT-PCR	6	O
,	1	O
we	2	O
found	5	O
that	4	O
CD45R0	6	B-Gene
signaling	9	O
inhibited	9	O
IL-2	4	B-Gene
mRNA	4	I-Gene
production	10	O
without	7	O
major	5	O
influence	9	O
on	2	O
IL-13	5	B-Gene
,	1	O
IL-5	4	B-Gene
,	1	O
or	2	O
IFN-gamma	9	B-Gene
mRNA	4	I-Gene
levels	6	O
.	1	O

Costimulation	13	O
with	4	O
OKT-3	5	B-Chemical
and	3	O
IL-2	4	B-Gene
optimally	9	O
induced	7	O
secretion	9	O
of	2	O
IFN-gamma	9	B-Gene
,	1	O
TNF-alpha	9	B-Gene
,	1	O
and	3	O
IL-5	4	B-Gene
,	1	O
which	5	O
was	3	O
not	3	O
decreased	9	O
by	2	O
CD45	4	B-Gene
signals	7	O
.	1	O

In	2	O
conclusion	10	O
,	1	O
we	2	O
illustrate	10	O
that	4	O
CD45R0	6	B-Gene
signals	7	O
control	7	O
early	5	O
cytokine	8	O
receptor	8	O
-associated	11	O
signaling	9	O
processes	9	O
and	3	O
mRNA	4	O
and	3	O
DNA	3	O
synthesis	9	O
in	2	O
activated	9	O
human	5	O
lymphoblasts	12	O
.	1	O

Furthermore	11	O
,	1	O
we	2	O
show	4	O
the	3	O
existence	9	O
of	2	O
CD45	4	B-Gene
epitopes	8	O
(	1	O
GAP8.3	6	O
)	1	O
,	1	O
which	5	O
are	3	O
active	6	O
and	3	O
critical	8	O
for	3	O
signaling	9	O
in	2	O
quiescent	9	O
lymphocytes	11	O
,	1	O
but	3	O
are	3	O
nonfunctional	13	O
in	2	O
activated	9	O
human	5	O
lymphoblasts	12	O
.	1	O

Positive	8	O
and	3	O
negative	8	O
roles	5	O
of	2	O
the	3	O
trans	5	O
-acting	7	O
T	1	B-Gene
cell	4	I-Gene
factor-1	8	I-Gene
for	3	O
the	3	O
acquisition	11	O
of	2	O
distinct	8	O
Ly-49	5	B-Gene
MHC	3	I-Gene
class	5	I-Gene
I	1	I-Gene
receptors	9	I-Gene
by	2	O
NK	2	O
cells	5	O
.	1	O

Members	7	O
of	2	O
the	3	O
Ly-49	5	B-Gene
gene	4	I-Gene
family	6	I-Gene
code	4	O
for	3	O
class	5	B-Gene
I	1	I-Gene
MHC-specific	12	I-Gene
receptors	9	I-Gene
that	4	O
regulate	8	O
NK	2	O
cell	4	O
function	8	O
.	1	O

Due	3	O
to	2	O
a	1	O
combinatorial	13	O
distribution	12	O
of	2	O
Ly-49	5	B-Gene
receptors	9	I-Gene
,	1	O
NK	2	O
cells	5	O
display	7	O
considerable	12	O
clonal	6	O
heterogeneity	13	O
.	1	O

The	3	O
acquisition	11	O
of	2	O
one	3	O
Ly-49	5	B-Gene
receptor	8	I-Gene
,	1	O
Ly-49A	6	B-Gene
is	2	O
strictly	8	O
dependent	9	O
on	2	O
the	3	O
transcriptional	15	B-Gene
trans	5	I-Gene
-acting	7	I-Gene
factor	6	I-Gene
T	1	I-Gene
cell-specific	13	I-Gene
factor-1	8	I-Gene
(	1	O
TCF-1	5	B-Gene
)	1	O
.	1	O

Indeed	6	O
,	1	O
TCF-1	5	B-Gene
binds	5	O
to	2	O
two	3	O
sites	5	O
in	2	O
the	3	O
Ly-49a	6	B-Gene
promoter	8	I-Gene
and	3	O
regulates	9	O
its	3	O
activity	8	O
,	1	O
suggesting	10	O
that	4	O
the	3	O
Ly-49a	6	B-Gene
gene	4	I-Gene
is	2	O
a	1	O
direct	6	O
TCF-1	5	B-Gene
target	6	O
.	1	O

TCF-1	5	B-Gene
deficiency	10	O
resulted	8	O
in	2	O
the	3	O
altered	7	O
usage	5	O
of	2	O
additional	10	O
Ly-49	5	B-Gene
receptors	9	I-Gene
.	1	O

We	2	O
show	4	O
in	2	O
this	4	O
study	5	O
,	1	O
using	5	O
TCF-1	5	B-Gene
beta	4	I-Gene
(	1	I-Gene
2	1	I-Gene
)	1	I-Gene
-microglobulin	14	I-Gene
double	6	O
-deficient	10	O
mice	4	O
,	1	O
that	4	O
these	5	O
repertoire	10	O
alterations	11	O
are	3	O
not	3	O
due	3	O
to	2	O
Ly-49	5	B-Gene
/	1	I-Gene
MHC	3	I-Gene
class	5	I-Gene
I	1	I-Gene
interactions	12	O
.	1	O

Our	3	O
findings	8	O
rather	6	O
suggest	7	O
a	1	O
TCF-1	5	B-Gene
-dependent	10	O
,	1	O
cell	4	O
autonomous	10	O
effect	6	O
on	2	O
the	3	O
acquisition	11	O
of	2	O
multiple	8	O
Ly-49	5	B-Gene
receptors	9	I-Gene
.	1	O

Besides	7	O
reduced	7	O
receptor	8	O
usage	5	O
(	1	O
Ly-49A	6	B-Gene
and	3	O
D	1	B-Partial_Gene
)	1	O
,	1	O
we	2	O
also	4	O
observed	8	O
no	2	O
effect	6	O
(	1	O
Ly-49C	6	B-Gene
)	1	O
and	3	O
significantly	13	O
expanded	8	O
(	1	O
Ly-49G	6	B-Gene
and	3	O
I	1	B-Partial_Gene
)	1	O
receptor	8	O
usage	5	O
in	2	O
the	3	O
absence	7	O
of	2	O
TCF-1	5	B-Gene
.	1	O

These	5	O
effects	7	O
did	3	O
not	3	O
in	2	O
all	3	O
cases	5	O
correlate	9	O
with	4	O
the	3	O
presence	8	O
of	2	O
TCF	3	B-Gene
binding	7	O
sites	5	O
in	2	O
the	3	O
respective	10	O
proximal	8	O
promoter	8	O
.	1	O

Therefore	9	O
,	1	O
besides	7	O
TCF-1	5	B-Gene
binding	7	O
to	2	O
the	3	O
proximal	8	O
promoter	8	O
,	1	O
Ly-49	5	B-Gene
acquisition	11	O
may	3	O
also	4	O
be	2	O
regulated	9	O
by	2	O
TCF-1	5	B-Gene
binding	7	O
to	2	O
more	4	O
distant	7	O
cis	3	O
-acting	7	O
elements	8	O
and	3	O
/	1	O
or	2	O
by	2	O
regulating	10	O
the	3	O
expression	10	O
of	2	O
additional	10	O
trans	5	O
-acting	7	O
factors	7	O
.	1	O

Consistent	10	O
with	4	O
the	3	O
observed	8	O
differential	12	O
,	1	O
positive	8	O
or	2	O
negative	8	O
role	4	O
of	2	O
TCF-1	5	B-Gene
for	3	O
Ly-49	5	B-Gene
receptor	8	I-Gene
acquisition	11	O
,	1	O
reporter	8	O
gene	4	O
assays	6	O
revealed	8	O
the	3	O
presence	8	O
of	2	O
an	2	O
inducing	8	O
as	2	O
well	4	O
as	2	O
a	1	O
repressing	10	O
TCF	3	B-Gene
site	4	O
in	2	O
certain	7	O
proximal	8	O
Ly-49	5	B-Gene
promoters	9	I-Gene
.	1	O

These	5	O
findings	8	O
reveal	6	O
an	2	O
important	9	O
role	4	O
of	2	O
TCF-1	5	B-Gene
for	3	O
the	3	O
formation	9	O
of	2	O
the	3	O
NK	2	O
cell	4	O
receptor	8	O
repertoire	10	O
.	1	O

A	1	O
prominent	9	O
role	4	O
for	3	O
activator	9	B-Gene
protein-1	9	I-Gene
in	2	O
the	3	O
transcription	13	O
of	2	O
the	3	O
human	5	B-Gene
2B4	3	I-Gene
(	1	I-Gene
CD244	5	I-Gene
)	1	I-Gene
gene	4	I-Gene
in	2	O
NK	2	O
cells	5	O
.	1	O

The	3	O
cell	4	B-Gene
surface	7	I-Gene
glycoprotein	12	I-Gene
2B4	3	I-Gene
(	1	O
CD244	5	B-Gene
)	1	O
of	2	O
the	3	O
Ig	2	B-Gene
superfamily	11	O
is	2	O
involved	8	O
in	2	O
the	3	O
regulation	10	O
of	2	O
NK	2	O
and	3	O
T	1	O
lymphocyte	10	O
functions	9	O
.	1	O

We	2	O
have	4	O
recently	8	O
identified	10	O
CD48	4	B-Gene
as	2	O
the	3	O
high	4	O
affinity	8	O
counterreceptor	15	O
for	3	O
2B4	3	B-Gene
in	2	O
both	4	O
mice	4	O
and	3	O
humans	6	O
.	1	O

The	3	O
cytoplasmic	11	O
domain	6	O
of	2	O
2B4	3	B-Gene
associates	10	O
with	4	O
src	3	B-Gene
homology	8	I-Gene
2	1	I-Gene
domain	6	I-Gene
-containing	11	I-Gene
protein	7	I-Gene
or	2	O
signaling	9	B-Gene
lymphocyte	10	I-Gene
activation	10	I-Gene
molecule	8	I-Gene
-associated	11	I-Gene
protein	7	I-Gene
,	1	O
whose	5	O
mutation	8	O
is	2	O
the	3	O
underlying	10	O
genetic	7	O
defect	6	O
in	2	O
the	3	O
X	1	O
-linked	7	O
lymphoproliferative	19	O
syndrome	8	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
we	2	O
report	6	O
the	3	O
molecular	9	O
cloning	7	O
and	3	O
characterization	16	O
of	2	O
the	3	O
human	5	B-Gene
2B4	3	I-Gene
(	1	I-Gene
h2B4	4	I-Gene
)	1	I-Gene
promoter	8	I-Gene
.	1	O

Through	7	O
primer	6	O
extension	9	O
analysis	8	O
,	1	O
we	2	O
found	5	O
that	4	O
the	3	O
transcription	13	O
of	2	O
the	3	O
h2B4	4	B-Gene
gene	4	I-Gene
initiates	9	O
at	2	O
multiple	8	O
start	5	O
sites	5	O
.	1	O

We	2	O
isolated	8	O
h2B4	4	B-Gene
genomic	7	O
clones	6	O
and	3	O
PCR	3	O
amplified	9	O
the	3	O
5	1	O
'untranslated	13	O
region	6	O
containing	10	O
the	3	O
promoter	8	O
elements	8	O
.	1	O

We	2	O
have	4	O
identified	10	O
a	1	O
functional	10	O
AP-1	4	B-Gene
site	4	O
that	4	O
lies	4	O
between	7	O
(	1	O
-106	4	O
to	2	O
-100	4	O
)	1	O
through	7	O
transient	9	O
transfection	12	O
analysis	8	O
in	2	O
YT	2	O
cells	5	O
,	1	O
a	1	O
human	5	O
NK	2	O
cell	4	O
line	4	O
.	1	O

EMSAs	5	O
with	4	O
Abs	3	O
specific	8	O
for	3	O
various	7	O
protein	7	O
factors	7	O
of	2	O
the	3	O
AP-1	4	B-Gene
family	6	I-Gene
revealed	8	O
that	4	O
multiple	8	O
members	7	O
of	2	O
the	3	O
Jun	3	B-Gene
family	6	I-Gene
are	3	O
involved	8	O
in	2	O
the	3	O
regulation	10	O
of	2	O
the	3	O
h2B4	4	B-Gene
gene	4	I-Gene
.	1	O

Mutation	8	O
of	2	O
the	3	O
AP-1	4	B-Gene
site	4	O
not	3	O
only	4	O
abolishes	9	O
protein	7	O
/	1	O
DNA	3	O
interactions	12	O
but	3	O
also	4	O
promoter	8	O
activity	8	O
.	1	O

These	5	O
results	7	O
demonstrate	11	O
a	1	O
significant	11	O
role	4	O
for	3	O
AP-1	4	B-Gene
in	2	O
the	3	O
transcriptional	15	O
regulation	10	O
of	2	O
the	3	O
h2B4	4	B-Gene
gene	4	I-Gene
.	1	O

Stepwise	8	O
lineage	7	O
restriction	11	O
of	2	O
progenitors	11	O
in	2	O
lympho-myelopoiesis	19	O
.	1	O

It	2	O
has	3	O
long	4	O
been	4	O
controversial	13	O
whether	7	O
hematopoiesis	13	O
progresses	10	O
through	7	O
ordered	7	O
stages	6	O
of	2	O
determination	13	O
as	2	O
in	2	O
embryonic	9	O
development	11	O
.	1	O

This	4	O
is	2	O
due	3	O
to	2	O
the	3	O
absence	7	O
of	2	O
a	1	O
methodology	11	O
capable	7	O
of	2	O
exactly	7	O
determining	11	O
the	3	O
developmental	13	O
potential	9	O
of	2	O
hematopoietic	13	O
stem	4	O
/	1	O
progenitor	10	O
cells	5	O
.	1	O

The	3	O
multilineage	12	O
progenitor	10	O
(	1	O
MLP	3	O
)	1	O
assay	5	O
enabled	7	O
us	2	O
to	2	O
discriminate	12	O
among	5	O
seven	5	O
types	5	O
of	2	O
hematopoietic	13	O
progenitors	11	O
,	1	O
which	5	O
are	3	O
multipotent	11	O
progenitor	10	O
p-MTB	5	O
(	1	O
capable	7	O
of	2	O
generating	10	O
myeloid	7	O
,	1	O
T	1	O
and	3	O
B	1	O
cells	5	O
)	1	O
,	1	O
bipotent	8	O
progenitors	11	O
p-MT	4	O
,	1	O
p-MB	4	O
and	3	O
p-TB	4	O
,	1	O
and	3	O
unipotent	9	O
progenitors	11	O
p-M	3	O
,	1	O
p-T	3	O
and	3	O
p-B	3	O
.	1	O

Among	5	O
these	5	O
seven	5	O
types	5	O
,	1	O
the	3	O
p-TB	4	O
type	4	O
progenitor	10	O
was	3	O
found	5	O
to	2	O
be	2	O
absent	6	O
.	1	O

These	5	O
findings	8	O
indicate	8	O
that	4	O
the	3	O
process	7	O
of	2	O
lineage	7	O
commitment	10	O
proceeds	8	O
through	7	O
an	2	O
ordered	7	O
but	3	O
not	3	O
random	6	O
process	7	O
.	1	O

By	2	O
extending	9	O
the	3	O
area	4	O
of	2	O
investigation	13	O
to	2	O
include	7	O
the	3	O
erythroid	9	O
lineage	7	O
,	1	O
more	4	O
convincing	10	O
evidence	8	O
for	3	O
the	3	O
ordered	7	O
process	7	O
was	3	O
obtained	8	O
.	1	O

Detailed	8	O
and	3	O
exact	5	O
illustration	12	O
of	2	O
the	3	O
process	7	O
of	2	O
hematopoiesis	13	O
will	4	O
provide	7	O
an	2	O
opportunity	11	O
to	2	O
revive	6	O
hematopoiesis	13	O
as	2	O
one	3	O
of	2	O
the	3	O
most	4	O
fascinating	11	O
targets	7	O
of	2	O
research	8	O
in	2	O
developmental	13	O
biology	7	O

Pax5	4	B-Gene
determines	10	O
the	3	O
identity	8	O
of	2	O
B	1	O
cells	5	O
from	4	O
the	3	O
beginning	9	O
to	2	O
the	3	O
end	3	O
of	2	O
B-lymphopoiesis	15	O
.	1	O

Despite	7	O
being	5	O
one	3	O
of	2	O
the	3	O
most	4	O
intensively	11	O
studied	7	O
cell	4	O
types	5	O
,	1	O
the	3	O
molecular	9	O
basis	5	O
of	2	O
B	1	O
cell	4	O
specification	13	O
is	2	O
largely	7	O
unknown	7	O
.	1	O

The	3	O
Pax5	4	B-Gene
gene	4	I-Gene
encoding	8	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
BSAP	4	I-Gene
is	2	O
required	8	O
for	3	O
progression	11	O
of	2	O
B-lymphopoiesis	15	O
beyond	6	O
the	3	O
pro-B	5	O
cell	4	O
stage	5	O
.	1	O

Pax5	4	B-Gene
-deficient	10	O
pro-B	5	O
cells	5	O
are	3	O
,	1	O
however	7	O
,	1	O
not	3	O
yet	3	O
committed	9	O
to	2	O
the	3	O
B-lymphoid	10	O
lineage	7	O
,	1	O
but	3	O
instead	7	O
have	4	O
a	1	O
broad	5	O
lymphomyeloid	13	O
developmental	13	O
potential	9	O
.	1	O

Pax5	4	B-Gene
appears	7	O
to	2	O
mediate	7	O
B-lineage	9	O
commitment	10	O
by	2	O
repressing	10	O
the	3	O
transcription	13	O
of	2	O
non-B-lymphoid	14	O
genes	5	O
and	3	O
by	2	O
simultaneously	14	O
activating	10	O
the	3	O
expression	10	O
of	2	O
B-lineage-specific	18	O
genes	5	O
.	1	O

Pax5	4	B-Gene
thus	4	O
functions	9	O
both	4	O
as	2	O
a	1	O
transcriptional	15	O
repressor	9	O
and	3	O
activator	9	O
,	1	O
depending	9	O
on	2	O
its	3	O
interactions	12	O
with	4	O
corepressors	12	O
of	2	O
the	3	O
Groucho	7	B-Gene
protein	7	I-Gene
family	6	I-Gene
or	2	O
with	4	O
positive	8	O
regulators	10	O
such	4	O
as	2	O
the	3	O
TATA	4	B-Gene
-binding	8	I-Gene
protein	7	I-Gene
.	1	O

Once	4	O
committed	9	O
to	2	O
the	3	O
B-lineage	9	O
,	1	O
B	1	O
cells	5	O
require	7	O
Pax5	4	B-Gene
function	8	O
to	2	O
maintain	8	O
their	5	O
B-lymphoid	10	O
identity	8	O
throughout	10	O
B	1	O
cell	4	O
development	11	O

Localized	9	O
pancreatic	10	O
NF-kappaB	9	B-Gene
activation	10	O
and	3	O
inflammatory	12	O
response	8	O
in	2	O
taurocholate	12	B-Chemical
-induced	8	O
pancreatitis	12	B-Disease
.	1	O

Transcription	13	B-Gene
factor	6	I-Gene
nuclear	7	I-Gene
factor-kappaB	13	I-Gene
(	1	O
NF-kappaB	9	B-Gene
)	1	O
is	2	O
activated	9	O
in	2	O
cerulein	8	O
pancreatitis	12	B-Disease
and	3	O
mediates	8	O
cytokine	8	O
expression	10	O
.	1	O

The	3	O
role	4	O
of	2	O
transcription	13	O
factor	6	O
activation	10	O
in	2	O
other	5	O
models	6	O
of	2	O
pancreatitis	12	B-Disease
has	3	O
not	3	O
been	4	O
established	11	O
.	1	O

Here	4	O
we	2	O
report	6	O
upregulation	12	O
of	2	O
NF-kappaB	9	B-Gene
and	3	O
inflammatory	12	O
molecules	9	O
,	1	O
and	3	O
their	5	O
correlation	11	O
with	4	O
local	5	O
pancreatic	10	B-Disease
injury	6	I-Disease
,	1	O
in	2	O
a	1	O
model	5	O
of	2	O
severe	6	B-Disease
pancreatitis	12	I-Disease
.	1	O

Rats	4	O
received	8	O
intraductal	11	O
infusion	8	O
of	2	O
taurocholate	12	B-Chemical
or	2	O
saline	6	O
,	1	O
and	3	O
the	3	O
pancreatic	10	O
head	4	O
and	3	O
tail	4	O
were	4	O
analyzed	8	O
separately	10	O
.	1	O

NF-kappaB	9	B-Gene
and	3	O
activator	9	B-Gene
protein-1	9	I-Gene
(	1	O
AP-1	4	B-Gene
)	1	O
activation	10	O
were	4	O
assessed	8	O
by	2	O
gel	3	O
shift	5	O
assay	5	O
,	1	O
and	3	O
mRNA	4	O
expression	10	O
of	2	O
interleukin-6	13	B-Gene
,	1	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor-alpha	12	I-Gene
,	1	O
KC	2	B-Gene
,	1	O
monocyte	8	B-Gene
chemoattractant	15	I-Gene
protein-1	9	I-Gene
,	1	O
and	3	O
inducible	9	B-Gene
nitric	6	I-Gene
oxide	5	I-Gene
synthase	8	I-Gene
was	3	O
assessed	8	O
by	2	O
semiquantitative	16	O
RT-PCR	6	O
.	1	O

Morphological	13	O
damage	6	O
and	3	O
trypsin	7	O
activation	10	O
were	4	O
much	4	O
greater	7	O
in	2	O
the	3	O
pancreatic	10	O
head	4	O
than	4	O
tail	4	O
,	1	O
in	2	O
parallel	8	O
with	4	O
a	1	O
stronger	8	O
activation	10	O
of	2	O
NF-kappaB	9	B-Gene
and	3	O
cytokine	8	O
mRNA	4	O
.	1	O

Saline	6	O
infusion	8	O
mildly	6	O
affected	8	O
these	5	O
parameters	10	O
.	1	O

AP-1	4	B-Gene
was	3	O
strongly	8	O
activated	9	O
in	2	O
both	4	O
pancreatic	10	O
segments	8	O
after	5	O
either	6	O
taurocholate	12	B-Chemical
or	2	O
saline	6	O
infusion	8	O
.	1	O

NF-kappaB	9	B-Gene
inhibition	10	O
with	4	O
N-acetylcysteine	16	B-Chemical
ameliorated	11	O
the	3	O
local	5	O
inflammatory	12	O
response	8	O
.	1	O

Correlation	11	O
between	7	O
localized	9	O
NF-kappaB	9	B-Gene
activation	10	O
,	1	O
cytokine	8	O
upregulation	12	O
,	1	O
and	3	O
tissue	6	O
damage	6	O
suggests	8	O
a	1	O
key	3	O
role	4	O
for	3	O
NF-kappaB	9	B-Gene
in	2	O
the	3	O
development	11	O
of	2	O
the	3	O
inflammatory	12	O
response	8	O
of	2	O
acute	5	B-Disease
pancreatitis	12	I-Disease
.	1	O

Stem	4	B-Gene
cell	4	I-Gene
factor	6	I-Gene
and	3	O
interleukin-3	13	B-Gene
induce	6	O
stepwise	8	O
generation	10	O
of	2	O
erythroid	9	O
precursor	9	O
cells	5	O
from	4	O
a	1	O
basic	5	B-Gene
fibroblast	10	I-Gene
growth	6	I-Gene
factor	6	I-Gene
-dependent	10	O
hematopoietic	13	O
stem	4	O
cell	4	O
line	4	O
,	1	O
A-6	3	O
.	1	O

A	1	O
m	1	O
ultipotent	10	O
immature	8	O
myeloid	7	O
cell	4	O
population	10	O
was	3	O
produced	8	O
from	4	O
a	1	O
basic	5	B-Gene
fibroblast	10	I-Gene
growth	6	I-Gene
factor	6	I-Gene
(	1	O
bFGF	4	B-Gene
)	1	O
-dependent	10	O
hematopoietic	13	O
stem	4	O
cell	4	O
line	4	O
,	1	O
A-6	3	O
,	1	O
when	4	O
cultured	8	O
with	4	O
stem	4	B-Gene
cell	4	I-Gene
factor	6	I-Gene
(	1	O
SCF	3	B-Gene
)	1	O
replacing	9	O
bFGF	4	B-Gene
.	1	O

Those	5	O
cells	5	O
were	4	O
positive	8	O
for	3	O
stem	4	O
cell	4	O
markers	7	O
,	1	O
c-kit	5	B-Gene
and	3	O
CD34	4	B-Gene
,	1	O
and	3	O
a	1	O
myeloid	7	O
cell	4	O
marker	6	O
,	1	O
F4	2	B-Gene
/	1	I-Gene
80	2	I-Gene
.	1	O

Some	4	O
cell	4	O
fractions	9	O
were	4	O
also	4	O
positive	8	O
for	3	O
Mac-1	5	B-Gene
,	1	O
a	1	O
macrophage	10	O
marker	6	O
or	2	O
Gr-1	4	B-Gene
,	1	O
a	1	O
granulocytic	12	O
maker	5	O
,	1	O
but	3	O
negative	8	O
for	3	O
an	2	O
erythroid	9	O
marker	6	O
TER119	6	B-Gene
.	1	O

They	4	O
also	4	O
showed	6	O
the	3	O
expression	10	O
of	2	O
mRNA	4	O
for	3	O
the	3	O
myeloid-specific	16	B-Gene
PU.1	4	I-Gene
but	3	O
did	3	O
not	3	O
that	4	O
for	3	O
the	3	O
erythroid-specific	18	B-Gene
GATA-1	6	I-Gene
.	1	O

Among	5	O
various	7	O
cytokines	9	O
,	1	O
interleukin-3	13	B-Gene
(	1	O
IL-3	4	B-Gene
)	1	O
induced	7	O
erythroid	9	O
precursor	9	O
cells	5	O
that	4	O
expressed	9	O
the	3	O
erythroid-specific	18	B-Gene
GATA-1	6	I-Gene
and	3	O
beta-major	10	B-Gene
globin	6	I-Gene
.	1	O

The	3	O
quantitative	12	O
analysis	8	O
showed	6	O
that	4	O
erythroid	9	O
precursor	9	O
cells	5	O
were	4	O
newly	5	O
produced	8	O
from	4	O
the	3	O
immature	8	O
myeloid	7	O
cells	5	O
by	2	O
cultivation	11	O
with	4	O
IL-3	4	B-Gene
.	1	O

SCF	3	B-Gene
and	3	O
IL-3	4	B-Gene
induced	7	O
stepwise	8	O
generation	10	O
of	2	O
erythroid	9	O
precursor	9	O
cells	5	O
from	4	O
an	2	O
A-6	3	O
hematopoietic	13	O
stem	4	O
cell	4	O
line	4	O
.	1	O

Copyright	9	O
2001	4	O
Academic	8	O
Press	5	O
.	1	O

Inhibition	10	O
of	2	O
the	3	O
transcription	13	B-Gene
factors	7	I-Gene
AP-1	4	I-Gene
and	3	O
NF-kappaB	9	B-Gene
in	2	O
CD4	3	B-Gene
T	1	O
cells	5	O
by	2	O
peroxisome	10	B-Gene
proliferator	12	I-Gene
-activated	10	I-Gene
receptor	8	I-Gene
gamma	5	I-Gene
ligands	7	I-Gene
.	1	O

The	3	O
peroxisome	10	B-Gene
proliferator	12	I-Gene
-activated	10	I-Gene
receptor	8	I-Gene
gamma	5	I-Gene
(	1	O
PPARgamma	9	B-Gene
)	1	O
,	1	O
a	1	O
member	6	O
of	2	O
the	3	O
nuclear	7	O
hormone	7	O
receptor	8	O
superfamily	11	O
,	1	O
is	2	O
essential	9	O
for	3	O
adipocyte	9	O
differentiation	15	O
and	3	O
glucose	7	B-Chemical
homeostasis	11	O
.	1	O

PPARgamma	9	B-Gene
has	3	O
been	4	O
found	5	O
recently	8	O
to	2	O
regulate	8	O
macrophage	10	O
activation	10	O
in	2	O
response	8	O
to	2	O
mitogens	8	O
and	3	O
inflammation	12	O
.	1	O

Our	3	O
study	5	O
shows	5	O
PPARgamma	9	B-Gene
to	2	O
be	2	O
preferentially	14	O
expressed	9	O
in	2	O
the	3	O
nuclei	6	O
of	2	O
resting	7	O
T	1	O
cells	5	O
and	3	O
to	2	O
increase	8	O
upon	4	O
activation	10	O
of	2	O
T	1	O
cells	5	O
by	2	O
either	6	O
anti-CD3	8	B-Gene
and	3	O
anti-CD28	9	B-Gene
or	2	O
phorbol	7	B-Chemical
myristyl	8	I-Chemical
acetate	7	I-Chemical
(	1	O
PMA	3	B-Chemical
)	1	O
.	1	O

We	2	O
also	4	O
found	5	O
the	3	O
PPARgamma	9	B-Gene
ligand	6	I-Gene
ciglitizone	11	B-Chemical
to	2	O
attenuate	9	O
the	3	O
activation	10	O
of	2	O
T	1	O
cells	5	O
by	2	O
inhibiting	10	O
cytokine	8	O
gene	4	O
expression	10	O
and	3	O
anti-CD3	8	B-Gene
and	3	O
anti-CD28	9	B-Gene
or	2	O
PMA	3	B-Chemical
-induced	8	O
proliferative	13	O
responses	9	O
.	1	O

Inhibition	10	O
of	2	O
both	4	O
the	3	O
proliferative	13	O
response	8	O
and	3	O
inflammatory	12	O
cytokine	8	O
expression	10	O
in	2	O
CD4	3	B-Gene
T	1	O
cells	5	O
was	3	O
correlated	10	O
with	4	O
suppression	11	O
of	2	O
the	3	O
activated	9	O
transcription	13	B-Gene
factors	7	I-Gene
AP1	3	I-Gene
and	3	O
NF-kappaB	9	B-Gene
.	1	O

PPARgamma	9	B-Gene
ligands	7	I-Gene
also	4	O
strongly	8	O
inhibited	9	O
SEA	3	B-Gene
-induced	8	O
Vbeta3	6	B-Gene
T	1	O
cell	4	O
activation	10	O
in	2	O
vivo	4	O
.	1	O

These	5	O
results	7	O
,	1	O
together	8	O
with	4	O
previous	8	O
findings	8	O
of	2	O
the	3	O
inhibitory	10	O
effect	6	O
of	2	O
PPARgamma	9	B-Gene
ligands	7	I-Gene
on	2	O
activated	9	O
macrophages	11	O
,	1	O
provide	7	O
clear	5	O
evidence	8	O
for	3	O
PPARgamma	9	B-Gene
as	2	O
a	1	O
negative	8	O
regulator	9	O
of	2	O
the	3	O
inflammatory	12	O
activation	10	O
of	2	O
both	4	O
macrophage	10	O
and	3	O
T	1	O
cells	5	O
.	1	O

PPARgamma	9	B-Gene
may	3	O
thus	4	O
be	2	O
a	1	O
potential	9	O
therapeutic	11	O
target	6	O
for	3	O
the	3	O
treatment	9	O
of	2	O
autoimmunity	12	O
.	1	O

Androgens	9	B-Chemical
indirectly	10	O
accelerate	10	O
thymocyte	9	O
apoptosis	9	O
.	1	O

Apoptotic	9	O
processes	9	O
,	1	O
or	2	O
the	3	O
disturbance	11	O
of	2	O
the	3	O
natural	7	O
regulation	10	O
of	2	O
these	5	O
processes	9	O
,	1	O
may	3	O
be	2	O
involved	8	O
in	2	O
the	3	O
pathogenesis	12	O
of	2	O
autoimmune	10	B-Disease
diseases	8	I-Disease
(	1	O
AID	3	B-Disease
)	1	O
.	1	O

Women	5	O
are	3	O
,	1	O
in	2	O
general	7	O
,	1	O
more	4	O
susceptible	11	O
than	4	O
men	3	O
to	2	O
develop	7	O
AID	3	B-Disease
like	4	O
rheumatoid	10	B-Disease
arthritis	9	I-Disease
.	1	O

Androgens	9	B-Chemical
and	3	O
glucocorticoids	15	B-Chemical
,	1	O
in	2	O
contrast	8	O
to	2	O
oestrogens	10	B-Chemical
,	1	O
have	4	O
favourable	10	O
effects	7	O
in	2	O
AID	3	B-Disease
models	6	O
as	2	O
well	4	O
as	2	O
in	2	O
human	5	O
AID	3	B-Disease
.	1	O

It	2	O
is	2	O
known	5	O
that	4	O
glucocorticoids	15	B-Chemical
(	1	O
GC	2	B-Chemical
)	1	O
,	1	O
used	4	O
for	3	O
treatment	9	O
of	2	O
AID	3	B-Disease
,	1	O
increase	8	O
apoptosis	9	O
in	2	O
the	3	O
thymus	6	O
resulting	9	O
in	2	O
decreased	9	O
numbers	7	O
of	2	O
CD4+	4	B-Gene
CD8+	4	I-Gene
thymocytes	10	O
.	1	O

It	2	O
was	3	O
asked	5	O
whether	7	O
androgens	9	B-Chemical
,	1	O
in	2	O
contrast	8	O
to	2	O
oestrogens	10	B-Chemical
,	1	O
exert	5	O
their	5	O
favourable	10	O
effects	7	O
in	2	O
the	3	O
treatment	9	O
of	2	O
AID	3	B-Disease
by	2	O
a	1	O
mechanism	9	O
comparable	10	O
to	2	O
that	4	O
described	9	O
for	3	O
GC	2	B-Chemical
by	2	O
eliminating	11	O
the	3	O
apoptosis	9	O
prone	5	O
CD4+	4	B-Gene
CD8+	4	I-Gene
population	10	O
in	2	O
the	3	O
thymus	6	O
.	1	O

Although	8	O
both	4	O
androgens	9	B-Chemical
and	3	O
oestrogens	10	B-Chemical
proved	6	O
thymolytic	10	O
,	1	O
a	1	O
significantly	13	O
decreased	9	O
percentage	10	O
of	2	O
CD4+	4	B-Gene
CD8+	4	I-Gene
thymocytes	10	O
was	3	O
observed	8	O
by	2	O
flow	4	O
cytometry	9	O
after	5	O
treatment	9	O
of	2	O
mice	4	O
with	4	O
the	3	O
androgen	8	B-Chemical
methyltestosterone	18	I-Chemical
,	1	O
but	3	O
not	3	O
with	4	O
the	3	O
oestrogen	9	B-Chemical
ethinylestradiol	16	I-Chemical
.	1	O

To	2	O
investigate	11	O
whether	7	O
the	3	O
observed	8	O
thymolytic	10	O
effects	7	O
were	4	O
due	3	O
to	2	O
the	3	O
presence	8	O
of	2	O
hormone	7	O
receptors	9	O
on	2	O
thymocytes	10	O
,	1	O
cells	5	O
were	4	O
isolated	8	O
from	4	O
the	3	O
thymus	6	O
and	3	O
incubated	9	O
with	4	O
androgens	9	B-Chemical
or	2	O
oestrogens	10	B-Chemical
to	2	O
measure	7	O
apoptosis	9	O
.	1	O

Several	7	O
techniques	10	O
were	4	O
used	4	O
to	2	O
determine	9	O
thymocyte	9	O
apoptosis	9	O
in	2	O
vitro	5	O
,	1	O
but	3	O
no	2	O
enhanced	8	O
apoptotic	9	O
signal	6	O
was	3	O
observed	8	O
.	1	O

Using	5	O
the	3	O
very	4	O
sensitive	9	O
TUNEL	5	O
assay	5	O
,	1	O
no	2	O
direct	6	O
effect	6	O
of	2	O
androgens	9	B-Chemical
on	2	O
thymocytes	10	O
in	2	O
vitro	5	O
could	5	O
be	2	O
observed	8	O
.	1	O

This	4	O
is	2	O
in	2	O
sharp	5	O
contrast	8	O
to	2	O
the	3	O
high	4	O
signal	6	O
observed	8	O
with	4	O
GC	2	B-Chemical
.	1	O

Therefore	9	O
,	1	O
upon	4	O
in	2	O
vivo	4	O
androgen	8	O
treatment	9	O
,	1	O
other	5	O
cells	5	O
containing	10	O
androgen	8	B-Gene
receptors	9	I-Gene
than	4	O
thymocytes	10	O
are	3	O
probably	8	O
involved	8	O
in	2	O
inducing	8	O
the	3	O
increase	8	O
in	2	O
thymic	6	O
apoptosis	9	O
.	1	O

To	2	O
study	5	O
the	3	O
role	4	O
of	2	O
the	3	O
androgen	8	B-Gene
receptor	8	I-Gene
on	2	O
thymocyte	9	O
apoptosis	9	O
,	1	O
androgen	8	B-Gene
receptor	8	I-Gene
mutant	6	I-Gene
(	1	O
Tfm	3	O
/	1	O
Y	1	O
)	1	O
mice	4	O
were	4	O
treated	7	O
with	4	O
androgens	9	B-Chemical
.	1	O

No	2	O
alterations	11	O
of	2	O
thymocyte	9	O
subpopulations	14	O
were	4	O
seen	4	O
,	1	O
suggesting	10	O
that	4	O
changes	7	O
in	2	O
the	3	O
percentage	10	O
of	2	O
CD4+	4	B-Gene
CD8+	4	I-Gene
thymocytes	10	O
after	5	O
administration	14	O
of	2	O
androgens	9	B-Chemical
depend	6	O
on	2	O
the	3	O
presence	8	O
of	2	O
functional	10	O
androgen	8	B-Gene
receptors	9	I-Gene
.	1	O

Thus	4	O
,	1	O
it	2	O
is	2	O
concluded	9	O
that	4	O
androgens	9	B-Chemical
indirectly	10	O
accelerate	10	O
thymocyte	9	O
apoptosis	9	O
in	2	O
vivo	4	O
.	1	O

A	1	O
transcriptional	15	O
block	5	O
in	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
at	2	O
the	3	O
-150	4	O
AP-1	4	B-Gene
site	4	O
in	2	O
effector	8	B-Gene
CD8+	4	I-Gene
T	1	O
cells	5	O
.	1	O

Both	4	O
CD4+	4	B-Gene
and	3	O
CD8+	4	B-Gene
T	1	O
cells	5	O
that	4	O
produce	7	O
IL-2	4	B-Gene
in	2	O
response	8	O
to	2	O
Ag	2	O
recognition	11	O
have	4	O
been	4	O
isolated	8	O
.	1	O

However	7	O
,	1	O
most	4	O
effector	8	B-Gene
CD8+	4	I-Gene
T	1	O
cells	5	O
recovered	9	O
after	5	O
exposure	8	O
to	2	O
Ag	2	O
do	2	O
not	3	O
produce	7	O
sufficient	10	O
IL-2	4	B-Gene
to	2	O
sustain	7	O
growth	6	O
,	1	O
and	3	O
depend	6	O
on	2	O
CD4+	4	B-Gene
T	1	O
helper	6	O
cells	5	O
for	3	O
this	4	O
obligate	8	O
growth	6	O
factor	6	O
.	1	O

IL-2	4	B-Gene
expression	10	O
in	2	O
CD4+	4	B-Gene
T	1	O
cells	5	O
is	2	O
primarily	9	O
controlled	10	O
at	2	O
the	3	O
level	5	O
of	2	O
transcription	13	O
,	1	O
but	3	O
mechanisms	10	O
restricting	11	O
IL-2	4	B-Gene
production	10	O
in	2	O
CD8+	4	B-Gene
T	1	O
cells	5	O
have	4	O
not	3	O
been	4	O
elucidated	10	O
.	1	O

To	2	O
evaluate	8	O
transcriptional	15	O
regulation	10	O
of	2	O
the	3	O
IL-2	4	B-Gene
gene	4	I-Gene
in	2	O
CD8+	4	B-Gene
T	1	O
cells	5	O
,	1	O
we	2	O
stably	6	O
transfected	11	O
reporter	8	O
genes	5	O
into	4	O
Ag	2	O
-specific	9	O
CD8+	4	B-Gene
T	1	O
cell	4	O
clones	6	O
.	1	O

CD28+	5	B-Gene
CD8	3	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
T	1	O
cells	5	O
unable	6	O
to	2	O
transcribe	10	O
the	3	O
IL-2	4	B-Gene
gene	4	I-Gene
in	2	O
response	8	O
to	2	O
antigenic	9	O
stimulation	11	O
had	3	O
a	1	O
block	5	O
in	2	O
transactivation	15	O
of	2	O
the	3	O
-150	4	O
CD28	4	B-Gene
response	8	I-Gene
element	7	I-Gene
(	1	I-Gene
CD28RE	6	I-Gene
)	1	I-Gene
/	1	I-Gene
AP-1	4	I-Gene
site	4	O
of	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
,	1	O
but	3	O
did	3	O
transactivate	13	O
the	3	O
composite	9	O
NFAT	4	B-Gene
/	1	I-Gene
AP-1	4	I-Gene
and	3	O
OCT	3	B-Gene
/	1	I-Gene
AP-1	4	I-Gene
sites	5	O
,	1	O
and	3	O
a	1	O
consensus	9	O
AP-1	4	B-Gene
motif	5	O
.	1	O

Mutation	8	O
of	2	O
the	3	O
nonconsensus	12	O
-150	4	O
AP-1	4	B-Gene
site	4	O
to	2	O
a	1	O
consensus	9	O
AP-1	4	B-Gene
site	4	O
,	1	O
or	2	O
insertion	9	O
of	2	O
a	1	O
CD28RE	6	B-Gene
/	1	I-Gene
AP-1	4	I-Gene
consensus	9	O
site	4	O
upstream	8	O
of	2	O
the	3	O
native	6	O
-150	4	O
CD28RE	6	B-Gene
/	1	I-Gene
AP-1	4	I-Gene
site	4	O
restored	8	O
transactivation	15	O
of	2	O
the	3	O
altered	7	O
promoter	8	O
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
the	3	O
defect	6	O
at	2	O
the	3	O
-150	4	O
site	4	O
may	3	O
reflect	7	O
the	3	O
absence	7	O
or	2	O
inactivity	10	O
of	2	O
a	1	O
required	8	O
factor	6	O
rather	6	O
than	4	O
repression	10	O
of	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
.	1	O

Tetramer	8	O
-guided	7	O
epitope	7	O
mapping	7	O
:	1	O
rapid	5	O
identification	14	O
and	3	O
characterization	16	O
of	2	O
immunodominant	14	O
CD4+	4	B-Gene
T	1	O
cell	4	O
epitopes	8	O
from	4	O
complex	7	O
antigens	8	O
.	1	O

T	1	O
cell	4	O
responses	9	O
to	2	O
Ags	3	O
involve	7	O
recognition	11	O
of	2	O
selected	8	O
peptide	7	O
epitopes	8	O
contained	9	O
within	6	O
the	3	O
antigenic	9	O
protein	7	O
.	1	O

In	2	O
this	4	O
report	6	O
,	1	O
we	2	O
describe	8	O
a	1	O
new	3	O
approach	8	O
for	3	O
direct	6	O
identification	14	O
of	2	O
CD4+	4	B-Gene
T	1	O
cell	4	O
epitopes	8	O
of	2	O
complex	7	O
Ags	3	O
that	4	O
uses	4	O
human	5	B-Gene
class	5	I-Gene
II	2	I-Gene
tetramers	9	O
to	2	O
identify	8	O
reactive	8	O
cells	5	O
.	1	O

With	4	O
a	1	O
panel	5	O
of	2	O
60	2	O
overlapping	11	O
peptides	8	O
covering	8	O
the	3	O
entire	6	O
sequence	8	O
of	2	O
the	3	O
VP16	4	B-Gene
protein	7	I-Gene
,	1	O
a	1	O
major	5	O
Ag	2	O
for	3	O
HSV-2	5	O
,	1	O
we	2	O
generated	9	O
a	1	O
panel	5	O
of	2	O
class	5	B-Gene
II	2	I-Gene
MHC	3	I-Gene
tetramers	9	O
loaded	6	O
with	4	O
peptide	7	O
pools	5	O
that	4	O
were	4	O
used	4	O
to	2	O
stain	5	O
peripheral	10	O
lymphocytes	11	O
of	2	O
an	2	O
HSV-2	5	O
infected	8	O
individual	10	O
.	1	O

With	4	O
this	4	O
approach	8	O
,	1	O
we	2	O
identified	10	O
four	4	O
new	3	O
DRA1*0101	9	B-Gene
/	1	O
DRB1*0401-	10	B-Gene
and	3	O
two	3	O
DRA1*0101	9	B-Gene
/	1	O
DRB1*0404	9	B-Gene
-restricted	11	O
,	1	O
VP16-specific	13	B-Gene
epitopes	8	O
.	1	O

By	2	O
using	5	O
tetramers	9	O
to	2	O
sort	4	O
individual	10	O
cells	5	O
,	1	O
we	2	O
easily	6	O
obtained	8	O
a	1	O
large	5	O
number	6	O
of	2	O
clones	6	O
specific	8	O
to	2	O
these	5	O
epitopes	8	O
.	1	O

Although	8	O
DRA1*0101	9	B-Gene
/	1	O
DRB1*0401	9	B-Gene
and	3	O
DRA1*0101	9	B-Gene
/	1	O
DRB1*0404	9	B-Gene
are	3	O
structurally	12	O
very	4	O
similar	7	O
,	1	O
nonoverlapping	14	O
VP16	4	B-Gene
epitopes	8	O
were	4	O
identified	10	O
,	1	O
illustrating	12	O
high	4	O
selectivity	11	O
of	2	O
individual	10	O
allele	6	O
polymorphisms	13	O
within	6	O
common	6	O
MHC	3	B-Gene
variants	8	O
.	1	O

This	4	O
rapid	5	O
approach	8	O
to	2	O
detecting	9	O
CD4+	4	B-Gene
T	1	O
cell	4	O
epitopes	8	O
from	4	O
complex	7	O
Ags	3	O
can	3	O
be	2	O
applied	7	O
to	2	O
any	3	O
known	5	O
Ag	2	O
that	4	O
gives	5	O
a	1	O
T	1	O
cell	4	O
response	8	O
.	1	O

Molecular	9	O
mechanism	9	O
of	2	O
cell	4	O
cycle	5	O
progression	11	O
induced	7	O
by	2	O
the	3	O
oncogene	8	B-Gene
product	7	I-Gene
Tax	3	I-Gene
of	2	O
human	5	O
T-cell	6	B-Disease
leukemia	8	I-Disease
virus	5	O
type	4	O
I	1	O
.	1	O

The	3	O
trans-activator	15	B-Gene
protein	7	I-Gene
Tax	3	I-Gene
of	2	O
human	5	O
T-cell	6	B-Disease
leukemia	8	I-Disease
virus	5	O
type	4	O
I	1	O
(	1	O
HTLV-I	6	O
)	1	O
plays	5	O
an	2	O
important	9	O
role	4	O
in	2	O
the	3	O
development	11	O
of	2	O
adult	5	B-Disease
T-cell	6	I-Disease
leukemia	8	I-Disease
through	7	O
,	1	O
at	2	O
least	5	O
in	2	O
part	4	O
,	1	O
its	3	O
ability	7	O
to	2	O
stimulate	9	O
cell	4	O
growth	6	O
.	1	O

We	2	O
previously	10	O
reported	8	O
that	4	O
Tax	3	B-Gene
induced	7	O
cell	4	O
cycle	5	O
progression	11	O
from	4	O
G0	2	O
/	1	O
G1	2	O
phase	5	O
to	2	O
S	1	O
and	3	O
G2	2	O
/	1	O
M	1	O
phases	6	O
in	2	O
human	5	O
T-cell	6	O
line	4	O
Kit	3	O
225	3	O
cells	5	O
.	1	O

To	2	O
elucidate	9	O
molecular	9	O
mechanism	9	O
of	2	O
Tax	3	B-Gene
-induced	8	O
cell	4	O
cycle	5	O
progression	11	O
,	1	O
we	2	O
systematically	14	O
examined	8	O
the	3	O
effects	7	O
of	2	O
Tax	3	B-Gene
on	2	O
biochemical	11	O
events	6	O
associated	10	O
with	4	O
cell	4	O
cycle	5	O
progression	11	O
.	1	O

Introduction	12	O
of	2	O
Tax	3	B-Gene
into	4	O
resting	7	O
Kit	3	O
225	3	O
cells	5	O
induced	7	O
activation	10	O
of	2	O
the	3	O
G1	2	O
/	1	O
S	1	O
transition	10	O
regulation	10	O
cascade	7	O
consisting	10	O
of	2	O
activation	10	O
of	2	O
cyclin	6	B-Gene
dependent	9	I-Gene
kinase	6	I-Gene
2	1	I-Gene
(	1	O
CDK2	4	B-Gene
)	1	O
and	3	O
CDK4	4	B-Gene
,	1	O
phosphorylation	15	O
of	2	O
the	3	O
Rb	2	B-Gene
family	6	I-Gene
proteins	8	I-Gene
and	3	O
an	2	O
increase	8	O
in	2	O
free	4	O
E2F	3	B-Gene
.	1	O

The	3	O
kinase	6	O
activation	10	O
was	3	O
found	5	O
to	2	O
result	6	O
from	4	O
Tax	3	B-Gene
-induced	8	O
expression	10	O
of	2	O
genes	5	O
for	3	O
cell	4	O
cycle	5	O
regulatory	10	O
molecules	9	O
including	9	O
cyclin	6	B-Gene
D2	2	I-Gene
,	1	O
cyclin	6	B-Gene
E	1	I-Gene
,	1	O
E2F1	4	B-Gene
,	1	O
CDK2	4	B-Gene
,	1	O
CDK4	4	B-Gene
and	3	O
CDK6	4	B-Gene
,	1	O
and	3	O
Tax	3	B-Gene
-induced	8	O
reduction	9	O
of	2	O
CDK	3	B-Gene
inhibitors	10	I-Gene
p19	3	I-Gene
(	1	O
INK4d	5	B-Gene
)	1	O
and	3	O
p27	3	B-Gene
(	1	O
Kip1	4	B-Gene
)	1	O
.	1	O

These	5	O
modulations	11	O
by	2	O
Tax	3	B-Gene
always	6	O
paralleled	10	O
the	3	O
ability	7	O
of	2	O
Tax	3	B-Gene
to	2	O
activate	8	O
the	3	O
NF-kappaB	9	B-Gene
transcription	13	O
pathway	7	O
.	1	O

These	5	O
results	7	O
indicate	8	O
the	3	O
important	9	O
role	4	O
of	2	O
Tax	3	B-Gene
-mediated	9	O
trans-activation	16	O
of	2	O
the	3	O
genes	5	O
for	3	O
cell	4	O
cycle	5	O
regulatory	10	O
molecules	9	O
in	2	O
Tax	3	B-Gene
-induced	8	O
cell	4	O
cycle	5	O
progression	11	O
.	1	O

Expression	10	O
of	2	O
interferon	10	B-Gene
consensus	9	I-Gene
sequence	8	I-Gene
binding	7	I-Gene
protein	7	I-Gene
induces	7	O
potent	6	O
immunity	8	O
against	7	O
BCR	3	B-Gene
/	1	I-Gene
ABL	3	I-Gene
-induced	8	O
leukemia	8	B-Disease
.	1	O

Mice	4	O
deficient	9	O
in	2	O
the	3	O
interferon	10	B-Gene
consensus	9	I-Gene
sequence	8	I-Gene
binding	7	I-Gene
protein	7	I-Gene
(	1	O
ICSBP	5	B-Gene
)	1	O
develop	7	O
a	1	O
disease	7	O
resembling	10	O
chronic	7	B-Disease
myeloid	7	I-Disease
leukemia	8	I-Disease
(	1	O
CML	3	B-Disease
)	1	O
,	1	O
which	5	O
in	2	O
humans	6	O
is	2	O
caused	6	O
by	2	O
the	3	O
BCR	3	B-Gene
/	1	I-Gene
ABL	3	I-Gene
oncoprotein	11	I-Gene
.	1	O

Interferon-alpha	16	B-Gene
(	1	O
IFN-alpha	9	B-Gene
)	1	O
induces	7	O
ICSBP	5	B-Gene
expression	10	O
and	3	O
is	2	O
an	2	O
effective	9	O
therapy	7	O
for	3	O
CML	3	B-Disease
.	1	O

This	4	O
study	5	O
examined	8	O
whether	7	O
enforced	8	O
expression	10	O
of	2	O
ICSBP	5	B-Gene
might	5	O
antagonize	10	O
BCR	3	B-Gene
/	1	I-Gene
ABL	3	I-Gene
-induced	8	O
leukemia	8	B-Disease
;	1	O
results	7	O
demonstrated	12	O
that	4	O
ICSBP	5	B-Gene
-modified	9	O
cells	5	O
generated	9	O
a	1	O
protective	10	O
CD8	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
cytotoxic	9	O
T-cell	6	O
response	8	O
against	7	O
BCR	3	B-Gene
/	1	I-Gene
ABL	3	I-Gene
-transformed	12	O
BaF3	4	O
cells	5	O
in	2	O
a	1	O
murine	6	O
leukemia	8	B-Disease
model	5	O
.	1	O

ICSBP	5	B-Gene
expression	10	O
represents	10	O
a	1	O
novel	5	O
means	5	O
of	2	O
stimulating	11	O
a	1	O
host	4	O
immune	6	O
response	8	O
to	2	O
BCR	3	B-Gene
/	1	I-Gene
ABL	3	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
leukemia	8	B-Disease
cells	5	O
and	3	O
a	1	O
potential	9	O
strategy	8	O
for	3	O
immunotherapy	13	O
of	2	O
CML	3	B-Disease
.	1	O

(	1	O
Blood.	6	O
2001	4	O
;	1	O
97	2	O
:	1	O
3491-3497	9	O
)	1	O

Antigen-receptor	16	O
cross	5	O
-linking	8	O
and	3	O
lipopolysaccharide	18	B-Chemical
trigger	7	O
distinct	8	O
phosphoinositide	16	B-Gene
3-kinase	8	I-Gene
-dependent	10	O
pathways	8	O
to	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
activation	10	O
in	2	O
primary	7	O
B	1	O
cells	5	O
.	1	O

The	3	O
NF-kappaB	9	B-Gene
/	1	I-Gene
Rel	3	I-Gene
transcription	13	I-Gene
factors	7	I-Gene
play	4	O
an	2	O
important	9	O
role	4	O
in	2	O
the	3	O
expression	10	O
of	2	O
genes	5	O
involved	8	O
in	2	O
B	1	O
cell	4	O
development	11	O
,	1	O
differentiation	15	O
and	3	O
function	8	O
.	1	O

Nuclear	7	B-Gene
NF-kappaB	9	I-Gene
is	2	O
induced	7	O
in	2	O
B	1	O
cells	5	O
by	2	O
engagement	10	O
of	2	O
either	6	O
the	3	O
BCR	3	B-Gene
or	2	O
CD40	4	B-Gene
or	2	O
by	2	O
stimulation	11	O
with	4	O
lipopolysaccharide	18	B-Chemical
(	1	O
LPS	3	B-Chemical
)	1	O
.	1	O

Despite	7	O
the	3	O
importance	10	O
of	2	O
NF-kappaB	9	B-Gene
to	2	O
B	1	O
cell	4	O
function	8	O
,	1	O
little	6	O
is	2	O
known	5	O
about	5	O
the	3	O
signaling	9	O
pathways	8	O
leading	7	O
to	2	O
NF-kappaB	9	B-Gene
activation	10	O
.	1	O

In	2	O
this	4	O
report	6	O
we	2	O
address	7	O
the	3	O
role	4	O
of	2	O
phosphoinositide	16	B-Gene
3'-kinase	9	I-Gene
(	1	O
PI	2	B-Gene
3-kinase	8	I-Gene
)	1	O
in	2	O
BCR	3	B-Gene
-	1	O
and	3	O
LPS	3	B-Chemical
-induced	8	O
NF-kappaB	9	B-Gene
activation	10	O
using	5	O
populations	11	O
of	2	O
primary	7	O
murine	6	O
resting	7	O
B	1	O
cells	5	O
.	1	O

Using	5	O
the	3	O
specific	8	O
pharmacological	15	O
inhibitors	10	O
of	2	O
PI	2	B-Gene
3-kinase	8	I-Gene
,	1	O
Wortmannin	10	B-Chemical
and	3	O
LY294002	8	B-Chemical
,	1	O
we	2	O
demonstrate	11	O
that	4	O
PI	2	B-Gene
3-kinase	8	I-Gene
activity	8	O
is	2	O
vital	5	O
for	3	O
BCR	3	B-Gene
-induced	8	O
NF-kappaB	9	B-Gene
DNA	3	I-Gene
-binding	8	O
activity	8	O
.	1	O

Furthermore	11	O
,	1	O
we	2	O
show	4	O
that	4	O
this	4	O
is	2	O
achieved	8	O
via	3	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
-dependent	10	O
degradation	11	O
of	2	O
IkappaBalpha	12	B-Gene
.	1	O

Similar	7	O
analyses	8	O
reveal	6	O
that	4	O
PI	2	B-Gene
3-kinase	8	I-Gene
is	2	O
also	4	O
critical	8	O
in	2	O
triggering	10	O
NF-kappaB	9	B-Gene
DNA	3	I-Gene
-binding	8	O
activity	8	O
and	3	O
IkappaBalpha	12	B-Gene
degradation	11	O
following	9	O
LPS	3	B-Chemical
stimulation	11	O
.	1	O

Interestingly	13	O
,	1	O
a	1	O
PKC	3	B-Gene
inhibitor	9	I-Gene
which	5	O
blocked	7	O
the	3	O
BCR	3	B-Gene
-induced	8	O
IkappaBalpha	12	B-Gene
degradation	11	O
had	3	O
no	2	O
effect	6	O
on	2	O
the	3	O
degradation	11	O
of	2	O
IkappaBalpha	12	B-Gene
after	5	O
LPS	3	B-Chemical
stimulation	11	O
.	1	O

Taken	5	O
together	8	O
,	1	O
our	3	O
results	7	O
indicate	8	O
the	3	O
involvement	11	O
of	2	O
PI	2	B-Gene
3-kinase	8	I-Gene
in	2	O
at	2	O
least	5	O
two	3	O
distinct	8	O
signaling	9	O
pathways	8	O
leading	7	O
to	2	O
activation	10	O
of	2	O
NF-kappaB	9	B-Gene
in	2	O
B	1	O
cells	5	O
.	1	O

The	3	O
translesion	11	O
DNA	3	B-Gene
polymerase	10	I-Gene
zeta	4	I-Gene
plays	5	O
a	1	O
major	5	O
role	4	O
in	2	O
Ig	2	B-Gene
and	3	O
bcl-6	5	B-Gene
somatic	7	O
hypermutation	13	O
.	1	O

Ig	2	B-Gene
somatic	7	O
mutations	9	O
would	5	O
be	2	O
introduced	10	O
by	2	O
a	1	O
polymerase	10	O
(	1	O
pol	3	O
)	1	O
while	5	O
repairing	9	O
DNA	3	O
outside	7	O
main	4	O
DNA	3	O
replication	11	O
.	1	O

We	2	O
show	4	O
that	4	O
human	5	O
B	1	O
cells	5	O
constitutively	14	O
express	7	O
the	3	O
translesion	11	B-Gene
pol	3	I-Gene
zeta	4	I-Gene
,	1	O
which	5	O
effectively	11	O
extends	7	O
DNA	3	O
past	4	O
mismatched	10	O
bases	5	O
(	1	O
mispair	7	O
extender	8	O
)	1	O
,	1	O
and	3	O
pol	3	B-Gene
eta	3	I-Gene
,	1	O
which	5	O
bypasses	8	O
DNA	3	O
lesions	7	O
in	2	O
an	2	O
error-free	10	O
fashion	7	O
.	1	O

Upon	4	O
B	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
(	1	O
BCR	3	B-Gene
)	1	O
engagement	10	O
and	3	O
coculture	9	O
with	4	O
activated	9	B-Gene
CD4+	4	I-Gene
T	1	O
cells	5	O
,	1	O
these	5	O
lymphocytes	11	O
upregulated	11	O
pol	3	B-Gene
zeta	4	I-Gene
,	1	O
downregulated	13	O
pol	3	B-Gene
eta	3	I-Gene
,	1	O
and	3	O
mutated	7	O
the	3	O
Ig	2	B-Gene
and	3	O
bcl-6	5	B-Gene
genes	5	I-Gene
.	1	O

Inhibition	10	O
of	2	O
the	3	O
pol	3	B-Gene
zeta	4	I-Gene
REV3	4	I-Gene
catalytic	9	I-Gene
subunit	7	I-Gene
by	2	O
specific	8	O
phosphorothioate	16	B-Chemical
-modified	9	O
oligonucleotides	16	O
impaired	8	O
Ig	2	B-Gene
and	3	O
bcl-6	5	B-Gene
hypermutation	13	I-Gene
and	3	O
UV	2	O
damage	6	O
-induced	8	O
DNA	3	O
mutagenesis	11	O
,	1	O
without	7	O
affecting	9	O
cell	4	O
cycle	5	O
or	2	O
viability	9	O
.	1	O

Thus	4	O
,	1	O
pol	3	B-Gene
zeta	4	I-Gene
plays	5	O
a	1	O
critical	8	O
role	4	O
in	2	O
Ig	2	B-Gene
and	3	O
bcl-6	5	B-Gene
hypermutation	13	I-Gene
,	1	O
perhaps	7	O
facilitated	11	O
by	2	O
the	3	O
downregulation	14	O
of	2	O
pol	3	B-Gene
eta	3	I-Gene
.	1	O

Requirement	11	O
for	3	O
p38	3	B-Gene
and	3	O
p44	3	B-Gene
/	1	I-Gene
p42	3	I-Gene
mitogen	7	I-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinases	7	I-Gene
in	2	O
RAGE	4	B-Gene
-mediated	9	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
transcriptional	15	O
activation	10	O
and	3	O
cytokine	8	O
secretion	9	O
.	1	O

Advanced	8	B-Gene
glycation	9	I-Gene
end	3	I-Gene
product	7	I-Gene
(	1	O
AGE	3	B-Gene
)	1	O
activation	10	O
of	2	O
the	3	O
signal	6	B-Gene
-transducing	12	I-Gene
receptor	8	I-Gene
for	3	I-Gene
AGE	3	I-Gene
(	1	O
RAGE	4	B-Gene
)	1	O
has	3	O
been	4	O
linked	6	O
to	2	O
a	1	O
proinflammatory	15	O
phenotypic	10	O
change	6	O
within	6	O
cells	5	O
.	1	O

However	7	O
,	1	O
the	3	O
precise	7	O
intracellular	13	O
signaling	9	O
pathways	8	O
involved	8	O
have	4	O
not	3	O
been	4	O
elucidated	10	O
.	1	O

We	2	O
demonstrate	11	O
here	4	O
that	4	O
human	5	B-Gene
serum	5	I-Gene
albumin	7	I-Gene
modified	8	O
with	4	O
N	1	B-Chemical
(	1	I-Chemical
varepsilon	10	I-Chemical
)	1	I-Chemical
-	1	I-Chemical
(	1	I-Chemical
carboxymethyl	13	I-Chemical
)	1	I-Chemical
lysine	6	I-Chemical
(	1	O
CML	3	B-Chemical
)	1	O
,	1	O
a	1	O
major	5	O
AGE	3	B-Gene
adduct	6	O
that	4	O
progressively	13	O
accumulates	11	O
with	4	O
aging	5	O
,	1	O
diabetes	8	B-Disease
,	1	O
and	3	O
renal	5	B-Disease
failure	7	I-Disease
,	1	O
induced	7	O
nuclear	7	B-Gene
factor	6	I-Gene
(	1	I-Gene
NF	2	I-Gene
)	1	I-Gene
-kappaB	7	I-Gene
-driven	7	O
reporter	8	O
gene	4	O
expression	10	O
in	2	O
human	5	O
monocytic	9	O
THP-1	5	O
cells	5	O
.	1	O

The	3	O
NF-kappaB	9	B-Gene
response	8	O
was	3	O
blocked	7	O
with	4	O
a	1	O
synthetic	9	O
peptide	7	O
corresponding	13	O
to	2	O
the	3	O
putative	8	O
ligand	6	O
-binding	8	O
domain	6	O
of	2	O
RAGE	4	B-Gene
,	1	O
with	4	O
anti-	5	B-Gene
RAGE	4	I-Gene
antiserum	9	I-Gene
,	1	O
and	3	O
by	2	O
coexpression	12	O
of	2	O
truncated	9	O
receptors	9	O
lacking	7	O
the	3	O
intracellular	13	O
domain	6	O
.	1	O

Signal	6	O
transduction	12	O
from	4	O
RAGE	4	B-Gene
to	2	O
NF-kappaB	9	B-Gene
involved	8	O
the	3	O
generation	10	O
of	2	O
reactive	8	B-Chemical
oxygen	6	I-Chemical
species	7	I-Chemical
,	1	O
since	5	O
reporter	8	O
gene	4	O
expression	10	O
was	3	O
blocked	7	O
with	4	O
the	3	O
antioxidant	11	O
N-acetyl-L-cysteine	19	B-Chemical
.	1	O

CML	3	B-Chemical
-modified	9	O
albumin	7	B-Gene
produced	8	O
rapid	5	O
transient	9	O
activation	10	O
of	2	O
tyrosine	8	B-Chemical
phosphorylation	15	O
,	1	O
extracellular	13	B-Gene
signal	6	I-Gene
-regulated	10	I-Gene
kinase	6	I-Gene
1	1	I-Gene
and	3	O
2	1	B-Partial_Gene
,	1	O
and	3	O
p38	3	B-Gene
mitogen	7	I-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
(	1	O
MAPK	4	B-Gene
)	1	O
,	1	O
but	3	O
not	3	O
c-Jun	5	B-Gene
NH	2	I-Gene
(	1	I-Gene
2	1	I-Gene
)	1	I-Gene
-terminal	9	I-Gene
kinase	6	I-Gene
.	1	O

RAGE	4	B-Gene
-mediated	9	O
NF-kappaB	9	B-Gene
activation	10	O
was	3	O
suppressed	10	O
by	2	O
the	3	O
selective	9	O
p38	3	B-Gene
MAPK	4	I-Gene
inhibitor	9	O
SB203580	8	B-Chemical
and	3	O
by	2	O
coexpression	12	O
of	2	O
a	1	O
kinase-dead	11	O
p38	3	B-Gene
dominant	8	O
-negative	9	O
mutant	6	O
.	1	O

Activation	10	O
of	2	O
NF-kappaB	9	B-Gene
by	2	O
CML	3	B-Chemical
-modified	9	O
albumin	7	B-Gene
increased	9	O
secretion	9	O
of	2	O
proinflammatory	15	O
cytokines	9	O
(	1	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor-alpha	12	I-Gene
,	1	O
interleukin-1beta	17	B-Gene
,	1	O
and	3	O
monocyte	8	B-Gene
chemoattractant	15	I-Gene
protein-1	9	I-Gene
)	1	O
severalfold	11	O
,	1	O
and	3	O
inhibition	10	O
of	2	O
p38	3	B-Gene
MAPK	4	I-Gene
blocked	7	O
these	5	O
increases	9	O
.	1	O

These	5	O
results	7	O
indicate	8	O
that	4	O
p38	3	B-Gene
MAPK	4	I-Gene
activation	10	O
mediates	8	O
RAGE	4	B-Gene
-induced	8	O
NF-kappaB	9	B-Gene
-dependent	10	O
secretion	9	O
of	2	O
proinflammatory	15	O
cytokines	9	O
and	3	O
suggest	7	O
that	4	O
accelerated	11	O
inflammation	12	O
may	3	O
be	2	O
a	1	O
consequence	11	O
of	2	O
cellular	8	O
activation	10	O
induced	7	O
by	2	O
this	4	O
receptor	8	O
.	1	O

STAT3	5	B-Gene
is	2	O
constitutively	14	O
active	6	O
in	2	O
some	4	O
patients	8	O
with	4	O
Polycythemia	12	B-Disease
rubra	5	I-Disease
vera	4	I-Disease
.	1	O

OBJECTIVE	9	O
:	1	O
Polycythemia	12	B-Disease
vera	4	I-Disease
is	2	O
a	1	O
clonal	6	O
stem	4	O
cell	4	O
disorder	8	O
characterized	13	O
by	2	O
hyperproliferation	18	O
of	2	O
the	3	O
erythroid	9	O
,	1	O
myeloid	7	O
,	1	O
and	3	O
megakaryocytic	14	O
lineages	8	O
.	1	O

While	5	O
it	2	O
has	3	O
been	4	O
shown	5	O
that	4	O
progenitor	10	O
cells	5	O
of	2	O
P.	2	B-Disease
vera	4	I-Disease
patients	8	O
are	3	O
hypersensitive	14	O
to	2	O
several	7	O
growth	6	O
factors	7	O
including	9	O
erythropoietin	14	B-Gene
,	1	O
insulin	7	B-Gene
-like	5	I-Gene
growth	6	I-Gene
factor-1	8	I-Gene
,	1	O
thrombopoietin	14	B-Gene
,	1	O
interleukin-3	13	B-Gene
,	1	O
and	3	O
granulocyte	11	B-Gene
/	1	I-Gene
monocyte	8	I-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
,	1	O
the	3	O
molecular	9	O
pathogenesis	12	O
of	2	O
this	4	O
disease	7	O
remains	7	O
unknown	7	O
.	1	O

Growth	6	O
factor	6	O
hypersensitivity	16	B-Disease
could	5	O
be	2	O
mediated	8	O
by	2	O
changes	7	O
in	2	O
signal	6	O
transduction	12	O
pathways	8	O
.	1	O

We	2	O
therefore	9	O
investigated	12	O
a	1	O
common	6	O
downstream	10	O
effector	8	O
of	2	O
cytokines	9	O
,	1	O
the	3	O
signal	6	B-Gene
transducers	11	I-Gene
and	3	I-Gene
activators	10	I-Gene
of	2	I-Gene
transcription	13	I-Gene
(	1	O
STATs	5	B-Gene
)	1	O
.	1	O

A	1	O
constitutive	12	O
activation	10	O
of	2	O
STAT	4	B-Gene
factors	7	I-Gene
could	5	O
explain	7	O
the	3	O
increased	9	O
proliferation	13	O
of	2	O
P.	2	B-Disease
vera	4	I-Disease
cells	5	O
even	4	O
in	2	O
the	3	O
absence	7	O
of	2	O
growth	6	O
factor	6	O
stimulation	11	O
.	1	O

METHODS	7	O
:	1	O
Peripheral	10	O
granulocytes	12	O
from	4	O
patients	8	O
with	4	O
P.	2	B-Disease
vera	4	I-Disease
and	3	O
from	4	O
healthy	7	O
volunteers	10	O
were	4	O
assayed	7	O
for	3	O
STAT1	5	B-Gene
,	1	O
3	1	B-Partial_Gene
,	1	O
and	3	O
5	1	B-Partial_Gene
DNA	3	O
binding	7	O
by	2	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assay	5	O
.	1	O

RESULTS	7	O
:	1	O
Four	4	O
of	2	O
14	2	O
P.	2	B-Disease
vera	4	I-Disease
patients	8	O
analyzed	8	O
showed	6	O
constitutive	12	O
STAT3	5	B-Gene
DNA	3	I-Gene
binding	7	O
in	2	O
unstimulated	12	O
peripheral	10	O
granulocytes	12	O
,	1	O
while	5	O
none	4	O
of	2	O
the	3	O
17	2	O
healthy	7	O
volunteers	10	O
tested	6	O
did	3	O
.	1	O

None	4	O
of	2	O
the	3	O
subjects	8	O
showed	6	O
constitutive	12	O
STAT1	5	B-Gene
or	2	O
STAT5	5	B-Gene
activity	8	O
.	1	O

Western	7	O
blotting	8	O
demonstrated	12	O
that	4	O
,	1	O
in	2	O
the	3	O
three	5	O
patients	8	O
,	1	O
STAT3	5	B-Gene
is	2	O
constitutively	14	O
phosphorylated	14	O
on	2	O
Tyr	3	B-Chemical
705	3	O
,	1	O
whereas	7	O
it	2	O
is	2	O
unphosphorylated	16	O
in	2	O
the	3	O
other	5	O
patients	8	O
and	3	O
in	2	O
controls	8	O
.	1	O

Interestingly	13	O
,	1	O
constitutive	12	O
STAT3	5	B-Gene
activity	8	O
did	3	O
not	3	O
correlate	9	O
with	4	O
the	3	O
duration	8	O
of	2	O
disease	7	O
or	2	O
the	3	O
treatment	9	O
regimen	7	O
.	1	O

It	2	O
was	3	O
observed	8	O
in	2	O
a	1	O
recently	8	O
diagnosed	9	O
patient	7	O
and	3	O
in	2	O
two	3	O
patients	8	O
treated	7	O
only	4	O
with	4	O
phlebotomy	10	O
.	1	O

CONCLUSION	10	O
:	1	O
Our	3	O
data	4	O
suggest	7	O
that	4	O
constitutive	12	O
phosphorylation	15	O
and	3	O
activation	10	O
of	2	O
STAT3	5	B-Gene
is	2	O
not	3	O
a	1	O
secondary	9	O
event	5	O
induced	7	O
by	2	O
mutagenizing	12	O
agents	6	O
or	2	O
by	2	O
prolonged	9	O
hyperproliferation	18	O
of	2	O
hematopoietic	13	O
cells	5	O
,	1	O
but	3	O
rather	6	O
represents	10	O
a	1	O
primary	7	O
molecular	9	O
aberration	10	O
.	1	O

Constitutively	14	O
active	6	O
STAT3	5	B-Gene
may	3	O
contribute	10	O
to	2	O
the	3	O
growth	6	O
factor	6	O
hypersensitivity	16	B-Disease
of	2	O
P.	2	B-Disease
vera	4	I-Disease
cells	5	O
.	1	O

T	1	O
helper-cell	11	O
phenotype	9	O
regulates	9	O
atherosclerosis	15	B-Disease
in	2	O
mice	4	O
under	5	O
conditions	10	O
of	2	O
mild	4	B-Disease
hypercholesterolemia	20	I-Disease
.	1	O

BACKGROUND	10	O
:	1	O
T	1	O
cells	5	O
are	3	O
implicated	10	O
in	2	O
atherosclerosis	15	B-Disease
,	1	O
but	3	O
little	6	O
is	2	O
known	5	O
about	5	O
the	3	O
genetic	7	O
control	7	O
or	2	O
molecular	9	O
pathways	8	O
,	1	O
especially	10	O
under	5	O
conditions	10	O
of	2	O
mild	4	B-Disease
hypercholesterolemia	20	I-Disease
.	1	O

METHODS	7	O
AND	3	O
RESULTS	7	O
:	1	O
BALB	4	O
/	1	O
c	1	O
mice	4	O
,	1	O
making	6	O
a	1	O
CD4+	4	B-Gene
Th2	3	O
(	1	O
IL-4+	5	B-Gene
)	1	O
cell	4	O
response	8	O
,	1	O
express	7	O
both	4	O
MHC	3	B-Gene
class	5	I-Gene
II	2	I-Gene
antigens	8	I-Gene
(	1	O
IA	2	O
(	1	O
d	1	O
)	1	O
,	1	O
IE	2	O
(	1	O
d	1	O
)	1	O
)	1	O
and	3	O
are	3	O
atherosclerosis	15	B-Disease
-resistant	10	O
.	1	O

C57Bl	5	O
/	1	O
6	1	O
mice	4	O
produce	7	O
a	1	O
CD4+	4	B-Gene
Th1	3	O
(	1	O
interferon	10	B-Gene
[	1	I-Gene
IFN	3	I-Gene
]	1	I-Gene
gamma+	6	I-Gene
)	1	O
response	8	O
,	1	O
express	7	O
IA	2	O
(	1	O
b	1	O
)	1	O
but	3	O
no	2	O
IE	2	O
,	1	O
and	3	O
are	3	O
atherosclerosis-prone	21	B-Disease
.	1	O

To	2	O
evaluate	8	O
T	1	O
helper-cell	11	O
phenotype	9	O
in	2	O
fatty	5	O
streak	6	O
formation	9	O
,	1	O
wild-type	9	O
C57Bl	5	O
/	1	O
6	1	O
mice	4	O
(	1	O
IA	2	O
(	1	O
b	1	O
)	1	O
+IE-	4	O
)	1	O
and	3	O
transgenic	10	O
mice	4	O
,	1	O
either	6	O
AB	2	O
(	1	O
o	1	O
)	1	O
,	1	O
IA	2	O
(	1	O
b	1	O
)	1	O
-IE-	4	O
;	1	O
ABEalpha	8	O
,	1	O
IA-IE	5	O
(	1	O
k	1	O
)	1	O
+	1	O
;	1	O
or	2	O
BL	2	O
:	1	O
TG	2	O
:	1	O
Ealpha	6	O
,	1	O
IA	2	O
(	1	O
b	1	O
)	1	O
+IE	3	O
(	1	O
k	1	O
)	1	O
+	1	O
,	1	O
were	4	O
fed	3	O
a	1	O
high-cholesterol	16	B-Chemical
diet	4	O
for	3	O
16	2	O
weeks	5	O
and	3	O
evaluated	9	O
histomorphometrically	21	O
for	3	O
aortic	6	B-Disease
lesions	7	I-Disease
.	1	O

Lesion	6	O
size	4	O
in	2	O
AB	2	O
(	1	O
o	1	O
)	1	O
,	1	O
ABEalpha	8	O
,	1	O
and	3	O
BL	2	O
:	1	O
TG	2	O
:	1	O
Ealpha	6	O
strains	7	O
was	3	O
decreased	9	O
by	2	O
54	2	O
%	1	O
,	1	O
79	2	O
%	1	O
,	1	O
and	3	O
82	2	O
%	1	O
,	1	O
respectively	12	O
,	1	O
compared	8	O
with	4	O
wild-type	9	O
,	1	O
correlating	11	O
with	4	O
decreased	9	O
Th1	3	O
and	3	O
increased	9	O
Th2	3	O
expression	10	O
and	3	O
suggesting	10	O
that	4	O
T	1	O
helper-cell	11	O
phenotype	9	O
is	2	O
important	9	O
in	2	O
fatty	5	O
lesion	6	O
development	11	O
.	1	O

Decreasing	10	O
Th1	3	O
cells	5	O
by	2	O
antibodies	10	O
(	1	O
alpha-CD4	9	B-Gene
)	1	O
or	2	O
cytokines	9	O
(	1	O
IL-4	4	B-Gene
)	1	O
also	4	O
caused	6	O
>	1	O
/	1	O
=80	3	O
%	1	O
reductions	10	O
in	2	O
lesion	6	O
size	4	O
.	1	O

Immunohistology	15	O
revealed	8	O
IFN-gamma	9	B-Gene
,	1	O
but	3	O
not	3	O
IL-4	4	B-Gene
,	1	O
colocalized	11	O
with	4	O
activated	9	O
macrophages	11	O
.	1	O

Confirming	10	O
these	5	O
findings	8	O
in	2	O
a	1	O
different	9	O
mouse	5	O
strain	6	O
,	1	O
BALB	4	O
/	1	O
c	1	O
Stat	4	B-Gene
6	1	I-Gene
knockout	8	O
mice	4	O
(	1	O
Th2	3	O
cell	4	O
-deficient	10	O
)	1	O
developed	9	O
aortic	6	B-Disease
lesions	7	I-Disease
comparable	10	O
to	2	O
C57Bl	5	O
/	1	O
6	1	O
mice	4	O
on	2	O
the	3	O
same	4	O
diet	4	O
.	1	O

CONCLUSIONS	11	O
:	1	O
In	2	O
mildly	6	O
hypercholesterolemic	20	O
C57Bl	5	O
/	1	O
6	1	O
mice	4	O
,	1	O
presence	8	O
of	2	O
IA	2	O
(	1	O
b	1	O
)	1	O
and	3	O
absence	7	O
of	2	O
IE	2	O
regulated	9	O
CD4+	4	B-Gene
T	1	O
helper-cell	11	O
phenotype	9	O
;	1	O
fatty	5	O
lesions	7	O
were	4	O
proportional	12	O
to	2	O
IFNgamma+	9	B-Gene
Th1	3	O
cells	5	O
in	2	O
both	4	O
C57Bl	5	O
/	1	O
6	1	O
and	3	O
BALB	4	O
/	1	O
c	1	O
strains	7	O
.	1	O

IFN-gamma	9	B-Gene
may	3	O
participate	11	O
through	7	O
macrophage	10	O
activation	10	O
,	1	O
whereas	7	O
IL-4	4	B-Gene
may	3	O
act	3	O
to	2	O
limit	5	O
Th1-cell	8	O
response	8	O
.	1	O

Smad3	5	B-Gene
and	3	O
Smad4	5	B-Gene
mediate	7	O
transforming	12	B-Gene
growth	6	I-Gene
factor-beta1	12	I-Gene
-induced	8	O
IgA	3	B-Gene
expression	10	O
in	2	O
murine	6	O
B	1	O
lymphocytes	11	O
.	1	O

Transforming	12	B-Gene
growth	6	I-Gene
factor	6	I-Gene
(	1	I-Gene
TGF	3	I-Gene
)	1	I-Gene
-beta1	6	I-Gene
is	2	O
well	4	O
established	11	O
as	2	O
a	1	O
critical	8	O
IgA	3	B-Gene
isotype	7	O
switching	9	O
factor	6	O
and	3	O
Smad	4	B-Gene
molecules	9	O
have	4	O
been	4	O
reported	8	O
to	2	O
act	3	O
as	2	O
transducers	11	O
and	3	O
transcriptional	15	O
factors	7	O
in	2	O
the	3	O
expression	10	O
of	2	O
TGF-beta1	9	B-Gene
-targeted	9	O
genes	5	O
.	1	O

We	2	O
examined	8	O
the	3	O
involvement	11	O
of	2	O
Smad	4	B-Gene
proteins	8	I-Gene
in	2	O
TGF-beta1	9	B-Gene
-induced	8	O
IgA	3	B-Gene
expression	10	O
.	1	O

First	5	O
,	1	O
we	2	O
found	5	O
that	4	O
TGF-beta1	9	B-Gene
significantly	13	O
increases	9	O
endogenous	10	O
germ-line	9	O
(	1	O
GL	2	O
)	1	O
alpha	5	O
transcripts	11	O
by	2	O
LPS	3	B-Chemical
-stimulated	11	O
CH12.LX.4933	12	O
(	1	O
mu	2	O
(	1	O
+	1	O
)	1	O
)	1	O
B	1	B-Disease
lymphoma	8	I-Disease
cells	5	O
.	1	O

To	2	O
investigate	11	O
its	3	O
signaling	9	O
mechanisms	10	O
,	1	O
the	3	O
lymphoma	8	B-Disease
cell	4	O
line	4	O
was	3	O
transfected	11	O
with	4	O
pFL3	4	O
that	4	O
contains	8	O
the	3	O
TGF-beta	8	B-Gene
-responsive	11	I-Gene
element	7	I-Gene
of	2	O
the	3	O
GLalpha	7	O
promoter	8	O
,	1	O
and	3	O
stimulated	10	O
with	4	O
TGF-beta1	9	B-Gene
.	1	O

Similar	7	O
to	2	O
endogenous	10	O
GLalpha	7	O
transcripts	11	O
,	1	O
TGF-beta1	9	B-Gene
induces	7	O
GLalpha	7	O
promoter	8	O
activity	8	O
and	3	O
overexpression	14	O
of	2	O
Smad3	5	B-Gene
markedly	8	O
enhances	8	O
the	3	O
promoter	8	O
activity	8	O
.	1	O

This	4	O
activity	8	O
is	2	O
further	7	O
augmented	9	O
by	2	O
cotransfected	13	O
Smad4	5	B-Gene
.	1	O

On	2	O
the	3	O
other	5	O
hand	4	O
,	1	O
Smad7	5	B-Gene
substantially	13	O
abrogates	9	O
the	3	O
synergistic	11	O
effect	6	O
of	2	O
Smad3	5	B-Gene
/	1	I-Gene
4	1	I-Gene
on	2	O
GLalpha	7	O
promoter	8	O
activity	8	O
.	1	O

In	2	O
addition	8	O
,	1	O
overexpression	14	O
of	2	O
Smad3	5	B-Gene
/	1	I-Gene
4	1	I-Gene
enhances	8	O
TGF-beta1	9	B-Gene
-induced	8	O
endogenous	10	O
GLalpha	7	O
transcripts	11	O
in	2	O
normal	6	O
spleen	6	O
B	1	O
cell	4	O
s	1	O
.	1	O

Finally	7	O
,	1	O
in	2	O
the	3	O
presence	8	O
of	2	O
TGF-beta1	9	B-Gene
,	1	O
overexpression	14	O
of	2	O
Smad3	5	B-Gene
/	1	I-Gene
4	1	I-Gene
selectively	11	O
increases	9	O
both	4	O
surface	7	O
IgA	3	B-Gene
expression	10	O
and	3	O
IgA	3	B-Gene
production	10	O
.	1	O

The	3	O
results	7	O
from	4	O
the	3	O
present	7	O
study	5	O
indicate	8	O
that	4	O
Smad3	5	B-Gene
,	1	O
Smad4	5	B-Gene
,	1	O
and	3	O
Smad7	5	B-Gene
,	1	O
at	2	O
least	5	O
in	2	O
part	4	O
,	1	O
serve	5	O
as	2	O
mediators	9	O
linking	7	O
TGF-beta1	9	B-Gene
to	2	O
transcriptional	15	O
regulation	10	O
of	2	O
IgA	3	B-Gene
switching	9	O
related	7	O
gene	4	O
and	3	O
regulation	10	O
of	2	O
IgA	3	B-Gene
class	5	O
switching	9	O
.	1	O

The	3	O
effect	6	O
of	2	O
HIV-1	5	O
regulatory	10	O
proteins	8	O
on	2	O
cellular	8	O
genes	5	O
:	1	O
derepression	12	O
of	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
by	2	O
Tat	3	B-Gene
.	1	O

In	2	O
HIV	3	O
-infected	9	O
individuals	11	O
dysregulation	13	O
of	2	O
the	3	O
immune	6	O
system	6	O
is	2	O
characterized	13	O
by	2	O
severe	6	O
disorders	9	O
of	2	O
the	3	O
cytokine	8	O
network	7	O
.	1	O

Increase	8	O
secretion	9	O
of	2	O
IL-2	4	B-Gene
,	1	O
the	3	O
major	5	O
T	1	O
cell	4	O
growth	6	O
and	3	O
differentiation	15	O
cytokine	8	O
,	1	O
may	3	O
play	4	O
a	1	O
decisive	8	O
role	4	O
in	2	O
sensitization	13	O
of	2	O
T	1	O
cells	5	O
for	3	O
activation	10	O
induced	7	O
apoptosis	9	O
and	3	O
indirect	8	O
death	5	O
of	2	O
activated	9	O
T	1	O
cells	5	O
through	7	O
augmented	9	O
virus	5	O
replication	11	O
.	1	O

We	2	O
investigated	12	O
the	3	O
cause	5	O
of	2	O
enhanced	8	O
IL-2	4	B-Gene
secretion	9	O
and	3	O
found	5	O
that	4	O
the	3	O
HIV	3	B-Gene
Tat	3	I-Gene
induces	7	O
this	4	O
effect	6	O
.	1	O

We	2	O
demonstrate	11	O
that	4	O
increased	9	O
IL-2	4	B-Gene
secretion	9	O
is	2	O
due	3	O
to	2	O
Tat	3	B-Gene
-enhanced	9	O
IL-2	4	B-Gene
promoter	8	I-Gene
activation	10	O
.	1	O

Tat	3	B-Gene
derepresses	11	O
and	3	O
activates	9	O
the	3	O
distal	6	O
AP-1	4	B-Gene
site	4	O
(	1	O
position	8	O
-185	4	O
to	2	O
-177	4	O
)	1	O
in	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
.	1	O

In	2	O
nonstimulated	13	O
T	1	O
cells	5	O
a	1	O
repressor	9	O
complex	7	O
containing	10	O
NF-IL6	6	B-Gene
,	1	O
JunB	4	B-Gene
,	1	O
c-Fos	5	B-Gene
and	3	O
Fra-1	5	B-Gene
is	2	O
formed	6	O
on	2	O
the	3	O
AP-1	4	B-Gene
(	1	O
IL-2	4	B-Gene
/	1	I-Gene
d	1	I-Gene
)	1	O
site	4	O
and	3	O
represses	9	O
IL-2	4	B-Gene
promoter	8	I-Gene
activity	8	O
.	1	O

After	5	O
T	1	O
cell	4	O
activation	10	O
,	1	O
a	1	O
heterodimeric	13	O
activator	9	O
containing	10	O
p65	3	B-Gene
and	3	O
c-Jun	5	B-Gene
binds	5	O
to	2	O
the	3	O
AP-1	4	B-Gene
(	1	O
IL-2	4	B-Gene
/	1	I-Gene
d	1	I-Gene
)	1	O
site	4	O
.	1	O

HIV	3	B-Gene
Tat	3	I-Gene
enhances	8	O
activation	10	O
of	2	O
NF-kappaB	9	B-Gene
and	3	O
consequently	12	O
,	1	O
activates	9	O
the	3	O
AP-1	4	B-Gene
(	1	O
IL-2	4	B-Gene
/	1	I-Gene
d	1	I-Gene
)	1	O
site	4	O
.	1	O

Our	3	O
data	4	O
provide	7	O
evidence	8	O
for	3	O
a	1	O
novel	5	O
mechanism	9	O
by	2	O
which	5	O
HIV	3	B-Gene
Tat	3	I-Gene
dysregulates	12	O
IL-2	4	B-Gene
production	10	O
and	3	O
therefore	9	O
may	3	O
contribute	10	O
to	2	O
the	3	O
HIV-1	5	O
infection	9	O
in	2	O
a	1	O
way	3	O
yet	3	O
to	2	O
be	2	O
clarified	9	O
.	1	O

Plasmin	7	B-Gene
-induced	8	O
expression	10	O
of	2	O
cytokines	9	O
and	3	O
tissue	6	B-Gene
factor	6	I-Gene
in	2	O
human	5	O
monocytes	9	O
involves	8	O
AP-1	4	B-Gene
and	3	O
IKKbeta	7	B-Gene
-mediated	9	O
NF-kappaB	9	B-Gene
activation	10	O
.	1	O

It	2	O
was	3	O
previously	10	O
shown	5	O
that	4	O
plasmin	7	B-Gene
activates	9	O
human	5	O
peripheral	10	O
monocytes	9	O
in	2	O
terms	5	O
of	2	O
lipid	5	O
mediator	8	O
release	7	O
and	3	O
chemotactic	11	O
migration	9	O
.	1	O

Here	4	O
it	2	O
is	2	O
demonstrated	12	O
that	4	O
plasmin	7	B-Gene
induces	7	O
proinflammatory	15	O
cytokine	8	O
release	7	O
and	3	O
tissue	6	B-Gene
factor	6	I-Gene
(	1	O
TF	2	B-Gene
)	1	O
expression	10	O
by	2	O
monocytes	9	O
.	1	O

Plasmin	7	B-Gene
0.043	5	O
to	2	O
1.43	4	O
CTA	3	O
U	1	O
/	1	O
mL	2	O
,	1	O
but	3	O
not	3	O
active	6	O
site	4	O
-blocked	8	O
plasmin	7	B-Gene
,	1	O
triggered	9	O
concentration	13	O
-dependent	10	O
expression	10	O
of	2	O
mRNA	4	O
for	3	O
interleukin-1alpha	18	B-Gene
(	1	O
IL-1alpha	9	B-Gene
)	1	O
,	1	O
IL-1beta	8	B-Gene
,	1	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor-alpha	12	I-Gene
(	1	O
TNF-alpha	9	B-Gene
)	1	O
,	1	O
and	3	O
TF	2	B-Gene
with	4	O
maximum	7	O
responses	9	O
after	5	O
4	1	O
hours	5	O
.	1	O

Plasmin	7	B-Gene
-mediated	9	O
mRNA	4	O
expression	10	O
was	3	O
inhibited	9	O
in	2	O
a	1	O
concentration	13	O
-dependent	10	O
manner	6	O
by	2	O
the	3	O
lysine	6	B-Chemical
analogue	8	O
trans-4-	8	B-Chemical
(	1	I-Chemical
aminomethyl	11	I-Chemical
)	1	I-Chemical
cyclohexane-1-carboxylic	24	I-Chemical
acid	4	I-Chemical
(	1	O
t-AMCA	6	B-Chemical
)	1	O
.	1	O

Increases	9	O
in	2	O
mRNA	4	O
levels	6	O
were	4	O
followed	8	O
by	2	O
concentration-	14	O
and	3	O
time	4	O
-dependent	10	O
release	7	O
of	2	O
IL-1alpha	9	B-Gene
,	1	O
IL-1beta	8	B-Gene
and	3	O
TNF-alpha	9	B-Gene
and	3	O
by	2	O
TF	2	B-Gene
expression	10	O
on	2	O
monocyte	8	O
surfaces	8	O
.	1	O

Neither	7	O
cytokines	9	O
nor	3	O
TF	2	B-Gene
could	5	O
be	2	O
detected	8	O
when	4	O
monocytes	9	O
were	4	O
preincubated	12	O
with	4	O
actinomycin	11	B-Chemical
D	1	I-Chemical
or	2	O
cycloheximide	13	B-Chemical
.	1	O

Electrophoretic	15	O
mobility	8	O
shift	5	O
assays	6	O
indicated	9	O
plasmin	7	B-Gene
-induced	8	O
activation	10	O
of	2	O
NF-kappaB	9	B-Gene
;	1	O
DNA	3	O
-binding	8	O
complexes	9	O
were	4	O
composed	8	O
of	2	O
p50	3	B-Gene
,	1	O
p65	3	B-Gene
,	1	O
and	3	O
c-Rel	5	B-Gene
,	1	O
as	2	O
shown	5	O
by	2	O
supershift	10	O
experiments	11	O
.	1	O

Nuclear	7	O
translocation	13	O
of	2	O
NF-kappaB	9	B-Gene
/	1	I-Gene
Rel	3	I-Gene
proteins	8	I-Gene
coincided	9	O
with	4	O
IkappaBalpha	12	B-Gene
degradation	11	O
.	1	O

At	2	O
variance	8	O
with	4	O
endotoxic	9	O
lipopolysaccharide	18	B-Chemical
,	1	O
plasmin	7	B-Gene
elicited	8	O
the	3	O
rapid	5	O
degradation	11	O
of	2	O
another	7	O
cytoplasmic	11	B-Gene
NF-kappaB	9	I-Gene
inhibitor	9	I-Gene
,	1	O
p105	4	B-Gene
.	1	O

Proteolysis	11	O
of	2	O
NF-kappaB	9	B-Gene
inhibitors	10	I-Gene
was	3	O
apparently	10	O
due	3	O
to	2	O
transient	9	O
activation	10	O
of	2	O
IkappaB	7	B-Gene
kinase	6	I-Gene
(	1	I-Gene
IKK	3	I-Gene
)	1	I-Gene
beta	4	I-Gene
that	4	O
reached	7	O
maximum	7	O
activity	8	O
at	2	O
1	1	O
hour	4	O
after	5	O
plasmin	7	B-Gene
stimulation	11	O
.	1	O

In	2	O
addition	8	O
,	1	O
AP-1	4	B-Gene
binding	7	O
was	3	O
increased	9	O
in	2	O
plasmin	7	B-Gene
-treated	8	O
monocytes	9	O
,	1	O
with	4	O
most	4	O
complexes	9	O
composed	8	O
of	2	O
JunD	4	B-Gene
,	1	O
c-Fos	5	B-Gene
,	1	O
and	3	O
FosB	4	B-Gene
.	1	O

These	5	O
findings	8	O
further	7	O
substantiate	12	O
the	3	O
role	4	O
of	2	O
plasmin	7	B-Gene
as	2	O
a	1	O
proinflammatory	15	O
activator	9	O
of	2	O
human	5	O
monocytes	9	O
and	3	O
reveal	6	O
an	2	O
important	9	O
new	3	O
link	4	O
between	7	O
the	3	O
plasminogen-plasmin	19	B-Gene
system	6	O
and	3	O
inflammation	12	O
.	1	O

(	1	O
Blood.	6	O
2001	4	O
;	1	O
97	2	O
:	1	O
3941-3950	9	O
)	1	O

Treatment	9	O
of	2	O
allergic	8	O
airway	6	B-Disease
inflammation	12	I-Disease
and	3	O
hyperresponsiveness	19	O
by	2	O
antisense	9	O
-induced	8	O
local	5	O
blockade	8	O
of	2	O
GATA-3	6	B-Gene
expression	10	O
.	1	O

Recent	6	O
studies	7	O
in	2	O
transgenic	10	O
mice	4	O
have	4	O
revealed	8	O
that	4	O
expression	10	O
of	2	O
a	1	O
dominant	8	O
negative	8	O
form	4	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
GATA-3	6	I-Gene
in	2	O
T	1	O
cells	5	O
can	3	O
prevent	7	O
T	1	O
helper	6	O
cell	4	O
type	4	O
2	1	O
(	1	O
Th2	3	O
)	1	O
-mediated	9	O
allergic	8	O
airway	6	B-Disease
inflammation	12	I-Disease
in	2	O
mice	4	O
.	1	O

However	7	O
,	1	O
it	2	O
remains	7	O
unclear	7	O
whether	7	O
GATA-3	6	B-Gene
plays	5	O
a	1	O
role	4	O
in	2	O
the	3	O
effector	8	O
phase	5	O
of	2	O
allergic	8	O
airway	6	B-Disease
inflammation	12	I-Disease
and	3	O
whether	7	O
antagonizing	12	O
the	3	O
expression	10	O
and	3	O
/	1	O
or	2	O
function	8	O
of	2	O
GATA-3	6	B-Gene
can	3	O
be	2	O
used	4	O
for	3	O
the	3	O
therapy	7	O
of	2	O
allergic	8	O
airway	6	B-Disease
inflammation	12	I-Disease
and	3	O
hyperresponsiveness	19	O
.	1	O

Here	4	O
,	1	O
we	2	O
analyzed	8	O
the	3	O
effects	7	O
of	2	O
locally	7	O
antagonizing	12	O
GATA-3	6	B-Gene
function	8	O
in	2	O
a	1	O
murine	6	O
model	5	O
of	2	O
asthma	6	B-Disease
.	1	O

We	2	O
could	5	O
suppress	8	O
GATA-3	6	B-Gene
expression	10	O
in	2	O
interleukin	11	B-Gene
(	1	I-Gene
IL	2	I-Gene
)	1	I-Gene
-4	2	I-Gene
-producing	10	O
T	1	O
cells	5	O
in	2	O
vitro	5	O
and	3	O
in	2	O
vivo	4	O
by	2	O
an	2	O
antisense	9	O
phosphorothioate	16	O
oligonucleotide	15	O
overlapping	11	O
the	3	O
translation	11	O
start	5	O
site	4	O
of	2	O
GATA-3	6	B-Gene
,	1	O
whereas	7	O
nonsense	8	O
control	7	O
oligonucleotides	16	O
were	4	O
virtually	9	O
inactive	8	O
.	1	O

In	2	O
a	1	O
murine	6	O
model	5	O
of	2	O
asthma	6	B-Disease
associated	10	O
with	4	O
allergic	8	B-Disease
pulmonary	9	I-Disease
inflammation	12	I-Disease
and	3	O
hyperresponsiveness	19	O
in	2	O
ovalbumin	9	B-Gene
(	1	O
OVA	3	B-Gene
)	1	O
-sensitized	11	O
mice	4	O
,	1	O
local	5	O
intranasal	10	O
administration	14	O
of	2	O
fluorescein	11	O
isothiocyanate	14	O
-labeled	8	O
GATA-3	6	B-Gene
antisense	9	O
oligonucleotides	16	O
led	3	O
to	2	O
DNA	3	O
uptake	6	O
in	2	O
lung	4	O
cells	5	O
associated	10	O
with	4	O
a	1	O
reduction	9	O
of	2	O
intracellular	13	B-Gene
GATA-3	6	I-Gene
expression	10	O
.	1	O

Such	4	O
intrapulmonary	14	O
blockade	8	O
of	2	O
GATA-3	6	B-Gene
expression	10	O
caused	6	O
an	2	O
abrogation	10	O
of	2	O
signs	5	O
of	2	O
lung	4	B-Disease
inflammation	12	I-Disease
including	9	O
infiltration	12	O
of	2	O
eosinophils	11	O
and	3	O
Th2	3	O
cytokine	8	O
production	10	O
.	1	O

Furthermore	11	O
,	1	O
treatment	9	O
with	4	O
antisense	9	O
but	3	O
not	3	O
nonsense	8	O
oligonucleotides	16	O
induced	7	O
a	1	O
significant	11	O
reduction	9	O
of	2	O
airway	6	B-Disease
hyperresponsiveness	19	I-Disease
in	2	O
OVA	3	B-Gene
-sensitized	11	O
mice	4	O
to	2	O
levels	6	O
comparable	10	O
to	2	O
saline	6	O
-treated	8	O
control	7	O
mice	4	O
,	1	O
as	2	O
assessed	8	O
by	2	O
both	4	O
enhanced	8	O
pause	5	O
(	1	O
PenH	4	O
)	1	O
responses	9	O
and	3	O
pulmonary	9	O
resistance	10	O
determined	10	O
by	2	O
body	4	O
plethysmography	15	O
.	1	O

These	5	O
data	4	O
indicate	8	O
a	1	O
critical	8	O
role	4	O
for	3	O
GATA-3	6	B-Gene
in	2	O
the	3	O
effector	8	O
phase	5	O
of	2	O
a	1	O
murine	6	O
asthma	6	B-Disease
model	5	O
and	3	O
suggest	7	O
that	4	O
local	5	O
delivery	8	O
of	2	O
GATA-3	6	B-Gene
antisense	9	O
oligonucleotides	16	O
may	3	O
be	2	O
a	1	O
novel	5	O
approach	8	O
for	3	O
the	3	O
treatment	9	O
of	2	O
airway	6	B-Disease
hyperresponsiveness	19	I-Disease
such	4	O
as	2	O
in	2	O
asthma	6	B-Disease
.	1	O

This	4	O
approach	8	O
has	3	O
the	3	O
potential	9	O
advantage	9	O
of	2	O
suppressing	11	O
the	3	O
expression	10	O
of	2	O
various	7	O
proinflammatory	15	O
Th2	3	O
cytokines	9	O
simultaneously	14	O
rather	6	O
than	4	O
suppressing	11	O
the	3	O
activity	8	O
of	2	O
a	1	O
single	6	O
cytokine	8	O
.	1	O

Pharmacokinetic	15	O
differences	11	O
between	7	O
a	1	O
T	1	O
cell	4	O
-tolerizing	11	O
and	3	O
a	1	O
T	1	O
cell	4	O
-activating	11	O
peptide	7	O
.	1	O

Vaccination	11	O
with	4	O
a	1	O
peptide	7	O
representing	12	O
a	1	O
CTL	3	O
epitope	7	O
from	4	O
the	3	O
human	5	B-Gene
papillomavirus	14	I-Gene
(	1	I-Gene
HPV	3	I-Gene
)	1	I-Gene
16	2	I-Gene
E7	2	I-Gene
protein	7	I-Gene
induces	7	O
a	1	O
specific	8	O
CTL	3	O
response	8	O
that	4	O
prevents	8	O
the	3	O
outgrowth	9	O
of	2	O
HPV16	5	B-Gene
E7	2	I-Gene
-expressing	11	O
tumors	6	B-Disease
.	1	O

In	2	O
contrast	8	O
,	1	O
vaccination	11	O
with	4	O
a	1	O
peptide	7	O
encoding	8	O
an	2	O
adenovirus	10	B-Gene
type	4	I-Gene
5	1	I-Gene
(	1	I-Gene
Ad5	3	I-Gene
)	1	I-Gene
E1A	3	I-Gene
CTL	3	O
epitope	7	O
results	7	O
in	2	O
CTL	3	O
tolerance	9	O
and	3	O
enhanced	8	O
growth	6	O
of	2	O
an	2	O
Ad5	3	B-Gene
E1A	3	I-Gene
-expressing	11	O
tumor	5	B-Disease
.	1	O

It	2	O
is	2	O
unclear	7	O
why	3	O
these	5	O
peptides	8	O
induce	6	O
such	4	O
opposite	8	O
effects	7	O
.	1	O

To	2	O
determine	9	O
whether	7	O
a	1	O
difference	10	O
in	2	O
pharmacokinetics	16	O
can	3	O
explain	7	O
the	3	O
functional	10	O
contrasts	9	O
,	1	O
tritiated	9	O
Ad5	3	B-Gene
E1A	3	I-Gene
and	3	O
HPV16	5	B-Gene
E7	2	I-Gene
peptides	8	O
were	4	O
injected	8	O
into	4	O
mice	4	O
.	1	O

Results	7	O
show	4	O
that	4	O
the	3	O
tolerizing	10	O
peptide	7	O
spread	6	O
through	7	O
the	3	O
body	4	O
16	2	O
times	5	O
faster	6	O
than	4	O
the	3	O
activating	10	O
peptide	7	O
and	3	O
was	3	O
cleared	7	O
at	2	O
least	5	O
2	1	O
times	5	O
faster	6	O
.	1	O

The	3	O
HPV16	5	B-Gene
E7	2	I-Gene
peptide	7	O
kinetics	8	O
correlated	10	O
with	4	O
the	3	O
kinetics	8	O
of	2	O
HPV16	5	B-Gene
E7	2	I-Gene
-specific	9	O
CTL	3	O
induction	9	O
.	1	O

In	2	O
contrast	8	O
,	1	O
Ad5	3	B-Gene
E1A	3	I-Gene
peptide	7	O
injection	9	O
resulted	8	O
in	2	O
physical	8	O
deletion	8	O
of	2	O
preexisting	11	O
Ad5	3	B-Gene
E1A	3	I-Gene
-specific	9	O
CTLs	4	O
within	6	O
24	2	O
h	1	O
after	5	O
injection	9	O
.	1	O

This	4	O
tolerization	12	O
occurred	8	O
at	2	O
the	3	O
time	4	O
when	4	O
the	3	O
peptide	7	O
reached	7	O
its	3	O
maximum	7	O
peptide	7	O
concentration	13	O
in	2	O
the	3	O
organs	6	O
.	1	O

These	5	O
data	4	O
suggest	7	O
that	4	O
ubiquitous	10	O
expression	10	O
of	2	O
the	3	O
tolerizing	10	O
Ad5	3	B-Gene
E1A	3	I-Gene
peptide	7	O
within	6	O
a	1	O
short	5	O
period	6	O
of	2	O
time	4	O
causes	6	O
activation	10	O
-induced	8	O
cell	4	O
death	5	O
of	2	O
Ad5	3	B-Gene
E1A	3	I-Gene
-specific	9	O
CTLs	4	O
.	1	O

Therefore	9	O
,	1	O
information	11	O
on	2	O
the	3	O
pharmacokinetics	16	O
of	2	O
peptides	8	O
is	2	O
vital	5	O
for	3	O
the	3	O
safety	6	O
and	3	O
efficacy	8	O
of	2	O
peptide	7	O
-based	6	O
vaccines	8	O
.	1	O

Stat6	5	B-Gene
is	2	O
necessary	9	O
and	3	O
sufficient	10	O
for	3	O
IL-4	4	B-Gene
's	2	O
role	4	O
in	2	O
Th2	3	O
differentiation	15	O
and	3	O
cell	4	O
expansion	9	O
.	1	O

IL-4	4	B-Gene
plays	5	O
a	1	O
critical	8	O
role	4	O
in	2	O
the	3	O
differentiation	15	O
of	2	O
T	1	O
CR	2	O
-stimulated	11	O
naive	5	O
CD4	3	B-Gene
T	1	O
cells	5	O
to	2	O
the	3	O
Th2	3	O
phenotype	9	O
.	1	O

In	2	O
response	8	O
to	2	O
IL-4	4	B-Gene
,	1	O
the	3	O
IL-4R	5	B-Gene
activates	9	O
a	1	O
set	3	O
of	2	O
phosphotyrosine	15	B-Chemical
binding	7	O
domain	6	O
-containing	11	O
proteins	8	O
,	1	O
including	9	O
insulin	7	B-Gene
receptor	8	I-Gene
substrate	9	I-Gene
1	1	I-Gene
/	1	I-Gene
2	1	I-Gene
,	1	O
Shc	3	B-Gene
,	1	O
and	3	O
IL-4R	5	B-Gene
interacting	11	I-Gene
protein	7	I-Gene
,	1	O
as	2	O
well	4	O
as	2	O
Stat6	5	B-Gene
.	1	O

Stat6	5	B-Gene
has	3	O
been	4	O
shown	5	O
to	2	O
be	2	O
required	8	O
for	3	O
Th2	3	O
differentiation	15	O
.	1	O

To	2	O
determine	9	O
the	3	O
roles	5	O
of	2	O
the	3	O
phosphotyrosine	15	B-Chemical
binding	7	O
adaptors	8	O
in	2	O
Th2	3	O
differentiation	15	O
,	1	O
we	2	O
prepared	8	O
a	1	O
retrovirus	10	O
containing	10	O
a	1	O
mutant	6	O
of	2	O
the	3	O
human	5	B-Gene
(	1	I-Gene
h	1	I-Gene
)	1	I-Gene
IL-4R	5	I-Gene
alpha-chain	11	I-Gene
,	1	O
Y497F	5	O
,	1	O
which	5	O
is	2	O
unable	6	O
to	2	O
recruit	7	O
these	5	O
adaptors	8	O
.	1	O

The	3	O
mutant	6	O
hIL-4Ralpha	11	B-Gene
,	1	O
as	2	O
well	4	O
as	2	O
the	3	O
wild-type	9	O
(	1	O
WT	2	O
)	1	O
hIL-4Ralpha	11	B-Gene
,	1	O
was	3	O
introduced	10	O
into	4	O
naive	5	O
CD4	3	B-Gene
T	1	O
cells	5	O
.	1	O

Upon	4	O
hIL-4	5	B-Gene
stimulation	11	O
,	1	O
Y497F	5	O
worked	6	O
as	2	O
well	4	O
as	2	O
the	3	O
WT	2	O
hIL-4Ralpha	11	B-Gene
in	2	O
driving	7	O
Th2	3	O
differentiation	15	O
,	1	O
as	2	O
measured	8	O
by	2	O
Gata3	5	B-Gene
up-regulation	13	O
and	3	O
IL-4	4	B-Gene
production	10	O
.	1	O

Furthermore	11	O
,	1	O
IL-4-driven	11	B-Gene
cell	4	O
expansion	9	O
was	3	O
also	4	O
normal	6	O
in	2	O
the	3	O
cells	5	O
infected	8	O
with	4	O
Y497F	5	O
,	1	O
although	8	O
cells	5	O
infected	8	O
with	4	O
Y497F	5	O
were	4	O
not	3	O
capable	7	O
of	2	O
phosphorylating	15	O
insulin	7	B-Gene
receptor	8	I-Gene
substrate	9	I-Gene
2	1	I-Gene
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
the	3	O
signal	6	O
pathway	7	O
mediated	8	O
by	2	O
Y497	4	O
is	2	O
dispensable	11	O
for	3	O
both	4	O
IL-4	4	B-Gene
-driven	7	O
Th2	3	O
differentiation	15	O
and	3	O
cell	4	O
expansion	9	O
.	1	O

Both	4	O
WT	2	O
and	3	O
Y497F	5	O
hIL-4Ralpha	11	B-Gene
lose	4	O
the	3	O
ability	7	O
to	2	O
drive	5	O
Th2	3	O
differentiation	15	O
and	3	O
cell	4	O
expansion	9	O
in	2	O
Stat6-knockout	14	B-Gene
CD4	3	B-Gene
T	1	O
cells	5	O
.	1	O

A	1	O
constitutively	14	O
activated	9	O
form	4	O
of	2	O
Stat6	5	B-Gene
introduced	10	O
into	4	O
CD4	3	B-Gene
T	1	O
cells	5	O
resulted	8	O
in	2	O
both	4	O
Th2	3	O
differentiation	15	O
and	3	O
enhanced	8	O
cell	4	O
expansion	9	O
.	1	O

Thus	4	O
,	1	O
activated	9	B-Gene
Stat6	5	I-Gene
is	2	O
necessary	9	O
and	3	O
sufficient	10	O
to	2	O
mediate	7	O
both	4	O
IL-4	4	B-Gene
-driven	7	O
Th2	3	O
differentiation	15	O
and	3	O
cell	4	O
expansion	9	O
in	2	O
CD4	3	B-Gene
T	1	O
cells	5	O
.	1	O

Cytokine	8	O
production	10	O
by	2	O
Vgamma	6	O
(	1	O
+	1	O
)	1	O
-T-cell	7	O
subsets	7	O
is	2	O
an	2	O
important	9	O
factor	6	O
determining	11	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
-Th-cell	8	O
phenotype	9	O
and	3	O
susceptibility	14	O
of	2	O
BALB	4	O
/	1	O
c	1	O
mice	4	O
to	2	O
coxsackievirus	14	O
B3	2	O
-induced	8	O
myocarditis	11	B-Disease
.	1	O

Two	3	O
coxsackievirus	14	O
B3	2	O
(	1	O
CVB3	4	O
)	1	O
variants	8	O
(	1	O
H3	2	O
and	3	O
H310A1	6	O
)	1	O
differ	6	O
by	2	O
a	1	O
single	6	O
amino	5	O
acid	4	O
mutation	8	O
in	2	O
the	3	O
VP2	3	B-Gene
capsid	6	I-Gene
protein	7	I-Gene
.	1	O

H3	2	O
induces	7	O
severe	6	B-Disease
myocarditis	11	I-Disease
in	2	O
BALB	4	O
/	1	O
c	1	O
mice	4	O
,	1	O
but	3	O
H310A1	6	O
is	2	O
amyocarditic	12	O
.	1	O

Infection	9	O
with	4	O
H3	2	O
,	1	O
but	3	O
not	3	O
H310A1	6	O
,	1	O
preferentially	14	O
activates	9	O
Vgamma4	7	O
Vdelta4	7	O
cells	5	O
,	1	O
which	5	O
are	3	O
strongly	8	O
positive	8	O
for	3	O
gamma	5	B-Gene
interferon	10	I-Gene
(	1	O
IFN-gamma	9	B-Gene
)	1	O
,	1	O
whereas	7	O
Vgamma1	7	O
Vdelta4	7	O
cells	5	O
are	3	O
increased	9	O
in	2	O
both	4	O
H3	2	O
and	3	O
H310A1	6	O
virus	5	O
-infected	9	O
animals	7	O
.	1	O

Depletion	9	O
of	2	O
Vgamma1	7	O
(	1	O
+	1	O
)	1	O
cells	5	O
using	5	O
monoclonal	10	O
anti-Vgamma1	12	O
antibody	8	O
enhanced	8	O
myocarditis	11	B-Disease
and	3	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
-	1	O
,	1	O
IFN-gamma	9	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
-cell	5	O
responses	9	O
in	2	O
both	4	O
H3-	3	O
and	3	O
H310A1	6	O
-infected	9	O
mice	4	O
yet	3	O
decreased	9	O
the	3	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
-	1	O
,	1	O
IL-4	4	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
-cell	5	O
response	8	O
.	1	O

Depleting	9	O
Vgamma4	7	O
(	1	O
+	1	O
)	1	O
cells	5	O
suppressed	10	O
myocarditis	11	B-Disease
and	3	O
reduced	7	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
IFN-gamma	9	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
cells	5	O
but	3	O
increased	9	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
IL-4	4	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
T	1	O
cells	5	O
.	1	O

The	3	O
role	4	O
of	2	O
cytokine	8	O
production	10	O
by	2	O
Vgamma1	7	O
(	1	O
+	1	O
)	1	O
and	3	O
Vgamma4	7	O
(	1	O
+	1	O
)	1	O
T	1	O
cells	5	O
was	3	O
investigated	12	O
by	2	O
adoptively	10	O
transferring	12	O
these	5	O
cells	5	O
isolated	8	O
from	4	O
H3	2	O
-infected	9	O
BALB	4	O
/	1	O
c	1	O
Stat4	5	B-Gene
knockout	8	O
(	1	O
Stat4ko	7	B-Gene
)	1	O
(	1	O
defective	9	O
in	2	O
IFN-gamma	9	B-Gene
expression	10	O
)	1	O
or	2	O
BALB	4	O
/	1	O
c	1	O
Stat6ko	7	B-Gene
(	1	O
defective	9	O
in	2	O
IL-4	4	B-Gene
expression	10	O
)	1	O
mice	4	O
into	4	O
H3	2	O
virus	5	O
-infected	9	O
wild-type	9	O
BALB	4	O
/	1	O
c	1	O
recipients	10	O
.	1	O

Vgamma4	7	O
and	3	O
Vgamma1	7	O
(	1	O
+	1	O
)	1	O
T	1	O
cells	5	O
from	4	O
Stat4ko	7	B-Gene
mice	4	O
expressed	9	O
IL-4	4	B-Gene
but	3	O
no	2	O
or	2	O
minimal	7	O
IFN-gamma	9	B-Gene
,	1	O
whereas	7	O
these	5	O
cell	4	O
populations	11	O
derived	7	O
from	4	O
Stat6ko	7	B-Gene
mice	4	O
expressed	9	O
IFN-gamma	9	B-Gene
but	3	O
no	2	O
IL-4	4	B-Gene
.	1	O

Stat4ko	7	B-Gene
Vgamma1	7	O
(	1	O
+	1	O
)	1	O
cells	5	O
(	1	O
IL-4	4	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
)	1	O
suppress	8	O
myocarditis	11	B-Disease
.	1	O

Stat6ko	7	B-Gene
Vgamma1	7	O
(	1	O
+	1	O
)	1	O
cells	5	O
(	1	O
IFN-gamma	9	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
)	1	O
were	4	O
not	3	O
inhibitory	10	O
.	1	O

Stat6ko	7	B-Gene
Vgamma4	7	O
(	1	O
+	1	O
)	1	O
cells	5	O
(	1	O
IFN-gamma	9	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
)	1	O
significantly	13	O
enhanced	8	O
myocarditis	11	B-Disease
.	1	O

Stat4ko	7	B-Gene
Vgamma4	7	O
(	1	O
+	1	O
)	1	O
cells	5	O
(	1	O
IL-4	4	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
)	1	O
neither	7	O
inhibited	9	O
nor	3	O
enhanced	8	O
disease	7	O
.	1	O

These	5	O
results	7	O
show	4	O
that	4	O
distinct	8	O
gammadelta-T-cell	17	O
subsets	7	O
control	7	O
myocarditis	11	B-Disease
susceptibility	14	O
and	3	O
bias	4	O
the	3	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
-Th-cell	8	O
response	8	O
.	1	O

The	3	O
cytokines	9	O
produced	8	O
by	2	O
the	3	O
Vgamma	6	O
subpopulation	13	O
have	4	O
a	1	O
significant	11	O
influence	9	O
on	2	O
the	3	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
-Th-cell	8	O
phenotype	9	O
.	1	O

Inhaled	7	O
nitric	6	B-Chemical
oxide	5	I-Chemical
down-regulates	14	O
intrapulmonary	14	O
nitric	6	B-Chemical
oxide	5	I-Chemical
production	10	O
in	2	O
lipopolysaccharide	18	B-Chemical
-induced	8	O
acute	5	B-Disease
lung	4	I-Disease
injury	6	I-Disease
.	1	O

OBJECTIVE	9	O
:	1	O
To	2	O
examine	7	O
whether	7	O
inhaled	7	O
nitric	6	B-Chemical
oxide	5	I-Chemical
(	1	O
NO	2	O
)	1	O
affected	8	O
the	3	O
intrapulmonary	14	O
production	10	O
of	2	O
NO	2	O
,	1	O
reactive	8	B-Chemical
oxygen	6	I-Chemical
species	7	I-Chemical
,	1	O
and	3	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
in	2	O
a	1	O
lipopolysaccharide	18	B-Chemical
(	1	O
LPS	3	B-Chemical
)	1	O
-induced	8	O
model	5	O
of	2	O
acute	5	B-Disease
lung	4	I-Disease
injury	6	I-Disease
.	1	O

DESIGN	6	O
:	1	O
Prospective	11	O
,	1	O
randomized	10	O
,	1	O
laboratory	10	O
study	5	O
.	1	O

SETTING	7	O
:	1	O
Experimental	12	O
laboratory	10	O
at	2	O
a	1	O
biomedical	10	O
institute	9	O
.	1	O

SUBJECTS	8	O
:	1	O
Twenty	6	O
male	4	O
rabbits	7	O
weighing	8	O
2.5-3.5	7	O
kg	2	O
.	1	O

INTERVENTIONS	13	O
:	1	O
Saline	6	O
or	2	O
LPS	3	B-Chemical
(	1	O
5	1	O
mg	2	O
/	1	O
kg	2	O
of	2	O
body	4	O
weight	6	O
)	1	O
was	3	O
administered	12	O
intravenously	13	O
with	4	O
or	2	O
without	7	O
NO	2	O
inhalation	10	O
(	1	O
10	2	O
ppm	3	O
)	1	O
in	2	O
each	4	O
group	5	O
of	2	O
five	4	O
rabbits	7	O
.	1	O

MEASUREMENTS	12	O
AND	3	O
MAIN	4	O
RESULTS	7	O
:	1	O
LPS	3	B-Chemical
increased	9	O
the	3	O
lung	4	O
leak	4	O
index	5	O
,	1	O
the	3	O
neutrophils	11	O
and	3	O
NO	2	O
levels	6	O
in	2	O
bronchoalveolar	15	O
lavage	6	O
fluid	5	O
,	1	O
and	3	O
NO	2	O
levels	6	O
produced	8	O
by	2	O
resting	7	O
and	3	O
stimulated	10	O
alveolar	8	O
macrophages	11	O
.	1	O

Inhaled	7	O
NO	2	O
decreased	9	O
the	3	O
lung	4	O
leak	4	O
index	5	O
,	1	O
the	3	O
neutrophils	11	O
and	3	O
NO	2	O
levels	6	O
as	2	O
measured	8	O
by	2	O
nitrite	7	B-Chemical
levels	6	O
in	2	O
the	3	O
lavage	6	O
fluid	5	O
,	1	O
and	3	O
NO	2	O
produced	8	O
by	2	O
the	3	O
resting	7	O
and	3	O
stimulated	10	O
alveolar	8	O
macrophages	11	O
.	1	O

Inhaled	7	O
NO	2	O
also	4	O
blocked	7	O
the	3	O
activities	10	O
of	2	O
reactive	8	B-Chemical
oxygen	6	I-Chemical
species	7	I-Chemical
and	3	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
binding	7	O
to	2	O
DNA	3	O
in	2	O
lavage	6	O
cells	5	O
and	3	O
in	2	O
alveolar	8	O
macrophages	11	O
.	1	O

CONCLUSION	10	O
:	1	O
Inhaled	7	O
NO	2	O
attenuates	10	O
LPS	3	B-Chemical
-induced	8	O
acute	5	B-Disease
lung	4	I-Disease
injury	6	I-Disease
,	1	O
possibly	8	O
by	2	O
decreasing	10	O
NO	2	O
production	10	O
in	2	O
the	3	O
lungs	5	O
.	1	O

The	3	O
mechanism	9	O
of	2	O
reducing	8	O
NO	2	O
production	10	O
resulting	9	O
from	4	O
inhaled	7	O
NO	2	O
may	3	O
involve	7	O
,	1	O
in	2	O
part	4	O
,	1	O
the	3	O
activities	10	O
of	2	O
reactive	8	B-Chemical
oxygen	6	I-Chemical
species	7	I-Chemical
and	3	O
/	1	O
or	2	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
.	1	O

Role	4	O
of	2	O
T-bet	5	B-Gene
in	2	O
commitment	10	O
of	2	O
TH1	3	O
cells	5	O
before	6	O
IL-12	5	B-Gene
-dependent	10	O
selection	9	O
.	1	O

How	3	O
cytokines	9	O
control	7	O
differentiation	15	O
of	2	O
helper	6	O
T	1	O
(	1	O
TH	2	O
)	1	O
cells	5	O
is	2	O
controversial	13	O
.	1	O

We	2	O
show	4	O
that	4	O
T-bet	5	B-Gene
,	1	O
without	7	O
apparent	8	O
assistance	10	O
from	4	O
interleukin	11	B-Gene
12	2	I-Gene
(	1	I-Gene
IL-12	5	I-Gene
)	1	I-Gene
/	1	I-Gene
STAT4	5	I-Gene
,	1	O
specifies	9	O
TH1	3	O
effector	8	O
fate	4	O
by	2	O
targeting	9	O
chromatin	9	O
remodeling	10	O
to	2	O
individual	10	O
interferon-gamma	16	B-Gene
(	1	I-Gene
IFN-gamma	9	I-Gene
)	1	I-Gene
alleles	7	I-Gene
and	3	O
by	2	O
inducing	8	O
IL-12	5	B-Gene
receptor	8	I-Gene
beta2	5	I-Gene
expression	10	O
.	1	O

Subsequently	12	O
,	1	O
it	2	O
appears	7	O
that	4	O
IL-12	5	B-Gene
/	1	I-Gene
STAT4	5	I-Gene
serves	6	O
two	3	O
essential	9	O
functions	9	O
in	2	O
the	3	O
development	11	O
of	2	O
TH1	3	O
cells	5	O
:	1	O
as	2	O
growth	6	O
signal	6	O
,	1	O
inducing	8	O
survival	8	O
and	3	O
cell	4	O
division	8	O
;	1	O
and	3	O
as	2	O
trans-activator	15	O
,	1	O
prolonging	10	O
IFN-gamma	9	B-Gene
synthesis	9	O
through	7	O
a	1	O
genetic	7	O
interaction	11	O
with	4	O
the	3	O
coactivator	11	O
,	1	O
CREB	4	B-Gene
-binding	8	I-Gene
protein	7	I-Gene
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
a	1	O
cytokine	8	O
does	4	O
not	3	O
simply	6	O
induce	6	O
TH	2	O
fate	4	O
choice	6	O
but	3	O
instead	7	O
may	3	O
act	3	O
as	2	O
an	2	O
essential	9	O
secondary	9	O
stimulus	8	O
that	4	O
mediates	8	O
selective	9	O
survival	8	O
of	2	O
a	1	O
lineage	7	O
.	1	O

Transcriptional	15	O
activation	10	O
by	2	O
a	1	O
matrix	6	O
associating	11	O
region	6	O
-binding	8	O
protein	7	O
.	1	O

contextual	10	O
requirements	12	O
for	3	O
the	3	O
function	8	O
of	2	O
bright	6	B-Gene
.	1	O

Bright	6	B-Gene
(	1	O
B	1	B-Gene
cell	4	I-Gene
regulator	9	I-Gene
of	2	I-Gene
IgH	3	I-Gene
transcription	13	I-Gene
)	1	O
is	2	O
a	1	O
B	1	O
cell	4	O
-specific	9	O
,	1	O
matrix	6	O
associating	11	O
region	6	O
-binding	8	O
protein	7	O
that	4	O
transactivates	14	O
gene	4	O
expression	10	O
from	4	O
the	3	O
IgH	3	B-Gene
intronic	8	I-Gene
enhancer	8	I-Gene
(	1	O
E	1	B-Gene
mu	2	I-Gene
)	1	O
.	1	O

We	2	O
show	4	O
here	4	O
that	4	O
Bright	6	B-Gene
has	3	O
multiple	8	O
contextual	10	O
requirements	12	O
to	2	O
function	8	O
as	2	O
a	1	O
transcriptional	15	O
activator	9	O
.	1	O

Bright	6	B-Gene
can	3	O
not	3	O
transactivate	13	O
via	3	O
out	3	O
of	2	O
context	7	O
,	1	O
concatenated	12	O
binding	7	O
sites	5	O
.	1	O

Transactivation	15	O
is	2	O
maximal	7	O
on	2	O
integrated	10	O
substrates	10	O
.	1	O

Two	3	O
of	2	O
the	3	O
three	5	O
previously	10	O
identified	10	O
binding	7	O
sites	5	O
in	2	O
E	1	B-Gene
mu	2	I-Gene
are	3	O
required	8	O
for	3	O
full	4	O
Bright	6	B-Gene
transactivation	15	O
.	1	O

The	3	O
Bright	6	B-Gene
DNA	3	I-Gene
binding	7	O
domain	6	O
defined	7	O
a	1	O
new	3	O
family	6	O
,	1	O
which	5	O
includes	8	O
SWI1	4	B-Gene
,	1	O
a	1	O
component	9	O
of	2	O
the	3	O
SWI.SNF	7	B-Gene
complex	7	I-Gene
shown	5	O
to	2	O
have	4	O
high	4	O
mobility	8	O
group	5	O
-like	5	O
DNA	3	O
binding	7	O
characteristics	15	O
.	1	O

Similar	7	O
to	2	O
one	3	O
group	5	O
of	2	O
high	4	B-Gene
mobility	8	I-Gene
group	5	I-Gene
box	3	I-Gene
proteins	8	I-Gene
,	1	O
Bright	6	B-Gene
distorts	8	O
E	1	B-Gene
mu	2	I-Gene
binding	7	O
site	4	O
-containing	11	O
DNA	3	O
on	2	O
binding	7	O
,	1	O
supporting	10	O
the	3	O
concept	7	O
that	4	O
it	2	O
mediates	8	O
E	1	B-Gene
mu	2	I-Gene
remodeling	10	O
.	1	O

Transfection	12	O
studies	7	O
further	7	O
implicate	9	O
Bright	6	B-Gene
in	2	O
facilitating	12	O
spatially	9	O
separated	9	O
promoter-enhancer	17	O
interactions	12	O
in	2	O
both	4	O
transient	9	O
and	3	O
stable	6	O
assays	6	O
.	1	O

Finally	7	O
,	1	O
we	2	O
show	4	O
that	4	O
overexpression	14	O
of	2	O
Bright	6	B-Gene
leads	5	O
to	2	O
enhanced	8	O
DNase	5	B-Gene
I	1	I-Gene
sensitivity	11	O
of	2	O
the	3	O
endogenous	10	B-Gene
E	1	I-Gene
mu	2	I-Gene
matrix	6	O
associating	11	O
regions	7	O
.	1	O

These	5	O
data	4	O
further	7	O
suggest	7	O
that	4	O
Bright	6	B-Gene
may	3	O
contribute	10	O
to	2	O
increased	9	O
gene	4	O
expression	10	O
by	2	O
remodeling	10	O
the	3	O
immunoglobulin	14	B-Gene
locus	5	I-Gene
during	6	O
B	1	O
cell	4	O
development	11	O
.	1	O

Synergistic	11	O
transcriptional	15	O
activation	10	O
of	2	O
human	5	B-Gene
Acyl-coenzyme	13	I-Gene
A	1	I-Gene
:	1	I-Gene
cholesterol	11	I-Gene
acyltransterase-1	17	I-Gene
gene	4	I-Gene
by	2	O
interferon-gamma	16	B-Gene
and	3	O
all-trans-retinoic	18	B-Chemical
acid	4	I-Chemical
THP-1	5	O
cells	5	O
.	1	O

Acyl-coenzyme	13	B-Gene
A	1	I-Gene
:	1	I-Gene
cholesterol	11	I-Gene
acyltransferase	15	I-Gene
(	1	O
ACAT	4	B-Gene
)	1	O
is	2	O
an	2	O
intracellular	13	O
enzyme	6	O
involved	8	O
in	2	O
cellular	8	O
cholesterol	11	B-Chemical
homeostasis	11	O
and	3	O
in	2	O
atherosclerotic	15	O
foam	4	O
cell	4	O
formation	9	O
.	1	O

Human	5	B-Gene
ACAT-1	6	I-Gene
gene	4	I-Gene
contains	8	O
two	3	O
promoters	9	O
(	1	O
P1	2	B-Gene
and	3	O
P7	2	B-Gene
)	1	O
,	1	O
each	4	O
located	7	O
in	2	O
a	1	O
different	9	O
chromosome	10	O
(	1	O
1	1	O
and	3	O
7	1	O
)	1	O
(	1	O
Li	2	O
,	1	O
B.	2	O
L.	2	O
,	1	O
Li	2	O
,	1	O
X.	2	O
L.	2	O
,	1	O
Duan	4	O
,	1	O
Z.	2	O
J.	2	O
,	1	O
Lee	3	O
,	1	O
O.	2	O
,	1	O
Lin	3	O
,	1	O
S.	2	O
,	1	O
Ma	2	O
,	1	O
Z.	2	O
M.	2	O
,	1	O
Chang	5	O
,	1	O
C.	2	O
C.	2	O
,	1	O
Yang	4	O
,	1	O
X.	2	O
Y.	2	O
,	1	O
Park	4	O
,	1	O
J.	2	O
P.	2	O
,	1	O
Mohandas	8	O
,	1	O
T.	2	O
K.	2	O
,	1	O
Noll	4	O
,	1	O
W.	2	O
,	1	O
Chan	4	O
,	1	O
L.	2	O
,	1	O
and	3	O
Chang	5	O
,	1	O
T.	2	O
Y.	2	O
(	1	O
1999	4	O
)	1	O
J.	2	O
Biol	4	O
Chem.	5	O
274	3	O
,	1	O
11060-11071	11	O
)	1	O
.	1	O

Interferon-gamma	16	B-Gene
(	1	O
IFN-gamma	9	B-Gene
)	1	O
,	1	O
a	1	O
cytokine	8	O
that	4	O
exerts	6	O
many	4	O
pro-atherosclerotic	19	O
effects	7	O
in	2	O
vivo	4	O
,	1	O
causes	6	O
up-regulation	13	O
of	2	O
ACAT-1	6	B-Gene
mRNA	4	I-Gene
in	2	O
human	5	O
blood	5	O
monocyte	8	O
-derived	8	O
macrophages	11	O
and	3	O
macrophage	10	O
-like	5	O
cells	5	O
but	3	O
not	3	O
in	2	O
other	5	O
cell	4	O
types	5	O
.	1	O

To	2	O
examine	7	O
the	3	O
molecular	9	O
nature	6	O
of	2	O
this	4	O
observation	11	O
,	1	O
we	2	O
identified	10	O
within	6	O
the	3	O
ACAT-1	6	B-Gene
P1	2	I-Gene
promoter	8	I-Gene
a	1	O
159-base	8	O
pair	4	O
core	4	O
region	6	O
.	1	O

This	4	O
region	6	O
contains	8	O
4	1	O
Sp1	3	B-Gene
elements	8	I-Gene
and	3	O
an	2	O
IFN-gamma	9	B-Gene
activated	9	O
sequence	8	O
(	1	O
GAS	3	O
)	1	O
that	4	O
overlaps	8	O
with	4	O
the	3	O
second	6	O
Sp1	3	B-Gene
element	7	I-Gene
.	1	O

In	2	O
the	3	O
monocytic	9	O
cell	4	O
line	4	O
THP-1	5	O
cell	4	O
,	1	O
the	3	O
combination	11	O
of	2	O
IFN-gamma	9	B-Gene
and	3	O
all-trans-retinoic	18	B-Chemical
acid	4	I-Chemical
(	1	O
a	1	O
known	5	O
differentiation	15	O
agent	5	O
)	1	O
enhances	8	O
the	3	O
ACAT-1	6	B-Gene
P1	2	I-Gene
promoter	8	I-Gene
but	3	O
not	3	O
the	3	O
P7	2	B-Gene
promoter	8	I-Gene
.	1	O

Additional	10	O
experiments	11	O
showed	6	O
that	4	O
all-trans-retinoic	18	B-Chemical
acid	4	I-Chemical
causes	6	O
large	5	O
induction	9	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
STAT1	5	I-Gene
,	1	O
while	5	O
IFN-gamma	9	B-Gene
causes	6	O
activation	10	O
of	2	O
STAT1	5	B-Gene
such	4	O
that	4	O
it	2	O
binds	5	O
to	2	O
the	3	O
GAS	3	O
/	1	O
Sp1	3	B-Gene
site	4	O
in	2	O
the	3	O
ACAT-1	6	B-Gene
P1	2	I-Gene
promoter	8	I-Gene
.	1	O

Our	3	O
work	4	O
provides	8	O
a	1	O
molecular	9	O
mechanism	9	O
to	2	O
account	7	O
for	3	O
the	3	O
effect	6	O
of	2	O
IFN-gamma	9	B-Gene
in	2	O
causing	7	O
transcriptional	15	O
activation	10	O
of	2	O
ACAT-1	6	B-Gene
in	2	O
macrophage	10	O
-like	5	O
cells	5	O
.	1	O

Partners	8	O
in	2	O
transcription	13	O
:	1	O
NFAT	4	B-Gene
and	3	O
AP-1	4	B-Gene
.	1	O

Combinatorial	13	O
regulation	10	O
is	2	O
a	1	O
powerful	8	O
mechanism	9	O
that	4	O
enables	7	O
tight	5	O
control	7	O
of	2	O
gene	4	O
expression	10	O
,	1	O
via	3	O
integration	11	O
of	2	O
multiple	8	O
signaling	9	O
pathways	8	O
that	4	O
induce	6	O
different	9	O
transcription	13	O
factors	7	O
required	8	O
for	3	O
enhanceosome	12	O
assembly	8	O
.	1	O

The	3	O
four	4	O
calcium	7	B-Chemical
-regulated	10	O
transcription	13	O
factors	7	O
of	2	O
the	3	O
NFAT	4	B-Gene
family	6	I-Gene
act	3	O
synergistically	15	O
with	4	O
AP-1	4	B-Gene
(	1	I-Gene
Fos	3	I-Gene
/	1	I-Gene
Jun	3	I-Gene
)	1	I-Gene
proteins	8	I-Gene
on	2	O
composite	9	O
DNA	3	O
elements	8	O
which	5	O
contain	7	O
adjacent	8	O
NFAT	4	B-Gene
and	3	O
AP-1	4	B-Gene
binding	7	O
sites	5	O
,	1	O
where	5	O
they	4	O
form	4	O
highly	6	O
stable	6	O
ternary	7	O
complexes	9	O
to	2	O
regulate	8	O
the	3	O
expression	10	O
of	2	O
diverse	7	O
inducible	9	O
genes	5	O
.	1	O

Concomitant	11	O
induction	9	O
of	2	O
NFAT	4	B-Gene
and	3	O
AP-1	4	B-Gene
requires	8	O
concerted	9	O
activation	10	O
of	2	O
two	3	O
different	9	O
signaling	9	O
pathways	8	O
:	1	O
calcium	7	B-Chemical
/	1	O
calcineurin	11	B-Gene
,	1	O
which	5	O
promotes	8	O
NFAT	4	B-Gene
dephosphorylation	17	O
,	1	O
nuclear	7	O
translocation	13	O
and	3	O
activation	10	O
;	1	O
and	3	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
(	1	I-Gene
PKC	3	I-Gene
)	1	I-Gene
/	1	I-Gene
Ras	3	I-Gene
,	1	O
which	5	O
promotes	8	O
the	3	O
synthesis	9	O
,	1	O
phosphorylation	15	O
and	3	O
activation	10	O
of	2	O
members	7	O
of	2	O
the	3	O
Fos	3	B-Gene
and	3	O
Jun	3	B-Gene
families	8	I-Gene
of	2	O
transcription	13	O
factors	7	O
.	1	O

A	1	O
fifth	5	O
member	6	O
of	2	O
the	3	O
NFAT	4	B-Gene
family	6	I-Gene
,	1	O
NFAT5	5	B-Gene
,	1	O
controls	8	O
the	3	O
cellular	8	O
response	8	O
to	2	O
osmotic	7	O
stress	6	O
,	1	O
by	2	O
a	1	O
mechanism	9	O
that	4	O
requires	8	O
dimer	5	O
formation	9	O
and	3	O
is	2	O
independent	11	O
of	2	O
calcineurin	11	B-Gene
or	2	O
of	2	O
interaction	11	O
with	4	O
AP-1	4	B-Gene
.	1	O

Pharmacological	15	O
interference	12	O
with	4	O
theNFAT	7	B-Gene
:	1	O
AP-1	4	B-Gene
interaction	11	O
may	3	O
be	2	O
useful	6	O
in	2	O
selective	9	O
manipulation	12	O
of	2	O
the	3	O
immune	6	O
response	8	O
.	1	O

Balanced	8	O
activation	10	O
of	2	O
NFAT	4	B-Gene
and	3	O
AP-1	4	B-Gene
is	2	O
known	5	O
to	2	O
be	2	O
required	8	O
for	3	O
productive	10	O
immune	6	O
responses	9	O
,	1	O
but	3	O
the	3	O
role	4	O
of	2	O
NFAT	4	B-Gene
:	1	O
AP-1	4	B-Gene
interactions	12	O
in	2	O
other	5	O
cell	4	O
types	5	O
and	3	O
biological	10	O
processes	9	O
remains	7	O
to	2	O
be	2	O
understood	10	O
.	1	O

D609	4	B-Chemical
inhibits	8	O
ionizing	8	O
radiation	9	O
-induced	8	O
oxidative	9	O
damage	6	O
by	2	O
acting	6	O
as	2	O
a	1	O
potent	6	O
antioxidant	11	O
.	1	O

Tricyclodecan-9-yl	18	B-Chemical
-xanthogenate	13	I-Chemical
(	1	O
D609	4	B-Chemical
)	1	O
has	3	O
been	4	O
extensively	11	O
studied	7	O
in	2	O
biological	10	O
systems	7	O
and	3	O
exhibits	8	O
a	1	O
variety	7	O
of	2	O
biological	10	O
functions	9	O
,	1	O
including	9	O
antiviral	9	O
,	1	O
antitumor	9	O
,	1	O
and	3	O
anti-inflammatory	17	O
activities	10	O
.	1	O

Most	4	O
of	2	O
these	5	O
activities	10	O
have	4	O
been	4	O
largely	7	O
attributed	10	O
to	2	O
the	3	O
inhibitory	10	O
effect	6	O
of	2	O
D609	4	B-Chemical
on	2	O
phosphatidylcholine-specific	28	B-Chemical
phospholipase	13	B-Gene
C	1	I-Gene
.	1	O

However	7	O
,	1	O
as	2	O
a	1	O
xanthate	8	B-Chemical
derivative	10	O
,	1	O
D609	4	B-Chemical
is	2	O
a	1	O
strong	6	O
electrolyte	11	O
and	3	O
readily	7	O
dissociates	11	O
to	2	O
xanthate	8	B-Chemical
anions	6	O
and	3	O
cations	7	O
of	2	O
alkali	6	O
metals	6	O
in	2	O
solution	8	O
.	1	O

Xanthate	8	B-Chemical
anions	6	O
and	3	O
protonated	10	O
xanthic	7	B-Chemical
acid	4	I-Chemical
contain	7	O
a	1	O
free	4	O
thiol	5	B-Chemical
moiety	6	O
and	3	O
are	3	O
highly	6	O
reductive	9	O
.	1	O

This	4	O
implies	7	O
that	4	O
D609	4	B-Chemical
and	3	O
other	5	O
xanthate	8	B-Chemical
derivatives	11	O
may	3	O
function	8	O
as	2	O
potent	6	O
antioxidants	12	O
.	1	O

Indeed	6	O
,	1	O
we	2	O
found	5	O
that	4	O
D609	4	B-Chemical
inhibited	9	O
the	3	O
Fenton	6	O
reaction	8	O
-induced	8	O
oxidation	9	O
of	2	O
dihydrorhodamine	16	B-Chemical
123	3	I-Chemical
in	2	O
a	1	O
dose	4	O
-dependent	10	O
manner	6	O
similar	7	O
to	2	O
that	4	O
of	2	O
pyrrolidinedithiocarbamate	26	B-Chemical
,	1	O
a	1	O
well	4	O
known	5	O
antioxidant	11	O
.	1	O

In	2	O
addition	8	O
,	1	O
D609	4	B-Chemical
inhibited	9	O
the	3	O
formation	9	O
of	2	O
the	3	O
alpha-phenyl-tert-butylnitrone-free	35	B-Chemical
radical	7	O
spin	4	O
adducts	7	O
and	3	O
lipid	5	O
peroxidation	12	O
of	2	O
synaptosomal	12	O
membranes	9	O
by	2	O
the	3	O
Fenton	6	O
reagents	8	O
.	1	O

Furthermore	11	O
,	1	O
preincubation	13	O
of	2	O
lymphocytes	11	O
with	4	O
D609	4	B-Chemical
resulted	8	O
in	2	O
a	1	O
significant	11	O
diminution	10	O
of	2	O
ionizing	8	O
radiation	9	O
(	1	O
IR	2	O
)	1	O
-induced	8	O
1	1	O
)	1	O
production	10	O
of	2	O
reactive	8	B-Chemical
oxygen	6	I-Chemical
species	7	I-Chemical
;	1	O
2	1	O
)	1	O
decrease	8	O
in	2	O
intracellular	13	O
reduced	7	O
glutathione	11	B-Chemical
;	1	O
3	1	O
)	1	O
oxidative	9	O
damage	6	O
to	2	O
proteins	8	O
and	3	O
lipids	6	B-Chemical
;	1	O
and	3	O
4	1	O
)	1	O
activation	10	O
of	2	O
nuclear	7	B-Gene
factor-kappaB	13	I-Gene
.	1	O

Moreover	8	O
,	1	O
when	4	O
D609	4	B-Chemical
(	1	O
50	2	O
mg	2	O
/	1	O
kg	2	O
i.v.	4	O
)	1	O
was	3	O
administered	12	O
to	2	O
mice	4	O
10	2	O
min	3	O
prior	5	O
to	2	O
total	5	O
body	4	O
IR	2	O
(	1	O
6.5	3	O
and	3	O
8.5	3	O
Gy	2	O
)	1	O
,	1	O
it	2	O
protected	9	O
the	3	O
mice	4	O
from	4	O
IR	2	O
-induced	8	O
lethality	9	O
.	1	O

Thus	4	O
,	1	O
these	5	O
results	7	O
indicate	8	O
that	4	O
D609	4	B-Chemical
is	2	O
a	1	O
potent	6	O
antioxidant	11	O
and	3	O
has	3	O
the	3	O
ability	7	O
to	2	O
inhibit	7	O
IR	2	O
-induced	8	O
cellular	8	O
oxidative	9	O
stress	6	O
.	1	O

The	3	O
role	4	O
of	2	O
Epstein-Barr	12	O
virus	5	O
in	2	O
neoplastic	10	O
transformation	14	O
.	1	O

In	2	O
this	4	O
review	6	O
,	1	O
we	2	O
focus	5	O
on	2	O
new	3	O
data	4	O
from	4	O
basic	5	O
,	1	O
translational	13	O
and	3	O
clinical	8	O
research	8	O
relating	8	O
to	2	O
the	3	O
Epstein-Barr	12	O
virus	5	O
(	1	O
EBV	3	O
)	1	O
.	1	O

Beside	6	O
its	3	O
well-known	10	O
tropism	7	O
for	3	O
B	1	O
lymphocytes	11	O
and	3	O
epithelial	10	O
cells	5	O
,	1	O
EBV	3	O
also	4	O
infects	7	O
T	1	O
lymphocytes	11	O
,	1	O
monocytes	9	O
and	3	O
granulocytes	12	O
.	1	O

After	5	O
primary	7	O
infection	9	O
,	1	O
EBV	3	O
persists	8	O
throughout	10	O
the	3	O
life	4	O
span	4	O
in	2	O
resting	7	O
memory	6	O
B	1	O
cells	5	O
,	1	O
from	4	O
where	5	O
it	2	O
is	2	O
reactivated	11	O
upon	4	O
breakdown	9	O
of	2	O
cellular	8	O
immunity	8	O
.	1	O

In	2	O
the	3	O
process	7	O
of	2	O
neoplastic	10	O
transformation	14	O
,	1	O
the	3	O
EBV	3	B-Gene
-encoded	8	I-Gene
latent	6	I-Gene
membrane	8	I-Gene
protein	7	I-Gene
1	1	I-Gene
(	1	I-Gene
LMP1	4	I-Gene
)	1	I-Gene
oncogene	8	I-Gene
represents	10	O
the	3	O
major	5	O
driving	7	O
force	5	O
.	1	O

LMP1	4	B-Gene
acts	4	O
like	4	O
a	1	O
constitutively	14	O
activated	9	O
receptor	8	O
of	2	O
the	3	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
receptor	8	I-Gene
family	6	I-Gene
and	3	O
allows	6	O
the	3	O
amplification	13	O
or	2	O
bypassing	9	O
of	2	O
physiological	13	O
regulatory	10	O
signals	7	O
through	7	O
direct	6	O
and	3	O
indirect	8	O
interactions	12	O
with	4	O
proteins	8	O
of	2	O
the	3	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
receptor	8	I-Gene
-associated	11	I-Gene
factor	6	I-Gene
(	1	I-Gene
TRAF	4	I-Gene
)	1	I-Gene
family	6	I-Gene
.	1	O

TRAF2	5	B-Gene
-mediated	9	O
NF-kappaB	9	B-Gene
activation	10	O
,	1	O
AP-1	4	B-Gene
induction	9	O
and	3	O
JAK3	4	B-Gene
/	1	I-Gene
STAT	4	I-Gene
activation	10	O
may	3	O
result	6	O
in	2	O
sustained	9	O
proliferation	13	O
leading	7	O
to	2	O
lymphoma	8	B-Disease
.	1	O

The	3	O
ability	7	O
of	2	O
LMP1	4	B-Gene
to	2	O
suppress	8	O
germinal	8	O
center	6	O
formation	9	O
and	3	O
its	3	O
capacity	8	O
to	2	O
mediate	7	O
its	3	O
own	3	O
transcriptional	15	O
activation	10	O
shed	4	O
new	3	O
light	5	O
on	2	O
the	3	O
pathogenesis	12	O
of	2	O
EBV	3	O
-associated	11	O
latency	7	O
type	4	O
II	2	O
lymphoproliferations	20	O
like	4	O
Hodgkin	7	B-Disease
's	2	I-Disease
disease	7	I-Disease
and	3	O
angioimmunoblastic	18	B-Disease
lymphadenopathy	15	I-Disease
.	1	O

The	3	O
carboxy	7	O
terminus	8	O
of	2	O
LMP1	4	B-Gene
is	2	O
also	4	O
a	1	O
reliable	8	O
marker	6	O
for	3	O
individual	10	O
EBV	3	O
strain	6	O
identification	14	O
and	3	O
thus	4	O
offers	6	O
new	3	O
possibilities	13	O
in	2	O
tracing	7	O
the	3	O
molecular	9	O
events	6	O
leading	7	O
to	2	O
posttransplant	14	O
lymphoproliferative	19	B-Disease
disorders	9	I-Disease
(	1	O
PTLDs	5	B-Disease
)	1	O
.	1	O

Cytotoxic	9	O
T	1	O
lymphocytes	11	O
directed	8	O
against	7	O
well	4	O
-characterized	14	O
epitopes	8	O
of	2	O
EBV	3	B-Gene
latency	7	I-Gene
genes	5	I-Gene
represent	9	O
an	2	O
already	7	O
successful	10	O
and	3	O
promising	9	O
therapeutic	11	O
approach	8	O
to	2	O
EBV	3	O
-associated	11	O
lymphomas	9	B-Disease
,	1	O
in	2	O
particular	10	O
PTLDs	5	B-Disease

The	3	O
Friend	6	B-Gene
of	2	I-Gene
GATA	4	I-Gene
proteins	8	I-Gene
U	1	I-Gene
-shaped	7	I-Gene
,	1	O
FOG-1	5	B-Gene
,	1	O
and	3	O
FOG-2	5	B-Gene
function	8	O
as	2	O
negative	8	O
regulators	10	O
of	2	O
blood	5	O
,	1	O
heart	5	O
,	1	O
and	3	O
eye	3	O
development	11	O
in	2	O
Drosophila	10	O
.	1	O

Friend	6	B-Gene
of	2	I-Gene
GATA	4	I-Gene
(	1	I-Gene
FOG	3	I-Gene
)	1	I-Gene
proteins	8	I-Gene
regulate	8	O
GATA	4	B-Gene
factor	6	I-Gene
-activated	10	O
gene	4	O
transcription	13	O
.	1	O

During	6	O
vertebrate	10	O
hematopoiesis	13	O
,	1	O
FOG	3	B-Gene
and	3	O
GATA	4	B-Gene
proteins	8	I-Gene
cooperate	9	O
to	2	O
promote	7	O
erythrocyte	11	O
and	3	O
megakaryocyte	13	O
differentiation	15	O
.	1	O

The	3	O
Drosophila	10	B-Gene
FOG	3	I-Gene
homologue	9	I-Gene
U	1	I-Gene
-shaped	7	I-Gene
(	1	O
Ush	3	B-Gene
)	1	O
is	2	O
expressed	9	O
similarly	9	O
in	2	O
the	3	O
blood	5	O
cell	4	O
anlage	6	O
during	6	O
embryogenesis	13	O
.	1	O

During	6	O
hematopoiesis	13	O
,	1	O
the	3	O
acute	5	B-Gene
myeloid	7	I-Gene
leukemia	8	I-Gene
1	1	I-Gene
homologue	9	I-Gene
Lozenge	7	I-Gene
and	3	O
Glial	5	B-Gene
cells	5	I-Gene
missing	7	I-Gene
are	3	O
required	8	O
for	3	O
the	3	O
production	10	O
of	2	O
crystal	7	O
cells	5	O
and	3	O
plasmatocytes	13	O
,	1	O
respectively	12	O
.	1	O

However	7	O
,	1	O
additional	10	O
factors	7	O
have	4	O
been	4	O
predicted	9	O
to	2	O
control	7	O
crystal	7	O
cell	4	O
proliferation	13	O
.	1	O

In	2	O
this	4	O
report	6	O
,	1	O
we	2	O
show	4	O
that	4	O
Ush	3	B-Gene
is	2	O
expressed	9	O
in	2	O
hemocyte	8	O
precursors	10	O
and	3	O
plasmatocytes	13	O
throughout	10	O
embryogenesis	13	O
and	3	O
larval	6	O
development	11	O
,	1	O
and	3	O
the	3	O
GATA	4	B-Gene
factor	6	I-Gene
Serpent	7	I-Gene
is	2	O
essential	9	O
for	3	O
Ush	3	B-Gene
embryonic	9	O
expression	10	O
.	1	O

Furthermore	11	O
,	1	O
loss	4	O
of	2	O
ush	3	B-Gene
function	8	O
results	7	O
in	2	O
an	2	O
overproduction	14	O
of	2	O
crystal	7	O
cells	5	O
,	1	O
whereas	7	O
forced	6	O
expression	10	O
of	2	O
Ush	3	B-Gene
reduces	7	O
this	4	O
cell	4	O
population	10	O
.	1	O

Murine	6	B-Gene
FOG-1	5	I-Gene
and	3	O
FOG-2	5	B-Gene
also	4	O
can	3	O
repress	7	O
crystal	7	O
cell	4	O
production	10	O
,	1	O
but	3	O
a	1	O
mutant	6	O
version	7	O
of	2	O
FOG-2	5	B-Gene
lacking	7	O
a	1	O
conserved	9	O
motif	5	O
that	4	O
binds	5	O
the	3	O
corepressor	11	O
C-terminal	10	O
binding	7	O
protein	7	O
fails	5	O
to	2	O
affect	6	O
the	3	O
cell	4	O
lineage	7	O
.	1	O

The	3	O
GATA	4	B-Gene
factor	6	I-Gene
Pannier	7	I-Gene
(	1	O
Pnr	3	B-Gene
)	1	O
is	2	O
required	8	O
for	3	O
eye	3	O
and	3	O
heart	5	O
development	11	O
in	2	O
Drosophila	10	O
.	1	O

When	4	O
Ush	3	B-Gene
,	1	O
FOG-1	5	B-Gene
,	1	O
FOG-2	5	B-Gene
,	1	O
or	2	O
mutant	6	B-Gene
FOG-2	5	I-Gene
is	2	O
coexpressed	11	O
with	4	O
Pnr	3	B-Gene
during	6	O
these	5	O
developmental	13	O
processes	9	O
,	1	O
severe	6	O
eye	3	O
and	3	O
heart	5	O
phenotypes	10	O
result	6	O
,	1	O
consistent	10	O
with	4	O
a	1	O
conserved	9	O
negative	8	O
regulation	10	O
of	2	O
Pnr	3	B-Gene
function	8	O
.	1	O

These	5	O
results	7	O
indicate	8	O
that	4	O
the	3	O
fly	3	O
and	3	O
mouse	5	B-Gene
FOG	3	I-Gene
proteins	8	I-Gene
function	8	O
similarly	9	O
in	2	O
three	5	O
distinct	8	O
cellular	8	O
contexts	8	O
in	2	O
Drosophila	10	O
,	1	O
but	3	O
may	3	O
use	3	O
different	9	O
mechanisms	10	O
to	2	O
regulate	8	O
genetic	7	O
events	6	O
in	2	O
blood	5	O
vs	2	O
.	1	O
cardial	7	O
or	2	O
eye	3	O
cell	4	O
lineages	8	O

Constitutive	12	O
expression	10	O
of	2	O
MHC	3	B-Gene
class	5	I-Gene
II	2	I-Gene
genes	5	I-Gene
in	2	O
melanoma	8	B-Disease
cell	4	O
lines	5	O
results	7	O
from	4	O
the	3	O
transcription	13	O
of	2	O
class	5	B-Gene
II	2	I-Gene
transactivator	14	I-Gene
abnormally	10	O
initiated	9	O
from	4	O
its	3	O
B	1	O
cell-specific	13	O
promoter	8	O
.	1	O

In	2	O
melanoma	8	B-Disease
cell	4	O
lines	5	O
,	1	O
two	3	O
different	9	O
patterns	8	O
of	2	O
MHC	3	B-Gene
class	5	I-Gene
II	2	I-Gene
expression	10	O
have	4	O
been	4	O
described	9	O
,	1	O
either	6	O
an	2	O
IFN	3	B-Gene
gamma-inducible	15	I-Gene
expression	10	O
of	2	O
HLA-DR	6	B-Gene
and	3	O
HLA-DP	6	B-Gene
,	1	O
with	4	O
a	1	O
faint	5	O
or	2	O
null	4	O
expression	10	O
of	2	O
HLA-DQ	6	B-Gene
,	1	O
resembling	10	O
that	4	O
described	9	O
for	3	O
melanocytes	11	O
,	1	O
or	2	O
a	1	O
constitutive	12	O
expression	10	O
,	1	O
i.e.	4	O
,	1	O
IFN-gamma	9	B-Gene
independent	11	O
,	1	O
of	2	O
all	3	O
three	5	O
HLA-D	5	B-Gene
isotypes	8	O
.	1	O

As	2	O
this	4	O
latter	6	O
phenotype	9	O
has	3	O
been	4	O
associated	10	O
with	4	O
a	1	O
more	4	O
rapid	5	O
progression	11	O
of	2	O
melanoma	8	B-Disease
tumors	6	I-Disease
,	1	O
we	2	O
have	4	O
analyzed	8	O
in	2	O
different	9	O
melanoma	8	B-Disease
cell	4	O
lines	5	O
the	3	O
molecular	9	O
mechanisms	10	O
leading	7	O
to	2	O
this	4	O
abnormal	8	O
pattern	7	O
of	2	O
MHC	3	B-Gene
class	5	I-Gene
II	2	I-Gene
expression	10	O
.	1	O

In	2	O
agreement	9	O
with	4	O
the	3	O
evidence	8	O
of	2	O
a	1	O
coordinate	10	O
transcription	13	O
of	2	O
the	3	O
HLA-D	5	B-Gene
genes	5	I-Gene
in	2	O
these	5	O
cell	4	O
lines	5	O
,	1	O
we	2	O
have	4	O
shown	5	O
the	3	O
constitutive	12	O
expression	10	O
of	2	O
CIITA	5	B-Gene
(	1	I-Gene
class	5	I-Gene
II	2	I-Gene
transactivator	14	I-Gene
)	1	I-Gene
transcripts	11	I-Gene
,	1	O
CIITA	5	B-Gene
being	5	O
known	5	O
as	2	O
the	3	O
master	6	O
switch	6	O
of	2	O
MHC	3	B-Gene
class	5	I-Gene
II	2	I-Gene
expression	10	O
.	1	O

Unexpectedly	12	O
,	1	O
these	5	O
transcripts	11	O
initiate	8	O
from	4	O
promoter	8	O
III	3	O
of	2	O
the	3	O
CIITA	5	B-Gene
gene	4	I-Gene
,	1	O
a	1	O
promoter	8	O
that	4	O
is	2	O
mainly	6	O
used	4	O
constitutively	14	O
in	2	O
B	1	O
lymphocytes	11	O
.	1	O

This	4	O
expression	10	O
was	3	O
further	7	O
shown	5	O
to	2	O
occur	5	O
through	7	O
factor	6	O
(	1	O
s	1	O
)	1	O
acting	6	O
on	2	O
the	3	O
enhancer	8	O
located	7	O
upstream	8	O
of	2	O
CIITA	5	B-Gene
promoter	8	I-Gene
III	3	I-Gene
,	1	O
which	5	O
was	3	O
previously	10	O
described	9	O
in	2	O
epithelioid	11	O
cells	5	O
as	2	O
an	2	O
IFN-gamma-response	18	B-Gene
sequence	8	O
.	1	O

The	3	O
hypothesis	10	O
of	2	O
a	1	O
general	7	O
abnormality	11	O
of	2	O
the	3	O
IFN-gamma	9	B-Gene
transduction	12	O
pathway	7	O
was	3	O
dismissed	9	O
.	1	O

Constitutive	12	O
transcription	13	O
of	2	O
CIITA	5	B-Gene
from	4	O
promoter	8	O
III	3	O
having	6	O
been	4	O
observed	8	O
in	2	O
unrelated	9	O
melanoma	8	B-Disease
cell	4	O
lines	5	O
,	1	O
we	2	O
propose	7	O
the	3	O
hypothesis	10	O
that	4	O
this	4	O
phenomenon	10	O
might	5	O
not	3	O
be	2	O
a	1	O
random	6	O
event	5	O
,	1	O
but	3	O
could	5	O
be	2	O
linked	6	O
to	2	O
the	3	O
neoplasic	9	O
state	5	O
of	2	O
the	3	O
melanoma	8	B-Disease
cells	5	O

Signal	6	O
thresholds	10	O
and	3	O
modular	7	O
synergy	7	O
during	6	O
expression	10	O
of	2	O
costimulatory	13	O
molecules	9	O
in	2	O
B	1	O
lymphocytes	11	O
.	1	O

We	2	O
analyzed	8	O
intracellular	13	O
pathways	8	O
modulating	10	O
surface	7	O
densities	9	O
of	2	O
CD80	4	B-Gene
and	3	O
CD86	4	B-Gene
in	2	O
B	1	O
cells	5	O
activated	9	O
through	7	O
ligation	8	O
of	2	O
the	3	O
Ag	2	O
receptor	8	O
,	1	O
and	3	O
the	3	O
adhesion	8	O
molecule	8	O
CD54	4	B-Gene
.	1	O

Whereas	7	O
B	1	B-Gene
cell	4	I-Gene
Ag	2	I-Gene
receptor	8	I-Gene
(	1	O
BCR	3	B-Gene
)	1	O
cross	5	O
-linking	8	O
alone	5	O
stimulated	10	O
increased	9	O
expression	10	O
of	2	O
CD86	4	B-Gene
,	1	O
up-regulation	13	O
of	2	O
CD80	4	B-Gene
required	8	O
dual	4	O
stimulation	11	O
with	4	O
anti-IgM	8	B-Gene
and	3	O
anti-CD54	9	B-Gene
.	1	O

The	3	O
principal	9	O
downstream	10	O
component	9	O
contributed	11	O
by	2	O
BCR	3	B-Gene
signaling	9	O
,	1	O
toward	6	O
both	4	O
CD80	4	B-Gene
and	3	O
CD86	4	B-Gene
induction	9	O
,	1	O
was	3	O
the	3	O
elevated	8	O
concentration	13	O
of	2	O
free	4	O
cytoplasmic	11	O
Ca	2	O
(	1	O
2+	2	O
)	1	O
,	1	O
recruited	9	O
by	2	O
way	3	O
of	2	O
capacitative	12	O
influx	6	O
.	1	O

This	4	O
alone	5	O
was	3	O
sufficient	10	O
to	2	O
generate	8	O
an	2	O
increase	8	O
in	2	O
CD86	4	B-Gene
levels	6	O
.	1	O

However	7	O
,	1	O
CD80	4	B-Gene
enhancement	11	O
required	8	O
the	3	O
concerted	9	O
action	6	O
of	2	O
both	4	O
intracellular	13	O
Ca	2	O
(	1	O
2+	2	O
)	1	O
concentration	13	O
and	3	O
CD54	4	B-Gene
-initiated	10	O
pathways	8	O
.	1	O

The	3	O
nexus	5	O
between	7	O
anti-IgM	8	B-Gene
and	3	O
anti-CD54	9	B-Gene
stimulation	11	O
,	1	O
in	2	O
the	3	O
context	7	O
of	2	O
CD80	4	B-Gene
regulation	10	O
,	1	O
was	3	O
identified	10	O
to	2	O
involve	7	O
a	1	O
self	4	O
-propagating	12	O
process	7	O
of	2	O
sequential	10	O
synergy	7	O
.	1	O

The	3	O
first	5	O
step	4	O
involved	8	O
amplified	9	O
accumulation	12	O
of	2	O
intracellular	13	O
cAMP	4	B-Chemical
,	1	O
as	2	O
a	1	O
result	6	O
of	2	O
cross-talk	10	O
between	7	O
BCR	3	B-Gene
-mobilized	10	O
Ca	2	O
(	1	O
2+	2	O
)	1	O
and	3	O
CD54	4	B-Gene
-derived	8	O
signals	7	O
.	1	O

This	4	O
then	4	O
facilitated	11	O
a	1	O
second	6	O
synergistic	11	O
interaction	11	O
between	7	O
Ca	2	O
(	1	O
2+	2	O
)	1	O
and	3	O
cAMP	4	B-Chemical
,	1	O
culminating	11	O
in	2	O
CD80	4	B-Gene
expression	10	O
.	1	O

Our	3	O
findings	8	O
of	2	O
distinct	8	O
signal	6	O
transducer	10	O
requirements	12	O
,	1	O
with	4	O
the	3	O
added	5	O
consequences	12	O
of	2	O
cross-talk	10	O
,	1	O
offers	6	O
an	2	O
explanation	11	O
for	3	O
variable	8	O
modulation	10	O
of	2	O
costimulatory	13	O
molecule	8	O
expression	10	O
in	2	O
response	8	O
to	2	O
diverse	7	O
physiological	13	O
stimuli	7	O
.	1	O

Importantly	11	O
,	1	O
these	5	O
results	7	O
also	4	O
reveal	6	O
how	3	O
concentration	13	O
threshold	9	O
barriers	8	O
for	3	O
recruitment	11	O
of	2	O
individual	10	O
second	6	O
messengers	10	O
can	3	O
be	2	O
overcome	8	O
by	2	O
constructive	12	O
convergence	11	O
of	2	O
signaling	9	O
modules	7	O
.	1	O

Down-regulation	15	O
of	2	O
IL-12	5	B-Gene
p40	3	I-Gene
gene	4	I-Gene
in	2	O
Plasmodium	10	O
berghei	7	O
-infected	9	O
mice	4	O
.	1	O

We	2	O
analyzed	8	O
the	3	O
mechanism	9	O
that	4	O
causes	6	O
suppression	11	O
of	2	O
IL-12	5	B-Gene
p40	3	I-Gene
gene	4	I-Gene
induction	9	O
during	6	O
Plasmodium	10	O
berghei	7	O
infection	9	O
.	1	O

Although	8	O
IL-12	5	B-Gene
together	8	O
with	4	O
IFN-gamma	9	B-Gene
plays	5	O
an	2	O
important	9	O
role	4	O
in	2	O
protection	10	O
against	7	O
pathogenic	10	O
infection	9	O
,	1	O
the	3	O
IL-12	5	B-Gene
p70	3	I-Gene
protein	7	I-Gene
production	10	O
of	2	O
infected	8	O
macrophages	11	O
is	2	O
lower	5	O
than	4	O
that	4	O
by	2	O
the	3	O
uninfected	10	O
macrophages	11	O
.	1	O

We	2	O
showed	6	O
in	2	O
the	3	O
present	7	O
study	5	O
that	4	O
the	3	O
induction	9	O
of	2	O
IL-12	5	B-Gene
p40	3	I-Gene
gene	4	I-Gene
but	3	O
not	3	O
IL-12	5	B-Gene
p35	3	I-Gene
gene	4	I-Gene
in	2	O
macrophages	11	O
of	2	O
P.	2	O
berghei	7	O
-infected	9	O
mice	4	O
was	3	O
profoundly	10	O
inhibited	9	O
.	1	O

The	3	O
inhibition	10	O
was	3	O
induced	7	O
by	2	O
interaction	11	O
with	4	O
macrophages	11	O
that	4	O
had	3	O
contacted	9	O
with	4	O
P.	2	O
berghei	7	O
-infected	9	O
erythrocytes	12	O
and	3	O
was	3	O
mediated	8	O
by	2	O
a	1	O
soluble	7	O
factor	6	O
,	1	O
IL-10	5	B-Gene
.	1	O

There	5	O
was	3	O
comparable	10	O
activation	10	O
of	2	O
NF-kappaB	9	B-Gene
in	2	O
uninfected	10	O
and	3	O
infected	8	O
cells	5	O
.	1	O

The	3	O
induction	9	O
of	2	O
IFN-regulatory	14	B-Gene
factor-1	8	I-Gene
gene	4	I-Gene
was	3	O
comparable	10	O
in	2	O
transcription	13	O
level	5	O
in	2	O
uninfected	10	O
and	3	O
infected	8	O
cells	5	O
,	1	O
while	5	O
the	3	O
unidentified	12	O
complex	7	O
formation	9	O
of	2	O
IFN-regulatory	14	B-Gene
factor-1	8	I-Gene
was	3	O
observed	8	O
in	2	O
infected	8	O
cells	5	O
.	1	O

Therefore	9	O
,	1	O
the	3	O
inhibition	10	O
of	2	O
the	3	O
IL-12	5	B-Gene
p40	3	I-Gene
gene	4	I-Gene
induction	9	O
appeared	8	O
to	2	O
be	2	O
regulated	9	O
at	2	O
transcriptional	15	O
regulation	10	O
level	5	O
of	2	O
the	3	O
gene	4	O
.	1	O

Transcription	13	B-Gene
factor	6	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
regulates	9	O
Ig	2	B-Gene
lambda	6	I-Gene
light	5	I-Gene
chain	5	I-Gene
gene	4	I-Gene
rearrangement	13	O
.	1	O

The	3	O
tissue-	7	O
and	3	O
stage-specific	14	O
assembly	8	O
of	2	O
Ig	2	B-Gene
and	3	O
TCR	3	B-Gene
genes	5	I-Gene
is	2	O
mediated	8	O
by	2	O
a	1	O
common	6	O
V	1	B-Gene
(	1	I-Gene
D	1	I-Gene
)	1	I-Gene
J	1	I-Gene
recombinase	11	I-Gene
complex	7	I-Gene
in	2	O
precursor	9	O
lymphocytes	11	O
.	1	O

Directed	8	O
alterations	11	O
in	2	O
the	3	O
accessibility	13	O
of	2	O
V	1	B-Partial_Gene
,	1	O
D	1	B-Partial_Gene
,	1	O
and	3	O
J	1	B-Gene
gene	4	I-Gene
segments	8	O
target	6	O
the	3	O
recombinase	11	B-Gene
to	2	O
specific	8	O
Ag	2	O
receptor	8	O
loci	4	O
.	1	O

Accessibility	13	O
within	6	O
a	1	O
given	5	O
locus	5	O
is	2	O
regulated	9	O
by	2	O
the	3	O
functional	10	O
interaction	11	O
of	2	O
transcription	13	O
factors	7	O
with	4	O
cognate	7	O
enhancer	8	O
elements	8	O
and	3	O
correlates	10	O
with	4	O
the	3	O
transcriptional	15	O
activity	8	O
of	2	O
unrearranged	12	O
gene	4	O
segments	8	O
.	1	O

As	2	O
demonstrated	12	O
in	2	O
our	3	O
prior	5	O
studies	7	O
,	1	O
rearrangement	13	O
of	2	O
the	3	O
Igkappa	7	B-Gene
locus	5	I-Gene
is	2	O
regulated	9	O
by	2	O
the	3	O
inducible	9	O
transcription	13	B-Gene
factor	6	I-Gene
NF-kappaB	9	I-Gene
.	1	O

In	2	O
contrast	8	O
to	2	O
the	3	O
Igkappa	7	B-Gene
locus	5	I-Gene
,	1	O
known	5	O
transcriptional	15	O
control	7	O
elements	8	O
in	2	O
the	3	O
Iglambda	8	B-Gene
locus	5	I-Gene
lack	4	O
functional	10	O
NF-kappaB	9	B-Gene
binding	7	O
sites	5	O
.	1	O

Consistent	10	O
with	4	O
this	4	O
observation	11	O
,	1	O
the	3	O
expression	10	O
of	2	O
assembled	9	O
Iglambda	8	B-Gene
genes	5	I-Gene
in	2	O
mature	6	O
B	1	O
cells	5	O
has	3	O
been	4	O
shown	5	O
to	2	O
be	2	O
NF-kappaB	9	B-Gene
independent	11	O
.	1	O

Nonetheless	11	O
,	1	O
we	2	O
now	3	O
show	4	O
that	4	O
specific	8	O
repression	10	O
of	2	O
NF-kappaB	9	B-Gene
inhibits	8	O
germline	8	O
transcription	13	O
and	3	O
recombination	13	O
of	2	O
Iglambda	8	B-Gene
gene	4	I-Gene
segments	8	O
in	2	O
precursor	9	O
B	1	O
cells	5	O
.	1	O

Molecular	9	O
analyses	8	O
indicate	8	O
that	4	O
the	3	O
block	5	O
in	2	O
NF-kappaB	9	B-Gene
impairs	7	O
Iglambda	8	B-Gene
rearrangement	13	O
at	2	O
the	3	O
level	5	O
of	2	O
recombinase	11	B-Gene
accessibility	13	O
.	1	O

In	2	O
contrast	8	O
,	1	O
the	3	O
activities	10	O
of	2	O
known	5	O
Iglambda	8	B-Gene
promoter	8	I-Gene
and	3	O
enhancer	8	O
elements	8	O
are	3	O
unaffected	10	O
in	2	O
the	3	O
same	4	O
cellular	8	O
background	10	O
.	1	O

These	5	O
findings	8	O
expand	6	O
the	3	O
range	5	O
of	2	O
NF-kappaB	9	B-Gene
action	6	O
in	2	O
precursor	9	O
B	1	O
cells	5	O
beyond	6	O
Igkappa	7	B-Gene
to	2	O
include	7	O
the	3	O
control	7	O
of	2	O
recombinational	15	O
accessibility	13	O
at	2	O
both	4	O
L	1	O
chain	5	O
loci	4	O
.	1	O

Moreover	8	O
,	1	O
our	3	O
results	7	O
strongly	8	O
suggest	7	O
the	3	O
existence	9	O
of	2	O
a	1	O
novel	5	O
Iglambda	8	B-Gene
regulatory	10	I-Gene
element	7	I-Gene
that	4	O
is	2	O
either	6	O
directly	8	O
or	2	O
indirectly	10	O
activated	9	O
by	2	O
NF-kappaB	9	B-Gene
during	6	O
the	3	O
early	5	O
stages	6	O
of	2	O
B	1	O
cell	4	O
development	11	O
.	1	O

Adipophilin	11	B-Gene
is	2	O
a	1	O
sensitive	9	O
marker	6	O
for	3	O
lipid	5	B-Chemical
loading	7	O
in	2	O
human	5	O
blood	5	O
monocytes	9	O
.	1	O

Adipophilin	11	B-Gene
,	1	O
a	1	O
marker	6	O
of	2	O
lipid	5	B-Chemical
accumulation	12	O
initially	9	O
described	9	O
in	2	O
adipocytes	10	O
,	1	O
was	3	O
recently	8	O
shown	5	O
to	2	O
be	2	O
induced	7	O
in	2	O
macrophage	10	O
foam	4	O
cells	5	O
.	1	O

We	2	O
found	5	O
that	4	O
even	4	O
freshly	7	O
isolated	8	O
blood	5	O
monocytes	9	O
express	7	O
adipophilin	11	B-Gene
and	3	O
that	4	O
the	3	O
amount	6	O
of	2	O
adipophilin	11	B-Gene
protein	7	I-Gene
is	2	O
variable	8	O
in	2	O
monocytes	9	O
from	4	O
different	9	O
healthy	7	O
individuals	11	O
.	1	O

However	7	O
,	1	O
the	3	O
physiological	13	O
expression	10	O
of	2	O
adipophilin	11	B-Gene
does	4	O
not	3	O
correlate	9	O
with	4	O
the	3	O
levels	6	O
of	2	O
free	4	O
fatty	5	B-Chemical
acids	5	I-Chemical
,	1	O
cholesterylesters	17	O
or	2	O
free	4	O
cholesterol	11	B-Chemical
.	1	O

Enzymatically	13	O
modified	8	O
low-density	11	O
lipoprotein	11	O
(	1	O
E-LDL	5	O
)	1	O
induces	7	O
rapid	5	O
foam	4	O
cell	4	O
formation	9	O
in	2	O
monocytes	9	O
and	3	O
upregulates	11	O
adipophilin	11	B-Gene
mRNA	4	I-Gene
and	3	O
protein	7	O
within	6	O
2	1	O
h	1	O
of	2	O
incubation	10	O
.	1	O

This	4	O
rapid	5	O
induction	9	O
of	2	O
adipophilin	11	B-Gene
is	2	O
accompanied	11	O
by	2	O
a	1	O
significant	11	O
increase	8	O
of	2	O
free	4	O
fatty	5	B-Chemical
acids	5	I-Chemical
in	2	O
monocytes	9	O
incubated	9	O
with	4	O
E-LDL	5	O
.	1	O

Adipophilin	11	B-Gene
facilitates	11	O
the	3	O
uptake	6	O
of	2	O
free	4	O
fatty	5	B-Chemical
acids	5	I-Chemical
,	1	O
and	3	O
here	4	O
we	2	O
demonstrate	11	O
that	4	O
free	4	O
fatty	5	B-Chemical
acids	5	I-Chemical
increase	8	O
is	2	O
related	7	O
to	2	O
the	3	O
early	5	O
upregulation	12	O
of	2	O
adipophilin	11	B-Gene
expression	10	O
in	2	O
blood	5	O
monocytes	9	O
.	1	O

Fatty	5	O
acids	5	O
are	3	O
ligands	7	O
for	3	O
peroxisome	10	B-Gene
proliferator	12	I-Gene
-activated	10	I-Gene
receptor-gamma	14	I-Gene
(	1	O
PPARgamma	9	B-Gene
)	1	O
,	1	O
and	3	O
the	3	O
upregulation	12	O
of	2	O
adipophilin	11	B-Gene
mRNA	4	I-Gene
by	2	O
PPARgamma	9	B-Gene
agonists	8	I-Gene
like	4	O
15d-PGJ	7	B-Chemical
(	1	I-Chemical
2	1	I-Chemical
)	1	I-Chemical
and	3	O
ciglitazone	11	B-Chemical
indicates	9	O
that	4	O
PPARgamma	9	B-Gene
may	3	O
mediate	7	O
the	3	O
induction	9	O
of	2	O
adipophilin	11	B-Gene
expression	10	O
in	2	O
human	5	O
blood	5	O
monocytes	9	O
.	1	O

Hepatic	7	O
ischemia-reperfusion	20	B-Disease
injury	6	I-Disease
.	1	O

BACKGROUND	10	O
:	1	O
The	3	O
morbidity	9	O
associated	10	O
with	4	O
liver	5	O
transplantation	15	O
and	3	O
major	5	O
hepatic	7	O
resections	10	O
is	2	O
partly	6	O
a	1	O
result	6	O
of	2	O
ischemia-reperfusion	20	B-Disease
injury	6	I-Disease
.	1	O

DATA	4	O
SOURCES	7	O
:	1	O
The	3	O
entire	6	O
world	5	O
literature	10	O
on	2	O
the	3	O
subject	7	O
was	3	O
searched	8	O
via	3	O
Medline	7	O
.	1	O

Keywords	8	O
included	8	O
reperfusion	11	B-Disease
injury	6	I-Disease
,	1	O
transplantation	15	O
,	1	O
liver	5	O
resection	9	O
,	1	O
nitric	6	B-Chemical
oxide	5	I-Chemical
,	1	O
endothelin	10	B-Gene
,	1	O
cytokines	9	O
,	1	O
Kupffer	7	O
cells	5	O
,	1	O
ischemic	8	O
/	1	O
ischaemic	9	O
preconditioning	15	O
,	1	O
and	3	O
nuclear	7	B-Gene
factor-kappa	12	I-Gene
B	1	I-Gene
.	1	O

CONCLUSIONS	11	O
:	1	O
An	2	O
imbalance	9	O
between	7	O
endothelin	10	B-Gene
and	3	O
nitric	6	B-Chemical
oxide	5	I-Chemical
levels	6	O
results	7	O
in	2	O
failure	7	O
of	2	O
the	3	O
hepatic	7	O
microcirculation	16	O
at	2	O
the	3	O
onset	5	O
of	2	O
reperfusion	11	O
.	1	O

Activation	10	O
of	2	O
nuclear	7	B-Gene
factor-kappa	12	I-Gene
B	1	I-Gene
in	2	O
the	3	O
liver	5	O
promotes	8	O
proinflammatory	15	O
cytokine	8	O
and	3	O
adhesion	8	O
molecule	8	O
synthesis	9	O
.	1	O

These	5	O
result	6	O
in	2	O
oxygen	6	B-Chemical
-derived	8	O
free	4	O
radical	7	O
production	10	O
and	3	O
neutrophil	10	O
recruitment	11	O
,	1	O
further	7	O
contributing	12	O
to	2	O
cellular	8	O
injury	6	O
.	1	O

Various	7	O
therapeutic	11	O
modalities	10	O
acting	6	O
on	2	O
the	3	O
above	5	O
mediators	9	O
have	4	O
been	4	O
successfully	12	O
used	4	O
to	2	O
attenuate	9	O
reperfusion	11	B-Disease
injury	6	I-Disease
in	2	O
animal	6	O
models	6	O
of	2	O
hepatic	7	O
transplantation	15	O
and	3	O
resection	9	O
.	1	O

Application	11	O
of	2	O
the	3	O
knowledge	9	O
gained	6	O
from	4	O
animal	6	O
models	6	O
of	2	O
hepatic	7	O
ischemia-reperfusion	20	O
to	2	O
the	3	O
clinical	8	O
setting	7	O
will	4	O
improve	7	O
the	3	O
outcome	7	O
of	2	O
hepatic	7	O
surgery	7	O
.	1	O

Troglitazone	12	B-Chemical
,	1	O
a	1	O
PPARgamma	9	B-Gene
ligand	6	I-Gene
,	1	O
inhibits	8	O
osteopontin	11	B-Gene
gene	4	I-Gene
expression	10	O
in	2	O
human	5	O
monocytes	9	O
/	1	O
macrophage	10	O
THP-1	5	O
cells	5	O
.	1	O

Peroxizome	10	B-Gene
proliferator	12	I-Gene
-activated	10	I-Gene
receptor-gamma	14	I-Gene
(	1	O
PPARgamma	9	B-Gene
)	1	O
is	2	O
a	1	O
member	6	O
of	2	O
the	3	O
nuclear	7	B-Gene
receptor	8	I-Gene
family	6	I-Gene
of	2	O
transcription	13	O
factors	7	O
that	4	O
regulate	8	O
adipocyte	9	O
differentiation	15	O
.	1	O

Recent	6	O
studies	7	O
indicate	8	O
that	4	O
liganded	8	B-Gene
PPARgamma	9	I-Gene
not	3	O
only	4	O
promotes	8	O
differentiation	15	O
but	3	O
also	4	O
inhibits	8	O
the	3	O
activation	10	O
of	2	O
macrophages	11	O
.	1	O

Osteopontin	11	B-Gene
,	1	O
a	1	O
component	9	O
of	2	O
extracellular	13	O
matrix	6	O
,	1	O
is	2	O
synthesized	11	O
by	2	O
macrophages	11	O
in	2	O
atherosclerotic	15	O
plaques	7	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
we	2	O
examined	8	O
whether	7	O
PPARgamma	9	B-Gene
ligand	6	I-Gene
regulates	9	O
osteopontin	11	B-Gene
gene	4	I-Gene
expression	10	O
in	2	O
THP-1	5	O
cells	5	O
,	1	O
a	1	O
cell	4	O
line	4	O
derived	7	O
from	4	O
human	5	O
monocytic	9	O
leukemia	8	B-Disease
cells	5	O
which	5	O
can	3	O
differentiate	13	O
to	2	O
macrophage	10	O
upon	4	O
stimulation	11	O
with	4	O
phorbol	7	B-Chemical
ester	5	I-Chemical
PMA	3	I-Chemical
.	1	O

Northern	8	O
blot	4	O
analysis	8	O
showed	6	O
that	4	O
osteopontin	11	B-Gene
expression	10	O
is	2	O
markedly	8	O
induced	7	O
in	2	O
response	8	O
to	2	O
PMA	3	B-Chemical
.	1	O

Troglitazone	12	B-Chemical
,	1	O
a	1	O
PPARgamma	9	B-Gene
ligand	6	I-Gene
,	1	O
dramatically	12	O
attenuated	10	O
the	3	O
PMA	3	B-Chemical
-induced	8	O
osteopontin	11	B-Gene
expression	10	O
.	1	O

Transient	9	O
transfection	12	O
assays	6	O
of	2	O
the	3	O
human	5	B-Gene
osteopontin	11	I-Gene
promoter	8	I-Gene
/	1	O
luciferase	10	O
construct	9	O
which	5	O
contains	8	O
a	1	O
5'-flanking	11	O
region	6	O
between	7	O
-1500	5	O
and	3	O
+87	3	O
relative	8	O
to	2	O
the	3	O
transcription	13	O
start	5	O
site	4	O
demonstrate	11	O
that	4	O
either	6	O
treatment	9	O
with	4	O
troglitazone	12	B-Chemical
or	2	O
cotransfection	14	O
of	2	O
PPARgamma	9	B-Gene
expression	10	O
vector	6	O
inhibits	8	O
osteopontin	11	B-Gene
promoter	8	I-Gene
activity	8	O
.	1	O

These	5	O
data	4	O
indicate	8	O
that	4	O
troglitazone	12	B-Chemical
reduces	7	O
osteopontin	11	B-Gene
gene	4	I-Gene
expression	10	O
at	2	O
transcriptional	15	O
level	5	O
through	7	O
PPARgamma	9	B-Gene
activation	10	O
,	1	O
and	3	O
suggest	7	O
the	3	O
role	4	O
of	2	O
troglitazone	12	B-Chemical
in	2	O
inhibiting	10	O
the	3	O
ability	7	O
of	2	O
macrophages	11	O
to	2	O
produce	7	O
extracellular	13	O
matrix	6	O
,	1	O
which	5	O
is	2	O
particularly	12	O
relevant	8	O
to	2	O
atherosclerotic	15	O
plaque	6	O
formation	9	O
.	1	O

Regulation	10	O
of	2	O
the	3	O
human	5	B-Gene
MAT2B	5	I-Gene
gene	4	I-Gene
encoding	8	O
the	3	O
regulatory	10	O
beta	4	O
subunit	7	O
of	2	O
methionine	10	B-Gene
adenosyltransferase	19	I-Gene
,	1	O
MAT	3	B-Gene
II	2	I-Gene
.	1	O

Methionine	10	B-Gene
adenosyltransferase	19	I-Gene
(	1	O
MAT	3	B-Gene
)	1	O
catalyzes	9	O
the	3	O
biosynthesis	12	O
of	2	O
S-adenosylmethionine	20	B-Chemical
(	1	O
AdoMet	6	B-Chemical
)	1	O
,	1	O
a	1	O
key	3	O
molecule	8	O
in	2	O
transmethylation	16	O
reactions	9	O
and	3	O
polyamine	9	B-Chemical
biosynthesis	12	O
.	1	O

The	3	O
MAT	3	B-Gene
II	2	I-Gene
isozyme	7	I-Gene
consists	8	O
of	2	O
a	1	O
catalytic	9	O
alpha2	6	O
and	3	O
a	1	O
regulatory	10	O
beta	4	O
subunit	7	O
.	1	O

Down-regulation	15	O
of	2	O
the	3	O
MAT	3	B-Gene
II	2	I-Gene
beta	4	I-Gene
subunit	7	I-Gene
expression	10	O
causes	6	O
a	1	O
6-10-fold	9	O
increase	8	O
in	2	O
intracellular	13	O
AdoMet	6	B-Chemical
levels	6	O
.	1	O

To	2	O
understand	10	O
the	3	O
mechanism	9	O
by	2	O
which	5	O
the	3	O
beta	4	O
subunit	7	O
expression	10	O
is	2	O
regulated	9	O
,	1	O
we	2	O
cloned	6	O
the	3	O
MAT2B	5	B-Gene
gene	4	I-Gene
,	1	O
determined	10	O
its	3	O
organization	12	O
,	1	O
characterized	13	O
its	3	O
5'-flanking	11	O
sequences	9	O
,	1	O
and	3	O
elucidated	10	O
the	3	O
in	2	O
vitro	5	O
and	3	O
in	2	O
vivo	4	O
regulation	10	O
of	2	O
its	3	O
promoter	8	O
.	1	O

Transcription	13	O
of	2	O
the	3	O
MAT2B	5	B-Gene
gene	4	I-Gene
initiates	9	O
at	2	O
position	8	O
-203	4	O
relative	8	O
to	2	O
the	3	O
translation	11	O
start	5	O
site	4	O
.	1	O

Promoter	8	O
deletion	8	O
analysis	8	O
defined	7	O
a	1	O
minimal	7	O
promoter	8	O
between	7	O
positions	9	O
+52	3	O
and	3	O
+93	3	O
base	4	O
pairs	5	O
,	1	O
a	1	O
GC-rich	7	O
region	6	O
.	1	O

Inclusion	9	O
of	2	O
the	3	O
sequences	9	O
between	7	O
-4	2	O
and	3	O
+52	3	O
enhanced	8	O
promoter	8	O
activity	8	O
;	1	O
this	4	O
was	3	O
primarily	9	O
because	7	O
of	2	O
an	2	O
Sp1	3	B-Gene
recognition	11	O
site	4	O
at	2	O
+9	2	O
/	1	O
+15	3	O
.	1	O

The	3	O
inclusion	9	O
of	2	O
sequences	9	O
up	2	O
to	2	O
position	8	O
-115	4	O
provided	8	O
full	4	O
activity	8	O
;	1	O
this	4	O
was	3	O
attributed	10	O
to	2	O
a	1	O
TATA	4	O
at	2	O
-32	3	O
.	1	O

The	3	O
Sp1	3	B-Gene
site	4	O
at	2	O
position	8	O
+9	2	O
was	3	O
key	3	O
for	3	O
the	3	O
formation	9	O
of	2	O
protein.DNA	11	O
complexes	9	O
.	1	O

Mutation	8	O
of	2	O
both	4	O
the	3	O
Sp1	3	B-Gene
site	4	O
at	2	O
+9	2	O
and	3	O
the	3	O
TATA	4	O
at	2	O
-32	3	O
reduced	7	O
promoter	8	O
activity	8	O
to	2	O
its	3	O
minimal	7	O
level	5	O
.	1	O

Supershift	10	O
assays	6	O
showed	6	O
no	2	O
effect	6	O
of	2	O
the	3	O
anti-Sp1	8	B-Gene
antibody	8	I-Gene
on	2	O
complex	7	O
formation	9	O
,	1	O
whereas	7	O
the	3	O
anti-Sp3	8	B-Gene
antibody	8	I-Gene
had	3	O
a	1	O
strong	6	O
effect	6	O
on	2	O
protein.DNA	11	O
complex	7	O
formation	9	O
,	1	O
suggesting	10	O
that	4	O
Sp3	3	B-Gene
is	2	O
one	3	O
of	2	O
the	3	O
main	4	O
factors	7	O
binding	7	O
to	2	O
this	4	O
Sp1	3	B-Gene
site	4	O
.	1	O

Chromatin	9	O
immunoprecipitation	19	O
assays	6	O
supported	9	O
the	3	O
involvement	11	O
of	2	O
both	4	O
Sp1	3	B-Gene
and	3	O
Sp3	3	B-Gene
in	2	O
complexes	9	O
formed	6	O
on	2	O
the	3	O
MAT2B	5	B-Gene
promoter	8	I-Gene
.	1	O

The	3	O
data	4	O
show	4	O
that	4	O
the	3	O
5'-untranslated	15	O
sequences	9	O
play	4	O
an	2	O
important	9	O
role	4	O
in	2	O
regulating	10	O
the	3	O
MAT2B	5	B-Gene
gene	4	I-Gene
and	3	O
identifies	10	O
the	3	O
Sp1	3	B-Gene
site	4	O
at	2	O
+9	2	O
as	2	O
a	1	O
potential	9	O
target	6	O
for	3	O
modulating	10	O
MAT2B	5	B-Gene
expression	10	O
,	1	O
a	1	O
process	7	O
that	4	O
can	3	O
have	4	O
a	1	O
major	5	O
effect	6	O
on	2	O
intracellular	13	O
AdoMet	6	B-Chemical
levels	6	O
.	1	O

Tumour-stromal	14	B-Disease
interactions	12	O
.	1	O

Role	4	O
of	2	O
the	3	O
stroma	6	O
in	2	O
mammary	7	O
development	11	O
.	1	O

Mammary	7	O
development	11	O
depends	7	O
on	2	O
branching	9	O
morphogenesis	13	O
,	1	O
namely	6	O
the	3	O
bifurcation	11	O
and	3	O
extension	9	O
of	2	O
ductal	6	O
growth	6	O
points	6	O
(	1	O
end	3	O
buds	4	O
)	1	O
and	3	O
secretory	9	O
lobules	7	O
into	4	O
a	1	O
more	4	O
or	2	O
less	4	O
fatty	5	O
stroma	6	O
.	1	O

Because	7	O
breast	6	B-Disease
carcinomas	10	I-Disease
are	3	O
overwhelmingly	14	O
ductal	6	O
in	2	O
origin	6	O
,	1	O
this	4	O
review	6	O
focuses	7	O
on	2	O
stromal	7	O
influences	10	O
guiding	7	O
postnatal	9	O
ductal	6	O
development	11	O
and	3	O
there	5	O
is	2	O
only	4	O
the	3	O
briefest	8	O
account	7	O
of	2	O
the	3	O
role	4	O
of	2	O
embryonic	9	O
stroma	6	O
(	1	O
mesenchyme	10	O
)	1	O
.	1	O

The	3	O
stroma	6	O
as	2	O
the	3	O
necessary	9	O
target	6	O
for	3	O
endocrine	9	O
mammogens	9	O
and	3	O
the	3	O
source	6	O
of	2	O
stimulatory	11	O
growth	6	O
factors	7	O
is	2	O
described	9	O
and	3	O
the	3	O
importance	10	O
of	2	O
mammary	7	O
epithelium	10	O
-induced	8	O
modifications	13	O
of	2	O
the	3	O
periductal	10	O
stroma	6	O
is	2	O
emphasized	10	O
.	1	O

Evidence	8	O
is	2	O
presented	9	O
that	4	O
if	2	O
they	4	O
are	3	O
to	2	O
grow	4	O
,	1	O
end	3	O
buds	4	O
must	4	O
condition	9	O
proximal	8	O
fatty	5	O
stroma	6	O
by	2	O
recruiting	10	O
white	5	O
blood	5	O
cells	5	O
as	2	O
well	4	O
as	2	O
inducing	8	O
stromal	7	O
cell	4	O
division	8	O
and	3	O
,	1	O
possibly	8	O
,	1	O
estrogen	8	B-Gene
receptors	9	I-Gene
.	1	O

The	3	O
induction	9	O
of	2	O
a	1	O
fibrous	7	O
stromal	7	O
tunic	5	O
around	6	O
the	3	O
end	3	O
bud	3	O
is	2	O
described	9	O
and	3	O
its	3	O
likely	6	O
role	4	O
as	2	O
a	1	O
complex	7	O
ductal	6	O
morphogen	9	O
is	2	O
discussed	9	O
;	1	O
a	1	O
possible	8	O
role	4	O
in	2	O
growth	6	O
inhibition	10	O
is	2	O
also	4	O
considered	10	O
.	1	O

Although	8	O
the	3	O
signals	7	O
governing	9	O
fibrotic	8	O
induction	9	O
,	1	O
ductal	6	O
morphogenesis	13	O
,	1	O
and	3	O
growth	6	O
inhibition	10	O
are	3	O
unknown	7	O
,	1	O
a	1	O
role	4	O
for	3	O
transforming	12	B-Gene
growth	6	I-Gene
factor-beta	11	I-Gene
is	2	O
highly	6	O
likely	6	O
and	3	O
is	2	O
discussed	9	O
.	1	O

Finally	7	O
,	1	O
a	1	O
need	4	O
for	3	O
new	3	O
conceptual	10	O
and	3	O
experimental	12	O
approaches	10	O
to	2	O
understanding	13	O
stromal-epithelial	18	O
signaling	9	O
is	2	O
discussed	9	O
.	1	O

Biomechanical	13	O
strain	6	O
induces	7	O
class	5	B-Gene
a	1	I-Gene
scavenger	9	I-Gene
receptor	8	I-Gene
expression	10	O
in	2	O
human	5	O
monocyte	8	O
/	1	O
macrophages	11	O
and	3	O
THP-1	5	O
cells	5	O
:	1	O
a	1	O
potential	9	O
mechanism	9	O
of	2	O
increased	9	O
atherosclerosis	15	B-Disease
in	2	O
hypertension	12	B-Disease
.	1	O

BACKGROUND	10	O
:	1	O
Although	8	O
hypertension	12	B-Disease
is	2	O
an	2	O
important	9	O
risk	4	O
factor	6	O
for	3	O
the	3	O
development	11	O
of	2	O
atherosclerosis	15	B-Disease
,	1	O
the	3	O
mechanisms	10	O
for	3	O
this	4	O
interaction	11	O
are	3	O
incompletely	12	O
described	9	O
.	1	O

Previous	8	O
studies	7	O
have	4	O
suggested	9	O
that	4	O
biomechanical	13	O
strain	6	O
regulates	9	O
macrophage	10	O
phenotype	9	O
.	1	O

We	2	O
tested	6	O
the	3	O
hypothesis	10	O
that	4	O
biomechanical	13	O
strain	6	O
can	3	O
induce	6	O
expression	10	O
of	2	O
the	3	O
class	5	B-Gene
A	1	I-Gene
scavenger	9	I-Gene
receptor	8	I-Gene
(	1	O
SRA	3	B-Gene
)	1	O
,	1	O
an	2	O
important	9	O
lipoprotein	11	O
receptor	8	O
in	2	O
atherogenesis	13	O
.	1	O

METHODS	7	O
AND	3	O
RESULTS	7	O
:	1	O
Human	5	O
monocyte	8	O
/	1	O
macrophages	11	O
or	2	O
THP-1	5	O
cells	5	O
were	4	O
cultured	8	O
in	2	O
a	1	O
device	6	O
that	4	O
imposes	7	O
uniform	7	O
biaxial	7	O
cyclic	6	O
1-Hz	4	O
strains	7	O
of	2	O
0	1	O
%	1	O
,	1	O
1	1	O
%	1	O
,	1	O
2	1	O
%	1	O
,	1	O
or	2	O
3	1	O
%	1	O
,	1	O
and	3	O
SRA	3	B-Gene
expression	10	O
was	3	O
analyzed	8	O
.	1	O

Mechanical	10	O
strains	7	O
induced	7	O
SRA	3	B-Gene
mRNA	4	I-Gene
(	1	O
3.5+	4	O
/	1	O
-0.6-fold	9	O
at	2	O
3	1	O
%	1	O
strain	6	O
for	3	O
48	2	O
hours	5	O
,	1	O
P	1	O
<	1	O
0.01	4	O
)	1	O
and	3	O
SRA	3	B-Gene
protein	7	I-Gene
in	2	O
THP-1	5	O
cells	5	O
in	2	O
an	2	O
amplitude	9	O
-dependent	10	O
manner	6	O
.	1	O

This	4	O
induction	9	O
was	3	O
accompanied	11	O
by	2	O
augmented	9	O
expression	10	O
of	2	O
the	3	O
class	5	B-Gene
B	1	I-Gene
scavenger	9	I-Gene
receptor	8	I-Gene
CD36	4	I-Gene
(	1	O
2.8+	4	O
/	1	O
-0.3-fold	9	O
,	1	O
P	1	O
<	1	O
0.001	5	O
)	1	O
but	3	O
not	3	O
by	2	O
increased	9	O
peroxisome	10	B-Gene
proliferator	12	I-Gene
-activated	10	I-Gene
receptor-gamma	14	I-Gene
expression	10	O
.	1	O

To	2	O
evaluate	8	O
this	4	O
effect	6	O
in	2	O
vivo	4	O
,	1	O
apolipoprotein	14	B-Gene
E	1	I-Gene
(	1	I-Gene
-	1	I-Gene
/	1	I-Gene
-	1	I-Gene
)	1	I-Gene
mice	4	O
were	4	O
randomly	8	O
assigned	8	O
to	2	O
receive	7	O
standard	8	O
chow	4	O
,	1	O
a	1	O
high-cholesterol	16	B-Chemical
diet	4	O
,	1	O
or	2	O
a	1	O
high-cholesterol	16	B-Chemical
diet	4	O
with	4	O
hypertension	12	B-Disease
induced	7	O
by	2	O
angiotensin	11	B-Gene
II	2	I-Gene
infusion	8	O
for	3	O
8	1	O
weeks	5	O
.	1	O

Immunohistochemistry	20	O
revealed	8	O
that	4	O
among	5	O
macrophages	11	O
in	2	O
atherosclerotic	15	O
lesions	7	O
of	2	O
the	3	O
aorta	5	O
,	1	O
the	3	O
proportion	10	O
of	2	O
macrophages	11	O
with	4	O
SRA	3	B-Gene
expression	10	O
was	3	O
highest	7	O
in	2	O
hypertensive	12	B-Disease
animals	7	O
on	2	O
a	1	O
high-cholesterol	16	B-Chemical
diet	4	O
(	1	O
43.9+	5	O
/	1	O
-0.7	4	O
%	1	O
,	1	O
versus	6	O
12.0+	5	O
/	1	O
-2.0	4	O
%	1	O
for	3	O
normotensive	12	O
animals	7	O
on	2	O
a	1	O
high-cholesterol	16	B-Chemical
diet	4	O
and	3	O
4.7+	4	O
/	1	O
-4.7	4	O
%	1	O
for	3	O
animals	7	O
on	2	O
standard	8	O
chow	4	O
;	1	O
P	1	O
<	1	O
0.001	5	O
)	1	O
.	1	O

CONCLUSIONS	11	O
:	1	O
Biomechanical	13	O
strain	6	O
induces	7	O
SRA	3	B-Gene
expression	10	O
by	2	O
monocyte	8	O
/	1	O
macrophages	11	O
,	1	O
suggesting	10	O
a	1	O
novel	5	O
mechanism	9	O
for	3	O
promotion	9	O
of	2	O
atherosclerosis	15	B-Disease
in	2	O
hypertensive	12	B-Disease
patients	8	O
.	1	O

Long-term	9	O
-impaired	9	O
expression	10	O
of	2	O
nuclear	7	B-Gene
factor-kappa	12	I-Gene
B	1	I-Gene
and	3	O
I	1	B-Gene
kappa	5	I-Gene
B	1	I-Gene
alpha	5	I-Gene
in	2	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
of	2	O
trauma	6	B-Disease
patients	8	O
.	1	O

Nuclear	7	B-Gene
factor	6	I-Gene
(	1	I-Gene
NF	2	I-Gene
)	1	I-Gene
-kappa	6	I-Gene
B	1	I-Gene
expression	10	O
and	3	O
dimer	5	O
characteristics	15	O
were	4	O
studied	7	O
in	2	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
(	1	O
PBMCs	5	O
)	1	O
of	2	O
major-trauma	12	B-Disease
patients	8	O
and	3	O
healthy	7	O
controls	8	O
.	1	O

Analysis	8	O
of	2	O
PBMCs	5	O
on	2	O
days	4	O
1	1	O
,	1	O
3	1	O
,	1	O
5	1	O
,	1	O
and	3	O
10	2	O
after	5	O
trauma	6	B-Disease
revealed	8	O
that	4	O
expression	10	O
of	2	O
both	4	O
p65p50	6	B-Gene
heterodimers	12	O
and	3	O
p50p50	6	B-Gene
homodimers	10	O
was	3	O
significantly	13	O
reduced	7	O
compared	8	O
with	4	O
that	4	O
in	2	O
controls	8	O
.	1	O

In	2	O
vitro	5	O
lipopolysaccharide	18	B-Chemical
(	1	O
LPS	3	B-Chemical
)	1	O
stimulation	11	O
of	2	O
PBMCs	5	O
induced	7	O
NF-kappa	8	B-Gene
B	1	I-Gene
translocation	13	O
.	1	O

However	7	O
,	1	O
throughout	10	O
the	3	O
survey	6	O
,	1	O
p65p50	6	B-Gene
activation	10	O
remained	8	O
significantly	13	O
lower	5	O
in	2	O
trauma	6	B-Disease
patients	8	O
than	4	O
in	2	O
controls	8	O
.	1	O

After	5	O
LPS	3	B-Chemical
stimulation	11	O
in	2	O
vitro	5	O
,	1	O
the	3	O
p65p50	6	B-Gene
/	1	I-Gene
p50p50	6	I-Gene
ratio	5	O
was	3	O
significantly	13	O
lower	5	O
in	2	O
PBMCs	5	O
from	4	O
trauma	6	B-Disease
patients	8	O
than	4	O
from	4	O
healthy	7	O
controls	8	O
.	1	O

The	3	O
ex	2	O
vivo	4	O
expression	10	O
of	2	O
I	1	B-Gene
kappa	5	I-Gene
B	1	I-Gene
alpha	5	I-Gene
was	3	O
higher	6	O
in	2	O
PBMCs	5	O
of	2	O
controls	8	O
than	4	O
of	2	O
trauma	6	B-Disease
patients	8	O
.	1	O

LPS	3	B-Chemical
did	3	O
not	3	O
induce	6	O
I	1	B-Gene
kappa	5	I-Gene
B	1	I-Gene
expression	10	O
in	2	O
PBMCs	5	O
from	4	O
trauma	6	B-Disease
patients	8	O
,	1	O
but	3	O
strong	6	O
induction	9	O
was	3	O
obtained	8	O
with	4	O
staphylococci	13	O
,	1	O
suggesting	10	O
that	4	O
this	4	O
defect	6	O
is	2	O
not	3	O
universal	9	O
and	3	O
depends	7	O
on	2	O
the	3	O
nature	6	O
of	2	O
the	3	O
activating	10	O
signal	6	O
.	1	O

Although	8	O
no	2	O
direct	6	O
correlation	11	O
was	3	O
found	5	O
between	7	O
levels	6	O
of	2	O
interleukin-10	14	B-Gene
or	2	O
transforming	12	B-Gene
growth	6	I-Gene
factor-beta	11	I-Gene
and	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
,	1	O
these	5	O
immunosuppressive	17	O
cytokines	9	O
were	4	O
significantly	13	O
elevated	8	O
in	2	O
trauma	6	B-Disease
patients	8	O
by	2	O
10	2	O
days	4	O
after	5	O
admission	9	O
.	1	O

The	3	O
long-term	9	O
low-basal	9	O
and	3	O
LPS	3	B-Chemical
-induced	8	O
nuclear	7	O
translocation	13	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
recalled	8	O
long-term	9	O
immunoparalysis	15	O
observed	8	O
in	2	O
patients	8	O
with	4	O
severe	6	O
inflammatory	12	O
stress	6	O
such	4	O
as	2	O
trauma	6	B-Disease
.	1	O

OX40	4	B-Gene
stimulation	11	O
by	2	O
gp34	4	B-Gene
/	1	I-Gene
OX40	4	I-Gene
ligand	6	I-Gene
enhances	8	O
productive	10	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
infection	9	O
.	1	O

OX40	4	B-Gene
is	2	O
a	1	O
member	6	O
of	2	O
the	3	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
(	1	I-Gene
TNF	3	I-Gene
)	1	I-Gene
receptor	8	I-Gene
superfamily	11	O
and	3	O
known	5	O
to	2	O
be	2	O
an	2	O
important	9	O
costimulatory	13	O
molecule	8	O
expressed	9	O
on	2	O
activated	9	O
T	1	O
cells	5	O
.	1	O

To	2	O
investigate	11	O
the	3	O
role	4	O
of	2	O
costimulation	13	O
of	2	O
OX40	4	B-Gene
in	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
(	1	O
HIV-1	5	O
)	1	O
infection	9	O
by	2	O
its	3	O
natural	7	O
ligand	6	O
,	1	O
gp34	4	B-Gene
,	1	O
the	3	O
OX40	4	B-Gene
-transfected	12	O
ACH-2	5	O
cell	4	O
line	4	O
,	1	O
ACH-2	5	O
/	1	O
OX40	4	B-Gene
,	1	O
chronically	11	O
infected	8	O
with	4	O
HIV-1	5	O
,	1	O
was	3	O
cocultured	10	O
with	4	O
paraformaldehyde	16	B-Chemical
(	1	O
PFA	3	B-Chemical
)	1	O
-fixed	6	O
gp34	4	B-Gene
-transfected	12	O
mouse	5	O
cell	4	O
line	4	O
,	1	O
SV-T2	5	O
/	1	O
gp34	4	B-Gene
.	1	O

The	3	O
results	7	O
showed	6	O
that	4	O
HIV-1	5	O
production	10	O
was	3	O
strongly	8	O
induced	7	O
.	1	O

This	4	O
was	3	O
followed	8	O
by	2	O
apparent	8	O
apoptosis	9	O
,	1	O
and	3	O
both	4	O
processes	9	O
were	4	O
specifically	12	O
inhibited	9	O
by	2	O
the	3	O
gp34	4	B-Gene
-specific	9	O
neutralizing	12	O
monoclonal	10	O
antibody	8	O
5A8	3	O
.	1	O

Endogenous	10	O
TNF	3	B-Gene
alpha	5	I-Gene
(	1	O
TNF-alpha	9	B-Gene
)	1	O
and	3	O
TNF-beta	8	B-Gene
production	10	O
were	4	O
not	3	O
involved	8	O
in	2	O
the	3	O
enhanced	8	O
HIV-1	5	O
production	10	O
.	1	O

Furthermore	11	O
,	1	O
enhanced	8	O
HIV-1	5	O
transcription	13	O
in	2	O
gp34	4	B-Gene
-stimulated	11	O
ACH-2	5	O
/	1	O
OX40	4	B-Gene
cells	5	O
was	3	O
dependent	9	O
on	2	O
the	3	O
kappa	5	O
B	1	O
site	4	O
of	2	O
the	3	O
HIV-1	5	O
long	4	O
terminal	8	O
repeat	6	O
,	1	O
and	3	O
the	3	O
OX40-gp34	9	B-Gene
interaction	11	O
activated	9	O
NF-kappa	8	B-Gene
B	1	I-Gene
consisting	10	O
of	2	O
p50	3	B-Gene
and	3	O
p65	3	B-Gene
subunits	8	I-Gene
.	1	O

When	4	O
primary	7	O
activated	9	B-Gene
CD4	3	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
T	1	O
cells	5	O
acutely	7	O
infected	8	O
with	4	O
HIV-1	5	O
(	1	O
NL4-3	5	O
)	1	O
(	1	O
CXCR4	5	B-Gene
-using	6	O
T-cell-line-tropic	18	O
)	1	O
were	4	O
cocultured	10	O
with	4	O
PFA	3	B-Chemical
-fixed	6	O
gp34	4	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
human	5	O
T-cell	6	B-Disease
leukemia	8	I-Disease
virus	5	O
type	4	O
1	1	O
-bearing	8	O
MT-2	4	O
cells	5	O
or	2	O
SV-T2	5	O
/	1	O
gp34	4	B-Gene
cells	5	O
,	1	O
HIV-1	5	O
production	10	O
was	3	O
also	4	O
markedly	8	O
enhanced	8	O
.	1	O

The	3	O
enhancement	11	O
was	3	O
again	5	O
significantly	13	O
inhibited	9	O
by	2	O
5A8	3	O
.	1	O

The	3	O
present	7	O
study	5	O
first	5	O
shows	5	O
that	4	O
OX40-gp34	9	B-Gene
interaction	11	O
stimulates	10	O
HIV-1	5	O
expression	10	O
and	3	O
suggests	8	O
that	4	O
OX40	4	B-Gene
triggering	10	O
by	2	O
gp34	4	B-Gene
may	3	O
play	4	O
an	2	O
important	9	O
role	4	O
in	2	O
enhancing	9	O
HIV-1	5	O
production	10	O
in	2	O
both	4	O
acutely	7	O
and	3	O
latently	8	O
infected	8	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
T	1	O
cells	5	O
in	2	O
vivo	4	O
.	1	O

Transcriptional	15	O
regulation	10	O
of	2	O
galectin-10	11	B-Gene
(	1	O
eosinophil	10	B-Gene
Charcot-Leyden	14	I-Gene
crystal	7	I-Gene
protein	7	I-Gene
)	1	O
:	1	O
a	1	O
GC	2	O
box	3	O
(	1	O
-44	3	O
to	2	O
-50	3	O
)	1	O
controls	8	O
butyric	7	B-Chemical
acid	4	I-Chemical
induction	9	O
of	2	O
gene	4	O
expression	10	O
.	1	O

Galectin-10	11	B-Gene
(	1	O
gal-10	6	B-Gene
,	1	O
also	4	O
known	5	O
as	2	O
Charcot-Leyden	14	B-Gene
crystal	7	I-Gene
protein	7	I-Gene
)	1	O
is	2	O
a	1	O
member	6	O
of	2	O
the	3	O
galectin	8	B-Gene
family	6	I-Gene
of	2	O
beta-galactoside	16	B-Gene
binding	7	I-Gene
proteins	8	I-Gene
that	4	O
is	2	O
expressed	9	O
uniquely	8	O
in	2	O
eosinophilic	12	O
and	3	O
basophilic	10	O
leukocytes	10	O
.	1	O

To	2	O
gain	4	O
a	1	O
better	6	O
understanding	13	O
of	2	O
galectin	8	B-Gene
gene	4	I-Gene
expression	10	O
,	1	O
we	2	O
present	7	O
an	2	O
analysis	8	O
of	2	O
the	3	O
transcriptional	15	O
regulation	10	O
of	2	O
the	3	O
gene	4	O
encoding	8	O
gal-10	6	B-Gene
.	1	O

Analysis	8	O
of	2	O
the	3	O
minimal	7	O
promoter	8	O
revealed	8	O
nine	4	O
consensus	9	O
-binding	8	O
sites	5	O
for	3	O
transcription	13	O
factors	7	O
,	1	O
including	9	O
several	7	O
that	4	O
are	3	O
also	4	O
found	5	O
in	2	O
the	3	O
minimal	7	O
promoters	9	O
of	2	O
galectins	9	B-Gene
-1	2	I-Gene
,	1	O
-2	2	B-Partial_Gene
,	1	O
and	3	O
-3	2	B-Partial_Gene
.	1	O

The	3	O
decrease	8	O
in	2	O
gal-10	6	B-Gene
promoter	8	I-Gene
activity	8	O
after	5	O
disruption	10	O
of	2	O
either	6	O
the	3	O
GC	2	O
box	3	O
(	1	O
-44	3	O
to	2	O
-50	3	O
)	1	O
or	2	O
the	3	O
Oct	3	B-Gene
site	4	O
(	1	O
-255	4	O
to	2	O
-261	4	O
)	1	O
suggests	8	O
that	4	O
these	5	O
sites	5	O
,	1	O
along	5	O
with	4	O
the	3	O
previously	10	O
characterized	13	O
GATA	4	B-Gene
and	3	O
EoTF	4	O
sites	5	O
,	1	O
are	3	O
necessary	9	O
for	3	O
full	4	O
promoter	8	O
activity	8	O
.	1	O

By	2	O
supershift	10	O
analysis	8	O
,	1	O
we	2	O
demonstrate	11	O
binding	7	O
of	2	O
the	3	O
transcription	13	B-Gene
factors	7	I-Gene
Sp1	3	I-Gene
and	3	O
Oct1	4	B-Gene
to	2	O
the	3	O
consensus	9	O
GC	2	O
box	3	O
and	3	O
the	3	O
Oct	3	B-Gene
site	4	O
,	1	O
respectively	12	O
.	1	O

Similar	7	O
to	2	O
gal-1	5	B-Gene
,	1	O
gal-10	6	B-Gene
expression	10	O
is	2	O
induced	7	O
by	2	O
butyric	7	B-Chemical
acid	4	I-Chemical
,	1	O
an	2	O
effect	6	O
that	4	O
is	2	O
lost	4	O
upon	4	O
ablation	8	O
of	2	O
the	3	O
GC	2	O
box	3	O
.	1	O

Additionally	12	O
,	1	O
we	2	O
demonstrate	11	O
AML3	4	B-Gene
binding	7	O
to	2	O
the	3	O
consensus	9	O
AML	3	B-Gene
site	4	O
and	3	O
YY1	3	B-Gene
binding	7	O
to	2	O
the	3	O
Inr	3	O
sequence	8	O
,	1	O
both	4	O
elements	8	O
functioning	11	O
as	2	O
silencers	9	O
in	2	O
the	3	O
gal-10	6	B-Gene
promoter	8	I-Gene
.	1	O

Nuclear	7	B-Gene
peroxisome	10	I-Gene
proliferator	12	I-Gene
-activated	10	I-Gene
receptors	9	I-Gene
alpha	5	I-Gene
and	3	O
gamma	5	B-Partial_Gene
have	4	O
opposing	8	O
effects	7	O
on	2	O
monocyte	8	O
chemotaxis	10	O
in	2	O
endometriosis	13	B-Disease
.	1	O

The	3	O
peroxisome	10	B-Gene
proliferator	12	I-Gene
-activated	10	I-Gene
receptors	9	I-Gene
(	1	I-Gene
PPARs	5	I-Gene
)	1	I-Gene
alpha	5	I-Gene
and	3	O
gamma	5	B-Partial_Gene
are	3	O
nuclear	7	O
receptors	9	O
that	4	O
play	4	O
important	9	O
roles	5	O
in	2	O
inflammatory	12	O
diseases	8	O
like	4	O
ulcerative	10	B-Disease
colitis	7	I-Disease
and	3	O
arthritis	9	B-Disease
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
we	2	O
examined	8	O
the	3	O
possible	8	O
role	4	O
of	2	O
PPARs	5	B-Gene
in	2	O
macrophage	10	O
attraction	10	O
into	4	O
the	3	O
peritoneal	10	O
cavity	6	O
of	2	O
patients	8	O
with	4	O
endometriosis	13	B-Disease
.	1	O

We	2	O
identified	10	O
PPAR-alpha	10	B-Gene
and	3	O
-gamma	6	B-Partial_Gene
messenger	9	I-Partial_Gene
RNA	3	I-Partial_Gene
by	2	O
RT-PCR	6	O
and	3	O
protein	7	O
by	2	O
immunoblotting	14	O
of	2	O
lysates	7	O
of	2	O
peritoneal	10	O
macrophages	11	O
and	3	O
monocytic	9	O
U937	4	O
cells	5	O
.	1	O

Using	5	O
immunocytochemistry	19	O
,	1	O
we	2	O
localized	9	O
PPAR-alpha	10	B-Gene
and	3	O
-gamma	6	B-Partial_Gene
within	6	O
the	3	O
nuclei	6	O
of	2	O
both	4	O
cell	4	O
types	5	O
.	1	O

Monocyte	8	O
chemotactic	11	O
activity	8	O
of	2	O
peritoneal	10	O
fluid	5	O
from	4	O
patients	8	O
with	4	O
endometriosis	13	B-Disease
was	3	O
quantified	10	O
in	2	O
Boyden	6	O
chambers	8	O
.	1	O

Migration	9	O
of	2	O
U937	4	O
cells	5	O
was	3	O
increased	9	O
by	2	O
WY	2	B-Chemical
14643	5	I-Chemical
and	3	O
reduced	7	O
by	2	O
rosiglitazone	13	B-Chemical
.	1	O

Peritoneal	10	O
fluid	5	O
from	4	O
patients	8	O
with	4	O
endometriosis	13	B-Disease
activated	9	O
U937	4	O
cells	5	O
transiently	11	O
transfected	11	O
with	4	O
a	1	O
PPAR-alpha	10	B-Gene
/	1	I-Gene
GAL4	4	I-Gene
luciferase	10	O
reporter	8	O
.	1	O

By	2	O
contrast	8	O
,	1	O
peritoneal	10	O
fluid	5	O
did	3	O
not	3	O
cause	5	O
significant	11	O
activation	10	O
of	2	O
PPAR-gamma	10	B-Gene
/	1	I-Gene
GAL4	4	I-Gene
constructs	10	O
.	1	O

The	3	O
U937	4	O
cells	5	O
transiently	11	O
transfected	11	O
with	4	O
a	1	O
PPAR	4	B-Gene
response	8	I-Gene
element	7	I-Gene
luciferase	10	O
reporter	8	O
showed	6	O
disease	7	O
stage	5	O
-dependent	10	O
up-regulation	13	O
when	4	O
treated	7	O
with	4	O
peritoneal	10	O
fluid	5	O
from	4	O
patients	8	O
with	4	O
endometriosis	13	B-Disease
.	1	O

Treatment	9	O
with	4	O
peritoneal	10	O
fluid	5	O
from	4	O
healthy	7	O
controls	8	O
down	4	O
-regulated	10	O
PPAR	4	B-Gene
response	8	I-Gene
element	7	I-Gene
transactivation	15	O
.	1	O

We	2	O
conclude	8	O
that	4	O
peritoneal	10	O
fluid	5	O
of	2	O
endometriosis	13	B-Disease
patients	8	O
contains	8	O
activators	10	O
of	2	O
PPAR-alpha	10	B-Gene
that	4	O
stimulate	9	O
macrophage	10	O
chemotaxis	10	O
.	1	O

Inhibitors	10	O
of	2	O
PPAR-alpha	10	B-Gene
or	2	O
activators	10	O
of	2	O
PPAR-gamma	10	B-Gene
could	5	O
be	2	O
developed	9	O
for	3	O
the	3	O
treatment	9	O
of	2	O
inflammation	12	O
associated	10	O
with	4	O
endometriosis	13	B-Disease
.	1	O

Nuclear	7	B-Gene
factor-kappaB	13	I-Gene
suppressive	11	O
and	3	O
inhibitor-kappaB	16	B-Gene
stimulatory	11	O
effects	7	O
of	2	O
troglitazone	12	B-Chemical
in	2	O
obese	5	O
patients	8	O
with	4	O
type	4	B-Disease
2	1	I-Disease
diabetes	8	I-Disease
:	1	O
evidence	8	O
of	2	O
an	2	O
antiinflammatory	16	O
action	6	O
?	1	O

It	2	O
has	3	O
been	4	O
shown	5	O
recently	8	O
that	4	O
troglitazone	12	B-Chemical
exerts	6	O
an	2	O
anti-inflammatory	17	O
effect	6	O
,	1	O
in	2	O
vitro	5	O
,	1	O
and	3	O
in	2	O
experimental	12	O
animals	7	O
.	1	O

To	2	O
test	4	O
these	5	O
properties	10	O
in	2	O
humans	6	O
,	1	O
we	2	O
investigated	12	O
the	3	O
effect	6	O
of	2	O
troglitazone	12	B-Chemical
on	2	O
the	3	O
proinflammatory	15	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
nuclear	7	I-Gene
factor-kappaB	13	I-Gene
and	3	O
its	3	O
inhibitory	10	B-Gene
protein	7	I-Gene
IkappaB	7	I-Gene
in	2	O
mononuclear	11	O
cells	5	O
(	1	O
MNC	3	O
)	1	O
and	3	O
plasma	6	B-Gene
soluble	7	I-Gene
intracellular	13	I-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
,	1	O
monocyte	8	B-Gene
chemoattractant	15	I-Gene
protein-1	9	I-Gene
,	1	O
plasminogen	11	B-Gene
activator	9	I-Gene
inhibitor-1	11	I-Gene
,	1	O
and	3	O
C	1	B-Gene
-reactive	9	I-Gene
protein	7	I-Gene
.	1	O

We	2	O
also	4	O
examined	8	O
the	3	O
effect	6	O
of	2	O
troglitazone	12	B-Chemical
on	2	O
reactive	8	B-Chemical
oxygen	6	I-Chemical
species	7	I-Chemical
generation	10	O
,	1	O
p47	3	B-Gene
(	1	I-Gene
phox	4	I-Gene
)	1	I-Gene
subunit	7	I-Gene
expression	10	O
,	1	O
9-hydroxyoctadecadienoic	24	B-Chemical
acid	4	I-Chemical
(	1	O
9-HODE	6	B-Chemical
)	1	O
,	1	O
13-HODE	7	B-Chemical
,	1	O
o-tyrosine	10	B-Chemical
,	1	O
and	3	O
m-tyrosine	10	B-Chemical
in	2	O
obese	5	O
patients	8	O
with	4	O
type	4	B-Disease
2	1	I-Disease
diabetes	8	I-Disease
.	1	O

Seven	5	O
obese	5	O
patients	8	O
with	4	O
type	4	B-Disease
2	1	I-Disease
diabetes	8	I-Disease
were	4	O
treated	7	O
with	4	O
troglitazone	12	B-Chemical
(	1	O
400	3	O
mg	2	O
/	1	O
day	3	O
)	1	O
for	3	O
4	1	O
weeks	5	O
.	1	O

Blood	5	O
samples	7	O
were	4	O
obtained	8	O
at	2	O
weekly	6	O
intervals	9	O
.	1	O

Nuclear	7	B-Gene
factor-kappaB	13	I-Gene
binding	7	O
activity	8	O
in	2	O
MNC	3	O
nuclear	7	O
extracts	8	O
was	3	O
significantly	13	O
inhibited	9	O
after	5	O
troglitazone	12	B-Chemical
treatment	9	O
at	2	O
week	4	O
1	1	O
and	3	O
continued	9	O
to	2	O
be	2	O
inhibited	9	O
up	2	O
to	2	O
week	4	O
4	1	O
.	1	O

On	2	O
the	3	O
other	5	O
hand	4	O
,	1	O
IkappaB	7	B-Gene
protein	7	I-Gene
levels	6	O
increased	9	O
significantly	13	O
after	5	O
troglitazone	12	B-Chemical
treatment	9	O
at	2	O
week	4	O
1	1	O
,	1	O
and	3	O
this	4	O
increase	8	O
persisted	9	O
throughout	10	O
the	3	O
study	5	O
.	1	O

Plasma	6	B-Gene
monocyte	8	I-Gene
chemoattractant	15	I-Gene
protein-1	9	I-Gene
and	3	O
soluble	7	B-Gene
intracellular	13	I-Gene
adhesion	8	I-Gene
molecule-1	10	I-Gene
concentrations	14	O
did	3	O
not	3	O
decrease	8	O
significantly	13	O
after	5	O
troglitazone	12	B-Chemical
treatment	9	O
,	1	O
although	8	O
there	5	O
was	3	O
a	1	O
trend	5	O
toward	6	O
inhibition	10	O
.	1	O

Reactive	8	B-Chemical
oxygen	6	I-Chemical
species	7	I-Chemical
generation	10	O
by	2	O
polymorphonuclear	17	O
cells	5	O
and	3	O
MNC	3	O
,	1	O
p47	3	B-Gene
(	1	I-Gene
phox	4	I-Gene
)	1	I-Gene
subunit	7	I-Gene
protein	7	I-Gene
quantities	10	O
,	1	O
plasminogen	11	B-Gene
activator	9	I-Gene
inhibitor-1	11	I-Gene
,	1	O
and	3	O
C	1	B-Gene
-reactive	9	I-Gene
protein	7	I-Gene
levels	6	O
decreased	9	O
significantly	13	O
after	5	O
troglitazone	12	B-Chemical
intake	6	O
.	1	O

13-HODE	7	B-Chemical
/	1	O
linoleic	8	B-Chemical
acid	4	I-Chemical
and	3	O
9-HODE	6	B-Chemical
/	1	O
linoleic	8	B-Chemical
acid	4	I-Chemical
ratios	6	O
also	4	O
decreased	9	O
after	5	O
troglitazone	12	B-Chemical
intake	6	O
.	1	O

However	7	O
,	1	O
o-tyrosine	10	B-Chemical
/	1	O
phenylalanine	13	B-Chemical
and	3	O
m-tyrosine	10	B-Chemical
/	1	O
phenylalanine	13	B-Chemical
ratios	6	O
did	3	O
not	3	O
change	6	O
significantly	13	O
.	1	O

These	5	O
data	4	O
show	4	O
that	4	O
troglitazone	12	B-Chemical
has	3	O
profound	8	O
antiinflammatory	16	O
effects	7	O
in	2	O
addition	8	O
to	2	O
antioxidant	11	O
effects	7	O
in	2	O
obese	5	O
type	4	O
2	1	O
diabetics	9	O
;	1	O
these	5	O
effects	7	O
may	3	O
be	2	O
relevant	8	O
to	2	O
the	3	O
recently	8	O
described	9	O
beneficial	10	O
antiatherosclerotic	19	O
effects	7	O
of	2	O
troglitazone	12	B-Chemical
at	2	O
the	3	O
vascular	8	O
level	5	O
.	1	O

GRbeta	6	B-Gene
expression	10	O
in	2	O
nasal	5	B-Disease
polyp	5	I-Disease
inflammatory	12	O
cells	5	O
and	3	O
its	3	O
relationship	12	O
to	2	O
the	3	O
anti-inflammatory	17	O
effects	7	O
of	2	O
intranasal	10	O
fluticasone	11	B-Chemical
.	1	O

BACKGROUND	10	O
:	1	O
Nasal	5	B-Disease
polyposis	9	I-Disease
disease	7	I-Disease
is	2	O
an	2	O
inflammatory	12	O
disorder	8	O
with	4	O
intense	7	O
eosinophilic	12	O
infiltration	12	O
of	2	O
respiratory	11	O
mucosa	6	O
that	4	O
is	2	O
often	5	O
difficult	9	O
to	2	O
control	7	O
with	4	O
topical	7	O
steroids	8	B-Chemical
.	1	O

Recent	6	O
evidence	8	O
suggests	8	O
that	4	O
overexpression	14	O
of	2	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
splice	6	O
variant	7	O
GRbeta	6	B-Gene
in	2	O
inflammatory	12	O
cells	5	O
might	5	O
contribute	10	O
to	2	O
steroid	7	B-Chemical
insensitivity	13	O
in	2	O
diseases	8	O
such	4	O
as	2	O
asthma	6	B-Disease
.	1	O

OBJECTIVE	9	O
:	1	O
The	3	O
purposes	8	O
of	2	O
this	4	O
investigation	13	O
were	4	O
to	2	O
determine	9	O
whether	7	O
nasal	5	B-Disease
polyp	5	I-Disease
(	1	O
NP	2	B-Disease
)	1	O
inflammatory	12	O
cells	5	O
overexpress	11	O
GRbeta	6	B-Gene
and	3	O
to	2	O
examine	7	O
whether	7	O
GRbeta	6	B-Gene
overexpression	14	O
is	2	O
associated	10	O
with	4	O
insensitivity	13	O
to	2	O
the	3	O
potent	6	O
topical	7	O
steroid	7	O
fluticasone	11	B-Chemical
propionate	10	I-Chemical
(	1	O
FP	2	B-Chemical
)	1	O
.	1	O

METHODS	7	O
:	1	O
Biopsies	8	O
were	4	O
obtained	8	O
from	4	O
10	2	O
subjects	8	O
with	4	O
NPs	3	B-Disease
before	6	O
and	3	O
4	1	O
weeks	5	O
after	5	O
treatment	9	O
with	4	O
intranasal	10	O
FP	2	B-Chemical
.	1	O

Middle	6	O
turbinates	10	O
biopsies	8	O
from	4	O
6	1	O
healthy	7	O
,	1	O
nonallergic	11	O
subjects	8	O
served	6	O
as	2	O
normal	6	O
controls	8	O
.	1	O

Biopsies	8	O
were	4	O
immunostained	13	O
for	3	O
inflammatory	12	O
cell	4	O
markers	7	O
as	2	O
well	4	O
as	2	O
GRbeta	6	B-Gene
and	3	O
probed	6	O
for	3	O
various	7	O
cytokine	8	O
mRNA	4	O
.	1	O

The	3	O
anti-inflammatory	17	O
response	8	O
to	2	O
FP	2	B-Chemical
was	3	O
examined	8	O
in	2	O
relation	8	O
to	2	O
pretreatment	12	O
levels	6	O
of	2	O
GRbeta	6	B-Gene
expression	10	O
.	1	O

RESULTS	7	O
:	1	O
The	3	O
total	5	O
numbers	7	O
of	2	O
inflammatory	12	O
cells	5	O
were	4	O
increased	9	O
in	2	O
NPs	3	B-Disease
.	1	O

The	3	O
percentage	10	O
of	2	O
inflammatory	12	O
cells	5	O
expressing	10	O
GRbeta	6	B-Gene
was	3	O
also	4	O
increased	9	O
(	1	O
40.5	4	O
%	1	O
+	1	O
/	1	O
-	1	O
19.2	4	O
%	1	O
vs	2	O
16.1	4	O
%	1	O
+	1	O
/	1	O
-	1	O
4.0	3	O
%	1	O
,	1	O
P	1	O
=.009	5	O
)	1	O
.	1	O

GRbeta	6	B-Gene
expression	10	O
in	2	O
NPs	3	B-Disease
was	3	O
almost	6	O
exclusive	9	O
to	2	O
T	1	O
lymphocytes	11	O
,	1	O
eosinophils	11	O
,	1	O
and	3	O
macrophages	11	O
.	1	O

An	2	O
inverse	7	O
correlation	11	O
was	3	O
observed	8	O
between	7	O
the	3	O
baseline	8	O
inflammatory	12	O
cell	4	O
GRbeta	6	B-Gene
expression	10	O
and	3	O
the	3	O
reduction	9	O
after	5	O
FP	2	B-Chemical
treatment	9	O
in	2	O
EG2	3	O
-positive	9	O
eosinophils	11	O
,	1	O
CD4	3	B-Gene
-positive	9	O
T	1	O
lymphocytes	11	O
,	1	O
endothelial	11	O
VCAM-1	6	B-Gene
expression	10	O
,	1	O
and	3	O
IL-4	4	B-Gene
mRNA	4	I-Gene
-positive	9	O
cells	5	O
.	1	O

NPs	3	B-Disease
that	4	O
were	4	O
``	2	O
FP	2	B-Chemical
-insensitive	12	O
''in	4	O
terms	5	O
of	2	O
suppression	11	O
of	2	O
eosinophil	10	O
numbers	7	O
(	1	O
major	5	O
basic	5	O
protein	7	O
-positive	9	O
)	1	O
had	3	O
a	1	O
significantly	13	O
greater	7	O
percentage	10	O
of	2	O
GRbeta	6	B-Gene
-positive	9	O
inflammatory	12	O
cells	5	O
,	1	O
a	1	O
higher	6	O
ratio	5	O
of	2	O
GRbeta	6	B-Gene
-positive	9	O
/	1	O
GRalpha	7	B-Gene
-positive	9	O
cells	5	O
,	1	O
and	3	O
increased	9	O
numbers	7	O
of	2	O
GRbeta	6	B-Gene
-positive	9	O
eosinophils	11	O
and	3	O
macrophages	11	O
in	2	O
comparison	10	O
with	4	O
those	5	O
that	4	O
were	4	O
``	2	O
FP	2	B-Chemical
-sensitive	10	O
.	1	O

''	2	O

``	2	O
FP	2	B-Chemical
-insensitive	12	O
''NPs	5	B-Disease
also	4	O
demonstrated	12	O
a	1	O
higher	6	O
percentage	10	O
of	2	O
IL-5	4	B-Gene
-positive	9	O
inflammatory	12	O
cells	5	O
expressing	10	O
GRbeta	6	B-Gene
before	6	O
and	3	O
after	5	O
FP	2	B-Chemical
treatment	9	O
.	1	O

CONCLUSION	10	O
:	1	O
GRbeta	6	B-Gene
expression	10	O
appears	7	O
to	2	O
be	2	O
a	1	O
marker	6	O
of	2	O
steroid	7	B-Chemical
insensitivity	13	O
in	2	O
NPs	3	B-Disease
.	1	O

Expression	10	O
of	2	O
GRbeta	6	B-Gene
by	2	O
NP	2	B-Disease
inflammatory	12	O
cells	5	O
,	1	O
particularly	12	O
T	1	O
cells	5	O
and	3	O
eosinophils	11	O
,	1	O
might	5	O
render	6	O
them	4	O
resistant	9	O
to	2	O
suppression	11	O
by	2	O
topical	7	O
steroids	8	B-Chemical
and	3	O
thereby	7	O
contribute	10	O
to	2	O
persistent	10	O
NP	2	B-Disease
inflammation	12	O
.	1	O

Macrophage	10	O
stimulation	11	O
with	4	O
Murabutide	10	B-Chemical
,	1	O
an	2	O
HIV	3	O
-suppressive	12	O
muramyl	7	O
peptide	7	O
derivative	10	O
,	1	O
selectively	11	O
activates	9	O
extracellular	13	B-Gene
signal	6	I-Gene
-regulated	10	I-Gene
kinases	7	I-Gene
1	1	I-Gene
and	3	O
2	1	B-Partial_Gene
,	1	O
C	1	B-Gene
/	1	I-Gene
EBPbeta	7	I-Gene
and	3	O
STAT1	5	B-Gene
:	1	O
role	4	O
of	2	O
CD14	4	B-Gene
and	3	O
Toll	4	B-Gene
-like	5	I-Gene
receptors	9	I-Gene
2	1	I-Gene
and	3	O
4	1	B-Partial_Gene
.	1	O

The	3	O
smallest	8	O
unit	4	O
of	2	O
bacterial	9	O
peptidoglycans	14	O
known	5	O
to	2	O
be	2	O
endowed	7	O
with	4	O
biological	10	O
activities	10	O
is	2	O
muramyl	7	B-Chemical
dipeptide	9	I-Chemical
(	1	O
MDP	3	B-Chemical
)	1	O
.	1	O

A	1	O
clinically	10	O
acceptable	10	O
synthetic	9	O
derivative	10	O
of	2	O
MDP	3	B-Chemical
,	1	O
namely	6	O
murabutide	10	B-Chemical
(	1	O
MB	2	B-Chemical
)	1	O
,	1	O
has	3	O
been	4	O
found	5	O
to	2	O
present	7	O
interesting	11	O
pharmacological	15	O
properties	10	O
and	3	O
to	2	O
suppress	8	O
HIV-1	5	O
replication	11	O
in	2	O
monocyte	8	O
-derived	8	O
macrophages	11	O
(	1	O
MDM	3	O
)	1	O
.	1	O

We	2	O
have	4	O
addressed	9	O
the	3	O
signaling	9	O
events	6	O
activated	9	O
in	2	O
MDM	3	O
following	9	O
stimulation	11	O
with	4	O
either	6	O
MB	2	B-Chemical
or	2	O
the	3	O
potent	6	O
immunostimulant	15	O
LPS	3	B-Chemical
.	1	O

We	2	O
also	4	O
examined	8	O
whether	7	O
signaling	9	O
by	2	O
muramyl	7	B-Chemical
peptides	8	I-Chemical
involves	8	O
the	3	O
use	3	O
of	2	O
cell	4	O
surface	7	O
receptors	9	O
,	1	O
including	9	O
CD14	4	B-Gene
and	3	O
Toll	4	B-Gene
-like	5	I-Gene
receptor	8	I-Gene
2	1	I-Gene
(	1	O
TLR2	4	B-Gene
)	1	O
or	2	O
TLR4	4	B-Gene
that	4	O
are	3	O
known	5	O
to	2	O
be	2	O
signal	6	O
-transducing	12	O
receptors	9	O
for	3	O
other	5	O
bacterial	9	O
cell	4	O
wall	4	O
components	10	O
.	1	O

We	2	O
demonstrate	11	O
that	4	O
,	1	O
unlike	6	O
LPS	3	B-Chemical
,	1	O
the	3	O
safe	4	O
immunomodulator	15	O
MB	2	B-Chemical
selectively	11	O
activates	9	O
extracellular	13	B-Gene
signal	6	I-Gene
-regulated	10	I-Gene
kinases	7	I-Gene
(	1	I-Gene
Erk	3	I-Gene
)	1	I-Gene
1	1	I-Gene
/	1	I-Gene
2	1	I-Gene
,	1	O
in	2	O
the	3	O
absence	7	O
of	2	O
detectable	10	O
Jun	3	B-Gene
N-terminal	10	I-Gene
kinase	6	I-Gene
(	1	O
JNK	3	B-Gene
)	1	O
or	2	O
p38	3	B-Gene
mitogen	7	I-Gene
-activated	10	I-Gene
kinase	6	I-Gene
activation	10	O
.	1	O

Furthermore	11	O
,	1	O
STAT1	5	B-Gene
activation	10	O
but	3	O
weak	4	O
or	2	O
no	2	O
activation	10	O
of	2	O
STAT3	5	B-Gene
or	2	O
STAT5	5	B-Gene
respectively	12	O
,	1	O
could	5	O
be	2	O
detected	8	O
in	2	O
MB	2	B-Chemical
-stimulated	11	O
MDM	3	O
.	1	O

Using	5	O
MonoMac6	8	O
cells	5	O
,	1	O
we	2	O
observed	8	O
high	4	O
C	1	B-Gene
/	1	I-Gene
EBPbeta	7	I-Gene
and	3	O
AP-1	4	B-Gene
but	3	O
weaker	6	O
and	3	O
transient	9	O
NF-kappaB	9	B-Gene
activation	10	O
by	2	O
MB	2	B-Chemical
.	1	O

Moreover	8	O
,	1	O
the	3	O
truncated	9	O
form	4	O
of	2	O
C	1	B-Gene
/	1	I-Gene
EBPbeta	7	I-Gene
,	1	O
known	5	O
to	2	O
repress	7	O
HIV-1	5	O
transcription	13	O
,	1	O
was	3	O
detected	8	O
in	2	O
extracts	8	O
from	4	O
MB	2	B-Chemical
-treated	8	O
THP-1	5	O
cells	5	O
.	1	O

Surprisingly	12	O
,	1	O
neither	7	O
MB	2	B-Chemical
nor	3	O
MDP	3	B-Chemical
were	4	O
able	4	O
to	2	O
transduce	9	O
signals	7	O
via	3	O
CD14	4	B-Gene
and	3	O
TLR2	4	B-Gene
or	2	O
4	1	B-Partial_Gene
.	1	O

These	5	O
findings	8	O
present	7	O
major	5	O
differences	11	O
in	2	O
the	3	O
early	5	O
cell	4	O
activation	10	O
process	7	O
between	7	O
LPS	3	B-Chemical
and	3	O
muramyl	7	B-Chemical
peptides	8	I-Chemical
,	1	O
and	3	O
strongly	8	O
argue	5	O
for	3	O
the	3	O
implication	11	O
of	2	O
co-receptors	12	O
other	5	O
than	4	O
TLR2	4	B-Gene
and	3	O
TLR4	4	B-Gene
in	2	O
mediating	9	O
the	3	O
signaling	9	O
events	6	O
induced	7	O
by	2	O
defined	7	O
subunits	8	O
of	2	O
bacterial	9	O
peptidoglycans	14	O
.	1	O

Type	4	B-Gene
I	1	I-Gene
interferons	11	I-Gene
and	3	O
IL-12	5	B-Gene
:	1	O
convergence	11	O
and	3	O
cross-regulation	16	O
among	5	O
mediators	9	O
of	2	O
cellular	8	O
immunity	8	O
.	1	O

Therapeutic	11	O
use	3	O
of	2	O
type	4	B-Gene
I	1	I-Gene
IFN	3	I-Gene
(	1	O
IFN-alpha	9	B-Gene
/	1	I-Gene
beta	4	I-Gene
)	1	O
has	3	O
become	6	O
common	6	O
.	1	O

Many	4	O
of	2	O
the	3	O
diverse	7	O
diseases	8	O
targeted	8	O
are	3	O
marked	6	O
by	2	O
pathogenetic	12	O
abnormalities	13	O
in	2	O
cell	4	O
-mediated	9	O
immunity	8	O
(	1	O
CMI	3	O
)	1	O
,	1	O
these	5	O
cellular	8	O
immune	6	O
responses	9	O
either	6	O
causing	7	O
injury	6	O
to	2	O
the	3	O
host	4	O
,	1	O
lacking	7	O
sufficient	10	O
vigor	5	O
for	3	O
virus	5	O
or	2	O
tumor	5	B-Disease
clearance	9	O
,	1	O
or	2	O
both	4	O
.	1	O

In	2	O
general	7	O
,	1	O
therapeutic	11	O
efficacy	8	O
is	2	O
limited	7	O
.	1	O

It	2	O
is	2	O
thus	4	O
notable	7	O
that	4	O
the	3	O
pleiotropic	11	O
effects	7	O
of	2	O
type	4	B-Gene
I	1	I-Gene
IFN	3	I-Gene
on	2	O
CMI	3	O
remain	6	O
poorly	6	O
understood	10	O
.	1	O

We	2	O
characterized	13	O
the	3	O
effects	7	O
of	2	O
type	4	B-Gene
I	1	I-Gene
IFN	3	I-Gene
on	2	O
the	3	O
production	10	O
of	2	O
IL-12	5	B-Gene
,	1	O
the	3	O
central	7	O
immunoregulatory	16	O
cytokine	8	O
of	2	O
the	3	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
T	1	O
cell	4	O
arm	3	O
of	2	O
CMI	3	O
.	1	O

We	2	O
show	4	O
that	4	O
type	4	B-Gene
I	1	I-Gene
IFN	3	I-Gene
are	3	O
potent	6	O
inhibitors	10	O
of	2	O
IL-12	5	B-Gene
production	10	O
by	2	O
human	5	O
monocytes	9	O
/	1	O
macrophages	11	O
.	1	O

The	3	O
underlying	10	O
mechanism	9	O
involves	8	O
transcriptional	15	O
inhibition	10	O
of	2	O
the	3	O
IL-12p40	8	B-Gene
gene	4	I-Gene
,	1	O
marked	6	O
by	2	O
down-regulation	15	O
of	2	O
PU.1	4	B-Gene
binding	7	O
activity	8	O
at	2	O
the	3	O
upstream	8	O
Ets	3	B-Gene
site	4	O
of	2	O
the	3	O
IL-12p40	8	B-Gene
promoter	8	I-Gene
.	1	O

Type	4	B-Gene
I	1	I-Gene
IFN	3	I-Gene
have	4	O
previously	10	O
been	4	O
shown	5	O
to	2	O
be	2	O
able	4	O
to	2	O
substitute	10	O
for	3	O
IL-12	5	B-Gene
in	2	O
driving	7	O
IFN-gamma	9	B-Gene
production	10	O
from	4	O
T	1	O
and	3	O
NK	2	O
cells	5	O
.	1	O

The	3	O
ability	7	O
of	2	O
IFN-alpha	9	B-Gene
/	1	I-Gene
beta	4	I-Gene
to	2	O
suppress	8	O
IL-12	5	B-Gene
production	10	O
while	5	O
up	2	O
-regulating	11	O
IFN-gamma	9	B-Gene
production	10	O
suggests	8	O
a	1	O
possible	8	O
mechanistic	11	O
basis	5	O
for	3	O
the	3	O
difficulties	12	O
of	2	O
employing	9	O
these	5	O
cytokines	9	O
in	2	O
diseases	8	O
involving	9	O
abnormalities	13	O
of	2	O
CMI	3	O
.	1	O

Glucocorticoid	14	B-Chemical
-regulated	10	O
transcription	13	O
factors	7	O
.	1	O

Glucocorticoids	15	B-Chemical
are	3	O
the	3	O
most	4	O
effective	9	O
antiinflammatory	16	O
drugs	5	O
used	4	O
in	2	O
the	3	O
treatment	9	O
of	2	O
asthma	6	B-Disease
.	1	O

They	4	O
act	3	O
by	2	O
binding	7	O
to	2	O
a	1	O
specific	8	O
receptor	8	O
(	1	O
GR	2	B-Gene
)	1	O
that	4	O
,	1	O
upon	4	O
activation	10	O
,	1	O
translocates	12	O
to	2	O
the	3	O
nucleus	7	O
and	3	O
either	6	O
increases	9	O
(	1	O
transactivates	14	O
)	1	O
or	2	O
decreases	9	O
(	1	O
transrepresses	14	O
)	1	O
gene	4	O
expression	10	O
.	1	O

Inhibition	10	O
of	2	O
pro-inflammatory	16	O
transcription	13	O
factors	7	O
such	4	O
as	2	O
activator	9	B-Gene
protein	7	I-Gene
(	1	I-Gene
AP	2	I-Gene
)	1	I-Gene
-1	2	I-Gene
,	1	O
signal	6	B-Gene
transducers	11	I-Gene
and	3	I-Gene
activators	10	I-Gene
of	2	I-Gene
transcription	13	I-Gene
(	1	O
STATs	5	B-Gene
)	1	O
,	1	O
nuclear	7	B-Gene
factor	6	I-Gene
of	2	I-Gene
activated	9	I-Gene
T	1	I-Gene
cells	5	I-Gene
(	1	O
NFAT	4	B-Gene
)	1	O
and	3	O
nuclear	7	B-Gene
factor	6	I-Gene
(	1	I-Gene
NF	2	I-Gene
)	1	I-Gene
-kappa	6	I-Gene
B	1	I-Gene
is	2	O
thought	7	O
to	2	O
be	2	O
a	1	O
major	5	O
action	6	O
of	2	O
glucocorticoids	15	B-Chemical
.	1	O

Acetylation	11	O
of	2	O
histones	8	B-Gene
allows	6	O
unwinding	9	O
of	2	O
the	3	O
local	5	O
DNA	3	O
structure	9	O
and	3	O
enables	7	O
RNA	3	B-Gene
polymerase	10	I-Gene
II	2	I-Gene
to	2	O
enhance	7	O
gene	4	O
transcription	13	O
.	1	O

Histone	7	B-Gene
acetylation	11	O
is	2	O
regulated	9	O
by	2	O
a	1	O
balance	7	O
between	7	O
the	3	O
activity	8	O
of	2	O
histone	7	B-Gene
acetyltransferases	18	I-Gene
(	1	O
HATs	4	B-Gene
)	1	O
and	3	O
histone	7	B-Gene
deacetylases	12	I-Gene
(	1	O
HDACs	5	B-Gene
)	1	O
.	1	O

GR	2	B-Gene
acts	4	O
as	2	O
a	1	O
direct	6	O
inhibitor	9	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
-induced	8	O
HAT	3	B-Gene
activity	8	O
and	3	O
also	4	O
by	2	O
recruiting	10	O
HDAC2	5	B-Gene
to	2	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
/	1	I-Gene
HAT	3	I-Gene
complex	7	I-Gene
.	1	O

A	1	O
sub-group	9	O
of	2	O
patients	8	O
with	4	O
glucocorticoid	14	B-Chemical
-insensitive	12	O
asthma	6	B-Disease
have	4	O
an	2	O
inability	9	O
to	2	O
induce	6	O
histone	7	B-Gene
acetylation	11	O
in	2	O
response	8	O
to	2	O
dexamethasone	13	B-Chemical
suggesting	10	O
reduced	7	O
expression	10	O
of	2	O
a	1	O
GR-specific	11	B-Gene
HAT	3	B-Gene
.	1	O

This	4	O
suggests	8	O
that	4	O
pharmacological	15	O
manipulation	12	O
of	2	O
specific	8	O
histone	7	B-Gene
acetylation	11	O
status	6	O
is	2	O
a	1	O
potentially	11	O
useful	6	O
approach	8	O
for	3	O
the	3	O
treatment	9	O
of	2	O
inflammatory	12	O
diseases	8	O
.	1	O

Identification	14	O
of	2	O
the	3	O
precise	7	O
mechanism	9	O
by	2	O
which	5	O
activated	9	O
GR	2	B-Gene
recruits	8	O
HDAC2	5	B-Gene
may	3	O
reveal	6	O
new	3	O
targets	7	O
for	3	O
the	3	O
development	11	O
of	2	O
drugs	5	O
that	4	O
may	3	O
dissociate	10	O
the	3	O
antiinflammatory	16	O
actions	7	O
of	2	O
glucocorticoids	15	B-Chemical
from	4	O
their	5	O
side	4	O
effects	7	O
that	4	O
are	3	O
largely	7	O
due	3	O
to	2	O
gene	4	O
induction	9	O
.	1	O

Copyright	9	O
Academic	8	O
Press	5	O
.	1	O

Targeting	9	O
of	2	O
p300	4	B-Gene
to	2	O
the	3	O
interleukin-2	13	B-Gene
promoter	8	I-Gene
via	3	O
CREB-Rel	8	B-Gene
cross-talk	10	O
during	6	O
mitogen	7	O
and	3	O
oncogenic	9	O
molecular	9	O
signaling	9	O
in	2	O
activated	9	O
T-cells	7	O
.	1	O

In	2	O
this	4	O
report	6	O
,	1	O
we	2	O
explore	7	O
the	3	O
mechanisms	10	O
of	2	O
targeting	9	O
of	2	O
p300	4	B-Gene
to	2	O
the	3	O
interleukin-2	13	B-Gene
(	1	I-Gene
IL-2	4	I-Gene
)	1	I-Gene
promoter	8	I-Gene
in	2	O
response	8	O
to	2	O
mitogenic	9	O
and	3	O
oncogenic	9	O
molecular	9	O
signals	7	O
.	1	O

Recruitment	11	O
of	2	O
p300	4	B-Gene
by	2	O
cAMP	4	B-Gene
-responsive	11	I-Gene
element	7	I-Gene
-binding	8	I-Gene
protein-Rel	11	I-Gene
cross-talk	10	O
at	2	O
the	3	O
composite	9	O
CD28	4	B-Gene
response	8	I-Gene
element	7	I-Gene
(	1	O
CD28RE	6	O
)	1	O
-	1	O
TRE	3	O
element	7	O
of	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
is	2	O
essential	9	O
for	3	O
promoter	8	O
inducibility	12	O
during	6	O
T-cell	6	O
activation	10	O
,	1	O
and	3	O
CD28RE-TRE	10	B-Gene
is	2	O
the	3	O
exclusive	9	O
target	6	O
of	2	O
the	3	O
human	5	B-Gene
T-cell	6	I-Gene
lymphotropic	12	I-Gene
virus	5	I-Gene
type	4	I-Gene
I	1	I-Gene
oncoprotein	11	I-Gene
Tax	3	I-Gene
.	1	O

The	3	O
intrinsic	9	O
histone	7	B-Gene
acetyltransferase	17	I-Gene
activity	8	O
of	2	O
p300	4	B-Gene
is	2	O
dispensable	11	O
for	3	O
activation	10	O
of	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
,	1	O
and	3	O
the	3	O
N-terminal	10	O
743	3	O
residues	8	O
contain	7	O
the	3	O
minimal	7	O
structural	10	O
requirements	12	O
for	3	O
synergistic	11	O
transactivation	15	O
of	2	O
the	3	O
CD28RE-TRE	10	B-Gene
,	1	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
,	1	O
and	3	O
endogenous	10	B-Gene
IL-2	4	I-Gene
gene	4	I-Gene
expression	10	O
.	1	O

Mutational	10	O
analysis	8	O
of	2	O
p300	4	B-Gene
reveals	7	O
differential	12	O
structural	10	O
requirements	12	O
for	3	O
the	3	O
N-terminal	10	O
p300	4	B-Gene
module	6	O
by	2	O
individual	10	O
cis	3	O
-elements	9	O
within	6	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
.	1	O

These	5	O
findings	8	O
provide	7	O
evidence	8	O
that	4	O
p300	4	B-Gene
assembles	9	O
at	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
to	2	O
form	4	O
an	2	O
enhanceosome	12	O
-like	5	O
signal	6	O
transduction	12	O
target	6	O
that	4	O
is	2	O
centrally	9	O
integrated	10	O
at	2	O
the	3	O
CD28RE-TRE	10	B-Gene
element	7	O
of	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
through	7	O
specific	8	O
protein	7	O
module	6	O
-targeted	9	O
associations	12	O
in	2	O
activated	9	O
T-cells	7	O
.	1	O

Cot	3	B-Gene
kinase	6	I-Gene
induces	7	O
cyclooxygenase-2	16	B-Gene
expression	10	O
in	2	O
T	1	O
cells	5	O
through	7	O
activation	10	O
of	2	O
the	3	O
nuclear	7	B-Gene
factor	6	I-Gene
of	2	I-Gene
activated	9	I-Gene
T	1	I-Gene
cells	5	I-Gene
.	1	O

Cyclooxygenase-2	16	B-Gene
(	1	O
COX-2	5	B-Gene
)	1	O
is	2	O
induced	7	O
in	2	O
human	5	O
T	1	O
lymphocytes	11	O
upon	4	O
T	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
triggering	10	O
.	1	O

Here	4	O
we	2	O
report	6	O
that	4	O
Cot	3	B-Gene
kinase	6	I-Gene
,	1	O
a	1	O
mitogen	7	B-Gene
-activated	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
kinase	6	I-Gene
kinase	6	I-Gene
involved	8	O
in	2	O
T	1	O
cell	4	O
activation	10	O
,	1	O
up-regulates	12	O
COX-2	5	B-Gene
gene	4	I-Gene
expression	10	O
in	2	O
Jurkat	6	O
T	1	O
cells	5	O
.	1	O

Induction	9	O
of	2	O
COX-2	5	B-Gene
promoter	8	I-Gene
activity	8	O
by	2	O
Cot	3	B-Gene
kinase	6	I-Gene
occurred	8	O
mainly	6	O
through	7	O
activation	10	O
of	2	O
the	3	O
nuclear	7	B-Gene
factor	6	I-Gene
of	2	I-Gene
activated	9	I-Gene
T	1	I-Gene
cells	5	I-Gene
(	1	O
NFAT	4	B-Gene
)	1	O
.	1	O

Mutation	8	O
of	2	O
the	3	O
distal	6	O
(	1	O
-105	4	O
/	1	O
-97	3	O
)	1	O
and	3	O
proximal	8	O
(	1	O
-76	3	O
/	1	O
-61	3	O
)	1	O
NFAT	4	B-Gene
response	8	I-Gene
elements	8	I-Gene
in	2	O
the	3	O
COX-2	5	B-Gene
promoter	8	I-Gene
abolished	9	O
the	3	O
activation	10	O
induced	7	O
by	2	O
Cot	3	B-Gene
kinase	6	I-Gene
.	1	O

Even	4	O
more	4	O
,	1	O
coexpression	12	O
of	2	O
a	1	O
dominant	8	O
negative	8	O
version	7	O
of	2	O
NFAT	4	B-Gene
inhibited	9	O
Cot	3	B-Gene
kinase	6	I-Gene
-mediated	9	O
COX-2	5	B-Gene
promoter	8	I-Gene
activation	10	O
,	1	O
whereas	7	O
cotransfection	14	O
of	2	O
a	1	O
constitutively	14	O
active	6	O
version	7	O
of	2	O
the	3	O
calcium	7	B-Gene
-dependent	10	I-Gene
phosphatase	11	I-Gene
calcineurin	11	I-Gene
synergizes	10	O
with	4	O
Cot	3	B-Gene
kinase	6	I-Gene
in	2	O
the	3	O
up-regulation	13	O
of	2	O
COX-2	5	B-Gene
promoter	8	I-Gene
-driven	7	O
transcription	13	O
.	1	O

Strikingly	10	O
,	1	O
Cot	3	B-Gene
kinase	6	I-Gene
increased	9	O
transactivation	15	O
mediated	8	O
by	2	O
a	1	O
GAL4-NFAT	9	B-Gene
fusion	6	I-Gene
protein	7	I-Gene
containing	10	O
the	3	O
N-terminal	10	O
transactivation	15	O
domain	6	O
of	2	O
NFATp	5	B-Gene
.	1	O

In	2	O
contrast	8	O
to	2	O
phorbol	7	B-Chemical
ester	5	I-Chemical
plus	4	O
calcium	7	B-Chemical
ionophore	9	O
A23187	6	B-Chemical
,	1	O
Cot	3	B-Gene
kinase	6	I-Gene
increases	9	O
both	4	O
COX-2	5	B-Gene
promoter	8	I-Gene
activity	8	O
and	3	O
NFAT	4	B-Gene
-mediated	9	O
transactivation	15	O
in	2	O
a	1	O
cyclosporin	11	B-Chemical
A	1	I-Chemical
-independent	12	O
manner	6	O
.	1	O

These	5	O
data	4	O
indicate	8	O
that	4	O
Cot	3	B-Gene
kinase	6	I-Gene
up-regulates	12	O
COX-2	5	B-Gene
promoter	8	I-Gene
-driven	7	O
transcription	13	O
through	7	O
the	3	O
NFAT	4	B-Gene
response	8	I-Gene
elements	8	I-Gene
,	1	O
being	5	O
the	3	O
Cot	3	B-Gene
kinase	6	I-Gene
-induced	8	O
NFAT	4	B-Gene
-dependent	10	O
transactivation	15	O
presumably	10	O
implicated	10	O
in	2	O
this	4	O
up-regulation	13	O
.	1	O

Invariant	9	O
chain	5	O
induces	7	O
B	1	O
cell	4	O
maturation	10	O
by	2	O
activating	10	O
a	1	O
TAF	3	B-Gene
(	1	I-Gene
II	2	I-Gene
)	1	I-Gene
105-NF-kappaB	13	I-Gene
-dependent	10	O
transcription	13	O
program	7	O
.	1	O

Early	5	O
stages	6	O
of	2	O
B	1	O
cell	4	O
development	11	O
occur	5	O
in	2	O
the	3	O
bone	4	O
marrow	6	O
,	1	O
resulting	9	O
in	2	O
formation	9	O
of	2	O
immature	8	O
B	1	O
cells	5	O
.	1	O

From	4	O
there	5	O
these	5	O
immature	8	O
cells	5	O
migrate	7	O
to	2	O
the	3	O
spleen	6	O
where	5	O
they	4	O
differentiate	13	O
to	2	O
mature	6	O
cells	5	O
.	1	O

This	4	O
final	5	O
maturation	10	O
step	4	O
is	2	O
crucial	7	O
for	3	O
the	3	O
B	1	O
cells	5	O
to	2	O
become	6	O
responsive	10	O
to	2	O
antigens	8	O
and	3	O
to	2	O
participate	11	O
in	2	O
the	3	O
immune	6	O
response	8	O
.	1	O

Recently	8	O
,	1	O
invariant	9	O
chain	5	O
(	1	O
Ii	2	O
)	1	O
,	1	O
a	1	O
major	5	B-Gene
histocompatibility	18	I-Gene
complex	7	I-Gene
class	5	I-Gene
II	2	I-Gene
chaperone	9	I-Gene
,	1	O
as	2	O
well	4	O
as	2	O
the	3	O
transcription	13	B-Gene
factors	7	I-Gene
c-Rel	5	I-Gene
and	3	O
p65	3	B-Gene
/	1	I-Gene
RelA	4	I-Gene
,	1	O
were	4	O
found	5	O
to	2	O
play	4	O
a	1	O
role	4	O
in	2	O
the	3	O
final	5	O
antigen	7	O
-independent	12	O
differentiation	15	O
stage	5	O
of	2	O
B	1	O
cells	5	O
in	2	O
the	3	O
spleen	6	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
we	2	O
investigated	12	O
a	1	O
possible	8	O
link	4	O
between	7	O
Ii	2	O
-dependent	10	O
B	1	O
cell	4	O
maturation	10	O
and	3	O
the	3	O
NF-kappaB	9	B-Gene
pathway	7	O
.	1	O

Our	3	O
studies	7	O
indicate	8	O
that	4	O
Ii	2	O
-induced	8	O
B	1	O
cell	4	O
maturation	10	O
involves	8	O
activation	10	O
of	2	O
transcription	13	O
mediated	8	O
by	2	O
the	3	O
NF-kappaB	9	B-Gene
p65	3	I-Gene
/	1	I-Gene
RelA	4	I-Gene
homodimer	9	O
and	3	O
requires	8	O
the	3	O
B	1	B-Gene
cell	4	I-Gene
-enriched	9	I-Gene
coactivator	11	I-Gene
TBP	3	I-Gene
-associated	11	I-Gene
factor	6	I-Gene
(	1	I-Gene
II	2	I-Gene
)	1	I-Gene
105	3	I-Gene
.	1	O

Constitutively	14	O
activated	9	B-Gene
Akt-1	5	I-Gene
is	2	O
vital	5	O
for	3	O
the	3	O
survival	8	O
of	2	O
human	5	O
monocyte	8	O
-differentiated	15	O
macrophages	11	O
.	1	O

Role	4	O
of	2	O
Mcl-1	5	B-Gene
,	1	O
independent	11	O
of	2	O
nuclear	7	B-Gene
factor	6	I-Gene
(	1	I-Gene
NF	2	I-Gene
)	1	I-Gene
-kappaB	7	I-Gene
,	1	O
Bad	3	B-Gene
,	1	O
or	2	O
caspase	7	B-Gene
activation	10	O
.	1	O

Recent	6	O
data	4	O
from	4	O
mice	4	O
deficient	9	O
for	3	O
phosphatase	11	B-Gene
and	3	I-Gene
tensin	6	I-Gene
homologue	9	I-Gene
deleted	7	O
from	4	O
chromosome	10	O
10	2	O
or	2	O
src	3	B-Gene
homology	8	I-Gene
2	1	I-Gene
domain	6	I-Gene
-containing	11	I-Gene
5	1	I-Gene
'inositol	9	I-Gene
phosphatase	11	I-Gene
,	1	O
phosphatases	12	B-Gene
that	4	O
negatively	10	O
regulate	8	O
the	3	O
phosphatidylinositol	20	B-Gene
3-kinase	8	I-Gene
(	1	O
PI3K	4	B-Gene
)	1	O
pathway	7	O
,	1	O
revealed	8	O
an	2	O
increased	9	O
number	6	O
of	2	O
macrophages	11	O
in	2	O
these	5	O
animals	7	O
,	1	O
suggesting	10	O
an	2	O
essential	9	O
role	4	O
for	3	O
the	3	O
PI3K	4	B-Gene
pathway	7	O
for	3	O
macro-phage	11	O
survival	8	O
.	1	O

Here	4	O
,	1	O
we	2	O
focused	7	O
on	2	O
the	3	O
role	4	O
of	2	O
the	3	O
PI3K	4	B-Gene
-regulated	10	O
serine	6	B-Gene
/	1	I-Gene
threonine	9	I-Gene
kinase	6	I-Gene
Akt-1	5	I-Gene
in	2	O
modulating	10	O
macrophage	10	O
survival	8	O
.	1	O

Akt-1	5	B-Gene
was	3	O
constitutively	14	O
activated	9	O
in	2	O
human	5	O
macrophages	11	O
and	3	O
addition	8	O
of	2	O
the	3	O
PI3K	4	B-Gene
inhibitor	9	O
,	1	O
LY294002	8	B-Chemical
,	1	O
suppressed	10	O
the	3	O
activation	10	O
of	2	O
Akt-1	5	B-Gene
and	3	O
induced	7	O
cell	4	O
death	5	O
.	1	O

Furthermore	11	O
,	1	O
suppression	11	O
of	2	O
Akt-1	5	B-Gene
by	2	O
inhibition	10	O
of	2	O
PI3K	4	B-Gene
or	2	O
a	1	O
dominant	8	O
negative	8	O
(	1	O
DN	2	O
)	1	O
Akt-1	5	B-Gene
resulted	8	O
in	2	O
loss	4	O
of	2	O
mitochondrial	13	O
transmembrane	13	O
potential	9	O
,	1	O
activation	10	O
of	2	O
caspases-9	10	B-Gene
and	3	O
-3	2	B-Partial_Gene
,	1	O
and	3	O
DNA	3	O
fragmentation	13	O
.	1	O

The	3	O
effects	7	O
of	2	O
PI3K	4	B-Gene
inhibition	10	O
were	4	O
reversed	8	O
by	2	O
the	3	O
ectopic	7	O
expression	10	O
of	2	O
constitutively	14	O
activated	9	B-Gene
Akt-1	5	I-Gene
or	2	O
Bcl-x	5	B-Gene
(	1	I-Gene
L	1	I-Gene
)	1	I-Gene
.	1	O

Inhibition	10	O
of	2	O
PI3K	4	B-Gene
/	1	I-Gene
Akt-1	5	I-Gene
pathway	7	O
either	6	O
by	2	O
LY294002	8	B-Chemical
or	2	O
DN	2	O
Akt-1	5	B-Gene
had	3	O
no	2	O
effect	6	O
on	2	O
the	3	O
constitutive	12	O
or	2	O
inducible	9	O
activation	10	O
of	2	O
nuclear	7	B-Gene
factor	6	I-Gene
(	1	I-Gene
NF	2	I-Gene
)	1	I-Gene
-kappaB	7	I-Gene
in	2	O
human	5	O
macrophages	11	O
.	1	O

However	7	O
,	1	O
after	5	O
inhibition	10	O
of	2	O
the	3	O
PI3K	4	B-Gene
/	1	I-Gene
Akt-1	5	I-Gene
pathway	7	O
,	1	O
a	1	O
marked	6	O
decrease	8	O
in	2	O
the	3	O
expression	10	O
of	2	O
the	3	O
antiapoptotic	13	O
molecule	8	O
Mcl-1	5	B-Gene
,	1	O
but	3	O
not	3	O
other	5	O
Bcl-2	5	B-Gene
family	6	I-Gene
members	7	O
was	3	O
observed	8	O
,	1	O
and	3	O
Mcl-1	5	B-Gene
rescued	7	O
macrophages	11	O
from	4	O
LY294002	8	B-Chemical
-induced	8	O
cell	4	O
death	5	O
.	1	O

Further	7	O
,	1	O
inhibition	10	O
of	2	O
Mcl-1	5	B-Gene
by	2	O
antisense	9	O
oligonucleotides	16	O
,	1	O
also	4	O
resulted	8	O
in	2	O
macrophage	10	O
apoptosis	9	O
.	1	O

Thus	4	O
,	1	O
our	3	O
findings	8	O
demonstrate	11	O
that	4	O
the	3	O
constitutive	12	O
activation	10	O
of	2	O
Akt-1	5	B-Gene
regulates	9	O
macrophage	10	O
survival	8	O
through	7	O
Mcl-1	5	B-Gene
,	1	O
which	5	O
is	2	O
independent	11	O
of	2	O
caspases	8	B-Gene
,	1	O
NF-kappaB	9	B-Gene
,	1	O
or	2	O
Bad	3	B-Gene
.	1	O

Regulation	10	O
of	2	O
interleukin	11	B-Gene
(	1	I-Gene
IL	2	I-Gene
)	1	I-Gene
-18	3	I-Gene
receptor	8	I-Gene
alpha	5	I-Gene
chain	5	I-Gene
expression	10	O
on	2	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
T	1	O
cells	5	O
during	6	O
T	1	O
helper	6	O
(	1	O
Th	2	O
)	1	O
1	1	O
/	1	O
Th2	3	O
differentiation	15	O
.	1	O

Critical	8	O
downregulatory	14	O
role	4	O
of	2	O
IL-4	4	B-Gene
.	1	O

Interleukin	11	B-Gene
(	1	I-Gene
IL	2	I-Gene
)	1	I-Gene
-18	3	I-Gene
has	3	O
been	4	O
well	4	O
characterized	13	O
as	2	O
a	1	O
costimulatory	13	O
factor	6	O
for	3	O
the	3	O
induction	9	O
of	2	O
IL-12	5	B-Gene
-mediated	9	O
interferon	10	B-Gene
(	1	I-Gene
IFN	3	I-Gene
)	1	I-Gene
-gamma	6	I-Gene
production	10	O
by	2	O
T	1	O
helper	6	O
(	1	O
Th	2	O
)	1	O
1	1	O
cells	5	O
,	1	O
but	3	O
also	4	O
can	3	O
induce	6	O
IL-4	4	B-Gene
production	10	O
and	3	O
thus	4	O
facilitate	10	O
the	3	O
differentiation	15	O
of	2	O
Th2	3	O
cells	5	O
.	1	O

To	2	O
determine	9	O
the	3	O
mechanisms	10	O
by	2	O
which	5	O
IL-18	5	B-Gene
might	5	O
regulate	8	O
these	5	O
diametrically	13	O
distinct	8	O
immune	6	O
responses	9	O
,	1	O
we	2	O
have	4	O
analyzed	8	O
the	3	O
role	4	O
of	2	O
cytokines	9	O
in	2	O
the	3	O
regulation	10	O
of	2	O
IL-18	5	B-Gene
receptor	8	I-Gene
alpha	5	I-Gene
chain	5	I-Gene
(	1	O
IL-18Ralpha	11	B-Gene
)	1	O
expression	10	O
.	1	O

The	3	O
majority	8	O
of	2	O
peripheral	10	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
T	1	O
cells	5	O
constitutively	14	O
expressed	9	O
the	3	O
IL-18Ralpha	11	B-Gene
.	1	O

Upon	4	O
antigen	7	O
stimulation	11	O
in	2	O
the	3	O
presence	8	O
of	2	O
IL-12	5	B-Gene
,	1	O
marked	6	O
enhancement	11	O
of	2	O
IL-18Ralpha	11	B-Gene
expression	10	O
was	3	O
observed	8	O
.	1	O

IL-12	5	B-Gene
-mediated	9	O
upregulation	12	O
of	2	O
IL-18Ralpha	11	B-Gene
required	8	O
IFN-gamma	9	B-Gene
.	1	O

Activated	9	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
T	1	O
cells	5	O
that	4	O
expressed	9	O
low	3	O
levels	6	O
of	2	O
IL-18Ralpha	11	B-Gene
could	5	O
produce	7	O
IFN-gamma	9	B-Gene
when	4	O
stimulated	10	O
with	4	O
the	3	O
combination	11	O
of	2	O
IL-12	5	B-Gene
and	3	O
IL-18	5	B-Gene
,	1	O
while	5	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
cells	5	O
which	5	O
expressed	9	O
high	4	O
levels	6	O
of	2	O
IL-18Ralpha	11	B-Gene
could	5	O
respond	7	O
to	2	O
IL-18	5	B-Gene
alone	5	O
.	1	O

In	2	O
contrast	8	O
,	1	O
T	1	O
cell	4	O
stimulation	11	O
in	2	O
the	3	O
presence	8	O
of	2	O
IL-4	4	B-Gene
resulted	8	O
in	2	O
a	1	O
downregulation	14	O
of	2	O
IL-18Ralpha	11	B-Gene
expression	10	O
.	1	O

Both	4	O
IL-4	4	B-Gene
(	1	O
-	1	O
/	1	O
)	1	O
-	1	O
and	3	O
signal	6	B-Gene
transducer	10	I-Gene
and	3	I-Gene
activator	9	I-Gene
of	2	I-Gene
transcription	13	I-Gene
(	1	I-Gene
Stat	4	I-Gene
)	1	I-Gene
6	1	I-Gene
(	1	O
-	1	O
/	1	O
)	1	O
-	1	O
T	1	O
cells	5	O
expressed	9	O
higher	6	O
levels	6	O
of	2	O
IL-18Ralpha	11	B-Gene
after	5	O
TCR	3	B-Gene
stimulation	11	O
.	1	O

Furthermore	11	O
,	1	O
activated	9	O
T	1	O
cells	5	O
from	4	O
Stat6	5	B-Gene
(	1	O
-	1	O
/	1	O
)	1	O
-	1	O
mice	4	O
produced	8	O
more	4	O
IFN-gamma	9	B-Gene
in	2	O
response	8	O
to	2	O
IL-18	5	B-Gene
than	4	O
wild-type	9	O
controls	8	O
.	1	O

Thus	4	O
,	1	O
positive	8	O
/	1	O
negative	8	O
regulation	10	O
of	2	O
the	3	O
IL-18Ralpha	11	B-Gene
by	2	O
the	3	O
major	5	O
inductive	9	O
cytokines	9	O
(	1	O
IL-12	5	B-Gene
and	3	O
IL-4	4	B-Gene
)	1	O
determines	10	O
the	3	O
capacity	8	O
of	2	O
IL-18	5	B-Gene
to	2	O
polarize	8	O
an	2	O
immune	6	O
response	8	O
.	1	O

Dendritic	9	O
cell	4	O
development	11	O
from	4	O
common	6	O
myeloid	7	O
progenitors	11	O
.	1	O

Dendritic	9	O
cells	5	O
(	1	O
DCs	3	O
)	1	O
are	3	O
professional	12	O
antigen	7	O
-presenting	11	O
cells	5	O
which	5	O
both	4	O
initiate	8	O
adaptive	8	O
immune	6	O
responses	9	O
and	3	O
control	7	O
tolerance	9	O
to	2	O
self-antigens	13	O
.	1	O

It	2	O
has	3	O
been	4	O
suggested	9	O
that	4	O
these	5	O
different	9	O
effects	7	O
on	2	O
responder	9	O
cells	5	O
depend	6	O
on	2	O
subsets	7	O
of	2	O
DCs	3	O
arising	7	O
from	4	O
either	6	O
myeloid	7	O
or	2	O
lymphoid	8	O
hematopoietic	13	O
origins	7	O
.	1	O

In	2	O
this	4	O
model	5	O
,	1	O
CD8	3	B-Gene
alpha+	6	I-Gene
Mac-1-	6	I-Gene
DCs	3	O
are	3	O
supposed	8	O
to	2	O
be	2	O
of	2	O
lymphoid	8	O
while	5	O
CD8	3	B-Gene
alpha-	6	I-Gene
Mac-1+	6	I-Gene
DCs	3	O
are	3	O
supposed	8	O
to	2	O
be	2	O
of	2	O
myeloid	7	O
origin	6	O
.	1	O

Here	4	O
we	2	O
summarize	9	O
our	3	O
findings	8	O
that	4	O
both	4	O
CD8	3	B-Gene
alpha+	6	I-Gene
and	3	O
CD8	3	B-Gene
alpha-	6	I-Gene
DCs	3	O
can	3	O
arise	5	O
from	4	O
clonogenic	10	O
common	6	O
myeloid	7	O
progenitors	11	O
(	1	O
CMPs	4	O
)	1	O
in	2	O
both	4	O
thymus	6	O
and	3	O
spleen	6	O
.	1	O

Therefore	9	O
CD8	3	B-Gene
alpha	5	I-Gene
expression	10	O
DCs	3	O
does	4	O
not	3	O
indicate	8	O
a	1	O
lymphoid	8	O
origin	6	O
and	3	O
differences	11	O
among	5	O
CD8	3	B-Gene
alpha+	6	I-Gene
and	3	O
CD8	3	B-Gene
alpha-	6	I-Gene
DCs	3	O
might	5	O
rather	6	O
reflect	7	O
maturation	10	O
status	6	O
than	4	O
ontogeny	8	O
.	1	O

On	2	O
the	3	O
basis	5	O
of	2	O
transplantation	15	O
studies	7	O
,	1	O
it	2	O
seems	5	O
likely	6	O
that	4	O
most	4	O
of	2	O
the	3	O
DCs	3	O
in	2	O
secondary	9	O
lymphoid	8	O
organs	6	O
and	3	O
a	1	O
substantial	11	O
fraction	8	O
of	2	O
thymic	6	O
DCs	3	O
are	3	O
myeloid	7	O
-derived	8	O
.	1	O

Down-regulation	15	O
of	2	O
TDT	3	B-Gene
transcription	13	O
in	2	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
CD8	3	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
thymocytes	10	O
by	2	O
Ikaros	6	B-Gene
proteins	8	I-Gene
in	2	O
direct	6	O
competition	11	O
with	4	O
an	2	O
Ets	3	B-Gene
activator	9	I-Gene
.	1	O

Ikaros	6	B-Gene
is	2	O
a	1	O
unique	6	O
regulator	9	O
of	2	O
lymphopoiesis	13	O
that	4	O
associates	10	O
with	4	O
pericentromeric	15	O
heterochromatin	15	O
and	3	O
has	3	O
been	4	O
implicated	10	O
in	2	O
heritable	9	O
gene	4	O
inactivation	12	O
.	1	O

Binding	7	O
and	3	O
competition	11	O
experiments	11	O
demonstrate	11	O
that	4	O
Ikaros	6	B-Gene
dimers	6	O
compete	7	O
with	4	O
an	2	O
Ets	3	B-Gene
activator	9	I-Gene
for	3	O
occupancy	9	O
of	2	O
the	3	O
lymphocyte-specific	19	B-Gene
TdT	3	I-Gene
promoter	8	I-Gene
.	1	O

Mutations	9	O
that	4	O
selectively	11	O
disrupt	7	O
Ikaros	6	B-Gene
binding	7	O
to	2	O
an	2	O
integrated	10	O
TdT	3	B-Gene
promoter	8	I-Gene
had	3	O
no	2	O
effect	6	O
on	2	O
promoter	8	O
function	8	O
in	2	O
a	1	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
CD8	3	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
thymocyte	9	O
line	4	O
.	1	O

However	7	O
,	1	O
these	5	O
mutations	9	O
abolished	9	O
down-regulation	15	O
on	2	O
differentiation	15	O
,	1	O
providing	9	O
evidence	8	O
that	4	O
Ikaros	6	B-Gene
plays	5	O
a	1	O
direct	6	O
role	4	O
in	2	O
repression	10	O
.	1	O

Reduced	7	O
access	6	O
to	2	O
restriction	11	O
enzyme	6	O
cleavage	8	O
suggested	9	O
that	4	O
chromatin	9	O
alterations	11	O
accompany	9	O
down-regulation	15	O
.	1	O

The	3	O
Ikaros	6	B-Gene
-dependent	10	O
down-regulation	15	O
event	5	O
and	3	O
the	3	O
observed	8	O
chromatin	9	O
alterations	11	O
appear	6	O
to	2	O
precede	7	O
pericentromeric	15	O
repositioning	13	O
.	1	O

Current	7	O
models	6	O
propose	7	O
that	4	O
the	3	O
functions	9	O
of	2	O
Ikaros	6	B-Gene
should	6	O
be	2	O
disrupted	9	O
by	2	O
a	1	O
small	5	O
isoform	7	O
that	4	O
retains	7	O
the	3	O
dimerization	12	O
domain	6	O
and	3	O
lacks	5	O
the	3	O
DNA	3	O
-binding	8	O
domain	6	O
.	1	O

Surprisingly	12	O
,	1	O
in	2	O
the	3	O
CD4	3	B-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
CD8	3	I-Gene
(	1	I-Gene
+	1	I-Gene
)	1	I-Gene
thymocyte	9	O
line	4	O
,	1	O
overexpression	14	O
of	2	O
a	1	O
small	5	O
Ikaros	6	B-Gene
isoform	7	I-Gene
had	3	O
no	2	O
effect	6	O
on	2	O
differentiation	15	O
or	2	O
on	2	O
the	3	O
pericentromeric	15	O
targeting	9	O
and	3	O
DNA	3	O
-binding	8	O
properties	10	O
of	2	O
Ikaros	6	B-Gene
.	1	O

Rather	6	O
,	1	O
the	3	O
small	5	O
isoform	7	O
assembled	9	O
into	4	O
multimeric	10	O
complexes	9	O
with	4	O
DNA-bound	9	O
Ikaros	6	B-Gene
at	2	O
the	3	O
pericentromeric	15	O
foci	4	O
.	1	O

The	3	O
capacity	8	O
for	3	O
in	2	O
vivo	4	O
multimer	8	O
formation	9	O
suggests	8	O
that	4	O
interactions	12	O
between	7	O
Ikaros	6	B-Gene
dimers	6	O
bound	5	O
to	2	O
the	3	O
TdT	3	B-Gene
promoter	8	I-Gene
and	3	O
those	5	O
bound	5	O
to	2	O
pericentromeric	15	O
repeat	6	O
sequences	9	O
may	3	O
contribute	10	O
to	2	O
the	3	O
pericentromeric	15	O
repositioning	13	O
of	2	O
the	3	O
inactive	8	O
gene	4	O
.	1	O

CD28	4	B-Gene
costimulation	13	O
is	2	O
required	8	O
not	3	O
only	4	O
to	2	O
induce	6	O
IL-12	5	B-Gene
receptor	8	I-Gene
but	3	O
also	4	O
to	2	O
render	6	O
janus	5	B-Gene
kinases	7	I-Gene
/	1	I-Gene
STAT4	5	I-Gene
responsive	10	O
to	2	O
IL-12	5	B-Gene
stimulation	11	O
in	2	O
TCR	3	B-Gene
-triggered	10	O
T	1	O
cells	5	O
.	1	O

The	3	O
activation	10	O
of	2	O
resting	7	O
T	1	O
cells	5	O
for	3	O
the	3	O
acquisition	11	O
of	2	O
various	7	O
functions	9	O
depends	7	O
on	2	O
whether	7	O
CD28	4	B-Gene
costimulatory	13	O
signals	7	O
are	3	O
provided	8	O
upon	4	O
T	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
stimulation	11	O
.	1	O

Here	4	O
,	1	O
we	2	O
investigated	12	O
how	3	O
CD28	4	B-Gene
costimulation	13	O
functions	9	O
to	2	O
allow	5	O
TCR	3	B-Gene
-triggered	10	O
resting	7	O
T	1	O
cells	5	O
to	2	O
acquire	7	O
IL-12	5	B-Gene
responsiveness	14	O
.	1	O

When	4	O
T	1	O
cells	5	O
are	3	O
stimulated	10	O
with	4	O
low	3	O
doses	5	O
of	2	O
anti-CD3	8	B-Gene
mAb	3	I-Gene
,	1	O
CD28	4	B-Gene
costimulation	13	O
was	3	O
required	8	O
for	3	O
the	3	O
optimal	7	O
levels	6	O
of	2	O
IL-12	5	B-Gene
receptor	8	I-Gene
(	1	O
IL-12R	6	B-Gene
)	1	O
expression	10	O
.	1	O

However	7	O
,	1	O
stimulation	11	O
of	2	O
T	1	O
cells	5	O
with	4	O
high	4	O
doses	5	O
of	2	O
anti-CD3	8	B-Gene
alone	5	O
induced	7	O
comparable	10	O
levels	6	O
of	2	O
IL-12R	6	B-Gene
expression	10	O
to	2	O
those	5	O
induced	7	O
upon	4	O
CD28	4	B-Gene
costimulation	13	O
.	1	O

Nevertheless	12	O
,	1	O
there	5	O
was	3	O
a	1	O
substantial	11	O
difference	10	O
in	2	O
IL-12	5	B-Gene
responsiveness	14	O
between	7	O
these	5	O
two	3	O
groups	6	O
of	2	O
T	1	O
cells	5	O
:	1	O
compared	8	O
to	2	O
anti-CD28	9	B-Gene
-costimulated	13	O
T	1	O
cells	5	O
,	1	O
T	1	O
cells	5	O
that	4	O
were	4	O
not	3	O
costimulated	12	O
with	4	O
anti-CD28	9	B-Gene
exhibited	9	O
decreased	9	O
levels	6	O
of	2	O
Janus	5	B-Gene
kinases	7	I-Gene
(	1	I-Gene
JAK	3	I-Gene
)	1	I-Gene
JAK2	4	I-Gene
/	1	I-Gene
TYK2	4	I-Gene
and	3	O
STAT4	5	B-Gene
phosphorylation	15	O
and	3	O
IFN-y	5	B-Gene
production	10	O
following	9	O
IL-12	5	B-Gene
stimulation	11	O
.	1	O

Importantly	11	O
,	1	O
STAT6	5	B-Gene
phosphorylation	15	O
following	9	O
IL-4	4	B-Gene
stimulation	11	O
was	3	O
not	3	O
decreased	9	O
in	2	O
anti-CD28	9	B-Gene
-uncostimulated	15	O
T	1	O
cells	5	O
.	1	O

These	5	O
resutls	7	O
indicate	8	O
that	4	O
CD28	4	B-Gene
costimulation	13	O
not	3	O
only	4	O
contributes	11	O
to	2	O
up	2	O
-regulating	11	O
IL-12R	6	B-Gene
expression	10	O
but	3	O
is	2	O
also	4	O
required	8	O
to	2	O
render	6	O
JAKs	4	B-Gene
/	1	I-Gene
STAT4	5	I-Gene
responsive	10	O
to	2	O
IL-12	5	B-Gene
stimulation	11	O
.	1	O

Single	6	O
dose	4	O
intranasal	10	O
administration	14	O
of	2	O
retinal	7	O
autoantigen	11	O
generates	9	O
a	1	O
rapid	5	O
accumulation	12	O
and	3	O
cell	4	O
activation	10	O
in	2	O
draining	8	O
lymph	5	O
node	4	O
and	3	O
spleen	6	O
:	1	O
implications	12	O
for	3	O
tolerance	9	O
therapy	7	O
.	1	O

BACKGROUND	10	O
/	1	O
AIMS	4	O
:	1	O
A	1	O
single	6	O
intranasal	10	O
delivery	8	O
of	2	O
retinal	7	O
autoantigen	11	O
suppresses	10	O
effectively	11	O
experimental	12	O
autoimmune	10	O
uveoretinitis	13	O
(	1	O
EAU	3	O
)	1	O
.	1	O

To	2	O
further	7	O
unravel	7	O
underlying	10	O
mechanisms	10	O
the	3	O
authors	7	O
wished	6	O
to	2	O
determine	9	O
,	1	O
firstly	7	O
,	1	O
the	3	O
kinetics	8	O
of	2	O
antigen	7	O
delivery	8	O
and	3	O
,	1	O
secondly	8	O
,	1	O
the	3	O
early	5	O
cellular	8	O
responses	9	O
involved	8	O
in	2	O
the	3	O
initial	7	O
stages	6	O
of	2	O
nasal	5	O
mucosal	7	O
tolerance	9	O
induction	9	O
.	1	O

METHODS	7	O
:	1	O
Flow	4	O
cytometry	9	O
,	1	O
cell	4	O
proliferation	13	O
assays	6	O
,	1	O
and	3	O
microscopy	10	O
were	4	O
used	4	O
to	2	O
track	5	O
antigen	7	O
following	9	O
a	1	O
single	6	O
,	1	O
intranasal	10	O
dose	4	O
of	2	O
Alexa-488	9	O
labelled	8	O
retinal	7	O
antigen	7	O
.	1	O

RESULTS	7	O
:	1	O
A	1	O
rapid	5	O
accumulation	12	O
of	2	O
antigen	7	O
within	6	O
both	4	O
superficial	11	O
cervical	8	O
lymph	5	O
nodes	5	O
(	1	O
SCLN	4	O
)	1	O
and	3	O
spleen	6	O
was	3	O
observed	8	O
after	5	O
30	2	O
minutes	7	O
.	1	O

Significant	11	O
proliferative	13	O
responses	9	O
to	2	O
IRBP	4	B-Gene
were	4	O
elicited	8	O
by	2	O
48	2	O
hours	5	O
indicating	10	O
that	4	O
systemic	8	O
priming	7	O
of	2	O
naive	5	O
T	1	O
cells	5	O
to	2	O
retinal	7	O
antigen	7	O
had	3	O
occurred	8	O
.	1	O

Cell	4	O
activation	10	O
was	3	O
further	7	O
confirmed	9	O
by	2	O
immunoprecipitation	19	O
studies	7	O
,	1	O
which	5	O
demonstrated	12	O
phosphorylation	15	O
of	2	O
STAT4	5	B-Gene
but	3	O
not	3	O
STAT6	5	B-Gene
in	2	O
both	4	O
lymph	5	O
nodes	5	O
and	3	O
spleen	6	O
.	1	O

However	7	O
,	1	O
at	2	O
24	2	O
hours	5	O
,	1	O
STAT4	5	B-Gene
heterodimerisation	18	O
with	4	O
STAT	4	B-Gene
3	1	I-Gene
was	3	O
only	4	O
observed	8	O
in	2	O
spleen	6	O
.	1	O

CONCLUSIONS	11	O
:	1	O
The	3	O
results	7	O
provide	7	O
novel	5	O
evidence	8	O
that	4	O
following	9	O
a	1	O
single	6	O
intranasal	10	O
application	11	O
rapid	5	O
transfer	8	O
of	2	O
antigen	7	O
occurs	6	O
.	1	O

Resulting	9	O
T	1	O
cell	4	O
proliferation	13	O
develops	8	O
consequent	10	O
to	2	O
differential	12	O
cell	4	O
signalling	10	O
in	2	O
SCLN	4	O
and	3	O
spleen	6	O
.	1	O

Further	7	O
understanding	13	O
of	2	O
these	5	O
underlying	10	O
cellular	8	O
mechanisms	10	O
,	1	O
in	2	O
particular	10	O
as	2	O
is	2	O
inferred	8	O
by	2	O
the	3	O
results	7	O
the	3	O
contribution	12	O
of	2	O
local	5	O
versus	6	O
systemic	8	O
tolerance	9	O
induction	9	O
,	1	O
may	3	O
assist	6	O
in	2	O
strategies	10	O
to	2	O
clinically	10	O
apply	5	O
mucosal	7	O
tolerance	9	O
therapy	7	O
successfully	12	O
.	1	O

Identification	14	O
of	2	O
phosphorylation	15	O
sites	5	O
for	3	O
Bruton	6	B-Gene
's	2	I-Gene
tyrosine	8	I-Gene
kinase	6	I-Gene
within	6	O
the	3	O
transcriptional	15	B-Gene
regulator	9	I-Gene
BAP	3	I-Gene
/	1	I-Gene
TFII-I	6	I-Gene
.	1	O

Bruton	6	B-Gene
's	2	I-Gene
tyrosine	8	I-Gene
kinase	6	I-Gene
(	1	O
Btk	3	B-Gene
)	1	O
,	1	O
a	1	O
member	6	O
of	2	O
the	3	O
Tec	3	B-Gene
family	6	I-Gene
of	2	O
cytosolic	9	O
kinases	7	O
,	1	O
is	2	O
essential	9	O
for	3	O
B	1	O
cell	4	O
development	11	O
and	3	O
function	8	O
.	1	O

BAP	3	B-Gene
/	1	I-Gene
TFII-I	6	I-Gene
,	1	O
a	1	O
protein	7	O
implicated	10	O
in	2	O
transcriptional	15	O
regulation	10	O
,	1	O
is	2	O
associated	10	O
with	4	O
Btk	3	B-Gene
in	2	O
B	1	O
cells	5	O
and	3	O
is	2	O
transiently	11	O
phosphorylated	14	O
on	2	O
tyrosine	8	B-Chemical
following	9	O
B	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
engagement	10	O
.	1	O

BAP	3	B-Gene
/	1	I-Gene
TFII-I	6	I-Gene
is	2	O
a	1	O
substrate	9	O
for	3	O
Btk	3	B-Gene
in	2	O
vitro	5	O
and	3	O
is	2	O
hyperphosphorylated	19	O
on	2	O
tyrosine	8	B-Chemical
upon	4	O
coexpression	12	O
with	4	O
Btk	3	B-Gene
in	2	O
mammalian	9	O
cells	5	O
.	1	O

In	2	O
an	2	O
effort	6	O
to	2	O
understand	10	O
the	3	O
physiologic	11	O
consequences	12	O
of	2	O
BAP	3	B-Gene
/	1	I-Gene
TFII-I	6	I-Gene
tyrosine	8	B-Chemical
phosphorylation	15	O
following	9	O
B	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
stimulation	11	O
,	1	O
site	4	O
-directed	9	O
mutagenesis	11	O
and	3	O
phosphopeptide	14	O
mapping	7	O
were	4	O
used	4	O
to	2	O
locate	6	O
the	3	O
predominant	11	O
sites	5	O
of	2	O
BAP	3	B-Gene
/	1	I-Gene
TFII-I	6	I-Gene
phosphorylation	15	O
by	2	O
Btk	3	B-Gene
in	2	O
vitro	5	O
.	1	O

These	5	O
residues	8	O
,	1	O
Tyr248	6	B-Chemical
,	1	O
Tyr357	6	B-Chemical
,	1	O
and	3	O
Tyr462	6	B-Chemical
,	1	O
were	4	O
also	4	O
found	5	O
to	2	O
be	2	O
the	3	O
major	5	O
sites	5	O
for	3	O
Btk	3	B-Gene
-dependent	10	O
phosphorylation	15	O
of	2	O
BAP	3	B-Gene
/	1	I-Gene
TFII-I	6	I-Gene
in	2	O
vivo	4	O
.	1	O

Residues	8	O
Tyr357	6	B-Chemical
and	3	O
Tyr462	6	B-Chemical
are	3	O
contained	9	O
within	6	O
the	3	O
loop	4	O
regions	7	O
of	2	O
adjacent	8	O
helix-loop-helix	16	O
-like	5	O
repeats	7	O
within	6	O
BAP	3	B-Gene
/	1	I-Gene
TFII-I	6	I-Gene
.	1	O

Mutation	8	O
of	2	O
either	6	O
Tyr248	6	B-Chemical
,	1	O
Tyr357	6	B-Chemical
,	1	O
or	2	O
Tyr462	6	B-Chemical
to	2	O
phenylalanine	13	B-Chemical
reduced	7	O
transcription	13	O
from	4	O
a	1	O
c-fos	5	B-Gene
promoter	8	I-Gene
relative	8	O
to	2	O
wild-type	9	O
BAP	3	B-Gene
/	1	I-Gene
TFII-I	6	I-Gene
in	2	O
transfected	11	O
COS-7	5	O
cells	5	O
,	1	O
consistent	10	O
with	4	O
the	3	O
interpretation	14	O
that	4	O
phosphorylation	15	O
at	2	O
these	5	O
sites	5	O
contributes	11	O
to	2	O
transcriptional	15	O
activation	10	O
.	1	O

Phosphorylation	15	O
of	2	O
BAP	3	B-Gene
/	1	I-Gene
TFII-I	6	I-Gene
by	2	O
Btk	3	B-Gene
may	3	O
link	4	O
engagement	10	O
of	2	O
receptors	9	O
such	4	O
as	2	O
surface	7	B-Gene
immunoglobulin	14	I-Gene
to	2	O
modulation	10	O
of	2	O
gene	4	O
expression	10	O
.	1	O

Activation	10	O
of	2	O
the	3	O
p21	3	B-Gene
(	1	I-Gene
CIP1	4	I-Gene
/	1	I-Gene
WAF1	4	I-Gene
)	1	I-Gene
promoter	8	I-Gene
by	2	O
bone	4	B-Gene
morphogenetic	13	I-Gene
protein-2	9	I-Gene
in	2	O
mouse	5	O
B	1	O
lineage	7	O
cells	5	O
.	1	O

BMPs	4	B-Gene
exert	5	O
a	1	O
negative	8	O
growth	6	O
effect	6	O
on	2	O
various	7	O
types	5	O
of	2	O
cells	5	O
.	1	O

We	2	O
have	4	O
previously	10	O
reported	8	O
that	4	O
BMP-2	5	B-Gene
inhibited	9	O
the	3	O
growth	6	O
of	2	O
HS-72	5	O
mouse	5	O
hybridoma	9	O
cells	5	O
by	2	O
inducing	8	O
p21	3	B-Gene
(	1	O
CIP1	4	B-Gene
/	1	I-Gene
WAF1	4	I-Gene
)	1	O
expression	10	O
.	1	O

In	2	O
the	3	O
present	7	O
study	5	O
,	1	O
we	2	O
demonstrated	12	O
that	4	O
BMP-2	5	B-Gene
activated	9	O
the	3	O
mouse	5	B-Gene
p21	3	I-Gene
(	1	I-Gene
CIP1	4	I-Gene
/	1	I-Gene
WAF1	4	I-Gene
)	1	I-Gene
promoter	8	I-Gene
in	2	O
HS-72	5	O
cells	5	O
,	1	O
and	3	O
that	4	O
a	1	O
29-base	7	O
pair	4	O
(	1	O
b	1	O
)	1	O
region	6	O
of	2	O
the	3	O
promoter	8	O
(	1	O
-1928	5	O
/	1	O
-1900	5	O
relative	8	O
to	2	O
the	3	O
TATA	4	O
box	3	O
)	1	O
,	1	O
conserved	9	O
between	7	O
mice	4	O
and	3	O
humans	6	O
,	1	O
was	3	O
responsive	10	O
to	2	O
BMP-2	5	B-Gene
as	2	O
well	4	O
as	2	O
expression	10	O
of	2	O
Smad1	5	B-Gene
,	1	O
Smad4	5	B-Gene
,	1	O
and	3	O
constitutively	14	O
active	6	O
mutants	7	O
of	2	O
BMP	3	B-Gene
type	4	I-Gene
I	1	I-Gene
receptors	9	I-Gene
.	1	O

Furthermore	11	O
,	1	O
an	2	O
oligonucleotide	15	O
containing	10	O
the	3	O
29-b	4	O
region	6	O
was	3	O
found	5	O
to	2	O
be	2	O
associated	10	O
with	4	O
Smad4	5	B-Gene
and	3	O
phosphorylated	14	B-Gene
Smad1	5	I-Gene
in	2	O
the	3	O
nuclear	7	O
extract	7	O
of	2	O
BMP-2	5	B-Gene
-stimulated	11	O
HS-72	5	O
cells	5	O
.	1	O

These	5	O
results	7	O
suggested	9	O
that	4	O
BMP-2	5	B-Gene
might	5	O
activate	8	O
p21	3	B-Gene
(	1	O
CIP1	4	B-Gene
/	1	I-Gene
WAF1	4	I-Gene
)	1	O
transcription	13	O
by	2	O
inducing	8	O
a	1	O
binding	7	O
of	2	O
Smad4	5	B-Gene
and	3	O
Smad1	5	B-Gene
to	2	O
the	3	O
29-b	4	O
region	6	O
in	2	O
HS-72	5	O
cells	5	O
.	1	O

TRAIL	5	B-Gene
/	1	I-Gene
Apo2L	5	I-Gene
ligand	6	I-Gene
selectively	11	O
induces	7	O
apoptosis	9	O
and	3	O
overcomes	9	O
drug	4	O
resistance	10	O
in	2	O
multiple	8	B-Disease
myeloma	7	I-Disease
:	1	O
therapeutic	11	O
applications	12	O
.	1	O

Multiple	8	B-Disease
myeloma	7	I-Disease
(	1	O
MM	2	B-Disease
)	1	O
remains	7	O
incurable	9	O
and	3	O
novel	5	O
treatments	10	O
are	3	O
urgently	8	O
needed	6	O
.	1	O

Preclinical	11	O
in	2	O
vitro	5	O
and	3	O
in	2	O
vivo	4	O
evaluations	11	O
were	4	O
performed	9	O
to	2	O
assess	6	O
the	3	O
potential	9	O
therapeutic	11	O
applications	12	O
of	2	O
human	5	B-Gene
recombinant	11	I-Gene
tumor	5	I-Gene
necrosis	8	I-Gene
factor	6	I-Gene
(	1	I-Gene
TNF	3	I-Gene
)	1	I-Gene
-related	8	I-Gene
apoptosis	9	I-Gene
-inducing	9	I-Gene
ligand	6	I-Gene
/	1	I-Gene
Apo2	4	I-Gene
ligand	6	I-Gene
(	1	O
TRAIL	5	B-Gene
/	1	I-Gene
Apo2L	5	I-Gene
)	1	O
in	2	O
MM	2	B-Disease
.	1	O

TRAIL	5	B-Gene
/	1	I-Gene
Apo2L	5	I-Gene
potently	8	O
induced	7	O
apoptosis	9	O
of	2	O
MM	2	B-Disease
cells	5	O
from	4	O
patients	8	O
and	3	O
the	3	O
majority	8	O
of	2	O
MM	2	B-Disease
cell	4	O
lines	5	O
,	1	O
including	9	O
cells	5	O
sensitive	9	O
or	2	O
resistant	9	O
to	2	O
dexamethasone	13	B-Chemical
(	1	O
Dex	3	B-Chemical
)	1	O
,	1	O
doxorubicin	11	B-Chemical
(	1	O
Dox	3	B-Chemical
)	1	O
,	1	O
melphalan	9	B-Chemical
,	1	O
and	3	O
mitoxantrone	12	B-Chemical
.	1	O

TRAIL	5	B-Gene
/	1	I-Gene
Apo2L	5	I-Gene
also	4	O
overcame	8	O
the	3	O
survival	8	O
effect	6	O
of	2	O
interleukin	11	B-Gene
6	1	I-Gene
on	2	O
MM	2	B-Disease
cells	5	O
and	3	O
did	3	O
not	3	O
affect	6	O
the	3	O
survival	8	O
of	2	O
peripheral	10	O
blood	5	O
and	3	O
bone	4	O
marrow	6	O
mononuclear	11	O
cells	5	O
and	3	O
purified	8	O
B	1	O
cells	5	O
from	4	O
healthy	7	O
donors	6	O
.	1	O

The	3	O
status	6	O
of	2	O
the	3	O
TRAIL	5	B-Gene
receptors	9	I-Gene
(	1	O
assessed	8	O
by	2	O
immunoblotting	14	O
and	3	O
flow	4	O
cytometry	9	O
)	1	O
could	5	O
not	3	O
predict	7	O
TRAIL	5	B-Gene
sensitivity	11	O
of	2	O
MM	2	B-Disease
cells	5	O
.	1	O

The	3	O
anti-MM	7	B-Disease
activity	8	O
of	2	O
TRAIL	5	B-Gene
/	1	I-Gene
Apo2L	5	I-Gene
was	3	O
confirmed	9	O
in	2	O
nu	2	O
/	1	O
xid	3	O
/	1	O
bg	2	O
mice	4	O
xenografted	11	O
with	4	O
human	5	O
MM	2	B-Disease
cells	5	O
;	1	O
TRAIL	5	B-Gene
(	1	O
500	3	O
microg	6	O
intraperitoneally	17	O
daily	5	O
for	3	O
14	2	O
days	4	O
)	1	O
was	3	O
well	4	O
tolerated	9	O
and	3	O
significantly	13	O
suppressed	10	O
the	3	O
growth	6	O
of	2	O
plasmacytomas	13	O
.	1	O

Dox	3	B-Chemical
up	2	O
-regulated	10	O
the	3	O
expression	10	O
of	2	O
the	3	O
TRAIL	5	B-Gene
receptor	8	I-Gene
death	5	I-Gene
receptor	8	I-Gene
5	1	I-Gene
(	1	O
DR5	3	B-Gene
)	1	O
and	3	O
synergistically	15	O
enhanced	8	O
the	3	O
effect	6	O
of	2	O
TRAIL	5	B-Gene
not	3	O
only	4	O
against	7	O
MM	2	B-Disease
cells	5	O
sensitive	9	O
to	2	O
,	1	O
but	3	O
also	4	O
against	7	O
those	5	O
resistant	9	O
to	2	O
,	1	O
Dex-	4	B-Chemical
or	2	O
Dox	3	B-Chemical
-induced	8	O
apoptosis	9	O
.	1	O

Nuclear	7	B-Gene
factor	6	I-Gene
(	1	I-Gene
NF	2	I-Gene
)	1	I-Gene
-kappaB	7	I-Gene
inhibitors	10	O
,	1	O
such	4	O
as	2	O
SN50	4	B-Chemical
(	1	O
a	1	O
cell-permeable	14	O
inhibitor	9	O
of	2	O
the	3	O
nuclear	7	O
translocation	13	O
and	3	O
transcriptional	15	O
activity	8	O
of	2	O
NF-kappaB	9	B-Gene
)	1	O
or	2	O
the	3	O
proteasome	10	O
inhibitor	9	O
PS-341	6	B-Chemical
,	1	O
enhanced	8	O
the	3	O
proapoptotic	12	O
activity	8	O
of	2	O
TRAIL	5	B-Gene
/	1	I-Gene
Apo2L	5	I-Gene
against	7	O
TRAIL	5	B-Gene
-sensitive	10	O
MM	2	B-Disease
cells	5	O
,	1	O
whereas	7	O
SN50	4	B-Chemical
reversed	8	O
the	3	O
TRAIL	5	B-Gene
resistance	10	O
of	2	O
ARH-77	6	O
and	3	O
IM-9	4	O
MM	2	B-Disease
cells	5	O
.	1	O

Importantly	11	O
,	1	O
normal	6	O
B	1	O
lymphocytes	11	O
were	4	O
not	3	O
sensitized	10	O
to	2	O
TRAIL	5	B-Gene
by	2	O
either	6	O
Dox	3	B-Chemical
,	1	O
SN50	4	B-Chemical
,	1	O
or	2	O
PS-341	6	B-Chemical
.	1	O

These	5	O
preclinical	11	O
studies	7	O
suggest	7	O
that	4	O
TRAIL	5	B-Gene
/	1	I-Gene
Apo2L	5	I-Gene
can	3	O
overcome	8	O
conventional	12	O
drug	4	O
resistance	10	O
and	3	O
provide	7	O
the	3	O
basis	5	O
for	3	O
clinical	8	O
trials	6	O
of	2	O
TRAIL	5	B-Gene
-based	6	O
treatment	9	O
regimens	8	O
to	2	O
improve	7	O
outcome	7	O
in	2	O
patients	8	O
with	4	O
MM	2	B-Disease
.	1	O

(	1	O
Blood.	6	O
2001	4	O
;	1	O
98	2	O
:	1	O
795-804	7	O
)	1	O

HTLV-1	6	B-Gene
p12	3	I-Gene
(	1	I-Gene
I	1	I-Gene
)	1	I-Gene
protein	7	I-Gene
enhances	8	O
STAT5	5	B-Gene
activation	10	O
and	3	O
decreases	9	O
the	3	O
interleukin-2	13	B-Gene
requirement	11	O
for	3	O
proliferation	13	O
of	2	O
primary	7	O
human	5	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
.	1	O

The	3	O
p12	3	B-Gene
(	1	I-Gene
I	1	I-Gene
)	1	I-Gene
protein	7	I-Gene
,	1	O
encoded	7	O
by	2	O
the	3	O
pX	2	O
open	4	O
reading	7	O
frame	5	O
I	1	O
of	2	O
the	3	O
human	5	O
T-lymphotropic	14	O
virus	5	O
type	4	O
1	1	O
(	1	O
HTLV-1	6	O
)	1	O
,	1	O
is	2	O
a	1	O
hydrophobic	11	O
protein	7	O
that	4	O
localizes	9	O
to	2	O
the	3	O
endoplasmic	11	O
reticulum	9	O
and	3	O
the	3	O
Golgi	5	O
.	1	O

Although	8	O
p12	3	B-Gene
(	1	I-Gene
I	1	I-Gene
)	1	I-Gene
contains	8	O
4	1	O
minimal	7	O
proline-rich	12	B-Chemical
,	1	O
src	3	B-Gene
homology	8	O
3	1	O
-binding	8	O
motifs	6	O
(	1	O
PXXP	4	O
)	1	O
,	1	O
a	1	O
characteristic	14	O
commonly	8	O
found	5	O
in	2	O
proteins	8	O
involved	8	O
in	2	O
signaling	9	O
pathways	8	O
,	1	O
it	2	O
has	3	O
not	3	O
been	4	O
known	5	O
whether	7	O
p12	3	B-Gene
(	1	I-Gene
I	1	I-Gene
)	1	I-Gene
has	3	O
a	1	O
role	4	O
in	2	O
modulating	10	O
intracellular	13	O
signaling	9	O
pathways	8	O
.	1	O

This	4	O
study	5	O
demonstrated	12	O
that	4	O
p12	3	B-Gene
(	1	I-Gene
I	1	I-Gene
)	1	I-Gene
binds	5	O
to	2	O
the	3	O
cytoplasmic	11	O
domain	6	O
of	2	O
the	3	O
interleukin-2	13	B-Gene
receptor	8	I-Gene
(	1	I-Gene
IL-2R	5	I-Gene
)	1	I-Gene
beta	4	I-Gene
chain	5	I-Gene
that	4	O
is	2	O
involved	8	O
in	2	O
the	3	O
recruitment	11	O
of	2	O
the	3	O
Jak1	4	B-Gene
and	3	O
Jak3	4	B-Gene
kinases	7	I-Gene
.	1	O

As	2	O
a	1	O
result	6	O
of	2	O
this	4	O
interaction	11	O
,	1	O
p12	3	B-Gene
(	1	I-Gene
I	1	I-Gene
)	1	I-Gene
increases	9	O
signal	6	B-Gene
transducers	11	I-Gene
and	3	I-Gene
activators	10	I-Gene
of	2	I-Gene
transcription	13	I-Gene
5	1	I-Gene
(	1	O
STAT5	5	B-Gene
)	1	O
DNA	3	O
binding	7	O
and	3	O
transcriptional	15	O
activity	8	O
and	3	O
this	4	O
effect	6	O
depends	7	O
on	2	O
the	3	O
presence	8	O
of	2	O
both	4	O
IL-2R	5	B-Gene
beta	4	I-Gene
and	3	O
gamma	5	B-Partial_Gene
(	1	I-Partial_Gene
c	1	I-Partial_Gene
)	1	I-Partial_Gene
chains	6	I-Partial_Gene
and	3	O
Jak3	4	B-Gene
.	1	O

Transduction	12	O
of	2	O
primary	7	O
human	5	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
(	1	O
PBMCs	5	O
)	1	O
with	4	O
a	1	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
-based	6	O
retroviral	10	O
vector	6	O
expressing	10	O
p12	3	B-Gene
(	1	I-Gene
I	1	I-Gene
)	1	I-Gene
also	4	O
resulted	8	O
in	2	O
increased	9	O
STAT5	5	B-Gene
phosphorylation	15	O
and	3	O
DNA	3	O
binding	7	O
.	1	O

However	7	O
,	1	O
p12	3	B-Gene
(	1	I-Gene
I	1	I-Gene
)	1	I-Gene
could	5	O
increase	8	O
proliferation	13	O
of	2	O
human	5	O
PBMCs	5	O
only	4	O
after	5	O
stimulation	11	O
of	2	O
T-cell	6	B-Gene
receptors	9	I-Gene
by	2	O
treatment	9	O
of	2	O
cells	5	O
with	4	O
low	3	O
concentrations	14	O
of	2	O
alphaCD3	8	B-Gene
and	3	O
alphaCD28	9	B-Gene
antibodies	10	I-Gene
.	1	O

In	2	O
addition	8	O
,	1	O
the	3	O
proliferative	13	O
advantage	9	O
of	2	O
p12	3	B-Gene
(	1	I-Gene
I	1	I-Gene
)	1	I-Gene
-transduced	11	O
PBMCs	5	O
was	3	O
evident	7	O
mainly	6	O
at	2	O
low	3	O
concentrations	14	O
of	2	O
IL-2	4	B-Gene
.	1	O

Together	8	O
,	1	O
these	5	O
data	4	O
indicate	8	O
that	4	O
p12	3	B-Gene
(	1	I-Gene
I	1	I-Gene
)	1	I-Gene
may	3	O
confer	6	O
a	1	O
proliferative	13	O
advantage	9	O
on	2	O
HTLV-1	6	O
-infected	9	O
cells	5	O
in	2	O
the	3	O
presence	8	O
of	2	O
suboptimal	10	O
antigen	7	O
stimulation	11	O
and	3	O
that	4	O
this	4	O
event	5	O
may	3	O
account	7	O
for	3	O
the	3	O
clonal	6	O
proliferation	13	O
of	2	O
infected	8	O
T	1	O
cells	5	O
in	2	O
vivo	4	O
.	1	O

(	1	O
Blood.	6	O
2001	4	O
;	1	O
98	2	O
:	1	O
823-829	7	O
)	1	O

Maturation	10	O
of	2	O
human	5	O
dendritic	9	O
cells	5	O
as	2	O
sulfasalazine	13	B-Chemical
target	6	O
.	1	O

AIM	3	O
:	1	O
Sulfasalazine	13	B-Chemical
,	1	O
a	1	O
nonsteroidal	12	O
anti-inflammatory	17	O
drug	4	O
,	1	O
is	2	O
effective	9	O
in	2	O
treating	8	O
some	4	O
autoimmune	10	B-Disease
diseases	8	I-Disease
,	1	O
but	3	O
its	3	O
mechanism	9	O
of	2	O
action	6	O
is	2	O
unclear	7	O
.	1	O

To	2	O
determine	9	O
whether	7	O
dendritic	9	O
cells	5	O
could	5	O
be	2	O
a	1	O
possible	8	O
target	6	O
of	2	O
the	3	O
drug	4	O
,	1	O
we	2	O
studied	7	O
the	3	O
effects	7	O
of	2	O
sulfasalazine	13	B-Chemical
and	3	O
its	3	O
metabolites	11	O
,	1	O
aminosalicylate	15	B-Chemical
and	3	O
sulfapyridine	13	B-Chemical
,	1	O
on	2	O
in	2	O
vitro	5	O
maturation	10	O
(	1	O
terminal	8	O
differentiation	15	O
)	1	O
of	2	O
human	5	O
myeloid	7	O
dendritic	9	O
cells	5	O
.	1	O

METHODS	7	O
:	1	O
We	2	O
prepared	8	O
immature	8	O
dendritic	9	O
cells	5	O
by	2	O
incubating	10	O
CD14	4	B-Gene
-positive	9	O
cells	5	O
in	2	O
the	3	O
presence	8	O
of	2	O
granulocyte-	12	B-Gene
macrophage	10	I-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
and	3	O
interleukin	11	B-Gene
(	1	I-Gene
IL	2	I-Gene
)	1	I-Gene
-4	2	I-Gene
.	1	O

The	3	O
cells	5	O
were	4	O
matured	7	O
by	2	O
addition	8	O
of	2	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
(	1	I-Gene
TNF	3	I-Gene
)	1	I-Gene
-a	2	I-Gene
,	1	O
IL-1	4	B-Gene
beta	4	I-Gene
,	1	O
and	3	O
prostaglandin	13	B-Chemical
E2	2	I-Chemical
in	2	O
the	3	O
presence	8	O
of	2	O
sulfasalazine	13	B-Chemical
or	2	O
its	3	O
metabolites	11	O
--	2	O
aminosalicylate	15	B-Chemical
and	3	O
sulfapyridine	13	B-Chemical
,	1	O
or	2	O
their	5	O
combinations	12	O
.	1	O

We	2	O
quantified	10	O
the	3	O
effect	6	O
of	2	O
drugs	5	O
on	2	O
the	3	O
dendritic	9	O
cell	4	O
characteristics	15	O
,	1	O
such	4	O
as	2	O
stimulation	11	O
of	2	O
autologous	10	O
and	3	O
allogeneic	10	O
pan-T	5	O
cell	4	O
proliferation	13	O
,	1	O
surface	7	O
marker	6	O
phenotype	9	O
,	1	O
IL-12	5	B-Gene
p40	3	I-Gene
subunit	7	I-Gene
secretion	9	O
,	1	O
and	3	O
activation	10	O
of	2	O
nuclear	7	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
(	1	I-Gene
NF	2	I-Gene
)	1	I-Gene
-kappa	6	I-Gene
B	1	I-Gene
.	1	O

RESULTS	7	O
:	1	O
Dendritic	9	O
cells	5	O
treated	7	O
with	4	O
sulfasalazine	13	B-Chemical
(	1	O
1.25	4	O
micromol	8	O
/	1	O
L	1	O
or	2	O
2.5	3	O
micromol	8	O
/	1	O
L	1	O
)	1	O
could	5	O
not	3	O
stimulate	9	O
T	1	O
cells	5	O
(	1	O
p	1	O
<	1	O
0.028	5	O
,	1	O
two	3	O
-sided	6	O
paired	6	O
t-test	6	O
)	1	O
.	1	O

In	2	O
distinction	11	O
to	2	O
drug-free	9	O
maturing	8	O
dendritic	9	O
cells	5	O
,	1	O
2.5	3	O
micromol	8	O
/	1	O
L	1	O
sulfasalazine	13	B-Chemical
upregulated	11	O
the	3	O
levels	6	O
of	2	O
CD14	4	B-Gene
and	3	O
CD68	4	B-Gene
and	3	O
downregulated	13	O
the	3	O
levels	6	O
of	2	O
CD40	4	B-Gene
,	1	O
CD80	4	B-Gene
,	1	O
and	3	O
CD83	4	B-Gene
(	1	O
for	3	O
all	3	O
CD	2	O
markers	7	O
,	1	O
p	1	O
<	1	O
0.03	4	O
for	3	O
difference	10	O
between	7	O
measurements	12	O
in	2	O
the	3	O
absence	7	O
and	3	O
the	3	O
presence	8	O
of	2	O
sulfasalazine	13	B-Chemical
)	1	O
.	1	O

From	4	O
concentration	13	O
-dependent	10	O
changes	7	O
in	2	O
CD83	4	B-Gene
expression	10	O
,	1	O
we	2	O
found	5	O
an	2	O
apparent	8	O
ID50	4	O
>	1	O
>	1	O
1.5	3	O
micromol	8	O
/	1	O
L	1	O
sulfasalazine	13	B-Chemical
.	1	O

The	3	O
apparent	8	O
ID50	4	O
value	5	O
for	3	O
aminosalicylate	15	B-Chemical
-inhibited	10	O
maturation	10	O
was	3	O
4	1	O
micromol	8	O
/	1	O
L	1	O
.	1	O

Sulfapyridine	13	B-Chemical
had	3	O
no	2	O
effect	6	O
.	1	O

At	2	O
1.25	4	O
micromol	8	O
/	1	O
L	1	O
,	1	O
sulfasalazine	13	B-Chemical
largely	7	O
inhibited	9	O
NF-kB	5	B-Gene
activation	10	O
in	2	O
dendritic	9	O
cells	5	O
.	1	O

CONCLUSION	10	O
:	1	O
Maturing	8	O
human	5	O
dendritic	9	O
cells	5	O
are	3	O
hundred-fold	12	O
more	4	O
sensitive	9	O
to	2	O
sulfasalazine	13	B-Chemical
than	4	O
T	1	O
cells	5	O
and	3	O
NK	2	O
cells	5	O
and	3	O
the	3	O
most	4	O
sensitive	9	O
human	5	O
cells	5	O
described	9	O
so	2	O
far	3	O
.	1	O

Thus	4	O
,	1	O
dendritic	9	O
cell	4	O
maturation	10	O
is	2	O
an	2	O
important	9	O
target	6	O
of	2	O
sulfasalazine	13	B-Chemical
.	1	O

Because	7	O
of	2	O
the	3	O
role	4	O
of	2	O
dendritic	9	O
cells	5	O
in	2	O
(	1	O
auto	4	O
)	1	O
immunity	8	O
,	1	O
inhibition	10	O
of	2	O
their	5	O
maturation	10	O
might	5	O
provide	7	O
a	1	O
target	6	O
for	3	O
further	7	O
optimization	12	O
of	2	O
sulfasalazine	13	B-Chemical
therapy	7	O
.	1	O

Suppression	11	O
of	2	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
alpha	5	I-Gene
production	10	O
by	2	O
cAMP	4	B-Chemical
in	2	O
human	5	O
monocytes	9	O
:	1	O
dissociation	12	O
with	4	O
mRNA	4	O
level	5	O
and	3	O
independent	11	O
of	2	O
interleukin-10	14	B-Gene
.	1	O

BACKGROUND	10	O
:	1	O
Elevation	9	O
of	2	O
cellular	8	O
cAMP	4	B-Chemical
inhibits	8	O
lipopolysaccharide	18	B-Chemical
(	1	O
LPS	3	B-Chemical
)	1	O
-stimulated	11	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
alpha	5	I-Gene
(	1	O
TNF-alpha	9	B-Gene
)	1	O
production	10	O
and	3	O
increases	9	O
the	3	O
expression	10	O
of	2	O
interleukin	11	B-Gene
(	1	I-Gene
IL	2	I-Gene
)	1	I-Gene
-10	3	I-Gene
in	2	O
mononuclear	11	O
cells	5	O
.	1	O

TNF-alpha	9	B-Gene
gene	4	I-Gene
expression	10	O
obligates	9	O
activation	10	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
nuclear	7	I-Gene
factor	6	I-Gene
kappaB	6	I-Gene
(	1	O
NF-kappaB	9	B-Gene
)	1	O
.	1	O

Exogenous	9	B-Gene
IL-10	5	I-Gene
inhibits	8	O
NF-kappaB	9	B-Gene
in	2	O
monocytes	9	O
and	3	O
thus	4	O
attenuates	10	O
TNF-alpha	9	B-Gene
production	10	O
.	1	O

We	2	O
examined	8	O
the	3	O
role	4	O
of	2	O
endogenous	10	B-Gene
IL-10	5	I-Gene
in	2	O
the	3	O
regulation	10	O
of	2	O
NF-kappaB	9	B-Gene
activation	10	O
and	3	O
TNF-alpha	9	B-Gene
production	10	O
in	2	O
human	5	O
monocytes	9	O
by	2	O
cAMP	4	B-Chemical
.	1	O

METHODS	7	O
:	1	O
Human	5	O
monocytes	9	O
were	4	O
stimulated	10	O
with	4	O
Escherichia	11	O
coli	4	O
LPS	3	B-Chemical
(	1	O
100	3	O
ng	2	O
/	1	O
ml	2	O
)	1	O
with	4	O
and	3	O
without	7	O
forskolin	9	B-Chemical
(	1	O
FSK	3	B-Chemical
,	1	O
50	2	O
microM	6	O
)	1	O
or	2	O
dibutyryl	9	B-Chemical
cyclic	6	I-Chemical
AMP	3	I-Chemical
(	1	O
dbcAMP	6	B-Chemical
,	1	O
100	3	O
microM	6	O
)	1	O
.	1	O

Cytokine	8	O
(	1	O
TNF-alpha	9	B-Gene
and	3	O
IL-10	5	B-Gene
)	1	O
release	7	O
was	3	O
measured	8	O
by	2	O
immunoassay	11	O
.	1	O

TNF-alpha	9	B-Gene
mRNA	4	I-Gene
was	3	O
measured	8	O
by	2	O
reverse	7	O
transcription	13	O
polymerase	10	O
chain	5	O
reaction	8	O
,	1	O
and	3	O
NF-kappaB	9	B-Gene
DNA	3	I-Gene
binding	7	O
activity	8	O
was	3	O
assessed	8	O
by	2	O
gel	3	O
mobility	8	O
shift	5	O
assay	5	O
.	1	O

RESULTS	7	O
:	1	O
cAMP	4	B-Chemical
-elevating	10	O
agents	6	O
inhibited	9	O
LPS	3	B-Chemical
-stimulated	11	O
TNF-alpha	9	B-Gene
release	7	O
(	1	O
0.77	4	O
+	1	O
/	1	O
-	1	O
0.13	4	O
ng	2	O
/	1	O
10	2	O
(	1	O
6	1	O
)	1	O
cells	5	O
in	2	O
LPS	3	B-Chemical
+	1	O
dbcAMP	6	B-Chemical
and	3	O
0.68	4	O
+	1	O
/	1	O
-	1	O
0.19	4	O
ng	2	O
/	1	O
10	2	O
(	1	O
6	1	O
)	1	O
cells	5	O
in	2	O
LPS	3	B-Chemical
+	1	O
FSK	3	B-Chemical
,	1	O
both	4	O
P	1	O
<	1	O
0.05	4	O
vs	2	O
1.61	4	O
+	1	O
/	1	O
-	1	O
0.34	4	O
ng	2	O
/	1	O
10	2	O
(	1	O
6	1	O
)	1	O
cells	5	O
in	2	O
LPS	3	B-Chemical
alone	5	O
)	1	O
.	1	O

Conversely	10	O
,	1	O
cAMP	4	B-Chemical
enhanced	8	O
LPS	3	B-Chemical
-stimulated	11	O
IL-10	5	B-Gene
release	7	O
(	1	O
100	3	O
+	1	O
/	1	O
-	1	O
21.5	4	O
pg	2	O
/	1	O
10	2	O
(	1	O
6	1	O
)	1	O
cells	5	O
in	2	O
LPS	3	B-Chemical
+	1	O
dbcAMP	6	B-Chemical
and	3	O
110	3	O
+	1	O
/	1	O
-	1	O
25.2	4	O
pg	2	O
/	1	O
10	2	O
(	1	O
6	1	O
)	1	O
cells	5	O
in	2	O
LPS	3	B-Chemical
+	1	O
FSK	3	B-Chemical
,	1	O
both	4	O
P	1	O
<	1	O
0.05	4	O
vs	2	O
53.3	4	O
+	1	O
/	1	O
-	1	O
12.8	4	O
pg	2	O
/	1	O
10	2	O
(	1	O
6	1	O
)	1	O
cells	5	O
in	2	O
LPS	3	B-Chemical
alone	5	O
)	1	O
.	1	O

Neither	7	O
TNF-alpha	9	B-Gene
mRNA	4	I-Gene
expression	10	O
nor	3	O
NF-kappaB	9	B-Gene
activation	10	O
stimulated	10	O
by	2	O
LPS	3	B-Chemical
was	3	O
inhibited	9	O
by	2	O
the	3	O
cAMP	4	B-Chemical
-elevating	10	O
agents	6	O
.	1	O

Neutralization	14	O
of	2	O
IL-10	5	B-Gene
with	4	O
a	1	O
specific	8	O
antibody	8	O
did	3	O
not	3	O
attenuate	9	O
the	3	O
effect	6	O
of	2	O
cAMP	4	B-Chemical
-elevating	10	O
agents	6	O
on	2	O
TNF-alpha	9	B-Gene
production	10	O
.	1	O

CONCLUSION	10	O
:	1	O
The	3	O
results	7	O
indicate	8	O
that	4	O
cAMP	4	B-Chemical
inhibits	8	O
LPS	3	B-Chemical
-stimulated	11	O
TNF-alpha	9	B-Gene
production	10	O
through	7	O
a	1	O
posttranscriptional	19	O
mechanism	9	O
that	4	O
is	2	O
independent	11	O
of	2	O
endogenous	10	B-Gene
IL-10	5	I-Gene
.	1	O

Copyright	9	O
2001	4	O
Academic	8	O
Press	5	O
.	1	O

Inhibition	10	O
of	2	O
AP-1	4	B-Gene
by	2	O
the	3	O
glucocorticoid-inducible	24	B-Chemical
protein	7	O
GILZ	4	B-Gene
.	1	O

The	3	O
immunosuppressive	17	O
effects	7	O
of	2	O
glucocorticoids	15	B-Chemical
arise	5	O
largely	7	O
by	2	O
inhibition	10	O
of	2	O
cytokine	8	O
gene	4	O
expression	10	O
,	1	O
which	5	O
has	3	O
been	4	O
ascribed	8	O
to	2	O
interference	12	O
between	7	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
and	3	O
transcription	13	O
factors	7	O
such	4	O
as	2	O
AP-1	4	B-Gene
and	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
as	2	O
well	4	O
as	2	O
by	2	O
competition	11	O
for	3	O
common	6	O
coactivators	12	O
.	1	O

Here	4	O
we	2	O
show	4	O
that	4	O
glucocorticoid	14	B-Chemical
-induced	8	O
inhibition	10	O
of	2	O
interleukin-2	13	B-Gene
mRNA	4	I-Gene
expression	10	O
in	2	O
activated	9	O
normal	6	O
T	1	O
cells	5	O
required	8	O
new	3	O
protein	7	O
synthesis	9	O
,	1	O
suggesting	10	O
that	4	O
this	4	O
phenomenon	10	O
is	2	O
secondary	9	O
to	2	O
expression	10	O
of	2	O
glucocorticoid	14	B-Chemical
-regulated	10	O
genes	5	O
.	1	O

One	3	O
of	2	O
the	3	O
most	4	O
prominent	9	O
glucocorticoid	14	B-Chemical
-induced	8	O
genes	5	O
is	2	O
glucocorticoid	14	B-Gene
-induced	8	I-Gene
leucine	7	I-Gene
zipper	6	I-Gene
(	1	O
GILZ	4	B-Gene
)	1	O
,	1	O
which	5	O
has	3	O
been	4	O
reported	8	O
to	2	O
inhibit	7	O
activation	10	O
-induced	8	O
up-regulation	13	O
of	2	O
Fas	3	B-Gene
ligand	6	I-Gene
(	1	I-Gene
FasL	4	I-Gene
)	1	I-Gene
mRNA	4	I-Gene
.	1	O

Indeed	6	O
,	1	O
transient	9	O
expression	10	O
of	2	O
GILZ	4	B-Gene
in	2	O
Jurkat	6	O
T	1	O
cells	5	O
blocked	7	O
induction	9	O
of	2	O
a	1	O
reporter	8	O
construct	9	O
driven	6	O
by	2	O
the	3	O
FasL	4	B-Gene
promoter	8	I-Gene
.	1	O

This	4	O
could	5	O
be	2	O
accounted	9	O
for	3	O
by	2	O
GILZ	4	B-Gene
-mediated	9	O
inhibition	10	O
of	2	O
Egr-2	5	B-Gene
and	3	O
Egr-3	5	B-Gene
,	1	O
NFAT	4	B-Gene
/	1	I-Gene
AP-1	4	I-Gene
-inducible	10	O
transcription	13	O
factors	7	O
that	4	O
bind	4	O
a	1	O
regulatory	10	O
element	7	O
in	2	O
the	3	O
FasL	4	B-Gene
promoter	8	I-Gene
and	3	O
up-regulate	11	O
FasL	4	B-Gene
expression	10	O
.	1	O

GILZ	4	B-Gene
also	4	O
potently	8	O
inhibited	9	O
AP-1-driven	11	B-Gene
and	3	O
IL-2	4	B-Gene
promoter-driven	15	I-Gene
reporter	8	O
constructs	10	O
,	1	O
and	3	O
recombinant	11	O
GILZ	4	B-Gene
specifically	12	O
interacted	10	O
with	4	O
c-Fos	5	B-Gene
and	3	O
c-Jun	5	B-Gene
in	2	O
vitro	5	O
and	3	O
inhibited	9	O
the	3	O
binding	7	O
of	2	O
active	6	O
AP-1	4	B-Gene
to	2	O
its	3	O
target	6	O
DNA	3	O
.	1	O

Whereas	7	O
homodimerization	16	O
of	2	O
GILZ	4	B-Gene
required	8	O
the	3	O
presence	8	O
of	2	O
its	3	O
leucine	7	B-Chemical
zipper	6	O
,	1	O
the	3	O
interaction	11	O
with	4	O
c-Fos	5	B-Gene
and	3	O
c-Jun	5	B-Gene
occurred	8	O
through	7	O
the	3	O
N-terminal	10	O
60-amino	8	O
acid	4	O
region	6	O
of	2	O
GILZ	4	B-Gene
.	1	O

Thus	4	O
,	1	O
GILZ	4	B-Gene
represents	10	O
a	1	O
glucocorticoid	14	B-Chemical
-induced	8	O
gene	4	O
product	7	O
that	4	O
can	3	O
inhibit	7	O
a	1	O
variety	7	O
of	2	O
activation	10	O
-induced	8	O
events	6	O
,	1	O
at	2	O
least	5	O
in	2	O
part	4	O
by	2	O
direct	6	O
interference	12	O
with	4	O
AP-1	4	B-Gene
,	1	O
and	3	O
is	2	O
therefore	9	O
a	1	O
candidate	9	O
for	3	O
a	1	O
mediator	8	O
of	2	O
glucocorticoid	14	B-Chemical
-induced	8	O
immunosuppression	17	O
.	1	O

Transcription	13	B-Gene
factor	6	I-Gene
LKLF	4	I-Gene
is	2	O
sufficient	10	O
to	2	O
program	7	O
T	1	O
cell	4	O
quiescence	10	O
via	3	O
a	1	O
c-Myc	5	B-Gene
--	2	O
dependent	9	O
pathway	7	O
.	1	O

T	1	O
lymphocytes	11	O
circulate	9	O
in	2	O
a	1	O
quiescent	9	O
state	5	O
until	5	O
they	4	O
encounter	9	O
cognate	7	O
antigen	7	O
bound	5	O
to	2	O
the	3	O
surface	7	O
of	2	O
an	2	O
antigen	7	O
-presenting	11	O
cell	4	O
.	1	O

The	3	O
molecular	9	O
pathways	8	O
that	4	O
regulate	8	O
T	1	O
cell	4	O
quiescence	10	O
remain	6	O
largely	7	O
unknown	7	O
.	1	O

Here	4	O
we	2	O
show	4	O
that	4	O
forced	6	O
expression	10	O
of	2	O
the	3	O
lung	4	B-Gene
Kruppel	7	I-Gene
-like	5	I-Gene
transcription	13	I-Gene
factor	6	I-Gene
(	1	O
LKLF	4	B-Gene
)	1	O
in	2	O
Jurkat	6	O
T	1	O
cells	5	O
is	2	O
sufficient	10	O
to	2	O
program	7	O
a	1	O
quiescent	9	O
phenotype	9	O
characterized	13	O
by	2	O
decreased	9	O
proliferation	13	O
,	1	O
reduced	7	O
cell	4	O
size	4	O
and	3	O
protein	7	O
synthesis	9	O
and	3	O
decreased	9	O
surface	7	O
expression	10	O
of	2	O
activation	10	O
markers	7	O
.	1	O

Conversely	10	O
,	1	O
LKLF	4	B-Gene
-deficient	10	O
peripheral	10	O
T	1	O
cells	5	O
produced	8	O
by	2	O
gene	4	O
targeting	9	O
showed	6	O
increased	9	O
proliferation	13	O
,	1	O
increased	9	O
cell	4	O
size	4	O
and	3	O
enhanced	8	O
expression	10	O
of	2	O
surface	7	O
activation	10	O
markers	7	O
in	2	O
vivo	4	O
.	1	O

LKLF	4	B-Gene
appeared	8	O
to	2	O
function	8	O
,	1	O
at	2	O
least	5	O
in	2	O
part	4	O
,	1	O
by	2	O
decreasing	10	O
expression	10	O
of	2	O
the	3	O
proto-oncogene	14	O
encoding	8	O
c-Myc	5	B-Gene
.	1	O

Forced	6	O
expression	10	O
of	2	O
LKLF	4	B-Gene
was	3	O
associated	10	O
with	4	O
markedly	8	O
decreased	9	O
c-Myc	5	B-Gene
expression	10	O
.	1	O

In	2	O
addition	8	O
,	1	O
many	4	O
effects	7	O
of	2	O
LKLF	4	B-Gene
expression	10	O
were	4	O
mimicked	8	O
by	2	O
expression	10	O
of	2	O
the	3	O
dominant	8	O
-negative	9	O
MadMyc	6	B-Gene
protein	7	I-Gene
and	3	O
rescued	7	O
by	2	O
overexpression	14	O
of	2	O
c-Myc	5	B-Gene
.	1	O

Thus	4	O
,	1	O
LKLF	4	B-Gene
is	2	O
both	4	O
necessary	9	O
and	3	O
sufficient	10	O
to	2	O
program	7	O
quiescence	10	O
in	2	O
T	1	O
cells	5	O
and	3	O
functions	9	O
,	1	O
in	2	O
part	4	O
,	1	O
by	2	O
negatively	10	O
regulating	10	O
a	1	O
c-Myc	5	B-Gene
--	2	O
dependent	9	O
pathway	7	O
.	1	O

The	3	O
RING	4	B-Gene
finger	6	I-Gene
protein	7	I-Gene
Siah-1	6	I-Gene
regulates	9	O
the	3	O
level	5	O
of	2	O
the	3	O
transcriptional	15	B-Gene
coactivator	11	I-Gene
OBF-1	5	I-Gene
.	1	O

The	3	O
transcriptional	15	B-Gene
coactivator	11	I-Gene
OBF-1	5	I-Gene
,	1	O
which	5	O
interacts	9	O
with	4	O
Oct-1	5	B-Gene
and	3	O
Oct-2	5	B-Gene
and	3	O
the	3	O
octamer	7	O
site	4	O
DNA	3	O
,	1	O
has	3	O
been	4	O
shown	5	O
to	2	O
be	2	O
critical	8	O
for	3	O
development	11	O
of	2	O
a	1	O
normal	6	O
immune	6	O
response	8	O
and	3	O
the	3	O
formation	9	O
of	2	O
germinal	8	O
centers	7	O
in	2	O
secondary	9	O
lymphoid	8	O
organs	6	O
.	1	O

Here	4	O
we	2	O
have	4	O
identified	10	O
the	3	O
RING	4	B-Gene
finger	6	I-Gene
protein	7	I-Gene
Siah-1	6	I-Gene
as	2	O
a	1	O
protein	7	O
interacting	11	O
specifically	12	O
with	4	O
OBF-1	5	B-Gene
.	1	O

This	4	O
interaction	11	O
is	2	O
mediated	8	O
by	2	O
the	3	O
C-terminal	10	O
part	4	O
of	2	O
Siah-1	6	B-Gene
and	3	O
by	2	O
residues	8	O
in	2	O
the	3	O
N-terminus	10	O
of	2	O
OBF-1	5	B-Gene
,	1	O
partly	6	O
distinct	8	O
from	4	O
the	3	O
residues	8	O
required	8	O
for	3	O
formation	9	O
of	2	O
a	1	O
complex	7	O
with	4	O
the	3	O
Oct	3	B-Gene
POU	3	O
domains	7	O
and	3	O
the	3	O
DNA	3	O
.	1	O

Interaction	11	O
between	7	O
Siah-1	6	B-Gene
and	3	O
OBF-1	5	B-Gene
leads	5	O
to	2	O
downregulation	14	O
of	2	O
OBF-1	5	B-Gene
protein	7	I-Gene
level	5	O
but	3	O
not	3	O
mRNA	4	O
,	1	O
and	3	O
to	2	O
a	1	O
corresponding	13	O
reduction	9	O
in	2	O
octamer	7	O
site	4	O
-dependent	10	O
transcription	13	O
activation	10	O
.	1	O

Inhibition	10	O
of	2	O
the	3	O
ubiquitin-proteasome	20	B-Gene
pathway	7	O
in	2	O
B	1	O
cells	5	O
leads	5	O
to	2	O
elevated	8	O
levels	6	O
of	2	O
OBF-1	5	B-Gene
protein	7	I-Gene
.	1	O

Furthermore	11	O
,	1	O
in	2	O
immunized	9	O
mice	4	O
,	1	O
OBF-1	5	B-Gene
protein	7	I-Gene
amounts	7	O
are	3	O
dramatically	12	O
increased	9	O
in	2	O
primary	7	O
activated	9	O
B	1	O
cells	5	O
,	1	O
without	7	O
concomitant	11	O
increase	8	O
in	2	O
OBF-1	5	B-Gene
mRNA	4	I-Gene
.	1	O

These	5	O
data	4	O
suggest	7	O
that	4	O
Siah-1	6	B-Gene
is	2	O
part	4	O
of	2	O
a	1	O
novel	5	O
regulatory	10	O
loop	4	O
controlling	11	O
the	3	O
level	5	O
of	2	O
OBF-1	5	B-Gene
protein	7	I-Gene
in	2	O
B	1	O
cells	5	O
.	1	O

Transcription	13	B-Gene
factor	6	I-Gene
STAT5A	6	I-Gene
is	2	O
a	1	O
substrate	9	O
of	2	O
Bruton	6	B-Gene
's	2	I-Gene
tyrosine	8	I-Gene
kinase	6	I-Gene
in	2	O
B	1	O
cells	5	O
.	1	O

STAT5A	6	B-Gene
is	2	O
a	1	O
molecular	9	O
regulator	9	O
of	2	O
proliferation	13	O
,	1	O
differentiation	15	O
,	1	O
and	3	O
apoptosis	9	O
in	2	O
lymphohematopoietic	19	O
cells	5	O
.	1	O

Here	4	O
we	2	O
show	4	O
that	4	O
STAT5A	6	B-Gene
can	3	O
serve	5	O
as	2	O
a	1	O
functional	10	O
substrate	9	O
of	2	O
Bruton	6	B-Gene
's	2	I-Gene
tyrosine	8	I-Gene
kinase	6	I-Gene
(	1	O
BTK	3	B-Gene
)	1	O
.	1	O

Purified	8	O
recombinant	11	B-Gene
BTK	3	I-Gene
was	3	O
capable	7	O
of	2	O
directly	8	O
binding	7	O
purified	8	O
recombinant	11	B-Gene
STAT5A	6	I-Gene
with	4	O
high	4	O
affinity	8	O
(	1	O
K	1	O
(	1	O
d	1	O
)	1	O
=	1	O
44	2	O
nm	2	O
)	1	O
,	1	O
as	2	O
determined	10	O
by	2	O
surface	7	O
plasmon	7	O
resonance	9	O
using	5	O
a	1	O
BIAcore	7	O
biosensor	9	O
system	6	O
.	1	O

BTK	3	B-Gene
was	3	O
also	4	O
capable	7	O
of	2	O
tyrosine	8	B-Chemical
-phosphorylating	16	O
ectopically	11	O
expressed	9	O
recombinant	11	B-Gene
STAT5A	6	I-Gene
on	2	O
Tyr	3	B-Chemical
(	1	O
694	3	O
)	1	O
both	4	O
in	2	O
vitro	5	O
and	3	O
in	2	O
vivo	4	O
in	2	O
a	1	O
Janus	5	B-Gene
kinase	6	I-Gene
3	1	I-Gene
-independent	12	O
fashion	7	O
.	1	O

BTK	3	B-Gene
phosphorylated	14	O
the	3	O
Y665F	5	O
,	1	O
Y668F	5	O
,	1	O
and	3	O
Y682F	5	O
,	1	O
Y683F	5	O
mutants	7	O
but	3	O
not	3	O
the	3	O
Y694F	5	O
mutant	6	O
of	2	O
STAT5A	6	B-Gene
.	1	O

STAT5A	6	B-Gene
mutations	9	O
in	2	O
the	3	O
Src	3	B-Gene
homology	8	O
2	1	O
(	1	O
SH2	3	O
)	1	O
and	3	O
SH3	3	O
domains	7	O
did	3	O
not	3	O
alter	5	O
the	3	O
BTK	3	B-Gene
-mediated	9	O
tyrosine	8	B-Chemical
phosphorylation	15	O
.	1	O

Recombinant	11	B-Gene
BTK	3	I-Gene
proteins	8	I-Gene
with	4	O
mutant	6	B-Gene
pleckstrin	10	I-Gene
homology	8	O
,	1	O
SH2	3	O
,	1	O
or	2	O
SH3	3	O
domains	7	O
were	4	O
capable	7	O
of	2	O
phosphorylating	15	O
STAT5A	6	B-Gene
,	1	O
whereas	7	O
recombinant	11	B-Gene
BTK	3	I-Gene
proteins	8	I-Gene
with	4	O
SH1	3	B-Gene
/	1	O
kinase	6	O
domain	6	O
mutations	9	O
were	4	O
not	3	O
.	1	O

In	2	O
pull-down	9	O
experiments	11	O
,	1	O
only	4	O
full-length	11	O
BTK	3	B-Gene
and	3	O
its	3	O
SH1	3	B-Gene
/	1	O
kinase	6	O
domain	6	O
(	1	O
but	3	O
not	3	O
the	3	O
pleckstrin	10	B-Gene
homology	8	O
,	1	O
SH2	3	O
,	1	O
or	2	O
SH3	3	O
domains	7	O
)	1	O
were	4	O
capable	7	O
of	2	O
binding	7	O
STAT5A	6	B-Gene
.	1	O

Ectopically	11	O
expressed	9	O
BTK	3	B-Gene
kinase	6	I-Gene
domain	6	O
was	3	O
capable	7	O
of	2	O
tyrosine	8	B-Chemical
-phosphorylating	16	O
STAT5A	6	B-Gene
both	4	O
in	2	O
vitro	5	O
and	3	O
in	2	O
vivo	4	O
.	1	O

BTK	3	B-Gene
-mediated	9	O
tyrosine	8	B-Chemical
phosphorylation	15	O
of	2	O
ectopically	11	O
expressed	9	O
wild	4	O
type	4	O
(	1	O
but	3	O
not	3	O
Tyr	3	B-Chemical
(	1	O
694	3	O
)	1	O
mutant	6	O
)	1	O
STAT5A	6	B-Gene
enhanced	8	O
its	3	O
DNA	3	O
binding	7	O
activity	8	O
.	1	O

In	2	O
BTK	3	B-Gene
-competent	10	O
chicken	7	O
B	1	O
cells	5	O
,	1	O
anti-IgM	8	B-Gene
-stimulated	11	O
tyrosine	8	B-Chemical
phosphorylation	15	O
of	2	O
STAT5	5	B-Gene
protein	7	I-Gene
was	3	O
prevented	9	O
by	2	O
pretreatment	12	O
with	4	O
the	3	O
BTK	3	B-Gene
inhibitor	9	O
LFM-A13	7	B-Chemical
but	3	O
not	3	O
by	2	O
pretreatment	12	O
with	4	O
the	3	O
JAK3	4	B-Gene
inhibitor	9	O
HI-P131	7	B-Chemical
.	1	O

B	1	B-Gene
cell	4	I-Gene
antigen	7	I-Gene
receptor	8	I-Gene
ligation	8	O
resulted	8	O
in	2	O
enhanced	8	O
tyrosine	8	B-Chemical
phosphorylation	15	O
of	2	O
STAT5	5	B-Gene
in	2	O
BTK	3	B-Gene
-deficient	10	O
chicken	7	O
B	1	O
cells	5	O
reconstituted	13	O
with	4	O
wild	4	B-Gene
type	4	I-Gene
human	5	I-Gene
BTK	3	I-Gene
but	3	O
not	3	O
in	2	O
BTK	3	B-Gene
-deficient	10	O
chicken	7	O
B	1	O
cells	5	O
reconstituted	13	O
with	4	O
kinase	6	O
-inactive	9	O
mutant	6	B-Gene
BTK	3	I-Gene
.	1	O

Similarly	9	O
,	1	O
anti-IgM	8	B-Gene
stimulation	11	O
resulted	8	O
in	2	O
enhanced	8	O
tyrosine	8	B-Chemical
phosphorylation	15	O
of	2	O
STAT5A	6	B-Gene
in	2	O
BTK	3	B-Gene
-competent	10	O
B	1	O
cells	5	O
from	4	O
wild	4	O
type	4	O
mice	4	O
but	3	O
not	3	O
in	2	O
BTK	3	B-Gene
-deficient	10	O
B	1	O
cells	5	O
from	4	O
XID	3	O
mice	4	O
.	1	O

In	2	O
contrast	8	O
to	2	O
B	1	O
cells	5	O
from	4	O
XID	3	O
mice	4	O
,	1	O
B	1	O
cells	5	O
from	4	O
JAK3	4	B-Gene
knockout	8	O
mice	4	O
showed	6	O
a	1	O
normal	6	O
STAT5A	6	B-Gene
phosphorylation	15	O
response	8	O
to	2	O
anti-IgM	8	B-Gene
stimulation	11	O
.	1	O

These	5	O
findings	8	O
provide	7	O
unprecedented	13	O
experimental	12	O
evidence	8	O
that	4	O
BTK	3	B-Gene
plays	5	O
a	1	O
nonredundant	12	O
and	3	O
pivotal	7	O
role	4	O
in	2	O
B	1	B-Gene
cell	4	I-Gene
antigen	7	I-Gene
receptor	8	I-Gene
-mediated	9	O
STAT5A	6	B-Gene
activation	10	O
in	2	O
B	1	O
cells	5	O

Corticosteroid	14	B-Chemical
-induced	8	O
lymphopenia	11	O
,	1	O
immunosuppression	17	O
,	1	O
and	3	O
body	4	O
defense	7	O
.	1	O

The	3	O
apparent	8	O
paradox	7	O
of	2	O
heightened	10	O
adrenal	7	O
corticosteroid	14	B-Chemical
levels	6	O
associated	10	O
with	4	O
reduction	9	O
in	2	O
the	3	O
competence	10	O
of	2	O
the	3	O
body	4	O
's	2	O
defensive	9	O
apparatus	9	O
to	2	O
cope	4	O
with	4	O
exposure	8	O
to	2	O
new	3	O
microbial	9	O
antigens	8	O
is	2	O
considered	10	O
.	1	O

The	3	O
question	8	O
is	2	O
asked	5	O
how	3	O
this	4	O
lowered	7	O
defensive	9	O
capability	10	O
,	1	O
which	5	O
occurs	6	O
in	2	O
the	3	O
face	4	O
of	2	O
a	1	O
threat	6	O
to	2	O
body	4	O
integrity	9	O
,	1	O
is	2	O
consistent	10	O
with	4	O
Cannon	6	O
's	2	O
principals	10	O
of	2	O
the	3	O
``	2	O
wisdom	6	O
of	2	O
the	3	O
body	4	O
.	1	O

''	2	O

The	3	O
suggestion	10	O
is	2	O
offered	7	O
that	4	O
the	3	O
immunologic	11	O
response	8	O
to	2	O
self-antigens	13	O
exposed	7	O
by	2	O
disease	7	O
or	2	O
trauma	6	O
may	3	O
be	2	O
suppressed	10	O
by	2	O
corticosteroid	14	B-Chemical
to	2	O
offset	6	O
the	3	O
likelihood	10	O
of	2	O
autoimmune	10	O
attack	6	O
.	1	O

Chronic	7	B-Disease
lymphatic	9	I-Disease
leukaemia	9	I-Disease
:	1	O
cellular	8	O
effects	7	O
of	2	O
glucocorticoids	15	B-Chemical
in	2	O
vitro	5	O
.	1	O

Glucocorticoid	14	B-Gene
receptor	8	I-Gene
levels	6	O
and	3	O
steroid	7	B-Chemical
induced	7	O
inhibition	10	O
of	2	O
nucleic	7	O
acid	4	O
precursors	10	O
have	4	O
been	4	O
examined	8	O
in	2	O
lymphocytes	11	O
from	4	O
27	2	O
patients	8	O
at	2	O
different	9	O
stages	6	O
of	2	O
chronic	7	B-Disease
lymphatic	9	I-Disease
leukaemia	9	I-Disease
.	1	O

No	2	O
correlation	11	O
can	3	O
be	2	O
found	5	O
between	7	O
the	3	O
level	5	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
and	3	O
the	3	O
stage	5	O
of	2	O
the	3	O
disease	7	O
.	1	O

On	2	O
the	3	O
other	5	O
hand	4	O
,	1	O
a	1	O
significant	11	O
difference	10	O
(	1	O
P	1	O
less	4	O
than	4	O
0.02	4	O
)	1	O
was	3	O
found	5	O
between	7	O
stage	5	O
O	1	O
and	3	O
stage	5	O
III	3	O
/	1	O
IV	2	O
patients	8	O
,	1	O
in	2	O
terms	5	O
of	2	O
the	3	O
in	2	O
vitro	5	O
effect	6	O
of	2	O
dexamethasone	13	B-Chemical
on	2	O
[	1	O
3H	2	O
]	1	O
uridine	7	B-Chemical
incorporation	13	O
.	1	O

Interaction	11	O
of	2	O
glucocorticoids	15	B-Chemical
with	4	O
macrophages	11	O
.	1	O

Identification	14	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
monocytes	9	O
and	3	O
macrophages	11	O
.	1	O

Glucocorticoid	14	B-Chemical
binding	7	O
was	3	O
measured	8	O
in	2	O
resident	8	O
and	3	O
thioglycollate	14	B-Chemical
-elicited	9	O
mouse	5	O
peritoneal	10	O
macrophages	11	O
,	1	O
rabbit	6	O
alveolar	8	O
macrophages	11	O
,	1	O
and	3	O
human	5	O
monocytes	9	O
.	1	O

Two	3	O
assays	6	O
of	2	O
binding	7	O
were	4	O
used	4	O
--	2	O
an	2	O
assay	5	O
with	4	O
intact	6	O
cells	5	O
in	2	O
suspension	10	O
or	2	O
monolayers	10	O
,	1	O
and	3	O
an	2	O
assay	5	O
of	2	O
cytosol	7	O
and	3	O
nuclear	7	O
forms	5	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
.	1	O

The	3	O
mononuclear	11	O
phagocytes	10	O
contained	9	O
approximately	13	O
equal	5	O
to	2	O
4	1	O
--	2	O
10	2	O
X	1	O
10	2	O
(	1	O
3	1	O
)	1	O
high	4	O
affinity	8	O
receptor	8	O
sites	5	O
per	3	O
cell	4	O
,	1	O
with	4	O
dissociation	12	O
constants	9	O
of	2	O
approximately	13	O
equal	5	O
to	2	O
2	1	O
--	2	O
8	1	O
nM	2	O
dexamethasone	13	B-Chemical
.	1	O

The	3	O
binding	7	O
to	2	O
the	3	O
saturable	9	O
sites	5	O
was	3	O
specific	8	O
for	3	O
steroids	8	B-Chemical
with	4	O
glucocorticoid	14	B-Chemical
or	2	O
antiglucocorticoid	18	B-Chemical
activity	8	O
.	1	O

Cortisol	8	B-Chemical
,	1	O
corticosterone	14	B-Chemical
,	1	O
and	3	O
progesterone	12	B-Chemical
competed	8	O
with	4	O
dexamethasone	13	B-Chemical
for	3	O
binding	7	O
,	1	O
whereas	7	O
estradiol	9	B-Chemical
,	1	O
dihydrotestosterone	19	B-Chemical
,	1	O
and	3	O
11-epicortisol	14	B-Chemical
competed	8	O
very	4	O
little	6	O
.	1	O

Binding	7	O
of	2	O
dexamethasone	13	B-Chemical
to	2	O
cytosol	7	O
and	3	O
nuclear	7	O
forms	5	O
of	2	O
the	3	O
receptor	8	O
complex	7	O
and	3	O
temperature	11	O
-sensitive	10	O
translocation	13	O
of	2	O
cytosol	7	O
forms	5	O
to	2	O
nuclear	7	O
forms	5	O
were	4	O
shown	5	O
.	1	O

At	2	O
37	2	O
degrees	7	O
C	1	O
the	3	O
predominant	11	O
form	4	O
of	2	O
the	3	O
hormone-receptor	16	B-Gene
complex	7	I-Gene
was	3	O
nuclear	7	O
.	1	O

These	5	O
results	7	O
demonstrate	11	O
that	4	O
corticosteroids	15	B-Chemical
interact	8	O
with	4	O
macrophages	11	O
at	2	O
physiological	13	O
concentrations	14	O
.	1	O

Nuclear	7	O
glucocorticoid	14	B-Chemical
binding	7	O
in	2	O
chronic	7	B-Disease
lymphatic	9	I-Disease
leukemia	8	I-Disease
lymphocytes	11	O
.	1	O

A	1	O
reliable	8	O
procedure	9	O
is	2	O
described	9	O
for	3	O
isolating	9	O
3H-triamcinolone	16	B-Gene
acetonide	9	I-Gene
(	1	I-Gene
3H-TA	5	I-Gene
)	1	I-Gene
receptor	8	I-Gene
complexes	9	I-Gene
from	4	O
purified	8	O
chronic	7	B-Disease
lymphatic	9	I-Disease
leukemia	8	I-Disease
(	1	O
CLL	3	B-Disease
)	1	O
lymphocyte	10	O
nuclei	6	O
,	1	O
based	5	O
on	2	O
the	3	O
use	3	O
of	2	O
carbobenzoxy-L-phenylalanine	28	B-Chemical
(	1	O
CBZ-L-phe	9	B-Chemical
)	1	O
to	2	O
prevent	7	O
breakdown	9	O
of	2	O
hormone-receptor	16	O
complexes	9	O
during	6	O
extraction	10	O
of	2	O
nuclei	6	O
with	4	O
0.6M	4	O
KCl	3	O
.	1	O

Using	5	O
this	4	O
method	6	O
,	1	O
specific	8	O
nuclear	7	O
glucocorticoid	14	B-Chemical
binding	7	O
was	3	O
demonstrated	12	O
in	2	O
14	2	O
/	1	O
14	2	O
patients	8	O
with	4	O
untreated	9	O
CLL	3	B-Disease
.	1	O

No	2	O
correlation	11	O
was	3	O
found	5	O
between	7	O
levels	6	O
of	2	O
nuclear	7	O
-associated	11	O
3H-TA	5	B-Chemical
and	3	O
peripheral	10	O
white	5	O
blood	5	O
cell	4	O
count	5	O
or	2	O
rosetting	9	O
ability	7	O
of	2	O
circulating	11	O
lymphocytes	11	O
.	1	O

The	3	O
leukocyte	9	O
migration	9	O
inhibition	10	O
response	8	O
to	2	O
certain	7	O
breast	6	B-Disease
cancer	6	I-Disease
-related	8	O
antigens	8	O
(	1	O
MCF-7	5	O
and	3	O
MuMTV	5	O
)	1	O
:	1	O
their	5	O
potential	9	O
as	2	O
discriminants	13	O
.	1	O

Certain	7	O
oncogenic	9	O
viruses	7	O
have	4	O
been	4	O
implicated	10	O
in	2	O
human	5	O
breast	6	B-Disease
cancer	6	I-Disease
,	1	O
including	9	O
the	3	O
murine	6	O
mammary	7	B-Disease
tumor	5	I-Disease
virus	5	O
(	1	O
MuMTV	5	O
)	1	O
and	3	O
the	3	O
Mason-Pfizer	12	O
monkey	6	O
virus	5	O
(	1	O
MPMV	4	O
)	1	O
.	1	O

We	2	O
have	4	O
used	4	O
the	3	O
leukocyte	9	O
migration	9	O
inhibition	10	O
(	1	O
LMI	3	O
)	1	O
response	8	O
to	2	O
assay	5	O
the	3	O
response	8	O
to	2	O
several	7	O
potential	9	O
breast	6	B-Disease
cancer	6	I-Disease
-related	8	O
antigens	8	O
,	1	O
including	9	O
MuMTV	5	O
,	1	O
MPMV	4	O
,	1	O
and	3	O
a	1	O
breast	6	B-Disease
cancer	6	I-Disease
cultured	8	O
cell	4	O
line	4	O
,	1	O
MCF-7	5	O
,	1	O
in	2	O
96	2	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
,	1	O
in	2	O
32	2	O
women	5	O
with	4	O
benign	6	O
breast	6	B-Disease
disease	7	I-Disease
,	1	O
and	3	O
in	2	O
67	2	O
normal	6	O
women	5	O
.	1	O

The	3	O
lowest	6	O
tenth	5	O
percentile	10	O
of	2	O
control	7	O
(	1	O
LMI	3	O
)	1	O
responses	9	O
was	3	O
used	4	O
as	2	O
the	3	O
cutoff	6	O
point	5	O
to	2	O
designate	9	O
responders	10	O
.	1	O

Breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
showed	6	O
significant	11	O
responses	9	O
to	2	O
MuMTV	5	O
(	1	O
49	2	O
%	1	O
and	3	O
to	2	O
MCF-7	5	O
(	1	O
50	2	O
%	1	O
)	1	O
,	1	O
but	3	O
not	3	O
to	2	O
MPMV	4	O
(	1	O
29	2	O
%	1	O
)	1	O
.	1	O

In	2	O
a	1	O
paired-antigen	14	O
study	5	O
using	5	O
MuMTV	5	O
and	3	O
MCF-7	5	O
,	1	O
75	2	O
%	1	O
of	2	O
the	3	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
responded	9	O
,	1	O
versus	6	O
18	2	O
%	1	O
of	2	O
the	3	O
normal	6	O
women	5	O
(	1	O
P	1	O
less	4	O
than	4	O
0.0050	6	O
)	1	O
.	1	O

The	3	O
potential	9	O
for	3	O
this	4	O
assay	5	O
to	2	O
distinguish	11	O
``	2	O
normal	6	O
''from	6	O
``	2	O
breast	6	B-Disease
cancer	6	I-Disease
''was	5	O
analyzed	8	O
using	5	O
a	1	O
migration	9	O
index	5	O
derived	7	O
from	4	O
discriminant	12	O
analysis	8	O
.	1	O

The	3	O
ability	7	O
of	2	O
the	3	O
assay	5	O
to	2	O
discriminate	12	O
``	2	O
normal	6	O
''from	6	O
``	2	O
cancer	6	B-Disease
''was	5	O
significant	11	O
(	1	O
P	1	O
less	4	O
than	4	O
0.001	5	O
)	1	O
and	3	O
showed	6	O
a	1	O
sensitivity	11	O
of	2	O
detecting	9	O
``	2	O
cancer	6	B-Disease
''of	4	O
75	2	O
%	1	O
.	1	O

The	3	O
overall	7	O
responses	9	O
to	2	O
MuMTV	5	O
and	3	O
MCF-7	5	O
were	4	O
analyzed	8	O
with	4	O
reference	9	O
to	2	O
certain	7	O
prognostic	10	O
factors	7	O
,	1	O
but	3	O
showed	6	O
no	2	O
relation	8	O
to	2	O
age	3	O
,	1	O
menstrual	9	O
status	6	O
,	1	O
estrogen	8	B-Gene
receptor	8	I-Gene
status	6	O
,	1	O
or	2	O
stage	5	O
of	2	O
disease	7	O
.	1	O

The	3	O
above	5	O
reactions	9	O
suggest	7	O
that	4	O
a	1	O
large	5	O
proportion	10	O
of	2	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
exhibit	7	O
presensitization	16	O
to	2	O
antigenfs	9	O
found	5	O
in	2	O
MuMTV	5	O
and	3	O
MCF-7	5	O
,	1	O
which	5	O
may	3	O
be	2	O
cross	5	O
-reactive	9	O
with	4	O
antigens	8	O
in	2	O
the	3	O
primary	7	O
cancer	6	B-Disease
.	1	O

These	5	O
responses	9	O
appear	6	O
to	2	O
be	2	O
independent	11	O
of	2	O
major	5	O
prognostic	10	O
variables	9	O
.	1	O

Further	7	O
refinement	10	O
of	2	O
this	4	O
assay	5	O
may	3	O
yield	5	O
one	3	O
which	5	O
is	2	O
more	4	O
highly	6	O
discriminating	14	O
for	3	O
breast	6	B-Disease
cancer	6	I-Disease
.	1	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
and	3	O
actions	7	O
in	2	O
rat	3	O
thymocytes	10	O
and	3	O
immunologically	15	O
stimulated	10	O
human	5	O
peripheral	10	O
lymphocytes	11	O
.	1	O

After	5	O
reviewing	9	O
briefly	7	O
our	3	O
earlier	7	O
studies	7	O
on	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
and	3	O
mechanisms	10	O
in	2	O
thymus	6	O
cells	5	O
,	1	O
we	2	O
have	4	O
outlined	8	O
results	7	O
from	4	O
the	3	O
following	9	O
two	3	O
areas	5	O
of	2	O
current	7	O
interest	8	O
in	2	O
our	3	O
laboratories	12	O
:	1	O
the	3	O
``	2	O
life-cycle	10	O
''of	4	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
and	3	O
complexes	9	O
in	2	O
thymus	6	O
cells	5	O
,	1	O
and	3	O
the	3	O
levels	6	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
and	3	O
sensitivity	11	O
in	2	O
immunologically	15	O
stimulated	10	O
human	5	O
peripheral	10	O
lymphocytes	11	O
.	1	O

Several	7	O
of	2	O
our	3	O
results	7	O
on	2	O
energetics	10	O
and	3	O
kinetics	8	O
of	2	O
hormone	7	O
binding	7	O
to	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
rat	3	O
thymus	6	O
cells	5	O
seem	4	O
to	2	O
require	7	O
extension	9	O
of	2	O
the	3	O
simplest	8	O
model	5	O
of	2	O
hormone-receptor	16	O
transformations	15	O
in	2	O
intact	6	O
cells	5	O
.	1	O

ATP-depletion	13	B-Chemical
experiments	11	O
suggest	7	O
the	3	O
existence	9	O
of	2	O
a	1	O
nonbinding	10	O
form	4	O
of	2	O
the	3	O
receptor	8	O
;	1	O
``	2	O
chase	5	O
''experiments	13	O
suggest	7	O
reaction	8	O
of	2	O
hormone	7	O
directly	8	O
with	4	O
nuclear-bound	13	O
receptor	8	O
;	1	O
experiments	11	O
on	2	O
depletion	9	O
and	3	O
replenishment	13	O
of	2	O
cytoplasmic	11	O
receptor	8	O
using	5	O
cortisol	8	B-Chemical
and	3	O
dexamethasone	13	B-Chemical
suggest	7	O
the	3	O
existence	9	O
of	2	O
at	2	O
least	5	O
two	3	O
subpopulations	14	O
of	2	O
nuclear-bound	13	O
hormone-receptor	16	O
complex	7	O
.	1	O

We	2	O
have	4	O
found	5	O
that	4	O
mitogen	7	O
or	2	O
immunologic	11	O
stimulation	11	O
of	2	O
human	5	O
peripheral	10	O
lymphocytes	11	O
in	2	O
culture	7	O
leads	5	O
within	6	O
24	2	O
h	1	O
or	2	O
so	2	O
to	2	O
a	1	O
striking	8	O
increase	8	O
in	2	O
the	3	O
number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
sites	5	O
per	3	O
cell	4	O
.	1	O

We	2	O
believe	7	O
this	4	O
increase	8	O
may	3	O
be	2	O
due	3	O
to	2	O
partial	7	O
synchronization	15	O
of	2	O
the	3	O
cell	4	O
population	10	O
in	2	O
a	1	O
phase	5	O
of	2	O
the	3	O
cell	4	O
cycle	5	O
in	2	O
which	5	O
receptor	8	O
content	7	O
is	2	O
high	4	O
.	1	O

Contrary	8	O
to	2	O
the	3	O
widely	6	O
held	4	O
view	4	O
that	4	O
mitogen	7	O
-stimulated	11	O
cells	5	O
become	6	O
insensitive	11	O
to	2	O
glucocorticoids	15	B-Chemical
,	1	O
our	3	O
experiments	11	O
show	4	O
that	4	O
with	4	O
respect	7	O
to	2	O
inhibition	10	O
of	2	O
thymidine	9	B-Chemical
and	3	O
uridine	7	B-Chemical
incorporation	13	O
and	3	O
glucose	7	B-Chemical
uptake	6	O
,	1	O
the	3	O
cells	5	O
are	3	O
highly	6	O
sensitive	9	O
to	2	O
dexamethasone	13	B-Chemical
at	2	O
24	2	O
,	1	O
48	2	O
,	1	O
and	3	O
72	2	O
h	1	O
after	5	O
stimulation	11	O
with	4	O
concanavalin	12	B-Gene
A	1	I-Gene
.	1	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
cytosol	7	O
and	3	O
nuclear	7	O
extract	7	O
of	2	O
human	5	O
leukocytes	10	O
.	1	O

Cortisol	8	B-Chemical
binding	7	O
by	2	O
cytosol	7	O
and	3	O
0.4	3	O
M	1	O
KCl	3	O
extract	7	O
of	2	O
the	3	O
nuclear	7	O
fraction	8	O
of	2	O
human	5	O
leukocytes	10	O
were	4	O
studied	7	O
by	2	O
gel	3	O
chromatography	14	O
and	3	O
ion	3	O
exchange	8	O
filtration	10	O
on	2	O
DEAE	4	B-Chemical
cellulose	9	O
.	1	O

The	3	O
cytoplasmic	11	O
cortisol	8	B-Gene
binding	7	I-Gene
protein	7	I-Gene
has	3	O
a	1	O
molecular	9	O
weight	6	O
95	2	O
000	3	O
and	3	O
the	3	O
soluble	7	O
nuclear	7	O
binding	7	O
protein	7	O
50	2	O
000	3	O
.	1	O

The	3	O
absence	7	O
of	2	O
the	3	O
uptake	6	O
of	2	O
radioactive	11	O
cortisol	8	B-Chemical
by	2	O
isolated	8	O
nuclei	6	O
and	3	O
the	3	O
apparent	8	O
requirement	11	O
of	2	O
the	3	O
cytosol	7	O
for	3	O
glucocorticoid	14	B-Chemical
specific	8	O
binding	7	O
in	2	O
nuclear	7	O
receptor	8	O
sites	5	O
was	3	O
observed	8	O
.	1	O

The	3	O
association	11	O
constant	8	O
characterising	14	O
the	3	O
binding	7	O
of	2	O
cortisol	8	B-Chemical
to	2	O
cytosol	7	O
was	3	O
KA	2	O
=	1	O
3.5	3	O
.	1	O

10	2	O
(	1	O
9	1	O
)	1	O
l	1	O
/	1	O
mol	3	O
.	1	O

Glucocorticoids	15	B-Chemical
and	3	O
lymphocytes	11	O
.	1	O

I	1	O
.	1	O

Increased	9	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
levels	6	O
in	2	O
antigen	7	O
-stimulated	11	O
lymphocytes	11	O
.	1	O

Recently	8	O
a	1	O
2-	2	O
to	2	O
3-fold	6	O
increase	8	O
in	2	O
the	3	O
number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
human	5	O
peripheral	10	O
lymphocytes	11	O
has	3	O
been	4	O
noted	5	O
after	5	O
in	2	O
vitro	5	O
mitogen	7	O
stimulation	11	O
.	1	O

Here	4	O
,	1	O
we	2	O
extend	6	O
these	5	O
observations	12	O
to	2	O
in	2	O
vivo	4	O
immunization	12	O
.	1	O

After	5	O
unilateral	10	O
immunization	12	O
of	2	O
adrenalectomized	16	O
male	4	O
rats	4	O
,	1	O
a	1	O
50	2	O
%	1	O
increase	8	O
in	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
sites	5	O
per	3	O
cell	4	O
,	1	O
determined	10	O
by	2	O
binding	7	O
of	2	O
dexamethasone	13	B-Chemical
,	1	O
was	3	O
observed	8	O
in	2	O
cell	4	O
suspensions	11	O
of	2	O
homolateral	11	O
lymph	5	O
nodes	5	O
over	4	O
those	5	O
from	4	O
the	3	O
contralateral	13	O
nonimmunized	12	O
side	4	O
of	2	O
the	3	O
same	4	O
animal	6	O
.	1	O

The	3	O
association	11	O
constant	8	O
for	3	O
dexamethasone	13	B-Chemical
was	3	O
similar	7	O
in	2	O
both	4	O
groups	6	O
,	1	O
as	2	O
was	3	O
the	3	O
stereospecificity	17	O
for	3	O
various	7	O
steroids	8	B-Chemical
,	1	O
the	3	O
time	4	O
course	6	O
of	2	O
cytoplasmic	11	O
and	3	O
nuclear	7	O
association	11	O
,	1	O
and	3	O
cytoplasmic-to-nuclear	22	O
translocation	13	O
.	1	O

Despite	7	O
a	1	O
50	2	O
%	1	O
increase	8	O
in	2	O
the	3	O
number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
sites	5	O
per	3	O
cell	4	O
,	1	O
the	3	O
cells	5	O
from	4	O
the	3	O
homolateral	11	O
and	3	O
controlateral	13	O
lymph	5	O
nodes	5	O
were	4	O
equally	7	O
sensitive	9	O
to	2	O
the	3	O
inhibitory	10	O
effects	7	O
of	2	O
dexamethasone	13	B-Chemical
,	1	O
as	2	O
determined	10	O
by	2	O
measurements	12	O
of	2	O
the	3	O
incorporation	13	O
of	2	O
radiolabeled	12	O
precursors	10	O
of	2	O
protein	7	O
,	1	O
RNA	3	O
,	1	O
and	3	O
DNA	3	O
,	1	O
or	2	O
measurements	12	O
of	2	O
in	2	O
vitro	5	O
cell	4	O
survival	8	O
.	1	O

Glucocorticoids	15	B-Chemical
and	3	O
lymphocytes	11	O
.	1	O

II	2	O
.	1	O

Cell	4	O
cycle	5	O
-dependent	10	O
changes	7	O
in	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
content	7	O
.	1	O

To	2	O
study	5	O
variations	10	O
in	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
levels	6	O
during	6	O
the	3	O
cell	4	O
cycle	5	O
,	1	O
we	2	O
have	4	O
separated	9	O
mitogen	7	O
-stimulated	11	O
human	5	O
peripheral	10	O
lymphocytes	11	O
and	3	O
rat	3	O
lymph	5	O
node	4	O
cells	5	O
by	2	O
unit	4	O
gravity	7	O
sedimentation	13	O
and	3	O
measured	8	O
glucocorticoid	14	B-Chemical
binding	7	O
in	2	O
the	3	O
resultant	9	O
fractions	9	O
.	1	O

By	2	O
morphologic	11	O
criteria	8	O
and	3	O
thymidine	9	B-Chemical
incorporation	13	O
,	1	O
the	3	O
fractions	9	O
were	4	O
separated	9	O
into	4	O
populations	11	O
of	2	O
G0	2	O
and	3	O
G1	2	O
phase	5	O
and	3	O
S	1	O
and	3	O
post-S	6	O
phase	5	O
cells	5	O
.	1	O

A	1	O
2-	2	O
to	2	O
3-fold	6	O
increase	8	O
in	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
sites	5	O
per	3	O
cell	4	O
,	1	O
for	3	O
cells	5	O
in	2	O
the	3	O
S	1	O
and	3	O
post-S	6	O
phase	5	O
over	4	O
those	5	O
in	2	O
G0	2	O
and	3	O
G1	2	O
,	1	O
was	3	O
observed	8	O
with	4	O
both	4	O
nonstimulated	13	O
rat	3	O
lymph	5	O
node	4	O
cell	4	O
suspensions	11	O
and	3	O
concanavalin	12	B-Gene
A	1	I-Gene
-stimulated	11	O
human	5	O
peripheral	10	O
lymphocytes	11	O
.	1	O

These	5	O
observations	12	O
together	8	O
with	4	O
those	5	O
from	4	O
other	5	O
studies	7	O
indicate	8	O
that	4	O
formation	9	O
of	2	O
new	3	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
near	4	O
the	3	O
S	1	O
phase	5	O
may	3	O
be	2	O
a	1	O
general	7	O
phenomenon	10	O
in	2	O
proliferating	13	O
cells	5	O
.	1	O

We	2	O
propose	7	O
that	4	O
this	4	O
increase	8	O
in	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
during	6	O
the	3	O
cell	4	O
cycle	5	O
may	3	O
explain	7	O
the	3	O
increase	8	O
in	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
mitogen	7	O
-stimulated	11	O
lymphocytes	11	O
.	1	O

Heterogeneity	13	O
of	2	O
the	3	O
in	2	O
vitro	5	O
responses	9	O
to	2	O
glucocorticoids	15	B-Chemical
in	2	O
acute	5	B-Disease
leukemia	8	I-Disease
.	1	O

In	2	O
leukocyte	9	O
population	10	O
freshly	7	O
isolated	8	O
from	4	O
the	3	O
blood	5	O
of	2	O
26	2	O
patients	8	O
with	4	O
acute	5	B-Disease
leukemia	8	I-Disease
,	1	O
we	2	O
have	4	O
measured	8	O
several	7	O
parameters	10	O
including	9	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
,	1	O
nucleoside	10	O
incorporation	13	O
,	1	O
percentage	10	O
of	2	O
cells	5	O
in	2	O
S	1	O
phase	5	O
,	1	O
and	3	O
steroid	7	B-Chemical
-induced	8	O
cell	4	O
lysis	5	O
.	1	O

In	2	O
addition	8	O
,	1	O
in	2	O
some	4	O
cases	5	O
,	1	O
the	3	O
short-term	10	O
response	8	O
to	2	O
steroid	7	B-Chemical
therapy	7	O
was	3	O
determined	10	O
.	1	O

Although	8	O
,	1	O
in	2	O
all	3	O
the	3	O
patients	8	O
studied	7	O
,	1	O
leukocytes	10	O
were	4	O
found	5	O
to	2	O
contain	7	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
,	1	O
we	2	O
failed	6	O
to	2	O
demonstrate	11	O
any	3	O
correlation	11	O
between	7	O
the	3	O
level	5	O
of	2	O
binding	7	O
sites	5	O
and	3	O
the	3	O
in	2	O
vitro	5	O
or	2	O
in	2	O
vivo	4	O
response	8	O
to	2	O
glucocorticoids	15	B-Chemical
.	1	O

This	4	O
absence	7	O
of	2	O
correlation	11	O
could	5	O
be	2	O
in	2	O
part	4	O
explained	9	O
by	2	O
the	3	O
marked	6	O
heterogeneity	13	O
of	2	O
the	3	O
steroid	7	B-Chemical
response	8	O
demonstrated	12	O
in	2	O
leukocyte	9	O
subpopulations	14	O
.	1	O

It	2	O
appears	7	O
,	1	O
however	7	O
,	1	O
that	4	O
the	3	O
degree	6	O
of	2	O
steroid	7	B-Chemical
action	6	O
in	2	O
vitro	5	O
as	2	O
well	4	O
as	2	O
the	3	O
extent	6	O
of	2	O
spontaneous	11	O
and	3	O
dexamethasone	13	B-Chemical
-induced	8	O
cell	4	O
death	5	O
may	3	O
be	2	O
related	7	O
to	2	O
the	3	O
number	6	O
of	2	O
cells	5	O
in	2	O
the	3	O
S	1	O
phase	5	O
of	2	O
the	3	O
cell	4	O
cycle	5	O
.	1	O

'Activation-labile	18	O
'glucocorticoid-receptor	24	B-Gene
complexes	9	I-Gene
of	2	O
a	1	O
steroid	7	B-Chemical
-resistant	10	O
variant	7	O
of	2	O
CEM-C7	6	O
human	5	O
lymphoid	8	O
cells	5	O
.	1	O

For	3	O
cytoplasmic	11	B-Gene
glucocorticoid-receptor	23	I-Gene
complexes	9	I-Gene
to	2	O
enter	5	O
and	3	O
accumulate	10	O
in	2	O
the	3	O
nucleus	7	O
a	1	O
temperature	11	O
-dependent	10	O
event	5	O
,	1	O
'activation	11	O
'is	3	O
required	8	O
.	1	O

Activation	10	O
can	3	O
be	2	O
achieved	8	O
in	2	O
vitro	5	O
by	2	O
increased	9	O
ionic	5	O
strength	8	O
,	1	O
dilution	8	O
or	2	O
gel	3	O
filtration	10	O
and	3	O
is	2	O
manifested	10	O
by	2	O
an	2	O
increased	9	O
affinity	8	O
of	2	O
steroid-receptor	16	B-Gene
complex	7	I-Gene
for	3	O
DNA	3	O
and	3	O
an	2	O
altered	7	O
elution	7	O
profile	7	O
from	4	O
ion-exchange	12	O
resins	6	O
.	1	O

Munck	5	O
and	3	O
Foley	5	O
have	4	O
shown	5	O
that	4	O
activated	9	O
complexes	9	O
isolated	8	O
from	4	O
thymocytes	10	O
elute	5	O
from	4	O
DEAE-cellulose	14	O
in	2	O
a	1	O
manner	6	O
identical	9	O
to	2	O
complexes	9	O
activated	9	O
in	2	O
vitro	5	O
.	1	O

We	2	O
report	6	O
here	4	O
that	4	O
DEAE-cellulose	14	O
chromatography	14	O
of	2	O
steroid-receptor	16	B-Gene
complexes	9	I-Gene
from	4	O
CEM-C7	6	O
,	1	O
a	1	O
cloned	6	O
human	5	O
leukaemic	9	O
T-cell	6	O
line	4	O
sensitive	9	O
to	2	O
the	3	O
cytolytic	9	O
action	6	O
of	2	O
glucocorticoids	15	B-Chemical
,	1	O
and	3	O
its	3	O
steroid	7	B-Chemical
-resistant	10	O
subclone	8	O
4R4	3	O
demonstrated	12	O
that	4	O
steroid	7	B-Gene
receptors	9	I-Gene
of	2	O
clone	5	O
4R4	3	O
can	3	O
not	3	O
form	4	O
stable	6	O
activated	9	O
complexes	9	O
.	1	O

This	4	O
defines	7	O
a	1	O
new	3	O
defect	6	O
in	2	O
receptor	8	O
action	6	O
,	1	O
activation	10	O
lability	8	O
(	1	O
r	1	O
+	1	O
act1	4	O
)	1	O
,	1	O
which	5	O
is	2	O
unlike	6	O
either	6	O
the	3	O
r-	2	O
,	1	O
r	1	O
+	1	O
nt-	3	O
,	1	O
or	2	O
r	1	O
+	1	O
nti	3	O
phenotypes	10	O
previously	10	O
described	9	O
for	3	O
mouse	5	O
lymphoid	8	O
variants	8	O
.	1	O

Immunochemical	14	O
differences	11	O
between	7	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
from	4	O
corticoid	9	B-Chemical
-sensitive	10	O
and	3	O
-resistant	10	O
malignant	9	O
lymphocytes	11	O
.	1	O

We	2	O
have	4	O
explored	8	O
the	3	O
possibility	11	O
of	2	O
using	5	O
antibodies	10	O
against	7	O
purified	8	B-Gene
rat	3	I-Gene
liver	5	I-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
to	2	O
study	5	O
the	3	O
immunochemical	14	O
properties	10	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
from	4	O
murine	6	O
and	3	O
human	5	O
malignant	9	O
lymphocytes	11	O
.	1	O

For	3	O
this	4	O
purpose	7	O
,	1	O
purified	8	B-Gene
immune	6	I-Gene
immunoglobulin	14	I-Gene
G	1	I-Gene
was	3	O
covalently	10	O
linked	6	O
to	2	O
Sepharose	9	O
CL-4B	5	O
.	1	O

We	2	O
then	4	O
examined	8	O
the	3	O
ability	7	O
of	2	O
the	3	O
affinity	8	O
gel	3	O
to	2	O
recognize	9	O
cytosolic	9	B-Gene
[	1	I-Gene
3H	2	I-Gene
]	1	I-Gene
triamcinolone	13	I-Gene
acetonide-receptor	18	I-Gene
complexes	9	I-Gene
from	4	O
the	3	O
corticoid	9	B-Chemical
-sensitive	10	O
(	1	O
CS	2	O
)	1	O
and	3	O
-resistant	10	O
strains	7	O
of	2	O
mouse	5	O
lymphoma	8	B-Disease
P1798	5	O
,	1	O
from	4	O
CS	2	O
lymphocytes	11	O
of	2	O
patients	8	O
with	4	O
chronic	7	B-Disease
lymphatic	9	I-Disease
leukemia	8	I-Disease
,	1	O
and	3	O
from	4	O
a	1	O
CS	2	O
clone	5	O
of	2	O
human	5	O
leukemic	8	O
lymphoblasts	12	O
in	2	O
tissue	6	O
culture	7	O
(	1	O
CH6	3	O
)	1	O
.	1	O

Mouse	5	O
thymus	6	O
was	3	O
used	4	O
as	2	O
a	1	O
source	6	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
from	4	O
normal	6	O
CS	2	O
lymphocytes	11	O
.	1	O

Whereas	7	O
the	3	O
immunoaffinity	14	O
column	6	O
retained	8	O
70	2	O
to	2	O
84	2	O
%	1	O
of	2	O
the	3	O
58-	3	O
to	2	O
62-A	4	O
(	1	O
Stokes	6	O
radius	6	O
)	1	O
[	1	B-Gene
3H	2	I-Gene
]	1	I-Gene
triamcinolone	13	I-Gene
acetonide-receptor	18	I-Gene
complexes	9	I-Gene
characteristic	14	O
of	2	O
the	3	O
CS	2	O
mouse	5	O
and	3	O
human	5	O
lymphocytes	11	O
,	1	O
it	2	O
failed	6	O
to	2	O
recognize	9	O
the	3	O
27-	3	O
to	2	O
28-A	4	O
(	1	O
Stokes	6	O
radius	6	O
)	1	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
present	7	O
in	2	O
corticoid	9	B-Chemical
-resistant	10	O
mouse	5	O
lymphoma	8	B-Disease
P1798	5	O
cells	5	O
.	1	O

Therefore	9	O
,	1	O
under	5	O
appropriate	11	O
experimental	12	O
conditions	10	O
,	1	O
it	2	O
was	3	O
possible	8	O
to	2	O
demonstrate	11	O
cross-reactivity	16	O
between	7	O
the	3	O
antiserum	9	O
against	7	O
rat	3	B-Gene
liver	5	I-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
and	3	O
the	3	O
58-	3	O
to	2	O
62-A	4	O
(	1	O
Stokes	6	O
radius	6	O
)	1	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
from	4	O
species	7	O
as	2	O
diverse	7	O
as	2	O
mouse	5	O
and	3	O
humans	6	O
.	1	O

Glucocorticoid	14	B-Gene
receptor	8	I-Gene
activation	10	O
and	3	O
inactivation	12	O
in	2	O
c	1	O
ultured	7	O
human	5	O
lymphocytes	11	O
.	1	O

Although	8	O
glucocorticoids	15	B-Chemical
are	3	O
not	3	O
cytolytic	9	O
for	3	O
and	3	O
do	2	O
not	3	O
inhibit	7	O
the	3	O
growth	6	O
of	2	O
the	3	O
IM-9	4	O
line	4	O
of	2	O
cultured	8	O
human	5	O
lymphoblasts	12	O
,	1	O
these	5	O
cells	5	O
have	4	O
a	1	O
high	4	O
steroid	7	B-Chemical
-binding	8	O
capacity	8	O
.	1	O

We	2	O
have	4	O
used	4	O
IM-9	4	O
cells	5	O
in	2	O
order	5	O
to	2	O
examine	7	O
whether	7	O
unoccupied	10	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
are	3	O
inactivated	11	O
and	3	O
activated	9	O
in	2	O
intact	6	O
cells	5	O
.	1	O

when	4	O
IM-9	4	O
cells	5	O
are	3	O
incubated	9	O
in	2	O
glucose-free	12	B-Chemical
medium	6	O
in	2	O
a	1	O
nitrogen	8	B-Chemical
atmosphere	10	O
,	1	O
both	4	O
their	5	O
ability	7	O
to	2	O
bind	4	O
triamcinolone	13	B-Chemical
acetonide	9	I-Chemical
and	3	O
their	5	O
ATP	3	B-Chemical
levels	6	O
decline	7	O
and	3	O
,	1	O
when	4	O
glucose	7	B-Chemical
and	3	O
oxygen	6	B-Chemical
are	3	O
reintroduced	12	O
,	1	O
ATP	3	B-Chemical
levels	6	O
and	3	O
receptor	8	O
activity	8	O
return	6	O
.	1	O

The	3	O
specific	8	O
glucocorticoid	14	B-Chemical
-binding	8	O
activity	8	O
of	2	O
cytosol	7	O
prepared	8	O
from	4	O
cells	5	O
exposed	7	O
to	2	O
various	7	O
degrees	7	O
of	2	O
energy	6	O
limitation	10	O
is	2	O
directly	8	O
correlated	10	O
with	4	O
the	3	O
ATP	3	B-Chemical
content	7	O
.	1	O

Receptor	8	O
activation	10	O
in	2	O
intact	6	O
cells	5	O
is	2	O
rapid	5	O
and	3	O
independent	11	O
of	2	O
protein	7	O
synthesis	9	O
.	1	O

Cytosol	7	O
prepared	8	O
from	4	O
inactivated	11	O
cells	5	O
can	3	O
not	3	O
be	2	O
activated	9	O
by	2	O
addition	8	O
of	2	O
ATP	3	B-Chemical
.	1	O

The	3	O
inactivation	12	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
that	4	O
occurs	6	O
when	4	O
cytosol	7	O
from	4	O
normal	6	O
IM-9	4	O
cells	5	O
is	2	O
incubated	9	O
at	2	O
25	2	O
degrees	7	O
C	1	O
is	2	O
inhibited	9	O
by	2	O
molybdate	9	B-Chemical
,	1	O
vanadate	8	B-Chemical
,	1	O
fluoride	8	B-Chemical
,	1	O
ATP	3	B-Chemical
,	1	O
and	3	O
several	7	O
other	5	O
nucleotides	11	O
.	1	O

The	3	O
experiments	11	O
with	4	O
intact	6	O
human	5	O
lymphoblasts	12	O
suggest	7	O
that	4	O
assays	6	O
of	2	O
specific	8	O
glucocorticoid	14	B-Chemical
-binding	8	O
capacity	8	O
do	2	O
not	3	O
necessarily	11	O
reflect	7	O
the	3	O
cellular	8	O
content	7	O
of	2	O
receptor	8	O
protein	7	O
.	1	O

Influence	9	O
of	2	O
sex	3	B-Gene
hormone	7	I-Gene
binding	7	I-Gene
globulin	8	I-Gene
and	3	O
serum	5	B-Gene
albumin	7	I-Gene
on	2	O
the	3	O
conversion	10	O
of	2	O
androstenedione	15	B-Chemical
to	2	O
testosterone	12	B-Chemical
by	2	O
human	5	O
erythrocytes	12	O
.	1	O

The	3	O
influence	9	O
of	2	O
human	5	B-Gene
serum	5	I-Gene
albumin	7	I-Gene
and	3	O
sex	3	B-Gene
hormone	7	I-Gene
binding	7	I-Gene
globulin	8	I-Gene
(	1	O
SHBG	4	B-Gene
)	1	O
on	2	O
the	3	O
enzymic	7	O
conversion	10	O
of	2	O
androstenedione	15	B-Chemical
to	2	O
testosterone	12	B-Chemical
in	2	O
human	5	O
erythrocytes	12	O
was	3	O
investigated	12	O
in	2	O
vitro	5	O
.	1	O

Total	5	O
plasma	6	O
and	3	O
albumin	7	B-Gene
delayed	7	O
the	3	O
conversion	10	O
rate	4	O
of	2	O
androstenedione	15	B-Chemical
,	1	O
while	5	O
SHBG	4	B-Gene
increased	9	O
it	2	O
markedly	8	O
.	1	O

The	3	O
effect	6	O
of	2	O
SHBG	4	B-Gene
was	3	O
largely	7	O
abolished	9	O
by	2	O
heating	7	O
to	2	O
60	2	O
degrees	7	O
C	1	O
for	3	O
1	1	O
h	1	O
and	3	O
by	2	O
saturating	10	O
its	3	O
binding	7	O
sites	5	O
by	2	O
DHT	3	B-Chemical
.	1	O

The	3	O
effect	6	O
of	2	O
both	4	O
proteins	8	O
was	3	O
found	5	O
to	2	O
be	2	O
related	7	O
to	2	O
their	5	O
concentration	13	O
.	1	O

It	2	O
appears	7	O
that	4	O
the	3	O
binding	7	O
sites	5	O
of	2	O
albumin	7	B-Gene
provide	7	O
a	1	O
mechanism	9	O
for	3	O
retarding	9	O
androstenedione	15	B-Chemical
uptake	6	O
by	2	O
the	3	O
erythrocytes	12	O
and	3	O
that	4	O
the	3	O
high	4	O
binding	7	O
affinity	8	O
of	2	O
SHBG	4	B-Gene
for	3	O
testosterone	12	B-Chemical
facilitates	11	O
the	3	O
diffusion	9	O
of	2	O
this	4	O
steroid	7	B-Chemical
out	3	O
of	2	O
the	3	O
cell	4	O
and	3	O
thus	4	O
,	1	O
displaces	9	O
the	3	O
chemical	8	O
equilibrium	11	O
within	6	O
the	3	O
cell	4	O
.	1	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
and	3	O
glucocorticoid	14	B-Chemical
sensitivity	11	O
of	2	O
human	5	O
leukemic	8	O
cells	5	O
.	1	O

We	2	O
have	4	O
established	11	O
optimal	7	O
conditions	10	O
for	3	O
the	3	O
measurement	11	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
in	2	O
human	5	O
white	5	O
cells	5	O
using	5	O
a	1	O
whole-cell	10	O
binding	7	O
assay	5	O
with	4	O
[	1	O
3H	2	O
]	1	O
dexamethasone	13	B-Chemical
as	2	O
the	3	O
ligand	6	O
,	1	O
and	3	O
the	3	O
subsequent	10	O
determination	13	O
of	2	O
the	3	O
GR	2	B-Gene
content	7	O
in	2	O
normal	6	O
human	5	O
lymphocytes	11	O
and	3	O
in	2	O
leukemic	8	O
cells	5	O
of	2	O
patients	8	O
with	4	O
various	7	O
forms	5	O
of	2	O
acute	5	O
and	3	O
chronic	7	B-Disease
leukemia	8	I-Disease
.	1	O

A	1	O
number	6	O
of	2	O
leukemia	8	B-Disease
cell	4	O
lines	5	O
in	2	O
continuous	10	O
culture	7	O
were	4	O
also	4	O
subjected	9	O
to	2	O
the	3	O
GR	2	B-Gene
assay	5	O
,	1	O
and	3	O
the	3	O
results	7	O
were	4	O
correlated	10	O
with	4	O
the	3	O
sensitivity	11	O
of	2	O
these	5	O
cell	4	O
lines	5	O
to	2	O
glucocorticoid	14	B-Chemical
steroids	8	B-Chemical
in	2	O
vitro	5	O
.	1	O

The	3	O
GR	2	B-Gene
content	7	O
of	2	O
normal	6	O
human	5	O
lymphocytes	11	O
amounted	8	O
to	2	O
4	1	O
,	1	O
850	3	O
+	1	O
/	1	O
-	1	O
1	1	O
,	1	O
340	3	O
(	1	O
mean	4	O
+	1	O
/	1	O
-	1	O
SD	2	O
)	1	O
receptors	9	O
/	1	O
cell	4	O
.	1	O

The	3	O
mean	4	O
equilibrium	11	O
dissociation	12	O
constant	8	O
(	1	O
KD	2	O
)	1	O
of	2	O
the	3	O
interaction	11	O
of	2	O
[	1	O
3H	2	O
]	1	O
dexamethasone	13	B-Chemical
with	4	O
the	3	O
GR	2	B-Gene
was	3	O
1.2	3	O
x	1	O
10	2	O
(	1	O
-8	2	O
)	1	O
M	1	O
.	1	O

Steroidal	9	O
compounds	9	O
with	4	O
a	1	O
known	5	O
glucocorticoid	14	B-Chemical
potency	7	O
effectively	11	O
competed	8	O
for	3	O
the	3	O
binding	7	O
,	1	O
whereas	7	O
steroids	8	B-Chemical
devoid	6	O
of	2	O
glucocorticoid	14	B-Chemical
activity	8	O
(	1	O
e.g.	4	O
estradiol-17	12	B-Chemical
beta	4	I-Chemical
and	3	O
testosterone	12	B-Chemical
)	1	O
were	4	O
ineffective	11	O
.	1	O

The	3	O
GR	2	B-Gene
content	7	O
of	2	O
the	3	O
blast	5	O
cells	5	O
obtained	8	O
from	4	O
eight	5	O
patients	8	O
suffering	9	O
from	4	O
acute	5	B-Disease
leukemia	8	I-Disease
and	3	O
four	4	O
patients	8	O
with	4	O
a	1	O
blast	5	O
crisis	6	O
of	2	O
chronic	7	B-Disease
myelocytic	10	I-Disease
leukemia	8	I-Disease
was	3	O
found	5	O
to	2	O
be	2	O
highly	6	O
variable	8	O
(	1	O
3	1	O
,	1	O
230-29	6	O
,	1	O
900	3	O
receptors	9	O
/	1	O
cell	4	O
)	1	O
,	1	O
while	5	O
the	3	O
lymphocytes	11	O
of	2	O
six	3	O
patients	8	O
with	4	O
chronic	7	B-Disease
lymphatic	9	I-Disease
leukemia	8	I-Disease
contained	9	O
a	1	O
rather	6	O
stable	6	O
GR	2	B-Gene
content	7	O
(	1	O
2	1	O
,	1	O
930-5	5	O
,	1	O
120	3	O
receptors	9	O
/	1	O
cell	4	O
)	1	O
,	1	O
which	5	O
was	3	O
comparable	10	O
with	4	O
that	4	O
of	2	O
normal	6	O
lymphocytes	11	O
.	1	O

GR	2	B-Gene
was	3	O
identified	10	O
in	2	O
all	3	O
the	3	O
12	2	O
malignant	9	O
continuous	10	O
white	5	O
cell	4	O
lines	5	O
studied	7	O
.	1	O

Large	5	O
cells	5	O
contained	9	O
more	4	O
GR	2	B-Gene
than	4	O
the	3	O
smaller	7	O
ones	4	O
.	1	O

There	5	O
was	3	O
no	2	O
apparent	8	O
correlation	11	O
between	7	O
the	3	O
GR	2	B-Gene
concentration	13	O
and	3	O
the	3	O
sensitivity	11	O
of	2	O
the	3	O
cells	5	O
in	2	O
vitro	5	O
to	2	O
glucocorticoids	15	B-Chemical
as	2	O
judged	6	O
by	2	O
[	1	O
3H	2	O
]	1	O
thymidine	9	B-Chemical
incorporation	13	O
studies	7	O
.	1	O

Distribution	12	O
of	2	O
the	3	O
surface	7	O
markers	7	O
in	2	O
the	3	O
leukemic	8	O
cell	4	O
lines	5	O
did	3	O
not	3	O
relate	6	O
to	2	O
the	3	O
GR	2	B-Gene
concentration	13	O
.	1	O

We	2	O
conclude	8	O
that	4	O
the	3	O
presence	8	O
of	2	O
GR	2	B-Gene
is	2	O
probably	8	O
a	1	O
universal	9	O
feature	7	O
of	2	O
the	3	O
leukemic	8	O
cells	5	O
,	1	O
and	3	O
,	1	O
from	4	O
a	1	O
clinical	8	O
standpoint	10	O
,	1	O
probably	8	O
does	4	O
not	3	O
alone	5	O
imply	5	O
steroid	7	B-Chemical
responsiveness	14	O
.	1	O

Glucocorticoid	14	B-Gene
receptor	8	I-Gene
content	7	O
of	2	O
T	1	O
lymphocytes	11	O
:	1	O
evidence	8	O
for	3	O
heterogeneity	13	O
.	1	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
were	4	O
measured	8	O
in	2	O
T	1	O
lymphocytes	11	O
that	4	O
were	4	O
isolated	8	O
from	4	O
peripheral	10	O
blood	5	O
by	2	O
either	6	O
nylon	5	B-Chemical
wool	4	O
filtration	10	O
or	2	O
E-rosette	9	O
sedimentation	13	O
.	1	O

T	1	O
cells	5	O
isolated	8	O
by	2	O
nylon	5	B-Chemical
wool	4	O
filtration	10	O
specifically	12	O
bind	4	O
6.7	3	O
+	1	O
/	1	O
-	1	O
0.2	3	O
fmol	4	O
of	2	O
dexamethasone	13	B-Chemical
per	3	O
million	7	O
cells	5	O
(	1	O
equivalent	10	O
to	2	O
4000	4	O
+	1	O
/	1	O
-	1	O
200	3	O
receptors	9	O
per	3	O
cell	4	O
)	1	O
,	1	O
whereas	7	O
T	1	O
cells	5	O
isolated	8	O
by	2	O
E-rosette	9	O
sedimentation	13	O
bind	4	O
12.0	4	O
+	1	O
/	1	O
-	1	O
0.7	3	O
fmol	4	O
of	2	O
dexamethasone	13	B-Chemical
per	3	O
million	7	O
cells	5	O
(	1	O
equivalent	10	O
to	2	O
7200	4	O
+	1	O
/	1	O
-	1	O
400	3	O
receptors	9	O
per	3	O
cell	4	O
)	1	O
.	1	O

This	4	O
difference	10	O
in	2	O
the	3	O
amount	6	O
of	2	O
dexamethasone	13	B-Chemical
bound	5	O
by	2	O
the	3	O
two	3	O
T	1	O
cell	4	O
preparations	12	O
was	3	O
significant	11	O
(	1	O
p	1	O
less	4	O
than	4	O
.001	4	O
)	1	O
and	3	O
was	3	O
present	7	O
immediately	11	O
after	5	O
cell	4	O
isolation	9	O
.	1	O

The	3	O
binding	7	O
affinities	10	O
of	2	O
the	3	O
different	9	O
T	1	O
cell	4	O
preparations	12	O
for	3	O
dexamethasone	13	B-Chemical
were	4	O
similar	7	O
.	1	O

T	1	O
cells	5	O
that	4	O
are	3	O
isolated	8	O
by	2	O
a	1	O
combination	11	O
of	2	O
nylon	5	B-Chemical
wool	4	O
filtration	10	O
followed	8	O
by	2	O
E-rosette	9	O
sedimentation	13	O
bind	4	O
the	3	O
same	4	O
amount	6	O
of	2	O
dexamethasone	13	B-Chemical
as	2	O
T	1	O
cells	5	O
isolated	8	O
by	2	O
nylon	5	B-Chemical
wool	4	O
filtration	10	O
alone	5	O
.	1	O

T	1	O
cells	5	O
isolated	8	O
by	2	O
a	1	O
combination	11	O
of	2	O
E-rosette	9	O
sedimentation	13	O
following	9	O
by	2	O
nylon	5	B-Chemical
wool	4	O
filtration	10	O
bind	4	O
less	4	O
dexamethasone	13	B-Chemical
than	4	O
do	2	O
T	1	O
cells	5	O
isolated	8	O
by	2	O
E-rosette	9	O
sedimentation	13	O
alone	5	O
.	1	O

These	5	O
findings	8	O
suggest	7	O
that	4	O
T	1	O
cells	5	O
are	3	O
heterogeneous	13	O
with	4	O
respect	7	O
to	2	O
their	5	O
quantity	8	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
.	1	O

Isolation	9	O
of	2	O
T	1	O
cells	5	O
by	2	O
E-rosette	9	O
sedimentation	13	O
enriches	8	O
for	3	O
T	1	O
cells	5	O
that	4	O
have	4	O
a	1	O
greater	7	O
number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
,	1	O
and	3	O
isolation	9	O
of	2	O
T	1	O
cells	5	O
by	2	O
nylon	5	B-Chemical
wool	4	O
filtration	10	O
enriches	8	O
for	3	O
T	1	O
cells	5	O
that	4	O
have	4	O
a	1	O
lesser	6	O
number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
.	1	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
and	3	O
sensitivity	11	O
in	2	O
leukemias	9	B-Disease
.	1	O

In	2	O
an	2	O
attempt	7	O
to	2	O
investigate	11	O
the	3	O
utility	7	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
determination	13	O
to	2	O
predict	7	O
clinical	8	O
responsiveness	14	O
in	2	O
human	5	O
leukemias	9	B-Disease
we	2	O
have	4	O
studied	7	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
the	3	O
leukemic	8	O
cells	5	O
from	4	O
46	2	O
patients	8	O
and	3	O
in	2	O
the	3	O
lymphocytes	11	O
from	4	O
18	2	O
normal	6	O
donors	6	O
.	1	O

In	2	O
the	3	O
normal	6	O
lymphocytes	11	O
there	5	O
were	4	O
3	1	O
,	1	O
875	3	O
(	1	O
Median	6	O
)	1	O
specific	8	O
binding	7	O
sites	5	O
per	3	O
cell	4	O
.	1	O

The	3	O
blasts	6	O
from	4	O
17	2	O
patients	8	O
with	4	O
ANLL	4	B-Disease
had	3	O
on	2	O
average	7	O
higher	6	O
levels	6	O
of	2	O
binding	7	O
sites	5	O
per	3	O
cell	4	O
(	1	O
Median	6	O
=	1	O
7	1	O
,	1	O
250	3	O
,	1	O
range	5	O
:	1	O
0	1	O
to	2	O
15	2	O
,	1	O
295	3	O
)	1	O
than	4	O
the	3	O
other	5	O
leukemias	9	B-Disease
.	1	O

Of	2	O
the	3	O
15	2	O
patients	8	O
with	4	O
CLL	3	B-Disease
,	1	O
six	3	O
had	3	O
received	8	O
glucocorticoid	14	B-Chemical
treatment	9	O
for	3	O
3	1	O
to	2	O
5	1	O
years	5	O
.	1	O

Their	5	O
lymphocytes	11	O
had	3	O
lower	5	O
number	6	O
of	2	O
receptors	9	O
(	1	O
Median	6	O
=	1	O
2	1	O
,	1	O
000	3	O
)	1	O
than	4	O
the	3	O
other	5	O
cases	5	O
which	5	O
were	4	O
newly	5	O
diagnosed	9	O
(	1	O
Median	6	O
=	1	O
4	1	O
,	1	O
500	3	O
)	1	O
.	1	O

Four	4	O
patients	8	O
had	3	O
ALL	3	B-Disease
/	1	O
AUL	3	B-Disease
,	1	O
three	5	O
patients	8	O
had	3	O
blast	5	O
crisis	6	O
as	2	O
terminal	8	O
phase	5	O
of	2	O
CML	3	B-Disease
,	1	O
and	3	O
seven	5	O
had	3	O
leukemic	8	O
Non-Hodgkin	11	B-Disease
lymphomas	9	I-Disease
(	1	O
Median	6	O
=	1	O
3	1	O
,	1	O
500	3	O
sites	5	O
/	1	O
cell	4	O
)	1	O
.	1	O

In	2	O
24	2	O
patients	8	O
we	2	O
have	4	O
also	4	O
studied	7	O
the	3	O
in	2	O
vitro	5	O
sensitivity	11	O
of	2	O
the	3	O
leukemic	8	O
cells	5	O
to	2	O
dexamethasone	13	B-Chemical
.	1	O

There	5	O
was	3	O
no	2	O
marked	6	O
correlation	11	O
between	7	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
levels	6	O
and	3	O
in	2	O
vitro	5	O
sensitivity	11	O
.	1	O

An	2	O
attempt	7	O
to	2	O
correlate	9	O
receptor	8	O
levels	6	O
with	4	O
clinical	8	O
responsiveness	14	O
demonstrated	12	O
that	4	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
determination	13	O
might	5	O
be	2	O
of	2	O
value	5	O
in	2	O
patients	8	O
with	4	O
lymphoid	8	O
malignancies	12	B-Disease
but	3	O
probably	8	O
not	3	O
in	2	O
patients	8	O
with	4	O
other	5	O
leukemias	9	B-Disease
.	1	O

Glucocorticoid	14	B-Gene
receptor	8	I-Gene
concentrations	14	O
and	3	O
terminal	8	B-Gene
transferase	11	I-Gene
activity	8	O
as	2	O
indicators	10	O
of	2	O
prognosis	9	O
in	2	O
acute	5	O
non-lymphocytic	15	B-Disease
leukaemia	9	I-Disease
.	1	O

Activity	8	O
of	2	O
terminal	8	B-Gene
deoxynucleotidyl	16	I-Gene
transferase	11	I-Gene
(	1	O
TdT	3	B-Gene
)	1	O
,	1	O
adenosine	9	B-Gene
deaminase	9	I-Gene
,	1	O
and	3	O
5'nucleotidase	14	B-Gene
and	3	O
the	3	O
cellular	8	O
concentration	13	O
of	2	O
glucocorticoid	14	B-Gene
(	1	I-Gene
dexamethasone	13	I-Gene
)	1	I-Gene
receptor	8	I-Gene
were	4	O
determined	10	O
in	2	O
25	2	O
patients	8	O
with	4	O
acute	5	O
non-lymphocytic	15	B-Disease
leukaemia	9	I-Disease
.	1	O

All	3	O
patients	8	O
were	4	O
treated	7	O
according	9	O
to	2	O
a	1	O
common	6	O
protocol	8	O
.	1	O

Increased	9	O
activity	8	O
of	2	O
TdT	3	B-Gene
(	1	O
greater	7	O
than	4	O
0.1	3	O
unit	4	O
/	1	O
microgram	9	O
DNA	3	O
)	1	O
was	3	O
found	5	O
in	2	O
11	2	O
patients	8	O
.	1	O

This	4	O
group	5	O
of	2	O
patients	8	O
was	3	O
shown	5	O
to	2	O
have	4	O
higher	6	O
remission	9	O
and	3	O
survival	8	O
rates	5	O
(	1	O
p	1	O
=	1	O
0.06	4	O
)	1	O
compared	8	O
with	4	O
patients	8	O
with	4	O
low	3	O
activity	8	O
of	2	O
TdT	3	B-Gene
.	1	O

The	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
concentration	13	O
of	2	O
the	3	O
leukaemic	9	O
blast	5	O
cells	5	O
ranged	6	O
from	4	O
0	1	O
to	2	O
0.94	4	O
fmol	4	O
/	1	O
microgram	9	O
DNA	3	O
.	1	O

Thirteen	8	O
patients	8	O
had	3	O
blast	5	O
cells	5	O
with	4	O
a	1	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
concentration	13	O
over	4	O
0.22	4	O
fmol	4	O
/	1	O
microgram	9	O
DNA	3	O
.	1	O

These	5	O
patients	8	O
had	3	O
significantly	13	O
increased	9	O
remission	9	O
and	3	O
survival	8	O
rates	5	O
(	1	O
p	1	O
=	1	O
0.006	5	O
)	1	O
compared	8	O
with	4	O
those	5	O
with	4	O
a	1	O
low	3	O
receptor	8	O
concentration	13	O
.	1	O

This	4	O
finding	7	O
can	3	O
not	3	O
be	2	O
explained	9	O
by	2	O
a	1	O
difference	10	O
in	2	O
sensitivity	11	O
to	2	O
glucocorticoids	15	B-Chemical
since	5	O
these	5	O
were	4	O
not	3	O
used	4	O
as	2	O
therapeutic	11	O
agents	6	O
.	1	O

Adenosine	9	B-Gene
deaminase	9	I-Gene
and	3	O
5'nucleotidase	14	B-Gene
activities	10	O
both	4	O
varied	6	O
within	6	O
two	3	O
orders	6	O
of	2	O
magnitude	9	O
.	1	O

No	2	O
correlation	11	O
could	5	O
be	2	O
found	5	O
between	7	O
activities	10	O
of	2	O
these	5	O
enzymes	7	O
and	3	O
remission	9	O
or	2	O
survival	8	O
rate	4	O
.	1	O

These	5	O
results	7	O
show	4	O
that	4	O
measurements	12	O
of	2	O
TdT	3	B-Gene
activity	8	O
and	3	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
concentration	13	O
yield	5	O
valuable	8	O
prognostic	10	O
information	11	O
in	2	O
acute	5	O
non-lymphocytic	15	B-Disease
leukaemia	9	I-Disease

Immunoglobulin	14	B-Gene
localization	12	O
in	2	O
benign	6	O
and	3	O
malignant	9	O
lesions	7	O
of	2	O
the	3	O
human	5	O
mammary	7	O
gland	5	O
.	1	O

Using	5	O
direct	6	O
imunofluorescence	17	O
,	1	O
lesions	7	O
from	4	O
266	3	O
human	5	O
breast	6	O
specimens	9	O
were	4	O
studied	7	O
for	3	O
the	3	O
presence	8	O
of	2	O
IgA	3	B-Gene
,	1	O
IgM	3	B-Gene
,	1	O
or	2	O
IgG	3	B-Gene
localization	12	O
.	1	O

The	3	O
lesions	7	O
included	8	O
benign	6	O
elements	8	O
from	4	O
66	2	O
subcutaneous	12	O
mastectomy	10	O
specimens	9	O
in	2	O
which	5	O
the	3	O
absence	7	O
of	2	O
simultaneous	12	O
breast	6	B-Disease
malignancy	10	I-Disease
was	3	O
documented	10	O
,	1	O
primary	7	O
breast	6	B-Disease
carcinomas	10	I-Disease
from	4	O
153	3	O
mastectomy	10	O
specimens	9	O
,	1	O
and	3	O
47	2	O
biopsies	8	O
containing	10	O
metastatic	10	O
breast	6	B-Disease
cancer	6	I-Disease
.	1	O

A	1	O
statistically	13	O
significant	11	O
association	11	O
of	2	O
IgA	3	B-Gene
and	3	O
IgM	3	B-Gene
with	4	O
benign	6	O
lesions	7	O
was	3	O
contrasted	10	O
to	2	O
the	3	O
association	11	O
of	2	O
IgG	3	B-Gene
with	4	O
malignant	9	O
lesions	7	O
.	1	O

In	2	O
both	4	O
primary	7	O
and	3	O
metastatic	10	O
lesions	7	O
,	1	O
IgG	3	B-Gene
localization	12	O
was	3	O
associated	10	O
with	4	O
estrogen-receptor-poor	22	B-Gene
primary	7	O
cancers	7	B-Disease
as	2	O
compared	8	O
with	4	O
estrogen-receptor-rich	22	B-Gene
primary	7	O
cancers	7	B-Disease
.	1	O

Among	5	O
primary	7	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
,	1	O
IgG	3	B-Gene
localization	12	O
in	2	O
the	3	O
tumor	5	B-Disease
correlated	10	O
with	4	O
relative	8	O
lymphopenia	11	B-Disease
.	1	O

A	1	O
shorter	7	O
disease-free	12	O
interval	8	O
was	3	O
noted	5	O
in	2	O
association	11	O
with	4	O
IgG	3	B-Gene
localization	12	O
among	5	O
the	3	O
metastatic	10	O
breast	6	O
lesions	7	O
.	1	O

No	2	O
statistically	13	O
significant	11	O
association	11	O
between	7	O
stage	5	O
of	2	O
disease	7	O
and	3	O
immunoglobulin	14	B-Gene
presence	8	O
was	3	O
demonstrable	12	O
.	1	O

Moderate-to-severe	18	B-Disease
intraductal	11	I-Disease
epithelial	10	I-Disease
hyperplasias	12	I-Disease
were	4	O
more	4	O
often	5	O
associated	10	O
with	4	O
immunoglobulin	14	B-Gene
G	1	I-Gene
localization	12	O
that	4	O
were	4	O
other	5	O
benign	6	O
lesions	7	O

Evidence	8	O
for	3	O
a	1	O
steroid	7	B-Gene
receptor	8	I-Gene
in	2	O
rheumatoid	10	O
synovial	8	O
tissue	6	O
cells	5	O
.	1	O

One	3	O
mechanism	9	O
by	2	O
which	5	O
glucocorticoids	15	B-Chemical
could	5	O
exert	5	O
their	5	O
anti-inflammatory	17	O
action	6	O
is	2	O
via	3	O
rapidly	7	O
saturable	9	O
,	1	O
stereo-specific	15	O
cytoplasmic	11	O
protein	7	O
receptors	9	O
.	1	O

This	4	O
report	6	O
is	2	O
of	2	O
an	2	O
investigation	13	O
into	4	O
such	4	O
a	1	O
possibility	11	O
in	2	O
synovial	8	O
cells	5	O
.	1	O

Synovium	8	O
,	1	O
obtained	8	O
from	4	O
knee	4	O
joints	6	O
of	2	O
rheumatoid	10	O
patients	8	O
undergoing	10	O
surgery	7	O
,	1	O
was	3	O
incubated	9	O
with	4	O
clostridiopeptidase	19	B-Gene
A	1	I-Gene
and	3	O
trypsin-EDTA	12	B-Chemical
to	2	O
obtain	6	O
cell	4	O
suspensions	11	O
.	1	O

These	5	O
,	1	O
together	8	O
with	4	O
cells	5	O
obtained	8	O
from	4	O
synovial	8	O
fluid	5	O
aspirated	9	O
from	4	O
patients	8	O
with	4	O
rheumatoid	10	B-Disease
arthritis	9	I-Disease
,	1	O
were	4	O
identified	10	O
by	2	O
electron	8	O
microscopy	10	O
.	1	O

Duplicate	9	O
samples	7	O
of	2	O
these	5	O
cell	4	O
suspensions	11	O
were	4	O
incubated	9	O
with	4	O
increasing	10	O
concentrations	14	O
of	2	O
H3Dexamethasone	15	B-Chemical
(	1	O
1	1	O
x	1	O
10	2	O
(	1	O
-10	3	O
)	1	O
M-1	3	O
x	1	O
10	2	O
(	1	O
-9	2	O
)	1	O
M	1	O
)	1	O
for	3	O
30	2	O
minutes	7	O
at	2	O
37	2	O
degrees	7	O
C	1	O
.	1	O

Analysis	8	O
of	2	O
the	3	O
proportion	10	O
of	2	O
steroid	7	B-Chemical
bound	5	O
to	2	O
whole	5	O
cells	5	O
showed	6	O
evidence	8	O
for	3	O
specific	8	O
,	1	O
rapidly	7	O
saturable	9	O
,	1	O
receptors	9	O
in	2	O
the	3	O
cells	5	O
obtained	8	O
from	4	O
synovial	8	O
tissue	6	O
,	1	O
but	3	O
this	4	O
was	3	O
not	3	O
found	5	O
in	2	O
synovial	8	O
fluid	5	O
cells	5	O
.	1	O

Electron	8	O
micrographs	11	O
showed	6	O
that	4	O
cells	5	O
obtained	8	O
from	4	O
synovial	8	O
tissue	6	O
consisted	9	O
of	2	O
synovial	8	O
fibroblast	10	O
-	1	O
and	3	O
macrophage-types	16	O
,	1	O
lymphocytes	11	O
,	1	O
monocytes	9	O
and	3	O
macrophages	11	O
.	1	O

Polymorphonuclear	17	O
leucocytes	10	O
appeared	8	O
to	2	O
be	2	O
absent	6	O
.	1	O

However	7	O
,	1	O
in	2	O
synovial	8	O
fluid	5	O
cell	4	O
type	4	O
polymorphonuclear	17	O
leucocytes	10	O
were	4	O
the	3	O
predominant	11	O
cell	4	O
type	4	O
.	1	O

We	2	O
concluded	9	O
from	4	O
this	4	O
,	1	O
that	4	O
one	3	O
or	2	O
more	4	O
of	2	O
the	3	O
cell	4	O
types	5	O
present	7	O
in	2	O
synovial	8	O
tissue	6	O
contain	7	O
a	1	O
specific	8	O
steroid	7	B-Gene
receptor	8	I-Gene
,	1	O
but	3	O
that	4	O
this	4	O
is	2	O
lacking	7	O
in	2	O
synovial	8	O
fluid	5	O
polymorphonuclear	17	O
leucocytes	10	O
.	1	O

Human	5	O
lymphoid	8	O
cell	4	O
lines	5	O
and	3	O
glucocorticoids	15	B-Chemical
:	1	O
II	2	O
.	1	O

Whole	5	O
cell	4	O
and	3	O
cytoplasmic	11	O
binding	7	O
properties	10	O
of	2	O
lymphoblastoid	14	O
,	1	O
leukaemia	9	B-Disease
and	3	O
lymphoma	8	B-Disease
lines	5	O
.	1	O

The	3	O
glucocorticoid	14	B-Chemical
binding	7	O
properties	10	O
of	2	O
18	2	O
human	5	O
lymphoid	8	O
cell	4	O
lines	5	O
(	1	O
HLCL	4	O
)	1	O
have	4	O
been	4	O
investigated	12	O
.	1	O

The	3	O
specificity	11	O
of	2	O
steroid	7	B-Chemical
binding	7	O
was	3	O
confirmed	9	O
with	4	O
various	7	O
glucocorticoid	14	B-Chemical
agonists	8	O
and	3	O
antagonists	11	O
.	1	O

A	1	O
gradation	9	O
in	2	O
whole	5	O
cell	4	O
and	3	O
cytoplasmic	11	O
glucocorticoid	14	B-Chemical
binding	7	O
capacity	8	O
was	3	O
observed	8	O
in	2	O
the	3	O
different	9	O
cell	4	O
line	4	O
types	5	O
:	1	O
lymphoblastoid	14	O
greater	7	O
than	4	O
lymphoma	8	B-Disease
greater	7	O
than	4	O
leukaemia	9	B-Disease
.	1	O

The	3	O
cytoplasmic	11	O
receptors	9	O
of	2	O
leukaemia	9	B-Disease
and	3	O
lymphoblastoid	14	O
lines	5	O
appeared	8	O
to	2	O
contain	7	O
both	4	O
proteinaceous	13	O
and	3	O
phospholipid	12	B-Chemical
components	10	O
.	1	O

Cytoplasmic	11	B-Gene
steroid-receptor	16	I-Gene
complexes	9	I-Gene
exhibited	9	O
a	1	O
wide	4	O
range	5	O
of	2	O
sedimentation	13	O
coefficients	12	O
(	1	O
8.5-11.3S	9	O
)	1	O
in	2	O
low	3	O
ionic	5	O
strength	8	O
buffer	6	O
but	3	O
there	5	O
was	3	O
no	2	O
correlation	11	O
with	4	O
cell	4	O
line	4	O
type	4	O
or	2	O
glucocorticoid	14	B-Chemical
sensitivity	11	O
.	1	O

Activation	10	O
of	2	O
these	5	O
complexes	9	O
by	2	O
heat	4	O
(	1	O
37	2	O
degrees	7	O
C	1	O
)	1	O
or	2	O
exposure	8	O
to	2	O
high	4	O
ionic	5	O
strength	8	O
buffer	6	O
(	1	O
0.3	3	O
M	1	O
NaCl	4	O
)	1	O
induced	7	O
nuclear	7	O
binding	7	O
of	2	O
steroid	7	B-Chemical
but	3	O
only	4	O
complexes	9	O
in	2	O
high	4	O
ionic	5	O
strength	8	O
buffer	6	O
manifested	10	O
changes	7	O
in	2	O
sedimentation	13	O
coefficient	11	O
.	1	O

No	2	O
correlation	11	O
was	3	O
observed	8	O
between	7	O
the	3	O
level	5	O
or	2	O
nature	6	O
of	2	O
glucocorticoid	14	B-Chemical
binding	7	O
and	3	O
the	3	O
cytolethal	10	O
or	2	O
cytostatic	10	O
responsiveness	14	O
of	2	O
HLCL	4	O
to	2	O
glucocorticoid	14	B-Chemical
treatment	9	O
in	2	O
vitro	5	O
.	1	O

The	3	O
resistance	10	O
to	2	O
cytolethal	10	O
effects	7	O
can	3	O
not	3	O
be	2	O
ascribed	8	O
to	2	O
a	1	O
failure	7	O
of	2	O
cells	5	O
to	2	O
take	4	O
up	2	O
and	3	O
bind	4	O
steroid	7	B-Chemical
or	2	O
to	2	O
significant	11	O
differences	11	O
in	2	O
the	3	O
molecular	9	O
species	7	O
of	2	O
cytoplasmic	11	O
receptors	9	O
present	7	O
.	1	O

The	3	O
molecular	9	O
mechanisms	10	O
by	2	O
which	5	O
glucocorticoids	15	B-Chemical
achieve	7	O
cytolethal	10	O
responses	9	O
in	2	O
human	5	O
lymphoid	8	O
cells	5	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
and	3	O
in	2	O
vitro	5	O
corticosensitivity	18	O
of	2	O
peanut	6	O
-positive	9	O
and	3	O
peanut	6	O
-negative	9	O
human	5	O
thymocyte	9	O
subpopulations	14	O
.	1	O

In	2	O
6	1	O
human	5	O
thymus	6	O
glands	6	O
,	1	O
the	3	O
immature	8	O
subset	6	O
of	2	O
thymocytes	10	O
was	3	O
separated	9	O
from	4	O
the	3	O
more	4	O
mature	6	O
one	3	O
,	1	O
by	2	O
differential	12	O
peanut	6	B-Gene
lectin	6	I-Gene
agglutination	13	O
.	1	O

These	5	O
2	1	O
cell	4	O
subpopulations	14	O
were	4	O
analyzed	8	O
for	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
content	7	O
by	2	O
using	5	O
a	1	O
whole	5	O
cell	4	O
assay	5	O
,	1	O
with	4	O
(	1	O
3H	2	O
)	1	O
-triamcinolone	14	B-Chemical
acetonide	9	I-Chemical
as	2	O
tracer	6	O
.	1	O

The	3	O
unagglutinated	14	O
thymocytes	10	O
(	1	O
peanut	6	O
negative	8	O
)	1	O
contained	9	O
about	5	O
2	1	O
times	5	O
more	4	O
receptor	8	O
sites	5	O
per	3	O
cell	4	O
than	4	O
agglutinated	12	O
(	1	O
peanut	6	O
positive	8	O
)	1	O
ones	4	O
(	1	O
7650	4	O
+	1	O
/	1	O
-	1	O
1550	4	O
S.D.	4	O
verus	5	O
3195	4	O
+	1	O
/	1	O
-	1	O
896	3	O
S.D.	4	O
)	1	O
.	1	O

The	3	O
affinity	8	O
for	3	O
steroid	7	B-Chemical
was	3	O
similar	7	O
in	2	O
both	4	O
cell	4	O
subsets	7	O
,	1	O
as	2	O
was	3	O
the	3	O
stereospecificity	17	O
for	3	O
glucocorticoids	15	O
,	1	O
the	3	O
time-course	11	O
of	2	O
steroid-receptor	16	B-Gene
association	11	O
,	1	O
and	3	O
cytoplasmic	11	O
to	2	O
nuclear	7	O
translocation	13	O
.	1	O

Despite	7	O
the	3	O
greater	7	O
number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
sites	5	O
,	1	O
the	3	O
peanut	6	O
-negative	9	O
thymocyte	9	O
subpopulation	13	O
did	3	O
not	3	O
differ	6	O
from	4	O
the	3	O
peanut	6	O
-positive	9	O
one	3	O
in	2	O
its	3	O
sensitivity	11	O
to	2	O
the	3	O
inhibitory	10	O
effects	7	O
of	2	O
triamcinolone	13	B-Chemical
acetonide	9	I-Chemical
,	1	O
as	2	O
determined	10	O
by	2	O
measurements	12	O
of	2	O
the	3	O
incorporation	13	O
of	2	O
radiolabeled	12	O
precursors	10	O
of	2	O
protein	7	O
and	3	O
DNA	3	O
.	1	O

Moreover	8	O
,	1	O
the	3	O
peanut	6	O
-negative	9	O
subset	6	O
appeared	8	O
more	4	O
resistant	9	O
in	2	O
vitro	5	O
to	2	O
the	3	O
steroid	7	B-Chemical
-induced	8	O
cell	4	O
lysis	5	O
as	2	O
compared	8	O
to	2	O
the	3	O
peanut	6	O
-positive	9	O
one	3	O
.	1	O

Thus	4	O
,	1	O
our	3	O
data	4	O
suggest	7	O
that	4	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
density	7	O
and	3	O
corticosensitivity	18	O
are	3	O
not	3	O
directly	8	O
correlated	10	O
and	3	O
that	4	O
the	3	O
number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
sites	5	O
may	3	O
be	2	O
dependent	9	O
on	2	O
the	3	O
degree	6	O
of	2	O
immunologic	11	O
maturation	10	O

[	1	O
Tumor	5	B-Disease
histology	9	O
and	3	O
steroid	7	B-Gene
receptors	9	I-Gene
in	2	O
breast	6	B-Disease
carcinoma	9	I-Disease
]	1	O

In	2	O
Specimens	9	O
of	2	O
115	3	O
patients	8	O
with	4	O
breast	6	B-Disease
cancer	6	I-Disease
4	1	O
tumorparameters	15	O
(	1	O
tumorsize	9	O
,	1	O
tumorboder	10	O
,	1	O
nucleargrade	12	O
,	1	O
lymphocytic	11	O
stromal	7	O
reaction	8	O
)	1	O
3	1	O
features	8	O
of	2	O
regional	8	O
lymphnodes	10	O
(	1	O
sinushistiocytosis	18	O
,	1	O
T-cellreaction	14	O
,	1	O
lymphnode	9	O
metastases	10	O
)	1	O
and	3	O
estrogen	8	B-Chemical
and	3	O
progesteron	11	B-Gene
receptors	9	I-Gene
were	4	O
determined	10	O
.	1	O

A	1	O
strong	6	O
sinushistiocytosis	18	O
and	3	O
T-cellreaction	14	O
could	5	O
be	2	O
verified	8	O
mainly	6	O
in	2	O
metastases	10	O
in	2	O
free	4	O
lymphnodes	10	O
.	1	O

The	3	O
steroid	7	B-Gene
receptor	8	I-Gene
content	7	O
does	4	O
not	3	O
correlate	9	O
with	4	O
histological	12	O
parameters	10	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
lymphoid	8	B-Disease
tumors	6	I-Disease
.	1	O

There	5	O
is	2	O
a	1	O
range	5	O
of	2	O
levels	6	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
numbers	7	O
seen	4	O
in	2	O
the	3	O
various	7	O
subclasses	10	O
of	2	O
acute	5	B-Disease
lymphatic	9	I-Disease
leukemia	8	I-Disease
(	1	O
ALL	3	B-Disease
)	1	O
.	1	O

This	4	O
variability	11	O
can	3	O
not	3	O
be	2	O
explained	9	O
by	2	O
the	3	O
known	5	O
correlation	11	O
between	7	O
active	6	O
cell	4	O
proliferation	13	O
and	3	O
an	2	O
increase	8	O
in	2	O
the	3	O
number	6	O
of	2	O
receptors	9	O
,	1	O
since	5	O
the	3	O
tumors	6	B-Disease
with	4	O
the	3	O
highest	7	O
growth	6	O
fraction	8	O
(	1	O
i.e.	4	O
,	1	O
Burkitt	7	B-Disease
's	2	I-Disease
lymphoma	8	I-Disease
and	3	O
T-cell	6	B-Disease
leukemia	8	I-Disease
)	1	O
tend	4	O
to	2	O
have	4	O
lower	5	O
average	7	O
receptor	8	O
numbers	7	O
than	4	O
do	2	O
tumors	6	B-Disease
with	4	O
lower	5	O
growth	6	O
fractions	9	O
such	4	O
as	2	O
common	6	O
ALL	3	B-Disease
.	1	O

All	3	O
clinical	8	O
specimens	9	O
from	4	O
patients	8	O
with	4	O
lymphatic	9	B-Disease
leukemia	8	I-Disease
have	4	O
some	4	O
measurable	10	O
level	5	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
;	1	O
therefore	9	O
,	1	O
the	3	O
resistance	10	O
seen	4	O
in	2	O
vivo	4	O
can	3	O
not	3	O
be	2	O
explained	9	O
by	2	O
the	3	O
lack	4	O
of	2	O
receptors	9	O
.	1	O

However	7	O
,	1	O
there	5	O
has	3	O
been	4	O
a	1	O
positive	8	O
correlation	11	O
,	1	O
in	2	O
our	3	O
hands	5	O
,	1	O
with	4	O
receptor	8	O
level	5	O
and	3	O
prognosis	9	O
.	1	O

On	2	O
the	3	O
basis	5	O
of	2	O
in	2	O
vitro	5	O
models	6	O
,	1	O
it	2	O
is	2	O
proposed	8	O
that	4	O
perhaps	7	O
the	3	O
high	4	O
receptor	8	O
cell	4	O
lines	5	O
(	1	O
i.e.	4	O
,	1	O
common	6	O
ALL	3	B-Disease
of	2	O
childhood	9	O
)	1	O
have	4	O
relative	8	O
stability	9	O
of	2	O
their	5	O
genetic	7	O
material	8	O
making	6	O
glucocorticoid	14	B-Chemical
-resistant	10	O
mutations	9	O
less	4	O
likely	6	O
to	2	O
occur	5	O
in	2	O
patients	8	O
with	4	O
these	5	O
cells	5	O
than	4	O
in	2	O
low-receptor	12	O
cell	4	O
lines	5	O
(	1	O
i.e.	4	O
,	1	O
T-cell	6	B-Disease
leukemia	8	I-Disease
)	1	O
.	1	O

This	4	O
greater	7	O
genetic	7	O
variability	11	O
in	2	O
the	3	O
low-receptor	12	O
lines	5	O
could	5	O
account	7	O
for	3	O
the	3	O
earlier	7	O
emergence	9	O
of	2	O
clinical	8	O
glucocorticoid	14	B-Chemical
resistance	10	O
in	2	O
these	5	O
patients	8	O
.	1	O

[	1	O
Glucocorticoid	14	B-Gene
receptor	8	I-Gene
level	5	O
in	2	O
the	3	O
blood	5	O
leukocytes	10	O
in	2	O
different	9	O
acute	5	O
diseases	8	O
]	1	O

Content	7	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
cytosol	7	O
of	2	O
blood	5	O
leukocytes	10	O
,	1	O
concentration	13	O
of	2	O
cortisol	8	B-Chemical
and	3	O
amount	6	O
of	2	O
leukocytes	10	O
in	2	O
blood	5	O
were	4	O
studied	7	O
in	2	O
20	2	O
patients	8	O
with	4	O
acute	5	O
impairments	11	O
within	6	O
the	3	O
second	6	O
day	3	O
of	2	O
the	3	O
disease	7	O
.	1	O

Content	7	O
of	2	O
receptors	9	O
in	2	O
cytosol	7	O
of	2	O
blood	5	O
leukocytes	10	O
was	3	O
studied	7	O
using	5	O
3H-triamcinolone	16	B-Chemical
acetonide	9	I-Chemical
.	1	O

Distinct	8	O
increase	8	O
in	2	O
amount	6	O
of	2	O
the	3	O
leukocyte	9	B-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
was	3	O
found	5	O
in	2	O
patients	8	O
with	4	O
poisoning	9	B-Disease
by	2	O
dichlorethane	13	O
and	3	O
hypnotic	8	O
drugs	5	O
under	5	O
conditions	10	O
of	2	O
acute	5	B-Disease
myocardial	10	I-Disease
infarction	10	I-Disease
.	1	O

In	2	O
acute	5	B-Disease
pancreatitis	12	I-Disease
content	7	O
of	2	O
the	3	O
leukocyte	9	O
receptors	9	O
was	3	O
not	3	O
altered	7	O
as	2	O
compared	8	O
with	4	O
controls	8	O
.	1	O

Concentration	13	O
of	2	O
endogenous	10	O
cortisol	8	B-Chemical
was	3	O
increased	9	O
in	2	O
blood	5	O
of	2	O
all	3	O
the	3	O
patients	8	O
,	1	O
except	6	O
of	2	O
the	3	O
cases	5	O
of	2	O
acetate	7	B-Chemical
intoxication	12	O
.	1	O

Reverse	7	O
correlation	11	O
was	3	O
observed	8	O
between	7	O
concentration	13	O
of	2	O
cortisol	8	B-Chemical
in	2	O
blood	5	O
and	3	O
content	7	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
leukocytes	10	O
.	1	O

But	3	O
in	2	O
the	3	O
patients	8	O
with	4	O
acute	5	B-Disease
pancreatitis	12	I-Disease
the	3	O
decrease	8	O
in	2	O
content	7	O
of	2	O
leukocyte	9	B-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
was	3	O
not	3	O
observed	8	O
although	8	O
there	5	O
was	3	O
an	2	O
increase	8	O
in	2	O
cortisol	8	B-Chemical
concentration	13	O
in	2	O
blood	5	O
.	1	O

The	3	O
role	4	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
immunological	13	O
processes	9	O
under	5	O
conditions	10	O
of	2	O
purulent	8	O
complications	13	O
and	3	O
possibility	11	O
to	2	O
regulate	8	O
the	3	O
metabolism	10	O
in	2	O
leukocytes	10	O

Decreased	9	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
binding	7	O
in	2	O
adrenal	7	B-Disease
insufficiency	13	I-Disease
.	1	O

To	2	O
examine	7	O
the	3	O
effect	6	O
of	2	O
glucocorticoid	14	B-Chemical
deficiency	10	O
on	2	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
,	1	O
we	2	O
examine	7	O
the	3	O
binding	7	O
of	2	O
[	1	O
3H	2	O
]	1	O
dexamethasone	13	B-Chemical
to	2	O
lymphocytes	11	O
in	2	O
normal	6	O
subjects	8	O
and	3	O
patients	8	O
with	4	O
adrenal	7	B-Disease
insufficiency	13	I-Disease
before	6	O
and	3	O
after	5	O
glucocorticoid	14	B-Chemical
replacement	11	O
therapy	7	O
.	1	O

Using	5	O
a	1	O
whole	5	O
cell	4	O
competitive	11	O
binding	7	O
assay	5	O
,	1	O
normal	6	O
human	5	O
lymphocytes	11	O
had	3	O
5977	4	O
+	1	O
/	1	O
-	1	O
1487	4	O
(	1	O
mean	4	O
+	1	O
/	1	O
-	1	O
SD	2	O
)	1	O
binding	7	O
sites	5	O
/	1	O
cell	4	O
and	3	O
a	1	O
dissociation	12	O
constant	8	O
of	2	O
10	2	O
+	1	O
/	1	O
-	1	O
2	1	O
nM	2	O
.	1	O

Lymphocytes	11	O
from	4	O
patients	8	O
with	4	O
untreated	9	O
adrenal	7	B-Disease
insufficiency	13	I-Disease
had	3	O
fewer	5	O
binding	7	O
sites	5	O
(	1	O
3364	4	O
+	1	O
/	1	O
-322	4	O
)	1	O
and	3	O
a	1	O
2-fold	6	O
increase	8	O
in	2	O
binding	7	O
affinity	8	O
(	1	O
5.4	3	O
+	1	O
/	1	O
-	1	O
0.9	3	O
mM	2	O
)	1	O
.	1	O

The	3	O
administration	14	O
of	2	O
conventional	12	O
replacement	11	O
doses	5	O
of	2	O
cortisone	9	B-Chemical
acetate	7	I-Chemical
for	3	O
6	1	O
months	6	O
caused	6	O
no	2	O
change	6	O
in	2	O
receptor	8	O
number	6	O
,	1	O
but	3	O
was	3	O
associated	10	O
with	4	O
a	1	O
decrease	8	O
in	2	O
binding	7	O
affinity	8	O
toward	6	O
normal	6	O
.	1	O

After	5	O
long	4	O
term	4	O
glucocorticoid	14	B-Chemical
replacement	11	O
therapy	7	O
,	1	O
binding	7	O
parameters	10	O
were	4	O
similar	7	O
to	2	O
those	5	O
in	2	O
patients	8	O
before	6	O
treatment	9	O
.	1	O

The	3	O
physiological	13	O
implications	12	O
of	2	O
the	3	O
decreased	9	O
receptor	8	O
number	6	O
and	3	O
increased	9	O
binding	7	O
affinity	8	O
in	2	O
adrenal	7	B-Disease
insufficiency	13	I-Disease
remain	6	O
to	2	O
be	2	O
elucidated	10	O
.	1	O

Glucocorticoid	14	B-Gene
receptor	8	I-Gene
and	3	O
in	2	O
vitro	5	O
sensitivity	11	O
to	2	O
steroid	7	B-Chemical
hormones	8	I-Chemical
in	2	O
human	5	O
lymphoproliferative	19	B-Disease
diseases	8	I-Disease
and	3	O
myeloid	7	B-Disease
leukemia	8	I-Disease
.	1	O

The	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
quantitation	12	O
by	2	O
a	1	O
whole-cell	10	O
assay	5	O
and	3	O
/	1	O
or	2	O
cytosol	7	O
technique	9	O
and	3	O
the	3	O
in	2	O
vitro	5	O
sensitivity	11	O
to	2	O
steroids	8	B-Chemical
have	4	O
been	4	O
assessed	8	O
in	2	O
peripheral	10	O
blood	5	O
cells	5	O
from	4	O
normal	6	O
donors	6	O
and	3	O
patients	8	O
with	4	O
chronic	7	B-Disease
lymphatic	9	I-Disease
leukemia	8	I-Disease
(	1	O
CLL	3	B-Disease
)	1	O
,	1	O
acute	5	B-Disease
lymphoblastic	13	I-Disease
leukemia	8	I-Disease
(	1	O
ALL	3	B-Disease
)	1	O
,	1	O
lymphosarcoma	13	B-Disease
cell	4	I-Disease
leukemia	8	I-Disease
(	1	O
LSCL	4	B-Disease
)	1	O
,	1	O
acute	5	B-Disease
nonlymphatic	12	I-Disease
leukemia	8	I-Disease
(	1	O
ANLL	4	B-Disease
)	1	O
,	1	O
and	3	O
chronic	7	B-Disease
myeloid	7	I-Disease
leukemia	8	I-Disease
(	1	O
CML	3	B-Disease
)	1	O
.	1	O

Within	6	O
the	3	O
lymphoproliferative	19	B-Disease
diseases	8	I-Disease
,	1	O
ALL	3	B-Disease
cells	5	O
exhibited	9	O
the	3	O
highest	7	O
GR	2	B-Gene
concentration	13	O
(	1	O
regardless	10	O
of	2	O
the	3	O
method	6	O
used	4	O
)	1	O
and	3	O
the	3	O
highest	7	O
in	2	O
vitro	5	O
inhibition	10	O
of	2	O
spontaneous	11	O
[	1	O
3H	2	O
]	1	O
thymidine	9	B-Chemical
(	1	O
[	1	O
3H	2	O
]	1	O
TdR	3	B-Chemical
)	1	O
uptake	6	O
by	2	O
glucocorticoids	15	B-Chemical
.	1	O

A	1	O
significant	11	O
relationship	12	O
between	7	O
GR	2	B-Gene
concentration	13	O
(	1	O
whole-cell	10	O
assay	5	O
)	1	O
and	3	O
in	2	O
vitro	5	O
sensitivity	11	O
to	2	O
dexamethasone	13	B-Chemical
was	3	O
also	4	O
found	5	O
.	1	O

On	2	O
the	3	O
contrary	8	O
,	1	O
CLL	3	B-Disease
cells	5	O
presented	9	O
the	3	O
highest	7	O
sensitivity	11	O
to	2	O
glucocorticoids	15	B-Chemical
in	2	O
PHA	3	B-Gene
-stimulated	11	O
cell	4	O
cultures	8	O
.	1	O

Cells	5	O
from	4	O
the	3	O
only	4	O
two	3	O
ALL	3	B-Disease
patients	8	O
who	3	O
did	3	O
not	3	O
undergo	7	O
a	1	O
remission	9	O
after	5	O
glucocorticoid	14	B-Chemical
-inclusive	10	O
chemotherapy	12	O
had	3	O
both	4	O
the	3	O
lowest	6	O
in	2	O
vitro	5	O
sensitivity	11	O
to	2	O
dexamethasone	13	B-Chemical
and	3	O
the	3	O
lowest	6	O
GR	2	B-Gene
concentration	13	O
with	4	O
whole-cell	10	O
assay	5	O
.	1	O

Concerning	10	O
myeloid	7	B-Disease
leukemia	8	I-Disease
,	1	O
ANLL	4	B-Disease
patients	8	O
had	3	O
GR	2	B-Gene
concentrations	14	O
slightly	8	O
higher	6	O
than	4	O
those	5	O
found	5	O
in	2	O
the	3	O
ALL	3	B-Disease
group	5	O
but	3	O
exhibited	9	O
the	3	O
lowest	6	O
degree	6	O
of	2	O
inhibition	10	O
of	2	O
spontaneous	11	O
[	1	O
3H	2	O
]	1	O
TdR	3	B-Chemical
uptake	6	O
by	2	O
dexamethasone	13	B-Chemical
(	1	O
stimulatory	11	O
effects	7	O
occurred	8	O
in	2	O
some	4	O
cases	5	O
)	1	O
.	1	O

CML	3	B-Disease
cells	5	O
exhibited	9	O
an	2	O
inhibition	10	O
degree	6	O
by	2	O
in	2	O
vitro	5	O
glucocorticoids	15	B-Chemical
significantly	13	O
higher	6	O
than	4	O
that	4	O
of	2	O
ANLL	4	B-Disease
cells	5	O
but	3	O
not	3	O
different	9	O
from	4	O
that	4	O
of	2	O
lymphoproliferative	19	B-Disease
diseases	8	I-Disease
.	1	O

No	2	O
clear	5	O
relationship	12	O
among	5	O
GR	2	B-Gene
pattern	7	O
,	1	O
in	2	O
vitro	5	O
cell	4	O
sensitivity	11	O
to	2	O
glucocorticoids	15	B-Chemical
,	1	O
and	3	O
clinicohematologic	18	O
parameters	10	O
was	3	O
observed	8	O
in	2	O
myeloid	7	B-Disease
leukemia	8	I-Disease
-bearing	8	O
patients	8	O
.	1	O

Metabolic	9	O
and	3	O
ultrastructural	15	O
aspects	7	O
of	2	O
the	3	O
in	2	O
vitro	5	O
lysis	5	O
of	2	O
chronic	7	B-Disease
lymphocytic	11	I-Disease
leukemia	8	I-Disease
cells	5	O
by	2	O
glucocorticoids	15	B-Chemical
.	1	O

Human	5	O
chronic	7	B-Disease
lymphocytic	11	I-Disease
leukemia	8	I-Disease
(	1	O
CLL	3	B-Disease
)	1	O
cells	5	O
like	4	O
prothymocytes	13	O
and	3	O
immunoactivated	15	O
T-lymphocytes	13	O
are	3	O
readily	7	O
lysed	5	O
in	2	O
vitro	5	O
by	2	O
pharmacological	15	O
concentrations	14	O
of	2	O
glucocorticoids	15	B-Chemical
such	4	O
as	2	O
cortisol	8	B-Chemical
,	1	O
whereas	7	O
peripheral	10	O
blood	5	O
lymphocytes	11	O
and	3	O
thymocytes	10	O
are	3	O
unaffected	10	O
by	2	O
the	3	O
hormone	7	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
metabolic	9	O
and	3	O
ultrastructural	15	O
aspects	7	O
of	2	O
the	3	O
cortisol	8	B-Chemical
-induced	8	O
killing	7	O
process	7	O
of	2	O
CLL	3	B-Disease
cells	5	O
are	3	O
recorded	8	O
.	1	O

In	2	O
vitro	5	O
lysis	5	O
was	3	O
found	5	O
to	2	O
be	2	O
temperature	11	O
dependent	9	O
and	3	O
was	3	O
detected	8	O
only	4	O
after	5	O
6	1	O
to	2	O
8	1	O
hr	2	O
incubation	10	O
with	4	O
cortisol	8	B-Chemical
by	2	O
means	5	O
of	2	O
the	3	O
trypan	6	O
blue	4	O
exclusion	9	O
test	4	O
.	1	O

However	7	O
,	1	O
30	2	O
min	3	O
of	2	O
incubation	10	O
with	4	O
cortisol	8	B-Chemical
at	2	O
either	6	O
37	2	O
degrees	7	O
or	2	O
4	1	O
degrees	7	O
followed	8	O
by	2	O
the	3	O
removal	7	O
of	2	O
the	3	O
hormone	7	O
was	3	O
still	5	O
sufficient	10	O
to	2	O
induce	6	O
the	3	O
lytic	5	O
process	7	O
.	1	O

Ultrastructural	15	O
studies	7	O
demonstrated	12	O
sequential	10	O
changes	7	O
in	2	O
the	3	O
cytoplasm	9	O
,	1	O
including	9	O
swelling	8	O
of	2	O
mitochondria	12	O
and	3	O
cytoplasmic	11	O
decompartmentalization	22	O
,	1	O
followed	8	O
by	2	O
loss	4	O
of	2	O
surface	7	O
microvilli	10	O
with	4	O
the	3	O
appearance	10	O
of	2	O
``	2	O
holes	5	O
''in	4	O
the	3	O
cell	4	O
membrane	8	O
,	1	O
and	3	O
subsequent	10	O
condensation	12	O
of	2	O
nuclear	7	O
chromatin	9	O
.	1	O

The	3	O
large	5	O
holes	5	O
in	2	O
the	3	O
membrane	8	O
appearing	9	O
after	5	O
6	1	O
hr	2	O
of	2	O
incubation	10	O
with	4	O
the	3	O
hormone	7	O
may	3	O
be	2	O
the	3	O
cause	5	O
for	3	O
the	3	O
penetration	11	O
of	2	O
the	3	O
viable	6	O
stain	5	O
into	4	O
the	3	O
dead	4	O
cells	5	O
,	1	O
as	2	O
seen	4	O
by	2	O
light	5	O
microscopy	10	O
.	1	O

Addition	8	O
of	2	O
metabolic	9	O
inhibitors	10	O
including	9	O
actinomycin	11	B-Chemical
D	1	I-Chemical
,	1	O
puromycin	9	B-Chemical
,	1	O
and	3	O
cycloheximide	13	B-Chemical
following	9	O
administration	14	O
of	2	O
cortisol	8	B-Chemical
resulted	8	O
in	2	O
inhibition	10	O
of	2	O
the	3	O
cell	4	O
lysis	5	O
.	1	O

An	2	O
excess	6	O
of	2	O
an	2	O
antagonist	10	O
such	4	O
as	2	O
cortexolone	11	B-Chemical
was	3	O
found	5	O
to	2	O
inhibit	7	O
the	3	O
cortisol	8	B-Chemical
-induced	8	O
cytolysis	9	O
of	2	O
the	3	O
CLL	3	B-Disease
cells	5	O
.	1	O

It	2	O
is	2	O
suggested	9	O
that	4	O
the	3	O
glucocorticoid	14	B-Chemical
-induced	8	O
lysis	5	O
of	2	O
human	5	O
CLL	3	B-Disease
cells	5	O
is	2	O
similar	7	O
to	2	O
the	3	O
phenomenon	10	O
observed	8	O
in	2	O
rat	3	O
or	2	O
murine	6	O
lymphocytes	11	O
and	3	O
is	2	O
mediated	8	O
by	2	O
interaction	11	O
of	2	O
the	3	O
steroid	7	B-Chemical
molecule	8	O
with	4	O
the	3	O
cytoplasmic	11	O
receptor	8	O
.	1	O

The	3	O
resulting	9	O
complex	7	O
appears	7	O
to	2	O
activate	8	O
specific	8	O
gene	4	O
(	1	O
s	1	O
)	1	O
the	3	O
products	8	O
of	2	O
which	5	O
eventually	10	O
cause	5	O
cytolysis	9	O
.	1	O

Regulation	10	O
of	2	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
in	2	O
human	5	O
lymphocytes	11	O
.	1	O

The	3	O
presence	8	O
of	2	O
a	1	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
in	2	O
human	5	O
lymphocytes	11	O
is	2	O
well	4	O
established	11	O
,	1	O
but	3	O
factors	7	O
affecting	9	O
its	3	O
regulation	10	O
have	4	O
not	3	O
been	4	O
described	9	O
.	1	O

Using	5	O
a	1	O
competitive	11	O
binding	7	O
whole	5	O
cell	4	O
assay	5	O
,	1	O
we	2	O
have	4	O
examined	8	O
the	3	O
binding	7	O
of	2	O
[	1	O
3H	2	O
]	1	O
-dexamethasone	14	B-Chemical
at	2	O
24	2	O
and	3	O
37	2	O
degrees	7	O
C	1	O
in	2	O
untreated	9	O
normal	6	O
subjects	8	O
and	3	O
in	2	O
healthy	7	O
subjects	8	O
taking	6	O
various	7	O
glucocorticoid	14	B-Chemical
preparations	12	O
.	1	O

At	2	O
24	2	O
degrees	7	O
C	1	O
normal	6	O
human	5	O
lymphocytes	11	O
had	3	O
6000	4	O
binding	7	O
sites	5	O
/	1	O
cell	4	O
and	3	O
a	1	O
dissociation	12	O
constant	8	O
of	2	O
4	1	O
x	1	O
10	2	O
(	1	O
-9	2	O
)	1	O
M	1	O
.	1	O

The	3	O
administration	14	O
of	2	O
1	1	O
mg	2	O
of	2	O
dexamethasone	13	B-Chemical
,	1	O
5	1	O
mg	2	O
of	2	O
prednisone	10	B-Chemical
,	1	O
and	3	O
37.5	4	O
mg	2	O
of	2	O
cortisone	9	B-Chemical
acetate	7	I-Chemical
resulted	8	O
in	2	O
a	1	O
30	2	O
%	1	O
decrease	8	O
in	2	O
binding	7	O
sites	5	O
after	5	O
1	1	O
week	4	O
with	4	O
no	2	O
change	6	O
in	2	O
binding	7	O
affinity	8	O
.	1	O

No	2	O
changes	7	O
in	2	O
the	3	O
number	6	O
of	2	O
binding	7	O
sites	5	O
was	3	O
noted	5	O
before	6	O
1	1	O
week	4	O
and	3	O
the	3	O
diminished	10	O
number	6	O
persisted	9	O
for	3	O
1	1	O
week	4	O
after	5	O
discontinuation	15	O
of	2	O
glucocorticoid	14	B-Chemical
treatment	9	O
.	1	O

Lymphocytes	11	O
from	4	O
hospitalized	12	O
patients	8	O
taking	6	O
40-60	5	O
mg	2	O
of	2	O
dexamethasone	13	B-Chemical
daily	5	O
demonstrated	12	O
the	3	O
same	4	O
change	6	O
in	2	O
number	6	O
of	2	O
binding	7	O
sites	5	O
that	4	O
was	3	O
seen	4	O
in	2	O
normal	6	O
subjects	8	O
taking	6	O
1	1	O
mg	2	O
of	2	O
dexamethasone	13	B-Chemical
.	1	O

When	4	O
binding	7	O
assays	6	O
were	4	O
carried	7	O
out	3	O
at	2	O
physiologic	11	O
temperature	11	O
there	5	O
was	3	O
the	3	O
same	4	O
decrease	8	O
in	2	O
number	6	O
of	2	O
binding	7	O
sites	5	O
after	5	O
dexamethasone	13	B-Chemical
administration	14	O
,	1	O
and	3	O
in	2	O
addition	8	O
,	1	O
there	5	O
was	3	O
a	1	O
two-fold	8	O
increase	8	O
in	2	O
binding	7	O
affinity	8	O
.	1	O

Glucocorticoid	14	B-Chemical
administration	14	O
results	7	O
in	2	O
a	1	O
time	4	O
-dependent	10	O
decrease	8	O
in	2	O
the	3	O
number	6	O
of	2	O
lymphocyte	10	O
glucocorticoid	14	B-Chemical
binding	7	O
sites	5	O
that	4	O
is	2	O
independent	11	O
of	2	O
the	3	O
type	4	O
of	2	O
glucocorticoid	14	B-Chemical
administered	12	O
.	1	O

This	4	O
is	2	O
the	3	O
first	5	O
in	2	O
vivo	4	O
demonstration	13	O
that	4	O
glucocorticoids	15	B-Chemical
modulate	8	O
their	5	O
own	3	O
receptors	9	O
in	2	O
man	3	O
.	1	O

Serum	5	O
sex	3	O
steroid	7	B-Chemical
and	3	O
peptide	7	O
hormone	7	O
concentrations	14	O
,	1	O
and	3	O
endometrial	11	O
estrogen	8	B-Chemical
and	3	O
progestin	9	B-Gene
receptor	8	I-Gene
levels	6	O
during	6	O
administration	14	O
of	2	O
human	5	B-Gene
leukocyte	9	I-Gene
interferon	10	I-Gene
.	1	O

Five	4	O
normally	8	O
cycling	7	O
healthy	7	O
women	5	O
were	4	O
given	5	O
daily	5	O
subcutaneous	12	O
injections	10	O
of	2	O
human	5	B-Gene
leukocyte	9	I-Gene
interferon	10	I-Gene
(	1	O
3	1	O
X	1	O
10	2	O
(	1	O
6	1	O
)	1	O
units	5	O
/	1	O
day	3	O
)	1	O
from	4	O
the	3	O
3rd	3	O
through	7	O
23rd	4	O
day	3	O
of	2	O
the	3	O
menstrual	9	O
cycle	5	O
,	1	O
and	3	O
serum	5	O
steroid	7	B-Chemical
and	3	O
peptide	7	O
hormone	7	O
concentrations	14	O
monitored	9	O
at	2	O
3-day	5	O
intervals	9	O
during	6	O
the	3	O
treatment	9	O
and	3	O
the	3	O
preceding	9	O
control	7	O
cycle	5	O
.	1	O

Concentrations	14	O
of	2	O
cytosol	7	O
and	3	O
nuclear	7	B-Gene
estrogen	8	I-Gene
receptors	9	I-Gene
(	1	O
ERC	3	B-Gene
and	3	O
ERN	3	B-Gene
,	1	O
respectively	12	O
)	1	O
and	3	O
progestin	9	B-Gene
receptors	9	I-Gene
(	1	O
PRC	3	B-Gene
and	3	O
PRN	3	B-Gene
)	1	O
were	4	O
also	4	O
measured	8	O
from	4	O
endometrial	11	O
biopsies	8	O
taken	5	O
on	2	O
the	3	O
24th	4	O
day	3	O
of	2	O
the	3	O
control	7	O
and	3	O
treatment	9	O
cycle	5	O
.	1	O

In	2	O
addition	8	O
,	1	O
an	2	O
extensive	9	O
monitoring	10	O
of	2	O
clinical	8	O
chemical	8	O
and	3	O
hematological	13	O
tests	5	O
from	4	O
the	3	O
blood	5	O
samples	7	O
were	4	O
performed	9	O
.	1	O

Serum	5	O
estradiol	9	B-Chemical
and	3	O
progesterone	12	B-Chemical
concentrations	14	O
were	4	O
significantly	13	O
decreased	9	O
during	6	O
the	3	O
treatment	9	O
cycle	5	O
,	1	O
suggesting	10	O
that	4	O
interferon	10	B-Gene
interacts	9	O
in	2	O
vivo	4	O
with	4	O
the	3	O
function	8	O
of	2	O
both	4	O
FSH	3	B-Gene
and	3	O
LH	2	B-Gene
.	1	O

No	2	O
significant	11	O
changes	7	O
were	4	O
observed	8	O
in	2	O
the	3	O
serum	5	O
peptide	7	O
hormone	7	O
concentrations	14	O
measured	8	O
(	1	O
FSH	3	B-Gene
,	1	O
LH	2	B-Gene
,	1	O
prolactin	9	B-Gene
,	1	O
insulin	7	B-Gene
,	1	O
growth	6	B-Gene
hormone	7	I-Gene
and	3	O
TSH	3	B-Gene
)	1	O
;	1	O
neither	7	O
were	4	O
the	3	O
levels	6	O
of	2	O
endometrial	11	B-Gene
ERC	3	I-Gene
,	1	O
ERN	3	B-Gene
,	1	O
PRC	3	B-Gene
and	3	O
PRN	3	B-Gene
affected	8	O
by	2	O
interferon	10	B-Gene
administration	14	O
.	1	O

As	2	O
expected	8	O
,	1	O
interferon	10	B-Gene
administration	14	O
resulted	8	O
in	2	O
decreased	9	O
leukocyte	9	O
counts	6	O
.	1	O

Moreover	8	O
,	1	O
an	2	O
increasing	10	O
tendency	8	O
in	2	O
the	3	O
activities	10	O
of	2	O
serum	5	B-Gene
alkaline	8	I-Gene
phosphatase	11	I-Gene
and	3	O
gamma-glutamyltransferase	25	B-Gene
during	6	O
the	3	O
interferon	10	B-Gene
therapy	7	O
shows	5	O
that	4	O
interferon	10	B-Gene
may	3	O
slightly	8	O
interfere	9	O
with	4	O
the	3	O
liver	5	O
function	8	O
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
one	3	O
of	2	O
the	3	O
mechanisms	10	O
by	2	O
which	5	O
interferon	10	B-Gene
treatment	9	O
may	3	O
affect	6	O
the	3	O
growth	6	O
of	2	O
hormone	7	O
-dependent	10	O
neoplasms	9	B-Disease
could	5	O
be	2	O
the	3	O
interaction	11	O
with	4	O
production	10	O
and	3	O
/	1	O
or	2	O
function	8	O
of	2	O
circulating	11	O
hormonal	8	O
compounds	9	O
.	1	O

Clinical	8	O
implications	12	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
human	5	O
leukemia	8	B-Disease
.	1	O

Normal	6	O
lymphoid	8	O
cells	5	O
contain	7	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
.	1	O

A	1	O
variety	7	O
of	2	O
stimuli	7	O
that	4	O
activate	8	O
these	5	O
cells	5	O
also	4	O
induce	6	O
increases	9	O
in	2	O
receptor	8	O
concentration	13	O
.	1	O

Similar	7	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
can	3	O
be	2	O
detected	8	O
in	2	O
lymphoid	8	O
cells	5	O
from	4	O
patients	8	O
with	4	O
acute	5	B-Disease
lymphoblastic	13	I-Disease
leukemia	8	I-Disease
(	1	O
ALL	3	B-Disease
)	1	O
.	1	O

Absence	7	O
of	2	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
(	1	O
usually	7	O
found	5	O
in	2	O
treated	7	O
patients	8	O
)	1	O
predicts	8	O
lack	4	O
of	2	O
glucocorticoid	14	B-Chemical
responsiveness	14	O
.	1	O

Furthermore	11	O
,	1	O
in	2	O
our	3	O
hands	5	O
,	1	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
levels	6	O
correlate	9	O
with	4	O
the	3	O
duration	8	O
of	2	O
complete	8	O
remission	9	O
in	2	O
ALL	3	B-Disease
(	1	O
though	6	O
not	3	O
in	2	O
other	5	O
forms	5	O
of	2	O
leukemia	8	B-Disease
)	1	O
.	1	O

This	4	O
association	11	O
is	2	O
independent	11	O
of	2	O
cell	4	O
type	4	O
,	1	O
age	3	O
,	1	O
sex	3	O
,	1	O
or	2	O
initial	7	O
leukocyte	9	O
count	5	O
.	1	O

The	3	O
level	5	O
of	2	O
receptor	8	O
shows	5	O
a	1	O
negative	8	O
correlation	11	O
with	4	O
increasing	10	O
aggressiveness	14	O
of	2	O
the	3	O
tumor	5	B-Disease
(	1	O
null-cell	9	O
leukemia	8	B-Disease
greater	7	O
than	4	O
T-cell	6	B-Disease
leukemia	8	I-Disease
greater	7	O
than	4	O
Burkitt	7	B-Disease
's	2	I-Disease
lymphoma	8	I-Disease
)	1	O
.	1	O

Corticosteroid	14	B-Chemical
-mediated	9	O
immunoregulation	16	O
in	2	O
man	3	O
.	1	O

Glucocorticoids	15	B-Chemical
have	4	O
profound	8	O
and	3	O
complex	7	O
effects	7	O
on	2	O
the	3	O
human	5	O
immune	6	O
response	8	O
.	1	O

However	7	O
,	1	O
the	3	O
precise	7	O
mechanisms	10	O
of	2	O
the	3	O
corticosteroid	14	B-Chemical
-induced	8	O
immunoregulation	16	O
in	2	O
man	3	O
have	4	O
not	3	O
been	4	O
precisely	9	O
defined	7	O
.	1	O

Intracytoplasmic	16	O
corticosteroid-specific	23	B-Chemical
receptors	9	O
appear	6	O
to	2	O
be	2	O
an	2	O
important	9	O
common	6	O
pathway	7	O
for	3	O
steroid	7	B-Chemical
-induced	8	O
changes	7	O
,	1	O
but	3	O
variations	10	O
of	2	O
receptor	8	O
parameters	10	O
do	2	O
not	3	O
account	7	O
for	3	O
the	3	O
multifaceted	12	O
effects	7	O
on	2	O
the	3	O
immune	6	O
system	6	O
.	1	O

Human	5	O
circulating	11	O
mononuclear	11	O
cells	5	O
redistribute	12	O
out	3	O
of	2	O
the	3	O
intravascular	13	O
compartment	11	O
following	9	O
treatment	9	O
with	4	O
corticosteroids	15	B-Chemical
.	1	O

Although	8	O
certain	7	O
components	10	O
at	2	O
this	4	O
redistribution	14	O
phenomenon	10	O
have	4	O
been	4	O
well	4	O
-characterized	14	O
,	1	O
the	3	O
importance	10	O
of	2	O
this	4	O
compartmental	13	O
cellular	8	O
shift	5	O
with	4	O
respect	7	O
to	2	O
the	3	O
mechanisms	10	O
of	2	O
corticosteroid	14	B-Chemical
-induced	8	O
immunoregulation	16	O
are	3	O
less	4	O
well	4	O
-defined	8	O
.	1	O

Recent	6	O
observations	12	O
that	4	O
activated	9	O
lymphocytes	11	O
may	3	O
be	2	O
sensitive	9	O
to	2	O
the	3	O
lytic	5	O
effects	7	O
of	2	O
glucocorticoids	15	B-Chemical
suggest	7	O
that	4	O
under	5	O
certain	7	O
situations	10	O
the	3	O
elimination	11	O
of	2	O
selected	8	O
subsets	7	O
of	2	O
cells	5	O
may	3	O
be	2	O
a	1	O
relevant	8	O
mechanism	9	O
of	2	O
corticosteroid	14	B-Chemical
-mediated	9	O
immunoregulation	16	O
in	2	O
man	3	O
.	1	O

Corticosteroid	14	B-Chemical
-mediated	9	O
effects	7	O
on	2	O
monocyte	8	O
function	8	O
may	3	O
be	2	O
an	2	O
important	9	O
mechanism	9	O
of	2	O
drug	4	O
-induced	8	O
immunoregulation	16	O
in	2	O
monocyte	8	O
-dependent	10	O
responses	9	O
.	1	O

In	2	O
some	4	O
experimental	12	O
conditions	10	O
,	1	O
corticosteroids	15	B-Chemical
inhibit	7	O
Interleukin	11	B-Gene
1	1	I-Gene
production	10	O
by	2	O
monocytes	9	O
.	1	O

The	3	O
immunoregulatory	16	O
effects	7	O
of	2	O
corticosteroids	15	B-Chemical
on	2	O
lymphocyte	10	O
immune	6	O
responses	9	O
are	3	O
complex	7	O
.	1	O

In	2	O
vitro	5	O
corticosteroids	15	B-Chemical
appear	6	O
to	2	O
selectively	11	O
affect	6	O
early	5	O
immunoregulatory	16	O
events	6	O
as	2	O
opposed	7	O
to	2	O
altering	8	O
an	2	O
established	11	O
response	8	O
.	1	O

Multiple	8	O
sites	5	O
of	2	O
steroid	7	B-Chemical
-induced	8	O
modulations	11	O
of	2	O
human	5	O
B	1	O
cell	4	O
responses	9	O
have	4	O
been	4	O
defined	7	O
.	1	O

Reduced	7	O
level	5	O
of	2	O
cellular	8	B-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
in	2	O
patients	8	O
with	4	O
anorexia	8	B-Disease
nervosa	7	I-Disease
.	1	O

Specific	8	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
were	4	O
measured	8	O
in	2	O
circulating	11	O
mononuclear	11	O
leukocytes	10	O
from	4	O
12	2	O
patients	8	O
with	4	O
anorexia	8	B-Disease
nervosa	7	I-Disease
and	3	O
21	2	O
healthy	7	O
control	7	O
subjects	8	O
.	1	O

Cells	5	O
from	4	O
patients	8	O
were	4	O
found	5	O
to	2	O
contain	7	O
a	1	O
significantly	13	O
(	1	O
p	1	O
less	4	O
than	4	O
0.01	4	O
)	1	O
lower	5	O
level	5	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
(	1	O
3830	4	O
+	1	O
/	1	O
-	1	O
210	3	O
sites	5	O
/	1	O
cell	4	O
,	1	O
mean	4	O
+	1	O
/	1	O
-	1	O
SE	2	O
)	1	O
than	4	O
those	5	O
from	4	O
controls	8	O
(	1	O
4930	4	O
+	1	O
/	1	O
-	1	O
250	3	O
sites	5	O
/	1	O
cell	4	O
)	1	O
.	1	O

A	1	O
partial	7	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
defect	6	O
may	3	O
well	4	O
explain	7	O
the	3	O
abnormal	8	O
cortisol	8	B-Chemical
metabolism	10	O
and	3	O
glucocorticoid	14	B-Chemical
resistance	10	O
commonly	8	O
found	5	O
in	2	O
patients	8	O
with	4	O
anorexia	8	B-Disease
nervosa	7	I-Disease
.	1	O

Administration	14	O
of	2	O
fibroblast	10	B-Gene
interferon	10	I-Gene
to	2	O
patients	8	O
with	4	O
advanced	8	O
breast	6	B-Disease
cancer	6	I-Disease
:	1	O
possible	8	O
effects	7	O
on	2	O
skin	4	O
metastasis	10	O
and	3	O
on	2	O
hormone	7	O
receptors	9	O
.	1	O

Eleven	6	O
patients	8	O
with	4	O
metastasized	12	O
breast	6	B-Disease
cancer	6	I-Disease
received	8	O
8	1	O
intramuscular	13	O
injections	10	O
of	2	O
6	1	O
x	1	O
10	2	O
(	1	O
6	1	O
)	1	O
units	5	O
of	2	O
human	5	B-Gene
fibroblast	10	I-Gene
interferon	10	I-Gene
over	4	O
a	1	O
period	6	O
of	2	O
40	2	O
days	4	O
.	1	O

The	3	O
injections	10	O
did	3	O
not	3	O
cause	5	O
local	5	O
irritation	10	O
or	2	O
inflammation	12	O
.	1	O

Fever	5	O
occurred	8	O
in	2	O
only	4	O
1	1	O
of	2	O
the	3	O
11	2	O
patients	8	O
.	1	O

Although	8	O
several	7	O
types	5	O
of	2	O
metastases	10	O
were	4	O
monitored	9	O
,	1	O
only	4	O
skin	4	O
nodules	7	O
consistently	12	O
(	1	O
10	2	O
out	3	O
of	2	O
11	2	O
patients	8	O
)	1	O
exhibited	9	O
changes	7	O
that	4	O
were	4	O
suggestive	10	O
of	2	O
a	1	O
therapeutic	11	O
effect	6	O
of	2	O
the	3	O
treatment	9	O
regimen	7	O
:	1	O
either	6	O
a	1	O
simple	6	O
decrease	8	O
in	2	O
size	4	O
of	2	O
some	4	O
nodules	7	O
or	2	O
central	7	O
necrosis	8	O
accompanied	11	O
by	2	O
an	2	O
inflammatory	12	O
reaction	8	O
.	1	O

NK-activity	11	O
of	2	O
peripheral	10	O
blood	5	O
leukocytes	10	O
was	3	O
significantly	13	O
increased	9	O
after	5	O
administration	14	O
of	2	O
the	3	O
first	5	O
dose	4	O
;	1	O
the	3	O
effect	6	O
of	2	O
subsequent	10	O
injections	10	O
was	3	O
less	4	O
clear	5	O
.	1	O

Receptors	9	O
for	3	O
estrogens	9	B-Chemical
and	3	O
progestogens	12	B-Chemical
were	4	O
increased	9	O
in	2	O
the	3	O
tumor	5	B-Disease
biopsies	8	O
of	2	O
2	1	O
out	3	O
of	2	O
2	1	O
and	3	O
5	1	O
out	3	O
of	2	O
6	1	O
patients	8	O
tested	6	O
respectively	12	O
.	1	O

Effects	7	O
of	2	O
chronic	7	O
glucocorticoid	14	B-Chemical
excess	6	O
in	2	O
man	3	O
on	2	O
insulin	7	B-Gene
binding	7	O
to	2	O
circulating	11	O
cells	5	O
:	1	O
differences	11	O
between	7	O
endogenous	10	O
and	3	O
exogenous	9	O
hypercorticism	14	B-Disease
.	1	O

We	2	O
measured	8	O
[	1	O
125I	4	O
]	1	O
insulin	7	B-Gene
binding	7	O
to	2	O
circulating	11	O
monocytes	9	O
or	2	O
erythrocytes	12	O
from	4	O
16	2	O
patients	8	O
with	4	O
chronic	7	O
glucocorticoid	14	B-Chemical
excess	6	O
,	1	O
9	1	O
chronically	11	O
treated	7	O
with	4	O
prednisone	10	B-Chemical
and	3	O
7	1	O
with	4	O
adrenocortical	14	B-Disease
hyperfunction	13	I-Disease
.	1	O

With	4	O
monocytes	9	O
,	1	O
[	1	O
125I	4	O
]	1	O
insulin	7	B-Gene
binding	7	O
was	3	O
iincreased	10	O
in	2	O
all	3	O
patients	8	O
.	1	O

Analysis	8	O
of	2	O
binding	7	O
data	4	O
indicated	9	O
that	4	O
increased	9	O
binding	7	O
in	2	O
patients	8	O
treated	7	O
with	4	O
prednisone	10	B-Chemical
was	3	O
due	3	O
to	2	O
an	2	O
ncrease	7	O
in	2	O
receptor	8	O
concentration	13	O
,	1	O
whereas	7	O
in	2	O
patients	8	O
with	4	O
adrenocortical	14	B-Disease
hyperfunction	13	I-Disease
,	1	O
it	2	O
was	3	O
due	3	O
to	2	O
an	2	O
increase	8	O
in	2	O
receptor	8	O
affinity	8	O
.	1	O

With	4	O
erythrocytes	12	O
from	4	O
patients	8	O
with	4	O
adrenocortical	14	B-Disease
hyperfunction	13	I-Disease
there	5	O
was	3	O
an	2	O
increase	8	O
in	2	O
receptor	8	O
affinity	8	O
and	3	O
a	1	O
decrease	8	O
in	2	O
receptor	8	O
concentration	13	O
,	1	O
so	2	O
that	4	O
the	3	O
binding	7	O
of	2	O
[	1	O
125I	4	O
]	1	O
insulin	7	B-Gene
was	3	O
normal	6	O
.	1	O

The	3	O
disparity	9	O
of	2	O
results	7	O
between	7	O
endogenous	10	O
and	3	O
exogenous	9	O
hypercorticism	14	B-Disease
,	1	O
between	7	O
the	3	O
two	3	O
cell	4	O
types	5	O
,	1	O
and	3	O
between	7	O
the	3	O
present	7	O
studies	7	O
and	3	O
previous	8	O
studies	7	O
suggest	7	O
that	4	O
the	3	O
effects	7	O
of	2	O
glucocorticoid	14	B-Chemical
excess	6	O
on	2	O
the	3	O
insulin	7	B-Gene
receptor	8	I-Gene
are	3	O
extremely	9	O
complex	7	O
and	3	O
wide	4	O
-ranging	8	O
and	3	O
that	4	O
in	2	O
this	4	O
condition	9	O
,	1	O
extrapolations	14	O
in	2	O
humans	6	O
from	4	O
data	4	O
with	4	O
circulating	11	O
cells	5	O
to	2	O
liver	5	O
and	3	O
muscle	6	O
may	3	O
not	3	O
be	2	O
appropriate	11	O
.	1	O

Immunosuppressive	17	O
effect	6	O
of	2	O
serum	5	O
progesterone	12	B-Chemical
during	6	O
pregnancy	9	O
depends	7	O
on	2	O
the	3	O
progesterone	12	B-Chemical
binding	7	O
capacity	8	O
of	2	O
the	3	O
lymphocytes	11	O
.	1	O

Cytotoxic	9	O
activity	8	O
and	3	O
progesterone	12	B-Chemical
binding	7	O
capacity	8	O
of	2	O
the	3	O
lymphocytes	11	O
,	1	O
together	8	O
with	4	O
serum	5	O
progesterone	12	B-Chemical
concentrations	14	O
,	1	O
were	4	O
determined	10	O
in	2	O
women	5	O
with	4	O
normal	6	O
pregnancy	9	O
or	2	O
with	4	O
a	1	O
clinical	8	O
diagnosis	9	O
of	2	O
threatened	10	O
abortion	8	O
or	2	O
threatened	10	O
premature	9	O
labour	6	O
.	1	O

The	3	O
lymphocytes	11	O
of	2	O
women	5	O
with	4	O
threatened	10	O
abortion	8	O
or	2	O
threatened	10	O
premature	9	O
labour	6	O
showed	6	O
significantly	13	O
higher	6	O
cytotoxic	9	O
activity	8	O
(	1	O
P	1	O
less	4	O
than	4	O
0.001	5	O
)	1	O
and	3	O
significantly	13	O
lower	5	O
progesterone	12	B-Chemical
binding	7	O
capacity	8	O
(	1	O
P	1	O
less	4	O
than	4	O
0.001	5	O
)	1	O
than	4	O
did	3	O
lymphocytes	11	O
obtained	8	O
from	4	O
the	3	O
healthy	7	O
pregnant	8	O
women	5	O
.	1	O

Significant	11	O
inverse	7	O
correlation	11	O
was	3	O
found	5	O
between	7	O
progesterone	12	B-Chemical
binding	7	O
capacity	8	O
and	3	O
cytotoxic	9	O
activity	8	O
of	2	O
the	3	O
lymphocytes	11	O
(	1	O
P	1	O
less	4	O
than	4	O
0.001	5	O
)	1	O
,	1	O
but	3	O
the	3	O
progesterone	12	B-Chemical
concentration	13	O
of	2	O
the	3	O
pregnancy	9	O
serum	5	O
appeared	8	O
to	2	O
have	4	O
no	2	O
influence	9	O
on	2	O
the	3	O
other	5	O
two	3	O
parameters	10	O
.	1	O

The	3	O
findings	8	O
indicate	8	O
that	4	O
intact	6	O
progesterone	12	B-Chemical
binding	7	O
capacity	8	O
of	2	O
the	3	O
lymphocytes	11	O
is	2	O
an	2	O
essential	9	O
factor	6	O
for	3	O
the	3	O
manifestation	13	O
of	2	O
the	3	O
blocking	8	O
effect	6	O
exerted	7	O
by	2	O
pregnancy	9	O
serum	5	O
on	2	O
lymphocyte	10	O
cytotoxicity	12	O
in	2	O
vitro	5	O
.	1	O

The	3	O
association	11	O
of	2	O
cytosol	7	B-Chemical
oestrogen	9	I-Chemical
and	3	O
progesterone	12	B-Gene
receptors	9	I-Gene
with	4	O
histological	12	O
features	8	O
of	2	O
breast	6	B-Disease
cancer	6	I-Disease
and	3	O
early	5	O
recurrence	10	O
of	2	O
disease	7	O
.	1	O

Two	3	O
hundred	7	O
and	3	O
eighty-eight	12	O
primary	7	O
breast	6	B-Disease
tumours	7	I-Disease
were	4	O
examined	8	O
for	3	O
the	3	O
presence	8	O
or	2	O
absence	7	O
of	2	O
oestrogen	9	B-Chemical
(	1	O
REc	3	B-Chemical
)	1	O
and	3	O
progesterone	12	B-Gene
(	1	I-Gene
RPc	3	I-Gene
)	1	I-Gene
receptors	9	I-Gene
.	1	O

Analysis	8	O
has	3	O
shown	5	O
a	1	O
relative	8	O
interdependence	15	O
between	7	O
the	3	O
steroid	7	B-Gene
receptor	8	I-Gene
status	6	O
of	2	O
primary	7	O
breast	6	B-Disease
cancer	6	I-Disease
and	3	O
other	5	O
prognostic	10	O
variables	9	O
such	4	O
as	2	O
histological	12	O
grade	5	O
,	1	O
lymphocytic	11	O
infiltration	12	O
and	3	O
tumour	6	B-Disease
elastosis	9	I-Disease
.	1	O

There	5	O
were	4	O
significant	11	O
associations	12	O
between	7	O
epithelial	10	O
cellularity	11	O
,	1	O
stromal	7	O
fibrosis	8	O
and	3	O
the	3	O
value	5	O
of	2	O
REc	3	B-Chemical
in	2	O
those	5	O
tumours	7	B-Disease
in	2	O
which	5	O
the	3	O
receptor	8	O
was	3	O
present	7	O
.	1	O

Cellularity	11	O
and	3	O
fibrosis	8	O
were	4	O
unrelated	9	O
to	2	O
the	3	O
presence	8	O
or	2	O
absence	7	O
of	2	O
oestrogen	9	B-Gene
receptor	8	I-Gene
.	1	O

By	2	O
contrast	8	O
,	1	O
neither	7	O
the	3	O
presence	8	O
or	2	O
absence	7	O
nor	3	O
the	3	O
value	5	O
of	2	O
RPc	3	B-Chemical
could	5	O
be	2	O
related	7	O
to	2	O
cellularity	11	O
or	2	O
fibrosis	8	O
.	1	O

The	3	O
value	5	O
of	2	O
REc	3	B-Chemical
and	3	O
RPc	3	B-Chemical
analysis	8	O
as	2	O
an	2	O
indicator	9	O
of	2	O
prognosis	9	O
was	3	O
examined	8	O
in	2	O
a	1	O
sub-group	9	O
of	2	O
175	3	O
patients	8	O
receiving	9	O
no	2	O
additional	10	O
treatment	9	O
following	9	O
mastectomy	10	O
.	1	O

Overall	7	O
relapse-free	12	O
survival	8	O
(	1	O
RFS	3	O
)	1	O
was	3	O
no	2	O
different	9	O
for	3	O
those	5	O
patients	8	O
with	4	O
receptors	9	O
compared	8	O
to	2	O
those	5	O
without	7	O
them	4	O
(	1	O
REc	3	B-Chemical
P	1	O
=	1	O
0.11	4	O
,	1	O
RPc	3	B-Chemical
P	1	O
=	1	O
0.7	3	O
)	1	O
.	1	O

There	5	O
was	3	O
no	2	O
difference	10	O
in	2	O
RFS	3	O
of	2	O
receptor	8	O
positive	8	O
and	3	O
negative	8	O
tumours	7	B-Disease
when	4	O
the	3	O
axillary	8	O
node	4	O
status	6	O
was	3	O
taken	5	O
into	4	O
account	7	O
.	1	O

Specific	8	O
estrogen	8	B-Chemical
binding	7	O
sites	5	O
in	2	O
human	5	O
lymphoid	8	O
cells	5	O
and	3	O
thymic	6	O
cells	5	O
.	1	O

The	3	O
binding	7	O
of	2	O
estrogen	8	B-Chemical
in	2	O
preparations	12	O
of	2	O
human	5	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
,	1	O
as	2	O
well	4	O
as	2	O
by	2	O
splenic	7	O
and	3	O
thymic	6	O
cells	5	O
is	2	O
demonstrated	12	O
by	2	O
three	5	O
different	9	O
approaches	10	O
(	1	O
Dextran	7	B-Chemical
-coated	7	O
charcoal	8	O
method	6	O
,	1	O
whole	5	O
cell	4	O
assay	5	O
,	1	O
and	3	O
gel	3	O
filtration	10	O
on	2	O
a	1	O
sepharose	9	O
4B	2	O
column	6	O
)	1	O
.	1	O

Scatchard	9	O
's	2	O
analysis	8	O
of	2	O
[	1	O
3H	2	O
]	1	O
-moxestrol	10	B-Chemical
(	1	O
R2858	5	B-Chemical
)	1	O
and	3	O
[	1	O
3H	2	O
]	1	O
-estradiol	10	B-Chemical
binding	7	O
proves	6	O
the	3	O
existence	9	O
of	2	O
a	1	O
single	6	O
class	5	O
of	2	O
receptor	8	O
sites	5	O
having	6	O
a	1	O
dissociation	12	O
constant	8	O
of	2	O
0.18-2.4	8	O
X	1	O
10	2	O
(	1	O
-9	2	O
)	1	O
M	1	O
.	1	O

Physicochemical	15	O
properties	10	O
of	2	O
the	3	O
binder	6	O
,	1	O
including	9	O
binding	7	O
capacity	8	O
and	3	O
steroid	7	B-Chemical
specificity	11	O
,	1	O
are	3	O
quite	5	O
similar	7	O
to	2	O
those	5	O
reported	8	O
for	3	O
the	3	O
thymus	6	O
of	2	O
small	5	O
mammalian	9	O
species	7	O
or	2	O
human	5	O
thymoma	7	B-Disease
.	1	O

Binding	7	O
of	2	O
progestins	10	B-Chemical
to	2	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
.	1	O

Correlation	11	O
to	2	O
their	5	O
glucocorticoid	14	B-Chemical
-like	5	O
effects	7	O
on	2	O
in	2	O
vitro	5	O
functions	9	O
of	2	O
human	5	O
mononuclear	11	O
leukocytes	10	O
.	1	O

A	1	O
number	6	O
of	2	O
physiological	13	O
and	3	O
synthetic	9	O
progestins	10	B-Chemical
were	4	O
tested	6	O
for	3	O
their	5	O
ability	7	O
to	2	O
compete	7	O
with	4	O
[	1	O
3H	2	O
]	1	O
dexamethasone	13	B-Chemical
for	3	O
the	3	O
binding	7	O
to	2	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
of	2	O
human	5	O
mononuclear	11	O
leukocytes	10	O
and	3	O
their	5	O
ability	7	O
to	2	O
elicit	6	O
glucocorticoid	14	B-Chemical
-like	5	O
effects	7	O
on	2	O
the	3	O
same	4	O
cells	5	O
.	1	O

As	2	O
compared	8	O
to	2	O
the	3	O
reference	9	O
compound	8	O
dexamethasone	13	B-Chemical
(	1	O
relative	8	O
receptor	8	O
binding	7	O
affinity	8	O
defined	7	O
as	2	O
100	3	O
%	1	O
)	1	O
,	1	O
two	3	O
potent	6	O
synthetic	9	O
progestins	10	B-Chemical
with	4	O
a	1	O
pregnane-type	13	B-Chemical
structure	9	O
,	1	O
megestrol	9	B-Chemical
acetate	7	I-Chemical
and	3	O
medroxyprogesterone	19	B-Chemical
acetate	7	I-Chemical
,	1	O
were	4	O
found	5	O
to	2	O
display	7	O
a	1	O
considerable	12	O
binding	7	O
affinity	8	O
towards	7	O
the	3	O
receptor	8	O
(	1	O
46	2	O
and	3	O
42	2	O
%	1	O
,	1	O
respectively	12	O
)	1	O
.	1	O

The	3	O
relative	8	O
binding	7	O
affinity	8	O
of	2	O
the	3	O
naturally	9	O
occurring	9	O
ligand	6	O
,	1	O
cortisol	8	B-Chemical
,	1	O
to	2	O
the	3	O
receptor	8	O
was	3	O
clearly	7	O
lower	5	O
(	1	O
25	2	O
%	1	O
)	1	O
.	1	O

The	3	O
effective	9	O
binding	7	O
of	2	O
medroxyprogesterone	19	B-Chemical
acetate	7	I-Chemical
to	2	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
was	3	O
confirmed	9	O
by	2	O
direct	6	O
binding	7	O
studies	7	O
utilizing	9	O
a	1	O
tritiated	9	O
derivative	10	O
of	2	O
this	4	O
steroid	7	B-Chemical
.	1	O

No	2	O
evidence	8	O
for	3	O
the	3	O
existence	9	O
of	2	O
a	1	O
specific	8	O
progesterone	12	B-Gene
receptor	8	I-Gene
in	2	O
human	5	O
mononuclear	11	O
leukocytes	10	O
was	3	O
obtained	8	O
as	2	O
judged	6	O
by	2	O
the	3	O
results	7	O
of	2	O
competition	11	O
experiments	11	O
where	5	O
a	1	O
progesterone	12	B-Gene
receptor-specific	17	I-Gene
ligand	6	O
[	1	O
3H	2	O
]	1	O
Org	3	B-Chemical
2058	4	I-Chemical
was	3	O
used	4	O
.	1	O

Medroxyprogesterone	19	B-Chemical
acetate	7	I-Chemical
and	3	O
megestrol	9	B-Chemical
acetate	7	I-Chemical
also	4	O
induced	7	O
glucocorticoid	14	B-Chemical
-like	5	O
effects	7	O
on	2	O
the	3	O
lymphocyte	10	O
functions	9	O
.	1	O

These	5	O
included	8	O
inhibition	10	O
of	2	O
the	3	O
proliferative	13	O
responses	9	O
to	2	O
the	3	O
T-cell	6	O
mitogens	8	O
concanavalin	12	B-Gene
A	1	I-Gene
and	3	O
phytohaemagglutinin	19	B-Gene
and	3	O
an	2	O
enhanced	8	O
accumulation	12	O
of	2	O
immunoglobulin	14	B-Gene
secreting	9	O
cells	5	O
in	2	O
pokeweed	8	O
mitogen	7	O
-stimulated	11	O
cultures	8	O
.	1	O

The	3	O
progestin	9	B-Chemical
effect	6	O
appears	7	O
to	2	O
be	2	O
mediated	8	O
through	7	O
a	1	O
radiosensitive	14	O
(	1	O
suppressor	10	O
)	1	O
subpopulation	13	O
of	2	O
T	1	O
lymphocytes	11	O
.	1	O

In	2	O
contrast	8	O
,	1	O
the	3	O
synthetic	9	O
progestins	10	B-Chemical
related	7	O
structurally	12	O
to	2	O
19-nortestosterone	18	B-Chemical
,	1	O
norethisterone	14	B-Chemical
and	3	O
d-norgestrel	12	B-Chemical
,	1	O
were	4	O
virtually	9	O
devoid	6	O
of	2	O
binding	7	O
affinity	8	O
towards	7	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
nor	3	O
did	3	O
they	4	O
measurably	10	O
influence	9	O
the	3	O
in	2	O
vitro	5	O
lymphocyte	10	O
functions	9	O
.	1	O

These	5	O
studies	7	O
demonstrate	11	O
that	4	O
certain	7	O
progestins	10	B-Chemical
in	2	O
common	6	O
clinical	8	O
use	3	O
probably	8	O
possess	7	O
inherent	8	O
glucocorticoid	14	B-Chemical
activity	8	O
and	3	O
suggest	7	O
that	4	O
side	4	O
effects	7	O
attributable	12	O
to	2	O
this	4	O
character	9	O
(	1	O
e.g.	4	O
suppression	11	O
of	2	O
the	3	O
pituitary-adrenal	17	O
axis	4	O
)	1	O
might	5	O
be	2	O
expected	8	O
when	4	O
these	5	O
compounds	9	O
are	3	O
used	4	O
in	2	O
pharmacological	15	O
doses	5	O
.	1	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
and	3	O
cortico-sensitivity	19	O
in	2	O
a	1	O
human	5	O
clonal	6	O
monocytic	9	O
cell	4	O
line	4	O
,	1	O
CM-SM	5	O
.	1	O

CM-SM	5	O
is	2	O
a	1	O
clonal	6	O
line	4	O
of	2	O
human	5	O
precursor	9	O
mononuclear	11	O
phagocytes	10	O
inducible	9	O
to	2	O
macrophage	10	O
differentiation	15	O
in	2	O
response	8	O
to	2	O
the	3	O
tumor	5	B-Disease
promoter	8	O
phorbol	7	B-Chemical
ester	5	I-Chemical
12-O-tetradecanoyl-phorbol-13-acetate	37	I-Chemical
(	1	O
TPA	3	B-Chemical
)	1	O
.	1	O

Untreated	9	O
CM-SM	5	O
cells	5	O
contain	7	O
single	6	O
class	5	O
,	1	O
high-affinity	13	O
(	1	O
KD	2	O
=	1	O
4.0	3	O
X	1	O
10	2	O
(	1	O
-9	2	O
)	1	O
M	1	O
)	1	O
glucocorticoid-specific	23	B-Gene
receptor	8	I-Gene
sites	5	O
(	1	O
approximately	13	O
60	2	O
,	1	O
000	3	O
per	3	O
cell	4	O
)	1	O
,	1	O
as	2	O
measured	8	O
by	2	O
a	1	O
whole	5	O
cell	4	O
assay	5	O
,	1	O
at	2	O
37	2	O
degrees	7	O
C	1	O
,	1	O
using	5	O
[	1	O
3H	2	O
]	1	O
triamcinolone	13	B-Chemical
acetonide	9	I-Chemical
(	1	O
TA	2	B-Chemical
)	1	O
.	1	O

Exposure	8	O
of	2	O
CM-SM	5	O
to	2	O
dexamethasone	13	B-Chemical
(	1	O
DEX	3	B-Chemical
)	1	O
produced	8	O
a	1	O
progressive	11	O
,	1	O
dose-	5	O
and	3	O
time	4	O
-related	8	O
series	6	O
of	2	O
changes	7	O
in	2	O
CM-SM	5	O
cell	4	O
growth	6	O
,	1	O
saturation	10	O
density	7	O
,	1	O
morphology	10	O
,	1	O
and	3	O
functional	10	O
properties	10	O
,	1	O
with	4	O
half-maximal	12	O
effects	7	O
at	2	O
about	5	O
10	2	O
(	1	O
-9	2	O
)	1	O
M	1	O
for	3	O
DEX	3	B-Chemical
.	1	O

TA-receptor	11	B-Chemical
sites	5	O
rapidly	7	O
decreased	9	O
(	1	O
about	5	O
70	2	O
%	1	O
)	1	O
after	5	O
DEX	3	B-Chemical
treatment	9	O
,	1	O
without	7	O
any	3	O
apparent	8	O
change	6	O
in	2	O
steroid	7	B-Chemical
specificity	11	O
and	3	O
affinity	8	O
.	1	O

After	5	O
5	1	O
days	4	O
in	2	O
culture	7	O
with	4	O
a	1	O
saturating	10	O
concentration	13	O
(	1	O
3.6	3	O
X	1	O
10	2	O
(	1	O
-8	2	O
)	1	O
M	1	O
)	1	O
of	2	O
hormone	7	O
,	1	O
the	3	O
cells	5	O
reached	7	O
a	1	O
saturation	10	O
density	7	O
of	2	O
about	5	O
9.0	3	O
X	1	O
10	2	O
(	1	O
6	1	O
)	1	O
viable	6	O
cells	5	O
/	1	O
ml	2	O
(	1	O
about	5	O
4.0	3	O
X	1	O
10	2	O
(	1	O
6	1	O
)	1	O
viable	6	O
cells	5	O
/	1	O
ml	2	O
in	2	O
the	3	O
controls	8	O
)	1	O
,	1	O
while	5	O
the	3	O
modal	5	O
volume	6	O
of	2	O
the	3	O
resulting	9	O
cell	4	O
population	10	O
was	3	O
approximately	13	O
60	2	O
%	1	O
,	1	O
as	2	O
compared	8	O
to	2	O
the	3	O
volume	6	O
of	2	O
untreated	9	O
cells	5	O
.	1	O

DEX	3	B-Chemical
-treated	8	O
cells	5	O
appeared	8	O
less	4	O
differentiated	14	O
than	4	O
controls	8	O
,	1	O
as	2	O
assessed	8	O
by	2	O
combined	8	O
morphologic	11	O
,	1	O
antigenic	9	O
,	1	O
and	3	O
cytoenzymatic	13	O
analyses	8	O
.	1	O

DEX	3	B-Chemical
almost	6	O
completely	10	O
inhibited	9	O
TPA	3	B-Chemical
activation	10	O
of	2	O
the	3	O
following	9	O
macrophage	10	O
functions	9	O
:	1	O
adherency	9	O
to	2	O
the	3	O
culture	7	O
plate	5	O
,	1	O
expression	10	O
of	2	O
lysosomal	9	O
enzymes	7	O
,	1	O
Fc	2	B-Gene
and	3	O
C3	2	B-Gene
receptors	9	I-Gene
,	1	O
and	3	O
stimulation	11	O
of	2	O
phagocytosis	12	O
.	1	O

After	5	O
removal	7	O
of	2	O
DEX	3	B-Chemical
,	1	O
the	3	O
cells	5	O
,	1	O
within	6	O
a	1	O
few	3	O
passages	8	O
,	1	O
returned	8	O
to	2	O
a	1	O
state	5	O
apparently	10	O
identical	9	O
to	2	O
the	3	O
untreated	9	O
controls	8	O
and	3	O
could	5	O
be	2	O
induced	7	O
to	2	O
macrophage	10	O
differentiation	15	O
in	2	O
response	8	O
to	2	O
TPA	3	B-Chemical
.	1	O

Human	5	O
breast	6	B-Disease
cancer	6	I-Disease
and	3	O
impaired	8	O
NK	2	O
cell	4	O
function	8	O
.	1	O

Recent	6	O
advances	8	O
in	2	O
tumor	5	B-Disease
immunology	10	O
have	4	O
led	3	O
to	2	O
the	3	O
discovery	9	O
of	2	O
a	1	O
new	3	O
lymphoid	8	O
cell	4	O
with	4	O
unique	6	O
antitumor	9	O
activity	8	O
.	1	O

Natural	7	O
killer	6	O
(	1	O
NK	2	O
)	1	O
cells	5	O
form	4	O
an	2	O
antitumor	9	O
surveillance	12	O
system	6	O
and	3	O
appear	6	O
to	2	O
be	2	O
vital	5	O
in	2	O
preventing	10	O
tumor	5	B-Disease
growth	6	O
and	3	O
metastasis	10	O
in	2	O
animal	6	O
models	6	O
.	1	O

We	2	O
studied	7	O
NK	2	O
activity	8	O
in	2	O
patients	8	O
with	4	O
benign	6	O
and	3	O
malignant	9	O
breast	6	B-Disease
disease	7	I-Disease
,	1	O
using	5	O
a	1	O
chromium-51	11	B-Chemical
release	7	O
microtiter	10	O
cytotoxicity	12	O
assay	5	O
with	4	O
K562	4	O
cells	5	O
as	2	O
targets	7	O
.	1	O

Compared	8	O
with	4	O
benign	6	O
controls	8	O
,	1	O
patients	8	O
with	4	O
malignancies	12	B-Disease
had	3	O
significantly	13	O
depressed	9	O
NK	2	O
-mediated	9	O
lysis	5	O
(	1	O
P	1	O
less	4	O
than	4	O
0.01	4	O
)	1	O
.	1	O

Furthermore	11	O
,	1	O
lysis	5	O
in	2	O
those	5	O
with	4	O
advanced	8	O
disease	7	O
(	1	O
stages	6	O
II	2	O
,	1	O
III	3	O
,	1	O
and	3	O
IV	2	O
)	1	O
was	3	O
significantly	13	O
less	4	O
than	4	O
in	2	O
those	5	O
with	4	O
limited	7	O
disease	7	O
(	1	O
stage	5	O
I	1	O
)	1	O
(	1	O
P	1	O
less	4	O
than	4	O
0.01	4	O
)	1	O
.	1	O

NK	2	O
activity	8	O
was	3	O
not	3	O
correlated	10	O
to	2	O
estrogen	8	B-Chemical
or	2	O
progesterone	12	B-Gene
receptor	8	I-Gene
states	6	O
.	1	O

Positive	8	O
correlation	11	O
of	2	O
a	1	O
depressed	9	O
natural	7	O
killer	6	O
activity	8	O
with	4	O
the	3	O
extent	6	O
of	2	O
tumor	5	B-Disease
spread	6	O
supports	8	O
the	3	O
concept	7	O
of	2	O
an	2	O
NK	2	O
cell	4	O
immune	6	O
surveillance	12	O
system	6	O
in	2	O
breast	6	B-Disease
cancer	6	I-Disease
and	3	O
emphasizes	10	O
its	3	O
importance	10	O
in	2	O
this	4	O
malignancy	10	B-Disease
.	1	O

Covalent	8	O
labeling	8	O
of	2	O
rat	3	O
thymocyte	9	O
and	3	O
human	5	B-Gene
lymphoid	8	I-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
.	1	O

Lymphoid	8	O
cells	5	O
contain	7	O
specific	8	O
receptors	9	O
for	3	O
glucocorticoids	15	B-Chemical
.	1	O

We	2	O
have	4	O
used	4	O
[	1	O
3H	2	O
]	1	O
dexamethasone-21-mesylate	25	B-Chemical
to	2	O
label	5	O
covalently	10	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
rat	3	O
thymic	6	O
lymphocytes	11	O
and	3	O
in	2	O
neoplastic	10	O
cells	5	O
obtained	8	O
from	4	O
patients	8	O
with	4	O
acute	5	B-Disease
lymphoblastic	13	I-Disease
leukemia	8	I-Disease
and	3	O
malignant	9	B-Disease
lymphoma	8	I-Disease
.	1	O

The	3	O
covalently	10	O
labeled	7	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
were	4	O
identified	10	O
by	2	O
polyacrylamide	14	O
gel	3	O
electrophoresis	15	O
(	1	O
in	2	O
the	3	O
presence	8	O
of	2	O
0.1	3	O
%	1	O
sodium	6	O
dodecyl	7	O
sulfate	7	O
)	1	O
.	1	O

In	2	O
cytosolic	9	O
fractions	9	O
prepared	8	O
from	4	O
rat	3	O
thymic	6	O
lymphocytes	11	O
,	1	O
[	1	O
3H	2	O
]	1	O
-dexamethasone-21-mesylate	26	B-Chemical
labels	6	O
a	1	O
protein	7	O
(	1	O
Mr	2	O
approximately	13	O
equal	5	O
to	2	O
95	2	O
,	1	O
000	3	O
)	1	O
which	5	O
was	3	O
identified	10	O
as	2	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
by	2	O
the	3	O
following	9	O
criteria	8	O
:	1	O
(	1	O
a	1	O
)	1	O
labeling	8	O
of	2	O
this	4	O
moiety	6	O
is	2	O
inhibited	9	O
by	2	O
treatment	9	O
with	4	O
a	1	O
100-fold	8	O
molar	5	O
excess	6	O
of	2	O
glucocorticoids	15	B-Chemical
,	1	O
such	4	O
as	2	O
dexamethasone	13	B-Chemical
and	3	O
triamcinolone	13	B-Chemical
acetonide	9	I-Chemical
;	1	O
and	3	O
(	1	O
b	1	O
)	1	O
the	3	O
covalently	10	O
labeled	7	O
Mr	2	O
approximately	13	O
equal	5	O
to	2	O
95	2	O
,	1	O
000	3	O
protein	7	O
is	2	O
activated	9	O
(	1	O
by	2	O
heating	7	O
at	2	O
20	2	O
degrees	7	O
for	3	O
30	2	O
min	3	O
)	1	O
to	2	O
a	1	O
form	4	O
that	4	O
binds	5	O
to	2	O
DNA-cellulose	13	O
.	1	O

When	4	O
intact	6	O
thymocytes	10	O
are	3	O
treated	7	O
with	4	O
[	1	O
3H	2	O
]	1	O
dexamethasone-21-mesylate	25	B-Chemical
,	1	O
an	2	O
Mr	2	O
approximately	13	O
equal	5	O
to	2	O
95	2	O
,	1	O
000	3	O
moiety	6	O
is	2	O
also	4	O
labeled	7	O
covalently	10	O
.	1	O

Approximately	13	O
35	2	O
%	1	O
of	2	O
the	3	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
can	3	O
be	2	O
labeled	7	O
covalently	10	O
when	4	O
intact	6	O
thymocytes	10	O
are	3	O
treated	7	O
with	4	O
100	3	O
nM	2	O
[	1	O
3H	2	O
]	1	O
dexamethasone-21-mesylate	25	B-Chemical
for	3	O
30	2	O
min	3	O
at	2	O
4	1	O
degrees	7	O
.	1	O

Neoplastic	10	O
cells	5	O
from	4	O
acute	5	B-Disease
lymphoblastic	13	I-Disease
leukemia	8	I-Disease
and	3	O
malignant	9	B-Disease
lymphoma	8	I-Disease
were	4	O
treated	7	O
with	4	O
[	1	O
3H	2	O
]	1	O
dexamethasone-21-mesylate	25	B-Chemical
.	1	O

In	2	O
all	3	O
samples	7	O
,	1	O
an	2	O
Mr	2	O
approximately	13	O
equal	5	O
to	2	O
95	2	O
,	1	O
000	3	O
moiety	6	O
was	3	O
labeled	7	O
covalently	10	O
;	1	O
labeling	8	O
was	3	O
inhibited	9	O
by	2	O
excess	6	O
glucocorticoid	14	B-Chemical
.	1	O

Smaller	7	O
moieties	8	O
were	4	O
also	4	O
identified	10	O
by	2	O
competition	11	O
experiments	11	O
;	1	O
these	5	O
may	3	O
represent	9	O
proteolytic	11	O
fragments	9	O
of	2	O
the	3	O
Mr	2	O
approximately	13	O
equal	5	O
to	2	O
95	2	O
,	1	O
000	3	O
receptor	8	O
.	1	O

Thus	4	O
,	1	O
in	2	O
rat	3	O
and	3	O
human	5	O
lymphoid	8	O
cells	5	O
,	1	O
[	1	O
3H	2	O
]	1	O
dexamethasone-21-mesylate	25	B-Chemical
can	3	O
be	2	O
used	4	O
to	2	O
label	5	O
covalently	10	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
.	1	O

Specific	8	O
high-affinity	13	O
receptors	9	O
for	3	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
in	2	O
human	5	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
:	1	O
presence	8	O
in	2	O
monocytes	9	O
and	3	O
induction	9	O
in	2	O
T	1	O
lymphocytes	11	O
following	9	O
activation	10	O
.	1	O

Human	5	O
peripheral	10	O
blood	5	O
monocytes	9	O
have	4	O
high	4	O
affinity	8	O
binding	7	O
sites	5	O
for	3	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
(	1	O
Kd	2	O
0.14	4	O
nM	2	O
,	1	O
sedimentation	13	O
coefficient	11	O
3.7S	4	O
)	1	O
.	1	O

Resting	7	O
human	5	O
peripheral	10	O
blood	5	O
T	1	O
lymphocytes	11	O
,	1	O
however	7	O
,	1	O
do	2	O
not	3	O
have	4	O
a	1	O
demonstrable	12	O
1	1	B-Gene
,	1	I-Gene
25-	3	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
.	1	O

After	5	O
activation	10	O
with	4	O
phytohemagglutinin	18	B-Gene
the	3	O
T	1	O
cells	5	O
exhibit	7	O
the	3	O
receptor	8	O
within	6	O
24	2	O
h	1	O
,	1	O
and	3	O
this	4	O
expression	10	O
is	2	O
blocked	7	O
by	2	O
cycloheximide	13	B-Chemical
.	1	O

The	3	O
receptor	8	O
in	2	O
activated	9	O
T	1	O
lymphocytes	11	O
has	3	O
a	1	O
sedimentation	13	O
coefficient	11	O
of	2	O
3.7S	4	O
and	3	O
a	1	O
high	4	O
affinity	8	O
(	1	O
Kd	2	O
0.10	4	O
nM	2	O
)	1	O
for	3	O
the	3	O
ligand	6	O
.	1	O

[	1	O
Glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
normal	6	O
human	5	O
lymphocytes	11	O
]	1	O

Glucocorticoid	14	B-Gene
(	1	I-Gene
GC	2	I-Gene
)	1	I-Gene
receptors	9	I-Gene
were	4	O
studied	7	O
in	2	O
intact	6	O
lymphocytes	11	O
from	4	O
11	2	O
donors	6	O
.	1	O

GC	2	B-Chemical
binding	7	O
parameters	10	O
were	4	O
found	5	O
to	2	O
be	2	O
highly	6	O
reproducible	12	O
in	2	O
repeated	8	O
experiments	11	O
with	4	O
lymphocytes	11	O
.	1	O

It	2	O
was	3	O
shown	5	O
that	4	O
GC	2	B-Gene
receptors	9	I-Gene
in	2	O
donors	6	O
'lymphocytes	12	O
could	5	O
be	2	O
distributed	11	O
into	4	O
two	3	O
different	9	O
classes	7	O
similarly	9	O
to	2	O
the	3	O
pattern	7	O
seen	4	O
in	2	O
skin	4	O
fibroblasts	11	O
.	1	O

Human	5	O
lymphocytes	11	O
are	3	O
an	2	O
adequate	8	O
object	6	O
for	3	O
studying	8	O
genetically	11	O
determined	10	O
variability	11	O
of	2	O
GC	2	B-Gene
receptors	9	I-Gene
and	3	O
its	3	O
clinical	8	O
importance	10	O
.	1	O

Presence	8	O
and	3	O
steroid	7	B-Chemical
inducibility	12	O
of	2	O
glutamine	9	B-Gene
synthetase	10	I-Gene
in	2	O
human	5	O
leukemic	8	O
cells	5	O
.	1	O

Glutamine	9	B-Gene
synthetase	10	I-Gene
(	1	O
EC	2	O
6.3.1.2	7	O
;	1	O
GS	2	B-Gene
)	1	O
is	2	O
present	7	O
in	2	O
lymphoblasts	12	O
from	4	O
patients	8	O
with	4	O
acute	5	B-Disease
lymphoblastic	13	I-Disease
leukemia	8	I-Disease
(	1	O
ALL	3	B-Disease
)	1	O
as	2	O
well	4	O
as	2	O
in	2	O
normal	6	O
peripheral	10	O
blood	5	O
lymphocytes	11	O
.	1	O

In	2	O
16	2	O
out	3	O
of	2	O
20	2	O
ALL	3	B-Disease
patients	8	O
studied	7	O
exposure	8	O
of	2	O
the	3	O
cells	5	O
to	2	O
physiological	13	O
concentrations	14	O
of	2	O
dexamethasone	13	B-Chemical
in	2	O
vitro	5	O
increased	9	O
enzyme	6	O
activity	8	O
above	5	O
the	3	O
control	7	O
levels	6	O
.	1	O

The	3	O
increase	8	O
was	3	O
specific	8	O
for	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
ligands	7	I-Gene
.	1	O

A	1	O
direct	6	O
correlation	11	O
was	3	O
found	5	O
between	7	O
the	3	O
magnitude	9	O
of	2	O
glucocorticoid	14	B-Chemical
-mediated	9	O
increase	8	O
of	2	O
GS	2	B-Gene
activity	8	O
and	3	O
the	3	O
cellular	8	O
levels	6	O
of	2	O
specific	8	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
assayed	7	O
in	2	O
the	3	O
same	4	O
cell	4	O
specimen	8	O
.	1	O

Moreover	8	O
,	1	O
the	3	O
basal	5	O
levels	6	O
of	2	O
the	3	O
enzyme	6	O
measured	8	O
in	2	O
cells	5	O
prior	5	O
to	2	O
exposure	8	O
to	2	O
dexamethasone	13	B-Chemical
correlated	10	O
negatively	10	O
with	4	O
receptor	8	O
density	7	O
.	1	O

It	2	O
is	2	O
suggested	9	O
that	4	O
the	3	O
presence	8	O
of	2	O
steroid-inducible	17	B-Chemical
GS	2	B-Gene
in	2	O
ALL	3	B-Disease
cells	5	O
may	3	O
prove	5	O
to	2	O
be	2	O
a	1	O
marker	6	O
for	3	O
functional	10	O
receptor	8	O
sites	5	O
.	1	O

Effect	6	O
of	2	O
cell	4	O
cycle	5	O
position	8	O
on	2	O
dexamethasone	13	B-Chemical
binding	7	O
by	2	O
mouse	5	O
and	3	O
human	5	O
lymphoid	8	O
cell	4	O
lines	5	O
:	1	O
correlation	11	O
between	7	O
an	2	O
increase	8	O
in	2	O
dexamethasone	13	B-Chemical
binding	7	O
during	6	O
S	1	O
phase	5	O
and	3	O
dexamethasone	13	B-Chemical
sensitivity	11	O
.	1	O

We	2	O
determined	10	O
the	3	O
effect	6	O
of	2	O
cell	4	O
cycle	5	O
position	8	O
on	2	O
the	3	O
amount	6	O
of	2	O
dexamethasone	13	B-Chemical
that	4	O
was	3	O
specifically	12	O
bound	5	O
by	2	O
mouse	5	O
and	3	O
human	5	O
lymphoid	8	O
cell	4	O
lines	5	O
.	1	O

Cell	4	O
lines	5	O
that	4	O
were	4	O
either	6	O
sensitive	9	O
or	2	O
resistant	9	O
to	2	O
growth	6	O
inhibition	10	O
by	2	O
dexamethasone	13	B-Chemical
were	4	O
compared	8	O
.	1	O

Exponentially	13	O
growing	7	O
cells	5	O
were	4	O
separated	9	O
by	2	O
centrifugal	11	O
elutriation	11	O
into	4	O
fractions	9	O
that	4	O
corresponded	12	O
to	2	O
different	9	O
positions	9	O
in	2	O
the	3	O
cell	4	O
cycle	5	O
.	1	O

The	3	O
cell	4	O
cycle	5	O
phase	5	O
distribution	12	O
of	2	O
each	4	O
fraction	8	O
was	3	O
estimated	9	O
by	2	O
flow	4	O
cytometry	9	O
and	3	O
autoradiography	15	O
.	1	O

The	3	O
amount	6	O
of	2	O
dexamethasone	13	B-Chemical
bound	5	O
per	3	O
cell	4	O
in	2	O
each	4	O
fraction	8	O
was	3	O
measured	8	O
by	2	O
a	1	O
whole	5	O
cell	4	O
binding	7	O
assay	5	O
.	1	O

In	2	O
three	5	O
dexamethasone	13	B-Chemical
-sensitive	10	O
cell	4	O
lines	5	O
(	1	O
two	3	O
mouse	5	O
and	3	O
one	3	O
human	5	O
)	1	O
,	1	O
we	2	O
found	5	O
that	4	O
the	3	O
amount	6	O
of	2	O
dexamethasone	13	B-Chemical
bound	5	O
per	3	O
cell	4	O
increased	9	O
2-4-fold	8	O
between	7	O
G1	2	O
phase	5	O
and	3	O
S	1	O
phase	5	O
,	1	O
and	3	O
then	4	O
decreased	9	O
during	6	O
G2	2	O
/	1	O
M	1	O
phase	5	O
.	1	O

Results	7	O
were	4	O
the	3	O
same	4	O
when	4	O
the	3	O
amount	6	O
of	2	O
dexamethasone	13	B-Chemical
bound	5	O
per	3	O
milligram	9	O
of	2	O
cell	4	O
protein	7	O
was	3	O
measured	8	O
.	1	O

Binding	7	O
affinity	8	O
was	3	O
the	3	O
same	4	O
during	6	O
G1	2	O
phase	5	O
and	3	O
S	1	O
phase	5	O
,	1	O
but	3	O
the	3	O
proportion	10	O
of	2	O
bound	5	O
dexamethasone	13	B-Chemical
that	4	O
translocated	12	O
to	2	O
the	3	O
nucleus	7	O
was	3	O
greater	7	O
during	6	O
S	1	O
phase	5	O
.	1	O

In	2	O
contrast	8	O
,	1	O
we	2	O
found	5	O
that	4	O
the	3	O
amount	6	O
of	2	O
dexamethasone	13	B-Chemical
bound	5	O
per	3	O
cell	4	O
by	2	O
three	5	O
dexamethasone	13	B-Chemical
-resistant	10	O
cell	4	O
lines	5	O
(	1	O
two	3	O
mouse	5	O
and	3	O
one	3	O
human	5	O
)	1	O
did	3	O
not	3	O
increase	8	O
during	6	O
S	1	O
phase	5	O
.	1	O

Our	3	O
results	7	O
indicate	8	O
that	4	O
cell	4	O
cycle	5	O
changes	7	O
in	2	O
dexamethasone	13	B-Chemical
binding	7	O
are	3	O
not	3	O
simply	6	O
related	7	O
to	2	O
changes	7	O
in	2	O
cell	4	O
protein	7	O
or	2	O
cell	4	O
volume	6	O
during	6	O
the	3	O
cell	4	O
cycle	5	O
.	1	O

An	2	O
increase	8	O
in	2	O
dexamethasone	13	B-Chemical
binding	7	O
during	6	O
S	1	O
phase	5	O
may	3	O
be	2	O
required	8	O
for	3	O
dexamethasone	13	B-Chemical
to	2	O
inhibit	7	O
cell	4	O
growth	6	O
,	1	O
and	3	O
a	1	O
failure	7	O
of	2	O
dexamethasone	13	B-Chemical
binding	7	O
to	2	O
increase	8	O
during	6	O
S	1	O
phase	5	O
might	5	O
represent	9	O
a	1	O
new	3	O
mechanism	9	O
of	2	O
dexamethasone	13	B-Chemical
resistance	10	O
in	2	O
lymphoid	8	O
cells	5	O
.	1	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
and	3	O
steroid	7	B-Chemical
sensitivity	11	O
in	2	O
normal	6	O
and	3	O
neoplastic	10	O
human	5	O
lymphoid	8	O
tissues	7	O
:	1	O
a	1	O
review	6	O
.	1	O

The	3	O
determination	13	O
of	2	O
estrogen	8	B-Chemical
and	3	O
progesterone	12	B-Gene
receptors	9	I-Gene
in	2	O
breast	6	B-Disease
cancer	6	I-Disease
has	3	O
been	4	O
shown	5	O
to	2	O
be	2	O
useful	6	O
in	2	O
predicting	10	O
the	3	O
response	8	O
to	2	O
endocrine	9	O
therapy	7	O
.	1	O

Given	5	O
their	5	O
well-known	10	O
inhibitory	10	O
effects	7	O
on	2	O
lymphoid	8	O
tissue	6	O
,	1	O
glucocorticoids	15	B-Chemical
have	4	O
been	4	O
used	4	O
widely	6	O
in	2	O
the	3	O
treatment	9	O
of	2	O
leukemia	8	B-Disease
.	1	O

Given	5	O
these	5	O
facts	5	O
,	1	O
over	4	O
the	3	O
last	4	O
10	2	O
years	5	O
,	1	O
several	7	O
investigators	13	O
have	4	O
measured	8	O
the	3	O
number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
normal	6	O
and	3	O
neoplastic	10	O
lymphoid	8	O
tissue	6	O
to	2	O
see	3	O
whether	7	O
their	5	O
number	6	O
correlated	10	O
with	4	O
glucocorticoid	14	B-Chemical
responsiveness	14	O
in	2	O
vitro	5	O
or	2	O
in	2	O
vivo	4	O
.	1	O

No	2	O
clear	5	O
correlation	11	O
could	5	O
be	2	O
established	11	O
between	7	O
the	3	O
level	5	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
and	3	O
the	3	O
in	2	O
vitro	5	O
action	6	O
of	2	O
steroids	8	B-Chemical
in	2	O
normal	6	O
and	3	O
neoplastic	10	O
lymphoid	8	O
tissue	6	O
.	1	O

In	2	O
contrast	8	O
,	1	O
attempts	8	O
to	2	O
correlate	9	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
levels	6	O
in	2	O
acute	5	B-Disease
lymphocytic	11	I-Disease
leukemia	8	I-Disease
to	2	O
in	2	O
vivo	4	O
steroid	7	B-Chemical
responsiveness	14	O
and	3	O
immunological	13	O
type	4	O
using	5	O
the	3	O
whole-cell	10	O
-binding	8	O
assay	5	O
for	3	O
receptor	8	O
determination	13	O
and	3	O
selecting	9	O
the	3	O
patients	8	O
according	9	O
to	2	O
age	3	O
and	3	O
immunological	13	O
criteria	8	O
have	4	O
been	4	O
more	4	O
successful	10	O
.	1	O

Effect	6	O
of	2	O
thymosin	8	B-Gene
on	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
activity	8	O
and	3	O
glucocorticoid	14	B-Chemical
sensitivity	11	O
of	2	O
human	5	O
thymocytes	10	O
.	1	O

Incubation	10	O
with	4	O
thymosin	8	B-Gene
fraction	8	O
5	1	O
,	1	O
(	1	O
TMS	3	B-Gene
F5	2	O
at	2	O
300	3	O
micrograms	10	O
/	1	O
ml	2	O
)	1	O
a	1	O
partially	9	O
purified	8	O
thymic	6	O
factor	6	O
,	1	O
reduced	7	O
the	3	O
steroid	7	B-Chemical
binding	7	O
activity	8	O
of	2	O
human	5	O
infant	6	O
thymocytes	10	O
from	4	O
9.6	3	O
+	1	O
/	1	O
-	1	O
2.1	3	O
fmole	5	O
/	1	O
ml	2	O
to	2	O
5.0	3	O
+	1	O
/	1	O
-	1	O
2.0	3	O
fmole	5	O
/	1	O
ml	2	O
.	1	O

The	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
activity	8	O
in	2	O
normal	6	O
infant	6	O
thymocytes	10	O
was	3	O
found	5	O
to	2	O
be	2	O
2	1	O
,	1	O
146	3	O
+	1	O
/	1	O
-	1	O
726	3	O
(	1	O
s.d.	4	O
)	1	O
sites	5	O
per	3	O
cell	4	O
with	4	O
dissociation	12	O
constant	8	O
of	2	O
1.4	3	O
+	1	O
/	1	O
-	1	O
0.6	3	O
X	1	O
10	2	O
(	1	O
-8	2	O
)	1	O
M	1	O
.	1	O

TMS	3	B-Gene
F5	2	O
also	4	O
increased	9	O
the	3	O
resistance	10	O
of	2	O
human	5	O
thymocytes	10	O
to	2	O
the	3	O
cytolytic	9	O
effect	6	O
of	2	O
dexamethasone	13	B-Chemical
(	1	O
2.5	3	O
X	1	O
10	2	O
(	1	O
-8	2	O
)	1	O
M	1	O
)	1	O
to	2	O
168.6	5	O
+	1	O
/	1	O
-	1	O
30.2	4	O
%	1	O
of	2	O
control	7	O
(	1	O
P	1	O
less	4	O
than	4	O
0.01	4	O
)	1	O
.	1	O

In	2	O
animals	7	O
,	1	O
medullary	9	O
and	3	O
peripheral	10	O
blood	5	O
T	1	O
cells	5	O
are	3	O
more	4	O
resistant	9	O
to	2	O
glucocorticoids	15	B-Chemical
than	4	O
immature	8	O
thymic	6	O
T	1	O
cells	5	O
.	1	O

The	3	O
results	7	O
show	4	O
that	4	O
thymosin	8	B-Gene
can	3	O
induce	6	O
changes	7	O
consistent	10	O
with	4	O
differentiation	15	O
in	2	O
human	5	O
thymocytes	10	O
.	1	O

These	5	O
in	2	O
vitro	5	O
results	7	O
are	3	O
consistent	10	O
with	4	O
a	1	O
physiological	13	O
role	4	O
of	2	O
thymosin	8	B-Gene
in	2	O
intrathymic	11	O
T	1	O
cell	4	O
maturation	10	O
in	2	O
man	3	O
.	1	O

Incubation	10	O
of	2	O
a	1	O
human	5	O
malignant	9	O
thymus	6	O
derived	7	O
T	1	O
cell	4	O
line	4	O
(	1	O
MOLT	4	O
3	1	O
)	1	O
with	4	O
TMS	3	B-Gene
F5	2	O
also	4	O
resulted	8	O
in	2	O
a	1	O
significant	11	O
reduction	9	O
of	2	O
the	3	O
number	6	O
of	2	O
steroid	7	B-Chemical
binding	7	O
sites	5	O
to	2	O
44.2	4	O
+	1	O
/	1	O
-	1	O
15.3	4	O
%	1	O
of	2	O
control	7	O
(	1	O
P	1	O
less	4	O
than	4	O
0.05	4	O
)	1	O
,	1	O
but	3	O
TMS	3	B-Gene
F5	2	O
did	3	O
not	3	O
significantly	13	O
reduce	6	O
the	3	O
glucocorticoid	14	B-Chemical
sensitivity	11	O
of	2	O
MOLT	4	O
3	1	O
cells	5	O
.	1	O

Glucocorticoid	14	B-Gene
receptor	8	I-Gene
number	6	O
and	3	O
intracellular	13	O
water	5	O
space	5	O
.	1	O

In	2	O
order	5	O
to	2	O
elucidate	9	O
the	3	O
relationship	12	O
between	7	O
cell	4	O
water	5	O
content	7	O
and	3	O
number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
,	1	O
eleven	6	O
normal	6	O
and	3	O
malignant	9	O
lymphoid	8	O
or	2	O
myelomonocytic	14	O
cell	4	O
types	5	O
originating	11	O
from	4	O
mouse	5	O
,	1	O
rat	3	O
and	3	O
man	3	O
were	4	O
investigated	12	O
.	1	O

The	3	O
cellular	8	O
water	5	O
space	5	O
was	3	O
measured	8	O
with	4	O
3H2O	4	O
,	1	O
and	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
number	6	O
was	3	O
measured	8	O
in	2	O
a	1	O
whole-cell	10	O
binding	7	O
assay	5	O
with	4	O
[	1	O
3H	2	O
]	1	O
dexamethasone	13	B-Chemical
at	2	O
30	2	O
and	3	O
37	2	O
degrees	7	O
C	1	O
.	1	O

The	3	O
intracellular	13	O
water	5	O
phase	5	O
concentration	13	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
(	1	O
around	6	O
40	2	O
nmol	4	O
/	1	O
l	1	O
cell	4	O
water	5	O
)	1	O
,	1	O
and	3	O
the	3	O
dependence	10	O
of	2	O
receptor	8	O
affinity	8	O
on	2	O
temperature	11	O
were	4	O
similar	7	O
in	2	O
normal	6	O
and	3	O
malignant	9	O
rodent	6	O
and	3	O
human	5	O
cells	5	O
.	1	O

It	2	O
is	2	O
concluded	9	O
that	4	O
comparisons	11	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
levels	6	O
are	3	O
best	4	O
made	4	O
on	2	O
the	3	O
basis	5	O
of	2	O
intracellular	13	O
receptor	8	O
concentrations	14	O
.	1	O

Thermodynamics	14	O
of	2	O
steroid	7	B-Chemical
binding	7	O
to	2	O
the	3	O
human	5	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
.	1	O

The	3	O
thermodynamics	14	O
of	2	O
the	3	O
interaction	11	O
of	2	O
glucocorticoids	15	B-Chemical
with	4	O
their	5	O
receptor	8	O
were	4	O
studied	7	O
in	2	O
cytosol	7	O
from	4	O
human	5	O
lymphoblastoid	14	O
cells	5	O
.	1	O

The	3	O
rate	4	O
and	3	O
affinity	8	O
constants	9	O
of	2	O
dexamethasone	13	B-Chemical
and	3	O
cortisol	8	B-Chemical
between	7	O
0	1	O
degree	6	O
and	3	O
25	2	O
degrees	7	O
C	1	O
were	4	O
calculated	10	O
by	2	O
curve	5	O
-fitting	8	O
from	4	O
time-course	11	O
and	3	O
equilibrium	11	O
kinetics	8	O
.	1	O

The	3	O
data	4	O
were	4	O
consistent	10	O
with	4	O
a	1	O
simple	6	O
reversible	10	O
bimolecular	11	O
interaction	11	O
.	1	O

Arrhenius	9	O
and	3	O
Va	2	O
n't	3	O
Hoff	4	O
plots	5	O
were	4	O
curvilinear	11	O
for	3	O
both	4	O
steroids	8	B-Chemical
.	1	O

At	2	O
equilibrium	11	O
,	1	O
the	3	O
solution	8	O
for	3	O
the	3	O
equation	8	O
delta	5	O
G	1	O
=	1	O
delta	5	O
H	1	O
-	1	O
T	1	O
X	1	O
delta	5	O
S	1	O
(	1	O
eqn.	4	O
1	1	O
)	1	O
was	3	O
(	1	O
in	2	O
kJ	2	O
X	1	O
mol-1	5	O
)	1	O
-47	3	O
=	1	O
36	2	O
-	1	O
83	2	O
(	1	O
dexamethasone	13	B-Chemical
)	1	O
and	3	O
-42	3	O
=	1	O
-9	2	O
-	1	O
33	2	O
(	1	O
cortisol	8	B-Chemical
)	1	O
at	2	O
0	1	O
degree	6	O
C	1	O
.	1	O

Enthalpy	8	O
and	3	O
entropy	7	O
changes	7	O
decreased	9	O
quasi-linearly	14	O
with	4	O
temperature	11	O
such	4	O
that	4	O
,	1	O
at	2	O
25	2	O
degrees	7	O
C	1	O
,	1	O
the	3	O
respective	10	O
values	6	O
were	4	O
-50	3	O
=	1	O
-75	3	O
+	1	O
25	2	O
and	3	O
-43	3	O
=	1	O
-48	3	O
+	1	O
5	1	O
.	1	O

Thus	4	O
,	1	O
for	3	O
both	4	O
steroids	8	B-Chemical
,	1	O
the	3	O
interaction	11	O
was	3	O
entropy-driven	14	O
at	2	O
low	3	O
temperature	11	O
and	3	O
became	6	O
entirely	8	O
enthalpy-driven	15	O
at	2	O
20	2	O
degrees	7	O
C	1	O
.	1	O

Thermodynamic	13	O
values	6	O
for	3	O
the	3	O
transition	10	O
state	5	O
were	4	O
calculated	10	O
from	4	O
the	3	O
rate	4	O
constants	9	O
.	1	O

For	3	O
the	3	O
forward	7	O
reaction	8	O
,	1	O
eqn	3	O
.	1	O

(	1	O
1	1	O
)	1	O
gave	4	O
45	2	O
=	1	O
84	2	O
-	1	O
39	2	O
(	1	O
dexamethasone	13	B-Chemical
)	1	O
and	3	O
46	2	O
=	1	O
60	2	O
-	1	O
14	2	O
(	1	O
cortisol	8	B-Chemical
)	1	O
at	2	O
0	1	O
degree	6	O
C	1	O
,	1	O
and	3	O
44	2	O
=	1	O
24	2	O
+	1	O
20	2	O
(	1	O
dexamethasone	13	B-Chemical
)	1	O
and	3	O
46	2	O
=	1	O
28	2	O
+	1	O
18	2	O
(	1	O
cortisol	8	B-Chemical
)	1	O
at	2	O
25	2	O
degrees	7	O
C	1	O
.	1	O

These	5	O
data	4	O
fit	3	O
quite	5	O
well	4	O
with	4	O
a	1	O
two-step	8	O
model	5	O
[	1	O
Ross	4	O
&	1	O
Subramanian	11	O
(	1	O
1981	4	O
)	1	O
Biochemistry	12	O
20	2	O
,	1	O
3096-3102	9	O
]	1	O
proposed	8	O
for	3	O
ligand-protein	14	O
interactions	12	O
,	1	O
which	5	O
involves	8	O
a	1	O
partial	7	O
immobilization	14	O
of	2	O
the	3	O
reacting	8	O
species	7	O
governed	8	O
by	2	O
hydrophobic	11	O
forces	6	O
,	1	O
followed	8	O
by	2	O
stabilization	13	O
of	2	O
the	3	O
complex	7	O
by	2	O
short-range	11	O
interactions	12	O
.	1	O

On	2	O
the	3	O
basis	5	O
of	2	O
this	4	O
model	5	O
,	1	O
an	2	O
analysis	8	O
of	2	O
the	3	O
transition-state	16	O
thermodynamics	14	O
led	3	O
to	2	O
the	3	O
conclusion	10	O
that	4	O
no	2	O
more	4	O
than	4	O
half	4	O
of	2	O
the	3	O
steroid	7	B-Chemical
molecular	9	O
area	4	O
is	2	O
engaged	7	O
in	2	O
the	3	O
binding	7	O
process	7	O
.	1	O

Cell	4	O
cycle	5	O
-related	8	O
changes	7	O
in	2	O
number	6	O
of	2	O
T-lymphocyte	12	B-Gene
receptors	9	I-Gene
for	3	O
glucocorticoids	15	B-Chemical
and	3	O
insulin	7	B-Gene
.	1	O

Enriched	8	O
human	5	O
peripheral	10	O
T-lymphocytes	13	O
were	4	O
stimulated	10	O
with	4	O
PHA	3	B-Gene
and	3	O
examined	8	O
for	3	O
variations	10	O
in	2	O
insulin	7	B-Gene
and	3	O
glucocorticoid	14	B-Gene
(	1	I-Gene
dexamethasone	13	I-Gene
)	1	I-Gene
receptor	8	I-Gene
numbers	7	O
during	6	O
the	3	O
early	5	O
phases	6	O
of	2	O
the	3	O
cell	4	O
cycle	5	O
.	1	O

Cells	5	O
in	2	O
G0	2	O
,	1	O
G1a	3	O
and	3	O
G1b	3	O
phases	6	O
,	1	O
where	5	O
the	3	O
G1a	3	O
-	1	O
G1b	3	O
transition	10	O
is	2	O
an	2	O
Interleukin	11	B-Gene
2	1	I-Gene
dependent	9	O
event	5	O
,	1	O
were	4	O
quantitated	11	O
by	2	O
flow	4	O
cytometry	9	O
.	1	O

Few	3	O
but	3	O
significant	11	O
numbers	7	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
(	1	O
2700	4	O
/	1	O
cell	4	O
)	1	O
and	3	O
no	2	O
insulin	7	B-Gene
receptors	9	I-Gene
(	1	O
-1	2	O
/	1	O
cell	4	O
)	1	O
were	4	O
found	5	O
in	2	O
the	3	O
resting	7	O
(	1	O
G0	2	O
)	1	O
phase	5	O
.	1	O

As	2	O
cells	5	O
entered	7	O
the	3	O
G1a	3	O
phase	5	O
the	3	O
specific	8	O
binding	7	O
of	2	O
dexamethasone	13	B-Chemical
increased	9	O
and	3	O
of	2	O
insulin	7	B-Gene
took	4	O
place	5	O
.	1	O

Although	8	O
the	3	O
specific	8	O
binding	7	O
further	7	O
increased	9	O
as	2	O
T-cells	7	O
entered	7	O
the	3	O
G1b	3	O
phase	5	O
(	1	O
as	2	O
measured	8	O
at	2	O
44	2	O
h	1	O
of	2	O
incubation	10	O
and	3	O
using	5	O
hydroxyurea	11	B-Chemical
-treated	8	O
cells	5	O
)	1	O
,	1	O
the	3	O
major	5	O
changes	7	O
in	2	O
the	3	O
specific	8	O
binding	7	O
of	2	O
dexamethasone	13	B-Chemical
took	4	O
place	5	O
during	6	O
the	3	O
period	6	O
16	2	O
-	1	O
20	2	O
h	1	O
after	5	O
stimulation	11	O
.	1	O

Based	5	O
on	2	O
these	5	O
findings	8	O
,	1	O
it	2	O
is	2	O
concluded	9	O
that	4	O
both	4	O
receptor	8	O
types	5	O
(	1	O
cell	4	O
membrane	8	O
and	3	O
cytoplasmic	11	O
receptors	9	O
)	1	O
are	3	O
being	5	O
formed	6	O
and	3	O
increased	9	O
at	2	O
G1	2	O
phase	5	O
prior	5	O
to	2	O
cell	4	O
proliferation	13	O
,	1	O
indicating	10	O
the	3	O
importance	10	O
of	2	O
G1	2	O
phase	5	O
in	2	O
immunoregulation	16	O
.	1	O

Specific	8	O
uptake	6	O
of	2	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxycholecalciferol	27	I-Chemical
by	2	O
human	5	O
chronic	7	B-Disease
myeloid	7	I-Disease
leukemia	8	I-Disease
cells	5	O
.	1	O

We	2	O
have	4	O
examined	8	O
mononuclear	11	O
cell	4	O
preparations	12	O
from	4	O
patients	8	O
with	4	O
chronic	7	B-Disease
myeloid	7	I-Disease
leukemia	8	I-Disease
[	1	O
CML	3	B-Disease
]	1	O
for	3	O
binding	7	O
of	2	O
and	3	O
response	8	O
to	2	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxycholecalciferol	27	I-Chemical
[	1	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
]	1	O
.	1	O

Whole	5	O
cells	5	O
specifically	12	O
took	4	O
up	2	O
[	1	O
3H	2	O
]	1	O
-1	2	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
with	4	O
high	4	O
affinity	8	O
(	1	O
Kd	2	O
3.6	3	O
X	1	O
10	2	O
(	1	O
-11	3	O
)	1	O
M	1	O
)	1	O
and	3	O
low	3	O
capacity	8	O
.	1	O

Subcellular	11	O
fractionation	13	O
of	2	O
labeled	7	O
cells	5	O
showed	6	O
that	4	O
binding	7	O
was	3	O
restricted	10	O
to	2	O
cytosols	8	O
and	3	O
nuclei	6	O
.	1	O

Sucrose	7	O
gradient	8	O
centrifugation	14	O
of	2	O
cells	5	O
preincubated	12	O
with	4	O
[	1	O
3H	2	O
]	1	O
-1	2	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
revealed	8	O
a	1	O
single	6	O
3.6S	4	O
peak	4	O
which	5	O
was	3	O
totally	7	O
displaced	9	O
with	4	O
100-fold	8	O
excess	6	O
nonradioactive	14	O
hormone	7	O
.	1	O

However	7	O
,	1	O
we	2	O
were	4	O
unable	6	O
to	2	O
demonstrate	11	O
specific	8	O
binding	7	O
of	2	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
by	2	O
postlabeling	12	O
standard	8	O
cytosol	7	O
preparations	12	O
.	1	O

In	2	O
addition	8	O
,	1	O
cytosols	8	O
prepared	8	O
from	4	O
a	1	O
mixture	7	O
of	2	O
CML	3	B-Disease
cells	5	O
and	3	O
1	1	B-Gene
,	1	I-Gene
25-	3	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
-positive	9	O
T47D	4	O
(	1	O
human	5	O
breast	6	B-Disease
cancer	6	I-Disease
)	1	O
cells	5	O
had	3	O
less	4	O
than	4	O
10	2	O
%	1	O
of	2	O
the	3	O
binding	7	O
measured	8	O
in	2	O
T47D	4	O
cytosol	7	O
alone	5	O
.	1	O

However	7	O
,	1	O
the	3	O
levels	6	O
of	2	O
binding	7	O
in	2	O
T47D	4	O
cytosols	8	O
were	4	O
not	3	O
reduced	7	O
if	2	O
the	3	O
receptors	9	O
were	4	O
occupied	8	O
with	4	O
[	1	O
3H	2	O
]	1	O
-1	2	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
prior	5	O
to	2	O
the	3	O
addition	8	O
of	2	O
the	3	O
CML	3	B-Disease
cytosols	8	O
.	1	O

Thus	4	O
,	1	O
CML	3	B-Disease
cells	5	O
appear	6	O
to	2	O
contain	7	O
both	4	O
the	3	O
receptor	8	O
for	3	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
and	3	O
an	2	O
unknown	7	O
substance	9	O
which	5	O
prevents	8	O
its	3	O
detection	9	O
following	9	O
the	3	O
preparation	11	O
of	2	O
cytosol	7	O
.	1	O

Cells	5	O
from	4	O
patients	8	O
with	4	O
CML	3	B-Disease
in	2	O
the	3	O
chronic	7	O
phase	5	O
specifically	12	O
bound	5	O
more	4	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
[	1	O
18.0	4	O
+	1	O
/	1	O
-	1	O
3.2	3	O
(	1	O
S.E.	4	O
)	1	O
fmol	4	O
/	1	O
10	2	O
(	1	O
7	1	O
)	1	O
cells	5	O
]	1	O
than	4	O
did	3	O
those	5	O
in	2	O
acute	5	O
myeloid	7	O
transformation	14	O
[	1	O
7.2	3	O
+	1	O
/	1	O
-	1	O
1.5	3	O
]	1	O
or	2	O
than	4	O
did	3	O
cells	5	O
from	4	O
patients	8	O
with	4	O
acute	5	B-Disease
myeloid	7	I-Disease
leukemia	8	I-Disease
[	1	O
2.6	3	O
+	1	O
/	1	O
-	1	O
0.8	3	O
]	1	O
.	1	O

Only	4	O
cells	5	O
from	4	O
the	3	O
first	5	O
group	5	O
of	2	O
patients	8	O
responded	9	O
to	2	O
the	3	O
addition	8	O
of	2	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
by	2	O
differentiating	15	O
along	5	O
the	3	O
monocyte-macrophage	19	O
pathway	7	O
.	1	O

We	2	O
conclude	8	O
that	4	O
the	3	O
differentiation-induction	25	O
effect	6	O
of	2	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
is	2	O
likely	6	O
to	2	O
depend	6	O
on	2	O
adequate	8	O
levels	6	O
of	2	O
receptor	8	O
and	3	O
that	4	O
intact	6	O
cells	5	O
rather	6	O
than	4	O
cytosol	7	O
preparations	12	O
should	6	O
be	2	O
studied	7	O
before	6	O
cells	5	O
of	2	O
a	1	O
particular	10	O
tissue	6	O
are	3	O
designated	10	O
as	2	O
receptor	8	O
negative	8	O
.	1	O

Multiple	8	O
forms	5	O
and	3	O
fragments	9	O
of	2	O
cytosolic	9	B-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
from	4	O
human	5	O
leukemic	8	O
cells	5	O
and	3	O
normal	6	O
lymphocytes	11	O
.	1	O

Therapy	7	O
with	4	O
glucocorticoids	15	B-Chemical
is	2	O
generally	9	O
more	4	O
effective	9	O
in	2	O
acute	5	B-Disease
lymphoblastic	13	I-Disease
leukemia	8	I-Disease
than	4	O
in	2	O
other	5	O
types	5	O
of	2	O
human	5	O
leukemia	8	B-Disease
.	1	O

Previous	8	O
studies	7	O
,	1	O
however	7	O
,	1	O
have	4	O
not	3	O
revealed	8	O
any	3	O
consistent	10	O
relationship	12	O
between	7	O
clinical	8	O
responsiveness	14	O
and	3	O
the	3	O
cellular	8	O
or	2	O
cytosolic	9	O
concentration	13	O
of	2	O
glucocorticoid	14	B-Chemical
-binding	8	O
sites	5	O
.	1	O

The	3	O
objectives	10	O
of	2	O
this	4	O
study	5	O
were	4	O
to	2	O
determine	9	O
whether	7	O
there	5	O
are	3	O
intrinsic	9	O
structural	10	O
differences	11	O
among	5	O
the	3	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
various	7	O
types	5	O
of	2	O
leukemic	8	O
cells	5	O
and	3	O
normal	6	O
lymphocytes	11	O
and	3	O
to	2	O
investigate	11	O
the	3	O
role	4	O
of	2	O
endogenous	10	O
peptidases	10	B-Gene
in	2	O
receptor	8	O
degradation	11	O
.	1	O

Cytosols	8	O
were	4	O
prepared	8	O
from	4	O
fresh	5	O
or	2	O
rapidly	7	O
frozen	6	O
leukocytes	10	O
from	4	O
6	1	O
healthy	7	O
adults	6	O
and	3	O
35	2	O
high-risk	9	O
leukemia	8	B-Disease
patients	8	O
(	1	O
median	6	O
white	5	O
blood	5	O
cell	4	O
count	5	O
,	1	O
150	3	O
,	1	O
000	3	O
cells	5	O
/	1	O
microliter	10	O
;	1	O
median	6	O
age	3	O
,	1	O
13	2	O
years	5	O
)	1	O
.	1	O

Receptors	9	O
were	4	O
labeled	7	O
with	4	O
[	1	O
3H	2	O
]	1	O
triamcinolone	13	B-Chemical
acetonide	9	I-Chemical
and	3	O
quantitated	11	O
by	2	O
charcoal-dextran	16	B-Chemical
treatment	9	O
or	2	O
Sephadex	8	O
LH-20	5	O
chromatography	14	O
.	1	O

Mean	4	O
and	3	O
median	6	O
cytosolic	9	O
receptor	8	O
concentrations	14	O
in	2	O
12	2	O
acute	5	B-Disease
lymphoblastic	13	I-Disease
leukemia	8	I-Disease
specimens	9	O
lacking	7	O
the	3	O
standard	8	O
B-cell	6	O
or	2	O
T-cell	6	O
markers	7	O
(	1	O
``	2	O
null	4	O
cells	5	O
''	2	O
)	1	O
were	4	O
approximately	13	O
4-fold	6	O
higher	6	O
than	4	O
in	2	O
23	2	O
other	5	O
leukemic	8	O
cell	4	O
specimens	9	O
.	1	O

No	2	O
other	5	O
consistent	10	O
differences	11	O
in	2	O
receptor	8	O
content	7	O
were	4	O
observed	8	O
.	1	O

Agarose	7	B-Chemical
filtration	10	O
and	3	O
ultracentrifugation	19	O
in	2	O
hypotonic	9	O
buffers	7	O
containing	10	O
20	2	O
mM	2	O
Na2MoO4	7	O
revealed	8	O
complexes	9	O
of	2	O
similar	7	O
size	4	O
and	3	O
shape	5	O
in	2	O
all	3	O
clinical	8	O
specimens	9	O
tested	6	O
and	3	O
two	3	O
established	11	O
leukemic	8	O
cell	4	O
lines	5	O
.	1	O

They	4	O
had	3	O
Stokes	6	O
radii	5	O
(	1	O
Rs	2	O
)	1	O
of	2	O
8.1	3	O
+	1	O
/	1	O
-	1	O
0.5	3	O
(	1	O
S.D.	4	O
)	1	O
nm	2	O
(	1	O
n	1	O
=	1	O
50	2	O
)	1	O
,	1	O
sedimentation	13	O
coefficients	12	O
of	2	O
9.5	3	O
+	1	O
/	1	O
-	1	O
0.3S	4	O
(	1	O
n	1	O
=	1	O
40	2	O
)	1	O
,	1	O
molecular	9	O
weights	7	O
of	2	O
approximately	13	O
330	3	O
,	1	O
000	3	O
,	1	O
and	3	O
axial	5	O
ratios	6	O
(	1	O
a	1	O
/	1	O
b	1	O
)	1	O
of	2	O
approximately	13	O
12	2	O
.	1	O

In	2	O
hypertonic	10	O
,	1	O
molybdate-free	14	B-Chemical
buffer	6	O
,	1	O
these	5	O
oligomeric	10	O
complexes	9	O
were	4	O
dissociated	11	O
into	4	O
subunits	8	O
with	4	O
Rs	2	O
of	2	O
5.9	3	O
+	1	O
/	1	O
-	1	O
0.3	3	O
nm	2	O
(	1	O
n	1	O
=	1	O
12	2	O
)	1	O
and	3	O
a	1	O
/	1	O
b	1	O
of	2	O
11	2	O
to	2	O
12	2	O
,	1	O
as	2	O
observed	8	O
previously	10	O
for	3	O
other	5	O
receptors	9	O
.	1	O

Fragmentation	13	O
of	2	O
the	3	O
oligomer	8	O
and	3	O
the	3	O
subunit	7	O
was	3	O
evident	7	O
in	2	O
some	4	O
cytosols	8	O
.	1	O

High	4	O
activities	10	O
of	2	O
peptidases	10	B-Gene
of	2	O
various	7	O
specificities	13	O
were	4	O
detected	8	O
in	2	O
leukemic	8	O
cell	4	O
cytosols	8	O
,	1	O
as	2	O
in	2	O
other	5	O
cytosols	8	O
,	1	O
by	2	O
fluorometric	12	O
assays	6	O
with	4	O
derivatives	11	O
of	2	O
7-amino-4-methylcoumarin	24	B-Chemical
.	1	O

Receptor	8	O
cleavage	8	O
by	2	O
these	5	O
and	3	O
other	5	O
endogenous	10	O
enzymes	7	O
may	3	O
account	7	O
for	3	O
previous	8	O
observations	12	O
of	2	O
``	2	O
abnormal	8	O
''receptors	11	O
in	2	O
cytosols	8	O
from	4	O
some	4	O
leukemic	8	O
specimens	9	O
.	1	O

We	2	O
conclude	8	O
that	4	O
intrinsic	9	O
structural	10	O
defects	7	O
in	2	O
the	3	O
receptors	9	O
are	3	O
unlikely	8	O
explanations	12	O
for	3	O
the	3	O
unresponsiveness	16	O
of	2	O
some	4	O
types	5	O
of	2	O
leukemia	8	B-Disease
to	2	O
steroid	7	B-Chemical
therapy	7	O
.	1	O

Identification	14	O
of	2	O
human	5	B-Gene
leukemic	8	I-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
using	5	O
affinity	8	O
labeling	8	O
and	3	O
anti-human	10	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
antibodies	10	I-Gene
.	1	O

Antisera	8	O
raised	6	O
against	7	O
human	5	B-Gene
lymphoid	8	I-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
were	4	O
used	4	O
in	2	O
combination	11	O
with	4	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
affinity	8	O
label	5	O
[	1	O
3H	2	O
]	1	O
dexamethasone	13	B-Chemical
21-mesylate	11	I-Chemical
[	1	O
(	1	O
3H	2	O
]	1	O
DM	2	B-Chemical
)	1	O
to	2	O
identify	8	O
the	3	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
of	2	O
the	3	O
human	5	O
B-lymphoblastoid	16	O
cell	4	O
line	4	O
IM-9	4	O
and	3	O
the	3	O
human	5	O
T-cell	6	O
leukemic	8	O
cell	4	O
line	4	O
CEM-C7	6	O
.	1	O

Antisera	8	O
were	4	O
obtained	8	O
following	9	O
immunization	12	O
of	2	O
New	3	O
Zealand	7	O
White	5	O
rabbits	7	O
with	4	O
[	1	O
3H	2	O
]	1	O
triamcinolone	13	B-Gene
acetonide	9	I-Gene
[	1	I-Gene
(	1	I-Gene
3H	2	I-Gene
]	1	I-Gene
TA	2	I-Gene
)	1	I-Gene
-glucocorticoid	15	I-Gene
receptor	8	I-Gene
complexes	9	I-Gene
partially	9	O
purified	8	O
by	2	O
two-stage	9	O
DNA-cellulose	13	O
chromatography	14	O
.	1	O

The	3	O
presence	8	O
of	2	O
anti-human	10	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
antibodies	10	I-Gene
was	3	O
verified	8	O
by	2	O
:	1	O
(	1	O
a	1	O
)	1	O
adsorption	10	O
of	2	O
[	1	O
3H	2	O
]	1	O
TA-receptor-antibody	20	B-Gene
complexes	9	I-Gene
to	2	O
Protein	7	O
A	1	O
;	1	O
(	1	O
b	1	O
)	1	O
a	1	O
shift	5	O
to	2	O
higher	6	O
apparent	8	O
molecular	9	O
weight	6	O
in	2	O
the	3	O
elution	7	O
position	8	O
from	4	O
Sephacryl	9	O
S300	4	O
of	2	O
[	1	O
3H	2	O
]	1	O
TA-receptor	11	B-Gene
complexes	9	I-Gene
incubated	9	O
with	4	O
immune	6	O
serum	5	O
;	1	O
and	3	O
(	1	O
c	1	O
)	1	O
the	3	O
ability	7	O
of	2	O
immune	6	O
serum	5	O
to	2	O
displace	8	O
[	1	O
3H	2	O
]	1	O
TA-receptor	11	B-Gene
complexes	9	I-Gene
on	2	O
sucrose	7	B-Chemical
gradients	9	O
.	1	O

These	5	O
antibodies	10	O
also	4	O
recognized	10	O
rat	3	O
liver	5	O
and	3	O
murine	6	O
S49	3	O
cell	4	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
.	1	O

Sodium	6	B-Chemical
dodecyl	7	I-Chemical
sulfate-polyacrylamide	22	I-Chemical
gel	3	O
electrophoresis	15	O
of	2	O
[	1	O
3H	2	O
]	1	O
DM	2	B-Chemical
-labeled	8	O
IM-9	4	O
cytosol	7	O
identified	10	O
a	1	O
major	5	O
competable	10	O
band	4	O
with	4	O
a	1	O
molecular	9	O
weight	6	O
of	2	O
approximately	13	O
90	2	O
,	1	O
000	3	O
,	1	O
three	5	O
minor	5	O
competable	10	O
components	10	O
with	4	O
molecular	9	O
weights	7	O
of	2	O
approximately	13	O
78	2	O
,	1	O
000	3	O
,	1	O
approximately	13	O
51	2	O
,	1	O
000	3	O
,	1	O
and	3	O
approximately	13	O
38	2	O
,	1	O
500	3	O
,	1	O
and	3	O
at	2	O
least	5	O
21	2	O
other	5	O
noncompetable	13	O
components	10	O
.	1	O

Following	9	O
immunoprecipitation	19	O
of	2	O
[	1	O
3H	2	O
]	1	O
DM	2	B-Chemical
-labeled	8	O
cytosol	7	O
with	4	O
immune	6	O
serum	5	O
,	1	O
only	4	O
the	3	O
Mr	2	O
90	2	O
,	1	O
000	3	O
and	3	O
78	2	O
,	1	O
000	3	O
components	10	O
were	4	O
seen	4	O
.	1	O

Sodium	6	B-Chemical
dodecyl	7	I-Chemical
sulfate-polyacrylamide	22	I-Chemical
gel	3	O
electrophoresis	15	O
of	2	O
[	1	O
3H	2	O
]	1	O
DM	2	B-Chemical
-labeled	8	O
CEM-C7	6	O
cytosol	7	O
revealed	8	O
a	1	O
larger	6	O
number	6	O
of	2	O
[	1	O
3H	2	O
]	1	O
DM	2	B-Chemical
-labeled	8	O
components	10	O
.	1	O

However	7	O
,	1	O
after	5	O
immunoprecipitation	19	O
of	2	O
[	1	O
3H	2	O
]	1	O
DM	2	B-Chemical
-labeled	8	O
CEM-C7	6	O
cytosol	7	O
,	1	O
a	1	O
predominant	11	O
competable	10	O
component	9	O
with	4	O
a	1	O
molecular	9	O
weight	6	O
of	2	O
90	2	O
,	1	O
000	3	O
was	3	O
easily	6	O
identified	10	O
.	1	O

This	4	O
component	9	O
was	3	O
markedly	8	O
diminished	10	O
when	4	O
cytosols	8	O
from	4	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
-deficient	10	O
cell	4	O
line	4	O
ICR-27	6	O
were	4	O
used	4	O
.	1	O

Thus	4	O
,	1	O
the	3	O
combination	11	O
of	2	O
affinity	8	O
labeling	8	O
and	3	O
anti-human	10	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
antibodies	10	I-Gene
is	2	O
capable	7	O
of	2	O
providing	9	O
direct	6	O
physical	8	O
identification	14	O
of	2	O
human	5	B-Gene
lymphoid	8	I-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
.	1	O

1	1	B-Chemical
,	1	I-Chemical
25-Dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
inhibits	8	O
antigen	7	O
-induced	8	O
T	1	O
cell	4	O
activation	10	O
.	1	O

The	3	O
proliferative	13	O
response	8	O
of	2	O
murine	6	O
spleen	6	O
and	3	O
thymus	6	O
cells	5	O
to	2	O
antigen	7	O
but	3	O
not	3	O
to	2	O
lectin	6	B-Gene
was	3	O
inhibited	9	O
by	2	O
the	3	O
active	6	O
metabolite	10	O
of	2	O
vitamin	7	B-Chemical
D3	2	I-Chemical
,	1	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
.	1	O

To	2	O
directly	8	O
examine	7	O
the	3	O
effect	6	O
of	2	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
on	2	O
T	1	O
cell	4	O
activation	10	O
in	2	O
the	3	O
absence	7	O
of	2	O
other	5	O
complicating	12	O
interactions	12	O
,	1	O
we	2	O
utilized	8	O
a	1	O
panel	5	O
of	2	O
cloned	6	O
Ia	2	O
-restricted	11	O
T	1	O
cell	4	O
hybridomas	10	O
that	4	O
secrete	7	O
IL	2	B-Gene
2	1	I-Gene
on	2	O
activation	10	O
by	2	O
cloned	6	O
Ia	2	O
-bearing	8	O
stimulator	10	O
cells	5	O
(	1	O
TA3	3	O
)	1	O
or	2	O
when	4	O
stimulated	10	O
by	2	O
mitogen	7	O
.	1	O

Physiologic	11	O
concentrations	14	O
of	2	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
(	1	O
0.01	4	O
to	2	O
0.1	3	O
nm	2	O
)	1	O
inhibited	9	O
the	3	O
antigen	7	O
-induced	8	O
secretion	9	O
of	2	O
IL	2	B-Gene
2	1	I-Gene
by	2	O
several	7	O
of	2	O
these	5	O
T	1	O
cell	4	O
hybridomas	10	O
.	1	O

This	4	O
inhibition	10	O
was	3	O
dependent	9	O
on	2	O
the	3	O
concentration	13	O
of	2	O
the	3	O
free	4	O
hormone	7	O
and	3	O
could	5	O
be	2	O
overcome	8	O
by	2	O
increasing	10	O
the	3	O
number	6	O
of	2	O
Ia	2	O
-bearing	8	O
stimulator	10	O
cells	5	O
used	4	O
.	1	O

Pretreatment	12	O
of	2	O
the	3	O
T	1	O
hybridoma	9	O
but	3	O
not	3	O
the	3	O
TA3	3	O
stimulator	10	O
cell	4	O
with	4	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
resulted	8	O
in	2	O
inhibition	10	O
of	2	O
activation	10	O
.	1	O

These	5	O
results	7	O
are	3	O
consistent	10	O
with	4	O
the	3	O
finding	7	O
that	4	O
specific	8	O
1	1	B-Gene
,	1	I-Gene
25-	3	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptors	9	I-Gene
are	3	O
present	7	O
on	2	O
the	3	O
T	1	O
cell	4	O
hybridomas	10	O
but	3	O
are	3	O
lacking	7	O
in	2	O
TA3	3	O
cells	5	O
.	1	O

1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
failed	6	O
,	1	O
however	7	O
,	1	O
to	2	O
inhibit	7	O
the	3	O
activation	10	O
of	2	O
the	3	O
T	1	O
cell	4	O
hybridomas	10	O
by	2	O
lectin	6	B-Gene
or	2	O
by	2	O
an	2	O
anti-Thy-1	10	B-Gene
antibody	8	I-Gene
.	1	O

These	5	O
findings	8	O
suggest	7	O
that	4	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
may	3	O
be	2	O
interfering	11	O
with	4	O
early	5	O
events	6	O
of	2	O
antigen	7	O
-induced	8	O
T	1	O
cell	4	O
activation	10	O
,	1	O
perhaps	7	O
by	2	O
hindering	9	O
T	1	O
cell	4	O
recognition	11	O
of	2	O
the	3	O
relevant	8	O
antigen	7	O
on	2	O
stimulator	10	O
cell	4	O
surfaces	8	O
.	1	O

This	4	O
system	6	O
should	6	O
prove	5	O
useful	6	O
in	2	O
studying	8	O
the	3	O
molecular	9	O
mechanisms	10	O
by	2	O
which	5	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
acts	4	O
to	2	O
inhibit	7	O
T	1	O
cell	4	O
activation	10	O
and	3	O
subsequent	10	O
IL	2	B-Gene
2	1	I-Gene
production	10	O
.	1	O

Short-term	10	O
and	3	O
long-term	9	O
effects	7	O
of	2	O
estrogen	8	B-Chemical
on	2	O
lymphoid	8	O
tissues	7	O
and	3	O
lymphoid	8	O
cells	5	O
with	4	O
some	4	O
remarks	7	O
on	2	O
the	3	O
significance	12	O
for	3	O
carcinogenesis	14	O
.	1	O

Estrogens	9	B-Chemical
have	4	O
long	4	O
been	4	O
thought	7	O
to	2	O
play	4	O
a	1	O
role	4	O
in	2	O
regulating	10	O
the	3	O
immune	6	O
system	6	O
.	1	O

The	3	O
difference	10	O
in	2	O
some	4	O
types	5	O
of	2	O
immune	6	O
responses	9	O
between	7	O
males	5	O
and	3	O
females	7	O
is	2	O
well-known	10	O
,	1	O
as	2	O
is	2	O
the	3	O
pronounced	10	O
thymic	6	O
involution	10	O
induced	7	O
by	2	O
exogenous	9	O
estrogens	9	B-Chemical
.	1	O

Estrogens	9	B-Chemical
stimulate	9	O
some	4	O
aspects	7	O
of	2	O
macrophage	10	O
activity	8	O
and	3	O
,	1	O
depending	9	O
on	2	O
dose	4	O
and	3	O
mitogen	7	O
,	1	O
inhibit	7	O
or	2	O
stimulate	9	O
lymphocyte	10	O
proliferative	13	O
response	8	O
in	2	O
vitro	5	O
.	1	O

Another	7	O
example	7	O
is	2	O
the	3	O
estrogen	8	B-Chemical
effect	6	O
on	2	O
the	3	O
delayed	7	O
type	4	O
hypersensitivity	16	B-Disease
response	8	O
.	1	O

A	1	O
broad	5	O
review	6	O
is	2	O
given	5	O
of	2	O
such	4	O
estrogen	8	B-Chemical
effects	7	O
on	2	O
lymphoid	8	O
tissue	6	O
and	3	O
immune	6	O
response	8	O
.	1	O

Most	4	O
of	2	O
the	3	O
studies	7	O
published	9	O
so	2	O
far	3	O
are	3	O
phenomenological	16	O
.	1	O

However	7	O
,	1	O
the	3	O
recent	6	O
description	11	O
of	2	O
estrogen	8	B-Gene
receptors	9	I-Gene
in	2	O
the	3	O
thymus	6	O
and	3	O
in	2	O
some	4	O
lymphocyte	10	O
subpopulations	14	O
,	1	O
as	2	O
well	4	O
as	2	O
a	1	O
deeper	6	O
understanding	13	O
of	2	O
regulating	10	O
factors	7	O
in	2	O
the	3	O
immune	6	O
system	6	O
,	1	O
open	4	O
the	3	O
possibility	11	O
of	2	O
a	1	O
more	4	O
detailed	8	O
understanding	13	O
of	2	O
the	3	O
estrogen	8	B-Chemical
mechanism	9	O
of	2	O
interference	12	O
.	1	O

Estrogen	8	B-Chemical
effects	7	O
in	2	O
adults	6	O
are	3	O
reversible	10	O
.	1	O

After	5	O
treating	8	O
neonatal	8	O
mice	4	O
with	4	O
the	3	O
synthetic	9	O
estrogen	8	B-Chemical
diethylstilbestrol	18	B-Chemical
(	1	O
DES	3	B-Chemical
)	1	O
,	1	O
disturbances	12	O
are	3	O
induced	7	O
in	2	O
lymphocyte	10	O
populations	11	O
and	3	O
lymphocyte	10	O
functions	9	O
which	5	O
are	3	O
permanent	9	O
and	3	O
irreversible	12	O
.	1	O

Lymphocytes	11	O
from	4	O
adult	5	O
,	1	O
neonatally	10	O
DES	3	B-Chemical
-treated	8	O
female	6	O
mice	4	O
have	4	O
a	1	O
reduced	7	O
mitogen	7	O
response	8	O
to	2	O
ConA	4	B-Gene
and	3	O
LPS	3	B-Chemical
(	1	O
T	1	O
and	3	O
B	1	O
cell	4	O
mitogen	7	O
)	1	O
and	3	O
the	3	O
delayed	7	O
type	4	O
hypersensitivity	16	B-Disease
response	8	O
is	2	O
depressed	9	O
.	1	O

A	1	O
detailed	8	O
analysis	8	O
demonstrated	12	O
a	1	O
decreased	9	O
T	1	O
helper	6	O
cell	4	O
population	10	O
.	1	O

The	3	O
activity	8	O
of	2	O
Natural	7	O
Killer	6	O
cells	5	O
is	2	O
permanently	11	O
reduced	7	O
and	3	O
this	4	O
functional	10	O
impairment	10	O
is	2	O
related	7	O
to	2	O
a	1	O
decreased	9	O
number	6	O
of	2	O
these	5	O
cells	5	O
,	1	O
in	2	O
turn	4	O
determined	10	O
at	2	O
the	3	O
bone	4	O
marrow	6	O
level	5	O
.	1	O

The	3	O
same	4	O
animals	7	O
have	4	O
an	2	O
increased	9	O
sensitivity	11	O
to	2	O
chemical	8	O
carcinogens	11	O
(	1	O
methylcholanthrene	18	B-Chemical
)	1	O
and	3	O
they	4	O
spontaneously	13	O
develop	7	O
epithelial	10	O
changes	7	O
in	2	O
the	3	O
uterine	7	O
cervix	6	O
which	5	O
morphologically	15	O
are	3	O
similar	7	O
to	2	O
adenocarcinoma	14	B-Disease
.	1	O

The	3	O
association	11	O
between	7	O
estrogen	8	B-Chemical
-associated	11	O
malignancy	10	B-Disease
and	3	O
estrogen	8	B-Chemical
effects	7	O
in	2	O
lymphocyte	10	O
functions	9	O
deserves	8	O
further	7	O
study	5	O
.	1	O

Structure	9	O
and	3	O
regulation	10	O
of	2	O
the	3	O
glucocorticoid	14	B-Gene
hormone	7	I-Gene
receptor	8	I-Gene
.	1	O

The	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
is	2	O
an	2	O
intracellular	13	O
protein	7	O
which	5	O
possesses	9	O
three	5	O
distinct	8	O
domains	7	O
,	1	O
one	3	O
that	4	O
binds	5	O
agonist	7	O
and	3	O
antagonist	10	O
steroids	8	B-Chemical
,	1	O
one	3	O
that	4	O
binds	5	O
DNA	3	O
,	1	O
and	3	O
one	3	O
that	4	O
binds	5	O
anti-receptor	13	O
antibodies	10	O
and	3	O
is	2	O
required	8	O
for	3	O
glucocorticoid	14	B-Chemical
modulation	10	O
of	2	O
gene	4	O
expression	10	O
.	1	O

In	2	O
intact	6	O
cells	5	O
,	1	O
receptor	8	O
number	6	O
,	1	O
affinity	8	O
and	3	O
activity	8	O
can	3	O
change	6	O
in	2	O
response	8	O
to	2	O
factors	7	O
that	4	O
bind	4	O
to	2	O
the	3	O
receptor	8	O
,	1	O
or	2	O
that	4	O
act	3	O
indirectly	10	O
through	7	O
ill	3	O
-defined	8	O
mechanisms	10	O
which	5	O
may	3	O
include	7	O
resumption	10	O
or	2	O
arrest	6	O
of	2	O
cell	4	O
cycling	7	O
and	3	O
variations	10	O
in	2	O
intracellular	13	O
calcium	7	B-Chemical
ion	3	O
concentrations	14	O
.	1	O

Some	4	O
of	2	O
these	5	O
factors	7	O
appear	6	O
to	2	O
exert	5	O
their	5	O
effect	6	O
by	2	O
controlling	11	O
critical	8	O
receptor	8	O
properties	10	O
such	4	O
as	2	O
ATP	3	B-Chemical
-dependent	10	O
phosphorylation	15	O
,	1	O
integrity	9	O
of	2	O
thiol	5	B-Chemical
groups	6	O
,	1	O
and	3	O
exposure	8	O
of	2	O
key	3	O
amino	5	O
acid	4	O
residues	8	O
.	1	O

Glucocorticoid	14	B-Chemical
agonists	8	O
promote	7	O
the	3	O
'transformation	15	O
'of	3	O
the	3	O
receptor	8	O
into	4	O
the	3	O
DNA	3	O
-binding	8	O
state	5	O
,	1	O
which	5	O
is	2	O
competent	9	O
for	3	O
modulating	10	O
gene	4	O
expression	10	O
.	1	O

Glucocorticoid	14	B-Chemical
antagonists	11	O
are	3	O
steroids	8	B-Chemical
that	4	O
interact	8	O
with	4	O
the	3	O
receptor	8	O
but	3	O
either	6	O
fail	4	O
to	2	O
produce	7	O
a	1	O
stable	6	O
complex	7	O
or	2	O
produce	7	O
a	1	O
stable	6	O
but	3	O
inefficient	11	O
complex	7	O
.	1	O

Although	8	O
substituent	11	O
groups	6	O
that	4	O
confer	6	O
agonist	7	O
or	2	O
antagonist	10	O
activity	8	O
to	2	O
the	3	O
steroid	7	B-Chemical
have	4	O
been	4	O
identified	10	O
,	1	O
the	3	O
molecular	9	O
determinants	12	O
of	2	O
this	4	O
difference	10	O
at	2	O
the	3	O
receptor	8	O
level	5	O
remain	6	O
unknown	7	O
.	1	O

Most	4	O
in	2	O
vitro	5	O
and	3	O
in	2	O
vivo	4	O
data	4	O
on	2	O
receptor	8	O
regulation	10	O
can	3	O
be	2	O
accommodated	12	O
by	2	O
postulating	11	O
the	3	O
existence	9	O
of	2	O
an	2	O
intracellular	13	O
cycle	5	O
that	4	O
involves	8	O
five	4	O
states	6	O
of	2	O
the	3	O
receptor	8	O
.	1	O

The	3	O
active	6	O
free	4	O
receptor	8	O
is	2	O
phosphorylated	14	O
,	1	O
reduced	7	O
,	1	O
and	3	O
presumably	10	O
oligomeric	10	O
(	1	O
state	5	O
A	1	O
)	1	O
.	1	O

Following	9	O
binding	7	O
of	2	O
an	2	O
agonist	7	O
(	1	O
state	5	O
B	1	O
)	1	O
,	1	O
it	2	O
can	3	O
become	6	O
transformed	11	O
by	2	O
dissociation	12	O
into	4	O
its	3	O
subunits	8	O
and	3	O
dephosphorylation	17	O
(	1	O
state	5	O
C	1	O
)	1	O
.	1	O

The	3	O
transformed	11	O
receptor	8	O
then	4	O
interacts	9	O
with	4	O
chromatin	9	O
(	1	O
state	5	O
D	1	O
)	1	O
.	1	O

Dissociation	12	O
of	2	O
the	3	O
steroid	7	B-Chemical
and	3	O
oxidation	9	O
of	2	O
receptor	8	O
thiol	5	B-Chemical
group	5	O
(	1	O
s	1	O
)	1	O
lead	4	O
to	2	O
the	3	O
inactive	8	O
receptor	8	O
form	4	O
(	1	O
state	5	O
E	1	O
)	1	O
.	1	O

Reduction	9	O
and	3	O
rephosphorylation	17	O
of	2	O
the	3	O
receptor	8	O
enable	6	O
it	2	O
to	2	O
bind	4	O
steroids	8	B-Chemical
again	5	O
so	2	O
that	4	O
the	3	O
cycle	5	O
is	2	O
closed	6	O
.	1	O

Drugs	5	O
affecting	9	O
the	3	O
hormonal	8	O
receptors	9	O
of	2	O
normal	6	O
and	3	O
leukaemic	9	O
peripheral	10	O
leucocytes	10	O
.	1	O

The	3	O
authors	7	O
investigated	12	O
the	3	O
behaviour	9	O
of	2	O
steroid	7	B-Chemical
hormone	7	I-Chemical
uptake	6	O
in	2	O
leukaemic	9	O
cells	5	O
(	1	O
CML	3	B-Disease
,	1	O
CLL	3	B-Disease
,	1	O
AML	3	B-Disease
,	1	O
ALL	3	B-Disease
)	1	O
,	1	O
in	2	O
basal	5	O
conditions	10	O
and	3	O
after	5	O
incubation	10	O
with	4	O
drugs	5	O
which	5	O
modify	6	O
the	3	O
cellular	8	O
concentration	13	O
of	2	O
cAMP	4	B-Chemical
,	1	O
PGE	3	B-Chemical
and	3	O
PGF	3	B-Chemical
.	1	O

The	3	O
results	7	O
demonstrated	12	O
the	3	O
presence	8	O
in	2	O
leukaemic	9	O
cells	5	O
of	2	O
an	2	O
alteration	10	O
in	2	O
the	3	O
incorporation	13	O
of	2	O
steroid	7	B-Chemical
hormones	8	I-Chemical
.	1	O

This	4	O
alteration	10	O
was	3	O
scarcely	8	O
modified	8	O
by	2	O
incubation	10	O
with	4	O
theophylline	12	B-Chemical
,	1	O
which	5	O
increases	9	O
cellular	8	O
concentration	13	O
of	2	O
cAMP	4	B-Chemical
.	1	O

On	2	O
the	3	O
other	5	O
hand	4	O
,	1	O
it	2	O
was	3	O
moderately	10	O
counteracted	12	O
by	2	O
thioproline	11	B-Chemical
and	3	O
was	3	O
evidently	9	O
inhibited	9	O
by	2	O
flurbiprofen	12	B-Chemical
,	1	O
which	5	O
also	4	O
reduced	7	O
cellular	8	O
concentrations	14	O
of	2	O
prostaglandins	14	B-Chemical
,	1	O
particularly	12	O
PGE2	4	B-Chemical
,	1	O
with	4	O
the	3	O
exception	9	O
of	2	O
PGF2	4	B-Chemical
which	5	O
showed	6	O
a	1	O
poor	4	O
response	8	O
.	1	O

Differences	11	O
were	4	O
observed	8	O
in	2	O
the	3	O
behavior	8	O
of	2	O
hormonal	8	O
uptake	6	O
of	2	O
CML	3	B-Disease
,	1	O
in	2	O
contrast	8	O
to	2	O
that	4	O
of	2	O
AML	3	B-Disease
,	1	O
CLL	3	B-Disease
and	3	O
ALL	3	B-Disease
peripheral	10	O
leucocytes	10	O
.	1	O

Characterization	16	O
of	2	O
aldosterone	11	B-Chemical
binding	7	O
sites	5	O
in	2	O
circulating	11	O
human	5	O
mononuclear	11	O
leukocytes	10	O
.	1	O

Aldosterone	11	B-Chemical
binding	7	O
sites	5	O
in	2	O
human	5	O
mononuclear	11	O
leukocytes	10	O
were	4	O
characterized	13	O
after	5	O
separation	10	O
of	2	O
cells	5	O
from	4	O
blood	5	O
by	2	O
a	1	O
Percoll	7	O
gradient	8	O
.	1	O

After	5	O
washing	7	O
and	3	O
resuspension	12	O
in	2	O
RPMI-1640	9	O
medium	6	O
,	1	O
cells	5	O
were	4	O
incubated	9	O
at	2	O
37	2	O
degrees	7	O
C	1	O
for	3	O
1	1	O
h	1	O
with	4	O
different	9	O
concentrations	14	O
of	2	O
[	1	O
3H	2	O
]	1	O
aldosterone	11	B-Chemical
plus	4	O
a	1	O
100-fold	8	O
concentration	13	O
of	2	O
RU-26988	8	B-Chemical
(	1	O
11	2	B-Chemical
alpha	5	I-Chemical
,	1	I-Chemical
17	2	I-Chemical
alpha-dihydroxy-17	18	I-Chemical
beta-propynylandrost-1	22	I-Chemical
,	1	I-Chemical
4	1	I-Chemical
,	1	I-Chemical
6-trien-3-one	13	I-Chemical
)	1	O
,	1	O
with	4	O
or	2	O
without	7	O
an	2	O
excess	6	O
of	2	O
unlabeled	9	O
aldosterone	11	B-Chemical
.	1	O

Aldosterone	11	B-Chemical
binds	5	O
to	2	O
a	1	O
single	6	O
class	5	O
of	2	O
receptors	9	O
with	4	O
an	2	O
affinity	8	O
of	2	O
2.7	3	O
+	1	O
/	1	O
-	1	O
0.5	3	O
nM	2	O
(	1	O
means	5	O
+	1	O
/	1	O
-	1	O
SD	2	O
,	1	O
n	1	O
=	1	O
14	2	O
)	1	O
and	3	O
a	1	O
capacity	8	O
of	2	O
290	3	O
+	1	O
/	1	O
-	1	O
108	3	O
sites	5	O
/	1	O
cell	4	O
(	1	O
n	1	O
=	1	O
14	2	O
)	1	O
.	1	O

The	3	O
specificity	11	O
data	4	O
show	4	O
a	1	O
hierarchy	9	O
of	2	O
affinity	8	O
of	2	O
desoxycorticosterone	20	B-Chemical
=	1	O
corticosterone	14	B-Chemical
=	1	O
aldosterone	11	B-Chemical
greater	7	O
than	4	O
hydrocortisone	14	B-Chemical
greater	7	O
than	4	O
dexamethasone	13	B-Chemical
.	1	O

The	3	O
results	7	O
indicate	8	O
that	4	O
mononuclear	11	O
leukocytes	10	O
could	5	O
be	2	O
useful	6	O
for	3	O
studying	8	O
the	3	O
physiological	13	O
significance	12	O
of	2	O
these	5	O
mineralocorticoid	17	B-Gene
receptors	9	I-Gene
and	3	O
their	5	O
regulation	10	O
in	2	O
humans	6	O
.	1	O

Primary	7	O
cortisol	8	B-Chemical
resistance	10	O
accompanied	11	O
by	2	O
a	1	O
reduction	9	O
in	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
two	3	O
members	7	O
of	2	O
the	3	O
same	4	O
family	6	O
.	1	O

This	4	O
report	6	O
describes	9	O
studies	7	O
of	2	O
a	1	O
man	3	O
suspected	9	O
of	2	O
having	6	O
primary	7	O
cortisol	8	B-Chemical
resistance	10	O
.	1	O

This	4	O
conclusion	10	O
is	2	O
based	5	O
on	2	O
his	3	O
high	4	O
plasma	6	O
cortisol	8	B-Chemical
levels	6	O
and	3	O
high	4	O
24-h	4	O
urinary	7	O
17-hydroxycorticosteroid	24	B-Chemical
and	3	O
cortisol	8	B-Chemical
excretion	9	O
,	1	O
plus	4	O
the	3	O
fact	4	O
that	4	O
he	2	O
had	3	O
no	2	O
manifestations	14	O
of	2	O
Cushing	7	B-Disease
's	2	I-Disease
syndrome	8	I-Disease
.	1	O

Among	5	O
family	6	O
members	7	O
tested	6	O
,	1	O
his	3	O
mother	6	O
also	4	O
had	3	O
hypercortisolemia	17	B-Disease
.	1	O

Both	4	O
mother	6	O
and	3	O
son	3	O
had	3	O
high	4	O
levels	6	O
of	2	O
unbound	7	O
plasma	6	O
cortisol	8	B-Chemical
,	1	O
but	3	O
their	5	O
plasma	6	B-Gene
ACTH	4	I-Gene
concentrations	14	O
were	4	O
within	6	O
the	3	O
normal	6	O
range	5	O
.	1	O

Both	4	O
were	4	O
partially	9	O
resistant	9	O
to	2	O
dexamethasone	13	B-Chemical
adrenal	7	O
suppression	11	O
,	1	O
and	3	O
both	4	O
had	3	O
mild	4	B-Disease
hypertension	12	I-Disease
without	7	O
hypokalemia	11	O
.	1	O

To	2	O
study	5	O
this	4	O
apparent	8	O
end-organ	9	O
resistance	10	O
to	2	O
cortisol	8	B-Chemical
,	1	O
we	2	O
examined	8	O
the	3	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
peripheral	10	O
mononuclear	11	O
cells	5	O
.	1	O

Using	5	O
whole	5	O
cell	4	O
assays	6	O
,	1	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
both	4	O
patients	8	O
were	4	O
found	5	O
to	2	O
have	4	O
reduced	7	O
total	5	O
binding	7	O
capacity	8	O
.	1	O

We	2	O
conclude	8	O
that	4	O
these	5	O
two	3	O
patients	8	O
,	1	O
members	7	O
of	2	O
the	3	O
same	4	O
family	6	O
,	1	O
have	4	O
primary	7	O
cortisol	8	B-Chemical
resistance	10	O
accompanied	11	O
by	2	O
a	1	O
reduced	7	O
number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
.	1	O

Plasmacytoid	12	O
blast	5	O
crisis	6	O
in	2	O
B-cell	6	B-Disease
chronic	7	I-Disease
lymphocytic	11	I-Disease
leukemia	8	I-Disease
:	1	O
effect	6	O
of	2	O
estradiol	9	B-Chemical
on	2	O
growth	6	O
and	3	O
differentiation	15	O
in	2	O
vitro	5	O
.	1	O

Evolution	9	O
of	2	O
a	1	O
case	4	O
of	2	O
chronic	7	B-Disease
lymphocytic	11	I-Disease
leukemia	8	I-Disease
(	1	O
CLL	3	B-Disease
)	1	O
into	4	O
blast	5	O
crisis	6	O
was	3	O
found	5	O
to	2	O
be	2	O
characterized	13	O
by	2	O
three	5	O
unusual	7	O
features	8	O
(	1	O
1	1	O
)	1	O
the	3	O
phenotype	9	O
of	2	O
the	3	O
emerging	8	O
blast	5	O
cells	5	O
was	3	O
that	4	O
of	2	O
pre-plasmacytoid	16	O
cells	5	O
as	2	O
shown	5	O
by	2	O
plasma	6	O
cell	4	O
morphology	10	O
and	3	O
an	2	O
immunological	13	O
phenotype	9	O
corresponding	13	O
partially	9	O
with	4	O
CLL-	4	B-Disease
or	2	O
intermediate	12	O
B-cells	7	O
,	1	O
partially	9	O
with	4	O
plasma	6	O
cells	5	O
(	1	O
terminal	8	B-Gene
transferase	11	I-Gene
-	1	O
,	1	O
common	6	B-Gene
acute	5	I-Gene
lymphocytic	11	I-Gene
leukemia	8	I-Gene
antigen	7	I-Gene
-	1	O
,	1	O
Ia+	3	B-Gene
,	1	O
surface	7	B-Gene
immunoglobulin	14	I-Gene
heavy	5	I-Gene
chains	6	I-Gene
-	1	O
,	1	O
surface	7	O
kappa	5	O
light	5	O
chains	6	O
+	1	O
,	1	O
intracytoplasmic	16	B-Gene
immunoglobulin	14	I-Gene
A+	2	I-Gene
and	3	O
G+	2	B-Partial_Gene
,	1	O
BA-1+	5	B-Gene
,	1	O
polyclonal	10	B-Gene
gammaglobulin	13	I-Gene
production	10	O
)	1	O
;	1	O
(	1	O
2	1	O
)	1	O
cytogenetic	11	O
analysis	8	O
of	2	O
spontaneous	11	O
metaphases	10	O
revealed	8	O
that	4	O
in	2	O
addition	8	O
to	2	O
the	3	O
typical	7	O
CLL	3	B-Disease
abnormality	11	O
,	1	O
trisomy	7	O
12	2	O
,	1	O
in	2	O
all	3	O
of	2	O
the	3	O
cells	5	O
,	1	O
an	2	O
additional	10	O
translocation	13	O
between	7	O
chromosomes	11	O
14	2	O
and	3	O
17	2	O
was	3	O
present	7	O
in	2	O
40	2	O
%	1	O
with	4	O
a	1	O
presumptive	11	O
breakpoint	10	O
on	2	O
chromosome	10	O
14	2	O
(	1	O
q12-3	5	O
)	1	O
never	5	O
described	9	O
before	6	O
(	1	O
commonly	8	O
q32	3	O
)	1	O
and	3	O
(	1	O
3	1	O
)	1	O
the	3	O
progression	11	O
of	2	O
the	3	O
disease	7	O
was	3	O
associated	10	O
with	4	O
a	1	O
striking	8	O
increase	8	O
in	2	O
the	3	O
expression	10	O
by	2	O
the	3	O
transformed	11	O
cells	5	O
of	2	O
specific	8	O
binding	7	O
sites	5	O
for	3	O
estradiol	9	B-Chemical
(	1	O
E2	2	B-Chemical
)	1	O
due	3	O
to	2	O
an	2	O
actual	6	O
increase	8	O
in	2	O
total	5	O
cellular	8	O
receptor	8	O
proteins	8	O
and	3	O
not	3	O
to	2	O
a	1	O
change	6	O
in	2	O
receptor	8	O
affinity	8	O
for	3	O
E2	2	B-Chemical
.	1	O

The	3	O
functional	10	O
status	6	O
of	2	O
the	3	O
steroid	7	B-Gene
receptors	9	I-Gene
was	3	O
confirmed	9	O
by	2	O
nuclear	7	O
transfer	8	O
of	2	O
the	3	O
cytoplasmic	11	O
hormone-receptor	16	O
complex	7	O
upon	4	O
temperature	11	O
activation	10	O
.	1	O

Since	5	O
the	3	O
rise	4	O
in	2	O
E2-receptor	11	B-Gene
display	7	O
paralleled	10	O
a	1	O
large	5	O
increase	8	O
in	2	O
the	3	O
proliferative	13	O
activity	8	O
of	2	O
the	3	O
cells	5	O
as	2	O
well	4	O
as	2	O
a	1	O
change	6	O
in	2	O
their	5	O
maturation	10	O
status	6	O
the	3	O
question	8	O
was	3	O
raised	6	O
as	2	O
to	2	O
whether	7	O
the	3	O
E2-receptor	11	B-Gene
should	6	O
be	2	O
considered	10	O
as	2	O
a	1	O
physiological	13	O
marker	6	O
of	2	O
growth	6	O
rate	4	O
or	2	O
of	2	O
cellular	8	O
differentiation	15	O
.	1	O

Exposure	8	O
of	2	O
the	3	O
patient	7	O
's	2	O
blast	5	O
cells	5	O
to	2	O
E2	2	B-Chemical
in	2	O
vitro	5	O
resulted	8	O
in	2	O
cessation	9	O
of	2	O
cell	4	O
growth	6	O
following	9	O
at	2	O
least	5	O
one	3	O
mitosis	7	O
after	5	O
addition	8	O
of	2	O
the	3	O
inducer	7	O
as	2	O
seen	4	O
from	4	O
the	3	O
replacement	11	O
of	2	O
the	3	O
large	5	O
blasts	6	O
by	2	O
small	5	O
CLL	3	B-Disease
-like	5	O
cells	5	O
without	7	O
definite	8	O
signs	5	O
of	2	O
alteration	10	O
of	2	O
the	3	O
differentiation	15	O
status	6	O
.	1	O

This	4	O
suggests	8	O
the	3	O
association	11	O
of	2	O
E2-receptor	11	B-Gene
expression	10	O
with	4	O
control	7	O
of	2	O
growth	6	O
rather	6	O
than	4	O
cell	4	O
maturation	10	O
.	1	O

Mononuclear	11	O
cells	5	O
infiltrating	12	O
human	5	O
mammary	7	B-Disease
carcinomas	10	I-Disease
:	1	O
immunohistochemical	19	O
analysis	8	O
with	4	O
monoclonal	10	O
antibodies	10	O
.	1	O

Breast	6	B-Disease
carcinomas	10	I-Disease
were	4	O
examined	8	O
by	2	O
the	3	O
immunoperoxidase	16	O
technique	9	O
using	5	O
antisera	8	O
specific	8	O
for	3	O
lymphocyte	10	O
subsets	7	O
,	1	O
monocytes	9	O
,	1	O
NK	2	O
cells	5	O
and	3	O
major	5	B-Gene
histocompatibility	18	I-Gene
antigens	8	I-Gene
(	1	O
HLA-A	5	B-Gene
,	1	O
-B	2	B-Partial_Gene
,	1	O
-C	2	B-Partial_Gene
;	1	O
Ia	2	B-Partial_Gene
-like	5	I-Partial_Gene
)	1	O
.	1	O

Sixty-four	10	O
per	3	O
cent	4	O
of	2	O
the	3	O
patients	8	O
had	3	O
a	1	O
moderate	8	O
or	2	O
strong	6	O
mononuclear	11	O
cell	4	O
infiltration	12	O
,	1	O
77	2	O
%	1	O
of	2	O
the	3	O
patients	8	O
without	7	O
mononuclear	11	O
cell	4	O
infiltration	12	O
had	3	O
receptors	9	O
for	3	O
estrogens	9	B-Chemical
as	2	O
compared	8	O
to	2	O
51	2	O
%	1	O
of	2	O
the	3	O
patients	8	O
with	4	O
infiltration	12	O
.	1	O

The	3	O
majority	8	O
of	2	O
the	3	O
infiltrating	12	O
mononuclear	11	O
cells	5	O
were	4	O
T	1	O
cells	5	O
;	1	O
generally	9	O
the	3	O
OKT8	4	O
cells	5	O
were	4	O
predominant	11	O
.	1	O

The	3	O
Leu	3	O
3A	2	O
/	1	O
OKT8	4	O
cell	4	O
ratio	5	O
was	3	O
not	3	O
related	7	O
to	2	O
histological	12	O
type	4	O
,	1	O
tumor	5	B-Disease
size	4	O
,	1	O
age	3	O
of	2	O
the	3	O
patient	7	O
or	2	O
presence	8	O
of	2	O
metastases	10	O
.	1	O

Some	4	O
of	2	O
the	3	O
T	1	O
cells	5	O
had	3	O
the	3	O
Ia	2	O
antigen	7	O
and	3	O
were	4	O
thus	4	O
probably	8	O
activated	9	O
.	1	O

The	3	O
B	1	O
cells	5	O
were	4	O
either	6	O
absent	6	O
or	2	O
less	4	O
numerous	8	O
than	4	O
the	3	O
T	1	O
cells	5	O
.	1	O

There	5	O
was	3	O
no	2	O
relation	8	O
between	7	O
their	5	O
distribution	12	O
and	3	O
the	3	O
various	7	O
parameters	10	O
studied	7	O
.	1	O

A	1	O
few	3	O
monocytes	9	O
were	4	O
heterogeneous	13	O
according	9	O
to	2	O
their	5	O
markers	7	O
(	1	O
OKM	3	O
I	1	O
and	3	O
acid	4	B-Gene
phosphatase	11	I-Gene
)	1	O
.	1	O

In	2	O
6	1	O
cases	5	O
only	4	O
there	5	O
was	3	O
a	1	O
strong	6	O
infiltration	12	O
of	2	O
mononuclear	11	O
cells	5	O
positive	8	O
for	3	O
acid	4	B-Gene
phosphatase	11	I-Gene
.	1	O

The	3	O
number	6	O
of	2	O
the	3	O
natural	7	O
killer	6	O
cells	5	O
was	3	O
also	4	O
low	3	O
.	1	O

Only	4	O
a	1	O
few	3	O
mononuclear	11	O
infiltrating	12	O
cells	5	O
had	3	O
receptors	9	O
for	3	O
transferrin	11	B-Gene
.	1	O

There	5	O
was	3	O
a	1	O
positive	8	O
correlation	11	O
between	7	O
the	3	O
inflammatory	12	O
infiltration	12	O
and	3	O
the	3	O
presence	8	O
of	2	O
HLA	3	B-Gene
class-I	7	I-Gene
antigens	8	I-Gene
on	2	O
tumor	5	B-Disease
cell	4	O
s	1	O
.	1	O

Some	4	O
of	2	O
the	3	O
antisera	8	O
specific	8	O
for	3	O
lymphocyte	10	O
subsets	7	O
also	4	O
stained	7	O
the	3	O
breast	6	B-Disease
carcinoma	9	I-Disease
cells	5	O
.	1	O

The	3	O
great	5	O
variations	10	O
in	2	O
the	3	O
subsets	7	O
of	2	O
mononuclear	11	O
cells	5	O
in	2	O
breast	6	B-Disease
carcinomas	10	I-Disease
may	3	O
correspond	10	O
to	2	O
various	7	O
systems	7	O
of	2	O
defense	7	O
against	7	O
neoplasm	8	O
.	1	O

Interleukin	11	B-Gene
2	1	I-Gene
receptor	8	I-Gene
(	1	O
Tac	3	B-Gene
antigen	7	I-Gene
)	1	O
expression	10	O
in	2	O
HTLV-I	6	O
-associated	11	O
adult	5	B-Disease
T-cell	6	I-Disease
leukemia	8	I-Disease
.	1	O

Interleukin-2	13	B-Gene
(	1	O
IL-2	4	B-Gene
)	1	O
is	2	O
a	1	O
lymphokine	10	O
synthesized	11	O
by	2	O
some	4	O
T-cells	7	O
following	9	O
activation	10	O
.	1	O

Resting	7	O
T-cells	7	O
do	2	O
not	3	O
express	7	O
IL-2	4	B-Gene
receptors	9	I-Gene
,	1	O
but	3	O
receptors	9	O
are	3	O
rapidly	7	O
expressed	9	O
on	2	O
T-cells	7	O
following	9	O
interaction	11	O
of	2	O
antigens	8	O
,	1	O
mitogens	8	O
,	1	O
or	2	O
monoclonal	10	O
antibodies	10	O
with	4	O
the	3	O
antigen-specific	16	O
T-cell	6	B-Gene
receptor	8	I-Gene
complex	7	I-Gene
.	1	O

Using	5	O
anti-Tac	8	B-Gene
,	1	O
a	1	O
monoclonal	10	O
antibody	8	O
that	4	O
recognizes	10	O
the	3	O
IL-2	4	B-Gene
receptor	8	I-Gene
,	1	O
the	3	O
receptor	8	O
has	3	O
been	4	O
purified	8	O
and	3	O
shown	5	O
to	2	O
be	2	O
a	1	O
Mr	2	O
33	2	O
,	1	O
000	3	O
peptide	7	O
that	4	O
is	2	O
posttranslationally	19	O
glycosylated	12	O
to	2	O
a	1	O
Mr	2	O
55	2	O
,	1	O
000	3	O
mature	6	O
form	4	O
.	1	O

Normal	6	O
resting	7	O
T-cells	7	O
and	3	O
most	4	O
leukemic	8	O
T-cell	6	O
populations	11	O
do	2	O
not	3	O
express	7	O
IL-2	4	B-Gene
receptors	9	I-Gene
;	1	O
however	7	O
,	1	O
the	3	O
leukemic	8	O
cells	5	O
of	2	O
the	3	O
11	2	O
patients	8	O
examined	8	O
who	3	O
had	3	O
human	5	O
T-cell	6	O
lymphotropic	12	O
virus	5	O
-associated	11	O
adult	5	B-Disease
T-cell	6	I-Disease
leukemia	8	I-Disease
expressed	9	O
the	3	O
Tac	3	B-Gene
antigen	7	I-Gene
.	1	O

In	2	O
human	5	O
T-cell	6	O
lymphotropic	12	O
virus-I	7	O
infected	8	O
cells	5	O
,	1	O
the	3	O
Mr	2	O
42	2	O
,	1	O
000	3	O
long	4	O
open	4	O
reading	7	O
frame	5	O
protein	7	O
encoded	7	O
in	2	O
part	4	O
by	2	O
the	3	O
pX	2	B-Gene
region	6	O
of	2	O
this	4	O
virus	5	O
may	3	O
act	3	O
as	2	O
a	1	O
transacting	11	O
transcriptional	15	O
activator	9	O
that	4	O
induces	7	O
IL-2	4	B-Gene
receptor	8	I-Gene
gene	4	I-Gene
transcription	13	O
,	1	O
thus	4	O
providing	9	O
an	2	O
explanation	11	O
for	3	O
the	3	O
constant	8	O
association	11	O
of	2	O
IL-2	4	B-Gene
receptor	8	I-Gene
expression	10	O
with	4	O
adult	5	O
T-cell	6	O
lymphotropic	12	O
virus-I	7	O
infection	9	O
of	2	O
lymphoid	8	O
cells	5	O
.	1	O

The	3	O
constant	8	O
expression	10	O
of	2	O
large	5	O
numbers	7	O
of	2	O
IL-2	4	B-Gene
receptors	9	I-Gene
which	5	O
may	3	O
be	2	O
aberrant	8	O
may	3	O
play	4	O
a	1	O
role	4	O
in	2	O
the	3	O
uncontrolled	12	O
growth	6	O
of	2	O
adult	5	B-Disease
T-cell	6	I-Disease
leukemia	8	I-Disease
cells	5	O
.	1	O

Two	3	O
patients	8	O
with	4	O
Tac	3	B-Gene
-positive	9	O
adult	5	B-Disease
T-cell	6	I-Disease
leukemia	8	I-Disease
have	4	O
been	4	O
treated	7	O
with	4	O
the	3	O
anti-Tac	8	B-Gene
.	1	O

One	3	O
of	2	O
the	3	O
patients	8	O
had	3	O
6-	2	O
and	3	O
3-mo	4	O
remissions	10	O
of	2	O
his	3	O
leukemia	8	B-Disease
following	9	O
two	3	O
courses	7	O
of	2	O
therapy	7	O
with	4	O
this	4	O
monoclonal	10	O
antibody	8	O
directed	8	O
toward	6	O
this	4	O
growth	6	O
factor	6	O
receptor	8	O
.	1	O

A	1	O
controlled	10	O
pore	4	O
glass	5	O
bead	4	O
assay	5	O
for	3	O
the	3	O
measurement	11	O
of	2	O
cytoplasmic	11	O
and	3	O
nuclear	7	B-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
.	1	O

An	2	O
assay	5	O
for	3	O
the	3	O
quantitation	12	O
of	2	O
cytoplasmic	11	O
and	3	O
nuclear	7	B-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
in	2	O
lymphoid	8	O
tissue	6	O
has	3	O
been	4	O
developed	9	O
using	5	O
controlled	10	O
pore	4	O
glass	5	O
(	1	O
CPG	3	B-Chemical
)	1	O
beads	5	O
.	1	O

Soluble	7	O
receptor	8	O
--	2	O
3H-steroid	10	B-Gene
complex	7	I-Gene
(	1	O
cytosol	7	O
or	2	O
nuclear	7	O
extract	7	O
)	1	O
is	2	O
adsorbed	8	O
quantitatively	14	O
within	6	O
the	3	O
crevasses	9	O
of	2	O
porous	6	O
glass	5	O
beads	5	O
.	1	O

Excess	6	O
labeled	7	O
steroid	7	B-Chemical
as	2	O
well	4	O
as	2	O
most	4	O
non-specifically	16	O
bound	5	O
steroid	7	B-Chemical
is	2	O
easily	6	O
washed	6	O
away	4	O
,	1	O
leaving	7	O
the	3	O
hormone-receptor	16	O
complex	7	O
retained	8	O
by	2	O
the	3	O
beads	5	O
.	1	O

Bound	5	O
3H-steroid	10	B-Gene
is	2	O
eluted	6	O
with	4	O
ethanol	7	B-Chemical
and	3	O
measured	8	O
for	3	O
radioactivity	13	O
.	1	O

This	4	O
procedure	9	O
which	5	O
is	2	O
simple	6	O
,	1	O
rapid	5	O
,	1	O
and	3	O
highly	6	O
reproducible	12	O
is	2	O
carried	7	O
out	3	O
using	5	O
frozen	6	O
samples	7	O
(	1	O
stable	6	O
for	3	O
many	4	O
months	6	O
)	1	O
containing	10	O
as	2	O
few	3	O
as	2	O
1	1	O
X	1	O
10	2	O
(	1	O
7	1	O
)	1	O
cells	5	O
.	1	O

A	1	O
comparison	10	O
of	2	O
the	3	O
CPG	3	B-Chemical
assay	5	O
to	2	O
dextran	7	B-Chemical
coated	6	O
charcoal	8	B-Chemical
and	3	O
a	1	O
whole	5	O
cell	4	O
assay	5	O
demonstrates	12	O
that	4	O
CPG	3	B-Chemical
and	3	O
dextran	7	B-Chemical
coated	6	O
charcoal	8	B-Chemical
give	4	O
equivalent	10	O
measurements	12	O
of	2	O
cytosolic	9	O
receptor	8	O
concentration	13	O
,	1	O
while	5	O
the	3	O
CPG	3	B-Chemical
and	3	O
whole	5	O
cell	4	O
assays	6	O
provide	7	O
equivalent	10	O
values	6	O
for	3	O
total	5	O
receptor	8	O
content	7	O
.	1	O

[	1	O
3H	2	O
]	1	O
cortivazol	10	B-Chemical
:	1	O
a	1	O
unique	6	O
high	4	O
affinity	8	O
ligand	6	O
for	3	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
.	1	O

Cortivazol	10	B-Chemical
(	1	O
CVZ	3	B-Chemical
)	1	O
and	3	O
deacylcortivazol	16	B-Chemical
(	1	O
DAC	3	B-Chemical
)	1	O
are	3	O
pyrazolosteroids	16	B-Chemical
with	4	O
potent	6	O
glucocorticoid	14	B-Chemical
activity	8	O
.	1	O

In	2	O
previous	8	O
work	4	O
we	2	O
showed	6	O
that	4	O
DAC	3	B-Chemical
is	2	O
40-fold	7	O
more	4	O
potent	6	O
than	4	O
dexamethasone	13	B-Chemical
(	1	O
DEX	3	B-Chemical
)	1	O
in	2	O
lysing	6	O
leukemic	8	O
lymphoblasts	12	O
.	1	O

To	2	O
assess	6	O
the	3	O
interaction	11	O
between	7	O
these	5	O
atypical	8	O
steroids	8	B-Chemical
and	3	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
,	1	O
we	2	O
examined	8	O
the	3	O
binding	7	O
of	2	O
[	1	O
3H	2	O
]	1	O
CVZ	3	B-Chemical
to	2	O
cytosol	7	O
from	4	O
glucocorticoid	14	B-Chemical
-sensitive	10	O
and	3	O
-resistant	10	O
variants	8	O
of	2	O
the	3	O
human	5	O
leukemic	8	O
cell	4	O
line	4	O
CEM	3	O
C7	2	O
.	1	O

In	2	O
glucocorticoid	14	B-Chemical
-sensitive	10	O
cells	5	O
[	1	O
3H	2	O
]	1	O
CVZ	3	B-Chemical
causes	6	O
a	1	O
2-fold	6	O
induction	9	O
of	2	O
glutamine	9	B-Gene
synthetase	10	I-Gene
and	3	O
binds	5	O
to	2	O
a	1	O
protein	7	O
in	2	O
the	3	O
4.6	3	O
S	1	O
region	6	O
of	2	O
high	4	O
salt	4	O
sucrose	7	O
gradients	9	O
.	1	O

On	2	O
DEAE-cellulose	14	O
chromatography	14	O
,	1	O
[	1	O
3H	2	O
]	1	O
CVZ-receptor	12	B-Chemical
complexes	9	O
show	4	O
a	1	O
shift	5	O
from	4	O
high	4	O
(	1	O
0.25	4	O
M	1	O
KP	2	O
)	1	O
to	2	O
low	3	O
salt	4	O
(	1	O
0.09	4	O
M	1	O
KP	2	O
)	1	O
eluting	7	O
forms	5	O
upon	4	O
activation	10	O
.	1	O

CVZ	3	B-Chemical
competes	8	O
for	3	O
a	1	O
97	2	O
,	1	O
000-dalton	10	O
protein	7	O
labeled	7	O
by	2	O
[	1	O
3H	2	O
]	1	O
dexamethasone	13	B-Chemical
mesylate	8	I-Chemical
.	1	O

Scatchard	9	O
analysis	8	O
of	2	O
the	3	O
binding	7	O
of	2	O
[	1	O
3H	2	O
]	1	O
CVZ	3	B-Chemical
in	2	O
glucocorticoid	14	B-Chemical
-sensitive	10	O
cells	5	O
revealed	8	O
a	1	O
curvilinear	11	O
plot	4	O
which	5	O
resolved	8	O
into	4	O
high	4	O
(	1	O
0.4	3	O
nM	2	O
)	1	O
and	3	O
low	3	O
(	1	O
11	2	O
nM	2	O
)	1	O
affinity	8	O
components	10	O
.	1	O

The	3	O
receptor	8	O
concentration	13	O
of	2	O
the	3	O
low	3	O
affinity	8	O
site	4	O
(	1	O
0.30	4	O
pmol	4	O
/	1	O
mg	2	O
protein	7	O
)	1	O
was	3	O
approximately	13	O
twice	5	O
that	4	O
of	2	O
the	3	O
high	4	O
affinity	8	O
site	4	O
(	1	O
0.14	4	O
pmol	4	O
/	1	O
mg	2	O
protein	7	O
)	1	O
.	1	O

Dissociation	12	O
experiments	11	O
with	4	O
dilution	8	O
and	3	O
/	1	O
or	2	O
excess	6	O
unlabeled	9	O
CVZ	3	B-Chemical
supported	9	O
the	3	O
presence	8	O
of	2	O
independent	11	O
sites	5	O
.	1	O

In	2	O
contrast	8	O
,	1	O
the	3	O
binding	7	O
of	2	O
[	1	O
3H	2	O
]	1	O
DEX	3	B-Chemical
to	2	O
C7	2	O
cytosol	7	O
revealed	8	O
a	1	O
single	6	O
class	5	O
of	2	O
binding	7	O
sites	5	O
(	1	O
Kd	2	O
=	1	O
1.9	3	O
nM	2	O
;	1	O
receptor	8	O
concentration	13	O
,	1	O
0.46	4	O
pmol	4	O
/	1	O
mg	2	O
protein	7	O
)	1	O
.	1	O

Examination	11	O
of	2	O
the	3	O
binding	7	O
of	2	O
[	1	O
3H	2	O
]	1	O
CVZ	3	B-Chemical
using	5	O
10	2	O
(	1	O
-5	2	O
)	1	O
M	1	O
DEX	3	B-Chemical
as	2	O
the	3	O
competing	9	O
ligand	6	O
showed	6	O
that	4	O
DEX	3	B-Chemical
binds	5	O
only	4	O
to	2	O
the	3	O
low	3	O
affinity	8	O
site	4	O
detected	8	O
by	2	O
[	1	O
3H	2	O
]	1	O
CVZ	3	B-Chemical
.	1	O

In	2	O
cytosol	7	O
from	4	O
a	1	O
glucocorticoid	14	B-Chemical
-resistant	10	O
cell	4	O
line	4	O
with	4	O
virtually	9	O
no	2	O
[	1	O
3H	2	O
]	1	O
DEX	3	B-Chemical
binding	7	O
,	1	O
[	1	O
3H	2	O
]	1	O
CVZ	3	B-Chemical
detected	8	O
a	1	O
single	6	O
high	4	O
affinity	8	O
binding	7	O
site	4	O
that	4	O
was	3	O
similar	7	O
in	2	O
dissociation	12	O
constant	8	O
(	1	O
0.8	3	O
nM	2	O
)	1	O
and	3	O
receptor	8	O
concentration	13	O
(	1	O
0.13	4	O
pmol	4	O
/	1	O
mg	2	O
protein	7	O
)	1	O
to	2	O
the	3	O
high	4	O
affinity	8	O
site	4	O
detected	8	O
in	2	O
the	3	O
glucocorticoid	14	B-Chemical
-sensitive	10	O
cell	4	O
line	4	O
C7	2	O
.	1	O

Differential	12	O
protection	10	O
of	2	O
normal	6	O
and	3	O
malignant	9	O
human	5	O
myeloid	7	O
progenitors	11	O
(	1	O
CFU-GM	6	O
)	1	O
from	4	O
Ara-C	5	B-Chemical
toxicity	8	O
using	5	O
cycloheximide	13	B-Chemical
.	1	O

Cycloheximide	13	B-Chemical
,	1	O
a	1	O
reversible	10	O
protein	7	O
synthesis	9	O
inhibitor	9	O
,	1	O
is	2	O
thought	7	O
to	2	O
block	5	O
DNA	3	O
replication	11	O
in	2	O
normal	6	O
cells	5	O
by	2	O
preventing	10	O
synthesis	9	O
of	2	O
a	1	O
labile	6	O
protein	7	O
.	1	O

In	2	O
animal	6	O
systems	7	O
,	1	O
cycloheximide	13	B-Chemical
protects	8	O
normal	6	O
cells	5	O
from	4	O
cytotoxic	9	O
S-phase	7	O
specific	8	O
agents	6	O
,	1	O
such	4	O
as	2	O
cytosine	8	B-Chemical
arabinoside	11	I-Chemical
(	1	O
Ara-C	5	B-Chemical
)	1	O
.	1	O

Malignant	9	O
cells	5	O
appear	6	O
not	3	O
to	2	O
be	2	O
susceptible	11	O
to	2	O
cycloheximide	13	B-Chemical
-induced	8	O
cycle	5	O
arrest	6	O
and	3	O
,	1	O
subsequently	12	O
,	1	O
may	3	O
not	3	O
be	2	O
protected	9	O
from	4	O
Ara-C	5	B-Chemical
cytotoxicity	12	O
.	1	O

The	3	O
effect	6	O
of	2	O
cycloheximide	13	B-Chemical
on	2	O
granulocyte	11	O
/	1	O
macrophage	10	O
progenitors	11	O
(	1	O
CFU-GM	6	O
)	1	O
after	5	O
in	2	O
vitro	5	O
Ara-C	5	B-Chemical
exposure	8	O
was	3	O
examined	8	O
using	5	O
normal	6	O
human	5	O
bone	4	O
marrow	6	O
,	1	O
malignant	9	O
progenitors	11	O
from	4	O
patients	8	O
with	4	O
chronic	7	B-Disease
myelogenous	11	I-Disease
leukemia	8	I-Disease
(	1	O
CML	3	B-Disease
)	1	O
,	1	O
and	3	O
clonogenic	10	O
cells	5	O
from	4	O
the	3	O
human	5	O
acute	5	B-Disease
nonlymphocytic	14	I-Disease
leukemia	8	I-Disease
cell	4	O
lines	5	O
HL-60	5	O
and	3	O
KG-1	4	O
.	1	O

Mononuclear	11	O
or	2	O
clonogenic	10	O
cells	5	O
were	4	O
incubated	9	O
for	3	O
one	3	O
hour	4	O
with	4	O
cycloheximide	13	B-Chemical
,	1	O
followed	8	O
by	2	O
the	3	O
addition	8	O
,	1	O
for	3	O
three	5	O
or	2	O
17	2	O
hours	5	O
,	1	O
of	2	O
Ara-C	5	B-Chemical
before	6	O
being	5	O
plated	6	O
in	2	O
a	1	O
methylcellulose	15	O
culture	7	O
system	6	O
.	1	O

CFU-GM	6	O
survival	8	O
was	3	O
significantly	13	O
increase	8	O
if	2	O
normal	6	O
cells	5	O
were	4	O
treated	7	O
with	4	O
cycloheximide	13	B-Chemical
before	6	O
Ara-C	5	B-Chemical
exposure	8	O
.	1	O

Similar	7	O
cycloheximide	13	B-Chemical
pretreatment	12	O
of	2	O
CML	3	B-Disease
progenitors	11	O
and	3	O
clonogenic	10	O
HL-60	5	O
and	3	O
KG-1	4	O
cells	5	O
failed	6	O
to	2	O
protect	7	O
CFU-GM	6	O
from	4	O
Ara-C	5	B-Chemical
-induced	8	O
cytotoxicity	12	O
.	1	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
of	2	O
mononuclear	11	O
leukocytes	10	O
from	4	O
myasthenia	10	B-Disease
gravis	6	I-Disease
patients	8	O
.	1	O

The	3	O
present	7	O
study	5	O
was	3	O
performed	9	O
to	2	O
analyse	7	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
binding	7	O
in	2	O
peripheral	10	O
blood	5	O
mononuclear	11	O
leukocytes	10	O
(	1	O
MNL	3	O
)	1	O
from	4	O
39	2	O
myasthenia	10	B-Disease
gravis	6	I-Disease
(	1	O
MG	2	B-Disease
)	1	O
patients	8	O
(	1	O
unoperated	10	O
patients	8	O
(	1	O
n	1	O
=	1	O
13	2	O
)	1	O
,	1	O
thymectomized	13	O
patients	8	O
(	1	O
n	1	O
=	1	O
14	2	O
)	1	O
and	3	O
patients	8	O
receiving	9	O
glucocorticoids	15	B-Chemical
:	1	O
thymectomized	13	O
(	1	O
n	1	O
=	1	O
11	2	O
)	1	O
and	3	O
unoperated	10	O
(	1	O
n	1	O
=	1	O
6	1	O
]	1	O
.	1	O

A	1	O
whole	5	O
cell	4	O
binding	7	O
assay	5	O
with	4	O
3	1	O
(	1	O
H	1	O
)	1	O
dexamethasone	13	B-Chemical
was	3	O
used	4	O
.	1	O

GR	2	B-Gene
mean	4	O
values	6	O
were	4	O
significantly	13	O
higher	6	O
in	2	O
the	3	O
MNL	3	O
of	2	O
MG	2	B-Disease
patients	8	O
(	1	O
thymectomized	13	O
or	2	O
not	3	O
)	1	O
not	3	O
receiving	9	O
glucocorticoid	14	B-Chemical
than	4	O
in	2	O
the	3	O
MNL	3	O
of	2	O
healthy	7	O
donors	6	O
.	1	O

Affinity	8	O
was	3	O
within	6	O
the	3	O
normal	6	O
range	5	O
.	1	O

Sex	3	O
,	1	O
age	3	O
or	2	O
clinical	8	O
forms	5	O
of	2	O
illness	7	O
did	3	O
not	3	O
influence	9	O
the	3	O
results	7	O
.	1	O

In	2	O
patients	8	O
receiving	9	O
prednisone	10	B-Chemical
(	1	O
Pd	2	B-Chemical
)	1	O
the	3	O
GR	2	B-Gene
values	6	O
were	4	O
significantly	13	O
lower	5	O
than	4	O
in	2	O
MG	2	B-Disease
patients	8	O
without	7	O
Pd	2	B-Chemical
therapy	7	O
,	1	O
independent	11	O
of	2	O
Pd	2	B-Chemical
dose	4	O
or	2	O
time	4	O
of	2	O
administration	14	O
.	1	O

No	2	O
differences	11	O
in	2	O
receptor	8	O
binding	7	O
between	7	O
normal	6	O
subjects	8	O
and	3	O
MG	2	B-Disease
patients	8	O
receiving	9	O
Pd	2	B-Chemical
have	4	O
been	4	O
found	5	O
.	1	O

Correlation	11	O
of	2	O
steroid	7	B-Gene
receptors	9	I-Gene
with	4	O
histologic	10	O
differentiation	15	O
in	2	O
mammary	7	B-Disease
carcinoma	9	I-Disease
.	1	O

A	1	O
Singapore	9	O
experience	10	O
.	1	O

Cancer	6	B-Disease
of	2	O
the	3	O
breast	6	O
is	2	O
the	3	O
most	4	O
common	6	O
tumor	5	B-Disease
in	2	O
females	7	O
in	2	O
Singapore	9	O
,	1	O
with	4	O
the	3	O
rate	4	O
of	2	O
20.7	4	O
per	3	O
100	3	O
,	1	O
000	3	O
per	3	O
year	4	O
(	1	O
1977	4	O
estimate	8	O
)	1	O
,	1	O
which	5	O
is	2	O
predicted	9	O
to	2	O
increase	8	O
to	2	O
29.8	4	O
per	3	O
100	3	O
,	1	O
000	3	O
women	5	O
per	3	O
year	4	O
by	2	O
1995	4	O
.	1	O

A	1	O
detailed	8	O
histopathologic	15	O
review	6	O
of	2	O
50	2	O
primary	7	O
breast	6	B-Disease
cancer	6	I-Disease
tumors	6	I-Disease
analyzed	8	O
for	3	O
estrogen	8	B-Gene
receptor	8	I-Gene
(	1	O
ER	2	B-Gene
)	1	O
level	5	O
was	3	O
carried	7	O
out	3	O
and	3	O
a	1	O
variety	7	O
of	2	O
morphologic	11	O
features	8	O
correlated	10	O
with	4	O
ER	2	B-Gene
results	7	O
to	2	O
identify	8	O
any	3	O
factors	7	O
that	4	O
will	4	O
improve	7	O
the	3	O
management	10	O
and	3	O
prognosis	9	O
for	3	O
breast	6	B-Disease
cancer	6	I-Disease
.	1	O

Cytosol	7	O
was	3	O
incubated	9	O
with	4	O
3H-estradiol	12	B-Chemical
in	2	O
the	3	O
presence	8	O
and	3	O
absence	7	O
of	2	O
cold	4	O
diethylstilbestrol	18	B-Chemical
,	1	O
and	3	O
bound	5	O
and	3	O
free	4	O
hormone	7	O
were	4	O
separated	9	O
by	2	O
Dextran	7	O
-coated	7	O
charcoal	8	O
method	6	O
.	1	O

Tumors	6	B-Disease
binding	7	O
more	4	O
than	4	O
5	1	O
fmol	4	O
/	1	O
mg	2	O
cytosol	7	O
protein	7	O
were	4	O
classified	10	O
as	2	O
ER	2	B-Gene
-positive	9	O
.	1	O

Progesterone	12	B-Gene
receptor	8	I-Gene
(	1	O
PR	2	B-Gene
)	1	O
level	5	O
was	3	O
analyzed	8	O
in	2	O
some	4	O
specimens	9	O
with	4	O
the	3	O
use	3	O
of	2	O
a	1	O
similar	7	O
method	6	O
.	1	O

Most	4	O
of	2	O
the	3	O
patients	8	O
were	4	O
Chinese	7	O
(	1	O
90	2	O
%	1	O
)	1	O
.	1	O

Three	5	O
patients	8	O
were	4	O
Malays	6	O
,	1	O
one	3	O
was	3	O
Indian	6	O
,	1	O
and	3	O
one	3	O
was	3	O
European	8	O
in	2	O
this	4	O
series	6	O
.	1	O

Results	7	O
indicated	9	O
that	4	O
there	5	O
was	3	O
strong	6	O
correlation	11	O
between	7	O
ER	2	B-Gene
level	5	O
,	1	O
age	3	O
,	1	O
and	3	O
histologic	10	O
grade	5	O
of	2	O
the	3	O
tumors	6	B-Disease
.	1	O

No	2	O
correlation	11	O
existed	7	O
between	7	O
absence	7	O
or	2	O
presence	8	O
of	2	O
lymph	5	O
node	4	O
metastases	10	O
and	3	O
ER	2	B-Gene
.	1	O

Although	8	O
there	5	O
was	3	O
a	1	O
trend	5	O
for	3	O
ER	2	B-Gene
-positive	9	O
tumors	6	B-Disease
to	2	O
have	4	O
a	1	O
low-grade	9	O
lymphocytic	11	O
infiltration	12	O
,	1	O
the	3	O
difference	10	O
was	3	O
not	3	O
statistically	13	O
significant	11	O
.	1	O

Mineralocorticoid	17	B-Chemical
and	3	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
circulating	11	O
mononuclear	11	O
leukocytes	10	O
of	2	O
patients	8	O
with	4	O
primary	7	B-Disease
hyperaldosteronism	18	I-Disease
.	1	O

Mineralocorticoid	17	B-Chemical
and	3	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
were	4	O
measured	8	O
in	2	O
circulating	11	O
mononuclear	11	O
leukocytes	10	O
in	2	O
5	1	O
patients	8	O
affected	8	O
by	2	O
Conn	4	B-Disease
's	2	I-Disease
syndrome	8	I-Disease
(	1	O
3	1	O
cases	5	O
of	2	O
bilateral	9	O
adrenal	7	B-Disease
hyperplasia	11	I-Disease
and	3	O
2	1	O
cases	5	O
of	2	O
adenoma	7	B-Disease
plus	4	O
unilateral	10	O
hyperplasia	11	O
)	1	O
.	1	O

The	3	O
number	6	O
of	2	O
the	3	O
binding	7	O
sites	5	O
per	3	O
cell	4	O
resulted	8	O
significantly	13	O
lower	5	O
(	1	O
189	3	O
+	1	O
/	1	O
-	1	O
114	3	O
,	1	O
mean	4	O
+	1	O
/	1	O
-	1	O
SD	2	O
)	1	O
,	1	O
as	2	O
compared	8	O
with	4	O
the	3	O
normal	6	O
controls	8	O
(	1	O
298	3	O
+	1	O
/	1	O
-	1	O
105	3	O
)	1	O
.	1	O

The	3	O
affinity	8	O
of	2	O
aldosterone	11	B-Chemical
for	3	O
the	3	O
receptor	8	O
was	3	O
found	5	O
to	2	O
be	2	O
not	3	O
different	9	O
than	4	O
that	4	O
of	2	O
healthy	7	O
control	7	O
subjects	8	O
.	1	O

The	3	O
capacity	8	O
and	3	O
the	3	O
affinity	8	O
of	2	O
dexamethasone	13	B-Chemical
for	3	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
ranged	6	O
in	2	O
the	3	O
normal	6	O
values	6	O
.	1	O

These	5	O
data	4	O
suggest	7	O
a	1	O
possible	8	O
down-regulation	15	O
of	2	O
mineralocorticoid	17	B-Gene
receptors	9	I-Gene
in	2	O
humans	6	O
.	1	O

Therapeutic	11	O
concentrations	14	O
of	2	O
glucocorticoids	15	B-Chemical
suppress	8	O
the	3	O
antimicrobial	13	O
activity	8	O
of	2	O
human	5	O
macrophages	11	O
without	7	O
impairing	9	O
their	5	O
responsiveness	14	O
to	2	O
gamma	5	B-Gene
interferon	10	I-Gene
.	1	O

By	2	O
exposing	8	O
human	5	O
blood	5	O
-derived	8	O
macrophages	11	O
and	3	O
alveolar	8	O
macrophages	11	O
in	2	O
vitro	5	O
to	2	O
dexamethasone	13	B-Chemical
,	1	O
we	2	O
showed	6	O
in	2	O
these	5	O
studies	7	O
that	4	O
glucocorticoids	15	B-Chemical
markedly	8	O
suppress	8	O
the	3	O
antimicrobial	13	O
activity	8	O
of	2	O
macrophages	11	O
but	3	O
not	3	O
macrophage	10	O
activation	10	O
by	2	O
lymphokines	11	O
.	1	O

As	2	O
little	6	O
as	2	O
2.5	3	O
X	1	O
10	2	O
(	1	O
-8	2	O
)	1	O
mol	3	O
/	1	O
liter	5	O
of	2	O
dexamethasone	13	B-Chemical
prevented	9	O
macrophages	11	O
from	4	O
inhibiting	10	O
germination	11	O
of	2	O
Aspergillus	11	O
spores	6	O
or	2	O
from	4	O
eliminating	11	O
ingested	8	O
bacteria	8	O
such	4	O
as	2	O
Listeria	8	O
,	1	O
Nocardia	8	O
,	1	O
or	2	O
Salmonella	10	O
.	1	O

Damage	6	O
to	2	O
macrophage	10	O
function	8	O
was	3	O
inhibited	9	O
by	2	O
progesterone	12	B-Chemical
and	3	O
appeared	8	O
to	2	O
be	2	O
receptor	8	O
-mediated	9	O
.	1	O

In	2	O
accordance	10	O
with	4	O
in	2	O
vivo	4	O
observations	12	O
,	1	O
dexamethasone	13	B-Chemical
required	8	O
24-36	5	O
h	1	O
to	2	O
suppress	8	O
antimicrobial	13	O
activity	8	O
.	1	O

While	5	O
glucocorticoids	15	B-Chemical
interfered	10	O
with	4	O
base-line	9	O
activity	8	O
of	2	O
macrophages	11	O
,	1	O
dexamethasone	13	B-Chemical
concentrations	14	O
comparable	10	O
to	2	O
drug	4	O
levels	6	O
in	2	O
patients	8	O
had	3	O
no	2	O
effect	6	O
on	2	O
macrophage	10	O
activation	10	O
.	1	O

Proliferating	13	O
lymphocytes	11	O
and	3	O
gamma-interferon	16	B-Gene
thus	4	O
increased	9	O
the	3	O
antimicrobial	13	O
activity	8	O
of	2	O
phagocytes	10	O
exposed	7	O
to	2	O
glucocorticoids	15	B-Chemical
over	4	O
that	4	O
of	2	O
control	7	O
cells	5	O
.	1	O

Macrophage	10	O
activation	10	O
and	3	O
correction	10	O
of	2	O
the	3	O
dexamethasone	13	B-Chemical
effect	6	O
by	2	O
gamma-interferon	16	B-Gene
,	1	O
however	7	O
,	1	O
was	3	O
dependent	9	O
on	2	O
the	3	O
pathogen	8	O
.	1	O

The	3	O
lymphokine	10	O
enhanced	8	O
the	3	O
antimicrobial	13	O
activity	8	O
of	2	O
dexamethasone	13	B-Chemical
-treated	8	O
macrophages	11	O
against	7	O
Listeria	8	O
and	3	O
Salmonella	10	O
but	3	O
not	3	O
against	7	O
Aspergillus	11	O
or	2	O
Nocardia	8	O
.	1	O

Dexamethasone	13	B-Chemical
-induced	8	O
damage	6	O
to	2	O
the	3	O
antimicrobial	13	O
activity	8	O
of	2	O
human	5	O
macrophages	11	O
in	2	O
vitro	5	O
parallels	9	O
observations	12	O
that	4	O
glucocorticoids	15	B-Chemical
render	6	O
laboratory	10	O
animals	7	O
susceptible	11	O
to	2	O
listeriosis	11	O
and	3	O
aspergillosis	13	O
by	2	O
damaging	8	O
resident	8	O
macrophages	11	O
.	1	O

Suppression	11	O
of	2	O
macrophage	10	O
antimicrobial	13	O
activity	8	O
should	6	O
thus	4	O
be	2	O
considered	10	O
when	4	O
treating	8	O
patients	8	O
with	4	O
glucocorticoids	15	B-Chemical
;	1	O
its	3	O
prevention	10	O
by	2	O
gamma-interferon	16	B-Gene
might	5	O
be	2	O
beneficial	10	O
for	3	O
some	4	O
but	3	O
not	3	O
all	3	O
pathogens	9	O
.	1	O

Defective	9	O
binding	7	O
and	3	O
function	8	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25-dihydroxyvitamin	19	I-Gene
D3	2	I-Gene
receptors	9	I-Gene
in	2	O
peripheral	10	O
mononuclear	11	O
cells	5	O
of	2	O
patients	8	O
with	4	O
end-organ	9	O
resistance	10	O
to	2	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D	1	I-Chemical
.	1	O

Lectin	6	B-Gene
-induced	8	O
DNA	3	O
synthesis	9	O
by	2	O
peripheral	10	O
mononuclear	11	O
cells	5	O
from	4	O
17	2	O
normal	6	O
donors	6	O
was	3	O
inhibited	9	O
(	1	O
40-60	5	O
%	1	O
)	1	O
by	2	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
(	1	O
1	1	O
,	1	O
25	2	O
[	1	O
OH	2	O
]	1	O
2D3	3	O
)	1	O
at	2	O
physiological	13	O
concentrations	14	O
(	1	O
10	2	O
(	1	O
-10	3	O
)	1	O
-10	3	O
(	1	O
-9	2	O
)	1	O
M	1	O
)	1	O
.	1	O

The	3	O
lymphocytes	11	O
acquire	7	O
specific	8	O
receptors	9	O
for	3	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
upon	4	O
activation	10	O
by	2	O
the	3	O
lectins	7	B-Gene
.	1	O

This	4	O
process	7	O
precedes	8	O
the	3	O
inhibitory	10	O
effect	6	O
of	2	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
.	1	O

We	2	O
studied	7	O
lymphocytes	11	O
from	4	O
six	3	O
patients	8	O
from	4	O
four	4	O
different	9	O
kindreds	8	O
with	4	O
the	3	O
syndrome	8	O
of	2	O
hereditary	10	O
end-organ	9	O
resistance	10	O
to	2	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D	2	O
(	1	O
the	3	O
so	2	O
-called	7	O
vitamin	7	B-Disease
D	1	I-Disease
-dependent	10	I-Disease
rickets	7	I-Disease
type	4	I-Disease
II	2	I-Disease
)	1	O
.	1	O

In	2	O
five	4	O
patients	8	O
(	1	O
three	5	O
kindreds	8	O
)	1	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
did	3	O
not	3	O
acquire	7	O
receptors	9	O
for	3	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
upon	4	O
phytohemagglutinin	18	B-Gene
-induced	8	O
activation	10	O
.	1	O

Moreover	8	O
,	1	O
in	2	O
contrast	8	O
to	2	O
normal	6	O
lymphocytes	11	O
,	1	O
the	3	O
mitogenic	9	O
stimulation	11	O
of	2	O
these	5	O
patients	8	O
'lymphocytes	12	O
by	2	O
phytohemagglutinin	18	B-Gene
and	3	O
concanavalin	12	B-Gene
A	1	I-Gene
was	3	O
not	3	O
inhibited	9	O
by	2	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
.	1	O

Activated	9	O
lymphocytes	11	O
of	2	O
the	3	O
sixth	5	O
patient	7	O
from	4	O
a	1	O
fourth	6	O
kindred	7	O
exhibited	9	O
normal	6	O
binding	7	O
of	2	O
[	1	O
3H	2	O
]	1	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
but	3	O
the	3	O
hormone	7	O
failed	6	O
to	2	O
inhibit	7	O
the	3	O
mitogenic	9	O
stimulation	11	O
.	1	O

A	1	O
similar	7	O
pattern	7	O
of	2	O
the	3	O
vitamin	7	B-Chemical
D	1	I-Chemical
effector	8	O
system	6	O
was	3	O
previously	10	O
observed	8	O
in	2	O
fibroblasts	11	O
cultured	8	O
from	4	O
skin	4	O
biopsies	8	O
of	2	O
the	3	O
same	4	O
group	5	O
of	2	O
patients	8	O
.	1	O

The	3	O
conclusions	11	O
from	4	O
these	5	O
findings	8	O
are	3	O
:	1	O
(	1	O
a	1	O
)	1	O
the	3	O
inhibition	10	O
of	2	O
mitogenic	9	O
stimulation	11	O
by	2	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
is	2	O
mediated	8	O
by	2	O
specific	8	O
functional	10	O
receptors	9	O
to	2	O
the	3	O
hormone	7	O
;	1	O
and	3	O
(	1	O
b	1	O
)	1	O
the	3	O
receptors	9	O
for	3	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
in	2	O
mononuclear	11	O
cells	5	O
are	3	O
probably	8	O
controlled	10	O
genetically	11	O
by	2	O
the	3	O
same	4	O
mechanisms	10	O
as	2	O
the	3	O
effector	8	O
system	6	O
in	2	O
well	4	O
-characterized	14	O
target	6	O
organs	6	O
of	2	O
the	3	O
hormone	7	O
,	1	O
such	4	O
as	2	O
intestine	9	O
and	3	O
kidney	6	O
.	1	O

Aldosterone-receptor	20	B-Gene
deficiency	10	O
in	2	O
pseudohypoaldosteronism	23	B-Disease
.	1	O

Pseudohypoaldosteronism	23	B-Disease
,	1	O
a	1	O
syndrome	8	O
characterized	13	O
by	2	O
salt	4	O
wasting	7	O
and	3	O
failure	7	O
to	2	O
thrive	6	O
,	1	O
usually	7	O
presents	8	O
in	2	O
infancy	7	O
as	2	O
high	4	O
urinary	7	O
levels	6	O
of	2	O
sodium	6	B-Chemical
despite	7	O
hyponatremia	12	B-Disease
,	1	O
hyperkalemia	12	B-Disease
,	1	O
hyperreninemia	14	B-Disease
,	1	O
and	3	O
elevated	8	O
aldosterone	11	B-Chemical
levels	6	O
.	1	O

We	2	O
have	4	O
investigated	12	O
this	4	O
syndrome	8	O
for	3	O
the	3	O
possibility	11	O
of	2	O
abnormal	8	O
Type	4	O
I	1	O
or	2	O
``	2	O
mineralocorticoid	17	B-Chemical
-like	5	O
''receptors	11	O
,	1	O
which	5	O
have	4	O
intrinsic	9	O
steroid	7	B-Chemical
specificity	11	O
indistinguishable	17	O
from	4	O
that	4	O
of	2	O
renal	5	B-Gene
mineralocorticoid	17	I-Gene
receptors	9	I-Gene
and	3	O
are	3	O
found	5	O
in	2	O
many	4	O
tissues	7	O
and	3	O
cells	5	O
,	1	O
including	9	O
mononuclear	11	O
leukocytes	10	O
.	1	O

We	2	O
have	4	O
studied	7	O
three	5	O
patients	8	O
with	4	O
pseudohypoaldosteronism	23	B-Disease
:	1	O
the	3	O
28-year-old	11	O
index	5	O
case	4	O
in	2	O
Melbourne	9	O
(	1	O
Patient	7	O
1	1	O
)	1	O
and	3	O
two	3	O
siblings	8	O
in	2	O
Munich	6	O
,	1	O
eight	5	O
and	3	O
two	3	O
years	5	O
of	2	O
age	3	O
(	1	O
Patients	8	O
2	1	O
and	3	O
3	1	O
)	1	O
;	1	O
clinically	10	O
,	1	O
Patient	7	O
3	1	O
had	3	O
a	1	O
less	4	O
severe	6	O
case	4	O
than	4	O
his	3	O
sister	6	O
.	1	O

Percoll	7	B-Chemical
-separated	10	O
control	7	O
monocytes	9	O
bound	5	O
[	1	O
3H	2	O
]	1	O
aldosterone	11	B-Chemical
with	4	O
high	4	O
affinity	8	O
(	1	O
Kd	2	O
approximately	13	O
3	1	O
nM	2	O
)	1	O
and	3	O
limited	7	O
capacity	8	O
(	1	O
150	3	O
to	2	O
600	3	O
sites	5	O
per	3	O
cell	4	O
)	1	O
.	1	O

On	2	O
repeated	8	O
examination	11	O
,	1	O
no	2	O
[	1	O
3H	2	O
]	1	O
aldosterone	11	B-Chemical
binding	7	O
was	3	O
found	5	O
in	2	O
monocytes	9	O
from	4	O
Patients	8	O
1	1	O
and	3	O
2	1	O
;	1	O
in	2	O
Patient	7	O
3	1	O
,	1	O
the	3	O
levels	6	O
were	4	O
62	2	O
sites	5	O
per	3	O
cell	4	O
,	1	O
more	4	O
than	4	O
2	1	O
S.D.	4	O
below	5	O
those	5	O
of	2	O
the	3	O
control	7	O
.	1	O

Levels	6	O
in	2	O
the	3	O
parents	7	O
of	2	O
the	3	O
Munich	6	O
patients	8	O
(	1	O
first	5	O
cousins	7	O
)	1	O
were	4	O
normal	6	O
.	1	O

It	2	O
appears	7	O
that	4	O
pseudohypoaldosteronism	23	B-Disease
is	2	O
caused	6	O
by	2	O
a	1	O
Type	4	O
I	1	O
receptor	8	O
defect	6	O
,	1	O
that	4	O
the	3	O
defect	6	O
may	3	O
be	2	O
complete	8	O
or	2	O
partial	7	O
,	1	O
that	4	O
transmission	12	O
may	3	O
be	2	O
autosomal	9	O
recessive	9	O
,	1	O
and	3	O
that	4	O
the	3	O
study	5	O
of	2	O
patients	8	O
with	4	O
pseudohypoaldosteronism	23	B-Disease
may	3	O
indicate	8	O
physiologic	11	O
roles	5	O
for	3	O
Type	4	O
I	1	O
receptors	9	O
in	2	O
nonepithelial	13	O
tissues	7	O
.	1	O

A	1	O
nuclear	7	O
factor	6	O
that	4	O
binds	5	O
to	2	O
a	1	O
conserved	9	O
sequence	8	O
motif	5	O
in	2	O
transcriptional	15	O
control	7	O
elements	8	O
of	2	O
immunoglobulin	14	B-Gene
genes	5	I-Gene
.	1	O

Trans	5	O
-acting	7	O
factors	7	O
that	4	O
mediate	7	O
B-cell	6	O
specific	8	O
transcription	13	O
of	2	O
immunoglobulin	14	B-Gene
genes	5	I-Gene
have	4	O
been	4	O
postulated	10	O
based	5	O
on	2	O
an	2	O
analysis	8	O
of	2	O
the	3	O
expression	10	O
of	2	O
exogenously	11	O
introduced	10	O
immunoglobulin	14	B-Gene
gene	4	I-Gene
recombinants	12	O
in	2	O
lymphoid	8	O
and	3	O
non-lymphoid	12	O
cells	5	O
.	1	O

Two	3	O
B-cell-specific	15	O
,	1	O
cis	3	O
-acting	7	O
transcriptional	15	O
regulatory	10	O
elements	8	O
have	4	O
been	4	O
identified	10	O
.	1	O

One	3	O
element	7	O
is	2	O
located	7	O
in	2	O
the	3	O
intron	6	O
between	7	O
the	3	O
variable	8	O
(	1	O
V	1	O
)	1	O
and	3	O
constant	8	O
(	1	O
C	1	O
)	1	O
regions	7	O
of	2	O
both	4	O
heavy	5	O
and	3	O
kappa	5	O
light-chain	11	O
genes	5	O
and	3	O
acts	4	O
as	2	O
a	1	O
transcriptional	15	O
enhancer	8	O
.	1	O

The	3	O
second	6	O
element	7	O
is	2	O
found	5	O
upstream	8	O
of	2	O
both	4	O
heavy	5	O
and	3	O
kappa	5	O
light-chain	11	O
gene	4	O
promoters	9	O
.	1	O

This	4	O
element	7	O
directs	7	O
lymphoid-specific	17	O
transcription	13	O
even	4	O
in	2	O
the	3	O
presence	8	O
of	2	O
viral	5	O
enhancers	9	O
.	1	O

We	2	O
have	4	O
sought	6	O
nuclear	7	O
factors	7	O
that	4	O
might	5	O
bind	4	O
specifically	12	O
to	2	O
these	5	O
two	3	O
regulatory	10	O
elements	8	O
by	2	O
application	11	O
of	2	O
a	1	O
modified	8	O
gel	3	O
electrophoresis	15	O
DNA	3	O
binding	7	O
assay	5	O
.	1	O

We	2	O
report	6	O
here	4	O
the	3	O
identification	14	O
of	2	O
a	1	O
human	5	O
B-cell	6	O
nuclear	7	O
factor	6	O
(	1	O
IgNF-A	6	O
)	1	O
that	4	O
binds	5	O
to	2	O
DNA	3	O
sequences	9	O
in	2	O
the	3	O
upstream	8	O
regions	7	O
of	2	O
both	4	O
the	3	O
mouse	5	O
heavy	5	O
and	3	O
kappa	5	O
light-chain	11	O
gene	4	O
promoters	9	O
and	3	O
also	4	O
to	2	O
the	3	O
mouse	5	O
heavy-chain	11	O
gene	4	O
enhancer	8	O
.	1	O

This	4	O
sequence-specific	17	O
binding	7	O
is	2	O
probably	8	O
mediated	8	O
by	2	O
a	1	O
highly	6	O
conserved	9	O
sequence	8	O
motif	5	O
,	1	O
ATTTGCAT	8	O
,	1	O
present	7	O
in	2	O
all	3	O
three	5	O
transcriptional	15	O
elements	8	O
.	1	O

Interestingly	13	O
,	1	O
a	1	O
factor	6	O
showing	7	O
similar	7	O
binding	7	O
specificity	11	O
to	2	O
IgNF-A	6	O
is	2	O
also	4	O
present	7	O
in	2	O
human	5	O
HeLa	4	O
cells	5	O
.	1	O

Lymphocyte	10	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
binding	7	O
in	2	O
depressed	9	O
patients	8	O
with	4	O
hypercortisolemia	17	B-Disease
.	1	O

Despite	7	O
elevated	8	O
levels	6	O
of	2	O
serum	5	O
and	3	O
urinary	7	O
cortisol	8	B-Chemical
,	1	O
patients	8	O
with	4	O
depressive	10	O
illness	7	O
manifest	8	O
none	4	O
of	2	O
the	3	O
clinical	8	O
stigmata	8	O
of	2	O
glucocorticoid	14	B-Chemical
excess	6	O
.	1	O

This	4	O
hypercortisolemia	17	B-Disease
in	2	O
the	3	O
absence	7	O
of	2	O
clinical	8	O
effects	7	O
suggests	8	O
a	1	O
state	5	O
of	2	O
hormone	7	O
resistance	10	O
and	3	O
could	5	O
be	2	O
mediated	8	O
by	2	O
alterations	11	O
in	2	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
.	1	O

Earlier	7	O
studies	7	O
have	4	O
shown	5	O
that	4	O
small	5	O
doses	5	O
of	2	O
glucocorticoids	15	B-Chemical
cause	5	O
a	1	O
decrease	8	O
in	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
binding	7	O
in	2	O
normal	6	O
human	5	O
lymphocytes	11	O
.	1	O

White	5	O
cells	5	O
from	4	O
depressed	9	O
patients	8	O
with	4	O
significant	11	O
hypercortisolemia	17	B-Disease
would	5	O
be	2	O
expected	8	O
to	2	O
show	4	O
a	1	O
similar	7	O
change	6	O
in	2	O
receptor	8	O
concentration	13	O
if	2	O
peripheral	10	O
tissues	7	O
are	3	O
adequately	10	O
exposed	7	O
to	2	O
and	3	O
sensitive	9	O
to	2	O
the	3	O
hormone	7	O
.	1	O

In	2	O
this	4	O
study	5	O
we	2	O
compared	8	O
the	3	O
binding	7	O
of	2	O
[	1	O
3H	2	O
]	1	O
dexamethasone	13	B-Chemical
to	2	O
lymphocytes	11	O
from	4	O
normal	6	O
subjects	8	O
and	3	O
depressed	9	O
patients	8	O
with	4	O
hypercortisolemia	17	B-Disease
.	1	O

Lymphocytes	11	O
from	4	O
normal	6	O
subjects	8	O
had	3	O
a	1	O
mean	4	O
receptor	8	O
concentration	13	O
of	2	O
10.2	4	O
+	1	O
/	1	O
-	1	O
0.66	4	O
fm	2	O
/	1	O
10	2	O
(	1	O
6	1	O
)	1	O
cells	5	O
(	1	O
S.E.M.	6	O
)	1	O
and	3	O
a	1	O
dissociation	12	O
constant	8	O
of	2	O
4.8	3	O
+	1	O
/	1	O
-	1	O
0.47	4	O
nM	2	O
.	1	O

Lymphocytes	11	O
from	4	O
depressed	9	O
patients	8	O
with	4	O
abnormal	8	O
0800	4	O
h	1	O
serum	5	O
cortisol	8	B-Chemical
after	5	O
dexamethasone	13	B-Chemical
had	3	O
a	1	O
mean	4	O
receptor	8	O
concentration	13	O
of	2	O
8.8	3	O
+	1	O
/	1	O
-	1	O
0.75	4	O
fm	2	O
/	1	O
10	2	O
(	1	O
6	1	O
)	1	O
cells	5	O
,	1	O
which	5	O
was	3	O
not	3	O
significantly	13	O
different	9	O
from	4	O
that	4	O
in	2	O
lymphocytes	11	O
from	4	O
normal	6	O
subjects	8	O
or	2	O
from	4	O
depressed	9	O
subjects	8	O
with	4	O
normal	6	O
post-dexamethasone	18	B-Chemical
cortisol	8	I-Chemical
levels	6	O
(	1	O
9.4	3	O
+	1	O
/	1	O
-	1	O
0.95	4	O
fm	2	O
/	1	O
10	2	O
(	1	O
6	1	O
)	1	O
cells	5	O
)	1	O
.	1	O

Lymphocytes	11	O
from	4	O
depressed	9	O
patients	8	O
with	4	O
elevated	8	O
urinary	7	O
free	4	O
cortisol	8	B-Chemical
excretion	9	O
(	1	O
UFC	3	O
)	1	O
also	4	O
had	3	O
normal	6	O
receptor	8	O
concentration	13	O
and	3	O
binding	7	O
affinity	8	O
for	3	O
dexamethasone	13	B-Chemical
.	1	O

The	3	O
lack	4	O
of	2	O
a	1	O
change	6	O
in	2	O
lymphocyte	10	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
concentration	13	O
in	2	O
the	3	O
presence	8	O
of	2	O
cortisol	8	B-Chemical
excess	6	O
suggests	8	O
the	3	O
possibility	11	O
that	4	O
hypercortisolemia	17	B-Disease
in	2	O
depressive	10	O
illness	7	O
represents	10	O
a	1	O
state	5	O
of	2	O
peripheral	10	O
glucocorticoid	14	B-Chemical
resistance	10	O
.	1	O

Immunological	13	O
interference	12	O
of	2	O
high	4	O
dose	4	O
corticosteroids	15	B-Chemical
.	1	O

High-dose	9	O
corticosteroids	15	B-Chemical
(	1	O
HDC	3	O
)	1	O
will	4	O
influence	9	O
cellular	8	O
as	2	O
well	4	O
as	2	O
humoral	7	O
participants	12	O
of	2	O
the	3	O
immune	6	O
response	8	O
.	1	O

The	3	O
lymphoid	8	O
tissue	6	O
will	4	O
decrease	8	O
in	2	O
size	4	O
and	3	O
weight	6	O
after	5	O
prolonged	9	O
treatment	9	O
with	4	O
HDC	3	O
.	1	O

Lymphocyte	10	O
functions	9	O
will	4	O
be	2	O
impaired	8	O
.	1	O

Reduced	7	O
synthesis	9	O
of	2	O
B-	2	O
as	2	O
well	4	O
as	2	O
T-lymphocytes	13	O
will	4	O
be	2	O
seen	4	O
.	1	O

The	3	O
inhibitory	10	O
effect	6	O
on	2	O
B-cell	6	O
function	8	O
can	3	O
be	2	O
observed	8	O
both	4	O
as	2	O
decreased	9	O
serum	5	O
levels	6	O
of	2	O
immunoglobulins	15	O
and	3	O
as	2	O
impaired	8	O
binding	7	O
of	2	O
antibodies	10	O
and	3	O
complement	10	O
to	2	O
the	3	O
cellular	8	O
surface	7	O
.	1	O

Reduced	7	O
T-cell	6	O
function	8	O
indicated	9	O
by	2	O
impaired	8	O
stimulation	11	O
by	2	O
PHA	3	B-Gene
and	3	O
porkweed	8	O
as	2	O
well	4	O
as	2	O
by	2	O
impaired	8	O
lymphokinin	11	B-Gene
effects	7	O
on	2	O
leukocyte	9	O
migration	9	O
inhibition	10	O
has	3	O
been	4	O
reported	8	O
.	1	O

Reduced	7	O
lymphocyte	10	O
adherence	9	O
to	2	O
antigen	7	O
and	3	O
suppressed	10	O
lymphocyte	10	O
reaction	8	O
have	4	O
also	4	O
been	4	O
observed	8	O
.	1	O

Humoral	7	O
factors	7	O
involved	8	O
in	2	O
chemotaxis	10	O
,	1	O
opsonisation	12	O
,	1	O
phagocytosis	12	O
,	1	O
vascular	8	O
permeability	12	O
leading	7	O
to	2	O
leakage	7	O
of	2	O
fluid	5	O
and	3	O
cells	5	O
and	3	O
factors	7	O
involved	8	O
in	2	O
lysis	5	O
of	2	O
antigens	8	O
are	3	O
impaired	8	O
.	1	O

This	4	O
can	3	O
be	2	O
explained	9	O
partly	6	O
by	2	O
the	3	O
observed	8	O
reduced	7	O
complement	10	O
activation	10	O
via	3	O
the	3	O
alternative	11	O
as	2	O
well	4	O
as	2	O
the	3	O
classical	9	O
pathway	7	O
in	2	O
association	11	O
with	4	O
HDC	3	O
therapy	7	O
.	1	O

Acute	5	O
processes	9	O
with	4	O
increased	9	O
vascular	8	O
permeability	12	O
and	3	O
accumulation	12	O
of	2	O
leukocytes	10	O
as	2	O
impairing	9	O
factors	7	O
could	5	O
be	2	O
influenced	10	O
beneficially	12	O
by	2	O
HDC	3	O
therapy	7	O
.	1	O

This	4	O
positive	8	O
effect	6	O
can	3	O
be	2	O
seen	4	O
in	2	O
treatment	9	O
of	2	O
septic	6	O
shock	5	O
or	2	O
rejection	9	O
of	2	O
a	1	O
transplant	10	O
.	1	O

However	7	O
,	1	O
if	2	O
sepsis	6	O
or	2	O
rejection	9	O
is	2	O
not	3	O
rapidly	7	O
reversed	8	O
,	1	O
complications	13	O
such	4	O
as	2	O
multisystem	11	O
organ	5	O
failure	7	O
and	3	O
bacteremia	10	O
are	3	O
prone	5	O
to	2	O
appear	6	O
.	1	O

[	1	O
Glucocorticoid	14	B-Gene
receptors	9	I-Gene
and	3	O
response	8	O
to	2	O
polychemotherapy	16	O
in	2	O
acute	5	B-Disease
lymphatic	9	I-Disease
leukemia	8	I-Disease
]	1	O

Glucocorticoid	14	B-Gene
receptor	8	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
levels	6	O
were	4	O
quantified	10	O
in	2	O
leukemic	8	O
blasts	6	O
from	4	O
peripheral	10	O
blood	5	O
of	2	O
86	2	O
patients	8	O
with	4	O
acute	5	B-Disease
lymphoblastic	13	I-Disease
leukemia	8	I-Disease
.	1	O

The	3	O
subsequent	10	O
achievement	11	O
of	2	O
complete	8	O
remission	9	O
after	5	O
combination	11	O
chemotherapy	12	O
was	3	O
correlated	10	O
with	4	O
high	4	O
receptor	8	O
levels	6	O
.	1	O

Forty-seven	11	O
of	2	O
50	2	O
patients	8	O
with	4	O
leukemic	8	O
cells	5	O
containing	10	O
more	4	O
than	4	O
6	1	O
,	1	O
000	3	O
receptor	8	O
sites	5	O
and	3	O
22	2	O
of	2	O
36	2	O
patients	8	O
with	4	O
cells	5	O
containing	10	O
less	4	O
than	4	O
6	1	O
,	1	O
000	3	O
receptor	8	O
sites	5	O
achieved	8	O
remission	9	O
.	1	O

The	3	O
study	5	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
leukemic	8	O
cells	5	O
may	3	O
predict	7	O
response	8	O
to	2	O
combination	11	O
chemotherapy	12	O
in	2	O
patients	8	O
with	4	O
acute	5	B-Disease
lymphoblastic	13	I-Disease
leukemia	8	I-Disease
.	1	O

The	3	O
new	3	O
world	5	O
primates	8	O
as	2	O
animal	6	O
models	6	O
of	2	O
glucocorticoid	14	B-Chemical
resistance	10	O
.	1	O

Many	4	O
New	3	O
World	5	O
primate	7	O
species	7	O
have	4	O
greatly	7	O
increased	9	O
plasma	6	O
cortisol	8	B-Chemical
concentrations	14	O
,	1	O
decreased	9	O
plasma	6	B-Gene
cortisol	8	I-Gene
binding	7	I-Gene
globulin	8	I-Gene
capacity	8	O
and	3	O
affinity	8	O
,	1	O
marked	6	O
resistance	10	O
of	2	O
the	3	O
hypothalamic-pituitary-adrenal	30	O
axis	4	O
to	2	O
suppression	11	O
by	2	O
dexamethasone	13	B-Chemical
,	1	O
and	3	O
no	2	O
biological	10	O
evidence	8	O
of	2	O
glucocorticoid	14	B-Chemical
excess	6	O
.	1	O

These	5	O
primates	8	O
also	4	O
have	4	O
high	4	O
levels	6	O
of	2	O
circulating	11	O
progesterone	12	B-Chemical
,	1	O
estrogen	8	B-Chemical
,	1	O
mineralocorticoid	17	B-Chemical
,	1	O
androgen	8	B-Chemical
and	3	O
vitamin	7	B-Chemical
D	1	I-Chemical
.	1	O

The	3	O
glucocorticoid	14	B-Chemical
target	6	O
tissues	7	O
that	4	O
have	4	O
been	4	O
examined	8	O
(	1	O
circulating	11	O
mononuclear	11	O
lymphocytes	11	O
and	3	O
cultured	8	O
skin	4	O
fibroblasts	11	O
)	1	O
have	4	O
normal	6	O
concentrations	14	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
with	4	O
decreased	9	O
affinity	8	O
for	3	O
dexamethasone	13	B-Chemical
.	1	O

Transformation	14	O
of	2	O
B-lymphocytes	13	O
with	4	O
the	3	O
Epstein-Barr	12	O
virus	5	O
leads	5	O
to	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
induction	9	O
that	4	O
is	2	O
less	4	O
than	4	O
that	4	O
observed	8	O
with	4	O
cells	5	O
from	4	O
Old	3	O
World	5	O
primates	8	O
.	1	O

The	3	O
receptor	8	O
in	2	O
these	5	O
cells	5	O
has	3	O
a	1	O
low	3	O
affinity	8	O
for	3	O
dexamethasone	13	B-Chemical
.	1	O

The	3	O
low	3	O
affinity	8	O
leads	5	O
to	2	O
an	2	O
increased	9	O
loss	4	O
of	2	O
specific	8	O
bound	5	O
ligand	6	O
during	6	O
thermal	7	O
activation	10	O
.	1	O

Meroreceptor	12	O
generation	10	O
is	2	O
normal	6	O
.	1	O

The	3	O
molecular	9	O
weight	6	O
of	2	O
the	3	O
receptor	8	O
,	1	O
determined	10	O
by	2	O
SDS-PAGE	8	O
,	1	O
is	2	O
similar	7	O
to	2	O
that	4	O
of	2	O
Old	3	O
World	5	O
primates	8	O
(	1	O
approximately	13	O
92	2	O
,	1	O
000	3	O
)	1	O
and	3	O
the	3	O
activation	10	O
pattern	7	O
per	3	O
se	2	O
,	1	O
examined	8	O
in	2	O
vitro	5	O
by	2	O
heating	7	O
cytosol	7	O
and	3	O
performing	10	O
phosphocellulose	16	O
chromatography	14	O
,	1	O
appears	7	O
similar	7	O
to	2	O
that	4	O
of	2	O
human	5	O
controls	8	O
.	1	O

The	3	O
ratios	6	O
of	2	O
nuclear	7	O
to	2	O
cytosolic	9	O
hormone-receptor-complexes	26	O
and	3	O
of	2	O
cytosolic	9	O
activated	9	O
to	2	O
unactivated	11	O
receptor	8	O
complexes	9	O
in	2	O
intact	6	O
cells	5	O
are	3	O
similar	7	O
to	2	O
Old	3	O
World	5	O
primates	8	O
.	1	O

Results	7	O
from	4	O
mixing	6	O
studies	7	O
do	2	O
not	3	O
support	7	O
the	3	O
hypothesis	10	O
that	4	O
a	1	O
binding	7	O
inhibitor	9	O
(	1	O
s	1	O
)	1	O
or	2	O
a	1	O
deficient	9	O
cytosolic	9	O
positive	8	O
modifier	8	O
(	1	O
s	1	O
)	1	O
of	2	O
binding	7	O
underlies	9	O
the	3	O
findings	8	O
in	2	O
these	5	O
primates	8	O
.	1	O

The	3	O
New	3	O
World	5	O
primates	8	O
,	1	O
unlike	6	O
men	3	O
with	4	O
the	3	O
syndrome	8	O
of	2	O
primary	7	O
cortisol	8	B-Chemical
resistance	10	O
,	1	O
have	4	O
compensated	11	O
for	3	O
their	5	O
condition	9	O
with	4	O
intra-adrenal	13	O
and	3	O
mineralocorticoid	17	B-Gene
receptor	8	I-Gene
adaptations	11	O
.	1	O

Thus	4	O
,	1	O
unlike	6	O
Old	3	O
World	5	O
primates	8	O
,	1	O
cortisol	8	B-Chemical
in	2	O
New	3	O
World	5	O
primates	8	O
has	3	O
only	4	O
weak	4	O
sodium	6	B-Chemical
-retaining	10	O
potency	7	O
because	7	O
the	3	O
aldosterone	11	B-Gene
receptor	8	I-Gene
has	3	O
a	1	O
low	3	O
affinity	8	O
for	3	O
cortisol	8	B-Chemical
.	1	O

The	3	O
common	6	O
element	7	O
that	4	O
would	5	O
explain	7	O
the	3	O
apparent	8	O
resistance	10	O
to	2	O
six	3	O
steroid	7	B-Chemical
hormones	8	I-Chemical
in	2	O
New	3	O
World	5	O
primates	8	O

Preferential	12	O
transcription	13	O
of	2	O
HTLV-I	6	O
LTR	3	O
in	2	O
cell-free	9	O
extracts	8	O
of	2	O
human	5	O
T	1	O
cells	5	O
producing	9	O
HTLV-I	6	O
viral	5	O
proteins	8	O
.	1	O

The	3	O
promoters	9	O
of	2	O
the	3	O
adenovirus	10	B-Gene
2	1	I-Gene
major	5	I-Gene
late	4	I-Gene
gene	4	I-Gene
,	1	O
the	3	O
mouse	5	B-Gene
beta-globin	11	I-Gene
gene	4	I-Gene
,	1	O
the	3	O
mouse	5	B-Gene
immunoglobulin	14	I-Gene
VH	2	I-Gene
gene	4	I-Gene
and	3	O
the	3	O
LTR	3	O
of	2	O
the	3	O
human	5	O
T-lymphotropic	14	O
retrovirus	10	O
type	4	O
I	1	O
were	4	O
tested	6	O
for	3	O
their	5	O
transcription	13	O
activities	10	O
in	2	O
cell-free	9	O
extracts	8	O
of	2	O
four	4	O
cell	4	O
lines	5	O
;	1	O
HeLa	4	O
,	1	O
CESS	4	O
(	1	O
Epstein-Barr	12	O
virus	5	O
-transformed	12	O
human	5	O
B	1	O
cell	4	O
line	4	O
)	1	O
,	1	O
MT-1	4	O
(	1	O
HTLV-I	6	O
-infected	9	O
human	5	O
T	1	O
cell	4	O
line	4	O
without	7	O
viral	5	O
protein	7	O
synthesis	9	O
)	1	O
,	1	O
and	3	O
MT-2	4	O
(	1	O
HTLV-I	6	O
-infected	9	O
human	5	O
T	1	O
cell	4	O
line	4	O
producing	9	O
viral	5	O
proteins	8	O
)	1	O
.	1	O

LTR	3	O
was	3	O
preferentially	14	O
transcribed	11	O
in	2	O
the	3	O
extracts	8	O
of	2	O
MT-2	4	O
although	8	O
the	3	O
other	5	O
three	5	O
genes	5	O
were	4	O
transcribed	11	O
with	4	O
relatively	10	O
constant	8	O
efficiencies	12	O
in	2	O
different	9	O
extracts	8	O
.	1	O

The	3	O
results	7	O
agree	5	O
well	4	O
with	4	O
the	3	O
previous	8	O
in	2	O
vivo	4	O
studies	7	O
on	2	O
the	3	O
promoter	8	O
activity	8	O
of	2	O
HTLV-I	6	O
LTR	3	O
.	1	O

Mixing	6	O
of	2	O
HeLa	4	O
and	3	O
MT-2	4	O
extracts	8	O
revealed	8	O
the	3	O
presence	8	O
of	2	O
a	1	O
LTR-specific	12	O
stimulating	11	O
activity	8	O
in	2	O
MT-2	4	O
extracts	8	O
.	1	O

Inhibition	10	O
by	2	O
cortisol	8	B-Chemical
of	2	O
human	5	O
natural	7	O
killer	6	O
(	1	O
NK	2	O
)	1	O
cell	4	O
activity	8	O
.	1	O

The	3	O
effects	7	O
of	2	O
cortisol	8	B-Chemical
on	2	O
the	3	O
natural	7	O
killer	6	O
(	1	O
NK	2	O
)	1	O
activity	8	O
of	2	O
human	5	O
peripheral	10	O
blood	5	O
mononuclear	11	O
(	1	O
PBM	3	O
)	1	O
cells	5	O
were	4	O
studied	7	O
in	2	O
vitro	5	O
using	5	O
a	1	O
direct	6	O
4-h	3	O
51Cr-release	12	O
assay	5	O
and	3	O
K	1	O
562	3	O
cell	4	O
line	4	O
as	2	O
a	1	O
target	6	O
.	1	O

Preincubation	13	O
for	3	O
20	2	O
h	1	O
of	2	O
PBM	3	O
cells	5	O
drawn	5	O
from	4	O
healthy	7	O
donors	6	O
with	4	O
1	1	O
X	1	O
10	2	O
(	1	O
-8	2	O
)	1	O
to	2	O
1	1	O
X	1	O
10	2	O
(	1	O
-5	2	O
)	1	O
M	1	O
cortisol	8	B-Chemical
resulted	8	O
in	2	O
a	1	O
significant	11	O
decrease	8	O
of	2	O
NK	2	O
cell	4	O
activity	8	O
.	1	O

The	3	O
magnitude	9	O
of	2	O
the	3	O
suppression	11	O
was	3	O
directly	8	O
related	7	O
to	2	O
the	3	O
steroid	7	B-Chemical
concentration	13	O
and	3	O
inversely	9	O
related	7	O
to	2	O
the	3	O
number	6	O
of	2	O
effector	8	O
cells	5	O
.	1	O

Cortisol	8	B-Chemical
was	3	O
able	4	O
to	2	O
minimize	8	O
the	3	O
enhancement	11	O
of	2	O
NK	2	O
cytotoxicity	12	O
obtainable	10	O
in	2	O
the	3	O
presence	8	O
of	2	O
immune	6	O
interferon	10	B-Gene
(	1	O
IFN-gamma	9	B-Gene
)	1	O
.	1	O

A	1	O
significantly	13	O
higher	6	O
suppression	11	O
was	3	O
achieved	8	O
after	5	O
sequential	10	O
exposure	8	O
of	2	O
PBM	3	O
cells	5	O
to	2	O
cortisol	8	B-Chemical
and	3	O
equimolar	9	O
levels	6	O
of	2	O
prostaglandin	13	B-Chemical
E2	2	I-Chemical
(	1	O
PgE2	4	B-Chemical
)	1	O
.	1	O

The	3	O
concomitant	11	O
incubation	10	O
with	4	O
theophylline	12	B-Chemical
and	3	O
isobutyl	8	B-Chemical
-methylxanthine	15	I-Chemical
failed	6	O
to	2	O
enhance	7	O
the	3	O
cortisol	8	B-Chemical
-induced	8	O
suppression	11	O
,	1	O
whereas	7	O
PgE2	4	B-Chemical
-dependent	10	O
inhibition	10	O
significantly	13	O
increased	9	O
after	5	O
exposure	8	O
of	2	O
PBM	3	O
cells	5	O
to	2	O
methyl	6	B-Chemical
-xanthines	10	I-Chemical
.	1	O

The	3	O
inhibitory	10	O
effect	6	O
of	2	O
cortisol	8	B-Chemical
was	3	O
partially	9	O
or	2	O
totally	7	O
prevented	9	O
by	2	O
the	3	O
concomitant	11	O
incubation	10	O
with	4	O
equimolar	9	O
amounts	7	O
of	2	O
11-deoxycortisol	16	B-Chemical
and	3	O
RU	2	B-Chemical
486	3	I-Chemical
but	3	O
not	3	O
of	2	O
progesterone	12	B-Chemical
.	1	O

Treatment	9	O
of	2	O
NK	2	O
effectors	9	O
with	4	O
a	1	O
monoclonal	10	B-Gene
anti-human	10	I-Gene
corticosteroid	14	I-Gene
-binding	8	I-Gene
globulin	8	I-Gene
(	1	I-Gene
CBG	3	I-Gene
)	1	I-Gene
antibody	8	I-Gene
produced	8	O
an	2	O
enhancement	11	O
of	2	O
the	3	O
spontaneous	11	O
NK	2	O
activity	8	O
and	3	O
a	1	O
partial	7	O
suppression	11	O
of	2	O
cortisol	8	B-Chemical
-mediated	9	O
effects	7	O
.	1	O

Our	3	O
results	7	O
suggest	7	O
that	4	O
endogenous	10	O
glucocorticoids	15	B-Chemical
play	4	O
a	1	O
role	4	O
in	2	O
the	3	O
regulation	10	O
of	2	O
NK	2	O
cell	4	O
-mediated	9	O
cytotoxicity	12	O
.	1	O

Since	5	O
the	3	O
effect	6	O
of	2	O
cortisol	8	B-Chemical
was	3	O
additive	8	O
to	2	O
that	4	O
of	2	O
PgE2	4	B-Chemical
and	3	O
was	3	O
not	3	O
changed	7	O
by	2	O
phosphodiesterase	17	B-Gene
inhibitors	10	I-Gene
,	1	O
it	2	O
is	2	O
conceivable	11	O
that	4	O
the	3	O
hormone	7	O
acts	4	O
at	2	O
a	1	O
level	5	O
different	9	O
from	4	O
the	3	O
adenylate	9	B-Gene
cyclase	7	I-Gene
-	1	I-Gene
phosphodiesterase	17	I-Gene
system	6	O
.	1	O

Data	4	O
obtained	8	O
with	4	O
the	3	O
use	3	O
of	2	O
antiglucocorticoids	19	O
and	3	O
the	3	O
anti-CBG	8	B-Gene
antibody	8	I-Gene
are	3	O
compatible	10	O
with	4	O
a	1	O
role	4	O
both	4	O
of	2	O
high-affinity	13	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
and	3	O
of	2	O
CBG	3	B-Gene
in	2	O
mediating	9	O
cortisol	8	B-Chemical
action	6	O
on	2	O
the	3	O
human	5	O
NK	2	O
cell	4	O
activity	8	O
.	1	O

Altered	7	O
interaction	11	O
between	7	O
triiodothyronine	16	B-Chemical
and	3	O
its	3	O
nuclear	7	O
receptors	9	O
in	2	O
absence	7	O
of	2	O
cortisol	8	B-Chemical
:	1	O
a	1	O
proposed	8	O
mechanism	9	O
for	3	O
increased	9	O
thyrotropin	11	B-Gene
secretion	9	O
in	2	O
corticosteroid	14	B-Chemical
deficiency	10	O
states	6	O
.	1	O

Thyroid	7	O
hormones	8	O
occasionally	12	O
appear	6	O
less	4	O
effective	9	O
when	4	O
administered	12	O
alone	5	O
to	2	O
patients	8	O
with	4	O
panhypopituitarism	18	B-Disease
,	1	O
and	3	O
manifestations	14	O
suggestive	10	O
of	2	O
hypothyroidism	14	B-Disease
have	4	O
been	4	O
reported	8	O
in	2	O
patients	8	O
suffering	9	O
from	4	O
untreated	9	O
Addison	7	B-Disease
's	2	I-Disease
disease	7	I-Disease
.	1	O

In	2	O
the	3	O
latter	6	O
condition	9	O
,	1	O
thyrotropin	11	B-Gene
secretion	9	O
is	2	O
increased	9	O
:	1	O
this	4	O
occurs	6	O
already	7	O
after	5	O
as	2	O
little	6	O
as	2	O
2	1	O
days	4	O
of	2	O
temporary	9	O
withdrawal	10	O
of	2	O
therapy	7	O
with	4	O
substitution	12	O
doses	5	O
of	2	O
corticosteroids	15	B-Chemical
while	5	O
circulating	11	O
levels	6	O
of	2	O
thyroid	7	B-Chemical
hormones	8	I-Chemical
remain	6	O
within	6	O
normal	6	O
limits	6	O
.	1	O

Therefore	9	O
,	1	O
a	1	O
possible	8	O
role	4	O
of	2	O
cortisol	8	B-Chemical
in	2	O
interaction	11	O
between	7	O
triiodothyronine	16	B-Chemical
and	3	O
its	3	O
nuclear	7	O
receptors	9	O
was	3	O
examined	8	O
at	2	O
the	3	O
level	5	O
of	2	O
circulating	11	O
lymphocytes	11	O
obtained	8	O
from	4	O
patients	8	O
with	4	O
primary	7	O
or	2	O
secondary	9	B-Disease
adrenocortical	14	I-Disease
failure	7	I-Disease
.	1	O

The	3	O
affinity	8	O
of	2	O
these	5	O
receptors	9	O
was	3	O
found	5	O
to	2	O
be	2	O
decreased	9	O
,	1	O
by	2	O
more	4	O
than	4	O
50	2	O
%	1	O
on	2	O
average	7	O
,	1	O
in	2	O
the	3	O
absence	7	O
of	2	O
cortisol	8	B-Chemical
treatments	10	O
.	1	O

This	4	O
change	6	O
was	3	O
promptly	8	O
corrected	9	O
upon	4	O
resumption	10	O
of	2	O
therapy	7	O
.	1	O

The	3	O
number	6	O
of	2	O
binding	7	O
sites	5	O
was	3	O
not	3	O
significantly	13	O
modified	8	O
.	1	O

The	3	O
influence	9	O
of	2	O
cortisol	8	B-Chemical
on	2	O
thyroid	7	B-Gene
hormone	7	I-Gene
receptors	9	I-Gene
discussed	9	O
here	4	O
might	5	O
account	7	O
for	3	O
the	3	O
clinical	8	O
observations	12	O
mentioned	9	O
above	5	O
.	1	O

Granulocyte-macrophage	22	B-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
.	1	O

Sensitive	9	O
and	3	O
receptor	8	O
-mediated	9	O
regulation	10	O
by	2	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
in	2	O
normal	6	O
human	5	O
peripheral	10	O
blood	5	O
lymphocytes	11	O
.	1	O

We	2	O
show	4	O
that	4	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
(	1	O
1	1	B-Chemical
,	1	I-Chemical
25	2	I-Chemical
[	1	I-Chemical
OH	2	I-Chemical
]	1	I-Chemical
2D3	3	I-Chemical
)	1	O
,	1	O
the	3	O
most	4	O
hormonally	10	O
active	6	O
metabolite	10	O
of	2	O
vitamin	7	B-Chemical
D3	2	I-Chemical
,	1	O
modulates	9	O
sensitively	11	O
and	3	O
specifically	12	O
both	4	O
the	3	O
protein	7	O
and	3	O
messenger	9	O
RNA	3	O
accumulation	12	O
of	2	O
the	3	O
multilineage	12	B-Gene
growth	6	I-Gene
factor	6	I-Gene
granulocyte-macrophage	22	I-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
(	1	O
GM-CSF	6	B-Gene
)	1	O
.	1	O

The	3	O
regulation	10	O
of	2	O
GM-CSF	6	B-Gene
expression	10	O
is	2	O
seen	4	O
in	2	O
both	4	O
normal	6	O
human	5	O
mitogen	7	O
-activated	10	O
T	1	O
lymphocytes	11	O
and	3	O
T	1	O
lymphocytes	11	O
from	4	O
a	1	O
line	4	O
(	1	O
S-LB1	5	O
)	1	O
transformed	11	O
with	4	O
human	5	O
T	1	O
cell	4	O
lymphotropic	12	O
virus	5	O
1	1	O
(	1	O
HTLV-1	6	O
)	1	O
.	1	O

In	2	O
contrast	8	O
,	1	O
cells	5	O
from	4	O
a	1	O
HTLV-1	6	O
transformed	11	O
T	1	O
lymphocyte	10	O
line	4	O
(	1	O
Ab-VDR	6	O
)	1	O
established	11	O
from	4	O
a	1	O
patient	7	O
with	4	O
vitamin	7	B-Disease
D	1	I-Disease
-resistant	10	I-Disease
rickets	7	I-Disease
type	4	I-Disease
II	2	I-Disease
with	4	O
undetectable	12	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
cellular	8	I-Gene
receptors	9	I-Gene
are	3	O
resistant	9	O
to	2	O
the	3	O
action	6	O
of	2	O
1	1	B-Chemical
,	1	I-Chemical
25	2	I-Chemical
(	1	I-Chemical
OH	2	I-Chemical
)	1	I-Chemical
2D3	3	I-Chemical
.	1	O

Inhibition	10	O
of	2	O
GM-CSF	6	B-Gene
expression	10	O
by	2	O
1	1	B-Chemical
,	1	I-Chemical
25	2	I-Chemical
(	1	I-Chemical
OH	2	I-Chemical
)	1	I-Chemical
2D3	3	I-Chemical
can	3	O
occur	5	O
independently	13	O
of	2	O
interleukin	11	B-Gene
2	1	I-Gene
regulation	10	O
and	3	O
is	2	O
probably	8	O
mediated	8	O
through	7	O
cellular	8	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptors	9	I-Gene
.	1	O

We	2	O
conclude	8	O
that	4	O
1	1	B-Chemical
,	1	I-Chemical
25	2	I-Chemical
(	1	I-Chemical
OH	2	I-Chemical
)	1	I-Chemical
2D3	3	I-Chemical
may	3	O
be	2	O
important	9	O
in	2	O
the	3	O
physiology	10	O
of	2	O
hematopoiesis	13	O
.	1	O

Decreased	9	O
deoxyribonucleic	16	O
acid	4	O
binding	7	O
of	2	O
glucocorticoid-receptor	23	B-Gene
complex	7	I-Gene
in	2	O
cultured	8	O
skin	4	O
fibroblasts	11	O
from	4	O
a	1	O
patient	7	O
with	4	O
the	3	O
glucocorticoid	14	B-Chemical
resistance	10	O
syndrome	8	O
.	1	O

A	1	O
patient	7	O
with	4	O
the	3	O
syndrome	8	O
of	2	O
glucocorticoid	14	B-Chemical
resistance	10	O
was	3	O
studied	7	O
.	1	O

A	1	O
27-yr-old	9	O
woman	5	O
initially	9	O
was	3	O
diagnosed	9	O
as	2	O
having	6	O
Cushing	7	B-Disease
's	2	I-Disease
disease	7	I-Disease
,	1	O
based	5	O
on	2	O
the	3	O
findings	8	O
of	2	O
high	4	O
plasma	6	B-Gene
ACTH	4	I-Gene
and	3	O
serum	5	O
cortisol	8	B-Chemical
levels	6	O
,	1	O
increased	9	O
urinary	7	O
cortisol	8	B-Chemical
secretion	9	O
,	1	O
resistance	10	O
to	2	O
adrenal	7	O
suppression	11	O
with	4	O
dexamethasone	13	B-Chemical
,	1	O
and	3	O
bilateral	9	O
adrenal	7	B-Disease
hyperplasia	11	I-Disease
by	2	O
computed	8	O
tomography	10	O
and	3	O
scintigraphy	12	O
of	2	O
the	3	O
adrenal	7	O
glands	6	O
.	1	O

However	7	O
,	1	O
she	3	O
had	3	O
no	2	O
signs	5	O
or	2	O
symptoms	8	O
of	2	O
Cushing	7	B-Disease
's	2	I-Disease
syndrome	8	I-Disease
.	1	O

During	6	O
a	1	O
5-yr	4	O
follow-up	9	O
,	1	O
no	2	O
clinical	8	O
abnormalities	13	O
developed	9	O
,	1	O
although	8	O
hypercortisolism	16	B-Disease
persisted	9	O
.	1	O

End-organ	9	O
resistance	10	O
to	2	O
cortisol	8	B-Chemical
was	3	O
suspected	9	O
.	1	O

To	2	O
explain	7	O
the	3	O
end-organ	9	O
resistance	10	O
to	2	O
cortisol	8	B-Chemical
,	1	O
the	3	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
in	2	O
peripheral	10	O
mononuclear	11	O
leukocytes	10	O
and	3	O
cultured	8	O
skin	4	O
fibroblasts	11	O
from	4	O
a	1	O
forearm	7	O
skin	4	O
biopsy	6	O
were	4	O
characterized	13	O
and	3	O
compared	8	O
with	4	O
the	3	O
results	7	O
of	2	O
similar	7	O
studies	7	O
in	2	O
normal	6	O
subjects	8	O
.	1	O

The	3	O
patient	7	O
's	2	O
GR	2	B-Gene
in	2	O
whole	5	O
cell	4	O
assays	6	O
had	3	O
an	2	O
increased	9	O
dissociation	12	O
constant	8	O
(	1	O
Kd	2	O
)	1	O
.	1	O

In	2	O
the	3	O
cytosol	7	O
of	2	O
cultured	8	O
skin	4	O
fibroblasts	11	O
from	4	O
the	3	O
patient	7	O
,	1	O
there	5	O
was	3	O
also	4	O
decreased	9	O
binding	7	O
capacity	8	O
.	1	O

The	3	O
thermal	7	O
stability	9	O
and	3	O
the	3	O
sedimentation	13	O
coefficient	11	O
in	2	O
a	1	O
sucrose	7	O
density	7	O
gradient	8	O
of	2	O
the	3	O
receptors	9	O
in	2	O
the	3	O
cytosol	7	O
of	2	O
cultured	8	O
skin	4	O
fibroblasts	11	O
from	4	O
the	3	O
patient	7	O
and	3	O
normal	6	O
subjects	8	O
were	4	O
similar	7	O
.	1	O

GR	2	B-Gene
complex	7	I-Gene
activation	10	O
,	1	O
analyzed	8	O
by	2	O
DEAE-cellulose	14	O
chromatography	14	O
,	1	O
was	3	O
decreased	9	O
in	2	O
the	3	O
patient	7	O
.	1	O

DNA	3	O
binding	7	O
of	2	O
the	3	O
GR	2	B-Gene
complex	7	I-Gene
after	5	O
temperature	11	O
-induced	8	O
activation	10	O
was	3	O
lower	5	O
in	2	O
the	3	O
patient	7	O
than	4	O
in	2	O
normal	6	O
subjects	8	O
.	1	O

Nuclear	7	O
translocation	13	O
of	2	O
GR	2	B-Gene
complexes	9	I-Gene
from	4	O
the	3	O
patient	7	O
was	3	O
also	4	O
slightly	8	O
decreased	9	O
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
the	3	O
patient	7	O
's	2	O
glucocorticoid	14	B-Chemical
resistance	10	O
was	3	O
due	3	O
to	2	O
a	1	O
decrease	8	O
in	2	O
the	3	O
affinity	8	O
of	2	O
the	3	O
receptor	8	O
for	3	O
glucocorticoids	15	B-Chemical
and	3	O
a	1	O
decrease	8	O
in	2	O
the	3	O
binding	7	O
of	2	O
the	3	O
GR	2	B-Gene
complex	7	I-Gene
to	2	O
DNA	3	O
.	1	O

Identification	14	O
and	3	O
purification	12	O
of	2	O
a	1	O
human	5	B-Gene
lymphoid-specific	17	I-Gene
octamer	7	I-Gene
-binding	8	I-Gene
protein	7	I-Gene
(	1	O
OTF-2	5	B-Gene
)	1	O
that	4	O
activates	9	O
transcription	13	O
of	2	O
an	2	O
immunoglobulin	14	B-Gene
promoter	8	I-Gene
in	2	O
vitro	5	O
.	1	O

The	3	O
octamer	7	O
sequence	8	O
5'-ATGCAAAT	11	O
,	1	O
in	2	O
either	6	O
orientation	11	O
,	1	O
serves	6	O
as	2	O
an	2	O
upstream	8	O
element	7	O
in	2	O
a	1	O
variety	7	O
of	2	O
promoters	9	O
and	3	O
also	4	O
occurs	6	O
as	2	O
a	1	O
modular	7	O
enhancer	8	O
element	7	O
.	1	O

It	2	O
is	2	O
of	2	O
particular	10	O
interest	8	O
in	2	O
immunoglobulin	14	B-Gene
genes	5	I-Gene
since	5	O
it	2	O
is	2	O
found	5	O
in	2	O
the	3	O
upstream	8	O
regions	7	O
of	2	O
all	3	O
heavy	5	O
and	3	O
light	5	O
chain	5	O
promoters	9	O
and	3	O
in	2	O
the	3	O
heavy	5	O
chain	5	O
enhancer	8	O
,	1	O
both	4	O
of	2	O
which	5	O
are	3	O
known	5	O
to	2	O
be	2	O
necessary	9	O
for	3	O
cell-specific	13	O
expression	10	O
.	1	O

We	2	O
report	6	O
here	4	O
the	3	O
chromatographic	15	O
separation	10	O
of	2	O
ubiquitous	10	O
and	3	O
B	1	B-Gene
cell-specific	13	I-Gene
octamer	7	I-Gene
-binding	8	I-Gene
proteins	8	I-Gene
.	1	O

The	3	O
B	1	O
cell	4	O
factor	6	O
was	3	O
purified	8	O
to	2	O
homogeneity	11	O
using	5	O
affinity	8	O
chromatography	14	O
and	3	O
consists	8	O
of	2	O
three	5	O
peptides	8	O
of	2	O
62	2	O
,	1	O
61	2	O
,	1	O
and	3	O
58.5	4	O
+	1	O
/	1	O
-	1	O
1.5	3	O
kd	2	O
.	1	O

Each	4	O
of	2	O
the	3	O
polypeptides	12	O
was	3	O
renatured	9	O
after	5	O
SDS-PAGE	8	O
and	3	O
shown	5	O
to	2	O
bind	4	O
to	2	O
the	3	O
octamer	7	O
sequence	8	O
.	1	O

The	3	O
specific	8	O
DNA	3	O
binding	7	O
activity	8	O
of	2	O
the	3	O
pure	4	O
B	1	O
cell-specific	13	O
factor	6	O
was	3	O
indistinguishable	17	O
from	4	O
that	4	O
of	2	O
the	3	O
affinity	8	O
-purified	9	O
ubiquitous	10	O
factor	6	O
.	1	O

This	4	O
B	1	B-Gene
cell-specific	13	I-Gene
octamer	7	I-Gene
-binding	8	I-Gene
factor	6	I-Gene
,	1	O
in	2	O
pure	4	O
form	4	O
,	1	O
activated	9	O
transcription	13	O
from	4	O
a	1	O
kappa	5	O
light	5	O
chain	5	O
promoter	8	O
in	2	O
vitro	5	O
,	1	O
thus	4	O
demonstrating	13	O
that	4	O
it	2	O
is	2	O
indeed	6	O
a	1	O
B	1	O
cell-specific	13	O
transcription	13	O
factor	6	O
for	3	O
this	4	O
gene	4	O
.	1	O

In	2	O
addition	8	O
to	2	O
the	3	O
ubiquitous	10	O
and	3	O
B	1	B-Gene
cell-specific	13	I-Gene
octamer	7	I-Gene
-binding	8	I-Gene
factors	7	I-Gene
,	1	O
we	2	O
identified	10	O
several	7	O
additional	10	O
proteins	8	O
,	1	O
one	3	O
of	2	O
which	5	O
is	2	O
B	1	O
cell	4	O
-specific	9	O
,	1	O
that	4	O
interact	8	O
with	4	O
the	3	O
kappa	5	O
promoter	8	O
.	1	O

Lymphocyte	10	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
binding	7	O
in	2	O
depression	10	B-Disease
:	1	O
normal	6	O
values	6	O
following	9	O
recovery	8	O
.	1	O

The	3	O
number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
sites	5	O
in	2	O
lymphocytes	11	O
and	3	O
plasma	6	O
cortisol	8	B-Chemical
concentrations	14	O
were	4	O
measured	8	O
in	2	O
20	2	O
patients	8	O
who	3	O
had	3	O
recovered	9	O
from	4	O
major	5	B-Disease
depressive	10	I-Disease
disorder	8	I-Disease
and	3	O
20	2	O
healthy	7	O
control	7	O
subjects	8	O
.	1	O

The	3	O
number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
sites	5	O
in	2	O
lymphocytes	11	O
from	4	O
the	3	O
recovered	9	O
depressed	9	O
group	5	O
was	3	O
not	3	O
significantly	13	O
different	9	O
from	4	O
that	4	O
of	2	O
the	3	O
control	7	O
group	5	O
.	1	O

Although	8	O
the	3	O
mean	4	O
plasma	6	O
cortisol	8	B-Chemical
concentration	13	O
in	2	O
recovered	9	O
depressives	11	O
was	3	O
higher	6	O
than	4	O
in	2	O
control	7	O
subjects	8	O
,	1	O
the	3	O
difference	10	O
only	4	O
just	4	O
reached	7	O
significance	12	O
.	1	O

This	4	O
study	5	O
shows	5	O
that	4	O
the	3	O
reduction	9	O
in	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
numbers	7	O
which	5	O
occurs	6	O
during	6	O
acute	5	B-Disease
depressive	10	I-Disease
illness	7	I-Disease
does	4	O
not	3	O
persist	7	O
on	2	O
recovery	8	O
and	3	O
is	2	O
,	1	O
therefore	9	O
,	1	O
state	5	O
-dependent	10	O
.	1	O

Identification	14	O
and	3	O
purification	12	O
of	2	O
a	1	O
human	5	B-Gene
immunoglobulin-enhancer	23	I-Gene
-binding	8	I-Gene
protein	7	I-Gene
(	1	O
NF-kappa	8	B-Gene
B	1	I-Gene
)	1	O
that	4	O
activates	9	O
transcription	13	O
from	4	O
a	1	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
promoter	8	O
in	2	O
vitro	5	O
.	1	O

The	3	O
enhancer	8	B-Gene
-binding	8	I-Gene
factor	6	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
,	1	O
which	5	O
is	2	O
found	5	O
only	4	O
in	2	O
cells	5	O
that	4	O
transcribe	10	O
immunoglobulin	14	B-Gene
light	5	I-Gene
chain	5	I-Gene
genes	5	I-Gene
,	1	O
has	3	O
been	4	O
purified	8	O
from	4	O
nuclear	7	O
extracts	8	O
of	2	O
Namalwa	7	O
cells	5	O
(	1	O
human	5	O
Burkitt	7	B-Disease
lymphoma	8	I-Disease
cells	5	O
)	1	O
by	2	O
sequence-specific	17	O
DNA	3	O
affinity	8	O
chromatography	14	O
.	1	O

The	3	O
purified	8	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
has	3	O
been	4	O
identified	10	O
as	2	O
a	1	O
51-kDa	6	O
polypeptide	11	O
by	2	O
UV	2	O
-crosslinking	13	O
analysis	8	O
.	1	O

``	2	O
Footprint	9	O
''and	5	O
methylation-interference	24	O
analyses	8	O
have	4	O
shown	5	O
that	4	O
purified	8	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
has	3	O
a	1	O
binding	7	O
activity	8	O
specific	8	O
for	3	O
the	3	O
kappa	5	O
light	5	O
chain	5	O
enhancer	8	O
sequence	8	O
.	1	O

The	3	O
purified	8	O
factor	6	O
activated	9	O
in	2	O
vitro	5	O
transcription	13	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
I	1	O
promoter	8	O
by	2	O
binding	7	O
to	2	O
an	2	O
upstream	8	O
NF-kappa	8	B-Gene
B	1	I-Gene
-binding	8	O
site	4	O

Inhibition	10	O
of	2	O
interleukin	11	B-Gene
2	1	I-Gene
-induced	8	O
proliferation	13	O
of	2	O
cloned	6	O
murine	6	O
T	1	O
cells	5	O
by	2	O
glucocorticoids	15	B-Chemical
.	1	O

Possible	8	O
involvement	11	O
of	2	O
an	2	O
inhibitory	10	O
protein	7	O
.	1	O

The	3	O
ability	7	O
of	2	O
glucocorticoids	15	B-Chemical
to	2	O
inhibit	7	O
interleukin	11	B-Gene
2	1	I-Gene
(	1	O
IL	2	B-Gene
2	1	I-Gene
)	1	O
-induced	8	O
T	1	O
cell	4	O
proliferation	13	O
in	2	O
two	3	O
cytotoxic	9	O
T	1	O
cell	4	O
(	1	O
CTL	3	O
)	1	O
clones	6	O
has	3	O
been	4	O
studied	7	O
.	1	O

A	1	O
complete	8	O
inhibition	10	O
of	2	O
DNA	3	O
synthesis	9	O
by	2	O
dexamethasone	13	B-Chemical
(	1	O
Dx	2	B-Chemical
)	1	O
could	5	O
be	2	O
observed	8	O
when	4	O
IL	2	B-Gene
2	1	I-Gene
-depleted	9	O
cultures	8	O
of	2	O
CTL	3	O
were	4	O
either	6	O
incubated	9	O
for	3	O
6	1	O
h	1	O
with	4	O
the	3	O
hormone	7	O
prior	5	O
to	2	O
the	3	O
addition	8	O
of	2	O
IL	2	B-Gene
2	1	I-Gene
or	2	O
treated	7	O
simultaneously	14	O
with	4	O
Dx	2	B-Chemical
and	3	O
a	1	O
low	3	O
concentration	13	O
of	2	O
IL	2	B-Gene
2	1	I-Gene
.	1	O

No	2	O
significant	11	O
reduction	9	O
in	2	O
the	3	O
number	6	O
and	3	O
affinity	8	O
of	2	O
IL	2	B-Gene
2	1	I-Gene
receptors	9	I-Gene
was	3	O
seen	4	O
after	5	O
6	1	O
h	1	O
incubation	10	O
with	4	O
Dx	2	B-Chemical
.	1	O

The	3	O
order	5	O
of	2	O
potency	7	O
observed	8	O
with	4	O
the	3	O
different	9	O
steroids	8	B-Chemical
indicated	9	O
that	4	O
this	4	O
inhibitory	10	O
effect	6	O
was	3	O
mediated	8	O
through	7	O
binding	7	O
to	2	O
a	1	O
specific	8	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
.	1	O

The	3	O
action	6	O
of	2	O
these	5	O
hormones	8	O
possibly	8	O
involves	8	O
the	3	O
synthesis	9	O
of	2	O
an	2	O
inhibitory	10	O
protein	7	O
(	1	O
s	1	O
)	1	O
,	1	O
since	5	O
the	3	O
presence	8	O
of	2	O
cycloheximide	13	B-Chemical
during	6	O
the	3	O
incubation	10	O
with	4	O
Dx	2	B-Chemical
prevented	9	O
the	3	O
inhibition	10	O
of	2	O
DNA	3	O
synthesis	9	O
.	1	O

Furthermore	11	O
,	1	O
supernatant	11	O
from	4	O
Dx	2	B-Chemical
-treated	8	O
CTL	3	O
contained	9	O
a	1	O
nondialyzable	13	O
factor	6	O
which	5	O
inhibited	9	O
DNA	3	O
synthesis	9	O
and	3	O
cell	4	O
growth	6	O
of	2	O
CTL	3	O
clones	6	O
induced	7	O
by	2	O
IL	2	B-Gene
2	1	I-Gene
.	1	O

Blocking	8	O
of	2	O
IL	2	B-Gene
2	1	I-Gene
synthesis	9	O
and	3	O
IL	2	B-Gene
2	1	I-Gene
receptor	8	I-Gene
formation	9	O
have	4	O
been	4	O
proposed	8	O
as	2	O
one	3	O
of	2	O
the	3	O
major	5	O
mechanisms	10	O
of	2	O
glucocorticoid	14	B-Chemical
-induced	8	O
immunosuppression	17	O
.	1	O

Our	3	O
results	7	O
indicate	8	O
that	4	O
these	5	O
hormones	8	O
may	3	O
also	4	O
affect	6	O
T	1	O
cell	4	O
proliferation	13	O
by	2	O
inhibiting	10	O
IL	2	B-Gene
2	1	I-Gene
activity	8	O
.	1	O

Octamer	7	B-Gene
-binding	8	I-Gene
proteins	8	I-Gene
from	4	O
B	1	O
or	2	O
HeLa	4	O
cells	5	O
stimulate	9	O
transcription	13	O
of	2	O
the	3	O
immunoglobulin	14	B-Gene
heavy-chain	11	I-Gene
promoter	8	I-Gene
in	2	O
vitro	5	O
.	1	O

The	3	O
B-cell	6	O
-type	5	O
specificity	11	O
of	2	O
the	3	O
immunoglobulin	14	B-Gene
(	1	I-Gene
Ig	2	I-Gene
)	1	I-Gene
heavy-chain	11	I-Gene
and	3	O
light-chain	11	B-Gene
promoters	9	I-Gene
is	2	O
mediated	8	O
by	2	O
an	2	O
octanucleotide	14	O
(	1	O
OCTA	4	O
)	1	O
element	7	O
,	1	O
ATGCAAAT	8	O
,	1	O
that	4	O
is	2	O
also	4	O
a	1	O
functional	10	O
component	9	O
of	2	O
other	5	O
RNA	3	B-Gene
polymerase	10	I-Gene
II	2	I-Gene
promoters	9	I-Gene
,	1	O
such	4	O
as	2	O
snRNA	5	O
and	3	O
histone	7	B-Gene
H2B	3	I-Gene
promoters	9	I-Gene
.	1	O

Two	3	O
nuclear	7	O
proteins	8	O
that	4	O
bind	4	O
specifically	12	O
and	3	O
with	4	O
high	4	O
affinity	8	O
to	2	O
the	3	O
OCTA	4	O
element	7	O
have	4	O
been	4	O
identified	10	O
.	1	O

NF-A1	5	B-Gene
is	2	O
present	7	O
in	2	O
a	1	O
variety	7	O
of	2	O
cell	4	O
types	5	O
,	1	O
whereas	7	O
the	3	O
presence	8	O
of	2	O
NF-A2	5	B-Gene
is	2	O
essentially	11	O
confined	8	O
to	2	O
B	1	O
cells	5	O
,	1	O
leading	7	O
to	2	O
the	3	O
hypothesis	10	O
that	4	O
NF-A2	5	B-Gene
activates	9	O
cell-type-specific	18	O
transcription	13	O
of	2	O
the	3	O
Ig	2	B-Gene
promoter	8	I-Gene
and	3	O
NF-A1	5	B-Gene
mediates	8	O
the	3	O
other	5	O
responses	9	O
of	2	O
the	3	O
OCTA	4	O
element	7	O
.	1	O

Extracts	8	O
of	2	O
the	3	O
B-cell	6	O
line	4	O
,	1	O
BJA-B	5	O
,	1	O
contain	7	O
high	4	O
levels	6	O
of	2	O
NF-A2	5	B-Gene
and	3	O
specifically	12	O
transcribe	10	O
Ig	2	B-Gene
promoters	9	I-Gene
.	1	O

In	2	O
contrast	8	O
,	1	O
extracts	8	O
from	4	O
HeLa	4	O
cells	5	O
transcribed	11	O
the	3	O
Ig	2	B-Gene
promoter	8	I-Gene
poorly	6	O
.	1	O

Surprisingly	12	O
,	1	O
addition	8	O
of	2	O
either	6	O
affinity	8	O
-enriched	9	O
NF-A2	5	B-Gene
or	2	O
NF-A1	5	B-Gene
to	2	O
either	6	O
a	1	O
HeLa	4	O
extract	7	O
or	2	O
a	1	O
partially	9	O
purified	8	O
reaction	8	O
system	6	O
specifically	12	O
stimulates	10	O
the	3	O
Ig	2	B-Gene
promoter	8	I-Gene
.	1	O

This	4	O
suggests	8	O
that	4	O
the	3	O
constitutive	12	O
OCTA	4	B-Gene
-binding	8	I-Gene
factor	6	I-Gene
NF-A1	5	I-Gene
can	3	O
activate	8	O
transcription	13	O
of	2	O
the	3	O
Ig	2	B-Gene
promoter	8	I-Gene
and	3	O
that	4	O
B-cell	6	O
-specific	9	O
transcription	13	O
of	2	O
this	4	O
promoter	8	O
,	1	O
at	2	O
least	5	O
in	2	O
vitro	5	O
,	1	O
is	2	O
partially	9	O
due	3	O
to	2	O
a	1	O
quantitative	12	O
difference	10	O
in	2	O
the	3	O
amount	6	O
of	2	O
OCTA	4	B-Gene
-binding	8	I-Gene
protein	7	I-Gene
.	1	O

Because	7	O
NF-A1	5	B-Gene
can	3	O
stimulate	9	O
Ig	2	B-Gene
transcription	13	O
,	1	O
the	3	O
inability	9	O
of	2	O
this	4	O
factor	6	O
to	2	O
activate	8	O
in	2	O
vivo	4	O
the	3	O
Ig	2	B-Gene
promoter	8	I-Gene
to	2	O
the	3	O
same	4	O
degree	6	O
as	2	O
the	3	O
snRNA	5	O
promoters	9	O
probably	8	O
reflects	8	O
a	1	O
difference	10	O
in	2	O
the	3	O
context	7	O
of	2	O
the	3	O
OCTA	4	O
element	7	O
in	2	O
these	5	O
two	3	O
types	5	O
of	2	O
promoters	9	O
.	1	O

[	1	O
Determination	13	O
of	2	O
the	3	O
sensitivity	11	O
to	2	O
glucocorticoids	15	B-Chemical
in	2	O
vitro	5	O
]	1	O

A	1	O
modified	8	O
method	6	O
for	3	O
the	3	O
determination	13	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
human	5	O
lymphocytes	11	O
is	2	O
suggested	9	O
.	1	O

The	3	O
principal	9	O
distinction	11	O
of	2	O
the	3	O
method	6	O
is	2	O
standardization	15	O
by	2	O
the	3	O
lymphocyte	10	O
count	5	O
in	2	O
a	1	O
sample	6	O
(	1	O
1	1	O
mln	3	O
)	1	O
and	3	O
the	3	O
labeled	7	O
hormone	7	O
concentration	13	O
.	1	O

The	3	O
modification	12	O
saves	5	O
time	4	O
and	3	O
money	5	O
,	1	O
limits	6	O
the	3	O
range	5	O
of	2	O
the	3	O
data	4	O
variations	10	O
,	1	O
and	3	O
makes	5	O
use	3	O
of	2	O
a	1	O
lesser	6	O
volume	6	O
of	2	O
blood	5	O
.	1	O

Examinations	12	O
of	2	O
70	2	O
children	8	O
aged	4	O
4	1	O
to	2	O
15	2	O
suffering	9	O
from	4	O
the	3	O
nephrotic	9	O
form	4	O
of	2	O
glomerulonephritis	18	B-Disease
have	4	O
made	4	O
it	2	O
possible	8	O
to	2	O
distinguish	11	O
two	3	O
groups	6	O
of	2	O
patients	8	O
:	1	O
with	4	O
relatively	10	O
high	4	O
values	6	O
of	2	O
specific	8	O
binding	7	O
X	1	O
=	1	O
6820.1	6	O
+	1	O
/	1	O
-	1	O
530.0	5	O
(	1	O
n	1	O
=	1	O
30	2	O
,	1	O
p	1	O
=	1	O
0.95	4	O
,	1	O
t	1	O
=	1	O
2.04	4	O
)	1	O
,	1	O
this	4	O
corresponding	13	O
to	2	O
a	1	O
clinical	8	O
form	4	O
of	2	O
hormone	7	O
-sensitive	10	O
glomerulonephritis	18	B-Disease
,	1	O
and	3	O
with	4	O
relatively	10	O
low	3	O
values	6	O
of	2	O
specific	8	O
binding	7	O
X	1	O
=	1	O
1815.2	6	O
+	1	O
/	1	O
-	1	O
302.8	5	O
(	1	O
n	1	O
=	1	O
40	2	O
,	1	O
p	1	O
=	1	O
0.95	4	O
,	1	O
t	1	O
=	1	O
1.96	4	O
)	1	O
,	1	O
that	4	O
corresponds	11	O
to	2	O
hormone	7	O
-resistant	10	O
glomerulonephritis	18	B-Disease
.	1	O

Dynamic	7	O
studies	7	O
have	4	O
not	3	O
shown	5	O
any	3	O
statistically	13	O
significant	11	O
changes	7	O
in	2	O
the	3	O
specific	8	O
binding	7	O
values	6	O
.	1	O

These	5	O
results	7	O
permit	6	O
regarding	9	O
the	3	O
specific	8	O
binding	7	O
value	5	O
as	2	O
a	1	O
prognostic	10	O
criterion	9	O
in	2	O
the	3	O
assessment	10	O
of	2	O
corticosteroid	14	B-Chemical
therapy	7	O
;	1	O
this	4	O
allows	6	O
a	1	O
wide	4	O
employment	10	O
of	2	O
the	3	O
described	9	O
method	6	O
in	2	O
practical	9	O
nephrology	10	O
.	1	O

Association	11	O
of	2	O
increased	9	O
lytic	5	O
effector	8	O
cell	4	O
function	8	O
with	4	O
high	4	O
estrogen	8	B-Gene
receptor	8	I-Gene
levels	6	O
in	2	O
tumor	5	B-Disease
-bearing	8	O
patients	8	O
with	4	O
breast	6	B-Disease
cancer	6	I-Disease
.	1	O

Tumor	5	B-Disease
-bearing	8	O
patients	8	O
with	4	O
breast	6	B-Disease
cancer	6	I-Disease
were	4	O
assayed	7	O
for	3	O
their	5	O
natural	7	O
killer	6	O
(	1	O
NK	2	O
)	1	O
cell	4	O
activity	8	O
and	3	O
for	3	O
the	3	O
function	8	O
of	2	O
activated	9	O
cytotoxic	9	O
T-cells	7	O
,	1	O
as	2	O
assessed	8	O
by	2	O
lectin	6	B-Gene
-dependent	10	O
cellular	8	O
cytotoxicity	12	O
(	1	O
LDCC	4	O
)	1	O
.	1	O

Tumor	5	B-Disease
-bearing	8	O
patients	8	O
with	4	O
breast	6	B-Disease
cancer	6	I-Disease
had	3	O
a	1	O
significant	11	O
increase	8	O
in	2	O
NK	2	O
activity	8	O
and	3	O
in	2	O
LDCC	4	O
,	1	O
as	2	O
compared	8	O
with	4	O
healthy	7	O
control	7	O
individuals	11	O
.	1	O

Although	8	O
the	3	O
enhanced	8	O
NK	2	O
cell	4	O
activity	8	O
and	3	O
LDCC	4	O
were	4	O
closely	7	O
associated	10	O
with	4	O
high	4	O
levels	6	O
(	1	O
greater	7	O
than	4	O
31	2	O
fmol	4	O
/	1	O
mg	2	O
)	1	O
of	2	O
estrogen	8	B-Gene
receptor	8	I-Gene
(	1	O
ER	2	B-Gene
)	1	O
content	7	O
in	2	O
the	3	O
primary	7	O
tumor	5	B-Disease
,	1	O
no	2	O
other	5	O
clinical	8	O
or	2	O
histologic	10	O
correlation	11	O
between	7	O
the	3	O
increase	8	O
in	2	O
either	6	O
parameter	9	O
of	2	O
cytotoxic	9	O
effector	8	O
cell	4	O
function	8	O
could	5	O
be	2	O
found	5	O
.	1	O

Thus	4	O
,	1	O
ER	2	B-Gene
levels	6	O
greater	7	O
than	4	O
31	2	O
fmol	4	O
/	1	O
mg	2	O
might	5	O
be	2	O
associated	10	O
with	4	O
increased	9	O
cytotoxic	9	O
effector	8	O
cell	4	O
function	8	O
in	2	O
tumor	5	B-Disease
-bearing	8	O
patients	8	O
with	4	O
breast	6	B-Disease
cancer	6	I-Disease
.	1	O

Properties	10	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
Epstein-Barr	12	O
virus	5	O
-transformed	12	O
lymphocytes	11	O
from	4	O
patients	8	O
with	4	O
familial	8	O
cortisol	8	B-Chemical
resistance	10	O
.	1	O

In	2	O
a	1	O
previous	8	O
report	6	O
of	2	O
two	3	O
patients	8	O
with	4	O
familial	8	O
glucocorticoid	14	B-Chemical
resistance	10	O
due	3	O
to	2	O
reduced	7	O
numbers	7	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
,	1	O
we	2	O
have	4	O
shown	5	O
decreased	9	O
numbers	7	O
of	2	O
GR	2	B-Gene
in	2	O
peripheral	10	O
mononuclear	11	O
cells	5	O
and	3	O
cultured	8	O
fibroblasts	11	O
but	3	O
normal	6	O
affinity	8	O
of	2	O
GR	2	B-Gene
in	2	O
both	4	O
patients	8	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
peripheral	10	O
lymphocytes	11	O
from	4	O
these	5	O
patients	8	O
,	1	O
one	3	O
patient	7	O
's	2	O
son	3	O
and	3	O
daughter	8	O
,	1	O
and	3	O
normal	6	O
subjects	8	O
were	4	O
transformed	11	O
with	4	O
Epstein-Barr	12	O
virus	5	O
.	1	O

Reduced	7	O
numbers	7	O
and	3	O
normal	6	O
affinity	8	O
of	2	O
GR	2	B-Gene
were	4	O
found	5	O
in	2	O
the	3	O
Epstein-Barr	12	O
virus	5	O
-transformed	12	O
lymphocytes	11	O
from	4	O
both	4	O
patients	8	O
while	5	O
the	3	O
son	3	O
and	3	O
daughter	8	O
had	3	O
normal	6	O
numbers	7	O
and	3	O
affinity	8	O
of	2	O
GR	2	B-Gene
.	1	O

The	3	O
thermal	7	O
stability	9	O
of	2	O
GR	2	B-Gene
and	3	O
thermal	7	O
activation	10	O
of	2	O
cytosolic	9	O
receptors	9	O
in	2	O
both	4	O
patients	8	O
were	4	O
found	5	O
to	2	O
be	2	O
normal	6	O
.	1	O

Although	8	O
the	3	O
percentages	11	O
of	2	O
nuclear	7	O
bound	5	O
GR	2	B-Gene
were	4	O
similar	7	O
in	2	O
both	4	O
patients	8	O
and	3	O
normal	6	O
controls	8	O
,	1	O
the	3	O
absolute	8	O
amounts	7	O
of	2	O
nuclear	7	O
bound	5	O
GR	2	B-Gene
of	2	O
the	3	O
patients	8	O
were	4	O
about	5	O
one-half	8	O
that	4	O
of	2	O
normal	6	O
controls	8	O
.	1	O

These	5	O
abnormal	8	O
properties	10	O
of	2	O
GR	2	B-Gene
(	1	O
reduced	7	O
numbers	7	O
of	2	O
GR	2	B-Gene
)	1	O
were	4	O
preserved	9	O
in	2	O
the	3	O
transformed	11	O
cells	5	O
from	4	O
the	3	O
patients	8	O
.	1	O

Novel	5	O
region	6	O
within	6	O
the	3	O
V	1	B-Gene
kappa	5	I-Gene
gene	4	I-Gene
promoter	8	I-Gene
is	2	O
responsible	11	O
for	3	O
tissue	6	O
and	3	O
stage-specific	14	O
expression	10	O
of	2	O
immunoglobulin	14	B-Gene
genes	5	I-Gene
in	2	O
human	5	O
lymphoid	8	O
neoplasms	9	O
.	1	O

Immunoglobulin	14	B-Gene
gene-specific	13	I-Gene
transacting	11	I-Gene
factors	7	I-Gene
have	4	O
been	4	O
shown	5	O
to	2	O
play	4	O
a	1	O
role	4	O
in	2	O
lymphoid	8	O
tissue-specific	15	O
expression	10	O
of	2	O
immunoglobulin	14	B-Gene
genes	5	I-Gene
.	1	O

The	3	O
role	4	O
of	2	O
these	5	O
factors	7	O
in	2	O
B-cell	6	O
differentiation	15	O
and	3	O
stage-specific	14	O
expression	10	O
of	2	O
these	5	O
genes	5	O
is	2	O
,	1	O
however	7	O
,	1	O
not	3	O
fully	5	O
understood	10	O
.	1	O

We	2	O
have	4	O
used	4	O
a	1	O
model	5	O
of	2	O
human	5	O
lymphoid	8	O
neoplasia	9	B-Disease
to	2	O
address	7	O
this	4	O
question	8	O
.	1	O

Different	9	O
fragments	9	O
of	2	O
unrearranged	12	O
human	5	O
variable	8	O
region	6	O
of	2	O
immunoglobulin	14	B-Gene
kappa	5	I-Gene
gene	4	I-Gene
(	1	O
V	1	B-Gene
kappa	5	I-Gene
)	1	O
were	4	O
used	4	O
for	3	O
cell-free	9	O
in	2	O
vitro	5	O
transcription	13	O
and	3	O
DNA	3	O
mobility	8	O
shift	5	O
assays	6	O
.	1	O

Previously	10	O
described	9	O
enhancement	11	O
of	2	O
in	2	O
vitro	5	O
transcription	13	O
that	4	O
was	3	O
only	4	O
seen	4	O
with	4	O
nuclear	7	O
extracts	8	O
derived	7	O
from	4	O
B-cell	6	O
neoplasms	9	O
corresponding	13	O
to	2	O
the	3	O
late	4	O
stages	6	O
of	2	O
B-cell	6	O
differentiation	15	O
was	3	O
shown	5	O
to	2	O
be	2	O
dependent	9	O
on	2	O
the	3	O
actions	7	O
of	2	O
these	5	O
factor	6	O
(	1	O
s	1	O
)	1	O
on	2	O
the	3	O
DNA	3	O
region	6	O
within	6	O
the	3	O
V	1	B-Gene
kappa	5	I-Gene
gene	4	I-Gene
promoter	8	I-Gene
.	1	O

This	4	O
region	6	O
is	2	O
located	7	O
within	6	O
the	3	O
920	3	O
bp	2	O
fragment	8	O
located	7	O
210	3	O
bp	2	O
upstream	8	O
from	4	O
the	3	O
coding	6	O
region	6	O
and	3	O
this	4	O
fragment	8	O
represents	10	O
a	1	O
possible	8	O
novel	5	O
DNA	3	O
region	6	O
,	1	O
which	5	O
plays	5	O
a	1	O
role	4	O
in	2	O
the	3	O
stage-	6	O
and	3	O
tissue-specific	15	O
expression	10	O
of	2	O
immunoglobulin	14	B-Gene
genes	5	I-Gene
.	1	O

Identification	14	O
of	2	O
a	1	O
novel	5	O
lymphoid	8	B-Gene
specific	8	I-Gene
octamer	7	I-Gene
binding	7	I-Gene
protein	7	I-Gene
(	1	O
OTF-2B	6	B-Gene
)	1	O
by	2	O
proteolytic	11	O
clipping	8	O
bandshift	9	O
assay	5	O
(	1	O
PCBA	4	O
)	1	O
.	1	O

The	3	O
octamer	7	O
sequence	8	O
ATGCAAAT	8	O
is	2	O
found	5	O
in	2	O
the	3	O
promoters	9	O
of	2	O
immunoglobulin	14	B-Gene
(	1	I-Gene
Ig	2	I-Gene
)	1	I-Gene
heavy	5	I-Gene
and	3	I-Gene
light	5	I-Gene
chain	5	I-Gene
genes	5	I-Gene
and	3	O
in	2	O
the	3	O
heavy	5	O
chain	5	O
enhancer	8	O
and	3	O
is	2	O
a	1	O
major	5	O
determinant	11	O
of	2	O
the	3	O
cell	4	O
type	4	O
specific	8	O
expression	10	O
of	2	O
Ig	2	B-Gene
genes	5	I-Gene
in	2	O
B	1	O
cells	5	O
.	1	O

An	2	O
apparent	8	O
paradox	7	O
is	2	O
that	4	O
the	3	O
same	4	O
sequence	8	O
serves	6	O
as	2	O
an	2	O
upstream	8	O
promoter	8	O
or	2	O
enhancer	8	O
element	7	O
in	2	O
a	1	O
variety	7	O
of	2	O
housekeeping	12	O
genes	5	O
such	4	O
as	2	O
the	3	O
histone	7	B-Gene
H2B	3	I-Gene
and	3	O
U	1	B-Gene
snRNA	5	I-Gene
genes	5	I-Gene
.	1	O

The	3	O
differential	12	O
usage	5	O
of	2	O
this	4	O
regulatory	10	O
sequence	8	O
motif	5	O
is	2	O
thought	7	O
to	2	O
be	2	O
mediated	8	O
by	2	O
different	9	O
species	7	O
of	2	O
octamer	7	B-Gene
binding	7	I-Gene
proteins	8	I-Gene
.	1	O

One	3	O
species	7	O
of	2	O
100	3	O
kd	2	O
,	1	O
designated	10	O
OTF-1	5	B-Gene
,	1	O
is	2	O
present	7	O
in	2	O
all	3	O
cell	4	O
types	5	O
and	3	O
may	3	O
exert	5	O
its	3	O
activating	10	O
function	8	O
only	4	O
when	4	O
it	2	O
can	3	O
interact	8	O
with	4	O
additional	10	O
adjacent	8	O
transcription	13	O
factors	7	O
.	1	O

The	3	O
lymphoid	8	B-Gene
cell	4	I-Gene
specific	8	I-Gene
octamer	7	I-Gene
binding	7	I-Gene
protein	7	I-Gene
of	2	O
60	2	O
kd	2	O
(	1	O
OTF-2A	6	B-Gene
)	1	O
specifically	12	O
stimulates	10	O
Ig	2	B-Gene
promoters	9	I-Gene
which	5	O
consist	7	O
essentially	11	O
of	2	O
a	1	O
TATA-box	8	O
and	3	O
an	2	O
octamer	7	O
sequence	8	O
upstream	8	O
of	2	O
it	2	O
.	1	O

Here	4	O
we	2	O
present	7	O
evidence	8	O
for	3	O
yet	3	O
another	7	O
B	1	B-Gene
cell	4	I-Gene
specific	8	I-Gene
octamer	7	I-Gene
binding	7	I-Gene
protein	7	I-Gene
of	2	O
75	2	O
kd	2	O
(	1	O
OTF-2B	6	B-Gene
)	1	O
.	1	O

From	4	O
several	7	O
findings	8	O
,	1	O
including	9	O
the	3	O
absence	7	O
of	2	O
OTF-2B	6	B-Gene
(	1	O
but	3	O
not	3	O
OTF-2A	6	B-Gene
)	1	O
from	4	O
a	1	O
lymphocyte	10	O
line	4	O
that	4	O
can	3	O
not	3	O
respond	7	O
to	2	O
the	3	O
IgH	3	B-Gene
enhancer	8	I-Gene
,	1	O
we	2	O
propose	7	O
a	1	O
role	4	O
of	2	O
the	3	O
novel	5	O
octamer	7	O
factor	6	O
in	2	O
the	3	O
long	4	O
range	5	O
activation	10	O
by	2	O
the	3	O
IgH	3	B-Gene
enhancer	8	I-Gene
.	1	O

We	2	O
have	4	O
used	4	O
the	3	O
proteolytic	11	O
clipping	8	O
bandshift	9	O
assay	5	O
(	1	O
PCBA	4	O
)	1	O
technique	9	O
to	2	O
distinguish	11	O
the	3	O
three	5	O
different	9	O
forms	5	O
found	5	O
in	2	O
B	1	O
cells	5	O
.	1	O

This	4	O
analysis	8	O
indicates	9	O
that	4	O
the	3	O
75	2	O
kd-species	10	O
OTF-2B	6	B-Gene
is	2	O
closely	7	O
related	7	O
to	2	O
the	3	O
60	2	O
kd	2	O
species	7	O
OTF-2A	6	B-Gene
.	1	O

Octamer	7	B-Gene
transcription	13	I-Gene
factors	7	I-Gene
1	1	I-Gene
and	3	O
2	1	B-Partial_Gene
each	4	O
bind	4	O
to	2	O
two	3	O
different	9	O
functional	10	O
elements	8	O
in	2	O
the	3	O
immunoglobulin	14	B-Gene
heavy-chain	11	I-Gene
promoter	8	I-Gene
.	1	O

Immunoglobulin	14	B-Gene
heavy-chain	11	I-Gene
genes	5	I-Gene
contain	7	O
two	3	O
conserved	9	O
sequence	8	O
elements	8	O
5	1	O
'to	3	O
the	3	O
site	4	O
of	2	O
transcription	13	O
initiation	10	O
:	1	O
the	3	O
octamer	7	O
ATGCAAAT	8	O
and	3	O
the	3	O
heptamer	8	O
CTCATGA	7	O
.	1	O

Both	4	O
of	2	O
these	5	O
elements	8	O
are	3	O
required	8	O
for	3	O
normal	6	O
cell-specific	13	O
promoter	8	O
function	8	O
.	1	O

The	3	O
present	7	O
study	5	O
demonstrates	12	O
that	4	O
both	4	O
the	3	O
ubiquitous	10	O
and	3	O
lymphoid-cell-specific	22	B-Gene
octamer	7	I-Gene
transcription	13	I-Gene
factors	7	I-Gene
(	1	O
OTF-1	5	B-Gene
and	3	O
OTF-2	5	B-Gene
,	1	O
respectively	12	O
)	1	O
interact	8	O
specifically	12	O
with	4	O
each	4	O
of	2	O
the	3	O
two	3	O
conserved	9	O
sequence	8	O
elements	8	O
,	1	O
forming	7	O
either	6	O
homo-	5	O
or	2	O
heterodimeric	13	O
complexes	9	O
.	1	O

This	4	O
was	3	O
surprising	10	O
,	1	O
since	5	O
the	3	O
heptamer	8	O
and	3	O
octamer	7	O
sequence	8	O
motifs	6	O
bear	4	O
no	2	O
obvious	7	O
similarity	10	O
to	2	O
each	4	O
other	5	O
.	1	O

Binding	7	O
of	2	O
either	6	O
factor	6	O
to	2	O
the	3	O
octamer	7	O
element	7	O
occurred	8	O
independently	13	O
.	1	O

However	7	O
,	1	O
OTF	3	B-Gene
interaction	11	O
with	4	O
the	3	O
heptamer	8	O
sequence	8	O
appeared	8	O
to	2	O
require	7	O
the	3	O
presence	8	O
of	2	O
an	2	O
intact	6	O
octamer	7	O
motif	5	O
and	3	O
occurred	8	O
with	4	O
a	1	O
spacing	7	O
of	2	O
either	6	O
2	1	O
or	2	O
14	2	O
base	4	O
pairs	5	O
between	7	O
the	3	O
two	3	O
elements	8	O
,	1	O
suggesting	10	O
coordinate	10	O
binding	7	O
resulting	9	O
from	4	O
protein-protein	15	O
interactions	12	O
.	1	O

The	3	O
degeneracy	10	O
in	2	O
sequences	9	O
recognized	10	O
by	2	O
the	3	O
OTFs	4	B-Gene
may	3	O
be	2	O
important	9	O
in	2	O
widening	8	O
the	3	O
range	5	O
over	4	O
which	5	O
gene	4	O
expression	10	O
can	3	O
be	2	O
modulated	9	O
and	3	O
in	2	O
establishing	12	O
cell	4	O
type	4	O
specificity	11	O
.	1	O

Kappa	5	O
B-specific	10	O
DNA	3	O
binding	7	O
proteins	8	O
:	1	O
role	4	O
in	2	O
the	3	O
regulation	10	O
of	2	O
human	5	B-Gene
interleukin-2	13	I-Gene
gene	4	I-Gene
expression	10	O
.	1	O

Transcriptional	15	O
activation	10	O
of	2	O
the	3	O
human	5	B-Gene
interleukin-2	13	I-Gene
(	1	I-Gene
IL-2	4	I-Gene
)	1	I-Gene
gene	4	I-Gene
,	1	O
like	4	O
induction	9	O
of	2	O
the	3	O
IL-2	4	B-Gene
receptor	8	I-Gene
alpha	5	I-Gene
(	1	I-Gene
IL-2R	5	I-Gene
alpha	5	I-Gene
)	1	I-Gene
gene	4	I-Gene
and	3	O
the	3	O
type	4	O
1	1	O
human	5	O
immunodeficiency	16	O
virus	5	O
(	1	O
HIV-1	5	O
)	1	O
,	1	O
is	2	O
shown	5	O
to	2	O
be	2	O
modulated	9	O
by	2	O
a	1	O
kappa	5	O
B	1	O
-like	5	O
enhancer	8	O
element	7	O
.	1	O

Mutation	8	O
of	2	O
a	1	O
kappa	5	O
B	1	O
core	4	O
sequence	8	O
identified	10	O
in	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
(	1	O
-206	4	O
to	2	O
-195	4	O
)	1	O
partially	9	O
inhibits	8	O
both	4	O
mitogen-	8	O
and	3	O
HTLV-I	6	B-Gene
Tax	3	I-Gene
-mediated	9	O
activation	10	O
of	2	O
this	4	O
transcription	13	O
unit	4	O
and	3	O
blocks	6	O
the	3	O
specific	8	O
binding	7	O
of	2	O
two	3	O
inducible	9	O
cellular	8	O
factors	7	O
.	1	O

These	5	O
kappa	5	O
B-specific	10	O
proteins	8	O
(	1	O
80	2	O
to	2	O
90	2	O
and	3	O
50	2	O
to	2	O
55	2	O
kilodaltons	11	O
)	1	O
similarly	9	O
interact	8	O
with	4	O
the	3	O
functional	10	O
kappa	5	O
B	1	O
enhancer	8	O
present	7	O
in	2	O
the	3	O
IL-2R	5	B-Gene
alpha	5	I-Gene
promoter	8	I-Gene
.	1	O

These	5	O
data	4	O
suggest	7	O
that	4	O
these	5	O
kappa	5	O
B-specific	10	O
proteins	8	O
have	4	O
a	1	O
role	4	O
in	2	O
the	3	O
coordinate	10	O
regulation	10	O
of	2	O
this	4	O
growth	6	O
factor-growth	13	O
factor	6	O
receptor	8	O
gene	4	O
system	6	O
that	4	O
controls	8	O
T	1	O
cell	4	O
proliferation	13	O
.	1	O

Tumor	5	B-Disease
and	3	O
serum	5	B-Gene
beta-2-microglobulin	20	I-Gene
expression	10	O
in	2	O
women	5	O
with	4	O
breast	6	B-Disease
cancer	6	I-Disease
.	1	O

To	2	O
investigate	11	O
whether	7	O
the	3	O
tumor	5	B-Disease
expression	10	O
of	2	O
beta-2-microglobulin	20	B-Gene
(	1	O
beta	4	B-Gene
2-M	3	I-Gene
)	1	O
could	5	O
serve	5	O
as	2	O
a	1	O
marker	6	O
of	2	O
tumor	5	B-Disease
biologic	8	O
behavior	8	O
,	1	O
the	3	O
authors	7	O
studied	7	O
specimens	9	O
of	2	O
breast	6	B-Disease
carcinomas	10	I-Disease
from	4	O
60	2	O
consecutive	11	O
female	6	O
patients	8	O
.	1	O

Presence	8	O
of	2	O
beta	4	B-Gene
2-M	3	I-Gene
was	3	O
analyzed	8	O
by	2	O
immunohistochemistry	20	O
.	1	O

No	2	O
significant	11	O
correlations	12	O
were	4	O
found	5	O
between	7	O
tumor	5	B-Gene
beta	4	I-Gene
2-M	3	I-Gene
expression	10	O
and	3	O
several	7	O
histologic	10	O
attributes	10	O
such	4	O
as	2	O
type	4	O
,	1	O
histologic	10	O
and	3	O
nuclear	7	O
grades	6	O
,	1	O
mitotic	7	O
index	5	O
,	1	O
necrosis	8	O
,	1	O
vascular	8	O
invasion	8	O
,	1	O
and	3	O
lymphocytic	11	O
infiltration	12	O
.	1	O

Likewise	8	O
,	1	O
beta	4	B-Gene
2-M	3	I-Gene
was	3	O
not	3	O
associated	10	O
with	4	O
markers	7	O
of	2	O
disease	7	O
extension	9	O
such	4	O
as	2	O
TNM	3	O
,	1	O
(	1	O
UICC	4	O
,	1	O
classification	14	O
of	2	O
malignant	9	B-Disease
tumors	6	I-Disease
)	1	O
staging	7	O
and	3	O
axillary	8	O
lymph	5	O
node	4	O
involvement	11	O
or	2	O
with	4	O
estrogen	8	B-Chemical
,	1	O
progesterone	12	B-Chemical
,	1	O
and	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
levels	6	O
.	1	O

However	7	O
,	1	O
there	5	O
was	3	O
a	1	O
significantly	13	O
positive	8	O
association	11	O
between	7	O
tumor	5	B-Gene
beta	4	I-Gene
2-M	3	I-Gene
expression	10	O
and	3	O
the	3	O
degree	6	O
of	2	O
lymphocytic	11	O
infiltration	12	O
in	2	O
the	3	O
tumor	5	B-Disease
tissue	6	O
.	1	O

Beta	4	B-Gene
2-M	3	I-Gene
serum	5	I-Gene
levels	6	O
were	4	O
determined	10	O
by	2	O
an	2	O
enzyme	6	O
-linked	7	O
immunosorbent	13	O
assay	5	O
in	2	O
samples	7	O
from	4	O
22	2	O
of	2	O
the	3	O
above	5	O
women	5	O
.	1	O

Although	8	O
some	4	O
of	2	O
the	3	O
highest	7	O
values	6	O
had	3	O
been	4	O
obtained	8	O
in	2	O
women	5	O
with	4	O
larger	6	O
(	1	O
T4	2	O
)	1	O
primary	7	O
tumors	6	B-Disease
,	1	O
the	3	O
authors	7	O
failed	6	O
to	2	O
detect	6	O
any	3	O
statistical	11	O
relationship	12	O
between	7	O
beta	4	B-Gene
2-M	3	I-Gene
expression	10	O
in	2	O
the	3	O
tumor	5	B-Disease
with	4	O
serum	5	O
levels	6	O
or	2	O
between	7	O
serum	5	B-Gene
beta	4	I-Gene
2-M	3	I-Gene
and	3	O
the	3	O
above	5	O
histologic	10	O
,	1	O
laboratory	10	O
,	1	O
and	3	O
clinical	8	O
factors	7	O
.	1	O

Estradiol	9	B-Gene
receptors	9	I-Gene
in	2	O
the	3	O
cytosol	7	O
of	2	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
in	2	O
hepatitis	9	B-Disease
B	1	I-Disease
virus	5	O
carriers	8	O
treated	7	O
with	4	O
interferon-alpha	16	B-Gene
.	1	O

Estradiol	9	B-Gene
receptors	9	I-Gene
in	2	O
the	3	O
cytosol	7	O
of	2	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
and	3	O
the	3	O
effects	7	O
of	2	O
interferon-alpha	16	B-Gene
(	1	O
IFN-alpha	9	B-Gene
)	1	O
on	2	O
estradiol	9	B-Gene
receptors	9	I-Gene
were	4	O
studied	7	O
in	2	O
asymptomatic	12	O
hepatitis	9	B-Disease
B	1	I-Disease
virus	5	O
(	1	O
HBV	3	O
)	1	O
carriers	8	O
,	1	O
patients	8	O
with	4	O
chronic	7	B-Disease
hepatitis	9	I-Disease
B	1	I-Disease
and	3	O
normal	6	O
controls	8	O
.	1	O

The	3	O
level	5	O
of	2	O
estradiol	9	B-Gene
receptors	9	I-Gene
in	2	O
the	3	O
cytosol	7	O
of	2	O
mononuclear	11	O
cells	5	O
was	3	O
significantly	13	O
lower	5	O
in	2	O
asymptomatic	12	O
HBV	3	O
carriers	8	O
and	3	O
patients	8	O
with	4	O
chronic	7	B-Disease
hepatitis	9	I-Disease
B	1	I-Disease
,	1	O
compared	8	O
to	2	O
normal	6	O
controls	8	O
.	1	O

This	4	O
low	3	O
level	5	O
of	2	O
cytosol	7	B-Gene
estradiol	9	I-Gene
receptors	9	I-Gene
in	2	O
patients	8	O
with	4	O
chronic	7	B-Disease
hepatitis	9	I-Disease
B	1	I-Disease
was	3	O
increased	9	O
by	2	O
the	3	O
administration	14	O
of	2	O
IFN-alpha	9	B-Gene
.	1	O

In	2	O
addition	8	O
,	1	O
when	4	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
from	4	O
patients	8	O
with	4	O
chronic	7	B-Disease
hepatitis	9	I-Disease
B	1	I-Disease
were	4	O
incubated	9	O
with	4	O
IFN-alpha	9	B-Gene
in	2	O
vitro	5	O
,	1	O
the	3	O
level	5	O
of	2	O
cytosol	7	B-Gene
estradiol	9	I-Gene
receptors	9	I-Gene
also	4	O
increased	9	O
by	2	O
increasing	10	O
the	3	O
concentration	13	O
of	2	O
IFN-alpha	9	B-Gene
.	1	O

We	2	O
previously	10	O
reported	8	O
that	4	O
the	3	O
response	8	O
of	2	O
mononuclear	11	O
cells	5	O
to	2	O
estrogen	8	B-Chemical
is	2	O
impaired	8	O
in	2	O
HBV	3	O
carriers	8	O
,	1	O
and	3	O
our	3	O
present	7	O
results	7	O
suggested	9	O
that	4	O
this	4	O
may	3	O
be	2	O
due	3	O
to	2	O
the	3	O
low	3	O
level	5	O
of	2	O
estradiol	9	B-Gene
receptors	9	I-Gene
in	2	O
the	3	O
cytosol	7	O
of	2	O
mononuclear	11	O
cells	5	O
.	1	O

In	2	O
vivo	4	O
responsiveness	14	O
to	2	O
glucocorticoid	14	B-Chemical
correlated	10	O
with	4	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
content	7	O
in	2	O
peripheral	10	O
blood	5	O
leukocytes	10	O
in	2	O
normal	6	O
humans	6	O
.	1	O

Dexamethasone	13	B-Chemical
loading	7	O
tests	5	O
(	1	O
0.1	3	O
mg	2	O
dexamethasone	13	B-Chemical
/	1	O
kg	2	O
,	1	O
iv	2	O
)	1	O
were	4	O
performed	9	O
in	2	O
18	2	O
normal	6	O
males	5	O
to	2	O
evaluate	8	O
the	3	O
individual	10	O
responsiveness	14	O
to	2	O
glucocorticoid	14	B-Chemical
.	1	O

There	5	O
were	4	O
inter-individual	16	O
differences	11	O
in	2	O
increase	8	O
in	2	O
peripheral	10	O
blood	5	O
polymorphonuclear	17	O
leukocyte	9	O
count	5	O
,	1	O
decrease	8	O
in	2	O
peripheral	10	O
blood	5	O
lymphocyte	10	O
count	5	O
,	1	O
and	3	O
increase	8	O
in	2	O
plasma	6	O
free	4	O
fatty	5	B-Chemical
acids	5	I-Chemical
levels	6	O
after	5	O
dexamethasone	13	B-Chemical
injection	9	O
.	1	O

In	2	O
addition	8	O
,	1	O
there	5	O
was	3	O
a	1	O
significant	11	O
correlation	11	O
between	7	O
the	3	O
maximum	7	O
increase	8	O
in	2	O
polymorphonuclear	17	O
leukocytes	10	O
and	3	O
the	3	O
maximum	7	O
decrease	8	O
in	2	O
lymphocytes	11	O
(	1	O
r	1	O
=	1	O
0.7514	6	O
,	1	O
p	1	O
less	4	O
than	4	O
0.0003	6	O
)	1	O
.	1	O

Simultaneous	12	O
measurements	12	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
content	7	O
by	2	O
whole-cell	10	O
assay	5	O
revealed	8	O
that	4	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
content	7	O
in	2	O
polymorphonuclear	17	O
leukocytes	10	O
linearly	8	O
correlated	10	O
with	4	O
that	4	O
in	2	O
the	3	O
corresponding	13	O
lymphocytes	11	O
(	1	O
r	1	O
=	1	O
0.9482	6	O
,	1	O
p	1	O
less	4	O
than	4	O
0.0001	6	O
)	1	O
.	1	O

There	5	O
were	4	O
also	4	O
significant	11	O
correlations	12	O
between	7	O
the	3	O
maximum	7	O
increase	8	O
in	2	O
polymorphonuclear	17	O
leukocytes	10	O
and	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
content	7	O
in	2	O
polymorphonuclear	17	O
leukocytes	10	O
(	1	O
r	1	O
=	1	O
0.7239	6	O
,	1	O
p	1	O
less	4	O
than	4	O
0.0007	6	O
)	1	O
,	1	O
and	3	O
between	7	O
the	3	O
maximum	7	O
decrease	8	O
in	2	O
lymphocytes	11	O
and	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
content	7	O
in	2	O
lymphocytes	11	O
(	1	O
r	1	O
=	1	O
0.7703	6	O
,	1	O
p	1	O
less	4	O
than	4	O
0.0002	6	O
)	1	O
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
individual	10	O
differences	11	O
are	3	O
preserved	9	O
both	4	O
in	2	O
glucocorticoid	14	B-Chemical
responsiveness	14	O
and	3	O
in	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
content	7	O
in	2	O
peripheral	10	O
blood	5	O
leukocytes	10	O
in	2	O
normal	6	O
humans	6	O
.	1	O

[	1	O
Preliminary	11	O
observation	11	O
of	2	O
level	5	O
free-form	9	O
E	1	O
receptor	8	O
levels	6	O
in	2	O
serum	5	O
of	2	O
normal	6	O
childbearing	12	O
-aged	5	O
and	3	O
pregnant	8	O
women	5	O
]	1	O

In	2	O
137	3	O
cases	5	O
of	2	O
childbearing	12	O
-aged	5	O
and	3	O
pregnant	8	O
women	5	O
,	1	O
free	4	O
form	4	O
E	1	O
receptor	8	O
levels	6	O
(	1	O
sE	2	O
)	1	O
in	2	O
serum	5	O
were	4	O
measured	8	O
by	2	O
ELISA	5	O
.	1	O

The	3	O
level	5	O
of	2	O
sE	2	O
was	3	O
significantly	13	O
decreased	9	O
during	6	O
the	3	O
first	5	O
trimester	9	O
,	1	O
slightly	8	O
higher	6	O
in	2	O
the	3	O
second	6	O
trimester	9	O
,	1	O
and	3	O
recovered	9	O
to	2	O
normal	6	O
in	2	O
the	3	O
third	5	O
trimester	9	O
.	1	O

The	3	O
level	5	O
remained	8	O
lower	5	O
in	2	O
29	2	O
PIH	3	O
women	5	O
but	3	O
appeared	8	O
higher	6	O
in	2	O
overdue	7	O
pregnancies	11	O
as	2	O
compared	8	O
with	4	O
the	3	O
normal	6	O
3rd	3	O
trimester	9	O
range	5	O
.	1	O

The	3	O
results	7	O
indicate	8	O
that	4	O
there	5	O
is	2	O
a	1	O
relationship	12	O
between	7	O
a	1	O
change	6	O
in	2	O
T	1	O
cell	4	O
function	8	O
and	3	O
pregnancy	9	O
.	1	O

Congenital	10	O
immunodeficiencies	18	O
associated	10	O
with	4	O
absence	7	O
of	2	O
HLA	3	B-Gene
class	5	I-Gene
II	2	I-Gene
antigens	8	I-Gene
on	2	O
lymphocytes	11	O
result	6	O
from	4	O
distinct	8	O
mutations	9	O
in	2	O
trans	5	O
-acting	7	O
factors	7	O
.	1	O

Coordinate	10	O
regulation	10	O
of	2	O
HLA	3	B-Gene
class	5	I-Gene
II	2	I-Gene
gene	4	I-Gene
expression	10	O
during	6	O
development	11	O
and	3	O
coinduction	11	O
of	2	O
class	5	O
II	2	O
genes	5	O
by	2	O
soluble	7	O
factors	7	O
suggests	8	O
that	4	O
common	6	O
trans	5	O
-acting	7	O
factor	6	O
(	1	O
s	1	O
)	1	O
control	7	O
expression	10	O
of	2	O
these	5	O
genes	5	O
.	1	O

In	2	O
B-lymphoblastoid	16	O
cell	4	O
lines	5	O
derived	7	O
from	4	O
two	3	O
independent	11	O
class	5	B-Disease
II	2	I-Disease
-deficient	10	I-Disease
bare	4	I-Disease
lymphocyte	10	I-Disease
syndrome	8	I-Disease
patients	8	O
,	1	O
we	2	O
observed	8	O
a	1	O
drastic	7	O
decrease	8	O
in	2	O
transcription	13	O
rates	5	O
of	2	O
the	3	O
class	5	O
II	2	O
genes	5	O
.	1	O

When	4	O
these	5	O
cell	4	O
lines	5	O
are	3	O
fused	5	O
,	1	O
class	5	O
II	2	O
genes	5	O
are	3	O
reexpressed	11	O
,	1	O
indicating	10	O
that	4	O
immunodeficiencies	18	O
in	2	O
bare	4	B-Disease
lymphocyte	10	I-Disease
syndrome	8	I-Disease
patients	8	O
are	3	O
the	3	O
result	6	O
of	2	O
two	3	O
distinct	8	O
mutations	9	O
.	1	O

Further	7	O
studies	7	O
show	4	O
that	4	O
genes	5	O
governing	9	O
the	3	O
expression	10	O
of	2	O
class	5	O
II	2	O
antigens	8	O
fall	4	O
into	4	O
at	2	O
least	5	O
three	5	O
complementation	15	O
groups	6	O
;	1	O
two	3	O
of	2	O
these	5	O
were	4	O
previously	10	O
unidentified	12	O
in	2	O
mutant	6	O
cell	4	O
lines	5	O
generated	9	O
in	2	O
vitro	5	O
.	1	O

In	2	O
addition	8	O
,	1	O
we	2	O
report	6	O
the	3	O
identification	14	O
of	2	O
two	3	O
discrete	8	O
complexes	9	O
,	1	O
NFX1.1	6	B-Gene
and	3	O
NFX1.2	6	B-Gene
,	1	O
that	4	O
bind	4	O
to	2	O
the	3	O
DRA	3	O
X	1	O
consensus	9	O
element	7	O
.	1	O

Though	6	O
the	3	O
mutation	8	O
in	2	O
at	2	O
least	5	O
one	3	O
mutant	6	O
line	4	O
generated	9	O
in	2	O
vitro	5	O
(	1	O
RJ2.2.5	7	O
)	1	O
affects	7	O
products	8	O
functioning	11	O
via	3	O
interaction	11	O
with	4	O
the	3	O
X	1	O
box	3	O
,	1	O
clear	5	O
alterations	11	O
in	2	O
either	6	O
NFX1.1	6	B-Gene
or	2	O
NFX1.2	6	B-Gene
are	3	O
not	3	O
found	5	O
in	2	O
any	3	O
of	2	O
the	3	O
mutant	6	O
cell	4	O
lines	5	O
.	1	O

Number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
lymphocytes	11	O
and	3	O
their	5	O
sensitivity	11	O
to	2	O
hormone	7	O
action	6	O
.	1	O

The	3	O
study	5	O
demonstrated	12	O
a	1	O
decreased	9	O
level	5	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
in	2	O
peripheral	10	O
blood	5	O
lymphocytes	11	O
from	4	O
hypercholesterolemic	20	O
subjects	8	O
,	1	O
and	3	O
an	2	O
elevated	8	O
level	5	O
in	2	O
patients	8	O
with	4	O
acute	5	B-Disease
myocardial	10	I-Disease
infarction	10	I-Disease
.	1	O

In	2	O
the	3	O
lymphocytes	11	O
with	4	O
a	1	O
high	4	O
GR	2	B-Gene
number	6	O
,	1	O
dexamethasone	13	B-Chemical
inhibited	9	O
[	1	O
3H	2	O
]	1	O
-thymidine	10	B-Chemical
and	3	O
[	1	O
3H	2	O
]	1	O
-acetate	8	B-Chemical
incorporation	13	O
into	4	O
DNA	3	O
and	3	O
cholesterol	11	B-Chemical
,	1	O
respectively	12	O
,	1	O
in	2	O
the	3	O
same	4	O
manner	6	O
as	2	O
in	2	O
the	3	O
control	7	O
cells	5	O
.	1	O

On	2	O
the	3	O
other	5	O
hand	4	O
,	1	O
a	1	O
decreased	9	O
GR	2	B-Gene
number	6	O
resulted	8	O
in	2	O
a	1	O
less	4	O
efficient	9	O
dexamethasone	13	B-Chemical
inhibition	10	O
of	2	O
the	3	O
incorporation	13	O
of	2	O
labeled	7	O
compounds	9	O
.	1	O

These	5	O
data	4	O
showed	6	O
that	4	O
the	3	O
sensitivity	11	O
of	2	O
lymphocytes	11	O
to	2	O
glucocorticoids	15	B-Chemical
changed	7	O
only	4	O
with	4	O
a	1	O
decrease	8	O
of	2	O
GR	2	B-Gene
level	5	O
.	1	O

Anti-Ro	7	B-Gene
(	1	I-Gene
SSA	3	I-Gene
)	1	I-Gene
autoantibodies	14	I-Gene
are	3	O
associated	10	O
with	4	O
T	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
beta	4	I-Gene
genes	5	I-Gene
in	2	O
systemic	8	B-Disease
lupus	5	I-Disease
erythematosus	13	I-Disease
patients	8	O
.	1	O

Several	7	O
of	2	O
the	3	O
heterogeneous	13	O
clinical	8	O
manifestations	14	O
of	2	O
systemic	8	B-Disease
lupus	5	I-Disease
erythematosus	13	I-Disease
have	4	O
been	4	O
associated	10	O
with	4	O
specific	8	O
autoantibodies	14	O
.	1	O

Associations	12	O
between	7	O
HLA	3	B-Gene
class	5	I-Gene
II	2	I-Gene
antigens	8	I-Gene
and	3	O
autoantibodies	14	O
to	2	O
the	3	O
ribonucleoproteins	18	B-Gene
Ro	2	I-Gene
(	1	O
SSA	3	B-Gene
)	1	O
and	3	O
La	2	B-Gene
(	1	O
SSB	3	B-Gene
)	1	O
have	4	O
been	4	O
reported	8	O
in	2	O
these	5	O
patients	8	O
.	1	O

Because	7	O
HLA	3	B-Gene
class	5	I-Gene
II	2	I-Gene
molecules	9	O
present	7	O
antigen	7	O
to	2	O
T	1	B-Gene
cell	4	I-Gene
receptors	9	I-Gene
(	1	O
TCRs	4	B-Gene
)	1	O
,	1	O
we	2	O
have	4	O
searched	8	O
for	3	O
a	1	O
TCR	3	B-Gene
gene	4	I-Gene
associated	10	O
with	4	O
the	3	O
production	10	O
of	2	O
anti-Ro	7	B-Gene
(	1	I-Gene
SSA	3	I-Gene
)	1	I-Gene
antibodies	10	I-Gene
.	1	O

A	1	O
pair	4	O
of	2	O
restriction	11	O
fragment	8	O
length	6	O
polymorphisms	13	O
(	1	O
RFLPs	5	O
)	1	O
,	1	O
one	3	O
of	2	O
which	5	O
hybridizes	10	O
to	2	O
the	3	O
TCR	3	B-Gene
constant	8	I-Gene
region	6	I-Gene
C	1	I-Gene
beta	4	I-Gene
1	1	I-Gene
and	3	O
the	3	O
other	5	O
to	2	O
the	3	O
C	1	B-Partial_Gene
beta	4	I-Partial_Gene
2	1	I-Partial_Gene
gene	4	I-Partial_Gene
,	1	O
has	3	O
been	4	O
identified	10	O
,	1	O
suggesting	10	O
these	5	O
may	3	O
be	2	O
genotypic	9	O
markers	7	O
for	3	O
an	2	O
extended	8	O
region	6	O
of	2	O
the	3	O
TCR	3	B-Gene
beta	4	I-Gene
locus	5	I-Gene
.	1	O

This	4	O
RFLP	4	O
pair	4	O
occurs	6	O
in	2	O
76	2	O
%	1	O
of	2	O
patients	8	O
with	4	O
Ro	2	B-Gene
(	1	O
SSA	3	B-Gene
)	1	O
precipitins	11	O
,	1	O
84	2	O
%	1	O
of	2	O
anti-	5	B-Gene
Ro	2	I-Gene
(	1	I-Gene
SSA	3	I-Gene
)	1	I-Gene
-positive	9	O
patients	8	O
lacking	7	O
La	2	B-Gene
(	1	O
SSB	3	B-Gene
)	1	O
precipitins	11	O
,	1	O
but	3	O
only	4	O
41	2	O
%	1	O
of	2	O
the	3	O
patients	8	O
lacking	7	O
both	4	O
precipitins	11	O
(	1	O
P	1	O
=	1	O
0.0004	6	O
)	1	O
.	1	O

This	4	O
disproportionate	16	O
occurrence	10	O
in	2	O
a	1	O
subset	6	O
of	2	O
lupus	5	B-Disease
patients	8	O
indicates	9	O
that	4	O
these	5	O
RFLPs	5	O
are	3	O
not	3	O
disease	7	O
susceptibility	14	O
markers	7	O
,	1	O
but	3	O
rather	6	O
are	3	O
important	9	O
markers	7	O
for	3	O
TCR	3	B-Gene
genes	5	I-Gene
whose	5	O
products	8	O
are	3	O
involved	8	O
in	2	O
the	3	O
production	10	O
of	2	O
anti-Ro	7	B-Gene
(	1	I-Gene
SSA	3	I-Gene
)	1	I-Gene
antibodies	10	I-Gene
.	1	O

The	3	O
majority	8	O
of	2	O
patients	8	O
who	3	O
have	4	O
these	5	O
RFLPs	5	O
and	3	O
HLA	3	B-Gene
class	5	I-Gene
II	2	I-Gene
antigens	8	I-Gene
previously	10	O
associated	10	O
with	4	O
the	3	O
anti-	5	B-Gene
Ro	2	I-Gene
(	1	I-Gene
SSA	3	I-Gene
)	1	I-Gene
response	8	O
make	4	O
this	4	O
antibody	8	O
,	1	O
suggesting	10	O
that	4	O
interactions	12	O
between	7	O
products	8	O
of	2	O
these	5	O
loci	4	O
occur	5	O
in	2	O
response	8	O
to	2	O
Ro	2	B-Gene
(	1	O
SSA	3	B-Gene
)	1	O
.	1	O

Reactivity	10	O
of	2	O
lymphocytes	11	O
to	2	O
a	1	O
progesterone	12	B-Gene
receptor-specific	17	I-Gene
monoclonal	10	O
antibody	8	O
.	1	O

In	2	O
this	4	O
study	5	O
we	2	O
present	7	O
evidence	8	O
for	3	O
reactivity	10	O
of	2	O
pregnancy	9	O
lymphocytes	11	O
,	1	O
but	3	O
not	3	O
nonpregnancy	12	O
lymphocytes	11	O
,	1	O
with	4	O
the	3	O
progesterone	12	B-Gene
receptor-specific	17	I-Gene
monoclonal	10	I-Gene
antibody	8	I-Gene
mPRI	4	I-Gene
.	1	O

Using	5	O
an	2	O
avidin	6	B-Gene
-biotin	7	I-Gene
peroxidase	10	I-Gene
detection	9	O
system	6	O
,	1	O
we	2	O
found	5	O
a	1	O
nuclear	7	O
staining	8	O
in	2	O
14.6	4	O
+	1	O
/	1	O
-	1	O
3.7	3	O
%	1	O
(	1	O
mean	4	O
+	1	O
/	1	O
-	1	O
SEM	3	O
,	1	O
N	1	O
=	1	O
27	2	O
)	1	O
of	2	O
pregnancy	9	O
lymphocytes	11	O
,	1	O
while	5	O
only	4	O
0.47	4	O
+	1	O
/	1	O
-	1	O
0.33	4	O
%	1	O
(	1	O
mean	4	O
+	1	O
/	1	O
-	1	O
SEM	3	O
,	1	O
N	1	O
=	1	O
15	2	O
)	1	O
of	2	O
nonpregnancy	12	O
lymphocytes	11	O
reacted	7	O
with	4	O
the	3	O
antibody	8	O
.	1	O

To	2	O
characterize	12	O
the	3	O
receptor	8	O
-bearing	8	O
subset	6	O
,	1	O
CD8+	4	B-Gene
and	3	O
CD4+	4	B-Gene
cells	5	O
were	4	O
depleted	8	O
by	2	O
complement	10	O
-dependent	10	O
lysis	5	O
.	1	O

Depletion	9	O
of	2	O
CD8+	4	B-Gene
cells	5	O
was	3	O
accompanied	11	O
by	2	O
62	2	O
+	1	O
/	1	O
-	1	O
18	2	O
%	1	O
loss	4	O
of	2	O
progesterone	12	B-Gene
receptor	8	I-Gene
-bearing	8	O
cells	5	O
,	1	O
while	5	O
depletion	9	O
of	2	O
CD4+	4	B-Gene
cells	5	O
resulted	8	O
in	2	O
a	1	O
twofold	7	O
increase	8	O
in	2	O
the	3	O
number	6	O
of	2	O
positively	10	O
staining	8	O
lymphocytes	11	O
.	1	O

In	2	O
nonpregnancy	12	O
lymphocytes	11	O
a	1	O
3-day	5	O
PHA	3	B-Gene
treatment	9	O
,	1	O
as	2	O
well	4	O
as	2	O
allogeneic	10	O
stimulation	11	O
,	1	O
resulted	8	O
in	2	O
a	1	O
significant	11	O
increase	8	O
in	2	O
the	3	O
number	6	O
of	2	O
receptor	8	O
-containing	11	O
cells	5	O
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
pregnancy	9	O
,	1	O
but	3	O
not	3	O
nonpregnancy	12	O
,	1	O
lymphocytes	11	O
contain	7	O
progesterone	12	B-Chemical
binding	7	O
structures	10	O
,	1	O
and	3	O
that	4	O
these	5	O
are	3	O
inducible	9	O
by	2	O
mitogenic	9	O
or	2	O
alloantigenic	13	O
stimuli	7	O
.	1	O

Characterization	16	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
enhancer	8	O
-binding	8	O
proteins	8	O
from	4	O
the	3	O
human	5	O
T-cell	6	O
line	4	O
Jurkat	6	O
.	1	O

The	3	O
transcription	13	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
(	1	O
HIV-1	5	O
)	1	O
is	2	O
under	5	O
the	3	O
control	7	O
of	2	O
cellular	8	O
proteins	8	O
that	4	O
bind	4	O
to	2	O
the	3	O
viral	5	O
long	4	O
terminal	8	O
repeat	6	O
(	1	O
LTR	3	O
)	1	O
.	1	O

Among	5	O
the	3	O
protein	7	O
-binding	8	O
regions	7	O
of	2	O
the	3	O
HIV-1	5	O
LTR	3	O
is	2	O
the	3	O
transcription-enhancer	22	O
region	6	O
.	1	O

We	2	O
show	4	O
that	4	O
at	2	O
least	5	O
one	3	O
inducible	9	O
,	1	O
C1	2	B-Gene
,	1	O
and	3	O
one	3	O
constitutive	12	O
,	1	O
C2	2	B-Gene
,	1	O
protein	7	O
can	3	O
bind	4	O
to	2	O
the	3	O
HIV	3	O
enhancer	8	O
in	2	O
Jurkat	6	O
cells	5	O
.	1	O

The	3	O
two	3	O
proteins	8	O
differ	6	O
in	2	O
their	5	O
surface	7	O
charge	6	O
,	1	O
since	5	O
they	4	O
are	3	O
separable	9	O
by	2	O
anion-exchange	14	O
chromatography	14	O
.	1	O

Bivalent	8	O
cations	7	O
such	4	O
as	2	O
Mg2+	4	O
and	3	O
Zn2+	4	O
differentially	14	O
affect	6	O
their	5	O
binding	7	O
to	2	O
oligonucleotides	16	O
which	5	O
contain	7	O
the	3	O
HIV-enhancer	12	O
domain	6	O
.	1	O

Both	4	O
C1	2	B-Gene
and	3	O
C2	2	B-Gene
proteins	8	I-Gene
also	4	O
bind	4	O
to	2	O
a	1	O
similar	7	O
sequence	8	O
found	5	O
in	2	O
the	3	O
interleukin-2-receptor	22	B-Gene
alpha-subunit	13	I-Gene
enhancer	8	I-Gene
.	1	O

The	3	O
inducible	9	O
C1	2	B-Gene
protein	7	I-Gene
was	3	O
partially	9	O
purified	8	O
by	2	O
three	5	O
chromatographic	15	O
steps	5	O
and	3	O
characterized	13	O
by	2	O
u.v.	4	O
cross	5	O
-linking	8	O
as	2	O
a	1	O
47	2	O
kDa	3	O
protein	7	O
.	1	O

A	1	O
factor	6	O
known	5	O
to	2	O
bind	4	O
to	2	O
endogenous	10	B-Gene
Ig	2	I-Gene
heavy	5	I-Gene
chain	5	I-Gene
enhancer	8	I-Gene
only	4	O
in	2	O
lymphocytes	11	O
is	2	O
a	1	O
ubiquitously	12	O
active	6	O
transcription	13	O
factor	6	O
.	1	O

The	3	O
transcriptional	15	O
enhancer	8	O
located	7	O
in	2	O
the	3	O
first	5	O
intron	6	O
of	2	O
the	3	O
immunoglobulin	14	B-Gene
heavy	5	I-Gene
chain	5	I-Gene
constant	8	O
region	6	O
is	2	O
a	1	O
major	5	O
determinant	11	O
of	2	O
B-cell-specific	15	O
expression	10	O
of	2	O
immunoglobulin	14	B-Gene
genes	5	I-Gene
.	1	O

Like	4	O
other	5	O
enhancers	9	O
,	1	O
the	3	O
Ig	2	B-Gene
heavy	5	I-Gene
chain	5	I-Gene
enhancer	8	I-Gene
contains	8	O
several	7	O
short	5	O
sequence	8	O
motifs	6	O
that	4	O
bind	4	O
specific	8	O
transcription	13	O
factors	7	O
.	1	O

Each	4	O
binding	7	O
site	4	O
contributes	11	O
to	2	O
the	3	O
overall	7	O
activity	8	O
of	2	O
the	3	O
enhancer	8	O
,	1	O
however	7	O
no	2	O
single	6	O
element	7	O
seems	5	O
absolutely	10	O
required	8	O
for	3	O
activity	8	O
.	1	O

For	3	O
a	1	O
better	6	O
understanding	13	O
of	2	O
the	3	O
Ig	2	B-Gene
heavy	5	I-Gene
chain	5	I-Gene
enhancer	8	I-Gene
components	10	O
,	1	O
we	2	O
have	4	O
cloned	6	O
and	3	O
analyzed	8	O
individual	10	O
sequence	8	O
elements	8	O
.	1	O

We	2	O
find	4	O
that	4	O
the	3	O
factor	6	O
that	4	O
binds	5	O
to	2	O
the	3	O
E3	2	O
enhancer	8	O
motif	5	O
,	1	O
CATGTGGC	8	O
,	1	O
is	2	O
a	1	O
ubiquitous	10	O
transcription	13	O
factor	6	O
.	1	O

It	2	O
is	2	O
present	7	O
in	2	O
an	2	O
active	6	O
form	4	O
in	2	O
both	4	O
B	1	O
cells	5	O
and	3	O
non-B	5	O
cells	5	O
,	1	O
where	5	O
it	2	O
can	3	O
mediate	7	O
transcriptional	15	O
activation	10	O
in	2	O
vitro	5	O
and	3	O
in	2	O
vivo	4	O
.	1	O

However	7	O
,	1	O
despite	7	O
its	3	O
ability	7	O
to	2	O
activate	8	O
transcription	13	O
of	2	O
a	1	O
transfected	11	O
reporter	8	O
gene	4	O
,	1	O
the	3	O
factor	6	O
is	2	O
apparently	10	O
unable	6	O
to	2	O
bind	4	O
to	2	O
the	3	O
endogenous	10	B-Gene
Ig	2	I-Gene
heavy	5	I-Gene
chain	5	I-Gene
enhancer	8	I-Gene
in	2	O
non-lymphoid	12	O
cells	5	O
:	1	O
In	2	O
previous	8	O
experiments	11	O
by	2	O
others	6	O
,	1	O
the	3	O
characteristic	14	O
in	2	O
vivo	4	O
footprint	9	O
of	2	O
this	4	O
factor	6	O
,	1	O
designated	10	O
NF-muE3	7	O
,	1	O
was	3	O
detected	8	O
in	2	O
B	1	O
cells	5	O
but	3	O
not	3	O
in	2	O
non-B	5	O
cells	5	O
.	1	O

From	4	O
this	4	O
and	3	O
other	5	O
findings	8	O
the	3	O
picture	7	O
emerges	7	O
that	4	O
there	5	O
are	3	O
at	2	O
least	5	O
three	5	O
categories	10	O
of	2	O
factors	7	O
which	5	O
mediate	7	O
cell-type-specific	18	O
transcription	13	O
in	2	O
B	1	O
lymphocytes	11	O
:	1	O
(	1	O
a	1	O
)	1	O
cell-specific	13	O
factors	7	O
such	4	O
as	2	O
Oct-2A	6	B-Gene
and	3	O
Oct-2B	6	B-Gene
that	4	O
are	3	O
not	3	O
expressed	9	O
in	2	O
most	4	O
other	5	O
cell	4	O
types	5	O
:	1	O
(	1	O
b	1	O
)	1	O
ubiquitous	10	O
factors	7	O
such	4	O
as	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
that	4	O
are	3	O
constitutively	14	O
active	6	O
in	2	O
B	1	O
cells	5	O
but	3	O
are	3	O
sequestered	11	O
in	2	O
an	2	O
inactive	8	O
form	4	O
in	2	O
other	5	O
cells	5	O
;	1	O
(	1	O
c	1	O
)	1	O
ubiquitously	12	O
active	6	O
factors	7	O
,	1	O
exemplified	11	O
by	2	O
the	3	O
one	3	O
binding	7	O
to	2	O
the	3	O
E3	2	O
sequence	8	O
motif	5	O
.	1	O

This	4	O
factor	6	O
is	2	O
present	7	O
in	2	O
an	2	O
active	6	O
form	4	O
in	2	O
a	1	O
variety	7	O
of	2	O
cell	4	O
types	5	O
but	3	O
is	2	O
apparently	10	O
unable	6	O
to	2	O
bind	4	O
to	2	O
the	3	O
endogenous	10	B-Gene
Ig	2	I-Gene
heavy	5	I-Gene
chain	5	I-Gene
enhancer	8	I-Gene
in	2	O
non-B	5	O
cells	5	O
,	1	O
perhaps	7	O
due	3	O
to	2	O
a	1	O
non	3	O
-permissive	11	O
chromatin	9	O
structure	9	O
of	2	O
the	3	O
Ig	2	B-Gene
heavy	5	I-Gene
chain	5	I-Gene
locus	5	I-Gene
.	1	O

Transcriptional	15	O
and	3	O
post-transcriptional	20	O
regulation	10	O
of	2	O
c-jun	5	B-Gene
expression	10	O
during	6	O
monocytic	9	O
differentiation	15	O
of	2	O
human	5	O
myeloid	7	O
leukemic	8	O
cells	5	O
.	1	O

AP-1	4	B-Gene
,	1	O
the	3	O
polypeptide	11	O
product	7	O
of	2	O
c-jun	5	B-Gene
,	1	O
recognizes	10	O
and	3	O
binds	5	O
to	2	O
specific	8	O
DNA	3	O
sequences	9	O
and	3	O
stimulates	10	O
transcription	13	O
of	2	O
genes	5	O
responsive	10	O
to	2	O
certain	7	O
growth	6	O
factors	7	O
and	3	O
phorbol	7	B-Chemical
esters	6	I-Chemical
such	4	O
as	2	O
12-O-tetradecanoylphorbol-13-acetate	36	B-Chemical
(	1	O
TPA	3	B-Chemical
)	1	O
.	1	O

We	2	O
studied	7	O
the	3	O
effects	7	O
of	2	O
TPA	3	B-Chemical
on	2	O
the	3	O
regulation	10	O
of	2	O
c-jun	5	B-Gene
gene	4	I-Gene
expression	10	O
in	2	O
HL-60	5	O
cells	5	O
during	6	O
monocytic	9	O
differentiation	15	O
.	1	O

Low	3	O
levels	6	O
of	2	O
c-jun	5	B-Gene
transcripts	11	I-Gene
were	4	O
detectable	10	O
in	2	O
untreated	9	O
HL-60	5	O
leukemic	8	O
cells	5	O
,	1	O
increased	9	O
significantly	13	O
by	2	O
6	1	O
h	1	O
,	1	O
and	3	O
reached	7	O
near	4	O
maximal	7	O
levels	6	O
by	2	O
24	2	O
h	1	O
of	2	O
exposure	8	O
to	2	O
32	2	O
nM	2	O
TPA	3	B-Chemical
.	1	O

Similar	7	O
kinetics	8	O
of	2	O
c-jun	5	B-Gene
induction	9	O
by	2	O
TPA	3	B-Chemical
were	4	O
observed	8	O
in	2	O
human	5	O
U-937	5	O
and	3	O
THP-1	5	O
monocytic	9	O
leukemia	8	B-Disease
cells	5	O
.	1	O

Similar	7	O
findings	8	O
were	4	O
obtained	8	O
with	4	O
bryostatin	10	B-Chemical
1	1	I-Chemical
(	1	O
10	2	O
nM	2	O
)	1	O
,	1	O
another	7	O
activator	9	O
of	2	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
and	3	O
inducer	7	O
of	2	O
monocytic	9	O
differentiation	15	O
.	1	O

Furthermore	11	O
,	1	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
(	1	O
0.5	3	O
microM	6	O
)	1	O
,	1	O
a	1	O
structurally	12	O
distinct	8	O
agent	5	O
which	5	O
also	4	O
induces	7	O
HL-60	5	O
monocytic	9	O
differentiation	15	O
,	1	O
increased	9	O
c-jun	5	B-Gene
expression	10	O
.	1	O

TPA	3	B-Chemical
treatment	9	O
of	2	O
HL-60	5	O
cells	5	O
in	2	O
the	3	O
presence	8	O
of	2	O
cycloheximide	13	B-Chemical
was	3	O
associated	10	O
with	4	O
superinduction	14	O
of	2	O
c-jun	5	B-Gene
transcripts	11	I-Gene
.	1	O

Run-on	6	O
analysis	8	O
demonstrated	12	O
detectable	10	O
levels	6	O
of	2	O
c-jun	5	B-Gene
gene	4	I-Gene
transcription	13	O
in	2	O
untreated	9	O
HL-60	5	O
cells	5	O
,	1	O
and	3	O
that	4	O
exposure	8	O
to	2	O
TPA	3	B-Chemical
increases	9	O
this	4	O
rate	4	O
3.3-fold	8	O
.	1	O

Treatment	9	O
of	2	O
HL-60	5	O
cells	5	O
with	4	O
both	4	O
TPA	3	B-Chemical
and	3	O
cycloheximide	13	B-Chemical
had	3	O
no	2	O
effect	6	O
on	2	O
the	3	O
rates	5	O
of	2	O
c-jun	5	B-Gene
transcription	13	O
.	1	O

The	3	O
half-life	9	O
of	2	O
c-jun	5	B-Gene
RNA	3	I-Gene
as	2	O
determined	10	O
by	2	O
treating	8	O
HL-60	5	O
cells	5	O
with	4	O
TPA	3	B-Chemical
and	3	O
actinomycin	11	B-Chemical
D	1	I-Chemical
was	3	O
30	2	O
min	3	O
.	1	O

In	2	O
contrast	8	O
,	1	O
the	3	O
half-life	9	O
of	2	O
c-jun	5	B-Gene
RNA	3	I-Gene
in	2	O
TPA	3	B-Chemical
-treated	8	O
HL-60	5	O
cells	5	O
exposed	7	O
to	2	O
cycloheximide	13	B-Chemical
and	3	O
actinomycin	11	B-Chemical
D	1	I-Chemical
was	3	O
greater	7	O
than	4	O
2	1	O
h	1	O
.	1	O

These	5	O
findings	8	O
suggested	9	O
that	4	O
the	3	O
increase	8	O
in	2	O
c-jun	5	B-Gene
RNA	3	I-Gene
observed	8	O
during	6	O
TPA	3	B-Chemical
-induced	8	O
monocytic	9	O
differentiation	15	O
is	2	O
mediated	8	O
by	2	O
both	4	O
transcriptional	15	O
and	3	O
post-transcriptional	20	O
mechanisms	10	O
.	1	O

NF-kappa	8	B-Gene
B	1	I-Gene
as	2	O
inducible	9	O
transcriptional	15	O
activator	9	O
of	2	O
the	3	O
granulocyte-macrophage	22	B-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
gene	4	I-Gene
.	1	O

The	3	O
expression	10	O
of	2	O
the	3	O
gene	4	O
encoding	8	O
the	3	O
granulocyte-macrophage	22	B-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
(	1	O
GM-CSF	6	B-Gene
)	1	O
is	2	O
induced	7	O
upon	4	O
activation	10	O
of	2	O
T	1	O
cells	5	O
with	4	O
phytohemagglutinin	18	B-Gene
and	3	O
active	6	O
phorbolester	12	B-Chemical
and	3	O
upon	4	O
expression	10	O
of	2	O
tax1	4	B-Gene
,	1	O
a	1	O
transactivating	15	O
protein	7	O
of	2	O
the	3	O
human	5	O
T-cell	6	B-Disease
leukemia	8	I-Disease
virus	5	O
type	4	O
I	1	O
.	1	O

The	3	O
same	4	O
agents	6	O
induce	6	O
transcription	13	O
from	4	O
the	3	O
interleukin-2	13	B-Gene
receptor	8	I-Gene
alpha-chain	11	I-Gene
and	3	O
interleukin-2	13	B-Gene
genes	5	I-Gene
,	1	O
depending	9	O
on	2	O
promoter	8	O
elements	8	O
that	4	O
bind	4	O
the	3	O
inducible	9	O
transcription	13	B-Gene
factor	6	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
(	1	O
or	2	O
an	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
-like	5	O
factor	6	O
)	1	O
.	1	O

We	2	O
therefore	9	O
tested	6	O
the	3	O
possibility	11	O
that	4	O
the	3	O
GM-CSF	6	B-Gene
gene	4	I-Gene
is	2	O
also	4	O
regulated	9	O
by	2	O
a	1	O
cognate	7	O
motif	5	O
for	3	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
transcription	13	I-Gene
factor	6	I-Gene
.	1	O

A	1	O
recent	6	O
functional	10	O
analysis	8	O
by	2	O
Miyatake	8	O
et	2	O
al	2	O
.	1	O

(	1	O
S.	2	O
Miyatake	8	O
,	1	O
M.	2	O
Seiki	5	O
,	1	O
M.	2	O
Yoshida	7	O
,	1	O
and	3	O
K.	2	O
Arai	4	O
,	1	O
Mol.	4	O
Cell.	5	O
Biol.	5	O
8	1	O
:	1	O
5581-5587	9	O
,	1	O
1988	4	O
)	1	O
described	9	O
a	1	O
short	5	O
promoter	8	O
region	6	O
in	2	O
the	3	O
GM-CSF	6	B-Gene
gene	4	I-Gene
that	4	O
conferred	9	O
strong	6	O
inducibility	12	O
by	2	O
T-cell	6	O
-activating	11	O
signals	7	O
and	3	O
tax1	4	B-Gene
,	1	O
but	3	O
no	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
-binding	8	O
motifs	6	O
were	4	O
identified	10	O
.	1	O

Using	5	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assays	6	O
,	1	O
we	2	O
showed	6	O
binding	7	O
of	2	O
purified	8	O
human	5	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
and	3	O
of	2	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
activated	9	O
in	2	O
Jurkat	6	O
T	1	O
cells	5	O
to	2	O
an	2	O
oligonucleotide	15	O
comprising	10	O
the	3	O
GM-CSF	6	B-Gene
promoter	8	I-Gene
element	7	I-Gene
responsible	11	O
for	3	O
mediating	9	O
responsiveness	14	O
to	2	O
T-cell	6	O
-activating	11	O
signals	7	O
and	3	O
tax1	4	B-Gene
.	1	O

As	2	O
shown	5	O
by	2	O
a	1	O
methylation	11	O
interference	12	O
analysis	8	O
and	3	O
oligonucleotide	15	O
competition	11	O
experiments	11	O
,	1	O
purified	8	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
binds	5	O
at	2	O
positions	9	O
-82	3	O
to	2	O
-91	3	O
(	1	O
GGGAACTACC	10	O
)	1	O
of	2	O
the	3	O
GM-CSF	6	B-Gene
promoter	8	I-Gene
sequence	8	O
with	4	O
an	2	O
affinity	8	O
similar	7	O
to	2	O
that	4	O
with	4	O
which	5	O
it	2	O
binds	5	O
to	2	O
the	3	O
biologically	12	O
functional	10	O
kappa	5	O
B	1	O
motif	5	O
in	2	O
the	3	O
beta	4	B-Gene
interferon	10	I-Gene
promoter	8	I-Gene
(	1	O
GGGAAATTCC	10	O
)	1	O
.	1	O

Two	3	O
kappa	5	O
B	1	O
-like	5	O
motifs	6	O
at	2	O
positions	9	O
-98	3	O
to	2	O
-108	4	O
of	2	O
the	3	O
GM-CSF	6	B-Gene
promoter	8	I-Gene
were	4	O
also	4	O
recognized	10	O
but	3	O
with	4	O
much	4	O
lower	5	O
affinities	10	O
.	1	O

Our	3	O
data	4	O
provide	7	O
strong	6	O
evidence	8	O
that	4	O
the	3	O
expression	10	O
of	2	O
the	3	O
GM-CSF	6	B-Gene
gene	4	I-Gene
following	9	O
T-cell	6	O
activation	10	O
is	2	O
controlled	10	O
by	2	O
binding	7	O
of	2	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
transcription	13	I-Gene
factor	6	I-Gene
to	2	O
a	1	O
high-affinity	13	O
binding	7	O
site	4	O
in	2	O
the	3	O
GM-CSF	6	B-Gene
promoter	8	I-Gene
.	1	O

The	3	O
ubiquitous	10	B-Gene
octamer	7	I-Gene
-binding	8	I-Gene
protein	7	I-Gene
(	1	I-Gene
s	1	I-Gene
)	1	I-Gene
is	2	O
sufficient	10	O
for	3	O
transcription	13	O
of	2	O
immunoglobulin	14	B-Gene
genes	5	I-Gene
.	1	O

All	3	O
immunoglobulin	14	B-Gene
genes	5	I-Gene
contain	7	O
a	1	O
conserved	9	O
octanucleotide	14	O
promoter	8	O
element	7	O
,	1	O
ATGCAAAT	8	O
,	1	O
which	5	O
has	3	O
been	4	O
shown	5	O
to	2	O
be	2	O
required	8	O
for	3	O
their	5	O
normal	6	O
B-cell-specific	15	O
transcription	13	O
.	1	O

Proteins	8	O
that	4	O
bind	4	O
this	4	O
octamer	7	O
have	4	O
been	4	O
purified	8	O
,	1	O
and	3	O
cDNAs	5	O
encoding	8	O
octamer	7	B-Gene
-binding	8	I-Gene
proteins	8	I-Gene
have	4	O
been	4	O
cloned	6	O
.	1	O

Some	4	O
of	2	O
these	5	O
proteins	8	O
(	1	O
referred	8	O
to	2	O
as	2	O
OTF-2	5	B-Gene
)	1	O
are	3	O
lymphoid	8	O
specific	8	O
,	1	O
whereas	7	O
at	2	O
least	5	O
one	3	O
other	5	O
,	1	O
and	3	O
possibly	8	O
more	4	O
(	1	O
referred	8	O
to	2	O
as	2	O
OTF-1	5	B-Gene
)	1	O
,	1	O
is	2	O
found	5	O
ubiquitously	12	O
in	2	O
all	3	O
cell	4	O
types	5	O
.	1	O

The	3	O
exact	5	O
role	4	O
of	2	O
these	5	O
different	9	O
proteins	8	O
in	2	O
directing	9	O
the	3	O
tissue-specific	15	O
expression	10	O
of	2	O
immunoglobulin	14	B-Gene
genes	5	I-Gene
is	2	O
unclear	7	O
.	1	O

We	2	O
have	4	O
identified	10	O
two	3	O
human	5	O
pre-B-cell	10	O
lines	5	O
that	4	O
contain	7	O
extremely	9	O
low	3	O
levels	6	O
of	2	O
OTF-2	5	B-Gene
yet	3	O
still	5	O
express	7	O
high	4	O
levels	6	O
of	2	O
steady-state	12	O
immunoglobulin	14	B-Gene
heavy-chain	11	I-Gene
mRNA	4	I-Gene
in	2	O
vivo	4	O
and	3	O
efficiently	11	O
transcribe	10	O
an	2	O
immunoglobulin	14	B-Gene
gene	4	I-Gene
in	2	O
vitro	5	O
.	1	O

Addition	8	O
of	2	O
a	1	O
highly	6	O
enriched	8	O
preparation	11	O
of	2	O
OTF-1	5	B-Gene
made	4	O
from	4	O
one	3	O
of	2	O
these	5	O
pre-B	5	O
cells	5	O
or	2	O
from	4	O
HeLa	4	O
cells	5	O
specifically	12	O
stimulated	10	O
in	2	O
vitro	5	O
transcription	13	O
of	2	O
an	2	O
immunoglobulin	14	B-Gene
gene	4	I-Gene
.	1	O

Furthermore	11	O
,	1	O
OFT-1	5	B-Gene
appeared	8	O
to	2	O
have	4	O
approximately	13	O
the	3	O
same	4	O
transactivation	15	O
ability	7	O
as	2	O
OTF-2	5	B-Gene
when	4	O
normalized	10	O
for	3	O
binding	7	O
activity	8	O
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
OTF-1	5	B-Gene
,	1	O
without	7	O
OTF-2	5	B-Gene
,	1	O
is	2	O
sufficient	10	O
for	3	O
transcription	13	O
of	2	O
immunoglobulin	14	B-Gene
genes	5	I-Gene
and	3	O
that	4	O
OTF-2	5	B-Gene
alone	5	O
is	2	O
not	3	O
responsible	11	O
for	3	O
the	3	O
B-cell-specific	15	O
regulation	10	O
of	2	O
immunoglobulin	14	B-Gene
gene	4	I-Gene
expression	10	O
.	1	O

Perceived	9	O
social	6	O
support	7	O
and	3	O
tumor	5	B-Disease
estrogen	8	B-Gene
/	1	I-Gene
progesterone	12	I-Gene
receptor	8	I-Gene
status	6	O
as	2	O
predictors	10	O
of	2	O
natural	7	O
killer	6	O
cell	4	O
activity	8	O
in	2	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
.	1	O

This	4	O
report	6	O
is	2	O
concerned	9	O
with	4	O
the	3	O
prediction	10	O
of	2	O
natural	7	O
killer	6	O
(	1	O
NK	2	O
)	1	O
cell	4	O
activity	8	O
in	2	O
61	2	O
Stage	5	O
I	1	O
and	3	O
II	2	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
,	1	O
between	7	O
the	3	O
ages	4	O
of	2	O
25	2	O
and	3	O
70	2	O
,	1	O
who	3	O
were	4	O
accrued	7	O
to	2	O
this	4	O
project	7	O
.	1	O

All	3	O
baseline	8	O
interview	9	O
and	3	O
testing	7	O
data	4	O
were	4	O
obtained	8	O
either	6	O
just	4	O
before	6	O
patients	8	O
were	4	O
discharged	10	O
from	4	O
the	3	O
hospital	8	O
,	1	O
or	2	O
at	2	O
their	5	O
first	5	O
outpatient	10	O
visit	5	O
,	1	O
within	6	O
two	3	O
weeks	5	O
of	2	O
discharge	9	O
.	1	O

A	1	O
major	5	O
interest	8	O
of	2	O
this	4	O
project	7	O
is	2	O
the	3	O
predictive	10	O
value	5	O
of	2	O
perceived	9	O
social	6	O
support	7	O
,	1	O
as	2	O
a	1	O
potential	9	O
``	2	O
stress	6	O
''buffer	8	O
,	1	O
related	7	O
to	2	O
NK	2	O
activity	8	O
.	1	O

In	2	O
the	3	O
main	4	O
model	5	O
reported	8	O
here	4	O
,	1	O
we	2	O
found	5	O
that	4	O
a	1	O
significant	11	O
amount	6	O
of	2	O
NK	2	O
activity	8	O
variance	8	O
could	5	O
be	2	O
explained	9	O
by	2	O
five	4	O
variables	9	O
.	1	O

Higher	6	O
NK	2	O
activity	8	O
could	5	O
be	2	O
predicted	9	O
by	2	O
the	3	O
perception	10	O
of	2	O
high	4	O
quality	7	O
emotional	9	O
support	7	O
from	4	O
a	1	O
spouse	6	O
or	2	O
intimate	8	O
other	5	O
,	1	O
perceived	9	O
social	6	O
support	7	O
from	4	O
the	3	O
patient	7	O
's	2	O
physician	9	O
,	1	O
estrogen	8	B-Gene
receptor	8	I-Gene
-negative	9	O
tumor	5	B-Disease
status	6	O
,	1	O
having	6	O
an	2	O
excisional	10	O
biopsy	6	O
as	2	O
surgical	8	O
treatment	9	O
,	1	O
and	3	O
actively	8	O
seeking	7	O
social	6	O
support	7	O
as	2	O
a	1	O
major	5	O
coping	6	O
strategy	8	O
(	1	O
R2	2	O
=	1	O
0.33	4	O
,	1	O
F	1	O
(	1	O
5	1	O
,	1	O
55	2	O
)	1	O
=	1	O
5.5	3	O
,	1	O
p	1	O
less	4	O
than	4	O
0.0004	6	O
)	1	O
.	1	O

Findings	8	O
are	3	O
discussed	9	O
in	2	O
terms	5	O
of	2	O
host	4	O
interaction	11	O
with	4	O
tumor	5	B-Disease
endocrine	9	O
status	6	O
,	1	O
and	3	O
the	3	O
role	4	O
that	4	O
social	6	O
support	7	O
might	5	O
play	4	O
in	2	O
modulating	10	O
such	4	O
activity	8	O
.	1	O

Octamer	7	B-Gene
transcription	13	I-Gene
factors	7	I-Gene
and	3	O
the	3	O
cell	4	O
type-specificity	16	O
of	2	O
immunoglobulin	14	B-Gene
gene	4	I-Gene
expression	10	O
.	1	O

Antibodies	10	O
are	3	O
produced	8	O
exclusively	11	O
in	2	O
B	1	O
lymphocytes	11	O
.	1	O

The	3	O
expression	10	O
of	2	O
the	3	O
antibody	8	O
-encoding	9	O
genes	5	O
,	1	O
the	3	O
immunoglobulin	14	B-Gene
(	1	I-Gene
Ig	2	I-Gene
)	1	I-Gene
genes	5	I-Gene
,	1	O
is	2	O
also	4	O
restricted	10	O
to	2	O
B	1	O
cells	5	O
.	1	O

The	3	O
octamer	7	O
sequence	8	O
ATGCAAAT	8	O
is	2	O
present	7	O
in	2	O
the	3	O
promoter	8	O
and	3	O
the	3	O
enhancer	8	O
of	2	O
Ig	2	B-Gene
genes	5	I-Gene
,	1	O
and	3	O
plays	5	O
an	2	O
important	9	O
role	4	O
in	2	O
its	3	O
tissue-specific	15	O
expression	10	O
.	1	O

This	4	O
sequence	8	O
motif	5	O
is	2	O
a	1	O
binding	7	O
site	4	O
for	3	O
nuclear	7	O
proteins	8	O
,	1	O
the	3	O
so	2	O
-called	7	O
octamer	7	B-Gene
transcription	13	I-Gene
factors	7	I-Gene
(	1	O
Oct	3	B-Gene
or	2	O
OTF	3	B-Gene
factors	7	I-Gene
)	1	O
.	1	O

The	3	O
Oct-1	5	B-Gene
protein	7	I-Gene
is	2	O
present	7	O
in	2	O
all	3	O
cell	4	O
types	5	O
analyzed	8	O
so	2	O
far	3	O
,	1	O
whereas	7	O
Oct-2A	6	B-Gene
and	3	O
Oct-2B	6	B-Gene
are	3	O
found	5	O
mainly	6	O
in	2	O
B	1	O
lymphocytes	11	O
.	1	O

All	3	O
three	5	O
proteins	8	O
show	4	O
the	3	O
same	4	O
sequence	8	O
specificity	11	O
and	3	O
binding	7	O
affinity	8	O
.	1	O

It	2	O
appears	7	O
that	4	O
the	3	O
B	1	O
cell-specific	13	O
expression	10	O
of	2	O
Ig	2	B-Gene
genes	5	I-Gene
is	2	O
mediated	8	O
at	2	O
least	5	O
in	2	O
part	4	O
by	2	O
cell	4	O
type-specific	13	O
Oct	3	B-Gene
factors	7	I-Gene
,	1	O
and	3	O
that	4	O
there	5	O
are	3	O
both	4	O
quantitative	12	O
and	3	O
qualitative	11	O
differences	11	O
between	7	O
Oct-1	5	B-Gene
and	3	O
Oct-2	5	B-Gene
factors	7	I-Gene
.	1	O

Recently	8	O
,	1	O
a	1	O
number	6	O
of	2	O
other	5	O
octamer	7	O
factor	6	O
variants	8	O
were	4	O
identified	10	O
.	1	O

Many	4	O
of	2	O
these	5	O
may	3	O
be	2	O
created	7	O
by	2	O
alternative	11	O
splicing	8	O
of	2	O
a	1	O
primary	7	O
transcript	10	O
of	2	O
one	3	O
Oct	3	B-Gene
factor	6	I-Gene
gene	4	I-Gene
and	3	O
may	3	O
serve	5	O
a	1	O
specific	8	O
function	8	O
in	2	O
the	3	O
fine	4	O
tuning	6	O
of	2	O
gene	4	O
expression	10	O
.	1	O

Pseudohypoaldosteronism	23	B-Disease
in	2	O
eight	5	O
families	8	O
:	1	O
different	9	O
forms	5	O
of	2	O
inheritance	11	O
are	3	O
evidence	8	O
for	3	O
various	7	O
genetic	7	O
defects	7	O
.	1	O

Pseudohypoaldosteronism	23	B-Disease
is	2	O
a	1	O
rare	4	O
hereditary	10	O
disorder	8	O
presenting	10	O
in	2	O
early	5	O
infancy	7	O
with	4	O
renal	5	O
salt	4	O
loss	4	O
leading	7	O
to	2	O
hyponatremia	12	B-Disease
and	3	O
hyperkalemia	12	B-Disease
despite	7	O
high	4	O
levels	6	O
of	2	O
plasma	6	O
aldosterone	11	B-Chemical
.	1	O

The	3	O
patients	8	O
are	3	O
insensitive	11	O
to	2	O
mineralocorticoids	18	B-Chemical
;	1	O
however	7	O
,	1	O
sodium	6	B-Chemical
supplementation	15	O
is	2	O
able	4	O
to	2	O
correct	7	O
electrolyte	11	O
abnormalities	13	O
.	1	O

Absent	6	O
or	2	O
greatly	7	O
diminished	10	O
type	4	B-Gene
I	1	I-Gene
aldosterone	11	I-Gene
receptors	9	I-Gene
in	2	O
peripheral	10	O
mononuclear	11	O
leucocytes	10	O
have	4	O
been	4	O
recently	8	O
demonstrated	12	O
and	3	O
explain	7	O
the	3	O
lack	4	O
of	2	O
response	8	O
to	2	O
mineralocorticoids	18	B-Chemical
.	1	O

We	2	O
have	4	O
studied	7	O
the	3	O
mode	4	O
of	2	O
inheritance	11	O
in	2	O
eight	5	O
families	8	O
with	4	O
a	1	O
total	5	O
of	2	O
nine	4	O
patients	8	O
.	1	O

There	5	O
was	3	O
evidence	8	O
for	3	O
an	2	O
autosomal	9	O
recessive	9	O
form	4	O
of	2	O
inheritance	11	O
in	2	O
four	4	O
families	8	O
,	1	O
while	5	O
the	3	O
other	5	O
four	4	O
families	8	O
appeared	8	O
to	2	O
have	4	O
an	2	O
autosomal	9	O
dominant	8	O
mode	4	O
of	2	O
transmission	12	O
.	1	O

In	2	O
three	5	O
families	8	O
the	3	O
autosomal	9	O
recessive	9	O
form	4	O
was	3	O
characterized	13	O
by	2	O
normal	6	O
receptor	8	O
as	2	O
well	4	O
as	2	O
hormone	7	O
data	4	O
in	2	O
both	4	O
parents	7	O
,	1	O
while	5	O
in	2	O
one	3	O
family	6	O
receptor	8	O
levels	6	O
in	2	O
both	4	O
parents	7	O
were	4	O
greatly	7	O
reduced	7	O
,	1	O
but	3	O
hormone	7	O
levels	6	O
were	4	O
normal	6	O
.	1	O

In	2	O
the	3	O
four	4	O
families	8	O
with	4	O
an	2	O
autosomal	9	O
dominant	8	O
mode	4	O
of	2	O
transmission	12	O
there	5	O
was	3	O
always	6	O
one	3	O
parent	6	O
with	4	O
reduced	7	O
receptor	8	O
binding	7	O
in	2	O
peripheral	10	O
mononuclear	11	O
leucocytes	10	O
and	3	O
elevated	8	O
serum	5	O
hormone	7	O
levels	6	O
.	1	O

These	5	O
parents	7	O
were	4	O
entirely	8	O
asymptomatic	12	O
.	1	O

In	2	O
an	2	O
extended	8	O
family	6	O
we	2	O
were	4	O
able	4	O
to	2	O
study	5	O
an	2	O
aunt	4	O
and	3	O
her	3	O
newborn	7	O
daughter	8	O
,	1	O
who	3	O
were	4	O
both	4	O
also	4	O
biochemically	13	O
affected	8	O
but	3	O
clinically	10	O
asymptomatic	12	O
.	1	O

It	2	O
,	1	O
therefore	9	O
,	1	O
appears	7	O
that	4	O
this	4	O
dual	4	O
pattern	7	O
of	2	O
genetic	7	O
transmission	12	O
may	3	O
indicate	8	O
differing	9	O
genetic	7	O
defects	7	O
which	5	O
cause	5	O
the	3	O
same	4	O
clinical	8	O
picture	7	O
of	2	O
pseudohypoaldosteronism	23	B-Disease
.	1	O

Steroid	7	B-Chemical
mediated	8	O
lysis	5	O
of	2	O
lymphoblasts	12	O
requires	8	O
the	3	O
DNA	3	O
binding	7	O
region	6	O
of	2	O
the	3	O
steroid	7	B-Gene
hormone	7	I-Gene
receptor	8	I-Gene
.	1	O

Glucocorticoids	15	B-Chemical
kill	4	O
certain	7	O
types	5	O
of	2	O
lymphoblasts	12	O
,	1	O
but	3	O
the	3	O
mechanisms	10	O
are	3	O
unknown	7	O
.	1	O

It	2	O
is	2	O
clear	5	O
that	4	O
sufficient	10	O
numbers	7	O
of	2	O
functional	10	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
are	3	O
required	8	O
to	2	O
mediate	7	O
lysis	5	O
,	1	O
but	3	O
whether	7	O
they	4	O
do	2	O
so	2	O
through	7	O
the	3	O
classical	9	O
model	5	O
of	2	O
steroid	7	B-Chemical
hormone	7	I-Chemical
activation	10	O
and	3	O
modulation	10	O
of	2	O
gene	4	O
expression	10	O
has	3	O
not	3	O
been	4	O
established	11	O
.	1	O

In	2	O
this	4	O
report	6	O
we	2	O
have	4	O
asked	5	O
which	5	O
region	6	O
(	1	O
s	1	O
)	1	O
of	2	O
the	3	O
steroid	7	B-Gene
receptor	8	I-Gene
are	3	O
important	9	O
for	3	O
mediating	9	O
lysis	5	O
in	2	O
leukemic	8	O
T	1	O
lymphoblasts	12	O
.	1	O

CEM-ICR	7	O
27	2	O
leukemic	8	O
lymphoblasts	12	O
,	1	O
a	1	O
clone	5	O
of	2	O
CEM	3	O
cells	5	O
which	5	O
lack	4	O
functional	10	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
and	3	O
therefore	9	O
are	3	O
neither	7	O
lysed	5	O
by	2	O
dexamethasone	13	B-Chemical
nor	3	O
capable	7	O
of	2	O
showing	7	O
glutamine	9	B-Gene
synthetase	10	I-Gene
induction	9	O
,	1	O
were	4	O
provided	8	O
with	4	O
steroid	7	B-Gene
receptors	9	I-Gene
by	2	O
DNA	3	O
transfections	13	O
of	2	O
various	7	O
receptor	8	O
gene	4	O
constructs	10	O
.	1	O

We	2	O
measured	8	O
steroid	7	B-Chemical
mediated	8	O
lysis	5	O
,	1	O
receptor	8	O
number	6	O
and	3	O
induction	9	O
of	2	O
glutamine	9	B-Gene
synthetase	10	I-Gene
in	2	O
the	3	O
transfected	11	O
cells	5	O
.	1	O

Our	3	O
results	7	O
provide	7	O
evidence	8	O
that	4	O
the	3	O
lysis	5	O
mechanism	9	O
in	2	O
the	3	O
ICR27	5	O
lymphoblasts	12	O
is	2	O
restored	8	O
when	4	O
functional	10	O
receptor	8	O
number	6	O
is	2	O
restored	8	O
.	1	O

The	3	O
DNA	3	O
binding	7	O
region	6	O
specifying	10	O
high	4	O
affinity	8	O
for	3	O
GRE	3	O
sites	5	O
is	2	O
required	8	O
.	1	O

Lysis	5	O
is	2	O
mediated	8	O
by	2	O
any	3	O
steroid	7	B-Chemical
that	4	O
allows	6	O
for	3	O
activation	10	O
of	2	O
the	3	O
receptor	8	O
containing	10	O
such	4	O
a	1	O
region	6	O
.	1	O

Our	3	O
data	4	O
support	7	O
the	3	O
view	4	O
that	4	O
steroid	7	B-Chemical
-mediated	9	O
cell	4	O
death	5	O
occurs	6	O
by	2	O
a	1	O
process	7	O
requiring	9	O
direct	6	O
interaction	11	O
of	2	O
steroid-receptor	16	B-Gene
complexes	9	I-Gene
with	4	O
the	3	O
genome	6	O
.	1	O

Definition	10	O
of	2	O
T-cell	6	O
specific	8	O
DNA	3	O
-binding	8	O
factors	7	O
that	4	O
interact	8	O
with	4	O
a	1	O
3'-silencer	11	O
in	2	O
the	3	O
CD4+	4	B-Gene
T-cell	6	I-Gene
gene	4	I-Gene
Rpt-1	5	I-Gene
.	1	O

Analysis	8	O
of	2	O
the	3	O
region	6	O
3	1	O
'to	3	O
the	3	O
CD4+	4	B-Gene
T-cell	6	I-Gene
gene	4	I-Gene
Rpt-1	5	I-Gene
(	1	O
encoding	8	O
regulatory	10	B-Gene
protein	7	I-Gene
T-lymphocyte	12	I-Gene
1	1	I-Gene
)	1	O
led	3	O
to	2	O
the	3	O
definition	10	O
of	2	O
a	1	O
silencer	8	O
element	7	O
that	4	O
inhibits	8	O
heterologous	12	O
gene	4	O
expression	10	O
in	2	O
certain	7	O
CD4+	4	B-Gene
T-cell	6	O
lines	5	O
but	3	O
not	3	O
in	2	O
B-cell	6	O
or	2	O
non-lymphoid	12	O
cell	4	O
lines	5	O
.	1	O

Functional	10	O
silencer	8	O
activity	8	O
in	2	O
vivo	4	O
was	3	O
associated	10	O
with	4	O
the	3	O
presence	8	O
of	2	O
a	1	O
specific	8	O
silencer-DNA-protein	20	O
complex	7	O
in	2	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assays	6	O
with	4	O
T-cell	6	O
extracts	8	O
.	1	O

Formation	9	O
of	2	O
this	4	O
complex	7	O
was	3	O
selectively	11	O
inhibited	9	O
by	2	O
the	3	O
region	6	O
in	2	O
HIV-1	5	O
containing	10	O
a	1	O
silencer	8	O
element	7	O
.	1	O

We	2	O
discuss	7	O
the	3	O
possibility	11	O
that	4	O
DNA	3	O
-binding	8	O
factors	7	O
may	3	O
coregulate	10	O
HIV-1	5	O
and	3	O
Rpt-1	5	B-Gene
gene	4	I-Gene
expression	10	O
through	7	O
a	1	O
common	6	O
transcriptional	15	O
silencer	8	O
element	7	O
.	1	O

Constitutive	12	O
expression	10	O
of	2	O
HIV-1	5	B-Gene
tat	3	I-Gene
protein	7	I-Gene
in	2	O
human	5	O
Jurkat	6	O
T	1	O
cells	5	O
using	5	O
a	1	O
BK	2	O
virus	5	O
vector	6	O
.	1	O

The	3	O
production	10	O
and	3	O
characterization	16	O
of	2	O
Jurkat	6	O
cell	4	O
lines	5	O
that	4	O
constitutively	14	O
express	7	O
functional	10	O
human	5	B-Gene
immune	6	I-Gene
deficiency	10	I-Gene
virus	5	I-Gene
type	4	I-Gene
1	1	I-Gene
(	1	I-Gene
HIV-1	5	I-Gene
)	1	I-Gene
tat	3	I-Gene
protein	7	I-Gene
,	1	O
using	5	O
a	1	O
BK	2	O
virus	5	O
plasmid	7	O
expression	10	O
vector	6	O
and	3	O
HIV-1	5	B-Gene
tat	3	I-Gene
cDNA	4	I-Gene
,	1	O
is	2	O
described	9	O
.	1	O

An	2	O
increased	9	O
growth	6	O
rate	4	O
of	2	O
these	5	O
Jurkat-tat	10	O
cell	4	O
lines	5	O
as	2	O
compared	8	O
with	4	O
control	7	O
cell	4	O
lines	5	O
was	3	O
observed	8	O
.	1	O

Tax	3	B-Gene
-independent	12	O
binding	7	O
of	2	O
multiple	8	O
cellular	8	O
factors	7	O
to	2	O
Tax-response	12	B-Gene
element	7	I-Gene
DNA	3	I-Gene
of	2	O
HTLV-I	6	O
.	1	O

The	3	O
human	5	O
T-cell	6	O
leukemia	8	O
virus	5	O
type	4	O
I	1	O
(	1	O
HTLV-I	6	O
)	1	O
promoter	8	O
contains	8	O
three	5	O
copies	6	O
of	2	O
imperfect	9	O
repeats	7	O
of	2	O
a	1	O
21-base	7	O
pair	4	O
sequence	8	O
designated	10	O
here	4	O
as	2	O
TRE	3	O
(	1	O
Tax-response	12	B-Gene
element	7	I-Gene
)	1	O
that	4	O
is	2	O
responsive	10	O
to	2	O
the	3	O
virally	7	O
encoded	7	O
transactivator	14	B-Gene
protein	7	I-Gene
Tax	3	I-Gene
.	1	O

We	2	O
have	4	O
identified	10	O
and	3	O
separated	9	O
four	4	O
nuclear	7	O
proteins	8	O
from	4	O
C81-66-45	9	O
cells	5	O
,	1	O
an	2	O
HTLV-I	6	O
immortalized	12	O
Tax	3	B-Gene
-expressing	11	O
human	5	O
T-lymphocyte	12	O
line	4	O
(	1	O
Salahuddin	10	O
et	2	O
al.	3	O
,	1	O
1983	4	O
)	1	O
,	1	O
that	4	O
interact	8	O
with	4	O
the	3	O
TRE-DNA	7	O
,	1	O
none	4	O
of	2	O
which	5	O
are	3	O
identical	9	O
with	4	O
the	3	O
Tax-protein	11	B-Gene
.	1	O

The	3	O
proteins	8	O
identified	10	O
have	4	O
molecular	9	O
weights	7	O
of	2	O
about	5	O
32	2	O
,	1	O
36	2	O
to	2	O
42	2	O
,	1	O
50	2	O
and	3	O
110	3	O
kD	2	O
.	1	O

Four	4	O
different	9	O
methods	7	O
were	4	O
used	4	O
to	2	O
identify	8	O
the	3	O
proteins	8	O
.	1	O

First	5	O
,	1	O
from	4	O
different	9	O
cell	4	O
lines	5	O
three	5	O
or	2	O
all	3	O
four	4	O
of	2	O
the	3	O
nuclear	7	O
proteins	8	O
were	4	O
specifically	12	O
cross	5	O
-linked	7	O
by	2	O
UV	2	O
irradiation	11	O
to	2	O
the	3	O
radioactively	13	O
labeled	7	O
TRE-DNA	7	B-Gene
fragment	8	O
.	1	O

Second	6	O
,	1	O
TRE-DNA	7	O
binding	7	O
proteins	8	O
sedimented	10	O
through	7	O
a	1	O
glycerol	8	B-Chemical
density	7	O
gradient	8	O
at	2	O
rates	5	O
corresponding	13	O
to	2	O
proteins	8	O
of	2	O
native	6	O
molecular	9	O
weights	7	O
of	2	O
35	2	O
to	2	O
50	2	O
kD	2	O
and	3	O
110	3	O
kD	2	O
.	1	O

Third	5	O
,	1	O
only	4	O
the	3	O
50	2	O
kD	2	O
protein	7	O
was	3	O
retained	8	O
on	2	O
a	1	O
biotinylated	12	B-Gene
DNA-streptavidin	16	I-Gene
matrix	6	I-Gene
when	4	O
the	3	O
DNA	3	O
fragment	8	O
contained	9	O
the	3	O
TRE-DNA	7	O
.	1	O

Fourth	6	O
,	1	O
extensive	9	O
purification	12	O
by	2	O
several	7	O
cycles	6	O
of	2	O
TRE	3	O
-DNA	4	O
affinity	8	O
chromatography	14	O
resulted	8	O
in	2	O
the	3	O
32	2	O
,	1	O
36	2	O
to	2	O
42	2	O
and	3	O
110	3	O
kD	2	O
proteins	8	O
and	3	O
to	2	O
less	4	O
extent	6	O
the	3	O
50	2	O
kD	2	O
factor	6	O
.	1	O

Two	3	O
abundant	8	O
proteins	8	O
of	2	O
75	2	O
and	3	O
80	2	O
kD	2	O
were	4	O
competed	8	O
out	3	O
by	2	O
poly	4	B-Chemical
[	1	I-Chemical
d	1	I-Chemical
(	1	I-Chemical
I-C	3	I-Chemical
)	1	I-Chemical
]	1	I-Chemical
in	2	O
all	3	O
reactions	9	O
.	1	O

The	3	O
cAMP-response	13	B-Chemical
element	7	O
CRE	3	O
,	1	O
TGACGTCA	8	O
,	1	O
present	7	O
in	2	O
the	3	O
21	2	O
base-pair	9	O
sequence	8	O
,	1	O
appears	7	O
to	2	O
be	2	O
essential	9	O
for	3	O
specific	8	O
protein-	8	O
TRE	3	O
-DNA	4	O
interactions	12	O
because	7	O
mutation	8	O
of	2	O
the	3	O
two	3	O
G	1	O
's	2	O
destroys	8	O
this	4	O
complex	7	O
.	1	O

This	4	O
result	6	O
suggests	8	O
that	4	O
the	3	O
cAMP	4	B-Gene
response	8	I-Gene
element	7	I-Gene
binding	7	I-Gene
protein	7	I-Gene
,	1	O
CREB	4	B-Gene
,	1	O
is	2	O
involved	8	O
in	2	O
the	3	O
protein-TRE-DNA	15	O
complex	7	O
and	3	O
in	2	O
mediating	9	O
the	3	O
Tax	3	B-Gene
response	8	O
.	1	O

[	1	O
1	1	B-Gene
,	1	I-Gene
25-Dihydroxyvitamin	19	I-Gene
D3	2	I-Gene
receptors	9	I-Gene
in	2	O
lymphocytes	11	O
and	3	O
T-	2	O
and	3	O
B-lymphocyte	12	O
count	5	O
in	2	O
patients	8	O
with	4	O
glomerulonephritis	18	B-Disease
]	1	O

Content	7	O
of	2	O
receptors	9	O
to	2	O
hormonal	8	O
form	4	O
of	2	O
vitamin	7	B-Chemical
D3	2	I-Chemical
,	1	O
1.25	4	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
,	1	O
constituted	11	O
27.3	4	O
fmole	5	O
/	1	O
mg	2	O
of	2	O
protein	7	O
in	2	O
lymphocytes	11	O
of	2	O
peripheric	10	O
blood	5	O
of	2	O
children	8	O
with	4	O
glomerulonephritis	18	B-Disease
.	1	O

In	2	O
the	3	O
patients	8	O
concentration	13	O
of	2	O
total	5	O
and	3	O
ionized	7	O
form	4	O
of	2	O
Ca2+	4	O
was	3	O
decreased	9	O
down	4	O
to	2	O
2.04	4	O
mmole	5	O
/	1	O
L	1	O
and	3	O
1.09	4	O
mmole	5	O
/	1	O
L	1	O
,	1	O
respectively	12	O
,	1	O
while	5	O
an	2	O
increase	8	O
in	2	O
parathormone	12	B-Gene
(	1	O
PTH	3	B-Gene
)	1	O
by	2	O
36	2	O
%	1	O
and	3	O
a	1	O
distinct	8	O
decrease	8	O
in	2	O
25	2	O
(	1	O
OH	2	O
)	1	O
D	1	O
concentration	13	O
(	1	O
lower	5	O
than	4	O
1.25	4	O
ng	2	O
/	1	O
ml	2	O
)	1	O
was	3	O
found	5	O
in	2	O
blood	5	O
;	1	O
content	7	O
of	2	O
cAMP	4	B-Chemical
was	3	O
also	4	O
decreased	9	O
in	2	O
lymphocytes	11	O
by	2	O
33	2	O
%	1	O
.	1	O

At	2	O
the	3	O
same	4	O
time	4	O
,	1	O
total	5	O
content	7	O
of	2	O
T	1	O
lymphocytes	11	O
was	3	O
decreased	9	O
1.5-fold	8	O
in	2	O
peripheric	10	O
blood	5	O
.	1	O

Treatment	9	O
with	4	O
I-hydroxyvitamin	16	B-Chemical
D3	2	I-Chemical
(	1	O
1-1.5	5	O
mg	2	O
daily	5	O
,	1	O
within	6	O
4	1	O
weeks	5	O
)	1	O
led	3	O
to	2	O
normalization	13	O
of	2	O
total	5	O
and	3	O
ionized	7	O
form	4	O
of	2	O
Ca2+	4	O
and	3	O
of	2	O
25	2	O
(	1	O
OH	2	O
)	1	O
D	1	O
,	1	O
but	3	O
did	3	O
not	3	O
affect	6	O
the	3	O
PTH	3	B-Gene
content	7	O
in	2	O
blood	5	O
.	1	O

Concentration	13	O
of	2	O
the	3	O
receptors	9	O
to	2	O
1.25	4	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
was	3	O
elevated	8	O
up	2	O
to	2	O
39.7	4	O
fmole	5	O
/	1	O
mg	2	O
after	5	O
I	1	O
week	4	O
of	2	O
the	3	O
treatment	9	O
,	1	O
whereas	7	O
it	2	O
was	3	O
decreased	9	O
to	2	O
the	3	O
initial	7	O
level	5	O
24.8	4	O
fmole	5	O
/	1	O
mg	2	O
within	6	O
4	1	O
weeks	5	O
;	1	O
simultaneous	12	O
alteration	10	O
in	2	O
the	3	O
cAMP	4	B-Chemical
content	7	O
was	3	O
observed	8	O
in	2	O
lymphocytes	11	O
.	1	O

Treatment	9	O
with	4	O
1-	2	O
(	1	O
OH	2	O
)	1	O
D3	2	O
normalized	10	O
also	4	O
the	3	O
T	1	O
lymphocytes	11	O
content	7	O
in	2	O
peripheric	10	O
blood	5	O
.	1	O

The	3	O
data	4	O
obtained	8	O
suggest	7	O
that	4	O
under	5	O
conditions	10	O
of	2	O
glomerulonephritis	18	B-Disease
only	4	O
high	4	O
content	7	O
of	2	O
receptors	9	O
to	2	O
1.25	4	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
in	2	O
lymphocytes	11	O
enabled	7	O
to	2	O
perform	7	O
the	3	O
cell	4	O
response	8	O
to	2	O
the	3	O
hormone	7	O
effect	6	O
.	1	O

Risk	4	O
factors	7	O
for	3	O
breast	6	O
recurrence	10	O
in	2	O
premenopausal	13	O
and	3	O
postmenopausal	14	O
patients	8	O
with	4	O
ductal	6	O
cancers	7	B-Disease
treated	7	O
by	2	O
conservation	12	O
therapy	7	O
.	1	O

Risk	4	O
factors	7	O
for	3	O
local	5	O
failure	7	O
were	4	O
evaluated	9	O
for	3	O
496	3	O
clinical	8	O
Stage	5	O
I-II	4	O
patients	8	O
with	4	O
infiltrating	12	O
ductal	6	B-Disease
carcinomas	10	I-Disease
(	1	O
median	6	O
follow-up	9	O
,	1	O
71	2	O
months	6	O
)	1	O
treated	7	O
by	2	O
conservative	12	O
surgery	7	O
and	3	O
radiotherapy	12	O
.	1	O

Monofactorial	13	O
analysis	8	O
identified	10	O
the	3	O
following	9	O
factors	7	O
to	2	O
be	2	O
correlated	10	O
with	4	O
increased	9	O
risk	4	O
:	1	O
moderate	8	O
/	1	O
marked	6	O
mononuclear	11	O
cell	4	O
reaction	8	O
(	1	O
MCR	3	O
)	1	O
,	1	O
high	4	O
histologic	10	O
grade	5	O
(	1	O
G	1	O
)	1	O
,	1	O
extensive	9	O
intraductal	11	O
component	9	O
(	1	O
EIC	3	O
)	1	O
,	1	O
tumor	5	B-Disease
necrosis	8	O
,	1	O
macroscopic	11	O
multiplicity	12	O
,	1	O
estrogen	8	B-Gene
receptor	8	I-Gene
negativity	10	O
,	1	O
anatomic	8	O
tumor	5	B-Disease
size	4	O
,	1	O
age	3	O
younger	7	O
than	4	O
40	2	O
years	5	O
,	1	O
and	3	O
vascular	8	O
invasion	8	O
.	1	O

Only	4	O
MCR	3	O
,	1	O
G	1	O
,	1	O
and	3	O
EIC	3	O
proved	6	O
significant	11	O
in	2	O
Cox	3	O
multivariate	12	O
analysis	8	O
.	1	O

These	5	O
risk	4	O
factors	7	O
were	4	O
highly	6	O
age	3	O
dependent	9	O
,	1	O
with	4	O
EIC	3	O
markedly	8	O
more	4	O
prevalent	9	O
in	2	O
women	5	O
younger	7	O
than	4	O
50	2	O
,	1	O
MCR	3	O
and	3	O
G	1	O
in	2	O
women	5	O
younger	7	O
than	4	O
40	2	O
.	1	O

Separate	8	O
Cox	3	O
analysis	8	O
for	3	O
premenopausal	13	O
patients	8	O
showed	6	O
that	4	O
MCR	3	O
/	1	O
EIC	3	O
determined	10	O
risk	4	O
independent	11	O
of	2	O
resection	9	O
margins	7	O
:	1	O
tumors	6	B-Disease
with	4	O
MCR	3	O
had	3	O
a	1	O
28	2	O
%	1	O
,	1	O
and	3	O
with	4	O
EIC	3	O
a	1	O
22	2	O
%	1	O
probability	11	O
of	2	O
recurring	9	O
locally	7	O
by	2	O
5	1	O
years	5	O
.	1	O

Premenopausal	13	O
patients	8	O
with	4	O
neither	7	O
risk	4	O
factor	6	O
had	3	O
a	1	O
very	4	O
low	3	O
failure	7	O
rate	4	O
(	1	O
2.6	3	O
%	1	O
at	2	O
5	1	O
years	5	O
)	1	O
,	1	O
regardless	10	O
of	2	O
age	3	O
.	1	O

For	3	O
postmenopausal	14	O
patients	8	O
risk	4	O
of	2	O
breast	6	O
recurrence	10	O
was	3	O
determined	10	O
both	4	O
by	2	O
adequacy	8	O
of	2	O
resection	9	O
margins	7	O
and	3	O
grade	5	O
,	1	O
with	4	O
a	1	O
high	4	O
local	5	O
failure	7	O
rate	4	O
for	3	O
patients	8	O
having	6	O
G3	2	O
tumors	6	B-Disease
with	4	O
positive	8	O
or	2	O
indeterminate	13	O
margins	7	O
(	1	O
31	2	O
%	1	O
at	2	O
5	1	O
years	5	O
)	1	O
.	1	O

The	3	O
authors	7	O
conclude	8	O
that	4	O
the	3	O
microscopic	11	O
examination	11	O
is	2	O
the	3	O
only	4	O
useful	6	O
tool	4	O
for	3	O
assessing	9	O
the	3	O
risk	4	O
of	2	O
local	5	O
failure	7	O
,	1	O
which	5	O
is	2	O
quite	5	O
low	3	O
for	3	O
the	3	O
majority	8	O
of	2	O
patients	8	O
treated	7	O
with	4	O
breast	6	O
conservation	12	O
.	1	O

High-risk	9	O
patients	8	O
can	3	O
be	2	O
recognized	10	O
morphologically	15	O
.	1	O

The	3	O
age	3	O
dependence	10	O
of	2	O
morphologic	11	O
risk	4	O
factors	7	O
appears	7	O
to	2	O
explain	7	O
the	3	O
high	4	O
local	5	O
failure	7	O
rate	4	O
seen	4	O
in	2	O
patients	8	O
younger	7	O
than	4	O
40	2	O
.	1	O

Effects	7	O
of	2	O
aldosterone	11	B-Chemical
on	2	O
intralymphocytic	16	O
sodium	6	B-Chemical
and	3	O
potassium	9	B-Chemical
in	2	O
patients	8	O
with	4	O
essential	9	O
hypertension	12	B-Disease
.	1	O

In	2	O
vitro	5	O
binding	7	O
of	2	O
aldosterone	11	B-Chemical
to	2	O
mineralocorticoid	17	B-Gene
receptors	9	I-Gene
on	2	O
human	5	O
mononuclear	11	O
leukocytes	10	O
(	1	O
HML	3	O
)	1	O
and	3	O
its	3	O
effects	7	O
on	2	O
the	3	O
intracellular	13	O
sodium	6	B-Chemical
and	3	O
potassium	9	B-Chemical
concentrations	14	O
of	2	O
HML	3	O
have	4	O
already	7	O
been	4	O
described	9	O
.	1	O

In	2	O
the	3	O
present	7	O
paper	5	O
this	4	O
easily	6	O
accessible	10	O
human	5	O
cell	4	O
model	5	O
was	3	O
investigated	12	O
in	2	O
13	2	O
patients	8	O
with	4	O
essential	9	O
hypertension	12	B-Disease
.	1	O

In	2	O
only	4	O
four	4	O
patients	8	O
sodium	6	B-Chemical
in	2	O
HML	3	O
without	7	O
incubation	10	O
was	3	O
elevated	8	O
compared	8	O
with	4	O
the	3	O
range	5	O
for	3	O
normal	6	O
persons	7	O
.	1	O

A	1	O
decrease	8	O
of	2	O
intracellular	13	O
sodium	6	B-Chemical
or	2	O
potassium	9	B-Chemical
occurred	8	O
during	6	O
incubation	10	O
without	7	O
aldosterone	11	B-Chemical
(	1	O
P	1	O
less	4	O
than	4	O
0.02	4	O
)	1	O
.	1	O

The	3	O
addition	8	O
of	2	O
1.4	3	O
nM	2	O
aldosterone	11	B-Chemical
did	3	O
not	3	O
prevent	7	O
this	4	O
loss	4	O
of	2	O
electrolytes	12	O
as	2	O
observed	8	O
in	2	O
normal	6	O
persons	7	O
.	1	O

Plasma	6	B-Gene
renin	5	I-Gene
activity	8	O
and	3	O
aldosterone	11	B-Chemical
were	4	O
not	3	O
correlated	10	O
with	4	O
the	3	O
electrolyte	11	O
response	8	O
and	3	O
were	4	O
within	6	O
the	3	O
normal	6	O
limits	6	O
.	1	O

The	3	O
number	6	O
of	2	O
mineralocorticoid	17	B-Gene
receptors	9	I-Gene
/	1	O
cell	4	O
were	4	O
within	6	O
or	2	O
close	5	O
to	2	O
the	3	O
normal	6	O
range	5	O
(	1	O
n	1	O
=	1	O
9	1	O
)	1	O
.	1	O

The	3	O
independence	12	O
of	2	O
intracellular	13	O
electrolytes	12	O
from	4	O
aldosterone	11	B-Chemical
despite	7	O
a	1	O
normal	6	O
number	6	O
of	2	O
mineralocorticoid	17	B-Gene
receptors	9	I-Gene
may	3	O
reflect	7	O
an	2	O
impairment	10	O
of	2	O
the	3	O
mineralocorticoid	17	B-Chemical
effector	8	O
mechanism	9	O
in	2	O
the	3	O
HML	3	O
of	2	O
patients	8	O
with	4	O
essential	9	O
hypertension	12	B-Disease
.	1	O

Megakaryocytic	14	O
and	3	O
erythrocytic	12	O
lineages	8	O
share	5	O
specific	8	O
transcription	13	O
factors	7	O
.	1	O

Erythroid-specific	18	O
genes	5	O
contain	7	O
binding	7	O
sites	5	O
for	3	O
NF-E1	5	B-Gene
(	1	O
also	4	O
called	6	O
GF-1	4	B-Gene
and	3	O
Eryf-1	6	B-Gene
;	1	O
refs	4	O
1-3	3	O
respectively	12	O
)	1	O
,	1	O
the	3	O
principal	9	O
DNA	3	O
-binding	8	O
protein	7	O
of	2	O
the	3	O
erythrocytic	12	O
lineage	7	O
.	1	O

NF-E1	5	B-Gene
expression	10	O
seems	5	O
to	2	O
be	2	O
restricted	10	O
to	2	O
the	3	O
erythrocytic	12	O
lineage	7	O
.	1	O

A	1	O
closely	7	O
related	7	O
(	1	O
if	2	O
not	3	O
identical	9	O
)	1	O
protein	7	O
is	2	O
found	5	O
in	2	O
both	4	O
a	1	O
human	5	O
megakaryocytic	14	O
cell	4	O
line	4	O
and	3	O
purified	8	O
human	5	O
megakaryocytes	14	O
;	1	O
it	2	O
binds	5	O
to	2	O
promoter	8	O
regions	7	O
of	2	O
two	3	O
megakaryocytic-specific	23	O
genes	5	O
.	1	O

The	3	O
binding	7	O
sites	5	O
and	3	O
partial	7	O
proteolysis	11	O
profile	7	O
of	2	O
this	4	O
protein	7	O
are	3	O
indistinguishable	17	O
from	4	O
those	5	O
of	2	O
the	3	O
erythroid	9	O
protein	7	O
;	1	O
also	4	O
,	1	O
NF-E1	5	B-Gene
messenger	9	I-Gene
RNA	3	I-Gene
is	2	O
the	3	O
same	4	O
size	4	O
in	2	O
both	4	O
the	3	O
megakaryocytic	14	O
and	3	O
erythroid	9	O
cell	4	O
lines	5	O
.	1	O

Furthermore	11	O
,	1	O
point	5	O
mutations	9	O
that	4	O
abolish	7	O
binding	7	O
of	2	O
NF-E1	5	B-Gene
result	6	O
in	2	O
a	1	O
70	2	O
%	1	O
decrease	8	O
in	2	O
the	3	O
transcriptional	15	O
activity	8	O
of	2	O
a	1	O
megakaryocytic-specific	23	O
promoter	8	O
.	1	O

We	2	O
also	4	O
find	4	O
that	4	O
NF-E2	5	B-Gene
,	1	O
another	7	O
trans	5	O
-acting	7	O
factor	6	O
of	2	O
the	3	O
erythrocytic	12	O
lineage	7	O
,	1	O
is	2	O
present	7	O
in	2	O
megakaryocytes	14	O
.	1	O

Transcriptional	15	O
effects	7	O
in	2	O
both	4	O
lineages	8	O
might	5	O
then	4	O
be	2	O
mediated	8	O
in	2	O
part	4	O
by	2	O
the	3	O
same	4	O
specific	8	O
trans	5	O
-acting	7	O
factors	7	O
.	1	O

Our	3	O
data	4	O
strengthen	10	O
the	3	O
idea	4	O
of	2	O
a	1	O
close	5	O
association	11	O
between	7	O
the	3	O
erythrocytic	12	O
and	3	O
the	3	O
megakaryocytic	14	O
lineages	8	O
and	3	O
could	5	O
also	4	O
explain	7	O
the	3	O
expression	10	O
of	2	O
markers	7	O
specific	8	O
to	2	O
the	3	O
erythrocytic	12	O
and	3	O
megakaryocytic	14	O
lineages	8	O
in	2	O
most	4	O
erythroblastic	14	O
and	3	O
megakaryoblastic	16	O
permanent	9	O
cell	4	O
lines	5	O
.	1	O

A	1	O
new	3	O
member	6	O
of	2	O
the	3	O
leucine	7	B-Chemical
zipper	6	O
class	5	O
of	2	O
proteins	8	O
that	4	O
binds	5	O
to	2	O
the	3	O
HLA	3	B-Gene
DR	2	I-Gene
alpha	5	I-Gene
promoter	8	I-Gene
.	1	O

Several	7	O
mutants	7	O
derived	7	O
from	4	O
transformed	11	O
human	5	O
B	1	O
cell	4	O
lines	5	O
are	3	O
defective	9	O
in	2	O
expressing	10	O
major	5	B-Gene
histocompatibility	18	I-Gene
complex	7	I-Gene
(	1	I-Gene
MHC	3	I-Gene
)	1	I-Gene
class	5	I-Gene
II	2	I-Gene
genes	5	I-Gene
.	1	O

The	3	O
failure	7	O
to	2	O
express	7	O
a	1	O
class	5	O
II	2	O
gene	4	O
in	2	O
at	2	O
least	5	O
one	3	O
such	4	O
mutant	6	O
line	4	O
has	3	O
been	4	O
mapped	6	O
to	2	O
the	3	O
MHC	3	B-Gene
class	5	I-Gene
II	2	I-Gene
X	1	O
box	3	O
,	1	O
a	1	O
conserved	9	O
transcriptional	15	O
element	7	O
in	2	O
the	3	O
promoter	8	O
region	6	O
.	1	O

A	1	O
complementary	13	O
DNA	3	O
encoding	8	O
a	1	O
DNA	3	O
-binding	8	O
protein	7	O
(	1	O
human	5	B-Gene
X	1	I-Gene
box	3	I-Gene
binding	7	I-Gene
protein	7	I-Gene
,	1	O
hXBP-1	6	B-Gene
)	1	O
whose	5	O
target	6	O
is	2	O
the	3	O
human	5	O
DR	2	O
alpha	5	O
X	1	O
box	3	O
and	3	O
the	3	O
3	1	O
'flanking	9	O
region	6	O
has	3	O
now	3	O
been	4	O
cloned	6	O
.	1	O

This	4	O
complementary	13	O
DNA	3	O
encoded	7	O
a	1	O
protein	7	O
with	4	O
structural	10	O
similarities	12	O
to	2	O
the	3	O
c-jun	5	B-Gene
proto-oncogene	14	I-Gene
product	7	I-Gene
,	1	O
and	3	O
its	3	O
target	6	O
sequence	8	O
was	3	O
closely	7	O
related	7	O
to	2	O
the	3	O
palindromic	11	O
target	6	O
sequence	8	O
of	2	O
c-jun	5	B-Gene
.	1	O

Mutation	8	O
of	2	O
the	3	O
hXBP-1	6	B-Gene
DNA	3	I-Gene
target	6	O
sequence	8	O
decreased	9	O
DR	2	B-Gene
alpha	5	I-Gene
promoter	8	I-Gene
activity	8	O
in	2	O
vivo	4	O
.	1	O

These	5	O
studies	7	O
suggest	7	O
that	4	O
the	3	O
hXBP-1	6	B-Gene
protein	7	I-Gene
acts	4	O
as	2	O
a	1	O
transcription	13	O
factor	6	O
in	2	O
B	1	O
cells	5	O
.	1	O

Identification	14	O
of	2	O
a	1	O
novel	5	O
factor	6	O
that	4	O
interacts	9	O
with	4	O
an	2	O
immunoglobulin	14	B-Gene
heavy-chain	11	I-Gene
promoter	8	I-Gene
and	3	O
stimulates	10	O
transcription	13	O
in	2	O
conjunction	11	O
with	4	O
the	3	O
lymphoid	8	B-Gene
cell-specific	13	I-Gene
factor	6	I-Gene
OTF2	4	I-Gene
.	1	O

The	3	O
tissue-specific	15	O
expression	10	O
of	2	O
the	3	O
MOPC	4	O
141	3	O
immunoglobulin	14	B-Gene
heavy-chain	11	I-Gene
gene	4	I-Gene
was	3	O
studied	7	O
by	2	O
using	5	O
in	2	O
vitro	5	O
transcription	13	O
.	1	O

B-cell-specific	15	O
transcription	13	O
of	2	O
this	4	O
gene	4	O
was	3	O
dependent	9	O
on	2	O
the	3	O
octamer	7	O
element	7	O
5'-ATGCAAAG-3',	15	O
located	7	O
in	2	O
the	3	O
upstream	8	O
region	6	O
of	2	O
this	4	O
promoter	8	O
and	3	O
in	2	O
the	3	O
promoters	9	O
of	2	O
all	3	O
other	5	O
immunoglobulin	14	B-Gene
heavy-	6	I-Gene
and	3	O
light-chain	11	B-Partial_Gene
genes	5	I-Partial_Gene
.	1	O

The	3	O
interaction	11	O
of	2	O
purified	8	O
octamer	7	B-Gene
transcription	13	I-Gene
factors	7	I-Gene
1	1	I-Gene
and	3	O
2	1	B-Partial_Gene
(	1	O
OTF1	4	B-Gene
and	3	O
OTF2	4	B-Gene
)	1	O
with	4	O
the	3	O
MOPC	4	O
141	3	O
promoter	8	O
was	3	O
studied	7	O
by	2	O
using	5	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assays	6	O
and	3	O
DNase	5	O
I	1	O
footprinting	12	O
.	1	O

Purified	8	B-Gene
OTF1	4	I-Gene
from	4	O
HeLa	4	O
cells	5	O
and	3	O
OTF1	4	B-Gene
and	3	O
OTF2	4	B-Gene
from	4	O
B	1	O
cells	5	O
bound	5	O
to	2	O
identical	9	O
sequences	9	O
within	6	O
the	3	O
heavy-chain	11	O
promoter	8	O
.	1	O

The	3	O
OTF	3	B-Gene
interactions	12	O
we	2	O
observed	8	O
extended	8	O
over	4	O
the	3	O
heptamer	8	O
element	7	O
5'-CTCAGGA-3',	14	O
and	3	O
it	2	O
seems	5	O
likely	6	O
that	4	O
the	3	O
binding	7	O
of	2	O
the	3	O
purified	8	O
factors	7	O
involves	8	O
cooperation	11	O
between	7	O
octamer	7	O
and	3	O
heptamer	8	O
sites	5	O
in	2	O
this	4	O
promoter	8	O
.	1	O

In	2	O
addition	8	O
to	2	O
these	5	O
elements	8	O
,	1	O
we	2	O
identified	10	O
a	1	O
second	6	O
regulatory	10	O
element	7	O
,	1	O
the	3	O
N	1	O
element	7	O
with	4	O
the	3	O
sequence	8	O
5'-GGAACCTCCCCC-3'	18	O
.	1	O

The	3	O
N	1	O
element	7	O
could	5	O
independently	13	O
mediate	7	O
low	3	O
levels	6	O
of	2	O
transcription	13	O
in	2	O
both	4	O
B-cell	6	O
and	3	O
HeLa-cell	9	O
extracts	8	O
,	1	O
and	3	O
,	1	O
in	2	O
conjunction	11	O
with	4	O
the	3	O
octamer	7	O
element	7	O
,	1	O
it	2	O
can	3	O
promote	7	O
high	4	O
levels	6	O
of	2	O
transcription	13	O
in	2	O
B-cell	6	O
extracts	8	O
.	1	O

The	3	O
N	1	O
element	7	O
bound	5	O
a	1	O
transcription	13	O
factor	6	O
,	1	O
NTF	3	B-Gene
,	1	O
that	4	O
is	2	O
ubiquitous	10	O
in	2	O
cell-type	9	O
distribution	12	O
,	1	O
and	3	O
NTF	3	B-Gene
was	3	O
distinct	8	O
from	4	O
any	3	O
of	2	O
the	3	O
previously	10	O
described	9	O
proteins	8	O
that	4	O
bind	4	O
to	2	O
similar	7	O
sequences	9	O
.	1	O

Based	5	O
on	2	O
these	5	O
results	7	O
,	1	O
we	2	O
propose	7	O
that	4	O
NTF	3	B-Gene
and	3	O
OTF2	4	B-Gene
interactions	12	O
(	1	O
both	4	O
with	4	O
their	5	O
cognate	7	O
DNA	3	O
elements	8	O
and	3	O
possibly	8	O
at	2	O
the	3	O
protein-protein	15	O
level	5	O
)	1	O
may	3	O
be	2	O
critical	8	O
to	2	O
B-cell-specific	15	O
expression	10	O
and	3	O
that	4	O
these	5	O
interactions	12	O
provide	7	O
additional	10	O
pathways	8	O
for	3	O
regulating	10	O
gene	4	O
expression	10	O
.	1	O

Effects	7	O
of	2	O
1	1	B-Chemical
alpha	5	I-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
on	2	O
the	3	O
human	5	O
chronic	7	B-Disease
myelogenous	11	I-Disease
leukemia	8	I-Disease
cell	4	O
line	4	O
RWLeu-4	7	O
.	1	O

The	3	O
effects	7	O
of	2	O
1	1	B-Chemical
alpha	5	I-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
(	1	O
VD3	3	B-Chemical
)	1	O
on	2	O
proliferation	13	O
,	1	O
differentiation	15	O
,	1	O
and	3	O
macromolecular	14	O
synthesis	9	O
in	2	O
the	3	O
new	3	O
Philadelphia	12	O
chromosome	10	O
-positive	9	O
chronic	7	B-Disease
myelogenous	11	I-Disease
leukemia	8	I-Disease
cell	4	O
line	4	O
,	1	O
RWLeu-4	7	O
,	1	O
were	4	O
investigated	12	O
.	1	O

Binding	7	O
of	2	O
[	1	O
3H	2	O
]	1	O
VD3	3	B-Chemical
was	3	O
saturable	9	O
,	1	O
with	4	O
approximately	13	O
2000-3000	9	O
sites	5	O
/	1	O
cell	4	O
,	1	O
and	3	O
half-maximal	12	O
binding	7	O
occurring	9	O
at	2	O
0.21-0.33	9	O
nM	2	O
.	1	O

Treatment	9	O
of	2	O
RWLeu-4	7	O
cells	5	O
with	4	O
VD3	3	B-Chemical
induced	7	O
24R-hydroxylase	15	B-Gene
activity	8	O
,	1	O
a	1	O
marker	6	O
of	2	O
vitamin	7	B-Chemical
D3	2	I-Chemical
responsiveness	14	O
in	2	O
many	4	O
tissues	7	O
.	1	O

Exposure	8	O
of	2	O
RWLeu-4	7	O
cells	5	O
to	2	O
VD3	3	B-Chemical
also	4	O
inhibited	9	O
proliferation	13	O
and	3	O
DNA	3	O
synthesis	9	O
with	4	O
a	1	O
50	2	O
%	1	O
effective	9	O
dose	4	O
of	2	O
3.5-10	6	O
nM	2	O
within	6	O
72	2	O
h	1	O
;	1	O
in	2	O
addition	8	O
,	1	O
protein	7	O
and	3	O
RNA	3	O
synthesis	9	O
were	4	O
inhibited	9	O
by	2	O
VD3	3	B-Chemical
treatment	9	O
.	1	O

Exposure	8	O
of	2	O
RWLeu-4	7	O
cells	5	O
to	2	O
5	1	O
nM	2	O
VD3	3	B-Chemical
for	3	O
72	2	O
h	1	O
caused	6	O
50	2	O
%	1	O
of	2	O
the	3	O
cells	5	O
to	2	O
differentiate	13	O
into	4	O
macrophage	10	O
/	1	O
monocyte	8	O
type	4	O
cells	5	O
as	2	O
judged	6	O
by	2	O
nitroblue	9	B-Chemical
tetrazolium	11	I-Chemical
staining	8	O
and	3	O
adherence	9	O
to	2	O
plastic	7	O
.	1	O

Progressive	11	O
expression	10	O
of	2	O
cell	4	O
surface	7	O
maturation-specific	19	O
antigens	8	O
of	2	O
the	3	O
monocyte	8	O
/	1	O
macrophage	10	O
lineage	7	O
was	3	O
induced	7	O
by	2	O
treatment	9	O
of	2	O
RWLeu-4	7	O
cells	5	O
with	4	O
VD3	3	B-Chemical
for	3	O
24	2	O
to	2	O
72	2	O
h	1	O
at	2	O
doses	5	O
that	4	O
inhibited	9	O
cellular	8	O
proliferation	13	O
.	1	O

c-myc	5	B-Gene
RNA	3	I-Gene
,	1	O
which	5	O
is	2	O
constitutively	14	O
expressed	9	O
in	2	O
RWLeu-4	7	O
cells	5	O
,	1	O
increased	9	O
after	5	O
0.5	3	O
h	1	O
of	2	O
treatment	9	O
with	4	O
50	2	O
nM	2	O
VD3	3	B-Chemical
and	3	O
then	4	O
rapidly	7	O
decreased	9	O
to	2	O
barely	6	O
detectable	10	O
levels	6	O
after	5	O
4	1	O
h	1	O
of	2	O
treatment	9	O
.	1	O

Finally	7	O
,	1	O
the	3	O
in	2	O
vitro	5	O
tyrosine	8	B-Gene
kinase	6	I-Gene
activity	8	O
associated	10	O
with	4	O
the	3	O
p210bcr-abl	11	B-Gene
oncogene	8	I-Gene
product	7	I-Gene
was	3	O
decreased	9	O
approximately	13	O
50	2	O
%	1	O
by	2	O
VD3	3	B-Chemical
treatment	9	O
.	1	O

Because	7	O
of	2	O
the	3	O
presence	8	O
of	2	O
a	1	O
functional	10	O
receptor-effector	17	O
system	6	O
for	3	O
VD3	3	B-Chemical
and	3	O
multiple	8	O
biological	10	O
responses	9	O
to	2	O
the	3	O
hormone	7	O
,	1	O
these	5	O
cells	5	O
provide	7	O
a	1	O
unique	6	O
model	5	O
system	6	O
with	4	O
which	5	O
to	2	O
probe	5	O
the	3	O
specific	8	O
effects	7	O
of	2	O
VD3	3	B-Chemical
on	2	O
cell	4	O
growth	6	O
and	3	O
differentiation	15	O
in	2	O
chronic	7	B-Disease
myelogenous	11	I-Disease
leukemia	8	I-Disease
.	1	O

Quantitative	12	O
immunohistochemical	19	O
analysis	8	O
of	2	O
mononuclear	11	O
infiltrates	11	O
in	2	O
breast	6	B-Disease
carcinomas	10	I-Disease
--	2	O
correlation	11	O
with	4	O
tumour	6	B-Disease
differentiation	15	O
.	1	O

Inflammatory	12	O
infiltrates	11	O
were	4	O
analysed	8	O
in	2	O
tissue	6	O
sections	8	O
of	2	O
76	2	O
breast	6	B-Disease
carcinomas	10	I-Disease
by	2	O
counting	8	O
the	3	O
percentage	10	O
of	2	O
macrophages	11	O
,	1	O
IgA+	4	B-Gene
and	3	O
IgG+	4	B-Gene
plasma	6	O
cells	5	O
,	1	O
T	1	O
cells	5	O
with	4	O
their	5	O
subpopulations	14	O
,	1	O
and	3	O
natural	7	O
killer	6	O
cells	5	O
,	1	O
and	3	O
by	2	O
measuring	9	O
postcapillary	13	O
venules	7	O
(	1	O
PCVs	4	O
,	1	O
found	5	O
in	2	O
12	2	O
cases	5	O
)	1	O
within	6	O
the	3	O
infiltrates	11	O
.	1	O

These	5	O
parameters	10	O
were	4	O
correlated	10	O
with	4	O
nuclear	7	O
grade	5	O
and	3	O
biochemically	13	O
determined	10	O
hormone	7	O
receptor	8	O
status	6	O
,	1	O
known	5	O
markers	7	O
of	2	O
tumour	6	B-Disease
differentiation	15	O
.	1	O

A	1	O
direct	6	O
correlation	11	O
was	3	O
found	5	O
between	7	O
the	3	O
extent	6	O
of	2	O
inflammation	12	O
and	3	O
nuclear	7	O
grade	5	O
(	1	O
P	1	O
less	4	O
than	4	O
0.0001	6	O
)	1	O
,	1	O
and	3	O
an	2	O
inverse	7	O
correlation	11	O
between	7	O
inflammation	12	O
and	3	O
oestrogen	9	B-Gene
receptor	8	I-Gene
(	1	O
OR	2	B-Gene
)	1	O
positivity	10	O
(	1	O
P	1	O
less	4	O
than	4	O
0.05	4	O
)	1	O
as	2	O
well	4	O
as	2	O
inflammation	12	O
and	3	O
progesterone	12	B-Gene
receptor	8	I-Gene
(	1	O
PR	2	B-Gene
)	1	O
positivity	10	O
(	1	O
P	1	O
less	4	O
than	4	O
0.05	4	O
)	1	O
.	1	O

The	3	O
percentage	10	O
of	2	O
the	3	O
OKT8+	5	B-Gene
suppressor	10	O
/	1	O
cytotoxic	9	O
T	1	O
cells	5	O
increased	9	O
when	4	O
the	3	O
inflammation	12	O
expanded	8	O
from	4	O
scanty	6	O
to	2	O
moderate	8	O
(	1	O
P	1	O
less	4	O
than	4	O
0.02	4	O
)	1	O
.	1	O

The	3	O
diameter	8	O
of	2	O
the	3	O
PCVs	4	O
also	4	O
increased	9	O
with	4	O
increasing	10	O
inflammatory	12	O
infiltrate	10	O
(	1	O
P	1	O
less	4	O
than	4	O
0.02	4	O
)	1	O
.	1	O

In	2	O
addition	8	O
,	1	O
a	1	O
direct	6	O
correlation	11	O
exists	6	O
between	7	O
the	3	O
diameter	8	O
of	2	O
the	3	O
PCVs	4	O
and	3	O
both	4	O
the	3	O
percentage	10	O
of	2	O
the	3	O
OKT8+	5	B-Gene
T	1	O
cells	5	O
(	1	O
P	1	O
less	4	O
than	4	O
0.04	4	O
)	1	O
and	3	O
the	3	O
Leu-7+	6	B-Gene
natural	7	O
killer	6	O
cells	5	O
(	1	O
P	1	O
less	4	O
than	4	O
0.03	4	O
)	1	O
.	1	O

Mapping	7	O
of	2	O
B-cell	6	O
epitopes	8	O
of	2	O
the	3	O
human	5	B-Gene
hepatitis	9	I-Gene
B	1	I-Gene
virus	5	I-Gene
X	1	I-Gene
protein	7	I-Gene
.	1	O

The	3	O
immune	6	O
response	8	O
to	2	O
the	3	O
X	1	B-Gene
protein	7	I-Gene
of	2	O
human	5	O
hepatitis	9	B-Disease
B	1	I-Disease
virus	5	O
(	1	O
HBV	3	O
)	1	O
was	3	O
studied	7	O
by	2	O
epitope	7	O
mapping	7	O
by	2	O
using	5	O
a	1	O
set	3	O
of	2	O
MS2-HBx	7	B-Gene
fusion	6	I-Gene
proteins	8	I-Gene
and	3	O
synthetic	9	O
peptides	8	O
.	1	O

Antibodies	10	O
in	2	O
sera	4	O
of	2	O
patients	8	O
with	4	O
acute	5	O
and	3	O
chronic	7	O
HBV	3	O
infection	9	O
showed	6	O
a	1	O
multispecific	13	O
immune	6	O
response	8	O
.	1	O

Each	4	O
serum	5	O
contained	9	O
antibodies	10	O
to	2	O
a	1	O
different	9	O
set	3	O
of	2	O
epitopes	8	O
,	1	O
which	5	O
taken	5	O
together	8	O
cover	5	O
most	4	O
of	2	O
the	3	O
HBx	3	B-Gene
sequence	8	O
.	1	O

Some	4	O
of	2	O
the	3	O
epitopes	8	O
were	4	O
detectable	10	O
only	4	O
by	2	O
immunoblotting	14	O
with	4	O
fusion	6	O
proteins	8	O
;	1	O
others	6	O
were	4	O
detectable	10	O
only	4	O
by	2	O
an	2	O
enzyme	6	O
-linked	7	O
immunosorbent	13	O
assay	5	O
(	1	O
ELISA	5	O
)	1	O
with	4	O
synthetic	9	O
peptides	8	O
.	1	O

The	3	O
carboxy-terminal	16	O
half	4	O
of	2	O
the	3	O
HBx	3	B-Gene
protein	7	I-Gene
was	3	O
preferentially	14	O
recognized	10	O
by	2	O
antibodies	10	O
from	4	O
patients	8	O
with	4	O
chronic	7	B-Disease
hepatitis	9	I-Disease
and	3	O
contained	9	O
a	1	O
short	5	O
immunodominant	14	O
antigenic	9	O
region	6	O
with	4	O
at	2	O
least	5	O
two	3	O
major	5	O
nonoverlapping	14	O
epitopes	8	O
.	1	O

Anti-	5	B-Gene
HBx	3	I-Gene
antibody	8	I-Gene
titers	6	O
as	2	O
revealed	8	O
by	2	O
peptide	7	O
ELISAs	6	O
were	4	O
highest	7	O
and	3	O
most	4	O
frequent	8	O
in	2	O
patients	8	O
with	4	O
chronic	7	B-Disease
hepatitis	9	I-Disease
and	3	O
usually	7	O
low	3	O
in	2	O
acutely	7	O
infected	8	O
patients	8	O
and	3	O
asymptomatic	12	O
carriers	8	O
.	1	O

The	3	O
data	4	O
demonstrate	11	O
a	1	O
remarkable	10	O
qualitative	11	O
and	3	O
quantitative	12	O
heterogeneity	13	O
of	2	O
the	3	O
humoral	7	O
HBx	3	B-Gene
immune	6	O
response	8	O
which	5	O
can	3	O
be	2	O
monitored	9	O
by	2	O
HBx	3	B-Gene
-specific	9	O
peptide	7	O
ELISAs	6	O
.	1	O

Such	4	O
tests	5	O
may	3	O
become	6	O
useful	6	O
diagnostic	10	O
tools	5	O
.	1	O

The	3	O
Epstein-Barr	12	O
virus	5	O
(	1	O
EBV	3	O
)	1	O
ORI1yt	6	O
enhancer	8	O
is	2	O
not	3	O
B-cell	6	O
specific	8	O
and	3	O
does	4	O
not	3	O
respond	7	O
synergistically	15	O
to	2	O
the	3	O
EBV	3	B-Gene
transcription	13	I-Gene
factors	7	I-Gene
R	1	I-Gene
and	3	O
Z	1	B-Gene
.	1	O

The	3	O
Epstein-Barr	12	O
virus	5	O
DR	2	O
promoter	8	O
is	2	O
located	7	O
upstream	8	O
of	2	O
the	3	O
PstI	4	O
repeats	7	O
,	1	O
and	3	O
in	2	O
addition	8	O
to	2	O
the	3	O
TATA	4	O
box	3	O
,	1	O
it	2	O
contains	8	O
an	2	O
upstream	8	O
region	6	O
(	1	O
positions	9	O
-69	3	O
to	2	O
-220	4	O
)	1	O
responsive	10	O
to	2	O
EB1	3	B-Gene
(	1	O
Z	1	B-Gene
)	1	O
(	1	O
the	3	O
BZLF1	5	B-Gene
-encoded	8	O
transcription	13	O
factor	6	O
)	1	O
and	3	O
an	2	O
enhancer	8	O
with	4	O
two	3	O
functionally	12	O
distinct	8	O
domains	7	O
,	1	O
A	1	O
and	3	O
B	1	O
.	1	O

Domain	6	O
B	1	O
has	3	O
been	4	O
described	9	O
as	2	O
a	1	O
B-cell-specific	15	B-Gene
EB1	3	I-Gene
-responsive	11	I-Gene
element	7	I-Gene
(	1	O
P.M.Lieberman	13	O
,	1	O
J.M.Hardwick	12	O
,	1	O
and	3	O
S.D.Hayward	11	O
,	1	O
J.Virol.63	10	O
:	1	O
3040-3050	9	O
,	1	O
1989	4	O
)	1	O
activated	9	O
synergistically	15	O
by	2	O
EB1	3	B-Gene
and	3	O
R	1	B-Gene
,	1	O
an	2	O
EBV	3	O
early	5	O
product	7	O
encoded	7	O
by	2	O
the	3	O
open	4	O
reading	7	O
frame	5	O
BRLF1	5	B-Gene
(	1	O
M.A.	4	O
Cox	3	O
,	1	O
J.Leahy	7	O
,	1	O
and	3	O
J.M.Hardwick	12	O
,	1	O
J.Virol.64	10	O
:	1	O
313-321	7	O
,	1	O
1990	4	O
)	1	O
.	1	O

We	2	O
show	4	O
here	4	O
that	4	O
domain	6	O
B	1	O
is	2	O
an	2	O
R	1	B-Gene
-responsive	11	I-Gene
element	7	I-Gene
in	2	O
HeLa	4	O
cells	5	O
and	3	O
is	2	O
therefore	9	O
not	3	O
an	2	O
EB1	3	B-Gene
-responsive	11	I-Gene
B-cell-specific	15	I-Gene
element	7	I-Gene
.	1	O

However	7	O
,	1	O
there	5	O
is	2	O
an	2	O
EB1	3	B-Gene
-binding	8	O
site	4	O
(	1	O
ZRE-B	5	O
)	1	O
located	7	O
within	6	O
the	3	O
R	1	B-Gene
-responsive	11	I-Gene
enhancer	8	I-Gene
region	6	O
.	1	O

ZRE-B	5	O
can	3	O
be	2	O
deleted	7	O
without	7	O
affecting	9	O
the	3	O
R	1	B-Gene
-dependent	10	I-Gene
enhancer	8	I-Gene
activity	8	O
.	1	O

Moreover	8	O
,	1	O
there	5	O
is	2	O
no	2	O
cooperation	11	O
or	2	O
synergy	7	O
between	7	O
R	1	B-Gene
and	3	O
EB1	3	B-Gene
when	4	O
activating	10	O
the	3	O
B	1	O
domain	6	O
(	1	O
ZRE-B	5	O
plus	4	O
the	3	O
R	1	B-Gene
-responsive	11	I-Gene
element	7	I-Gene
)	1	O
positioned	10	O
as	2	O
an	2	O
enhancer	8	O
.	1	O

ZRE-B	5	O
is	2	O
therefore	9	O
not	3	O
part	4	O
of	2	O
the	3	O
R-	2	B-Gene
inducible	9	O
enhancer	8	O
.	1	O

We	2	O
have	4	O
tested	6	O
several	7	O
subregions	10	O
of	2	O
the	3	O
DR	2	O
enhancer	8	O
B	1	O
domain	6	O
,	1	O
either	6	O
alone	5	O
or	2	O
in	2	O
combination	11	O
,	1	O
for	3	O
their	5	O
capacity	8	O
to	2	O
transmit	8	O
the	3	O
R	1	B-Gene
-activating	11	O
signal	6	O
to	2	O
the	3	O
rabbit	6	B-Gene
beta-globin	11	I-Gene
promoter	8	I-Gene
.	1	O

We	2	O
found	5	O
that	4	O
the	3	O
R	1	B-Gene
-responsive	11	I-Gene
element	7	I-Gene
is	2	O
composed	8	O
of	2	O
four	4	O
protoenhancers	14	O
that	4	O
span	4	O
the	3	O
whole	5	O
B	1	O
domain	6	O
.	1	O

These	5	O
protoenhancers	14	O
alone	5	O
are	3	O
weakly	6	O
or	2	O
not	3	O
responsive	10	O
to	2	O
R	1	B-Gene
.	1	O

One	3	O
of	2	O
the	3	O
protoenhancers	14	O
contains	8	O
the	3	O
overlapping	11	O
palindromes	11	O
5'-TTGTCCcgtGGACAAaTGTCC-3'	27	O
.	1	O

However	7	O
,	1	O
one	3	O
palindrome	10	O
,	1	O
either	6	O
alone	5	O
or	2	O
duplicated	10	O
,	1	O
or	2	O
the	3	O
overlapping	11	O
palindromes	11	O
did	3	O
not	3	O
respond	7	O
to	2	O
R	1	B-Gene
.	1	O

Human	5	B-Gene
immunodeficiency	16	I-Gene
virus	5	I-Gene
vpr	3	I-Gene
product	7	O
is	2	O
a	1	O
virion	6	O
-associated	11	O
regulatory	10	O
protein	7	O
.	1	O

The	3	O
vpr	3	B-Gene
product	7	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
(	1	O
HIV-1	5	O
)	1	O
acts	4	O
in	2	O
trans	5	O
to	2	O
accelerate	10	O
virus	5	O
replication	11	O
and	3	O
cytopathic	10	O
effect	6	O
in	2	O
T	1	O
cells	5	O
.	1	O

Here	4	O
it	2	O
is	2	O
shown	5	O
that	4	O
the	3	O
HIV-1	5	O
viral	5	O
particle	8	O
contains	8	O
multiple	8	O
copies	6	O
of	2	O
the	3	O
vpr	3	B-Gene
protein	7	I-Gene
.	1	O

The	3	O
vpr	3	B-Gene
product	7	O
is	2	O
the	3	O
first	5	O
regulatory	10	O
protein	7	O
of	2	O
HIV-1	5	O
to	2	O
be	2	O
found	5	O
in	2	O
the	3	O
virus	5	O
particle	8	O
.	1	O

This	4	O
observation	11	O
raises	6	O
the	3	O
possibility	11	O
that	4	O
vpr	3	B-Gene
acts	4	O
to	2	O
facilitate	10	O
the	3	O
early	5	O
steps	5	O
of	2	O
infection	9	O
before	6	O
de	2	O
novo	4	O
viral	5	O
protein	7	O
synthesis	9	O
occurs	6	O
.	1	O

Type	4	O
II	2	O
estrogen	8	B-Chemical
binding	7	O
sites	5	O
in	2	O
human	5	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
:	1	O
variations	10	O
during	6	O
the	3	O
menstrual	9	O
cycle	5	O
.	1	O

We	2	O
have	4	O
previously	10	O
reported	8	O
that	4	O
human	5	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
(	1	O
PBMC	4	O
)	1	O
contain	7	O
type	4	O
II	2	O
estrogen	8	B-Chemical
binding	7	O
sites	5	O
(	1	O
type	4	O
II	2	O
EBS	3	O
)	1	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
the	3	O
fluctuations	12	O
of	2	O
type	4	O
II	2	O
EBS	3	O
during	6	O
the	3	O
menstrual	9	O
cycle	5	O
were	4	O
analyzed	8	O
in	2	O
6	1	O
normally	8	O
menstruating	12	O
women	5	O
.	1	O

Approximately	13	O
3	1	O
times	5	O
higher	6	O
levels	6	O
of	2	O
type	4	O
II	2	O
EBS	3	O
were	4	O
found	5	O
in	2	O
the	3	O
periovulatory	13	O
period	6	O
with	4	O
respect	7	O
to	2	O
both	4	O
follicular	10	O
and	3	O
luteal	6	O
phases	6	O
.	1	O

In	2	O
postmenopausal	14	O
women	5	O
the	3	O
mean	4	O
type	4	O
II	2	O
EBS	3	O
levels	6	O
were	4	O
similar	7	O
to	2	O
those	5	O
observed	8	O
in	2	O
the	3	O
follicular	10	O
phase	5	O
of	2	O
the	3	O
cycle	5	O
.	1	O

However	7	O
,	1	O
in	2	O
3	1	O
postmenopausal	14	O
patients	8	O
a	1	O
short	5	O
course	6	O
of	2	O
estrogen	8	B-Chemical
or	2	O
tamoxifen	9	B-Chemical
resulted	8	O
in	2	O
a	1	O
marked	6	O
increase	8	O
of	2	O
type	4	O
II	2	O
EBS	3	O
levels	6	O
.	1	O

Tamoxifen	9	B-Chemical
was	3	O
also	4	O
found	5	O
to	2	O
compete	7	O
with	4	O
17	2	B-Chemical
beta-estradiol	14	I-Chemical
for	3	O
type	4	O
II	2	O
EBS	3	O
in	2	O
PBMC	4	O
,	1	O
although	8	O
to	2	O
a	1	O
lesser	6	O
extent	6	O
than	4	O
diethylstilbestrol	18	B-Chemical
.	1	O

Effects	7	O
of	2	O
mitogenic	9	O
agents	6	O
upon	4	O
glucocorticoid	14	B-Chemical
action	6	O
in	2	O
human	5	O
tonsillar	9	O
T-lymphocytes	13	O
.	1	O

The	3	O
treatment	9	O
of	2	O
human	5	O
tonsillar	9	O
T-lymphocytes	13	O
with	4	O
4-phorbol	9	B-Chemical
12-myristate	12	I-Chemical
13-acetate	10	I-Chemical
(	1	O
PMA	3	B-Chemical
)	1	O
,	1	O
resulted	8	O
in	2	O
about	5	O
two	3	O
fold	4	O
increase	8	O
in	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
number	6	O
,	1	O
without	7	O
any	3	O
significant	11	O
change	6	O
in	2	O
the	3	O
receptor	8	O
affinity	8	O
.	1	O

This	4	O
increase	8	O
disappeared	11	O
in	2	O
the	3	O
presence	8	O
of	2	O
cycloheximide	13	B-Chemical
.	1	O

Alone	5	O
,	1	O
PMA	3	B-Chemical
and	3	O
calcium	7	B-Chemical
ionophore	9	O
A23187	6	B-Chemical
did	3	O
not	3	O
affect	6	O
,	1	O
but	3	O
together	8	O
stimulated	10	O
,	1	O
like	4	O
phytohaemagglutinin	19	B-Gene
(	1	O
PHA	3	B-Gene
)	1	O
,	1	O
leucine	7	B-Chemical
and	3	O
,	1	O
in	2	O
particular	10	O
,	1	O
thymidine	9	B-Chemical
incorporation	13	O
.	1	O

PMA	3	B-Chemical
enhanced	8	O
slightly	8	O
the	3	O
stimulatory	11	O
effect	6	O
of	2	O
PHA	3	B-Gene
.	1	O

Alone	5	O
,	1	O
these	5	O
agents	6	O
failed	6	O
to	2	O
alter	5	O
the	3	O
suppressive	11	O
effect	6	O
of	2	O
dexamethasone	13	B-Chemical
on	2	O
thymidine	9	B-Chemical
and	3	O
leucine	7	B-Chemical
incorporation	13	O
;	1	O
however	7	O
,	1	O
PMA-A23187	10	B-Chemical
and	3	O
PMA	3	B-Chemical
-PHA	4	B-Gene
combinations	12	O
appeared	8	O
to	2	O
antagonize	10	O
the	3	O
suppression	11	O
by	2	O
dexamethasone	13	B-Chemical
.	1	O

Lymphocyte	10	O
cell	4	O
lines	5	O
from	4	O
vitamin	7	B-Disease
D	1	I-Disease
-dependent	10	I-Disease
rickets	7	I-Disease
type	4	I-Disease
II	2	I-Disease
show	4	O
functional	10	O
defects	7	O
in	2	O
the	3	O
1	1	B-Gene
alpha	5	I-Gene
,	1	I-Gene
25-dihydroxyvitamin	19	I-Gene
D3	2	I-Gene
receptor	8	I-Gene
.	1	O

Lymphocyte	10	O
cell	4	O
lines	5	O
were	4	O
established	11	O
from	4	O
five	4	O
patients	8	O
with	4	O
vitamin	7	B-Disease
D	1	I-Disease
-dependent	10	I-Disease
rickets	7	I-Disease
,	1	I-Disease
type	4	I-Disease
II	2	I-Disease
(	1	O
VDDR-II	7	B-Disease
)	1	O
.	1	O

These	5	O
lines	5	O
were	4	O
established	11	O
by	2	O
infection	9	O
with	4	O
human	5	O
T-lymphotrophic	15	O
virus	5	O
type	4	O
I	1	O
(	1	O
HTLV-I	6	O
)	1	O
.	1	O

Binding	7	O
of	2	O
[	1	O
3H	2	O
]	1	O
1	1	B-Chemical
alpha	5	I-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
(	1	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
)	1	O
to	2	O
its	3	O
receptor	8	O
in	2	O
these	5	O
cell	4	O
lines	5	O
was	3	O
compared	8	O
to	2	O
binding	7	O
studies	7	O
using	5	O
a	1	O
T-lymphocyte	12	O
cell	4	O
line	4	O
(	1	O
S-LB1	5	O
)	1	O
from	4	O
a	1	O
normal	6	O
individual	10	O
.	1	O

The	3	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
of	2	O
S-LB1	5	O
was	3	O
comparable	10	O
to	2	O
the	3	O
well	4	O
-characterized	14	O
chick	5	B-Gene
intestinal	10	I-Gene
1	1	I-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
in	2	O
terms	5	O
of	2	O
its	3	O
ligand	6	O
binding	7	O
affinity	8	O
and	3	O
capacity	8	O
,	1	O
its	3	O
mobility	8	O
on	2	O
5-20	4	O
%	1	O
sucrose	7	B-Chemical
gradients	9	O
,	1	O
and	3	O
its	3	O
adsorption	10	O
to	2	O
and	3	O
elution	7	O
properties	10	O
from	4	O
DNA-cellulose	13	O
.	1	O

Three	5	O
cell	4	O
lines	5	O
established	11	O
from	4	O
patients	8	O
with	4	O
VDDR-II	7	B-Disease
(	1	O
Rh-	3	O
VDR	3	O
,	1	O
Sh-	3	O
VDR	3	O
,	1	O
and	3	O
Ab-	3	O
VDR	3	O
)	1	O
showed	6	O
no	2	O
specific	8	O
binding	7	O
of	2	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
to	2	O
a	1	O
receptor	8	O
and	3	O
treatment	9	O
of	2	O
the	3	O
cultured	8	O
cells	5	O
with	4	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
did	3	O
not	3	O
stimulate	9	O
production	10	O
of	2	O
24	2	B-Chemical
,	1	I-Chemical
25-dihydroxy-vitamin	20	I-Chemical
D3	2	I-Chemical
(	1	O
24	2	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
)	1	O
,	1	O
a	1	O
response	8	O
which	5	O
is	2	O
diagnostic	10	O
of	2	O
the	3	O
presence	8	O
of	2	O
a	1	O
functional	10	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
.	1	O

In	2	O
a	1	O
fourth	6	O
cell	4	O
line	4	O
,	1	O
A1-VDR	6	O
,	1	O
the	3	O
receptor	8	O
for	3	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
had	3	O
a	1	O
low	3	O
binding	7	O
capacity	8	O
and	3	O
25	2	B-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
D3-24-hydroxylase	17	I-Gene
activity	8	O
was	3	O
not	3	O
detectable	10	O
.	1	O

Induction	9	O
of	2	O
24	2	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
synthesis	9	O
by	2	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
was	3	O
observed	8	O
in	2	O
the	3	O
fifth	5	O
cell	4	O
line	4	O
,	1	O
designated	10	O
Ro-VDR	6	O
,	1	O
although	8	O
the	3	O
sensitivity	11	O
to	2	O
hormone	7	O
treatment	9	O
was	3	O
lower	5	O
than	4	O
in	2	O
the	3	O
control	7	O
cell	4	O
line	4	O
from	4	O
a	1	O
normal	6	O
donor	5	O
.	1	O

The	3	O
capacity	8	O
of	2	O
the	3	O
receptor	8	O
for	3	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
was	3	O
low	3	O
in	2	O
Ro-VDR	6	O
.	1	O

In	2	O
all	3	O
cell	4	O
lines	5	O
where	5	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
binding	7	O
to	2	O
a	1	O
receptor	8	O
was	3	O
detectable	10	O
,	1	O
the	3	O
receptor	8	O
had	3	O
the	3	O
typical	7	O
sedimentation	13	O
coefficient	11	O
of	2	O
3.7	3	O
S	1	O
on	2	O
sucrose	7	B-Chemical
density	7	O
gradient	8	O
analysis	8	O
.	1	O

Binding	7	O
and	3	O
elution	7	O
properties	10	O
to	2	O
DNA-cellulose	13	O
,	1	O
however	7	O
,	1	O
differed	8	O
from	4	O
normal	6	O
in	2	O
both	4	O
Ro-VDR	6	O
and	3	O
A1-VDR	6	O
cells	5	O
where	5	O
elution	7	O
from	4	O
DNA-cellulose	13	O
occurred	8	O
at	2	O
a	1	O
lower	5	O
salt	4	O
concentration	13	O
than	4	O
is	2	O
typical	7	O
of	2	O
the	3	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
.	1	O

While	5	O
Ro-VDR	6	O
cells	5	O
showed	6	O
typical	7	O
nuclear	7	O
localization	12	O
of	2	O
the	3	O
unoccupied	10	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
,	1	O
neither	7	O
the	3	O
unoccupied	10	O
nor	3	O
the	3	O
occupied	8	O
receptor	8	O
from	4	O
A1-VDR	6	O
cells	5	O
was	3	O
completely	10	O
localized	9	O
in	2	O
the	3	O
nucleus	7	O
.	1	O

In	2	O
a	1	O
series	6	O
of	2	O
functional	10	O
studies	7	O
we	2	O
found	5	O
that	4	O
modulation	10	O
of	2	O
the	3	O
level	5	O
of	2	O
the	3	O
mRNAs	5	O
coding	6	O
for	3	O
both	4	O
the	3	O
c-myc	5	B-Gene
oncogene	8	I-Gene
and	3	O
the	3	O
growth	6	O
factor	6	O
known	5	O
as	2	O
granulocyte-monocyte	20	O
colony	6	O
stimulating	11	O
activity	8	O
by	2	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
correlated	10	O
with	4	O
the	3	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
status	6	O
of	2	O
these	5	O
cells	5	O
.	1	O

Use	3	O
of	2	O
these	5	O
cell	4	O
lines	5	O
will	4	O
facilitate	10	O
further	7	O
study	5	O
of	2	O
the	3	O
molecular	9	O
defect	6	O
(	1	O
s	1	O
)	1	O
in	2	O
the	3	O
receptor	8	O
for	3	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
in	2	O
vitamin	7	B-Disease
D	1	I-Disease
-dependent	10	I-Disease
rickets	7	I-Disease
type	4	I-Disease
II	2	I-Disease
and	3	O
will	4	O
allow	5	O
a	1	O
correlation	11	O
with	4	O
impairment	10	O
of	2	O
cellular	8	O
functions	9	O
.	1	O

Involvement	11	O
of	2	O
a	1	O
second	6	O
lymphoid-specific	17	O
enhancer	8	O
element	7	O
in	2	O
the	3	O
regulation	10	O
of	2	O
immunoglobulin	14	B-Gene
heavy-chain	11	I-Gene
gene	4	I-Gene
expression	10	O
.	1	O

To	2	O
determine	9	O
whether	7	O
enhancer	8	O
elements	8	O
in	2	O
addition	8	O
to	2	O
the	3	O
highly	6	O
conserved	9	O
octamer	7	O
(	1	O
OCTA	4	O
)	1	O
-nucleotide	11	O
motif	5	O
are	3	O
important	9	O
for	3	O
lymphoid-specific	17	O
expression	10	O
of	2	O
the	3	O
immunoglobulin	14	B-Gene
heavy-chain	11	I-Gene
(	1	I-Gene
IgH	3	I-Gene
)	1	I-Gene
gene	4	I-Gene
,	1	O
we	2	O
have	4	O
investigated	12	O
the	3	O
effect	6	O
of	2	O
mutating	8	O
the	3	O
binding	7	O
site	4	O
for	3	O
a	1	O
putative	8	O
additional	10	O
lymphoid-specific	17	O
transcription	13	O
factor	6	O
,	1	O
designated	10	O
NF-microB	9	O
,	1	O
in	2	O
the	3	O
murine	6	O
IgH	3	B-Gene
enhancer	8	I-Gene
.	1	O

We	2	O
demonstrate	11	O
that	4	O
the	3	O
NF-microB	9	O
-binding	8	O
site	4	O
plays	5	O
a	1	O
critical	8	O
role	4	O
in	2	O
the	3	O
IgH	3	B-Gene
enhancer	8	I-Gene
,	1	O
because	7	O
mutation	8	O
of	2	O
the	3	O
microB	6	O
DNA	3	O
motif	5	O
decreased	9	O
transcriptional	15	O
activity	8	O
of	2	O
the	3	O
IgH	3	B-Gene
enhancer	8	I-Gene
in	2	O
cells	5	O
of	2	O
the	3	O
B-cell	6	O
lineage	7	O
but	3	O
not	3	O
in	2	O
nonlymphoid	11	O
cells	5	O
.	1	O

This	4	O
effect	6	O
was	3	O
comparable	10	O
to	2	O
or	2	O
even	4	O
stronger	8	O
than	4	O
the	3	O
effect	6	O
of	2	O
a	1	O
mutation	8	O
in	2	O
the	3	O
OCTA	4	O
site	4	O
.	1	O

Moreover	8	O
,	1	O
combined	8	O
mutation	8	O
of	2	O
both	4	O
microB	6	O
and	3	O
OCTA	4	O
sites	5	O
further	7	O
reduced	7	O
enhancer	8	O
activity	8	O
in	2	O
lymphoid	8	O
cells	5	O
.	1	O

Interestingly	13	O
,	1	O
alteration	10	O
of	2	O
either	6	O
the	3	O
microB	6	O
or	2	O
E3	2	O
site	4	O
in	2	O
a	1	O
70-base-pair	12	O
fragment	8	O
of	2	O
the	3	O
IgH	3	B-Gene
enhancer	8	I-Gene
that	4	O
lacks	5	O
the	3	O
binding	7	O
site	4	O
for	3	O
OCTA	4	O
abolished	9	O
enhancer	8	O
activity	8	O
in	2	O
lymphoid	8	O
cells	5	O
completely	10	O
.	1	O

Nevertheless	12	O
,	1	O
a	1	O
multimer	8	O
of	2	O
the	3	O
microB	6	O
motif	5	O
alone	5	O
showed	6	O
no	2	O
enhancer	8	O
activity	8	O
.	1	O

DNase	5	O
footprinting	12	O
analysis	8	O
corroborated	12	O
the	3	O
functional	10	O
data	4	O
showing	7	O
that	4	O
a	1	O
lymphoid-specific	17	O
protein	7	O
binds	5	O
to	2	O
the	3	O
microB	6	O
DNA	3	O
motif	5	O
.	1	O

Our	3	O
results	7	O
suggest	7	O
that	4	O
the	3	O
microB	6	O
element	7	O
is	2	O
a	1	O
new	3	O
crucial	7	O
element	7	O
important	9	O
for	3	O
lymphoid-specific	17	O
expression	10	O
of	2	O
the	3	O
IgH	3	B-Gene
gene	4	I-Gene
but	3	O
that	4	O
interaction	11	O
with	4	O
another	7	O
enhancer	8	O
element	7	O
is	2	O
essential	9	O
for	3	O
its	3	O
activity	8	O
.	1	O

Heterogeneity	13	O
of	2	O
antigen	7	O
molecules	9	O
recognized	10	O
by	2	O
anti-tax1	9	B-Gene
monoclonal	10	I-Gene
antibody	8	I-Gene
Lt-4	4	I-Gene
in	2	O
cell	4	O
lines	5	O
bearing	7	O
human	5	O
T	1	B-Disease
cell	4	I-Disease
leukemia	8	I-Disease
virus	5	O
type	4	O
I	1	O
and	3	O
related	7	O
retroviruses	12	O
.	1	O

Using	5	O
a	1	O
monoclonal	10	O
antibody	8	O
,	1	O
Lt-4	4	B-Gene
,	1	O
directed	8	O
against	7	O
human	5	B-Gene
T	1	I-Gene
cell	4	I-Gene
leukemia	8	I-Gene
virus	5	I-Gene
type	4	I-Gene
I	1	I-Gene
(	1	I-Gene
HTLV-I	6	I-Gene
)	1	I-Gene
trans-activator	15	I-Gene
(	1	I-Gene
tax1	4	I-Gene
)	1	I-Gene
antigen	7	I-Gene
,	1	O
we	2	O
examined	8	O
the	3	O
expression	10	O
of	2	O
tax1	4	B-Gene
and	3	O
related	7	O
antigens	8	O
in	2	O
a	1	O
variety	7	O
of	2	O
T	1	O
cell	4	O
lines	5	O
bearing	7	O
HTLV-I	6	O
and	3	O
related	7	O
retroviruses	12	O
,	1	O
simian	6	O
T	1	B-Disease
cell	4	I-Disease
leukemia	8	I-Disease
virus	5	O
type	4	O
I	1	O
(	1	O
STLV-I	6	O
)	1	O
and	3	O
HTLV-II	7	O
,	1	O
by	2	O
immunofluorescence	18	O
and	3	O
immunoblot	10	O
assays	6	O
.	1	O

Lt-4	4	B-Gene
reacted	7	O
with	4	O
all	3	O
HTLV-I	6	O
-bearing	8	O
cell	4	O
lines	5	O
tested	6	O
and	3	O
five	4	O
out	3	O
of	2	O
eight	5	O
simian	6	O
cell	4	O
lines	5	O
bearing	7	O
STLV-I	6	O
,	1	O
but	3	O
not	3	O
with	4	O
an	2	O
HTLV-II	7	O
-bearing	8	O
cell	4	O
line	4	O
.	1	O

Lt-4	4	B-Gene
detected	8	O
40	2	O
kd	2	O
tax1	4	B-Gene
antigen	7	I-Gene
molecules	9	O
in	2	O
most	4	O
HTLV-I	6	O
-bearing	8	O
cell	4	O
lines	5	O
except	6	O
one	3	O
cell	4	O
line	4	O
that	4	O
expressed	9	O
39	2	O
kd	2	O
tax1	4	B-Gene
antigen	7	I-Gene
.	1	O

In	2	O
the	3	O
STLV-I	6	O
-bearing	8	O
T	1	O
cell	4	O
lines	5	O
,	1	O
tax1	4	B-Gene
-related	8	O
antigen	7	O
molecules	9	O
detected	8	O
by	2	O
Lt-4	4	B-Gene
were	4	O
heterogeneous	13	O
,	1	O
having	6	O
molecular	9	O
weights	7	O
in	2	O
the	3	O
range	5	O
of	2	O
36-41	5	O
kd	2	O
.	1	O

The	3	O
expression	10	O
of	2	O
c-fos	5	B-Gene
,	1	O
c-jun	5	B-Gene
,	1	O
and	3	O
c-myc	5	B-Gene
genes	5	I-Gene
is	2	O
regulated	9	O
by	2	O
heat	4	O
shock	5	O
in	2	O
human	5	O
lymphoid	8	O
cells	5	O
.	1	O

The	3	O
effect	6	O
of	2	O
heat	4	O
shock	5	O
on	2	O
the	3	O
expression	10	O
of	2	O
the	3	O
nuclear	7	B-Gene
protooncogenes	14	I-Gene
c-fos	5	I-Gene
,	1	O
c-jun	5	B-Gene
,	1	O
and	3	O
c-myc	5	B-Gene
was	3	O
studied	7	O
in	2	O
human	5	O
lymphoid	8	O
cells	5	O
.	1	O

Heat	4	O
shock	5	O
caused	6	O
an	2	O
increase	8	O
in	2	O
c-fos	5	B-Gene
and	3	O
c-jun	5	B-Gene
mRNA	4	I-Gene
levels	6	O
and	3	O
a	1	O
decrease	8	O
in	2	O
c-myc	5	B-Gene
mRNA	4	I-Gene
levels	6	O
in	2	O
pre-B	5	O
(	1	O
Hyon	4	O
)	1	O
and	3	O
T	1	O
(	1	O
DND-41	6	O
)	1	O
cell	4	O
lines	5	O
as	2	O
well	4	O
as	2	O
in	2	O
freshly	7	O
isolated	8	O
normal	6	O
human	5	O
thymocytes	10	O
.	1	O

The	3	O
changes	7	O
in	2	O
the	3	O
mRNA	4	O
levels	6	O
of	2	O
these	5	O
protooncogenes	14	O
in	2	O
Hyon	4	O
cells	5	O
were	4	O
most	4	O
pronounced	10	O
at	2	O
42	2	O
and	3	O
43	2	O
degrees	7	O
C	1	O
;	1	O
kinetic	7	O
analysis	8	O
demonstrated	12	O
that	4	O
the	3	O
changes	7	O
could	5	O
be	2	O
detected	8	O
within	6	O
30	2	O
min	3	O
of	2	O
heat	4	O
shock	5	O
.	1	O

Altered	7	O
transcription	13	O
of	2	O
c-fos	5	B-Gene
and	3	O
c-myc	5	B-Gene
genes	5	I-Gene
was	3	O
the	3	O
primary	7	O
effect	6	O
of	2	O
heat	4	O
shock	5	O
.	1	O

Secondarily	11	O
,	1	O
heat	4	O
shock	5	O
of	2	O
Hyon	4	O
cells	5	O
stabilized	10	O
the	3	O
c-myc	5	B-Gene
mRNA	4	I-Gene
level	5	O
by	2	O
increasing	10	O
its	3	O
half-life	9	O
from	4	O
24	2	O
to	2	O
45	2	O
min	3	O
.	1	O

The	3	O
overall	7	O
effect	6	O
of	2	O
heat	4	O
shock	5	O
on	2	O
c-myc	5	B-Gene
mRNA	4	I-Gene
level	5	O
,	1	O
however	7	O
,	1	O
was	3	O
a	1	O
marked	6	O
inhibition	10	O
of	2	O
its	3	O
transcription	13	O
.	1	O

These	5	O
results	7	O
demonstrate	11	O
that	4	O
the	3	O
transcription	13	O
of	2	O
nuclear	7	O
protooncogenes	14	O
is	2	O
regulated	9	O
by	2	O
heat	4	O
shock	5	O
indicating	10	O
a	1	O
role	4	O
for	3	O
nuclear	7	O
protooncogenes	14	O
in	2	O
the	3	O
stress	6	O
response	8	O
of	2	O
lymphoid	8	O
cells	5	O
.	1	O

A	1	O
novel	5	O
T-cell	6	O
protein	7	O
which	5	O
recognizes	10	O
a	1	O
palindromic	11	O
sequence	8	O
in	2	O
the	3	O
negative	8	O
regulatory	10	O
element	7	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
long	4	O
terminal	8	O
repeat	6	O
.	1	O

Two	3	O
major	5	O
protein	7	O
-binding	8	O
sites	5	O
within	6	O
the	3	O
negative	8	O
regulatory	10	O
element	7	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
long	4	O
terminal	8	O
repeat	6	O
have	4	O
been	4	O
identified	10	O
.	1	O

One	3	O
(	1	O
site	4	O
B	1	O
)	1	O
contained	9	O
a	1	O
palindromic	11	O
sequence	8	O
with	4	O
homology	8	O
to	2	O
steroid	7	B-Chemical
/	1	O
thyroid	7	B-Chemical
hormone	7	I-Chemical
response	8	O
elements	8	O
but	3	O
was	3	O
distinct	8	O
from	4	O
previously	10	O
described	9	O
binding	7	O
sites	5	O
of	2	O
this	4	O
class	5	O
.	1	O

A	1	O
novel	5	O
T-cell	6	O
protein	7	O
recognized	10	O
the	3	O
palindromic	11	O
sequence	8	O
within	6	O
site	4	O
B	1	O
and	3	O
also	4	O
bound	5	O
estrogen-	9	B-Chemical
or	2	O
thyroid	7	B-Chemical
hormone-response	16	I-Chemical
elements	8	O
with	4	O
lower	5	O
affinity	8	O
.	1	O

A	1	O
7-base-pair	11	O
mutation	8	O
in	2	O
the	3	O
site	4	O
B	1	O
palindrome	10	O
,	1	O
which	5	O
destroyed	9	O
protein	7	O
binding	7	O
,	1	O
resulted	8	O
in	2	O
increased	9	O
expression	10	O
from	4	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
long	4	O
terminal	8	O
repeat	6	O
in	2	O
T	1	O
cells	5	O
.	1	O

Epstein-Barr	12	B-Gene
virus	5	I-Gene
nuclear	7	I-Gene
antigen	7	I-Gene
2	1	I-Gene
transactivates	14	O
latent	6	B-Gene
membrane	8	I-Gene
protein	7	I-Gene
LMP1	4	I-Gene
.	1	O

Several	7	O
lines	5	O
of	2	O
evidence	8	O
are	3	O
compatible	10	O
with	4	O
the	3	O
hypothesis	10	O
that	4	O
Epstein-Barr	12	B-Gene
virus	5	I-Gene
(	1	I-Gene
EBV	3	I-Gene
)	1	I-Gene
nuclear	7	I-Gene
antigen	7	I-Gene
2	1	I-Gene
(	1	O
EBNA-2	6	B-Gene
)	1	O
or	2	O
leader	6	O
protein	7	O
(	1	O
EBNA-LP	7	B-Gene
)	1	O
affects	7	O
expression	10	O
of	2	O
the	3	O
EBV	3	B-Gene
latent	6	I-Gene
infection	9	I-Gene
membrane	8	I-Gene
protein	7	I-Gene
LMP1	4	I-Gene
.	1	O

We	2	O
now	3	O
demonstrate	11	O
the	3	O
following	9	O
.	1	O

(	1	O
i	1	O
)	1	O
Acute	5	O
transfection	12	O
and	3	O
expression	10	O
of	2	O
EBNA-2	6	B-Gene
under	5	O
control	7	O
of	2	O
simian	6	O
virus	5	O
40	2	O
or	2	O
Moloney	7	B-Gene
murine	6	I-Gene
leukemia	8	I-Gene
virus	5	I-Gene
promoters	9	I-Gene
resulted	8	O
in	2	O
increased	9	O
LMP1	4	B-Gene
expression	10	O
in	2	O
P3HR-1	6	O
-infected	9	O
Burkitt	7	B-Disease
's	2	I-Disease
lymphoma	8	I-Disease
cells	5	O
and	3	O
the	3	O
P3HR-1	6	O
or	2	O
Daudi	5	O
cell	4	O
line	4	O
.	1	O

(	1	O
ii	2	O
)	1	O
Transfection	12	O
and	3	O
expression	10	O
of	2	O
EBNA-LP	7	B-Gene
alone	5	O
had	3	O
no	2	O
effect	6	O
on	2	O
LMP1	4	B-Gene
expression	10	O
and	3	O
did	3	O
not	3	O
act	3	O
synergistically	15	O
with	4	O
EBNA-2	6	B-Gene
to	2	O
affect	6	O
LMP1	4	B-Gene
expression	10	O
.	1	O

(	1	O
iii	3	O
)	1	O
LMP1	4	B-Gene
expression	10	O
in	2	O
Daudi	5	O
and	3	O
P3HR-1	6	O
-infected	9	O
cells	5	O
was	3	O
controlled	10	O
at	2	O
the	3	O
mRNA	4	O
level	5	O
,	1	O
and	3	O
EBNA-2	6	B-Gene
expression	10	O
in	2	O
Daudi	5	O
cells	5	O
increased	9	O
LMP1	4	B-Gene
mRNA	4	I-Gene
.	1	O

(	1	O
iv	2	O
)	1	O
No	2	O
other	5	O
EBV	3	O
genes	5	O
were	4	O
required	8	O
for	3	O
EBNA-2	6	B-Gene
transactivation	15	O
of	2	O
LMP1	4	B-Gene
since	5	O
cotransfection	14	O
of	2	O
recombinant	11	B-Gene
EBNA-2	6	I-Gene
expression	10	O
vectors	7	O
and	3	O
genomic	7	O
LMP1	4	B-Gene
DNA	3	I-Gene
fragments	9	O
enhanced	8	O
LMP1	4	B-Gene
expression	10	O
in	2	O
the	3	O
EBV	3	O
-negative	9	O
B-lymphoma	10	O
cell	4	O
lines	5	O
BJAB	4	O
,	1	O
Louckes	7	O
,	1	O
and	3	O
BL30	4	O
.	1	O

(	1	O
v	1	O
)	1	O
An	2	O
EBNA-2	6	B-Gene
-responsive	11	O
element	7	O
was	3	O
found	5	O
within	6	O
the	3	O
-512	4	O
to	2	O
+40	3	O
LMP1	4	B-Gene
DNA	3	I-Gene
since	5	O
this	4	O
DNA	3	O
linked	6	O
to	2	O
a	1	O
chloramphenicol	15	O
acetyltransferase	17	O
reporter	8	O
gene	4	O
was	3	O
transactivated	14	O
by	2	O
cotransfection	14	O
with	4	O
an	2	O
EBNA-2	6	B-Gene
expression	10	O
vector	6	O
.	1	O

(	1	O
vi	2	O
)	1	O
The	3	O
EBV	3	B-Gene
type	4	I-Gene
2	1	I-Gene
EBNA-2	6	I-Gene
transactivated	14	O
LMP1	4	B-Gene
as	2	O
well	4	O
as	2	O
the	3	O
EBV	3	B-Gene
type	4	I-Gene
1	1	I-Gene
EBNA-2	6	I-Gene
.	1	O

(	1	O
vii	3	O
)	1	O
Two	3	O
deletions	9	O
within	6	O
the	3	O
EBNA-2	6	B-Gene
gene	4	I-Gene
which	5	O
rendered	8	O
EBV	3	O
transformation	14	O
incompetent	11	O
did	3	O
not	3	O
transactivate	13	O
LMP1	4	B-Gene
,	1	O
whereas	7	O
a	1	O
transformation	14	O
-competent	10	O
EBNA-2	6	B-Gene
deletion	8	O
mutant	6	O
did	3	O
transactivate	13	O
LMP1	4	B-Gene
.	1	O

LMP1	4	B-Gene
is	2	O
a	1	O
potent	6	O
effector	8	O
of	2	O
B-lymphocyte	12	O
activation	10	O
and	3	O
can	3	O
act	3	O
synergistically	15	O
with	4	O
EBNA-2	6	B-Gene
to	2	O
induce	6	O
cellular	8	O
CD23	4	B-Gene
gene	4	I-Gene
expression	10	O
.	1	O

Thus	4	O
,	1	O
EBNA-2	6	B-Gene
transactivation	15	O
of	2	O
LMP1	4	B-Gene
amplifies	9	O
the	3	O
biological	10	O
impact	6	O
of	2	O
EBNA-2	6	B-Gene
and	3	O
underscores	11	O
its	3	O
central	7	O
role	4	O
in	2	O
EBV	3	O
-induced	8	O
growth	6	O
transformation	14	O
.	1	O

Involvement	11	O
of	2	O
cyclic	6	B-Gene
AMP	3	I-Gene
-dependent	10	I-Gene
protein	7	I-Gene
kinases	7	I-Gene
in	2	O
the	3	O
signal	6	O
transduction	12	O
pathway	7	O
for	3	O
interleukin-1	13	B-Gene
.	1	O

Expression	10	O
of	2	O
a	1	O
highly	6	O
specific	8	O
protein	7	O
inhibitor	9	O
for	3	O
cyclic	6	B-Gene
AMP	3	I-Gene
-dependent	10	I-Gene
protein	7	I-Gene
kinases	7	I-Gene
in	2	O
interleukin-1	13	B-Gene
(	1	O
IL-1	4	B-Gene
)	1	O
-responsive	11	O
cells	5	O
blocked	7	O
IL-1	4	B-Gene
-induced	8	O
gene	4	O
transcription	13	O
that	4	O
was	3	O
driven	6	O
by	2	O
the	3	O
kappa	5	B-Gene
immunoglobulin	14	I-Gene
enhancer	8	I-Gene
or	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
long	4	O
terminal	8	O
repeat	6	O
.	1	O

This	4	O
inhibitor	9	O
did	3	O
not	3	O
affect	6	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
-mediated	9	O
gene	4	O
transcription	13	O
,	1	O
suggesting	10	O
that	4	O
cyclic	6	B-Gene
AMP	3	I-Gene
-dependent	10	I-Gene
protein	7	I-Gene
kinases	7	I-Gene
are	3	O
involved	8	O
in	2	O
the	3	O
signal	6	O
transduction	12	O
pathway	7	O
for	3	O
IL-1	4	B-Gene
in	2	O
a	1	O
number	6	O
of	2	O
responsive	10	O
cell	4	O
types	5	O
.	1	O

Protein	7	B-Gene
kinase	6	I-Gene
inhibitor	9	O
H-7	3	B-Chemical
blocks	6	O
accumulation	12	O
of	2	O
unspliced	9	O
mRNA	4	O
of	2	O
human	5	O
T-cell	6	B-Disease
leukemia	8	I-Disease
virus	5	O
type	4	O
I	1	O
(	1	O
HTLV-I	6	O
)	1	O
.	1	O

Rex	3	B-Gene
,	1	O
the	3	O
post-transcriptional	20	O
regulator	9	O
of	2	O
human	5	O
T-cell	6	B-Disease
leukemia	8	I-Disease
virus	5	O
type	4	O
I	1	O
(	1	O
HTLV-I	6	O
)	1	O
,	1	O
is	2	O
known	5	O
to	2	O
induce	6	O
accumulation	12	O
of	2	O
the	3	O
unspliced	9	O
viral	5	O
gag-pol	7	B-Gene
mRNA	4	I-Gene
.	1	O

Rex	3	B-Gene
is	2	O
a	1	O
phosphoprotein	14	O
found	5	O
in	2	O
the	3	O
cell	4	O
nucleolus	9	O
,	1	O
whose	5	O
function	8	O
may	3	O
be	2	O
regulated	9	O
by	2	O
its	3	O
localization	12	O
and	3	O
phosphorylation	15	O
.	1	O

We	2	O
have	4	O
examined	8	O
the	3	O
role	4	O
of	2	O
phosphorylation	15	O
on	2	O
Rex	3	B-Gene
function	8	O
by	2	O
using	5	O
a	1	O
protein	7	B-Gene
kinase	6	I-Gene
inhibitor	9	I-Gene
,	1	O
H-7	3	B-Chemical
[	1	O
1-	2	B-Chemical
(	1	I-Chemical
5-isoquinolinyl-sulfonyl	24	I-Chemical
)	1	I-Chemical
-2-methylpiperazine	19	I-Chemical
]	1	O
.	1	O

Treatment	9	O
of	2	O
an	2	O
HTLV-I	6	O
infected	8	O
human	5	O
T-cell	6	O
line	4	O
with	4	O
H-7	3	B-Chemical
blocked	7	O
specifically	12	O
accumulation	12	O
of	2	O
the	3	O
unspliced	9	O
gag-pol	7	B-Gene
mRNA	4	I-Gene
,	1	O
resulting	9	O
in	2	O
the	3	O
decreased	9	O
Gag	3	B-Gene
protein	7	I-Gene
synthesis	9	O
that	4	O
corresponds	11	O
with	4	O
the	3	O
decreased	9	O
in	2	O
vivo	4	O
phosphorylation	15	O
of	2	O
Rex	3	B-Gene
.	1	O

In	2	O
contrast	8	O
,	1	O
other	5	O
viral	5	O
and	3	O
cellular	8	O
products	8	O
have	4	O
not	3	O
been	4	O
influenced	10	O
by	2	O
the	3	O
level	5	O
of	2	O
H-7	3	B-Chemical
used	4	O
.	1	O

Therefore	9	O
,	1	O
the	3	O
phosphorylation	15	O
of	2	O
Rex	3	B-Gene
is	2	O
required	8	O
for	3	O
the	3	O
viral	5	O
RNA	3	O
partition	9	O
of	2	O
HTLV-I	6	O
.	1	O

Increased	9	O
glucocorticoid	14	B-Chemical
responsiveness	14	O
of	2	O
CD4+	4	B-Gene
T-cell	6	O
clonal	6	O
lines	5	O
grown	5	O
in	2	O
serum-free	10	O
media	5	O
.	1	O

CEM-C7	6	O
,	1	O
a	1	O
human	5	B-Gene
leukemic	8	I-Gene
CD4+	4	I-Gene
T-lymphocyte	12	O
cell	4	O
line	4	O
and	3	O
three	5	O
of	2	O
its	3	O
subclones	9	O
,	1	O
CEM-4R4	7	O
,	1	O
CEM-3R43	8	O
,	1	O
and	3	O
ICR-27	6	O
,	1	O
previously	10	O
cultured	8	O
in	2	O
a	1	O
medium	6	O
supplemented	12	O
with	4	O
5	1	O
to	2	O
10	2	O
%	1	O
fetal	5	O
bovine	6	O
serum	5	O
,	1	O
have	4	O
been	4	O
adapted	7	O
to	2	O
serum-free	10	O
media	5	O
.	1	O

The	3	O
best	4	O
medium	6	O
of	2	O
those	5	O
tested	6	O
was	3	O
RPMI	4	O
1640	4	O
supplemented	12	O
with	4	O
5	1	O
micrograms	10	O
/	1	O
ml	2	O
each	4	O
transferrin	11	B-Gene
and	3	O
insulin	7	B-Gene
+	1	O
5	1	O
ng	2	O
/	1	O
ml	2	O
sodium	6	B-Chemical
selenite	8	I-Chemical
+	1	O
/	1	O
-	1	O
0.1	3	O
%	1	O
bovine	6	B-Gene
serum	5	I-Gene
albumin	7	I-Gene
.	1	O

While	5	O
growing	7	O
either	6	O
with	4	O
or	2	O
without	7	O
albumin	7	B-Gene
,	1	O
the	3	O
several	7	O
clonal	6	O
lines	5	O
of	2	O
CEM	3	O
cells	5	O
displayed	9	O
growth	6	O
similar	7	O
to	2	O
serum	5	O
-supplemented	13	O
cultures	8	O
.	1	O

Cell	4	O
proliferation	13	O
of	2	O
CEM-C7	6	O
cells	5	O
cultured	8	O
in	2	O
both	4	O
serum-free	10	O
media	5	O
has	3	O
been	4	O
sustained	9	O
for	3	O
3	1	O
mo	2	O
.	1	O

with	4	O
culture	7	O
doubling	8	O
times	5	O
of	2	O
about	5	O
25	2	O
h	1	O
for	3	O
both	4	O
serum	5	O
-supplemented	13	O
and	3	O
serum-free	10	O
cultures	8	O
(	1	O
viability	9	O
greater	7	O
than	4	O
or	2	O
equal	5	O
to	2	O
90	2	O
%	1	O
)	1	O
.	1	O

Cell	4	O
morphology	10	O
remained	8	O
essentially	11	O
the	3	O
same	4	O
in	2	O
serum-free	10	O
or	2	O
serum	5	O
containing	10	O
media	5	O
.	1	O

The	3	O
expression	10	O
of	2	O
CD4	3	B-Gene
,	1	O
a	1	O
marker	6	O
for	3	O
T	1	O
-derived	8	O
lymphoid	8	O
cells	5	O
,	1	O
was	3	O
not	3	O
significantly	13	O
different	9	O
in	2	O
serum-free	10	O
medium	6	O
.	1	O

When	4	O
grown	5	O
in	2	O
serum-free	10	O
medium	6	O
,	1	O
CEM-C7	6	O
cells	5	O
exhibited	9	O
increased	9	O
steroid	7	B-Chemical
responsiveness	14	O
as	2	O
evidenced	9	O
by	2	O
increased	9	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
binding	7	O
sites	5	O
,	1	O
increased	9	O
induction	9	O
of	2	O
glutamine	9	B-Gene
synthetase	10	I-Gene
,	1	O
and	3	O
cell	4	O
lysis	5	O
at	2	O
lower	5	O
concentrations	14	O
of	2	O
steroid	7	B-Chemical
.	1	O

Receptor	8	O
mutant	6	O
subclones	9	O
of	2	O
CEM-C7	6	O
,	1	O
which	5	O
are	3	O
proven	6	O
to	2	O
be	2	O
completely	10	O
unresponsive	12	O
to	2	O
micromolar	10	O
concentrations	14	O
of	2	O
dexamethasone	13	B-Chemical
when	4	O
grown	5	O
in	2	O
serum	5	O
-supplemented	13	O
medium	6	O
,	1	O
become	6	O
partially	9	O
sensitive	9	O
to	2	O
the	3	O
hormone	7	O
after	5	O
growth	6	O
in	2	O
defined	7	O
medium	6	O
.	1	O

The	3	O
increased	9	O
sensitivity	11	O
of	2	O
CEM-C7	6	O
cells	5	O
and	3	O
its	3	O
subclones	9	O
to	2	O
dexamethasone	13	B-Chemical
in	2	O
serum-free	10	O
medium	6	O
returned	8	O
to	2	O
previous	8	O
levels	6	O
when	4	O
these	5	O
cells	5	O
were	4	O
recultured	10	O
in	2	O
serum	5	O
-containing	11	O
medium	6	O
.	1	O

Our	3	O
results	7	O
suggest	7	O
that	4	O
substances	10	O
in	2	O
serum	5	O
influence	9	O
steroid	7	B-Chemical
effects	7	O
on	2	O
these	5	O
cells	5	O
and	3	O
that	4	O
the	3	O
molecular	9	O
details	7	O
of	2	O
glucocorticoid	14	B-Chemical
hormone	7	O
action	6	O
may	3	O
be	2	O
pursued	7	O
more	4	O
precisely	9	O
in	2	O
a	1	O
clearly	7	O
defined	7	O
culture	7	O
medium	6	O
.	1	O

Lipopolysaccharide	18	B-Chemical
is	2	O
a	1	O
potent	6	O
monocyte	8	O
/	1	O
macrophage-specific	19	O
stimulator	10	O
of	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
expression	10	O
.	1	O

Lipopolysaccharide	18	B-Chemical
(	1	O
LPS	3	B-Chemical
)	1	O
potently	8	O
stimulates	10	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1-long	6	O
terminal	8	O
repeat	6	O
(	1	O
HIV-1-LTR	9	O
)	1	O
CAT	3	O
constructs	10	O
transfected	11	O
into	4	O
monocyte	8	O
/	1	O
macrophage	10	O
-like	5	O
cell	4	O
lines	5	O
but	3	O
not	3	O
a	1	O
T	1	O
cell	4	O
line	4	O
.	1	O

This	4	O
effect	6	O
appears	7	O
to	2	O
be	2	O
mediated	8	O
through	7	O
the	3	O
induction	9	O
of	2	O
nuclear	7	B-Gene
factor	6	I-Gene
kappa	5	I-Gene
B	1	I-Gene
(	1	O
NF-kappa	8	B-Gene
B	1	I-Gene
)	1	O
.	1	O

Electrophoretic	15	O
mobility	8	O
shift	5	O
assays	6	O
demonstrate	11	O
that	4	O
LPS	3	B-Chemical
induces	7	O
a	1	O
DNA	3	O
binding	7	O
activity	8	O
indistinguishable	17	O
from	4	O
NF-kappa	8	B-Gene
B	1	I-Gene
in	2	O
U937	4	O
and	3	O
THP-1	5	O
cells	5	O
.	1	O

LPS	3	B-Chemical
is	2	O
also	4	O
shown	5	O
to	2	O
dramatically	12	O
increase	8	O
HIV-1	5	O
production	10	O
from	4	O
a	1	O
chronically	11	O
infected	8	O
monocyte	8	O
/	1	O
macrophage	10	O
-like	5	O
cloned	6	O
cell	4	O
line	4	O
,	1	O
U1	2	O
,	1	O
which	5	O
produces	8	O
very	4	O
low	3	O
levels	6	O
of	2	O
HIV-1	5	O
at	2	O
baseline	8	O
.	1	O

The	3	O
stimulation	11	O
of	2	O
viral	5	O
production	10	O
from	4	O
this	4	O
cell	4	O
line	4	O
occurs	6	O
only	4	O
if	2	O
these	5	O
cells	5	O
are	3	O
treated	7	O
with	4	O
granulocyte	11	B-Gene
/	1	I-Gene
macrophage	10	I-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
(	1	O
GM-CSF	6	B-Gene
)	1	O
before	6	O
treatment	9	O
with	4	O
LPS	3	B-Chemical
.	1	O

This	4	O
stimulation	11	O
of	2	O
HIV-1	5	O
production	10	O
is	2	O
correlated	10	O
with	4	O
an	2	O
increase	8	O
in	2	O
the	3	O
level	5	O
of	2	O
HIV-1	5	O
RNA	3	O
and	3	O
and	3	O
activation	10	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
.	1	O

LPS	3	B-Chemical
is	2	O
not	3	O
able	4	O
to	2	O
induce	6	O
HIV-1	5	O
production	10	O
in	2	O
a	1	O
cloned	6	O
T	1	O
cell	4	O
line	4	O
.	1	O

The	3	O
effect	6	O
of	2	O
LPS	3	B-Chemical
on	2	O
HIV-1	5	O
replication	11	O
occurs	6	O
at	2	O
picogram	8	O
per	3	O
milliliter	10	O
concentrations	14	O
and	3	O
may	3	O
be	2	O
clinically	10	O
significant	11	O
in	2	O
understanding	13	O
the	3	O
variability	11	O
of	2	O
the	3	O
natural	7	O
history	7	O
of	2	O
HIV-1	5	O
infection	9	O
.	1	O

Stimulation	11	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
2	1	O
(	1	O
HIV-2	5	O
)	1	O
gene	4	O
expression	10	O
by	2	O
the	3	O
cytomegalovirus	15	O
and	3	O
HIV-2	5	O
transactivator	14	O
gene	4	O
.	1	O

Human	5	O
immunodeficiency	16	O
virus	5	O
(	1	O
HIV	3	O
)	1	O
often	5	O
causes	6	O
latent	6	O
infection	9	O
.	1	O

Transactivation	15	O
by	2	O
some	4	O
DNA	3	O
viruses	7	O
has	3	O
been	4	O
implicated	10	O
in	2	O
inducing	8	O
HIV-1	5	O
replication	11	O
and	3	O
pathogenesis	12	O
.	1	O

The	3	O
transactivator	14	B-Gene
(	1	I-Gene
IE-2	4	I-Gene
)	1	I-Gene
gene	4	I-Gene
of	2	O
the	3	O
human	5	O
cytomegalovirus	15	O
(	1	O
CMV	3	O
)	1	O
can	3	O
enhance	7	O
HIV-2	5	O
as	2	O
well	4	O
as	2	O
HIV-1	5	O
gene	4	O
expression	10	O
in	2	O
vitro	5	O
.	1	O

This	4	O
inducer	7	O
can	3	O
act	3	O
in	2	O
concert	7	O
with	4	O
the	3	O
HIV-2	5	B-Gene
tat	3	I-Gene
gene	4	I-Gene
and	3	O
T-cell	6	O
activation	10	O
in	2	O
enhancing	9	O
gene	4	O
expression	10	O
in	2	O
human	5	B-Gene
CD4+	4	I-Gene
lymphocytes	11	O
.	1	O

While	5	O
the	3	O
HIV-2	5	O
and	3	O
HIV-1	5	B-Gene
tat	3	I-Gene
genes	5	I-Gene
and	3	O
T-cell	6	O
activators	10	O
apparently	10	O
employ	6	O
independent	11	O
modes	5	O
of	2	O
action	6	O
,	1	O
the	3	O
CMV	3	O
transactivator	14	O
in	2	O
combination	11	O
with	4	O
the	3	O
HIV-2	5	B-Gene
tat	3	I-Gene
or	2	O
T-cell	6	O
activators	10	O
may	3	O
employ	6	O
a	1	O
gene	4	O
activation	10	O
pathway	7	O
with	4	O
some	4	O
common	6	O
and	3	O
some	4	O
distinct	8	O
components	10	O
.	1	O

Both	4	O
HIV-2	5	O
and	3	O
CMV	3	O
transactivators	15	O
enhance	7	O
HIV-2	5	O
gene	4	O
expression	10	O
by	2	O
transcriptional	15	O
activation	10	O
involving	9	O
transcript	10	O
initiation	10	O
as	2	O
well	4	O
as	2	O
elongation	10	O
,	1	O
with	4	O
CMV	3	O
transactivator	14	O
affecting	9	O
elongation	10	O
more	4	O
than	4	O
the	3	O
initiation	10	O
.	1	O

A	1	O
significant	11	O
proportion	10	O
of	2	O
transcripts	11	O
appear	6	O
to	2	O
terminate	9	O
prematurely	11	O
in	2	O
the	3	O
absence	7	O
of	2	O
transactivators	15	O
.	1	O

Deletion	8	O
mutation	8	O
analysis	8	O
of	2	O
the	3	O
HIV-2	5	O
long	4	O
terminal	8	O
repeat	6	O
(	1	O
LTR	3	O
)	1	O
suggests	8	O
that	4	O
the	3	O
element	7	O
that	4	O
responds	8	O
to	2	O
CMV	3	O
transactivation	15	O
in	2	O
human	5	B-Gene
CD4+	4	I-Gene
lymphocytes	11	O
is	2	O
either	6	O
a	1	O
diffuse	7	O
one	3	O
or	2	O
located	7	O
downstream	10	O
of	2	O
the	3	O
HIV-2	5	O
enhancer	8	O
element	7	O
.	1	O

Sequence-specific	17	O
DNA	3	O
binding	7	O
of	2	O
the	3	O
proto-oncoprotein	17	B-Gene
ets-1	5	I-Gene
defines	7	O
a	1	O
transcriptional	15	O
activator	9	O
sequence	8	O
within	6	O
the	3	O
long	4	O
terminal	8	O
repeat	6	O
of	2	O
the	3	O
Moloney	7	O
murine	6	O
sarcoma	7	B-Disease
virus	5	O
.	1	O

The	3	O
ets	3	B-Gene
proto-oncogene	14	I-Gene
family	6	I-Gene
is	2	O
a	1	O
group	5	O
of	2	O
sequence	8	O
-related	8	O
genes	5	O
whose	5	O
normal	6	O
cellular	8	O
function	8	O
is	2	O
unknown	7	O
.	1	O

In	2	O
a	1	O
study	5	O
of	2	O
cellular	8	O
proteins	8	O
involved	8	O
in	2	O
the	3	O
transcriptional	15	O
regulation	10	O
of	2	O
murine	6	O
retroviruses	12	O
in	2	O
T	1	O
lymphocytes	11	O
,	1	O
we	2	O
have	4	O
discovered	10	O
that	4	O
a	1	O
member	6	O
of	2	O
the	3	O
ets	3	B-Gene
gene	4	I-Gene
family	6	I-Gene
encodes	7	O
a	1	O
sequence-specific	17	O
DNA	3	O
-binding	8	O
protein	7	O
.	1	O

A	1	O
mouse	5	B-Gene
ets-1	5	I-Gene
cDNA	4	I-Gene
clone	5	I-Gene
was	3	O
obtained	8	O
by	2	O
screening	9	O
a	1	O
mouse	5	O
thymus	6	O
cDNA	4	O
expression	10	O
library	7	O
with	4	O
a	1	O
double	6	O
-stranded	9	O
oligonucleotide	15	O
probe	5	O
representing	12	O
20	2	O
bp	2	O
of	2	O
the	3	O
Moloney	7	O
murine	6	O
sarcoma	7	B-Disease
virus	5	O
(	1	O
MSV	3	O
)	1	O
long	4	O
terminal	8	O
repeat	6	O
(	1	O
LTR	3	O
)	1	O
.	1	O

The	3	O
cDNA	4	O
sequence	8	O
has	3	O
an	2	O
813-bp	6	O
open	4	O
reading	7	O
frame	5	O
(	1	O
ORF	3	O
)	1	O
whose	5	O
predicted	9	O
amino	5	O
acid	4	O
sequence	8	O
is	2	O
97.6	4	O
%	1	O
identical	9	O
to	2	O
the	3	O
272	3	O
carboxy-terminal	16	O
amino	5	O
acids	5	O
of	2	O
the	3	O
human	5	B-Gene
ets-1	5	I-Gene
protein	7	I-Gene
.	1	O

The	3	O
ORF	3	O
was	3	O
expressed	9	O
in	2	O
bacteria	8	O
,	1	O
and	3	O
the	3	O
30-kD	5	O
protein	7	O
product	7	O
was	3	O
shown	5	O
to	2	O
bind	4	O
DNA	3	O
in	2	O
a	1	O
sequence-specific	17	O
manner	6	O
by	2	O
mobility-shift	14	O
assays	6	O
,	1	O
Southwestern	12	O
blot	4	O
analysis	8	O
,	1	O
and	3	O
methylation	11	O
interference	12	O
.	1	O

A	1	O
mutant	6	O
LTR	3	O
containing	10	O
four	4	O
base	4	O
pair	4	O
substitutions	13	O
in	2	O
the	3	O
ets-1	5	B-Gene
binding	7	O
site	4	O
was	3	O
constructed	11	O
and	3	O
was	3	O
shown	5	O
to	2	O
have	4	O
reduced	7	O
binding	7	O
in	2	O
vitro	5	O
.	1	O

Transcriptional	15	O
efficiency	10	O
of	2	O
the	3	O
MSV	3	O
LTR	3	O
promoter	8	O
containing	10	O
this	4	O
disrupted	9	O
ets-1	5	B-Gene
binding	7	O
site	4	O
was	3	O
compared	8	O
to	2	O
the	3	O
activity	8	O
of	2	O
a	1	O
wild-type	9	O
promoter	8	O
in	2	O
mouse	5	O
T	1	O
lymphocytes	11	O
in	2	O
culture	7	O
,	1	O
and	3	O
15-	3	O
to	2	O
20-fold	7	O
reduction	9	O
in	2	O
expression	10	O
of	2	O
a	1	O
reporter	8	O
gene	4	O
was	3	O
observed	8	O
.	1	O

We	2	O
propose	7	O
that	4	O
ets-1	5	B-Gene
functions	9	O
as	2	O
a	1	O
transcriptional	15	O
activator	9	O
of	2	O
mammalian	9	O
type-C	6	O
retroviruses	12	O
and	3	O
speculate	9	O
that	4	O
ets	3	B-Gene
-related	8	O
genes	5	O
constitute	10	O
a	1	O
new	3	O
group	5	O
of	2	O
eukaryotic	10	O
DNA	3	O
-binding	8	O
proteins	8	O
.	1	O

Cloning	7	O
of	2	O
a	1	O
transcriptionally	17	O
active	6	O
human	5	B-Gene
TATA	4	I-Gene
binding	7	I-Gene
factor	6	I-Gene
.	1	O

Transcription	13	B-Gene
factor	6	I-Gene
IID	3	I-Gene
(	1	O
TFIID	5	B-Gene
)	1	O
binds	5	O
to	2	O
the	3	O
TATA	4	O
box	3	O
promoter	8	O
element	7	O
and	3	O
regulates	9	O
the	3	O
expression	10	O
of	2	O
most	4	O
eukaryotic	10	O
genes	5	O
transcribed	11	O
by	2	O
RNA	3	B-Gene
polymerase	10	I-Gene
II	2	I-Gene
.	1	O

Complementary	13	O
DNA	3	O
(	1	O
cDNA	4	O
)	1	O
encoding	8	O
a	1	O
human	5	B-Gene
TFIID	5	I-Gene
protein	7	I-Gene
has	3	O
been	4	O
cloned	6	O
.	1	O

The	3	O
human	5	B-Gene
TFIID	5	I-Gene
polypeptide	11	I-Gene
has	3	O
339	3	O
amino	5	O
acids	5	O
and	3	O
a	1	O
molecular	9	O
size	4	O
of	2	O
37	2	O
,	1	O
745	3	O
daltons	7	O
.	1	O

The	3	O
carboxyl-terminal	17	B-Chemical
181	3	O
amino	5	O
acids	5	O
of	2	O
the	3	O
human	5	B-Gene
TFIID	5	I-Gene
protein	7	I-Gene
shares	6	O
80	2	O
%	1	O
identity	8	O
with	4	O
the	3	O
TFIID	5	B-Gene
protein	7	I-Gene
from	4	O
Saccharomyces	13	O
cerevisiae	10	O
.	1	O

The	3	O
amino	5	O
terminus	8	O
contains	8	O
an	2	O
unusual	7	O
repeat	6	O
of	2	O
38	2	O
consecutive	11	O
glutamine	9	B-Chemical
residues	8	I-Chemical
and	3	O
an	2	O
X-Thr-Pro	9	B-Chemical
repeat	6	O
.	1	O

Expression	10	O
of	2	O
DNA	3	O
in	2	O
reticulocyte	12	O
lysates	7	O
or	2	O
in	2	O
Escherichia	11	O
coli	4	O
yielded	7	O
a	1	O
protein	7	O
that	4	O
was	3	O
competent	9	O
for	3	O
both	4	O
DNA	3	O
binding	7	O
and	3	O
transcription	13	O
activation	10	O
.	1	O

Mononuclear	11	B-Gene
leukocyte	9	I-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
binding	7	O
characteristics	15	O
and	3	O
down-regulation	15	O
in	2	O
major	5	B-Disease
depression	10	I-Disease
.	1	O

Some	4	O
patients	8	O
with	4	O
major	5	B-Disease
depressive	10	I-Disease
disorder	8	I-Disease
(	1	O
MDD	3	B-Disease
)	1	O
have	4	O
elevated	8	O
plasma	6	O
cortisol	8	B-Chemical
concentrations	14	O
and	3	O
show	4	O
failure	7	O
to	2	O
suppress	8	O
cortisol	8	B-Chemical
secretion	9	O
upon	4	O
administration	14	O
of	2	O
dexamethasone	13	B-Chemical
(	1	O
DEX	3	B-Chemical
)	1	O
,	1	O
yet	3	O
they	4	O
do	2	O
not	3	O
have	4	O
Cushingoid	10	O
features	8	O
.	1	O

To	2	O
study	5	O
whether	7	O
this	4	O
represents	10	O
glucocorticoid	14	B-Chemical
(	1	O
GC	2	B-Chemical
)	1	O
resistance	10	O
,	1	O
[	1	O
3H	2	O
]	1	O
-DEX	4	B-Chemical
-binding	8	O
assays	6	O
were	4	O
used	4	O
to	2	O
measure	7	O
,	1	O
in	2	O
vitro	5	O
,	1	O
the	3	O
GC	2	B-Gene
receptor	8	I-Gene
affinity	8	O
(	1	O
1	1	O
/	1	O
Kd	2	O
)	1	O
and	3	O
number	6	O
(	1	O
Bmax	4	O
)	1	O
in	2	O
mononuclear	11	O
leukocytes	10	O
of	2	O
11	2	O
MDD	3	B-Disease
patients	8	O
and	3	O
15	2	O
control	7	O
subjects	8	O
.	1	O

No	2	O
receptor	8	O
abnormalities	13	O
were	4	O
detected	8	O
in	2	O
the	3	O
MDD	3	B-Disease
group	5	O
;	1	O
thus	4	O
any	3	O
cellular	8	O
defect	6	O
leading	7	O
to	2	O
a	1	O
lack	4	O
of	2	O
responsiveness	14	O
to	2	O
GC	2	B-Chemical
in	2	O
the	3	O
MDD	3	B-Disease
patients	8	O
,	1	O
if	2	O
present	7	O
,	1	O
probably	8	O
lies	4	O
beyond	6	O
the	3	O
initial	7	O
receptor	8	O
binding	7	O
.	1	O

DEX	3	B-Chemical
(	1	O
1.0	3	O
mg	2	O
orally	6	O
)	1	O
was	3	O
administered	12	O
to	2	O
study	5	O
in	2	O
vivo	4	O
GC	2	B-Gene
receptor	8	I-Gene
down-regulation	15	O
.	1	O

Compared	8	O
to	2	O
the	3	O
control	7	O
group	5	O
,	1	O
fewer	5	O
depressed	9	O
subjects	8	O
down	4	O
-regulated	10	O
Bmax	4	O
after	5	O
DEX	3	B-Chemical
.	1	O

By	2	O
paired	6	O
t-test	6	O
,	1	O
Bmax	4	O
decreased	9	O
significantly	13	O
in	2	O
the	3	O
control	7	O
group	5	O
but	3	O
not	3	O
in	2	O
the	3	O
depressed	9	O
group	5	O
.	1	O

Receptor	8	O
number	6	O
on	2	O
the	3	O
control	7	O
day	3	O
did	3	O
not	3	O
correlate	9	O
significantly	13	O
with	4	O
the	3	O
degree	6	O
of	2	O
receptor	8	O
down-regulation	15	O
,	1	O
severity	8	O
of	2	O
depression	10	B-Disease
or	2	O
cortisol	8	B-Chemical
concentrations	14	O
across	6	O
all	3	O
the	3	O
subjects	8	O
.	1	O

These	5	O
results	7	O
do	2	O
not	3	O
lend	4	O
support	7	O
to	2	O
previous	8	O
reports	7	O
suggesting	10	O
that	4	O
GC	2	B-Chemical
resistance	10	O
in	2	O
MDD	3	B-Disease
results	7	O
from	4	O
a	1	O
GC	2	B-Gene
receptor	8	I-Gene
-binding	8	O
abnormality	11	O
,	1	O
and	3	O
they	4	O
emphasize	9	O
the	3	O
importance	10	O
of	2	O
considering	11	O
receptor	8	O
studies	7	O
in	2	O
the	3	O
context	7	O
of	2	O
GC	2	B-Chemical
-mediated	9	O
cell	4	O
processes	9	O
in	2	O
order	5	O
to	2	O
identify	8	O
the	3	O
exact	5	O
cellular	8	O
defect	6	O
(	1	O
s	1	O
)	1	O
leading	7	O
to	2	O
GC	2	B-Chemical
resistance	10	O
.	1	O

The	3	O
Epstein-Barr	12	B-Gene
virus	5	I-Gene
(	1	I-Gene
EBV	3	I-Gene
)	1	I-Gene
BMRF1	5	I-Gene
promoter	8	I-Gene
for	3	O
early	5	O
antigen	7	O
(	1	O
EA-D	4	B-Gene
)	1	O
is	2	O
regulated	9	O
by	2	O
the	3	O
EBV	3	O
transactivators	15	O
,	1	O
BRLF1	5	B-Gene
and	3	O
BZLF1	5	B-Gene
,	1	O
in	2	O
a	1	O
cell-specific	13	O
manner	6	O
.	1	O

The	3	O
Epstein-Barr	12	B-Gene
virus	5	I-Gene
early	5	I-Gene
antigen	7	I-Gene
diffuse	7	O
component	9	O
(	1	O
EA-D	4	B-Gene
)	1	O
is	2	O
essential	9	O
for	3	O
Epstein-Barr	12	B-Gene
virus	5	I-Gene
DNA	3	I-Gene
polymerase	10	I-Gene
activity	8	O
,	1	O
and	3	O
its	3	O
activity	8	O
is	2	O
suppressed	10	O
during	6	O
latent	6	O
infection	9	O
.	1	O

We	2	O
investigated	12	O
the	3	O
regulation	10	O
of	2	O
the	3	O
promoter	8	O
(	1	O
BMRF1	5	B-Gene
)	1	O
for	3	O
this	4	O
early	5	O
gene	4	O
by	2	O
studying	8	O
its	3	O
responsiveness	14	O
in	2	O
vitro	5	O
to	2	O
two	3	O
immediate-early	15	O
viral	5	O
transactivators	15	O
,	1	O
BZLF1	5	B-Gene
(	1	O
Z	1	B-Gene
)	1	O
and	3	O
BRLF1	5	B-Gene
(	1	O
R	1	B-Gene
)	1	O
,	1	O
focusing	8	O
on	2	O
the	3	O
differences	11	O
in	2	O
response	8	O
in	2	O
lymphoid	8	O
cells	5	O
and	3	O
epithelial	10	O
cells	5	O
.	1	O

In	2	O
lymphoid	8	O
cells	5	O
,	1	O
Z	1	B-Gene
or	2	O
R	1	B-Gene
alone	5	O
produced	8	O
only	4	O
small	5	O
increases	9	O
in	2	O
EA-D	4	B-Gene
promoter	8	I-Gene
activity	8	O
,	1	O
whereas	7	O
both	4	O
transactivators	15	O
together	8	O
produced	8	O
a	1	O
large	5	O
stimulatory	11	O
effect	6	O
.	1	O

In	2	O
epithelial	10	O
cells	5	O
,	1	O
the	3	O
Z	1	B-Gene
transactivator	14	I-Gene
alone	5	O
produced	8	O
maximal	7	O
stimulation	11	O
of	2	O
the	3	O
EA-D	4	B-Gene
promoter	8	I-Gene
;	1	O
the	3	O
effect	6	O
of	2	O
R	1	B-Gene
and	3	O
Z	1	B-Gene
together	8	O
was	3	O
no	2	O
greater	7	O
than	4	O
that	4	O
of	2	O
Z	1	B-Gene
alone	5	O
.	1	O

Deletional	10	O
analysis	8	O
and	3	O
site	4	O
-directed	9	O
mutagenesis	11	O
of	2	O
the	3	O
EA-D	4	B-Gene
promoter	8	I-Gene
demonstrated	12	O
that	4	O
in	2	O
epithelial	10	O
cells	5	O
the	3	O
potential	9	O
AP-1	4	B-Gene
binding	7	O
site	4	O
plays	5	O
an	2	O
essential	9	O
role	4	O
in	2	O
Z	1	B-Gene
responsiveness	14	O
,	1	O
although	8	O
sequences	9	O
further	7	O
upstream	8	O
are	3	O
also	4	O
important	9	O
.	1	O

In	2	O
lymphoid	8	O
cells	5	O
,	1	O
only	4	O
the	3	O
upstream	8	O
sequences	9	O
are	3	O
required	8	O
for	3	O
transactivation	15	O
by	2	O
the	3	O
Z	1	B-Gene
/	1	I-Gene
R	1	I-Gene
combination	11	O
,	1	O
and	3	O
the	3	O
AP-1	4	B-Gene
site	4	O
is	2	O
dispensable	11	O
.	1	O

These	5	O
data	4	O
suggest	7	O
that	4	O
EA-D	4	B-Gene
(	1	I-Gene
BMRF1	5	I-Gene
)	1	I-Gene
promoter	8	I-Gene
regulation	10	O
by	2	O
Z	1	B-Gene
and	3	O
R	1	B-Gene
is	2	O
cell	4	O
type	4	O
specific	8	O
and	3	O
appears	7	O
to	2	O
involve	7	O
different	9	O
mechanisms	10	O
in	2	O
each	4	O
cell	4	O
type	4	O
.	1	O

Inducible	9	O
nuclear	7	O
factor	6	O
binding	7	O
to	2	O
the	3	O
kappa	5	O
B	1	O
elements	8	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
enhancer	8	O
in	2	O
T	1	O
cells	5	O
can	3	O
be	2	O
blocked	7	O
by	2	O
cyclosporin	11	B-Chemical
A	1	I-Chemical
in	2	O
a	1	O
signal	6	O
-dependent	10	O
manner	6	O
.	1	O

Cyclosporin	11	B-Chemical
A	1	I-Chemical
(	1	O
CsA	3	B-Chemical
)	1	O
is	2	O
thought	7	O
to	2	O
exert	5	O
its	3	O
immunosuppressive	17	O
effects	7	O
by	2	O
inhibiting	10	O
the	3	O
expression	10	O
of	2	O
a	1	O
distinct	8	O
set	3	O
of	2	O
lymphokine	10	O
genes	5	O
which	5	O
are	3	O
induced	7	O
upon	4	O
T-cell	6	O
activation	10	O
,	1	O
among	5	O
them	4	O
the	3	O
gene	4	O
coding	6	O
for	3	O
interleukin-2	13	B-Gene
.	1	O

In	2	O
addition	8	O
,	1	O
the	3	O
activation	10	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
(	1	O
HIV	3	O
)	1	O
is	2	O
partially	9	O
suppressed	10	O
.	1	O

To	2	O
better	6	O
understand	10	O
the	3	O
molecular	9	O
mechanisms	10	O
underlying	10	O
suppression	11	O
by	2	O
CsA	3	B-Chemical
,	1	O
we	2	O
have	4	O
investigated	12	O
the	3	O
effects	7	O
of	2	O
this	4	O
drug	4	O
on	2	O
transcription	13	O
factors	7	O
in	2	O
T	1	O
cells	5	O
.	1	O

Here	4	O
we	2	O
report	6	O
that	4	O
the	3	O
formation	9	O
of	2	O
two	3	O
distinct	8	O
mitogen-inducible	17	O
DNA	3	O
-binding	8	O
complexes	9	O
,	1	O
the	3	O
kappa	5	O
B	1	O
complex	7	O
within	6	O
the	3	O
HIV	3	B-Gene
enhancer	8	I-Gene
and	3	O
the	3	O
NFAT-1	6	B-Gene
complex	7	I-Gene
within	6	O
the	3	O
interleukin-2	13	B-Gene
enhancer	8	I-Gene
,	1	O
is	2	O
inhibited	9	O
in	2	O
the	3	O
presence	8	O
of	2	O
CsA	3	B-Chemical
.	1	O

The	3	O
kappa	5	O
B	1	O
-binding	8	O
activity	8	O
with	4	O
the	3	O
HIV	3	B-Gene
enhancer	8	I-Gene
is	2	O
inhibited	9	O
only	4	O
if	2	O
it	2	O
is	2	O
activated	9	O
via	3	O
the	3	O
mitogen	7	O
phytohemagglutinin	18	B-Gene
whereas	7	O
phorbol	7	B-Chemical
myristate	9	I-Chemical
acetate	7	I-Chemical
-mediated	9	O
activation	10	O
is	2	O
completely	10	O
insensitive	11	O
to	2	O
the	3	O
drug	4	O
.	1	O

This	4	O
suggests	8	O
a	1	O
model	5	O
in	2	O
which	5	O
functionally	12	O
indistinguishable	17	O
kappa	5	O
B	1	O
complexes	9	O
can	3	O
be	2	O
activated	9	O
via	3	O
two	3	O
separate	8	O
pathways	8	O
of	2	O
signal	6	O
transduction	12	O
distinguishable	15	O
by	2	O
CsA	3	B-Chemical
.	1	O

Two	3	O
distinct	8	O
forms	5	O
of	2	O
active	6	O
transcription	13	B-Gene
factor	6	I-Gene
CREB	4	I-Gene
(	1	O
cAMP	4	B-Gene
response	8	I-Gene
element	7	I-Gene
binding	7	I-Gene
protein	7	I-Gene
)	1	O
.	1	O

Mammalian	9	O
cells	5	O
express	7	O
two	3	O
distinct	8	O
forms	5	O
of	2	O
transcription	13	B-Gene
factor	6	I-Gene
CREB	4	I-Gene
(	1	O
cAMP	4	B-Gene
response	8	I-Gene
element	7	I-Gene
binding	7	I-Gene
protein	7	I-Gene
)	1	O
that	4	O
are	3	O
apparently	10	O
the	3	O
products	8	O
of	2	O
alternative	11	O
splicing	8	O
of	2	O
the	3	O
CREB	4	B-Gene
gene	4	I-Gene
transcript	10	I-Gene
.	1	O

The	3	O
two	3	O
proteins	8	O
differ	6	O
by	2	O
a	1	O
14-amino	8	O
acid	4	O
serine-rich	11	B-Chemical
insertion	9	O
present	7	O
in	2	O
one	3	O
of	2	O
the	3	O
CREB	4	B-Gene
isoforms	8	I-Gene
.	1	O

We	2	O
show	4	O
that	4	O
both	4	O
CREB	4	B-Gene
isoforms	8	I-Gene
are	3	O
expressed	9	O
in	2	O
many	4	O
cell	4	O
types	5	O
and	3	O
mammalian	9	O
species	7	O
.	1	O

Both	4	O
encode	6	O
proteins	8	O
that	4	O
bind	4	O
specifically	12	O
to	2	O
a	1	O
cAMP	4	B-Chemical
response	8	O
element	7	O
in	2	O
vitro	5	O
.	1	O

As	2	O
expected	8	O
for	3	O
proteins	8	O
of	2	O
this	4	O
class	5	O
,	1	O
the	3	O
CREB	4	B-Gene
proteins	8	I-Gene
bind	4	O
DNA	3	O
as	2	O
dimers	6	O
.	1	O

Both	4	O
proteins	8	O
impart	6	O
cAMP	4	B-Chemical
-regulated	10	O
transcriptional	15	O
activity	8	O
to	2	O
a	1	O
heterologous	12	O
DNA	3	O
-binding	8	O
domain	6	O
,	1	O
showing	7	O
that	4	O
cAMP	4	B-Chemical
directly	8	O
modulates	9	O
the	3	O
transcriptional	15	O
stimulatory	11	O
activity	8	O
of	2	O
CREB	4	B-Gene
.	1	O

The	3	O
presence	8	O
of	2	O
multiple	8	O
CREB	4	B-Gene
isoforms	8	I-Gene
with	4	O
identical	9	O
DNA	3	O
-binding	8	O
specificities	13	O
but	3	O
differences	11	O
in	2	O
the	3	O
presumed	8	O
regulatory	10	O
domain	6	O
raises	6	O
the	3	O
possibility	11	O
that	4	O
CREB	4	B-Gene
proteins	8	I-Gene
may	3	O
be	2	O
able	4	O
to	2	O
integrate	9	O
distinct	8	O
regulatory	10	O
signals	7	O
at	2	O
the	3	O
level	5	O
of	2	O
gene	4	O
transcription	13	O
.	1	O

Complementary	13	O
DNA	3	O
encoding	8	O
the	3	O
human	5	B-Gene
T-cell	6	I-Gene
FK506	5	I-Gene
-binding	8	I-Gene
protein	7	I-Gene
,	1	O
a	1	O
peptidylprolyl	14	B-Gene
cis-trans	9	I-Gene
isomerase	9	I-Gene
distinct	8	O
from	4	O
cyclophilin	11	B-Gene
.	1	O

The	3	O
recently	8	O
discovered	10	O
macrolide	9	O
FK506	5	B-Chemical
has	3	O
been	4	O
demonstrated	12	O
to	2	O
have	4	O
potent	6	O
immunosuppressive	17	O
activity	8	O
at	2	O
concentrations	14	O
100-fold	8	O
lower	5	O
than	4	O
cyclosporin	11	B-Chemical
A	1	I-Chemical
,	1	O
a	1	O
cyclic	6	O
undecapeptide	13	O
that	4	O
is	2	O
used	4	O
to	2	O
prevent	7	O
rejection	9	O
after	5	O
transplantation	15	O
of	2	O
bone	4	O
marrow	6	O
and	3	O
organs	6	O
,	1	O
such	4	O
as	2	O
kidney	6	O
,	1	O
heart	5	O
,	1	O
and	3	O
liver	5	O
.	1	O

After	5	O
the	3	O
recent	6	O
discovery	9	O
that	4	O
the	3	O
cyclosporin	11	B-Gene
A	1	I-Gene
-binding	8	I-Gene
protein	7	I-Gene
cyclophilin	11	I-Gene
is	2	O
identical	9	O
to	2	O
peptidylprolyl	14	B-Gene
cis-trans	9	I-Gene
isomerase	9	I-Gene
,	1	O
a	1	O
cellular	8	O
binding	7	O
protein	7	O
for	3	O
FK506	5	B-Chemical
was	3	O
found	5	O
to	2	O
be	2	O
distinct	8	O
from	4	O
cyclophilin	11	B-Gene
but	3	O
to	2	O
have	4	O
the	3	O
same	4	O
enzymatic	9	O
activity	8	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
we	2	O
isolated	8	O
a	1	O
cDNA	4	O
coding	6	O
for	3	O
FK506	5	B-Gene
-binding	8	I-Gene
protein	7	I-Gene
(	1	O
FKBP	4	B-Gene
)	1	O
from	4	O
human	5	O
peripheral	10	O
blood	5	O
T	1	O
cells	5	O
by	2	O
using	5	O
mixed	5	O
20-mer	6	O
oligonucleotide	15	O
probes	6	O
synthesized	11	O
on	2	O
the	3	O
basis	5	O
of	2	O
the	3	O
sequence	8	O
,	1	O
Glu-Asp-Gly-Lys-Lys-Phe-Asp	27	B-Chemical
,	1	O
reported	8	O
for	3	O
bovine	6	B-Gene
FKBP	4	I-Gene
.	1	O

The	3	O
DNA	3	O
isolated	8	O
contained	9	O
an	2	O
open	4	O
reading	7	O
frame	5	O
encoding	8	O
108	3	O
amino	5	O
acid	4	O
residues	8	O
.	1	O

The	3	O
first	5	O
40	2	O
residues	8	O
of	2	O
the	3	O
deduced	7	O
amino	5	O
acid	4	O
sequence	8	O
were	4	O
identical	9	O
to	2	O
those	5	O
of	2	O
the	3	O
reported	8	O
amino-terminal	14	O
sequence	8	O
of	2	O
bovine	6	B-Gene
FKBP	4	I-Gene
,	1	O
indicating	10	O
that	4	O
the	3	O
DNA	3	O
sequence	8	O
isolated	8	O
represents	10	O
the	3	O
gene	4	O
coding	6	O
for	3	O
FKBP	4	B-Gene
.	1	O

Computer	8	O
-assisted	9	O
analysis	8	O
of	2	O
the	3	O
deduced	7	O
amino	5	O
acid	4	O
sequence	8	O
indicates	9	O
that	4	O
FKBP	4	B-Gene
exhibits	8	O
no	2	O
internal	8	O
homology	8	O
and	3	O
does	4	O
not	3	O
have	4	O
significant	11	O
sequence	8	O
similarity	10	O
to	2	O
any	3	O
other	5	O
amino	5	O
acid	4	O
sequences	9	O
of	2	O
known	5	O
proteins	8	O
,	1	O
including	9	O
cyclophilin	11	B-Gene
.	1	O

This	4	O
result	6	O
suggests	8	O
that	4	O
two	3	O
catalytically	13	O
similar	7	O
proteins	8	O
,	1	O
cyclophilin	11	B-Gene
and	3	O
FKBP	4	B-Gene
,	1	O
evolved	7	O
independently	13	O
.	1	O

In	2	O
Northern	8	O
blot	4	O
analysis	8	O
,	1	O
mRNA	4	O
species	7	O
of	2	O
approximately	13	O
1.8	3	O
kilobases	9	O
that	4	O
hybridized	10	O
with	4	O
human	5	B-Gene
FKBP	4	I-Gene
cDNA	4	I-Gene
were	4	O
detected	8	O
in	2	O
poly	4	O
(	1	O
A	1	O
)	1	O
+	1	O
RNAs	4	O
from	4	O
brain	5	O
,	1	O
lung	4	O
,	1	O
liver	5	O
,	1	O
and	3	O
placental	9	O
cells	5	O
and	3	O
leukocytes	10	O
.	1	O

Induction	9	O
of	2	O
Jurkat	6	O
leukemic	8	O
T	1	O
cells	5	O
with	4	O
phorbol	7	B-Chemical
12-myristate	12	I-Chemical
13-acetate	10	I-Chemical
and	3	O
ionomycin	9	B-Chemical
did	3	O
not	3	O
affect	6	O
the	3	O
level	5	O
of	2	O
FKBP	4	B-Gene
mRNA	4	I-Gene
.	1	O

Southern	8	O
blot	4	O
analysis	8	O
of	2	O
human	5	O
genomic	7	O
DNA	3	O
digested	8	O
with	4	O
different	9	O
restriction	11	O
enzymes	7	O
suggests	8	O
the	3	O
existence	9	O
of	2	O
only	4	O
a	1	O
few	3	O
copies	6	O
of	2	O
the	3	O
DNA	3	O
sequence	8	O
encoding	8	O
FKBP	4	B-Gene
.	1	O

This	4	O
is	2	O
in	2	O
contrast	8	O
to	2	O
the	3	O
result	6	O
that	4	O
as	2	O
many	4	O
as	2	O
20	2	O
copies	6	O
of	2	O
the	3	O
cyclophilin	11	B-Gene
gene	4	I-Gene
and	3	O
possible	8	O
pseudogenes	11	O
may	3	O
be	2	O
present	7	O
in	2	O
the	3	O
mammalian	9	O
genome	6	O
.	1	O

[	1	O
The	3	O
inhibitory	10	O
effect	6	O
of	2	O
hydrocortisone	14	B-Chemical
on	2	O
the	3	O
chemotactic	11	O
migration	9	O
of	2	O
human	5	O
leukocytes	10	O
]	1	O

Random	6	O
migration	9	O
(	1	O
RM	2	O
)	1	O
and	3	O
chemotactic	11	O
migration	9	O
(	1	O
ChtM	4	O
)	1	O
of	2	O
human	5	O
leukocytes	10	O
to	2	O
yeast	5	O
activated	9	O
serum	5	O
were	4	O
studied	7	O
with	4	O
the	3	O
modified	8	O
Boyden	6	O
chamber	7	O
method	6	O
.	1	O

Both	4	O
RM	2	O
and	3	O
ChtM	4	O
showed	6	O
circadian	9	O
rhythm	6	O
.	1	O

Leukocytes	10	O
migrated	8	O
most	4	O
rapidly	7	O
at	2	O
night	5	O
.	1	O

The	3	O
difference	10	O
between	7	O
the	3	O
peak	4	O
(	1	O
0	1	O
:	1	O
00	2	O
)	1	O
and	3	O
trough	6	O
values	6	O
(	1	O
8	1	O
:	1	O
00	2	O
)	1	O
of	2	O
RM	2	O
and	3	O
ChtM	4	O
was	3	O
significant	11	O
statistically	13	O
(	1	O
P	1	O
less	4	O
than	4	O
0.01	4	O
)	1	O
.	1	O

ChtM	4	O
was	3	O
inhibited	9	O
by	2	O
hydrocortisone	14	B-Chemical
(	1	O
F	1	O
)	1	O
of	2	O
physiological	13	O
concentration	13	O
(	1	O
10	2	O
(	1	O
-9	2	O
)	1	O
-10	3	O
(	1	O
-7	2	O
)	1	O
mol	3	O
/	1	O
L	1	O
)	1	O
which	5	O
was	3	O
dose	4	O
-dependent	10	O
and	3	O
completely	10	O
antagonized	11	O
by	2	O
the	3	O
competitive	11	O
antagonist	10	O
,	1	O
RU38486	7	B-Chemical
.	1	O

The	3	O
inhibitory	10	O
effect	6	O
was	3	O
much	4	O
more	4	O
evident	7	O
with	4	O
higher	6	O
dose	4	O
(	1	O
more	4	O
than	4	O
10	2	O
(	1	O
-5	2	O
)	1	O
mol	3	O
/	1	O
L	1	O
)	1	O
and	3	O
it	2	O
was	3	O
also	4	O
reversed	8	O
by	2	O
RU38486	7	B-Chemical
,	1	O
but	3	O
only	4	O
partially	9	O
.	1	O

It	2	O
is	2	O
suggested	9	O
that	4	O
glucocorticoids	15	B-Chemical
(	1	O
GC	2	B-Chemical
)	1	O
may	3	O
be	2	O
a	1	O
physiological	13	O
regulator	9	O
of	2	O
the	3	O
activity	8	O
of	2	O
leukocytes	10	O
and	3	O
its	3	O
inhibitory	10	O
action	6	O
on	2	O
ChtM	4	O
may	3	O
be	2	O
involved	8	O
in	2	O
antiinflammatory	16	O
mechanisms	10	O
of	2	O
GC	2	B-Chemical
of	2	O
pharmacological	15	O
doses	5	O
.	1	O

The	3	O
action	6	O
of	2	O
physiological	13	O
and	3	O
pharmacological	15	O
concentration	13	O
of	2	O
GC	2	B-Chemical
may	3	O
be	2	O
mediated	8	O
by	2	O
low	3	O
affinity	8	O
specific	8	O
binding	7	O
sites	5	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
.	1	O

The	3	O
56-59-kilodalton	16	O
protein	7	O
identified	10	O
in	2	O
untransformed	13	O
steroid	7	B-Gene
receptor	8	I-Gene
complexes	9	I-Gene
is	2	O
a	1	O
unique	6	O
protein	7	O
that	4	O
exists	6	O
in	2	O
cytosol	7	O
in	2	O
a	1	O
complex	7	O
with	4	O
both	4	O
the	3	O
70-	3	B-Partial_Gene
and	3	O
90-kilodalton	13	B-Gene
heat	4	I-Gene
shock	5	I-Gene
proteins	8	I-Gene
.	1	O

It	2	O
has	3	O
previously	10	O
been	4	O
shown	5	O
that	4	O
9S	2	O
,	1	O
untransformed	13	O
progestin	9	B-Chemical
,	1	O
estrogen	8	B-Chemical
,	1	O
androgen	8	B-Chemical
,	1	O
and	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
complexes	9	I-Gene
in	2	O
rabbit	6	O
uterine	7	O
and	3	O
liver	5	O
cytosols	8	O
contain	7	O
a	1	O
59-kDa	6	O
protein	7	O
[	1	O
Tai	3	O
,	1	O
P.K.	4	O
,	1	O
Maeda	5	O
,	1	O
Y.	2	O
,	1	O
Nakao	5	O
,	1	O
K.	2	O
,	1	O
Wakim	5	O
,	1	O
N.G.	4	O
,	1	O
Duhring	7	O
,	1	O
J.L.	4	O
,	1	O
&	1	O
Faber	5	O
,	1	O
L.E.	4	O
(	1	O
1986	4	O
)	1	O
Biochemistry	12	O
25	2	O
,	1	O
5269-5275	9	O
]	1	O
.	1	O

In	2	O
this	4	O
work	4	O
we	2	O
show	4	O
that	4	O
the	3	O
monoclonal	10	O
antibody	8	O
KN	2	O
382	3	O
/	1	O
EC1	3	O
raised	6	O
against	7	O
the	3	O
rabbit	6	O
59-kDa	6	O
protein	7	O
reacts	6	O
with	4	O
9S	2	O
,	1	O
untransformed	13	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
complexes	9	I-Gene
in	2	O
cytosol	7	O
prepared	8	O
from	4	O
human	5	O
IM-9	4	O
lymphocytes	11	O
but	3	O
not	3	O
with	4	O
4S	2	O
salt	4	O
-transformed	12	O
receptors	9	O
.	1	O

The	3	O
human	5	O
protein	7	O
recognized	10	O
by	2	O
the	3	O
EC1	3	B-Gene
antibody	8	I-Gene
is	2	O
a	1	O
56-kDa	6	B-Gene
protein	7	I-Gene
(	1	O
p56	3	B-Gene
)	1	O
of	2	O
moderate	8	O
abundance	9	O
located	7	O
predominantly	13	O
in	2	O
the	3	O
cytoplasm	9	O
by	2	O
indirect	8	O
immunofluorescence	18	O
.	1	O

There	5	O
are	3	O
at	2	O
least	5	O
six	3	O
isomorphs	9	O
of	2	O
p56	3	B-Gene
by	2	O
two-dimensional	15	O
gel	3	O
analysis	8	O
.	1	O

N-Terminal	10	O
sequencing	10	O
(	1	O
20	2	O
amino	5	O
acids	5	O
)	1	O
shows	5	O
that	4	O
p56	3	B-Gene
is	2	O
a	1	O
unique	6	O
human	5	O
protein	7	O
.	1	O

When	4	O
p56	3	B-Gene
is	2	O
immunoadsorbed	14	O
from	4	O
IM-9	4	O
cell	4	O
cytosol	7	O
,	1	O
both	4	O
the	3	O
70-	3	B-Partial_Gene
and	3	O
90-kDa	6	B-Gene
heat	4	I-Gene
shock	5	I-Gene
proteins	8	I-Gene
are	3	O
coadsorbed	10	O
in	2	O
an	2	O
immune-specific	15	O
manner	6	O
.	1	O

Neither	7	O
heat	4	B-Gene
shock	5	I-Gene
protein	7	I-Gene
reacts	6	O
directly	8	O
with	4	O
the	3	O
EC1	3	B-Gene
antibody	8	I-Gene
.	1	O

We	2	O
conclude	8	O
that	4	O
p56	3	B-Gene
exists	6	O
in	2	O
cytosol	7	O
in	2	O
a	1	O
higher	6	O
order	5	O
complex	7	O
containing	10	O
hsp70	5	B-Gene
and	3	O
hsp90	5	B-Gene
,	1	O
both	4	O
of	2	O
which	5	O
in	2	O
turn	4	O
have	4	O
been	4	O
found	5	O
to	2	O
be	2	O
associated	10	O
with	4	O
untransformed	13	O
steroid	7	B-Gene
receptors	9	I-Gene
.	1	O

Tandem	6	O
AP-1	4	B-Gene
-binding	8	O
sites	5	O
within	6	O
the	3	O
human	5	B-Gene
beta-globin	11	I-Gene
dominant	8	O
control	7	O
region	6	O
function	8	O
as	2	O
an	2	O
inducible	9	O
enhancer	8	O
in	2	O
erythroid	9	O
cells	5	O
.	1	O

A	1	O
powerful	8	O
enhancer	8	O
has	3	O
been	4	O
mapped	6	O
to	2	O
an	2	O
18-bp	5	O
DNA	3	O
segment	7	O
located	7	O
11	2	O
kb	2	O
5	1	O
'to	3	O
the	3	O
human	5	B-Gene
epsilon-globin	14	I-Gene
gene	4	I-Gene
within	6	O
the	3	O
dominant	8	O
control	7	O
or	2	O
locus	5	O
-activating	11	O
region	6	O
.	1	O

This	4	O
enhancer	8	O
is	2	O
inducible	9	O
in	2	O
K562	4	O
human	5	O
erythroleukemia	15	B-Disease
cells	5	O
,	1	O
increasing	10	O
linked	6	O
gamma-globin	12	B-Gene
promoter	8	I-Gene
/	1	O
luciferase	10	O
gene	4	O
expression	10	O
to	2	O
170-fold	8	O
over	4	O
an	2	O
enhancerless	12	O
construct	9	O
.	1	O

The	3	O
enhancer	8	O
consists	8	O
of	2	O
tandem	6	O
AP-1	4	B-Gene
-binding	8	O
sites	5	O
,	1	O
phased	6	O
10	2	O
bp	2	O
apart	5	O
,	1	O
which	5	O
are	3	O
both	4	O
required	8	O
for	3	O
full	4	O
activity	8	O
.	1	O

DNA-protein	11	O
binding	7	O
assays	6	O
with	4	O
nuclear	7	O
extracts	8	O
from	4	O
induced	7	O
cells	5	O
demonstrate	11	O
a	1	O
high	4	O
molecular	9	O
weight	6	O
complex	7	O
on	2	O
the	3	O
enhancer	8	O
.	1	O

The	3	O
formation	9	O
of	2	O
this	4	O
complex	7	O
also	4	O
requires	8	O
both	4	O
AP-1	4	B-Gene
sites	5	O
and	3	O
correlates	10	O
with	4	O
maximal	7	O
enhancer	8	O
activity	8	O
.	1	O

Induction	9	O
of	2	O
the	3	O
enhancer	8	O
may	3	O
have	4	O
a	1	O
role	4	O
in	2	O
the	3	O
increase	8	O
in	2	O
globin	6	B-Gene
gene	4	I-Gene
transcription	13	O
that	4	O
characterizes	13	O
erythroid	9	O
maturation	10	O
.	1	O

Enhancer	8	O
activity	8	O
appears	7	O
to	2	O
be	2	O
mediated	8	O
by	2	O
the	3	O
binding	7	O
of	2	O
a	1	O
complex	7	O
of	2	O
proteins	8	O
from	4	O
the	3	O
jun	3	B-Gene
and	3	O
fos	3	B-Gene
families	8	I-Gene
to	2	O
tandem	6	O
AP-1	4	B-Gene
consensus	9	O
sequences	9	O
.	1	O

Detection	9	O
in	2	O
non-erythroid	13	O
cells	5	O
of	2	O
a	1	O
factor	6	O
with	4	O
the	3	O
binding	7	O
characteristics	15	O
of	2	O
the	3	O
erythroid	9	O
cell	4	O
transcription	13	B-Gene
factor	6	I-Gene
EF1	3	I-Gene
.	1	O

The	3	O
erythroid	9	O
transcription	13	B-Gene
factor	6	I-Gene
erythroid	9	I-Gene
factor-1	8	I-Gene
(	1	O
EF1	3	B-Gene
)	1	O
plays	5	O
a	1	O
critical	8	O
role	4	O
in	2	O
the	3	O
transcription	13	O
of	2	O
erythroid-specific	18	O
genes	5	O
.	1	O

Here	4	O
we	2	O
report	6	O
the	3	O
presence	8	O
of	2	O
a	1	O
factor	6	O
with	4	O
the	3	O
mobility	8	O
and	3	O
sequence-specific	17	O
DNA	3	O
-binding	8	O
characteristics	15	O
of	2	O
EF1	3	B-Gene
at	2	O
low	3	O
abundance	9	O
in	2	O
a	1	O
wide	4	O
variety	7	O
of	2	O
non-erythroid	13	O
cell	4	O
types	5	O
.	1	O

This	4	O
is	2	O
the	3	O
first	5	O
report	6	O
of	2	O
an	2	O
EF1	3	B-Gene
-like	5	O
activity	8	O
in	2	O
non-erythroid	13	O
cells	5	O
and	3	O
indicates	9	O
that	4	O
this	4	O
factor	6	O
may	3	O
play	4	O
a	1	O
role	4	O
in	2	O
the	3	O
regulation	10	O
of	2	O
genes	5	O
expressed	9	O
in	2	O
such	4	O
cells	5	O
.	1	O

Nuclear	7	B-Gene
3	1	I-Gene
,	1	I-Gene
5	1	I-Gene
,	1	I-Gene
3'-triiodothyronine	19	I-Gene
receptors	9	I-Gene
(	1	O
T3R	3	B-Gene
)	1	O
of	2	O
circulating	11	O
human	5	O
lymphocytes	11	O
in	2	O
hyper-	6	O
and	3	O
hypothyroidism	14	B-Disease
and	3	O
nonthyroidal	12	O
diseases	8	O
.	1	O

The	3	O
clinical	8	O
implications	12	O
of	2	O
nuclear	7	B-Gene
T3R	3	I-Gene
alterations	11	O
of	2	O
circulating	11	O
lymphocytes	11	O
in	2	O
hyperthyroidism	15	B-Disease
,	1	O
hypothyroidism	14	B-Disease
and	3	O
nonthyroidal	12	O
diseases	8	O
were	4	O
investigated	12	O
.	1	O

Nuclear	7	B-Gene
T3R	3	I-Gene
in	2	O
lymphocytes	11	O
was	3	O
determined	10	O
by	2	O
radio-ligand	12	O
binding	7	O
analysis	8	O
.	1	O

The	3	O
results	7	O
showed	6	O
that	4	O
in	2	O
hyper-	6	O
and	3	O
hypothyroid	11	O
patients	8	O
the	3	O
nuclear	7	O
affinity	8	O
(	1	O
Ka	2	O
)	1	O
for	3	O
T3	2	O
was	3	O
similar	7	O
to	2	O
that	4	O
of	2	O
normal	6	O
subjects	8	O
.	1	O

In	2	O
hyperthyroidism	15	B-Disease
nuclear	7	O
T3	2	O
maximal	7	O
binding	7	O
capacity	8	O
(	1	O
MBC	3	O
)	1	O
was	3	O
unaltered	9	O
,	1	O
whereas	7	O
in	2	O
hypothyroidism	14	B-Disease
the	3	O
MBC	3	O
was	3	O
significantly	13	O
increased	9	O
.	1	O

In	2	O
the	3	O
patients	8	O
with	4	O
diabetes	8	B-Disease
mellitus	8	I-Disease
,	1	O
chronic	7	B-Disease
renal	5	I-Disease
failure	7	I-Disease
and	3	O
hepatic	7	B-Disease
cirrhosis	9	I-Disease
,	1	O
the	3	O
nuclear	7	B-Gene
T3R	3	I-Gene
MBC	3	O
of	2	O
lymphocytes	11	O
was	3	O
about	5	O
1.5-1.6	7	O
times	5	O
of	2	O
the	3	O
normal	6	O
controls	8	O
.	1	O

It	2	O
was	3	O
concluded	9	O
that	4	O
there	5	O
existed	7	O
hormonal	8	O
regulation	10	O
of	2	O
nuclear	7	B-Gene
T3R	3	I-Gene
,	1	O
and	3	O
up-regulation	13	O
was	3	O
seen	4	O
in	2	O
hypothyroidism	14	B-Disease
and	3	O
low	3	O
T3	2	O
syndrome	8	O
.	1	O

Cell	4	O
type	4	O
specificity	11	O
and	3	O
activation	10	O
requirements	12	O
for	3	O
NFAT-1	6	B-Gene
(	1	O
nuclear	7	B-Gene
factor	6	I-Gene
of	2	I-Gene
activated	9	I-Gene
T-cells	7	I-Gene
)	1	O
transcriptional	15	O
activity	8	O
determined	10	O
by	2	O
a	1	O
new	3	O
method	6	O
using	5	O
transgenic	10	O
mice	4	O
to	2	O
assay	5	O
transcriptional	15	O
activity	8	O
of	2	O
an	2	O
individual	10	O
nuclear	7	O
factor	6	O
.	1	O

Nuclear	7	B-Gene
factor	6	I-Gene
of	2	I-Gene
activated	9	I-Gene
T-cells	7	I-Gene
(	1	O
NFAT-1	6	B-Gene
)	1	O
is	2	O
a	1	O
transcription	13	O
factor	6	O
which	5	O
is	2	O
considered	10	O
to	2	O
be	2	O
an	2	O
important	9	O
regulator	9	O
in	2	O
early	5	O
T-cell	6	O
activation	10	O
.	1	O

We	2	O
have	4	O
developed	9	O
a	1	O
system	6	O
to	2	O
monitor	7	O
the	3	O
transcriptional	15	O
activity	8	O
of	2	O
NFAT-1	6	B-Gene
at	2	O
the	3	O
single	6	O
cell	4	O
level	5	O
in	2	O
whole	5	O
animals	7	O
.	1	O

The	3	O
system	6	O
is	2	O
based	5	O
on	2	O
the	3	O
use	3	O
of	2	O
an	2	O
oligomerized	12	O
NFAT-1	6	B-Gene
binding	7	O
motif	5	O
that	4	O
directs	7	O
transcription	13	O
of	2	O
SV40	4	B-Gene
T-antigen	9	I-Gene
in	2	O
transgenic	10	O
mice	4	O
.	1	O

This	4	O
report	6	O
represents	10	O
the	3	O
first	5	O
demonstration	13	O
that	4	O
a	1	O
multimerized	12	O
short	5	O
binding	7	O
motif	5	O
can	3	O
function	8	O
appropriately	13	O
in	2	O
transgenic	10	O
mice	4	O
.	1	O

NFAT-1	6	B-Gene
activity	8	O
had	3	O
previously	10	O
been	4	O
thought	7	O
to	2	O
be	2	O
confined	8	O
to	2	O
activated	9	O
T-lymphocytes	13	O
upon	4	O
release	7	O
of	2	O
intracellular	13	O
calcium	7	B-Chemical
.	1	O

By	2	O
targeting	9	O
NFAT-1	6	B-Gene
-dependent	10	O
gene	4	O
expression	10	O
in	2	O
transgenic	10	O
mice	4	O
we	2	O
discovered	10	O
new	3	O
sites	5	O
of	2	O
NFAT-1	6	B-Gene
activity	8	O
.	1	O

Besides	7	O
in	2	O
T-lymphocytes	13	O
NFAT-1	6	B-Gene
activity	8	O
could	5	O
also	4	O
be	2	O
induced	7	O
in	2	O
T-lymphocyte	12	O
-depleted	9	O
spleen	6	O
cells	5	O
and	3	O
purified	8	O
B-lymphocytes	13	O
and	3	O
requires	8	O
agents	6	O
that	4	O
both	4	O
release	7	O
intracellular	13	O
calcium	7	B-Chemical
and	3	O
activate	8	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
.	1	O

A	1	O
difference	10	O
in	2	O
the	3	O
time	4	O
course	6	O
of	2	O
appearance	10	O
of	2	O
NFAT-1	6	B-Gene
activity	8	O
between	7	O
T-lymphocytes	13	O
and	3	O
non-T-lymphocytes	17	O
was	3	O
revealed	8	O
.	1	O

Constitutive	12	O
expression	10	O
was	3	O
observed	8	O
in	2	O
a	1	O
small	5	O
population	10	O
of	2	O
cells	5	O
in	2	O
the	3	O
dermis	6	O
and	3	O
some	4	O
mice	4	O
have	4	O
developed	9	O
skin	4	O
lesions	7	O
.	1	O

Interestingly	13	O
,	1	O
the	3	O
tissue	6	O
pattern	7	O
of	2	O
expression	10	O
of	2	O
the	3	O
NFAT-1	6	B-Gene
activity	8	O
resembles	9	O
the	3	O
expression	10	O
pattern	7	O
described	9	O
for	3	O
HIV-LTR	7	B-Gene
/	1	I-Gene
tat	3	I-Gene
transgenic	10	O
mice	4	O
(	1	O
Vogel	5	O
,	1	O
J.	2	O
,	1	O
Hinrichs	8	O
,	1	O
S.	2	O
H.	2	O
,	1	O
Reynolds	8	O
,	1	O
R.	2	O
K.	2	O
,	1	O
Luciw	5	O
,	1	O
P.	2	O
A.	2	O
,	1	O
and	3	O
Jay	3	O
,	1	O
G.	2	O
(	1	O
1988	4	O
)	1	O
Nature	6	O
335	3	O
,	1	O
606-611	7	O
)	1	O
.	1	O

This	4	O
similarity	10	O
in	2	O
expression	10	O
and	3	O
the	3	O
fact	4	O
that	4	O
NFAT-1	6	B-Gene
has	3	O
been	4	O
shown	5	O
to	2	O
bind	4	O
functional	10	O
sequences	9	O
in	2	O
HIV-LTR	7	O
suggest	7	O
a	1	O
role	4	O
for	3	O
NFAT-1	6	B-Gene
in	2	O
dermal	6	O
activation	10	O
of	2	O
the	3	O
HIV-LTR	7	O
.	1	O

Induction	9	O
of	2	O
immediate	9	O
early	5	O
response	8	O
genes	5	O
by	2	O
macrophage	10	B-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
in	2	O
normal	6	O
human	5	O
monocytes	9	O
.	1	O

A	1	O
group	5	O
of	2	O
coordinately	12	O
induced	7	O
protooncogenes	14	O
,	1	O
cytoskeletal	12	O
,	1	O
and	3	O
extracellular	13	O
matrix	6	O
genes	5	O
have	4	O
been	4	O
termed	6	O
immediate	9	O
early	5	O
response	8	O
genes	5	O
,	1	O
and	3	O
their	5	O
induction	9	O
has	3	O
been	4	O
associated	10	O
with	4	O
growth	6	O
factor	6	O
-stimulated	11	O
cell	4	O
proliferation	13	O
.	1	O

We	2	O
have	4	O
investigated	12	O
the	3	O
induction	9	O
of	2	O
these	5	O
genes	5	O
by	2	O
macrophage-CSF	14	B-Gene
(	1	O
M-CSF	5	B-Gene
)	1	O
in	2	O
human	5	O
monocytes	9	O
that	4	O
do	2	O
not	3	O
proliferate	11	O
in	2	O
response	8	O
to	2	O
M-CSF	5	B-Gene
but	3	O
require	7	O
the	3	O
factor	6	O
for	3	O
optimal	7	O
cell	4	O
differentiation	15	O
.	1	O

Normal	6	O
human	5	O
monocytes	9	O
were	4	O
isolated	8	O
,	1	O
carefully	9	O
washed	6	O
,	1	O
and	3	O
incubated	9	O
for	3	O
36	2	O
to	2	O
48	2	O
h	1	O
in	2	O
fetal	5	B-Chemical
bovine	6	I-Chemical
serum	5	I-Chemical
-containing	11	O
medium	6	O
.	1	O

At	2	O
the	3	O
end	3	O
of	2	O
this	4	O
incubation	10	O
the	3	O
resting	7	O
cells	5	O
were	4	O
stimulated	10	O
with	4	O
M-CSF	5	B-Gene
,	1	O
and	3	O
RNA	3	O
was	3	O
isolated	8	O
for	3	O
analysis	8	O
by	2	O
Northern	8	O
blotting	8	O
.	1	O

RNA	3	O
from	4	O
control	7	O
resting	7	O
cells	5	O
contained	9	O
low	3	O
to	2	O
undetectable	12	O
levels	6	O
of	2	O
c-jun	5	B-Gene
,	1	O
fibronectin	11	B-Gene
receptor	8	I-Gene
,	1	O
and	3	O
actin	5	B-Gene
mRNA	4	I-Gene
.	1	O

Within	6	O
15	2	O
to	2	O
30	2	O
min	3	O
of	2	O
addition	8	O
of	2	O
M-CSF	5	B-Gene
,	1	O
however	7	O
,	1	O
there	5	O
was	3	O
a	1	O
dramatic	8	O
coordinate	10	O
induction	9	O
of	2	O
these	5	O
genes	5	O
.	1	O

The	3	O
c-jun	5	B-Gene
gene	4	I-Gene
expression	10	O
was	3	O
very	4	O
transient	9	O
and	3	O
was	3	O
not	3	O
detectable	10	O
by	2	O
60	2	O
min	3	O
after	5	O
M-CSF	5	B-Gene
addition	8	O
.	1	O

In	2	O
contrast	8	O
,	1	O
the	3	O
expression	10	O
of	2	O
actin	5	B-Gene
and	3	O
fibronectin	11	B-Gene
receptor	8	I-Gene
mRNA	4	I-Gene
was	3	O
more	4	O
sustained	9	O
,	1	O
and	3	O
the	3	O
expression	10	O
of	2	O
these	5	O
genes	5	O
remained	8	O
elevated	8	O
at	2	O
24	2	O
to	2	O
48	2	O
h	1	O
after	5	O
M-CSF	5	B-Gene
addition	8	O
.	1	O

We	2	O
also	4	O
observed	8	O
the	3	O
induction	9	O
of	2	O
the	3	O
myelomonocytic	14	O
specific	8	O
tyrosine	8	B-Gene
kinase	6	I-Gene
hck	3	I-Gene
gene	4	I-Gene
simultaneously	14	O
with	4	O
the	3	O
other	5	O
immediate	9	O
early	5	O
response	8	O
genes	5	O
.	1	O

The	3	O
protein	7	O
synthesis	9	O
inhibitor	9	O
cycloheximide	13	B-Chemical
did	3	O
not	3	O
block	5	O
the	3	O
induction	9	O
of	2	O
any	3	O
of	2	O
these	5	O
genes	5	O
,	1	O
and	3	O
in	2	O
fact	4	O
,	1	O
super	5	O
-induced	8	O
the	3	O
expression	10	O
of	2	O
c-jun	5	B-Gene
and	3	O
hck	3	B-Gene
.	1	O

Nuclear	7	O
run	3	O
on	2	O
transcription	13	O
of	2	O
the	3	O
c-jun	5	B-Gene
,	1	O
hck	3	B-Gene
,	1	O
and	3	O
actin	5	B-Gene
genes	5	I-Gene
.	1	O

Therefore	9	O
,	1	O
in	2	O
normal	6	O
human	5	B-Gene
monocytes	9	I-Gene
M-CSF	5	I-Gene
induces	7	O
immediate	9	O
early	5	O
response	8	O
genes	5	O
without	7	O
inducing	8	O
cell	4	O
proliferation	13	O
.	1	O

These	5	O
genes	5	O
may	3	O
then	4	O
play	4	O
a	1	O
role	4	O
in	2	O
altering	8	O
the	3	O
physiologic	11	O
status	6	O
of	2	O
the	3	O
cells	5	O
in	2	O
response	8	O
to	2	O
CSF	3	B-Gene
.	1	O

Cell-specific	13	O
differences	11	O
in	2	O
activation	10	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
regulatory	10	I-Gene
elements	8	I-Gene
of	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
and	3	O
beta	4	B-Gene
interferon	10	I-Gene
promoters	9	I-Gene
by	2	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
.	1	O

Three	5	O
aspects	7	O
of	2	O
the	3	O
involvement	11	O
of	2	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
in	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
(	1	O
HIV	3	O
)	1	O
pathogenesis	12	O
were	4	O
examined	8	O
.	1	O

Tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
alpha	5	I-Gene
(	1	I-Gene
TNF-alpha	9	I-Gene
)	1	I-Gene
mRNA	4	I-Gene
production	10	O
was	3	O
analyzed	8	O
by	2	O
polymerase	10	O
chain	5	O
reaction	8	O
amplification	13	O
in	2	O
monocytic	9	O
U937	4	O
cells	5	O
and	3	O
in	2	O
a	1	O
chronically	11	O
HIV	3	O
infected	8	O
U937	4	O
cell	4	O
line	4	O
(	1	O
U9-IIIB	7	O
)	1	O
.	1	O

TNF-alpha	9	B-Gene
RNA	3	I-Gene
was	3	O
undetectable	12	O
in	2	O
U937	4	O
cells	5	O
,	1	O
whereas	7	O
a	1	O
low	3	O
constitutive	12	O
level	5	O
was	3	O
detected	8	O
in	2	O
U9-IIIB	7	O
cells	5	O
.	1	O

Paramyxovirus	13	O
infection	9	O
induced	7	O
a	1	O
5-	2	O
to	2	O
10-fold	7	O
increase	8	O
in	2	O
the	3	O
steady-state	12	O
level	5	O
of	2	O
TNF-alpha	9	B-Gene
RNA	3	I-Gene
in	2	O
U9-IIIB	7	O
cells	5	O
compared	8	O
with	4	O
U937	4	O
cells	5	O
,	1	O
suggesting	10	O
that	4	O
HIV	3	O
-infected	9	O
monocytic	9	O
cells	5	O
produced	8	O
higher	6	O
levels	6	O
of	2	O
TNF-alpha	9	B-Gene
than	4	O
did	3	O
normal	6	O
cells	5	O
after	5	O
a	1	O
secondary	9	O
virus	5	O
infection	9	O
.	1	O

The	3	O
effects	7	O
of	2	O
TNF-alpha	9	B-Gene
on	2	O
gene	4	O
expression	10	O
were	4	O
examined	8	O
by	2	O
transient	9	O
expression	10	O
assays	6	O
using	5	O
reporter	8	O
chloramphenicol	15	O
acetyltransferase	17	O
plasmids	8	O
linked	6	O
to	2	O
regulatory	10	O
elements	8	O
from	4	O
the	3	O
HIV	3	O
long	4	O
terminal	8	O
repeat	6	O
(	1	O
LTR	3	O
)	1	O
and	3	O
the	3	O
beta	4	B-Gene
interferon	10	I-Gene
promoter	8	I-Gene
.	1	O

In	2	O
U937	4	O
and	3	O
Jurkat	6	O
T	1	O
lymphoid	8	O
cells	5	O
,	1	O
the	3	O
inducibility	12	O
of	2	O
the	3	O
different	9	O
hybrid	6	O
promoters	9	O
by	2	O
TNF-alpha	9	B-Gene
or	2	O
phorbol	7	B-Chemical
ester	5	I-Chemical
varied	6	O
in	2	O
a	1	O
cell	4	O
type-	5	O
and	3	O
promoter	8	O
context-specific	16	O
manner	6	O
;	1	O
the	3	O
levels	6	O
of	2	O
gene	4	O
activity	8	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
-containing	11	O
plasmids	8	O
correlated	10	O
directly	8	O
with	4	O
induction	9	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
DNA	3	I-Gene
-binding	8	O
activity	8	O
.	1	O

Although	8	O
the	3	O
intact	6	O
beta	4	B-Gene
interferon	10	I-Gene
promoter	8	I-Gene
was	3	O
only	4	O
weakly	6	O
stimulated	10	O
by	2	O
phorbol	7	B-Chemical
ester	5	I-Chemical
or	2	O
TNF-alpha	9	B-Gene
,	1	O
multimers	9	O
of	2	O
the	3	O
PRDII	5	O
NF-kappa	8	B-Gene
B	1	I-Gene
-binding	8	O
domain	6	O
were	4	O
inducible	9	O
by	2	O
both	4	O
agents	6	O
.	1	O

TNF-alpha	9	B-Gene
was	3	O
able	4	O
to	2	O
increase	8	O
expression	10	O
of	2	O
the	3	O
HIV	3	O
LTR	3	O
in	2	O
T	1	O
cells	5	O
,	1	O
but	3	O
in	2	O
monocytic	9	O
cells	5	O
,	1	O
TNF-alpha	9	B-Gene
did	3	O
not	3	O
induce	6	O
the	3	O
HIV	3	O
LTR	3	O
above	5	O
a	1	O
constitutive	12	O
level	5	O
of	2	O
activity	8	O
.	1	O

This	4	O
level	5	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
-independent	12	O
activity	8	O
appears	7	O
to	2	O
be	2	O
sufficient	10	O
for	3	O
virus	5	O
multiplication	14	O
,	1	O
since	5	O
TNF-alpha	9	B-Gene
treatment	9	O
had	3	O
no	2	O
effect	6	O
on	2	O
the	3	O
kinetics	8	O
of	2	O
de	2	O
novo	4	O
HIV	3	O
type	4	O
1	1	O
(	1	O
HIV-1	5	O
)	1	O
infection	9	O
and	3	O
viral	5	O
RNA	3	O
production	10	O
in	2	O
U937	4	O
cells	5	O
.	1	O

However	7	O
,	1	O
in	2	O
Jurkat	6	O
cells	5	O
,	1	O
TNF-alpha	9	B-Gene
dramatically	12	O
enhanced	8	O
the	3	O
spread	6	O
of	2	O
HIV-1	5	O
through	7	O
the	3	O
cell	4	O
population	10	O
and	3	O
increased	9	O
viral	5	O
RNA	3	O
synthesis	9	O
,	1	O
indicating	10	O
that	4	O
in	2	O
T	1	O
cells	5	O
HIV-1	5	O
multiplication	14	O
was	3	O
stimulated	10	O
by	2	O
TNF-alpha	9	B-Gene
treatment	9	O
.	1	O

The	3	O
internal	8	O
methionine	10	B-Chemical
codons	6	O
of	2	O
human	5	B-Gene
T-cell	6	I-Gene
leukemia	8	I-Gene
virus	5	I-Gene
type	4	I-Gene
II	2	I-Gene
rex	3	I-Gene
gene	4	I-Gene
are	3	O
not	3	O
required	8	O
for	3	O
p24rex	6	B-Gene
production	10	O
or	2	O
virus	5	O
replication	11	O
and	3	O
transformation	14	O
.	1	O

Human	5	O
T-cell	6	B-Disease
leukemia	8	I-Disease
virus	5	O
types	5	O
I	1	O
(	1	O
HTLV-I	6	O
)	1	O
and	3	O
II	2	O
(	1	O
HTLV-II	7	O
)	1	O
have	4	O
two	3	O
nonstructural	13	O
trans	5	O
-acting	7	O
regulatory	10	O
genes	5	O
,	1	O
tax	3	B-Gene
and	3	O
rex	3	B-Gene
,	1	O
located	7	O
in	2	O
the	3	O
3	1	O
'region	7	O
of	2	O
the	3	O
viral	5	O
genome	6	O
.	1	O

The	3	O
tax	3	B-Gene
gene	4	I-Gene
product	7	I-Gene
(	1	O
HTLV-I	6	B-Gene
p40tax	6	I-Gene
and	3	O
HTLV-II	7	B-Gene
p37tax	6	I-Gene
)	1	O
is	2	O
the	3	O
transcriptional	15	O
activator	9	O
of	2	O
the	3	O
viral	5	O
long	4	O
terminal	8	O
repeat	6	O
.	1	O

The	3	O
rex	3	B-Gene
gene	4	I-Gene
encodes	7	O
two	3	O
protein	7	O
products	8	O
,	1	O
p27rex	6	B-Gene
/	1	I-Gene
p21rex	6	I-Gene
and	3	O
p26rex	6	B-Gene
/	1	I-Gene
p24rex	6	I-Gene
in	2	O
HTLV-I	6	O
and	3	O
HTLV-II	7	O
,	1	O
respectively	12	O
.	1	O

Rex	3	B-Gene
acts	4	O
posttranscriptionally	21	O
to	2	O
facilitate	10	O
accumulation	12	O
of	2	O
full-length	11	O
gag	3	B-Gene
/	1	I-Gene
pol	3	I-Gene
and	3	O
singly	6	O
spliced	7	O
env	3	B-Gene
mRNA	4	I-Gene
in	2	O
the	3	O
cytoplasm	9	O
of	2	O
HTLV	4	O
-infected	9	O
cells	5	O
.	1	O

Previous	8	O
studies	7	O
showed	6	O
that	4	O
the	3	O
first	5	O
ATG	3	O
of	2	O
the	3	O
rex	3	B-Gene
gene	4	I-Gene
is	2	O
critical	8	O
for	3	O
Rex	3	B-Gene
production	10	O
and	3	O
function	8	O
.	1	O

The	3	O
importance	10	O
of	2	O
the	3	O
internal	8	O
ATGs	4	O
to	2	O
Rex	3	B-Gene
function	8	O
is	2	O
not	3	O
known	5	O
.	1	O

However	7	O
,	1	O
in	2	O
vitro	5	O
mutagenesis	11	O
of	2	O
the	3	O
HTLV-I	6	B-Gene
rex	3	I-Gene
gene	4	I-Gene
has	3	O
provided	8	O
indirect	8	O
evidence	8	O
which	5	O
suggests	8	O
that	4	O
p21rex	6	B-Gene
,	1	O
and	3	O
by	2	O
analogy	7	O
HTLV-II	7	B-Gene
p24rex	6	I-Gene
,	1	O
results	7	O
from	4	O
initiation	10	O
at	2	O
an	2	O
internal	8	O
AUG	3	O
of	2	O
the	3	O
tax	3	B-Gene
/	1	I-Gene
rex	3	I-Gene
mRNA	4	I-Gene
.	1	O

By	2	O
using	5	O
an	2	O
infectious	10	O
molecular	9	O
clone	5	O
of	2	O
HTLV-II	7	O
,	1	O
we	2	O
investigated	12	O
the	3	O
importance	10	O
of	2	O
the	3	O
internal	8	O
ATGs	4	O
of	2	O
the	3	O
rex	3	B-Gene
gene	4	I-Gene
on	2	O
Rex	3	B-Gene
protein	7	I-Gene
production	10	O
and	3	O
function	8	O
.	1	O

Our	3	O
results	7	O
indicate	8	O
that	4	O
p24rex	6	B-Gene
of	2	O
HTLV-II	7	O
is	2	O
not	3	O
initiated	9	O
at	2	O
an	2	O
internal	8	O
AUG	3	O
and	3	O
that	4	O
the	3	O
internal	8	O
methionine	10	B-Chemical
codons	6	O
are	3	O
not	3	O
crucial	7	O
to	2	O
the	3	O
function	8	O
of	2	O
the	3	O
rex	3	B-Gene
gene	4	I-Gene
and	3	O
,	1	O
ultimately	10	O
,	1	O
the	3	O
transforming	12	O
properties	10	O
of	2	O
the	3	O
virus	5	O
.	1	O

Interferon	10	B-Gene
affects	7	O
nuclear	7	O
proteins	8	O
in	2	O
cells	5	O
of	2	O
clinically	10	O
sensitive	9	O
chronic	7	B-Disease
myelogenous	11	I-Disease
leukemia	8	I-Disease
patients	8	O
.	1	O

Cytoplasmic	11	O
protein	7	O
extracts	8	O
from	4	O
chronic	7	B-Disease
myelogenous	11	I-Disease
leukemia	8	I-Disease
(	1	O
CML	3	B-Disease
)	1	O
cells	5	O
contained	9	O
an	2	O
activity	8	O
that	4	O
altered	7	O
the	3	O
electrophoretic	15	O
mobility	8	O
of	2	O
complexes	9	O
formed	6	O
between	7	O
nuclear	7	O
proteins	8	O
and	3	O
the	3	O
transcriptional	15	O
enhancers	9	O
of	2	O
interferon	10	B-Gene
(	1	O
IFN	3	B-Gene
)	1	O
-inducible	10	O
genes	5	O
.	1	O

Exposure	8	O
of	2	O
CML	3	B-Disease
cells	5	O
to	2	O
IFN-alpha	9	B-Gene
diminished	10	O
the	3	O
effect	6	O
of	2	O
the	3	O
CML	3	B-Disease
cytoplasmic	11	O
proteins	8	O
on	2	O
these	5	O
nuclear	7	O
protein-DNA	11	O
complexes	9	O
.	1	O

The	3	O
presence	8	O
of	2	O
clinical	8	O
responsiveness	14	O
to	2	O
IFN-alpha	9	B-Gene
correlated	10	O
with	4	O
the	3	O
sensitivity	11	O
to	2	O
the	3	O
IFN	3	B-Gene
-induced	8	O
change	6	O
in	2	O
the	3	O
electrophoretic	15	O
mobility	8	O
of	2	O
nuclear	7	O
protein-DNA	11	O
complexes	9	O
.	1	O

These	5	O
data	4	O
suggest	7	O
that	4	O
the	3	O
action	6	O
of	2	O
IFN-alpha	9	B-Gene
in	2	O
CML	3	B-Disease
may	3	O
be	2	O
linked	6	O
to	2	O
a	1	O
pathway	7	O
that	4	O
can	3	O
result	6	O
in	2	O
posttranslational	17	O
modification	12	O
of	2	O
nuclear	7	O
proteins	8	O
.	1	O

Retroviral	10	O
mediated	8	O
transfer	8	O
and	3	O
expression	10	O
of	2	O
exogenous	9	O
genes	5	O
in	2	O
primary	7	O
lymphoid	8	O
cells	5	O
:	1	O
assaying	8	O
for	3	O
a	1	O
viral	5	O
transactivator	14	O
activity	8	O
in	2	O
normal	6	O
and	3	O
malignant	9	O
cells	5	O
.	1	O

In	2	O
this	4	O
report	6	O
we	2	O
describe	8	O
the	3	O
use	3	O
of	2	O
recombinant	11	O
retroviruses	12	O
to	2	O
characterize	12	O
the	3	O
activity	8	O
of	2	O
an	2	O
exogenous	9	O
promoter	8	O
in	2	O
primary	7	O
cells	5	O
obtained	8	O
from	4	O
patients	8	O
with	4	O
lymphoproliferative	19	B-Disease
disorders	9	I-Disease
.	1	O

The	3	O
infection	9	O
of	2	O
a	1	O
variety	7	O
of	2	O
cultured	8	O
and	3	O
primary	7	O
lymphoid	8	O
cells	5	O
with	4	O
a	1	O
recombinant	11	O
retrovirus	10	O
containing	10	O
a	1	O
histone	7	B-Gene
promoter-driven	15	I-Gene
beta-galactosidase	18	I-Gene
gene	4	I-Gene
is	2	O
shown	5	O
to	2	O
result	6	O
in	2	O
the	3	O
expression	10	O
of	2	O
beta-galactosidase	18	B-Gene
in	2	O
50	2	O
%	1	O
to	2	O
100	3	O
%	1	O
of	2	O
the	3	O
cells	5	O
.	1	O

A	1	O
similar	7	O
infection	9	O
with	4	O
a	1	O
recombinant	11	O
retrovirus	10	O
containing	10	O
the	3	O
beta-galactosidase	18	B-Gene
gene	4	I-Gene
with	4	O
an	2	O
adenovirus	10	O
E2	2	O
promoter	8	O
,	1	O
results	7	O
in	2	O
beta-galactosidase	18	B-Gene
activity	8	O
in	2	O
a	1	O
limited	7	O
number	6	O
of	2	O
cultured	8	O
and	3	O
primary	7	O
cells	5	O
.	1	O

Since	5	O
the	3	O
adenovirus	10	O
E2	2	O
promoter	8	O
has	3	O
been	4	O
well	4	O
characterized	13	O
and	3	O
is	2	O
known	5	O
to	2	O
be	2	O
regulated	9	O
by	2	O
transactivators	15	O
encoded	7	O
by	2	O
many	4	O
viruses	7	O
,	1	O
the	3	O
activity	8	O
of	2	O
this	4	O
promoter	8	O
in	2	O
specific	8	O
cell	4	O
types	5	O
is	2	O
discussed	9	O
in	2	O
reference	9	O
to	2	O
both	4	O
the	3	O
biology	7	O
of	2	O
the	3	O
cell	4	O
and	3	O
the	3	O
possible	8	O
presence	8	O
of	2	O
as	2	O
yet	3	O
undetected	10	O
viral	5	O
gene	4	O
products	8	O
.	1	O

[	1	O
Glucocorticoid	14	B-Gene
receptors	9	I-Gene
on	2	O
human	5	O
peripheral	10	O
mononuclear	11	O
and	3	O
polymorphonuclear	17	O
leucocytes	10	O
:	1	O
changes	7	O
in	2	O
patients	8	O
with	4	O
yang-deficiency	15	O
]	1	O

It	2	O
was	3	O
found	5	O
that	4	O
,	1	O
in	2	O
former	6	O
works	5	O
,	1	O
the	3	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
(	1	O
GCR	3	B-Gene
)	1	O
on	2	O
peripheral	10	O
mixed	5	O
leucocytes	10	O
in	2	O
patients	8	O
with	4	O
Yang-deficiency	15	O
were	4	O
decreased	9	O
.	1	O

In	2	O
this	4	O
work	4	O
,	1	O
the	3	O
mixed	5	O
leucocytes	10	O
were	4	O
further	7	O
separated	9	O
into	4	O
mononuclear	11	O
(	1	O
MNL	3	O
)	1	O
and	3	O
polymorphonuclear	17	O
(	1	O
PML	3	O
)	1	O
leucocytes	10	O
,	1	O
and	3	O
GCR	3	B-Gene
were	4	O
determined	10	O
in	2	O
each	4	O
part	4	O
of	2	O
leucocytes	10	O
.	1	O

GCR	3	B-Gene
on	2	O
MNL	3	O
and	3	O
PML	3	O
in	2	O
6	1	O
Yang	4	O
deficient	9	O
patients	8	O
were	4	O
3473	4	O
+	1	O
/	1	O
-	1	O
413	3	O
and	3	O
4433	4	O
+	1	O
/	1	O
-	1	O
651	3	O
sites	5	O
/	1	O
cell	4	O
respectively	12	O
,	1	O
statistically	13	O
significant	11	O
from	4	O
the	3	O
normal	6	O
control	7	O
group	5	O
(	1	O
4462	4	O
+	1	O
/	1	O
-	1	O
962	3	O
and	3	O
5622	4	O
+	1	O
/	1	O
-	1	O
782	3	O
sites	5	O
/	1	O
cell	4	O
respectively	12	O
,	1	O
P	1	O
less	4	O
than	4	O
0.05	4	O
)	1	O
.	1	O

GCR	3	B-Gene
on	2	O
MNL	3	O
,	1	O
PML	3	O
and	3	O
mixed	5	O
leucocytes	10	O
in	2	O
5	1	O
patients	8	O
were	4	O
determined	10	O
simultaneously	14	O
,	1	O
and	3	O
all	3	O
lowered	7	O
from	4	O
the	3	O
control	7	O
group	5	O
.	1	O

The	3	O
results	7	O
were	4	O
3369	4	O
+	1	O
/	1	O
-	1	O
370	3	O
,	1	O
4986	4	O
+	1	O
/	1	O
-	1	O
419	3	O
and	3	O
4524	4	O
+	1	O
/	1	O
-	1	O
852	3	O
sites	5	O
/	1	O
cell	4	O
respectively	12	O
,	1	O
with	4	O
the	3	O
lowest	6	O
GCR	3	B-Gene
on	2	O
MNL	3	O
and	3	O
highest	7	O
on	2	O
PML	3	O
.	1	O

Two	3	O
glucocorticoid	14	B-Chemical
binding	7	O
sites	5	O
on	2	O
the	3	O
human	5	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
.	1	O

Glucocorticoids	15	B-Chemical
are	3	O
known	5	O
to	2	O
have	4	O
a	1	O
lytic	5	O
effect	6	O
in	2	O
leukemic	8	O
cells	5	O
via	3	O
interactions	12	O
with	4	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
.	1	O

Cortisol	8	B-Chemical
and	3	O
various	7	O
synthetic	9	O
glucocorticoids	15	B-Chemical
bind	4	O
to	2	O
the	3	O
GR	2	B-Gene
with	4	O
one-site	8	O
kinetics	8	O
.	1	O

Cortivazol	10	B-Chemical
(	1	O
CVZ	3	B-Chemical
)	1	O
is	2	O
a	1	O
unique	6	O
,	1	O
high	4	O
potency	7	O
synthetic	9	O
glucocorticoid	14	B-Chemical
,	1	O
which	5	O
has	3	O
a	1	O
phenylpyrazol	13	B-Chemical
fused	5	O
to	2	O
the	3	O
A	1	O
-ring	5	O
of	2	O
the	3	O
steroid	7	B-Chemical
nucleus	7	O
and	3	O
displays	8	O
binding	7	O
consistent	10	O
with	4	O
two	3	O
or	2	O
more	4	O
sites	5	O
in	2	O
the	3	O
cytosol	7	O
from	4	O
CEM	3	O
C7	2	O
cells	5	O
(	1	O
a	1	O
human	5	O
acute	5	O
lymphoblastic	13	O
T-cell	6	O
line	4	O
)	1	O
.	1	O

It	2	O
has	3	O
previously	10	O
been	4	O
shown	5	O
that	4	O
the	3	O
lower	5	O
affinity	8	O
class	5	O
of	2	O
sites	5	O
are	3	O
similar	7	O
in	2	O
affinity	8	O
and	3	O
site	4	O
molarity	8	O
to	2	O
those	5	O
recognized	10	O
by	2	O
dexamethasone	13	B-Chemical
.	1	O

The	3	O
higher	6	O
affinity	8	O
sites	5	O
bind	4	O
CVZ	3	B-Chemical
with	4	O
20-	3	O
to	2	O
50-fold	7	O
greater	7	O
affinity	8	O
,	1	O
consistent	10	O
with	4	O
CVZ	3	B-Chemical
's	2	O
enhanced	8	O
biological	10	O
effects	7	O
.	1	O

In	2	O
mutant	6	O
leukemic	8	O
cells	5	O
resistant	9	O
to	2	O
the	3	O
lytic	5	O
effects	7	O
of	2	O
dexamethasone	13	B-Chemical
,	1	O
CVZ	3	B-Chemical
both	4	O
lyses	5	O
the	3	O
cells	5	O
and	3	O
recognizes	10	O
a	1	O
single	6	O
class	5	O
of	2	O
sites	5	O
similar	7	O
to	2	O
the	3	O
high	4	O
affinity	8	O
site	4	O
in	2	O
CEM	3	O
C7	2	O
cells	5	O
.	1	O

We	2	O
have	4	O
carried	7	O
out	3	O
experiments	11	O
to	2	O
define	6	O
the	3	O
nature	6	O
of	2	O
the	3	O
higher	6	O
affinity	8	O
CVZ	3	B-Chemical
binding	7	O
site	4	O
.	1	O

We	2	O
now	3	O
show	4	O
that	4	O
:	1	O
1	1	O
)	1	O
CVZ	3	B-Chemical
has	3	O
more	4	O
than	4	O
one	3	O
binding	7	O
site	4	O
in	2	O
a	1	O
second	6	O
,	1	O
independent	11	O
,	1	O
B-cell	6	O
line	4	O
,	1	O
IM-9	4	O
;	1	O
2	1	O
)	1	O
the	3	O
antiglucocorticoid	18	O
RU	2	B-Chemical
38486	5	I-Chemical
is	2	O
able	4	O
to	2	O
block	5	O
both	4	O
CVZ	3	B-Chemical
's	2	O
higher	6	O
and	3	O
lower	5	O
affinity	8	O
sites	5	O
;	1	O
3	1	O
)	1	O
all	3	O
of	2	O
CVZ	3	B-Chemical
's	2	O
binding	7	O
sites	5	O
are	3	O
on	2	O
a	1	O
protein	7	O
immunologically	15	O
indistinguishable	17	O
from	4	O
the	3	O
human	5	B-Gene
GR	2	I-Gene
;	1	O
and	3	O
4	1	O
)	1	O
freshly	7	O
isolated	8	O
clones	6	O
of	2	O
CVZ	3	B-Chemical
-resistant	10	O
cells	5	O
have	4	O
lost	4	O
all	3	O
binding	7	O
sites	5	O
for	3	O
CVZ	3	B-Chemical
.	1	O

These	5	O
data	4	O
indicate	8	O
that	4	O
CVZ	3	B-Chemical
is	2	O
recognizing	11	O
two	3	O
glucocorticoid	14	B-Chemical
binding	7	O
sites	5	O
on	2	O
the	3	O
human	5	B-Gene
GR	2	I-Gene
or	2	O
a	1	O
protein	7	O
very	4	O
similar	7	O
to	2	O
it	2	O
.	1	O

[	1	O
The	3	O
role	4	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
and	3	O
HLA	3	B-Gene
antigens	8	I-Gene
in	2	O
the	3	O
pathogenesis	12	O
of	2	O
Cushing	7	B-Disease
's	2	I-Disease
syndrome	8	I-Disease
]	1	O

Lymphocytic	11	O
levels	6	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
were	4	O
evaluated	9	O
in	2	O
114	3	O
patients	8	O
suffering	9	O
from	4	O
Icenko	6	O
-Cushing	8	B-Disease
's	2	I-Disease
syndrome	8	I-Disease
.	1	O

Incidence	9	O
of	2	O
HLA	3	B-Gene
antigens	8	I-Gene
was	3	O
determined	10	O
in	2	O
94	2	O
of	2	O
them	4	O
.	1	O

A	1	O
significant	11	O
rise	4	O
of	2	O
A10	3	O
and	3	O
B27	3	O
antigen	7	O
incidence	9	O
compared	8	O
to	2	O
that	4	O
in	2	O
normal	6	O
subjects	8	O
allows	6	O
these	5	O
antigens	8	O
to	2	O
be	2	O
considered	10	O
genetic	7	O
markers	7	O
of	2	O
Icenko	6	O
-Cushing	8	B-Disease
's	2	I-Disease
syndrome	8	I-Disease
.	1	O

The	3	O
levels	6	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
lymphocytes	11	O
of	2	O
the	3	O
patients	8	O
are	3	O
lower	5	O
than	4	O
in	2	O
normal	6	O
subjects	8	O
both	4	O
in	2	O
the	3	O
active	6	O
stage	5	O
of	2	O
the	3	O
disease	7	O
and	3	O
following	9	O
bilateral	9	O
total	5	O
adrenalectomy	13	O
.	1	O

The	3	O
patients	8	O
carrying	8	O
B27	3	O
antigen	7	O
had	3	O
lymphocytic	11	O
receptor	8	O
concentrations	14	O
under	5	O
the	3	O
levels	6	O
of	2	O
such	4	O
in	2	O
patients	8	O
free	4	O
of	2	O
the	3	O
antigen	7	O
carriage	8	O
.	1	O

Antigen	7	O
B27	3	O
seems	5	O
to	2	O
be	2	O
a	1	O
cause	5	O
of	2	O
lower	5	O
levels	6	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
blood	5	O
lymphocytes	11	O
.	1	O

Astrocytes	10	O
and	3	O
glioblastoma	12	B-Disease
cells	5	O
express	7	O
novel	5	O
octamer-DNA	11	O
binding	7	O
proteins	8	O
distinct	8	O
from	4	O
the	3	O
ubiquitous	10	O
Oct-1	5	B-Gene
and	3	O
B	1	O
cell	4	O
type	4	O
Oct-2	5	B-Gene
proteins	8	I-Gene
.	1	O

The	3	O
'octamer	8	O
'sequence	9	O
,	1	O
ATGCAAAT	8	O
or	2	O
its	3	O
complement	10	O
ATTTGCAT	8	O
,	1	O
is	2	O
a	1	O
key	3	O
element	7	O
for	3	O
the	3	O
transcriptional	15	O
regulation	10	O
of	2	O
immunoglobulin	14	B-Gene
genes	5	I-Gene
in	2	O
B-lymphocytes	13	O
as	2	O
well	4	O
as	2	O
a	1	O
number	6	O
of	2	O
housekeeping	12	O
genes	5	O
in	2	O
all	3	O
cell	4	O
types	5	O
.	1	O

In	2	O
lymphocytes	11	O
,	1	O
the	3	O
octamer	7	B-Gene
-binding	8	I-Gene
protein	7	I-Gene
Oct-2A	6	I-Gene
and	3	O
variants	8	O
thereof	7	O
are	3	O
thought	7	O
to	2	O
contribute	10	O
to	2	O
the	3	O
B-cell	6	O
specific	8	O
gene	4	O
expression	10	O
,	1	O
while	5	O
the	3	O
ubiquitous	10	B-Gene
protein	7	I-Gene
Oct-1	5	I-Gene
seems	5	O
to	2	O
control	7	O
general	7	O
octamer	7	O
site	4	O
-dependent	10	O
transcription	13	O
.	1	O

Various	7	O
other	5	O
genes	5	O
,	1	O
for	3	O
example	7	O
interleukin-1	13	B-Gene
and	3	O
MHC	3	B-Gene
class	5	I-Gene
II	2	I-Gene
genes	5	I-Gene
,	1	O
contain	7	O
an	2	O
octamer	7	O
sequence	8	O
in	2	O
the	3	O
promoter	8	O
and	3	O
are	3	O
expressed	9	O
in	2	O
cells	5	O
of	2	O
both	4	O
the	3	O
immune	6	O
and	3	O
nervous	7	O
systems	7	O
.	1	O

This	4	O
prompted	8	O
us	2	O
to	2	O
analyze	7	O
the	3	O
octamer	7	B-Gene
-binding	8	I-Gene
proteins	8	I-Gene
in	2	O
the	3	O
latter	6	O
cells	5	O
.	1	O

Using	5	O
the	3	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assay	5	O
,	1	O
at	2	O
least	5	O
six	3	O
novel	5	O
octamer	7	B-Gene
binding	7	I-Gene
proteins	8	I-Gene
were	4	O
detected	8	O
in	2	O
nuclear	7	O
extracts	8	O
of	2	O
cultured	8	O
mouse	5	O
astrocytes	10	O
.	1	O

These	5	O
proteins	8	O
are	3	O
differentially	14	O
expressed	9	O
in	2	O
human	5	O
glioblastoma	12	B-Disease
and	3	O
neuroblastoma	13	B-Disease
cell	4	O
lines	5	O
.	1	O

The	3	O
nervous	7	O
system	6	O
-derived	8	O
(	1	O
N-Oct	5	B-Gene
)	1	O
proteins	8	O
bound	5	O
to	2	O
the	3	O
octamer	7	O
DNA	3	O
sequence	8	O
in	2	O
a	1	O
manner	6	O
which	5	O
is	2	O
indistinguishable	17	O
from	4	O
the	3	O
Oct-1	5	B-Gene
and	3	O
Oct-2A	6	B-Gene
proteins	8	I-Gene
.	1	O

The	3	O
relationship	12	O
of	2	O
the	3	O
N-Oct	5	B-Gene
proteins	8	I-Gene
to	2	O
Oct-1	5	B-Gene
and	3	O
Oct-2A	6	B-Gene
was	3	O
analyzed	8	O
by	2	O
proteolytic	11	O
clipping	8	O
bandshift	9	O
assays	6	O
and	3	O
by	2	O
their	5	O
reactivity	10	O
towards	7	O
antisera	8	O
raised	6	O
against	7	O
recombinant	11	B-Gene
Oct-1	5	I-Gene
and	3	O
Oct-2A	6	B-Gene
proteins	8	I-Gene
.	1	O

On	2	O
the	3	O
basis	5	O
of	2	O
these	5	O
assays	6	O
,	1	O
all	3	O
N-Oct-factors	13	B-Gene
were	4	O
found	5	O
to	2	O
be	2	O
distinct	8	O
from	4	O
the	3	O
ubiquitous	10	O
Oct-1	5	B-Gene
and	3	O
the	3	O
lymphoid-specific	17	B-Gene
Oct-2A	6	I-Gene
proteins	8	I-Gene
.	1	O

In	2	O
melanoma	8	B-Disease
cells	5	O
that	4	O
contain	7	O
the	3	O
N-Oct-3	7	B-Gene
factor	6	I-Gene
,	1	O
a	1	O
transfected	11	O
lymphocyte-specific	19	O
promoter	8	O
was	3	O
neither	7	O
activated	9	O
nor	3	O
was	3	O
it	2	O
repressed	9	O
upon	4	O
contransfection	15	O
with	4	O
an	2	O
Oct-2A	6	B-Gene
expression	10	O
vector	6	O
.	1	O

We	2	O
therefore	9	O
speculate	9	O
that	4	O
N-Oct-3	7	B-Gene
and	3	O
other	5	O
N-Oct	5	B-Gene
factors	7	I-Gene
have	4	O
a	1	O
specific	8	O
role	4	O
in	2	O
gene	4	O
expression	10	O
in	2	O
cells	5	O
of	2	O
the	3	O
nervous	7	O
system	6	O
.	1	O

Progesterone	12	B-Chemical
suppression	11	O
of	2	O
pregnancy	9	O
lymphocytes	11	O
is	2	O
not	3	O
mediated	8	O
by	2	O
glucocorticoid	14	B-Chemical
effect	6	O
.	1	O

This	4	O
study	5	O
investigated	12	O
whether	7	O
the	3	O
suppressive	11	O
effect	6	O
of	2	O
progesterone	12	B-Chemical
on	2	O
pregnancy	9	O
lymphocytes	11	O
is	2	O
mediated	8	O
by	2	O
specific	8	O
progesterone	12	B-Gene
receptors	9	I-Gene
.	1	O

The	3	O
effects	7	O
of	2	O
a	1	O
competitive	11	O
progesterone	12	B-Chemical
antagonist	10	O
(	1	O
RU486	5	B-Chemical
)	1	O
and	3	O
a	1	O
specific	8	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
blocker	7	O
(	1	O
RU43044	7	B-Chemical
)	1	O
were	4	O
tested	6	O
on	2	O
the	3	O
release	7	O
of	2	O
a	1	O
blocking	8	O
factor	6	O
by	2	O
progesterone	12	B-Chemical
-treated	8	O
pregnancy	9	O
lymphocytes	11	O
.	1	O

RU	2	B-Chemical
486	3	I-Chemical
tested	6	O
at	2	O
an	2	O
equal	5	O
concentration	13	O
as	2	O
progesterone	12	B-Chemical
significantly	13	O
inhibited	9	O
the	3	O
production	10	O
of	2	O
the	3	O
blocking	8	O
factor	6	O
,	1	O
while	5	O
RU	2	B-Chemical
43044	5	I-Chemical
was	3	O
without	7	O
effect	6	O
.	1	O

These	5	O
data	4	O
suggest	7	O
that	4	O
in	2	O
pregnancy	9	O
,	1	O
lymphocyte	10	O
progesterone	12	B-Chemical
acts	4	O
on	2	O
specific	8	O
progesterone	12	B-Gene
receptors	9	I-Gene
and	3	O
glucocorticoid	14	B-Chemical
binding	7	O
sites	5	O
are	3	O
not	3	O
involved	8	O
.	1	O

Decreased	9	O
concentration	13	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25-dihydroxyvitamin	19	I-Gene
D3	2	I-Gene
receptors	9	I-Gene
in	2	O
peripheral	10	O
mononuclear	11	O
cells	5	O
of	2	O
patients	8	O
with	4	O
X	1	B-Disease
-linked	7	I-Disease
hypophosphatemic	16	I-Disease
rickets	7	I-Disease
:	1	O
effect	6	O
of	2	O
phosphate	9	B-Chemical
supplementation	15	O
.	1	O

Abnormal	8	O
renal	5	O
tubular	7	O
phosphate	9	B-Chemical
transport	9	O
is	2	O
considered	10	O
to	2	O
be	2	O
the	3	O
primary	7	O
defect	6	O
in	2	O
X	1	B-Disease
-linked	7	I-Disease
hypophosphatemic	16	I-Disease
rickets	7	I-Disease
(	1	O
XLH	3	B-Disease
)	1	O
.	1	O

However	7	O
,	1	O
the	3	O
resistance	10	O
to	2	O
vitamin	7	B-Chemical
D	1	I-Chemical
treatment	9	O
in	2	O
XLH	3	B-Disease
can	3	O
not	3	O
be	2	O
explained	9	O
by	2	O
hypophosphatemia	16	B-Disease
alone	5	O
.	1	O

Since	5	O
most	4	O
of	2	O
the	3	O
actions	7	O
of	2	O
vitamin	7	B-Chemical
D	1	I-Chemical
are	3	O
mediated	8	O
by	2	O
its	3	O
receptors	9	O
(	1	O
VDR	3	B-Gene
)	1	O
,	1	O
abnormalities	13	O
of	2	O
VDR	3	B-Gene
have	4	O
been	4	O
postulated	10	O
in	2	O
XLH	3	B-Disease
.	1	O

In	2	O
order	5	O
to	2	O
investigate	11	O
this	4	O
possibility	11	O
,	1	O
we	2	O
measured	8	O
the	3	O
concentration	13	O
of	2	O
VDR	3	B-Gene
in	2	O
PHA	3	B-Gene
-activated	10	O
peripheral	10	O
mononuclear	11	O
cells	5	O
from	4	O
10	2	O
XLH	3	B-Disease
patients	8	O
.	1	O

Patients	8	O
without	7	O
phosphate	9	B-Chemical
supplementation	15	O
showed	6	O
significantly	13	O
lower	5	O
concentration	13	O
(	1	O
21.7	4	O
+	1	O
/	1	O
-	1	O
5.1	3	O
fmol	4	O
/	1	O
mg	2	O
protein	7	O
,	1	O
mean	4	O
+	1	O
/	1	O
-	1	O
SEM	3	O
)	1	O
compared	8	O
to	2	O
the	3	O
normal	6	O
controls	8	O
(	1	O
60.7	4	O
+	1	O
/	1	O
-	1	O
4.0	3	O
)	1	O
.	1	O

On	2	O
the	3	O
contrary	8	O
,	1	O
there	5	O
was	3	O
no	2	O
significant	11	O
difference	10	O
between	7	O
the	3	O
phosphate	9	B-Chemical
-supplemented	13	O
patients	8	O
(	1	O
58.3	4	O
+	1	O
/	1	O
-	1	O
2.7	3	O
)	1	O
and	3	O
controls	8	O
.	1	O

There	5	O
was	3	O
a	1	O
significant	11	O
positive	8	O
correlation	11	O
between	7	O
VDR	3	B-Gene
concentration	13	O
and	3	O
serum	5	O
phosphate	9	B-Chemical
(	1	O
P	1	O
less	4	O
than	4	O
0.05	4	O
)	1	O
.	1	O

In	2	O
two	3	O
patients	8	O
,	1	O
VDR	3	B-Gene
was	3	O
increased	9	O
after	5	O
daily	5	O
phosphate	9	B-Chemical
supplementation	15	O
was	3	O
started	7	O
.	1	O

These	5	O
results	7	O
indicate	8	O
that	4	O
a	1	O
decreased	9	O
concentration	13	O
of	2	O
VDR	3	B-Gene
secondary	9	O
to	2	O
persistent	10	O
hypophosphatemia	16	B-Disease
is	2	O
one	3	O
of	2	O
the	3	O
causes	6	O
of	2	O
vitamin	7	B-Chemical
D	1	I-Chemical
resistance	10	O
in	2	O
XLH	3	B-Disease
.	1	O

Characterization	16	O
of	2	O
defensin	8	B-Gene
resistance	10	O
phenotypes	10	O
associated	10	O
with	4	O
mutations	9	O
in	2	O
the	3	O
phoP	4	B-Gene
virulence	9	I-Gene
regulon	7	I-Gene
of	2	O
Salmonella	10	O
typhimurium	11	O
.	1	O

The	3	O
defensin	8	B-Gene
sensitivities	13	O
of	2	O
Salmonella	10	O
typhimurium	11	O
strains	7	O
with	4	O
mutations	9	O
in	2	O
the	3	O
phoP	4	B-Gene
/	1	I-Gene
phoQ	4	I-Gene
two	3	I-Gene
-component	10	I-Gene
virulence	9	I-Gene
regulon	7	I-Gene
were	4	O
tested	6	O
by	2	O
using	5	O
purified	8	B-Gene
defensins	9	I-Gene
NP-1	4	I-Gene
and	3	O
NP-2	4	B-Gene
.	1	O

Strains	7	O
with	4	O
mutations	9	O
in	2	O
either	6	O
gene	4	O
of	2	O
the	3	O
regulatory	10	O
pair	4	O
(	1	O
phoP	4	B-Gene
[	1	O
transcriptional	15	O
activator	9	O
]	1	O
or	2	O
phoQ	4	B-Gene
[	1	O
membrane	8	B-Gene
sensor	6	I-Gene
kinase	6	I-Gene
]	1	O
)	1	O
had	3	O
increased	9	O
sensitivities	13	O
to	2	O
defensin	8	B-Gene
.	1	O

The	3	O
predicted	9	O
periplasmic	11	O
domain	6	O
of	2	O
the	3	O
PhoQ	4	B-Gene
protein	7	I-Gene
contained	9	O
a	1	O
markedly	8	O
anionic	7	O
domain	6	O
that	4	O
could	5	O
interact	8	O
with	4	O
cationic	8	O
proteins	8	O
and	3	O
that	4	O
could	5	O
be	2	O
responsible	11	O
for	3	O
resistance	10	O
to	2	O
defensin	8	B-Gene
.	1	O

Because	7	O
insertion	9	O
mutations	9	O
in	2	O
phoP	4	B-Gene
are	3	O
polar	5	O
on	2	O
phoQ	4	B-Gene
,	1	O
we	2	O
constructed	11	O
strains	7	O
that	4	O
expressed	9	O
the	3	O
PhoQ	4	B-Gene
protein	7	I-Gene
in	2	O
the	3	O
absence	7	O
of	2	O
PhoP	4	B-Gene
to	2	O
test	4	O
whether	7	O
resistance	10	O
to	2	O
defensin	8	B-Gene
requires	8	O
only	4	O
the	3	O
phoQ	4	B-Gene
gene	4	I-Gene
product	7	I-Gene
.	1	O

We	2	O
found	5	O
that	4	O
resistance	10	O
to	2	O
defensin	8	B-Gene
requires	8	O
the	3	O
function	8	O
of	2	O
both	4	O
components	10	O
of	2	O
this	4	O
regulatory	10	O
system	6	O
,	1	O
because	7	O
strains	7	O
expressing	10	O
PhoQ	4	B-Gene
without	7	O
PhoP	4	B-Gene
were	4	O
still	5	O
markedly	8	O
sensitive	9	O
to	2	O
defensins	9	B-Gene
.	1	O

This	4	O
implied	7	O
that	4	O
a	1	O
pag	3	B-Gene
(	1	I-Gene
phoP	4	I-Gene
-activated	10	I-Gene
gene	4	I-Gene
)	1	I-Gene
product	7	I-Gene
is	2	O
responsible	11	O
for	3	O
defensin	8	B-Gene
resistance	10	O
.	1	O

We	2	O
also	4	O
tested	6	O
for	3	O
the	3	O
ability	7	O
of	2	O
defensins	9	B-Gene
NP-1	4	I-Gene
,	1	O
NP-5	4	B-Gene
,	1	O
and	3	O
HNP-1	5	B-Gene
to	2	O
activate	8	O
pag	3	B-Gene
expression	10	O
and	3	O
found	5	O
that	4	O
these	5	O
peptides	8	O
have	4	O
no	2	O
effect	6	O
.	1	O

Defensin	8	B-Gene
resistance	10	O
is	2	O
not	3	O
the	3	O
only	4	O
virulence	9	O
characteristic	14	O
controlled	10	O
by	2	O
the	3	O
PhoP-PhoQ	9	B-Gene
regulon	7	I-Gene
because	7	O
mutations	9	O
in	2	O
pagC	4	B-Gene
,	1	O
as	2	O
well	4	O
as	2	O
ones	4	O
in	2	O
the	3	O
phoP	4	B-Gene
locus	5	I-Gene
that	4	O
resulted	8	O
in	2	O
constitutive	12	O
pag	3	B-Gene
activation	10	O
(	1	O
phenotype	9	O
PhoPc	5	B-Gene
)	1	O
,	1	O
had	3	O
no	2	O
effect	6	O
on	2	O
defensin	8	B-Gene
resistance	10	O
,	1	O
even	4	O
though	6	O
they	4	O
rendered	8	O
the	3	O
organism	8	O
avirulent	9	O
and	3	O
deficient	9	O
in	2	O
survival	8	O
within	6	O
macrophages	11	O
.	1	O

The	3	O
virulence	9	O
defect	6	O
conferred	9	O
by	2	O
mutations	9	O
in	2	O
the	3	O
phoP	4	B-Gene
-phoQ	5	I-Gene
two	3	O
-component	10	O
regulatory	10	O
system	6	O
is	2	O
not	3	O
completely	10	O
explained	9	O
by	2	O
alterations	11	O
in	2	O
resistance	10	O
to	2	O
cationic	8	O
proteins	8	O
and	3	O
involves	8	O
the	3	O
control	7	O
of	2	O
other	5	O
proteins	8	O
necessary	9	O
for	3	O
S.	2	O
typhimurium	11	O
survival	8	O
within	6	O
macrophages	11	O
.	1	O

Adherence	9	O
-dependent	10	O
increase	8	O
in	2	O
human	5	B-Gene
monocyte	8	I-Gene
PDGF	4	I-Gene
(	1	I-Gene
B	1	I-Gene
)	1	I-Gene
mRNA	4	I-Gene
is	2	O
associated	10	O
with	4	O
increases	9	O
in	2	O
c-fos	5	B-Gene
,	1	O
c-jun	5	B-Gene
,	1	O
and	3	O
EGR2	4	B-Gene
mRNA	4	I-Gene
.	1	O

Adherence	9	O
is	2	O
an	2	O
important	9	O
initial	7	O
step	4	O
in	2	O
the	3	O
transition	10	O
of	2	O
a	1	O
circulating	11	O
monocyte	8	O
to	2	O
a	1	O
tissue	6	O
macrophage	10	O
.	1	O

This	4	O
differentiation	15	O
is	2	O
accompanied	11	O
by	2	O
an	2	O
augmented	9	O
capacity	8	O
to	2	O
generate	8	O
growth	6	O
factors	7	O
.	1	O

We	2	O
hypothesized	12	O
that	4	O
adherence	9	O
itself	6	O
might	5	O
be	2	O
an	2	O
important	9	O
trigger	7	O
for	3	O
a	1	O
sequence	8	O
of	2	O
gene	4	O
activation	10	O
culminating	11	O
in	2	O
cells	5	O
with	4	O
increased	9	O
mRNA	4	O
encoding	8	O
profibrotic	11	O
growth	6	O
factors	7	O
such	4	O
as	2	O
platelet	8	B-Gene
-derived	8	I-Gene
growth	6	I-Gene
factor	6	I-Gene
B	1	I-Gene
subunit	7	I-Gene
(	1	O
PDGF	4	B-Gene
[	1	I-Gene
B	1	I-Gene
]	1	I-Gene
)	1	O
and	3	O
transforming	12	B-Gene
growth	6	I-Gene
factor-beta	11	I-Gene
(	1	O
TGF-beta	8	B-Gene
)	1	O
.	1	O

After	5	O
in	2	O
vitro	5	O
adherence	9	O
,	1	O
human	5	O
monocytes	9	O
had	3	O
a	1	O
biphasic	8	O
increase	8	O
in	2	O
PDGF	4	B-Gene
(	1	I-Gene
B	1	I-Gene
)	1	I-Gene
mRNA	4	I-Gene
with	4	O
peaks	5	O
at	2	O
6	1	O
h	1	O
and	3	O
13	2	O
d	1	O
.	1	O

No	2	O
increase	8	O
in	2	O
TGF-beta	8	B-Gene
mRNA	4	I-Gene
was	3	O
observed	8	O
.	1	O

The	3	O
6-h	3	O
increase	8	O
in	2	O
PDGF	4	B-Gene
(	1	I-Gene
B	1	I-Gene
)	1	I-Gene
mRNA	4	I-Gene
was	3	O
adherence	9	O
dependent	9	O
,	1	O
and	3	O
in	2	O
addition	8	O
,	1	O
was	3	O
abrogated	9	O
when	4	O
the	3	O
cytoskeletal	12	O
integrity	9	O
was	3	O
compromised	11	O
by	2	O
cytochalasin	12	B-Chemical
D	1	I-Chemical
.	1	O

The	3	O
6-h	3	O
increase	8	O
in	2	O
PDGF	4	B-Gene
(	1	I-Gene
B	1	I-Gene
)	1	I-Gene
mRNA	4	I-Gene
was	3	O
unaltered	9	O
by	2	O
adherence	9	O
in	2	O
the	3	O
presence	8	O
of	2	O
the	3	O
monocyte	8	O
stimulus	8	O
lipopolysaccharide	18	B-Chemical
.	1	O

Adherence	9	O
to	2	O
either	6	O
fibronectin	11	B-Gene
or	2	O
collagen	8	B-Gene
-coated	7	O
plastic	7	O
had	3	O
little	6	O
consistent	10	O
effect	6	O
on	2	O
PDGF	4	B-Gene
(	1	I-Gene
B	1	I-Gene
)	1	I-Gene
mRNA	4	I-Gene
accumulation	12	O
.	1	O

The	3	O
increased	9	O
PDGF	4	B-Gene
(	1	I-Gene
B	1	I-Gene
)	1	I-Gene
mRNA	4	I-Gene
observed	8	O
in	2	O
adherent	8	O
monocytes	9	O
was	3	O
accompanied	11	O
by	2	O
increases	9	O
in	2	O
mRNAs	5	O
of	2	O
the	3	O
early	5	B-Gene
growth	6	I-Gene
response	8	I-Gene
genes	5	I-Gene
c-fos	5	I-Gene
(	1	O
maximal	7	O
at	2	O
20	2	O
min	3	O
)	1	O
,	1	O
c-jun	5	B-Gene
,	1	O
and	3	O
EGR2	4	B-Gene
(	1	O
maximal	7	O
at	2	O
6-24	4	O
h	1	O
)	1	O
.	1	O

The	3	O
increase	8	O
in	2	O
c-jun	5	B-Gene
and	3	O
EGR2	4	B-Gene
,	1	O
but	3	O
not	3	O
c-fos	5	B-Gene
,	1	O
mRNA	4	O
was	3	O
also	4	O
abrogated	9	O
by	2	O
cytochalasin	12	B-Chemical
D	1	I-Chemical
.	1	O

These	5	O
observations	12	O
suggest	7	O
that	4	O
adherence	9	O
results	7	O
in	2	O
increases	9	O
of	2	O
c-fos	5	B-Gene
,	1	O
c-jun	5	B-Gene
,	1	O
EGR2	4	B-Gene
,	1	O
and	3	O
PDGF	4	B-Gene
(	1	I-Gene
B	1	I-Gene
)	1	I-Gene
mRNA	4	I-Gene
.	1	O

In	2	O
addition	8	O
,	1	O
the	3	O
increases	9	O
in	2	O
c-jun	5	B-Gene
,	1	O
EGR2	4	B-Gene
,	1	O
and	3	O
PDGF	4	B-Gene
(	1	I-Gene
B	1	I-Gene
)	1	I-Gene
may	3	O
depend	6	O
on	2	O
cytoskeletal	12	O
rearrangement	13	O
.	1	O

Modulation	10	O
of	2	O
these	5	O
events	6	O
at	2	O
the	3	O
time	4	O
of	2	O
adherence	9	O
offers	6	O
a	1	O
mechanism	9	O
by	2	O
which	5	O
differential	12	O
priming	7	O
of	2	O
the	3	O
cells	5	O
may	3	O
be	2	O
accomplished	12	O
.	1	O

NF-X2	5	B-Gene
that	4	O
binds	5	O
to	2	O
the	3	O
DRA	3	B-Gene
X2-box	6	O
is	2	O
activator	9	B-Gene
protein	7	I-Gene
1	1	I-Gene
.	1	O

Expression	10	O
cloning	7	O
of	2	O
c-Jun	5	B-Gene
.	1	O

Human	5	B-Gene
class	5	I-Gene
II	2	I-Gene
MHC	3	I-Gene
Ag	2	I-Gene
are	3	O
a	1	O
family	6	O
of	2	O
cell	4	O
surface	7	O
glycoproteins	13	O
.	1	O

Their	5	O
constitutive	12	O
expression	10	O
is	2	O
limited	7	O
to	2	O
B	1	O
lymphocytes	11	O
and	3	O
thymic	6	O
epithelial	10	O
cells	5	O
.	1	O

In	2	O
many	4	O
other	5	O
cells	5	O
their	5	O
expression	10	O
can	3	O
be	2	O
induced	7	O
by	2	O
IFN-gamma	9	B-Gene
.	1	O

Conserved	9	O
upstream	8	O
promoter	8	O
sequences	9	O
regulate	8	O
this	4	O
tissue-specific	15	O
expression	10	O
of	2	O
class	5	O
II	2	O
genes	5	O
.	1	O

In	2	O
the	3	O
DRA	3	B-Gene
promoter	8	I-Gene
,	1	O
one	3	O
of	2	O
these	5	O
cis	3	O
-acting	7	O
regulatory	10	O
motifs	6	O
is	2	O
the	3	O
X2-box	6	O
to	2	O
which	5	O
nuclear	7	B-Gene
factor	6	I-Gene
X2	2	I-Gene
(	1	O
NF-X2	5	B-Gene
)	1	O
binds	5	O
.	1	O

Here	4	O
,	1	O
we	2	O
present	7	O
the	3	O
isolation	9	O
and	3	O
characterization	16	O
of	2	O
the	3	O
full-length	11	O
cDNA	4	O
clone	5	O
encoding	8	O
NF-X2	5	B-Gene
.	1	O

This	4	O
cDNA	4	O
clone	5	O
was	3	O
isolated	8	O
by	2	O
expression	10	O
cDNA	4	O
cloning	7	O
,	1	O
and	3	O
encodes	7	O
the	3	O
human	5	B-Gene
c-Jun	5	I-Gene
protein	7	I-Gene
,	1	O
which	5	O
together	8	O
with	4	O
c-Fos	5	B-Gene
forms	5	O
the	3	O
heterodimeric	13	O
activator	9	B-Gene
protein-1	9	I-Gene
transcription	13	I-Gene
complex	7	I-Gene
.	1	O

Whereas	7	O
c-Fos	5	B-Gene
/	1	I-Gene
c-Jun	5	I-Gene
heterodimers	12	O
do	2	O
not	3	O
exist	5	O
in	2	O
B	1	O
cells	5	O
,	1	O
they	4	O
form	4	O
and	3	O
bind	4	O
to	2	O
the	3	O
X2-box	6	O
in	2	O
class	5	O
II	2	O
nonexpressing	13	O
cells	5	O
.	1	O

Thus	4	O
,	1	O
c-Fos	5	B-Gene
/	1	I-Gene
c-Jun	5	I-Gene
heterodimers	12	O
might	5	O
contribute	10	O
to	2	O
the	3	O
repression	10	O
of	2	O
DRA	3	B-Gene
gene	4	I-Gene
expression	10	O
.	1	O

Immunohistochemical	19	O
study	5	O
of	2	O
steroid	7	B-Chemical
hormones	8	I-Chemical
and	3	O
an	2	O
estrogen	8	O
binding	7	O
assay	5	O
in	2	O
malignant	9	O
soft	4	O
tissue	6	O
tumors	6	B-Disease
.	1	O

Immunohistochemically	21	O
,	1	O
the	3	O
immunoreaction	14	O
against	7	O
5	1	O
steroid	7	B-Chemical
hormone	7	I-Chemical
anti-sera	9	O
(	1	O
estradiol	9	B-Chemical
,	1	O
estriol	7	B-Chemical
,	1	O
cortisol	8	B-Chemical
,	1	O
progesterone	12	B-Chemical
and	3	O
testosterone	12	B-Chemical
)	1	O
was	3	O
examined	8	O
in	2	O
39	2	O
cases	5	O
with	4	O
the	3	O
malignant	9	O
soft	4	O
tissue	6	O
tumors	6	B-Disease
(	1	O
fibrosarcoma	12	B-Disease
:	1	O
8	1	O
,	1	O
malignant	9	B-Disease
fibrous	7	I-Disease
histiocytoma	12	I-Disease
:	1	O
6	1	O
,	1	O
rhabdomyosarcoma	16	B-Disease
:	1	O
10	2	O
,	1	O
leiomyosarcoma	14	B-Disease
:	1	O
10	2	O
,	1	O
liposarcoma	11	B-Disease
:	1	O
5	1	O
)	1	O
.	1	O

Seventeen	9	O
cases	5	O
revealed	8	O
distinct	8	O
immunostaining	14	O
against	7	O
at	2	O
least	5	O
1	1	O
of	2	O
the	3	O
5	1	O
steroid	7	B-Chemical
hormones	8	I-Chemical
.	1	O

Immunostained	13	O
tumor	5	B-Disease
cells	5	O
were	4	O
more	4	O
frequently	10	O
distributed	11	O
in	2	O
the	3	O
area	4	O
where	5	O
tumor	5	B-Disease
cell	4	O
infiltration	12	O
was	3	O
more	4	O
invasive	8	O
.	1	O

The	3	O
majority	8	O
of	2	O
the	3	O
positive	8	O
cases	5	O
occurred	8	O
in	2	O
female	6	O
cases	5	O
.	1	O

Furthermore	11	O
,	1	O
the	3	O
existence	9	O
of	2	O
estrogen	8	B-Gene
receptor	8	I-Gene
(	1	O
estrogen	8	B-Chemical
binding	7	O
activity	8	O
)	1	O
was	3	O
examined	8	O
histochemically	15	O
in	2	O
39	2	O
cases	5	O
and	3	O
it	2	O
was	3	O
detected	8	O
in	2	O
8	1	O
.	1	O

We	2	O
concluded	9	O
that	4	O
steroid	7	B-Chemical
hormones	8	I-Chemical
might	5	O
be	2	O
closely	7	O
related	7	O
to	2	O
tumor	5	B-Disease
cell	4	O
infiltration	12	O
of	2	O
some	4	O
malignant	9	O
soft	4	O
tissue	6	O
tumors	6	B-Disease
.	1	O

Interferon-gamma	16	B-Gene
and	3	O
the	3	O
sexual	6	O
dimorphism	10	O
of	2	O
autoimmunity	12	O
.	1	O

The	3	O
sexual	6	O
difference	10	O
in	2	O
the	3	O
incidence	9	O
of	2	O
autoimmune	10	B-Disease
diseases	8	I-Disease
has	3	O
remained	8	O
an	2	O
enigma	6	O
for	3	O
many	4	O
years	5	O
.	1	O

In	2	O
the	3	O
examination	11	O
of	2	O
the	3	O
induction	9	O
of	2	O
autoimmunity	12	O
in	2	O
transgenic	10	O
mice	4	O
,	1	O
evidence	8	O
has	3	O
been	4	O
obtained	8	O
further	7	O
implicating	11	O
the	3	O
lymphokine	10	B-Gene
interferon-gamma	16	I-Gene
in	2	O
the	3	O
etiology	8	O
of	2	O
autoimmunity	12	O
.	1	O

Sex	3	O
steroid	7	B-Chemical
regulation	10	O
of	2	O
the	3	O
production	10	O
of	2	O
this	4	O
molecule	8	O
,	1	O
as	2	O
well	4	O
as	2	O
other	5	O
cytokines	9	O
,	1	O
may	3	O
help	4	O
explain	7	O
the	3	O
gender-specific	15	O
differences	11	O
in	2	O
the	3	O
immune	6	O
system	6	O
,	1	O
including	9	O
autoimmunity	12	O
.	1	O

Cloning	7	O
of	2	O
a	1	O
mitogen-inducible	17	O
gene	4	O
encoding	8	O
a	1	O
kappa	5	O
B	1	O
DNA	3	O
-binding	8	O
protein	7	O
with	4	O
homology	8	O
to	2	O
the	3	O
rel	3	B-Gene
oncogene	8	I-Gene
and	3	O
to	2	O
cell-cycle	10	O
motifs	6	O
.	1	O

We	2	O
have	4	O
cloned	6	O
and	3	O
characterized	13	O
a	1	O
mitogen-inducible	17	O
gene	4	O
isolated	8	O
from	4	O
human	5	O
T	1	O
cells	5	O
that	4	O
predicts	8	O
a	1	O
protein	7	O
of	2	O
968	3	O
amino	5	O
acids	5	O
.	1	O

The	3	O
amino-terminal	14	O
domain	6	O
has	3	O
regions	7	O
homologous	10	O
to	2	O
the	3	O
oncogene	8	B-Gene
rel	3	I-Gene
and	3	O
to	2	O
the	3	O
developmentally	15	O
important	9	O
gene	4	B-Gene
dorsal	6	I-Gene
of	2	O
Drosophila	10	O
.	1	O

The	3	O
carboxy-terminal	16	O
domain	6	O
contains	8	O
repeat	6	O
structures	10	O
found	5	O
in	2	O
a	1	O
variety	7	O
of	2	O
proteins	8	O
that	4	O
are	3	O
involved	8	O
in	2	O
cell-cycle	10	O
control	7	O
of	2	O
yeast	5	O
and	3	O
in	2	O
tissue	6	O
differentiation	15	O
in	2	O
Drosophila	10	O
and	3	O
Ceanorhabditis	14	O
elegans	7	O
,	1	O
as	2	O
well	4	O
as	2	O
in	2	O
the	3	O
putative	8	O
human	5	B-Gene
oncogene	8	I-Gene
bcl-3	5	I-Gene
and	3	O
in	2	O
the	3	O
ankyrin	7	B-Gene
protein	7	I-Gene
.	1	O

A	1	O
truncated	9	O
form	4	O
of	2	O
the	3	O
product	7	O
of	2	O
this	4	O
gene	4	O
translated	10	O
in	2	O
vitro	5	O
is	2	O
a	1	O
DNA	3	O
-binding	8	O
protein	7	O
which	5	O
interacts	9	O
specifically	12	O
with	4	O
the	3	O
kappa	5	O
B	1	O
binding	7	O
site	4	O
found	5	O
in	2	O
many	4	O
inducible	9	O
genes	5	O
,	1	O
including	9	O
the	3	O
enhancer	8	O
in	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
.	1	O

This	4	O
gene	4	O
is	2	O
yet	3	O
another	7	O
in	2	O
a	1	O
growing	7	O
list	4	O
of	2	O
important	9	O
regulatory	10	O
molecules	9	O
whose	5	O
expression	10	O
is	2	O
transcriptionally	17	O
induced	7	O
upon	4	O
cellular	8	O
activation	10	O
.	1	O

Stimulation	11	O
of	2	O
a	1	O
human	5	O
T-cell	6	O
clone	5	O
with	4	O
anti-CD3	8	B-Gene
or	2	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
induces	7	O
NF-kappa	8	B-Gene
B	1	I-Gene
translocation	13	O
but	3	O
not	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
1	1	O
enhancer	8	O
-dependent	10	O
transcription	13	O
.	1	O

The	3	O
expression	10	O
of	2	O
transiently	11	O
transfected	11	O
expression	10	O
vectors	7	O
under	5	O
the	3	O
control	7	O
of	2	O
the	3	O
long	4	O
terminal	8	O
repeat	6	O
(	1	O
LTR	3	O
)	1	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
(	1	O
HIV	3	O
)	1	O
or	2	O
its	3	O
enhancer	8	O
sequence	8	O
and	3	O
the	3	O
translocation	13	O
of	2	O
the	3	O
HIV	3	B-Gene
enhancer	8	I-Gene
-binding	8	I-Gene
protein	7	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
were	4	O
analyzed	8	O
in	2	O
two	3	O
human	5	O
T-cell	6	O
clones	6	O
stimulated	10	O
through	7	O
their	5	O
T-cell	6	B-Gene
receptor	8	I-Gene
complex	7	I-Gene
or	2	O
by	2	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
or	2	O
phorbol	7	B-Chemical
12-myristate	12	I-Chemical
13-acetate	10	I-Chemical
.	1	O

We	2	O
found	5	O
a	1	O
dissociation	12	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
translocation	13	O
from	4	O
transactivation	15	O
of	2	O
either	6	O
the	3	O
HIV	3	O
LTR	3	O
or	2	O
the	3	O
HIV	3	O
enhancer	8	O
.	1	O

Interleukin	11	B-Gene
2	1	I-Gene
induced	7	O
proliferation	13	O
but	3	O
not	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
translocation	13	O
or	2	O
LTR	3	O
transactivation	15	O
.	1	O

Phorbol	7	B-Chemical
ester	5	I-Chemical
or	2	O
specific	8	O
antigen	7	O
recognition	11	O
induced	7	O
HIV	3	O
LTR	3	O
transactivation	15	O
,	1	O
whereas	7	O
stimulation	11	O
with	4	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
or	2	O
antibody	8	O
to	2	O
CD3	3	B-Gene
did	3	O
not	3	O
.	1	O

The	3	O
two	3	O
latter	6	O
signals	7	O
were	4	O
nevertheless	12	O
able	4	O
to	2	O
induce	6	O
NF-kappa	8	B-Gene
B	1	I-Gene
translocation	13	O
with	4	O
a	1	O
pattern	7	O
in	2	O
the	3	O
band-shift	10	O
assay	5	O
indistinguishable	17	O
from	4	O
that	4	O
observed	8	O
using	5	O
phorbol	7	B-Chemical
ester	5	I-Chemical
.	1	O

Our	3	O
finding	7	O
that	4	O
induction	9	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
by	2	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
or	2	O
antibody	8	O
to	2	O
CD3	3	B-Gene
is	2	O
not	3	O
sufficient	10	O
to	2	O
induce	6	O
HIV	3	O
enhancer	8	O
-dependent	10	O
transcription	13	O
in	2	O
cloned	6	O
T	1	O
cells	5	O
contrasts	9	O
with	4	O
results	7	O
obtained	8	O
in	2	O
most	4	O
lymphoblastoid	14	O
T-cell	6	O
lines	5	O
and	3	O
indicates	9	O
that	4	O
normal	6	O
T	1	O
lymphocytes	11	O
differ	6	O
from	4	O
tumoral	7	O
T	1	O
cells	5	O
in	2	O
terms	5	O
of	2	O
requirements	12	O
for	3	O
HIV	3	O
LTR	3	O
activation	10	O
.	1	O

Furthermore	11	O
,	1	O
our	3	O
results	7	O
suggest	7	O
that	4	O
events	6	O
linked	6	O
to	2	O
T-cell	6	O
activation	10	O
,	1	O
in	2	O
addition	8	O
to	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
translocation	13	O
per	3	O
se	2	O
,	1	O
induce	6	O
functional	10	O
interactions	12	O
of	2	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
complex	7	I-Gene
with	4	O
the	3	O
HIV	3	O
enhancer	8	O
.	1	O

Regulation	10	O
of	2	O
gene	4	O
expression	10	O
with	4	O
double	6	O
-stranded	9	O
phosphorothioate	16	O
oligonucleotides	16	O
.	1	O

Alteration	10	O
of	2	O
gene	4	O
transcription	13	O
by	2	O
inhibition	10	O
of	2	O
specific	8	O
transcriptional	15	O
regulatory	10	O
proteins	8	O
is	2	O
necessary	9	O
for	3	O
determining	11	O
how	3	O
these	5	O
factors	7	O
participate	11	O
in	2	O
cellular	8	O
differentiation	15	O
.	1	O

The	3	O
functions	9	O
of	2	O
these	5	O
proteins	8	O
can	3	O
be	2	O
antagonized	11	O
by	2	O
several	7	O
methods	7	O
,	1	O
each	4	O
with	4	O
specific	8	O
limitations	11	O
.	1	O

Inhibition	10	O
of	2	O
sequence-specific	17	O
DNA	3	O
-binding	8	O
proteins	8	O
was	3	O
achieved	8	O
with	4	O
double	6	O
-stranded	9	O
(	1	O
ds	2	O
)	1	O
phosphorothioate	16	O
oligonucleotides	16	O
that	4	O
contained	9	O
octamer	7	O
or	2	O
kappa	5	O
B	1	O
consensus	9	O
sequences	9	O
.	1	O

The	3	O
phosphorothioate	16	O
oligonucleotides	16	O
specifically	12	O
bound	5	O
either	6	O
octamer	7	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
or	2	O
nuclear	7	B-Gene
factor	6	I-Gene
(	1	I-Gene
NF	2	I-Gene
)	1	I-Gene
-kappa	6	I-Gene
B	1	I-Gene
.	1	O

The	3	O
modified	8	O
oligonucleotides	16	O
accumulated	11	O
in	2	O
cells	5	O
more	4	O
effectively	11	O
than	4	O
standard	8	O
ds	2	O
oligonucleotides	16	O
and	3	O
modulated	9	O
gene	4	O
expression	10	O
in	2	O
a	1	O
specific	8	O
manner	6	O
.	1	O

Octamer	7	O
-dependent	10	O
activation	10	O
of	2	O
a	1	O
reporter	8	O
plasmid	7	O
or	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
-dependent	10	O
activation	10	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
(	1	O
HIV	3	O
)	1	O
enhancer	8	O
was	3	O
inhibited	9	O
when	4	O
the	3	O
appropriate	11	O
phosphorothioate	16	O
oligonucleotide	15	O
was	3	O
added	5	O
to	2	O
a	1	O
transiently	11	O
transfected	11	O
B	1	O
cell	4	O
line	4	O
.	1	O

Addition	8	O
of	2	O
phosphorothioate	16	O
oligonucleotides	16	O
that	4	O
contained	9	O
the	3	O
octamer	7	O
consensus	9	O
to	2	O
Jurkat	6	O
T	1	B-Disease
leukemia	8	I-Disease
cells	5	O
inhibited	9	O
interleukin-2	13	B-Gene
(	1	O
IL-2	4	B-Gene
)	1	O
secretion	9	O
to	2	O
a	1	O
degree	6	O
similar	7	O
to	2	O
that	4	O
observed	8	O
with	4	O
a	1	O
mutated	7	O
octamer	7	O
site	4	O
in	2	O
the	3	O
IL-2	4	B-Gene
enhancer	8	I-Gene
.	1	O

The	3	O
ds	2	O
phosphorothioate	16	O
oligonucleotides	16	O
probably	8	O
compete	7	O
for	3	O
binding	7	O
of	2	O
specific	8	O
transcription	13	O
factors	7	O
and	3	O
may	3	O
provide	7	O
anti-viral	10	O
,	1	O
immunosuppressive	17	O
,	1	O
or	2	O
other	5	O
therapeutic	11	O
effects	7	O
.	1	O

[	1	O
The	3	O
effect	6	O
of	2	O
24	2	B-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
(	1	O
dioxyvit	8	B-Chemical
)	1	O
on	2	O
Ca	2	O
metabolism	10	O
and	3	O
immune	6	O
status	6	O
during	6	O
chronic	7	B-Disease
kidney	6	I-Disease
failure	7	I-Disease
]	1	O

Active	6	O
metabolite	10	O
of	2	O
vitamin	7	B-Chemical
D3	2	I-Chemical
,	1	O
24R	3	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
(	1	O
dioxyvit	8	B-Chemical
)	1	O
was	3	O
used	4	O
at	2	O
a	1	O
daily	5	O
dose	4	O
of	2	O
100	3	O
micrograms	10	O
in	2	O
treatment	9	O
of	2	O
children	8	O
affected	8	O
with	4	O
tubulointerstitial	18	B-Disease
disease	7	I-Disease
of	2	I-Disease
kidney	6	I-Disease
and	3	O
with	4	O
chronic	7	O
glomerulonephritis	18	B-Disease
under	5	O
conditions	10	O
of	2	O
kidney	6	B-Disease
insufficiency	13	I-Disease
.	1	O

The	3	O
drug	4	O
exhibited	9	O
distinct	8	O
normalizing	11	O
effect	6	O
on	2	O
patterns	8	O
of	2	O
calcium	7	B-Chemical
metabolism	10	O
:	1	O
increase	8	O
of	2	O
total	5	O
and	3	O
ionized	7	O
Ca2+	4	O
and	3	O
of	2	O
25-OHD	6	O
,	1	O
decrease	8	O
in	2	O
concentration	13	O
of	2	O
parath	6	O
hormone	7	O
and	3	O
osteocalcine	12	B-Gene
in	2	O
blood	5	O
serum	5	O
as	2	O
well	4	O
as	2	O
on	2	O
immunological	13	O
parameters	10	O
:	1	O
restoration	11	O
of	2	O
decreased	9	O
content	7	O
of	2	O
T-	2	O
and	3	O
0-lymphocytes	13	O
.	1	O

Concentration	13	O
of	2	O
receptors	9	O
of	2	O
hormonal	8	O
form	4	O
of	2	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
was	3	O
found	5	O
to	2	O
be	2	O
minimal	7	O
in	2	O
lymphocytes	11	O
under	5	O
conditions	10	O
of	2	O
chronic	7	B-Disease
kidney	6	I-Disease
insufficiency	13	I-Disease
,	1	O
while	5	O
their	5	O
expression	10	O
,	1	O
after	5	O
the	3	O
dioxyvit	8	B-Chemical
action	6	O
,	1	O
was	3	O
detected	8	O
only	4	O
in	2	O
patients	8	O
with	4	O
glomerulonephritis	18	B-Disease
.	1	O

Specific	8	O
calcitropic	11	O
effect	6	O
of	2	O
dioxyvit	8	B-Chemical
with	4	O
simultaneous	12	O
correction	10	O
of	2	O
vitamin	7	B-Chemical
D	1	I-Chemical
deficiency	10	O
were	4	O
apparently	10	O
responsible	11	O
for	3	O
high	4	O
efficacy	8	O
of	2	O
the	3	O
drug	4	O
in	2	O
treatment	9	O
of	2	O
calcium	7	B-Chemical
metabolism	10	O
and	3	O
immunity	8	O
impairments	11	O
in	2	O
children	8	O
with	4	O
renal	5	O
deteriorations	14	O
at	2	O
the	3	O
step	4	O
of	2	O
chronic	7	B-Disease
kidney	6	I-Disease
insufficiency	13	I-Disease
.	1	O

Single	6	O
cell	4	O
assay	5	O
of	2	O
a	1	O
transcription	13	O
factor	6	O
reveals	7	O
a	1	O
threshold	9	O
in	2	O
transcription	13	O
activated	9	O
by	2	O
signals	7	O
emanating	9	O
from	4	O
the	3	O
T-cell	6	B-Gene
antigen	7	I-Gene
receptor	8	I-Gene
.	1	O

Stimulation	11	O
of	2	O
T	1	O
lymphocytes	11	O
through	7	O
their	5	O
antigen	7	O
receptor	8	O
leads	5	O
to	2	O
the	3	O
appearance	10	O
of	2	O
several	7	O
transcription	13	O
factors	7	O
,	1	O
including	9	O
NF-AT	5	B-Gene
and	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
,	1	O
which	5	O
are	3	O
involved	8	O
in	2	O
regulating	10	O
genes	5	O
required	8	O
for	3	O
immunologic	11	O
activation	10	O
.	1	O

To	2	O
investigate	11	O
the	3	O
activity	8	O
of	2	O
a	1	O
single	6	O
transcription	13	O
factor	6	O
in	2	O
individual	10	O
viable	6	O
cells	5	O
,	1	O
we	2	O
have	4	O
applied	7	O
an	2	O
assay	5	O
that	4	O
uses	4	O
the	3	O
fluorescence	12	O
-activated	10	O
cell	4	O
sorter	6	O
to	2	O
quantitate	10	O
beta-galactosidase	18	B-Gene
(	1	O
beta-gal	8	B-Gene
)	1	O
.	1	O

We	2	O
have	4	O
analyzed	8	O
the	3	O
distribution	12	O
of	2	O
NF-AT	5	B-Gene
transcriptional	15	O
activity	8	O
among	5	O
T	1	O
cells	5	O
undergoing	10	O
activation	10	O
by	2	O
using	5	O
a	1	O
construct	9	O
in	2	O
which	5	O
three	5	O
tandem	6	O
copies	6	O
of	2	O
the	3	O
NF-AT	5	B-Gene
-binding	8	O
site	4	O
directs	7	O
transcription	13	O
of	2	O
the	3	O
lacZ	4	B-Gene
gene	4	I-Gene
.	1	O

Unexpectedly	12	O
,	1	O
stimulation	11	O
of	2	O
cloned	6	O
stably	6	O
transfected	11	O
Jurkat	6	O
T	1	O
cells	5	O
leads	5	O
to	2	O
a	1	O
bimodal	7	O
pattern	7	O
of	2	O
beta-gal	8	B-Gene
expression	10	O
in	2	O
which	5	O
some	4	O
cells	5	O
express	7	O
no	2	O
beta-gal	8	B-Gene
and	3	O
others	6	O
express	7	O
high	4	O
levels	6	O
.	1	O

This	4	O
expression	10	O
pattern	7	O
can	3	O
not	3	O
be	2	O
accounted	9	O
for	3	O
by	2	O
cell-cycle	10	O
position	8	O
or	2	O
heritable	9	O
variation	9	O
.	1	O

Further	7	O
results	7	O
,	1	O
in	2	O
which	5	O
beta-gal	8	B-Gene
activity	8	O
is	2	O
correlated	10	O
with	4	O
NF-AT	5	B-Gene
-binding	8	O
activity	8	O
,	1	O
indicate	8	O
that	4	O
the	3	O
concentration	13	O
of	2	O
NF-AT	5	B-Gene
must	4	O
exceed	6	O
a	1	O
critical	8	O
threshold	9	O
before	6	O
transcription	13	O
initiates	9	O
.	1	O

This	4	O
threshold	9	O
likely	6	O
reflects	8	O
the	3	O
NF-AT	5	B-Gene
concentration	13	O
-dependent	10	O
assembly	8	O
of	2	O
transcription	13	O
complexes	9	O
at	2	O
the	3	O
promoter	8	O
.	1	O

Similar	7	O
constructs	10	O
controlled	10	O
by	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
or	2	O
the	3	O
entire	6	O
interleukin-2	13	B-Gene
enhancer	8	I-Gene
show	4	O
bimodal	7	O
expression	10	O
patterns	8	O
during	6	O
induction	9	O
,	1	O
suggesting	10	O
that	4	O
thresholds	10	O
set	3	O
by	2	O
the	3	O
concentration	13	O
of	2	O
transcription	13	O
factors	7	O
may	3	O
be	2	O
a	1	O
common	6	O
property	8	O
of	2	O
inducible	9	O
genes	5	O
.	1	O

Type-II	7	O
estrogen	8	B-Chemical
binding	7	O
sites	5	O
in	2	O
a	1	O
lymphoblastoid	14	O
cell	4	O
line	4	O
and	3	O
growth-inhibitory	17	O
effect	6	O
of	2	O
estrogen	8	B-Chemical
,	1	O
anti-estrogen	13	B-Chemical
and	3	O
bioflavonoids	13	B-Chemical
.	1	O

Type-II	7	O
estrogen	8	B-Chemical
-binding	8	O
sites	5	O
(	1	O
type-II	7	O
EBS	3	O
)	1	O
have	4	O
been	4	O
demonstrated	12	O
in	2	O
the	3	O
human	5	O
lymphoblastoid	14	O
cell	4	O
line	4	O
IM-9	4	O
using	5	O
a	1	O
whole-cell	10	O
assay	5	O
with	4	O
(	1	O
6	1	O
,	1	O
7-3H	4	O
)	1	O
estradiol	9	B-Chemical
(	1	O
3H-E2	5	B-Chemical
)	1	O
as	2	O
tracer	6	O
.	1	O

Competition	11	O
analysis	8	O
showed	6	O
that	4	O
the	3	O
anti-estrogen	13	B-Chemical
tamoxifen	9	B-Chemical
and	3	O
the	3	O
flavonoids	10	B-Chemical
quercetin	9	I-Chemical
and	3	O
rutin	5	B-Chemical
competed	8	O
for	3	O
(	1	O
3H	2	O
)	1	O
-E2	3	B-Chemical
binding	7	O
to	2	O
type-II	7	O
EBS	3	O
.	1	O

Growth	6	O
experiments	11	O
demonstrated	12	O
that	4	O
diethylstilbestrol	18	B-Chemical
(	1	O
DES	3	B-Chemical
)	1	O
tamoxifen	9	B-Chemical
(	1	O
TAM	3	B-Chemical
)	1	O
,	1	O
quercetin	9	B-Chemical
and	3	O
rutin	5	B-Chemical
exerted	7	O
a	1	O
reversible	10	O
dose	4	O
-dependent	10	O
inhibition	10	O
of	2	O
cell	4	O
proliferation	13	O
in	2	O
the	3	O
range	5	O
of	2	O
concentrations	14	O
between	7	O
10	2	O
nM	2	O
and	3	O
10	2	O
microM	6	O
.	1	O

The	3	O
relative	8	O
binding	7	O
affinity	8	O
of	2	O
quercetin	9	B-Chemical
,	1	O
rutin	5	B-Chemical
,	1	O
DES	3	B-Chemical
and	3	O
TAM	3	B-Chemical
for	3	O
type-II	7	O
EBS	3	O
correlated	10	O
well	4	O
with	4	O
their	5	O
potency	7	O
as	2	O
cell	4	O
growth	6	O
inhibitors	10	O
.	1	O

Moreover	8	O
,	1	O
hesperidin	10	B-Chemical
,	1	O
a	1	O
flavonoid	9	B-Chemical
which	5	O
does	4	O
not	3	O
bind	4	O
to	2	O
type-II	7	O
EBS	3	O
,	1	O
was	3	O
ineffective	11	O
in	2	O
inhibiting	10	O
cell	4	O
growth	6	O
.	1	O

Cell-cycle	10	O
analysis	8	O
showed	6	O
that	4	O
the	3	O
growth-inhibitory	17	O
effect	6	O
of	2	O
DES	3	B-Chemical
,	1	O
TAM	3	B-Chemical
or	2	O
quercetin	9	B-Chemical
was	3	O
due	3	O
to	2	O
a	1	O
blocking	8	O
effect	6	O
in	2	O
the	3	O
G0-G1	5	O
phases	6	O
.	1	O

Our	3	O
results	7	O
suggest	7	O
that	4	O
high	4	O
estrogen	8	B-Chemical
and	3	O
anti-estrogen	13	B-Chemical
concentrations	14	O
and	3	O
flavonoids	10	B-Chemical
may	3	O
regulate	8	O
IM-9	4	O
cell	4	O
growth	6	O
through	7	O
a	1	O
common	6	O
mechanism	9	O
involving	9	O
a	1	O
binding	7	O
interaction	11	O
with	4	O
type-II	7	O
EBS	3	O
.	1	O

Two	3	O
distinct	8	O
signal	6	O
transmission	12	O
pathways	8	O
in	2	O
T	1	O
lymphocytes	11	O
are	3	O
inhibited	9	O
by	2	O
complexes	9	O
formed	6	O
between	7	O
an	2	O
immunophilin	12	B-Gene
and	3	O
either	6	O
FK506	5	B-Chemical
or	2	O
rapamycin	9	B-Chemical
.	1	O

Proliferation	13	O
and	3	O
immunologic	11	O
function	8	O
of	2	O
T	1	O
lymphocytes	11	O
are	3	O
initiated	9	O
by	2	O
signals	7	O
from	4	O
the	3	O
antigen	7	O
receptor	8	O
that	4	O
are	3	O
inhibited	9	O
by	2	O
the	3	O
immunosuppressant	17	O
FK506	5	B-Chemical
but	3	O
not	3	O
by	2	O
its	3	O
structural	10	O
analog	6	O
,	1	O
rapamycin	9	B-Chemical
.	1	O

On	2	O
the	3	O
other	5	O
hand	4	O
,	1	O
interleukin	11	B-Gene
2	1	I-Gene
(	1	O
IL-2	4	B-Gene
)	1	O
-induced	8	O
signals	7	O
are	3	O
blocked	7	O
by	2	O
rapamycin	9	B-Chemical
but	3	O
not	3	O
by	2	O
FK506	5	B-Chemical
.	1	O

Remarkably	10	O
,	1	O
these	5	O
two	3	O
drugs	5	O
inhibit	7	O
each	4	O
other	5	O
's	2	O
actions	7	O
,	1	O
raising	7	O
the	3	O
possibility	11	O
that	4	O
both	4	O
act	3	O
by	2	O
means	5	O
of	2	O
a	1	O
common	6	O
immunophilin	12	B-Gene
(	1	O
immunosuppressant	17	O
binding	7	O
protein	7	O
)	1	O
.	1	O

We	2	O
find	4	O
that	4	O
the	3	O
dissociation	12	O
constant	8	O
of	2	O
rapamycin	9	B-Chemical
to	2	O
the	3	O
FK506	5	B-Gene
binding	7	I-Gene
protein	7	I-Gene
FKBP	4	I-Gene
(	1	O
Kd	2	O
=	1	O
0.2	3	O
nM	2	O
)	1	O
is	2	O
close	5	O
to	2	O
the	3	O
dissociation	12	O
constant	8	O
of	2	O
FK506	5	B-Chemical
to	2	O
FKBP	4	B-Gene
(	1	O
Kd	2	O
=	1	O
0.4	3	O
nM	2	O
)	1	O
and	3	O
to	2	O
their	5	O
effective	9	O
biologic	8	O
inhibitory	10	O
concentrations	14	O
.	1	O

However	7	O
,	1	O
an	2	O
excess	6	O
of	2	O
rapamycin	9	B-Chemical
is	2	O
needed	6	O
to	2	O
revert	6	O
FK506	5	B-Chemical
-mediated	9	O
inhibition	10	O
of	2	O
IL-2	4	B-Gene
production	10	O
,	1	O
apoptosis	9	O
,	1	O
and	3	O
transcriptional	15	O
activation	10	O
of	2	O
NF-AT	5	B-Gene
,	1	O
a	1	O
T-cell-specific	15	O
transcription	13	O
factor	6	O
necessary	9	O
for	3	O
IL-2	4	B-Gene
gene	4	I-Gene
activation	10	O
.	1	O

Similarly	9	O
,	1	O
an	2	O
excess	6	O
of	2	O
FK506	5	B-Chemical
is	2	O
needed	6	O
to	2	O
revert	6	O
rapamycin	9	B-Chemical
-mediated	9	O
inhibition	10	O
of	2	O
IL-2	4	B-Gene
-induced	8	O
proliferation	13	O
.	1	O

The	3	O
drug	4	O
concentrations	14	O
required	8	O
for	3	O
antagonism	10	O
may	3	O
be	2	O
explained	9	O
by	2	O
the	3	O
relative	8	O
affinity	8	O
of	2	O
the	3	O
drugs	5	O
to	2	O
,	1	O
and	3	O
by	2	O
the	3	O
abundance	9	O
of	2	O
,	1	O
the	3	O
immunophilin	12	B-Gene
FKBP	4	I-Gene
.	1	O

FKBP	4	B-Gene
has	3	O
been	4	O
shown	5	O
to	2	O
catalyze	8	O
the	3	O
interconversion	15	O
of	2	O
the	3	O
cis-	4	O
and	3	O
trans-rotamers	14	O
of	2	O
the	3	O
peptidyl-prolyl	15	O
amide	5	O
bond	4	O
of	2	O
peptide	7	O
substrates	10	O
;	1	O
here	4	O
we	2	O
show	4	O
that	4	O
rapamycin	9	B-Chemical
,	1	O
like	4	O
FK506	5	B-Chemical
,	1	O
is	2	O
a	1	O
potent	6	O
inhibitor	9	O
of	2	O
the	3	O
rotamase	8	B-Gene
activity	8	O
of	2	O
FKBP	4	B-Gene
(	1	O
Ki	2	O
=	1	O
0.2	3	O
nM	2	O
)	1	O
.	1	O

Neither	7	O
FKBP	4	B-Gene
binding	7	O
nor	3	O
inhibition	10	O
of	2	O
rotamase	8	B-Gene
activity	8	O
of	2	O
FKBP	4	B-Gene
alone	5	O
is	2	O
sufficient	10	O
to	2	O
explain	7	O
the	3	O
biologic	8	O
actions	7	O
of	2	O
these	5	O
drugs	5	O
.	1	O

Rather	6	O
,	1	O
these	5	O
findings	8	O
suggest	7	O
that	4	O
immunophilin	12	B-Gene
bound	5	O
to	2	O
FK506	5	B-Chemical
interferes	10	O
with	4	O
antigen	7	O
receptor	8	O
-induced	8	O
signals	7	O
,	1	O
while	5	O
rapamycin	9	B-Chemical
bound	5	O
to	2	O
the	3	O
immunophilin	12	B-Gene
interferes	10	O
with	4	O
IL-2	4	B-Gene
-induced	8	O
signals	7	O
.	1	O

Disruption	10	O
of	2	O
the	3	O
human	5	B-Gene
SCL	3	I-Gene
locus	5	I-Gene
by	2	O
``	2	O
illegitimate	12	O
''V-	4	B-Gene
(	1	I-Gene
D	1	I-Gene
)	1	I-Gene
-J	2	I-Gene
recombinase	11	I-Gene
activity	8	O
.	1	O

A	1	O
fusion	6	O
complementary	13	O
DNA	3	O
in	2	O
the	3	O
T	1	O
cell	4	O
line	4	O
HSB-2	5	O
elucidates	10	O
a	1	O
provocative	11	O
mechanism	9	O
for	3	O
the	3	O
disruption	10	O
of	2	O
the	3	O
putative	8	O
hematopoietic	13	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
SCL	3	I-Gene
.	1	O

The	3	O
fusion	6	O
cDNA	4	O
results	7	O
from	4	O
an	2	O
interstitial	12	O
deletion	8	O
between	7	O
a	1	O
previously	10	O
unknown	7	O
locus	5	O
,	1	O
SIL	3	B-Gene
(	1	O
SCL	3	B-Gene
interrupting	12	I-Gene
locus	5	I-Gene
)	1	O
,	1	O
and	3	O
the	3	O
5	1	O
'untranslated	13	O
region	6	O
of	2	O
SCL	3	B-Gene
.	1	O

Similar	7	O
to	2	O
1	1	O
;	1	O
14	2	O
translocations	14	O
,	1	O
this	4	O
deletion	8	O
disrupts	8	O
the	3	O
SCL	3	B-Gene
5	1	O
'regulatory	11	O
region	6	O
.	1	O

This	4	O
event	5	O
is	2	O
probably	8	O
mediated	8	O
by	2	O
V-	2	B-Gene
(	1	I-Gene
D	1	I-Gene
)	1	I-Gene
-J	2	I-Gene
recombinase	11	I-Gene
activity	8	O
,	1	O
although	8	O
neither	7	O
locus	5	O
is	2	O
an	2	O
immunoglobulin	14	B-Gene
or	2	O
a	1	O
T	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
.	1	O

Two	3	O
other	5	O
T	1	O
cell	4	O
lines	5	O
,	1	O
CEM	3	O
and	3	O
RPMI	4	O
8402	4	O
,	1	O
have	4	O
essentially	11	O
identical	9	O
deletions	9	O
.	1	O

Thus	4	O
,	1	O
in	2	O
lymphocytes	11	O
,	1	O
growth	6	O
-affecting	10	O
genes	5	O
other	5	O
than	4	O
immune	6	O
receptors	9	O
risk	4	O
rearrangements	14	O
.	1	O

Differences	11	O
in	2	O
transcriptional	15	O
enhancers	9	O
of	2	O
HIV-1	5	O
and	3	O
HIV-2	5	O
.	1	O

Response	8	O
to	2	O
T	1	O
cell	4	O
activation	10	O
signals	7	O
.	1	O

T	1	O
cell	4	O
activation	10	O
results	7	O
in	2	O
high	4	O
levels	6	O
of	2	O
HIV	3	O
replication	11	O
and	3	O
is	2	O
thought	7	O
to	2	O
be	2	O
one	3	O
mechanism	9	O
leading	7	O
to	2	O
the	3	O
conversion	10	O
from	4	O
latent	6	O
to	2	O
active	6	O
viral	5	O
infection	9	O
.	1	O

In	2	O
HIV-1	5	O
,	1	O
the	3	O
sequences	9	O
that	4	O
respond	7	O
to	2	O
these	5	O
signaling	9	O
events	6	O
are	3	O
found	5	O
in	2	O
the	3	O
long	4	O
terminal	8	O
repeat	6	O
(	1	O
LTR	3	O
)	1	O
and	3	O
comprise	8	O
the	3	O
transcriptional	15	O
enhancer	8	O
,	1	O
which	5	O
contains	8	O
two	3	O
conserved	9	O
binding	7	O
sites	5	O
for	3	O
the	3	O
nuclear	7	B-Gene
factor	6	I-Gene
kappa	5	I-Gene
B	1	I-Gene
(	1	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
)	1	O
.	1	O

The	3	O
corresponding	13	O
region	6	O
in	2	O
the	3	O
second	6	O
AIDS	4	B-Disease
retrovirus	10	O
,	1	O
HIV-2	5	O
,	1	O
contains	8	O
a	1	O
conserved	9	O
and	3	O
a	1	O
divergent	9	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
binding	7	O
site	4	O
.	1	O

We	2	O
demonstrate	11	O
that	4	O
the	3	O
HIV-1	5	O
LTR	3	O
responds	8	O
better	6	O
than	4	O
the	3	O
HIV-2	5	O
LTR	3	O
to	2	O
T	1	O
cell	4	O
activation	10	O
signals	7	O
.	1	O

These	5	O
qualitative	11	O
differences	11	O
in	2	O
the	3	O
response	8	O
to	2	O
T	1	O
cell	4	O
activation	10	O
are	3	O
reproduced	10	O
not	3	O
only	4	O
when	4	O
HIV-1	5	O
or	2	O
HIV-2	5	O
enhancers	9	O
are	3	O
placed	6	O
upstream	8	O
of	2	O
a	1	O
heterologous	12	O
promoter	8	O
but	3	O
also	4	O
when	4	O
these	5	O
enhancers	9	O
are	3	O
switched	8	O
between	7	O
their	5	O
respective	10	O
LTR	3	O
.	1	O

In	2	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assays	6	O
,	1	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
binds	5	O
to	2	O
both	4	O
conserved	9	O
sites	5	O
in	2	O
the	3	O
HIV-1	5	O
transcriptional	15	O
enhancer	8	O
and	3	O
only	4	O
to	2	O
the	3	O
single	6	O
conserved	9	O
site	4	O
in	2	O
the	3	O
HIV-2	5	O
transcriptional	15	O
enhancer	8	O
.	1	O

Instead	7	O
of	2	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
,	1	O
the	3	O
activator	9	B-Gene
protein	7	I-Gene
3	1	I-Gene
binds	5	O
to	2	O
the	3	O
divergent	9	O
site	4	O
in	2	O
HIV-2	5	O
.	1	O

In	2	O
conclusion	10	O
,	1	O
HIV-1	5	O
and	3	O
HIV-2	5	O
are	3	O
differentially	14	O
regulated	9	O
by	2	O
T	1	O
cell	4	O
activation	10	O
signals	7	O
,	1	O
and	3	O
this	4	O
difference	10	O
may	3	O
account	7	O
for	3	O
the	3	O
longer	6	O
period	6	O
of	2	O
viral	5	O
latency	7	O
observed	8	O
with	4	O
HIV-2	5	O
than	4	O
with	4	O
HIV-1	5	O
infection	9	O
.	1	O

Induction	9	O
of	2	O
NF-KB	5	B-Gene
during	6	O
monocyte	8	O
differentiation	15	O
by	2	O
HIV	3	O
type	4	O
1	1	O
infection	9	O
.	1	O

The	3	O
production	10	O
of	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
(	1	O
HIV-1	5	O
)	1	O
progeny	7	O
was	3	O
followed	8	O
in	2	O
the	3	O
U937	4	O
promonocytic	12	O
cell	4	O
line	4	O
after	5	O
stimulation	11	O
either	6	O
with	4	O
retinoic	8	B-Chemical
acid	4	I-Chemical
or	2	O
PMA	3	B-Chemical
,	1	O
and	3	O
in	2	O
purified	8	O
human	5	O
monocytes	9	O
and	3	O
macrophages	11	O
.	1	O

Electrophoretic	15	O
mobility	8	O
shift	5	O
assays	6	O
and	3	O
Southwestern	12	O
blotting	8	O
experiments	11	O
were	4	O
used	4	O
to	2	O
detect	6	O
the	3	O
binding	7	O
of	2	O
cellular	8	B-Gene
transactivation	15	I-Gene
factor	6	I-Gene
NF-KB	5	I-Gene
to	2	O
the	3	O
double	6	O
repeat-KB	9	O
enhancer	8	O
sequence	8	O
located	7	O
in	2	O
the	3	O
long	4	O
terminal	8	O
repeat	6	O
.	1	O

PMA	3	B-Chemical
treatment	9	O
,	1	O
and	3	O
not	3	O
retinoic	8	B-Chemical
acid	4	I-Chemical
treatment	9	O
of	2	O
the	3	O
U937	4	O
cells	5	O
acts	4	O
in	2	O
inducing	8	O
NF-KB	5	B-Gene
expression	10	O
in	2	O
the	3	O
nuclei	6	O
.	1	O

In	2	O
nuclear	7	O
extracts	8	O
from	4	O
monocytes	9	O
or	2	O
macrophages	11	O
,	1	O
induction	9	O
of	2	O
NF-KB	5	B-Gene
occurred	8	O
only	4	O
if	2	O
the	3	O
cells	5	O
were	4	O
previously	10	O
infected	8	O
with	4	O
HIV-1	5	O
.	1	O

When	4	O
U937	4	O
cells	5	O
were	4	O
infected	8	O
with	4	O
HIV-1	5	O
,	1	O
no	2	O
induction	9	O
of	2	O
NF-KB	5	B-Gene
factor	6	I-Gene
was	3	O
detected	8	O
,	1	O
whereas	7	O
high	4	O
level	5	O
of	2	O
progeny	7	O
virions	7	O
was	3	O
produced	8	O
,	1	O
suggesting	10	O
that	4	O
this	4	O
factor	6	O
was	3	O
not	3	O
required	8	O
for	3	O
viral	5	O
replication	11	O
.	1	O

These	5	O
results	7	O
indicate	8	O
that	4	O
in	2	O
monocytic	9	O
cell	4	O
lineage	7	O
,	1	O
HIV-1	5	O
could	5	O
mimic	5	O
some	4	O
differentiation	15	O
/	1	O
activation	10	O
stimuli	7	O
allowing	8	O
nuclear	7	B-Gene
NF-KB	5	I-Gene
expression	10	O
.	1	O

Activation	10	O
of	2	O
human	5	B-Gene
CD4	3	I-Gene
T	1	O
lymphocytes	11	O
.	1	O

Interaction	11	O
of	2	O
fibronectin	11	B-Gene
with	4	O
VLA-5	5	B-Gene
receptor	8	I-Gene
on	2	O
CD4	3	B-Gene
cells	5	O
induces	7	O
the	3	O
AP-1	4	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
.	1	O

Fibronectin	11	B-Gene
synergized	10	O
with	4	O
anti-CD3	8	B-Gene
antibody	8	I-Gene
to	2	O
promote	7	O
CD4	3	B-Gene
cell	4	O
proliferation	13	O
in	2	O
a	1	O
serum-free	10	O
culture	7	O
system	6	O
whereas	7	O
no	2	O
proliferation	13	O
was	3	O
observed	8	O
when	4	O
CD4	3	B-Gene
cells	5	O
were	4	O
cultured	8	O
with	4	O
anti-CD3	8	B-Gene
alone	5	O
or	2	O
fibronectin	11	B-Gene
alone	5	O
.	1	O

In	2	O
addition	8	O
,	1	O
anti-CD29	9	B-Gene
(	1	O
integrin	8	B-Gene
beta	4	I-Gene
1	1	I-Gene
)	1	O
as	2	O
well	4	O
as	2	O
anti-VLA-5	10	B-Gene
(	1	I-Gene
human	5	I-Gene
fibronectin	11	I-Gene
receptor	8	I-Gene
)	1	I-Gene
antibodies	10	I-Gene
blocked	7	O
this	4	O
CD4	3	B-Gene
cell	4	O
activation	10	O
in	2	O
this	4	O
system	6	O
.	1	O

Although	8	O
anti-CD3	8	B-Gene
alone	5	O
or	2	O
fibronectin	11	B-Gene
alone	5	O
can	3	O
not	3	O
induce	6	O
IL-2	4	B-Gene
message	7	O
by	2	O
CD4	3	B-Gene
cells	5	O
,	1	O
the	3	O
combination	11	O
of	2	O
anti-CD3	8	B-Gene
plus	4	O
fibronectin	11	B-Gene
induced	7	O
IL-2	4	B-Gene
message	7	O
by	2	O
CD4	3	B-Gene
cells	5	O
.	1	O

In	2	O
an	2	O
analysis	8	O
of	2	O
the	3	O
molecular	9	O
mechanism	9	O
by	2	O
which	5	O
IL-2	4	B-Gene
message	7	O
was	3	O
generated	9	O
,	1	O
we	2	O
showed	6	O
that	4	O
a	1	O
fibronectin	11	B-Gene
-VLA-5	6	I-Gene
fibronectin	11	I-Gene
receptor	8	I-Gene
interaction	11	O
may	3	O
contribute	10	O
an	2	O
independent	11	O
signal	6	O
distinct	8	O
from	4	O
the	3	O
CD3	3	B-Gene
pathway	7	O
of	2	O
activation	10	O
by	2	O
the	3	O
induction	9	O
of	2	O
an	2	O
AP-1	4	B-Gene
transcriptional	15	I-Gene
factor	6	I-Gene
.	1	O

Thus	4	O
the	3	O
VLA-5	5	B-Gene
fibronectin	11	I-Gene
receptor	8	I-Gene
on	2	O
CD4	3	B-Gene
cells	5	O
can	3	O
play	4	O
a	1	O
complementary	13	O
role	4	O
in	2	O
CD3	3	B-Gene
-	1	I-Gene
TCR	3	I-Gene
-mediated	9	O
signal	6	O
transduction	12	O
through	7	O
its	3	O
interaction	11	O
with	4	O
fibronectin	11	B-Gene
.	1	O

TAR	3	O
independent	11	O
activation	10	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
in	2	O
phorbol	7	B-Chemical
ester	5	I-Chemical
stimulated	10	O
T	1	O
lymphocytes	11	O
.	1	O

Multiple	8	O
regulatory	10	O
elements	8	O
in	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
long	4	O
terminal	8	O
repeat	6	O
(	1	O
HIV	3	O
LTR	3	O
)	1	O
are	3	O
required	8	O
for	3	O
activation	10	O
of	2	O
HIV	3	O
gene	4	O
expression	10	O
.	1	O

Previous	8	O
transfection	12	O
studies	7	O
of	2	O
HIV	3	O
LTR	3	O
constructs	10	O
linked	6	O
to	2	O
the	3	O
chloramphenicol	15	B-Gene
acetyltransferase	17	I-Gene
gene	4	I-Gene
indicated	9	O
that	4	O
multiple	8	O
regulatory	10	O
regions	7	O
including	9	O
the	3	O
enhancer	8	O
,	1	O
SP1	3	B-Gene
,	1	O
TATA	4	O
and	3	O
TAR	3	O
regions	7	O
were	4	O
important	9	O
for	3	O
HIV	3	O
gene	4	O
expression	10	O
.	1	O

To	2	O
characterize	12	O
these	5	O
regulatory	10	O
elements	8	O
further	7	O
,	1	O
mutations	9	O
in	2	O
these	5	O
regions	7	O
were	4	O
inserted	8	O
into	4	O
both	4	O
the	3	O
5	1	O
'and	4	O
3	1	O
'HIV	4	O
LTRs	4	O
and	3	O
infectious	10	O
proviral	8	O
constructs	10	O
were	4	O
assembled	9	O
.	1	O

These	5	O
constructs	10	O
were	4	O
transfected	11	O
into	4	O
either	6	O
HeLa	4	O
cells	5	O
,	1	O
Jurkat	6	O
cells	5	O
or	2	O
U937	4	O
cells	5	O
in	2	O
both	4	O
the	3	O
presence	8	O
and	3	O
absence	7	O
of	2	O
phorbol	7	B-Chemical
esters	6	I-Chemical
which	5	O
have	4	O
previously	10	O
been	4	O
demonstrated	12	O
to	2	O
activate	8	O
HIV	3	O
gene	4	O
expression	10	O
.	1	O

Viral	5	O
gene	4	O
expression	10	O
was	3	O
assayed	7	O
by	2	O
the	3	O
level	5	O
of	2	O
p24	3	B-Gene
gag	3	I-Gene
protein	7	I-Gene
released	8	O
from	4	O
cultures	8	O
transfected	11	O
with	4	O
the	3	O
proviral	8	O
constructs	10	O
.	1	O

Results	7	O
in	2	O
all	3	O
cell	4	O
lines	5	O
indicated	9	O
that	4	O
mutations	9	O
of	2	O
the	3	O
SP1	3	B-Gene
,	1	O
TATA	4	O
and	3	O
the	3	O
TAR	3	O
loop	4	O
and	3	O
stem	4	O
secondary	9	O
structure	9	O
resulted	8	O
in	2	O
marked	6	O
decreases	9	O
in	2	O
gene	4	O
expression	10	O
while	5	O
mutations	9	O
of	2	O
the	3	O
enhancer	8	O
motif	5	O
or	2	O
TAR	3	O
primary	7	O
sequence	8	O
resulted	8	O
in	2	O
only	4	O
slight	6	O
decreases	9	O
.	1	O

However	7	O
,	1	O
viruses	7	O
containing	10	O
mutations	9	O
in	2	O
either	6	O
the	3	O
TAR	3	O
loop	4	O
sequences	9	O
or	2	O
stem	4	O
secondary	9	O
structure	9	O
which	5	O
were	4	O
very	4	O
defective	9	O
for	3	O
gene	4	O
expression	10	O
in	2	O
untreated	9	O
Jurkat	6	O
cells	5	O
,	1	O
gave	4	O
nearly	6	O
wild-type	9	O
levels	6	O
of	2	O
gene	4	O
expression	10	O
in	2	O
phorbol	7	B-Chemical
ester	5	I-Chemical
-treated	8	O
Jurkat	6	O
cells	5	O
but	3	O
not	3	O
in	2	O
phorbol	7	B-Chemical
ester	5	I-Chemical
-treated	8	O
HeLa	4	O
or	2	O
U937	4	O
cells	5	O
.	1	O

High	4	O
level	5	O
gene	4	O
expression	10	O
of	2	O
these	5	O
TAR	3	O
mutant	6	O
constructs	10	O
in	2	O
phorbol	7	B-Chemical
ester	5	I-Chemical
-treated	8	O
Jurkat	6	O
cells	5	O
was	3	O
eliminated	10	O
by	2	O
second	6	O
site	4	O
mutations	9	O
in	2	O
the	3	O
enhancer	8	O
region	6	O
or	2	O
by	2	O
disruption	10	O
of	2	O
the	3	O
tat	3	B-Gene
gene	4	I-Gene
.	1	O

(	1	O
ABSTRACT	8	O
TRUNCATED	9	O
AT	2	O
250	3	O
WORDS	5	O
)	1	O

The	3	O
actions	7	O
of	2	O
cyclosporin	11	B-Chemical
A	1	I-Chemical
and	3	O
FK506	5	B-Chemical
suggest	7	O
a	1	O
novel	5	O
step	4	O
in	2	O
the	3	O
activation	10	O
of	2	O
T	1	O
lymphocytes	11	O
.	1	O

Cyclosporin	11	B-Chemical
A	1	I-Chemical
and	3	O
FK506	5	B-Chemical
are	3	O
immunosuppressive	17	O
compounds	9	O
that	4	O
have	4	O
similar	7	O
inhibitory	10	O
effects	7	O
on	2	O
the	3	O
expression	10	O
of	2	O
several	7	O
lymphokines	11	O
produced	8	O
by	2	O
T	1	O
lymphocytes	11	O
.	1	O

Despite	7	O
their	5	O
similar	7	O
effects	7	O
the	3	O
drugs	5	O
bind	4	O
to	2	O
two	3	O
different	9	O
cytosolic	9	O
protein	7	O
,	1	O
cyclophilin	11	B-Gene
and	3	O
FKBP	4	B-Gene
respectively	12	O
,	1	O
which	5	O
raises	6	O
the	3	O
possibility	11	O
that	4	O
they	4	O
have	4	O
different	9	O
modes	5	O
of	2	O
action	6	O
.	1	O

Using	5	O
constructs	10	O
in	2	O
which	5	O
mRNA	4	O
production	10	O
controlled	10	O
by	2	O
a	1	O
specific	8	O
transcription	13	O
factor	6	O
could	5	O
be	2	O
readily	7	O
measured	8	O
we	2	O
found	5	O
that	4	O
both	4	O
cyclosporin	11	B-Chemical
A	1	I-Chemical
and	3	O
FK506	5	B-Chemical
completely	10	O
inhibited	9	O
transcription	13	O
activated	9	O
by	2	O
NF-AT	5	B-Gene
,	1	O
NFIL2	5	B-Gene
A	1	I-Gene
,	1	O
NFIL2	5	B-Gene
B	1	I-Gene
and	3	O
partially	9	O
inhibited	9	O
transcription	13	O
activated	9	O
by	2	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
.	1	O

Cyclosporin	11	B-Chemical
A	1	I-Chemical
and	3	O
FK506	5	B-Chemical
inhibited	9	O
only	4	O
transcriptional	15	O
activation	10	O
that	4	O
was	3	O
dependent	9	O
on	2	O
Ca2+	4	O
mobilization	12	O
.	1	O

However	7	O
,	1	O
cyclosporin	11	B-Chemical
A	1	I-Chemical
and	3	O
FK506	5	B-Chemical
did	3	O
not	3	O
inhibit	7	O
Ca2+	4	O
mobilization	12	O
dependent	9	O
expression	10	O
of	2	O
c-fos	5	B-Gene
mRNA	4	I-Gene
indicating	10	O
that	4	O
only	4	O
a	1	O
subset	6	O
of	2	O
signalling	10	O
pathways	8	O
regulated	9	O
by	2	O
Ca2+	4	O
is	2	O
sensitive	9	O
to	2	O
these	5	O
drugs	5	O
.	1	O

Furthermore	11	O
,	1	O
we	2	O
did	3	O
not	3	O
observe	7	O
any	3	O
qualitative	11	O
differences	11	O
between	7	O
the	3	O
effect	6	O
of	2	O
cyclosporin	11	B-Chemical
A	1	I-Chemical
and	3	O
FK506	5	B-Chemical
on	2	O
six	3	O
different	9	O
transcription	13	O
factors	7	O
which	5	O
suggests	8	O
that	4	O
these	5	O
drugs	5	O
may	3	O
interfere	9	O
with	4	O
the	3	O
activity	8	O
of	2	O
a	1	O
novel	5	O
Ca2+	4	O
dependent	9	O
step	4	O
that	4	O
regulates	9	O
several	7	O
transcription	13	O
factors	7	O
.	1	O

Lymphoid	8	O
specific	8	O
gene	4	O
expression	10	O
of	2	O
the	3	O
adenovirus	10	O
early	5	O
region	6	O
3	1	O
promoter	8	O
is	2	O
mediated	8	O
by	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
binding	7	O
motifs	6	O
.	1	O

A	1	O
primary	7	O
site	4	O
of	2	O
infection	9	O
by	2	O
human	5	O
adenoviruses	12	O
is	2	O
lymphoid	8	O
cells	5	O
.	1	O

However	7	O
,	1	O
analysis	8	O
of	2	O
the	3	O
viral	5	O
control	7	O
elements	8	O
and	3	O
the	3	O
cellular	8	O
factors	7	O
that	4	O
regulate	8	O
adenoviral	10	O
gene	4	O
expression	10	O
in	2	O
lymphocytes	11	O
has	3	O
not	3	O
been	4	O
reported	8	O
.	1	O

The	3	O
adenovirus	10	B-Gene
early	5	I-Gene
region	6	I-Gene
3	1	I-Gene
(	1	I-Gene
ES	2	I-Gene
)	1	I-Gene
gene	4	I-Gene
products	8	I-Gene
are	3	O
involved	8	O
in	2	O
the	3	O
maintenance	11	O
of	2	O
viral	5	O
persistence	11	O
by	2	O
complexing	10	O
with	4	O
the	3	O
class	5	B-Gene
I	1	I-Gene
MHC	3	I-Gene
antigens	8	I-Gene
,	1	O
thus	4	O
preventing	10	O
their	5	O
cell	4	O
surface	7	O
expression	10	O
with	4	O
a	1	O
resultant	9	O
decrease	8	O
in	2	O
host	4	O
immunologic	11	O
destruction	11	O
.	1	O

To	2	O
determine	9	O
whether	7	O
different	9	O
cellular	8	O
factors	7	O
were	4	O
involved	8	O
in	2	O
E3	2	B-Gene
regulation	10	O
in	2	O
lymphocytes	11	O
as	2	O
compared	8	O
with	4	O
HeLa	4	O
cells	5	O
,	1	O
both	4	O
DNA	3	O
binding	7	O
and	3	O
transfection	12	O
analysis	8	O
with	4	O
the	3	O
E3	2	B-Gene
promoter	8	I-Gene
in	2	O
both	4	O
cell	4	O
types	5	O
were	4	O
performed	9	O
.	1	O

These	5	O
studies	7	O
detected	8	O
two	3	O
novel	5	O
domains	7	O
referred	8	O
to	2	O
as	2	O
L1	2	O
and	3	O
L2	2	O
with	4	O
a	1	O
variety	7	O
of	2	O
lymphoid	8	O
but	3	O
not	3	O
HeLa	4	O
extracts	8	O
.	1	O

Each	4	O
of	2	O
these	5	O
domains	7	O
possessed	9	O
strong	6	O
homology	8	O
to	2	O
motifs	6	O
previously	10	O
found	5	O
to	2	O
bind	4	O
the	3	O
cellular	8	B-Gene
factor	6	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
.	1	O

Transfections	13	O
of	2	O
E3	2	B-Gene
constructs	10	O
linked	6	O
to	2	O
the	3	O
chloramphenicol	15	O
acetyltransferase	17	O
gene	4	O
revealed	8	O
that	4	O
mutagenesis	11	O
of	2	O
the	3	O
distal	6	O
NF-kappa	8	B-Gene
B	1	I-Gene
motif	5	O
(	1	O
L2	2	O
)	1	O
had	3	O
minimal	7	O
effects	7	O
on	2	O
promoter	8	O
expression	10	O
in	2	O
HeLa	4	O
cells	5	O
,	1	O
but	3	O
resulted	8	O
in	2	O
dramatic	8	O
decreases	9	O
in	2	O
expression	10	O
by	2	O
lymphoid	8	O
cells	5	O
.	1	O

In	2	O
contrast	8	O
,	1	O
mutagenesis	11	O
of	2	O
proximal	8	O
NF-kappa	8	B-Gene
B	1	I-Gene
motif	5	O
(	1	O
L1	2	O
)	1	O
had	3	O
minimal	7	O
effects	7	O
on	2	O
gene	4	O
expression	10	O
in	2	O
both	4	O
HeLa	4	O
cells	5	O
and	3	O
lymphoid	8	O
cells	5	O
but	3	O
resulted	8	O
in	2	O
a	1	O
small	5	O
,	1	O
but	3	O
reproducible	12	O
,	1	O
increase	8	O
in	2	O
gene	4	O
expression	10	O
in	2	O
lymphoid	8	O
cells	5	O
when	4	O
coupled	7	O
to	2	O
the	3	O
L2	2	O
mutation	8	O
.	1	O

Reversing	9	O
the	3	O
position	8	O
and	3	O
subsequent	10	O
mutagenesis	11	O
of	2	O
the	3	O
L1	2	O
and	3	O
L2	2	O
domains	7	O
indicated	9	O
that	4	O
the	3	O
primary	7	O
sequence	8	O
of	2	O
these	5	O
motifs	6	O
rather	6	O
than	4	O
their	5	O
position	8	O
in	2	O
the	3	O
E3	2	B-Gene
promoter	8	I-Gene
was	3	O
critical	8	O
for	3	O
regulating	10	O
gene	4	O
expression	10	O
.	1	O

(	1	O
ABSTRACT	8	O
TRUNCATED	9	O
AT	2	O
250	3	O
WORDS	5	O
)	1	O

Positive	8	O
and	3	O
negative	8	O
regulation	10	O
of	2	O
immunoglobulin	14	B-Gene
gene	4	I-Gene
expression	10	O
by	2	O
a	1	O
novel	5	O
B-cell-specific	15	O
enhancer	8	O
element	7	O
.	1	O

A	1	O
new	3	O
B-cell-specific	15	O
enhancer	8	O
element	7	O
has	3	O
been	4	O
identified	10	O
3	1	O
'of	3	O
E4	2	O
and	3	O
the	3	O
octamerlike	11	O
motifs	6	O
in	2	O
the	3	O
human	5	B-Gene
immunoglobulin	14	I-Gene
heavy-chain	11	I-Gene
gene	4	I-Gene
enhancer	8	I-Gene
.	1	O

Tandem	6	O
copies	6	O
of	2	O
this	4	O
67-bp	5	O
MnlI-AluI	9	O
fragment	8	O
,	1	O
when	4	O
fused	5	O
to	2	O
the	3	O
chloramphenicol	15	O
acetyltransferase	17	O
gene	4	O
driven	6	O
by	2	O
the	3	O
conalbumin	10	B-Gene
promoter	8	I-Gene
,	1	O
stimulated	10	O
transcription	13	O
in	2	O
B	1	O
cells	5	O
but	3	O
not	3	O
in	2	O
Jurkat	6	O
T	1	O
cells	5	O
or	2	O
HeLa	4	O
cells	5	O
.	1	O

Footprinting	12	O
analysis	8	O
revealed	8	O
that	4	O
the	3	O
identical	9	O
sequence	8	O
CCGAAACTGAAAAGG	15	O
,	1	O
designated	10	O
E6	2	O
,	1	O
was	3	O
protected	9	O
by	2	O
nuclear	7	O
extracts	8	O
from	4	O
B	1	O
cells	5	O
,	1	O
T	1	O
cells	5	O
,	1	O
or	2	O
HeLa	4	O
cells	5	O
.	1	O

Gel	3	O
mobility	8	O
shift	5	O
assays	6	O
using	5	O
a	1	O
synthetic	9	O
E6	2	O
motif	5	O
detected	8	O
a	1	O
B-cell-specific	15	O
complex	7	O
in	2	O
addition	8	O
to	2	O
a	1	O
ubiquitous	10	O
band	4	O
found	5	O
also	4	O
in	2	O
T	1	O
cells	5	O
and	3	O
HeLa	4	O
cells	5	O
.	1	O

In	2	O
agreement	9	O
with	4	O
the	3	O
results	7	O
of	2	O
gel	3	O
retardation	11	O
assays	6	O
,	1	O
tandem	6	O
copies	6	O
of	2	O
the	3	O
E6	2	O
motif	5	O
stimulated	10	O
transcription	13	O
in	2	O
ARH77	5	O
and	3	O
Raji	4	O
cells	5	O
but	3	O
not	3	O
in	2	O
Jurkat	6	O
or	2	O
HeLa	4	O
cells	5	O
.	1	O

Furthermore	11	O
,	1	O
a	1	O
mutant	6	O
E6	2	O
motif	5	O
lost	4	O
both	4	O
in	2	O
vitro	5	O
binding	7	O
activity	8	O
and	3	O
in	2	O
vivo	4	O
enhancer	8	O
activity	8	O
.	1	O

In	2	O
striking	8	O
contrast	8	O
to	2	O
the	3	O
mouse	5	B-Gene
Ig	2	I-Gene
heavy-chain	11	I-Gene
enhancer	8	I-Gene
,	1	O
in	2	O
which	5	O
the	3	O
octamer	7	O
motif	5	O
acts	4	O
as	2	O
a	1	O
B-cell-specific	15	O
enhancer	8	O
element	7	O
,	1	O
the	3	O
human	5	O
enhancer	8	O
contains	8	O
an	2	O
octamerlike	11	O
sequence	8	O
with	4	O
one	3	O
base	4	O
substitution	12	O
which	5	O
bound	5	O
octamer	7	B-Gene
-binding	8	I-Gene
proteins	8	I-Gene
with	4	O
only	4	O
very	4	O
low	3	O
affinity	8	O
and	3	O
showed	6	O
no	2	O
enhancer	8	O
activity	8	O
of	2	O
its	3	O
own	3	O
.	1	O

Interestingly	13	O
,	1	O
the	3	O
MnlI-AluI	9	O
fragment	8	O
could	5	O
suppress	8	O
the	3	O
basal-level	11	O
activity	8	O
of	2	O
the	3	O
conalbumin	10	B-Gene
promoter	8	I-Gene
in	2	O
both	4	O
Jurkat	6	O
and	3	O
HeLa	4	O
cells	5	O
.	1	O

Moreover	8	O
,	1	O
simian	6	O
virus	5	O
40	2	O
enhancer	8	O
activity	8	O
was	3	O
blocked	7	O
by	2	O
the	3	O
MnlI-AluI	9	O
fragment	8	O
in	2	O
HeLa	4	O
cells	5	O
but	3	O
not	3	O
in	2	O
B	1	O
cells	5	O
.	1	O

Thus	4	O
,	1	O
the	3	O
novel	5	O
enhancer	8	O
element	7	O
identified	10	O
in	2	O
this	4	O
study	5	O
is	2	O
probably	8	O
a	1	O
target	6	O
site	4	O
for	3	O
both	4	O
positive	8	O
and	3	O
negative	8	O
factors	7	O
.	1	O

[	1	O
Effect	6	O
of	2	O
the	3	O
regimen	7	O
of	2	O
kidney	6	O
-tonifying	10	O
and	3	O
qi	2	O
-invigorating	13	O
on	2	O
aging	5	O
changes	7	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
]	1	O

The	3	O
plasma	6	O
cortisol	8	B-Chemical
concentration	13	O
and	3	O
the	3	O
sites	5	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
(	1	O
GCR	3	B-Gene
)	1	O
in	2	O
the	3	O
peripheral	10	O
lymphocytes	11	O
were	4	O
measured	8	O
in	2	O
32	2	O
healthy	7	O
aged	4	O
persons	7	O
and	3	O
13	2	O
young	5	O
adults	6	O
.	1	O

In	2	O
animal	6	O
experiment	10	O
,	1	O
GCR	3	B-Gene
of	2	O
spleen	6	O
lymphocytic	11	O
cell	4	O
was	3	O
also	4	O
measured	8	O
in	2	O
18	2	O
aged	4	O
rats	4	O
and	3	O
9	1	O
young	5	O
rats	4	O
.	1	O

The	3	O
results	7	O
showed	6	O
that	4	O
GCR	3	B-Gene
was	3	O
significantly	13	O
lower	5	O
in	2	O
the	3	O
aged	4	O
persons	7	O
or	2	O
rats	4	O
than	4	O
that	4	O
in	2	O
the	3	O
young	5	O
while	5	O
the	3	O
plasma	6	O
cortisol	8	B-Chemical
level	5	O
did	3	O
n't	3	O
change	6	O
with	4	O
aging	5	O
.	1	O

So	2	O
we	2	O
think	5	O
that	4	O
GCR	3	B-Gene
is	2	O
more	4	O
sensitive	9	O
than	4	O
the	3	O
plasma	6	O
cortisol	8	B-Chemical
level	5	O
to	2	O
reflect	7	O
the	3	O
aging	5	O
change	6	O
of	2	O
the	3	O
adrenal	7	O
cortex	6	O
function	8	O
.	1	O

After	5	O
the	3	O
treatment	9	O
with	4	O
the	3	O
regimen	7	O
of	2	O
Kidney	6	O
-tonifying	10	O
and	3	O
Qi	2	O
-invigorating	13	O
,	1	O
the	3	O
GCR	3	B-Gene
of	2	O
the	3	O
aged	4	O
persons	7	O
and	3	O
rats	4	O
was	3	O
enhanced	8	O
,	1	O
and	3	O
in	2	O
this	4	O
way	3	O
,	1	O
the	3	O
function	8	O
of	2	O
the	3	O
aged	4	O
adrenal	7	O
cortex	6	O
was	3	O
improved	8	O
.	1	O

An	2	O
in	2	O
vitro	5	O
globin	6	B-Gene
gene	4	I-Gene
switching	9	O
model	5	O
based	5	O
on	2	O
differentiated	14	O
embryonic	9	O
stem	4	O
cells	5	O
.	1	O

We	2	O
used	4	O
mouse	5	O
embryonic	9	O
stem	4	O
(	1	O
ES	2	O
)	1	O
cells	5	O
to	2	O
study	5	O
globin	6	B-Gene
gene	4	I-Gene
expression	10	O
and	3	O
switching	9	O
in	2	O
vitro	5	O
.	1	O

We	2	O
show	4	O
that	4	O
ES	2	O
-derived	8	O
embryoid	8	O
bodies	6	O
express	7	O
the	3	O
full	4	O
complement	10	O
of	2	O
mouse	5	B-Gene
embryonic	9	I-Gene
globin	6	I-Gene
genes	5	I-Gene
in	2	O
the	3	O
correct	7	O
temporal	8	O
order	5	O
and	3	O
that	4	O
on	2	O
further	7	O
differentiation	15	O
,	1	O
a	1	O
switch	6	O
occurs	6	O
to	2	O
the	3	O
fetal	5	O
/	1	O
adult	5	O
genes	5	O
.	1	O

In	2	O
addition	8	O
,	1	O
the	3	O
erythroid-specific	18	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
NF-E1	5	I-Gene
was	3	O
shown	5	O
to	2	O
be	2	O
expressed	9	O
coordinately	12	O
with	4	O
that	4	O
of	2	O
globin	6	B-Gene
in	2	O
embryoid	8	O
bodies	6	O
.	1	O

We	2	O
conclude	8	O
from	4	O
these	5	O
experiments	11	O
that	4	O
the	3	O
ES	2	O
cell	4	O
system	6	O
provides	8	O
a	1	O
good	4	O
model	5	O
to	2	O
study	5	O
hematopoietic	13	O
development	11	O
.	1	O

When	4	O
the	3	O
human	5	O
epsilon-	8	B-Partial_Gene
or	2	O
beta-globin	11	B-Gene
genes	5	I-Gene
driven	6	O
by	2	O
the	3	O
dominant	8	O
control	7	O
region	6	O
(	1	O
DCR	3	O
)	1	O
are	3	O
introduced	10	O
into	4	O
this	4	O
system	6	O
,	1	O
the	3	O
human	5	B-Gene
epsilon-globin	14	I-Gene
gene	4	I-Gene
,	1	O
in	2	O
contrast	8	O
to	2	O
the	3	O
beta-globin	11	B-Gene
gene	4	I-Gene
,	1	O
is	2	O
not	3	O
deregulated	11	O
by	2	O
the	3	O
presence	8	O
of	2	O
the	3	O
DCR	3	O
and	3	O
is	2	O
expressed	9	O
strictly	8	O
as	2	O
an	2	O
embryonic	9	O
gene	4	O
.	1	O

We	2	O
conclude	8	O
from	4	O
this	4	O
that	4	O
the	3	O
epsilon-globin	14	B-Gene
gene	4	I-Gene
is	2	O
not	3	O
regulated	9	O
by	2	O
competition	11	O
with	4	O
other	5	O
genes	5	O
in	2	O
the	3	O
human	5	B-Gene
beta-globin	11	I-Gene
locus	5	I-Gene
.	1	O

Oncogene	8	O
amplification	13	O
correlates	10	O
with	4	O
dense	5	O
lymphocyte	10	O
infiltration	12	O
in	2	O
human	5	O
breast	6	B-Disease
cancers	7	I-Disease
:	1	O
a	1	O
role	4	O
for	3	O
hematopoietic	13	B-Gene
growth	6	I-Gene
factor	6	I-Gene
release	7	O
by	2	O
tumor	5	B-Disease
cells	5	O
?	1	O

One	3	O
hundred	7	O
six	3	O
primary	7	O
breast	6	B-Disease
cancer	6	I-Disease
samples	7	O
were	4	O
analysed	8	O
for	3	O
c-erbB2	7	B-Gene
,	1	O
int-2	5	B-Gene
,	1	O
and	3	O
c-myc	5	B-Gene
gene	4	I-Gene
amplification	13	O
.	1	O

Surgically	10	O
confirmed	9	O
nodal	5	O
involvement	11	O
was	3	O
observed	8	O
in	2	O
42	2	O
%	1	O
.	1	O

Level	5	O
of	2	O
gene	4	O
amplification	13	O
was	3	O
studied	7	O
by	2	O
Southern	8	O
and	3	O
/	1	O
or	2	O
slot	4	O
blot	4	O
techniques	10	O
.	1	O

Amplified	9	O
c-erbB2	7	B-Gene
gene	4	I-Gene
sequences	9	O
were	4	O
present	7	O
in	2	O
21.5	4	O
%	1	O
of	2	O
all	3	O
samples	7	O
.	1	O

Int-2	5	B-Gene
was	3	O
amplified	9	O
in	2	O
13.1	4	O
%	1	O
and	3	O
c-myc	5	B-Gene
was	3	O
amplified	9	O
in	2	O
10.3	4	O
%	1	O
.	1	O

In	2	O
a	1	O
non-parametric	14	O
test	4	O
(	1	O
Kruskal-Wallis	14	O
)	1	O
a	1	O
strong	6	O
negative	8	O
association	11	O
was	3	O
found	5	O
between	7	O
high	4	O
levels	6	O
of	2	O
c-erbB2	7	B-Gene
amplification	13	O
and	3	O
absence	7	O
of	2	O
estrogen	8	B-Gene
receptor	8	I-Gene
(	1	O
ER	2	B-Gene
)	1	O
(	1	O
P	1	O
=	1	O
.0009	5	O
)	1	O
or	2	O
progesterone	12	B-Gene
receptor	8	I-Gene
(	1	O
PR	2	B-Gene
)	1	O
(	1	O
P	1	O
=	1	O
.011	4	O
)	1	O
expression	10	O
.	1	O

No	2	O
correlations	12	O
were	4	O
found	5	O
between	7	O
all	3	O
or	2	O
high	4	O
levels	6	O
of	2	O
amplification	13	O
of	2	O
each	4	O
oncogene	8	O
separately	10	O
or	2	O
combined	8	O
with	4	O
T	1	O
,	1	O
N	1	O
,	1	O
grade	5	O
,	1	O
multifocality	13	O
of	2	O
tumor	5	B-Disease
,	1	O
or	2	O
associated	10	O
carcinoma	9	B-Disease
in	2	O
situ	4	O
.	1	O

There	5	O
was	3	O
a	1	O
trend	5	O
approaching	11	O
statistical	11	O
significance	12	O
for	3	O
patients	8	O
with	4	O
c-erbB2	7	B-Gene
amplifications	14	O
to	2	O
have	4	O
positive	8	O
lymph	5	O
nodes	5	O
at	2	O
surgery	7	O
(	1	O
P	1	O
=	1	O
0.09	4	O
)	1	O
.	1	O

A	1	O
somewhat	8	O
surprising	10	O
finding	7	O
however	7	O
was	3	O
a	1	O
very	4	O
strong	6	O
association	11	O
between	7	O
oncogene	8	O
amplification	13	O
and	3	O
dense	5	O
lymphocyte	10	O
infiltration	12	O
of	2	O
the	3	O
tumor	5	B-Disease
(	1	O
P	1	O
=	1	O
.05	3	O
)	1	O
.	1	O

This	4	O
correlation	11	O
is	2	O
even	4	O
stronger	8	O
when	4	O
only	4	O
high	4	O
levels	6	O
of	2	O
amplification	13	O
are	3	O
considered	10	O
,	1	O
either	6	O
for	3	O
each	4	O
oncogene	8	O
separately	10	O
(	1	O
P	1	O
=	1	O
.0048	5	O
)	1	O
or	2	O
in	2	O
combination	11	O
(	1	O
P	1	O
=	1	O
.0007	5	O
)	1	O
.	1	O

We	2	O
propose	7	O
that	4	O
malignant	9	O
cell	4	O
cytokine	8	O
production	10	O
may	3	O
help	4	O
explain	7	O
this	4	O
observation	11	O
.	1	O

The	3	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
independent	11	O
cis	3	O
-acting	7	O
sequences	9	O
in	2	O
HIV-1	5	O
LTR	3	O
responsive	10	O
to	2	O
T-cell	6	O
activation	10	O
.	1	O

The	3	O
rate	4	O
of	2	O
transcription	13	O
initiation	10	O
directed	8	O
by	2	O
the	3	O
long	4	O
terminal	8	O
repeat	6	O
(	1	O
LTR	3	O
)	1	O
of	2	O
HIV-1	5	O
increases	9	O
in	2	O
response	8	O
to	2	O
mitogenic	9	O
stimuli	7	O
of	2	O
T	1	O
cells	5	O
.	1	O

Here	4	O
we	2	O
show	4	O
that	4	O
the	3	O
response	8	O
of	2	O
the	3	O
HIV-1	5	O
LTR	3	O
may	3	O
be	2	O
governed	8	O
by	2	O
two	3	O
independent	11	O
sequences	9	O
located	7	O
5	1	O
'to	3	O
the	3	O
site	4	O
of	2	O
transcription	13	O
initiation	10	O
sequences	9	O
that	4	O
bind	4	O
either	6	O
NFAT-1	6	B-Gene
or	2	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
.	1	O

The	3	O
rate	4	O
of	2	O
LTR	3	O
-directed	9	O
gene	4	O
expression	10	O
increased	9	O
in	2	O
response	8	O
to	2	O
treatment	9	O
with	4	O
either	6	O
a	1	O
phorbol	7	B-Chemical
ester	5	I-Chemical
or	2	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
alpha	5	I-Gene
if	2	O
either	6	O
the	3	O
NFAT-1	6	B-Gene
or	2	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
binding	7	O
sites	5	O
were	4	O
deleted	7	O
,	1	O
but	3	O
failed	6	O
to	2	O
respond	7	O
to	2	O
these	5	O
mitogenic	9	O
stimuli	7	O
if	2	O
both	4	O
sequences	9	O
were	4	O
absent	6	O
.	1	O

The	3	O
HIV-1	5	O
mutant	6	O
virus	5	O
containing	10	O
both	4	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
and	3	O
NFAT-1	6	B-Gene
deletion	8	O
was	3	O
able	4	O
to	2	O
replicate	9	O
although	8	O
at	2	O
a	1	O
much	4	O
decreased	9	O
growth	6	O
rate	4	O
,	1	O
while	5	O
the	3	O
deletion	8	O
of	2	O
NFAT-1	6	B-Gene
alone	5	O
increased	9	O
the	3	O
viral	5	O
growth	6	O
rate	4	O
in	2	O
Jurkat	6	O
cells	5	O
.	1	O

Neither	7	O
deletion	8	O
of	2	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
nor	3	O
deletion	8	O
of	2	O
NFAT-1	6	B-Gene
decreased	9	O
activation	10	O
of	2	O
viral	5	O
replication	11	O
by	2	O
phorbol	7	B-Chemical
ester	5	I-Chemical
.	1	O

Specific	8	O
depletion	9	O
of	2	O
the	3	O
B-cell	6	O
population	10	O
induced	7	O
by	2	O
aberrant	8	O
expression	10	O
of	2	O
human	5	B-Gene
interferon	10	I-Gene
regulatory	10	I-Gene
factor	6	I-Gene
1	1	I-Gene
gene	4	I-Gene
in	2	O
transgenic	10	O
mice	4	O
.	1	O

Interferons	11	B-Gene
(	1	O
IFNs	4	B-Gene
)	1	O
are	3	O
well	4	O
known	5	O
both	4	O
as	2	O
antiviral	9	O
proteins	8	O
and	3	O
as	2	O
potent	6	O
regulators	10	O
of	2	O
cell	4	O
growth	6	O
and	3	O
differentiation	15	O
.	1	O

In	2	O
fact	4	O
,	1	O
IFNs	4	B-Gene
inhibit	7	O
growth	6	O
of	2	O
various	7	O
normal	6	O
and	3	O
transformed	11	O
cell	4	O
types	5	O
.	1	O

Previously	10	O
,	1	O
a	1	O
nuclear	7	O
factor	6	O
,	1	O
IRF-1	5	B-Gene
(	1	O
interferon	10	B-Gene
regulatory	10	I-Gene
factor	6	I-Gene
1	1	I-Gene
)	1	O
,	1	O
which	5	O
binds	5	O
to	2	O
type	4	B-Gene
I	1	I-Gene
IFN	3	I-Gene
and	3	O
some	4	O
IFN-inducible	13	B-Gene
gene	4	O
promoters	9	O
,	1	O
was	3	O
identified	10	O
and	3	O
cloned	6	O
.	1	O

Since	5	O
the	3	O
IRF-1	5	B-Gene
gene	4	I-Gene
is	2	O
both	4	O
virus	5	O
and	3	O
IFN	3	B-Gene
inducible	9	O
,	1	O
an	2	O
intriguing	10	O
issue	5	O
is	2	O
raised	6	O
as	2	O
to	2	O
whether	7	O
the	3	O
IRF-1	5	B-Gene
gene	4	I-Gene
is	2	O
functioning	11	O
in	2	O
IFN	3	B-Gene
-mediated	9	O
regulation	10	O
of	2	O
cell	4	O
growth	6	O
and	3	O
differentiation	15	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
we	2	O
generated	9	O
transgenic	10	O
mice	4	O
carrying	8	O
the	3	O
human	5	B-Gene
IRF-1	5	I-Gene
gene	4	I-Gene
linked	6	O
to	2	O
the	3	O
human	5	B-Gene
immunoglobulin	14	I-Gene
heavy-chain	11	I-Gene
enhancer	8	I-Gene
.	1	O

In	2	O
the	3	O
transgenic	10	O
mice	4	O
,	1	O
all	3	O
the	3	O
lymphoid	8	O
tissues	7	O
examined	8	O
showed	6	O
a	1	O
dramatic	8	O
reduction	9	O
in	2	O
the	3	O
number	6	O
of	2	O
B	1	O
lymphocytes	11	O
(	1	O
B	1	O
cells	5	O
)	1	O
.	1	O

Preparation	11	O
and	3	O
analysis	8	O
of	2	O
bone	4	O
marrow	6	O
cells	5	O
from	4	O
the	3	O
chimeric	8	O
mice	4	O
indicated	9	O
that	4	O
the	3	O
bone	4	O
marrow	6	O
is	2	O
the	3	O
effective	9	O
site	4	O
for	3	O
specific	8	O
depletion	9	O
of	2	O
the	3	O
B-cell	6	O
population	10	O
.	1	O

In	2	O
fact	4	O
,	1	O
transgenic	10	O
bone	4	O
marrow	6	O
cells	5	O
cocultured	10	O
with	4	O
a	1	O
bone	4	O
marrow	6	O
-derived	8	O
stromal	7	O
cell	4	O
line	4	O
revealed	8	O
an	2	O
altered	7	O
B-cell	6	O
maturation	10	O
pattern	7	O
.	1	O

Identification	14	O
and	3	O
cloning	7	O
of	2	O
TCF-1	5	B-Gene
,	1	O
a	1	O
T	1	O
lymphocyte-specific	19	O
transcription	13	O
factor	6	O
containing	10	O
a	1	O
sequence-specific	17	O
HMG	3	B-Gene
box	3	O
.	1	O

CD3	3	B-Gene
-epsilon	8	I-Gene
expression	10	O
is	2	O
controlled	10	O
by	2	O
a	1	O
downstream	10	O
T	1	O
lymphocyte-specific	19	O
enhancer	8	O
element	7	O
.	1	O

We	2	O
report	6	O
the	3	O
identification	14	O
of	2	O
a	1	O
T	1	O
cell-specific	13	O
transcription	13	O
factor	6	O
,	1	O
TCF-1	5	B-Gene
,	1	O
binding	7	O
to	2	O
this	4	O
element	7	O
.	1	O

The	3	O
multimerized	12	O
recognition	11	O
motif	5	O
of	2	O
TCF-1	5	B-Gene
constituted	11	O
a	1	O
T	1	O
cell-specific	13	O
enhancer	8	O
.	1	O

Subsequent	10	O
cloning	7	O
of	2	O
TCF-1	5	B-Gene
identified	10	O
three	5	O
splice	6	O
alternatives	12	O
.	1	O

TCF-1	5	B-Gene
contained	9	O
a	1	O
single	6	O
DNA	3	O
-binding	8	O
HMG	3	B-Gene
box	3	O
most	4	O
closely	7	O
related	7	O
to	2	O
similar	7	O
boxes	5	O
in	2	O
the	3	O
putative	8	O
mammalian	9	B-Gene
sex	3	I-Gene
-determining	12	I-Gene
gene	4	I-Gene
SRY	3	I-Gene
and	3	O
in	2	O
the	3	O
Schizosaccharomyces	19	B-Gene
pombe	5	I-Gene
Mc	2	I-Gene
mating	6	I-Gene
type	4	I-Gene
gene	4	I-Gene
.	1	O

TCF-1	5	B-Gene
mRNA	4	I-Gene
was	3	O
expressed	9	O
uniquely	8	O
in	2	O
T	1	O
lymphocytes	11	O
.	1	O

Upon	4	O
cotransfection	14	O
into	4	O
non-T	5	O
cells	5	O
,	1	O
TCF-1	5	B-Gene
could	5	O
transactivate	13	O
through	7	O
its	3	O
cognate	7	O
motif	5	O
.	1	O

These	5	O
results	7	O
identify	8	O
TCF-1	5	B-Gene
as	2	O
a	1	O
T	1	O
cell-specific	13	O
transcription	13	O
factor	6	O
,	1	O
which	5	O
might	5	O
play	4	O
a	1	O
role	4	O
in	2	O
the	3	O
establishment	13	O
of	2	O
the	3	O
mature	6	O
T	1	O
cell	4	O
phenotype	9	O
.	1	O

Nuclear	7	B-Gene
factor	6	I-Gene
kappa	5	I-Gene
B	1	I-Gene
activates	9	O
proenkephalin	13	B-Gene
transcription	13	O
in	2	O
T	1	O
lymphocytes	11	O
.	1	O

Upon	4	O
activation	10	O
,	1	O
T	1	O
lymphocytes	11	O
accumulate	10	O
high	4	O
levels	6	O
of	2	O
the	3	O
neuropeptide	12	O
enkephalin	10	O
which	5	O
correlate	9	O
with	4	O
high	4	O
levels	6	O
of	2	O
proenkephalin	13	B-Gene
mRNA	4	I-Gene
in	2	O
the	3	O
cells	5	O
.	1	O

Here	4	O
we	2	O
investigated	12	O
the	3	O
transcriptional	15	O
basis	5	O
for	3	O
these	5	O
changes	7	O
.	1	O

The	3	O
proenkephalin	13	B-Gene
promoter	8	I-Gene
contains	8	O
a	1	O
sequence	8	O
GGGGACGTCCCC	12	O
,	1	O
named	5	O
B2	2	O
,	1	O
which	5	O
is	2	O
similar	7	O
to	2	O
the	3	O
kappa	5	O
B	1	O
sequence	8	O
GGGGACTTTCC	11	O
,	1	O
the	3	O
binding	7	O
site	4	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
nuclear	7	I-Gene
factor	6	I-Gene
(	1	I-Gene
NF	2	I-Gene
)	1	I-Gene
-kappa	6	I-Gene
B	1	I-Gene
.	1	O

Activation	10	O
of	2	O
T	1	O
lymphocytes	11	O
induces	7	O
an	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
-like	5	O
binding	7	O
activity	8	O
to	2	O
the	3	O
B2	2	O
site	4	O
,	1	O
concomitant	11	O
with	4	O
activation	10	O
of	2	O
the	3	O
proenkephalin	13	B-Gene
promoter	8	I-Gene
.	1	O

Mutations	9	O
at	2	O
the	3	O
B2	2	O
site	4	O
abolish	7	O
this	4	O
transcriptional	15	O
activation	10	O
.	1	O

The	3	O
purified	8	O
homodimer	9	O
(	1	O
two	3	O
p50s	4	B-Gene
)	1	O
of	2	O
the	3	O
DNA	3	O
-binding	8	O
subunit	7	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
binds	5	O
the	3	O
B2	2	O
site	4	O
of	2	O
proenkephalin	13	B-Gene
relatively	10	O
better	6	O
than	4	O
does	4	O
the	3	O
heterotetramer	14	O
(	1	O
two	3	O
p65s	4	B-Gene
plus	4	O
two	3	O
p50s	4	B-Gene
)	1	O
form	4	O
of	2	O
the	3	O
factor	6	O
.	1	O

Thus	4	O
,	1	O
it	2	O
appears	7	O
that	4	O
the	3	O
T-cell-specific	15	O
activation	10	O
of	2	O
the	3	O
proenkephalin	13	B-Gene
promoter	8	I-Gene
is	2	O
mediated	8	O
by	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
.	1	O

However	7	O
,	1	O
as	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
is	2	O
ubiquitous	10	O
and	3	O
the	3	O
transcriptional	15	O
activation	10	O
through	7	O
the	3	O
B2	2	O
site	4	O
is	2	O
T	1	O
cell	4	O
specific	8	O
,	1	O
yet	3	O
another	7	O
T-cell-specific	15	O
factor	6	O
which	5	O
synergizes	10	O
with	4	O
NF-kappa	8	B-Gene
B	1	I-Gene
should	6	O
be	2	O
considered	10	O
.	1	O

Functional	10	O
analysis	8	O
of	2	O
cis	3	O
-linked	7	O
regulatory	10	O
sequences	9	O
in	2	O
the	3	O
HLA	3	B-Gene
DRA	3	I-Gene
promoter	8	I-Gene
by	2	O
transcription	13	O
in	2	O
vitro	5	O
.	1	O

Two	3	O
consensus	9	O
sequences	9	O
,	1	O
called	6	O
X	1	O
and	3	O
Y	1	O
boxes	5	O
,	1	O
capable	7	O
of	2	O
binding	7	O
nuclear	7	O
proteins	8	O
and	3	O
regulating	10	O
expression	10	O
in	2	O
B	1	O
cells	5	O
have	4	O
been	4	O
defined	7	O
within	6	O
the	3	O
immediate	9	O
upstream	8	O
region	6	O
of	2	O
major	5	B-Gene
histocompatibility	18	I-Gene
complex	7	I-Gene
(	1	I-Gene
MHC	3	I-Gene
)	1	I-Gene
class	5	I-Gene
II	2	I-Gene
promoters	9	I-Gene
.	1	O

Unlike	6	O
other	5	O
class	5	O
II	2	O
promoters	9	O
,	1	O
the	3	O
HLA-DR	6	B-Gene
alpha	5	I-Gene
(	1	I-Gene
DRA	3	I-Gene
)	1	I-Gene
promoter	8	I-Gene
also	4	O
contains	8	O
one	3	O
element	7	O
identical	9	O
to	2	O
the	3	O
``	2	O
octamer	7	O
''motif	7	O
of	2	O
immunoglobulin	14	B-Gene
variable	8	I-Gene
region	6	I-Gene
promoters	9	I-Gene
that	4	O
is	2	O
responsible	11	O
for	3	O
B	1	O
cell-specific	13	O
transcription	13	O
.	1	O

This	4	O
``	2	O
octamer	7	O
``	2	O
in	2	O
the	3	O
context	7	O
of	2	O
DRA	3	B-Gene
appears	7	O
capable	7	O
of	2	O
binding	7	O
both	4	O
the	3	O
ubiquitous	10	O
(	1	O
OTF-1	5	B-Gene
)	1	O
and	3	O
lymphoid-specific	17	O
(	1	O
OTF-2	5	B-Gene
)	1	O
``	2	O
octamer	7	O
''binding	9	O
proteins	8	O
,	1	O
but	3	O
at	2	O
least	5	O
one	3	O
other	5	O
distinct	8	O
``	2	O
octamer	7	O
''complex	9	O
was	3	O
found	5	O
.	1	O

In	2	O
order	5	O
to	2	O
characterize	12	O
the	3	O
function	8	O
of	2	O
cis	3	O
-acting	7	O
elements	8	O
,	1	O
we	2	O
have	4	O
developed	9	O
an	2	O
in	2	O
vitro	5	O
system	6	O
in	2	O
which	5	O
a	1	O
DRA	3	B-Gene
promoter	8	I-Gene
construct	9	O
is	2	O
transcribed	11	O
more	4	O
efficiently	11	O
in	2	O
extracts	8	O
from	4	O
B	1	O
cells	5	O
than	4	O
in	2	O
extracts	8	O
from	4	O
class	5	O
II	2	O
-negative	9	O
HeLa	4	O
cells	5	O
.	1	O

5	1	O
'deletion	9	O
constructs	10	O
which	5	O
lacked	6	O
the	3	O
Y	1	O
box	3	O
,	1	O
but	3	O
retained	8	O
the	3	O
``	2	O
octamer	7	O
''motif	7	O
and	3	O
TATA	4	O
box	3	O
were	4	O
completely	10	O
inactive	8	O
,	1	O
and	3	O
internal	8	O
deletion	8	O
of	2	O
the	3	O
Y	1	O
box	3	O
reduced	7	O
transcription	13	O
by	2	O
95	2	O
%	1	O
.	1	O

Using	5	O
supercoiled	11	O
,	1	O
but	3	O
not	3	O
linear	6	O
templates	9	O
,	1	O
we	2	O
observed	8	O
differences	11	O
in	2	O
transcription	13	O
efficiencies	12	O
from	4	O
templates	9	O
lacking	7	O
or	2	O
disrupting	10	O
the	3	O
X	1	O
consensus	9	O
element	7	O
that	4	O
reflect	7	O
effects	7	O
of	2	O
random	6	O
replacement	11	O
of	2	O
X	1	O
box	3	O
sequences	9	O
in	2	O
transient	9	O
expression	10	O
assays	6	O
.	1	O

Demonstration	13	O
of	2	O
the	3	O
complete	8	O
dependence	10	O
on	2	O
the	3	O
Y	1	O
box	3	O
in	2	O
this	4	O
system	6	O
suggests	8	O
that	4	O
,	1	O
despite	7	O
its	3	O
demonstrated	12	O
importance	10	O
in	2	O
the	3	O
DRA	3	B-Gene
promoter	8	I-Gene
,	1	O
the	3	O
DRA	3	B-Gene
``	2	O
octamer	7	O
''does	6	O
not	3	O
utilize	7	O
OTF-2	5	B-Gene
in	2	O
a	1	O
manner	6	O
analogous	9	O
to	2	O
immunoglobulin	14	B-Gene
promoters	9	I-Gene
in	2	O
B	1	O
cells	5	O
.	1	O

Expression	10	O
of	2	O
c-jun	5	B-Gene
,	1	O
jun	3	B-Gene
B	1	I-Gene
and	3	O
jun	3	B-Gene
D	1	I-Gene
proto-oncogenes	15	I-Gene
in	2	O
human	5	O
peripheral-blood	16	O
granulocytes	12	O
.	1	O

We	2	O
have	4	O
found	5	O
that	4	O
purified	8	O
human	5	O
peripheral-blood	16	O
granulocytes	12	O
express	7	O
constitutively	14	O
significant	11	O
levels	6	O
of	2	O
proto-oncogenes	15	B-Gene
c-jun	5	I-Gene
,	1	O
jun	3	B-Gene
B	1	I-Gene
and	3	O
jun	3	B-Gene
D	1	I-Gene
mRNA	4	I-Gene
.	1	O

Upon	4	O
functional	10	O
activation	10	O
of	2	O
granulocytes	12	O
by	2	O
4	1	B-Chemical
beta-phorbol	12	I-Chemical
12-myristate	12	I-Chemical
13-acetate	10	I-Chemical
(	1	O
PMA	3	B-Chemical
)	1	O
,	1	O
the	3	O
levels	6	O
of	2	O
c-jun	5	B-Gene
,	1	O
jun	3	B-Gene
B	1	I-Gene
and	3	O
jun	3	B-Gene
D	1	I-Gene
transcripts	11	I-Gene
were	4	O
increased	9	O
.	1	O

The	3	O
three	5	O
jun	3	B-Gene
genes	5	I-Gene
showed	6	O
a	1	O
similar	7	O
time	4	O
course	6	O
in	2	O
their	5	O
induction	9	O
by	2	O
PMA	3	B-Chemical
,	1	O
maximal	7	O
mRNA	4	O
levels	6	O
being	5	O
reached	7	O
after	5	O
60	2	O
min	3	O
of	2	O
induction	9	O
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
expression	10	O
of	2	O
c-jun	5	B-Gene
,	1	O
jun	3	B-Gene
B	1	I-Gene
and	3	O
jun	3	B-Gene
D	1	I-Gene
genes	5	I-Gene
might	5	O
be	2	O
involved	8	O
in	2	O
terminal	8	O
granulocyte	11	O
differentiation	15	O
or	2	O
in	2	O
regulating	10	O
granulocyte	11	O
functionality	13	O
.	1	O

Oestrogen	9	B-Gene
receptor	8	I-Gene
(	1	O
ER	2	B-Gene
)	1	O
analysis	8	O
in	2	O
B-cell	6	B-Disease
chronic	7	I-Disease
lymphocytic	11	I-Disease
leukemia	8	I-Disease
:	1	O
correlation	11	O
of	2	O
biochemical	11	O
and	3	O
immunocytochemical	18	O
methods	7	O
.	1	O

Oestrogen	9	B-Gene
receptors	9	I-Gene
(	1	O
ER	2	B-Gene
)	1	O
are	3	O
present	7	O
in	2	O
neoplastic	10	O
lymphoid	8	O
cells	5	O
and	3	O
have	4	O
been	4	O
considered	10	O
a	1	O
physiological	13	O
marker	6	O
of	2	O
growth	6	O
rate	4	O
or	2	O
differentiation	15	O
.	1	O

Tamoxifen	9	B-Chemical
,	1	O
an	2	O
oestrogen	9	B-Chemical
antagonist	10	O
,	1	O
has	3	O
been	4	O
given	5	O
in	2	O
some	4	O
patients	8	O
with	4	O
CLL	3	B-Disease
and	3	O
Hodgkin	7	B-Disease
's	2	I-Disease
disease	7	I-Disease
,	1	O
with	4	O
dramatic	8	O
response	8	O
in	2	O
single	6	O
cases	5	O
.	1	O

Until	5	O
now	3	O
,	1	O
ER	2	B-Gene
status	6	O
has	3	O
been	4	O
assessed	8	O
using	5	O
a	1	O
steroid	7	O
binding	7	O
assay	5	O
(	1	O
SBA	3	O
)	1	O
which	5	O
has	3	O
many	4	O
inherent	8	O
problems	8	O
.	1	O

Recently	8	O
,	1	O
the	3	O
development	11	O
of	2	O
monoclonal	10	O
antibodies	10	O
directed	8	O
against	7	O
ER	2	B-Gene
has	3	O
been	4	O
applied	7	O
to	2	O
the	3	O
study	5	O
of	2	O
breast	6	B-Disease
carcinomas	10	I-Disease
and	3	O
results	7	O
obtained	8	O
show	4	O
good	4	O
correlation	11	O
with	4	O
the	3	O
quantitative	12	O
SBA	3	O
.	1	O

We	2	O
studied	7	O
49	2	O
cases	5	O
of	2	O
B-cell	6	B-Disease
chronic	7	I-Disease
lymphocytic	11	I-Disease
leukemia	8	I-Disease
(	1	O
CLL	3	B-Disease
)	1	O
using	5	O
immunostaining	14	O
of	2	O
cytospin	8	O
preparations	12	O
.	1	O

In	2	O
30	2	O
of	2	O
these	5	O
cases	5	O
ER	2	B-Gene
enzyme	6	O
immunoassay	11	O
(	1	O
ER	2	B-Gene
-EIA	4	O
)	1	O
was	3	O
also	4	O
performed	9	O
.	1	O

Cultured	8	O
MCF-7	5	O
cells	5	O
,	1	O
derived	7	O
from	4	O
a	1	O
pleural	7	B-Disease
effusion	8	I-Disease
of	2	O
a	1	O
breast	6	B-Disease
cancer	6	I-Disease
patient	7	O
,	1	O
known	5	O
to	2	O
contain	7	O
high	4	O
levels	6	O
of	2	O
ER	2	B-Gene
were	4	O
used	4	O
as	2	O
a	1	O
positive	8	O
control	7	O
(	1	O
40-48	5	O
%	1	O
ER	2	B-Gene
positive	8	O
cells	5	O
by	2	O
immunocytochemistry	19	O
;	1	O
200	3	O
fmol	4	O
/	1	O
mg	2	O
protein	7	O
by	2	O
EIA	3	O
)	1	O
.	1	O

All	3	O
of	2	O
the	3	O
CLL	3	B-Disease
cases	5	O
except	6	O
two	3	O
(	1	O
96	2	O
%	1	O
)	1	O
were	4	O
negative	8	O
for	3	O
ER	2	B-Gene
(	1	O
less	4	O
than	4	O
1	1	O
%	1	O
staining	8	O
;	1	O
less	4	O
than	4	O
4	1	O
fmol	4	O
/	1	O
mg	2	O
protein	7	O
)	1	O
.	1	O

The	3	O
two	3	O
positive	8	O
cases	5	O
expressed	9	O
granular	8	B-Gene
ER	2	I-Gene
staining	8	O
over	4	O
the	3	O
nucleus	7	O
(	1	O
9.2	3	O
and	3	O
12.1	4	O
%	1	O
positive	8	O
cells	5	O
)	1	O
and	3	O
were	4	O
positive	8	O
by	2	O
EIA	3	O
and	3	O
SBA	3	O
.	1	O

It	2	O
is	2	O
concluded	9	O
that	4	O
(	1	O
i	1	O
)	1	O
patients	8	O
with	4	O
CLL	3	B-Disease
rarely	6	O
express	7	O
ER	2	B-Gene
and	3	O
(	1	O
ii	2	O
)	1	O
immunocytochemical	18	O
staining	8	O
of	2	O
cytospin	8	O
preparations	12	O
is	2	O
a	1	O
valid	5	O
technique	9	O
for	3	O
the	3	O
measurement	11	O
of	2	O
ER	2	B-Gene
.	1	O

It	2	O
is	2	O
of	2	O
interest	8	O
that	4	O
one	3	O
of	2	O
the	3	O
positive	8	O
cases	5	O
was	3	O
diagnosed	9	O
as	2	O
CLL	3	B-Disease
with	4	O
Richter	7	O
's	2	O
transformation	14	O
confirming	10	O
earlier	7	O
findings	8	O
.	1	O

Thyroid	7	B-Gene
hormone	7	I-Gene
receptors	9	I-Gene
form	4	O
distinct	8	O
nuclear	7	O
protein	7	O
-dependent	10	O
and	3	O
independent	11	O
complexes	9	O
with	4	O
a	1	O
thyroid	7	B-Chemical
hormone	7	I-Chemical
response	8	O
element	7	O
.	1	O

We	2	O
have	4	O
examined	8	O
the	3	O
binding	7	O
of	2	O
nuclear	7	O
proteins	8	O
and	3	O
recombinant	11	B-Gene
thyroid	7	I-Gene
hormone	7	I-Gene
receptors	9	I-Gene
(	1	O
TRs	3	B-Gene
)	1	O
to	2	O
the	3	O
palindromic	11	O
thyroid	7	B-Chemical
hormone	7	I-Chemical
responsive	10	O
element	7	O
AGGTCATGACCT	12	O
(	1	O
TREp	4	O
)	1	O
using	5	O
a	1	O
gel	3	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assay	5	O
.	1	O

Four	4	O
specific	8	O
protein-DNA	11	O
complexes	9	O
were	4	O
detected	8	O
after	5	O
incubation	10	O
of	2	O
nuclear	7	O
extracts	8	O
(	1	O
NE	2	O
)	1	O
from	4	O
T3	2	O
-responsive	11	O
pituitary	9	O
(	1	O
GH3	3	O
)	1	O
cells	5	O
with	4	O
a	1	O
TREp	4	O
-containing	11	O
DNA	3	O
fragment	8	O
.	1	O

This	4	O
was	3	O
compared	8	O
with	4	O
the	3	O
TREp	4	O
binding	7	O
of	2	O
reticulocyte	12	O
lysate	6	O
-synthesized	12	O
TRs	3	B-Gene
.	1	O

TR	2	B-Gene
alpha	5	I-Gene
1	1	I-Gene
and	3	O
TR	2	B-Gene
beta	4	I-Gene
2	1	I-Gene
each	4	O
formed	6	O
a	1	O
single	6	O
major	5	O
TR	2	B-Gene
:	1	O
TREp	4	O
complex	7	O
which	5	O
comigrated	10	O
with	4	O
the	3	O
least	5	O
retarded	8	O
complex	7	O
formed	6	O
by	2	O
GH3	3	O
NE	2	O
,	1	O
while	5	O
TR	2	B-Gene
beta	4	I-Gene
1	1	I-Gene
formed	6	O
multiple	8	O
complexes	9	O
suggesting	10	O
that	4	O
it	2	O
can	3	O
bind	4	O
to	2	O
TREp	4	O
as	2	O
an	2	O
oligomer	8	O
.	1	O

Interestingly	13	O
,	1	O
coincubation	12	O
of	2	O
35S-TR	6	B-Gene
alpha	5	I-Gene
1	1	I-Gene
,	1	O
GH3	3	O
NE	2	O
,	1	O
and	3	O
unlabeled	9	O
TREp	4	O
resulted	8	O
in	2	O
not	3	O
only	4	O
the	3	O
35S-TR	6	B-Gene
:	1	O
TREp	4	O
complex	7	O
,	1	O
but	3	O
in	2	O
two	3	O
additional	10	O
more	4	O
greatly	7	O
retarded	8	O
complexes	9	O
containing	10	O
35S-TR	6	B-Gene
alpha	5	I-Gene
1	1	I-Gene
and	3	O
comigrating	11	O
with	4	O
those	5	O
formed	6	O
by	2	O
GH3	3	O
extract	7	O
alone	5	O
.	1	O

Incubation	10	O
of	2	O
each	4	O
of	2	O
the	3	O
TRs	3	B-Gene
with	4	O
NE	2	O
from	4	O
COS-7	5	O
cells	5	O
,	1	O
which	5	O
do	2	O
not	3	O
possess	7	O
sufficient	10	O
endogenous	10	B-Gene
TRs	3	I-Gene
to	2	O
mediate	7	O
T3-responses	12	O
,	1	O
resulted	8	O
in	2	O
formation	9	O
of	2	O
a	1	O
new	3	O
,	1	O
more	4	O
greatly	7	O
shifted	7	O
complex	7	O
.	1	O

A	1	O
similar	7	O
,	1	O
heat	4	O
labile	6	O
activity	8	O
which	5	O
altered	7	O
mobility	8	O
of	2	O
the	3	O
TR	2	B-Gene
:	1	O
TRE	3	O
complex	7	O
was	3	O
also	4	O
present	7	O
in	2	O
NE	2	O
from	4	O
T3	2	O
-unresponsive	13	O
JEG-3	5	O
cells	5	O
.	1	O

At	2	O
high	4	O
concentration	13	O
of	2	O
NE	2	O
,	1	O
all	3	O
of	2	O
the	3	O
TR	2	B-Gene
bound	5	O
to	2	O
TREp	4	O
was	3	O
more	4	O
greatly	7	O
retarded	8	O
than	4	O
in	2	O
the	3	O
absence	7	O
of	2	O
NE	2	O
.	1	O

Truncation	10	O
of	2	O
TR	2	B-Gene
alpha	5	I-Gene
1	1	I-Gene
at	2	O
amino	5	O
acid	4	O
210	3	O
prevented	9	O
additional	10	O
complex	7	O
formation	9	O
in	2	O
the	3	O
presence	8	O
of	2	O
NE	2	O
without	7	O
affecting	9	O
DNA	3	O
binding	7	O
,	1	O
suggesting	10	O
that	4	O
the	3	O
carboxyl-terminus	17	B-Chemical
of	2	O
the	3	O
TRs	3	B-Gene
is	2	O
essential	9	O
for	3	O
interaction	11	O
with	4	O
nuclear	7	O
proteins	8	O
.	1	O

(	1	O
ABSTRACT	8	O
TRUNCATED	9	O
AT	2	O
250	3	O
WORDS	5	O
)	1	O

Platelet	8	B-Chemical
-activating	11	I-Chemical
factor	6	I-Chemical
induces	7	O
phospholipid	12	B-Chemical
turnover	8	O
,	1	O
calcium	7	B-Chemical
flux	4	O
,	1	O
arachidonic	11	B-Chemical
acid	4	I-Chemical
liberation	10	O
,	1	O
eicosanoid	10	B-Chemical
generation	10	O
,	1	O
and	3	O
oncogene	8	O
expression	10	O
in	2	O
a	1	O
human	5	O
B	1	O
cell	4	O
line	4	O
.	1	O

Platelet	8	B-Chemical
-activating	11	I-Chemical
factor	6	I-Chemical
is	2	O
a	1	O
potent	6	O
mediator	8	O
of	2	O
the	3	O
inflammatory	12	O
response	8	O
.	1	O

Studies	7	O
of	2	O
the	3	O
actions	7	O
of	2	O
platelet	8	B-Chemical
-activating	11	I-Chemical
factor	6	I-Chemical
have	4	O
centered	8	O
mainly	6	O
around	6	O
neutrophils	11	O
,	1	O
monocytes	9	O
,	1	O
and	3	O
platelets	9	O
.	1	O

In	2	O
this	4	O
report	6	O
we	2	O
begin	5	O
to	2	O
uncover	7	O
the	3	O
influence	9	O
of	2	O
platelet	8	B-Chemical
-activating	11	I-Chemical
factor	6	I-Chemical
on	2	O
B	1	O
lymphocytes	11	O
.	1	O

Employing	9	O
the	3	O
EBV	3	O
-transformed	12	O
human	5	O
B	1	O
cell	4	O
line	4	O
SKW6.4	6	O
,	1	O
we	2	O
demonstrate	11	O
that	4	O
platelet	8	B-Chemical
-activating	11	I-Chemical
factor	6	I-Chemical
significantly	13	O
alters	6	O
membrane	8	O
phospholipid	12	B-Chemical
metabolism	10	O
indicated	9	O
by	2	O
the	3	O
incorporation	13	O
of	2	O
32P	3	O
into	4	O
phosphatidylcholine	19	B-Chemical
,	1	O
phosphatidylinositol	20	B-Chemical
,	1	O
and	3	O
phosphatidic	12	B-Chemical
acid	4	I-Chemical
but	3	O
not	3	O
significantly	13	O
into	4	O
phosphatidylethanolamine	24	B-Chemical
at	2	O
concentrations	14	O
ranging	7	O
from	4	O
10	2	O
(	1	O
-9	2	O
)	1	O
to	2	O
10	2	O
(	1	O
-6	2	O
)	1	O
M	1	O
.	1	O

The	3	O
inactive	8	O
precursor	9	O
,	1	O
lyso-platelet	13	B-Chemical
-activating	11	I-Chemical
factor	6	I-Chemical
,	1	O
at	2	O
a	1	O
concentration	13	O
as	2	O
high	4	O
as	2	O
10	2	O
(	1	O
-7	2	O
)	1	O
M	1	O
had	3	O
no	2	O
effect	6	O
on	2	O
any	3	O
of	2	O
the	3	O
membrane	8	O
phospholipids	13	B-Chemical
.	1	O

We	2	O
also	4	O
show	4	O
that	4	O
platelet	8	B-Chemical
-activating	11	I-Chemical
factor	6	I-Chemical
from	4	O
10	2	O
(	1	O
-12	3	O
)	1	O
to	2	O
10	2	O
(	1	O
-6	2	O
)	1	O
M	1	O
induced	7	O
rapid	5	O
and	3	O
significant	11	O
elevation	9	O
in	2	O
intracellular	13	O
calcium	7	B-Chemical
levels	6	O
,	1	O
whereas	7	O
lyso-	5	B-Chemical
platelet	8	I-Chemical
-activating	11	I-Chemical
factor	6	I-Chemical
was	3	O
again	5	O
ineffective	11	O
.	1	O

We	2	O
further	7	O
demonstrate	11	O
the	3	O
impact	6	O
of	2	O
platelet	8	B-Chemical
-activating	11	I-Chemical
factor	6	I-Chemical
binding	7	O
to	2	O
B	1	O
cells	5	O
by	2	O
measuring	9	O
platelet	8	B-Chemical
-activating	11	I-Chemical
factor	6	I-Chemical
induced	7	O
arachidonic	11	B-Chemical
acid	4	I-Chemical
release	7	O
and	3	O
5-hydroxyeicosatetraenoic	25	B-Chemical
acid	4	I-Chemical
production	10	O
.	1	O

Moreover	8	O
,	1	O
platelet	8	B-Chemical
-activating	11	I-Chemical
factor	6	I-Chemical
was	3	O
capable	7	O
of	2	O
inducing	8	O
transcription	13	O
of	2	O
the	3	O
nuclear	7	B-Gene
proto-oncogenes	15	I-Gene
c-fos	5	I-Gene
and	3	O
c-jun	5	B-Gene
.	1	O

Finally	7	O
we	2	O
explored	8	O
the	3	O
possible	8	O
role	4	O
of	2	O
5-hydroxyeicosatetraenoic	25	B-Chemical
acid	4	I-Chemical
as	2	O
a	1	O
regulator	9	O
of	2	O
arachidonic	11	B-Chemical
acid	4	I-Chemical
liberation	10	O
demonstrating	13	O
that	4	O
endogenous	10	B-Gene
5-lipoxygenase	14	I-Gene
activity	8	O
modulates	9	O
platelet	8	B-Chemical
-activating	11	I-Chemical
factor	6	I-Chemical
induced	7	O
arachidonic	11	B-Chemical
acid	4	I-Chemical
release	7	O
perhaps	7	O
acting	6	O
at	2	O
the	3	O
level	5	O
of	2	O
phospholipase	13	B-Gene
A2	2	I-Gene
.	1	O

In	2	O
summary	7	O
,	1	O
platelet	8	B-Chemical
-activating	11	I-Chemical
factor	6	I-Chemical
is	2	O
shown	5	O
here	4	O
to	2	O
have	4	O
a	1	O
direct	6	O
and	3	O
profound	8	O
effect	6	O
on	2	O
a	1	O
pure	4	O
B	1	O
cell	4	O
line	4	O
.	1	O

[	1	O
Glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
peripheral	10	O
blood	5	O
lymphocytes	11	O
of	2	O
patients	8	O
with	4	O
bronchial	9	B-Disease
asthma	6	I-Disease
]	1	O

Quantitation	12	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
(	1	O
GCR	3	B-Gene
)	1	O
and	3	O
the	3	O
study	5	O
of	2	O
their	5	O
affinity	8	O
for	3	O
glucocorticosteroids	20	B-Chemical
(	1	O
GCS	3	B-Chemical
)	1	O
were	4	O
made	4	O
in	2	O
peripheral	10	O
blood	5	O
lymphocytes	11	O
of	2	O
bronchial	9	B-Disease
asthma	6	I-Disease
(	1	O
BA	2	B-Disease
)	1	O
patients	8	O
in	2	O
consideration	13	O
of	2	O
GCR	3	B-Gene
treatment	9	O
and	3	O
serum	5	O
levels	6	O
of	2	O
endogenous	10	O
cortisol	8	B-Chemical
.	1	O

It	2	O
is	2	O
stated	6	O
that	4	O
GCR	3	B-Gene
of	2	O
healthy	7	O
controls	8	O
and	3	O
GCS	3	B-Chemical
-untreated	10	O
patients	8	O
outnumbered	11	O
those	5	O
of	2	O
cortisol	8	B-Chemical
-dependent	10	O
BA	2	B-Disease
patients	8	O
on	2	O
hormone	7	O
therapy	7	O
.	1	O

Following	9	O
discontinuation	15	O
of	2	O
glucocorticoid	14	B-Chemical
drugs	5	O
GCR	3	B-Gene
count	5	O
in	2	O
cortisol	8	B-Chemical
-dependent	10	O
BA	2	B-Disease
tends	5	O
to	2	O
rise	4	O
.	1	O

Endogenous	10	O
cortisol	8	B-Chemical
has	3	O
no	2	O
effect	6	O
on	2	O
GCR	3	B-Gene
level	5	O
estimated	9	O
by	2	O
3H-triamcinolone	16	B-Chemical
acetonide	9	I-Chemical
.	1	O

A	1	O
novel	5	O
HIV-1	5	O
isolate	7	O
containing	10	O
alterations	11	O
affecting	9	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
element	7	I-Gene
.	1	O

Three	5	O
molecular	9	O
clones	6	O
of	2	O
HIV-1	5	O
,	1	O
derived	7	O
from	4	O
a	1	O
single	6	O
isolate	7	O
(	1	O
AL1	3	O
)	1	O
,	1	O
exhibited	9	O
distinct	8	O
replicative	11	O
and	3	O
cytopathic	10	O
properties	10	O
during	6	O
propagation	11	O
in	2	O
a	1	O
human	5	O
T	1	O
cell	4	O
line	4	O
.	1	O

The	3	O
phenotypic	10	O
differences	11	O
observed	8	O
were	4	O
attributable	12	O
,	1	O
in	2	O
large	5	O
part	4	O
,	1	O
to	2	O
changes	7	O
affecting	9	O
the	3	O
viral	5	O
LTR	3	O
.	1	O

Nucleotide	10	O
sequence	8	O
and	3	O
PCR	3	O
analyses	8	O
demonstrated	12	O
the	3	O
presence	8	O
of	2	O
novel	5	O
duplications	12	O
or	2	O
deletions	9	O
involving	9	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
motif	5	O
.	1	O

These	5	O
changes	7	O
in	2	O
the	3	O
enhancer	8	O
element	7	O
were	4	O
identified	10	O
in	2	O
the	3	O
original	8	O
AL1	3	O
virus	5	O
stock	5	O
.	1	O

Subcloning	10	O
of	2	O
the	3	O
variant	7	O
NF-kappa	8	B-Gene
B	1	I-Gene
segments	8	O
into	4	O
LTR-driven	10	O
CAT	3	O
expression	10	O
vectors	7	O
confirmed	9	O
a	1	O
correlation	11	O
between	7	O
promoter	8	O
activity	8	O
and	3	O
replicative	11	O
/	1	O
cytopathic	10	O
capacity	8	O
.	1	O

1	1	B-Gene
,	1	I-Gene
25-Dihydroxyvitamin	19	I-Gene
D3	2	I-Gene
receptor	8	I-Gene
RNA	3	I-Gene
:	1	O
expression	10	O
in	2	O
hematopoietic	13	O
cells	5	O
.	1	O

1	1	B-Chemical
,	1	I-Chemical
25-Dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
[	1	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
]	1	O
induces	7	O
differentiation	15	O
and	3	O
inhibits	8	O
proliferation	13	O
of	2	O
myeloid	7	O
leukemic	8	O
cells	5	O
from	4	O
various	7	O
lines	5	O
and	3	O
patients	8	O
;	1	O
these	5	O
effects	7	O
are	3	O
probably	8	O
mediated	8	O
through	7	O
the	3	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
.	1	O

Little	6	O
is	2	O
known	5	O
of	2	O
expression	10	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
RNA	3	I-Gene
in	2	O
hematopoietic	13	O
cells	5	O
.	1	O

We	2	O
examined	8	O
the	3	O
expression	10	O
and	3	O
modulation	10	O
of	2	O
expression	10	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
RNA	3	I-Gene
in	2	O
various	7	O
proliferating	13	O
and	3	O
nonproliferating	16	O
hematopoietic	13	O
cells	5	O
.	1	O

Constitutive	12	O
expression	10	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
RNA	3	I-Gene
was	3	O
detected	8	O
in	2	O
various	7	O
kinds	5	O
of	2	O
hematopoietic	13	O
cells	5	O
,	1	O
including	9	O
macrophages	11	O
and	3	O
activated	9	O
T	1	O
lymphocytes	11	O
,	1	O
as	2	O
well	4	O
as	2	O
in	2	O
cell	4	O
lines	5	O
KG-1	4	O
(	1	O
myeloblasts	11	O
)	1	O
,	1	O
HL-60	5	O
(	1	O
promyelocytes	13	O
)	1	O
,	1	O
ML-3	4	O
(	1	O
myelomonoblasts	15	O
)	1	O
,	1	O
U937	4	O
,	1	O
THP-1	5	O
(	1	O
monoblasts	10	O
)	1	O
,	1	O
K562	4	O
(	1	O
erythroblasts	13	O
)	1	O
,	1	O
and	3	O
S-LB1	5	O
(	1	O
HTLV-1	6	O
-transfected	12	O
T	1	O
lymphocytes	11	O
)	1	O
.	1	O

Receptor	8	O
transcripts	11	O
were	4	O
4.6	3	O
kilobases	9	O
(	1	O
kb	2	O
)	1	O
,	1	O
and	3	O
no	2	O
variant	7	O
sizes	5	O
were	4	O
observed	8	O
.	1	O

All	3	O
cell	4	O
lines	5	O
examined	8	O
in	2	O
this	4	O
group	5	O
also	4	O
expressed	9	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptors	9	I-Gene
.	1	O

Most	4	O
B	1	O
lymphocyte	10	O
lines	5	O
expressed	9	O
negligible	10	O
levels	6	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
RNA	3	I-Gene
and	3	O
protein	7	O
;	1	O
however	7	O
;	1	O
analysis	8	O
of	2	O
a	1	O
lymphoid	8	O
/	1	O
myeloid	7	O
somatic	7	O
hybrid	6	O
suggested	9	O
that	4	O
suppression	11	O
of	2	O
expression	10	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
RNA	3	I-Gene
in	2	O
B	1	O
lymphocytes	11	O
may	3	O
be	2	O
a	1	O
dominant	8	O
characteristic	14	O
.	1	O

HL-60	5	O
cells	5	O
were	4	O
cultured	8	O
with	4	O
10	2	O
(	1	O
-7	2	O
)	1	O
mol	3	O
/	1	O
L	1	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
for	3	O
24	2	O
to	2	O
72	2	O
hours	5	O
,	1	O
and	3	O
levels	6	O
of	2	O
expression	10	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
and	3	O
its	3	O
RNA	3	O
were	4	O
examined	8	O
.	1	O

Levels	6	O
of	2	O
RNA	3	O
coding	6	O
for	3	O
the	3	O
receptor	8	O
were	4	O
not	3	O
modulated	9	O
by	2	O
exposure	8	O
to	2	O
high	4	O
levels	6	O
of	2	O
ligand	6	O
.	1	O

Levels	6	O
of	2	O
occupied	8	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
protein	7	I-Gene
increased	9	O
in	2	O
these	5	O
HL-60	5	O
cells	5	O
;	1	O
but	3	O
the	3	O
total	5	O
number	6	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptors	9	I-Gene
decreased	9	O
about	5	O
50	2	O
%	1	O
at	2	O
24	2	O
hours	5	O
and	3	O
returned	8	O
toward	6	O
normal	6	O
at	2	O
72	2	O
hours	5	O
.	1	O

Steady-state	12	O
levels	6	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
RNA	3	I-Gene
were	4	O
not	3	O
affected	8	O
by	2	O
terminal	8	O
differentiation	15	O
of	2	O
HL-60	5	O
toward	6	O
either	6	O
granulocytes	12	O
or	2	O
macrophages	11	O
.	1	O

Nondividing	11	O
macrophages	11	O
from	4	O
normal	6	O
individuals	11	O
also	4	O
expressed	9	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
RNA	3	I-Gene
.	1	O

In	2	O
contrast	8	O
,	1	O
nondividing	11	O
peripheral	10	O
blood	5	O
lymphocytes	11	O
from	4	O
normal	6	O
individuals	11	O
did	3	O
not	3	O
express	7	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
RNA	3	I-Gene
;	1	O
with	4	O
stimulation	11	O
of	2	O
proliferation	13	O
of	2	O
these	5	O
cells	5	O
,	1	O
accumulation	12	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
RNA	3	I-Gene
increased	9	O
markedly	8	O
.	1	O

Half-life	9	O
(	1	O
t1	2	O
/	1	O
2	1	O
)	1	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
RNA	3	I-Gene
in	2	O
T	1	O
lymphocytes	11	O
was	3	O
short	5	O
(	1	O
1	1	O
hour	4	O
)	1	O
as	2	O
determined	10	O
by	2	O
measuring	9	O
decay	5	O
of	2	O
the	3	O
message	7	O
after	5	O
addition	8	O
of	2	O
actinomycin	11	B-Chemical
D	1	I-Chemical
.	1	O

Consistent	10	O
with	4	O
this	4	O
short	5	O
t1	2	O
/	1	O
2	1	O
,	1	O
accumulation	12	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
RNA	3	I-Gene
increased	9	O
in	2	O
cells	5	O
as	2	O
their	5	O
protein	7	O
synthesis	9	O
was	3	O
inhibited	9	O
.	1	O

Further	7	O
studies	7	O
are	3	O
required	8	O
to	2	O
understand	10	O
the	3	O
physiologic	11	O
role	4	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptors	9	I-Gene
in	2	O
myeloid	7	O
cells	5	O
and	3	O
proliferating	13	O
T	1	O
lymphocytes	11	O
.	1	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
on	2	O
mononuclear	11	O
leukocytes	10	O
in	2	O
Alzheimer	9	B-Disease
's	2	I-Disease
disease	7	I-Disease
.	1	O

Several	7	O
lines	5	O
of	2	O
evidence	8	O
suggest	7	O
disturbances	12	O
of	2	O
the	3	O
hypothalamic-pituitary-adrenal	30	O
(	1	O
HPA	3	O
)	1	O
system	6	O
in	2	O
Alzheimer	9	B-Disease
's	2	I-Disease
disease	7	I-Disease
(	1	O
AD	2	B-Disease
)	1	O
.	1	O

In	2	O
an	2	O
exploration	11	O
of	2	O
the	3	O
potential	9	O
role	4	O
of	2	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
in	2	O
AD	2	B-Disease
,	1	O
GR	2	B-Gene
density	7	O
and	3	O
affinity	8	O
were	4	O
assessed	8	O
on	2	O
mononuclear	11	O
leukocytes	10	O
of	2	O
12	2	O
AD	2	B-Disease
patients	8	O
and	3	O
12	2	O
healthy	7	O
controls	8	O
.	1	O

GR	2	B-Gene
binding	7	O
characteristics	15	O
did	3	O
not	3	O
differ	6	O
between	7	O
patients	8	O
and	3	O
controls	8	O
or	2	O
between	7	O
patients	8	O
subdivided	10	O
according	9	O
to	2	O
diagnosis	9	O
or	2	O
associated	10	O
clinical	8	O
features	8	O
.	1	O

These	5	O
data	4	O
suggest	7	O
that	4	O
the	3	O
abnormalities	13	O
of	2	O
the	3	O
HPA	3	O
system	6	O
in	2	O
AD	2	B-Disease
are	3	O
not	3	O
related	7	O
to	2	O
a	1	O
GR	2	B-Gene
deficiency	10	O
.	1	O

Kappa	5	B-Gene
B	1	I-Gene
binding	7	I-Gene
proteins	8	I-Gene
are	3	O
constitutively	14	O
expressed	9	O
in	2	O
an	2	O
IL-2	4	B-Gene
autocrine	9	O
human	5	O
T	1	O
cell	4	O
line	4	O
.	1	O

The	3	O
IL-2	4	B-Gene
and	3	O
the	3	O
IL-2-R	6	B-Gene
alpha	5	I-Gene
genes	5	I-Gene
are	3	O
both	4	O
expressed	9	O
transiently	11	O
in	2	O
normal	6	O
T	1	O
lymphocytes	11	O
after	5	O
Ag	2	O
or	2	O
mitogen	7	O
activation	10	O
.	1	O

In	2	O
contrast	8	O
,	1	O
the	3	O
human	5	O
T	1	O
cell	4	O
line	4	O
,	1	O
IARC	4	O
301	3	O
,	1	O
expresses	9	O
these	5	O
two	3	O
genes	5	O
constitutively	14	O
and	3	O
we	2	O
have	4	O
previously	10	O
demonstrated	12	O
that	4	O
its	3	O
growth	6	O
depends	7	O
on	2	O
the	3	O
autocrine	9	O
production	10	O
of	2	O
this	4	O
T	1	B-Gene
cell	4	I-Gene
growth	6	I-Gene
factor	6	I-Gene
and	3	O
high	4	O
affinity	8	O
IL-2R	5	B-Gene
.	1	O

To	2	O
dissect	7	O
the	3	O
molecular	9	O
basis	5	O
for	3	O
the	3	O
unusual	7	O
persistent	10	O
expression	10	O
of	2	O
the	3	O
IL-2	4	B-Gene
and	3	O
IL-2-R	6	B-Gene
alpha	5	I-Gene
genes	5	I-Gene
in	2	O
these	5	O
IARC	4	O
301	3	O
T	1	O
cells	5	O
,	1	O
we	2	O
have	4	O
analyzed	8	O
the	3	O
interactions	12	O
of	2	O
constitutively	14	O
expressed	9	O
nuclear	7	O
proteins	8	O
with	4	O
the	3	O
5	1	O
'flanking	9	O
regions	7	O
of	2	O
the	3	O
IL-2	4	B-Gene
and	3	O
IL-2-R	6	B-Gene
alpha	5	I-Gene
genes	5	I-Gene
using	5	O
both	4	O
DNase	5	B-Gene
I	1	I-Gene
footprinting	12	O
and	3	O
gel	3	O
retardation	11	O
techniques	10	O
.	1	O

We	2	O
have	4	O
found	5	O
that	4	O
a	1	O
region	6	O
in	2	O
both	4	O
genes	5	O
(	1	O
-276	4	O
to	2	O
-250	4	O
for	3	O
IL-2-R	6	B-Gene
alpha	5	I-Gene
and	3	O
-203	4	O
to	2	O
-183	4	O
for	3	O
IL-2	4	B-Gene
)	1	O
,	1	O
which	5	O
corresponds	11	O
to	2	O
a	1	O
kappa	5	O
B	1	O
enhancer	8	O
element	7	O
,	1	O
is	2	O
specifically	12	O
protected	9	O
by	2	O
nuclear	7	O
proteins	8	O
from	4	O
IARC	4	O
301	3	O
.	1	O

In	2	O
agreement	9	O
with	4	O
this	4	O
finding	7	O
,	1	O
both	4	O
the	3	O
IL-2	4	B-Gene
and	3	O
IL-2-R	6	B-Gene
alpha	5	I-Gene
promoters	9	I-Gene
are	3	O
active	6	O
in	2	O
transient	9	O
transfection	12	O
assays	6	O
in	2	O
IARC	4	O
301	3	O
cells	5	O
.	1	O

In	2	O
contrast	8	O
,	1	O
mutation	8	O
of	2	O
the	3	O
kappa	5	O
B	1	O
enhancer	8	O
results	7	O
in	2	O
markedly	8	O
attenuated	10	O
activities	10	O
of	2	O
both	4	O
promoters	9	O
.	1	O

Two	3	O
proteins	8	O
binding	7	O
the	3	O
kappa	5	O
B	1	O
sequence	8	O
,	1	O
NF-kappa	8	B-Gene
B	1	I-Gene
and	3	O
KBF1	4	B-Gene
,	1	O
are	3	O
constitutively	14	O
expressed	9	O
in	2	O
IARC	4	O
301	3	O
nuclei	6	O
and	3	O
induced	7	O
by	2	O
PMA	3	B-Chemical
and	3	O
PHA	3	B-Gene
in	2	O
Jurkat	6	O
.	1	O

They	4	O
bind	4	O
to	2	O
the	3	O
kappa	5	O
B	1	O
motifs	6	O
with	4	O
different	9	O
relative	8	O
affinities	10	O
that	4	O
may	3	O
reflect	7	O
their	5	O
different	9	O
contribution	12	O
in	2	O
the	3	O
expression	10	O
of	2	O
various	7	O
promoters	9	O
.	1	O

The	3	O
functional	10	O
domains	7	O
of	2	O
the	3	O
murine	6	B-Gene
Thy-1	5	I-Gene
gene	4	I-Gene
promoter	8	I-Gene
.	1	O

The	3	O
Thy-1	5	B-Gene
gene	4	I-Gene
promoter	8	I-Gene
resembles	9	O
a	1	O
``	2	O
housekeeping	12	O
''promoter	10	O
in	2	O
that	4	O
it	2	O
is	2	O
located	7	O
within	6	O
a	1	O
methylation-free	16	O
island	6	O
,	1	O
lacks	5	O
a	1	O
canonical	9	O
TATA	4	O
box	3	O
,	1	O
and	3	O
displays	8	O
heterogeneity	13	O
in	2	O
the	3	O
5'-end	6	O
termini	7	O
of	2	O
the	3	O
mRNA	4	O
.	1	O

Using	5	O
transgenic	10	O
mice	4	O
,	1	O
we	2	O
show	4	O
that	4	O
this	4	O
promoter	8	O
does	4	O
not	3	O
confer	6	O
any	3	O
tissue	6	O
specificity	11	O
and	3	O
is	2	O
active	6	O
only	4	O
in	2	O
a	1	O
position	8	O
-dependent	10	O
manner	6	O
.	1	O

It	2	O
can	3	O
only	4	O
be	2	O
activated	9	O
in	2	O
a	1	O
tissue-specific	15	O
manner	6	O
by	2	O
elements	8	O
that	4	O
lie	3	O
downstream	10	O
of	2	O
the	3	O
initiation	10	O
site	4	O
.	1	O

We	2	O
have	4	O
analyzed	8	O
the	3	O
functional	10	O
domains	7	O
of	2	O
the	3	O
minimal	7	O
Thy-1	5	B-Gene
promoter	8	I-Gene
and	3	O
show	4	O
that	4	O
the	3	O
dominant	8	O
promoter	8	O
elements	8	O
consist	7	O
of	2	O
multiple	8	O
binding	7	O
sites	5	O
for	3	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
Sp1	3	I-Gene
,	1	O
an	2	O
inverted	8	O
CCAAT	5	O
box	3	O
,	1	O
and	3	O
sequences	9	O
proximal	8	O
to	2	O
the	3	O
transcription	13	O
start	5	O
site	4	O
.	1	O

DNase	5	B-Gene
I	1	I-Gene
and	3	O
gel	3	O
mobility	8	O
shift	5	O
assays	6	O
show	4	O
the	3	O
binding	7	O
of	2	O
a	1	O
number	6	O
of	2	O
nuclear	7	O
factors	7	O
to	2	O
these	5	O
elements	8	O
,	1	O
including	9	O
Sp1	3	B-Gene
and	3	O
CP1	3	B-Gene
.	1	O

Our	3	O
results	7	O
show	4	O
that	4	O
the	3	O
structure	9	O
of	2	O
this	4	O
promoter	8	O
only	4	O
permits	7	O
productive	10	O
interactions	12	O
of	2	O
the	3	O
two	3	O
transcription	13	B-Gene
factors	7	I-Gene
Sp1	3	I-Gene
and	3	O
CP1	3	B-Gene
with	4	O
the	3	O
basal	5	O
transcription	13	O
machinery	9	O
in	2	O
the	3	O
presence	8	O
of	2	O
enhancer	8	O
sequences	9	O
.	1	O

Estrogen	8	B-Gene
receptor	8	I-Gene
concentration	13	O
and	3	O
social	6	O
factors	7	O
as	2	O
predictors	10	O
of	2	O
natural	7	O
killer	6	O
cell	4	O
activity	8	O
in	2	O
early-stage	11	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
.	1	O

Confirmation	12	O
of	2	O
a	1	O
model	5	O
.	1	O

Previous	8	O
work	4	O
of	2	O
ours	4	O
has	3	O
demonstrated	12	O
that	4	O
a	1	O
significant	11	O
amount	6	O
of	2	O
natural	7	O
killer	6	O
(	1	O
NK	2	O
)	1	O
activity	8	O
variance	8	O
after	5	O
surgery	7	O
in	2	O
stage	5	O
I	1	O
and	3	O
II	2	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
could	5	O
be	2	O
accounted	9	O
for	3	O
by	2	O
both	4	O
the	3	O
estrogen	8	B-Gene
receptor	8	I-Gene
(	1	O
ER	2	B-Gene
)	1	O
status	6	O
of	2	O
the	3	O
tumor	5	B-Disease
and	3	O
by	2	O
social	6	O
factors	7	O
,	1	O
namely	6	O
,	1	O
perceived	9	O
social	6	O
support	7	O
and	3	O
seeking	7	O
social	6	O
support	7	O
as	2	O
a	1	O
general	7	O
coping	6	O
strategy	8	O
.	1	O

As	2	O
considerable	12	O
evidence	8	O
has	3	O
accumulated	11	O
that	4	O
social	6	O
support	7	O
in	2	O
both	4	O
animal	6	O
and	3	O
human	5	O
populations	11	O
may	3	O
have	4	O
survival	8	O
value	5	O
,	1	O
we	2	O
sought	6	O
to	2	O
test	4	O
the	3	O
reliability	11	O
of	2	O
this	4	O
regression	10	O
model	5	O
,	1	O
using	5	O
coping	6	O
and	3	O
perceived	9	O
support	7	O
factor	6	O
values	6	O
obtained	8	O
at	2	O
3	1	O
months	6	O
after	5	O
surgery	7	O
to	2	O
account	7	O
for	3	O
concurrent	10	O
follow-up	9	O
NK	2	O
activity	8	O
in	2	O
this	4	O
serially	8	O
assessed	8	O
group	5	O
of	2	O
patients	8	O
.	1	O

It	2	O
was	3	O
found	5	O
that	4	O
the	3	O
most	4	O
significant	11	O
variable	8	O
predicting	10	O
NK	2	O
activity	8	O
at	2	O
follow-up	9	O
was	3	O
tumor	5	B-Disease
ER	2	B-Gene
concentration	13	O
,	1	O
with	4	O
higher	6	O
NK	2	O
activity	8	O
associated	10	O
with	4	O
ER	2	B-Gene
-status	7	O
.	1	O

In	2	O
addition	8	O
,	1	O
seeking	7	O
social	6	O
support	7	O
as	2	O
a	1	O
coping	6	O
strategy	8	O
,	1	O
as	2	O
well	4	O
as	2	O
the	3	O
perceived	9	O
quality	7	O
of	2	O
support	7	O
,	1	O
also	4	O
entered	7	O
the	3	O
model	5	O
to	2	O
account	7	O
for	3	O
a	1	O
significant	11	O
amount	6	O
of	2	O
NK	2	O
activity	8	O
variance	8	O
(	1	O
multivariate	12	O
F	1	O
=	1	O
5.25	4	O
,	1	O
p	1	O
less	4	O
than	4	O
0.001	5	O
)	1	O
.	1	O

If	2	O
,	1	O
as	2	O
the	3	O
literature	10	O
suggests	8	O
,	1	O
NK	2	O
activity	8	O
is	2	O
relevant	8	O
to	2	O
breast	6	B-Disease
cancer	6	I-Disease
control	7	O
,	1	O
and	3	O
since	5	O
ER	2	B-Gene
-tumors	7	B-Disease
have	4	O
a	1	O
worse	5	O
prognosis	9	O
,	1	O
we	2	O
suggest	7	O
here	4	O
that	4	O
perhaps	7	O
such	4	O
tumors	6	B-Disease
are	3	O
resistant	9	O
to	2	O
control	7	O
by	2	O
NK	2	O
cells	5	O
because	7	O
they	4	O
lack	4	O
the	3	O
ability	7	O
to	2	O
attract	7	O
an	2	O
accumulation	12	O
of	2	O
effector	8	O
cells	5	O
to	2	O
the	3	O
tumor	5	B-Disease
site	4	O
,	1	O
or	2	O
because	7	O
blocking	8	O
factors	7	O
at	2	O
the	3	O
site	4	O
of	2	O
the	3	O
tumor	5	B-Disease
prevent	7	O
local	5	O
tumor	5	B-Disease
control	7	O
at	2	O
the	3	O
site	4	O
of	2	O
action	6	O
.	1	O

The	3	O
finding	7	O
related	7	O
to	2	O
social	6	O
support	7	O
also	4	O
replicates	10	O
results	7	O
from	4	O
an	2	O
independent	11	O
sample	6	O
of	2	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
.	1	O

This	4	O
finding	7	O
,	1	O
taken	5	O
together	8	O
with	4	O
other	5	O
evidence	8	O
that	4	O
this	4	O
social	6	O
variable	8	O
is	2	O
associated	10	O
with	4	O
longer	6	O
survival	8	O
in	2	O
breast	6	B-Disease
cancer	6	I-Disease
populations	11	O
,	1	O
underscores	11	O
the	3	O
potential	9	O
importance	10	O
of	2	O
this	4	O
social	6	O
support	7	O
variable	8	O
.	1	O

Our	3	O
findings	8	O
also	4	O
suggest	7	O
one	3	O
possible	8	O
immunological	13	O
variable	8	O
involved	8	O
,	1	O
with	4	O
potential	9	O
clinical	8	O
significance	12	O
,	1	O
for	3	O
this	4	O
patient	7	O
population	10	O
.	1	O

Comparison	10	O
of	2	O
constitutive	12	O
and	3	O
inducible	9	O
transcriptional	15	O
enhancement	11	O
mediated	8	O
by	2	O
kappa	5	O
B	1	O
-related	8	O
sequences	9	O
:	1	O
modulation	10	O
of	2	O
activity	8	O
in	2	O
B	1	O
cells	5	O
by	2	O
human	5	B-Gene
T-cell	6	I-Gene
leukemia	8	I-Gene
virus	5	I-Gene
type	4	I-Gene
I	1	I-Gene
tax	3	I-Gene
gene	4	I-Gene
.	1	O

The	3	O
kappa	5	O
B	1	O
sequence	8	O
(	1	O
GGGACTTTCC	10	O
)	1	O
binds	5	O
a	1	O
factor	6	O
,	1	O
NF-kappa	8	B-Gene
B	1	I-Gene
,	1	O
that	4	O
is	2	O
constitutively	14	O
found	5	O
in	2	O
its	3	O
functional	10	O
,	1	O
DNA	3	O
binding	7	O
form	4	O
only	4	O
in	2	O
B	1	O
lymphocytes	11	O
.	1	O

A	1	O
factor	6	O
with	4	O
apparently	10	O
indistinguishable	17	O
sequence	8	O
specificity	11	O
can	3	O
be	2	O
induced	7	O
in	2	O
many	4	O
other	5	O
cell	4	O
types	5	O
,	1	O
where	5	O
it	2	O
is	2	O
used	4	O
to	2	O
regulate	8	O
inducible	9	O
gene	4	O
expression	10	O
.	1	O

For	3	O
example	7	O
,	1	O
kappa	5	O
B	1	O
-related	8	O
sequences	9	O
have	4	O
been	4	O
shown	5	O
to	2	O
be	2	O
important	9	O
for	3	O
the	3	O
transcription	13	O
of	2	O
a	1	O
few	3	O
inducible	9	O
genes	5	O
,	1	O
such	4	O
as	2	O
the	3	O
interleukin	11	B-Gene
2	1	I-Gene
receptor	8	I-Gene
alpha-chain	11	I-Gene
gene	4	I-Gene
and	3	O
the	3	O
beta-interferon	15	B-Gene
gene	4	I-Gene
.	1	O

However	7	O
,	1	O
these	5	O
genes	5	O
are	3	O
not	3	O
constitutively	14	O
active	6	O
in	2	O
B	1	O
lymphocytes	11	O
,	1	O
suggesting	10	O
that	4	O
other	5	O
regulatory	10	O
mechanisms	10	O
must	4	O
play	4	O
a	1	O
role	4	O
in	2	O
determining	11	O
the	3	O
patterns	8	O
of	2	O
expression	10	O
.	1	O

We	2	O
have	4	O
investigated	12	O
the	3	O
constitutive	12	O
and	3	O
inducible	9	O
transcriptional	15	O
activity	8	O
mediated	8	O
by	2	O
five	4	O
kappa	5	O
B	1	O
-related	8	O
sequence	8	O
elements	8	O
in	2	O
two	3	O
different	9	O
cell	4	O
types	5	O
.	1	O

We	2	O
show	4	O
that	4	O
in	2	O
S194	4	O
plasma	6	O
cells	5	O
the	3	O
activity	8	O
of	2	O
each	4	O
element	7	O
correlates	10	O
well	4	O
with	4	O
the	3	O
relative	8	O
affinity	8	O
of	2	O
B-cell	6	O
-derived	8	O
NF-kappa	8	B-Gene
B	1	I-Gene
for	3	O
that	4	O
element	7	O
.	1	O

This	4	O
leads	5	O
to	2	O
significantly	13	O
lower	5	O
transcription	13	O
enhancement	11	O
by	2	O
sites	5	O
derived	7	O
from	4	O
the	3	O
interleukin	11	B-Gene
2	1	I-Gene
receptor	8	I-Gene
or	2	O
T-cell	6	B-Gene
receptor	8	I-Gene
genes	5	I-Gene
in	2	O
S194	4	O
cells	5	O
.	1	O

However	7	O
,	1	O
in	2	O
either	6	O
EL-4	4	O
(	1	O
T	1	O
)	1	O
cells	5	O
or	2	O
S194	4	O
cells	5	O
,	1	O
both	4	O
lower-affinity	14	O
sites	5	O
can	3	O
be	2	O
significantly	13	O
induced	7	O
by	2	O
the	3	O
tax	3	B-Gene
gene	4	I-Gene
product	7	I-Gene
of	2	O
human	5	O
T-cell	6	B-Disease
leukemia	8	I-Disease
virus	5	O
type	4	O
I	1	O
,	1	O
showing	7	O
that	4	O
NF-kappa	8	B-Gene
B	1	I-Gene
activity	8	O
can	3	O
be	2	O
modulated	9	O
even	4	O
in	2	O
a	1	O
B-cell	6	O
line	4	O
that	4	O
constitutively	14	O
expresses	9	O
this	4	O
factor	6	O
.	1	O

Isolation	9	O
of	2	O
a	1	O
rel	3	B-Gene
-related	8	O
human	5	O
cDNA	4	O
that	4	O
potentially	11	O
encodes	7	O
the	3	O
65-kD	5	O
subunit	7	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
[	1	O
published	9	O
erratum	7	O
appears	7	O
in	2	O
Science	7	O
1991	4	O
Oct	3	O
4	1	O
;	1	O
254	3	O
(	1	O
5028	4	O
)	1	O
:	1	O
11	2	O
]	1	O

A	1	O
DNA	3	O
probe	5	O
that	4	O
spanned	7	O
a	1	O
domain	6	O
conserved	9	O
among	5	O
the	3	O
proto-oncogene	14	B-Gene
c-rel	5	I-Gene
,	1	O
the	3	O
Drosophila	10	O
morphogen	9	O
dorsal	6	O
,	1	O
and	3	O
the	3	O
p50	3	B-Gene
DNA	3	I-Gene
binding	7	O
subunit	7	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
was	3	O
generated	9	O
from	4	O
Jurkat	6	O
T	1	O
cell	4	O
complementary	13	O
DNA	3	O
with	4	O
the	3	O
polymerase	10	O
chain	5	O
reaction	8	O
(	1	O
PCR	3	O
)	1	O
and	3	O
degenerate	10	O
oligonucleotides	16	O
.	1	O

This	4	O
probe	5	O
was	3	O
used	4	O
to	2	O
identify	8	O
a	1	O
rel	3	B-Gene
-related	8	O
complementary	13	O
DNA	3	O
that	4	O
hybridized	10	O
to	2	O
a	1	O
2.6-kilobase	12	O
messenger	9	O
RNA	3	O
present	7	O
in	2	O
human	5	O
T	1	O
and	3	O
B	1	O
lymphocytes	11	O
.	1	O

In	2	O
vitro	5	O
transcription	13	O
and	3	O
translation	11	O
of	2	O
the	3	O
complementary	13	O
DNA	3	O
resulted	8	O
in	2	O
the	3	O
synthesis	9	O
of	2	O
a	1	O
protein	7	O
with	4	O
an	2	O
apparent	8	O
molecular	9	O
size	4	O
of	2	O
65	2	O
kilodaltons	11	O
(	1	O
kD	2	O
)	1	O
.	1	O

The	3	O
translated	10	O
protein	7	O
showed	6	O
weak	4	O
DNA	3	O
binding	7	O
with	4	O
a	1	O
specificity	11	O
for	3	O
the	3	O
kappa	5	O
B	1	O
binding	7	O
motif	5	O
.	1	O

This	4	O
protein-DNA	11	O
complex	7	O
comigrated	10	O
with	4	O
the	3	O
complex	7	O
obtained	8	O
with	4	O
the	3	O
purified	8	O
human	5	B-Gene
p65	3	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
subunit	7	I-Gene
and	3	O
binding	7	O
was	3	O
inhibited	9	O
by	2	O
I	1	B-Gene
kappa	5	I-Gene
B-alpha	7	I-Gene
and	3	O
-beta	5	B-Partial_Gene
proteins	8	I-Partial_Gene
.	1	O

In	2	O
addition	8	O
,	1	O
the	3	O
65-kD	5	O
protein	7	O
associated	10	O
with	4	O
the	3	O
p50	3	B-Gene
subunit	7	I-Gene
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
and	3	O
the	3	O
kappa	5	O
B	1	O
probe	5	O
to	2	O
form	4	O
a	1	O
complex	7	O
with	4	O
the	3	O
same	4	O
electrophoretic	15	O
mobility	8	O
as	2	O
the	3	O
NF-kappa	8	B-Gene
B-DNA	5	I-Gene
complex	7	I-Gene
.	1	O

Therefore	9	O
the	3	O
rel	3	B-Gene
-related	8	O
65-kD	5	O
protein	7	O
may	3	O
represent	9	O
the	3	O
p65	3	B-Gene
subunit	7	I-Gene
of	2	O
the	3	O
active	6	O
NF-kappa	8	B-Gene
B	1	I-Gene
transcription	13	I-Gene
factor	6	I-Gene
complex	7	I-Gene
.	1	O

Lymphocyte	10	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
number	6	O
in	2	O
posttraumatic	13	B-Disease
stress	6	I-Disease
disorder	8	I-Disease
.	1	O

OBJECTIVE	9	O
:	1	O
The	3	O
authors	7	O
'objective	10	O
was	3	O
to	2	O
investigate	11	O
the	3	O
possibility	11	O
that	4	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
changes	7	O
may	3	O
be	2	O
involved	8	O
in	2	O
the	3	O
dysregulation	13	O
of	2	O
the	3	O
hypothalamic-pituitary-adrenal	30	O
(	1	O
HPA	3	O
)	1	O
axis	4	O
in	2	O
posttraumatic	13	B-Disease
stress	6	I-Disease
disorder	8	I-Disease
(	1	O
PTSD	4	B-Disease
)	1	O
.	1	O

METHOD	6	O
:	1	O
They	4	O
measured	8	O
the	3	O
number	6	O
of	2	O
lymphocyte	10	O
cytosolic	9	B-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
and	3	O
plasma	6	O
cortisol	8	B-Chemical
concentrations	14	O
in	2	O
15	2	O
consecutively	13	O
admitted	8	O
male	4	O
combat	6	O
Vietnam	7	O
veterans	8	O
with	4	O
PTSD	4	B-Disease
and	3	O
in	2	O
a	1	O
normal	6	O
comparison	10	O
group	5	O
of	2	O
11	2	O
subjects	8	O
.	1	O

RESULTS	7	O
:	1	O
Both	4	O
the	3	O
patients	8	O
and	3	O
the	3	O
normal	6	O
comparison	10	O
subjects	8	O
showed	6	O
a	1	O
morning-to-afternoon	20	O
decline	7	O
in	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
concentrations	14	O
,	1	O
paralleling	11	O
the	3	O
normal	6	O
diurnal	7	O
decline	7	O
in	2	O
cortisol	8	B-Chemical
levels	6	O
.	1	O

The	3	O
number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
was	3	O
63	2	O
%	1	O
greater	7	O
in	2	O
the	3	O
morning	7	O
and	3	O
26	2	O
%	1	O
greater	7	O
in	2	O
the	3	O
afternoon	9	O
in	2	O
the	3	O
patients	8	O
with	4	O
PTSD	4	B-Disease
than	4	O
in	2	O
the	3	O
normal	6	O
subjects	8	O
.	1	O

No	2	O
group	5	O
differences	11	O
in	2	O
cortisol	8	B-Chemical
levels	6	O
were	4	O
observed	8	O
,	1	O
nor	3	O
were	4	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
number	6	O
and	3	O
cortisol	8	B-Chemical
levels	6	O
correlated	10	O
.	1	O

The	3	O
number	6	O
of	2	O
morning	7	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
was	3	O
positively	10	O
correlated	10	O
with	4	O
symptoms	8	O
of	2	O
PTSD	4	B-Disease
and	3	O
anxiety	7	B-Disease
.	1	O

CONCLUSIONS	11	O
:	1	O
These	5	O
results	7	O
provide	7	O
further	7	O
evidence	8	O
for	3	O
a	1	O
dysregulation	13	O
of	2	O
the	3	O
HPA	3	O
axis	4	O
in	2	O
PTSD	4	B-Disease
.	1	O

The	3	O
finding	7	O
that	4	O
patients	8	O
with	4	O
PTSD	4	B-Disease
had	3	O
a	1	O
substantially	13	O
greater	7	O
number	6	O
of	2	O
lymphocyte	10	B-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
than	4	O
normal	6	O
comparison	10	O
subjects	8	O
is	2	O
consistent	10	O
with	4	O
the	3	O
authors	7	O
'previous	9	O
observations	12	O
of	2	O
low	3	O
24-hour	7	O
urinary	7	O
cortisol	8	B-Chemical
excretion	9	O
in	2	O
subjects	8	O
with	4	O
PTSD	4	B-Disease
.	1	O

Furthermore	11	O
,	1	O
the	3	O
receptor	8	O
changes	7	O
observed	8	O
are	3	O
opposite	8	O
of	2	O
those	5	O
reported	8	O
in	2	O
major	5	B-Disease
depressive	10	I-Disease
disorder	8	I-Disease
.	1	O

The	3	O
present	7	O
data	4	O
,	1	O
along	5	O
with	4	O
other	5	O
findings	8	O
of	2	O
HPA	3	O
abnormalities	13	O
in	2	O
PTSD	4	B-Disease
,	1	O
support	7	O
the	3	O
possibility	11	O
of	2	O
a	1	O
greater	7	O
negative	8	O
feedback	8	O
sensitivity	11	O
at	2	O
one	3	O
or	2	O
more	4	O
levels	6	O
of	2	O
the	3	O
HPA	3	O
axis	4	O
.	1	O

Sex	3	O
and	3	O
age	3	O
distribution	12	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptors	9	I-Gene
in	2	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
from	4	O
normal	6	O
human	5	O
subjects	8	O
.	1	O

Specific	8	O
receptors	9	O
for	3	O
1	1	B-Chemical
,	1	I-Chemical
25	2	I-Chemical
Dihydroxyvitamin	16	I-Chemical
D3	2	I-Chemical
have	4	O
been	4	O
described	9	O
in	2	O
human	5	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
(	1	O
PBMC	4	O
)	1	O
.	1	O

We	2	O
have	4	O
tried	5	O
to	2	O
find	4	O
out	3	O
whether	7	O
these	5	O
receptors	9	O
could	5	O
show	4	O
any	3	O
difference	10	O
in	2	O
sex	3	O
or	2	O
age	3	O
distribution	12	O
.	1	O

Twenty	6	O
two	3	O
healthy	7	O
men	3	O
aged	4	O
21-66	5	O
yr	2	O
(	1	O
mean	4	O
+	1	O
/	1	O
-	1	O
SD	2	O
41.0	4	O
+	1	O
/	1	O
-	1	O
13.6	4	O
)	1	O
and	3	O
nineteen	8	O
healthy	7	O
women	5	O
aged	4	O
22-60	5	O
yr	2	O
(	1	O
38.9	4	O
+	1	O
/	1	O
-	1	O
13.9	4	O
)	1	O
have	4	O
been	4	O
studied	7	O
.	1	O

The	3	O
mean	4	O
dissociation	12	O
constant	8	O
(	1	O
Kd	2	O
)	1	O
was	3	O
similar	7	O
in	2	O
both	4	O
sexes	5	O
(	1	O
1.35	4	O
+	1	O
/	1	O
-	1	O
0.70	4	O
x	1	O
10	2	O
(	1	O
-10	3	O
)	1	O
M	1	O
in	2	O
males	5	O
,	1	O
1.13	4	O
+	1	O
/	1	O
-	1	O
0.66	4	O
x	1	O
10	2	O
(	1	O
-10	3	O
)	1	O
M	1	O
in	2	O
females	7	O
)	1	O
,	1	O
but	3	O
the	3	O
concentration	13	O
of	2	O
binding	7	O
sites	5	O
(	1	O
Nmax	4	O
)	1	O
was	3	O
significantly	13	O
lower	5	O
in	2	O
females	7	O
(	1	O
2.32	4	O
+	1	O
/	1	O
-	1	O
0.92	4	O
fmol	4	O
/	1	O
10	2	O
(	1	O
7	1	O
)	1	O
PBMC	4	O
vs	2	O
4.43	4	O
+	1	O
/	1	O
-	1	O
1.38	4	O
fmol	4	O
/	1	O
10	2	O
(	1	O
7	1	O
)	1	O
PBMC	4	O
in	2	O
males	5	O
;	1	O
p	1	O
=	1	O
0.0001	6	O
)	1	O
.	1	O

Neither	7	O
Kd	2	O
nor	3	O
Nmax	4	O
were	4	O
significantly	13	O
correlated	10	O
with	4	O
age	3	O
.	1	O

No	2	O
difference	10	O
was	3	O
found	5	O
between	7	O
pre	3	O
and	3	O
postmenopausal	14	O
women	5	O
.	1	O

Further	7	O
studies	7	O
are	3	O
needed	6	O
to	2	O
elucidate	9	O
if	2	O
this	4	O
sex	3	O
difference	10	O
in	2	O
PBMC	4	O
receptors	9	O
for	3	O
1.25	4	B-Chemical
Dihydroxyvitamin	16	I-Chemical
D3	2	I-Chemical
is	2	O
of	2	O
any	3	O
pathophysiological	18	O
relevance	9	O
.	1	O

Transcriptional	15	O
down-regulation	15	O
of	2	O
c-myc	5	B-Gene
expression	10	O
by	2	O
protein	7	O
synthesis	9	O
-dependent	10	O
and	3	O
-independent	12	O
pathways	8	O
in	2	O
a	1	O
human	5	O
T	1	B-Disease
lymphoblastic	13	I-Disease
tumor	5	I-Disease
cell	4	O
line	4	O
.	1	O

We	2	O
show	4	O
that	4	O
in	2	O
the	3	O
human	5	O
T	1	B-Disease
lymphoblastic	13	I-Disease
tumor	5	I-Disease
cell	4	O
line	4	O
Molt4	5	O
c-myc	5	B-Gene
mRNA	4	I-Gene
and	3	O
protein	7	O
expression	10	O
is	2	O
down	4	O
-regulated	10	O
after	5	O
exposure	8	O
to	2	O
dimethyl	8	B-Chemical
sulfoxide	9	I-Chemical
,	1	O
to	2	O
phorbol	7	B-Chemical
myristate	9	I-Chemical
acetate	7	I-Chemical
,	1	O
or	2	O
to	2	O
the	3	O
calcium	7	B-Chemical
ionophore	9	O
A23187	6	B-Chemical
,	1	O
which	5	O
raises	6	O
the	3	O
intracellular	13	O
calcium	7	B-Chemical
concentration	13	O
.	1	O

A	1	O
block	5	O
to	2	O
RNA	3	O
elongation	10	O
is	2	O
largely	7	O
responsible	11	O
for	3	O
decreased	9	O
c-myc	5	B-Gene
transcription	13	O
.	1	O

Although	8	O
negative	8	O
regulation	10	O
by	2	O
dimethyl	8	B-Chemical
sulfoxide	9	I-Chemical
takes	5	O
place	5	O
even	4	O
when	4	O
protein	7	O
synthesis	9	O
is	2	O
inhibited	9	O
by	2	O
cycloheximide	13	B-Chemical
,	1	O
the	3	O
phorbol	7	B-Chemical
myristate	9	I-Chemical
acetate	7	I-Chemical
effect	6	O
is	2	O
blocked	7	O
to	2	O
some	4	O
extent	6	O
only	4	O
by	2	O
cycloheximide	13	B-Chemical
.	1	O

The	3	O
calcium	7	B-Chemical
ionophore	9	O
-induced	8	O
c-myc	5	B-Gene
suppression	11	O
,	1	O
however	7	O
,	1	O
strictly	8	O
requires	8	O
de	2	O
novo	4	O
protein	7	O
synthesis	9	O
.	1	O

Therefore	9	O
,	1	O
two	3	O
different	9	O
negative	8	O
regulatory	10	O
pathways	8	O
are	3	O
involved	8	O
in	2	O
c-myc	5	B-Gene
regulation	10	O
:	1	O
one	3	O
which	5	O
is	2	O
independent	11	O
and	3	O
one	3	O
which	5	O
depends	7	O
on	2	O
de	2	O
novo	4	O
protein	7	O
synthesis	9	O
.	1	O

The	3	O
latter	6	O
one	3	O
appears	7	O
to	2	O
be	2	O
mediated	8	O
by	2	O
a	1	O
rapidly	7	O
calcium	7	B-Chemical
-dependent	10	O
induced	7	O
gene	4	O
product	7	O
.	1	O

Human	5	O
immunodeficiency	16	O
virus	5	O
type-2	6	O
gene	4	O
expression	10	O
:	1	O
two	3	O
enhancers	9	O
and	3	O
their	5	O
activation	10	O
by	2	O
T-cell	6	O
activators	10	O
.	1	O

The	3	O
human	5	O
immunodeficiency	16	O
viruses	7	O
(	1	O
HIVs	4	O
)	1	O
may	3	O
include	7	O
a	1	O
spectrum	8	O
of	2	O
retroviruses	12	O
with	4	O
varying	7	O
potential	9	O
to	2	O
infect	6	O
their	5	O
host	4	O
,	1	O
undergo	7	O
long	4	O
periods	7	O
of	2	O
latent	6	O
infection	9	O
,	1	O
and	3	O
induce	6	O
pathology	9	O
.	1	O

Since	5	O
expression	10	O
of	2	O
the	3	O
viruses	7	O
is	2	O
in	2	O
large	5	O
part	4	O
regulated	9	O
by	2	O
the	3	O
sequence	8	O
elements	8	O
in	2	O
their	5	O
long	4	O
terminal	8	O
repeats	7	O
(	1	O
LTRs	4	O
)	1	O
,	1	O
this	4	O
study	5	O
was	3	O
directed	8	O
to	2	O
an	2	O
analysis	8	O
of	2	O
the	3	O
regulatory	10	O
elements	8	O
in	2	O
the	3	O
HIV-2	5	O
LTR	3	O
.	1	O

The	3	O
HIV-2	5	O
LTR	3	O
was	3	O
found	5	O
to	2	O
contain	7	O
two	3	O
enhancers	9	O
.	1	O

One	3	O
of	2	O
these	5	O
enhancers	9	O
is	2	O
,	1	O
in	2	O
part	4	O
,	1	O
identical	9	O
to	2	O
the	3	O
HIV-1	5	O
enhancer	8	O
.	1	O

This	4	O
enhancer	8	O
in	2	O
HIV-1	5	O
is	2	O
the	3	O
T-cell	6	O
activation	10	O
response	8	O
element	7	O
;	1	O
in	2	O
HIV-2	5	O
,	1	O
however	7	O
,	1	O
it	2	O
is	2	O
the	3	O
second	6	O
enhancer	8	O
that	4	O
is	2	O
mainly	6	O
responsible	11	O
for	3	O
activation	10	O
in	2	O
response	8	O
to	2	O
T-cell	6	O
activators	10	O
.	1	O

The	3	O
second	6	O
enhancer	8	O
interacts	9	O
with	4	O
two	3	O
nuclear	7	O
binding	7	O
proteins	8	O
(	1	O
85	2	O
kD	2	O
and	3	O
27	2	O
kD	2	O
mobility	8	O
)	1	O
that	4	O
appear	6	O
to	2	O
be	2	O
required	8	O
for	3	O
optimal	7	O
enhancer	8	O
function	8	O
and	3	O
activation	10	O
.	1	O

Observations	12	O
such	4	O
as	2	O
these	5	O
encourage	9	O
the	3	O
speculation	11	O
that	4	O
there	5	O
may	3	O
be	2	O
subtle	6	O
differences	11	O
in	2	O
the	3	O
regulation	10	O
of	2	O
HIV-1	5	O
and	3	O
HIV-2	5	O
expression	10	O
that	4	O
may	3	O
be	2	O
relevant	8	O
to	2	O
the	3	O
possible	8	O
longer	6	O
latency	7	O
and	3	O
reduced	7	O
pathogenicity	13	O
of	2	O
HIV-2	5	O
.	1	O

Suppression	11	O
of	2	O
signals	7	O
required	8	O
for	3	O
activation	10	O
of	2	O
transcription	13	B-Gene
factor	6	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
in	2	O
cells	5	O
constitutively	14	O
expressing	10	O
the	3	O
HTLV-I	6	B-Gene
Tax	3	I-Gene
protein	7	I-Gene
.	1	O

Transient	9	O
short-term	10	O
expression	10	O
of	2	O
the	3	O
Tax	3	B-Gene
protein	7	I-Gene
of	2	O
human	5	O
T-cell	6	B-Disease
leukemia	8	I-Disease
virus	5	O
type-I	6	O
(	1	O
HTLV-I	6	O
)	1	O
leads	5	O
to	2	O
activation	10	O
of	2	O
the	3	O
pleiotropic	11	O
transcription	13	B-Gene
factor	6	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
.	1	O

Consistent	10	O
with	4	O
findings	8	O
obtained	8	O
with	4	O
transient	9	O
expression	10	O
assays	6	O
,	1	O
we	2	O
observed	8	O
marked	6	O
accumulation	12	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
in	2	O
the	3	O
nucleus	7	O
of	2	O
Namalwa	7	O
B	1	O
lymphoid	8	O
cells	5	O
,	1	O
which	5	O
constitutively	14	O
express	7	O
Tax	3	B-Gene
.	1	O

In	2	O
contrast	8	O
,	1	O
NF-kappa	8	B-Gene
B	1	I-Gene
activity	8	O
was	3	O
not	3	O
detected	8	O
in	2	O
the	3	O
nucleus	7	O
following	9	O
long-term	9	O
expression	10	O
of	2	O
Tax	3	B-Gene
in	2	O
Jurkat	6	O
T	1	O
lymphocytes	11	O
.	1	O

The	3	O
ability	7	O
of	2	O
both	4	O
mitogens	8	O
and	3	O
cytokines	9	O
to	2	O
activate	8	O
NF-kappa	8	B-Gene
B	1	I-Gene
was	3	O
also	4	O
blocked	7	O
in	2	O
Jurkat	6	O
cells	5	O
constitutively	14	O
expressing	10	O
Tax	3	B-Gene
.	1	O

However	7	O
,	1	O
the	3	O
activation	10	O
of	2	O
other	5	O
mitogen-inducible	17	O
transcription	13	O
factors	7	O
,	1	O
such	4	O
as	2	O
Fos	3	B-Gene
and	3	O
Jun	3	B-Gene
,	1	O
was	3	O
unaffected	10	O
.	1	O

Thus	4	O
,	1	O
depending	9	O
on	2	O
the	3	O
cellular	8	O
environment	11	O
,	1	O
the	3	O
short-	6	O
and	3	O
long-term	9	O
effects	7	O
of	2	O
Tax	3	B-Gene
expression	10	O
can	3	O
be	2	O
quite	5	O
different	9	O
.	1	O

Consequently	12	O
,	1	O
one	3	O
function	8	O
of	2	O
Tax	3	B-Gene
in	2	O
cells	5	O
infected	8	O
with	4	O
HTLV-I	6	O
might	5	O
involve	7	O
cell-type-specific	18	O
suppression	11	O
,	1	O
as	2	O
opposed	7	O
to	2	O
activation	10	O
,	1	O
of	2	O
distinct	8	O
signal	6	O
pathways	8	O
.	1	O

The	3	O
cells	5	O
lines	5	O
described	9	O
here	4	O
should	6	O
be	2	O
useful	6	O
for	3	O
the	3	O
delineation	11	O
of	2	O
signaling	9	O
pathways	8	O
utilized	8	O
in	2	O
the	3	O
selective	9	O
regulation	10	O
of	2	O
gene	4	O
expression	10	O
.	1	O

A	1	O
thymus-specific	15	O
member	6	O
of	2	O
the	3	O
HMG	3	B-Gene
protein	7	I-Gene
family	6	I-Gene
regulates	9	O
the	3	O
human	5	B-Gene
T	1	I-Gene
cell	4	I-Gene
receptor	8	I-Gene
C	1	I-Gene
alpha	5	I-Gene
enhancer	8	I-Gene
.	1	O

The	3	O
human	5	B-Gene
T	1	I-Gene
cell-specific	13	I-Gene
transcription	13	I-Gene
factor	6	I-Gene
TCF-1	5	I-Gene
alpha	5	I-Gene
plays	5	O
a	1	O
key	3	O
role	4	O
in	2	O
the	3	O
tissue-specific	15	O
activation	10	O
of	2	O
the	3	O
T	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
(	1	I-Gene
TCR	3	I-Gene
)	1	I-Gene
C	1	I-Gene
alpha	5	I-Gene
enhancer	8	I-Gene
and	3	O
binds	5	O
to	2	O
pyrimidine-rich	15	B-Chemical
elements	8	O
(	1	O
5'-PyCTTTG-3')	14	O
present	7	O
in	2	O
a	1	O
variety	7	O
of	2	O
other	5	O
T	1	O
cell-specific	13	O
control	7	O
regions	7	O
.	1	O

Using	5	O
amino	5	O
acid	4	O
sequence	8	O
information	11	O
derived	7	O
from	4	O
the	3	O
DNA	3	O
affinity	8	O
-purified	9	O
protein	7	O
,	1	O
we	2	O
have	4	O
now	3	O
isolated	8	O
cDNA	4	O
clones	6	O
encoding	8	O
TCF-1	5	B-Gene
alpha	5	I-Gene
.	1	O

The	3	O
TCF-1	5	B-Gene
alpha	5	I-Gene
cDNA	4	I-Gene
contains	8	O
a	1	O
single	6	O
68-amino-acid	13	O
domain	6	O
that	4	O
is	2	O
homologous	10	O
to	2	O
a	1	O
region	6	O
conserved	9	O
among	5	O
high-mobility	13	B-Gene
group	5	I-Gene
(	1	O
HMG	3	B-Gene
)	1	O
and	3	O
nonhistone	10	O
chromosomal	11	O
proteins	8	O
.	1	O

Expression	10	O
of	2	O
full-length	11	O
and	3	O
mutant	6	O
cDNA	4	O
clones	6	O
in	2	O
bacteria	8	O
reveal	6	O
that	4	O
the	3	O
single	6	O
HMG	3	B-Gene
motif	5	O
,	1	O
which	5	O
is	2	O
predicted	9	O
to	2	O
contain	7	O
two	3	O
extended	8	O
alpha-helical	13	O
segments	8	O
,	1	O
is	2	O
sufficient	10	O
to	2	O
direct	6	O
the	3	O
sequence-specific	17	O
binding	7	O
of	2	O
TCF-1	5	B-Gene
alpha	5	I-Gene
to	2	O
DNA	3	O
.	1	O

Northern	8	O
blot	4	O
experiments	11	O
demonstrate	11	O
further	7	O
that	4	O
TCF-1	5	B-Gene
alpha	5	I-Gene
mRNA	4	I-Gene
is	2	O
highly	6	O
tissue	6	O
specific	8	O
,	1	O
found	5	O
primarily	9	O
in	2	O
the	3	O
thymus	6	O
or	2	O
T	1	O
cell	4	O
lines	5	O
.	1	O

The	3	O
immature	8	O
CEM	3	O
T	1	O
cell	4	O
line	4	O
expresses	9	O
relatively	10	O
low	3	O
levels	6	O
of	2	O
TCF-1	5	B-Gene
alpha	5	I-Gene
mRNA	4	I-Gene
,	1	O
which	5	O
are	3	O
increased	9	O
upon	4	O
activation	10	O
of	2	O
these	5	O
cells	5	O
by	2	O
phorbol	7	B-Chemical
esters	6	I-Chemical
.	1	O

Interestingly	13	O
,	1	O
the	3	O
cloned	6	O
TCF-1	5	B-Gene
alpha	5	I-Gene
protein	7	I-Gene
is	2	O
a	1	O
potent	6	O
transcriptional	15	O
activator	9	O
of	2	O
the	3	O
human	5	B-Gene
TCR	3	I-Gene
alpha	5	I-Gene
enhancer	8	I-Gene
in	2	O
nonlymphoid	11	O
cell	4	O
lines	5	O
,	1	O
whereas	7	O
the	3	O
activity	8	O
of	2	O
the	3	O
endogenous	10	O
protein	7	O
in	2	O
T	1	O
cell	4	O
lines	5	O
is	2	O
strongly	8	O
dependent	9	O
on	2	O
an	2	O
additional	10	O
T	1	O
cell-specific	13	O
protein	7	O
that	4	O
interacts	9	O
with	4	O
the	3	O
core	4	O
enhancer	8	O
.	1	O

TCF-1	5	B-Gene
alpha	5	I-Gene
is	2	O
currently	9	O
unique	6	O
among	5	O
the	3	O
newly	5	O
emerging	8	O
family	6	O
of	2	O
DNA	3	O
-binding	8	O
regulatory	10	O
proteins	8	O
that	4	O
share	5	O
the	3	O
HMG	3	B-Gene
motif	5	O
in	2	O
that	4	O
it	2	O
is	2	O
a	1	O
highly	6	O
tissue-specific	15	O
RNA	3	O
polymerase	10	O
II	2	O
transcription	13	O
factor	6	O
.	1	O

Immune	6	O
response	8	O
of	2	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
to	2	O
HBx-antigen	11	B-Gene
of	2	O
hepatitis	9	B-Disease
B	1	I-Disease
virus	5	O
.	1	O

The	3	O
hepatitis	9	B-Disease
B	1	I-Disease
virus	5	O
genome	6	O
encodes	7	O
a	1	O
transcriptional	15	O
transactivator	14	O
protein	7	O
designated	10	O
HBxAg	5	B-Gene
.	1	O

We	2	O
have	4	O
investigated	12	O
whether	7	O
this	4	O
antigen	7	O
is	2	O
a	1	O
target	6	O
structure	9	O
for	3	O
human	5	O
T-lymphocytes	13	O
.	1	O

Using	5	O
recombinant	11	B-Gene
HBxAg	5	I-Gene
protein	7	I-Gene
,	1	O
we	2	O
found	5	O
HBxAg	5	B-Gene
-specific	9	O
stimulation	11	O
of	2	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
in	2	O
patients	8	O
with	4	O
acute	5	B-Disease
hepatitis	9	I-Disease
B	1	I-Disease
virus	5	O
infection	9	O
(	1	O
6	1	O
of	2	O
6	1	O
)	1	O
and	3	O
chronic	7	B-Disease
hepatitis	9	I-Disease
B	1	I-Disease
virus	5	O
infection	9	O
(	1	O
6	1	O
of	2	O
17	2	O
)	1	O
but	3	O
not	3	O
in	2	O
healthy	7	O
individuals	11	O
.	1	O

With	4	O
HBxAg	5	B-Gene
-specific	9	O
synthetic	9	O
polypeptides	12	O
,	1	O
several	7	O
T-cell	6	O
epitopes	8	O
were	4	O
identified	10	O
.	1	O

Most	4	O
were	4	O
located	7	O
in	2	O
the	3	O
carboxyterminal	15	O
half	4	O
of	2	O
the	3	O
HBxAg	5	B-Gene
protein	7	I-Gene
.	1	O

Five	4	O
T-cell	6	O
clones	6	O
specific	8	O
for	3	O
a	1	O
T-cell	6	O
epitope	7	O
located	7	O
at	2	O
the	3	O
carboxyterminal	15	O
region	6	O
of	2	O
HBxAg	5	B-Gene
were	4	O
established	11	O
and	3	O
found	5	O
to	2	O
belong	6	O
to	2	O
the	3	O
CD2	3	B-Gene
/	1	I-Gene
CD4	3	I-Gene
-positive	9	O
,	1	O
CD8	3	B-Gene
-negative	9	O
subtype	7	O
.	1	O

These	5	O
data	4	O
establish	9	O
for	3	O
the	3	O
first	5	O
time	4	O
HBxAg	5	B-Gene
as	2	O
an	2	O
antigen	7	O
in	2	O
the	3	O
cellular	8	O
immune	6	O
response	8	O
.	1	O

A	1	O
study	5	O
on	2	O
the	3	O
circadian	9	O
rhythm	6	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
.	1	O

Circadian	9	O
rhythm	6	O
in	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
was	3	O
studied	7	O
in	2	O
the	3	O
rat	3	O
liver	5	O
and	3	O
human	5	O
peripheral	10	O
leukocytes	10	O
.	1	O

For	3	O
rats	4	O
exposed	7	O
to	2	O
a	1	O
natural	7	O
environmental	13	O
photic	6	O
cycle	5	O
or	2	O
a	1	O
12L	3	O
:	1	O
12D	3	O
artificial	10	O
light	5	O
regime	6	O
,	1	O
peak	4	O
values	6	O
of	2	O
hepatic	7	B-Gene
GR	2	I-Gene
were	4	O
detected	8	O
between	7	O
23	2	O
:	1	O
00	2	O
and	3	O
02	2	O
:	1	O
00	2	O
h	1	O
.	1	O

Except	6	O
for	3	O
a	1	O
4-hour	6	O
advancement	11	O
of	2	O
the	3	O
peak	4	O
,	1	O
a	1	O
similar	7	O
circadian	9	O
rhythm	6	O
of	2	O
hepatic	7	B-Gene
GR	2	I-Gene
was	3	O
detected	8	O
in	2	O
rats	4	O
reared	6	O
under	5	O
a	1	O
reversed	8	O
lighting	8	O
regimen	7	O
(	1	O
12D	3	O
:	1	O
12L	3	O
;	1	O
lights	6	O
on	2	O
between	7	O
18	2	O
:	1	O
30	2	O
and	3	O
06	2	O
:	1	O
30	2	O
h	1	O
)	1	O
.	1	O

In	2	O
human	5	O
leukocytes	10	O
,	1	O
the	3	O
peak	4	O
value	5	O
of	2	O
GR	2	B-Gene
was	3	O
found	5	O
to	2	O
parallel	8	O
that	4	O
of	2	O
plasma	6	O
cortisol	8	B-Chemical
with	4	O
high	4	O
and	3	O
low	3	O
values	6	O
detected	8	O
at	2	O
04	2	O
:	1	O
00-08	5	O
:	1	O
00	2	O
h	1	O
and	3	O
23	2	O
:	1	O
00-24	5	O
:	1	O
00	2	O
h	1	O
,	1	O
respectively	12	O
.	1	O

In	2	O
patients	8	O
suffering	9	O
from	4	O
Cushing	7	B-Disease
's	2	I-Disease
syndrome	8	I-Disease
,	1	O
the	3	O
circadian	9	O
rhythm	6	O
of	2	O
plasma	6	O
cortisol	8	B-Chemical
either	6	O
disappeared	11	O
or	2	O
was	3	O
inverted	8	O
while	5	O
that	4	O
of	2	O
GR	2	B-Gene
did	3	O
not	3	O
significantly	13	O
deviate	7	O
from	4	O
the	3	O
normal	6	O
subjects	8	O
.	1	O

For	3	O
apoplexic	9	O
patients	8	O
with	4	O
lesions	7	O
localized	9	O
to	2	O
the	3	O
base	4	O
of	2	O
the	3	O
brain	5	O
as	2	O
indicated	9	O
by	2	O
computerized	12	O
tomography	10	O
,	1	O
the	3	O
diurnal	7	O
variation	9	O
of	2	O
GR	2	B-Gene
was	3	O
abolished	9	O
.	1	O

Conversely	10	O
,	1	O
diurnal	7	O
rhythmicity	11	O
persisted	9	O
in	2	O
apoplexy	8	O
patients	8	O
whose	5	O
lesions	7	O
were	4	O
in	2	O
the	3	O
cerebral	8	O
cortex	6	O
.	1	O

Thus	4	O
,	1	O
we	2	O
postulated	10	O
that	4	O
the	3	O
circadian	9	O
modification	12	O
of	2	O
GR	2	B-Gene
was	3	O
independent	11	O
of	2	O
the	3	O
diurnal	7	O
fluctuations	12	O
in	2	O
plasma	6	O
cortisol	8	B-Chemical
level	5	O
or	2	O
the	3	O
circadian	9	O
variations	10	O
in	2	O
environmental	13	O
lighting	8	O
and	3	O
that	4	O
the	3	O
rhythmicity	11	O
might	5	O
be	2	O
regulated	9	O
by	2	O
the	3	O
'circadian	10	O
pacemaker	9	O
'located	8	O
in	2	O
the	3	O
human	5	O
basal	5	O
brain	5	O
.	1	O

These	5	O
diurnal	7	O
variations	10	O
in	2	O
GR	2	B-Gene
might	5	O
serve	5	O
to	2	O
coordinate	10	O
the	3	O
reactivity	10	O
of	2	O
the	3	O
target	6	O
cells	5	O
to	2	O
cortisol	8	B-Chemical
because	7	O
the	3	O
diurnal	7	O
rhythms	7	O
of	2	O
a	1	O
GR	2	B-Gene
-mediated	9	O
response	8	O
,	1	O
the	3	O
fractional	10	O
inhibition	10	O
of	2	O
chemotactic	11	O
migration	9	O
rate	4	O
of	2	O
polymorphonuclear	17	O
leukocytes	10	O
by	2	O
cortisol	8	B-Chemical
,	1	O
were	4	O
found	5	O
to	2	O
be	2	O
synchronous	11	O
with	4	O
those	5	O
of	2	O
GR	2	B-Gene
.	1	O

Multiple	8	O
Oct2	4	B-Gene
isoforms	8	I-Gene
are	3	O
generated	9	O
by	2	O
alternative	11	O
splicing	8	O
.	1	O

The	3	O
interaction	11	O
of	2	O
the	3	O
Oct2	4	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
with	4	O
the	3	O
cognate	7	O
octamer	7	O
motif	5	O
ATGCAAAT	8	O
is	2	O
a	1	O
critical	8	O
determinant	11	O
of	2	O
the	3	O
lymphoid-specific	17	O
expression	10	O
of	2	O
immunoglobulin	14	B-Gene
genes	5	I-Gene
.	1	O

Ectopic	7	O
expression	10	O
of	2	O
cloned	6	O
Oct2	4	B-Gene
cDNA	4	I-Gene
was	3	O
shown	5	O
to	2	O
be	2	O
sufficient	10	O
to	2	O
reconstitute	12	O
at	2	O
least	5	O
some	4	O
aspects	7	O
of	2	O
this	4	O
regulation	10	O
in	2	O
non-lymphoid	12	O
cells	5	O
.	1	O

We	2	O
describe	8	O
the	3	O
isolation	9	O
and	3	O
characterization	16	O
of	2	O
multiple	8	O
cDNAs	5	O
encoding	8	O
mouse	5	B-Gene
Oct2	4	I-Gene
from	4	O
a	1	O
mature	6	O
B-cell	6	O
line	4	O
and	3	O
we	2	O
show	4	O
that	4	O
a	1	O
variety	7	O
of	2	O
isoforms	8	O
of	2	O
this	4	O
transcription	13	O
factor	6	O
is	2	O
generated	9	O
from	4	O
a	1	O
single	6	O
gene	4	O
by	2	O
an	2	O
alternative	11	O
splicing	8	O
mechanism	9	O
.	1	O

All	3	O
the	3	O
isoforms	8	O
retain	6	O
the	3	O
previously	10	O
characterized	13	O
POU-domain	10	O
and	3	O
are	3	O
therefore	9	O
able	4	O
to	2	O
bind	4	O
to	2	O
the	3	O
octamer	7	O
motif	5	O
.	1	O

Different	9	O
amounts	7	O
of	2	O
the	3	O
various	7	O
isoforms	8	O
are	3	O
present	7	O
within	6	O
the	3	O
same	4	O
B-cell	6	O
regardless	10	O
of	2	O
the	3	O
developmental	13	O
stage	5	O
of	2	O
B-cell	6	O
differentiation	15	O
and	3	O
at	2	O
least	5	O
some	4	O
of	2	O
the	3	O
isoforms	8	O
are	3	O
conserved	9	O
between	7	O
mouse	5	O
and	3	O
humans	6	O
.	1	O

In	2	O
cotransfection	14	O
experiments	11	O
we	2	O
show	4	O
that	4	O
all	3	O
the	3	O
isoforms	8	O
are	3	O
able	4	O
to	2	O
activate	8	O
an	2	O
octamer	7	O
containing	10	O
promoter	8	O
element	7	O
in	2	O
fibroblasts	11	O
revealing	9	O
an	2	O
unexpected	10	O
functional	10	O
redundancy	10	O
.	1	O

Finally	7	O
,	1	O
we	2	O
show	4	O
that	4	O
one	3	O
of	2	O
the	3	O
isoforms	8	O
encodes	7	O
the	3	O
previously	10	O
described	9	O
lymphoid-specific	17	B-Gene
Oct2B	5	I-Gene
protein	7	I-Gene
which	5	O
has	3	O
been	4	O
suggested	9	O
to	2	O
be	2	O
involved	8	O
in	2	O
the	3	O
function	8	O
of	2	O
the	3	O
octamer	7	O
motif	5	O
in	2	O
the	3	O
context	7	O
of	2	O
the	3	O
immunoglobulin	14	B-Gene
heavy-chain	11	I-Gene
(	1	I-Gene
IgH	3	I-Gene
)	1	I-Gene
enhancer	8	I-Gene
.	1	O

Murine	6	O
and	3	O
human	5	B-Gene
T-lymphocyte	12	I-Gene
GATA-3	6	I-Gene
factors	7	I-Gene
mediate	7	O
transcription	13	O
through	7	O
a	1	O
cis-regulatory	14	O
element	7	O
within	6	O
the	3	O
human	5	B-Gene
T-cell	6	I-Gene
receptor	8	I-Gene
delta	5	I-Gene
gene	4	I-Gene
enhancer	8	I-Gene
.	1	O

A	1	O
family	6	O
of	2	O
transcriptional	15	O
activators	10	O
has	3	O
recently	8	O
been	4	O
identified	10	O
in	2	O
chickens	8	O
;	1	O
these	5	O
transcriptional	15	O
activators	10	O
recognize	9	O
a	1	O
common	6	O
consensus	9	O
motif	5	O
(	1	O
WGATAR	6	O
)	1	O
through	7	O
a	1	O
conserved	9	O
C4	2	O
zinc	4	B-Chemical
finger	6	O
DNA	3	O
-binding	8	O
domain	6	O
.	1	O

One	3	O
of	2	O
the	3	O
members	7	O
of	2	O
this	4	O
multigene	9	O
family	6	O
,	1	O
cGATA-3	7	B-Gene
,	1	O
is	2	O
most	4	O
abundantly	10	O
expressed	9	O
in	2	O
the	3	O
T-lymphocyte	12	O
cell	4	O
lineage	7	O
.	1	O

Analysis	8	O
of	2	O
human	5	O
and	3	O
murine	6	B-Gene
GATA-3	6	I-Gene
factors	7	I-Gene
shows	5	O
a	1	O
striking	8	O
degree	6	O
of	2	O
amino	5	O
acid	4	O
sequence	8	O
identity	8	O
and	3	O
similar	7	O
patterns	8	O
of	2	O
tissue	6	O
specificity	11	O
of	2	O
expression	10	O
in	2	O
these	5	O
three	5	O
organisms	9	O
.	1	O

The	3	O
murine	6	O
and	3	O
human	5	O
factors	7	O
are	3	O
abundantly	10	O
expressed	9	O
in	2	O
a	1	O
variety	7	O
of	2	O
human	5	O
and	3	O
murine	6	O
T-cell	6	O
lines	5	O
and	3	O
can	3	O
activate	8	O
transcription	13	O
through	7	O
a	1	O
tissue-specific	15	O
GATA	4	O
-binding	8	O
site	4	O
identified	10	O
within	6	O
the	3	O
human	5	B-Gene
T-cell	6	I-Gene
receptor	8	I-Gene
delta	5	I-Gene
gene	4	I-Gene
enhancer	8	I-Gene
.	1	O

We	2	O
infer	5	O
that	4	O
the	3	O
murine	6	O
and	3	O
human	5	B-Gene
GATA-3	6	I-Gene
proteins	8	I-Gene
play	4	O
a	1	O
central	7	O
and	3	O
highly	6	O
conserved	9	O
role	4	O
in	2	O
vertebrate	10	O
T-cell-specific	15	O
transcriptional	15	O
regulation	10	O
.	1	O

Processing	10	O
of	2	O
the	3	O
precursor	9	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
by	2	O
the	3	O
HIV-1	5	B-Gene
protease	8	I-Gene
during	6	O
acute	5	O
infection	9	O
.	1	O

Transcription	13	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
type-1	6	O
(	1	O
HIV-1	5	O
)	1	O
genome	6	O
is	2	O
regulated	9	O
in	2	O
part	4	O
by	2	O
cellular	8	O
factors	7	O
and	3	O
is	2	O
stimulated	10	O
by	2	O
activation	10	O
of	2	O
latently	8	O
infected	8	O
T	1	O
cells	5	O
.	1	O

T-cell	6	O
activation	10	O
also	4	O
correlates	10	O
with	4	O
the	3	O
induction	9	O
of	2	O
the	3	O
factor	6	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
which	5	O
binds	5	O
to	2	O
two	3	O
adjacent	8	O
sites	5	O
in	2	O
the	3	O
HIV-1	5	O
long	4	O
terminal	8	O
repeat	6	O
.	1	O

This	4	O
factor	6	O
consists	8	O
of	2	O
two	3	O
DNA	3	O
-binding	8	O
subunits	8	O
of	2	O
relative	8	O
molecular	9	O
mass	4	O
50	2	O
,	1	O
000	3	O
(	1	O
50K	3	O
)	1	O
associated	10	O
with	4	O
two	3	O
65K	3	O
subunits	8	O
.	1	O

It	2	O
is	2	O
located	7	O
in	2	O
the	3	O
nucleus	7	O
in	2	O
mature	6	O
B	1	O
cells	5	O
,	1	O
but	3	O
is	2	O
present	7	O
in	2	O
other	5	O
cell	4	O
types	5	O
as	2	O
an	2	O
inactive	8	O
cytoplasmic	11	O
complex	7	O
.	1	O

External	8	O
stimuli	7	O
,	1	O
including	9	O
those	5	O
that	4	O
activate	8	O
T	1	O
cells	5	O
,	1	O
result	6	O
in	2	O
nuclear	7	O
translocation	13	O
of	2	O
active	6	O
NF-kappa	8	B-Gene
B	1	I-Gene
.	1	O

The	3	O
cloning	7	O
of	2	O
the	3	O
complementary	13	O
DNA	3	O
for	3	O
the	3	O
50K	3	O
subunit	7	O
helped	6	O
to	2	O
identify	8	O
an	2	O
exclusively	11	O
cytoplasmic	11	O
105K	4	O
precursor	9	O
(	1	O
p105	4	B-Gene
)	1	O
(	1	O
V.B.	4	O
,	1	O
P.K.	4	O
and	3	O
A.I.	4	O
,	1	O
manuscript	10	O
submitted	9	O
)	1	O
.	1	O

The	3	O
expression	10	O
of	2	O
active	6	O
NF-kappa	8	B-Gene
B	1	I-Gene
might	5	O
therefore	9	O
also	4	O
be	2	O
regulated	9	O
by	2	O
the	3	O
extent	6	O
of	2	O
processing	10	O
of	2	O
p105	4	B-Gene
.	1	O

Because	7	O
HIV-1	5	O
requires	8	O
active	6	O
NF-kappa	8	B-Gene
B	1	I-Gene
for	3	O
efficient	9	O
transcription	13	O
,	1	O
we	2	O
tested	6	O
the	3	O
effect	6	O
of	2	O
HIV-1	5	O
infection	9	O
on	2	O
the	3	O
processing	10	O
of	2	O
the	3	O
human	5	O
105K	4	O
precursor	9	O
.	1	O

We	2	O
show	4	O
here	4	O
that	4	O
the	3	O
HIV-1	5	B-Gene
protease	8	I-Gene
can	3	O
process	7	O
p105	4	B-Gene
and	3	O
increases	9	O
levels	6	O
of	2	O
active	6	O
nuclear	7	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
complex	7	I-Gene
.	1	O

A	1	O
novel	5	O
T-cell	6	O
trans-activator	15	O
that	4	O
recognizes	10	O
a	1	O
phorbol	7	B-Chemical
ester-inducible	15	I-Chemical
element	7	O
of	2	O
the	3	O
interleukin-2	13	B-Gene
promoter	8	I-Gene
.	1	O

The	3	O
interleukin	11	B-Gene
2	1	I-Gene
(	1	I-Gene
IL-2	4	I-Gene
)	1	I-Gene
gene	4	I-Gene
promoter	8	I-Gene
is	2	O
recognized	10	O
by	2	O
several	7	O
cell-type-specific	18	O
and	3	O
ubiquitous	10	O
transcriptional	15	O
regulators	10	O
that	4	O
integrate	9	O
information	11	O
transmitted	11	O
by	2	O
various	7	O
signaling	9	O
systems	7	O
leading	7	O
to	2	O
IL-2	4	B-Gene
production	10	O
and	3	O
T-cell	6	O
activation	10	O
.	1	O

Using	5	O
a	1	O
combination	11	O
of	2	O
transfection	12	O
,	1	O
protein-DNA	11	O
binding	7	O
,	1	O
and	3	O
in	2	O
vitro	5	O
transcription	13	O
methods	7	O
,	1	O
we	2	O
have	4	O
discovered	10	O
the	3	O
novel	5	O
T-cell-specific	15	B-Gene
transcriptional	15	I-Gene
activator	9	I-Gene
TCF-1	5	I-Gene
(	1	O
for	3	O
T-Cell	6	B-Gene
Factor-1	8	I-Gene
)	1	O
,	1	O
which	5	O
recognizes	10	O
a	1	O
T-cell-specific	15	O
response	8	O
element	7	O
(	1	O
TCE	3	O
)	1	O
located	7	O
within	6	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
.	1	O

Although	8	O
the	3	O
TCE	3	O
is	2	O
similar	7	O
in	2	O
sequence	8	O
to	2	O
a	1	O
consensus	9	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
site	4	O
,	1	O
several	7	O
criteria	8	O
indicate	8	O
that	4	O
TCF-1	5	B-Gene
is	2	O
distinct	8	O
from	4	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
.	1	O

However	7	O
,	1	O
like	4	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
,	1	O
TCF-1	5	B-Gene
activity	8	O
is	2	O
induced	7	O
by	2	O
phorbol	7	B-Chemical
esters	6	I-Chemical
and	3	O
other	5	O
T-cell	6	O
activators	10	O
.	1	O

Vitamin	7	B-Gene
D	1	I-Gene
receptor	8	I-Gene
expression	10	O
in	2	O
human	5	O
lymphocytes	11	O
.	1	O

Signal	6	O
requirements	12	O
and	3	O
characterization	16	O
by	2	O
western	7	O
blots	5	O
and	3	O
DNA	3	O
sequencing	10	O
.	1	O

The	3	O
signals	7	O
controlling	11	O
the	3	O
expression	10	O
of	2	O
the	3	O
receptor	8	O
protein	7	O
for	3	O
1	1	B-Chemical
alpha	5	I-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
in	2	O
normal	6	O
human	5	O
lymphocytes	11	O
and	3	O
the	3	O
relationship	12	O
of	2	O
this	4	O
protein	7	O
to	2	O
the	3	O
classical	9	O
vitamin	7	B-Gene
D	1	I-Gene
receptor	8	I-Gene
were	4	O
examined	8	O
.	1	O

Lymphocytes	11	O
activated	9	O
with	4	O
the	3	O
OKT3	4	B-Chemical
antibody	8	O
to	2	O
the	3	O
T-cell	6	B-Gene
antigen	7	I-Gene
receptor	8	I-Gene
expressed	9	O
fewer	5	O
binding	7	O
sites	5	O
as	2	O
compared	8	O
to	2	O
lymphocytes	11	O
that	4	O
were	4	O
activated	9	O
by	2	O
the	3	O
polyclonal	10	O
activator	9	O
phytohemagglutinin	18	B-Gene
(	1	O
PHA	3	B-Gene
)	1	O
.	1	O

However	7	O
,	1	O
combination	11	O
of	2	O
OKT3	4	B-Chemical
and	3	O
phorbol	7	B-Chemical
myristate	9	I-Chemical
acetate	7	I-Chemical
produced	8	O
a	1	O
concentration	13	O
of	2	O
binding	7	O
sites	5	O
similar	7	O
to	2	O
the	3	O
PHA	3	B-Gene
-activated	10	O
cells	5	O
.	1	O

The	3	O
receptor	8	O
from	4	O
OKT3	4	B-Chemical
and	3	O
OKT3	4	B-Chemical
+	1	O
phorbol	7	B-Chemical
myristate	9	I-Chemical
acetate	7	I-Chemical
-activated	10	O
lymphocytes	11	O
exhibited	9	O
decreased	9	O
binding	7	O
to	2	O
DNA-cellulose	13	O
compared	8	O
to	2	O
PHA	3	B-Gene
-activated	10	O
lymphocytes	11	O
.	1	O

In	2	O
lymphocytes	11	O
activated	9	O
either	6	O
by	2	O
PHA	3	B-Gene
or	2	O
OKT3	4	B-Chemical
(	1	O
but	3	O
not	3	O
in	2	O
resting	7	O
cells	5	O
)	1	O
,	1	O
a	1	O
50-kDa	6	O
species	7	O
cross	5	O
-reacting	9	O
with	4	O
a	1	O
monoclonal	10	O
antibody	8	O
against	7	O
the	3	O
intestinal	10	B-Gene
vitamin	7	I-Gene
D	1	I-Gene
receptor	8	I-Gene
was	3	O
detected	8	O
.	1	O

Finally	7	O
,	1	O
RNA	3	O
from	4	O
activated	9	O
lymphocytes	11	O
was	3	O
amplified	9	O
by	2	O
polymerase	10	O
chain	5	O
reaction	8	O
using	5	O
oligonucleotide	15	O
primers	7	O
flanking	8	O
the	3	O
196	3	O
base	4	O
pair	4	O
long	4	O
region	6	O
encoding	8	O
the	3	O
DNA	3	O
-binding	8	O
domain	6	O
of	2	O
the	3	O
human	5	O
intestinal	10	O
receptor	8	O
.	1	O

The	3	O
amplified	9	O
product	7	O
showed	6	O
an	2	O
identical	9	O
nucleotide	10	O
sequence	8	O
to	2	O
the	3	O
DNA	3	O
-binding	8	O
domain	6	O
of	2	O
the	3	O
human	5	O
intestinal	10	O
receptor	8	O
.	1	O

These	5	O
findings	8	O
suggest	7	O
that	4	O
expression	10	O
of	2	O
the	3	O
1	1	B-Gene
,	1	I-Gene
25-	3	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
in	2	O
lymphocytes	11	O
is	2	O
triggered	9	O
by	2	O
distinct	8	O
and	3	O
contingent	10	O
signals	7	O
,	1	O
and	3	O
that	4	O
the	3	O
protein	7	O
and	3	O
the	3	O
mRNA	4	O
encoding	8	O
it	2	O
are	3	O
identical	9	O
to	2	O
the	3	O
classical	9	O
vitamin	7	B-Gene
D	1	I-Gene
receptor	8	I-Gene
.	1	O

[	1	O
Estrogen	8	B-Gene
receptor	8	I-Gene
content	7	O
of	2	O
peripheral	10	O
blood	5	O
lymphocytes	11	O
in	2	O
patients	8	O
with	4	O
systemic	8	B-Disease
lupus	5	I-Disease
erythematosus	13	I-Disease
]	1	O

ER	2	B-Gene
content	7	O
in	2	O
lymphocytes	11	O
of	2	O
peripheral	10	O
blood	5	O
from	4	O
27	2	O
SLE	3	B-Disease
patients	8	O
and	3	O
20	2	O
healthy	7	O
controls	8	O
were	4	O
determined	10	O
by	2	O
dextran	7	O
-coated	7	O
charcoal	8	O
assay	5	O
.	1	O

ER	2	B-Gene
content	7	O
in	2	O
lymphocytes	11	O
of	2	O
each	4	O
sample	6	O
was	3	O
expressed	9	O
by	2	O
both	4	O
fmol	4	O
/	1	O
mg	2	O
of	2	O
lymphocyte	10	B-Gene
cytosolic	9	I-Gene
protein	7	I-Gene
and	3	O
fmol	4	O
/	1	O
micrograms	10	O
of	2	O
lymphocyte	10	O
DNA	3	O
.	1	O

The	3	O
results	7	O
showed	6	O
that	4	O
there	5	O
was	3	O
no	2	O
significant	11	O
difference	10	O
between	7	O
the	3	O
ER	2	B-Gene
content	7	O
of	2	O
lymphocytes	11	O
from	4	O
the	3	O
controls	8	O
and	3	O
that	4	O
from	4	O
patients	8	O
with	4	O
SLE	3	B-Disease
.	1	O

But	3	O
the	3	O
logarithmic	11	O
mean	4	O
of	2	O
ER	2	B-Gene
content	7	O
in	2	O
lymphocytes	11	O
,	1	O
expressed	9	O
by	2	O
fmol	4	O
/	1	O
mg	2	O
of	2	O
cytosolic	9	O
protein	7	O
,	1	O
in	2	O
14	2	O
patients	8	O
with	4	O
active	6	O
SLE	3	B-Disease
(	1	O
0.9356	6	O
+	1	O
/	1	O
-	1	O
0.31	4	O
)	1	O
was	3	O
significantly	13	O
higher	6	O
than	4	O
that	4	O
in	2	O
13	2	O
patients	8	O
with	4	O
inactive	8	O
SLE	3	B-Disease
(	1	O
0.2979	6	O
+	1	O
/	1	O
-	1	O
0.23	4	O
,	1	O
P	1	O
less	4	O
than	4	O
0.001	5	O
)	1	O
and	3	O
in	2	O
the	3	O
controls	8	O
(	1	O
0.6204	6	O
+	1	O
/	1	O
-	1	O
0.52	4	O
,	1	O
P	1	O
less	4	O
than	4	O
0.001	5	O
)	1	O
.	1	O

The	3	O
normal	6	O
upper	5	O
limit	5	O
of	2	O
ER	2	B-Gene
content	7	O
in	2	O
lymphocytes	11	O
,	1	O
expressed	9	O
by	2	O
fmol	4	O
/	1	O
micrograms	10	O
of	2	O
DNA	3	O
,	1	O
was	3	O
0.136	5	O
.	1	O

The	3	O
elevated	8	O
rate	4	O
of	2	O
ER	2	B-Gene
content	7	O
in	2	O
lymphocytes	11	O
in	2	O
14	2	O
active	6	O
SLE	3	B-Disease
(	1	O
92.9	4	O
%	1	O
)	1	O
was	3	O
also	4	O
higher	6	O
than	4	O
that	4	O
in	2	O
quieiescent	11	O
patients	8	O
(	1	O
23.1	4	O
%	1	O
,	1	O
P	1	O
less	4	O
than	4	O
0.001	5	O
)	1	O
and	3	O
in	2	O
the	3	O
controls	8	O
(	1	O
10	2	O
%	1	O
,	1	O
P	1	O
less	4	O
than	4	O
0.001	5	O
)	1	O
.	1	O

Moreover	8	O
,	1	O
the	3	O
elevated	8	O
level	5	O
of	2	O
ER	2	B-Gene
content	7	O
was	3	O
found	5	O
to	2	O
be	2	O
related	7	O
to	2	O
the	3	O
positive	8	O
antidsDNA	9	O
antibody	8	O
and	3	O
hypocomplementemia	18	O
.	1	O

Cloning	7	O
of	2	O
murine	6	B-Gene
TCF-1	5	I-Gene
,	1	O
a	1	O
T	1	O
cell-specific	13	O
transcription	13	O
factor	6	O
interacting	11	O
with	4	O
functional	10	O
motifs	6	O
in	2	O
the	3	O
CD3-epsilon	11	B-Gene
and	3	O
T	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
alpha	5	I-Gene
enhancers	9	I-Gene
.	1	O

CD3	3	B-Gene
-epsilon	8	I-Gene
gene	4	I-Gene
expression	10	O
is	2	O
confined	8	O
to	2	O
the	3	O
T	1	O
cell	4	O
lineage	7	O
.	1	O

We	2	O
have	4	O
recently	8	O
identified	10	O
and	3	O
cloned	6	O
a	1	O
human	5	O
transcription	13	O
factor	6	O
,	1	O
TCF-1	5	B-Gene
,	1	O
that	4	O
binds	5	O
to	2	O
a	1	O
functional	10	O
element	7	O
in	2	O
the	3	O
T	1	O
lymphocyte-specific	19	O
enhancer	8	O
of	2	O
CD3-epsilon	11	B-Gene
.	1	O

In	2	O
a	1	O
panel	5	O
of	2	O
human	5	O
cell	4	O
lines	5	O
,	1	O
TCF-1	5	B-Gene
expression	10	O
was	3	O
restricted	10	O
to	2	O
T	1	O
lineage	7	O
cells	5	O
.	1	O

TCF-1	5	B-Gene
belonged	8	O
to	2	O
a	1	O
novel	5	O
family	6	O
of	2	O
genes	5	O
that	4	O
contain	7	O
the	3	O
so	2	O
-called	7	O
high	4	B-Gene
mobility	8	I-Gene
group	5	I-Gene
1	1	I-Gene
(	1	O
HMG	3	B-Gene
)	1	O
box	3	O
.	1	O

Here	4	O
we	2	O
report	6	O
the	3	O
cloning	7	O
of	2	O
murine	6	B-Gene
TCF-1	5	I-Gene
.	1	O

Two	3	O
splice	6	O
alternatives	12	O
were	4	O
identified	10	O
that	4	O
were	4	O
not	3	O
previously	10	O
observed	8	O
in	2	O
human	5	B-Gene
TCF-1	5	I-Gene
.	1	O

Murine	6	O
and	3	O
human	5	B-Gene
TCF-1	5	I-Gene
displayed	9	O
a	1	O
95.5	4	O
%	1	O
overall	7	O
amino	5	O
acid	4	O
homology	8	O
.	1	O

Recombinant	11	O
murine	6	O
and	3	O
human	5	B-Gene
TCF-1	5	I-Gene
recognized	10	O
the	3	O
same	4	O
sequence	8	O
motif	5	O
in	2	O
the	3	O
CD3-epsilon	11	B-Gene
enhancer	8	I-Gene
as	2	O
judged	6	O
by	2	O
gel	3	O
retardation	11	O
and	3	O
methylation	11	O
interference	12	O
assays	6	O
.	1	O

With	4	O
the	3	O
murine	6	O
cDNA	4	O
clones	6	O
several	7	O
aspects	7	O
of	2	O
TCF-1	5	B-Gene
were	4	O
analyzed	8	O
.	1	O

First	5	O
,	1	O
deletion	8	O
analysis	8	O
revealed	8	O
that	4	O
a	1	O
region	6	O
of	2	O
TCF-1	5	B-Gene
containing	10	O
the	3	O
HMG	3	B-Gene
box	3	O
was	3	O
sufficient	10	O
for	3	O
sequence-specific	17	O
binding	7	O
.	1	O

Second	6	O
,	1	O
by	2	O
high	4	O
stringency	10	O
Northern	8	O
blotting	8	O
and	3	O
in	2	O
situ	4	O
hybridization	13	O
,	1	O
TCF-1	5	B-Gene
expression	10	O
was	3	O
shown	5	O
to	2	O
be	2	O
confined	8	O
to	2	O
the	3	O
thymus	6	O
and	3	O
to	2	O
the	3	O
T	1	O
cell	4	O
areas	5	O
of	2	O
the	3	O
spleen	6	O
.	1	O

Third	5	O
,	1	O
TCF-1	5	B-Gene
bound	5	O
specifically	12	O
to	2	O
a	1	O
functional	10	O
T	1	O
cell-specific	13	O
element	7	O
in	2	O
the	3	O
T	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
alpha	5	I-Gene
(	1	I-Gene
TCR-alpha	9	I-Gene
)	1	I-Gene
enhancer	8	I-Gene
.	1	O

The	3	O
T	1	O
lineage-specific	16	O
expression	10	O
and	3	O
the	3	O
affinity	8	O
for	3	O
functional	10	O
motifs	6	O
in	2	O
the	3	O
TCR-alpha	9	B-Gene
and	3	O
CD3-epsilon	11	B-Gene
enhancers	9	I-Gene
imply	5	O
an	2	O
important	9	O
role	4	O
for	3	O
TCF-1	5	B-Gene
in	2	O
the	3	O
establishment	13	O
of	2	O
the	3	O
mature	6	O
T	1	O
cell	4	O
phenotype	9	O
.	1	O

HIV	3	O
enhancer	8	O
activity	8	O
perpetuated	11	O
by	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
induction	9	O
on	2	O
infection	9	O
of	2	O
monocytes	9	O
[	1	O
see	3	O
comments	8	O
]	1	O

Permissiveness	14	O
to	2	O
replication	11	O
of	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
(	1	O
HIV	3	O
)	1	O
differs	7	O
in	2	O
T	1	O
lymphocytes	11	O
and	3	O
macrophages	11	O
.	1	O

In	2	O
T	1	O
cells	5	O
,	1	O
HIV	3	O
transcription	13	O
is	2	O
poorly	6	O
detected	8	O
in	2	O
vivo	4	O
.	1	O

Cloned	6	O
,	1	O
normal	6	O
T	1	O
lymphocytes	11	O
show	4	O
very	4	O
little	6	O
,	1	O
if	2	O
any	3	O
,	1	O
basal	5	O
activity	8	O
of	2	O
the	3	O
HIV	3	O
enhancer	8	O
and	3	O
low	3	O
nuclear	7	O
expression	10	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
,	1	O
a	1	O
potent	6	O
transcriptional	15	O
activator	9	O
of	2	O
the	3	O
HIV	3	O
enhancer	8	O
.	1	O

In	2	O
contrast	8	O
,	1	O
fixed	5	O
tissue	6	O
macrophages	11	O
express	7	O
detectable	10	O
HIV	3	O
proteins	8	O
,	1	O
indicating	10	O
permanent	9	O
virus	5	O
transcription	13	O
.	1	O

One	3	O
explanation	11	O
for	3	O
the	3	O
perpetuation	12	O
of	2	O
virus	5	O
infection	9	O
in	2	O
macrophages	11	O
could	5	O
be	2	O
sustained	9	O
nuclear	7	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
expression	10	O
.	1	O

However	7	O
,	1	O
the	3	O
U937	4	O
monocytic	9	O
cell	4	O
line	4	O
,	1	O
which	5	O
is	2	O
fully	5	O
permissive	10	O
to	2	O
HIV	3	O
replication	11	O
,	1	O
is	2	O
known	5	O
to	2	O
express	7	O
only	4	O
low	3	O
levels	6	O
of	2	O
nuclear	7	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
.	1	O

We	2	O
show	4	O
here	4	O
that	4	O
chronic	7	O
HIV	3	O
infection	9	O
results	7	O
in	2	O
both	4	O
induction	9	O
of	2	O
a	1	O
nuclear	7	O
factor	6	O
with	4	O
antigenic	9	O
properties	10	O
indistinguishable	17	O
from	4	O
those	5	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
and	3	O
permanently	11	O
increased	9	O
HIV	3	O
enhancer	8	O
activity	8	O
.	1	O

This	4	O
phenomenon	10	O
,	1	O
which	5	O
is	2	O
independent	11	O
of	2	O
tumour	6	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
,	1	O
is	2	O
associated	10	O
with	4	O
HIV	3	O
replication	11	O
,	1	O
and	3	O
is	2	O
thus	4	O
likely	6	O
to	2	O
explain	7	O
at	2	O
least	5	O
in	2	O
part	4	O
the	3	O
perpetuation	12	O
of	2	O
HIV	3	O
infection	9	O
in	2	O
monocytes	9	O
.	1	O

Role	4	O
for	3	O
the	3	O
Epstein-Barr	12	B-Gene
virus	5	I-Gene
nuclear	7	I-Gene
antigen	7	I-Gene
2	1	I-Gene
in	2	O
viral	5	O
promoter	8	O
switching	9	O
during	6	O
initial	7	O
stages	6	O
of	2	O
infection	9	O
.	1	O

During	6	O
latent	6	O
Epstein-Barr	12	O
virus	5	O
(	1	O
EBV	3	O
)	1	O
infection	9	O
of	2	O
human	5	O
B	1	O
lymphocytes	11	O
,	1	O
six	3	O
viral	5	O
nuclear	7	O
antigen	7	O
(	1	O
EBNAs	5	B-Gene
)	1	O
are	3	O
expressed	9	O
from	4	O
long	4	O
primary	7	O
transcripts	11	O
by	2	O
means	5	O
of	2	O
alternative	11	O
splicing	8	O
and	3	O
alternative	11	O
polyadenylylation	17	O
sites	5	O
.	1	O

These	5	O
transcripts	11	O
initiate	8	O
from	4	O
one	3	O
of	2	O
two	3	O
promoters	9	O
,	1	O
Cp	2	O
or	2	O
Wp	2	O
,	1	O
that	4	O
function	8	O
in	2	O
a	1	O
mutually	8	O
exclusive	9	O
fashion	7	O
.	1	O

Wp	2	O
is	2	O
exclusively	11	O
utilized	8	O
during	6	O
the	3	O
initial	7	O
stages	6	O
of	2	O
infection	9	O
of	2	O
primary	7	O
B	1	O
lymphocytes	11	O
,	1	O
followed	8	O
by	2	O
a	1	O
switch	6	O
to	2	O
Cp	2	O
usage	5	O
.	1	O

These	5	O
studies	7	O
have	4	O
been	4	O
extended	8	O
to	2	O
show	4	O
that	4	O
(	1	O
i	1	O
)	1	O
a	1	O
mutant	6	O
EBV	3	O
strain	6	O
lacking	7	O
the	3	O
gene	4	O
encoding	8	O
EBNA	4	B-Gene
2	1	I-Gene
fails	5	O
to	2	O
switch	6	O
from	4	O
Wp	2	O
to	2	O
Cp	2	O
usage	5	O
in	2	O
primary	7	O
B	1	O
lymphocytes	11	O
,	1	O
although	8	O
the	3	O
virus	5	O
contains	8	O
a	1	O
functional	10	O
Cp	2	O
;	1	O
(	1	O
ii	2	O
)	1	O
a	1	O
region	6	O
from	4	O
-429	4	O
to	2	O
-245	4	O
base	4	O
pairs	5	O
upstream	8	O
of	2	O
Cp	2	O
is	2	O
essential	9	O
for	3	O
Cp	2	O
activity	8	O
in	2	O
B	1	O
lymphocytes	11	O
,	1	O
but	3	O
only	4	O
in	2	O
the	3	O
context	7	O
of	2	O
upstream	8	O
and	3	O
downstream	10	O
sequences	9	O
;	1	O
(	1	O
iii	3	O
)	1	O
this	4	O
region	6	O
contains	8	O
an	2	O
EBNA	4	B-Gene
2	1	I-Gene
-dependent	10	O
enhancer	8	O
;	1	O
and	3	O
(	1	O
iv	2	O
)	1	O
DNase	5	B-Gene
I	1	I-Gene
protection	10	O
employing	9	O
nuclear	7	O
extracts	8	O
from	4	O
B	1	O
and	3	O
T	1	O
lymphocytes	11	O
revealed	8	O
a	1	O
B-cell-specific	15	O
footprint	9	O
in	2	O
the	3	O
region	6	O
of	2	O
the	3	O
EBNA	4	B-Gene
2	1	I-Gene
-dependent	10	O
enhancer	8	O
.	1	O

These	5	O
results	7	O
support	7	O
a	1	O
model	5	O
for	3	O
viral	5	O
promoter	8	O
switching	9	O
during	6	O
the	3	O
initial	7	O
stages	6	O
of	2	O
infection	9	O
in	2	O
which	5	O
Wp	2	O
activity	8	O
leads	5	O
to	2	O
the	3	O
expression	10	O
of	2	O
EBNA	4	B-Gene
2	1	I-Gene
,	1	O
followed	8	O
by	2	O
activation	10	O
of	2	O
Cp	2	O
through	7	O
the	3	O
EBNA	4	B-Gene
2	1	I-Gene
-dependent	10	O
enhancer	8	O
.	1	O

Glucocorticoid	14	B-Gene
receptor	8	I-Gene
characteristics	15	O
in	2	O
monocytes	9	O
of	2	O
patients	8	O
with	4	O
corticosteroid	14	B-Chemical
-resistant	10	O
bronchial	9	B-Disease
asthma	6	I-Disease
.	1	O

The	3	O
mechanism	9	O
of	2	O
corticosteroid	14	B-Chemical
resistance	10	O
in	2	O
bronchial	9	B-Disease
asthma	6	I-Disease
has	3	O
been	4	O
studied	7	O
by	2	O
determining	11	O
the	3	O
rank	4	O
order	5	O
of	2	O
potency	7	O
for	3	O
different	9	O
corticosteroids	15	B-Chemical
in	2	O
inhibiting	10	O
the	3	O
generation	10	O
of	2	O
a	1	O
3	1	O
kD	2	O
molecule	8	O
from	4	O
peripheral	10	O
blood	5	O
monocytes	9	O
isolated	8	O
from	4	O
corticosteroid	14	B-Chemical
-sensitive	10	O
(	1	O
CS	2	O
)	1	O
and	3	O
corticosteroid	14	B-Chemical
-resistant	10	O
(	1	O
CR	2	O
)	1	O
asthmatic	9	O
subjects	8	O
,	1	O
which	5	O
augments	8	O
leukotriene	11	B-Chemical
B4	2	I-Chemical
(	1	O
LTB4	4	B-Chemical
)	1	O
generation	10	O
by	2	O
human	5	O
neutrophils	11	O
(	1	O
PMN	3	O
)	1	O
stimulated	10	O
by	2	O
calcium	7	B-Chemical
ionophore	9	O
.	1	O

In	2	O
addition	8	O
,	1	O
binding	7	O
studies	7	O
with	4	O
(	1	O
3H	2	O
)	1	O
dexamethasone	13	B-Chemical
have	4	O
been	4	O
performed	9	O
to	2	O
determine	9	O
the	3	O
dissociation	12	O
constant	8	O
(	1	O
Kd	2	O
)	1	O
and	3	O
receptor	8	O
numbers	7	O
(	1	O
Ro	2	O
)	1	O
in	2	O
the	3	O
monocytes	9	O
of	2	O
these	5	O
two	3	O
groups	6	O
of	2	O
subjects	8	O
.	1	O

The	3	O
concentration	13	O
of	2	O
corticosteroid	14	B-Chemical
producing	9	O
50	2	O
%	1	O
inhibition	10	O
(	1	O
IC50	4	O
)	1	O
was	3	O
600	3	O
nM	2	O
,	1	O
70	2	O
nM	2	O
,	1	O
and	3	O
0.5	3	O
nM	2	O
for	3	O
hydrocortisone	14	B-Chemical
,	1	O
methylprednisolone	18	B-Chemical
,	1	O
and	3	O
dexamethasone	13	B-Chemical
,	1	O
respectively	12	O
,	1	O
in	2	O
monocytes	9	O
from	4	O
CS	2	O
individuals	11	O
.	1	O

There	5	O
was	3	O
only	4	O
weak	4	O
inhibition	10	O
of	2	O
the	3	O
generation	10	O
of	2	O
enhancing	9	O
activity	8	O
by	2	O
the	3	O
corticosteroids	15	B-Chemical
in	2	O
the	3	O
CR	2	O
asthmatic	9	O
individuals	11	O
.	1	O

The	3	O
dexamethasone	13	B-Chemical
Kd	2	O
was	3	O
2.45	4	O
+	1	O
/	1	O
-	1	O
0.58	4	O
nM	2	O
(	1	O
mean	4	O
+	1	O
/	1	O
-	1	O
SEM	3	O
,	1	O
n	1	O
=	1	O
6	1	O
)	1	O
in	2	O
the	3	O
CS	2	O
group	5	O
and	3	O
1.6	3	O
+	1	O
/	1	O
-	1	O
0.35	4	O
nM	2	O
(	1	O
mean	4	O
+	1	O
/	1	O
-	1	O
SEM	3	O
,	1	O
n	1	O
=	1	O
6	1	O
)	1	O
in	2	O
the	3	O
CR	2	O
group	5	O
of	2	O
patients	8	O
(	1	O
p	1	O
=	1	O
0.14	4	O
)	1	O
.	1	O

The	3	O
Ro	2	O
in	2	O
the	3	O
CS	2	O
group	5	O
was	3	O
3	1	O
,	1	O
605	3	O
+	1	O
/	1	O
-	1	O
984	3	O
binding	7	O
sites	5	O
per	3	O
nucleus	7	O
(	1	O
mean	4	O
+	1	O
/	1	O
-	1	O
SEM	3	O
,	1	O
n	1	O
=	1	O
6	1	O
)	1	O
and	3	O
4	1	O
,	1	O
757	3	O
+	1	O
/	1	O
-	1	O
692	3	O
binding	7	O
sites	5	O
per	3	O
nucleus	7	O
(	1	O
mean	4	O
+	1	O
/	1	O
-	1	O
SEM	3	O
,	1	O
n	1	O
=	1	O
6	1	O
)	1	O
in	2	O
the	3	O
CR	2	O
group	5	O
(	1	O
p	1	O
=	1	O
0.23	4	O
)	1	O
.	1	O

These	5	O
findings	8	O
indicate	8	O
that	4	O
corticosteroid	14	B-Chemical
resistance	10	O
in	2	O
bronchial	9	B-Disease
asthma	6	I-Disease
can	3	O
not	3	O
be	2	O
explained	9	O
by	2	O
abnormalities	13	O
in	2	O
corticosteroid	14	B-Gene
receptor	8	I-Gene
characteristics	15	O
.	1	O

Tissue-specific	15	O
expression	10	O
of	2	O
the	3	O
platelet	8	B-Gene
GPIIb	5	I-Gene
gene	4	I-Gene
.	1	O

One	3	O
of	2	O
the	3	O
major	5	O
objectives	10	O
in	2	O
the	3	O
study	5	O
of	2	O
thrombogenesis	14	O
is	2	O
to	2	O
determine	9	O
the	3	O
mechanisms	10	O
by	2	O
which	5	O
a	1	O
hematopoietic	13	O
progenitor	10	O
is	2	O
activated	9	O
and	3	O
committed	9	O
to	2	O
the	3	O
megakaryocytic	14	O
lineage	7	O
.	1	O

Recent	6	O
development	11	O
of	2	O
primary	7	O
cultures	8	O
of	2	O
human	5	O
megakaryocytes	14	O
and	3	O
the	3	O
molecular	9	O
cloning	7	O
of	2	O
genes	5	O
that	4	O
are	3	O
specific	8	O
to	2	O
this	4	O
lineage	7	O
offer	5	O
the	3	O
possibility	11	O
of	2	O
getting	7	O
some	4	O
insights	8	O
into	4	O
the	3	O
genetic	7	O
mechanisms	10	O
that	4	O
control	7	O
megakaryocytopoiesis	20	O
.	1	O

One	3	O
gene	4	O
of	2	O
interest	8	O
is	2	O
the	3	O
glycoprotein	12	B-Gene
IIb	3	I-Gene
(	1	I-Gene
GPIIb	5	I-Gene
)	1	I-Gene
gene	4	I-Gene
;	1	O
GPIIb	5	B-Gene
,	1	O
the	3	O
alpha	5	O
subunit	7	O
of	2	O
the	3	O
platelet	8	B-Gene
cytoadhesin	11	I-Gene
GPIIb-IIIa	10	I-Gene
,	1	O
is	2	O
produced	8	O
in	2	O
megakaryocytes	14	O
at	2	O
an	2	O
early	5	O
stage	5	O
of	2	O
the	3	O
differentiation	15	O
,	1	O
whereas	7	O
the	3	O
other	5	O
subunit	7	O
of	2	O
this	4	O
complex	7	O
,	1	O
GPIIIa	6	B-Gene
,	1	O
is	2	O
expressed	9	O
in	2	O
other	5	O
cells	5	O
.	1	O

For	3	O
these	5	O
reasons	7	O
,	1	O
the	3	O
5'-flanking	11	O
region	6	O
of	2	O
the	3	O
GPIIb	5	B-Gene
gene	4	I-Gene
was	3	O
used	4	O
to	2	O
identify	8	O
the	3	O
regions	7	O
that	4	O
interact	8	O
with	4	O
DNA	3	O
-binding	8	O
nuclear	7	O
factors	7	O
.	1	O

A	1	O
fragment	8	O
extending	9	O
from	4	O
-643	4	O
to	2	O
+33	3	O
is	2	O
capable	7	O
of	2	O
controlling	11	O
the	3	O
tissue-specific	15	O
expression	10	O
of	2	O
the	3	O
CAT	3	O
gene	4	O
in	2	O
transfection	12	O
experiments	11	O
.	1	O

Within	6	O
this	4	O
region	6	O
,	1	O
we	2	O
have	4	O
identified	10	O
several	7	O
sequences	9	O
that	4	O
are	3	O
implicated	10	O
in	2	O
DNA	3	O
protein	7	O
interactions	12	O
as	2	O
shown	5	O
in	2	O
DNAse	5	O
I	1	O
footprints	10	O
and	3	O
gel	3	O
mobility	8	O
shift	5	O
assays	6	O
.	1	O

One	3	O
region	6	O
,	1	O
centered	8	O
at	2	O
-54	3	O
,	1	O
is	2	O
similar	7	O
to	2	O
a	1	O
nuclear	7	B-Gene
factor	6	I-Gene
E1	2	I-Gene
-binding	8	O
site	4	O
,	1	O
and	3	O
a	1	O
region	6	O
located	7	O
at	2	O
position	8	O
-233	4	O
contains	8	O
a	1	O
CCAAT	5	O
motif	5	O
.	1	O

Two	3	O
domains	7	O
centered	8	O
at	2	O
positions	9	O
-345	4	O
and	3	O
-540	4	O
,	1	O
respectively	12	O
,	1	O
bind	4	O
proteins	8	O
that	4	O
are	3	O
present	7	O
in	2	O
megakaryocytic	14	O
cells	5	O
and	3	O
nonrelated	10	O
cells	5	O
as	2	O
well	4	O
.	1	O

Finally	7	O
,	1	O
two	3	O
other	5	O
domains	7	O
,	1	O
located	7	O
at	2	O
positions	9	O
-460	4	O
and	3	O
-510	4	O
,	1	O
interact	8	O
with	4	O
proteins	8	O
that	4	O
are	3	O
only	4	O
present	7	O
in	2	O
megakaryocytic	14	O
cells	5	O
.	1	O

In	2	O
addition	8	O
,	1	O
deletion	8	O
of	2	O
the	3	O
region	6	O
containing	10	O
these	5	O
two	3	O
domains	7	O
results	7	O
in	2	O
a	1	O
significant	11	O
decrease	8	O
of	2	O
the	3	O
promoter	8	O
activity	8	O
.	1	O

It	2	O
is	2	O
very	4	O
likely	6	O
that	4	O
these	5	O
domains	7	O
bind	4	O
megakaryocyte-specific	22	O
nuclear	7	O
proteins	8	O
acting	6	O
as	2	O
positive	8	O
transcription	13	O
factors	7	O
.	1	O

Demonstration	13	O
of	2	O
estrogen	8	B-Chemical
and	3	O
progesterone	12	B-Gene
receptors	9	I-Gene
as	2	O
well	4	O
as	2	O
Ki-67	5	B-Gene
and	3	O
p-145	5	O
antigens	8	O
in	2	O
single	6	O
tumor	5	B-Disease
cells	5	O
from	4	O
blood	5	O
and	3	O
pleural	7	B-Disease
effusions	9	I-Disease
using	5	O
a	1	O
slide	5	O
assay	5	O
.	1	O

We	2	O
describe	8	O
a	1	O
slide	5	O
assay	5	O
that	4	O
allows	6	O
the	3	O
demonstration	13	O
of	2	O
antigens	8	O
localized	9	O
in	2	O
the	3	O
nucleus	7	O
from	4	O
isolated	8	O
white	5	O
blood	5	O
cells	5	O
as	2	O
well	4	O
as	2	O
from	4	O
single	6	O
tumor	5	B-Disease
cells	5	O
derived	7	O
from	4	O
malignant	9	O
effusions	9	O
.	1	O

With	4	O
the	3	O
antibodies	10	B-Gene
Ki-67	5	I-Gene
and	3	O
anti-p-145	10	O
an	2	O
increased	9	O
rate	4	O
of	2	O
nuclear	7	O
and	3	O
nucleolar	9	O
staining	8	O
resulted	8	O
in	2	O
cells	5	O
from	4	O
highly	6	O
malignant	9	B-Disease
lymphomas	9	I-Disease
.	1	O

An	2	O
almost	6	O
identical	9	O
reaction	8	O
was	3	O
obtained	8	O
when	4	O
tumor	5	B-Disease
cells	5	O
from	4	O
malignant	9	O
effusions	9	O
were	4	O
tested	6	O
.	1	O

Cells	5	O
isolated	8	O
from	4	O
the	3	O
blood	5	O
of	2	O
patients	8	O
with	4	O
leukemic	8	O
spread	6	O
of	2	O
lymphomas	9	B-Disease
of	2	O
low	3	O
malignancy	10	O
yielded	7	O
a	1	O
weak	4	O
staining	8	O
comparable	10	O
to	2	O
that	4	O
of	2	O
normal	6	O
mesothelial	11	O
cells	5	O
from	4	O
non-tumorous	12	O
cavity	6	O
fluids	6	O
.	1	O

The	3	O
detection	9	O
of	2	O
estrogen	8	B-Chemical
and	3	O
progesterone	12	B-Gene
receptors	9	I-Gene
(	1	O
ER	2	B-Gene
and	3	O
PR	2	B-Gene
)	1	O
localized	9	O
in	2	O
the	3	O
cell	4	O
nucleus	7	O
can	3	O
be	2	O
achieved	8	O
by	2	O
the	3	O
same	4	O
assay	5	O
.	1	O

The	3	O
reaction	8	O
is	2	O
enhanced	8	O
by	2	O
incubation	10	O
of	2	O
the	3	O
tumor	5	B-Disease
cells	5	O
for	3	O
30	2	O
min	3	O
at	2	O
37	2	O
degrees	7	O
C	1	O
prior	5	O
to	2	O
fixation	8	O
.	1	O

Pleural	7	B-Disease
effusions	9	I-Disease
from	4	O
20	2	O
patients	8	O
with	4	O
breast	6	B-Disease
cancer	6	I-Disease
were	4	O
tested	6	O
.	1	O

ER	2	B-Gene
was	3	O
positive	8	O
in	2	O
13	2	O
and	3	O
PR	2	B-Gene
was	3	O
positive	8	O
in	2	O
12	2	O
of	2	O
the	3	O
20	2	O
samples	7	O
.	1	O

In	2	O
5	1	O
cases	5	O
there	5	O
was	3	O
a	1	O
divergent	9	O
reaction	8	O
with	4	O
ER	2	B-Gene
and	3	O
PR	2	B-Gene
antibody	8	I-Gene
.	1	O

The	3	O
hormone	7	O
receptors	9	O
of	2	O
the	3	O
primary	7	O
tumor	5	B-Disease
were	4	O
known	5	O
in	2	O
15	2	O
(	1	O
ER	2	B-Gene
)	1	O
and	3	O
14	2	O
(	1	O
PR	2	B-Gene
)	1	O
patients	8	O
,	1	O
respectively	12	O
.	1	O

In	2	O
each	4	O
cohort	6	O
there	5	O
was	3	O
only	4	O
one	3	O
case	4	O
with	4	O
a	1	O
negative	8	O
reaction	8	O
of	2	O
the	3	O
primary	7	O
tumor	5	B-Disease
and	3	O
a	1	O
positive	8	O
reaction	8	O
with	4	O
the	3	O
isolated	8	O
tumor	5	B-Disease
cells	5	O
from	4	O
the	3	O
pleural	7	B-Disease
effusions	9	I-Disease
.	1	O

These	5	O
results	7	O
indicate	8	O
that	4	O
the	3	O
demonstration	13	O
of	2	O
hormone	7	O
receptor	8	O
proteins	8	O
in	2	O
cells	5	O
from	4	O
malignant	9	O
effusions	9	O
is	2	O
possible	8	O
and	3	O
that	4	O
there	5	O
is	2	O
a	1	O
correlation	11	O
with	4	O
the	3	O
status	6	O
of	2	O
the	3	O
primary	7	O
site	4	O
of	2	O
cancer	6	B-Disease
.	1	O

Differentiation	15	O
-associated	11	O
expression	10	O
of	2	O
the	3	O
Epstein-Barr	12	B-Gene
virus	5	I-Gene
BZLF1	5	I-Gene
transactivator	14	I-Gene
protein	7	I-Gene
in	2	O
oral	4	B-Disease
hairy	5	I-Disease
leukoplakia	11	I-Disease
.	1	O

The	3	O
BZLF1	5	B-Gene
protein	7	I-Gene
of	2	O
Epstein-Barr	12	O
virus	5	O
(	1	O
EBV	3	O
)	1	O
is	2	O
a	1	O
key	3	O
immediate-early	15	O
protein	7	O
which	5	O
has	3	O
been	4	O
shown	5	O
to	2	O
disrupt	7	O
virus	5	O
latency	7	O
in	2	O
EBV	3	O
-infected	9	O
B	1	O
cells	5	O
.	1	O

We	2	O
have	4	O
generated	9	O
a	1	O
monoclonal	10	O
antibody	8	O
,	1	O
BZ1	3	O
,	1	O
to	2	O
BZLF1	5	B-Gene
which	5	O
reacts	6	O
in	2	O
immunohistology	15	O
,	1	O
immunoblotting	14	O
,	1	O
and	3	O
immunoprecipitation	19	O
and	3	O
which	5	O
recognizes	10	O
both	4	O
the	3	O
active	6	O
,	1	O
dimeric	7	O
form	4	O
and	3	O
the	3	O
inactive	8	O
,	1	O
monomeric	9	O
form	4	O
of	2	O
the	3	O
protein	7	O
.	1	O

Biopsies	8	O
of	2	O
oral	4	B-Disease
hairy	5	I-Disease
leukoplakia	11	I-Disease
,	1	O
an	2	O
AIDS	4	B-Disease
-associated	11	O
lesion	6	O
characterized	13	O
by	2	O
high-level	10	O
EBV	3	O
replication	11	O
,	1	O
were	4	O
examined	8	O
by	2	O
immunohistochemistry	20	O
using	5	O
the	3	O
BZ1	3	O
monoclonal	10	O
antibody	8	O
.	1	O

A	1	O
differentiation	15	O
-associated	11	O
pattern	7	O
of	2	O
BZLF1	5	B-Gene
expression	10	O
was	3	O
observed	8	O
,	1	O
BZ1	3	O
reacting	8	O
with	4	O
nuclei	6	O
of	2	O
the	3	O
upper	5	O
spinous	7	O
layer	5	O
of	2	O
the	3	O
lesion	6	O
.	1	O

This	4	O
finding	7	O
suggests	8	O
that	4	O
the	3	O
BZLF1	5	B-Gene
promoter	8	I-Gene
may	3	O
be	2	O
regulated	9	O
by	2	O
the	3	O
degree	6	O
of	2	O
squamous	8	O
differentiation	15	O
.	1	O

A	1	O
comparison	10	O
of	2	O
in	2	O
situ	4	O
hybridization	13	O
to	2	O
EBV	3	O
DNA	3	O
and	3	O
viral	5	O
capsid	6	O
antigen	7	O
staining	8	O
with	4	O
BZ1	3	O
reactivity	10	O
suggested	9	O
that	4	O
BZLF1	5	B-Gene
expression	10	O
precedes	8	O
rampant	7	O
virus	5	O
replication	11	O
.	1	O

The	3	O
inability	9	O
to	2	O
detect	6	O
EBV	3	O
in	2	O
the	3	O
lower	5	O
epithelial	10	O
layers	6	O
of	2	O
oral	4	B-Disease
hairy	5	I-Disease
leukoplakia	11	I-Disease
raises	6	O
questions	9	O
concerning	10	O
the	3	O
nature	6	O
of	2	O
EBV	3	O
latency	7	O
and	3	O
persistence	11	O
in	2	O
stratified	10	O
squamous	8	O
epithelium	10	O
.	1	O

Transactivation	15	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
promoter	8	O
by	2	O
human	5	O
herpesvirus	11	O
6	1	O
(	1	O
HHV-6	5	O
)	1	O
strains	7	O
GS	2	O
and	3	O
Z-29	4	O
in	2	O
primary	7	O
human	5	O
T	1	O
lymphocytes	11	O
and	3	O
identification	14	O
of	2	O
transactivating	15	O
HHV-6	5	O
(	1	O
GS	2	O
)	1	O
gene	4	O
fragments	9	O
.	1	O

Human	5	O
herpesvirus	11	O
6	1	O
(	1	O
HHV-6	5	O
)	1	O
can	3	O
activate	8	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
(	1	O
HIV	3	O
)	1	O
promoter	8	O
and	3	O
accelerate	10	O
cytopathic	10	O
effects	7	O
in	2	O
HIV	3	O
-infected	9	O
human	5	O
T	1	O
cells	5	O
.	1	O

This	4	O
study	5	O
examines	8	O
the	3	O
regions	7	O
of	2	O
the	3	O
HIV	3	O
promoter	8	O
required	8	O
for	3	O
HHV-6	5	O
transactivation	15	O
in	2	O
a	1	O
heterogeneous	13	O
population	10	O
of	2	O
primary	7	O
human	5	O
T	1	O
lymphocytes	11	O
with	4	O
or	2	O
without	7	O
antigenic	9	O
stimulation	11	O
.	1	O

Two	3	O
different	9	O
strains	7	O
of	2	O
HHV-6	5	O
,	1	O
GS	2	O
and	3	O
Z29	3	O
,	1	O
transactivated	14	O
the	3	O
HIV	3	O
promoter	8	O
.	1	O

The	3	O
GS	2	O
strain	6	O
transactivated	14	O
the	3	O
promoter	8	O
in	2	O
both	4	O
stimulated	10	O
and	3	O
resting	7	O
T	1	O
cells	5	O
,	1	O
while	5	O
the	3	O
Z29	3	O
strain	6	O
increased	9	O
HIV	3	O
promoter	8	O
activity	8	O
only	4	O
in	2	O
stimulated	10	O
T	1	O
cells	5	O
.	1	O

Three	5	O
DNA	3	O
clones	6	O
containing	10	O
HHV-6	5	O
(	1	O
GS	2	O
)	1	O
genomic	7	O
fragments	9	O
transactivated	14	O
the	3	O
HIV	3	O
promoter	8	O
in	2	O
cotransfected	13	O
T	1	O
cells	5	O
.	1	O

A	1	O
21.4-kb	7	O
DNA	3	O
clone	5	O
,	1	O
pZVB70	6	O
,	1	O
showed	6	O
the	3	O
highest	7	O
transactivating	15	O
ability	7	O
,	1	O
while	5	O
two	3	O
other	5	O
DNA	3	O
fragments	9	O
,	1	O
pZVB10	6	O
(	1	O
6.2	3	O
kb	2	O
)	1	O
and	3	O
pZVH14	6	O
(	1	O
8.7	3	O
kb	2	O
)	1	O
,	1	O
showed	6	O
lower	5	O
activity	8	O
.	1	O

One	3	O
of	2	O
these	5	O
clones	6	O
,	1	O
pZVH14	6	O
,	1	O
activated	9	O
the	3	O
HIV	3	O
promoter	8	O
construct	9	O
containing	10	O
a	1	O
mutation	8	O
in	2	O
the	3	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
site	4	O
.	1	O

However	7	O
,	1	O
this	4	O
mutated	7	B-Gene
NF	2	I-Gene
kappa	5	I-Gene
B	1	I-Gene
promoter	8	I-Gene
was	3	O
not	3	O
transactivated	14	O
during	6	O
HHV-6	5	O
(	1	O
GS	2	O
)	1	O
infection	9	O
or	2	O
after	5	O
cotransfection	14	O
with	4	O
pZVB70	6	O
or	2	O
pZVB10	6	O
.	1	O

These	5	O
data	4	O
indicate	8	O
that	4	O
the	3	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
sites	5	O
of	2	O
the	3	O
HIV	3	O
promoter	8	O
are	3	O
essential	9	O
for	3	O
its	3	O
transactivation	15	O
during	6	O
HHV-6	5	O
(	1	O
GS	2	O
)	1	O
infection	9	O
.	1	O

By	2	O
increasing	10	O
HIV	3	O
promoter	8	O
activity	8	O
in	2	O
primary	7	O
T	1	O
lymphocytes	11	O
,	1	O
HHV-6	5	O
may	3	O
consequently	12	O
increase	8	O
HIV	3	O
replication	11	O
,	1	O
leading	7	O
to	2	O
an	2	O
increase	8	O
in	2	O
the	3	O
cytopathic	10	O
effect	6	O
on	2	O
coinfected	10	O
human	5	O
T	1	O
cells	5	O
.	1	O

The	3	O
rhombotin	9	B-Gene
family	6	I-Gene
of	2	O
cysteine-rich	13	B-Chemical
LIM-domain	10	O
oncogenes	9	O
:	1	O
distinct	8	O
members	7	O
are	3	O
involved	8	O
in	2	O
T-cell	6	O
translocations	14	O
to	2	O
human	5	O
chromosomes	11	O
11p15	5	O
and	3	O
11p13	5	O
.	1	O

A	1	O
chromosomal	11	O
translocation	13	O
in	2	O
a	1	O
T-cell	6	B-Disease
leukemia	8	I-Disease
involving	9	O
the	3	O
short	5	O
arm	3	O
of	2	O
human	5	O
chromosome	10	O
11	2	O
at	2	O
band	4	O
11p15	5	O
disrupts	8	O
the	3	O
rhombotin	9	B-Gene
gene	4	I-Gene
.	1	O

This	4	O
gene	4	O
encodes	7	O
a	1	O
protein	7	O
with	4	O
duplicated	10	O
cysteine-rich	13	B-Chemical
regions	7	O
called	6	O
LIM	3	O
domains	7	O
,	1	O
which	5	O
show	4	O
homology	8	O
to	2	O
zinc	4	B-Gene
-binding	8	I-Gene
proteins	8	I-Gene
and	3	O
to	2	O
iron-sulfur	11	B-Chemical
centers	7	O
of	2	O
ferredoxins	11	B-Gene
.	1	O

Two	3	O
homologues	10	O
of	2	O
the	3	O
rhombotin	9	B-Gene
gene	4	I-Gene
have	4	O
now	3	O
been	4	O
isolated	8	O
.	1	O

One	3	O
of	2	O
these	5	O
,	1	O
designated	10	O
Rhom-2	6	B-Gene
,	1	O
is	2	O
located	7	O
on	2	O
human	5	O
chromosome	10	O
11	2	O
at	2	O
band	4	O
11p13	5	O
,	1	O
where	5	O
a	1	O
cluster	7	O
of	2	O
T-cell	6	B-Disease
leukemia-specific	17	I-Disease
translocations	14	O
occur	5	O
;	1	O
all	3	O
translocation	13	O
breakpoints	11	O
at	2	O
11p13	5	O
are	3	O
upstream	8	O
of	2	O
the	3	O
Rhom-2	6	B-Gene
gene	4	I-Gene
.	1	O

Human	5	O
and	3	O
mouse	5	B-Gene
Rhom-2	6	I-Gene
are	3	O
highly	6	O
conserved	9	O
and	3	O
,	1	O
like	4	O
rhombotin	9	B-Gene
,	1	O
encode	6	O
two	3	O
tandem	6	O
cysteine-rich	13	B-Chemical
LIM	3	O
domains	7	O
.	1	O

Rhom-2	6	B-Gene
mRNA	4	I-Gene
is	2	O
expressed	9	O
in	2	O
early	5	O
mouse	5	O
development	11	O
in	2	O
central	7	O
nervous	7	O
system	6	O
,	1	O
lung	4	O
,	1	O
kidney	6	O
,	1	O
liver	5	O
,	1	O
and	3	O
spleen	6	O
but	3	O
only	4	O
very	4	O
low	3	O
levels	6	O
occur	5	O
in	2	O
thymus	6	O
.	1	O

The	3	O
other	5	O
gene	4	O
,	1	O
designated	10	O
Rhom-3	6	B-Gene
,	1	O
is	2	O
not	3	O
on	2	O
chromosome	10	O
11	2	O
but	3	O
also	4	O
retains	7	O
homology	8	O
to	2	O
the	3	O
LIM	3	O
domain	6	O
of	2	O
rhombotin	9	B-Gene
.	1	O

Since	5	O
the	3	O
Rhom-2	6	B-Gene
gene	4	I-Gene
is	2	O
such	4	O
a	1	O
common	6	O
site	4	O
of	2	O
chromosomal	11	O
damage	6	O
in	2	O
T-cell	6	O
tumors	6	B-Disease
,	1	O
the	3	O
consistency	11	O
of	2	O
translocations	14	O
near	4	O
the	3	O
rhombotin	9	B-Gene
gene	4	I-Gene
was	3	O
further	7	O
examined	8	O
.	1	O

A	1	O
second	6	O
translocation	13	O
adjacent	8	O
to	2	O
rhombotin	9	B-Gene
was	3	O
found	5	O
and	3	O
at	2	O
the	3	O
same	4	O
position	8	O
as	2	O
in	2	O
the	3	O
previous	8	O
example	7	O
.	1	O

Therefore	9	O
,	1	O
chromosome	10	O
bands	5	O
11p15	5	O
(	1	O
rhombotin	9	B-Gene
)	1	O
and	3	O
11p13	5	O
(	1	O
Rhom-2	6	B-Gene
)	1	O
are	3	O
consistent	10	O
sites	5	O
of	2	O
chromosome	10	O
translocation	13	O
in	2	O
T-cell	6	B-Disease
leukemia	8	I-Disease
,	1	O
with	4	O
the	3	O
11p15	5	O
target	6	O
more	4	O
rarely	6	O
involved	8	O
.	1	O

The	3	O
results	7	O
define	6	O
the	3	O
rhombotin	9	B-Gene
gene	4	I-Gene
family	6	I-Gene
as	2	O
a	1	O
class	5	O
of	2	O
T-cell	6	O
oncogenes	9	O
with	4	O
duplicated	10	O
cysteine-rich	13	B-Chemical
LIM	3	O
domains	7	O
.	1	O

The	3	O
human	5	O
myelomonocytic	14	O
cell	4	O
line	4	O
U-937	5	O
as	2	O
a	1	O
model	5	O
for	3	O
studying	8	O
alterations	11	O
in	2	O
steroid	7	B-Chemical
-induced	8	O
monokine	8	O
gene	4	O
expression	10	O
:	1	O
marked	6	O
enhancement	11	O
of	2	O
lipopolysaccharide	18	B-Chemical
-stimulated	11	O
interleukin-1	13	B-Gene
beta	4	I-Gene
messenger	9	I-Gene
RNA	3	I-Gene
levels	6	O
by	2	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
.	1	O

The	3	O
active	6	O
metabolite	10	O
of	2	O
vitamin	7	B-Chemical
D	1	I-Chemical
,	1	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
[	1	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
]	1	O
,	1	O
is	2	O
a	1	O
potent	6	O
regulator	9	O
of	2	O
human	5	O
monocyte	8	O
/	1	O
macrophage	10	O
function	8	O
in	2	O
vitro	5	O
.	1	O

To	2	O
establish	9	O
a	1	O
model	5	O
for	3	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
regulation	10	O
of	2	O
human	5	O
monocyte	8	O
monokine	8	O
synthesis	9	O
,	1	O
three	5	O
human	5	O
cell	4	O
lines	5	O
(	1	O
U-937	5	O
,	1	O
THP-1	5	O
,	1	O
and	3	O
HL-60	5	O
)	1	O
were	4	O
examined	8	O
for	3	O
:	1	O
1	1	O
)	1	O
the	3	O
presence	8	O
of	2	O
functional	10	O
1	1	B-Gene
,	1	I-Gene
25-	3	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptors	9	I-Gene
;	1	O
2	1	O
)	1	O
the	3	O
accumulation	12	O
of	2	O
interleukin-1	13	B-Gene
beta	4	I-Gene
(	1	I-Gene
IL-1	4	I-Gene
beta	4	I-Gene
)	1	I-Gene
mRNA	4	I-Gene
and	3	O
IL-1	4	B-Gene
beta	4	I-Gene
protein	7	I-Gene
in	2	O
response	8	O
to	2	O
lipopolysaccharide	18	B-Chemical
(	1	O
LPS	3	B-Chemical
)	1	O
;	1	O
and	3	O
3	1	O
)	1	O
the	3	O
regulation	10	O
of	2	O
this	4	O
response	8	O
by	2	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
.	1	O

All	3	O
three	5	O
cell	4	O
lines	5	O
expressed	9	O
vitamin	7	B-Gene
D	1	I-Gene
receptor	8	I-Gene
and	3	O
had	3	O
increased	9	O
levels	6	O
of	2	O
IL-1	4	B-Gene
beta	4	I-Gene
mRNA	4	I-Gene
in	2	O
response	8	O
to	2	O
LPS	3	B-Chemical
.	1	O

Preincubation	13	O
of	2	O
cells	5	O
with	4	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
augmented	9	O
IL-1	4	B-Gene
beta	4	I-Gene
mRNA	4	I-Gene
levels	6	O
only	4	O
in	2	O
U-937	5	O
and	3	O
HL-60	5	O
cells	5	O
.	1	O

From	4	O
these	5	O
data	4	O
,	1	O
and	3	O
taking	6	O
into	4	O
consideration	13	O
their	5	O
state	5	O
of	2	O
differentiation	15	O
and	3	O
relative	8	O
ease	4	O
of	2	O
culture	7	O
,	1	O
U-937	5	O
was	3	O
chosen	6	O
over	4	O
HL-60	5	O
and	3	O
THP-1	5	O
as	2	O
the	3	O
cell	4	O
line	4	O
we	2	O
further	7	O
characterized	13	O
.	1	O

In	2	O
U-937	5	O
cells	5	O
,	1	O
optimum	7	O
time	4	O
and	3	O
dose	4	O
of	2	O
pretreatment	12	O
with	4	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
were	4	O
determined	10	O
to	2	O
be	2	O
12-24	5	O
h	1	O
at	2	O
a	1	O
receptor	8	O
saturating	10	O
concentration	13	O
of	2	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
(	1	O
10	2	O
nM	2	O
)	1	O
.	1	O

Preincubation	13	O
of	2	O
cells	5	O
with	4	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
had	3	O
no	2	O
effect	6	O
on	2	O
the	3	O
time	4	O
course	6	O
of	2	O
IL-1	4	B-Gene
beta	4	I-Gene
mRNA	4	I-Gene
appearance	10	O
in	2	O
response	8	O
to	2	O
LPS	3	B-Chemical
.	1	O

However	7	O
,	1	O
exposure	8	O
of	2	O
U-937	5	O
cells	5	O
to	2	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
increased	9	O
by	2	O
200	3	O
%	1	O
the	3	O
level	5	O
of	2	O
IL-1	4	B-Gene
beta	4	I-Gene
mRNA	4	I-Gene
detected	8	O
and	3	O
decreased	9	O
by	2	O
three	5	O
orders	6	O
of	2	O
magnitude	9	O
the	3	O
concentration	13	O
of	2	O
LPS	3	B-Chemical
required	8	O
to	2	O
achieve	7	O
steady	6	O
state	5	O
mRNA	4	O
levels	6	O
equivalent	10	O
to	2	O
those	5	O
observed	8	O
in	2	O
U-937	5	O
cells	5	O
not	3	O
preincubated	12	O
with	4	O
the	3	O
hormone.2	9	O
+	1	O
o	1	O

Cortivazol	10	B-Chemical
mediated	8	O
induction	9	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
messenger	9	I-Gene
ribonucleic	11	I-Gene
acid	4	I-Gene
in	2	O
wild-type	9	O
and	3	O
dexamethasone	13	B-Chemical
-resistant	10	O
human	5	O
leukemic	8	O
(	1	O
CEM	3	O
)	1	O
cells	5	O
.	1	O

Cortivazol	10	B-Chemical
is	2	O
a	1	O
phenylpyrazolo	14	B-Chemical
glucocorticoid	14	I-Chemical
of	2	O
high	4	O
potency	7	O
and	3	O
unusual	7	O
structure	9	O
.	1	O

In	2	O
both	4	O
wild-type	9	O
and	3	O
highly	6	O
dexamethasone	13	B-Chemical
(	1	O
dex	3	B-Chemical
)	1	O
-resistant	10	O
clones	6	O
of	2	O
the	3	O
human	5	O
leukemic	8	O
cell	4	O
line	4	O
CEM	3	O
,	1	O
exposure	8	O
to	2	O
cortivazol	10	B-Chemical
leads	5	O
to	2	O
cell	4	O
death	5	O
.	1	O

It	2	O
has	3	O
been	4	O
shown	5	O
recently	8	O
that	4	O
in	2	O
wild-type	9	O
CEM	3	O
cells	5	O
but	3	O
not	3	O
in	2	O
a	1	O
dex	3	B-Chemical
-resistant	10	O
,	1	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
-defective	10	O
clone	5	O
ICR-27	6	O
TK-3	4	O
,	1	O
dex	3	B-Chemical
induces	7	O
GR	2	B-Gene
mRNA	4	I-Gene
.	1	O

To	2	O
test	4	O
the	3	O
hypothesis	10	O
that	4	O
cortivazol	10	B-Chemical
acts	4	O
in	2	O
dex	3	B-Chemical
-resistant	10	O
cells	5	O
by	2	O
making	6	O
use	3	O
of	2	O
the	3	O
residual	8	O
GR	2	B-Gene
found	5	O
there	5	O
,	1	O
wild-type	9	O
and	3	O
dex	3	B-Chemical
-resistant	10	O
clones	6	O
were	4	O
treated	7	O
with	4	O
various	7	O
concentrations	14	O
of	2	O
cortivazol	10	B-Chemical
and	3	O
induction	9	O
of	2	O
GR	2	B-Gene
mRNA	4	I-Gene
was	3	O
studied	7	O
.	1	O

Cortivazol	10	B-Chemical
significantly	13	O
induced	7	O
GR	2	B-Gene
mRNA	4	I-Gene
in	2	O
the	3	O
normal	6	O
CEM-C7	6	O
as	2	O
well	4	O
as	2	O
in	2	O
two	3	O
classes	7	O
of	2	O
dex	3	B-Chemical
-resistant	10	O
clones	6	O
,	1	O
although	8	O
the	3	O
dex	3	B-Chemical
-resistant	10	O
clones	6	O
needed	6	O
at	2	O
least	5	O
10	2	O
times	5	O
more	4	O
cortivazol	10	B-Chemical
than	4	O
the	3	O
normal	6	O
cells	5	O
for	3	O
significant	11	O
GR	2	B-Gene
mRNA	4	I-Gene
induction	9	O
.	1	O

Increased	9	O
levels	6	O
of	2	O
GR	2	B-Gene
mRNA	4	I-Gene
were	4	O
noticed	7	O
as	2	O
early	5	O
as	2	O
3	1	O
h	1	O
after	5	O
treatment	9	O
.	1	O

A	1	O
general	7	O
correlation	11	O
between	7	O
induction	9	O
of	2	O
GR	2	B-Gene
mRNA	4	I-Gene
and	3	O
lysis	5	O
of	2	O
the	3	O
normal	6	O
and	3	O
dex	3	B-Chemical
-resistant	10	O
cells	5	O
was	3	O
found	5	O
.	1	O

Positive	8	O
induction	9	O
of	2	O
GR	2	B-Gene
mRNA	4	I-Gene
might	5	O
be	2	O
one	3	O
of	2	O
the	3	O
earliest	8	O
crucial	7	O
steps	5	O
in	2	O
the	3	O
lysis	5	O
of	2	O
normal	6	O
and	3	O
dex	3	B-Chemical
-resistant	10	O
CEM	3	O
cells	5	O
,	1	O
or	2	O
might	5	O
serve	5	O
as	2	O
a	1	O
marker	6	O
for	3	O
the	3	O
process	7	O
.	1	O

However	7	O
,	1	O
the	3	O
lysis	5	O
pathway	7	O
in	2	O
the	3	O
dex	3	B-Chemical
-resistant	10	O
cells	5	O
is	2	O
defective	9	O
in	2	O
that	4	O
dex	3	B-Chemical
-resistant	10	O
clones	6	O
needed	6	O
significantly	13	O
more	4	O
cortivazol	10	B-Chemical
than	4	O
the	3	O
normal	6	O
cells	5	O
for	3	O
lysis	5	O
of	2	O
the	3	O
cells	5	O
.	1	O

A	1	O
case	4	O
of	2	O
hypersensitivity	16	B-Disease
to	2	O
thyroid	7	B-Chemical
hormones	8	I-Chemical
with	4	O
normally	8	O
functioning	11	O
thyroid	7	O
gland	5	O
and	3	O
increased	9	O
nuclear	7	B-Gene
triiodothyronine	16	I-Gene
receptors	9	I-Gene
.	1	O

A	1	O
52-year-old	11	O
male	4	O
presented	9	O
himself	7	O
with	4	O
tachycardia	11	B-Disease
crises	6	O
which	5	O
appeared	8	O
first	5	O
during	6	O
childhood	9	O
,	1	O
increased	9	O
in	2	O
frequency	9	O
without	7	O
goiter	6	O
or	2	O
exophthalmos	12	O
.	1	O

Cardiac	7	O
and	3	O
adrenergic	10	O
diseases	8	O
were	4	O
excluded	8	O
.	1	O

The	3	O
thyroid	7	O
function	8	O
was	3	O
normal	6	O
regarding	9	O
T4	2	B-Chemical
,	1	O
free	4	O
T4	2	B-Chemical
and	3	O
T3	2	B-Chemical
,	1	O
TBG	3	B-Gene
,	1	O
radioiodine	11	O
uptake	6	O
,	1	O
TSH	3	B-Gene
and	3	O
T3	2	B-Chemical
suppressibility	15	O
;	1	O
however	7	O
the	3	O
TSH	3	B-Gene
response	8	O
to	2	O
TRH	3	B-Gene
was	3	O
decreased	9	O
.	1	O

The	3	O
lymphocyte	10	B-Gene
nuclear	7	I-Gene
T3	2	I-Gene
receptor	8	I-Gene
was	3	O
found	5	O
with	4	O
an	2	O
affinity	8	O
close	5	O
to	2	O
that	4	O
of	2	O
normal	6	O
volunteers	10	O
(	1	O
Ka	2	O
:	1	O
1.42	4	O
x	1	O
10	2	O
(	1	O
10	2	O
)	1	O
M-1	3	O
vs	2	O
1.95	4	O
+	1	O
/	1	O
-	1	O
0.35	4	O
x	1	O
10	2	O
(	1	O
10	2	O
)	1	O
M-1	3	O
)	1	O
and	3	O
a	1	O
binding	7	O
capacity	8	O
markedly	8	O
increased	9	O
(	1	O
9.9	3	O
vs	2	O
3.7	3	O
+	1	O
/	1	O
-	1	O
0.4	3	O
fmol	4	O
T3	2	B-Chemical
/	1	O
100	3	O
micrograms	10	O
DNA	3	O
)	1	O
.	1	O

Pindolol	8	B-Chemical
was	3	O
inefficient	11	O
on	2	O
the	3	O
dysrhythmia	11	B-Disease
which	5	O
disappeared	11	O
with	4	O
carbimazole	11	B-Chemical
and	3	O
relapsed	8	O
after	5	O
withdrawal	10	O
of	2	O
the	3	O
antithyroid	11	O
drug	4	O
.	1	O

Under	5	O
carbimazole	11	B-Chemical
,	1	O
the	3	O
plasma	6	O
T4	2	B-Chemical
markedly	8	O
decreased	9	O
(	1	O
27.7	4	O
+	1	O
/	1	O
-	1	O
3.6	3	O
nmol	4	O
/	1	O
l	1	O
)	1	O
but	3	O
the	3	O
patient	7	O
remained	8	O
euthyroid	9	O
.	1	O

The	3	O
clinical	8	O
course	6	O
and	3	O
the	3	O
laboratory	10	O
data	4	O
suggest	7	O
that	4	O
the	3	O
tachycardia	11	B-Disease
crises	6	O
are	3	O
the	3	O
consequence	11	O
of	2	O
a	1	O
hypersensitivity	16	B-Disease
of	2	O
the	3	O
heart	5	O
to	2	O
thyroid	7	B-Chemical
hormones	8	I-Chemical
,	1	O
associated	10	O
with	4	O
an	2	O
increased	9	O
number	6	O
of	2	O
T3	2	B-Gene
nuclear	7	I-Gene
receptor	8	I-Gene
sites	5	O
in	2	O
lymphocytes	11	O
.	1	O

Expression	10	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptors	9	I-Gene
on	2	O
alveolar	8	O
lymphocytes	11	O
from	4	O
patients	8	O
with	4	O
pulmonary	9	O
granulomatous	13	B-Disease
diseases	8	I-Disease
.	1	O

1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
is	2	O
known	5	O
to	2	O
be	2	O
produced	8	O
at	2	O
sites	5	O
of	2	O
granulomatous	13	O
reactions	9	O
.	1	O

In	2	O
order	5	O
to	2	O
characterize	12	O
the	3	O
cell	4	O
types	5	O
that	4	O
are	3	O
targets	7	O
for	3	O
this	4	O
immunoregulatory	16	O
hormone	7	O
,	1	O
we	2	O
have	4	O
evaluated	9	O
the	3	O
expression	10	O
of	2	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptors	9	I-Gene
on	2	O
peripheral	10	O
blood	5	O
T-lymphocytes	13	O
and	3	O
those	5	O
recovered	9	O
from	4	O
the	3	O
lung	4	O
by	2	O
bronchoalveolar	15	O
lavage	6	O
from	4	O
patients	8	O
with	4	O
pulmonary	9	O
granulomatous	13	B-Disease
diseases	8	I-Disease
(	1	O
tuberculosis	12	B-Disease
and	3	O
sarcoidosis	11	B-Disease
)	1	O
and	3	O
from	4	O
normal	6	O
control	7	O
subjects	8	O
using	5	O
combined	8	O
autoradiographic	16	O
and	3	O
immunohistochemical	19	O
techniques	10	O
.	1	O

Lavage	6	O
T-lymphocytes	13	O
from	4	O
patients	8	O
with	4	O
tuberculosis	12	B-Disease
or	2	O
with	4	O
sarcoidosis	11	B-Disease
,	1	O
but	3	O
not	3	O
those	5	O
from	4	O
normal	6	O
control	7	O
subjects	8	O
,	1	O
expressed	9	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptors	9	I-Gene
as	2	O
demonstrated	12	O
by	2	O
binding	7	O
of	2	O
[	1	O
3H	2	O
]	1	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
,	1	O
which	5	O
was	3	O
inhibited	9	O
by	2	O
the	3	O
presence	8	O
of	2	O
excess	6	O
unlabeled	9	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
,	1	O
but	3	O
not	3	O
by	2	O
the	3	O
presence	8	O
of	2	O
unlabeled	9	O
25	2	O
(	1	O
OH	2	O
)	1	O
D3	2	O
(	1	O
receptor	8	O
-positive	9	O
lymphocytes	11	O
:	1	O
sarcoidosis	11	B-Disease
,	1	O
20	2	O
+	1	O
/	1	O
-	1	O
12	2	O
%	1	O
;	1	O
tuberculosis	12	B-Disease
,	1	O
31	2	O
+	1	O
/	1	O
-	1	O
17	2	O
%	1	O
)	1	O
.	1	O

In	2	O
contrast	8	O
,	1	O
blood	5	O
lymphocytes	11	O
from	4	O
patients	8	O
with	4	O
granulomatous	13	B-Disease
diseases	8	I-Disease
did	3	O
not	3	O
express	7	O
detectable	10	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptors	9	I-Gene
.	1	O

The	3	O
percentage	10	O
of	2	O
lavage	6	O
T-lymphocytes	13	O
expressing	10	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptors	9	I-Gene
was	3	O
significantly	13	O
greater	7	O
for	3	O
patients	8	O
with	4	O
tuberculosis	12	B-Disease
presenting	10	O
with	4	O
isolated	8	O
hilar	5	O
adenopathy	10	B-Disease
than	4	O
for	3	O
patients	8	O
with	4	O
pulmonary	9	O
infiltrates	11	O
and	3	O
/	1	O
or	2	O
cavities	8	O
.	1	O

1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptors	9	I-Gene
were	4	O
expressed	9	O
to	2	O
a	1	O
greater	7	O
extent	6	O
on	2	O
CD8+	4	B-Gene
T-lymphocytes	13	O
than	4	O
on	2	O
CD4+	4	B-Gene
T-lymphocytes	13	O
in	2	O
sarcoidosis	11	B-Disease
,	1	O
whereas	7	O
a	1	O
greater	7	O
proportion	10	O
of	2	O
CD4+	4	B-Gene
than	4	O
of	2	O
CD8+	4	B-Gene
T-lymphocytes	13	O
from	4	O
patients	8	O
with	4	O
tuberculosis	12	B-Disease
were	4	O
receptor	8	O
-positive	9	O
.	1	O

These	5	O
findings	8	O
support	7	O
the	3	O
conclusion	10	O
that	4	O
the	3	O
interaction	11	O
of	2	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
with	4	O
its	3	O
receptor	8	O
on	2	O
T-lymphocytes	13	O
may	3	O
play	4	O
an	2	O
important	9	O
role	4	O
in	2	O
the	3	O
regulation	10	O
of	2	O
granulomatous	13	O
reactions	9	O
,	1	O
but	3	O
because	7	O
these	5	O
receptors	9	O
are	3	O
expressed	9	O
on	2	O
different	9	O
lymphocyte	10	O
populations	11	O
,	1	O
the	3	O
net	3	O
effect	6	O
of	2	O
this	4	O
potent	6	O
immunoregulatory	16	O
molecule	8	O
is	2	O
likely	6	O
different	9	O
in	2	O
sarcoidosis	11	B-Disease
and	3	O
tuberculosis	12	B-Disease
.	1	O

Inhibition	10	O
of	2	O
transcription	13	O
factors	7	O
belonging	9	O
to	2	O
the	3	O
rel	3	B-Gene
/	1	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
family	6	I-Gene
by	2	O
a	1	O
transdominant	13	O
negative	8	O
mutant	6	O
.	1	O

The	3	O
KBF1	4	B-Gene
factor	6	I-Gene
,	1	O
which	5	O
binds	5	O
to	2	O
the	3	O
enhancer	8	O
A	1	O
located	7	O
in	2	O
the	3	O
promoter	8	O
of	2	O
the	3	O
mouse	5	B-Gene
MHC	3	I-Gene
class	5	I-Gene
I	1	I-Gene
gene	4	I-Gene
H-2Kb	5	I-Gene
,	1	O
is	2	O
indistinguishable	17	O
from	4	O
the	3	O
p50	3	B-Gene
DNA	3	I-Gene
binding	7	O
subunit	7	O
of	2	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
,	1	O
which	5	O
regulates	9	O
a	1	O
series	6	O
of	2	O
genes	5	O
involved	8	O
in	2	O
immune	6	O
and	3	O
inflammatory	12	O
responses	9	O
.	1	O

The	3	O
KBF1	4	B-Gene
/	1	I-Gene
p50	3	I-Gene
factor	6	I-Gene
binds	5	O
as	2	O
a	1	O
homodimer	9	O
but	3	O
can	3	O
also	4	O
form	4	O
heterodimers	12	O
with	4	O
the	3	O
products	8	O
of	2	O
other	5	O
members	7	O
of	2	O
the	3	O
same	4	O
family	6	O
,	1	O
like	4	O
the	3	O
c-rel	5	B-Gene
and	3	O
v-rel	5	B-Gene
(	1	I-Gene
proto	5	I-Gene
)	1	I-Gene
oncogenes	9	I-Gene
.	1	O

The	3	O
dimerization	12	O
domain	6	O
of	2	O
KBF1	4	B-Gene
/	1	I-Gene
p50	3	I-Gene
is	2	O
contained	9	O
between	7	O
amino	5	O
acids	5	O
201	3	O
and	3	O
367	3	O
.	1	O

A	1	O
mutant	6	O
of	2	O
KBF1	4	B-Gene
/	1	I-Gene
p50	3	I-Gene
(	1	O
delta	5	O
SP	2	O
)	1	O
,	1	O
unable	6	O
to	2	O
bind	4	O
to	2	O
DNA	3	O
but	3	O
able	4	O
to	2	O
form	4	O
homo-	5	O
or	2	O
heterodimers	12	O
,	1	O
has	3	O
been	4	O
constructed	11	O
.	1	O

This	4	O
protein	7	O
reduces	7	O
or	2	O
abolishes	9	O
in	2	O
vitro	5	O
the	3	O
DNA	3	O
binding	7	O
activity	8	O
of	2	O
wild-type	9	O
proteins	8	O
of	2	O
the	3	O
same	4	O
family	6	O
(	1	O
KBF1	4	B-Gene
/	1	I-Gene
p50	3	I-Gene
,	1	O
c-	2	B-Partial_Gene
and	3	O
v-rel	5	B-Gene
)	1	O
.	1	O

This	4	O
mutant	6	O
also	4	O
functions	9	O
in	2	O
vivo	4	O
as	2	O
a	1	O
trans	5	O
-acting	7	O
dominant	8	O
negative	8	O
regulator	9	O
:	1	O
the	3	O
transcriptional	15	O
inducibility	12	O
of	2	O
the	3	O
HIV	3	O
long	4	O
terminal	8	O
repeat	6	O
(	1	O
which	5	O
contains	8	O
two	3	O
potential	9	O
NF-kappa	8	O
B	1	O
binding	7	O
sites	5	O
)	1	O
by	2	O
phorbol	7	B-Chemical
ester	5	I-Chemical
(	1	O
PMA	3	B-Chemical
)	1	O
is	2	O
inhibited	9	O
when	4	O
it	2	O
is	2	O
co	2	O
-transfected	12	O
into	4	O
CD4+	4	B-Gene
T	1	O
cells	5	O
with	4	O
the	3	O
delta	5	O
SP	2	O
mutant	6	O
.	1	O

Similarly	9	O
the	3	O
basal	5	O
as	2	O
well	4	O
as	2	O
TNF	3	B-Gene
or	2	O
IL1	3	B-Gene
-induced	8	O
activity	8	O
of	2	O
the	3	O
MHC	3	B-Gene
class	5	I-Gene
I	1	I-Gene
H-2Kb	5	I-Gene
promoter	8	I-Gene
can	3	O
be	2	O
inhibited	9	O
by	2	O
this	4	O
mutant	6	O
in	2	O
two	3	O
different	9	O
cell	4	O
lines	5	O
.	1	O

These	5	O
results	7	O
constitute	10	O
the	3	O
first	5	O
formal	6	O
demonstration	13	O
that	4	O
these	5	O
genes	5	O
are	3	O
regulated	9	O
by	2	O
members	7	O
of	2	O
the	3	O
rel	3	B-Gene
/	1	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
family	6	I-Gene
.	1	O

Human	5	B-Gene
erythroid	9	I-Gene
5-aminolevulinate	17	I-Gene
synthase	8	I-Gene
:	1	O
promoter	8	O
analysis	8	O
and	3	O
identification	14	O
of	2	O
an	2	O
iron	4	B-Chemical
-responsive	11	O
element	7	O
in	2	O
the	3	O
mRNA	4	O
.	1	O

5-Aminolevulinate	17	B-Gene
synthase	8	I-Gene
(	1	O
ALAS	4	B-Gene
)	1	O
catalyzes	9	O
the	3	O
first	5	O
step	4	O
of	2	O
the	3	O
heme	4	B-Chemical
biosynthetic	12	O
pathway	7	O
.	1	O

cDNA	4	O
clones	6	O
for	3	O
the	3	O
human	5	B-Gene
erythroid	9	I-Gene
ALAS	4	I-Gene
isozyme	7	I-Gene
were	4	O
isolated	8	O
from	4	O
a	1	O
fetal	5	O
liver	5	O
library	7	O
.	1	O

It	2	O
can	3	O
be	2	O
deduced	7	O
that	4	O
the	3	O
erythroid	9	B-Gene
ALAS	4	I-Gene
precursor	9	I-Gene
protein	7	I-Gene
has	3	O
a	1	O
molecular	9	O
weight	6	O
of	2	O
64.6	4	O
kd	2	O
,	1	O
and	3	O
is	2	O
similar	7	O
in	2	O
size	4	O
to	2	O
the	3	O
previously	10	O
isolated	8	O
human	5	B-Gene
housekeeping	12	I-Gene
ALAS	4	I-Gene
precursor	9	I-Gene
of	2	O
molecular	9	O
weight	6	O
70.6	4	O
kd	2	O
.	1	O

The	3	O
mature	6	O
mitochondrial	13	O
forms	5	O
of	2	O
the	3	O
erythroid	9	O
and	3	O
housekeeping	12	B-Gene
ALAS	4	I-Gene
isozymes	8	I-Gene
are	3	O
predicted	9	O
to	2	O
have	4	O
molecular	9	O
weights	7	O
of	2	O
59.5	4	O
kd	2	O
and	3	O
64.6	4	O
kd	2	O
,	1	O
respectively	12	O
.	1	O

The	3	O
two	3	O
isozymes	8	O
show	4	O
little	6	O
amino	5	O
acid	4	O
identity	8	O
in	2	O
their	5	O
N-terminal	10	O
signal	6	O
sequences	9	O
but	3	O
have	4	O
considerable	12	O
sequence	8	O
identity	8	O
in	2	O
the	3	O
C-terminal	10	O
two-thirds	10	O
of	2	O
their	5	O
proteins	8	O
.	1	O

An	2	O
analysis	8	O
of	2	O
the	3	O
immediate	9	O
promoter	8	O
of	2	O
the	3	O
human	5	B-Gene
erythroid	9	I-Gene
ALAS	4	I-Gene
gene	4	I-Gene
revealed	8	O
several	7	O
putative	8	O
erythroid-specific	18	O
cis	3	O
-acting	7	O
elements	8	O
including	9	O
both	4	O
a	1	O
GATA-1	6	B-Gene
and	3	O
an	2	O
NF-E2	5	B-Gene
binding	7	O
site	4	O
.	1	O

An	2	O
iron	4	B-Chemical
-responsive	11	O
element	7	O
(	1	O
IRE	3	O
)	1	O
motif	5	O
has	3	O
been	4	O
identified	10	O
in	2	O
the	3	O
5'-untranslated	15	O
region	6	O
of	2	O
the	3	O
human	5	B-Gene
erythroid	9	I-Gene
ALAS	4	I-Gene
mRNA	4	I-Gene
,	1	O
but	3	O
is	2	O
not	3	O
present	7	O
in	2	O
the	3	O
housekeeping	12	B-Gene
ALAS	4	I-Gene
mRNA	4	I-Gene
.	1	O

Gel	3	O
retardation	11	O
experiments	11	O
established	11	O
that	4	O
this	4	O
IRE	3	O
motif	5	O
formed	6	O
a	1	O
protein	7	O
-	1	O
RNA	3	O
complex	7	O
with	4	O
cytosolic	9	O
extracts	8	O
from	4	O
human	5	O
K562	4	O
cells	5	O
and	3	O
this	4	O
binding	7	O
was	3	O
strongly	8	O
competed	8	O
with	4	O
IRE	3	O
transcripts	11	O
from	4	O
ferritin	8	B-Gene
or	2	O
transferrin	11	B-Gene
receptor	8	I-Gene
mRNAs	5	I-Gene
.	1	O

A	1	O
transcript	10	O
of	2	O
the	3	O
ALAS	4	B-Gene
IRE	3	I-Gene
,	1	O
mutated	7	O
in	2	O
the	3	O
conserved	9	O
loop	4	O
of	2	O
the	3	O
IRE	3	O
,	1	O
did	3	O
not	3	O
readily	7	O
form	4	O
this	4	O
protein	7	O
-	1	O
RNA	3	O
complex	7	O
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
the	3	O
IRE	3	O
motif	5	O
in	2	O
the	3	O
ALAS	4	B-Gene
mRNA	4	I-Gene
is	2	O
functional	10	O
and	3	O
imply	5	O
that	4	O
translation	11	O
of	2	O
the	3	O
mRNA	4	O
is	2	O
controlled	10	O
by	2	O
cellular	8	O
iron	4	B-Chemical
availability	12	O
during	6	O
erythropoiesis	14	O
.	1	O

Human	5	B-Gene
tumor	5	I-Gene
necrosis	8	I-Gene
factor	6	I-Gene
alpha	5	I-Gene
gene	4	I-Gene
regulation	10	O
in	2	O
phorbol	7	B-Chemical
ester	5	I-Chemical
stimulated	10	O
T	1	O
and	3	O
B	1	O
cell	4	O
lines	5	O
.	1	O

The	3	O
minimal	7	O
region	6	O
of	2	O
the	3	O
human	5	B-Gene
tumor	5	I-Gene
necrosis	8	I-Gene
factor	6	I-Gene
alpha	5	I-Gene
(	1	I-Gene
TNF-alpha	9	I-Gene
)	1	I-Gene
gene	4	I-Gene
promoter	8	I-Gene
necessary	9	O
for	3	O
its	3	O
transcriptional	15	O
induction	9	O
by	2	O
phorbol	7	B-Chemical
esters	6	I-Chemical
(	1	O
PMA	3	B-Chemical
)	1	O
in	2	O
human	5	O
T	1	O
and	3	O
B	1	O
lymphocyte	10	O
cell	4	O
lines	5	O
has	3	O
been	4	O
localized	9	O
between	7	O
-52	3	O
and	3	O
+89	3	O
nucleotides	11	O
(	1	O
nt	2	O
)	1	O
relative	8	O
to	2	O
the	3	O
gene	4	O
's	2	O
transcriptional	15	O
start	5	O
site	4	O
.	1	O

Comparison	10	O
of	2	O
these	5	O
sequences	9	O
to	2	O
those	5	O
required	8	O
to	2	O
mediate	7	O
virus	5	O
or	2	O
lipopolysaccharide	18	B-Chemical
(	1	O
LPS	3	B-Chemical
)	1	O
induction	9	O
of	2	O
the	3	O
gene	4	O
reveal	6	O
significant	11	O
differences	11	O
,	1	O
and	3	O
thus	4	O
,	1	O
the	3	O
sequence	8	O
requirements	12	O
for	3	O
PMA	3	B-Chemical
induction	9	O
are	3	O
distinct	8	O
from	4	O
those	5	O
that	4	O
mediate	7	O
induction	9	O
by	2	O
virus	5	O
or	2	O
LPS	3	B-Chemical
.	1	O

Although	8	O
three	5	O
sites	5	O
in	2	O
the	3	O
TNF-alpha	9	B-Gene
promoter	8	I-Gene
(	1	O
kappa	5	O
1	1	O
,	1	O
kappa	5	O
2	1	O
,	1	O
and	3	O
kappa	5	O
3	1	O
)	1	O
specifically	12	O
bind	4	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
in	2	O
lymphoid	8	O
nuclear	7	O
extracts	8	O
,	1	O
TNF-alpha	9	B-Gene
mRNA	4	I-Gene
induction	9	O
by	2	O
PMA	3	B-Chemical
does	4	O
not	3	O
correlate	9	O
with	4	O
NF-kappa	8	B-Gene
B	1	I-Gene
binding	7	O
activities	10	O
displayed	9	O
by	2	O
different	9	O
T	1	O
and	3	O
B	1	O
cell	4	O
lines	5	O
.	1	O

Moreover	8	O
,	1	O
kappa	5	O
1-kappa	7	O
3	1	O
can	3	O
each	4	O
be	2	O
deleted	7	O
from	4	O
the	3	O
TNF-alpha	9	B-Gene
promoter	8	I-Gene
with	4	O
little	6	O
effect	6	O
on	2	O
the	3	O
gene	4	O
's	2	O
inducibility	12	O
by	2	O
PMA	3	B-Chemical
.	1	O

Therefore	9	O
,	1	O
TNF-alpha	9	B-Gene
mRNA	4	I-Gene
induction	9	O
by	2	O
PMA	3	B-Chemical
,	1	O
like	4	O
its	3	O
induction	9	O
by	2	O
virus	5	O
and	3	O
LPS	3	B-Chemical
,	1	O
is	2	O
not	3	O
primarily	9	O
mediated	8	O
by	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
,	1	O
but	3	O
rather	6	O
is	2	O
mediated	8	O
through	7	O
other	5	O
sequences	9	O
and	3	O
protein	7	O
factors	7	O
.	1	O

Surprisingly	12	O
,	1	O
multimers	9	O
of	2	O
kappa	5	O
1-kappa	7	O
3	1	O
can	3	O
confer	6	O
PMA	3	B-Chemical
inducibility	12	O
on	2	O
a	1	O
heterologous	12	O
promoter	8	O
in	2	O
a	1	O
B	1	O
(	1	O
Raji	4	O
)	1	O
,	1	O
but	3	O
not	3	O
a	1	O
T	1	O
(	1	O
HUT78	5	O
)	1	O
cell	4	O
line	4	O
.	1	O

However	7	O
they	4	O
are	3	O
not	3	O
functional	10	O
on	2	O
a	1	O
truncated	9	B-Gene
TNF-alpha	9	I-Gene
promoter	8	I-Gene
,	1	O
indicating	10	O
that	4	O
promoter	8	O
context	7	O
and	3	O
cell	4	O
type	4	O
specificity	11	O
influence	9	O
the	3	O
PMA	3	B-Chemical
inducible	9	O
function	8	O
of	2	O
these	5	O
NF-kappa	8	B-Gene
B	1	I-Gene
binding	7	O
sites	5	O
.	1	O

Towards	7	O
a	1	O
molecular	9	O
understanding	13	O
of	2	O
T-cell	6	O
differentiation	15	O
.	1	O

Lymphoid	8	O
differentiation	15	O
is	2	O
one	3	O
of	2	O
the	3	O
best	4	O
studied	7	O
examples	8	O
of	2	O
mammalian	9	O
development	11	O
.	1	O

Here	4	O
Hans	4	O
Clevers	7	O
and	3	O
Michael	7	O
Owen	4	O
describe	8	O
how	3	O
the	3	O
cloning	7	O
of	2	O
the	3	O
genes	5	O
that	4	O
encode	6	O
T-cell-specific	15	O
membrane	8	O
proteins	8	O
allows	6	O
the	3	O
identification	14	O
of	2	O
transcription	13	O
factors	7	O
that	4	O
control	7	O
the	3	O
expression	10	O
of	2	O
these	5	O
T-cell	6	O
genes	5	O
.	1	O

Such	4	O
transcription	13	O
factors	7	O
play	4	O
a	1	O
key	3	O
role	4	O
in	2	O
the	3	O
development	11	O
of	2	O
the	3	O
mature	6	O
T-cell	6	O
phenotype	9	O
by	2	O
functioning	11	O
as	2	O
'master	7	O
regulators	10	O
of	2	O
T-cell	6	O
differentiation'	16	O
.	1	O

Regulation	10	O
of	2	O
jun	3	B-Gene
and	3	O
fos	3	B-Gene
gene	4	I-Gene
expression	10	O
in	2	O
human	5	O
monocytes	9	O
by	2	O
the	3	O
macrophage	10	B-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
.	1	O

The	3	O
macrophage	10	B-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
(	1	O
M-CSF	5	B-Gene
)	1	O
is	2	O
required	8	O
for	3	O
the	3	O
growth	6	O
and	3	O
differentiation	15	O
of	2	O
mononuclear	11	O
phagocytes	10	O
.	1	O

However	7	O
,	1	O
the	3	O
signaling	9	O
events	6	O
responsible	11	O
for	3	O
these	5	O
effects	7	O
remain	6	O
unclear	7	O
.	1	O

The	3	O
present	7	O
studies	7	O
have	4	O
examined	8	O
the	3	O
effects	7	O
of	2	O
M-CSF	5	B-Gene
on	2	O
potential	9	O
signaling	9	O
pathways	8	O
involving	9	O
expression	10	O
of	2	O
the	3	O
jun	3	B-Gene
and	3	O
fos	3	B-Gene
early	5	I-Gene
response	8	I-Gene
genes	5	I-Gene
.	1	O

Low	3	O
levels	6	O
of	2	O
c-jun	5	B-Gene
transcripts	11	I-Gene
were	4	O
detectable	10	O
in	2	O
resting	7	O
human	5	O
peripheral	10	O
blood	5	O
monocytes	9	O
.	1	O

Treatment	9	O
of	2	O
these	5	O
cells	5	O
with	4	O
10	2	O
(	1	O
3	1	O
)	1	O
units	5	O
/	1	O
ml	2	O
human	5	B-Gene
recombinant	11	I-Gene
M-CSF	5	I-Gene
was	3	O
associated	10	O
with	4	O
rapid	5	O
and	3	O
transient	9	O
increases	9	O
in	2	O
c-jun	5	B-Gene
mRNA	4	I-Gene
levels	6	O
.	1	O

Nuclear	7	O
run-on	6	O
assays	6	O
and	3	O
mRNA	4	O
stability	9	O
studies	7	O
demonstrated	12	O
that	4	O
M-CSF	5	B-Gene
regulates	9	O
c-jun	5	B-Gene
expression	10	O
by	2	O
both	4	O
an	2	O
increase	8	O
in	2	O
transcription	13	O
rate	4	O
and	3	O
a	1	O
prolongation	12	O
in	2	O
the	3	O
half-life	9	O
of	2	O
c-jun	5	B-Gene
transcripts	11	I-Gene
.	1	O

M-CSF	5	B-Gene
treatment	9	O
was	3	O
also	4	O
associated	10	O
with	4	O
a	1	O
rapid	5	O
induction	9	O
of	2	O
the	3	O
jun-B	5	B-Gene
gene	4	I-Gene
,	1	O
although	8	O
expression	10	O
of	2	O
this	4	O
gene	4	O
was	3	O
prolonged	9	O
compared	8	O
to	2	O
that	4	O
of	2	O
c-jun	5	B-Gene
.	1	O

We	2	O
further	7	O
demonstrate	11	O
that	4	O
M-CSF	5	B-Gene
increases	9	O
c-fos	5	B-Gene
mRNA	4	I-Gene
levels	6	O
in	2	O
human	5	O
monocytes	9	O
through	7	O
control	7	O
at	2	O
both	4	O
the	3	O
transcriptional	15	O
and	3	O
posttranscriptional	19	O
levels	6	O
.	1	O

Maximal	7	O
induction	9	O
of	2	O
the	3	O
c-fos	5	B-Gene
gene	4	I-Gene
was	3	O
followed	8	O
by	2	O
that	4	O
for	3	O
the	3	O
fos-B	5	B-Gene
gene	4	I-Gene
.	1	O

Moreover	8	O
,	1	O
M-CSF	5	B-Gene
-induced	8	O
expression	10	O
of	2	O
the	3	O
fos	3	B-Gene
-related	8	O
gene	4	O
,	1	O
fra-1	5	B-Gene
,	1	O
was	3	O
delayed	7	O
compared	8	O
to	2	O
that	4	O
for	3	O
both	4	O
c-fos	5	B-Gene
and	3	O
fos-B	5	B-Gene
.	1	O

Taken	5	O
together	8	O
,	1	O
the	3	O
results	7	O
indicate	8	O
that	4	O
M-CSF	5	B-Gene
treatment	9	O
is	2	O
associated	10	O
with	4	O
differential	12	O
activation	10	O
of	2	O
multiple	8	O
members	7	O
of	2	O
the	3	O
jun	3	B-Gene
/	1	I-Gene
fos	3	I-Gene
family	6	I-Gene
and	3	O
that	4	O
expression	10	O
of	2	O
these	5	O
genes	5	O
could	5	O
contribute	10	O
to	2	O
nuclear	7	O
signaling	9	O
mechanisms	10	O
that	4	O
regulate	8	O
a	1	O
specific	8	O
program	7	O
of	2	O
monocyte	8	O
differentiation	15	O
.	1	O

Cloning	7	O
of	2	O
a	1	O
human	5	B-Gene
homeobox	8	I-Gene
gene	4	I-Gene
that	4	O
resembles	9	O
a	1	O
diverged	8	O
Drosophila	10	B-Gene
homeobox	8	I-Gene
gene	4	I-Gene
and	3	O
is	2	O
expressed	9	O
in	2	O
activated	9	O
lymphocytes	11	O
.	1	O

A	1	O
new	3	O
homeobox	8	B-Gene
gene	4	I-Gene
,	1	O
HB24	4	B-Gene
,	1	O
has	3	O
been	4	O
isolated	8	O
from	4	O
a	1	O
human	5	O
B-lymphocyte	12	O
cDNA	4	O
library	7	O
.	1	O

Northern	8	O
blot	4	O
analysis	8	O
of	2	O
polyadenylated	14	O
RNA	3	O
purified	8	O
from	4	O
activated	9	O
human	5	O
B	1	O
cells	5	O
revealed	8	O
a	1	O
single	6	O
mRNA	4	O
transcript	10	O
of	2	O
approximately	13	O
2.3	3	O
kb	2	O
.	1	O

Two	3	O
cDNA	4	O
clones	6	O
were	4	O
sequenced	9	O
and	3	O
provided	8	O
2	1	O
,	1	O
250	3	O
nucleotides	11	O
(	1	O
nt	2	O
)	1	O
of	2	O
DNA	3	O
sequence	8	O
information	11	O
.	1	O

There	5	O
is	2	O
a	1	O
single	6	O
methionine	10	B-Chemical
codon	5	O
-initiated	10	O
open	4	O
reading	7	O
frame	5	O
of	2	O
1	1	O
,	1	O
458	3	O
nt	2	O
in	2	O
frame	5	O
with	4	O
a	1	O
homeobox	8	O
and	3	O
a	1	O
CAX	3	O
repeat	6	O
,	1	O
and	3	O
the	3	O
open	4	O
reading	7	O
frame	5	O
is	2	O
predicted	9	O
to	2	O
encode	6	O
a	1	O
protein	7	O
of	2	O
51	2	O
,	1	O
659	3	O
daltons	7	O
.	1	O

When	4	O
the	3	O
homeodomain	11	O
from	4	O
HB24	4	B-Gene
was	3	O
compared	8	O
to	2	O
known	5	O
mammalian	9	O
and	3	O
Drosophila	10	O
homeodomains	12	O
it	2	O
was	3	O
found	5	O
to	2	O
be	2	O
only	4	O
moderately	10	O
conserved	9	O
,	1	O
but	3	O
when	4	O
it	2	O
was	3	O
compared	8	O
to	2	O
a	1	O
highly	6	O
diverged	8	O
Drosophila	10	O
homeodomain	11	O
,	1	O
H2.0	4	B-Gene
,	1	O
it	2	O
was	3	O
found	5	O
to	2	O
be	2	O
80	2	O
%	1	O
identical	9	O
.	1	O

The	3	O
HB24	4	B-Gene
mRNA	4	I-Gene
was	3	O
absent	6	O
or	2	O
present	7	O
at	2	O
low	3	O
levels	6	O
in	2	O
normal	6	O
B	1	O
and	3	O
T	1	O
lymphocytes	11	O
;	1	O
however	7	O
,	1	O
with	4	O
the	3	O
appropriate	11	O
activation	10	O
signal	6	O
HB24	4	B-Gene
mRNA	4	I-Gene
was	3	O
induced	7	O
within	6	O
several	7	O
hours	5	O
even	4	O
in	2	O
the	3	O
presence	8	O
of	2	O
cycloheximide	13	B-Chemical
.	1	O

Characterization	16	O
of	2	O
HB24	4	B-Gene
expression	10	O
in	2	O
lymphoid	8	O
and	3	O
select	6	O
developing	10	O
tissues	7	O
was	3	O
performed	9	O
by	2	O
in	2	O
situ	4	O
hybridization	13	O
.	1	O

Positive	8	O
hybridization	13	O
was	3	O
found	5	O
in	2	O
thymus	6	O
,	1	O
tonsil	6	O
,	1	O
bone	4	O
marrow	6	O
,	1	O
developing	10	O
vessels	7	O
,	1	O
and	3	O
in	2	O
fetal	5	O
brain	5	O
.	1	O

HB24	4	B-Gene
is	2	O
likely	6	O
to	2	O
have	4	O
an	2	O
important	9	O
role	4	O
in	2	O
lymphocytes	11	O
as	2	O
well	4	O
as	2	O
in	2	O
certain	7	O
developing	10	O
tissues	7	O
.	1	O

Severe	6	O
5-fluorouracil	14	B-Chemical
toxicity	8	O
secondary	9	O
to	2	O
dihydropyrimidine	17	B-Gene
dehydrogenase	13	I-Gene
deficiency	10	O
.	1	O

A	1	O
potentially	11	O
more	4	O
common	6	O
pharmacogenetic	15	O
syndrome	8	O
.	1	O

This	4	O
study	5	O
describes	9	O
the	3	O
inheritance	11	O
of	2	O
a	1	O
defect	6	O
in	2	O
pyrimidine	10	B-Chemical
catabolism	10	O
and	3	O
its	3	O
association	11	O
with	4	O
drug	4	O
-induced	8	O
toxicity	8	O
in	2	O
a	1	O
patient	7	O
receiving	9	O
5-fluorouracil	14	B-Chemical
(	1	O
FUra	4	B-Chemical
)	1	O
as	2	O
adjuvant	8	O
chemotherapy	12	O
for	3	O
breast	6	B-Disease
carcinoma	9	I-Disease
.	1	O

The	3	O
study	5	O
population	10	O
included	8	O
the	3	O
affected	8	O
patient	7	O
(	1	O
proband	7	O
)	1	O
,	1	O
nine	4	O
of	2	O
her	3	O
blood	5	O
relatives	9	O
,	1	O
and	3	O
seven	5	O
healthy	7	O
volunteers	10	O
.	1	O

The	3	O
activity	8	O
of	2	O
dihydropyrimidine	17	B-Gene
dehydrogenase	13	I-Gene
(	1	O
DPD	3	B-Gene
)	1	O
,	1	O
the	3	O
initial	7	O
enzyme	6	O
of	2	O
pyrimidine	10	B-Chemical
(	1	O
and	3	O
FUra	4	B-Chemical
)	1	O
catabolism	10	O
,	1	O
in	2	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
was	3	O
measured	8	O
in	2	O
each	4	O
subject	7	O
by	2	O
a	1	O
specific	8	O
radiometric	11	O
assay	5	O
using	5	O
FUra	4	B-Chemical
as	2	O
the	3	O
substrate	9	O
.	1	O

The	3	O
proband	7	O
had	3	O
no	2	O
detectable	10	O
DPD	3	B-Gene
activity	8	O
.	1	O

When	4	O
enzyme	6	O
levels	6	O
in	2	O
the	3	O
proband	7	O
and	3	O
relatives	9	O
were	4	O
compared	8	O
with	4	O
that	4	O
in	2	O
controls	8	O
,	1	O
an	2	O
autosomal	9	O
recessive	9	O
pattern	7	O
of	2	O
inheritance	11	O
was	3	O
demonstrated	12	O
.	1	O

This	4	O
is	2	O
the	3	O
third	5	O
patient	7	O
with	4	O
severe	6	O
FUra	4	B-Chemical
toxicity	8	O
secondary	9	O
to	2	O
an	2	O
alteration	10	O
in	2	O
pyrimidine	10	B-Chemical
catabolism	10	O
and	3	O
the	3	O
second	6	O
from	4	O
our	3	O
clinic	6	O
population	10	O
suggesting	10	O
that	4	O
the	3	O
frequency	9	O
of	2	O
this	4	O
genetic	7	O
defect	6	O
may	3	O
be	2	O
greater	7	O
than	4	O
previously	10	O
thought	7	O
.	1	O

Monitoring	10	O
DPD	3	B-Gene
activity	8	O
may	3	O
be	2	O
important	9	O
in	2	O
the	3	O
management	10	O
of	2	O
patients	8	O
experiencing	12	O
severe	6	O
toxicity	8	O
secondary	9	O
to	2	O
FUra	4	B-Chemical
chemotherapy	12	O
.	1	O

Characterization	16	O
of	2	O
an	2	O
immediate-early	15	O
gene	4	O
induced	7	O
in	2	O
adherent	8	O
monocytes	9	O
that	4	O
encodes	7	O
I	1	B-Gene
kappa	5	I-Gene
B	1	I-Gene
-like	5	O
activity	8	O
.	1	O

We	2	O
have	4	O
cloned	6	O
a	1	O
group	5	O
of	2	O
cDNAs	5	O
representing	12	O
mRNAs	5	O
that	4	O
are	3	O
rapidly	7	O
induced	7	O
following	9	O
adherence	9	O
of	2	O
human	5	O
monocytes	9	O
.	1	O

One	3	O
of	2	O
the	3	O
induced	7	O
transcripts	11	O
(	1	O
MAD-3	5	B-Gene
)	1	O
encodes	7	O
a	1	O
protein	7	O
of	2	O
317	3	O
amino	5	O
acids	5	O
with	4	O
one	3	O
domain	6	O
containing	10	O
five	4	O
tandem	6	O
repeats	7	O
of	2	O
the	3	O
cdc10	5	B-Gene
/	1	I-Gene
ankyrin	7	I-Gene
motif	5	O
,	1	O
which	5	O
is	2	O
60	2	O
%	1	O
similar	7	O
(	1	O
46	2	O
%	1	O
identical	9	O
)	1	O
to	2	O
the	3	O
ankyrin	7	B-Gene
repeat	6	O
region	6	O
of	2	O
the	3	O
precursor	9	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
/	1	I-Gene
KBF1	4	I-Gene
p50	3	I-Gene
.	1	O

The	3	O
C-terminus	10	O
has	3	O
a	1	O
putative	8	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
phosphorylation	15	O
site	4	O
.	1	O

In	2	O
vitro	5	O
translated	10	O
MAD-3	5	B-Gene
protein	7	I-Gene
was	3	O
found	5	O
to	2	O
specifically	12	O
inhibit	7	O
the	3	O
DNA	3	O
-binding	8	O
activity	8	O
of	2	O
the	3	O
p50	3	B-Gene
/	1	I-Gene
p65	3	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
complex	7	I-Gene
but	3	O
not	3	O
that	4	O
of	2	O
the	3	O
p50	3	B-Gene
/	1	I-Gene
p50	3	I-Gene
KBF1	4	I-Gene
factor	6	I-Gene
or	2	O
of	2	O
other	5	O
DNA	3	O
-binding	8	O
proteins	8	O
.	1	O

The	3	O
MAD-3	5	B-Gene
cDNA	4	I-Gene
encodes	7	O
an	2	O
I	1	B-Gene
kappa	5	I-Gene
B	1	I-Gene
-like	5	I-Gene
protein	7	I-Gene
that	4	O
is	2	O
likely	6	O
to	2	O
be	2	O
involved	8	O
in	2	O
regulation	10	O
of	2	O
transcriptional	15	O
responses	9	O
to	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
,	1	O
including	9	O
adhesion	8	O
-dependent	10	O
pathways	8	O
of	2	O
monocyte	8	O
activation	10	O
.	1	O

Reactive	8	O
oxygen	6	B-Chemical
intermediates	13	O
as	2	O
apparently	10	O
widely	6	O
used	4	O
messengers	10	O
in	2	O
the	3	O
activation	10	O
of	2	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
transcription	13	I-Gene
factor	6	I-Gene
and	3	O
HIV-1	5	O
.	1	O

Hydrogen	8	B-Chemical
peroxide	8	I-Chemical
and	3	O
oxygen	6	B-Chemical
radicals	8	I-Chemical
are	3	O
agents	6	O
commonly	8	O
produced	8	O
during	6	O
inflammatory	12	O
processes	9	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
we	2	O
show	4	O
that	4	O
micromolar	10	O
concentrations	14	O
of	2	O
H2O2	4	O
can	3	O
induce	6	O
the	3	O
expression	10	O
and	3	O
replication	11	O
of	2	O
HIV-1	5	O
in	2	O
a	1	O
human	5	O
T	1	O
cell	4	O
line	4	O
.	1	O

The	3	O
effect	6	O
is	2	O
mediated	8	O
by	2	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
transcription	13	I-Gene
factor	6	I-Gene
which	5	O
is	2	O
potently	8	O
and	3	O
rapidly	7	O
activated	9	O
by	2	O
an	2	O
H2O2	4	O
treatment	9	O
of	2	O
cells	5	O
from	4	O
its	3	O
inactive	8	O
cytoplasmic	11	O
form	4	O
.	1	O

N-acetyl-L-cysteine	19	B-Chemical
(	1	O
NAC	3	B-Chemical
)	1	O
,	1	O
a	1	O
well	4	O
characterized	13	O
antioxidant	11	O
which	5	O
counteracts	11	O
the	3	O
effects	7	O
of	2	O
reactive	8	O
oxygen	6	B-Chemical
intermediates	13	O
(	1	O
ROI	3	O
)	1	O
in	2	O
living	6	O
cells	5	O
,	1	O
prevented	9	O
the	3	O
activation	10	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
by	2	O
H2O2	4	O
.	1	O

NAC	3	B-Chemical
and	3	O
other	5	O
thiol	5	B-Chemical
compounds	9	O
also	4	O
blocked	7	O
the	3	O
activation	10	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
by	2	O
cycloheximide	13	B-Chemical
,	1	O
double	6	O
-stranded	9	O
RNA	3	O
,	1	O
calcium	7	B-Chemical
ionophore	9	O
,	1	O
TNF-alpha	9	B-Gene
,	1	O
active	6	O
phorbol	7	B-Chemical
ester	5	I-Chemical
,	1	O
interleukin-1	13	B-Gene
,	1	O
lipopolysaccharide	18	B-Chemical
and	3	O
lectin	6	B-Gene
.	1	O

This	4	O
suggests	8	O
that	4	O
diverse	7	O
agents	6	O
thought	7	O
to	2	O
activate	8	O
NF-kappa	8	B-Gene
B	1	I-Gene
by	2	O
distinct	8	O
intracellular	13	O
pathways	8	O
might	5	O
all	3	O
act	3	O
through	7	O
a	1	O
common	6	O
mechanism	9	O
involving	9	O
the	3	O
synthesis	9	O
of	2	O
ROI	3	O
.	1	O

ROI	3	O
appear	6	O
to	2	O
serve	5	O
as	2	O
messengers	10	O
mediating	9	O
directly	8	O
or	2	O
indirectly	10	O
the	3	O
release	7	O
of	2	O
the	3	O
inhibitory	10	O
subunit	7	O
I	1	B-Gene
kappa	5	I-Gene
B	1	I-Gene
from	4	O
NF-kappa	8	B-Gene
B	1	I-Gene
.	1	O

HTLV-1	6	B-Gene
Tax	3	I-Gene
induces	7	O
expression	10	O
of	2	O
various	7	O
immediate	9	O
early	5	O
serum	5	O
responsive	10	O
genes	5	O
.	1	O

Human	5	O
T-cell	6	B-Disease
leukemia	8	I-Disease
virus	5	O
type	4	O
1	1	O
(	1	O
HTLV-1	6	O
)	1	O
is	2	O
an	2	O
etiological	11	O
agent	5	O
of	2	O
adult	5	B-Disease
T-cell	6	I-Disease
leukemia	8	I-Disease
(	1	O
ATL	3	B-Disease
)	1	O
.	1	O

We	2	O
showed	6	O
here	4	O
by	2	O
mobility-shift	14	O
assay	5	O
that	4	O
T-cell	6	O
lines	5	O
transformed	11	O
with	4	O
the	3	O
virus	5	O
contained	9	O
high	4	O
levels	6	O
of	2	O
AP-1	4	B-Gene
activities	10	O
.	1	O

Consistent	10	O
with	4	O
this	4	O
result	6	O
,	1	O
these	5	O
cell	4	O
lines	5	O
expressed	9	O
increased	9	O
levels	6	O
of	2	O
mRNAs	5	O
encoding	8	O
the	3	O
AP-1	4	B-Gene
proteins	8	I-Gene
,	1	O
c-Fos	5	B-Gene
,	1	O
Fra-1	5	B-Gene
,	1	O
c-Jun	5	B-Gene
,	1	O
JunB	4	B-Gene
,	1	O
and	3	O
JunD	4	B-Gene
.	1	O

Previously	10	O
,	1	O
transcription	13	O
of	2	O
the	3	O
c-fos	5	B-Gene
gene	4	I-Gene
has	3	O
been	4	O
reported	8	O
to	2	O
be	2	O
transactivated	14	O
by	2	O
the	3	O
viral	5	O
transcription	13	O
factor	6	O
,	1	O
Tax1	4	B-Gene
.	1	O

By	2	O
using	5	O
the	3	O
human	5	O
T-cell	6	O
line	4	O
(	1	O
JPX-9	5	O
)	1	O
,	1	O
in	2	O
which	5	O
expression	10	O
of	2	O
the	3	O
Tax1	4	B-Gene
is	2	O
inducible	9	O
,	1	O
we	2	O
showed	6	O
that	4	O
expression	10	O
of	2	O
mRNAs	5	O
for	3	O
Fra-1	5	B-Gene
,	1	O
c-Jun	5	B-Gene
,	1	O
and	3	O
JunD	4	B-Gene
was	3	O
also	4	O
transactivated	14	O
by	2	O
Tax1	4	B-Gene
.	1	O

Moreover	8	O
,	1	O
Tax1	4	B-Gene
activated	9	O
expression	10	O
of	2	O
two	3	O
other	5	O
transcription	13	O
factors	7	O
having	6	O
zinc	4	B-Chemical
finger	6	O
motifs	6	O
,	1	O
Egr-1	5	B-Gene
and	3	O
Egr-2	5	B-Gene
,	1	O
in	2	O
the	3	O
same	4	O
cells	5	O
.	1	O

The	3	O
Tax1-inducible	14	B-Gene
transcription	13	O
factors	7	O
identified	10	O
here	4	O
are	3	O
encoded	7	O
by	2	O
the	3	O
members	7	O
of	2	O
immediate	9	O
early	5	O
genes	5	O
under	5	O
the	3	O
control	7	O
of	2	O
growth	6	O
signals	7	O
.	1	O

Thus	4	O
,	1	O
Tax1	4	B-Gene
was	3	O
suggested	9	O
to	2	O
replace	7	O
growth	6	O
signals	7	O
,	1	O
at	2	O
least	5	O
in	2	O
part	4	O
,	1	O
by	2	O
this	4	O
mechanism	9	O
.	1	O

[	1	O
Differential	12	O
diagnostic	10	O
value	5	O
of	2	O
receptors	9	O
of	2	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
(	1	O
calcitriol	10	B-Chemical
)	1	O
determination	13	O
in	2	O
lymphocytes	11	O
of	2	O
children	8	O
with	4	O
rickets	7	B-Disease
and	3	O
rickets	7	B-Disease
-like	5	I-Disease
diseases	8	I-Disease
]	1	O

The	3	O
authors	7	O
provide	7	O
the	3	O
results	7	O
of	2	O
studying	8	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
(	1	O
calcitriol	10	B-Chemical
)	1	O
in	2	O
lymphocytes	11	O
of	2	O
children	8	O
with	4	O
rickets	7	B-Disease
and	3	O
rickets	7	B-Disease
-like	5	I-Disease
diseases	8	I-Disease
.	1	O

It	2	O
is	2	O
proposed	8	O
that	4	O
the	3	O
character	9	O
of	2	O
their	5	O
expression	10	O
under	5	O
the	3	O
influence	9	O
of	2	O
vitamin	7	B-Chemical
D	1	I-Chemical
may	3	O
be	2	O
used	4	O
with	4	O
differential	12	O
diagnostic	10	O
purposes	8	O
in	2	O
view	4	O
.	1	O

Contribution	12	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
and	3	O
Sp1	3	B-Gene
binding	7	O
motifs	6	O
to	2	O
the	3	O
replicative	11	O
capacity	8	O
of	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
:	1	O
distinct	8	O
patterns	8	O
of	2	O
viral	5	O
growth	6	O
are	3	O
determined	10	O
by	2	O
T-cell	6	O
types	5	O
.	1	O

Starting	8	O
with	4	O
a	1	O
replication	11	O
-incompetent	12	O
molecular	9	O
clone	5	O
of	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
,	1	O
lacking	7	O
all	3	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
and	3	O
Sp1	3	B-Gene
binding	7	O
sites	5	O
present	7	O
in	2	O
the	3	O
native	6	O
long	4	O
terminal	8	O
repeat	6	O
(	1	O
LTR	3	O
)	1	O
,	1	O
proviruses	10	O
containing	10	O
reconstructed	13	O
LTRs	4	O
with	4	O
individual	10	O
or	2	O
combinations	12	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
and	3	O
Sp1	3	B-Gene
elements	8	I-Gene
were	4	O
generated	9	O
and	3	O
evaluated	9	O
for	3	O
their	5	O
capacity	8	O
to	2	O
produce	7	O
virus	5	O
progeny	7	O
following	9	O
transfection-cocultivation	26	O
.	1	O

Virus	5	O
stocks	6	O
obtained	8	O
from	4	O
these	5	O
experiments	11	O
exhibited	9	O
a	1	O
continuum	9	O
of	2	O
replicative	11	O
capacities	10	O
in	2	O
different	9	O
human	5	O
T-cell	6	O
types	5	O
depending	9	O
on	2	O
which	5	O
element	7	O
(	1	O
s	1	O
)	1	O
was	3	O
present	7	O
in	2	O
the	3	O
LTR	3	O
.	1	O

For	3	O
example	7	O
,	1	O
in	2	O
experiments	11	O
involving	9	O
proviral	8	O
clones	6	O
with	4	O
LTRs	4	O
containing	10	O
one	3	O
or	2	O
two	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
elements	8	I-Gene
(	1	O
and	3	O
no	2	O
Sp1	3	B-Gene
binding	7	O
sites	5	O
)	1	O
,	1	O
a	1	O
hierarchy	9	O
of	2	O
cellular	8	O
permissivity	12	O
to	2	O
virus	5	O
replication	11	O
(	1	O
peripheral	10	O
blood	5	O
lymphocytes	11	O
=	1	O
MT4	3	O
greater	7	O
than	4	O
H9	2	O
greater	7	O
than	4	O
CEM	3	O
greater	7	O
than	4	O
Jurkat	6	O
)	1	O
was	3	O
observed	8	O
.	1	O

Of	2	O
note	4	O
was	3	O
the	3	O
associated	10	O
emergence	9	O
of	2	O
second-site	11	O
LTR	3	O
revertants	10	O
which	5	O
involved	8	O
an	2	O
alteration	10	O
of	2	O
the	3	O
TATA	4	O
box	3	O
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
LTR	3	O
possesses	9	O
functional	10	O
redundancy	10	O
which	5	O
ensures	7	O
virus	5	O
replication	11	O
in	2	O
different	9	O
T-cell	6	O
types	5	O
and	3	O
is	2	O
capable	7	O
of	2	O
changing	8	O
depending	9	O
on	2	O
the	3	O
particular	10	O
combination	11	O
of	2	O
transcriptional	15	O
factors	7	O
present	7	O
.	1	O

Enhancement	11	O
of	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
1	1	O
replication	11	O
in	2	O
monocytes	9	O
by	2	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxycholecalciferol	27	I-Chemical
.	1	O

Human	5	O
immunodeficiency	16	O
virus	5	O
(	1	O
HIV	3	O
)	1	O
expression	10	O
and	3	O
replication	11	O
are	3	O
under	5	O
tight	5	O
regulatory	10	O
control	7	O
.	1	O

We	2	O
demonstrate	11	O
that	4	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxycholecalciferol	27	I-Chemical
[	1	O
1	1	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
]	1	O
enhances	8	O
the	3	O
replication	11	O
of	2	O
monocyte-	9	O
and	3	O
lymphocyte-tropic	17	O
strains	7	O
of	2	O
HIV-1	5	O
up	2	O
to	2	O
10	2	O
,	1	O
000-fold	8	O
in	2	O
monocyte	8	O
cell	4	O
lines	5	O
,	1	O
peripheral	10	O
blood	5	O
monocytes	9	O
,	1	O
and	3	O
unfractionated	14	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
.	1	O

1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
is	2	O
therefore	9	O
one	3	O
of	2	O
the	3	O
most	4	O
potent	6	O
regulators	10	O
of	2	O
HIV-1	5	O
replication	11	O
described	9	O
to	2	O
date	4	O
.	1	O

Precursors	10	O
of	2	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
enhance	7	O
HIV-1	5	O
replication	11	O
in	2	O
proportion	10	O
to	2	O
their	5	O
affinity	8	O
for	3	O
the	3	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
intracellular	13	I-Gene
receptor	8	I-Gene
,	1	O
suggesting	10	O
that	4	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
influences	10	O
HIV-1	5	O
replication	11	O
by	2	O
mechanisms	10	O
involving	9	O
this	4	O
receptor	8	O
.	1	O

These	5	O
studies	7	O
may	3	O
have	4	O
important	9	O
implications	12	O
for	3	O
the	3	O
design	6	O
of	2	O
effective	9	O
therapy	7	O
of	2	O
HIV-1	5	O
infection	9	O
.	1	O

Inhibition	10	O
of	2	O
HIV-1	5	O
replication	11	O
and	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
activity	8	O
by	2	O
cysteine	8	B-Chemical
and	3	O
cysteine	8	B-Chemical
derivatives	11	O
.	1	O

HIV-1	5	O
proviral	8	O
DNA	3	O
contains	8	O
two	3	O
binding	7	O
sites	5	O
for	3	O
the	3	O
transcription	13	B-Gene
factor	6	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
.	1	O

HIV-1	5	O
-infected	9	O
individuals	11	O
have	4	O
,	1	O
on	2	O
average	7	O
,	1	O
abnormally	10	O
high	4	O
levels	6	O
of	2	O
tumour	6	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
alpha	5	I-Gene
(	1	O
TNF	3	B-Gene
alpha	5	I-Gene
)	1	O
and	3	O
abnormally	10	O
low	3	O
plasma	6	O
cysteine	8	B-Chemical
levels	6	O
.	1	O

We	2	O
therefore	9	O
investigated	12	O
the	3	O
effects	7	O
of	2	O
cysteine	8	B-Chemical
and	3	O
related	7	O
thiols	6	O
on	2	O
HIV-1	5	O
replication	11	O
and	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
expression	10	O
.	1	O

The	3	O
experiments	11	O
in	2	O
this	4	O
report	6	O
show	4	O
that	4	O
cysteine	8	B-Chemical
or	2	O
N-acetylcysteine	16	B-Chemical
(	1	O
NAC	3	B-Chemical
)	1	O
raise	5	O
the	3	O
intracellular	13	O
glutathione	11	B-Chemical
(	1	O
GSH	3	B-Chemical
)	1	O
level	5	O
and	3	O
inhibit	7	O
HIV-1	5	O
replication	11	O
in	2	O
persistently	12	O
infected	8	O
Molt-4	6	O
and	3	O
U937	4	O
cells	5	O
.	1	O

However	7	O
,	1	O
inhibition	10	O
of	2	O
HIV-1	5	O
replication	11	O
appears	7	O
not	3	O
to	2	O
be	2	O
directly	8	O
correlated	10	O
with	4	O
GSH	3	B-Chemical
levels	6	O
.	1	O

Cysteine	8	B-Chemical
and	3	O
NAC	3	B-Chemical
also	4	O
inhibit	7	O
NF-kappa	8	B-Gene
B	1	I-Gene
activity	8	O
as	2	O
determined	10	O
by	2	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assays	6	O
and	3	O
chloramphenicol	15	O
acetyl-transferase	18	O
(	1	O
CAT	3	O
)	1	O
gene	4	O
expression	10	O
under	5	O
control	7	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
binding	7	O
sites	5	O
in	2	O
uninfected	10	O
cells	5	O
.	1	O

This	4	O
suggests	8	O
that	4	O
the	3	O
cysteine	8	B-Chemical
deficiency	10	O
in	2	O
HIV-1	5	O
-infected	9	O
individuals	11	O
may	3	O
cause	5	O
an	2	O
over-expression	15	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
-dependent	10	I-Gene
genes	5	I-Gene
and	3	O
enhance	7	O
HIV-1	5	O
replication	11	O
.	1	O

NAC	3	B-Chemical
may	3	O
be	2	O
considered	10	O
for	3	O
the	3	O
treatment	9	O
of	2	O
HIV-1	5	O
-infected	9	O
individuals	11	O
.	1	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
systemic	8	B-Disease
lupus	5	I-Disease
erythematosus	13	I-Disease
.	1	O

Glucocorticosteroids	20	B-Chemical
remain	6	O
the	3	O
major	5	O
treatment	9	O
modality	8	O
for	3	O
systemic	8	B-Disease
lupus	5	I-Disease
erythematosus	13	I-Disease
(	1	O
SLE	3	B-Disease
)	1	O
,	1	O
but	3	O
their	5	O
mechanism	9	O
of	2	O
action	6	O
is	2	O
unclear	7	O
.	1	O

Over	4	O
the	3	O
past	4	O
decade	6	O
it	2	O
has	3	O
become	6	O
clear	5	O
that	4	O
glucocorticosteroid	19	B-Gene
receptors	9	I-Gene
play	4	O
a	1	O
significant	11	O
role	4	O
in	2	O
the	3	O
mechanism	9	O
of	2	O
glucocorticosteroid	19	B-Chemical
action	6	O
.	1	O

We	2	O
studied	7	O
glucocorticosteroid	19	B-Gene
receptor	8	I-Gene
density	7	O
and	3	O
affinity	8	O
on	2	O
peripheral	10	O
blood	5	O
mononuclear	11	O
cells	5	O
by	2	O
the	3	O
glucocorticosteroid	19	B-Chemical
binding	7	O
assay	5	O
in	2	O
33	2	O
patients	8	O
with	4	O
SLE	3	B-Disease
who	3	O
had	3	O
taken	5	O
no	2	O
glucocorticosteroid	19	B-Chemical
for	3	O
the	3	O
previous	8	O
6	1	O
months	6	O
and	3	O
in	2	O
32	2	O
healthy	7	O
controls	8	O
.	1	O

Patients	8	O
'disease	8	O
activity	8	O
was	3	O
measured	8	O
by	2	O
the	3	O
SLE	3	B-Disease
Disease	7	O
Activity	8	O
Index	5	O
(	1	O
SLEDAI	6	O
)	1	O
.	1	O

Glucocorticosteroid	19	B-Gene
receptors	9	I-Gene
on	2	O
leukocytes	10	O
of	2	O
patients	8	O
with	4	O
SLE	3	B-Disease
were	4	O
significantly	13	O
higher	6	O
than	4	O
in	2	O
healthy	7	O
controls	8	O
(	1	O
4419	4	O
+	1	O
/	1	O
-	1	O
306	3	O
vs	2	O
3369	4	O
+	1	O
/	1	O
-	1	O
196	3	O
,	1	O
p	1	O
less	4	O
than	4	O
0.005	5	O
)	1	O
.	1	O

The	3	O
binding	7	O
affinity	8	O
was	3	O
not	3	O
different	9	O
between	7	O
patients	8	O
and	3	O
controls	8	O
.	1	O

There	5	O
was	3	O
no	2	O
correlation	11	O
between	7	O
glucocorticosteroid	19	B-Gene
receptor	8	I-Gene
number	6	O
and	3	O
SLE	3	B-Disease
disease	7	O
activity	8	O
.	1	O

[	1	O
Changes	7	O
in	2	O
leucocytic	10	B-Gene
estrogen	8	I-Gene
receptor	8	I-Gene
levels	6	O
in	2	O
patients	8	O
with	4	O
gynecomastia	12	B-Disease
]	1	O

The	3	O
number	6	O
of	2	O
estrogen	8	B-Gene
receptor	8	I-Gene
(	1	O
ER	2	B-Gene
)	1	O
in	2	O
human	5	O
peripheral	10	O
leucocytes	10	O
in	2	O
13	2	O
men	3	O
with	4	O
gynecomastia	12	B-Disease
were	4	O
measured	8	O
by	2	O
radioligand	11	O
binding	7	O
method	6	O
.	1	O

The	3	O
results	7	O
were	4	O
compared	8	O
with	4	O
those	5	O
of	2	O
13	2	O
sex-and	7	O
age	3	O
-matched	8	O
healthy	7	O
subjects	8	O
.	1	O

It	2	O
was	3	O
found	5	O
that	4	O
the	3	O
number	6	O
of	2	O
ER	2	B-Gene
in	2	O
leucocytes	10	O
was	3	O
significantly	13	O
increased	9	O
in	2	O
gynecomastia	12	B-Disease
(	1	O
Rs	2	O
of	2	O
leucocytes	10	O
were	4	O
1054	4	O
+	1	O
/	1	O
-	1	O
254	3	O
sites	5	O
/	1	O
cell	4	O
)	1	O
.	1	O

It	2	O
suggested	9	O
that	4	O
increase	8	O
of	2	O
ER	2	B-Gene
levels	6	O
play	4	O
an	2	O
important	9	O
role	4	O
in	2	O
the	3	O
pathogenesis	12	O
of	2	O
gynecomastia	12	B-Disease
.	1	O

[	1	O
Changes	7	O
in	2	O
levels	6	O
of	2	O
leucocytic	10	B-Gene
estrogen	8	I-Gene
receptor	8	I-Gene
in	2	O
patients	8	O
with	4	O
menopausal	10	O
type	4	B-Disease
II	2	I-Disease
diabetes	8	I-Disease
and	3	O
its	3	O
significance	12	O
]	1	O

The	3	O
number	6	O
of	2	O
estrogen	8	B-Gene
receptors	9	I-Gene
(	1	O
ER	2	B-Gene
)	1	O
in	2	O
human	5	O
peripheral	10	O
leucocytes	10	O
in	2	O
12	2	O
women	5	O
with	4	O
menopausal	10	O
type	4	B-Disease
II	2	I-Disease
diabetes	8	I-Disease
was	3	O
measured	8	O
with	4	O
radio-ligand	12	O
binding	7	O
method	6	O
.	1	O

The	3	O
results	7	O
were	4	O
compared	8	O
with	4	O
those	5	O
of	2	O
12	2	O
menopausal	10	O
women	5	O
without	7	O
diabetes	8	B-Disease
and	3	O
12	2	O
normal	6	O
women	5	O
of	2	O
childbearing	12	O
age	3	O
.	1	O

It	2	O
was	3	O
found	5	O
that	4	O
the	3	O
number	6	O
of	2	O
ER	2	B-Gene
in	2	O
the	3	O
patients	8	O
was	3	O
significantly	13	O
decreased	9	O
.	1	O

Our	3	O
data	4	O
indicate	8	O
that	4	O
decrease	8	O
of	2	O
ER	2	B-Gene
level	5	O
in	2	O
leukocytes	10	O
may	3	O
be	2	O
related	7	O
to	2	O
the	3	O
pathogenesis	12	O
of	2	O
type	4	B-Disease
II	2	I-Disease
diabetes	8	I-Disease
in	2	O
menopausal	10	O
period	6	O
.	1	O

Lymphocyte	10	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
binding	7	O
during	6	O
depression	10	B-Disease
and	3	O
after	5	O
clinical	8	O
recovery	8	O
.	1	O

Lymphocyte	10	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
binding	7	O
parameters	10	O
were	4	O
studied	7	O
in	2	O
15	2	O
severely	8	O
depressed	9	O
patients	8	O
during	6	O
depression	10	B-Disease
and	3	O
after	5	O
clinical	8	O
recovery	8	O
,	1	O
and	3	O
in	2	O
15	2	O
healthy	7	O
controls	8	O
.	1	O

There	5	O
was	3	O
no	2	O
difference	10	O
in	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
number	6	O
or	2	O
affinity	8	O
between	7	O
depressed	9	O
patients	8	O
and	3	O
recovered	9	O
or	2	O
control	7	O
subjects	8	O
.	1	O

Afternoon	9	O
ACTH	4	B-Gene
and	3	O
cortisol	8	B-Chemical
concentrations	14	O
did	3	O
not	3	O
differ	6	O
significantly	13	O
between	7	O
the	3	O
three	5	O
groups	6	O
.	1	O

No	2	O
relationship	12	O
could	5	O
be	2	O
established	11	O
between	7	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
binding	7	O
and	3	O
antidepressant	14	O
medication	10	O
.	1	O

These	5	O
data	4	O
support	7	O
the	3	O
view	4	O
of	2	O
an	2	O
impaired	8	O
ligand	6	O
-induced	8	O
plasticity	10	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
regulation	10	O
rather	6	O
than	4	O
the	3	O
hypothesis	10	O
of	2	O
decreased	9	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
numbers	7	O
during	6	O
depression	10	B-Disease
.	1	O

Nuclear	7	O
association	11	O
of	2	O
a	1	O
T-cell	6	O
transcription	13	O
factor	6	O
blocked	7	O
by	2	O
FK-506	6	B-Chemical
and	3	O
cyclosporin	11	B-Chemical
A	1	I-Chemical
[	1	O
see	3	O
comments	8	O
]	1	O

Cyclosporin	11	B-Chemical
A	1	I-Chemical
and	3	O
FK506	5	B-Chemical
inhibit	7	O
T-	2	O
and	3	O
B-cell	6	O
activation	10	O
and	3	O
other	5	O
processes	9	O
essential	9	O
to	2	O
an	2	O
effective	9	O
immune	6	O
response	8	O
.	1	O

In	2	O
T	1	O
lymphocytes	11	O
these	5	O
drugs	5	O
disrupt	7	O
an	2	O
unknown	7	O
step	4	O
in	2	O
the	3	O
transmission	12	O
of	2	O
signals	7	O
from	4	O
the	3	O
T-cell	6	B-Gene
antigen	7	I-Gene
receptor	8	I-Gene
to	2	O
cytokine	8	O
genes	5	O
that	4	O
coordinate	10	O
the	3	O
immune	6	O
response	8	O
.	1	O

The	3	O
putative	8	O
intracellular	13	O
receptors	9	O
for	3	O
FK506	5	B-Chemical
and	3	O
cyclosporin	11	B-Chemical
are	3	O
cis-trans	9	B-Gene
prolyl	6	I-Gene
isomerases	10	I-Gene
.	1	O

Binding	7	O
of	2	O
the	3	O
drug	4	O
inhibits	8	O
isomerase	9	O
activity	8	O
,	1	O
but	3	O
studies	7	O
with	4	O
other	5	O
prolyl	6	B-Gene
isomerase	9	I-Gene
inhibitors	10	O
and	3	O
analysis	8	O
of	2	O
cyclosporin	11	B-Chemical
-resistant	10	O
mutants	7	O
in	2	O
yeast	5	O
suggest	7	O
that	4	O
the	3	O
effects	7	O
of	2	O
the	3	O
drug	4	O
result	6	O
from	4	O
the	3	O
formation	9	O
of	2	O
an	2	O
inhibitory	10	O
complex	7	O
between	7	O
the	3	O
drug	4	O
and	3	O
isomerase	9	O
,	1	O
and	3	O
not	3	O
from	4	O
inhibition	10	O
of	2	O
isomerase	9	O
activity	8	O
.	1	O

A	1	O
transcription	13	O
factor	6	O
,	1	O
NF-AT	5	B-Gene
,	1	O
which	5	O
is	2	O
essential	9	O
for	3	O
early	5	O
T-cell	6	O
gene	4	O
activation	10	O
,	1	O
seems	5	O
to	2	O
be	2	O
a	1	O
specific	8	O
target	6	O
of	2	O
cyclosporin	11	B-Chemical
A	1	I-Chemical
and	3	O
FK506	5	B-Chemical
action	6	O
because	7	O
transcription	13	O
directed	8	O
by	2	O
this	4	O
protein	7	O
is	2	O
blocked	7	O
in	2	O
T	1	O
cells	5	O
treated	7	O
with	4	O
these	5	O
drugs	5	O
,	1	O
with	4	O
little	6	O
or	2	O
no	2	O
effect	6	O
on	2	O
other	5	O
transcription	13	O
factors	7	O
such	4	O
as	2	O
AP-1	4	B-Gene
and	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
.	1	O

Here	4	O
we	2	O
demonstrate	11	O
that	4	O
NF-AT	5	B-Gene
is	2	O
formed	6	O
when	4	O
a	1	O
signal	6	O
from	4	O
the	3	O
antigen	7	O
receptor	8	O
induces	7	O
a	1	O
pre	3	O
-existing	9	O
cytoplasmic	11	O
subunit	7	O
to	2	O
translocate	11	O
to	2	O
the	3	O
nucleus	7	O
and	3	O
combine	7	O
with	4	O
a	1	O
newly	5	O
synthesized	11	O
nuclear	7	O
subunit	7	O
of	2	O
NF-AT	5	B-Gene
.	1	O

FK506	5	B-Chemical
and	3	O
cyclosporin	11	B-Chemical
A	1	I-Chemical
block	5	O
translocation	13	O
of	2	O
the	3	O
cytoplasmic	11	O
component	9	O
without	7	O
affecting	9	O
synthesis	9	O
of	2	O
the	3	O
nuclear	7	O
subunit	7	O
.	1	O

Regulation	10	O
of	2	O
M-CSF	5	B-Gene
expression	10	O
by	2	O
M-CSF	5	B-Gene
:	1	O
role	4	O
of	2	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
and	3	O
transcription	13	B-Gene
factor	6	I-Gene
NF	2	I-Gene
kappa	5	I-Gene
B	1	I-Gene
.	1	O

Macrophage-colony	17	B-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
(	1	O
M-CSF	5	B-Gene
)	1	O
,	1	O
also	4	O
referred	8	O
to	2	O
as	2	O
CSF-1	5	B-Gene
,	1	O
regulates	9	O
the	3	O
survival	8	O
,	1	O
growth	6	O
,	1	O
differentiation	15	O
and	3	O
functional	10	O
activity	8	O
of	2	O
monocytes	9	O
by	2	O
binding	7	O
to	2	O
a	1	O
single	6	O
class	5	O
of	2	O
high-affinity	13	O
cell	4	O
surface	7	O
receptors	9	O
,	1	O
known	5	O
to	2	O
be	2	O
the	3	O
product	7	O
of	2	O
the	3	O
c-fms	5	B-Gene
protooncogene	13	I-Gene
.	1	O

The	3	O
detection	9	O
of	2	O
both	4	O
M-CSF	5	B-Gene
and	3	O
c-fms	5	B-Gene
expression	10	O
by	2	O
cells	5	O
of	2	O
the	3	O
monocyte	8	O
lineage	7	O
has	3	O
suggested	9	O
that	4	O
M-CSF	5	B-Gene
may	3	O
act	3	O
by	2	O
an	2	O
autocrine	9	O
mechanism	9	O
.	1	O

Interestingly	13	O
,	1	O
it	2	O
has	3	O
been	4	O
shown	5	O
that	4	O
M-CSF	5	B-Gene
can	3	O
induce	6	O
the	3	O
expression	10	O
of	2	O
its	3	O
own	3	O
gene	4	O
.	1	O

Although	8	O
sensitivity	11	O
to	2	O
M-CSF	5	B-Gene
can	3	O
be	2	O
modulated	9	O
by	2	O
regulation	10	O
of	2	O
receptor	8	O
expression	10	O
and	3	O
function	8	O
,	1	O
M-CSF	5	B-Gene
responsiveness	14	O
is	2	O
largely	7	O
determined	10	O
at	2	O
a	1	O
postreceptor	12	O
level	5	O
.	1	O

To	2	O
date	4	O
,	1	O
little	6	O
is	2	O
known	5	O
about	5	O
the	3	O
intracellular	13	O
pathway	7	O
of	2	O
M-CSF	5	B-Gene
signal	6	O
transduction	12	O
.	1	O

We	2	O
have	4	O
therefore	9	O
investigated	12	O
the	3	O
changes	7	O
in	2	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
(	1	O
PKC	3	B-Gene
)	1	O
activity	8	O
upon	4	O
exposure	8	O
of	2	O
monocytes	9	O
to	2	O
M-CSF	5	B-Gene
.	1	O

We	2	O
show	4	O
that	4	O
M-CSF	5	B-Gene
activates	9	O
and	3	O
translocates	12	O
PKC	3	B-Gene
.	1	O

Inhibition	10	O
of	2	O
PKC	3	B-Gene
by	2	O
the	3	O
isoquinoline	12	B-Chemical
derivative	10	O
H7	2	O
abolishes	9	O
induction	9	O
of	2	O
M-CSF	5	B-Gene
by	2	O
M-CSF	5	B-Gene
.	1	O

Furthermore	11	O
,	1	O
activation	10	O
of	2	O
PKC	3	B-Gene
was	3	O
pertussis-toxin	15	B-Gene
-sensitive	10	O
and	3	O
was	3	O
associated	10	O
with	4	O
the	3	O
detection	9	O
of	2	O
an	2	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
protein	7	I-Gene
in	2	O
nuclear	7	O
extracts	8	O
of	2	O
M-CSF	5	B-Gene
-induced	8	O
blood	5	O
monocytes	9	O
but	3	O
not	3	O
in	2	O
monocytes	9	O
exposed	7	O
to	2	O
medium	6	O
treatment	9	O
only	4	O
.	1	O

The	3	O
results	7	O
suggest	7	O
that	4	O
M-CSF	5	B-Gene
induction	9	O
of	2	O
M-CSF	5	B-Gene
involves	8	O
G	1	B-Gene
proteins	8	I-Gene
,	1	O
PKC	3	B-Gene
and	3	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
.	1	O

NF-kappa	8	B-Gene
B	1	I-Gene
activation	10	O
by	2	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
alpha	5	I-Gene
in	2	O
the	3	O
Jurkat	6	O
T	1	O
cell	4	O
line	4	O
is	2	O
independent	11	O
of	2	O
protein	7	B-Gene
kinase	6	I-Gene
A	1	I-Gene
,	1	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
,	1	O
and	3	O
Ca	2	O
(	1	O
2+	2	O
)	1	O
-regulated	10	O
kinases	7	O
.	1	O

NF-kappa	8	B-Gene
B	1	I-Gene
is	2	O
a	1	O
DNA	3	O
-binding	8	O
regulatory	10	O
factor	6	O
able	4	O
to	2	O
control	7	O
transcription	13	O
of	2	O
a	1	O
number	6	O
of	2	O
genes	5	O
,	1	O
including	9	O
human	5	O
immunodeficiency	16	O
virus	5	O
(	1	O
HIV	3	O
)	1	O
genes	5	O
.	1	O

In	2	O
T	1	O
cells	5	O
,	1	O
NF-kappa	8	B-Gene
B	1	I-Gene
is	2	O
activated	9	O
upon	4	O
cellular	8	O
treatment	9	O
by	2	O
phorbol	7	B-Chemical
esters	6	I-Chemical
and	3	O
the	3	O
cytokine	8	B-Gene
tumor	5	I-Gene
necrosis	8	I-Gene
factor	6	I-Gene
alpha	5	I-Gene
(	1	O
TNF	3	B-Gene
alpha	5	I-Gene
)	1	O
.	1	O

In	2	O
the	3	O
present	7	O
work	4	O
,	1	O
we	2	O
investigated	12	O
the	3	O
molecular	9	O
events	6	O
leading	7	O
to	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
activation	10	O
by	2	O
TNF	3	B-Gene
alpha	5	I-Gene
in	2	O
a	1	O
human	5	O
T	1	O
cell	4	O
line	4	O
(	1	O
Jurkat	6	O
)	1	O
and	3	O
its	3	O
subclone	8	O
JCT6	4	O
,	1	O
which	5	O
presents	8	O
a	1	O
deficiency	10	O
in	2	O
the	3	O
PKA	3	B-Gene
transduction	12	O
pathway	7	O
.	1	O

We	2	O
found	5	O
that	4	O
in	2	O
both	4	O
cell	4	O
lines	5	O
,	1	O
both	4	O
phorbol	7	B-Chemical
ester	5	I-Chemical
and	3	O
TNF	3	B-Gene
alpha	5	I-Gene
were	4	O
able	4	O
to	2	O
activate	8	O
NF-kappa	8	B-Gene
B	1	I-Gene
.	1	O

Phorbol	7	B-Chemical
activation	10	O
was	3	O
positively	10	O
modulated	9	O
by	2	O
Ca2+	4	O
influx	6	O
while	5	O
TNF	3	B-Gene
alpha	5	I-Gene
activation	10	O
was	3	O
not	3	O
.	1	O

Furthermore	11	O
,	1	O
while	5	O
PMA	3	B-Chemical
activation	10	O
was	3	O
inhibited	9	O
by	2	O
the	3	O
PKC	3	B-Gene
inhibitor	9	O
staurosporin	12	B-Chemical
,	1	O
the	3	O
TNF	3	B-Gene
alpha	5	I-Gene
effect	6	O
was	3	O
unchanged	9	O
.	1	O

TNF	3	B-Gene
alpha	5	I-Gene
did	3	O
not	3	O
activate	8	O
cAMP	4	B-Chemical
production	10	O
and	3	O
its	3	O
signal	6	O
was	3	O
not	3	O
modulated	9	O
by	2	O
cAMP	4	B-Chemical
activators	10	O
.	1	O

Moreover	8	O
,	1	O
cAMP	4	B-Chemical
activators	10	O
did	3	O
not	3	O
activate	8	O
NF-kappa	8	B-Gene
B	1	I-Gene
in	2	O
Jurkat	6	O
cells	5	O
.	1	O

Thus	4	O
,	1	O
TNF	3	B-Gene
alpha	5	I-Gene
-induced	8	O
NF-kappa	8	B-Gene
B	1	I-Gene
activation	10	O
was	3	O
found	5	O
to	2	O
be	2	O
mediated	8	O
by	2	O
none	4	O
of	2	O
the	3	O
major	5	O
signal	6	O
-mediating	10	O
kinases	7	O
such	4	O
as	2	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
(	1	O
PKC	3	B-Gene
)	1	O
,	1	O
protein	7	B-Gene
kinase	6	I-Gene
A	1	I-Gene
,	1	O
or	2	O
Ca	2	O
(	1	O
2+	2	O
)	1	O
-regulated	10	O
kinases	7	O
.	1	O

Furthermore	11	O
,	1	O
we	2	O
found	5	O
that	4	O
cytoplasmic	11	O
acidification	13	O
facilitated	11	O
NF-kappa	8	B-Gene
B	1	I-Gene
activation	10	O
by	2	O
both	4	O
TNF	3	B-Gene
alpha	5	I-Gene
and	3	O
PKC	3	B-Gene
,	1	O
by	2	O
a	1	O
mechanism	9	O
that	4	O
increases	9	O
NF-kappa	8	B-Gene
B	1	I-Gene
/	1	I-Gene
I	1	I-Gene
kappa	5	I-Gene
B	1	I-Gene
dissociation	12	O
without	7	O
affecting	9	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
translocation	13	O
step	4	O
.	1	O

NF-kappa	8	B-Gene
B	1	I-Gene
activity	8	O
in	2	O
T	1	O
cells	5	O
stably	6	O
expressing	10	O
the	3	O
Tax	3	B-Gene
protein	7	I-Gene
of	2	O
human	5	O
T	1	O
cell	4	O
lymphotropic	12	O
virus	5	O
type	4	O
I	1	O
.	1	O

The	3	O
effect	6	O
of	2	O
constitutive	12	O
Tax	3	B-Gene
expression	10	O
on	2	O
the	3	O
interaction	11	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
with	4	O
its	3	O
recognition	11	O
sequence	8	O
and	3	O
on	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
-dependent	10	O
gene	4	O
expression	10	O
was	3	O
examined	8	O
in	2	O
T	1	O
lymphoid	8	O
Jurkat	6	O
cell	4	O
lines	5	O
(	1	O
19D	3	O
and	3	O
9J	2	O
)	1	O
stably	6	O
transformed	11	O
with	4	O
a	1	O
Tax	3	B-Gene
expression	10	O
vector	6	O
.	1	O

Tax	3	B-Gene
expressing	10	O
T	1	O
cell	4	O
lines	5	O
contained	9	O
a	1	O
constitutive	12	O
level	5	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
binding	7	O
activity	8	O
,	1	O
detectable	10	O
by	2	O
mobility	8	O
shift	5	O
assay	5	O
and	3	O
uv	2	O
cross	5	O
-linking	8	O
using	5	O
a	1	O
palindromic	11	O
NF-kappa	8	B-Gene
B	1	I-Gene
probe	5	O
homologous	10	O
to	2	O
the	3	O
interferon	10	B-Gene
beta	4	I-Gene
PRDII	5	O
site	4	O
.	1	O

In	2	O
Jurkat	6	O
and	3	O
NC2.10	6	O
induction	9	O
with	4	O
phorbol	7	B-Chemical
esters	6	I-Chemical
resulted	8	O
in	2	O
the	3	O
appearance	10	O
of	2	O
new	3	O
DNA	3	O
binding	7	O
proteins	8	O
of	2	O
85	2	O
,	1	O
75	2	O
,	1	O
and	3	O
54	2	O
kDa	3	O
,	1	O
whereas	7	O
in	2	O
Tax	3	B-Gene
expressing	10	O
cells	5	O
the	3	O
85-kDa	6	O
protein	7	O
and	3	O
a	1	O
92-kDa	6	O
DNA	3	O
binding	7	O
protein	7	O
were	4	O
constitutively	14	O
induced	7	O
.	1	O

Expression	10	O
of	2	O
Tax	3	B-Gene
protein	7	I-Gene
in	2	O
19D	3	O
and	3	O
9J	2	O
resulted	8	O
in	2	O
transcription	13	O
of	2	O
the	3	O
endogenous	10	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
-dependent	10	O
granulocyte-macrophage	22	B-Gene
colony	6	I-Gene
stimulating	11	I-Gene
factor	6	I-Gene
gene	4	I-Gene
and	3	O
increased	9	O
basal	5	O
level	5	O
expression	10	O
of	2	O
transfected	11	O
NF-kappa	8	B-Gene
B	1	I-Gene
-regulated	10	O
promoters	9	O
.	1	O

Nonetheless	11	O
transcription	13	O
of	2	O
both	4	O
the	3	O
endogenous	10	O
and	3	O
the	3	O
transfected	11	O
gene	4	O
was	3	O
inducible	9	O
by	2	O
PMA	3	B-Chemical
treatment	9	O
.	1	O

Tax	3	B-Gene
expression	10	O
in	2	O
Jurkat	6	O
T	1	O
cells	5	O
may	3	O
alter	5	O
the	3	O
stoichiometry	13	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
DNA	3	I-Gene
binding	7	I-Gene
proteins	8	I-Gene
and	3	O
thus	4	O
change	6	O
the	3	O
expression	10	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
-regulated	10	O
promoters	9	O
.	1	O

Regulation	10	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
human	5	O
mononuclear	11	O
cells	5	O
:	1	O
effects	7	O
of	2	O
glucocorticoid	14	B-Chemical
treatment	9	O
,	1	O
Cushing	7	B-Disease
's	2	I-Disease
disease	7	I-Disease
and	3	O
ketoconazole	12	B-Chemical
.	1	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
(	1	O
GcR	3	B-Gene
)	1	O
were	4	O
determined	10	O
by	2	O
a	1	O
whole	5	O
cell	4	O
assay	5	O
in	2	O
human	5	O
mononulear	10	O
leukocytes	10	O
(	1	O
hMNL	4	O
)	1	O
from	4	O
control	7	O
subjects	8	O
,	1	O
patients	8	O
receiving	9	O
glucocorticoid	14	B-Chemical
therapy	7	O
for	3	O
systemic	8	O
diseases	8	O
and	3	O
Cushing	7	B-Disease
's	2	I-Disease
disease	7	I-Disease
patients	8	O
with	4	O
or	2	O
without	7	O
ketoconazole	12	B-Chemical
therapy	7	O
.	1	O

Prolonged	9	O
corticosteroid	14	B-Chemical
treatment	9	O
resulted	8	O
in	2	O
down-regulation	15	O
of	2	O
GcR	3	B-Gene
,	1	O
while	5	O
the	3	O
mean	4	O
level	5	O
of	2	O
GcR	3	B-Gene
in	2	O
Cushing	7	B-Disease
's	2	I-Disease
disease	7	I-Disease
was	3	O
normal	6	O
.	1	O

In	2	O
this	4	O
group	5	O
,	1	O
however	7	O
,	1	O
receptor	8	O
levels	6	O
and	3	O
morning	7	O
plasma	6	O
cortisol	8	B-Chemical
values	6	O
showed	6	O
a	1	O
negative	8	O
correlation	11	O
,	1	O
indicating	10	O
a	1	O
subtle	6	O
down-regulatory	15	O
effect	6	O
.	1	O

Furthermore	11	O
,	1	O
GcR	3	B-Gene
were	4	O
unaltered	9	O
after	5	O
these	5	O
patients	8	O
received	8	O
ketoconazole	12	B-Chemical
,	1	O
in	2	O
spite	5	O
of	2	O
a	1	O
marked	6	O
reduction	9	O
in	2	O
morning	7	O
plasma	6	O
cortisol	8	B-Chemical
and	3	O
urinary	7	O
free	4	O
cortisol	8	B-Chemical
.	1	O

We	2	O
also	4	O
observed	8	O
that	4	O
ketoconazole	12	B-Chemical
was	3	O
a	1	O
weak	4	O
competitor	10	O
of	2	O
GcR	3	B-Gene
in	2	O
intact	6	O
cells	5	O
,	1	O
although	8	O
it	2	O
significantly	13	O
inhibited	9	O
[	1	O
3H	2	O
]	1	O
dexamethasone	13	B-Chemical
binding	7	O
in	2	O
cytosolic	9	O
preparations	12	O
from	4	O
rat	3	O
tissues	7	O
.	1	O

The	3	O
results	7	O
suggested	9	O
that	4	O
GcR	3	B-Gene
in	2	O
hMNL	4	O
are	3	O
down	4	O
-regulated	10	O
by	2	O
synthetic	9	O
steroids	8	B-Chemical
given	5	O
in	2	O
vivo	4	O
,	1	O
but	3	O
they	4	O
showed	6	O
very	4	O
mild	4	O
down-regulation	15	O
in	2	O
hypercortisolemic	17	O
patients	8	O
suffering	9	O
from	4	O
Cushing	7	B-Disease
's	2	I-Disease
disease	7	I-Disease
.	1	O

Finally	7	O
,	1	O
we	2	O
did	3	O
not	3	O
observed	8	O
either	6	O
up-regulation	13	O
or	2	O
antagonism	10	O
of	2	O
GcR	3	B-Gene
by	2	O
ketoconazole	12	B-Chemical
treatment	9	O
,	1	O
at	2	O
the	3	O
time	4	O
that	4	O
cortisol	8	B-Chemical
levels	6	O
of	2	O
patients	8	O
with	4	O
Cushing	7	B-Disease
's	2	I-Disease
disease	7	I-Disease
were	4	O
reduced	7	O
.	1	O

This	4	O
indicates	9	O
that	4	O
the	3	O
beneficial	10	O
effects	7	O
of	2	O
ketoconazole	12	B-Chemical
in	2	O
Cushing	7	B-Disease
's	2	I-Disease
disease	7	I-Disease
are	3	O
due	3	O
to	2	O
adrenal	7	O
cortisol	8	B-Chemical
suppression	11	O
and	3	O
not	3	O
to	2	O
interaction	11	O
with	4	O
GcR	3	B-Gene
of	2	O
target	6	O
cells	5	O
,	1	O
and	3	O
that	4	O
the	3	O
process	7	O
of	2	O
GcR	3	B-Gene
regulation	10	O
in	2	O
hMNL	4	O
is	2	O
a	1	O
complex	7	O
phenomenon	10	O
awaiting	8	O
further	7	O
elucidation	11	O
.	1	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
lymphocytes	11	O
in	2	O
anorexia	8	B-Disease
nervosa	7	I-Disease
.	1	O

OBJECTIVE	9	O
:	1	O
The	3	O
aim	3	O
was	3	O
to	2	O
explore	7	O
the	3	O
down-regulation	15	O
of	2	O
the	3	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
during	6	O
hypercortisolaemia	18	B-Disease
in	2	O
anorexia	8	B-Disease
nervosa	7	I-Disease
.	1	O

DESIGN	6	O
:	1	O
Urine	5	O
and	3	O
plasma	6	O
samples	7	O
were	4	O
obtained	8	O
for	3	O
cortisol	8	B-Chemical
determination	13	O
and	3	O
blood	5	O
lymphocytes	11	O
were	4	O
isolated	8	O
for	3	O
receptor	8	O
binding	7	O
studies	7	O
.	1	O

PATIENTS	8	O
:	1	O
Sixteen	7	O
anorexic	8	O
patients	8	O
,	1	O
aged	4	O
16-27	5	O
years	5	O
,	1	O
with	4	O
a	1	O
mean	4	O
+	1	O
/	1	O
-	1	O
SEM	3	O
body	4	O
mass	4	O
index	5	O
of	2	O
14.2	4	O
+	1	O
/	1	O
-	1	O
2.0	3	O
(	1	O
ranging	7	O
from	4	O
11.1	4	O
to	2	O
17.4	4	O
)	1	O
,	1	O
and	3	O
15	2	O
normal	6	O
women	5	O
were	4	O
studied	7	O
.	1	O

Six	3	O
patients	8	O
were	4	O
reinvestigated	14	O
after	5	O
a	1	O
significant	11	O
weight	6	O
gain	4	O
.	1	O

MEASUREMENTS	12	O
:	1	O
The	3	O
binding	7	O
capacity	8	O
and	3	O
affinity	8	O
of	2	O
the	3	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
were	4	O
measured	8	O
with	4	O
dexamethasone	13	B-Chemical
as	2	O
ligand	6	O
on	2	O
lymphocytes	11	O
.	1	O

RESULTS	7	O
:	1	O
In	2	O
patients	8	O
,	1	O
both	4	O
total	5	O
and	3	O
free	4	O
plasma	6	O
cortisol	8	B-Chemical
concentrations	14	O
were	4	O
higher	6	O
than	4	O
in	2	O
the	3	O
normal	6	O
women	5	O
,	1	O
as	2	O
was	3	O
their	5	O
urinary	7	O
free	4	O
cortisol	8	B-Chemical
;	1	O
the	3	O
number	6	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
per	3	O
cell	4	O
(	1	O
Ro	2	O
)	1	O
and	3	O
the	3	O
binding	7	O
affinity	8	O
(	1	O
Kd	2	O
)	1	O
for	3	O
dexamethasone	13	B-Chemical
were	4	O
,	1	O
however	7	O
,	1	O
not	3	O
significantly	13	O
different	9	O
(	1	O
Ro	2	O
:	1	O
7687	4	O
+	1	O
/	1	O
-	1	O
1750	4	O
vs	2	O
7347	4	O
+	1	O
/	1	O
-	1	O
1285	4	O
sites	5	O
/	1	O
cell	4	O
;	1	O
Kd	2	O
:	1	O
7.7	3	O
+	1	O
/	1	O
-	1	O
2.4	3	O
vs	2	O
7.4	3	O
+	1	O
/	1	O
-	1	O
1.7	3	O
nM	2	O
at	2	O
24	2	O
degrees	7	O
C	1	O
)	1	O
.	1	O

After	5	O
weight	6	O
gain	4	O
(	1	O
14	2	O
+	1	O
/	1	O
-	1	O
2	1	O
to	2	O
16	2	O
+	1	O
/	1	O
-	1	O
2	1	O
kg	2	O
/	1	O
m2	2	O
)	1	O
,	1	O
receptor	8	O
numbers	7	O
were	4	O
8421	4	O
+	1	O
/	1	O
-	1	O
2126	4	O
(	1	O
pre	3	O
)	1	O
and	3	O
9011	4	O
+	1	O
/	1	O
-	1	O
500	3	O
(	1	O
post	4	O
)	1	O
sites	5	O
/	1	O
cell	4	O
,	1	O
which	5	O
are	3	O
not	3	O
significantly	13	O
different	9	O
(	1	O
P	1	O
greater	7	O
than	4	O
0.2	3	O
)	1	O
;	1	O
the	3	O
Kd	2	O
was	3	O
unchanged	9	O
(	1	O
9.3	3	O
+	1	O
/	1	O
-	1	O
2.6	3	O
vs	2	O
9.2	3	O
+	1	O
/	1	O
-	1	O
2.4	3	O
nM	2	O
)	1	O
.	1	O

CONCLUSIONS	11	O
Hypercortisolaemia	18	B-Disease
does	4	O
not	3	O
down-regulate	13	O
the	3	O
lymphocyte	10	B-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
in	2	O
anorexia	8	B-Disease
nervosa	7	I-Disease
and	3	O
a	1	O
post-receptor	13	O
defect	6	O
might	5	O
be	2	O
involved	8	O
in	2	O
peripheral	10	O
tissue	6	O
resistance	10	O
to	2	O
the	3	O
effects	7	O
of	2	O
glucocorticoid	14	B-Chemical
hormones	8	I-Chemical
in	2	O
undernutrition	14	B-Disease
.	1	O

Tumor	5	B-Gene
necrosis	8	I-Gene
factor-alpha	12	I-Gene
mRNA	4	I-Gene
accumulation	12	O
in	2	O
human	5	O
myelomonocytic	14	O
cell	4	O
lines	5	O
.	1	O

Role	4	O
of	2	O
transcriptional	15	O
regulation	10	O
by	2	O
DNA	3	O
sequence	8	O
motifs	6	O
and	3	O
mRNA	4	O
stabilization	13	O
.	1	O

The	3	O
cytokine	8	B-Gene
TNF	3	I-Gene
mediates	8	O
many	4	O
of	2	O
the	3	O
pathologic	10	O
signs	5	O
of	2	O
cachexia	8	O
,	1	O
inflammation	12	O
,	1	O
and	3	O
sepsis	6	B-Disease
.	1	O

The	3	O
current	7	O
work	4	O
describes	9	O
the	3	O
regulation	10	O
of	2	O
TNF	3	B-Gene
in	2	O
human	5	O
myelomonocytic	14	O
cell	4	O
lines	5	O
after	5	O
PMA	3	B-Chemical
stimulation	11	O
.	1	O

The	3	O
cell	4	O
lines	5	O
exhibit	7	O
a	1	O
low	3	O
level	5	O
of	2	O
constitutive	12	O
TNF	3	B-Gene
mRNA	4	I-Gene
expression	10	O
.	1	O

Within	6	O
2	1	O
to	2	O
4	1	O
h	1	O
of	2	O
PMA	3	B-Chemical
exposure	8	O
,	1	O
steady	6	O
state	5	O
levels	6	O
of	2	O
TNF	3	B-Gene
mRNA	4	I-Gene
are	3	O
markedly	8	O
elevated	8	O
in	2	O
all	3	O
myelomonocytic	14	O
cell	4	O
lines	5	O
studied	7	O
.	1	O

This	4	O
rise	4	O
is	2	O
due	3	O
to	2	O
increased	9	O
mRNA	4	O
stability	9	O
,	1	O
which	5	O
increased	9	O
by	2	O
almost	6	O
twofold	7	O
,	1	O
and	3	O
to	2	O
an	2	O
overall	7	O
increase	8	O
in	2	O
transcription	13	O
,	1	O
which	5	O
rises	5	O
by	2	O
more	4	O
than	4	O
sixfold	7	O
.	1	O

At	2	O
the	3	O
level	5	O
of	2	O
the	3	O
genomic	7	B-Gene
TNF	3	I-Gene
gene	4	I-Gene
,	1	O
a	1	O
DNase	5	O
I	1	O
hypersensitive	14	O
site	4	O
is	2	O
detected	8	O
within	6	O
the	3	O
TNF	3	B-Gene
promoter	8	I-Gene
between	7	O
-200	4	O
to	2	O
-100	4	O
bp	2	O
relative	8	O
to	2	O
the	3	O
transcription	13	O
initiation	10	O
site	4	O
.	1	O

Although	8	O
absent	6	O
in	2	O
nonexpressing	13	O
erythroleukemia	15	B-Disease
cell	4	O
lines	5	O
,	1	O
the	3	O
DNase	5	O
I	1	O
site	4	O
is	2	O
present	7	O
in	2	O
uninduced	9	O
myelomonocytic	14	O
cell	4	O
lines	5	O
and	3	O
is	2	O
not	3	O
changed	7	O
after	5	O
PMA	3	B-Chemical
induction	9	O
.	1	O

The	3	O
PMA	3	B-Chemical
induction	9	O
of	2	O
c-fos	5	B-Gene
mRNA	4	I-Gene
correlated	10	O
well	4	O
with	4	O
TNF	3	B-Gene
gene	4	I-Gene
induction	9	O
;	1	O
expression	10	O
of	2	O
genes	5	O
encoding	8	O
other	5	O
proteins	8	O
in	2	O
the	3	O
AP-1	4	B-Gene
complex	7	I-Gene
(	1	O
junB	4	B-Gene
and	3	O
junD	4	B-Gene
)	1	O
were	4	O
also	4	O
induced	7	O
by	2	O
PMA	3	B-Chemical
.	1	O

The	3	O
nuclear	7	O
extracts	8	O
from	4	O
resting	7	O
and	3	O
induced	7	O
ML-1	4	O
cells	5	O
contain	7	O
proteins	8	O
binding	7	O
specifically	12	O
to	2	O
the	3	O
AP-1	4	B-Gene
,	1	O
AP-2	4	B-Gene
,	1	O
and	3	O
NF	2	B-Gene
kappa	5	I-Gene
B	1	I-Gene
sequence	8	O
located	7	O
within	6	O
the	3	O
TNF	3	B-Gene
promoter	8	I-Gene
.	1	O

PMA	3	B-Chemical
induction	9	O
increases	9	O
the	3	O
level	5	O
of	2	O
a	1	O
number	6	O
of	2	O
specific	8	O
binding	7	O
complexes	9	O
relative	8	O
to	2	O
the	3	O
resting	7	O
cells	5	O
.	1	O

The	3	O
regulatory	10	O
mechanisms	10	O
of	2	O
the	3	O
human	5	O
and	3	O
murine	6	B-Gene
TNF	3	I-Gene
genes	5	I-Gene
are	3	O
discussed	9	O
.	1	O

The	3	O
effect	6	O
of	2	O
toremifene	10	B-Chemical
therapy	7	O
on	2	O
serum	5	B-Gene
immunoglobulin	14	I-Gene
levels	6	O
in	2	O
breast	6	B-Disease
cancer	6	I-Disease
.	1	O

Estrogens	9	B-Chemical
and	3	O
anti-estrogens	14	B-Chemical
enhance	7	O
the	3	O
number	6	O
of	2	O
immunoglobulin	14	B-Gene
(	1	O
Ig	2	B-Gene
)	1	O
-secreting	10	O
cells	5	O
in	2	O
pokeweed	8	B-Chemical
mitogen	7	I-Chemical
(	1	O
PWM	3	B-Chemical
)	1	O
-stimulated	11	O
lymphocyte	10	O
cultures	8	O
.	1	O

Lymphocytes	11	O
from	4	O
patients	8	O
who	3	O
have	4	O
received	8	O
anti-estrogen	13	B-Chemical
therapy	7	O
show	4	O
similar	7	O
enhancement	11	O
of	2	O
Ig	2	B-Gene
-secreting	10	O
cells	5	O
after	5	O
PWM	3	B-Chemical
stimulation	11	O
.	1	O

In	2	O
this	4	O
study	5	O
the	3	O
effect	6	O
of	2	O
anti-estrogen	13	B-Chemical
(	1	O
toremifene	10	B-Chemical
)	1	O
therapy	7	O
on	2	O
serum	5	B-Gene
immunoglobulin	14	I-Gene
(	1	O
IgA	3	B-Gene
,	1	O
IgM	3	B-Gene
,	1	O
IgG	3	B-Gene
)	1	O
levels	6	O
in	2	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
was	3	O
investigated	12	O
.	1	O

Serum	5	B-Gene
Ig	2	I-Gene
levels	6	O
were	4	O
followed	8	O
up	2	O
to	2	O
two	3	O
years	5	O
after	5	O
or	2	O
during	6	O
the	3	O
therapy	7	O
.	1	O

An	2	O
unexpected	10	O
finding	7	O
was	3	O
that	4	O
the	3	O
Ig	2	B-Gene
levels	6	O
decreased	9	O
during	6	O
the	3	O
follow-up	9	O
period	6	O
.	1	O

This	4	O
decrease	8	O
was	3	O
seen	4	O
in	2	O
patients	8	O
who	3	O
responded	9	O
to	2	O
the	3	O
therapy	7	O
as	2	O
well	4	O
as	2	O
in	2	O
those	5	O
who	3	O
did	3	O
not	3	O
.	1	O

HIV1	4	O
infection	9	O
of	2	O
human	5	O
monocytes	9	O
and	3	O
macrophages	11	O
promotes	8	O
induction	9	O
or	2	O
translocation	13	O
of	2	O
NF-KB	5	B-Gene
-related	8	I-Gene
factors	7	I-Gene
.	1	O

In	2	O
1991	4	O
,	1	O
we	2	O
demonstrated	12	O
,	1	O
using	5	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assays	6	O
,	1	O
that	4	O
3	1	O
different	9	O
factors	7	O
(	1	O
termed	6	O
B1	2	O
,	1	O
B2	2	O
and	3	O
B3	2	O
)	1	O
with	4	O
affinity	8	O
for	3	O
the	3	O
KB-enhancer	11	O
target	6	O
sequence	8	O
were	4	O
specifically	12	O
detected	8	O
in	2	O
nuclear	7	O
extracts	8	O
from	4	O
HIV1	4	O
-infected	9	O
monocytes	9	O
and	3	O
macrophages	11	O
.	1	O

The	3	O
B2	2	O
factor	6	O
was	3	O
induced	7	O
in	2	O
the	3	O
nuclei	6	O
of	2	O
these	5	O
cells	5	O
only	4	O
upon	4	O
HIV1	4	O
infection	9	O
.	1	O

The	3	O
B3	2	O
factor	6	O
was	3	O
only	4	O
slightly	8	O
evident	7	O
in	2	O
nuclei	6	O
of	2	O
uninfected	10	O
cells	5	O
but	3	O
was	3	O
readily	7	O
detectable	10	O
in	2	O
nuclei	6	O
of	2	O
infected	8	O
monocytes	9	O
.	1	O

Its	3	O
expression	10	O
remained	8	O
very	4	O
low	3	O
in	2	O
nuclei	6	O
of	2	O
HIV1	4	O
-infected	9	O
macrophages	11	O
.	1	O

In	2	O
this	4	O
paper	5	O
,	1	O
we	2	O
demonstrate	11	O
that	4	O
the	3	O
B2	2	O
factor	6	O
is	2	O
expressed	9	O
in	2	O
the	3	O
cytosol	7	O
of	2	O
monocytes	9	O
and	3	O
macrophages	11	O
as	2	O
a	1	O
DNA	3	O
-binding	8	O
protein	7	O
,	1	O
indicating	10	O
that	4	O
it	2	O
is	2	O
not	3	O
associated	10	O
with	4	O
an	2	O
inhibitor	9	O
(	1	O
IKB	3	B-Gene
)	1	O
.	1	O

This	4	O
factor	6	O
remained	8	O
clustered	9	O
in	2	O
the	3	O
cytosol	7	O
and	3	O
was	3	O
translocated	12	O
to	2	O
the	3	O
nuclei	6	O
only	4	O
after	5	O
HIV1	4	O
infection	9	O
.	1	O

The	3	O
B3	2	O
factor	6	O
is	2	O
detected	8	O
in	2	O
the	3	O
cytosol	7	O
only	4	O
when	4	O
cells	5	O
are	3	O
HIV1	4	O
-infected	9	O
.	1	O

The	3	O
role	4	O
of	2	O
HIV1	4	O
infection	9	O
in	2	O
the	3	O
expression	10	O
and	3	O
the	3	O
translocation	13	O
of	2	O
these	5	O
factors	7	O
is	2	O
discussed	9	O
.	1	O

Induction	9	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
during	6	O
monocyte	8	O
differentiation	15	O
is	2	O
associated	10	O
with	4	O
activation	10	O
of	2	O
HIV-gene	8	O
expression	10	O
.	1	O

Cells	5	O
of	2	O
the	3	O
monocyte-macrophage	19	O
lineage	7	O
are	3	O
important	9	O
targets	7	O
of	2	O
HIV	3	O
infection	9	O
.	1	O

We	2	O
report	6	O
here	4	O
that	4	O
the	3	O
phenotypic	10	O
differentiation	15	O
of	2	O
monocyte	8	O
cell	4	O
lines	5	O
induced	7	O
by	2	O
phorbol	7	B-Chemical
esters	6	I-Chemical
or	2	O
tumour	6	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
alpha	5	I-Gene
(	1	O
TNF	3	B-Gene
alpha	5	I-Gene
)	1	O
is	2	O
associated	10	O
with	4	O
expression	10	O
of	2	O
nuclear	7	B-Gene
factor	6	I-Gene
kappa	5	I-Gene
B	1	I-Gene
(	1	O
NF-kappa	8	B-Gene
B	1	I-Gene
)	1	O
.	1	O

In	2	O
parallel	8	O
with	4	O
such	4	O
differentiation	15	O
,	1	O
HIV	3	O
transcription	13	O
,	1	O
monitored	9	O
using	5	O
an	2	O
HIV	3	O
long	4	O
terminal	8	O
repeat	6	O
reporter	8	O
gene	4	O
construct	9	O
,	1	O
is	2	O
activated	9	O
in	2	O
such	4	O
cells	5	O
under	5	O
the	3	O
influence	9	O
of	2	O
enhanced	8	O
NF-kappa	8	B-Gene
B	1	I-Gene
expression	10	O
.	1	O

Also	4	O
,	1	O
in	2	O
a	1	O
promonocyte	11	O
cell	4	O
line	4	O
chronically	11	O
infected	8	O
with	4	O
HIV	3	O
,	1	O
NF-kappa	8	B-Gene
B	1	I-Gene
expression	10	O
and	3	O
HIV	3	O
transcription	13	O
were	4	O
enhanced	8	O
on	2	O
stimulation	11	O
with	4	O
phorbol	7	B-Chemical
ester	5	I-Chemical
or	2	O
TNF	3	B-Gene
alpha	5	I-Gene
.	1	O

Thus	4	O
,	1	O
stimulation	11	O
of	2	O
monocyte	8	O
cell	4	O
lines	5	O
by	2	O
phorbol	7	B-Chemical
esters	6	I-Chemical
or	2	O
TNF	3	B-Gene
alpha	5	I-Gene
induces	7	O
cell	4	O
differentiation	15	O
and	3	O
activates	9	O
HIV	3	O
transcription	13	O
.	1	O

Such	4	O
a	1	O
process	7	O
may	3	O
have	4	O
fundamental	11	O
implications	12	O
in	2	O
AIDS	4	B-Disease
pathogenesis	12	O
in	2	O
vivo	4	O
and	3	O
may	3	O
be	2	O
important	9	O
in	2	O
disease	7	O
progression	11	O
induced	7	O
by	2	O
opportunistic	13	O
infections	10	O
directly	8	O
or	2	O
indirectly	10	O
involving	9	O
macrophages	11	O
.	1	O

A	1	O
nuclear	7	B-Gene
factor	6	I-Gene
NF-GM2	6	I-Gene
that	4	O
interacts	9	O
with	4	O
a	1	O
regulatory	10	O
region	6	O
of	2	O
the	3	O
GM-CSF	6	B-Gene
gene	4	I-Gene
essential	9	O
for	3	O
its	3	O
induction	9	O
in	2	O
responses	9	O
to	2	O
T-cell	6	O
activation	10	O
:	1	O
purification	12	O
from	4	O
human	5	O
T-cell	6	B-Disease
leukemia	8	I-Disease
line	4	O
Jurkat	6	O
cells	5	O
and	3	O
similarity	10	O
to	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
.	1	O

Activation	10	O
of	2	O
T	1	O
cells	5	O
by	2	O
antigen	7	O
,	1	O
lectin	6	B-Gene
,	1	O
or	2	O
a	1	O
combination	11	O
of	2	O
phorbol-12-myristate	20	B-Chemical
acetate	7	I-Chemical
(	1	O
PMA	3	B-Chemical
)	1	O
and	3	O
calcium	7	B-Chemical
ionophore	9	O
(	1	O
A23187	6	B-Chemical
)	1	O
leads	5	O
to	2	O
the	3	O
induction	9	O
of	2	O
genes	5	O
for	3	O
a	1	O
set	3	O
of	2	O
lymphokines	11	O
,	1	O
including	9	O
granulocyte-macrophage	22	B-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
(	1	O
GM-CSF	6	B-Gene
)	1	O
.	1	O

We	2	O
demonstrated	12	O
in	2	O
earlier	7	O
studies	7	O
that	4	O
the	3	O
upstream	8	O
region	6	O
of	2	O
the	3	O
mouse	5	B-Gene
GM-CSF	6	I-Gene
promoter	8	I-Gene
at	2	O
positions	9	O
between	7	O
-95	3	O
and	3	O
-73	3	O
is	2	O
essential	9	O
for	3	O
transcriptional	15	O
activation	10	O
in	2	O
response	8	O
to	2	O
PMA	3	B-Chemical
/	1	O
A23187	6	B-Chemical
.	1	O

This	4	O
region	6	O
contains	8	O
two	3	O
DNA	3	O
-binding	8	O
motifs	6	O
,	1	O
GM2	3	O
and	3	O
GC-box	6	O
.	1	O

The	3	O
GM2	3	O
sequence	8	O
(	1	O
GGTAGTTCCC	10	O
)	1	O
is	2	O
recognized	10	O
by	2	O
an	2	O
inducible	9	O
factor	6	B-Gene
NF-GM2	6	I-Gene
;	1	O
the	3	O
other	5	O
(	1	O
CCGCCC	6	O
)	1	O
by	2	O
constitutive	12	O
factors	7	O
A1	2	O
,	1	O
A2	2	O
,	1	O
and	3	O
B	1	O
.	1	O

To	2	O
elucidate	9	O
the	3	O
mechanism	9	O
of	2	O
GM-CSF	6	B-Gene
gene	4	I-Gene
activation	10	O
,	1	O
we	2	O
have	4	O
purified	8	O
the	3	O
inducible	9	O
factor	6	B-Gene
NF-GM2	6	I-Gene
from	4	O
the	3	O
nuclear	7	O
extract	7	O
of	2	O
stimulated	10	O
Jurkat	6	O
cells	5	O
on	2	O
the	3	O
basis	5	O
of	2	O
specific	8	O
DNA	3	O
-binding	8	O
activity	8	O
.	1	O

The	3	O
purified	8	B-Gene
NF-GM2	6	I-Gene
consists	8	O
of	2	O
50	2	O
(	1	O
p50	3	B-Gene
)	1	O
and	3	O
65	2	O
kDa	3	O
(	1	O
p65	3	B-Gene
)	1	O
polypeptides	12	O
and	3	O
has	3	O
a	1	O
binding	7	O
activity	8	O
specific	8	O
for	3	O
both	4	O
the	3	O
GM-CSF	6	B-Gene
and	3	O
immunoglobulin	14	B-Gene
kappa	5	I-Gene
(	1	O
GGAAAGTCCC	10	O
)	1	O
enhancers	9	O
.	1	O

Electrophoretically	19	O
purified	8	B-Gene
p50	3	I-Gene
alone	5	O
can	3	O
form	4	O
a	1	O
protein-DNA	11	O
complex	7	O
,	1	O
but	3	O
in	2	O
the	3	O
mixture	7	O
,	1	O
p50	3	B-Gene
associates	10	O
preferentially	14	O
with	4	O
p65	3	B-Gene
to	2	O
form	4	O
the	3	O
NF-GM2	6	B-Gene
complex	7	I-Gene
.	1	O

In	2	O
addition	8	O
,	1	O
p65	3	B-Gene
gave	4	O
per	3	O
se	2	O
,	1	O
with	4	O
low	3	O
affinity	8	O
,	1	O
a	1	O
protein-DNA	11	O
complex	7	O
that	4	O
migrated	8	O
more	4	O
slowly	6	O
than	4	O
native	6	O
NF-GM2	6	B-Gene
complex	7	I-Gene
.	1	O

Furthermore	11	O
,	1	O
an	2	O
antiserum	9	O
against	7	O
KBF1	4	B-Gene
(	1	O
identical	9	O
to	2	O
50	2	B-Gene
kDa	3	I-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
protein	7	I-Gene
)	1	O
reacted	7	O
with	4	O
the	3	O
p50	3	B-Gene
of	2	O
NF-GM2	6	B-Gene
,	1	O
indicating	10	O
that	4	O
the	3	O
NF-GM2	6	B-Gene
polypeptide	11	O
can	3	O
not	3	O
be	2	O
immunologically	15	O
differentiated	14	O
from	4	O
the	3	O
50	2	O
kDa	3	O
subunit	7	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
.	1	O

The	3	O
purified	8	B-Gene
NF-GM2	6	I-Gene
activated	9	O
in	2	O
vitro	5	O
transcription	13	O
from	4	O
the	3	O
kappa	5	O
B	1	O
enhancer	8	O
,	1	O
while	5	O
it	2	O
failed	6	O
to	2	O
stimulate	9	O
transcription	13	O
from	4	O
the	3	O
GM-CSF	6	B-Gene
promoter	8	I-Gene
harboring	9	O
the	3	O
GM2	3	O
sequence	8	O
.	1	O

This	4	O
suggests	8	O
that	4	O
the	3	O
activation	10	O
mechanism	9	O
of	2	O
the	3	O
GM-CSF	6	B-Gene
gene	4	I-Gene
through	7	O
the	3	O
GM2	3	O
/	1	O
GC-box	6	O
sequence	8	O
is	2	O
different	9	O
from	4	O
that	4	O
of	2	O
genes	5	O
carrying	8	O
the	3	O
kappa	5	O
B	1	O
enhancer	8	O
alone	5	O
.	1	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
normal	6	O
leukocytes	10	O
:	1	O
effects	7	O
of	2	O
age	3	O
,	1	O
gender	6	O
,	1	O
season	6	O
,	1	O
and	3	O
plasma	6	O
cortisol	8	B-Chemical
concentrations	14	O
.	1	O

We	2	O
measured	8	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
in	2	O
mononuclear	11	O
leukocytes	10	O
(	1	O
MNL	3	O
)	1	O
isolated	8	O
from	4	O
peripheral	10	O
blood	5	O
of	2	O
145	3	O
apparently	10	O
healthy	7	O
volunteers	10	O
(	1	O
86	2	O
men	3	O
and	3	O
59	2	O
women	5	O
)	1	O
.	1	O

An	2	O
age	3	O
-related	8	O
decrease	8	O
in	2	O
the	3	O
number	6	O
of	2	O
GR	2	B-Gene
was	3	O
suggested	9	O
between	7	O
subjects	8	O
younger	7	O
than	4	O
20	2	O
years	5	O
and	3	O
elderly	7	O
subjects	8	O
;	1	O
there	5	O
was	3	O
no	2	O
apparent	8	O
seasonal	8	O
variation	9	O
in	2	O
GR	2	B-Gene
.	1	O

Gender	6	O
difference	10	O
in	2	O
the	3	O
number	6	O
of	2	O
GR	2	B-Gene
was	3	O
not	3	O
significant	11	O
,	1	O
although	8	O
women	5	O
showed	6	O
slightly	8	O
fewer	5	O
GR	2	B-Gene
.	1	O

Eight	5	O
patients	8	O
with	4	O
dermatomyositis	15	B-Disease
/	1	O
polymyositis	12	B-Disease
were	4	O
examined	8	O
to	2	O
determine	9	O
whether	7	O
the	3	O
number	6	O
of	2	O
GR	2	B-Gene
in	2	O
MNL	3	O
could	5	O
be	2	O
down	4	O
-regulated	10	O
by	2	O
their	5	O
cognate	7	O
ligands	7	O
.	1	O

The	3	O
number	6	O
of	2	O
GR	2	B-Gene
in	2	O
MNL	3	O
from	4	O
these	5	O
patients	8	O
was	3	O
significantly	13	O
decreased	9	O
one	3	O
month	5	O
after	5	O
the	3	O
initiation	10	O
of	2	O
prednisolone	12	O
therapy	7	O
.	1	O

However	7	O
,	1	O
in	2	O
normal	6	O
subjects	8	O
,	1	O
the	3	O
GR	2	B-Gene
in	2	O
MNL	3	O
did	3	O
not	3	O
demonstrate	11	O
circadian	9	O
variation	9	O
,	1	O
in	2	O
contrast	8	O
to	2	O
concentrations	14	O
of	2	O
plasma	6	O
cortisol	8	B-Chemical
.	1	O

To	2	O
be	2	O
or	2	O
not	3	O
to	2	O
be	2	O
a	1	O
responder	9	O
in	2	O
T-cell	6	O
responses	9	O
:	1	O
ubiquitous	10	O
oligopeptides	13	O
in	2	O
all	3	O
proteins	8	O
.	1	O

Amino	5	O
acid	4	O
sequences	9	O
of	2	O
all	3	O
proteins	8	O
are	3	O
essays	6	O
written	7	O
in	2	O
the	3	O
same	4	O
language	8	O
.	1	O

Accordingly	11	O
,	1	O
the	3	O
same	4	O
set	3	O
of	2	O
words	5	O
and	3	O
phrases	7	O
(	1	O
oligopeptides	13	O
)	1	O
appear	6	O
in	2	O
totally	7	O
unrelated	9	O
proteins	8	O
.	1	O

The	3	O
reason	6	O
that	4	O
only	4	O
certain	7	O
individuals	11	O
of	2	O
particular	10	O
major	5	B-Gene
histocompatibility	18	I-Gene
complex	7	I-Gene
(	1	O
MHC	3	B-Gene
)	1	O
haplotypes	10	O
can	3	O
mount	5	O
T-cell	6	O
responses	9	O
against	7	O
a	1	O
given	5	O
antigen	7	O
of	2	O
pathogens	9	O
is	2	O
found	5	O
in	2	O
the	3	O
fact	4	O
that	4	O
T-cell	6	B-Gene
receptors	9	I-Gene
are	3	O
designed	8	O
to	2	O
recognize	9	O
18-20	5	O
residue-long	12	O
peptide	7	O
fragments	9	O
sandwiched	10	O
between	7	O
two	3	O
alpha-helices	13	O
of	2	O
class	5	B-Gene
I	1	I-Gene
or	2	O
class	5	B-Gene
II	2	I-Gene
MHC	3	I-Gene
molecules	9	O
.	1	O

At	2	O
this	4	O
range	5	O
of	2	O
peptide	7	O
lengths	7	O
,	1	O
most	4	O
would	5	O
appear	6	O
as	2	O
self	4	O
,	1	O
while	5	O
nonselfness	11	O
of	2	O
the	3	O
remainders	10	O
are	3	O
destined	8	O
to	2	O
be	2	O
quite	5	O
ambiguous	9	O
,	1	O
hence	5	O
creating	8	O
responders	10	O
and	3	O
nonresponders	13	O
.	1	O

Anti-CD2	8	B-Gene
receptor	8	I-Gene
antibodies	10	I-Gene
activate	8	O
the	3	O
HIV	3	O
long	4	O
terminal	8	O
repeat	6	O
in	2	O
T	1	O
lymphocytes	11	O
.	1	O

The	3	O
CD2	3	B-Gene
T	1	O
lymphocyte	10	O
glycoprotein	12	O
surface	7	O
molecule	8	O
mediates	8	O
both	4	O
cell	4	O
to	2	O
cell	4	O
adhesion	8	O
and	3	O
T	1	O
cell	4	O
activation	10	O
,	1	O
two	3	O
processes	9	O
that	4	O
are	3	O
involved	8	O
in	2	O
the	3	O
spread	6	O
of	2	O
HIV	3	O
infection	9	O
.	1	O

Treatment	9	O
of	2	O
chronically	11	O
HIV	3	O
-infected	9	O
PBMC	4	O
with	4	O
anti-CD2	8	B-Gene
mAb	3	I-Gene
has	3	O
been	4	O
shown	5	O
to	2	O
induce	6	O
the	3	O
expression	10	O
of	2	O
infectious	10	O
virus	5	O
from	4	O
these	5	O
cultures	8	O
.	1	O

In	2	O
this	4	O
study	5	O
we	2	O
investigated	12	O
the	3	O
mechanisms	10	O
whereby	7	O
anti-CD2	8	B-Gene
antibodies	10	I-Gene
stimulate	9	O
viral	5	O
production	10	O
.	1	O

We	2	O
demonstrate	11	O
that	4	O
treatment	9	O
of	2	O
transiently	11	O
transfected	11	O
T	1	O
lymphocytes	11	O
with	4	O
anti-CD2	8	B-Gene
antibodies	10	I-Gene
results	7	O
in	2	O
activation	10	O
of	2	O
the	3	O
HIV	3	O
long	4	O
terminal	8	O
repeat	6	O
.	1	O

Furthermore	11	O
,	1	O
CAT	3	O
assays	6	O
using	5	O
mutated	7	O
HIV	3	O
long	4	O
terminal	8	O
repeat-CAT	10	O
constructs	10	O
and	3	O
gel	3	O
shift	5	O
assays	6	O
demonstrate	11	O
that	4	O
this	4	O
activation	10	O
is	2	O
dependent	9	O
on	2	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
enhancer	8	I-Gene
.	1	O

These	5	O
studies	7	O
suggest	7	O
that	4	O
interaction	11	O
of	2	O
CD2	3	B-Gene
with	4	O
its	3	O
natural	7	O
ligand	6	O
,	1	O
LFA-3	5	B-Gene
,	1	O
may	3	O
play	4	O
a	1	O
role	4	O
in	2	O
regulation	10	O
of	2	O
HIV	3	O
expression	10	O
.	1	O

Nuclear	7	O
transcription	13	O
factors	7	O
that	4	O
bind	4	O
to	2	O
elements	8	O
of	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
.	1	O

Induction	9	O
requirements	12	O
in	2	O
primary	7	O
human	5	O
T	1	O
cells	5	O
.	1	O

Prior	5	O
studies	7	O
have	4	O
identified	10	O
several	7	O
elements	8	O
that	4	O
contribute	10	O
to	2	O
the	3	O
activity	8	O
of	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
in	2	O
the	3	O
stimulated	10	O
T	1	O
cell	4	O
line	4	O
,	1	O
Jurkat	6	O
.	1	O

The	3	O
sites	5	O
and	3	O
their	5	O
corresponding	13	O
nuclear	7	O
binding	7	O
factors	7	O
include	7	O
:	1	O
NF-kappa	8	B-Gene
B	1	I-Gene
,	1	O
AP-1	4	B-Gene
,	1	O
AP-3	4	B-Gene
,	1	O
OCT-1	5	B-Gene
,	1	O
and	3	O
NF-AT	5	B-Gene
.	1	O

The	3	O
latter	6	O
``	2	O
nuclear	7	B-Gene
factor	6	I-Gene
for	3	I-Gene
activated	9	I-Gene
T	1	I-Gene
cells	5	I-Gene
``	2	O
likely	6	O
contributes	11	O
to	2	O
the	3	O
tissue	6	O
specificity	11	O
of	2	O
IL-2	4	B-Gene
gene	4	I-Gene
expression	10	O
.	1	O

Using	5	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assays	6	O
,	1	O
we	2	O
have	4	O
studied	7	O
these	5	O
transcription	13	O
factors	7	O
in	2	O
primary	7	O
T	1	O
cells	5	O
from	4	O
human	5	O
blood	5	O
to	2	O
verify	6	O
their	5	O
presence	8	O
in	2	O
a	1	O
physiologic	11	O
setting	7	O
and	3	O
to	2	O
identify	8	O
the	3	O
signals	7	O
that	4	O
stimulate	9	O
factor	6	O
activity	8	O
.	1	O

All	3	O
factors	7	O
are	3	O
induced	7	O
in	2	O
the	3	O
nuclei	6	O
of	2	O
T	1	O
cells	5	O
upon	4	O
activation	10	O
with	4	O
mitogens	8	O
but	3	O
not	3	O
with	4	O
exogenous	9	B-Gene
IL-2	4	I-Gene
growth	6	I-Gene
factor	6	I-Gene
.	1	O

However	7	O
,	1	O
the	3	O
signaling	9	O
requirements	12	O
and	3	O
sensitivity	11	O
to	2	O
protein	7	O
synthesis	9	O
inhibitors	10	O
differ	6	O
considerably	12	O
.	1	O

Only	4	O
the	3	O
activities	10	O
for	3	O
NF-AT	5	B-Gene
and	3	O
AP-1	4	B-Gene
sites	5	O
require	7	O
two	3	O
signals	7	O
for	3	O
optimal	7	O
induction	9	O
,	1	O
i.e.	4	O
,	1	O
PMA	3	B-Chemical
plus	4	O
either	6	O
lectin	6	B-Gene
or	2	O
antibody	8	O
to	2	O
the	3	O
CD3	3	B-Gene
or	2	O
CD28	4	B-Gene
surface	7	O
molecules	9	O
.	1	O

Other	5	O
factors	7	O
are	3	O
induced	7	O
by	2	O
lectin	6	B-Gene
,	1	O
antibody	8	O
,	1	O
and	3	O
/	1	O
or	2	O
PMA	3	B-Chemical
alone	5	O
.	1	O

After	5	O
appropriate	11	O
stimulation	11	O
,	1	O
both	4	O
NF-AT	5	B-Gene
and	3	O
AP-1	4	B-Gene
are	3	O
peculiarly	10	O
sensitive	9	O
to	2	O
the	3	O
protein	7	O
synthesis	9	O
inhibitor	9	O
anisomycin	10	B-Chemical
.	1	O

Our	3	O
data	4	O
correlate	9	O
the	3	O
activity	8	O
of	2	O
NF-AT	5	B-Gene
and	3	O
AP-1	4	B-Gene
in	2	O
gel	3	O
shift	5	O
assays	6	O
with	4	O
the	3	O
two	3	O
signals	7	O
requirements	12	O
for	3	O
IL-2	4	B-Gene
gene	4	I-Gene
expression	10	O
.	1	O

An	2	O
erythroid	9	O
specific	8	O
enhancer	8	O
upstream	8	O
to	2	O
the	3	O
gene	4	O
encoding	8	O
the	3	O
cell-type	9	O
specific	8	O
transcription	13	B-Gene
factor	6	I-Gene
GATA-1	6	I-Gene
.	1	O

The	3	O
transcription	13	B-Gene
factor	6	I-Gene
GATA-1	6	I-Gene
is	2	O
expressed	9	O
in	2	O
a	1	O
subset	6	O
of	2	O
hemopoietic	11	O
cells	5	O
,	1	O
where	5	O
it	2	O
mediates	8	O
the	3	O
cell-type	9	O
specific	8	O
expression	10	O
of	2	O
several	7	O
genes	5	O
.	1	O

We	2	O
have	4	O
cloned	6	O
the	3	O
mouse	5	O
and	3	O
human	5	B-Gene
GATA-1	6	I-Gene
genes	5	I-Gene
.	1	O

A	1	O
region	6	O
upstream	8	O
to	2	O
the	3	O
first	5	O
exon	4	O
,	1	O
and	3	O
highly	6	O
conserved	9	O
between	7	O
mouse	5	O
and	3	O
man	3	O
,	1	O
acts	4	O
as	2	O
an	2	O
erythroid	9	O
specific	8	O
enhancer	8	O
in	2	O
transient	9	O
assays	6	O
,	1	O
if	2	O
linked	6	O
to	2	O
the	3	O
GATA-1	6	B-Gene
or	2	O
to	2	O
the	3	O
SV40	4	B-Gene
promoter	8	I-Gene
.	1	O

The	3	O
activity	8	O
of	2	O
the	3	O
enhancer	8	O
is	2	O
almost	6	O
completely	10	O
dependent	9	O
on	2	O
the	3	O
integrity	9	O
of	2	O
a	1	O
dimeric	7	O
GATA-1	6	B-Gene
binding	7	O
site	4	O
.	1	O

Demonstration	13	O
of	2	O
a	1	O
1	1	B-Gene
,	1	I-Gene
25-dihydroxyvitamin	19	I-Gene
D3	2	I-Gene
-responsive	11	I-Gene
protein	7	I-Gene
in	2	O
human	5	O
lymphocytes	11	O
:	1	O
immunologic	11	O
crossreactivity	15	O
and	3	O
inverse	7	O
regulation	10	O
with	4	O
the	3	O
vitamin	7	B-Gene
D	1	I-Gene
receptor	8	I-Gene
.	1	O

Using	5	O
Western	7	O
blot	4	O
analysis	8	O
with	4	O
a	1	O
monoclonal	10	O
antibody	8	O
recognizing	11	O
a	1	O
17-amino	8	O
acid	4	O
epitope	7	O
of	2	O
the	3	O
1	1	B-Gene
,	1	I-Gene
25-dihydroxyvitamin	19	I-Gene
D3	2	I-Gene
[	1	I-Gene
1	1	I-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
]	1	I-Gene
receptor	8	I-Gene
,	1	O
we	2	O
have	4	O
detected	8	O
two	3	O
crossreacting	13	O
proteins	8	O
in	2	O
activated	9	O
normal	6	O
human	5	O
lymphocytes	11	O
.	1	O

The	3	O
smaller	7	O
of	2	O
the	3	O
two	3	O
proteins	8	O
(	1	O
50	2	O
kDa	3	O
)	1	O
was	3	O
indistinguishable	17	O
from	4	O
the	3	O
classical	9	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
and	3	O
,	1	O
similar	7	O
to	2	O
the	3	O
classical	9	O
1	1	B-Gene
,	1	I-Gene
25	2	I-Gene
(	1	I-Gene
OH	2	I-Gene
)	1	I-Gene
2D3	3	I-Gene
receptor	8	I-Gene
,	1	O
was	3	O
upregulated	11	O
in	2	O
a	1	O
dose	4	O
-dependent	10	O
fashion	7	O
by	2	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
.	1	O

The	3	O
larger	6	O
crossreacting	13	O
protein	7	O
exhibited	9	O
an	2	O
electrophoretic	15	O
mobility	8	O
of	2	O
80	2	O
kDa	3	O
,	1	O
was	3	O
localized	9	O
in	2	O
the	3	O
cell	4	O
cytosol	7	O
,	1	O
and	3	O
appeared	8	O
to	2	O
be	2	O
specific	8	O
for	3	O
activated	9	O
lymphocytes	11	O
since	5	O
it	2	O
was	3	O
not	3	O
detected	8	O
in	2	O
several	7	O
other	5	O
human	5	O
cells	5	O
including	9	O
monocytes	9	O
.	1	O

More	4	O
strikingly	10	O
,	1	O
the	3	O
80-kDa	6	O
protein	7	O
was	3	O
downregulated	13	O
in	2	O
a	1	O
dose	4	O
-dependent	10	O
fashion	7	O
by	2	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
;	1	O
this	4	O
effect	6	O
was	3	O
independent	11	O
of	2	O
the	3	O
mode	4	O
of	2	O
lymphocyte	10	O
activation	10	O
and	3	O
specific	8	O
for	3	O
the	3	O
1	1	O
,	1	O
25	2	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
metabolite	10	O
of	2	O
vitamin	7	B-Chemical
D3	2	I-Chemical
.	1	O

However	7	O
,	1	O
two	3	O
potent	6	O
immunosuppressive	17	O
agents	6	O
,	1	O
glucocorticoids	15	B-Chemical
and	3	O
cyclosporin	11	B-Chemical
A	1	I-Chemical
,	1	O
also	4	O
inhibited	9	O
the	3	O
80-kDa	6	O
protein	7	O
.	1	O

T-helper-cell	13	O
determinants	12	O
in	2	O
protein	7	O
antigens	8	O
are	3	O
preferentially	14	O
located	7	O
in	2	O
cysteine-rich	13	B-Chemical
antigen	7	O
segments	8	O
resistant	9	O
to	2	O
proteolytic	11	O
cleavage	8	O
by	2	O
cathepsin	9	B-Gene
B	1	I-Gene
,	1	O
L	1	B-Partial_Gene
,	1	O
and	3	O
D	1	B-Partial_Gene
.	1	O

We	2	O
report	6	O
on	2	O
a	1	O
computer	8	O
algorithm	9	O
capable	7	O
of	2	O
predicting	10	O
the	3	O
location	8	O
of	2	O
T-helper-cell	13	O
epitopes	8	O
in	2	O
protein	7	O
antigen	7	O
(	1	O
Ag	2	O
)	1	O
by	2	O
analysing	9	O
the	3	O
Ag	2	O
amino	5	O
acid	4	O
sequence	8	O
.	1	O

The	3	O
algorithm	9	O
was	3	O
constructed	11	O
with	4	O
the	3	O
aim	3	O
of	2	O
identifying	11	O
segments	8	O
in	2	O
Ag	2	O
which	5	O
are	3	O
resistant	9	O
to	2	O
proteolytic	11	O
degradation	11	O
by	2	O
the	3	O
enzymes	7	O
cathepsin	9	B-Gene
B	1	I-Gene
,	1	O
L	1	B-Partial_Gene
,	1	O
and	3	O
D	1	B-Partial_Gene
.	1	O

These	5	O
are	3	O
prominent	9	O
enzymes	7	O
in	2	O
the	3	O
endocytic	9	O
pathway	7	O
through	7	O
which	5	O
soluble	7	O
protein	7	O
Ag	2	O
enter	5	O
APC	3	O
,	1	O
and	3	O
resistant	9	O
segments	8	O
in	2	O
Ag	2	O
may	3	O
,	1	O
therefore	9	O
,	1	O
be	2	O
expected	8	O
to	2	O
contain	7	O
more	4	O
T-cell	6	O
determinants	12	O
than	4	O
susceptible	11	O
segments	8	O
.	1	O

From	4	O
information	11	O
available	9	O
in	2	O
the	3	O
literature	10	O
on	2	O
the	3	O
substrate	9	O
specificity	11	O
of	2	O
the	3	O
three	5	O
enzymes	7	O
,	1	O
it	2	O
is	2	O
clear	5	O
that	4	O
a	1	O
cysteine	8	B-Chemical
is	2	O
not	3	O
accepted	8	O
in	2	O
any	3	O
of	2	O
the	3	O
S2	2	O
,	1	O
S1	2	O
,	1	O
S1',	4	O
and	3	O
S2	2	O
'subsites	9	O
of	2	O
cathepsin	9	B-Gene
B	1	I-Gene
and	3	O
L	1	B-Partial_Gene
,	1	O
and	3	O
not	3	O
in	2	O
the	3	O
S1	2	O
and	3	O
S1	2	O
'subsites	9	O
of	2	O
cathepsin	9	B-Gene
D	1	I-Gene
.	1	O

Moreover	8	O
,	1	O
we	2	O
have	4	O
noticed	7	O
that	4	O
cysteine	8	B-Chemical
-containing	11	O
T-cell	6	O
determinants	12	O
in	2	O
a	1	O
number	6	O
of	2	O
protein	7	O
Ag	2	O
are	3	O
particularly	12	O
rich	4	O
in	2	O
the	3	O
amino	5	O
acids	5	O
alanine	7	B-Chemical
,	1	O
glycine	7	B-Chemical
,	1	O
lysine	6	B-Chemical
,	1	O
leucine	7	B-Chemical
,	1	O
serine	6	B-Chemical
,	1	O
threonine	9	B-Chemical
,	1	O
and	3	O
valine	6	B-Chemical
.	1	O

By	2	O
searching	9	O
protein	7	O
Ag	2	O
for	3	O
clusters	8	O
of	2	O
amino	5	O
acids	5	O
containing	10	O
cysteine	8	B-Chemical
and	3	O
two	3	O
of	2	O
the	3	O
other	5	O
amino	5	O
acids	5	O
we	2	O
were	4	O
able	4	O
to	2	O
predict	7	O
17	2	O
out	3	O
of	2	O
23	2	O
empirically	11	O
known	5	O
T-cell	6	O
determinants	12	O
in	2	O
the	3	O
Ag	2	O
with	4	O
a	1	O
relatively	10	O
low	3	O
number	6	O
of	2	O
false	5	O
(	1	O
positive	8	O
)	1	O
predictions	11	O
.	1	O

Furthermore	11	O
,	1	O
we	2	O
present	7	O
a	1	O
new	3	O
principle	9	O
for	3	O
searching	9	O
Ag	2	O
for	3	O
potential	9	O
amphipatic	10	O
alpha-helical	13	O
protein	7	O
segments	8	O
.	1	O

Such	4	O
segments	8	O
accord	6	O
well	4	O
with	4	O
empirically	11	O
known	5	O
T-cell	6	O
determinants	12	O
and	3	O
our	3	O
algorithm	9	O
produces	8	O
a	1	O
lower	5	O
number	6	O
of	2	O
false	5	O
positive	8	O
predictions	11	O
than	4	O
the	3	O
principle	9	O
based	5	O
on	2	O
discrete	8	O
Fourier	7	O
transformations	15	O
previously	10	O
described	9	O
.	1	O

A	1	O
human	5	O
putative	8	O
lymphocyte	10	O
G0	2	O
/	1	O
G1	2	O
switch	6	O
gene	4	O
containing	10	O
a	1	O
CpG-rich	8	O
island	6	O
encodes	7	O
a	1	O
small	5	O
basic	5	O
protein	7	O
with	4	O
the	3	O
potential	9	O
to	2	O
be	2	O
phosphorylated	14	O
.	1	O

Genes	5	O
actively	8	O
involved	8	O
in	2	O
the	3	O
G0	2	O
/	1	O
G1	2	O
switch	6	O
(	1	O
G0S	3	O
genes	5	O
)	1	O
may	3	O
be	2	O
differentially	14	O
expressed	9	O
during	6	O
the	3	O
lectin	6	B-Gene
-induced	8	O
switch	6	O
of	2	O
lymphocytes	11	O
from	4	O
the	3	O
G0	2	O
to	2	O
the	3	O
G1	2	O
phases	6	O
of	2	O
the	3	O
cell	4	O
cycle	5	O
.	1	O

This	4	O
paper	5	O
presents	8	O
studies	7	O
of	2	O
G0S2	4	B-Gene
,	1	O
a	1	O
member	6	O
of	2	O
a	1	O
set	3	O
of	2	O
putative	8	O
G0S	3	O
genes	5	O
,	1	O
for	3	O
which	5	O
cDNAs	5	O
were	4	O
cloned	6	O
and	3	O
selected	8	O
on	2	O
the	3	O
basis	5	O
of	2	O
differential	12	O
cDNA	4	O
hybridization	13	O
.	1	O

G0S2	4	B-Gene
mRNA	4	I-Gene
increases	9	O
transiently	11	O
within	6	O
1-2	3	O
hr	2	O
of	2	O
the	3	O
addition	8	O
of	2	O
lectin	6	B-Gene
or	2	O
cycloheximide	13	B-Chemical
to	2	O
cultured	8	O
blood	5	O
mononuclear	11	O
cells	5	O
.	1	O

Comparison	10	O
of	2	O
a	1	O
nearly	6	O
full-length	11	O
cDNA	4	O
sequence	8	O
with	4	O
the	3	O
corresponding	13	O
genomic	7	O
sequence	8	O
reveals	7	O
one	3	O
small	5	O
intron	6	O
and	3	O
an	2	O
open	4	O
reading	7	O
frame	5	O
in	2	O
the	3	O
second	6	O
exon	4	O
.	1	O

The	3	O
derived	7	O
103-amino-acid	14	O
basic	5	O
protein	7	O
has	3	O
two	3	O
potential	9	O
alpha-helical	13	O
domains	7	O
separated	9	O
by	2	O
a	1	O
hydrophobic	11	O
region	6	O
with	4	O
the	3	O
potential	9	O
to	2	O
generate	8	O
turns	5	O
and	3	O
assume	6	O
a	1	O
beta-sheet	10	O
conformation	12	O
.	1	O

Consistent	10	O
with	4	O
involvement	11	O
in	2	O
the	3	O
G0	2	O
/	1	O
G1	2	O
switch	6	O
,	1	O
the	3	O
protein	7	O
contains	8	O
potential	9	O
sites	5	O
for	3	O
phosphorylation	15	O
by	2	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
and	3	O
casein	6	B-Gene
kinase	6	I-Gene
II	2	I-Gene
.	1	O

The	3	O
gene	4	O
contains	8	O
a	1	O
CpG-rich	8	O
island	6	O
suggesting	10	O
expression	10	O
in	2	O
the	3	O
germ	4	O
line	4	O
.	1	O

An	2	O
upstream	8	O
segment	7	O
contains	8	O
tandem	6	O
dinucleotide	12	O
repeats	7	O
(	1	O
CT	2	O
)	1	O
19	2	O
/	1	O
(	1	O
CA	2	O
)	1	O
16	2	O
.	1	O

There	5	O
is	2	O
a	1	O
suitably	8	O
located	7	O
TATA	4	O
box	3	O
,	1	O
but	3	O
potential	9	O
sites	5	O
for	3	O
CCAAT-box	9	O
binding	7	O
factors	7	O
are	3	O
far	3	O
upstream	8	O
,	1	O
embedded	8	O
in	2	O
a	1	O
42-nucleotide	13	O
repeat	6	O
element	7	O
.	1	O

Potential	9	O
sites	5	O
for	3	O
transcription	13	B-Gene
factors	7	I-Gene
AP1	3	I-Gene
,	1	O
AP2	3	B-Gene
,	1	O
and	3	O
AP3	3	B-Gene
are	3	O
consistent	10	O
with	4	O
rapid	5	O
transcriptional	15	O
activation	10	O
in	2	O
response	8	O
to	2	O
inducing	8	O
agents	6	O
.	1	O

Synergism	9	O
between	7	O
two	3	O
distinct	8	O
elements	8	O
of	2	O
the	3	O
HTLV-I	6	O
enhancer	8	O
during	6	O
activation	10	O
by	2	O
the	3	O
trans-activator	15	O
of	2	O
HTLV-I	6	O
.	1	O

We	2	O
have	4	O
conducted	9	O
functional	10	O
studies	7	O
of	2	O
the	3	O
enhancer	8	O
elements	8	O
of	2	O
human	5	O
T-cell	6	B-Disease
leukemia	8	I-Disease
virus	5	O
type	4	O
I	1	O
(	1	O
HTLV-I	6	O
)	1	O
using	5	O
the	3	O
human	5	O
T-cell	6	O
lines	5	O
Jurkat	6	O
and	3	O
MOLT	4	O
4	1	O
,	1	O
which	5	O
are	3	O
negative	8	O
for	3	O
HTLV-I	6	O
,	1	O
and	3	O
MT-2	4	O
and	3	O
TL-Mor	6	O
,	1	O
which	5	O
carry	5	O
the	3	O
proviral	8	O
genome	6	O
of	2	O
HTLV-I	6	O
.	1	O

Two	3	O
distinct	8	O
elements	8	O
have	4	O
been	4	O
implicated	10	O
in	2	O
function	8	O
of	2	O
the	3	O
HTLV-I	6	O
enhancer	8	O
.	1	O

One	3	O
is	2	O
the	3	O
21-base-pair	12	O
(	1	O
bp	2	O
)	1	O
core	4	O
element	7	O
that	4	O
is	2	O
responsible	11	O
for	3	O
trans-activation	16	O
by	2	O
the	3	O
HTLV-I	6	B-Gene
trans-activator	15	I-Gene
p40tax	6	I-Gene
and	3	O
that	4	O
has	3	O
the	3	O
ability	7	O
to	2	O
bind	4	O
to	2	O
cyclic-AMP	10	B-Gene
responsive	10	I-Gene
element	7	I-Gene
binding	7	I-Gene
factor	6	I-Gene
(	1	I-Gene
CREB	4	I-Gene
)	1	I-Gene
-like	5	I-Gene
factor	6	I-Gene
(	1	O
s	1	O
)	1	O
.	1	O

The	3	O
other	5	O
is	2	O
a	1	O
region	6	O
interposed	10	O
between	7	O
the	3	O
21-bp	5	O
elements	8	O
.	1	O

In	2	O
this	4	O
study	5	O
we	2	O
demonstrate	11	O
that	4	O
a	1	O
subfragment	11	O
(	1	O
C26	3	O
)	1	O
in	2	O
the	3	O
region	6	O
between	7	O
the	3	O
21-bp	5	O
elements	8	O
is	2	O
involved	8	O
in	2	O
trans-activation	16	O
by	2	O
p40tax	6	B-Gene
,	1	O
possibly	8	O
through	7	O
binding	7	O
to	2	O
an	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
-like	5	I-Gene
nuclear	7	I-Gene
factor	6	I-Gene
or	2	O
factors	7	O
.	1	O

Formation	9	O
of	2	O
the	3	O
protein-DNA	11	O
complex	7	O
with	4	O
the	3	O
C26	3	O
subfragment	11	O
was	3	O
positively	10	O
affected	8	O
by	2	O
p40tax	6	B-Gene
.	1	O

The	3	O
C26	3	O
element	7	O
conferred	9	O
partial	7	O
responsiveness	14	O
to	2	O
p40tax	6	B-Gene
when	4	O
linked	6	O
to	2	O
one	3	O
copy	4	O
of	2	O
the	3	O
21-bp	5	O
element	7	O
that	4	O
,	1	O
by	2	O
itself	6	O
,	1	O
showed	6	O
little	6	O
activation	10	O
in	2	O
response	8	O
to	2	O
p40tax	6	B-Gene
.	1	O

However	7	O
,	1	O
the	3	O
C26	3	O
element	7	O
alone	5	O
,	1	O
even	4	O
when	4	O
repeated	8	O
,	1	O
could	5	O
not	3	O
be	2	O
activated	9	O
by	2	O
p40tax	6	B-Gene
,	1	O
unlike	6	O
other	5	O
NF-kappa	8	B-Gene
B	1	I-Gene
-binding	8	O
elements	8	O
.	1	O

In	2	O
contrast	8	O
,	1	O
the	3	O
C26	3	O
element	7	O
itself	6	O
was	3	O
profoundly	10	O
activated	9	O
upon	4	O
stimulation	11	O
with	4	O
12-O-tetradecanoylphorbol-13-acetate	36	B-Chemical
.	1	O

These	5	O
findings	8	O
therefore	9	O
suggest	7	O
that	4	O
the	3	O
HTLV-I	6	O
enhancer	8	O
contains	8	O
multiple	8	O
functional	10	O
elements	8	O
,	1	O
including	9	O
binding	7	O
sites	5	O
for	3	O
at	2	O
least	5	O
CREB-	5	B-Gene
and	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
-like	5	I-Gene
factors	7	I-Gene
,	1	O
which	5	O
synergistically	15	O
cooperate	9	O
in	2	O
activation	10	O
of	2	O
the	3	O
HTLV-I	6	O
enhancer	8	O
in	2	O
response	8	O
to	2	O
p40tax	6	B-Gene
.	1	O

Our	3	O
results	7	O
also	4	O
demonstrate	11	O
that	4	O
TPA	3	B-Gene
-dependent	10	O
activation	10	O
of	2	O
the	3	O
HTLV-I	6	O
enhancer	8	O
may	3	O
be	2	O
mediated	8	O
through	7	O
the	3	O
C26	3	O
element	7	O
.	1	O

v-erbA	6	B-Gene
overexpression	14	O
is	2	O
required	8	O
to	2	O
extinguish	10	O
c-erbA	6	B-Gene
function	8	O
in	2	O
erythroid	9	O
cell	4	O
differentiation	15	O
and	3	O
regulation	10	O
of	2	O
the	3	O
erbA	4	B-Gene
target	6	I-Gene
gene	4	I-Gene
CAII	4	I-Gene
.	1	O

The	3	O
v-erbA	6	B-Gene
oncoprotein	11	I-Gene
represents	10	O
a	1	O
retrovirus	10	O
-transduced	11	O
oncogenic	9	O
version	7	O
of	2	O
the	3	O
thyroid	7	B-Gene
hormone	7	I-Gene
(	1	I-Gene
T3	2	I-Gene
/	1	I-Gene
T4	2	I-Gene
)	1	I-Gene
receptor	8	I-Gene
c-erbA	6	I-Gene
(	1	O
type	4	O
alpha	5	O
)	1	O
.	1	O

It	2	O
contributes	11	O
to	2	O
virus	5	O
-induced	8	O
erythroleukemia	15	B-Disease
by	2	O
efficiently	11	O
arresting	9	O
differentiation	15	O
of	2	O
red	3	O
cell	4	O
progenitors	11	O
and	3	O
by	2	O
suppressing	11	O
transcription	13	O
of	2	O
erythrocyte-specific	20	O
genes	5	O
.	1	O

Here	4	O
,	1	O
we	2	O
show	4	O
that	4	O
v-erbA	6	B-Gene
and	3	O
c-erbA	6	B-Gene
bind	4	O
directly	8	O
to	2	O
sequences	9	O
within	6	O
the	3	O
promoter	8	O
of	2	O
the	3	O
erythrocyte-specific	20	B-Gene
carbonic	8	I-Gene
anhydrase	9	I-Gene
II	2	I-Gene
(	1	O
CAII	4	B-Gene
)	1	O
,	1	O
a	1	O
gene	4	O
whose	5	O
transcription	13	O
is	2	O
efficiently	11	O
suppressed	10	O
by	2	O
v-erbA	6	B-Gene
.	1	O

This	4	O
erbA	4	B-Gene
-binding	8	O
site	4	O
confers	7	O
thyroid	7	B-Chemical
hormone	7	I-Chemical
responsiveness	14	O
to	2	O
a	1	O
heterologous	12	O
promoter	8	O
in	2	O
transient	9	O
expression	10	O
experiments	11	O
and	3	O
is	2	O
a	1	O
target	6	O
for	3	O
efficient	9	O
down-regulation	15	O
of	2	O
CAII	4	B-Gene
transcription	13	O
by	2	O
the	3	O
v-erbA	6	B-Gene
oncoprotein	11	I-Gene
.	1	O

In	2	O
stably	6	O
transformed	11	O
erythroblasts	13	O
coexpressing	12	O
the	3	O
v-erbA	6	B-Gene
oncoprotein	11	I-Gene
and	3	O
the	3	O
c-erbA	6	B-Gene
/	1	I-Gene
T3	2	I-Gene
receptor	8	I-Gene
at	2	O
an	2	O
approximately	13	O
equimolar	9	O
ratio	5	O
,	1	O
c-erbA	6	B-Gene
activity	8	O
is	2	O
dominant	8	O
over	4	O
v-erbA	6	B-Gene
.	1	O

T3	2	B-Chemical
efficiently	11	O
induced	7	O
erythroid	9	O
differentiation	15	O
in	2	O
these	5	O
cells	5	O
,	1	O
thus	4	O
overcoming	10	O
the	3	O
v-erbA	6	B-Gene
-mediated	9	O
differentiation	15	O
arrest	6	O
.	1	O

Likewise	8	O
,	1	O
T3	2	B-Chemical
activated	9	O
CAII	4	B-Gene
transcription	13	O
as	2	O
well	4	O
as	2	O
transient	9	O
expression	10	O
of	2	O
a	1	O
T3	2	B-Chemical
-responsive	11	O
reporter	8	O
gene	4	O
containing	10	O
the	3	O
CAII-specific	13	B-Gene
erbA	4	B-Gene
-binding	8	O
site	4	O
.	1	O

The	3	O
c-erbA	6	B-Gene
-dependent	10	O
activation	10	O
of	2	O
this	4	O
CAII	4	B-Gene
reporter	8	O
construct	9	O
could	5	O
only	4	O
be	2	O
suppressed	10	O
by	2	O
very	4	O
high	4	O
amounts	7	O
of	2	O
v-erbA	6	B-Gene
.	1	O

Our	3	O
results	7	O
suggest	7	O
that	4	O
overexpression	14	O
of	2	O
v-erbA	6	B-Gene
is	2	O
required	8	O
for	3	O
its	3	O
function	8	O
as	2	O
an	2	O
oncoprotein	11	O
.	1	O

Inhibition	10	O
of	2	O
phorbol	7	B-Chemical
ester	5	I-Chemical
-induced	8	O
monocytic	9	O
differentiation	15	O
by	2	O
dexamethasone	13	B-Chemical
is	2	O
associated	10	O
with	4	O
down-regulation	15	O
of	2	O
c-fos	5	B-Gene
and	3	O
c-jun	5	B-Gene
(	1	O
AP-1	4	B-Gene
)	1	O
.	1	O

Previous	8	O
studies	7	O
have	4	O
shown	5	O
that	4	O
treatment	9	O
of	2	O
human	5	O
myeloid	7	B-Disease
leukemia	8	I-Disease
cells	5	O
with	4	O
12-O-tetradecanoylphorbol-13-acetate	36	B-Chemical
(	1	O
TPA	3	B-Chemical
)	1	O
is	2	O
associated	10	O
with	4	O
induction	9	O
of	2	O
monocytic	9	O
differentiation	15	O
and	3	O
expression	10	O
of	2	O
the	3	O
c-jun	5	B-Gene
and	3	O
c-fos	5	B-Gene
early	5	I-Gene
response	8	I-Gene
genes	5	I-Gene
.	1	O

The	3	O
present	7	O
work	4	O
demonstrates	12	O
that	4	O
the	3	O
glucocorticoid	14	B-Chemical
dexamethasone	13	B-Chemical
inhibits	8	O
TPA	3	B-Chemical
-induced	8	O
increases	9	O
in	2	O
c-jun	5	B-Gene
and	3	O
c-fos	5	B-Gene
mRNA	4	I-Gene
levels	6	O
in	2	O
U-937	5	O
leukemia	8	B-Disease
cells	5	O
.	1	O

These	5	O
findings	8	O
were	4	O
associated	10	O
with	4	O
a	1	O
block	5	O
in	2	O
appearance	10	O
of	2	O
the	3	O
monocytic	9	O
phenotype	9	O
,	1	O
including	9	O
inhibition	10	O
of	2	O
TPA	3	B-Chemical
-induced	8	O
increases	9	O
in	2	O
lamin	5	B-Gene
A	1	I-Gene
,	1	O
lamin	5	B-Gene
C	1	I-Gene
,	1	O
and	3	O
vimentin	8	B-Gene
transcripts	11	O
.	1	O

Other	5	O
studies	7	O
have	4	O
demonstrated	12	O
that	4	O
TPA	3	B-Chemical
-induced	8	O
monocytic	9	O
differentiation	15	O
and	3	O
expression	10	O
of	2	O
the	3	O
c-jun	5	B-Gene
and	3	O
c-fos	5	B-Gene
genes	5	I-Gene
in	2	O
myeloid	7	B-Disease
leukemia	8	I-Disease
cells	5	O
are	3	O
regulated	9	O
by	2	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
(	1	O
PKC	3	B-Gene
)	1	O
.	1	O

The	3	O
finding	7	O
that	4	O
dexamethasone	13	B-Chemical
has	3	O
no	2	O
effect	6	O
on	2	O
TPA	3	B-Chemical
-induced	8	O
activation	10	O
of	2	O
PKC	3	B-Gene
suggests	8	O
that	4	O
this	4	O
glucocorticoid	14	B-Chemical
inhibits	8	O
signals	7	O
downstream	10	O
or	2	O
parallel	8	O
to	2	O
this	4	O
enzyme	6	O
.	1	O

Nuclear	7	O
run-on	6	O
assays	6	O
demonstrate	11	O
that	4	O
:	1	O
(	1	O
1	1	O
)	1	O
induction	9	O
of	2	O
c-jun	5	B-Gene
and	3	O
c-fos	5	B-Gene
expression	10	O
by	2	O
TPA	3	B-Chemical
is	2	O
regulated	9	O
by	2	O
transcriptional	15	O
mechanisms	10	O
,	1	O
(	1	O
2	1	O
)	1	O
TPA	3	B-Chemical
-induced	8	O
expression	10	O
of	2	O
c-jun	5	B-Gene
and	3	O
c-fos	5	B-Gene
does	4	O
not	3	O
require	7	O
protein	7	O
synthesis	9	O
,	1	O
and	3	O
(	1	O
3	1	O
)	1	O
TPA	3	B-Chemical
-induced	8	O
expression	10	O
of	2	O
both	4	O
genes	5	O
is	2	O
inhibited	9	O
at	2	O
the	3	O
transcriptional	15	O
level	5	O
by	2	O
dexamethasone	13	B-Chemical
.	1	O

To	2	O
further	7	O
define	6	O
the	3	O
effects	7	O
of	2	O
dexamethasone	13	B-Chemical
at	2	O
the	3	O
molecular	9	O
level	5	O
,	1	O
we	2	O
prepared	8	O
a	1	O
series	6	O
of	2	O
deleted	7	O
c-jun	5	B-Gene
promoter	8	I-Gene
fragments	9	O
linked	6	O
to	2	O
the	3	O
chloramphenicol	15	O
acetyltransferase	17	O
(	1	O
CAT	3	O
)	1	O
gene	4	O
.	1	O

Increases	9	O
in	2	O
CAT	3	O
activity	8	O
during	6	O
transient	9	O
expression	10	O
of	2	O
these	5	O
constructs	10	O
in	2	O
TPA	3	B-Chemical
-treated	8	O
U-937	5	O
cells	5	O
could	5	O
be	2	O
assigned	8	O
to	2	O
the	3	O
region	6	O
(	1	O
-97	3	O
to	2	O
-20	3	O
)	1	O
of	2	O
the	3	O
promoter	8	O
that	4	O
contains	8	O
the	3	O
AP-1	4	B-Gene
binding	7	O
site	4	O
.	1	O

This	4	O
induction	9	O
of	2	O
CAT	3	O
activity	8	O
was	3	O
sensitive	9	O
to	2	O
dexamethasone	13	B-Chemical
.	1	O

These	5	O
findings	8	O
suggest	7	O
that	4	O
dexamethasone	13	B-Chemical
down-regulates	14	O
TPA	3	B-Chemical
-induced	8	O
transcription	13	O
of	2	O
the	3	O
c-jun	5	B-Gene
gene	4	I-Gene
during	6	O
monocytic	9	O
differentiation	15	O
by	2	O
inhibiting	10	O
activation	10	O
of	2	O
the	3	O
AP-1	4	B-Gene
site	4	O
.	1	O

Charybdotoxin	13	B-Gene
-sensitive	10	O
,	1	O
Ca	2	O
(	1	O
2+	2	O
)	1	O
-dependent	10	O
membrane	8	O
potential	9	O
changes	7	O
are	3	O
not	3	O
involved	8	O
in	2	O
human	5	O
T	1	O
or	2	O
B	1	O
cell	4	O
activation	10	O
and	3	O
proliferation	13	O
.	1	O

The	3	O
involvement	11	O
of	2	O
ion	3	O
channels	8	O
in	2	O
B	1	O
and	3	O
T	1	O
lymphocyte	10	O
activation	10	O
is	2	O
supported	9	O
by	2	O
many	4	O
reports	7	O
of	2	O
changes	7	O
in	2	O
ion	3	O
fluxes	6	O
and	3	O
membrane	8	O
potential	9	O
after	5	O
mitogen	7	O
binding	7	O
.	1	O

Human	5	O
T	1	O
and	3	O
B	1	O
lymphocytes	11	O
demonstrate	11	O
an	2	O
early	5	O
and	3	O
transient	9	O
hyperpolarization	17	O
after	5	O
ligand	6	O
binding	7	O
.	1	O

Inasmuch	8	O
as	2	O
the	3	O
change	6	O
in	2	O
membrane	8	O
potential	9	O
is	2	O
dependent	9	O
on	2	O
elevation	9	O
of	2	O
free	4	O
cytosolic	9	O
calcium	7	B-Chemical
,	1	O
the	3	O
hyperpolarization	17	O
is	2	O
presumably	10	O
through	7	O
opening	7	O
of	2	O
Ca	2	O
(	1	O
2+	2	O
)	1	O
-stimulated	11	O
K+	2	O
channels	8	O
.	1	O

We	2	O
have	4	O
used	4	O
charybdotoxin	13	B-Gene
,	1	O
a	1	O
known	5	O
inhibitor	9	O
of	2	O
Ca	2	O
(	1	O
2+	2	O
)	1	O
-dependent	10	O
K+	2	O
channels	8	O
,	1	O
to	2	O
study	5	O
the	3	O
role	4	O
of	2	O
these	5	O
channels	8	O
in	2	O
lymphocyte	10	O
activation	10	O
and	3	O
mitogenesis	11	O
.	1	O

We	2	O
demonstrate	11	O
that	4	O
charybdotoxin	13	B-Gene
inhibits	8	O
the	3	O
ligand	6	O
-induced	8	O
transient	9	O
membrane	8	O
hyperpolarization	17	O
in	2	O
B	1	O
and	3	O
T	1	O
cells	5	O
in	2	O
a	1	O
dose	4	O
-dependent	10	O
fashion	7	O
,	1	O
without	7	O
affecting	9	O
changes	7	O
in	2	O
cytosolic	9	O
Ca2+	4	O
.	1	O

However	7	O
,	1	O
blockade	8	O
of	2	O
the	3	O
Ca	2	O
(	1	O
2+	2	O
)	1	O
-activated	10	O
K+	2	O
channel	7	O
is	2	O
not	3	O
associated	10	O
with	4	O
changes	7	O
in	2	O
cell-cycle	10	O
gene	4	O
activation	10	O
,	1	O
IL-2	4	B-Gene
production	10	O
,	1	O
IL-2R	5	B-Gene
expression	10	O
or	2	O
B	1	O
and	3	O
T	1	O
cell	4	O
mitogenesis	11	O
.	1	O

These	5	O
results	7	O
imply	5	O
that	4	O
membrane	8	O
potential	9	O
changes	7	O
secondary	9	O
to	2	O
the	3	O
ligand	6	O
-dependent	10	O
opening	7	O
of	2	O
Ca	2	O
(	1	O
2+	2	O
)	1	O
-activated	10	O
K+	2	O
channels	8	O
are	3	O
not	3	O
involved	8	O
in	2	O
B	1	O
and	3	O
T	1	O
lymphocyte	10	O
activation	10	O
and	3	O
mitogenesis	11	O
.	1	O

Evaluation	10	O
of	2	O
the	3	O
role	4	O
of	2	O
ligand	6	O
and	3	O
thermal	7	O
activation	10	O
of	2	O
specific	8	O
DNA	3	O
binding	7	O
by	2	O
in	2	O
vitro	5	O
synthesized	11	O
human	5	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
.	1	O

We	2	O
have	4	O
used	4	O
a	1	O
DNA	3	O
-binding	8	O
/	1	O
immunoprecipitation	19	O
assay	5	O
to	2	O
analyze	7	O
the	3	O
capacity	8	O
of	2	O
human	5	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
(	1	O
hGR	3	B-Gene
)	1	O
,	1	O
generated	9	O
in	2	O
rabbit	6	O
reticulocyte	12	O
lysates	7	O
,	1	O
to	2	O
bind	4	O
DNA	3	O
.	1	O

In	2	O
vitro	5	O
translated	10	O
hGR	3	B-Gene
was	3	O
indistinguishable	17	O
from	4	O
native	6	O
hGR	3	B-Gene
,	1	O
as	2	O
determined	10	O
by	2	O
migration	9	O
on	2	O
sodium	6	B-Chemical
dodecyl	7	I-Chemical
sulfate-polyacrylamide	22	B-Chemical
gels	4	O
,	1	O
sedimentation	13	O
on	2	O
sucrose	7	B-Chemical
density	7	O
gradients	9	O
,	1	O
and	3	O
reactivity	10	O
with	4	O
antipeptide	11	O
antibodies	10	O
generated	9	O
against	7	O
hGR	3	B-Gene
.	1	O

In	2	O
addition	8	O
,	1	O
cell-free	9	O
synthesized	11	O
hGR	3	B-Gene
was	3	O
capable	7	O
of	2	O
specific	8	O
binding	7	O
to	2	O
glucocorticoid	14	B-Chemical
response	8	O
element	7	O
(	1	O
GRE	3	O
)	1	O
-containing	11	O
DNA	3	O
fragments	9	O
.	1	O

Using	5	O
this	4	O
assay	5	O
system	6	O
,	1	O
we	2	O
have	4	O
evaluated	9	O
the	3	O
contributions	13	O
of	2	O
ligand	6	O
binding	7	O
and	3	O
heat	4	O
activation	10	O
to	2	O
DNA	3	O
binding	7	O
by	2	O
these	5	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
.	1	O

In	2	O
vitro	5	O
translated	10	O
hGR	3	B-Gene
was	3	O
capable	7	O
of	2	O
selective	9	O
DNA	3	O
binding	7	O
even	4	O
in	2	O
the	3	O
absence	7	O
of	2	O
glucocorticoid	14	B-Chemical
.	1	O

Treatment	9	O
with	4	O
dexamethasone	13	B-Chemical
or	2	O
the	3	O
antiglucocorticoid	18	O
RU486	5	B-Chemical
had	3	O
no	2	O
additional	10	O
effect	6	O
on	2	O
the	3	O
DNA	3	O
-binding	8	O
capacity	8	O
when	4	O
receptor	8	O
preparations	12	O
were	4	O
maintained	10	O
at	2	O
0	1	O
C	1	O
(	1	O
no	2	O
activation	10	O
)	1	O
.	1	O

In	2	O
contrast	8	O
,	1	O
addition	8	O
of	2	O
either	6	O
ligand	6	O
or	2	O
antagonist	10	O
in	2	O
combination	11	O
with	4	O
a	1	O
heat	4	O
activation	10	O
step	4	O
promoted	8	O
DNA	3	O
binding	7	O
by	2	O
approximately	13	O
3-fold	6	O
over	4	O
that	4	O
of	2	O
heat	4	O
-activated	10	O
unliganded	10	O
receptors	9	O
.	1	O

Agonist	7	O
(	1	O
dexamethasone	13	B-Chemical
)	1	O
was	3	O
slightly	8	O
more	4	O
effective	9	O
in	2	O
supporting	10	O
specific	8	O
DNA	3	O
binding	7	O
than	4	O
antagonist	10	O
(	1	O
RU486	5	B-Chemical
)	1	O
.	1	O

DNA	3	O
binding	7	O
by	2	O
in	2	O
vitro	5	O
synthesized	11	O
GR	2	B-Gene
was	3	O
blocked	7	O
by	2	O
the	3	O
addition	8	O
of	2	O
sodium	6	B-Chemical
molybdate	9	I-Chemical
to	2	O
the	3	O
receptor	8	O
preparations	12	O
before	6	O
steroid	7	B-Chemical
addition	8	O
and	3	O
thermal	7	O
activation	10	O
.	1	O

Addition	8	O
of	2	O
KCl	3	O
resulted	8	O
in	2	O
less	4	O
DNA	3	O
binding	7	O
either	6	O
due	3	O
to	2	O
blockage	8	O
of	2	O
DNA-	4	O
receptor	8	O
complex	7	O
formation	9	O
or	2	O
disruption	10	O
of	2	O
the	3	O
complexes	9	O
.	1	O

The	3	O
specificity	11	O
of	2	O
DNA	3	O
binding	7	O
by	2	O
cell-free	9	O
synthesized	11	O
hGR	3	B-Gene
was	3	O
analyzed	8	O
further	7	O
by	2	O
examining	9	O
the	3	O
abilities	9	O
of	2	O
various	7	O
DNAs	4	O
to	2	O
compete	7	O
for	3	O
binding	7	O
to	2	O
a	1	O
naturally	9	O
occurring	9	O
GRE	3	O
found	5	O
in	2	O
the	3	O
mouse	5	O
mammary	7	B-Disease
tumor	5	I-Disease
virus-long	10	O
terminal	8	O
repeat	6	O
.	1	O

Oligonucleotides	16	O
containing	10	O
the	3	O
consensus	9	O
GRE	3	O
were	4	O
the	3	O
most	4	O
efficient	9	O
competitors	11	O
,	1	O
and	3	O
fragments	9	O
containing	10	O
regulatory	10	O
sequences	9	O
from	4	O
glucocorticoid-repressible	26	B-Chemical
genes	5	O
were	4	O
somewhat	8	O
competitive	11	O
,	1	O
whereas	7	O
single	6	O
stranded	8	O
oligonucleotides	16	O
were	4	O
unable	6	O
to	2	O
compete	7	O
for	3	O
mouse	5	O
mammary	7	B-Disease
tumor	5	I-Disease
virus-long	10	O
terminal	8	O
repeat	6	O
DNA	3	O
binding	7	O
,	1	O
except	6	O
when	4	O
competitor	10	O
was	3	O
present	7	O
at	2	O
extremely	9	O
high	4	O
concentrations	14	O
.	1	O

Together	8	O
these	5	O
studies	7	O
indicate	8	O
that	4	O
hGR	3	B-Gene
synthesized	11	O
in	2	O
rabbit	6	O
reticulocyte	12	O
lysates	7	O
displays	8	O
many	4	O
of	2	O
the	3	O
same	4	O
properties	10	O
,	1	O
including	9	O
GRE	3	O
-specific	9	O
DNA	3	O
binding	7	O
,	1	O
observed	8	O
for	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
present	7	O
in	2	O
cytosolic	9	O
extracts	8	O
of	2	O
mammalian	9	O
cells	5	O
and	3	O
tissues	7	O
.	1	O

Similarities	12	O
between	7	O
the	3	O
effects	7	O
of	2	O
dexamethasone	13	B-Chemical
and	3	O
RU486	5	B-Chemical
suggest	7	O
that	4	O
the	3	O
antiglucocorticoid	18	O
properties	10	O
of	2	O
RU486	5	B-Chemical
do	2	O
not	3	O
occur	5	O
at	2	O
the	3	O
level	5	O
of	2	O
specific	8	O
DNA	3	O
binding	7	O
.	1	O

One	3	O
base	4	O
pair	4	O
change	6	O
abolishes	9	O
the	3	O
T	1	O
cell	4	O
-restricted	11	O
activity	8	O
of	2	O
a	1	O
kB	2	B-Gene
-like	5	I-Gene
proto-enhancer	14	I-Gene
element	7	I-Gene
from	4	O
the	3	O
interleukin	11	B-Gene
2	1	I-Gene
promoter	8	I-Gene
.	1	O

The	3	O
inducible	9	O
,	1	O
T	1	O
cell-specific	13	O
enhancers	9	O
of	2	O
murine	6	O
and	3	O
human	5	B-Gene
Interleukin	11	I-Gene
2	1	I-Gene
(	1	I-Gene
Il-2	4	I-Gene
)	1	I-Gene
genes	5	I-Gene
contain	7	O
the	3	O
kB	2	O
-like	5	O
sequence	8	O
GGGATTTCACC	11	O
as	2	O
an	2	O
essential	9	O
cis	3	O
-acting	7	O
enhancer	8	O
motif	5	O
.	1	O

When	4	O
cloned	6	O
in	2	O
multiple	8	O
copies	6	O
this	4	O
so	2	O
-called	7	O
TCEd	4	O
(	1	O
distal	6	O
T	1	O
cell	4	O
element	7	O
)	1	O
acts	4	O
as	2	O
an	2	O
inducible	9	O
proto-enhancer	14	O
element	7	O
in	2	O
E14	3	O
T	1	B-Disease
lymphoma	8	I-Disease
cells	5	O
,	1	O
but	3	O
not	3	O
in	2	O
HeLa	4	O
cells	5	O
.	1	O

In	2	O
extracts	8	O
of	2	O
induced	7	O
,	1	O
Il-2	4	B-Gene
secreting	9	O
El4	3	O
cells	5	O
three	5	O
individual	10	O
protein	7	O
factors	7	O
bind	4	O
to	2	O
TCEd	4	O
DNA	3	O
.	1	O

The	3	O
binding	7	O
of	2	O
the	3	O
most	4	O
prominent	9	O
factor	6	O
,	1	O
named	5	O
TCF-1	5	B-Gene
(	1	O
T	1	B-Gene
cell	4	I-Gene
factor	6	I-Gene
1	1	I-Gene
)	1	O
,	1	O
is	2	O
correlated	10	O
with	4	O
the	3	O
proto-enhancer	14	O
activity	8	O
of	2	O
TCEd	4	O
.	1	O

TCF-1	5	B-Gene
consists	8	O
of	2	O
two	3	O
polypeptides	12	O
of	2	O
about	5	O
50	2	O
kD	2	O
and	3	O
105	3	O
kD	2	O
;	1	O
the	3	O
former	6	O
seems	5	O
to	2	O
be	2	O
related	7	O
to	2	O
the	3	O
50	2	O
kD	2	O
polypeptide	11	O
of	2	O
NF-kB	5	B-Gene
.	1	O

Purified	8	B-Gene
NF-kB	5	I-Gene
is	2	O
also	4	O
able	4	O
to	2	O
bind	4	O
to	2	O
the	3	O
TCEd	4	O
,	1	O
but	3	O
TCF-1	5	B-Gene
binds	5	O
stronger	8	O
than	4	O
NF-kB	5	B-Gene
to	2	O
TCEd	4	O
DNA	3	O
.	1	O

The	3	O
conversion	10	O
of	2	O
the	3	O
TCEd	4	O
to	2	O
a	1	O
'perfect	8	O
'NF-kB	6	B-Gene
binding	7	O
site	4	O
leads	5	O
to	2	O
a	1	O
tighter	7	O
binding	7	O
of	2	O
NF-kB	5	B-Gene
to	2	O
TCEd	4	O
DNA	3	O
and	3	O
,	1	O
as	2	O
a	1	O
functional	10	O
consequence	11	O
,	1	O
to	2	O
the	3	O
activity	8	O
of	2	O
the	3	O
'converted	10	O
'TCEd	5	O
motifs	6	O
in	2	O
HeLa	4	O
cells	5	O
.	1	O

Thus	4	O
,	1	O
the	3	O
substitution	12	O
of	2	O
the	3	O
underlined	10	O
A	1	O
residue	7	O
to	2	O
a	1	O
C	1	O
within	6	O
the	3	O
GGGATTTCACC	11	O
motif	5	O
abolishes	9	O
its	3	O
T	1	O
cell	4	O
-restricted	11	O
activity	8	O
and	3	O
leads	5	O
to	2	O
its	3	O
functioning	11	O
in	2	O
both	4	O
El4	3	O
cells	5	O
and	3	O
HeLa	4	O
cells	5	O
.	1	O

These	5	O
results	7	O
indicate	8	O
that	4	O
lymphocyte-specific	19	O
factors	7	O
binding	7	O
to	2	O
the	3	O
TCEd	4	O
are	3	O
involved	8	O
in	2	O
the	3	O
control	7	O
of	2	O
T	1	O
cell	4	O
specific-transcription	22	O
of	2	O
the	3	O
Il-2	4	B-Gene
gene	4	I-Gene
.	1	O

Negative	8	O
regulation	10	O
of	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
expression	10	O
in	2	O
monocytes	9	O
:	1	O
role	4	O
of	2	O
the	3	O
65-kDa	6	O
plus	4	O
50-kDa	6	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
dimer	5	O
.	1	O

Although	8	O
monocytic	9	O
cells	5	O
can	3	O
provide	7	O
a	1	O
reservoir	9	O
for	3	O
viral	5	O
production	10	O
in	2	O
vivo	4	O
,	1	O
their	5	O
regulation	10	O
of	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
(	1	O
HIV-1	5	O
)	1	O
transcription	13	O
can	3	O
be	2	O
either	6	O
latent	6	O
,	1	O
restricted	10	O
,	1	O
or	2	O
productive	10	O
.	1	O

These	5	O
differences	11	O
in	2	O
gene	4	O
expression	10	O
have	4	O
not	3	O
been	4	O
molecularly	11	O
defined	7	O
.	1	O

In	2	O
THP-1	5	O
cells	5	O
with	4	O
restricted	10	O
HIV	3	O
expression	10	O
,	1	O
there	5	O
is	2	O
an	2	O
absence	7	O
of	2	O
DNA-protein	11	O
binding	7	O
complex	7	O
formation	9	O
with	4	O
the	3	O
HIV-1	5	B-Gene
promoter-enhancer	17	I-Gene
associated	10	O
with	4	O
markedly	8	O
less	4	O
viral	5	O
RNA	3	O
production	10	O
.	1	O

This	4	O
absence	7	O
of	2	O
binding	7	O
was	3	O
localized	9	O
to	2	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
region	6	O
of	2	O
the	3	O
HIV-1	5	O
enhancer	8	O
;	1	O
the	3	O
65-kDa	6	O
plus	4	O
50-kDa	6	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
heterodimer	11	O
was	3	O
preferentially	14	O
lost	4	O
.	1	O

Adding	6	O
purified	8	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
protein	7	I-Gene
to	2	O
nuclear	7	O
extracts	8	O
from	4	O
cells	5	O
with	4	O
restricted	10	O
expression	10	O
overcomes	9	O
this	4	O
lack	4	O
of	2	O
binding	7	O
.	1	O

In	2	O
addition	8	O
,	1	O
treatment	9	O
of	2	O
these	5	O
nuclear	7	O
extracts	8	O
with	4	O
sodium	6	B-Chemical
deoxycholate	12	I-Chemical
restored	8	O
their	5	O
ability	7	O
to	2	O
form	4	O
the	3	O
heterodimer	11	O
,	1	O
suggesting	10	O
the	3	O
presence	8	O
of	2	O
an	2	O
inhibitor	9	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
activity	8	O
.	1	O

Furthermore	11	O
,	1	O
treatment	9	O
of	2	O
nuclear	7	O
extracts	8	O
from	4	O
these	5	O
cells	5	O
that	4	O
had	3	O
restricted	10	O
expression	10	O
with	4	O
lipopolysaccharide	18	B-Chemical
increased	9	O
viral	5	O
production	10	O
and	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
activity	8	O
.	1	O

Antiserum	9	O
specific	8	O
for	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
binding	7	I-Gene
proteins	8	I-Gene
,	1	O
but	3	O
not	3	O
c-rel-specific	14	B-Gene
antiserum	9	I-Gene
,	1	O
disrupted	9	O
heterodimer	11	O
complex	7	O
formation	9	O
.	1	O

Thus	4	O
,	1	O
both	4	O
NF-kappa	8	B-Gene
B	1	I-Gene
-binding	8	I-Gene
complexes	9	I-Gene
are	3	O
needed	6	O
for	3	O
optimal	7	O
viral	5	O
transcription	13	O
.	1	O

Binding	7	O
of	2	O
the	3	O
65-kDa	6	O
plus	4	O
50-kDa	6	O
heterodimer	11	O
to	2	O
the	3	O
HIV-1	5	O
enhancer	8	O
can	3	O
be	2	O
negatively	10	O
regulated	9	O
in	2	O
monocytes	9	O
,	1	O
providing	9	O
one	3	O
mechanism	9	O
restricting	11	O
HIV-1	5	O
gene	4	O
expression	10	O
.	1	O

Isolation	9	O
of	2	O
a	1	O
candidate	9	O
repressor	9	O
/	1	O
activator	9	O
,	1	O
NF-E1	5	B-Gene
(	1	O
YY-1	4	B-Gene
,	1	O
delta	5	B-Gene
)	1	O
,	1	O
that	4	O
binds	5	O
to	2	O
the	3	O
immunoglobulin	14	B-Gene
kappa	5	I-Gene
3	1	I-Gene
'enhancer	9	I-Gene
and	3	O
the	3	O
immunoglobulin	14	B-Gene
heavy-chain	11	I-Gene
mu	2	I-Gene
E1	2	I-Gene
site	4	O
.	1	O

We	2	O
have	4	O
determined	10	O
that	4	O
the	3	O
developmental	13	O
control	7	O
of	2	O
immunoglobulin	14	B-Gene
kappa	5	I-Gene
3	1	I-Gene
'enhancer	9	I-Gene
(	1	O
kappa	5	B-Gene
E3')	4	I-Gene
activity	8	O
is	2	O
the	3	O
result	6	O
of	2	O
the	3	O
combined	8	O
influence	9	O
of	2	O
positive-	9	O
and	3	O
negative	8	O
-acting	7	O
elements	8	O
.	1	O

We	2	O
show	4	O
that	4	O
a	1	O
central	7	O
core	4	O
in	2	O
the	3	O
kappa	5	B-Gene
E3	2	I-Gene
'enhancer	9	I-Gene
is	2	O
active	6	O
at	2	O
the	3	O
pre-B-cell	10	O
stage	5	O
but	3	O
is	2	O
repressed	9	O
by	2	O
flanking	8	O
negative	8	O
-acting	7	O
elements	8	O
.	1	O

The	3	O
negative	8	O
-acting	7	O
sequences	9	O
repress	7	O
enhancer	8	O
activity	8	O
in	2	O
a	1	O
position-	9	O
and	3	O
orientation	11	O
-independent	12	O
manner	6	O
at	2	O
the	3	O
pre-B-cell	10	O
stage	5	O
.	1	O

We	2	O
have	4	O
isolated	8	O
a	1	O
human	5	O
cDNA	4	O
clone	5	O
encoding	8	O
a	1	O
zinc	4	B-Chemical
finger	6	O
protein	7	O
(	1	O
NF-E1	5	B-Gene
)	1	O
that	4	O
binds	5	O
to	2	O
the	3	O
negative	8	O
-acting	7	O
segment	7	O
of	2	O
the	3	O
kappa	5	B-Gene
E3	2	I-Gene
'enhancer	9	I-Gene
.	1	O

This	4	O
protein	7	O
also	4	O
binds	5	O
to	2	O
the	3	O
immunoglobulin	14	B-Gene
heavy-chain	11	I-Gene
enhancer	8	I-Gene
mu	2	I-Gene
E1	2	I-Gene
site	4	O
.	1	O

NF-E1	5	B-Gene
is	2	O
encoded	7	O
by	2	O
the	3	O
same	4	O
gene	4	O
as	2	O
the	3	O
YY-1	4	B-Gene
protein	7	I-Gene
,	1	O
which	5	O
binds	5	O
to	2	O
the	3	O
adeno	5	O
-associated	11	O
virus	5	O
P5	2	O
promoter	8	O
.	1	O

NF-E1	5	B-Gene
is	2	O
also	4	O
the	3	O
human	5	O
homologue	9	O
of	2	O
the	3	O
mouse	5	B-Gene
delta	5	I-Gene
protein	7	I-Gene
,	1	O
which	5	O
binds	5	O
to	2	O
ribosomal	9	O
protein	7	O
gene	4	O
promoters	9	O
.	1	O

The	3	O
predicted	9	O
amino	5	O
acid	4	O
sequence	8	O
of	2	O
this	4	O
protein	7	O
contains	8	O
features	8	O
characteristic	14	O
of	2	O
transcriptional	15	O
activators	10	O
as	2	O
well	4	O
as	2	O
transcriptional	15	O
repressors	10	O
.	1	O

Cotransfection	14	O
studies	7	O
with	4	O
this	4	O
cDNA	4	O
indicate	8	O
that	4	O
it	2	O
can	3	O
repress	7	O
basal	5	O
promoter	8	O
activity	8	O
.	1	O

The	3	O
apparent	8	O
dual	4	O
function	8	O
of	2	O
this	4	O
protein	7	O
is	2	O
discussed	9	O
.	1	O

Clone	5	O
pAT	3	O
133	3	O
identifies	10	O
a	1	O
gene	4	O
that	4	O
encodes	7	O
another	7	O
human	5	O
member	6	O
of	2	O
a	1	O
class	5	O
of	2	O
growth	6	O
factor	6	O
-induced	8	O
genes	5	O
with	4	O
almost	6	O
identical	9	O
zinc	4	B-Chemical
-finger	7	O
domains	7	O
.	1	O

We	2	O
report	6	O
the	3	O
structure	9	O
and	3	O
regulation	10	O
of	2	O
a	1	O
gene	4	O
represented	11	O
by	2	O
clone	5	O
pAT	3	O
133	3	O
,	1	O
which	5	O
is	2	O
induced	7	O
upon	4	O
transition	10	O
from	4	O
a	1	O
resting	7	O
state	5	O
(	1	O
G0	2	O
)	1	O
through	7	O
the	3	O
early	5	O
phase	5	O
of	2	O
the	3	O
cell	4	O
cycle	5	O
(	1	O
G1	2	O
)	1	O
.	1	O

The	3	O
pAT	3	O
133	3	O
gene	4	O
is	2	O
immediately	11	O
induced	7	O
,	1	O
with	4	O
FOS	3	B-Gene
-like	5	O
kinetics	8	O
,	1	O
in	2	O
human	5	O
T	1	O
cells	5	O
and	3	O
in	2	O
fibroblasts	11	O
.	1	O

Primary	7	O
structure	9	O
analysis	8	O
showed	6	O
that	4	O
the	3	O
encoded	7	O
protein	7	O
contains	8	O
three	5	O
tandem	6	O
zinc	4	B-Chemical
-finger	7	O
sequences	9	O
of	2	O
the	3	O
type	4	O
Cys2-Xaa12-His2	15	B-Chemical
.	1	O

This	4	O
zinc	4	B-Chemical
-finger	7	O
region	6	O
,	1	O
which	5	O
is	2	O
thought	7	O
to	2	O
bind	4	O
DNA	3	O
in	2	O
a	1	O
sequence-specific	17	O
manner	6	O
,	1	O
is	2	O
similar	7	O
(	1	O
greater	7	O
than	4	O
80	2	O
%	1	O
on	2	O
the	3	O
amino	5	O
acid	4	O
level	5	O
)	1	O
to	2	O
two	3	O
previously	10	O
described	9	O
transcription	13	B-Gene
factors	7	I-Gene
pAT	3	I-Gene
225	3	I-Gene
/	1	I-Gene
EGR1	4	I-Gene
and	3	O
pAT	3	B-Gene
591	3	I-Gene
/	1	I-Gene
EGR2	4	I-Gene
.	1	O

Except	6	O
for	3	O
the	3	O
conserved	9	O
zinc	4	B-Chemical
-finger	7	O
domains	7	O
,	1	O
the	3	O
amino	5	O
acid	4	O
sequences	9	O
of	2	O
the	3	O
three	5	O
proteins	8	O
are	3	O
distinct	8	O
.	1	O

This	4	O
structural	10	O
similarity	10	O
suggests	8	O
that	4	O
the	3	O
pAT	3	O
133	3	O
gene	4	O
encodes	7	O
a	1	O
transcription	13	O
factor	6	O
with	4	O
a	1	O
specific	8	O
biological	10	O
function	8	O
.	1	O

Comparing	9	O
the	3	O
regulation	10	O
of	2	O
these	5	O
related	7	O
zinc	4	B-Chemical
-finger	7	O
-encoding	9	O
genes	5	O
showed	6	O
coordinate	10	O
induction	9	O
upon	4	O
mitogenic	9	O
stimulation	11	O
of	2	O
resting	7	O
T	1	O
lymphocytes	11	O
and	3	O
of	2	O
resting	7	O
fibroblasts	11	O
.	1	O

However	7	O
,	1	O
upon	4	O
transition	10	O
from	4	O
a	1	O
proliferating	13	O
(	1	O
G1	2	O
)	1	O
to	2	O
a	1	O
resting	7	O
state	5	O
of	2	O
the	3	O
cell	4	O
cycle	5	O
the	3	O
three	5	O
genes	5	O
were	4	O
differently	11	O
regulated	9	O
.	1	O

In	2	O
human	5	O
histiocytic	11	O
U937	4	O
cells	5	O
mRNA	4	O
of	2	O
clone	5	O
pAT	3	O
133	3	O
was	3	O
constitutively	14	O
expressed	9	O
,	1	O
whereas	7	O
mRNA	4	O
of	2	O
pAT	3	B-Gene
225	3	I-Gene
/	1	I-Gene
EGR1	4	I-Gene
was	3	O
induced	7	O
upon	4	O
induction	9	O
of	2	O
terminal	8	O
differentiation	15	O
.	1	O

In	2	O
contrast	8	O
mRNA	4	O
representing	12	O
pAT	3	B-Gene
591	3	I-Gene
/	1	I-Gene
EGR2	4	I-Gene
was	3	O
not	3	O
expressed	9	O
in	2	O
these	5	O
cells	5	O
.	1	O

This	4	O
difference	10	O
in	2	O
gene	4	O
regulation	10	O
suggests	8	O
distinct	8	O
biological	10	O
roles	5	O
in	2	O
the	3	O
control	7	O
of	2	O
cell	4	O
proliferation	13	O
for	3	O
the	3	O
respective	10	O
proteins	8	O
.	1	O

cAMP	4	B-Chemical
-dependent	10	I-Chemical
regulation	10	O
of	2	O
proenkephalin	13	B-Gene
by	2	O
JunD	4	B-Gene
and	3	O
JunB	4	B-Gene
:	1	O
positive	8	O
and	3	O
negative	8	O
effects	7	O
of	2	O
AP-1	4	B-Gene
proteins	8	I-Gene
.	1	O

We	2	O
demonstrate	11	O
that	4	O
JunD	4	B-Gene
,	1	O
a	1	O
component	9	O
of	2	O
the	3	O
AP-1	4	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
complex	7	I-Gene
,	1	O
activates	9	O
transcription	13	O
of	2	O
the	3	O
human	5	B-Gene
proenkephalin	13	I-Gene
gene	4	I-Gene
in	2	O
a	1	O
fashion	7	O
that	4	O
is	2	O
completely	10	O
dependent	9	O
upon	4	O
the	3	O
cAMP	4	B-Gene
-dependent	10	I-Gene
protein	7	I-Gene
kinase	6	I-Gene
,	1	O
protein	7	B-Gene
kinase	6	I-Gene
A	1	I-Gene
.	1	O

Activation	10	O
of	2	O
proenkephalin	13	B-Gene
transcription	13	O
by	2	O
JunD	4	B-Gene
is	2	O
dependent	9	O
upon	4	O
a	1	O
previously	10	O
characterized	13	O
cAMP-	5	B-Chemical
,	1	O
phorbol	7	B-Chemical
ester-	6	I-Chemical
,	1	O
and	3	O
Ca	2	O
(	1	O
2+	2	O
)	1	O
-inducible	10	O
enhancer	8	O
,	1	O
and	3	O
JunD	4	B-Gene
is	2	O
shown	5	O
to	2	O
bind	4	O
the	3	O
enhancer	8	O
as	2	O
a	1	O
homodimer	9	O
.	1	O

Another	7	O
component	9	O
of	2	O
the	3	O
AP-1	4	B-Gene
transcription	13	I-Gene
complex	7	I-Gene
,	1	O
JunB	4	B-Gene
,	1	O
is	2	O
shown	5	O
to	2	O
inhibit	7	O
activation	10	O
mediated	8	O
by	2	O
JunD	4	B-Gene
.	1	O

As	2	O
a	1	O
homodimer	9	O
JunB	4	B-Gene
is	2	O
unable	6	O
to	2	O
bind	4	O
the	3	O
enhancer	8	O
;	1	O
however	7	O
in	2	O
the	3	O
presence	8	O
of	2	O
c-Fos	5	B-Gene
,	1	O
high-affinity	13	O
binding	7	O
is	2	O
observed	8	O
.	1	O

Furthermore	11	O
,	1	O
JunD	4	B-Gene
is	2	O
shown	5	O
to	2	O
activate	8	O
transcription	13	O
of	2	O
genes	5	O
linked	6	O
to	2	O
both	4	O
cAMP	4	B-Chemical
and	3	O
phorbol	7	B-Chemical
ester	5	I-Chemical
response	8	O
elements	8	O
in	2	O
a	1	O
protein	7	B-Gene
kinase	6	I-Gene
A	1	I-Gene
-dependent	10	O
fashion	7	O
,	1	O
further	7	O
blurring	8	O
the	3	O
distinction	11	O
between	7	O
these	5	O
response	8	O
elements	8	O
.	1	O

These	5	O
results	7	O
demonstrate	11	O
that	4	O
the	3	O
transcriptional	15	O
activity	8	O
of	2	O
an	2	O
AP-1	4	B-Gene
-related	8	O
protein	7	O
is	2	O
regulated	9	O
by	2	O
the	3	O
cAMP	4	B-Chemical
-dependent	10	I-Chemical
second-messenger	16	O
pathway	7	O
and	3	O
suggest	7	O
that	4	O
JunD	4	B-Gene
and	3	O
other	5	O
AP-1	4	B-Gene
-related	8	O
proteins	8	O
may	3	O
play	4	O
an	2	O
important	9	O
role	4	O
in	2	O
the	3	O
regulation	10	O
of	2	O
gene	4	O
expression	10	O
by	2	O
cAMP	4	B-Chemical
-dependent	10	I-Chemical
intracellular	13	O
signaling	9	O
pathways	8	O
.	1	O

Glucocorticoid	14	B-Chemical
resistance	10	O
in	2	O
chronic	7	B-Disease
asthma	6	I-Disease
.	1	O

Glucocorticoid	14	B-Chemical
pharmacokinetics	16	O
,	1	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
characteristics	15	O
,	1	O
and	3	O
inhibition	10	O
of	2	O
peripheral	10	O
blood	5	O
T	1	O
cell	4	O
proliferation	13	O
by	2	O
glucocorticoids	15	B-Chemical
in	2	O
vitro	5	O
.	1	O

A	1	O
total	5	O
of	2	O
37	2	O
chronic	7	O
,	1	O
severe	6	O
,	1	O
nonsmoking	10	O
asthmatic	9	O
patients	8	O
with	4	O
documented	10	O
reversible	10	O
airways	7	B-Disease
obstruction	11	I-Disease
were	4	O
classified	10	O
as	2	O
glucocorticoid	14	B-Chemical
-sensitive	10	O
or	2	O
-resistant	10	O
on	2	O
the	3	O
basis	5	O
of	2	O
changes	7	O
in	2	O
FEV1	4	O
,	1	O
FVC	3	O
,	1	O
and	3	O
peak	4	O
expiratory	10	O
flow	4	O
(	1	O
PEF	3	O
)	1	O
after	5	O
oral	4	O
prednisolone	12	B-Chemical
.	1	O

The	3	O
resistant	9	O
patients	8	O
showed	6	O
no	2	O
significant	11	O
improvements	12	O
in	2	O
airflow	7	O
limitation	10	O
.	1	O

Phytohemagglutinin	18	B-Gene
(	1	O
PHA	3	B-Gene
)	1	O
-induced	8	O
proliferation	13	O
of	2	O
peripheral	10	O
blood	5	O
T	1	O
lymphocytes	11	O
from	4	O
the	3	O
sensitive	9	O
but	3	O
not	3	O
the	3	O
resistant	9	O
asthmatic	9	O
patients	8	O
was	3	O
significantly	13	O
(	1	O
p	1	O
less	4	O
than	4	O
0.01	4	O
)	1	O
inhibited	9	O
by	2	O
dexamethasone	13	B-Chemical
(	1	O
10	2	O
(	1	O
-7	2	O
)	1	O
mol	3	O
/	1	O
L	1	O
)	1	O
,	1	O
reflecting	10	O
a	1	O
shift	5	O
of	2	O
the	3	O
dose-response	13	O
curve	5	O
.	1	O

When	4	O
all	3	O
the	3	O
asthmatic	9	O
patients	8	O
were	4	O
analyzed	8	O
together	8	O
,	1	O
there	5	O
was	3	O
a	1	O
significant	11	O
correlation	11	O
between	7	O
the	3	O
degree	6	O
of	2	O
sensitivity	11	O
of	2	O
T	1	O
cells	5	O
to	2	O
dexamethasone	13	B-Chemical
and	3	O
the	3	O
clinical	8	O
responsiveness	14	O
to	2	O
prednisolone	12	B-Chemical
(	1	O
p	1	O
less	4	O
than	4	O
0.01	4	O
)	1	O
.	1	O

No	2	O
differences	11	O
were	4	O
observed	8	O
between	7	O
six	3	O
of	2	O
the	3	O
sensitive	9	O
and	3	O
resistant	9	O
patients	8	O
in	2	O
the	3	O
clearance	9	O
of	2	O
plasma	6	O
prednisolone	12	B-Chemical
derived	7	O
from	4	O
orally	6	O
administered	12	O
prednisone	10	B-Chemical
.	1	O

Peripheral	10	B-Gene
blood	5	I-Gene
mononuclear	11	I-Gene
cell	4	I-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
were	4	O
also	4	O
characterized	13	O
in	2	O
five	4	O
sensitive	9	O
and	3	O
seven	5	O
resistant	9	O
patients	8	O
.	1	O

The	3	O
numbers	7	O
and	3	O
binding	7	O
affinities	10	O
of	2	O
these	5	O
receptors	9	O
could	5	O
not	3	O
account	7	O
for	3	O
the	3	O
observed	8	O
difference	10	O
in	2	O
the	3	O
susceptibility	14	O
of	2	O
these	5	O
cells	5	O
to	2	O
functional	10	O
inhibition	10	O
by	2	O
dexamethasone	13	B-Chemical
in	2	O
vitro	5	O
.	1	O

These	5	O
results	7	O
suggest	7	O
that	4	O
clinical	8	O
glucocorticoid	14	B-Chemical
resistance	10	O
in	2	O
chronic	7	B-Disease
asthma	6	I-Disease
does	4	O
not	3	O
reflect	7	O
abnormal	8	O
glucocorticoid	14	B-Chemical
clearance	9	O
but	3	O
may	3	O
be	2	O
due	3	O
at	2	O
least	5	O
partly	6	O
to	2	O
a	1	O
relative	8	O
insensitivity	13	O
of	2	O
T	1	O
lymphocytes	11	O
to	2	O
glucocorticoids	15	B-Chemical
.	1	O

This	4	O
lack	4	O
of	2	O
sensitivity	11	O
is	2	O
unexplained	11	O
but	3	O
is	2	O
not	3	O
attributable	12	O
to	2	O
abnormalities	13	O
of	2	O
cellular	8	B-Gene
glucocorticoid	14	I-Gene
receptors	9	I-Gene
.	1	O

Regulation	10	O
of	2	O
interleukin-1	13	B-Gene
beta	4	I-Gene
production	10	O
by	2	O
glucocorticoids	15	B-Chemical
in	2	O
human	5	O
monocytes	9	O
:	1	O
the	3	O
mechanism	9	O
of	2	O
action	6	O
depends	7	O
on	2	O
the	3	O
activation	10	O
signal	6	O
.	1	O

Glucocorticoids	15	B-Chemical
are	3	O
known	5	O
to	2	O
downregulate	12	O
interleukin-1	13	B-Gene
beta	4	I-Gene
production	10	O
in	2	O
monocytic	9	O
cells	5	O
by	2	O
two	3	O
different	9	O
mechanims	9	O
:	1	O
direct	6	O
inhibition	10	O
of	2	O
the	3	O
gene	4	O
transcription	13	O
and	3	O
destabilization	15	O
of	2	O
the	3	O
preformed	9	O
interleukin-1	13	B-Gene
beta	4	I-Gene
mRNA	4	I-Gene
.	1	O

Now	3	O
we	2	O
have	4	O
examined	8	O
the	3	O
effect	6	O
of	2	O
the	3	O
nature	6	O
of	2	O
the	3	O
monocyte	8	O
activating	10	O
signal	6	O
on	2	O
these	5	O
two	3	O
inhibitory	10	O
mechanims	9	O
.	1	O

When	4	O
human	5	O
monocytes	9	O
were	4	O
preincubated	12	O
with	4	O
dexamethasone	13	B-Chemical
for	3	O
1	1	O
hour	4	O
and	3	O
then	4	O
stimulated	10	O
either	6	O
with	4	O
bacterial	9	O
lipopolysaccharide	18	B-Chemical
or	2	O
phorbol	7	B-Chemical
myristate	9	I-Chemical
,	1	O
it	2	O
was	3	O
found	5	O
that	4	O
dexamethasone	13	B-Chemical
inhibited	9	O
the	3	O
lipopolysaccharide	18	B-Chemical
-induced	8	O
interleukin-1	13	B-Gene
beta	4	I-Gene
protein	7	I-Gene
production	10	O
,	1	O
but	3	O
the	3	O
phorbol	7	B-Chemical
myristate	9	I-Chemical
-induced	8	O
production	10	O
was	3	O
increased	9	O
3-10	4	O
fold	4	O
.	1	O

This	4	O
difference	10	O
was	3	O
also	4	O
seen	4	O
at	2	O
the	3	O
mRNA	4	O
level	5	O
.	1	O

When	4	O
dexamethasone	13	B-Chemical
was	3	O
added	5	O
to	2	O
the	3	O
cultures	8	O
3	1	O
hours	5	O
after	5	O
the	3	O
stimulators	11	O
,	1	O
it	2	O
clearly	7	O
decreased	9	O
the	3	O
interleukin-1	13	B-Gene
beta	4	I-Gene
mRNA	4	I-Gene
levels	6	O
regardless	10	O
of	2	O
the	3	O
stimulator	10	O
used	4	O
(	1	O
although	8	O
the	3	O
effect	6	O
was	3	O
clearly	7	O
weaker	6	O
on	2	O
the	3	O
PMA	3	B-Chemical
-induced	8	O
mRNA	4	O
)	1	O
.	1	O

Thus	4	O
these	5	O
data	4	O
suggest	7	O
that	4	O
the	3	O
phorbol	7	B-Chemical
myristate	9	I-Chemical
-induced	8	O
signal	6	O
(	1	O
prolonged	9	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
activation	10	O
?	1	O
)	1	O
can	3	O
not	3	O
be	2	O
inhibited	9	O
by	2	O
prior	5	O
incubation	10	O
with	4	O
dexamethasone	13	B-Chemical
and	3	O
it	2	O
also	4	O
protects	8	O
the	3	O
induced	7	O
mRNA	4	O
for	3	O
the	3	O
degradative	11	O
action	6	O
of	2	O
dexamethasone	13	B-Chemical
.	1	O

Identification	14	O
of	2	O
transcriptional	15	O
suppressor	10	O
proteins	8	O
that	4	O
bind	4	O
to	2	O
the	3	O
negative	8	O
regulatory	10	O
element	7	O
of	2	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
.	1	O

Two	3	O
different	9	O
proteins	8	O
which	5	O
independently	13	O
bound	5	O
to	2	O
neighboring	11	O
sequences	9	O
within	6	O
the	3	O
negative	8	O
regulatory	10	O
element	7	O
(	1	O
NRE	3	O
)	1	O
of	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
1	1	O
(	1	O
HIV-1	5	O
)	1	O
were	4	O
detected	8	O
in	2	O
the	3	O
nuclear	7	O
extract	7	O
of	2	O
a	1	O
virus	5	O
-infected	9	O
human	5	O
T	1	O
cell	4	O
line	4	O
.	1	O

One	3	O
of	2	O
the	3	O
factors	7	O
bound	5	O
to	2	O
a	1	O
novel	5	O
dyad	4	O
symmetrical	11	O
sequence	8	O
.	1	O

This	4	O
sequence	8	O
is	2	O
well	4	O
conserved	9	O
in	2	O
various	7	O
HIV-1	5	O
isolates	8	O
and	3	O
partial	7	O
homology	8	O
was	3	O
found	5	O
with	4	O
the	3	O
promoter	8	O
region	6	O
of	2	O
the	3	O
human	5	B-Gene
retinoblastoma	14	I-Gene
gene	4	I-Gene
.	1	O

Similar	7	O
DNA	3	O
binding	7	O
activity	8	O
was	3	O
detected	8	O
in	2	O
a	1	O
variety	7	O
of	2	O
virus	5	O
-uninfected	11	O
human	5	O
T	1	O
cell	4	O
lines	5	O
and	3	O
HeLa	4	O
cells	5	O
by	2	O
means	5	O
of	2	O
a	1	O
gel	3	O
mobility	8	O
shift	5	O
assay	5	O
.	1	O

The	3	O
other	5	O
factor	6	O
bound	5	O
to	2	O
a	1	O
putative	8	O
AP-1	4	B-Gene
recognition	11	O
sequence	8	O
predicted	9	O
for	3	O
the	3	O
HIV-1	5	O
NRE	3	O
.	1	O

However	7	O
,	1	O
this	4	O
factor	6	O
did	3	O
not	3	O
bind	4	O
to	2	O
a	1	O
typical	7	O
AP-1	4	B-Gene
site	4	O
.	1	O

The	3	O
insertion	9	O
of	2	O
multiple	8	O
copies	6	O
of	2	O
the	3	O
binding	7	O
site	4	O
for	3	O
the	3	O
former	6	O
or	2	O
latter	6	O
factor	6	O
into	4	O
a	1	O
heterologous	12	O
promoter	8	O
reduced	7	O
the	3	O
promoter	8	O
activity	8	O
to	2	O
one	3	O
-tenth	6	O
or	2	O
one-third	9	O
,	1	O
respectively	12	O
.	1	O

Thus	4	O
,	1	O
each	4	O
factor	6	O
may	3	O
function	8	O
as	2	O
a	1	O
novel	5	O
negative	8	O
regulator	9	O
of	2	O
transcription	13	O
.	1	O

Constitutive	12	O
activation	10	O
of	2	O
NF-kB	5	B-Gene
in	2	O
human	5	O
thymocytes	10	O
.	1	O

NF-kB	5	B-Gene
is	2	O
a	1	O
eukaryotic	10	O
transcription	13	O
regulatory	10	O
factor	6	O
.	1	O

In	2	O
T	1	O
cells	5	O
and	3	O
T	1	O
cell	4	O
lines	5	O
,	1	O
NF-kB	5	B-Gene
is	2	O
bound	5	O
to	2	O
a	1	O
cytoplasmic	11	O
proteic	7	O
inhibitor	9	O
,	1	O
the	3	O
IkB	3	B-Gene
.	1	O

Treatment	9	O
of	2	O
T	1	O
cells	5	O
with	4	O
mitogens	8	O
(	1	O
phorbol	7	B-Chemical
esters	6	I-Chemical
)	1	O
or	2	O
cytokines	9	O
(	1	O
TNF	3	B-Gene
alpha	5	I-Gene
)	1	O
induces	7	O
NF-kB	5	B-Gene
nuclear	7	O
translocation	13	O
and	3	O
the	3	O
subsequent	10	O
expression	10	O
of	2	O
NF-kB	5	B-Gene
dependent	9	O
T	1	O
cell	4	O
genes	5	O
.	1	O

Here	4	O
we	2	O
examined	8	O
the	3	O
activation	10	O
of	2	O
NF-kB	5	B-Gene
in	2	O
human	5	O
T	1	O
cell	4	O
thymic	6	O
progenitors	11	O
.	1	O

We	2	O
report	6	O
differences	11	O
in	2	O
(	1	O
Ca2+	4	O
)	1	O
i	1	O
requirement	11	O
for	3	O
NF-kB	5	B-Gene
activation	10	O
in	2	O
thymocytes	10	O
as	2	O
compared	8	O
to	2	O
mature	6	O
T	1	O
cells	5	O
.	1	O

Furthermore	11	O
,	1	O
our	3	O
results	7	O
indicated	9	O
that	4	O
thymocytes	10	O
have	4	O
a	1	O
constitutively	14	O
active	6	O
form	4	O
of	2	O
NF-kB	5	B-Gene
,	1	O
suggesting	10	O
that	4	O
they	4	O
are	3	O
activated	9	O
in	2	O
vivo	4	O
.	1	O

Elevated	8	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
concentrations	14	O
before	6	O
and	3	O
after	5	O
glucocorticoid	14	B-Chemical
therapy	7	O
in	2	O
peripheral	10	O
mononuclear	11	O
leukocytes	10	O
of	2	O
patients	8	O
with	4	O
atopic	6	B-Disease
dermatitis	10	I-Disease
.	1	O

The	3	O
number	6	O
and	3	O
affinity	8	O
of	2	O
glucocorticoid	14	B-Chemical
binding	7	O
sites	5	O
in	2	O
peripheral	10	O
mononuclear	11	O
leukocytes	10	O
of	2	O
patients	8	O
with	4	O
atopic	6	B-Disease
dermatitis	10	I-Disease
(	1	O
AD	2	B-Disease
)	1	O
and	3	O
healthy	7	O
controls	8	O
were	4	O
determined	10	O
under	5	O
baseline	8	O
conditions	10	O
and	3	O
after	5	O
a	1	O
defined	7	O
oral	4	O
glucocorticoid	14	B-Chemical
treatment	9	O
.	1	O

Patients	8	O
with	4	O
AD	2	B-Disease
(	1	O
n	1	O
=	1	O
15	2	O
)	1	O
exhibited	9	O
significantly	13	O
more	4	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
per	3	O
cell	4	O
than	4	O
the	3	O
control	7	O
group	5	O
(	1	O
n	1	O
=	1	O
22	2	O
)	1	O
,	1	O
while	5	O
the	3	O
GR	2	B-Gene
affinity	8	O
did	3	O
not	3	O
differ	6	O
.	1	O

Methylprednisolone	18	B-Chemical
treatment	9	O
resulted	8	O
in	2	O
a	1	O
significant	11	O
reduction	9	O
of	2	O
the	3	O
GR	2	B-Gene
sites	5	O
per	3	O
cell	4	O
in	2	O
the	3	O
steroid	7	B-Chemical
-treated	8	O
control	7	O
group	5	O
(	1	O
n	1	O
=	1	O
10	2	O
)	1	O
in	2	O
contrast	8	O
to	2	O
the	3	O
patients	8	O
.	1	O

The	3	O
dissociation	12	O
constant	8	O
was	3	O
not	3	O
affected	8	O
by	2	O
methylprednisolone	18	B-Chemical
treatment	9	O
in	2	O
either	6	O
group	5	O
.	1	O

In	2	O
view	4	O
of	2	O
the	3	O
therapeutic	11	O
efficiency	10	O
of	2	O
glucocorticoids	15	B-Chemical
in	2	O
AD	2	B-Disease
and	3	O
findings	8	O
of	2	O
abnormal	8	O
cAMP	4	B-Chemical
and	3	O
cAMP-phosphodiesterase	22	B-Gene
activity	8	O
,	1	O
the	3	O
elevated	8	O
GR	2	B-Gene
concentrations	14	O
in	2	O
AD	2	B-Disease
lend	4	O
support	7	O
to	2	O
the	3	O
hypothesis	10	O
of	2	O
a	1	O
compensatory	12	O
GR	2	B-Gene
upregulation	12	O
due	3	O
to	2	O
an	2	O
insufficient	12	O
action	6	O
of	2	O
endogenous	10	O
cortisol	8	B-Chemical
or	2	O
to	2	O
altered	7	O
cAMP	4	B-Chemical
-induced	8	O
GR	2	B-Gene
expression	10	O
.	1	O

The	3	O
role	4	O
of	2	O
jun	3	B-Gene
and	3	O
fos	3	B-Gene
gene	4	I-Gene
family	6	I-Gene
members	7	O
in	2	O
12-O-tetradecanoylphorbol-13-acetate	36	B-Chemical
induced	7	O
hemopoietic	11	O
differentiation	15	O
.	1	O

Terminal	8	O
differentiation	15	O
of	2	O
the	3	O
leukemic	8	O
cell	4	O
lines	5	O
U-937	5	O
and	3	O
HL-60	5	O
by	2	O
12-O-tetradecanoylphorbol-13-acetate	36	B-Chemical
is	2	O
accompanied	11	O
by	2	O
marked	6	O
changes	7	O
in	2	O
gene	4	O
expression	10	O
.	1	O

In	2	O
this	4	O
study	5	O
,	1	O
we	2	O
demonstrate	11	O
that	4	O
the	3	O
expression	10	O
of	2	O
jun	3	B-Gene
and	3	O
fos	3	B-Gene
gene	4	I-Gene
family	6	I-Gene
members	7	O
is	2	O
induced	7	O
with	4	O
variable	8	O
kinetics	8	O
during	6	O
12-O-tetradecanoylphorbol-13-acetate	36	B-Chemical
induced	7	O
differentiation	15	O
,	1	O
with	4	O
c-jun	5	B-Gene
expression	10	O
best	4	O
paralleling	11	O
differentiation	15	O
.	1	O

The	3	O
generation	10	O
of	2	O
AP-1	4	B-Gene
complexes	9	I-Gene
,	1	O
as	2	O
measured	8	O
by	2	O
DNA	3	O
binding	7	O
activity	8	O
,	1	O
closely	7	O
parallels	9	O
morphological	13	O
differentiation	15	O
.	1	O

Furthermore	11	O
,	1	O
the	3	O
ability	7	O
of	2	O
these	5	O
complexes	9	O
to	2	O
regulate	8	O
gene	4	O
expression	10	O
is	2	O
demonstrated	12	O
by	2	O
increased	9	O
transcription	13	O
from	4	O
an	2	O
AP-1	4	B-Gene
driven	6	O
reporter	8	O
construct	9	O
and	3	O
marked	6	O
increases	9	O
in	2	O
the	3	O
expression	10	O
of	2	O
endogenous	10	B-Gene
AP-1	4	I-Gene
regulated	9	O
genes	5	O
.	1	O

Differentiation	15	O
assays	6	O
using	5	O
water	5	B-Chemical
soluble	7	O
phorbol	7	B-Chemical
esters	6	I-Chemical
reveal	6	O
that	4	O
differentiation	15	O
becomes	7	O
irreversible	12	O
soon	4	O
after	5	O
AP-1	4	B-Gene
appears	7	O
.	1	O

This	4	O
tight	5	O
correlation	11	O
between	7	O
c-jun	5	B-Gene
expression	10	O
,	1	O
the	3	O
generation	10	O
of	2	O
AP-1	4	B-Gene
activity	8	O
,	1	O
and	3	O
differentiation	15	O
suggests	8	O
a	1	O
critical	8	O
role	4	O
for	3	O
this	4	O
gene	4	O
and	3	O
transcriptional	15	O
complex	7	O
during	6	O
this	4	O
process	7	O
.	1	O

TCF-1	5	B-Gene
,	1	O
a	1	O
T	1	O
cell-specific	13	O
transcription	13	O
factor	6	O
of	2	O
the	3	O
HMG	3	B-Gene
box	3	I-Gene
family	6	I-Gene
,	1	O
interacts	9	O
with	4	O
sequence	8	O
motifs	6	O
in	2	O
the	3	O
TCR	3	B-Gene
beta	4	I-Gene
and	3	O
TCR	3	B-Gene
delta	5	I-Gene
enhancers	9	I-Gene
.	1	O

We	2	O
have	4	O
recently	8	O
identified	10	O
and	3	O
cloned	6	O
TCF-1	5	B-Gene
,	1	O
a	1	O
T	1	O
cell-specific	13	O
transcription	13	O
factor	6	O
with	4	O
specificity	11	O
for	3	O
the	3	O
AACAAAG	7	O
motif	5	O
in	2	O
the	3	O
CD3	3	O
epsilon	7	O
enhancer	8	O
and	3	O
for	3	O
the	3	O
TTCAAAG	7	O
motif	5	O
in	2	O
the	3	O
TCR	3	B-Gene
alpha	5	I-Gene
enhancer	8	I-Gene
.	1	O

TCF-1	5	B-Gene
belongs	7	O
to	2	O
the	3	O
family	6	O
of	2	O
transcription	13	O
-regulating	11	O
proteins	8	O
which	5	O
share	5	O
a	1	O
region	6	O
of	2	O
homology	8	O
termed	6	O
the	3	O
HMG-box	7	B-Gene
.	1	O

Here	4	O
,	1	O
we	2	O
show	4	O
by	2	O
gel	3	O
retardation	11	O
analysis	8	O
that	4	O
TCF-1	5	B-Gene
specifically	12	O
recognizes	10	O
the	3	O
T	1	O
beta	4	O
5	1	O
element	7	O
of	2	O
the	3	O
TCR	3	B-Gene
beta	4	I-Gene
enhancer	8	I-Gene
and	3	O
the	3	O
T	1	O
delta	5	O
7	1	O
element	7	O
of	2	O
the	3	O
TCR	3	B-Gene
delta	5	I-Gene
enhancer	8	I-Gene
.	1	O

Comparison	10	O
of	2	O
the	3	O
sequences	9	O
of	2	O
all	3	O
elements	8	O
recognized	10	O
by	2	O
TCF-1	5	B-Gene
defines	7	O
a	1	O
consensus	9	O
motif	5	O
A	1	O
/	1	O
T	1	O
A	1	O
/	1	O
T	1	O
C	1	O
A	1	O
A	1	O
/	1	O
G	1	O
A	1	O
G	1	O
.	1	O

These	5	O
observations	12	O
imply	5	O
that	4	O
TCF-1	5	B-Gene
is	2	O
involved	8	O
in	2	O
the	3	O
control	7	O
of	2	O
several	7	O
T	1	O
cell-specific	13	O
genes	5	O
and	3	O
might	5	O
thus	4	O
play	4	O
an	2	O
important	9	O
role	4	O
in	2	O
the	3	O
establishment	13	O
and	3	O
maintenance	11	O
of	2	O
the	3	O
mature	6	O
T	1	O
cell	4	O
phenotype	9	O
.	1	O

The	3	O
cellular	8	B-Gene
oncogene	8	I-Gene
c-myb	5	I-Gene
can	3	O
interact	8	O
synergistically	15	O
with	4	O
the	3	O
Epstein-Barr	12	B-Gene
virus	5	I-Gene
BZLF1	5	I-Gene
transactivator	14	I-Gene
in	2	O
lymphoid	8	O
cells	5	O
.	1	O

Regulation	10	O
of	2	O
replicative	11	O
functions	9	O
in	2	O
the	3	O
Epstein-Barr	12	O
virus	5	O
(	1	O
EBV	3	O
)	1	O
genome	6	O
is	2	O
mediated	8	O
through	7	O
activation	10	O
of	2	O
a	1	O
virally	7	O
encoded	7	O
transcription	13	O
factor	6	O
,	1	O
Z	1	B-Gene
(	1	O
BZLF1	5	B-Gene
)	1	O
.	1	O

We	2	O
have	4	O
shown	5	O
that	4	O
the	3	O
Z	1	B-Gene
gene	4	I-Gene
product	7	I-Gene
,	1	O
which	5	O
binds	5	O
to	2	O
AP-1	4	B-Gene
sites	5	O
as	2	O
a	1	O
homodimer	9	O
and	3	O
has	3	O
sequence	8	O
similarity	10	O
to	2	O
c-Fos	5	B-Gene
,	1	O
can	3	O
efficiently	11	O
activate	8	O
the	3	O
EBV	3	O
early	5	O
promoter	8	O
,	1	O
BMRF1	5	B-Gene
,	1	O
in	2	O
certain	7	O
cell	4	O
types	5	O
(	1	O
i.e.	4	O
,	1	O
HeLa	4	O
cells	5	O
)	1	O
but	3	O
not	3	O
others	6	O
(	1	O
i.e.	4	O
,	1	O
Jurkat	6	O
cells	5	O
)	1	O
.	1	O

Here	4	O
we	2	O
demonstrate	11	O
that	4	O
the	3	O
c-myb	5	B-Gene
proto-oncogene	14	I-Gene
product	7	I-Gene
,	1	O
which	5	O
is	2	O
itself	6	O
a	1	O
DNA	3	B-Gene
-binding	8	I-Gene
protein	7	I-Gene
and	3	O
transcriptional	15	O
transactivator	14	O
,	1	O
can	3	O
interact	8	O
synergistically	15	O
with	4	O
Z	1	B-Gene
in	2	O
activating	10	O
the	3	O
BMRF1	5	B-Gene
promoter	8	I-Gene
in	2	O
Jurkat	6	O
cells	5	O
(	1	O
a	1	O
T-cell	6	O
line	4	O
)	1	O
or	2	O
Raji	4	O
cells	5	O
(	1	O
an	2	O
EBV	3	O
-positive	9	O
B-cell	6	O
)	1	O
,	1	O
whereas	7	O
the	3	O
c-myb	5	B-Gene
gene	4	I-Gene
product	7	I-Gene
by	2	O
itself	6	O
has	3	O
little	6	O
effect	6	O
.	1	O

The	3	O
simian	6	O
virus	5	O
40	2	O
early	5	O
promoter	8	O
is	2	O
also	4	O
synergistically	15	O
activated	9	O
by	2	O
the	3	O
Z	1	B-Gene
/	1	I-Gene
c-myb	5	I-Gene
combination	11	O
.	1	O

Synergistic	11	O
transactivation	15	O
of	2	O
the	3	O
BMRF1	5	B-Gene
promoter	8	I-Gene
by	2	O
the	3	O
Z	1	B-Gene
/	1	I-Gene
c-myb	5	I-Gene
combination	11	O
appears	7	O
to	2	O
involve	7	O
direct	6	O
binding	7	O
by	2	O
the	3	O
Z	1	B-Gene
protein	7	I-Gene
but	3	O
not	3	O
the	3	O
c-myb	5	B-Gene
protein	7	I-Gene
.	1	O

A	1	O
30-bp	5	O
sequence	8	O
in	2	O
the	3	O
BMRF1	5	B-Gene
promoter	8	I-Gene
which	5	O
contains	8	O
a	1	O
Z	1	B-Gene
binding	7	O
site	4	O
(	1	O
a	1	O
consensus	9	O
AP-1	4	B-Gene
site	4	O
)	1	O
is	2	O
sufficient	10	O
to	2	O
transfer	8	O
high-level	10	O
lymphoid-specific	17	O
responsiveness	14	O
to	2	O
the	3	O
Z	1	B-Gene
/	1	I-Gene
c-myb	5	I-Gene
combination	11	O
to	2	O
a	1	O
heterologous	12	O
promoter	8	O
.	1	O

That	4	O
the	3	O
c-myb	5	B-Gene
oncogene	8	I-Gene
product	7	I-Gene
can	3	O
interact	8	O
synergistically	15	O
with	4	O
an	2	O
EBV	3	O
-encoded	8	O
member	6	O
of	2	O
the	3	O
leucine	7	B-Chemical
zipper	6	O
protein	7	O
family	6	O
suggests	8	O
c-myb	5	B-Gene
is	2	O
likely	6	O
to	2	O
engage	6	O
in	2	O
similar	7	O
interactions	12	O
with	4	O
cellularly	10	O
encoded	7	O
transcription	13	O
factors	7	O
.	1	O

Characterization	16	O
of	2	O
a	1	O
cofactor	8	O
that	4	O
regulates	9	O
dimerization	12	O
of	2	O
a	1	O
mammalian	9	O
homeodomain	11	O
protein	7	O
.	1	O

Dimerization	12	O
among	5	O
transcription	13	O
factors	7	O
has	3	O
become	6	O
a	1	O
recurrent	9	O
theme	5	O
in	2	O
the	3	O
regulation	10	O
of	2	O
eukaryotic	10	O
gene	4	O
expression	10	O
.	1	O

Hepatocyte	10	B-Gene
nuclear	7	I-Gene
factor-1	8	I-Gene
alpha	5	I-Gene
(	1	O
HNF-1	5	B-Gene
alpha	5	I-Gene
)	1	O
is	2	O
a	1	O
homeodomain	11	O
-containing	11	O
protein	7	O
that	4	O
functions	9	O
as	2	O
a	1	O
dimer	5	O
.	1	O

A	1	O
dimerization	12	B-Gene
cofactor	8	I-Gene
of	2	I-Gene
HNF-1	5	I-Gene
alpha	5	I-Gene
(	1	O
DCoH	4	B-Gene
)	1	O
was	3	O
identified	10	O
that	4	O
displayed	9	O
a	1	O
restricted	10	O
tissue	6	O
distribution	12	O
and	3	O
did	3	O
not	3	O
bind	4	O
to	2	O
DNA	3	O
,	1	O
but	3	O
,	1	O
rather	6	O
,	1	O
selectively	11	O
stabilized	10	O
HNF-1	5	B-Gene
alpha	5	I-Gene
dimers	6	O
.	1	O

The	3	O
formation	9	O
of	2	O
a	1	O
stable	6	O
tetrameric	10	O
DCoH-HNF-1	10	B-Gene
alpha	5	I-Gene
complex	7	I-Gene
,	1	O
which	5	O
required	8	O
the	3	O
dimerization	12	O
domain	6	O
of	2	O
HNF-1	5	B-Gene
alpha	5	I-Gene
,	1	O
did	3	O
not	3	O
change	6	O
the	3	O
DNA	3	O
binding	7	O
characteristics	15	O
of	2	O
HNF-1	5	B-Gene
alpha	5	I-Gene
,	1	O
but	3	O
enhanced	8	O
its	3	O
transcriptional	15	O
activity	8	O
.	1	O

However	7	O
,	1	O
DCoH	4	B-Gene
did	3	O
not	3	O
confer	6	O
transcriptional	15	O
activation	10	O
to	2	O
the	3	O
GAL4	4	B-Gene
DNA	3	I-Gene
binding	7	O
domain	6	O
.	1	O

These	5	O
results	7	O
indicate	8	O
that	4	O
DCoH	4	B-Gene
regulates	9	O
formation	9	O
of	2	O
transcriptionally	17	O
active	6	O
tetrameric	10	O
complexes	9	O
and	3	O
may	3	O
contribute	10	O
to	2	O
the	3	O
developmental	13	O
specificity	11	O
of	2	O
the	3	O
complex	7	O
.	1	O

High	4	O
affinity	8	O
aldosterone	11	B-Chemical
binding	7	O
to	2	O
plasma	6	O
membrane	8	O
rich	4	O
fractions	9	O
from	4	O
mononuclear	11	O
leukocytes	10	O
:	1	O
is	2	O
there	5	O
a	1	O
membrane	8	O
receptor	8	O
for	3	O
mineralocorticoids	18	B-Chemical
?	1	O

In	2	O
vitro	5	O
effects	7	O
of	2	O
aldosterone	11	B-Chemical
on	2	O
the	3	O
intracellular	13	O
concentrations	14	O
of	2	O
sodium	6	B-Chemical
,	1	O
potassium	9	B-Chemical
and	3	O
calcium	7	B-Chemical
,	1	O
cell	4	O
volume	6	O
and	3	O
the	3	O
sodium-proton-antiport	22	B-Chemical
have	4	O
been	4	O
described	9	O
in	2	O
intact	6	O
human	5	O
mononuclear	11	O
leukocytes	10	O
(	1	O
HML	3	O
)	1	O
.	1	O

In	2	O
the	3	O
present	7	O
paper	5	O
,	1	O
the	3	O
binding	7	O
of	2	O
a	1	O
[	1	O
125I	4	O
]	1	O
-labeled	8	O
aldosterone	11	B-Chemical
derivative	10	O
to	2	O
plasma	6	O
membrane	8	O
rich	4	O
fractions	9	O
of	2	O
HML	3	O
was	3	O
studied	7	O
.	1	O

High	4	O
affinity	8	O
binding	7	O
of	2	O
the	3	O
radioligand	11	O
with	4	O
an	2	O
apparent	8	O
Kd	2	O
of	2	O
approximately	13	O
0.1	3	O
nM	2	O
was	3	O
found	5	O
.	1	O

Aldosterone	11	B-Chemical
displaced	9	O
the	3	O
tracer	6	O
at	2	O
a	1	O
similar	7	O
Kd	2	O
.	1	O

Both	4	O
canrenone	9	B-Chemical
and	3	O
cortisol	8	B-Chemical
were	4	O
inactive	8	O
as	2	O
ligands	7	O
up	2	O
to	2	O
concentrations	14	O
of	2	O
0.1	3	O
microM	6	O
.	1	O

The	3	O
findings	8	O
are	3	O
the	3	O
first	5	O
to	2	O
demonstrate	11	O
membrane	8	O
binding	7	O
sites	5	O
with	4	O
a	1	O
high	4	O
affinity	8	O
for	3	O
aldosterone	11	B-Chemical
,	1	O
but	3	O
not	3	O
for	3	O
cortisol	8	B-Chemical
.	1	O

These	5	O
data	4	O
are	3	O
perfectly	9	O
compatible	10	O
with	4	O
major	5	O
properties	10	O
of	2	O
steroidal	9	O
effects	7	O
on	2	O
the	3	O
sodium-proton-antiport	22	B-Chemical
in	2	O
HML	3	O
and	3	O
thus	4	O
very	4	O
likely	6	O
represent	9	O
membrane	8	O
receptors	9	O
for	3	O
aldosterone	11	B-Chemical
.	1	O

Transcription	13	O
factor	6	O
requirements	12	O
for	3	O
U2	2	B-Gene
snRNA	5	I-Gene
-encoding	9	O
gene	4	O
activation	10	O
in	2	O
B	1	O
lymphoid	8	O
cells	5	O
.	1	O

Transcription	13	O
of	2	O
a	1	O
human	5	B-Gene
U2	2	I-Gene
small	5	I-Gene
nuclear	7	I-Gene
RNA	3	I-Gene
(	1	O
snRNA	5	O
)	1	O
-encoding	9	O
gene	4	O
in	2	O
HeLa	4	O
cells	5	O
requires	8	O
a	1	O
distal	6	O
enhancer	8	O
element	7	O
,	1	O
which	5	O
is	2	O
composed	8	O
of	2	O
one	3	O
octamer	7	O
motif	5	O
(	1	O
Oct	3	O
)	1	O
and	3	O
three	5	O
Sp	2	B-Gene
1	1	I-Gene
-binding	8	O
sites	5	O
.	1	O

To	2	O
study	5	O
the	3	O
transcription	13	O
factor	6	O
requirement	11	O
in	2	O
B-cells	7	O
,	1	O
different	9	O
U2	2	B-Gene
enhancer	8	I-Gene
constructions	13	O
were	4	O
transfected	11	O
into	4	O
the	3	O
lymphoid	8	O
cell	4	O
line	4	O
,	1	O
BJA-B	5	O
.	1	O

The	3	O
results	7	O
showed	6	O
that	4	O
the	3	O
activation	10	O
of	2	O
U2	2	B-Gene
snRNA	5	I-Gene
transcription	13	O
in	2	O
B-cells	7	O
also	4	O
requires	8	O
an	2	O
enhancer	8	O
comprising	10	O
both	4	O
the	3	O
Oct	3	O
and	3	O
at	2	O
least	5	O
one	3	O
Sp	2	B-Gene
1	1	I-Gene
-binding	8	O
site	4	O
.	1	O

Deletion	8	O
of	2	O
all	3	O
the	3	O
Sp	2	B-Gene
1	1	I-Gene
-binding	8	O
sites	5	O
from	4	O
the	3	O
enhancer	8	O
reduces	7	O
transcription	13	O
by	2	O
80-90	5	O
%	1	O
in	2	O
HeLa	4	O
,	1	O
as	2	O
well	4	O
as	2	O
in	2	O
BJA-B	5	O
cells	5	O
,	1	O
whereas	7	O
the	3	O
removal	7	O
of	2	O
the	3	O
octamer	7	O
-binding	8	O
site	4	O
reduces	7	O
transcription	13	O
to	2	O
levels	6	O
below	5	O
detection	9	O
in	2	O
both	4	O
cell	4	O
types	5	O
.	1	O

Enhancers	9	O
containing	10	O
a	1	O
single	6	O
Oct	3	O
have	4	O
,	1	O
nevertheless	12	O
,	1	O
the	3	O
capacity	8	O
to	2	O
partially	9	O
activate	8	O
U2	2	B-Gene
snRNA	5	I-Gene
transcription	13	O
in	2	O
both	4	O
HeLa	4	O
cells	5	O
,	1	O
in	2	O
which	5	O
only	4	O
OTF-1	5	B-Gene
is	2	O
expressed	9	O
,	1	O
and	3	O
in	2	O
BJA-B	5	O
cells	5	O
in	2	O
which	5	O
OTF-2	5	B-Gene
is	2	O
the	3	O
predominantly	13	O
expressed	9	O
octamer	7	B-Gene
-binding	8	I-Gene
factor	6	I-Gene
.	1	O

The	3	O
most	4	O
likely	6	O
interpretation	14	O
of	2	O
our	3	O
results	7	O
is	2	O
that	4	O
both	4	O
the	3	O
ubiquitous	10	O
transcription	13	O
factor	6	O
,	1	O
OTF-1	5	B-Gene
,	1	O
and	3	O
the	3	O
B-cell-specific	15	O
transcription	13	O
factor	6	O
,	1	O
OTF-2	5	B-Gene
,	1	O
can	3	O
activate	8	O
U2	2	B-Gene
snRNA	5	I-Gene
transcription	13	O
.	1	O

The	3	O
results	7	O
also	4	O
revealed	8	O
a	1	O
similar	7	O
functional	10	O
cooperation	11	O
between	7	O
the	3	O
transcription	13	O
factors	7	O
which	5	O
bind	4	O
to	2	O
the	3	O
Oct	3	O
and	3	O
the	3	O
adjacent	8	O
Sp	2	B-Gene
1	1	I-Gene
-binding	8	O
site	4	O
in	2	O
BJA-B	5	O
cells	5	O
,	1	O
as	2	O
has	3	O
been	4	O
observed	8	O
in	2	O
HeLa	4	O
cells	5	O
,	1	O
since	5	O
a	1	O
template	8	O
which	5	O
contains	8	O
a	1	O
weak	4	O
binding	7	O
site	4	O
for	3	O
OTFs	4	B-Gene
expresses	9	O
wild-type	9	O
levels	6	O
of	2	O
U2	2	B-Gene
snRNA	5	I-Gene
in	2	O
both	4	O
cell	4	O
types	5	O
when	4	O
the	3	O
weak	4	O
octamer	7	O
-binding	8	O
site	4	O
is	2	O
combined	8	O
with	4	O
a	1	O
Sp	2	B-Gene
1	1	I-Gene
-binding	8	O
site	4	O
.	1	O

Cortisol	8	B-Chemical
receptor	8	O
resistance	10	O
:	1	O
the	3	O
variability	11	O
of	2	O
its	3	O
clinical	8	O
presentation	12	O
and	3	O
response	8	O
to	2	O
treatment	9	O
.	1	O

Primary	7	O
(	1	O
partial	7	O
)	1	O
cortisol	8	B-Chemical
receptor	8	O
resistance	10	O
was	3	O
previously	10	O
reported	8	O
in	2	O
a	1	O
total	5	O
of	2	O
7	1	O
patients	8	O
and	3	O
14	2	O
asymptomatic	12	O
family	6	O
members	7	O
.	1	O

Its	3	O
occurrence	10	O
is	2	O
considered	10	O
to	2	O
be	2	O
extremely	9	O
rare	4	O
.	1	O

In	2	O
the	3	O
present	7	O
study	5	O
we	2	O
report	6	O
on	2	O
6	1	O
patients	8	O
(	1	O
2	1	O
males	5	O
and	3	O
4	1	O
females	7	O
)	1	O
with	4	O
the	3	O
syndrome	8	O
.	1	O

The	3	O
first	5	O
male	4	O
patient	7	O
presented	9	O
with	4	O
mild	4	B-Disease
hypertension	12	I-Disease
.	1	O

Hydrochlorothiazide	19	B-Chemical
therapy	7	O
resulted	8	O
in	2	O
life	4	O
-threatening	12	O
hypokalemia	11	B-Disease
.	1	O

The	3	O
second	6	O
male	4	O
patient	7	O
had	3	O
slight	6	O
hypertension	12	B-Disease
without	7	O
hypokalemia	11	B-Disease
.	1	O

All	3	O
four	4	O
female	6	O
patients	8	O
presented	9	O
between	7	O
the	3	O
age	3	O
of	2	O
20-30	5	O
yr	2	O
with	4	O
acne	4	B-Disease
,	1	O
hirsutism	9	B-Disease
,	1	O
and	3	O
irregular	9	O
menstruations	13	O
.	1	O

Low	3	O
dose	4	O
dexamethasone	13	B-Chemical
therapy	7	O
(	1	O
1-1.5	5	O
mg	2	O
/	1	O
day	3	O
)	1	O
was	3	O
of	2	O
clinical	8	O
benefit	7	O
in	2	O
these	5	O
patients	8	O
.	1	O

All	3	O
patients	8	O
showed	6	O
insufficient	12	O
suppression	11	O
of	2	O
serum	5	O
cortisol	8	B-Chemical
concentrations	14	O
in	2	O
the	3	O
overnight	9	O
1-mg	4	O
dexamethasone	13	O
test	4	O
.	1	O

The	3	O
diurnal	7	O
rhythm	6	O
of	2	O
ACTH	4	B-Gene
and	3	O
cortisol	8	B-Chemical
was	3	O
intact	6	O
,	1	O
albeit	6	O
at	2	O
an	2	O
elevated	8	O
level	5	O
.	1	O

There	5	O
was	3	O
a	1	O
normal	6	O
increase	8	O
in	2	O
ACTH	4	B-Gene
,	1	O
cortisol	8	B-Chemical
,	1	O
and	3	O
GH	2	B-Gene
(	1	O
except	6	O
in	2	O
one	3	O
obese	5	O
patient	7	O
)	1	O
in	2	O
response	8	O
to	2	O
insulin	7	B-Gene
-induced	8	O
hypoglycemia	12	B-Disease
,	1	O
while	5	O
cortisol	8	B-Chemical
production	10	O
was	3	O
elevated	8	O
in	2	O
three	5	O
patients	8	O
.	1	O

Circulating	11	O
adrenal	7	O
androgen	8	B-Chemical
levels	6	O
were	4	O
increased	9	O
in	2	O
all	3	O
patients	8	O
.	1	O

Glucocorticoid	14	B-Gene
receptors	9	I-Gene
were	4	O
investigated	12	O
in	2	O
a	1	O
whole	5	O
cell	4	O
dexamethasone	13	O
binding	7	O
assay	5	O
in	2	O
mononuclear	11	O
leukocytes	10	O
.	1	O

In	2	O
the	3	O
first	5	O
male	4	O
patient	7	O
,	1	O
the	3	O
number	6	O
of	2	O
receptors	9	O
was	3	O
very	4	O
low	3	O
,	1	O
while	5	O
the	3	O
affinity	8	O
was	3	O
lower	5	O
than	4	O
that	4	O
in	2	O
controls	8	O
.	1	O

A	1	O
lowered	7	O
affinity	8	O
to	2	O
dexamethasone	13	B-Chemical
was	3	O
found	5	O
in	2	O
one	3	O
female	6	O
patient	7	O
,	1	O
while	5	O
a	1	O
lowered	7	O
number	6	O
of	2	O
receptors	9	O
was	3	O
found	5	O
in	2	O
three	5	O
patients	8	O
.	1	O

In	2	O
the	3	O
second	6	O
male	4	O
patient	7	O
,	1	O
no	2	O
abnormalities	13	O
were	4	O
found	5	O
.	1	O

As	2	O
a	1	O
bioassay	8	O
for	3	O
glucocorticoid	14	B-Chemical
action	6	O
we	2	O
also	4	O
measured	8	O
dexamethasone	13	B-Chemical
suppressibility	15	O
of	2	O
mitogen	7	O
-stimulated	11	O
incorporation	13	O
of	2	O
[	1	O
3H	2	O
]	1	O
thymidine	9	B-Chemical
in	2	O
mononuclear	11	O
leukocytes	10	O
.	1	O

In	2	O
the	3	O
male	4	O
patient	7	O
with	4	O
normal	6	O
receptor	8	O
status	6	O
,	1	O
dexamethasone	13	B-Chemical
suppressibility	15	O
of	2	O
[	1	O
3H	2	O
]	1	O
thymidine	9	B-Chemical
incorporation	13	O
was	3	O
significantly	13	O
lower	5	O
than	4	O
that	4	O
in	2	O
healthy	7	O
controls	8	O
with	4	O
respect	7	O
to	2	O
both	4	O
maximal	7	O
suppression	11	O
and	3	O
IC50	4	O
.	1	O

Partial	7	O
cortisol	8	B-Chemical
receptor	8	O
resistance	10	O
might	5	O
be	2	O
less	4	O
rare	4	O
than	4	O
previously	10	O
thought	7	O
.	1	O

In	2	O
the	3	O
six	3	O
patients	8	O
presented	9	O
,	1	O
at	2	O
least	5	O
three	5	O
different	9	O
forms	5	O
can	3	O
be	2	O
recognized	10	O
.	1	O

Therapy	7	O
with	4	O
dexamethasone	13	B-Chemical
was	3	O
successful	10	O
in	2	O
female	6	O
patients	8	O
with	4	O
acne	4	B-Disease
and	3	O
hirsutism	9	B-Disease
,	1	O
as	2	O
the	3	O
secondary	9	O
increase	8	O
in	2	O
the	3	O
production	10	O
of	2	O
adrenal	7	O
androgens	9	B-Chemical
was	3	O
effectively	11	O
controlled	10	O
.	1	O

Kappa	5	O
B-specific	10	O
DNA	3	O
binding	7	O
proteins	8	O
are	3	O
differentially	14	O
inhibited	9	O
by	2	O
enhancer	8	O
mutations	9	O
and	3	O
biological	10	O
oxidation	9	O
.	1	O

Kappa	5	O
B	1	O
(	1	O
kappa	5	O
B	1	O
)	1	O
enhancer	8	O
binding	7	O
proteins	8	O
isolated	8	O
from	4	O
the	3	O
nuclei	6	O
of	2	O
activated	9	O
human	5	O
T	1	O
cells	5	O
produce	7	O
two	3	O
distinct	8	O
nucleoprotein	13	O
complexes	9	O
when	4	O
incubated	9	O
with	4	O
the	3	O
kappa	5	O
B	1	O
element	7	O
from	4	O
the	3	O
interleukin-2	13	B-Gene
receptor-alpha	14	I-Gene
(	1	I-Gene
IL-2R	5	I-Gene
alpha	5	I-Gene
)	1	I-Gene
gene	4	I-Gene
.	1	O

These	5	O
two	3	O
DNA-protein	11	O
complexes	9	O
are	3	O
composed	8	O
of	2	O
at	2	O
least	5	O
four	4	O
host	4	O
proteins	8	O
(	1	O
p50	3	B-Gene
,	1	O
p55	3	B-Gene
,	1	O
p75	3	B-Gene
,	1	O
p85	3	B-Gene
)	1	O
,	1	O
each	4	O
of	2	O
which	5	O
shares	6	O
structural	10	O
similarity	10	O
with	4	O
the	3	O
v-rel	5	B-Gene
oncogene	8	I-Gene
product	7	I-Gene
.	1	O

Nuclear	7	O
expression	10	O
of	2	O
these	5	O
proteins	8	O
is	2	O
induced	7	O
with	4	O
distinctly	10	O
biphasic	8	O
kinetics	8	O
following	9	O
phorbol	7	B-Chemical
ester	5	I-Chemical
activation	10	O
of	2	O
T	1	O
cells	5	O
(	1	O
p55	3	B-Gene
/	1	I-Gene
p75	3	I-Gene
early	5	O
and	3	O
p50	3	B-Gene
/	1	I-Gene
p85	3	I-Gene
late	4	O
)	1	O
.	1	O

DNA-protein	11	O
crosslinking	12	O
studies	7	O
have	4	O
revealed	8	O
that	4	O
the	3	O
more	4	O
rapidly	7	O
migrating	9	O
B2	2	O
complex	7	O
contains	8	O
both	4	O
p50	3	B-Gene
and	3	O
p55	3	B-Gene
while	5	O
the	3	O
more	4	O
slowly	6	O
migrating	9	O
B1	2	O
complex	7	O
is	2	O
composed	8	O
of	2	O
p50	3	B-Gene
,	1	O
p55	3	B-Gene
,	1	O
p75	3	B-Gene
,	1	O
and	3	O
p85	3	B-Gene
.	1	O

Site	4	O
-directed	9	O
mutagenesis	11	O
of	2	O
the	3	O
wild-type	9	B-Gene
IL-2R	5	I-Gene
alpha	5	I-Gene
kappa	5	O
B	1	O
enhancer	8	O
(	1	O
GGGGAATCTCCC	12	O
)	1	O
has	3	O
revealed	8	O
that	4	O
the	3	O
binding	7	O
of	2	O
p50	3	B-Gene
and	3	O
p55	3	B-Gene
(	1	O
B2	2	O
complex	7	O
)	1	O
is	2	O
particularly	12	O
sensitive	9	O
to	2	O
alteration	10	O
of	2	O
the	3	O
5	1	O
'triplet	8	O
of	2	O
deoxyguanosine	14	B-Chemical
residues	8	I-Chemical
.	1	O

In	2	O
contrast	8	O
,	1	O
formation	9	O
of	2	O
the	3	O
B1	2	O
complex	7	O
,	1	O
reflecting	10	O
the	3	O
binding	7	O
of	2	O
p75	3	B-Gene
and	3	O
p85	3	B-Gene
,	1	O
critically	10	O
depends	7	O
upon	4	O
the	3	O
more	4	O
3	1	O
'sequences	10	O
of	2	O
this	4	O
enhancer	8	O
element	7	O
.	1	O

DNA	3	O
binding	7	O
by	2	O
all	3	O
four	4	O
of	2	O
these	5	O
Rel	3	B-Gene
-related	8	O
factors	7	O
is	2	O
blocked	7	O
by	2	O
selective	9	O
chemical	8	O
modification	12	O
of	2	O
lysine	6	B-Chemical
and	3	O
arginine	8	B-Chemical
residues	8	I-Chemical
,	1	O
suggesting	10	O
that	4	O
both	4	O
of	2	O
these	5	O
basic	5	O
amino	5	O
acids	5	O
are	3	O
required	8	O
for	3	O
binding	7	O
to	2	O
the	3	O
kappa	5	O
B	1	O
element	7	O
.	1	O

Similarly	9	O
,	1	O
covalent	8	O
modification	12	O
of	2	O
free	4	O
sulfhydryl	10	B-Chemical
groups	6	O
with	4	O
diamide	7	O
(	1	O
reversible	10	O
)	1	O
or	2	O
N-ethylmaleimide	16	B-Chemical
(	1	O
irreversible	12	O
)	1	O
results	7	O
in	2	O
a	1	O
complete	8	O
loss	4	O
of	2	O
DNA	3	O
binding	7	O
activity	8	O
.	1	O

In	2	O
contrast	8	O
,	1	O
mild	4	O
oxidation	9	O
with	4	O
glucose	7	B-Gene
oxidase	7	I-Gene
selectively	11	O
inhibits	8	O
p75	3	B-Gene
and	3	O
p85	3	B-Gene
binding	7	O
while	5	O
not	3	O
blocking	8	O
p50	3	B-Gene
and	3	O
p55	3	B-Gene
interactions	12	O
.	1	O

These	5	O
findings	8	O
suggest	7	O
that	4	O
reduced	7	O
cysteine	8	B-Chemical
thiols	6	O
play	4	O
an	2	O
important	9	O
role	4	O
in	2	O
the	3	O
DNA	3	O
binding	7	O
activity	8	O
of	2	O
this	4	O
family	6	O
of	2	O
Rel	3	B-Gene
-related	8	O
transcription	13	O
factors	7	O
.	1	O

A	1	O
novel	5	O
mitogen-inducible	17	O
gene	4	O
product	7	O
related	7	O
to	2	O
p50	3	B-Gene
/	1	I-Gene
p105-NF-kappa	13	I-Gene
B	1	I-Gene
participates	12	O
in	2	O
transactivation	15	O
through	7	O
a	1	O
kappa	5	O
B	1	O
site	4	O
.	1	O

A	1	O
Rel	3	B-Gene
-related	8	O
,	1	O
mitogen-inducible	17	O
,	1	O
kappa	5	O
B	1	O
-binding	8	O
protein	7	O
has	3	O
been	4	O
cloned	6	O
as	2	O
an	2	O
immediate-early	15	O
activation	10	O
gene	4	O
of	2	O
human	5	O
peripheral	10	O
blood	5	O
T	1	O
cells	5	O
.	1	O

The	3	O
cDNA	4	O
has	3	O
an	2	O
open	4	O
reading	7	O
frame	5	O
of	2	O
900	3	O
amino	5	O
acids	5	O
capable	7	O
of	2	O
encoding	8	O
a	1	O
97-kDa	6	O
protein	7	O
.	1	O

This	4	O
protein	7	O
is	2	O
most	4	O
similar	7	O
to	2	O
the	3	O
105-kDa	7	O
precursor	9	O
polypeptide	11	O
of	2	O
p50-NF-kappa	12	B-Gene
B	1	I-Gene
.	1	O

Like	4	O
the	3	O
105-kDa	7	O
precursor	9	O
,	1	O
it	2	O
contains	8	O
an	2	O
amino-terminal	14	O
Rel	3	B-Gene
-related	8	O
domain	6	O
of	2	O
about	5	O
300	3	O
amino	5	O
acids	5	O
and	3	O
a	1	O
carboxy-terminal	16	B-Chemical
domain	6	O
containing	10	O
six	3	O
full	4	O
cell	4	O
cycle	5	O
or	2	O
ankyrin	7	B-Gene
repeats	7	O
.	1	O

In	2	O
vitro	5	O
-translated	11	O
proteins	8	O
,	1	O
truncated	9	O
downstream	10	O
of	2	O
the	3	O
Rel	3	B-Gene
domain	6	O
and	3	O
excluding	9	O
the	3	O
repeats	7	O
,	1	O
bind	4	O
kappa	5	O
B	1	O
sites	5	O
.	1	O

We	2	O
refer	5	O
to	2	O
the	3	O
kappa	5	O
B	1	O
-binding	8	O
,	1	O
truncated	9	O
protein	7	O
as	2	O
p50B	4	B-Gene
by	2	O
analogy	7	O
with	4	O
p50-NF-kappa	12	B-Gene
B	1	I-Gene
and	3	O
to	2	O
the	3	O
full-length	11	O
protein	7	O
as	2	O
p97	3	B-Gene
.	1	O

p50B	4	B-Gene
is	2	O
able	4	O
to	2	O
form	4	O
heteromeric	11	O
kappa	5	O
B	1	O
-binding	8	O
complexes	9	O
with	4	O
RelB	4	B-Gene
,	1	O
as	2	O
well	4	O
as	2	O
with	4	O
p65	3	B-Gene
and	3	O
p50	3	B-Gene
,	1	O
the	3	O
two	3	O
subunits	8	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
.	1	O

Transient-transfection	22	O
experiments	11	O
in	2	O
embryonal	9	B-Disease
carcinoma	9	I-Disease
cells	5	O
demonstrate	11	O
a	1	O
functional	10	O
cooperation	11	O
between	7	O
p50B	4	B-Gene
and	3	O
RelB	4	B-Gene
or	2	O
p65	3	B-Gene
in	2	O
transactivation	15	O
of	2	O
a	1	O
reporter	8	O
plasmid	7	O
dependent	9	O
on	2	O
a	1	O
kappa	5	O
B	1	O
site	4	O
.	1	O

The	3	O
data	4	O
imply	5	O
the	3	O
existence	9	O
of	2	O
a	1	O
complex	7	O
family	6	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
-like	5	O
transcription	13	O
factors	7	O
.	1	O

[	1	O
Changes	7	O
in	2	O
leucocytic	10	B-Gene
estrogen	8	I-Gene
receptor	8	I-Gene
levels	6	O
in	2	O
patients	8	O
with	4	O
climacteric	11	O
syndrome	8	O
and	3	O
therapeutic	11	O
effect	6	O
of	2	O
liuwei	6	B-Chemical
dihuang	7	I-Chemical
pills	5	I-Chemical
]	1	O

The	3	O
numbers	7	O
of	2	O
estrogen	8	B-Gene
receptor	8	I-Gene
(	1	O
ER	2	B-Gene
)	1	O
in	2	O
human	5	O
peripheral	10	O
leucocytes	10	O
in	2	O
22	2	O
women	5	O
with	4	O
climacteric	11	O
syndrome	8	O
were	4	O
measured	8	O
by	2	O
radioligand	11	O
method	6	O
.	1	O

The	3	O
results	7	O
were	4	O
compared	8	O
with	4	O
those	5	O
of	2	O
12	2	O
normal	6	O
child	5	O
-bearing-age	12	O
women	5	O
.	1	O

It	2	O
wat	3	O
found	5	O
that	4	O
the	3	O
contents	8	O
of	2	O
leucocytic	10	B-Gene
ER	2	I-Gene
in	2	O
climacteric	11	O
syndrome	8	O
patients	8	O
were	4	O
significantly	13	O
lower	5	O
than	4	O
normal	6	O
child	5	O
-bearing-age	12	O
women	5	O
.	1	O

The	3	O
authors	7	O
used	4	O
a	1	O
Chinese	7	O
prescription	12	O
--	2	O
Liuwei	6	B-Chemical
Dihuang	7	I-Chemical
Pills	5	I-Chemical
(	1	O
LDP	3	B-Chemical
)	1	O
to	2	O
treat	5	O
the	3	O
patients	8	O
for	3	O
2	1	O
months	6	O
.	1	O

The	3	O
numbers	7	O
of	2	O
leucocytic	10	B-Gene
ER	2	I-Gene
were	4	O
significantly	13	O
increased	9	O
after	5	O
treatment	9	O
.	1	O

The	3	O
data	4	O
indicate	8	O
that	4	O
decrease	8	O
of	2	O
ER	2	B-Gene
levels	6	O
in	2	O
cell	4	O
may	3	O
involve	7	O
in	2	O
the	3	O
pathogenesis	12	O
of	2	O
climacteric	11	O
syndrome	8	O
.	1	O

LDP	3	B-Chemical
not	3	O
only	4	O
increases	9	O
plasma	6	O
estradiol	9	B-Chemical
levels	6	O
,	1	O
but	3	O
also	4	O
increases	9	O
the	3	O
leucocytic	10	B-Gene
ER	2	I-Gene
levels	6	O
.	1	O

This	4	O
may	3	O
be	2	O
the	3	O
basis	5	O
of	2	O
the	3	O
therapeutic	11	O
effect	6	O
on	2	O
the	3	O
disease	7	O
.	1	O

A	1	O
novel	5	O
primer	6	O
extension	9	O
method	6	O
to	2	O
detect	6	O
the	3	O
number	6	O
of	2	O
CAG	3	O
repeats	7	O
in	2	O
the	3	O
androgen	8	B-Gene
receptor	8	I-Gene
gene	4	I-Gene
in	2	O
families	8	O
with	4	O
X	1	B-Disease
-linked	7	I-Disease
spinal	6	I-Disease
and	3	I-Disease
bulbar	6	I-Disease
muscular	8	I-Disease
atrophy	7	I-Disease
.	1	O

X	1	B-Disease
-linked	7	I-Disease
spinal	6	I-Disease
and	3	I-Disease
bulbar	6	I-Disease
muscular	8	I-Disease
atrophy	7	I-Disease
(	1	O
SBMA	4	B-Disease
)	1	O
,	1	O
an	2	O
adult-onset	11	O
form	4	O
of	2	O
motor	5	B-Disease
neuron	6	I-Disease
disease	7	I-Disease
,	1	O
was	3	O
recently	8	O
reported	8	O
to	2	O
be	2	O
caused	6	O
by	2	O
amplification	13	O
of	2	O
the	3	O
CAG	3	O
repeats	7	O
in	2	O
the	3	O
androgen	8	B-Gene
receptor	8	I-Gene
gene	4	I-Gene
.	1	O

We	2	O
report	6	O
here	4	O
a	1	O
simple	6	O
and	3	O
rapid	5	O
strategy	8	O
to	2	O
detect	6	O
the	3	O
precise	7	O
number	6	O
of	2	O
the	3	O
CAGs	4	O
.	1	O

After	5	O
the	3	O
DNA	3	O
fragment	8	O
containing	10	O
the	3	O
CAG	3	O
repeats	7	O
is	2	O
amplified	9	O
by	2	O
the	3	O
polymerase	10	O
chain	5	O
reaction	8	O
,	1	O
a	1	O
primer	6	O
extension	9	O
is	2	O
carried	7	O
out	3	O
;	1	O
the	3	O
extension	9	O
of	2	O
the	3	O
end	3	O
-labelled	9	O
reverse	7	O
primer	6	O
adjacent	8	O
to	2	O
3	1	O
'end	4	O
of	2	O
CAG	3	O
repeats	7	O
stops	5	O
at	2	O
the	3	O
first	5	O
T	1	O
after	5	O
CAG	3	O
repeats	7	O
with	4	O
the	3	O
incorporation	13	O
of	2	O
dideoxy	7	B-Chemical
ATP	3	I-Chemical
in	2	O
the	3	O
reaction	8	O
mixture	7	O
.	1	O

The	3	O
resultant	9	O
primer	6	O
products	8	O
are	3	O
analysed	8	O
by	2	O
denaturing	10	O
polyacrylamide	14	O
gel	3	O
electrophoresis	15	O
and	3	O
autoradiography	15	O
.	1	O

This	4	O
method	6	O
could	5	O
be	2	O
quite	5	O
useful	6	O
to	2	O
detect	6	O
not	3	O
only	4	O
CAG	3	O
repeats	7	O
in	2	O
SBMA	4	B-Disease
but	3	O
also	4	O
other	5	O
polymorphic	11	O
dinucleotide	12	O
and	3	O
trinucleotide	13	O
repeats	7	O
.	1	O

Activity	8	O
of	2	O
the	3	O
kappa	5	O
B	1	O
enhancer	8	O
of	2	O
the	3	O
interleukin-2	13	B-Gene
receptor	8	I-Gene
alpha	5	I-Gene
chain	5	I-Gene
in	2	O
somatic	7	O
cell	4	O
hybrids	7	O
is	2	O
accompanied	11	O
by	2	O
the	3	O
nuclear	7	O
localization	12	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
.	1	O

The	3	O
two	3	O
nuclear	7	O
proteins	8	O
NF-kappa	8	B-Gene
B	1	I-Gene
(	1	O
consisting	10	O
of	2	O
subunits	8	O
p50	3	B-Gene
an	2	O
dp65	4	B-Gene
)	1	O
and	3	O
the	3	O
DNA	3	O
-binding	8	O
subunit	7	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
(	1	O
p50	3	B-Gene
)	1	O
by	2	O
itself	6	O
,	1	O
also	4	O
called	6	O
KBF1	4	B-Gene
,	1	O
are	3	O
constitutively	14	O
expressed	9	O
and	3	O
localized	9	O
in	2	O
the	3	O
nucleus	7	O
of	2	O
the	3	O
human	5	O
T-cell	6	O
line	4	O
IARC	4	O
301.5	5	O
.	1	O

In	2	O
order	5	O
to	2	O
define	6	O
the	3	O
roles	5	O
of	2	O
these	5	O
two	3	O
factors	7	O
,	1	O
which	5	O
bind	4	O
to	2	O
the	3	O
same	4	O
kappa	5	O
B	1	O
enhancers	9	O
,	1	O
in	2	O
transcription	13	O
activation	10	O
we	2	O
have	4	O
prepared	8	O
somatic	7	O
cell	4	O
hybrids	7	O
between	7	O
IARC	4	O
301.5	5	O
and	3	O
a	1	O
murine	6	O
myeloma	7	B-Disease
.	1	O

Most	4	O
hybrids	7	O
express	7	O
both	4	O
KBF1	4	B-Gene
and	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
in	2	O
their	5	O
nuclei	6	O
,	1	O
but	3	O
one	3	O
hybrid	6	O
expresses	9	O
only	4	O
KBF1	4	B-Gene
.	1	O

The	3	O
kappa	5	O
B	1	O
enhancer	8	O
of	2	O
the	3	O
gene	4	O
encoding	8	O
the	3	O
interleukin-2	13	B-Gene
(	1	I-Gene
IL-2	4	I-Gene
)	1	I-Gene
receptor	8	I-Gene
alpha	5	I-Gene
chain	5	I-Gene
(	1	O
IL-2R	5	B-Gene
alpha	5	I-Gene
)	1	O
is	2	O
functional	10	O
only	4	O
in	2	O
the	3	O
hybrids	7	O
expressing	10	O
nuclear	7	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
.	1	O

These	5	O
findings	8	O
show	4	O
that	4	O
nuclear	7	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
is	2	O
necessary	9	O
to	2	O
activate	8	O
the	3	O
kappa	5	O
B	1	O
enhancer	8	O
,	1	O
while	5	O
KBF1	4	B-Gene
by	2	O
itself	6	O
is	2	O
not	3	O
sufficient	10	O
.	1	O

We	2	O
propose	7	O
that	4	O
KBF1	4	B-Gene
is	2	O
a	1	O
competitive	11	O
inhibitor	9	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
and	3	O
discuss	7	O
how	3	O
these	5	O
factors	7	O
may	3	O
be	2	O
involved	8	O
in	2	O
the	3	O
transient	9	O
expression	10	O
of	2	O
IL-2	4	B-Gene
and	3	O
IL-2	4	B-Gene
alpha	5	I-Gene
genes	5	I-Gene
during	6	O
the	3	O
immune	6	O
response	8	O
.	1	O

Influence	9	O
of	2	O
estradiol	9	B-Chemical
and	3	O
tamoxifen	9	B-Chemical
on	2	O
susceptibility	14	O
of	2	O
human	5	O
breast	6	B-Disease
cancer	6	I-Disease
cell	4	O
lines	5	O
to	2	O
lysis	5	O
by	2	O
lymphokine	10	O
-activated	10	O
killer	6	O
cells	5	O
.	1	O

The	3	O
design	6	O
of	2	O
combination	11	O
hormonal	8	O
and	3	O
immunotherapeutic	17	O
protocols	9	O
for	3	O
breast	6	B-Disease
cancer	6	I-Disease
patients	8	O
may	3	O
be	2	O
facilitated	11	O
by	2	O
analysis	8	O
of	2	O
preclinical	11	O
in	2	O
vitro	5	O
model	5	O
systems	7	O
.	1	O

Estrogen	8	B-Gene
receptor	8	I-Gene
positive	8	O
(	1	O
ER+	3	B-Gene
:	1	O
MCF-7	5	O
)	1	O
and	3	O
negative	8	O
(	1	O
ER-	3	B-Gene
:	1	O
MDA-MB-231	10	O
)	1	O
human	5	O
breast	6	B-Disease
cancer	6	I-Disease
cell	4	O
lines	5	O
were	4	O
utilized	8	O
to	2	O
evaluate	8	O
the	3	O
effects	7	O
of	2	O
tamoxifen	9	B-Chemical
(	1	O
TAM	3	B-Chemical
)	1	O
and	3	O
estradiol	9	B-Chemical
(	1	O
E2	2	B-Chemical
)	1	O
on	2	O
modulation	10	O
of	2	O
breast	6	B-Disease
cancer	6	I-Disease
target	6	O
susceptibility	14	O
to	2	O
lysis	5	O
by	2	O
lymphokine	10	O
-activated	10	O
killer	6	O
(	1	O
LAK	3	O
)	1	O
cells	5	O
.	1	O

E2	2	B-Chemical
-stimulated	11	O
ER+	3	B-Gene
cells	5	O
were	4	O
more	4	O
susceptible	11	O
to	2	O
lysis	5	O
by	2	O
LAK	3	O
cells	5	O
than	4	O
corresponding	13	O
TAM	3	B-Chemical
-treated	8	O
or	2	O
control	7	O
cells	5	O
,	1	O
while	5	O
treatment	9	O
of	2	O
ER-	3	B-Gene
cells	5	O
with	4	O
either	6	O
E2	2	B-Chemical
or	2	O
TAM	3	B-Chemical
alone	5	O
did	3	O
not	3	O
alter	5	O
from	4	O
control	7	O
their	5	O
susceptibility	14	O
to	2	O
this	4	O
immune	6	O
-mediated	9	O
lysis	5	O
.	1	O

All	3	O
ER+	3	B-Gene
and	3	O
ER-	3	B-Gene
cells	5	O
tested	6	O
remained	8	O
sensitive	9	O
after	5	O
treatment	9	O
with	4	O
TAM	3	B-Chemical
to	2	O
lysis	5	O
by	2	O
LAK	3	O
cells	5	O
.	1	O

In	2	O
addition	8	O
,	1	O
an	2	O
adenocarcinoma	14	B-Disease
reactive	8	O
human-mouse	11	O
chimeric	8	O
monoclonal	10	O
antibody	8	O
(	1	O
ING-1	5	B-Gene
)	1	O
was	3	O
able	4	O
to	2	O
significantly	13	O
boost	5	O
in	2	O
vivo	4	O
generated	9	O
LAK	3	O
cell	4	O
-mediated	9	O
lysis	5	O
of	2	O
control	7	O
,	1	O
E2	2	B-Chemical
-treated	8	O
,	1	O
and	3	O
TAM	3	B-Chemical
-treated	8	O
ER+	3	B-Gene
and	3	O
ER-	3	B-Gene
cells	5	O
.	1	O

These	5	O
in	2	O
vitro	5	O
results	7	O
provide	7	O
a	1	O
preclinical	11	O
rationale	9	O
for	3	O
in	2	O
vivo	4	O
testing	7	O
of	2	O
TAM	3	B-Chemical
,	1	O
interleukin-2	13	B-Gene
(	1	O
IL-2	4	B-Gene
)	1	O
,	1	O
and	3	O
breast	6	B-Disease
cancer	6	I-Disease
reactive	8	O
antibody	8	O
-dependent	10	O
cellular	8	O
cytotoxicity	12	O
facilitating	12	O
antibody	8	O
in	2	O
patients	8	O
with	4	O
refractory	10	O
or	2	O
high	4	O
risk	4	O
breast	6	B-Disease
cancer	6	I-Disease
.	1	O

Glucocorticoid	14	B-Gene
receptor	8	I-Gene
and	3	O
inhibition	10	O
of	2	O
3-O-methyl-D-glucose	20	B-Chemical
uptake	6	O
by	2	O
glucocorticoids	15	B-Chemical
in	2	O
peripheral	10	O
blood	5	O
leukocytes	10	O
from	4	O
normal	6	O
humans	6	O
:	1	O
correlation	11	O
between	7	O
receptor	8	O
level	5	O
and	3	O
hormone	7	O
effect	6	O
in	2	O
vitro	5	O
.	1	O

We	2	O
have	4	O
measured	8	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
concentration	13	O
in	2	O
mononuclear	11	O
and	3	O
polymorphonuclear	17	O
leukocytes	10	O
,	1	O
both	4	O
of	2	O
which	5	O
were	4	O
isolated	8	O
from	4	O
peripheral	10	O
blood	5	O
from	4	O
ten	3	O
healthy	7	O
male	4	O
volunteers	10	O
.	1	O

In	2	O
parallel	8	O
,	1	O
the	3	O
inhibitory	10	O
effect	6	O
of	2	O
dexamethasone	13	B-Chemical
on	2	O
3-O-methyl-D-glucose	20	B-Chemical
uptake	6	O
was	3	O
assayed	7	O
in	2	O
the	3	O
corresponding	13	O
mononuclear	11	O
leukocytes	10	O
.	1	O

The	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
levels	6	O
in	2	O
mononuclear	11	O
leukocytes	10	O
correlated	10	O
with	4	O
those	5	O
in	2	O
polymorphonuclear	17	O
leukocytes	10	O
,	1	O
and	3	O
there	5	O
was	3	O
a	1	O
linear	6	O
relationship	12	O
between	7	O
the	3	O
cellular	8	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
levels	6	O
and	3	O
glucocorticoid	14	B-Chemical
-mediated	9	O
inhibition	10	O
of	2	O
the	3	O
uptake	6	O
of	2	O
3-O-methyl-D-glucose	20	B-Chemical
in	2	O
mononuclear	11	O
leukocytes	10	O
.	1	O

When	4	O
mononuclear	11	O
leukocytes	10	O
were	4	O
incubated	9	O
in	2	O
the	3	O
presence	8	O
of	2	O
8-bromo-cAMP	12	B-Chemical
,	1	O
cellular	8	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
levels	6	O
increased	9	O
and	3	O
a	1	O
more	4	O
pronounced	10	O
inhibitory	10	O
effect	6	O
of	2	O
dexamethasone	13	B-Chemical
was	3	O
observed	8	O
on	2	O
the	3	O
transport	9	O
of	2	O
3-O-methyl-D-glucose	20	B-Chemical
.	1	O

We	2	O
conclude	8	O
that	4	O
the	3	O
cellular	8	B-Gene
glucocorticoid	14	I-Gene
receptor	8	I-Gene
levels	6	O
in	2	O
peripheral	10	O
blood	5	O
leukocytes	10	O
reflect	7	O
in	2	O
vitro	5	O
responsiveness	14	O
to	2	O
glucocorticoids	15	B-Chemical
in	2	O
mononuclear	11	O
leukocytes	10	O
from	4	O
healthy	7	O
males	5	O
,	1	O
and	3	O
that	4	O
the	3	O
individual	10	O
responsiveness	14	O
may	3	O
alter	5	O
upon	4	O
changes	7	O
in	2	O
the	3	O
cellular	8	O
levels	6	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
.	1	O

Stimulation	11	O
of	2	O
interferon	10	B-Gene
beta	4	I-Gene
gene	4	I-Gene
transcription	13	O
in	2	O
vitro	5	O
by	2	O
purified	8	B-Gene
NF-kappa	8	I-Gene
B	1	I-Gene
and	3	O
a	1	O
novel	5	O
TH	2	B-Gene
protein	7	I-Gene
.	1	O

The	3	O
human	5	B-Gene
interferon	10	I-Gene
beta	4	I-Gene
(	1	I-Gene
IFN-beta	8	I-Gene
)	1	I-Gene
regulatory	10	I-Gene
element	7	I-Gene
consists	8	O
of	2	O
multiple	8	O
enhanson	8	O
domains	7	O
which	5	O
are	3	O
targets	7	O
for	3	O
transcription	13	O
factors	7	O
involved	8	O
in	2	O
inducible	9	O
expression	10	O
of	2	O
the	3	O
promoter	8	O
.	1	O

To	2	O
further	7	O
characterize	12	O
the	3	O
protein-DNA	11	O
interactions	12	O
mediating	9	O
IFN-beta	8	B-Gene
induction	9	O
,	1	O
positive	8	O
regulatory	10	O
domain	6	O
(	1	O
PRD	3	O
)	1	O
II	2	O
binding	7	O
proteins	8	O
were	4	O
purified	8	O
from	4	O
phorbol	7	B-Chemical
ester	5	I-Chemical
induced	7	O
Jurkat	6	O
T-cells	7	O
and	3	O
from	4	O
IFN	3	B-Gene
primed	6	O
,	1	O
cycloheximide	13	B-Chemical
/	1	O
polyinosinic-polycytidylic	26	B-Chemical
acid	4	I-Chemical
treated	7	O
HeLa	4	O
S3	2	O
cells	5	O
.	1	O

From	4	O
HeLa	4	O
cells	5	O
,	1	O
two	3	O
major	5	O
proteins	8	O
of	2	O
52	2	O
and	3	O
45	2	O
kilodaltons	11	O
(	1	O
kD	2	O
)	1	O
copurified	10	O
with	4	O
DNA	3	O
binding	7	O
activity	8	O
,	1	O
whereas	7	O
from	4	O
T-cells	7	O
,	1	O
four	4	O
proteins	8	O
--	2	O
a	1	O
major	5	O
protein	7	O
of	2	O
52	2	O
kD	2	O
and	3	O
three	5	O
minor	5	O
proteins	8	O
of	2	O
82	2	O
,	1	O
67	2	O
,	1	O
and	3	O
43-47	5	O
kD	2	O
--	2	O
were	4	O
purified	8	O
.	1	O

Also	4	O
,	1	O
an	2	O
induction	9	O
specific	8	O
DNA	3	O
binding	7	O
protein	7	O
was	3	O
purified	8	O
from	4	O
HeLa	4	O
cells	5	O
that	4	O
interacted	10	O
with	4	O
the	3	O
(	1	O
AAGTGA	6	O
)	1	O
4	1	O
tetrahexamer	12	O
sequence	8	O
and	3	O
the	3	O
PRDI	4	O
domain	6	O
.	1	O

This	4	O
protein	7	O
is	2	O
immunologically	15	O
distinct	8	O
from	4	O
IRF-1	5	B-Gene
/	1	I-Gene
ISGF2	5	I-Gene
.	1	O

Uninduced	9	O
or	2	O
Sendai	6	O
virus	5	O
induced	7	O
HeLa	4	O
extracts	8	O
were	4	O
used	4	O
to	2	O
examine	7	O
transcription	13	O
in	2	O
vitro	5	O
using	5	O
a	1	O
series	6	O
of	2	O
IFN	3	B-Gene
beta	4	I-Gene
promoter	8	I-Gene
deletions	9	O
.	1	O

Deletions	9	O
upstream	8	O
of	2	O
the	3	O
PRDII	5	O
element	7	O
increased	9	O
transcription	13	O
in	2	O
the	3	O
uninduced	9	O
extract	7	O
,	1	O
indicating	10	O
predominantly	13	O
negative	8	O
regulation	10	O
of	2	O
the	3	O
promoter	8	O
.	1	O

A	1	O
2-4-fold	8	O
increase	8	O
in	2	O
IFN-beta	8	B-Gene
promoter	8	I-Gene
transcription	13	O
was	3	O
observed	8	O
in	2	O
Sendai	6	O
virus	5	O
induced	7	O
extracts	8	O
,	1	O
and	3	O
deletion	8	O
of	2	O
PRDI	4	O
and	3	O
PRDII	5	O
elements	8	O
decreased	9	O
this	4	O
induced	7	O
level	5	O
of	2	O
transcription	13	O
.	1	O

When	4	O
purified	8	O
PRDII	5	O
and	3	O
tetrahexamer	12	O
binding	7	O
proteins	8	O
were	4	O
added	5	O
to	2	O
the	3	O
induced	7	O
extract	7	O
,	1	O
a	1	O
4-fold	6	O
increase	8	O
in	2	O
transcription	13	O
was	3	O
observed	8	O
.	1	O

These	5	O
experiments	11	O
demonstrate	11	O
that	4	O
it	2	O
is	2	O
possible	8	O
to	2	O
modulate	8	O
IFN-beta	8	B-Gene
transcription	13	O
in	2	O
vitro	5	O
but	3	O
indicate	8	O
that	4	O
additional	10	O
proteins	8	O
may	3	O
be	2	O
required	8	O
to	2	O
fully	5	O
activate	8	O
IFN-beta	8	B-Gene
transcription	13	O
.	1	O

Structure	9	O
function	8	O
analysis	8	O
of	2	O
vitamin	7	B-Chemical
D	1	I-Chemical
analogs	7	O
with	4	O
C	1	O
-ring	5	O
modifications	13	O
.	1	O

Analogs	7	O
of	2	O
1	1	B-Chemical
alpha	5	I-Chemical
,	1	I-Chemical
25-dihydroxyvitamin	19	I-Chemical
D3	2	I-Chemical
(	1	O
1	1	O
alpha	5	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
)	1	O
with	4	O
substitutions	13	O
on	2	O
C-11	4	O
were	4	O
synthesized	11	O
.	1	O

Small	5	O
apolar	6	O
substitutions	13	O
(	1	O
11	2	O
alpha-methyl	12	O
,	1	O
11	2	O
alpha-fluoromethyl	18	O
)	1	O
did	3	O
not	3	O
markedly	8	O
decrease	8	O
the	3	O
affinity	8	O
for	3	O
the	3	O
vitamin	7	B-Gene
D	1	I-Gene
receptor	8	I-Gene
,	1	O
but	3	O
larger	6	O
(	1	O
11	2	O
alpha-chloromethyl	18	O
or	2	O
11	2	O
alpha-	6	O
or	2	O
11	2	O
beta-phenyl	11	O
)	1	O
or	2	O
more	4	O
polar	5	O
substitutions	13	O
(	1	O
11	2	O
alpha-hydroxymethyl	19	O
,	1	O
11	2	O
alpha-	6	O
(	1	O
2-hydroxyethyl	14	O
]	1	O
decreased	9	O
the	3	O
affinity	8	O
to	2	O
less	4	O
than	4	O
5	1	O
%	1	O
of	2	O
that	4	O
of	2	O
1	1	O
alpha	5	O
,	1	O
25-OH	5	O
)	1	O
2D3	3	O
.	1	O

Their	5	O
affinity	8	O
for	3	O
the	3	O
vitamin	7	B-Gene
D	1	I-Gene
-binding	8	I-Gene
protein	7	I-Gene
,	1	O
however	7	O
,	1	O
increased	9	O
up	2	O
to	2	O
4-fold	6	O
.	1	O

The	3	O
biological	10	O
activity	8	O
of	2	O
11	2	B-Chemical
alpha-methyl-1	14	I-Chemical
alpha	5	I-Chemical
,	1	I-Chemical
25-	3	I-Chemical
(	1	I-Chemical
OH	2	I-Chemical
)	1	I-Chemical
2D3	3	I-Chemical
closely	7	O
resembled	9	O
that	4	O
of	2	O
the	3	O
natural	7	O
hormone	7	O
on	2	O
normal	6	O
and	3	O
leukemic	8	O
cell	4	O
proliferation	13	O
and	3	O
bone	4	O
resorption	10	O
,	1	O
whereas	7	O
its	3	O
in	2	O
vivo	4	O
effect	6	O
on	2	O
calcium	7	B-Chemical
metabolism	10	O
of	2	O
the	3	O
rachitic	8	O
chick	5	O
was	3	O
about	5	O
50	2	O
%	1	O
of	2	O
that	4	O
of	2	O
1	1	O
alpha	5	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
.	1	O

The	3	O
11	2	O
beta-methyl	11	O
analog	6	O
had	3	O
a	1	O
greater	7	O
than	4	O
10-fold	7	O
lower	5	O
activity	8	O
.	1	O

The	3	O
differentiating	15	O
effects	7	O
of	2	O
the	3	O
other	5	O
C-11	4	O
analogs	7	O
on	2	O
human	5	O
promyeloid	10	O
leukemia	8	B-Disease
cells	5	O
(	1	O
HL-60	5	O
)	1	O
agreed	6	O
well	4	O
with	4	O
their	5	O
bone	4	O
-resorbing	10	O
activity	8	O
and	3	O
receptor	8	O
affinity	8	O
,	1	O
but	3	O
they	4	O
demonstrated	12	O
lower	5	O
calcemic	8	O
effects	7	O
in	2	O
vivo	4	O
.	1	O

Large	5	O
or	2	O
polar	5	O
substitutions	13	O
on	2	O
C-11	4	O
of	2	O
1	1	O
alpha	5	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
thus	4	O
impair	6	O
the	3	O
binding	7	O
of	2	O
the	3	O
vitamin	7	B-Gene
D	1	I-Gene
receptor	8	I-Gene
but	3	O
increase	8	O
the	3	O
affinity	8	O
to	2	O
vitamin	7	B-Gene
D	1	I-Gene
-binding	8	I-Gene
protein	7	I-Gene
.	1	O

The	3	O
effects	7	O
of	2	O
many	4	O
C-11	4	O
-substituted	12	O
1	1	O
alpha	5	O
,	1	O
25-	3	O
(	1	O
OH	2	O
)	1	O
2D3	3	O
analogs	7	O
on	2	O
HL-60	5	O
cell	4	O
differentiation	15	O
exceeded	8	O
their	5	O
activity	8	O
on	2	O
calcium	7	B-Chemical
metabolism	10	O
.	1	O

Transcriptional	15	O
regulation	10	O
during	6	O
T-cell	6	O
development	11	O
:	1	O
the	3	O
alpha	5	B-Gene
TCR	3	I-Gene
gene	4	I-Gene
as	2	O
a	1	O
molecular	9	O
model	5	O
.	1	O

The	3	O
regulation	10	O
of	2	O
gene	4	O
expression	10	O
during	6	O
lymphocyte	10	O
differentiation	15	O
is	2	O
a	1	O
complex	7	O
process	7	O
involving	9	O
interactions	12	O
between	7	O
multiple	8	O
positive	8	O
and	3	O
negative	8	O
transcriptional	15	O
regulatory	10	O
elements	8	O
.	1	O

In	2	O
this	4	O
article	7	O
,	1	O
transcriptional	15	O
regulation	10	O
of	2	O
the	3	O
archetypal	10	O
T-cell-specific	15	O
gene	4	O
,	1	O
alpha	5	B-Gene
TCR	3	I-Gene
,	1	O
is	2	O
discussed	9	O
.	1	O

Major	5	O
recent	6	O
developments	12	O
,	1	O
including	9	O
the	3	O
identification	14	O
of	2	O
novel	5	O
families	8	O
of	2	O
transcription	13	O
factors	7	O
that	4	O
regulate	8	O
multiple	8	O
T-cell	6	O
genes	5	O
during	6	O
thymocyte	9	O
ontogeny	8	O
and	3	O
T-cell	6	O
activation	10	O
,	1	O
are	3	O
described	9	O
.	1	O

Cortisol	8	B-Chemical
resistance	10	O
in	2	O
acquired	8	B-Disease
immunodeficiency	16	I-Disease
syndrome	8	I-Disease
.	1	O

This	4	O
study	5	O
concerns	8	O
9	1	O
iv	2	O
drug	4	O
abusers	7	O
with	4	O
acquired	8	B-Disease
immunodeficiency	16	I-Disease
syndrome	8	I-Disease
(	1	O
AIDS	4	B-Disease
)	1	O
who	3	O
developed	9	O
hypercortisolism	16	B-Disease
without	7	O
the	3	O
clinical	8	O
signs	5	O
or	2	O
metabolic	9	O
consequences	12	O
of	2	O
hypercortisolism	16	B-Disease
.	1	O

All	3	O
patients	8	O
were	4	O
characterized	13	O
by	2	O
an	2	O
Addisonian	10	O
picture	7	O
(	1	O
weakness	8	O
,	1	O
weight	6	O
loss	4	O
,	1	O
hypotension	11	B-Disease
,	1	O
hyponatremia	12	B-Disease
,	1	O
and	3	O
intense	7	O
mucocutaneous	13	O
melanosis	9	B-Disease
)	1	O
.	1	O

An	2	O
acquired	8	O
form	4	O
of	2	O
peripheral	10	O
resistance	10	O
to	2	O
glucocorticoids	15	B-Chemical
was	3	O
suspected	9	O
.	1	O

We	2	O
,	1	O
therefore	9	O
,	1	O
examined	8	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
characteristics	15	O
on	2	O
mononuclear	11	O
leukocytes	10	O
by	2	O
measuring	9	O
[	1	O
3H	2	O
]	1	O
dexamethasone	13	B-Chemical
binding	7	O
and	3	O
the	3	O
effect	6	O
of	2	O
dexamethasone	13	B-Chemical
on	2	O
[	1	O
3H	2	O
]	1	O
thymidine	9	B-Chemical
incorporation	13	O
,	1	O
which	5	O
is	2	O
one	3	O
of	2	O
the	3	O
effects	7	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
activation	10	O
.	1	O

Glucocorticoid	14	B-Gene
receptor	8	I-Gene
density	7	O
was	3	O
increased	9	O
in	2	O
AIDS	4	B-Disease
patients	8	O
with	4	O
an	2	O
Addisonian	10	O
picture	7	O
(	1	O
group	5	O
1	1	O
;	1	O
16.2	4	O
+	1	O
/	1	O
-	1	O
9.4	3	O
fmol	4	O
/	1	O
million	7	O
cells	5	O
)	1	O
compared	8	O
to	2	O
values	6	O
in	2	O
12	2	O
AIDS	4	B-Disease
patients	8	O
without	7	O
an	2	O
Addisonian	10	O
picture	7	O
(	1	O
group	5	O
2	1	O
;	1	O
6.05	4	O
+	1	O
/	1	O
-	1	O
2.6	3	O
fmol	4	O
/	1	O
million	7	O
cells	5	O
;	1	O
P	1	O
less	4	O
than	4	O
0.01	4	O
)	1	O
and	3	O
sex-	4	O
and	3	O
age	3	O
-matched	8	O
controls	8	O
(	1	O
3.15	4	O
+	1	O
/	1	O
-	1	O
2.3	3	O
fmol	4	O
/	1	O
million	7	O
cells	5	O
;	1	O
P	1	O
less	4	O
than	4	O
0.01	4	O
)	1	O
.	1	O

The	3	O
affinity	8	O
of	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
(	1	O
Kd	2	O
)	1	O
was	3	O
strikingly	10	O
decreased	9	O
(	1	O
9.36	4	O
+	1	O
/	1	O
-	1	O
3.44	4	O
nM	2	O
in	2	O
group	5	O
1	1	O
;	1	O
3.2	3	O
+	1	O
/	1	O
-	1	O
1.5	3	O
nM	2	O
in	2	O
group	5	O
2	1	O
;	1	O
2.0	3	O
+	1	O
/	1	O
-	1	O
0.8	3	O
nM	2	O
in	2	O
controls	8	O
;	1	O
P	1	O
less	4	O
than	4	O
0.01	4	O
)	1	O
.	1	O

[	1	O
3H	2	O
]	1	O
Thymidine	9	B-Chemical
incorporation	13	O
was	3	O
decreased	9	O
dose	4	O
-dependently	12	O
by	2	O
dexamethasone	13	B-Chemical
in	2	O
controls	8	O
and	3	O
patients	8	O
;	1	O
the	3	O
effect	6	O
was	3	O
significantly	13	O
blunted	7	O
(	1	O
P	1	O
less	4	O
than	4	O
0.05	4	O
)	1	O
in	2	O
group	5	O
1	1	O
patients	8	O
,	1	O
which	5	O
suggests	8	O
that	4	O
activation	10	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
is	2	O
impaired	8	O
as	2	O
a	1	O
result	6	O
of	2	O
the	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
abnormality	11	O
.	1	O

In	2	O
conclusion	10	O
,	1	O
AIDS	4	B-Disease
patients	8	O
with	4	O
hypercortisolism	16	B-Disease
and	3	O
clinical	8	O
features	8	O
of	2	O
peripheral	10	O
resistance	10	O
to	2	O
glucocorticoids	15	B-Chemical
are	3	O
characterized	13	O
by	2	O
abnormal	8	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
on	2	O
lymphocytes	11	O
.	1	O

Resistance	10	O
to	2	O
glucocorticoids	15	B-Chemical
implies	7	O
a	1	O
complex	7	O
change	6	O
in	2	O
immune-endocrine	16	O
function	8	O
,	1	O
which	5	O
may	3	O
be	2	O
important	9	O
in	2	O
the	3	O
course	6	O
of	2	O
immunodeficiency	16	B-Disease
syndrome	8	I-Disease
.	1	O

Induction	9	O
of	2	O
monocytic	9	O
differentiation	15	O
and	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
-like	5	O
activities	10	O
by	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
1	1	O
infection	9	O
of	2	O
myelomonoblastic	16	O
cells	5	O
.	1	O

The	3	O
effects	7	O
of	2	O
human	5	O
immunodeficiency	16	O
virus	5	O
1	1	O
(	1	O
HIV-1	5	O
)	1	O
infection	9	O
on	2	O
cellular	8	O
differentiation	15	O
and	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
DNA	3	I-Gene
binding	7	O
activity	8	O
have	4	O
been	4	O
investigated	12	O
in	2	O
a	1	O
new	3	O
model	5	O
of	2	O
myeloid	7	O
differentiation	15	O
.	1	O

PLB-985	7	O
cells	5	O
represent	9	O
a	1	O
bipotential	11	O
myelomonoblastic	16	O
cell	4	O
population	10	O
capable	7	O
of	2	O
either	6	O
granulocytic	12	O
or	2	O
monocytic	9	O
differentiation	15	O
after	5	O
induction	9	O
with	4	O
appropriate	11	O
inducers	8	O
.	1	O

By	2	O
virtue	6	O
of	2	O
the	3	O
presence	8	O
of	2	O
CD4	3	B-Gene
on	2	O
the	3	O
cell	4	O
surface	7	O
,	1	O
PLB-985	7	O
cells	5	O
were	4	O
chronically	11	O
infected	8	O
with	4	O
HIV-1	5	O
strain	6	O
IIIB	4	O
.	1	O

PLB-IIIB	8	O
cells	5	O
clearly	7	O
possessed	9	O
a	1	O
more	4	O
monocytic	9	O
phenotype	9	O
than	4	O
the	3	O
parental	8	O
myeloblasts	11	O
,	1	O
as	2	O
determined	10	O
by	2	O
differential	12	O
staining	8	O
,	1	O
increased	9	O
expression	10	O
of	2	O
the	3	O
myeloid-specific	16	O
surface	7	O
markers	7	O
,	1	O
and	3	O
transcription	13	O
of	2	O
the	3	O
c-fms	5	B-Gene
proto-oncogene	14	I-Gene
.	1	O

NF-kappa	8	B-Gene
B	1	I-Gene
binding	7	O
activity	8	O
was	3	O
inducible	9	O
by	2	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
and	3	O
phorbol	7	B-Chemical
myristate	9	I-Chemical
acetate	7	I-Chemical
in	2	O
PLB-985	7	O
.	1	O

However	7	O
,	1	O
in	2	O
PLB-IIIB	8	O
cells	5	O
,	1	O
constitutive	12	O
expression	10	O
of	2	O
a	1	O
novel	5	O
NF-kappa	8	B-Gene
B	1	I-Gene
complex	7	I-Gene
was	3	O
detected	8	O
,	1	O
composed	8	O
of	2	O
proteins	8	O
ranging	7	O
between	7	O
70	2	O
and	3	O
110	3	O
kD	2	O
.	1	O

These	5	O
proteins	8	O
interacted	10	O
specifically	12	O
with	4	O
the	3	O
symmetric	9	O
NF-kappa	8	B-Gene
B	1	I-Gene
site	4	O
from	4	O
the	3	O
interferon	10	B-Gene
beta	4	I-Gene
(	1	I-Gene
IFN-beta	8	I-Gene
)	1	I-Gene
promoter	8	I-Gene
.	1	O

Mutations	9	O
affecting	9	O
the	3	O
5	1	O
'guanine	8	B-Chemical
residues	8	O
of	2	O
the	3	O
kappa	5	O
B	1	O
site	4	O
were	4	O
unable	6	O
to	2	O
compete	7	O
for	3	O
these	5	O
NF-kappa	8	B-Gene
B	1	I-Gene
-related	8	O
proteins	8	O
.	1	O

Inducibility	12	O
of	2	O
endogenous	10	B-Gene
IFN-beta	8	I-Gene
and	3	O
IFN-alpha	9	B-Gene
RNA	3	I-Gene
was	3	O
also	4	O
increased	9	O
in	2	O
PLB-IIIB	8	O
cells	5	O
.	1	O

These	5	O
studies	7	O
indicate	8	O
that	4	O
HIV-1	5	O
infection	9	O
of	2	O
myelomonoblastic	16	O
cells	5	O
may	3	O
select	6	O
for	3	O
a	1	O
more	4	O
mature	6	O
monocytic	9	O
phenotype	9	O
and	3	O
that	4	O
unique	6	O
subunit	7	O
associations	12	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
DNA	3	I-Gene
binding	7	I-Gene
proteins	8	I-Gene
may	3	O
contribute	10	O
to	2	O
differential	12	O
NF-kappa	8	B-Gene
B	1	I-Gene
-mediated	9	O
gene	4	O
expression	10	O
.	1	O

The	3	O
AP-1	4	B-Gene
site	4	O
at	2	O
-150	4	O
bp	2	O
,	1	O
but	3	O
not	3	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
site	4	O
,	1	O
is	2	O
likely	6	O
to	2	O
represent	9	O
the	3	O
major	5	O
target	6	O
of	2	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
in	2	O
the	3	O
interleukin	11	B-Gene
2	1	I-Gene
promoter	8	I-Gene
.	1	O

Stimulation	11	O
of	2	O
T	1	O
cells	5	O
with	4	O
antigen	7	O
results	7	O
in	2	O
activation	10	O
of	2	O
several	7	O
kinases	7	O
,	1	O
including	9	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
(	1	O
PKC	3	B-Gene
)	1	O
,	1	O
that	4	O
may	3	O
mediate	7	O
the	3	O
later	5	O
induction	9	O
of	2	O
activation	10	O
-related	8	O
genes	5	O
.	1	O

We	2	O
have	4	O
examined	8	O
the	3	O
potential	9	O
role	4	O
of	2	O
PKC	3	B-Gene
in	2	O
induction	9	O
of	2	O
the	3	O
interleukin	11	B-Gene
2	1	I-Gene
(	1	I-Gene
IL-2	4	I-Gene
)	1	I-Gene
gene	4	I-Gene
in	2	O
T	1	O
cells	5	O
stimulated	10	O
through	7	O
the	3	O
T	1	B-Gene
cell	4	I-Gene
receptor	8	I-Gene
/	1	I-Gene
CD3	3	I-Gene
complex	7	I-Gene
.	1	O

We	2	O
have	4	O
previously	10	O
shown	5	O
that	4	O
prolonged	9	O
treatment	9	O
of	2	O
the	3	O
untransformed	13	O
T	1	O
cell	4	O
clone	5	O
Ar-5	4	O
with	4	O
phorbol	7	B-Chemical
esters	6	I-Chemical
results	7	O
in	2	O
downmodulation	14	O
of	2	O
the	3	O
alpha	5	O
and	3	O
beta	4	O
isozymes	8	O
of	2	O
PKC	3	B-Gene
,	1	O
and	3	O
abrogates	9	O
induction	9	O
of	2	O
IL-2	4	B-Gene
mRNA	4	I-Gene
and	3	O
protein	7	O
.	1	O

Here	4	O
we	2	O
show	4	O
that	4	O
phorbol	7	B-Chemical
ester	5	I-Chemical
treatment	9	O
also	4	O
abolishes	9	O
induction	9	O
of	2	O
chloramphenicol	15	B-Gene
acetyltransferase	17	I-Gene
activity	8	O
in	2	O
Ar-5	4	O
cells	5	O
transfected	11	O
with	4	O
a	1	O
plasmid	7	O
containing	10	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
linked	6	O
to	2	O
this	4	O
reporter	8	O
gene	4	O
.	1	O

The	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
contains	8	O
binding	7	O
sites	5	O
for	3	O
nuclear	7	O
factors	7	O
including	9	O
NFAT-1	6	B-Gene
,	1	O
Oct	3	B-Gene
,	1	O
NF-kappa	8	B-Gene
B	1	I-Gene
,	1	O
and	3	O
AP-1	4	B-Gene
,	1	O
which	5	O
are	3	O
all	3	O
potentially	11	O
sensitive	9	O
to	2	O
activation	10	O
of	2	O
PKC	3	B-Gene
.	1	O

We	2	O
show	4	O
that	4	O
induction	9	O
of	2	O
a	1	O
trimer	6	O
of	2	O
the	3	O
NFAT	4	B-Gene
and	3	O
Oct	3	B-Gene
sites	5	O
is	2	O
not	3	O
sensitive	9	O
to	2	O
phorbol	7	B-Chemical
ester	5	I-Chemical
treatment	9	O
,	1	O
and	3	O
that	4	O
mutations	9	O
in	2	O
the	3	O
NF-kappa	8	B-Gene
B	1	I-Gene
site	4	O
have	4	O
no	2	O
effect	6	O
on	2	O
inducibility	12	O
of	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
.	1	O

In	2	O
contrast	8	O
,	1	O
mutations	9	O
in	2	O
the	3	O
AP-1	4	B-Gene
site	4	O
located	7	O
at	2	O
-150	4	O
bp	2	O
almost	6	O
completely	10	O
abrogate	8	O
induction	9	O
of	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
,	1	O
and	3	O
appearance	10	O
of	2	O
an	2	O
inducible	9	O
nuclear	7	O
factor	6	O
binding	7	O
to	2	O
this	4	O
site	4	O
is	2	O
sensitive	9	O
to	2	O
PKC	3	B-Gene
depletion	9	O
.	1	O

Moreover	8	O
,	1	O
cotransfections	15	O
with	4	O
c-fos	5	B-Gene
and	3	O
c-jun	5	B-Gene
expression	10	O
plasmids	8	O
markedly	8	O
enhance	7	O
induction	9	O
of	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
in	2	O
minimally	9	O
stimulated	10	O
T	1	O
cells	5	O
.	1	O

Our	3	O
results	7	O
indicate	8	O
that	4	O
the	3	O
AP-1	4	B-Gene
site	4	O
at	2	O
-150	4	O
bp	2	O
represents	10	O
a	1	O
major	5	O
,	1	O
if	2	O
not	3	O
the	3	O
only	4	O
,	1	O
site	4	O
of	2	O
PKC	3	B-Gene
responsiveness	14	O
in	2	O
the	3	O
IL-2	4	B-Gene
promoter	8	I-Gene
.	1	O

Interleukin	11	B-Gene
6	1	I-Gene
-induced	8	O
differentiation	15	O
of	2	O
a	1	O
human	5	O
B	1	O
cell	4	O
line	4	O
into	4	O
IgM	3	B-Gene
-secreting	10	O
plasma	6	O
cells	5	O
is	2	O
mediated	8	O
by	2	O
c-fos	5	B-Gene
.	1	O

The	3	O
role	4	O
of	2	O
the	3	O
protooncogene	13	B-Gene
c-fos	5	I-Gene
in	2	O
interleukin	11	B-Gene
(	1	I-Gene
IL	2	I-Gene
)	1	I-Gene
6	1	I-Gene
-induced	8	O
B	1	O
cell	4	O
differentiation	15	O
was	3	O
assessed	8	O
.	1	O

Treatment	9	O
of	2	O
SKW	3	O
6.4	3	O
cells	5	O
with	4	O
IL	2	B-Gene
6	1	I-Gene
induced	7	O
a	1	O
transient	9	O
and	3	O
early	5	O
stimulation	11	O
of	2	O
c-fos	5	B-Gene
sense	5	I-Gene
mRNA	4	I-Gene
expression	10	O
.	1	O

The	3	O
effect	6	O
appeared	8	O
within	6	O
30	2	O
min	3	O
and	3	O
returned	8	O
to	2	O
basal	5	O
levels	6	O
after	5	O
2	1	O
h	1	O
.	1	O

The	3	O
addition	8	O
of	2	O
antisense	9	O
oligonucleotides	16	O
to	2	O
c-fos	5	B-Gene
significantly	13	O
inhibited	9	O
IL	2	B-Gene
6	1	I-Gene
-induced	8	O
IgM	3	B-Gene
production	10	O
by	2	O
SKW	3	O
6.4	3	O
cells	5	O
(	1	O
p	1	O
less	4	O
than	4	O
0.001	5	O
)	1	O
,	1	O
whereas	7	O
control	7	O
oligonucleotides	16	O
had	3	O
no	2	O
inhibitory	10	O
effect	6	O
.	1	O

These	5	O
results	7	O
indicate	8	O
that	4	O
activation	10	O
of	2	O
c-fos	5	B-Gene
is	2	O
involved	8	O
in	2	O
IL	2	B-Gene
6	1	I-Gene
-induced	8	O
differentiation	15	O
of	2	O
SKW	3	O
6.4	3	O
cells	5	O
into	4	O
IgM	3	B-Gene
-secreting	10	O
cells	5	O
.	1	O

Binding	7	O
of	2	O
erythroid	9	O
and	3	O
non-erythroid	13	O
nuclear	7	O
proteins	8	O
to	2	O
the	3	O
silencer	8	O
of	2	O
the	3	O
human	5	B-Gene
epsilon-globin	14	I-Gene
-encoding	9	O
gene	4	O
.	1	O

To	2	O
clarify	7	O
the	3	O
molecular	9	O
mechanisms	10	O
involved	8	O
in	2	O
the	3	O
developmental	13	O
control	7	O
of	2	O
hemoglobin	10	B-Gene
-encoding	9	O
genes	5	O
we	2	O
have	4	O
been	4	O
studying	8	O
the	3	O
expression	10	O
of	2	O
these	5	O
genes	5	O
in	2	O
human	5	O
cells	5	O
in	2	O
continuous	10	O
culture	7	O
.	1	O

We	2	O
have	4	O
previously	10	O
reported	8	O
the	3	O
presence	8	O
of	2	O
a	1	O
transcriptional	15	O
control	7	O
element	7	O
with	4	O
the	3	O
properties	10	O
of	2	O
a	1	O
silencer	8	O
extending	9	O
from	4	O
-392	4	O
to	2	O
-177	4	O
bp	2	O
relative	8	O
to	2	O
the	3	O
cap	3	O
site	4	O
of	2	O
the	3	O
human	5	B-Gene
epsilon-globin	14	I-Gene
-encoding	9	O
gene	4	O
[	1	O
Cao	3	O
et	2	O
al.	3	O
,	1	O
Proc.Natl.Acad.Sci.USA	22	O
86	2	O
(	1	O
1989	4	O
)	1	O
5306-5309	9	O
]	1	O
.	1	O

We	2	O
also	4	O
showed	6	O
that	4	O
this	4	O
silencer	8	O
has	3	O
stronger	8	O
inhibitory	10	O
activity	8	O
in	2	O
HeLa	4	O
cells	5	O
,	1	O
as	2	O
compared	8	O
to	2	O
K562	4	O
human	5	O
erythroleukemia	15	B-Disease
cells	5	O
.	1	O

Using	5	O
deletion	8	O
mutants	7	O
and	3	O
cis	3	O
-cloned	7	O
synthetic	9	O
oligodeoxyribonucleotides	25	O
in	2	O
transient	9	O
expression	10	O
assays	6	O
,	1	O
nucleotide	10	O
sequences	9	O
responsible	11	O
for	3	O
this	4	O
effect	6	O
have	4	O
now	3	O
been	4	O
further	7	O
delimited	9	O
to	2	O
44	2	O
bp	2	O
located	7	O
from	4	O
-294	4	O
to	2	O
-251	4	O
bp	2	O
.	1	O

Gel	3	O
electrophoresis	15	O
mobility	8	O
shift	5	O
assays	6	O
and	3	O
DNaseI	6	O
footprinting	12	O
assays	6	O
demonstrate	11	O
that	4	O
these	5	O
negative	8	O
regulatory	10	O
sequences	9	O
are	3	O
recognized	10	O
differently	11	O
by	2	O
proteins	8	O
present	7	O
in	2	O
nuclear	7	O
extracts	8	O
obtained	8	O
from	4	O
HeLa	4	O
and	3	O
K562	4	O
cells	5	O
.	1	O

Two	3	O
binding	7	O
proteins	8	O
are	3	O
detected	8	O
in	2	O
K562	4	O
nuclear	7	O
extracts	8	O
,	1	O
while	5	O
only	4	O
one	3	O
is	2	O
found	5	O
in	2	O
extracts	8	O
from	4	O
HeLa	4	O
cells	5	O
.	1	O

Possible	8	O
mechanisms	10	O
by	2	O
which	5	O
these	5	O
proteins	8	O
may	3	O
regulate	8	O
transcription	13	O
of	2	O
the	3	O
epsilon-globin	14	B-Gene
-encoding	9	O
gene	4	O
in	2	O
erythroid	9	O
and	3	O
non-erythroid	13	O
cells	5	O
are	3	O
discussed	9	O
.	1	O

Gangliosides	12	B-Chemical
suppress	8	O
tumor	5	B-Gene
necrosis	8	I-Gene
factor	6	I-Gene
production	10	O
in	2	O
human	5	O
monocytes	9	O
.	1	O

Both	4	O
normal	6	O
and	3	O
malignant	9	O
cells	5	O
contain	7	O
gangliosides	12	B-Chemical
as	2	O
important	9	O
cell	4	O
membrane	8	O
constituents	12	O
that	4	O
,	1	O
after	5	O
being	5	O
shed	4	O
,	1	O
may	3	O
influence	9	O
cells	5	O
of	2	O
the	3	O
immune	6	O
system	6	O
.	1	O

We	2	O
have	4	O
studied	7	O
the	3	O
impact	6	O
of	2	O
gangliosides	12	B-Chemical
on	2	O
the	3	O
expression	10	O
of	2	O
TNF	3	B-Gene
in	2	O
blood	5	O
monocytes	9	O
and	3	O
in	2	O
the	3	O
monocytic	9	O
cell	4	O
line	4	O
Mono	4	O
Mac	3	O
6	1	O
.	1	O

Although	8	O
under	5	O
standard	8	O
culture	7	O
conditions	10	O
,	1	O
bovine	6	O
brain	5	O
gangliosides	12	B-Chemical
(	1	O
100	3	O
micrograms	10	O
/	1	O
ml	2	O
)	1	O
suppressed	10	O
LPS	3	B-Chemical
-stimulated	11	O
TNF	3	B-Gene
production	10	O
5-fold	6	O
in	2	O
PBMC	4	O
and	3	O
10-fold	7	O
in	2	O
Mono	4	O
Mac	3	O
6	1	O
cells	5	O
,	1	O
suppression	11	O
was	3	O
more	4	O
efficient	9	O
under	5	O
serum-free	10	O
conditions	10	O
.	1	O

Looking	7	O
at	2	O
highly	6	O
purified	8	O
gangliosides	12	B-Chemical
,	1	O
GD3	3	B-Chemical
,	1	O
GD1a	4	B-Chemical
,	1	O
GM3	3	B-Chemical
,	1	O
GM2	3	B-Chemical
,	1	O
and	3	O
GM1	3	B-Chemical
were	4	O
all	3	O
effective	9	O
in	2	O
reducing	8	O
TNF	3	B-Gene
production	10	O
in	2	O
PBMC	4	O
,	1	O
and	3	O
in	2	O
Mono	4	O
Mac	3	O
6	1	O
by	2	O
factor	6	O
10	2	O
to	2	O
50	2	O
.	1	O

The	3	O
suppressive	11	O
activity	8	O
was	3	O
lost	4	O
in	2	O
molecules	9	O
,	1	O
lacking	7	O
the	3	O
sugar	5	O
moiety	6	O
or	2	O
the	3	O
lipid	5	B-Chemical
moiety	6	O
.	1	O

Gangliosides	12	B-Chemical
appear	6	O
to	2	O
act	3	O
at	2	O
an	2	O
early	5	O
step	4	O
of	2	O
activation	10	O
in	2	O
that	4	O
TNF	3	B-Gene
transcripts	11	I-Gene
were	4	O
reduced	7	O
and	3	O
the	3	O
mobilization	12	O
of	2	O
the	3	O
nuclear	7	B-Gene
factor	6	I-Gene
kappa	5	I-Gene
B	1	I-Gene
was	3	O
blocked	7	O
.	1	O

Furthermore	11	O
,	1	O
in	2	O
time	4	O
kinetics	8	O
,	1	O
gangliosides	12	B-Chemical
were	4	O
effective	9	O
for	3	O
up	2	O
to	2	O
30	2	O
min	3	O
after	5	O
addition	8	O
of	2	O
LPS	3	B-Chemical
,	1	O
but	3	O
not	3	O
thereafter	10	O
.	1	O

However	7	O
,	1	O
the	3	O
expression	10	O
of	2	O
the	3	O
CD14	4	B-Gene
Ag	2	I-Gene
,	1	O
a	1	O
receptor	8	O
molecule	8	O
for	3	O
LPS-LPS	7	B-Gene
binding	7	I-Gene
protein	7	I-Gene
complexes	9	I-Gene
,	1	O
was	3	O
unaffected	10	O
by	2	O
gangliosides	12	B-Chemical
.	1	O

Finally	7	O
,	1	O
when	4	O
using	5	O
Staphylococcus	14	O
aureus	6	O
or	2	O
platelet	8	B-Chemical
activating	10	I-Chemical
factor	6	I-Chemical
as	2	O
a	1	O
stimulus	8	O
,	1	O
gangliosides	12	B-Chemical
were	4	O
able	4	O
to	2	O
suppress	8	O
TNF	3	B-Gene
production	10	O
in	2	O
Mono	4	O
Mac	3	O
6	1	O
cells	5	O
by	2	O
factor	6	O
5	1	O
to	2	O
10	2	O
,	1	O
as	2	O
well	4	O
.	1	O

On	2	O
the	3	O
other	5	O
hand	4	O
,	1	O
phorbol	7	B-Chemical
ester	5	I-Chemical
-induced	8	O
production	10	O
of	2	O
O2-	3	O
was	3	O
similar	7	O
in	2	O
cells	5	O
treated	7	O
with	4	O
and	3	O
without	7	O
gangliosides	12	B-Chemical
.	1	O

Taken	5	O
together	8	O
,	1	O
our	3	O
data	4	O
demonstrate	11	O
that	4	O
TNF	3	B-Gene
gene	4	I-Gene
expression	10	O
in	2	O
monocytes	9	O
induced	7	O
by	2	O
different	9	O
types	5	O
of	2	O
stimuli	7	O
can	3	O
be	2	O
blocked	7	O
by	2	O
gangliosides	12	B-Chemical
at	2	O
an	2	O
early	5	O
step	4	O
of	2	O
signal	6	O
transduction	12	O
.	1	O

T	1	O
cell-specific	13	O
negative	8	O
regulation	10	O
of	2	O
transcription	13	O
of	2	O
the	3	O
human	5	B-Gene
cytokine	8	I-Gene
IL-4	4	I-Gene
.	1	O

IL-4	4	B-Gene
secreted	8	O
by	2	O
activated	9	O
T	1	O
cells	5	O
is	2	O
a	1	O
pleiotropic	11	O
cytokine	8	O
affecting	9	O
growth	6	O
and	3	O
differentiation	15	O
of	2	O
diverse	7	O
cell	4	O
types	5	O
such	4	O
as	2	O
T	1	O
cells	5	O
,	1	O
B	1	O
cells	5	O
,	1	O
and	3	O
mast	4	O
cells	5	O
.	1	O

We	2	O
investigated	12	O
the	3	O
upstream	8	O
regulatory	10	O
elements	8	O
of	2	O
the	3	O
human	5	B-Gene
IL-4	4	I-Gene
promoter	8	I-Gene
.	1	O

A	1	O
novel	5	O
T	1	O
cell-specific	13	O
negative	8	O
regulatory	10	O
element	7	O
(	1	O
NRE	3	O
)	1	O
composed	8	O
of	2	O
two	3	O
protein	7	O
-binding	8	O
sites	5	O
were	4	O
mapped	6	O
in	2	O
the	3	O
5	1	O
'flanking	9	O
region	6	O
of	2	O
the	3	O
IL-4	4	B-Gene
gene	4	I-Gene
:	1	O
-311CTCCCTTCT-303	17	O
(	1	O
NRE-I	5	O
)	1	O
and	3	O
-288CTTTTTGCTT-TGC-300	22	O
(	1	O
NRE-II	6	O
)	1	O
.	1	O

A	1	O
T	1	B-Gene
cell-specific	13	I-Gene
protein	7	I-Gene
Neg-1	5	I-Gene
and	3	O
a	1	O
ubiquitous	10	O
protein	7	B-Gene
Neg-2	5	I-Gene
binding	7	O
to	2	O
NRE-I	5	O
and	3	O
NRE-II	6	O
,	1	O
respectively	12	O
,	1	O
were	4	O
identified	10	O
.	1	O

Furthermore	11	O
,	1	O
a	1	O
positive	8	O
regulatory	10	O
element	7	O
was	3	O
found	5	O
45	2	O
bp	2	O
downstream	10	O
of	2	O
the	3	O
NRE	3	O
.	1	O

The	3	O
enhancer	8	O
activity	8	O
of	2	O
the	3	O
PRE	3	O
was	3	O
completely	10	O
suppressed	10	O
when	4	O
the	3	O
NRE	3	O
was	3	O
present	7	O
.	1	O

These	5	O
data	4	O
suggest	7	O
that	4	O
IL-4	4	B-Gene
promoter	8	I-Gene
activity	8	O
is	2	O
normally	8	O
down	4	O
-regulated	10	O
by	2	O
an	2	O
NRE	3	O
via	3	O
repression	10	O
of	2	O
the	3	O
enhancer	8	O
positive	8	O
regulatory	10	O
element	7	O
.	1	O

These	5	O
data	4	O
may	3	O
have	4	O
implications	12	O
for	3	O
the	3	O
stringent	9	O
control	7	O
of	2	O
IL-4	4	B-Gene
expression	10	O
in	2	O
T	1	O
cells	5	O
.	1	O

[	1	O
Regulatory	10	O
effect	6	O
of	2	O
insulin	7	B-Gene
on	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
in	2	O
human	5	O
peripheral	10	O
leukocytes	10	O
]	1	O

The	3	O
regulatory	10	O
effect	6	O
of	2	O
insulin	7	B-Gene
on	2	O
the	3	O
specific	8	O
binding	7	O
power	5	O
of	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
(	1	O
GR	2	B-Gene
)	1	O
of	2	O
human	5	O
leukocytes	10	O
was	3	O
assessed	8	O
by	2	O
the	3	O
unoccupied	10	O
receptor	8	O
sites	5	O
capable	7	O
of	2	O
combining	9	O
with	4	O
[	1	O
3H	2	O
]	1	O
labelled	8	O
dexamethasone	13	B-Chemical
measured	8	O
at	2	O
3	1	O
and	3	O
24	2	O
h	1	O
after	5	O
incubation	10	O
with	4	O
various	7	O
concentrations	14	O
of	2	O
insulin	7	B-Gene
added	5	O
to	2	O
the	3	O
medium	6	O
.	1	O

After	5	O
3	1	O
h	1	O
incubation	10	O
the	3	O
specific	8	O
binding	7	O
power	5	O
with	4	O
[	1	O
3H	2	O
]	1	O
Dex	3	B-Chemical
was	3	O
decreased	9	O
by	2	O
23.3	4	O
+	1	O
/	1	O
-	1	O
10.0	4	O
,	1	O
32.2	4	O
+	1	O
/	1	O
-	1	O
13.2	4	O
and	3	O
54.3	4	O
+	1	O
/	1	O
-	1	O
9.2	3	O
%	1	O
(	1	O
P	1	O
greater	7	O
than	4	O
0.05	4	O
,	1	O
P	1	O
greater	7	O
than	4	O
0.05	4	O
and	3	O
P	1	O
less	4	O
than	4	O
0.01	4	O
as	2	O
compared	8	O
with	4	O
the	3	O
control	7	O
value	5	O
of	2	O
100	3	O
in	2	O
the	3	O
absence	7	O
of	2	O
insulin	7	B-Gene
)	1	O
respectively	12	O
in	2	O
the	3	O
presence	8	O
of	2	O
20	2	O
mU	2	O
/	1	O
L	1	O
(	1	O
physiological	13	O
testing	7	O
concentration	13	O
)	1	O
,	1	O
200	3	O
mU	2	O
/	1	O
L	1	O
(	1	O
physiological	13	O
upper	5	O
limit	5	O
)	1	O
and	3	O
2	1	O
,	1	O
000	3	O
mU	2	O
/	1	O
L	1	O
(	1	O
pharmacological	15	O
concentration	13	O
)	1	O
insulin	7	B-Gene
in	2	O
the	3	O
incubation	10	O
medium	6	O
.	1	O

After	5	O
24	2	O
h	1	O
incubation	10	O
the	3	O
decrease	8	O
of	2	O
these	5	O
values	6	O
increased	9	O
respectively	12	O
to	2	O
43.5	4	O
+	1	O
/	1	O
-	1	O
19.0	4	O
,	1	O
56.1	4	O
+	1	O
/	1	O
-	1	O
20.7	4	O
and	3	O
80.2	4	O
+	1	O
/	1	O
-	1	O
15.5	4	O
(	1	O
P	1	O
less	4	O
than	4	O
0.05	4	O
,	1	O
P	1	O
less	4	O
than	4	O
0.01	4	O
and	3	O
P	1	O
less	4	O
than	4	O
0.01	4	O
compared	8	O
with	4	O
control	7	O
)	1	O
.	1	O

Thus	4	O
the	3	O
inhibitory	10	O
effect	6	O
of	2	O
insulin	7	B-Gene
on	2	O
the	3	O
GR	2	B-Gene
binding	7	O
power	5	O
is	2	O
both	4	O
dose-	5	O
and	3	O
time	4	O
-dependent	10	O
,	1	O
which	5	O
strongly	8	O
suggests	8	O
that	4	O
GR	2	B-Gene
is	2	O
tonically	9	O
controlled	10	O
by	2	O
insulin	7	B-Gene
concentration	13	O
change	6	O
under	5	O
physiological	13	O
conditions	10	O
.	1	O

Human	5	O
T	1	O
cell	4	O
activation	10	O
through	7	O
the	3	O
activation-inducer	18	B-Gene
molecule	8	I-Gene
/	1	I-Gene
CD69	4	I-Gene
enhances	8	O
the	3	O
activity	8	O
of	2	O
transcription	13	B-Gene
factor	6	I-Gene
AP-1	4	I-Gene
.	1	O

The	3	O
induction	9	O
of	2	O
the	3	O
AP-1	4	B-Gene
transcription	13	I-Gene
factor	6	I-Gene
has	3	O
been	4	O
ascribed	8	O
to	2	O
the	3	O
early	5	O
events	6	O
leading	7	O
to	2	O
T	1	O
cell	4	O
differentiation	15	O
and	3	O
activation	10	O
.	1	O

We	2	O
have	4	O
studied	7	O
the	3	O
regulation	10	O
of	2	O
AP-1	4	B-Gene
activity	8	O
in	2	O
human	5	O
peripheral	10	O
blood	5	O
T	1	O
lymphocytes	11	O
stimulated	10	O
through	7	O
the	3	O
activation	10	B-Gene
inducer	7	I-Gene
molecule	8	I-Gene
(	1	I-Gene
AIM	3	I-Gene
)	1	I-Gene
/	1	I-Gene
CD69	4	I-Gene
activation	10	O
pathway	7	O
.	1	O

Phorbol	7	B-Chemical
esters	6	I-Chemical
are	3	O
required	8	O
to	2	O
induce	6	O
AIM	3	B-Gene
/	1	I-Gene
CD69	4	I-Gene
cell-surface	12	O
expression	10	O
as	2	O
well	4	O
as	2	O
for	3	O
triggering	10	O
the	3	O
proliferation	13	O
of	2	O
T	1	O
cells	5	O
in	2	O
conjunction	11	O
with	4	O
anti-AIM	8	B-Gene
mAb	3	I-Gene
.	1	O

Mobility	8	O
shift	5	O
assays	6	O
showed	6	O
that	4	O
addition	8	O
of	2	O
anti-AIM	8	B-Gene
mAb	3	I-Gene
to	2	O
PMA	3	B-Chemical
-treated	8	O
T	1	O
lymphocytes	11	O
markedly	8	O
enhanced	8	O
the	3	O
binding	7	O
activity	8	O
of	2	O
AP-1	4	B-Gene
to	2	O
its	3	O
cognate	7	O
sequence	8	O
,	1	O
the	3	O
phorbol	7	B-Chemical
ester	5	I-Chemical
response	8	O
element	7	O
.	1	O

In	2	O
contrast	8	O
,	1	O
anti-AIM	8	B-Gene
mAb	3	I-Gene
did	3	O
not	3	O
induce	6	O
any	3	O
change	6	O
in	2	O
the	3	O
binding	7	O
activity	8	O
of	2	O
NF-kappa	8	B-Gene
B	1	I-Gene
,	1	O
a	1	O
transcription	13	O
factor	6	O
whose	5	O
activity	8	O
is	2	O
also	4	O
regulated	9	O
by	2	O
protein	7	B-Gene
kinase	6	I-Gene
C	1	I-Gene
.	1	O

The	3	O
increase	8	O
in	2	O
AP-1	4	B-Gene
-binding	8	O
activity	8	O
was	3	O
accompanied	11	O
by	2	O
the	3	O
marked	6	O
stimulation	11	O
of	2	O
the	3	O
transcription	13	O
of	2	O
c-fos	5	B-Gene
but	3	O
not	3	O
that	4	O
of	2	O
c-jun	5	B-Gene
.	1	O

Blockade	8	O
of	2	O
the	3	O
DNA	3	O
-binding	8	O
complexes	9	O
with	4	O
an	2	O
anti-Fos	8	B-Gene
mAb	3	I-Gene
demonstrated	12	O
a	1	O
direct	6	O
participation	13	O
of	2	O
c-Fos	5	B-Gene
in	2	O
the	3	O
AP-1	4	B-Gene
complexes	9	I-Gene
induced	7	O
by	2	O
anti-AIM	8	B-Gene
mAb	3	I-Gene
.	1	O

Most	4	O
of	2	O
the	3	O
AP-1	4	B-Gene
activity	8	O
could	5	O
be	2	O
eliminated	10	O
when	4	O
the	3	O
anti-AIM	8	B-Gene
mAb	3	I-Gene
was	3	O
added	5	O
to	2	O
the	3	O
culture	7	O
medium	6	O
in	2	O
the	3	O
presence	8	O
of	2	O
cycloheximide	13	B-Chemical
,	1	O
suggesting	10	O
that	4	O
de	2	O
novo	4	O
protein	7	O
synthesis	9	O
is	2	O
crucial	7	O
for	3	O
the	3	O
induction	9	O
of	2	O
AP-1	4	B-Gene
-binding	8	O
activity	8	O
.	1	O

These	5	O
data	4	O
provide	7	O
the	3	O
evidence	8	O
that	4	O
activation	10	O
of	2	O
human	5	O
peripheral	10	O
blood	5	O
T	1	O
cells	5	O
through	7	O
the	3	O
AIM	3	B-Gene
activation	10	O
pathway	7	O
regulate	8	O
the	3	O
activity	8	O
of	2	O
AP-1	4	B-Gene
.	1	O

Therefore	9	O
,	1	O
this	4	O
pathway	7	O
appears	7	O
as	2	O
a	1	O
crucial	7	O
step	4	O
in	2	O
the	3	O
initiation	10	O
of	2	O
early	5	O
T	1	O
cell	4	O
activation	10	O
events	6	O
.	1	O

cis	3	O
-acting	7	O
sequences	9	O
required	8	O
for	3	O
inducible	9	O
interleukin-2	13	B-Gene
enhancer	8	I-Gene
function	8	O
bind	4	O
a	1	O
novel	5	O
Ets	3	B-Gene
-related	8	O
protein	7	O
,	1	O
Elf-1	5	B-Gene
.	1	O

The	3	O
recent	6	O
definition	10	O
of	2	O
a	1	O
consensus	9	O
DNA	3	O
binding	7	O
sequence	8	O
for	3	O
the	3	O
Ets	3	B-Gene
family	6	I-Gene
of	2	O
transcription	13	O
factors	7	O
has	3	O
allowed	7	O
the	3	O
identification	14	O
of	2	O
potential	9	O
Ets	3	B-Gene
binding	7	O
sites	5	O
in	2	O
the	3	O
promoters	9	O
and	3	O
enhancers	9	O
of	2	O
many	4	O
inducible	9	O
T-cell	6	O
genes	5	O
.	1	O

In	2	O
the	3	O
studies	7	O
described	9	O
in	2	O
this	4	O
report	6	O
,	1	O
we	2	O
have	4	O
identified	10	O
two	3	O
potential	9	O
Ets	3	B-Gene
binding	7	O
sites	5	O
,	1	O
EBS1	4	O
and	3	O
EBS2	4	O
,	1	O
which	5	O
are	3	O
conserved	9	O
in	2	O
both	4	O
the	3	O
human	5	O
and	3	O
murine	6	B-Gene
interleukin-2	13	I-Gene
enhancers	9	I-Gene
.	1	O

Within	6	O
the	3	O
human	5	O
enhancer	8	O
,	1	O
these	5	O
two	3	O
sites	5	O
are	3	O
located	7	O
within	6	O
the	3	O
previously	10	O
defined	7	O
DNase	5	O
I	1	O
footprints	10	O
,	1	O
NFAT-1	6	B-Gene
and	3	O
NFIL-2B	7	B-Gene
,	1	O
respectively	12	O
.	1	O

Electrophoretic	15	O
mobility	8	O
shift	5	O
and	3	O
methylation	11	O
interference	12	O
analyses	8	O
demonstrated	12	O
that	4	O
EBS1	4	O
and	3	O
EBS2	4	O
are	3	O
essential	9	O
for	3	O
the	3	O
formation	9	O
of	2	O
the	3	O
NFAT-1	6	B-Gene
and	3	O
NFIL-2B	7	B-Gene
nuclear	7	I-Gene
protein	7	I-Gene
complexes	9	I-Gene
.	1	O

Furthermore	11	O
,	1	O
in	2	O
vitro	5	O
mutagenesis	11	O
experiments	11	O
demonstrated	12	O
that	4	O
inducible	9	O
interleukin-2	13	B-Gene
enhancer	8	I-Gene
function	8	O
requires	8	O
the	3	O
presence	8	O
of	2	O
either	6	O
EBS1	4	O
or	2	O
EBS2	4	O
.	1	O

Two	3	O
well	4	O
-characterized	14	O
Ets	3	B-Gene
family	6	I-Gene
members	7	O
,	1	O
Ets-1	5	B-Gene
and	3	O
Ets-2	5	B-Gene
,	1	O
are	3	O
reciprocally	12	O
expressed	9	O
during	6	O
T-cell	6	O
activation	10	O
.	1	O

Surprisingly	12	O
,	1	O
however	7	O
,	1	O
neither	7	O
of	2	O
these	5	O
proteins	8	O
bound	5	O
in	2	O
vitro	5	O
to	2	O
EBS1	4	O
or	2	O
EBS2	4	O
.	1	O

We	2	O
therefore	9	O
screened	8	O
a	1	O
T-cell	6	O
cDNA	4	O
library	7	O
under	5	O
low	3	O
-stringency	11	O
conditions	10	O
with	4	O
a	1	O
probe	5	O
from	4	O
the	3	O
DNA	3	O
binding	7	O
domain	6	O
of	2	O
Ets-1	5	B-Gene
and	3	O
isolated	8	O
a	1	O
novel	5	O
Ets	3	B-Gene
family	6	I-Gene
member	6	O
,	1	O
Elf-1	5	B-Gene
.	1	O

Elf-1	5	B-Gene
contains	8	O
a	1	O
DNA	3	O
binding	7	O
domain	6	O
that	4	O
is	2	O
nearly	6	O
identical	9	O
to	2	O
that	4	O
of	2	O
E74	3	B-Gene
,	1	O
the	3	O
ecdysone-inducible	18	B-Chemical
Drosophila	10	O
transcription	13	O
factor	6	O
required	8	O
for	3	O
metamorphosis	13	O
(	1	O
hence	5	O
the	3	O
name	4	O
Elf-1	5	B-Gene
,	1	O
for	3	O
E74	3	B-Gene
-like	5	I-Gene
factor	6	I-Gene
1	1	I-Gene
)	1	O
.	1	O

Elf-1	5	B-Gene
bound	5	O
specifically	12	O
to	2	O
both	4	O
EBS1	4	O
and	3	O
EBS2	4	O
in	2	O
electrophoretic	15	O
mobility	8	O
shift	5	O
assays	6	O
.	1	O

It	2	O
also	4	O
bound	5	O
to	2	O
the	3	O
purine-rich	11	B-Chemical
CD3R	4	B-Gene
element	7	I-Gene
from	4	O
the	3	O
human	5	O
immunodeficiency	16	O
virus	5	O
type	4	O
2	1	O
long	4	O
terminal	8	O
repeat	6	O
,	1	O
which	5	O
is	2	O
required	8	O
for	3	O
inducible	9	O
virus	5	O
expression	10	O
in	2	O
response	8	O
to	2	O
signalling	10	O
through	7	O
the	3	O
T-cell	6	B-Gene
receptor	8	I-Gene
.	1	O

Taken	5	O
together	8	O
,	1	O
these	5	O
results	7	O
demonstrate	11	O
that	4	O
multiple	8	O
Ets	3	B-Gene
family	6	I-Gene
members	7	O
with	4	O
apparently	10	O
distinct	8	O
DNA	3	O
binding	7	O
specificities	13	O
regulate	8	O
differential	12	O
gene	4	O
expression	10	O
in	2	O
resting	7	O
and	3	O
activated	9	O
T	1	O
cells	5	O
.	1	O

In	2	O
vivo	4	O
and	3	O
in	2	O
vitro	5	O
effects	7	O
of	2	O
glucocorticoids	15	B-Chemical
on	2	O
lymphocyte	10	O
proliferation	13	O
in	2	O
man	3	O
:	1	O
relationship	12	O
to	2	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
.	1	O

Interrelations	14	O
between	7	O
the	3	O
hypothalamic-pituitary-adrenal	30	O
system	6	O
(	1	O
HPA	3	B-Gene
)	1	O
and	3	O
the	3	O
immune	6	O
system	6	O
represent	9	O
a	1	O
well	4	O
-documented	11	O
biological	10	O
phenomenon	10	O
.	1	O

While	5	O
in	2	O
vitro	5	O
administration	14	O
of	2	O
glucocorticoids	15	B-Chemical
may	3	O
inhibit	7	O
concanavalin	12	B-Gene
A	1	I-Gene
(	1	O
Con	3	B-Gene
A	1	I-Gene
)	1	O
-	1	O
and	3	O
phytohemagglutinin	18	B-Gene
(	1	O
PHA	3	B-Gene
)	1	O
-induced	8	O
T-cell	6	O
proliferation	13	O
,	1	O
pokeweed	8	B-Chemical
mitogen	7	I-Chemical
(	1	O
PWM	3	B-Chemical
)	1	O
-driven	7	O
B-cell	6	O
mitogenesis	11	O
is	2	O
relatively	10	O
resistant	9	O
to	2	O
glucocorticoids	15	B-Chemical
.	1	O

To	2	O
further	7	O
explore	7	O
the	3	O
link	4	O
between	7	O
the	3	O
HPA	3	B-Gene
and	3	O
the	3	O
immune	6	O
system	6	O
in	2	O
relation	8	O
to	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
function	8	O
,	1	O
dose-response	13	O
curves	6	O
were	4	O
obtained	8	O
for	3	O
Con	3	B-Gene
A	1	I-Gene
-and	4	O
PHA	3	B-Gene
-induced	8	O
T-cell	6	O
mitogenesis	11	O
,	1	O
PWM	3	O
-generated	10	O
B-cell	6	O
mitogenesis	11	O
and	3	O
spontaneous	11	O
lymphocyte	10	O
proliferation	13	O
in	2	O
13	2	O
healthy	7	O
controls	8	O
.	1	O

Glucocorticoid	14	B-Chemical
effects	7	O
were	4	O
assessed	8	O
in	2	O
vivo	4	O
by	2	O
depletion	9	O
of	2	O
endogenous	10	O
glucocorticoids	15	B-Chemical
after	5	O
oral	4	O
administration	14	O
of	2	O
1.5	3	O
g	1	O
metyrapone	10	B-Chemical
(	1	O
MET	3	B-Chemical
)	1	O
and	3	O
subsequent	10	O
glucocorticoid	14	B-Chemical
replacement	11	O
,	1	O
and	3	O
in	2	O
vitro	5	O
by	2	O
incubation	10	O
of	2	O
the	3	O
cells	5	O
with	4	O
different	9	O
doses	5	O
of	2	O
dexamethasone	13	B-Chemical
(	1	O
DEX	3	B-Chemical
)	1	O
.	1	O

There	5	O
was	3	O
a	1	O
significant	11	O
decrease	8	O
in	2	O
PWM	3	O
-induced	8	O
B-cell	6	O
mitogenesis	11	O
and	3	O
a	1	O
more	4	O
pronounced	10	O
effect	6	O
of	2	O
DEX	3	B-Chemical
administered	12	O
in	2	O
vitro	5	O
on	2	O
spontaneous	11	O
lymphocyte	10	O
proliferation	13	O
after	5	O
MET	3	B-Chemical
treatment	9	O
when	4	O
compared	8	O
with	4	O
the	3	O
DEX	3	B-Chemical
plus	4	O
MET	3	B-Chemical
pretreated	10	O
condition	9	O
in	2	O
vivo	4	O
.	1	O

These	5	O
data	4	O
suggest	7	O
that	4	O
the	3	O
inhibition	10	O
of	2	O
spontaneous	11	O
lymphocyte	10	O
proliferation	13	O
by	2	O
glucocorticoids	15	B-Chemical
in	2	O
vitro	5	O
is	2	O
related	7	O
to	2	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
function	8	O
.	1	O

The	3	O
decrease	8	O
in	2	O
PWM	3	O
-generated	10	O
B-cell	6	O
proliferation	13	O
following	9	O
cortisol	8	B-Chemical
depletion	9	O
by	2	O
MET	3	B-Chemical
may	3	O
be	2	O
seen	4	O
in	2	O
connection	10	O
with	4	O
impaired	8	O
glucocorticoid	14	B-Chemical
-mediated	9	O
induction	9	O
of	2	O
interleukin-1	13	B-Gene
receptor	8	I-Gene
synthesis	9	O
.	1	O

Mineralocorticoids	18	B-Chemical
and	3	O
mineralocorticoid	17	B-Gene
receptors	9	I-Gene
in	2	O
mononuclear	11	O
leukocytes	10	O
in	2	O
patients	8	O
with	4	O
pregnancy	9	B-Disease
-induced	8	I-Disease
hypertension	12	I-Disease
.	1	O

To	2	O
examine	7	O
the	3	O
role	4	O
of	2	O
mineralocorticoids	18	B-Chemical
in	2	O
the	3	O
pathophysiology	15	O
of	2	O
pregnancy	9	B-Disease
-induced	8	I-Disease
hypertension	12	I-Disease
(	1	O
PIH	3	B-Disease
)	1	O
,	1	O
we	2	O
studied	7	O
plasma	6	O
aldosterone	11	B-Chemical
and	3	O
18-hydroxycorticosterone	24	B-Chemical
levels	6	O
in	2	O
25	2	O
women	5	O
with	4	O
PIH	3	B-Disease
and	3	O
25	2	O
normal	6	O
pregnant	8	O
women	5	O
,	1	O
as	2	O
controls	8	O
.	1	O

Furthermore	11	O
,	1	O
we	2	O
evaluated	9	O
the	3	O
mineralocorticoid	17	B-Gene
receptor	8	I-Gene
(	1	O
MR	2	B-Gene
)	1	O
status	6	O
in	2	O
mononuclear	11	O
leukocytes	10	O
in	2	O
the	3	O
2	1	O
groups	6	O
.	1	O

MR	2	B-Gene
count	5	O
was	3	O
significantly	13	O
(	1	O
P	1	O
less	4	O
than	4	O
0.0005	6	O
)	1	O
decreased	9	O
in	2	O
the	3	O
PIH	3	B-Disease
group	5	O
(	1	O
148	3	O
+	1	O
/	1	O
-	1	O
9	1	O
binding	7	O
sites	5	O
/	1	O
cell	4	O
)	1	O
compared	8	O
with	4	O
the	3	O
control	7	O
group	5	O
(	1	O
300	3	O
+	1	O
/	1	O
-	1	O
17	2	O
binding	7	O
sites	5	O
/	1	O
cell	4	O
;	1	O
mean	4	O
+	1	O
/	1	O
-	1	O
SEM	3	O
)	1	O
.	1	O

Plasma	6	O
aldosterone	11	B-Chemical
in	2	O
women	5	O
with	4	O
PIH	3	B-Disease
was	3	O
281	3	O
+	1	O
/	1	O
-	1	O
61	2	O
pmol	4	O
/	1	O
L	1	O
;	1	O
in	2	O
normal	6	O
pregnant	8	O
women	5	O
it	2	O
was	3	O
697	3	O
+	1	O
/	1	O
-	1	O
172	3	O
pmol	4	O
/	1	O
L	1	O
(	1	O
P	1	O
less	4	O
than	4	O
0.025	5	O
)	1	O
.	1	O

Plasma	6	O
18-hydroxycorticosterone	24	B-Chemical
was	3	O
also	4	O
significantly	13	O
(	1	O
P	1	O
less	4	O
than	4	O
0.025	5	O
)	1	O
lower	5	O
(	1	O
PIH	3	B-Disease
,	1	O
1071	4	O
+	1	O
/	1	O
-	1	O
149	3	O
pmol	4	O
/	1	O
L	1	O
;	1	O
controls	8	O
,	1	O
1907	4	O
+	1	O
/	1	O
-	1	O
318	3	O
pmol	4	O
/	1	O
L	1	O
)	1	O
.	1	O

These	5	O
values	6	O
were	4	O
determined	10	O
at	2	O
the	3	O
onset	5	O
of	2	O
clinical	8	O
symptoms	8	O
of	2	O
PIH	3	B-Disease
.	1	O

These	5	O
results	7	O
can	3	O
not	3	O
be	2	O
explained	9	O
by	2	O
receptor	8	O
down-regulation	15	O
due	3	O
to	2	O
higher	6	O
levels	6	O
of	2	O
mineralocorticoids	18	B-Chemical
in	2	O
PIH	3	B-Disease
;	1	O
a	1	O
hitherto	8	O
unknown	7	O
mineralocorticoid	17	B-Chemical
may	3	O
,	1	O
thus	4	O
,	1	O
be	2	O
responsible	11	O
for	3	O
the	3	O
hypertension	12	B-Disease
and	3	O
altered	7	O
MR	2	B-Gene
status	6	O
.	1	O

Mineralocorticoid	17	B-Chemical
effector	8	O
mechanism	9	O
in	2	O
preeclampsia	12	B-Disease
.	1	O

Mineralocorticoid	17	B-Chemical
effector	8	O
mechanisms	10	O
were	4	O
evaluated	9	O
in	2	O
29	2	O
patients	8	O
with	4	O
preeclampsia	12	B-Disease
and	3	O
in	2	O
25	2	O
uncomplicated	13	O
pregnancies	11	O
by	2	O
measurement	11	O
of	2	O
plasma	6	O
aldosterone	11	B-Chemical
,	1	O
levels	6	O
of	2	O
mineralocorticoid	17	B-Gene
receptor	8	I-Gene
(	1	O
MR	2	B-Gene
)	1	O
in	2	O
mononuclear	11	O
leucocytes	10	O
,	1	O
and	3	O
subtraction	11	O
potential	9	O
difference	10	O
(	1	O
SPD	3	B-Gene
;	1	O
rectal	6	O
minus	5	O
oral	4	O
values	6	O
)	1	O
.	1	O

Mean	4	O
values	6	O
for	3	O
plasma	6	O
aldosterone	11	B-Chemical
were	4	O
not	3	O
different	9	O
between	7	O
the	3	O
two	3	O
groups	6	O
,	1	O
but	3	O
significant	11	O
differences	11	O
were	4	O
observed	8	O
for	3	O
MR	2	B-Gene
(	1	O
preeclampsia	12	B-Disease
,	1	O
81	2	O
+	1	O
/	1	O
-	1	O
44	2	O
receptors	9	O
/	1	O
cell	4	O
;	1	O
controls	8	O
,	1	O
306	3	O
+	1	O
/	1	O
-	1	O
168	3	O
)	1	O
and	3	O
SPD	3	B-Gene
(	1	O
preeclampsia	12	B-Disease
,	1	O
65	2	O
+	1	O
/	1	O
-	1	O
7	1	O
mV	2	O
;	1	O
controls	8	O
,	1	O
12	2	O
+	1	O
/	1	O
-	1	O
5	1	O
mV	2	O
)	1	O
.	1	O

In	2	O
six	3	O
cases	5	O
we	2	O
determined	10	O
MR	2	B-Gene
,	1	O
plasma	6	O
aldosterone	11	B-Chemical
,	1	O
and	3	O
SPD	3	B-Gene
in	2	O
patients	8	O
with	4	O
preeclampsia	12	B-Disease
before	6	O
and	3	O
3	1	O
months	6	O
after	5	O
delivery	8	O
.	1	O

MR	2	B-Gene
were	4	O
reduced	7	O
before	6	O
delivery	8	O
(	1	O
96	2	O
+	1	O
/	1	O
-	1	O
27	2	O
receptors	9	O
/	1	O
cell	4	O
)	1	O
,	1	O
and	3	O
SPD	3	B-Gene
increased	9	O
(	1	O
64	2	O
+	1	O
/	1	O
-	1	O
8	1	O
mV	2	O
)	1	O
,	1	O
with	4	O
both	4	O
parameters	10	O
normalizing	11	O
after	5	O
delivery	8	O
(	1	O
MR	2	B-Gene
,	1	O
242	3	O
+	1	O
/	1	O
-	1	O
79	2	O
;	1	O
SPD	3	B-Gene
,	1	O
14.0	4	O
+	1	O
/	1	O
-	1	O
4	1	O
mV	2	O
)	1	O
.	1	O

Aldosterone	11	B-Chemical
levels	6	O
returned	8	O
to	2	O
normal	6	O
nonpregnant	11	O
values	6	O
after	5	O
delivery	8	O
.	1	O

These	5	O
data	4	O
suggest	7	O
an	2	O
important	9	O
role	4	O
for	3	O
abnormalities	13	O
in	2	O
mineralocorticoid	17	B-Chemical
effector	8	O
mechanisms	10	O
in	2	O
the	3	O
etiology	8	O
of	2	O
preeclampsia	12	B-Disease
and	3	O
could	5	O
be	2	O
an	2	O
useful	6	O
marker	6	O
for	3	O
diagnosis	9	O
.	1	O

A	1	O
lymphoid	8	O
cell-specific	13	O
nuclear	7	O
factor	6	O
containing	10	O
c-Rel	5	B-Gene
-like	5	I-Gene
proteins	8	I-Gene
preferentially	14	O
interacts	9	O
with	4	O
interleukin-6	13	B-Gene
kappa	5	I-Gene
B	1	I-Gene
-related	8	O
motifs	6	O
whose	5	O
activities	10	O
are	3	O
repressed	9	O
in	2	O
lymphoid	8	O
cells	5	O
.	1	O

The	3	O
proto-oncoprotein	17	B-Gene
c-Rel	5	I-Gene
is	2	O
a	1	O
member	6	O
of	2	O
the	3	O
nuclear	7	B-Gene
factor	6	I-Gene
kappa	5	I-Gene
B	1	I-Gene
transcription	13	I-Gene
factor	6	I-Gene
family	6	I-Gene
,	1	O
which	5	O
includes	8	O
the	3	O
p50	3	B-Gene
and	3	O
p65	3	B-Gene
subunits	8	I-Gene
of	2	O
nuclear	7	B-Gene
factor	6	I-Gene
kappa	5	I-Gene
B	1	I-Gene
.	1	O

We	2	O
show	4	O
here	4	O
that	4	O
c-Rel	5	B-Gene
binds	5	O
to	2	O
kappa	5	O
B	1	O
sites	5	O
as	2	O
homodimers	10	O
as	2	O
well	4	O
as	2	O
heterodimers	12	O
with	4	O
p50	3	B-Gene
.	1	O

These	5	O
homodimers	10	O
and	3	O
heterodimers	12	O
show	4	O
distinct	8	O
DNA	3	O
-binding	8	O
specificities	13	O
and	3	O
affinities	10	O
for	3	O
various	7	O
kappa	5	O
B	1	O
motifs	6	O
.	1	O

In	2	O
particular	10	O
,	1	O
the	3	O
c-Rel	5	B-Gene
homodimer	9	O
has	3	O
a	1	O
high	4	O
affinity	8	O
for	3	O
interleukin-6	13	B-Gene
(	1	O
IL-6	4	B-Gene
)	1	O
and	3	O
beta	4	B-Gene
interferon	10	I-Gene
kappa	5	I-Gene
B	1	I-Gene
sites	5	O
.	1	O

In	2	O
spite	5	O
of	2	O
its	3	O
association	11	O
with	4	O
p50	3	B-Gene
in	2	O
vitro	5	O
,	1	O
however	7	O
,	1	O
we	2	O
found	5	O
a	1	O
lymphoid	8	O
cell-specific	13	O
nuclear	7	O
factor	6	O
in	2	O
vivo	4	O
that	4	O
contains	8	O
c-Rel	5	B-Gene
but	3	O
not	3	O
p50	3	B-Gene
epitopes	8	O
;	1	O
this	4	O
factor	6	O
,	1	O
termed	6	O
IL-6	4	B-Gene
kappa	5	I-Gene
B	1	I-Gene
binding	7	I-Gene
factor	6	I-Gene
II	2	I-Gene
,	1	O
appears	7	O
to	2	O
contain	7	O
the	3	O
c-Rel	5	B-Gene
homodimer	9	O
and	3	O
preferentially	14	O
recognizes	10	O
several	7	O
IL-6	4	B-Gene
kappa	5	I-Gene
B	1	I-Gene
-related	8	O
kappa	5	O
B	1	O
motifs	6	O
.	1	O

Although	8	O
it	2	O
has	3	O
been	4	O
previously	10	O
shown	5	O
that	4	O
the	3	O
IL-6	4	B-Gene
kappa	5	I-Gene
B	1	I-Gene
motif	5	O
functions	9	O
as	2	O
a	1	O
potent	6	O
IL-1	4	B-Gene
/	1	I-Gene
tumor	5	I-Gene
necrosis	8	I-Gene
factor	6	I-Gene
-responsive	11	I-Gene
element	7	I-Gene
in	2	O
nonlymphoid	11	O
cells	5	O
,	1	O
its	3	O
activity	8	O
was	3	O
found	5	O
to	2	O
be	2	O
repressed	9	O
in	2	O
lymphoid	8	O
cells	5	O
such	4	O
as	2	O
a	1	O
Jurkat	6	O
T-cell	6	O
line	4	O
.	1	O

We	2	O
also	4	O
present	7	O
evidence	8	O
that	4	O
IL-6	4	B-Gene
kappa	5	I-Gene
B	1	I-Gene
binding	7	I-Gene
factor	6	I-Gene
II	2	I-Gene
functions	9	O
as	2	O
a	1	O
repressor	9	O
specific	8	O
for	3	O
IL-6	4	B-Gene
kappa	5	I-Gene
B	1	I-Gene
-related	8	O
kappa	5	O
B	1	O
motifs	6	O
in	2	O
lymphoid	8	O
cells	5	O
.	1	O

Modulation	10	O
of	2	O
normal	6	O
erythroid	9	O
differentiation	15	O
by	2	O
the	3	O
endogenous	10	O
thyroid	7	B-Chemical
hormone	7	I-Chemical
and	3	O
retinoic	8	B-Gene
acid	4	I-Gene
receptors	9	I-Gene
:	1	O
a	1	O
possible	8	O
target	6	O
for	3	O
v-erbA	6	B-Gene
oncogene	8	I-Gene
action	6	O
.	1	O

The	3	O
v-erbA	6	B-Gene
oncogene	8	I-Gene
,	1	O
a	1	O
mutated	7	O
version	7	O
of	2	O
the	3	O
thyroid	7	B-Gene
hormone	7	I-Gene
receptor	8	I-Gene
alpha	5	I-Gene
(	1	O
c-erbA	6	B-Gene
/	1	I-Gene
TR-alpha	8	I-Gene
)	1	O
,	1	O
inhibits	8	O
erythroid	9	O
differentiation	15	O
and	3	O
constitutively	14	O
represses	9	O
transcription	13	O
of	2	O
certain	7	O
erythrocyte	11	O
genes	5	O
,	1	O
suggesting	10	O
a	1	O
normal	6	O
function	8	O
of	2	O
the	3	O
proto-oncogene	14	B-Gene
c-erbA	6	I-Gene
in	2	O
erythropoiesis	14	O
.	1	O

Here	4	O
we	2	O
demonstrate	11	O
that	4	O
the	3	O
endogenous	10	B-Gene
thyroid	7	I-Gene
hormone	7	I-Gene
receptor	8	I-Gene
alpha	5	I-Gene
(	1	O
c-erbA	6	B-Gene
/	1	I-Gene
TR-alpha	8	I-Gene
)	1	O
and	3	O
the	3	O
closely	7	O
related	7	O
retinoic	8	B-Gene
acid	4	I-Gene
receptor	8	I-Gene
alpha	5	I-Gene
(	1	O
RAR-alpha	9	B-Gene
)	1	O
play	4	O
a	1	O
role	4	O
in	2	O
the	3	O
regulation	10	O
of	2	O
normal	6	O
erythroid	9	O
differentiation	15	O
.	1	O

Retinoic	8	B-Chemical
acid	4	I-Chemical
(	1	O
RA	2	B-Chemical
)	1	O
distinctly	10	O
modulated	9	O
the	3	O
erythroid	9	O
differentiation	15	O
program	7	O
of	2	O
normal	6	O
erythroid	9	O
progenitors	11	O
and	3	O
erythroblasts	13	O
reversibly	10	O
transformed	11	O
by	2	O
a	1	O
conditional	11	O
tyrosine	8	B-Gene
kinase	6	I-Gene
oncogene	8	I-Gene
.	1	O

When	4	O
added	5	O
pulsewise	9	O
to	2	O
immature	8	O
cells	5	O
,	1	O
differentiation	15	O
was	3	O
accelerated	11	O
while	5	O
more	4	O
mature	6	O
cells	5	O
underwent	9	O
premature	9	O
cell	4	O
death	5	O
.	1	O

Thyroid	7	B-Chemical
hormone	7	I-Chemical
(	1	O
T3	2	B-Chemical
)	1	O
alone	5	O
caused	6	O
similar	7	O
but	3	O
weaker	6	O
effects	7	O
.	1	O

Interestingly	13	O
,	1	O
T3	2	B-Chemical
strongly	8	O
enhanced	8	O
the	3	O
action	6	O
of	2	O
RA	2	B-Chemical
,	1	O
suggesting	10	O
cooperative	11	O
action	6	O
of	2	O
the	3	O
two	3	O
receptors	9	O
in	2	O
modulating	10	O
erythroid	9	O
differentiation	15	O
.	1	O

Expression	10	O
of	2	O
the	3	O
human	5	B-Gene
RAR-alpha	9	I-Gene
in	2	O
receptor	8	O
-negative	9	O
erythroblasts	13	O
conferred	9	O
RA	2	B-Chemical
-induced	8	O
regulation	10	O
of	2	O
differentiation	15	O
to	2	O
the	3	O
otherwise	9	O
unresponsive	12	O
cells	5	O
,	1	O
thus	4	O
showing	7	O
that	4	O
the	3	O
RAR-alpha	9	B-Gene
is	2	O
essential	9	O
for	3	O
the	3	O
RA	2	B-Chemical
effect	6	O
.	1	O

Likewise	8	O
,	1	O
enhanced	8	O
expression	10	O
of	2	O
exogenous	9	B-Gene
c-erbA	6	I-Gene
/	1	I-Gene
TR-alpha	8	I-Gene
in	2	O
erythroblasts	13	O
rendered	8	O
them	4	O
susceptible	11	O
to	2	O
modulation	10	O
of	2	O
differentiation	15	O
by	2	O
T3	2	B-Chemical
,	1	O
suggesting	10	O
a	1	O
similar	7	O
function	8	O
of	2	O
both	4	O
receptors	9	O
.	1	O

Leukotriene	11	B-Chemical
B4	2	I-Chemical
stimulates	10	O
c-fos	5	B-Gene
and	3	O
c-jun	5	B-Gene
gene	4	I-Gene
transcription	13	O
and	3	O
AP-1	4	B-Gene
binding	7	O
activity	8	O
in	2	O
human	5	O
monocytes	9	O
.	1	O

We	2	O
have	4	O
examined	8	O
the	3	O
effect	6	O
of	2	O
leukotriene	11	B-Chemical
B4	2	I-Chemical
(	1	O
LTB4	4	B-Chemical
)	1	O
,	1	O
a	1	O
potent	6	O
lipid	5	B-Chemical
proinflammatory	15	O
mediator	8	O
,	1	O
on	2	O
the	3	O
expression	10	O
of	2	O
the	3	O
proto-oncogenes	15	B-Gene
c-jun	5	I-Gene
and	3	O
c-fos	5	B-Gene
.	1	O

In	2	O
addition	8	O
,	1	O
we	2	O
looked	6	O
at	2	O
the	3	O
modulation	10	O
of	2	O
nuclear	7	O
factors	7	O
binding	7	O
specifically	12	O
to	2	O
the	3	O
AP-1	4	B-Gene
element	7	I-Gene
after	5	O
LTB4	4	B-Chemical
stimulation	11	O
.	1	O

LTB4	4	B-Chemical
increased	9	O
the	3	O
expression	10	O
of	2	O
the	3	O
c-fos	5	B-Gene
gene	4	I-Gene
in	2	O
a	1	O
time-	5	O
and	3	O
concentration	13	O
-dependent	10	O
manner	6	O
.	1	O

The	3	O
c-jun	5	B-Gene
mRNA	4	I-Gene
,	1	O
which	5	O
is	2	O
constitutively	14	O
expressed	9	O
in	2	O
human	5	O
peripheral-blood	16	O
monocytes	9	O
at	2	O
relatively	10	O
high	4	O
levels	6	O
,	1	O
was	3	O
also	4	O
slightly	8	O
augmented	9	O
by	2	O
LTB4	4	B-Chemical
,	1	O
although	8	O
to	2	O
a	1	O
much	4	O
lower	5	O
extent	6	O
than	4	O
c-fos	5	B-Gene
.	1	O

The	3	O
kinetics	8	O
of	2	O
expression	10	O
of	2	O
the	3	O
two	3	O
genes	5	O
were	4	O
also	4	O
slightly	8	O
different	9	O
,	1	O
with	4	O
c-fos	5	B-Gene
mRNA	4	I-Gene
reaching	8	O
a	1	O
peak	4	O
at	2	O
15	2	O
min	3	O
after	5	O
stimulation	11	O
and	3	O
c-jun	5	B-Gene
at	2	O
30	2	O
min	3	O
.	1	O

Both	4	O
messages	8	O
rapidly	7	O
declined	8	O
thereafter	10	O
.	1	O

Stability	9	O
of	2	O
the	3	O
c-fos	5	B-Gene
and	3	O
c-jun	5	B-Gene
mRNA	4	I-Gene
was	3	O
not	3	O
affected	8	O
by	2	O
LTB4	4	B-Chemical
,	1	O
as	2	O
assessed	8	O
after	5	O
actinomycin	11	B-Chemical
D	1	I-Chemical
treatment	9	O
.	1	O

Nuclear	7	O
transcription	13	O
studies	7	O
in	2	O
vitro	5	O
showed	6	O
that	4	O
LTB4	4	B-Chemical
increased	9	O
the	3	O
transcription	13	O
of	2	O
the	3	O
c-fos	5	B-Gene
gene	4	I-Gene
7-fold	6	O
and	3	O
the	3	O
c-jun	5	B-Gene
gene	4	I-Gene
1.4-fold	8	O
.	1	O

Resting	7	O
monocytes	9	O
contained	9	O
nuclear	7	O
factors	7	O
binding	7	O
to	2	O
the	3	O
AP-1	4	B-Gene
element	7	I-Gene
,	1	O
but	3	O
stimulation	11	O
of	2	O
monocytes	9	O
with	4	O
LTB4	4	B-Chemical
induced	7	O
greater	7	O
AP-1	4	B-Gene
-binding	8	O
activity	8	O
of	2	O
nuclear	7	O
proteins	8	O
.	1	O

These	5	O
results	7	O
indicate	8	O
that	4	O
LTB4	4	B-Chemical
may	3	O
regulate	8	O
the	3	O
production	10	O
of	2	O
different	9	O
cytokines	9	O
by	2	O
modulating	10	O
the	3	O
yield	5	O
and	3	O
/	1	O
or	2	O
the	3	O
function	8	O
of	2	O
transcription	13	O
factors	7	O
such	4	O
as	2	O
AP-1	4	B-Gene
-binding	8	O
proto-oncogene	14	O
products	8	O
.	1	O

An	2	O
11-base-pair	12	O
DNA	3	O
sequence	8	O
motif	5	O
apparently	10	O
unique	6	O
to	2	O
the	3	O
human	5	B-Gene
interleukin	11	I-Gene
4	1	I-Gene
gene	4	I-Gene
confers	7	O
responsiveness	14	O
to	2	O
T-cell	6	O
activation	10	O
signals	7	O
.	1	O

We	2	O
have	4	O
identified	10	O
a	1	O
DNA	3	O
segment	7	O
that	4	O
confers	7	O
responsiveness	14	O
to	2	O
antigen	7	O
stimulation	11	O
signals	7	O
on	2	O
the	3	O
human	5	B-Gene
interleukin	11	I-Gene
(	1	I-Gene
IL	2	I-Gene
)	1	I-Gene
4	1	I-Gene
gene	4	I-Gene
in	2	O
Jurkat	6	O
cells	5	O
.	1	O

The	3	O
human	5	B-Gene
IL-4	4	I-Gene
gene	4	I-Gene
,	1	O
of	2	O
10	2	O
kilobases	9	O
,	1	O
is	2	O
composed	8	O
of	2	O
four	4	O
exons	5	O
and	3	O
three	5	O
introns	7	O
.	1	O

A	1	O
cis	3	O
-acting	7	O
element	7	O
(	1	O
P	1	O
sequence	8	O
)	1	O
resides	7	O
in	2	O
the	3	O
5	1	O
'upstream	9	O
region	6	O
;	1	O
no	2	O
additional	10	O
DNA	3	O
segments	8	O
with	4	O
enhancer	8	O
activity	8	O
were	4	O
identified	10	O
in	2	O
the	3	O
human	5	B-Gene
IL-4	4	I-Gene
gene	4	I-Gene
.	1	O

For	3	O
further	7	O
mapping	7	O
purposes	8	O
,	1	O
a	1	O
fusion	6	O
promoter	8	O
was	3	O
constructed	11	O
with	4	O
the	3	O
granulocyte	11	B-Gene
/	1	I-Gene
macrophage	10	I-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
basic	5	I-Gene
promoter	8	I-Gene
containing	10	O
60	2	O
base	4	O
pairs	5	O
of	2	O
sequence	8	O
upstream	8	O
from	4	O
the	3	O
cap	3	O
site	4	O
of	2	O
the	3	O
mouse	5	B-Gene
granulocyte	11	I-Gene
/	1	I-Gene
macrophage	10	I-Gene
colony	6	I-Gene
-stimulating	12	I-Gene
factor	6	I-Gene
gene	4	I-Gene
and	3	O
various	7	O
lengths	7	O
of	2	O
the	3	O
5	1	O
'upstream	9	O
sequence	8	O
of	2	O
the	3	O
IL-4	4	B-Gene
gene	4	I-Gene
.	1	O

The	3	O
P	1	O
sequence	8	O
was	3	O
located	7	O
between	7	O
positions	9	O
-79	3	O
and	3	O
-69	3	O
relative	8	O
to	2	O
the	3	O
transcription	13	O
start	5	O
site	4	O
of	2	O
the	3	O
human	5	B-Gene
IL-4	4	I-Gene
gene	4	I-Gene
,	1	O
and	3	O
this	4	O
location	8	O
was	3	O
confirmed	9	O
by	2	O
base-substitution	17	O
mutations	9	O
.	1	O

The	3	O
plasmids	8	O
carrying	8	O
multiple	8	O
copies	6	O
of	2	O
the	3	O
P	1	O
sequence	8	O
showed	6	O
higher	6	O
responsiveness	14	O
to	2	O
the	3	O
stimulation	11	O
.	1	O

The	3	O
binding	7	O
protein	7	O
(	1	O
s	1	O
)	1	O
that	4	O
recognize	9	O
the	3	O
P	1	O
sequence	8	O
of	2	O
the	3	O
IL-4	4	B-Gene
gene	4	I-Gene
were	4	O
identified	10	O
by	2	O
DNA-mobility-shift	18	O
assays	6	O
.	1	O

The	3	O
binding	7	O
of	2	O
NF	2	O
(	1	O
P	1	O
)	1	O
(	1	O
a	1	O
DNA	3	O
binding	7	O
protein	7	O
that	4	O
specifically	12	O
recognizes	10	O
the	3	O
P	1	O
sequence	8	O
)	1	O
to	2	O
the	3	O
P	1	O
sequence	8	O
was	3	O
abolished	9	O
when	4	O
oligonucleotides	16	O
carrying	8	O
base	4	O
substitutions	13	O
were	4	O
used	4	O
,	1	O
indicating	10	O
that	4	O
the	3	O
NF	2	O
(	1	O
P	1	O
)	1	O
interaction	11	O
is	2	O
sequence-specific	17	O
and	3	O
that	4	O
binding	7	O
specificity	11	O
of	2	O
the	3	O
protein	7	O
paralleled	10	O
the	3	O
sequence	8	O
requirements	12	O
for	3	O
IL-4	4	B-Gene
expression	10	O
in	2	O
vivo	4	O
.	1	O

The	3	O
P	1	O
sequence	8	O
does	4	O
not	3	O
share	5	O
homology	8	O
with	4	O
the	3	O
5	1	O
'upstream	9	O
sequence	8	O
of	2	O
the	3	O
IL-2	4	B-Gene
gene	4	I-Gene
,	1	O
even	4	O
though	6	O
surrounding	11	O
sequences	9	O
of	2	O
the	3	O
IL-4	4	B-Gene
gene	4	I-Gene
share	5	O
high	4	O
homology	8	O
with	4	O
the	3	O
IL-2	4	B-Gene
gene	4	I-Gene
.	1	O

We	2	O
conclude	8	O
that	4	O
a	1	O
different	9	O
set	3	O
of	2	O
proteins	8	O
recognize	9	O
IL-2	4	B-Gene
and	3	O
IL-4	4	B-Gene
genes	5	I-Gene
.	1	O

Glucocorticoid	14	B-Gene
receptor	8	I-Gene
binding	7	O
in	2	O
three	5	O
different	9	O
cell	4	O
types	5	O
in	2	O
major	5	B-Disease
depressive	10	I-Disease
disorder	8	I-Disease
:	1	O
lack	4	O
of	2	O
evidence	8	O
of	2	O
receptor	8	O
binding	7	O
defect	6	O
.	1	O

1	1	O
.	1	O

In	2	O
order	5	O
to	2	O
further	7	O
understand	10	O
the	3	O
apparent	8	O
glucocorticoid	14	B-Chemical
resistance	10	O
in	2	O
major	5	B-Disease
depressive	10	I-Disease
disorder	8	I-Disease
,	1	O
circadian	9	O
variation	9	O
in	2	O
cortisol	8	B-Chemical
concentration	13	O
,	1	O
dexamethasone	13	B-Chemical
suppression	11	O
and	3	O
glucocorticoid	14	B-Gene
receptor	8	I-Gene
binding	7	O
in	2	O
mononuclear	11	O
leukocytes	10	O
,	1	O
polymorphonuclear	17	O
leukocytes	10	O
and	3	O
cultured	8	O
skin	4	O
fibroblasts	11	O
were	4	O
measured	8	O
in	2	O
rigidly	7	O
defined	7	O
major	5	B-Disease
depressive	10	I-Disease
disorder	8	I-Disease
patients	8	O
and	3	O
non	3	O
-depressed	10	O
psychiatric	11	O
controls	8	O
.	1	O

2	1	O
.	1	O

Mononuclear	11	O
leukocytes	10	O
binding	7	O
to	2	O
glucocorticoid	14	B-Chemical
correlated	10	O
significantly	13	O
with	4	O
polymorphonuclear	17	O
leukocytes	10	O
binding	7	O
to	2	O
glucocorticoid	14	B-Chemical
,	1	O
but	3	O
both	4	O
determinations	14	O
failed	6	O
to	2	O
differentiate	13	O
major	5	B-Disease
depressive	10	I-Disease
disorder	8	I-Disease
and	3	O
control	7	O
subjects	8	O
.	1	O

3	1	O
.	1	O

Initial	7	O
and	3	O
post-dexamethasone	18	B-Chemical
in	2	O
vitro	5	O
fibroblast	10	O
binding	7	O
to	2	O
glucocorticoid	14	B-Chemical
was	3	O
not	3	O
different	9	O
between	7	O
major	5	B-Disease
depressive	10	I-Disease
disorder	8	I-Disease
and	3	O
non	3	O
-depressed	10	O
control	7	O
subjects	8	O
.	1	O

4	1	O
.	1	O

The	3	O
phenomenon	10	O
of	2	O
glucocorticoid	14	B-Chemical
resistance	10	O
in	2	O
major	5	B-Disease
depressive	10	I-Disease
disorder	8	I-Disease
remains	7	O
unexplained	11	O
.	1	O

[	1	O
Hormonal	8	O
interactions	12	O
and	3	O
glucocorticoid	14	B-Gene
receptors	9	I-Gene
in	2	O
patients	8	O
with	4	O
the	3	O
nephrotic	9	B-Disease
syndrome	8	I-Disease
]	1	O

As	2	O
many	4	O
as	2	O
27	2	O
children	8	O
aged	4	O
6	1	O
to	2	O
15	2	O
years	5	O
with	4	O
morphologically	15	O
verified	8	O
nephropathies	13	B-Disease
were	4	O
examined	8	O
.	1	O

Four	4	O
variants	8	O
of	2	O
changes	7	O
in	2	O
the	3	O
thyroid	7	O
status	6	O
,	1	O
characteristic	14	O
of	2	O
children	8	O
with	4	O
different	9	O
variants	8	O
of	2	O
nephrotic	9	B-Disease
syndrome	8	I-Disease
were	4	O
distinguished	13	O
:	1	O
1	1	O
)	1	O
biochemical	11	O
signs	5	O
of	2	O
primary	7	O
hypothyroidism	14	B-Disease
,	1	O
2	1	O
)	1	O
biochemical	11	O
signs	5	O
of	2	O
secondary	9	O
hypothyroidism	14	B-Disease
,	1	O
3	1	O
)	1	O
low	3	O
content	7	O
of	2	O
T3	2	B-Chemical
,	1	O
4	1	O
)	1	O
dysfunction	11	O
of	2	O
the	3	O
hypophyseal	11	O
and	3	O
thyroid	7	O
system	6	O
.	1	O

It	2	O
is	2	O
shown	5	O
that	4	O
the	3	O
low	3	O
level	5	O
of	2	O
steroid	7	B-Gene
receptors	9	I-Gene
,	1	O
thyroid	7	B-Chemical
hormones	8	I-Chemical
that	4	O
the	3	O
low	3	O
level	5	O
of	2	O
steroid	7	B-Gene
receptors	9	I-Gene
,	1	O
thyroid	7	B-Chemical
hormones	8	I-Chemical
(	1	O
T3	2	B-Chemical
and	3	O
T4	2	B-Chemical
)	1	O
and	3	O
cortisol	8	B-Chemical
is	2	O
typical	7	O
of	2	O
children	8	O
with	4	O
the	3	O
signs	5	O
of	2	O
renal	5	B-Disease
dysplasia	9	I-Disease
.	1	O

It	2	O
is	2	O
assumed	7	O
that	4	O
superaddition	13	O
under	5	O
such	4	O
conditions	10	O
of	2	O
immune	6	O
glomerulopathy	14	B-Disease
(	1	O
glomerulonephritis	18	B-Disease
and	3	O
nephrotic	9	B-Disease
syndrome	8	I-Disease
)	1	O
gives	5	O
rise	4	O
to	2	O
the	3	O
resistance	10	O
to	2	O
the	3	O
treatment	9	O
with	4	O
glucocorticoids	15	B-Chemical
.	1	O

Kinetics	8	O
of	2	O
nuclear	7	O
translocation	13	O
and	3	O
turnover	8	O
of	2	O
the	3	O
vitamin	7	B-Gene
D	1	I-Gene
receptor	8	I-Gene
in	2	O
human	5	O
HL60	4	O
leukemia	8	B-Disease
cells	5	O
and	3	O
peripheral	10	O
blood	5	O
lymphocytes	11	O
--	2	O
coincident	10	O
rise	4	O
of	2	O
DNA	3	O
-relaxing	9	O
activity	8	O
in	2	O
nuclear	7	O
extracts	8	O
.	1	O

High	4	O
affinity	8	O
receptors	9	O
(	1	O
VDR	3	B-Gene
)	1	O
for	3	O
1	1	B-Chemical
,	1	I-Chemical
25-dihydroxycholecalciferol	27	I-Chemical
(	1	O
calcitriol	10	B-Chemical
)	1	O
are	3	O
expressed	9	O
in	2	O
HL60	4	O
human	5	O
leukemia	8	B-Disease
cells	5	O
and	3	O
in	2	O
low	3	O
numbers	7	O
in	2	O
peripheral	10	O
blood	5	O
lymphocytes	11	O
(	1	O
PBL	3	O
)	1	O
.	1	O

HL60	4	O
cells	5	O
,	1	O
expressing	10	O
some	4	O
characteristics	15	O
of	2	O
promyelocytes	13	O
,	1	O
can	3	O
be	2	O
induced	7	O
to	2	O
monocytoid	10	O
differentiation	15	O
by	2	O
calcitriol	10	B-Chemical
.	1	O

Specific	8	O
nuclear	7	O
translocation	13	O
of	2	O
[	1	O
3H	2	O
]	1	O
calcitriol	10	B-Chemical
/	1	O
VDR	3	B-Gene
was	3	O
examined	8	O
after	5	O
exposure	8	O
of	2	O
whole	5	O
cells	5	O
to	2	O
10	2	O
(	1	O
-9	2	O
)	1	O
M	1	O
/	1	O
l	1	O
calcitriol	10	B-Chemical
in	2	O
the	3	O
presence	8	O
and	3	O
absence	7	O
of	2	O
a	1	O
500-fold	8	O
excess	6	O
of	2	O
unlabeled	9	O
ligand	6	O
and	3	O
subsequent	10	O
isolation	9	O
of	2	O
nuclei	6	O
.	1	O

Specific	8	O
nuclear	7	O
translocation	13	O
of	2	O
[	1	O
3H	2	O
]	1	O
calcitriol	10	B-Chemical
/	1	O
VDR	3	B-Gene
was	3	O
found	5	O
to	2	O
be	2	O
time	4	O
dependent	9	O
reaching	8	O
a	1	O
maximum	7	O
of	2	O
approximately	13	O
2100	4	O
binding	7	O
sites	5	O
/	1	O
nucleus	7	O
after	5	O
3	1	O
h	1	O
of	2	O
incubation	10	O
in	2	O
HL60	4	O
cells	5	O
,	1	O
whereas	7	O
a	1	O
maximum	7	O
of	2	O
approximately	13	O
310	3	O
binding	7	O
sites	5	O
/	1	O
nucleus	7	O
was	3	O
found	5	O
after	5	O
3	1	O
h	1	O
in	2	O
PBL	3	O
.	1	O

Pulse	5	O
exposure	8	O
of	2	O
HL60	4	O
to	2	O
radiolabeled	12	O
hormone	7	O
for	3	O
3	1	O
h	1	O
followed	8	O
by	2	O
culture	7	O
in	2	O
medium	6	O
without	7	O
serum	5	O
and	3	O
calcitriol	10	B-Chemical
lead	4	O
to	2	O
nuclear	7	O
retention	9	O
of	2	O
approximately	13	O
1600	4	O
radiolabeled	12	O
VDR	3	B-Gene
by	2	O
8	1	O
h	1	O
and	3	O
approximately	13	O
1000	4	O
VDR	3	B-Gene
by	2	O
24	2	O
h	1	O
.	1	O

Radiolabeled	12	O
VDR	3	B-Gene
disappeared	11	O
from	4	O
the	3	O
nuclear	7	O
compartment	11	O
with	4	O
a	1	O
halflife	8	O
of	2	O
approximately	13	O
30	2	O
min	3	O
if	2	O
cells	5	O
were	4	O
cultured	8	O
with	4	O
identical	9	O
concentrations	14	O
of	2	O
unlabeled	9	O
hormone	7	O
after	5	O
the	3	O
pulse	5	O
(	1	O
pulse	5	O
/	1	O
chase	5	O
-experiments	12	O
)	1	O
.	1	O

No	2	O
difference	10	O
of	2	O
VDR	3	B-Gene
retention	9	O
in	2	O
pulse	5	O
and	3	O
pulse	5	O
/	1	O
chase	5	O
-experiments	12	O
was	3	O
seen	4	O
in	2	O
PBL	3	O
,	1	O
where	5	O
VDR	3	B-Gene
halflife	8	O
was	3	O
approximately	13	O
30	2	O
min	3	O
.	1	O

No	2	O
specific	8	O
translocation	13	O
into	4	O
the	3	O
nuclear	7	O
compartment	11	O
was	3	O
seen	4	O
when	4	O
isolated	8	O
nuclei	6	O
were	4	O
incubated	9	O
in	2	O
[	1	O
3H	2	O
]	1	O
calcitriol	10	B-Chemical
.	1	O

Radiolabeled	12	O
hormone	7	O
/	1	O
receptor	8	O
complexes	9	O
of	2	O
nuclei	6	O
isolated	8	O
from	4	O
cells	5	O
exposed	7	O
for	3	O
3	1	O
h	1	O
to	2	O
radiolabeled	12	O
hormone	7	O
--	2	O
in	2	O
contrast	8	O
to	2	O
identical	9	O
experiments	11	O
with	4	O
intact	6	O
cells	5	O
--	2	O
did	3	O
not	3	O
disappear	9	O
from	4	O
the	3	O
nuclear	7	O
compartment	11	O
upon	4	O
incubation	10	O
of	2	O
nuclei	6	O
with	4	O
identical	9	O
concentrations	14	O
of	2	O
the	3	O
unlabeled	9	O
compound	8	O
.	1	O

The	3	O
activity	8	O
of	2	O
DNA	3	O
relaxing	8	O
enzymes	7	O
(	1	O
e.g	3	O
.	1	O
topoisomerases	14	B-Gene
I	1	I-Gene
and	3	O
II	2	B-Partial_Gene
)	1	O
in	2	O
nuclear	7	O
extracts	8	O
was	3	O
measured	8	O
using	5	O
a	1	O
PBR	3	O
322-relaxation-assay	20	O
.	1	O

Enhanced	8	O
overall	7	O
enzyme	6	O
activity	8	O
was	3	O
found	5	O
in	2	O
nuclear	7	O
extracts	8	O
by	2	O
1	1	O
h	1	O
after	5	O
incubation	10	O
with	4	O
calcitriol	10	B-Chemical
(	1	O
final	5	O
ethanol	7	B-Chemical
concentration	13	O
0.0001	6	O
%	1	O
v	1	O
/	1	O
v	1	O
)	1	O
in	2	O
HL60	4	O
and	3	O
PBL	3	O
.	1	O

The	3	O
enhanced	8	O
activity	8	O
disappeared	11	O
after	5	O
2	1	O
h	1	O
in	2	O
PBL	3	O
,	1	O
whereas	7	O
it	2	O
was	3	O
still	5	O
enhanced	8	O
by	2	O
4	1	O
h	1	O
in	2	O
HL60	4	O
.	1	O

No	2	O
effect	6	O
was	3	O
seen	4	O
in	2	O
ethanol	7	B-Chemical
treated	7	O
controls	8	O
.	1	O

We	2	O
conclude	8	O
that	4	O
a	1	O
specific	8	O
nuclear	7	O
translocation	13	O
mechanism	9	O
exists	6	O
for	3	O
calcitriol	10	B-Chemical
in	2	O
both	4	O
cell	4	O
types	5	O
examined	8	O
,	1	O
most	4	O
likely	6	O
due	3	O
to	2	O
translocation	13	O
of	2	O
receptor	8	O
proteins	8	O
after	5	O
hormone	7	O
binding	7	O
.	1	O

Translocated	12	O
hormone	7	O
/	1	O
receptor	8	O
complexes	9	O
compete	7	O
for	3	O
a	1	O
limited	7	O
number	6	O
of	2	O
specific	8	O
nuclear	7	O
binding	7	O
sites	5	O
.	1	O

Enhanced	8	O
activity	8	O
of	2	O
topoisomerases	14	B-Gene
in	2	O
nuclear	7	O
extracts	8	O
upon	4	O
translocation	13	O
of	2	O
VDR	3	B-Gene
might	5	O
reflect	7	O
interaction	11	O
of	2	O
both	4	O
within	6	O
the	3	O
nuclear	7	O
compartment	11	O
,	1	O
thus	4	O
initiating	10	O
DNA	3	O
-unwinding	10	O
,	1	O
a	1	O
prerequisite	12	O
of	2	O
transcription	13	O
initiation	10	O
.	1	O

